DDrare: Database of Drug Development for Rare Diseases

Searched query = "Parkinson disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = (11C)PE2I; (2-chloro-5-[11C]methoxy-N-(((3s,5s,7s)-3,5,7-trifluoroadamantan-1-yl)methyl) benzamide); (3beta, 5beta, 25R)-spirostan-3-ol; (3ß, 5ß, 25R)-spirostan-3-ol; (6S)-6-{propyl-[2-[2-thienyl]ethyl]amino}-5,6,7,8-tetrahydro-1-naphtalenol; (R)-troloxamide quinone; (S)- 2- Amino- 4,5,6,7- tetrahydro- 6- (propylamino)benzothiazol; (S)-(+)-2-(4-(3-fluorobenzyl)oxybenzyl)aminopropanamide methanesulfonate; (minus)-L-alpha-hydrazino-3,4-dihydroxy-alpha-methylbenzenepropanoic acid monohydrate; 0 mg tropicamide; 0.04 mg Lu AE04621; 0.08 mg Lu AE04621; 0.2 mg Lu AE04621; 0.3 mg tropicamide; 0.4 mg Lu AE04621; 0.6 mg Lu AE04621; 0.8 mg Lu AE04621; 0.9% sodium chloride; 0.9% sodium chloride (normal saline); 00000; 000000; 009-0; 009-1; 009-2; 009-3; 009-4; 009-5; 009-A0; 009-A1; 009-A2; 009-A3; 1 mg QD to 15 mg QD PF-06649751; 1 mg QD to 7 mg QD PF-06649751 (if de-escalated in parent study); 1 mg tropicamide; 1. Tesofensine (NS 2330); 1.0 mg Lu AE04621; 1.0 mg rasagiline mesylate; 1.2 mg Lu AE04621; 100; 11C-PBR28; 11C-PiB; 11C-Raclopride; 11C-methylreboxetine; 125; 13N-Ammonia; 15 mg QD PF-06649751; 15 mg QD de-escalated to 7 mg QD PF-06649751 in parent study remain at 7 mg QD; 15O H2O; 18-FDTBZ; 18F florbetaben; 18F- DTBZ; 18F-AV-133; 18F-AV-45; 18F-DOPA; 18F-DOPA PET; 18F-DTBZ; 18F-DTBZ AV-133; 18F-Dopa; 18F-Dopamne; 18F-FDG; 1[(6- Allyl- 8beta- ergolinyl)carbonyl]- 1- [3- (dimethylamino)propyl]-; 1[(6- Allyl- 8beta- ergolinyl)carbonyl]- 1- [3- (dimethylamino)propyl]- 3- ethylurea; 1[(6- Allyl- 8ß- ergolinyl)carbonyl]- 1- [3- (dimethylamino)propyl]-; 1[(6- Allyl- 8ß- ergolinyl)carbonyl]- 1- [3- (dimethylamino)propyl]- 3- ethylurea; 2 mg perampanel; 2,5-Dichloro-3-(5-(3,4-dihydroxy-5-nitrophenyl)-1,2,4-oxadiazol-3-yl)-4,6-dimethylpyridine-1-oxide; 2-[[[(2R)-1-[1-[(4-CHLORO-3-METHYLPHENYL)METHYL]-4- PIPERIDINYL]-5-OXO-2-PYRROLIDINYL]CARBONYL]AMINO]- N,N,6-TRIMETHYL-4-PYRIDINECARBOXAMIDE,DIHYDROCHLORIDE; 200 mg BIA 6-512; 207-3120; 240mg Amantadine HCl ER tablets; 25 mg BIA9 1067; 25 mg Ongentys; 25330; 3 mg QD to 15 mg QD PF-06649751; 3 mg QD to 7 mg QD PF-06649751 (de-escalated in parent study); 3 mg tropicamide; 3- (9,10- Didehydro- 6- methyl- 8?- ergolinyl)-1,1- diethylurea hydrogenmaleate; 3-(3,4-Dihydroxyphenyl)-L-alanine; 320mg Amantadine HCl ER tablets; 4 mg perampanel; 50 mg BIA 9 1067; 50 mg Ongentys; 6abeta - apomorphine-10,11-diol hydrochloride hemihydrate; 6aß - apomorphine-10,11-diol hydrochloride hemihydrate; 7 mg QD to 15 mg QD PF-06649751; 7 mg QD to 7 mg QD PF-06649751 (de-escalated in parent study); 7-beta-Hydroxyepiandrosterone; 7-beta-hydroxyepiandrosterone; 75; 8-OHdG; A-dopamine; AAV2-GDNF; AB1010; ABBV-0805; ABBV-951; ABT-SLV187; ACP-103; ACR325; AD-810N (zonisamide); ADS-5102; ADS-5102 (extended release amantadine HCl); ADX48621; AFFITOPE® PD01A; AFFITOPE® PD01A + Adjuvant; AFQ056; AFQ056 with L-dopa; AFQ065; AHA; AKST4290; AL; ALTROPANE®; AMANTADINE; AMANTADINE HYDROCHLORIDE; AMBROSAN 60mg Tablets; ANAVEX2-73; ANHYDROUS CARBIDOPA; AP; AP-CD/LD; AP09004; APL-130277; APO-go; APO-go®; APOKINON; APOKYN; APOMORPHINE HYDROCHLORIDE; APOMORPHINE HYDROCHLORIDE HEMIHYDRATE; APORON; AQW051; ARICEPT; AS2; ASyn Mab; AT 10; ATM FOG in PD; AV-101; AVALOX - 400 MG COMPRESSE RIVESTITE CON FILM 5 COMPRESSE IN BLISTER PP/AL; AVE8112; AVP-923; AVP-923-45; AZD3241; AZD3241 300 mg BID; AZD3241 600 mg BID; AZD3241 Alternative titration scheme with formulation 1 or 2; AZD3241 ER formulation 1; AZD3241 Extended release tablets 100 mg; AZD3241 Extended release tablets 25 mg; AZILECT; AZILECT 1 mg comprimidos; AZILECT®; Acamprosate; Accordion Pill Carbidopa/Levodopa; Accordion Pill ¿ Carbidopa/Levodopa 50/400 mg; Accordion Pill ¿ Carbidopa/Levodopa 50/500 mg; Accordion Pill? Carbidopa/Levodopa 50/400 mg; Accordion Pill? Carbidopa/Levodopa 50/500 mg; Accordion Pill™ Carbidopa/Levodopa; Accordion Pill™ Carbidopa/Levodopa 50/400 mg; Accordion Pill™ Carbidopa/Levodopa 50/500 mg; Acetate; Acetylcysteine; Active Investigational Treatment ENT-01; Active comparator; Active drug (BIIB014) at 10, 30, 100, or 300 mg once daily.; Active drug: pimavanserin 17mg (2 strength tablets); Adjuvant without active component; Administration of stable isotope-labelled leucine-; Agomelatine; Agomelatine or PIacebo; Alanine; Allogeneic bone marrow-derived MSCs (1 x 10 6 MSC/kg); Allogeneic bone marrow-derived MSCs (10 x 10 6 MSC/kg); Allogeneic bone marrow-derived MSCs (3 x 10 6 MSC/kg); Allogeneic bone marrow-derived MSCs (6 x 10 6 MSC/kg); Allopurinol; Altropane; Amantadin-ratiopharm 100mg; Amantadine; Amantadine 300 mg; Amantadine HCl ER; Amantadine HCl Extended Release; Amantadine HCl Extended Release Capsule; Amantadine hydrochloride; Amantadine hydrochloride (HCl); Amantadine sulfate; Ambroxol; Ambroxol hydrochloride; Ammonia; Amoxicillin; Ampreloxetine; Ampreloxetine chydrochloride; Ampreloxetine hydrochloride; Ampyra; Ampyra first,; Anti-Parkinson medication; Antiparkinsonian Agent(s); Aplindore; Aplindore MR tablets; Apo-go; Apo-go®; Apokyn; Apomor; Apomorp; Apomorphine; Apomorphine 0.25% (2.5mg/ml); Apomorphine HCl injection; Apomorphine Hydrocloride; Apomorphine Hydrocloride Hemihydrate; Apomorphine Nasal Powder; Apomorphine hydrochloride; Apomorphine hydrochloride 1.8mg inhalation powder, pre-dispensed; Apomorphine hydrochloride 2.8mg inhalation powder, pre-dispensed; Apomorphine hydrochloride 4.0 mg inhalation powder, pre-dispensed; Apomorphine hydrochloride 5.8 mg inhalation powder, pre-dispensed; Apomorphine infusion; Aricept 5 mg-Filmtabletten; Aricept 5mg-Filmtabletten; Aripiprazole; Armodafinil; Artane; Atomoxetine; Atypical Antipsychotics; Autologous mesenchymal stem cells; Avalox; Azathioprine; Azilect; Azilect 1mg; Azilect®; B-CIT and SPECT imaging; B6, B12, L-methylfolate; BAVISANT HYDROCHLORIDE MONOHYDRATE; BEN-2001; BENSERAZIDE; BENSERAZIDE HYDROCHLORIDE; BF 2.649; BF 2.649 10 mg; BF 2.649 20 mg; BF 2.649 40 mg; BF 2.649 5 mg; BF2.649; BF2.649 (Pitolisant); BF2.649 (pitolisant); BI-Sifrol®; BIA; BIA 3-202; BIA 3-202 (200 mg); BIA 6-512; BIA 6-512 100 mg; BIA 6-512 100 mg dose; BIA 6-512 200 mg dose; BIA 6-512 25 mg; BIA 6-512 25 mg dose; BIA 6-512 400 mg; BIA 6-512 50 mg dose; BIA 9-1067; BIA 9-1067 (test); BIA 9-1067 15 mg; BIA 9-1067 25 mg; BIA 9-1067 30 mg; BIA 9-1067 5 mg; BIA 9-1067 micronized; BIA 9-1067 non-micronized; BIIB014; BIIB054; BIIB094; BOTOX; BOTULINUM TOXIN TYPE A; BROMOCRIPTINE; BTRX-246040; BTX-A; BYDUREON; Balance; Band; Bavisant; Bavisant dihydrochloride monohydrate; Beam; Bee venom; Behavioral: Assessment of cognition; Behavioral: Assessment of depression; Behavioral: Assessment of motor and non-motors symptoms of PD Evaluation of hyper- and hypodopaminergic behaviors; Behavioral: Assessment of quality of life; Behavioral: Assessment of severity of ICD (impulse control disorders); Behavioral: Assessment of severity of Parkinson Disease; Behavioral: Attention Control; Behavioral: Augmented Reality Multi-Modal Training; Behavioral: BCI-FIT active querying; Behavioral: BCI-FIT adaptive signal modeling; Behavioral: BCI-FIT language modeling; Behavioral: BCI-FIT multi-modal access; Behavioral: Balance & Strengthening Exercises; Behavioral: Balance Training; Behavioral: Brisk walking and balance training; Behavioral: Building Better Caregivers Workshop; Behavioral: CBT and sleep hygiene; Behavioral: CO-OP treatment protocol; Behavioral: Cognitive and Behavioral experimental tasks; Behavioral: Combined balance and brisk walking training; Behavioral: Conservative Measures for Orthostatic Hypotension; Behavioral: Dexterity; Behavioral: Dual Task; Behavioral: ECOCAPTURE; Behavioral: Emotion Assessment; Behavioral: Exercise; Behavioral: Exercise only; Behavioral: Flexibility and strengthening exercise; Behavioral: Gait and balance; Behavioral: Healthy age-matched controls; Behavioral: ICM_APATHY_TASKS; Behavioral: Levodopa or acupuncture; Behavioral: Low-Impact Exercise Control; Behavioral: Memory; Behavioral: PAT sessions; Behavioral: Participant open-response writing; Behavioral: Participant self-assessment surveys; Behavioral: Pelvic floor muscle exercise-based behavioral therapy; Behavioral: Phonation; Behavioral: Physical Therapy; Behavioral: Resistance Training; Behavioral: Rest; Behavioral: Role of dopamine; Behavioral: Single Task; Behavioral: Strength training; Behavioral: Tai Chi; Behavioral: Traditional Multi-Modal Training; Behavioral: Upper limb exercise; Behavioral: balance training; Behavioral: exercise; Behavioral: exercise+multi-modal sensory feedback (MMSF); Behavioral: gait and balance training program; Behavioral: physical exam and UPDRS part III assessment; Behavioral: stretching; Benserazide; Benzofuran; Berachin; Best Medical Treatment; Best médical treatment; Betaquik MCT supplement; Better; Bisphosphonates; BoNT-A; Bone marrow derived mesenchymal stem cells; Botox; Botulinum Toxin; Botulinum Toxin Type A; Botulinum Toxin Type B; Botulinum Toxin Type B (Myobloc); Botulinum Toxin: Xeomin; Botulinum toxin; Botulinum toxin type A; Bromocriptine; Bromocriptine and other dopamine agonists; Bumetanide; Bumetanide white, oblong, scored tablet; Bupleurum+Ginkgo; Buspirone; Buspirone Hydrochloride; Buspirone hydrochloride; Butylphthalide; Bydureon; Bydureon 2 mg powder and solvent for prolonged-release suspension; Byetta; Byetta 5 micrograms; CABERGOLINA; CAPTURE; CARBIDOPA; CARBIDOPA (FU); CARBIDOPA ANIDRA; CARBIDOPA FU; CARBIDOPA INN; CARBIDOPA LEVODOPA; CARBIDOPA MONOHYDRATE; CARBODOPA LEVADOPA; CBD; CD; CD-LD CR; CD-LD IR; CDNF; CEP-1347; CEP-1347 10mg; CEP-1347 50mg; CEP1347; CEP1347 25mg; CERE-120; CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN]); CERE-120: Adeno-Associated Virus Delivery of Neurturin; CERETEC (TM) Estabilizado; CIPRALEX; CJH1 (CLR4001); CLE; CLENBUTEROL HYDROCHLORIDE; CLOZAPINE; CO; COMTAN; COMTAN 200* 60 CPR 200 MG; COMTAN®; CP; CST-103; CST-139; CVD00118-E; CVL-751; CVN424 High Dose; CVN424 Low Dose; CVT-301; CVT-301 (Dose Level 1); CVT-301 (Dose Level 2); CVT-301 35mg; CVT-301 50mg; CVT-301 High Dose; CVT-301 Low Dose; CVT-301, LIP; CVXL-0107; CX-8998; CYMBALTA; Cabaser; Cabaseril; Cabaseril, 1,0 mg Tablette; Cabaseril, 2,0 mg Tablette; Cabergolina; Cabergoline; Caffeine; Caffeine 100-200 mg BID; Caffeine alkaloid; Calcium; Cannabidiol; Cannabidiol (CBD); Cannabis; Cannabis Oil; Cannabis, Medical; Capsaicin; Capsaicin vapor; Capsules containing: carbidopa (25 mg), levodopa (100 mg), entacapone (200 mg); Carbidopa; Carbidopa 20 mg; Carbidopa 200mg oral dose; Carbidopa 27.5 mg; Carbidopa 65 mg capsule; Carbidopa Levodopa; Carbidopa Monohydrate; Carbidopa and Levodopa 25mg/100mg; Carbidopa and Levodopa Tablets, USP; Carbidopa and Levodopa tablets, USP; Carbidopa monohydrate; Carbidopa, levodopa, entacapone; Carbidopa- Levodopa; Carbidopa-4'-Monophosphate; Carbidopa-Levodopa; Carbidopa-Levodopa 25 Mg-100 Mg Oral Tablet; Carbidopa-levodopa; Carbidopa/Levodopa, immediate release; Carbidopa/Levodopa/Entacapone; Carbidopa/l-dopa; Carbidopa/l-dopa/entacapone; Carbidopa/levodopa; Carbidopa/levodopa/entacapone; Carbidopamonohydraat; Carbodopa/levadopa; Carbon; Carnosine; Carnosine supplementation; Carvedilol; Catapres ampoules; Catapressan; Ceftriaxone; Cerebral Dopamine Neurotrophic Factor; Ceretec; Champix; Chloride; Chocolate; Cipralex; Circadin; Circadin®; Citalopram; Citalopram 20mg; Clarithromycin; Clarithromycin (Not used as of 4/2020); Clarium 50 mg Retardtabletten; Clartihromycin, amoxicillin, and omeprazole; Clenbuterol; Clenbuterol HCl; Clonazepam; Clonidine; Clonidine hydrochloride; Clozapine; CoFactor; CoQ10; Cocoa; Coenzyme Q10; Coenzyme Q10 Nanodispersion (Nanoquinone); Coenzyme Q10 with vitamin E; Coenzyme q10; Cogane; Cogane™ (PYM50028); Cohort 1:Nilotinib Oral Capsules (150mg or 300mg); Cohort 2: Nilotinib Oral Capsules (dose to be determined from Cohort 1); Combination Product: L-dopa 140 mg; Combination Product: L-dopa 35 mg; Combination Product: L-dopa 70mg; Combination Product: L-dopa 70mg/carbidopa 7mg; Combination Product: ND0612 Solution for SC infusion; Combination injection of EPO and G-CSF; Comparator: carbidopa; Comparator: levodopa; Comtan; Comtan®; ComtanÂ®; Comtess; Comtess®; Continuous Apomorphine infusion; Continuous Release Dopamine Agonists; Continuous Subcutaneous Lisuride Infusion; Continuous intrajejunal infusion of levodopa-carbidopa; Control; Controlled-release levodopa / carbidopa; Cord blood therapy; Cortef; Creatine; Cu(II)ATSM; CyberKnife; Cysteine; Cystoscopic injection of Botox into the urinary bladder; D-Serine; D-serine (~2g/day); DA-9701; DA-9805 45mg; DA-9805 90mg; DAAOI-P; DATSCAN; DC158AM; DCI; DCS; DEBRUMYL; DEFERIPRONE; DEXMEDETOMIDINA; DEXMEDETOMIDINE; DHA; DM; DM-1992; DMI; DNL151; DNL201; DNS-7801 (high dose); DNS-7801 (low-dose); DONEPEZIL; DOPS; DPA; DPA-714-PET/MRI; DUODOPA; DUODOPA®Intestinal Gel; DaTSCAN; DaTSCAN 74 MBq/ml solution for injection; DaTSCAN™; DaTSCAN™ Ioflupane (123I) Injection; DaTscan; Dacepton 5 mg/ml; Dacepton 5 mg/ml infuusioneste, liuos; Daily ingestion of Lactobacillus plantarum PS128; Darifenacin; Dark chocolate (85% cocoa); DatSCAN; Datscan; Deanol; Deanol pyroglutamate; Deferiprone; Deferiprone (Ferriprox); Deferiprone 20mg; Deferiprone 30mg; Deferiprone 600 mg delayed release tablet; Deferiprone DR; Desipramine; Desipramine (DMI); Desmopressin; Desmopressin Acetat; Desmotabs; Desmotabs® 0,2 mg Tabletten; Desmotabs® 0,2mg Tabletten; Determination of drug effects through amantadine cessation; Device: AHA Exergame System; Device: Abdominal compression; Device: ActiMyo recording; Device: Active tPCS; Device: Adaptor: Hakko Adaptor; Device: B-STN DBS; Device: Balance Training; Device: Balance Training with Nintendo Wii Fit; Device: CADD-Legacy ambulatory infusion pump; Device: CADD-Legacy® 1400 ambulatory infusion pump; Device: Carbon Fiber Ankle Foot Orthosis (AFO); Device: Clonidine (Catapressan); Device: Deep Brain Stimulation; Device: Infusion Pump: CADD-Legacy® 1400 Pump; Device: Inspiratory Muscle Training; Device: J-tube; Device: Jejunal extension tube; Device: Kinetra and Soletra (neurostimulator, Medtronic); Device: Light box ( Litebook company); Device: Light box (Litebook company); Device: MS Band 2; Device: Magnetic Resonance Imaging; Device: Massage with a spiky ball; Device: NJ-Tube: Silicon ED Tube; Device: Nebulizer; Device: OCT - TCE; Device: PEG tube; Device: Percutaneous endoscopic gastrostomy tube; Device: Renishaw Drug Delivery System; Device: Resistive respiratory loads; Device: SPECT imaging; Device: Sham tPCS; Device: SpotOn balance glasses; Device: Stimulator OFF; Device: Stimulator ON; Device: active tDCS; Device: deep brain stimulation; Device: functional Magnetic Resonance Imaging; Device: jejunal extension tube (J-tube); Device: percutaneous endoscopic gastrostomy tube (PEG tube); Device: sham compression; Device: sham tDCS; Dexdor; Dexmedetomidina; Dexmedetomidine; Dexmedetomidine Hydrochloride Infusion; Dextromethorphan; Diagnostic Test: Auto-Assessment Manikins (SAM); Diagnostic Test: Barcelona test (BT); Diagnostic Test: Beam test to predict falls; Diagnostic Test: Beck Depression Inventory-II (BDI-II); Diagnostic Test: Elecsys (Roche) Abeta42, Ttau and Ptau; Diagnostic Test: Flutemetamol F18 Injection; Diagnostic Test: Frontal assessment battery (FAB); Diagnostic Test: Global Deterioration Scale (GDS); Diagnostic Test: Lumipulse (Fujirebio) Abeta42, Ttau and Ptau; Diagnostic Test: Measurement of serum level of anti-dementia drug; Diagnostic Test: Memory alteration test (M@T); Diagnostic Test: Mini Cognitive Examination (MCE); Diagnostic Test: Neuropsychological assessment; Diagnostic Test: Positive and Negative Affect Scale (PANAS); Diagnostic Test: Respiratory Muscle Strength; Diagnostic Test: Rey-Osterrieth Complex Figure Test (ROCFT); Diagnostic Test: Spanish-Complutense Verbal Learning Test (TAVEC); Diagnostic Test: Supplementary Neuropsychological Assessment - Parkinson's Disease; Diagnostic Test: [18F]-RO6958948; Different diets; Dihydroergotoxine Mesylate; Dipivefrin; Dipivefrine; Dipraglurant; Ditropan elixir; Docosahexaenoic Acid (DHA); Docosahexaenoic acid; Domperidone; Domperidone (drug); Dompéridone; Donepezil; Donepezil Sandoz; Donepezil hydrochloride; Dopamine; Dopamine Agent; Dopamine Agonists (pramipexole, ropirinole); Dopaminergic Agonist + Apomorphine; Dopaminergic Agonists; Doxepin; Doxepin and Zopiclone; Droxidopa; Droxidopa 100 MG [Northera]; Duloxetine; Duloxetine hydrochloride; Duodopa; Duodopa LD/CD 20/5 mg/mL; Duodopa gel intestinale; Duodopa intestinal gel; Duodopa intestinalgel; Duodopa, 20 mg/ml + 5 mg/ml, intestinal gel; Duodopa, levodopa 20 mg/ml + carbidopa 5 mg/ml, intestinal gel; Dynacirc CR (Isradipine); E2007; EBIXA®; EGCG; ELC200; ELTOPRAZINE; EMD 128130; EMD128130; EN; ENA713; ENA713B; ENT-01; ENTACAPONA; ENTACAPONE; ENTACAPONE INN; EPI-589; EPI-743 200mg; EPI-743 400mg; ER CD-LD; ER tablet 100 mg AZD3241; ER tablet 25 mg AZD3241; ETHNODYNE VISIO; EXELON; EXENATIDE; Ebixa; Eliprodil; Elobixibat; Eltoprazine; Eltoprazine HCl; Eltoprazine Hydrochloride; Entacapon; Entacapona; Entacapone; Entacapone 400mg oral dose; Entacapone and carbidopa; Entecapone; Equal; Eradication of Helcobacter Pylori; Eradication therapy for H.pylori infection; Eradication therapy for Helicobacter pylori; Erythromycin; Erythropoietin; Erythropoietin human recombinant (EPOrh); Escitalopram; Escitalopram oxalate; Eszopiclone; Ethylmethylcarbamic acid 3-[(1S)-1-(dimethylamino)ethyl]phenyl ester (**See other 2 names below); Exametazime; Exelon; Exelon 4.6 mg/24 h transdermal patch; Exelon 9.5 mg/24 h transdermal patch; Exelon Patch; Exelon Patch (rivastigmine transdermal system); Exelon path transdermal; Exelon ®; Exenatide; Exenatide 10 micrograms; Exenatide 5 micrograms; Exenatide extended release 2mg (Bydureon); F-18 FPCIT; FB-101; FLECAINIDE ACETATE; FLORBETABEN (18F); FPF1100NW; FPFS-1169; Famotidine; Febuxostat; Ferriprox; Ferriprox 500 mg; Ferrprox (Deferiprone); Fesoterodine; Fetal porcine cells, Neurocell-PD; Filgrastim; Finamine tablets; Finasteride; Fipamezole; Fipamezole ODT; Fipamezole ODT Cohort 2; Fipamezole hydrochloride; Fipamezole hydrochloride 30 mg oral disintegrating tablets; Fipamezole hydrochloride 60 mg oral disintegrating tablets; Fipamezole hydrochloride 90 mg oral disintegrating tablets; Flecainide; Flecainide acetate; Flecainidum; Florbetapir F 18; Fludrocortisone; Flumazenil; Flutemetamol; Flutemetamol F18; Folic Acid, Vitamin B6, Vitamin B12; Folic acid; Foliglurax; Foliglurax 10 mg (treatment A); Foliglurax 30 mg (treatment B); Foscarbidopa; Foscarbidopa and Foslevodopa; Foslevodopa; G-CSF; GABAPENTIN; GABAPENTINA; GABAPENTINA KERN PHARMA; GENZ-682452; GM1 ganglioside; GM608; GOCOVRI; GPI 1485; GRF6021; GSH; GSK962040; GSK962040 (25 mg tablet); GZ/SAR402671; Gabapentin; Gabapentina; Galantamine; Ganoderma; Genetic: Optional pharmacogenetic assessment; Genz-682452-AU; Ghrelin; Ginkgo; Glial Cell Line-Derived Neurotrophic Factor (GDNF); Glial cell line-derived neurotrophic factor; Glucose; Glutathione; Glycerol; Glycerol Phenylbutyrate; Glycerol phenylbutyrate; Glycopyrrolate; Gold; Gold Nanocrystals; Grapefruit; Green Tea; Green Tea Polyphenols (EGCG/ECG); Group AD Anti-PD + Antidepressant; Group R Rasagiline; Group R+AD Rasagiline + Antidepressant; Guar gum; HB-adMSCs; HEC122505MsOH; HF0220; HP-3000 (ropinirole hydrochloride patch); HP-3000 placebo; HP-3000(ropinirole hydrochloride patch); Helicobacter pylori eradication therapy; Heptaminol; Heptaminol hydrochloride; Herbal Medicinal Mixture (Roucongrong, Heshouwu etc.); Hericium erinaceus mycelium; Heshouwu; High Protein. T-Diet plus Range; High dose AFFITOPE® PD03A + Adjuvant; High dose ANAVEX2-73; Human Amniotic Epithelial Stem Cells; Human Stem Cells; Human neural stem cell; Hydrocortisone; Hydrocortisone cream; Hydrocortisone cream 1%; Hydrocortisone cream 10mg/g FNA Fagron; Hydrogen; Hydrolyzed guar gum; I 123; I-123; I-123-5-IA85380; I123; IBEROGAST; IOFLUPANE (123I); IPRONIAZID; IPT803; IPX054 100 mg; IPX054 150 mg; IPX054 200 mg; IPX054 250 mg; IPX054 300 mg; IPX066; IPX066 145 mg; IPX066 145 mg LD; IPX066 195 mg; IPX066 195 mg LD; IPX066 245 mg; IPX066 245 mg LD; IPX066 95 mg; IPX066 95 mg LD; IPX066-145; IPX066-195; IPX066-245; IPX066-95; IPX203; IPX203 140 mg; IPX203 180 mg; IPX203 210 mg; IPX203 270 mg; IPX203 280 mg; IPX203 350 mg; IPX203 ER CD-LD; IR CD-LD; IR CD-LD (carbidopa-levodopa) tablets; IR LD / CD; IR LD/CD; IRL752; IRL790; IRX4204; ISC-hpNSC; ISTRADEFYLLINE; ITI-214; IV Apomorphine; IV Levodopa; IZD174; Idebenone; Immediate Release carbidopa/levodopa 10/100 mg; Immediate Release carbidopa/levodopa 25/100 mg; Immediate release carbidopa/levodopa; Impact; Incobotulinum Toxin A; IncobotulinumtoxinA; IncobotulinumtoxinA (100 Units); IncobotulinumtoxinA (75 Units); Infudopa i.v.; Infudopa s.c.; Infusions of young plasma; Inhaled VR040; Injection of Umbilical cord derived MSCs; Injection of apomorphine; Injection of normal saline; Inosine; Intracerebral microinjections; Intranasal Insulin; Intranasal glutathione - (in)GSH; Intravenous Infusion; Intravenous Levodopa; Intravenous and Oral n-acetyl cysteine; Intravesical injection of Botulinum A toxin; Ioflupane 123I (DATSCAN®); Ioflupane I 123; Ioflupane [123 I]; Ioflupane [123I]; Ipratropium; Ipratropium bromide (drug); Iproniazid; Ips-nsc cells; Isicom; Isoflurane; Isradipine; Isradipine CR 10mg; Isradipine CR 20mg; Isradipine CR 5mg; Istradefylline; Istradefylline ( KW-6002); Istradefylline (KW-6002); Istradefylline 20 mg; Istradefylline 20 mg or 40 mg; Istradefylline 40 mg; JM; JM-010; JM-010 group A; JM-010 group B; JNJ-31001074; JNJ31-31001074; JP 1730; JP-1730/F01; JP-1730/F02; JP-1730/F03; JZP-110; K0706; KDT-3594; KM-819; KW-6002; KW-6002 (istradefylline); KW-6356; KW-6356 High Dose; KW-6356 Low Dose; KW-6356 Middle Dose; KW-6356 X Dose; KW-6356 Y Dose; KW-6500; Ketone Ester Elite endurance Nutrition Drink; Ketone ester drink; Kinoquinone (proposed); L-123 Ioflupane; L-3-(3,4-Dihydroxyphenyl)alanine; L-DOPA; L-DOPS; L-Dopa; L-Dopa/ MODOPAR; L-dopa; L-methylfolate; L-tyrosine; LA; LCIG; LCIG (Duodopa); LD / BE; LD+DDCI; LD-DDCI; LD/CD; LEVODOPA; LEVODOPA (DC.IT) (FU); LEVODOPA / BENSERAZIDE 200 + 50 MG; LEVODOPA DC.IT FU; LEVODOPA INN; LEVODOPA/BENZERASIDE; LEVODOPA/CARBIDOPA; LISURIDE; LODALÈS®; LUBIPROSTONE; LY03003; LY03003 ( Rotigotine, extended-release microspheres); LY03003 (rotigotine extended release microspheres for intramuscular [IM] injection); LY03003( the name of rotigotine); LY03003(Rotigotine,extended-release microspheres); LY03009 F1; LY03009 F2; LY03009 F3; LY03009 F4; LY300164; LY3154207; Lactobacillus casei DG (Enterolactis duo®); Lactobacillus plantarum; Lactobacillus plantarum PS128; Lactose; Leptin; Leucine; Levetiracetam; Levodopa; Levodopa (L-DOPA) + Standard care; Levodopa (L-dopa); Levodopa (delivered intravenously); Levodopa (drug), intraduodenal administration; Levodopa / Benserazid; Levodopa 100 mg / benserazide 25 mg; Levodopa 100 mg A CAP; Levodopa 125 mg A CAP; Levodopa 150 mg A CAP; Levodopa 25mg/100mg; Levodopa 75 mg A CAP; Levodopa Benserazide Madopar; Levodopa Benserazide Teva Italia; Levodopa CR (controlled release); Levodopa Cyclops; Levodopa MR; Levodopa acute challenge; Levodopa and Domperidone; Levodopa and carbidopa; Levodopa and carbidopa SC solution; Levodopa and carbidopa solution for SC administration; Levodopa and decarboxylase inhibitor; Levodopa carbidopa (LC) oral encapsulated immediate release (IR) tablets; Levodopa carbidopa intestinal gel (LCIG); Levodopa dispersible; Levodopa infusion; Levodopa powder for inhalation; Levodopa tablet; Levodopa, carbidopa, ODM-104; Levodopa, carbidopa, entacapone; Levodopa, decarboxylase inhibitor and COMT inhibitor; Levodopa-4'-Monophosphate; Levodopa-Carbidopa; Levodopa-Carbidopa Intestinal Gel; Levodopa-Carbidopa Intestinal Gel (LCIG); Levodopa-Carbidopa Multilayer Extended Release Tablet; Levodopa-Carbidopa XL tablet (M); Levodopa-carbidopa; Levodopa-carbidopa (LC) oral encapsulated immediate release (IR) tablets; Levodopa-carbidopa Immediate Release (LC-IR) Tablets; Levodopa-carbidopa intestinal gel; Levodopa-carbidopa intestinal gel (LCIG); Levodopa-carbidopa-entacapone; Levodopa/Benzerazide; Levodopa/Carbidopa; Levodopa/Carbidopa (LD/CD); Levodopa/Carbidopa (Sinemet); Levodopa/Carbidopa Hydrate; Levodopa/Carbidopa Solution; Levodopa/Carbidopa(200mg/50mg); Levodopa/DDCI; Levodopa/benserazide; Levodopa/benserazide 100/25 mg; Levodopa/carbidopa; Levodopa/carbidopa 100/25; Levodopa/carbidopa hydrate; Levodopa/carbidopa solution; Levodopa/carbidopa/entacapone; Levodopa/dopa decarboxylase inhibitor; Liatermin; Liatermin (r-metHuGDNF); Lidocaine; Lingzhi (Ganoderma); Lipuro; Liquigen MCT oil; Liraglutide; Lisparin; Lisuride; Lisuride Hydrogenmaleate; Lisuride TTS; Lisuride TTS 10cm²; Lisuride TTS 20cm²; Lisuride Transdermal System; Lithium; Lixisenatide; Local Anesthesia (lidocaine hydrochloride); Local Trade Name, 2mg; Local Trade Name, 4mg; Local Trade Name, 8mg; Lodosyn®; Lovastatin; Low dose AFFITOPE® PD03A + Adjuvant; Lu 00-800; Lu AF28996; Lu AF82422; Lubiprostone; MANTADIX; MARS; MCT; ME2125 (safinamide mesilate); MEDI1341; MEMANTINE; MEMANTINE HYDROCHLORIDE; METHYLPHENIDATE HYDROCHLORIDE; MIRAPEXIN*30CPR 0,7MG; MK0657; MOCLOBEMIDE; MODAFINIL; MODOPAR; MOTILIUM; MOXIFLOXACINA CLORIDRATO; MSC; Madopar; Madopar 125 mg, orodispersible tablet; Madopar 200+50 mg; Madopar LT; Madopar® 125; Madopar® 250; Madopar® HBS; Madopar® HBS 125; Magnesium; Magnesium oxide; Maltodextrin; Mannitol; Mantadix; Masitinib; Masitinib mesylate; Mavoglurant; Melatonin; Melatonin PR; Melatonin(Circadin®); Melevodopa; Melevodopa and decarboxylase inhibitor; Melperon; Melperone; Melperone HCl; Memantin Orion; Memantine; Memantine (drug); Memantine hydrochloride; Mesdopetam; Mesdopetam (IRL790); Mesencephalic Neuronal Precursor Cells; Mesenchymal stem cells; Mestinon; Metabolic Cofactor Supplementation; Metformin; Methylphenidate; Methylphenidate (MPD); Methylprednisolone; Mg; Mid dose ANAVEX2-73; Midazolam; Midodrine; Minocycline; Minodronic acid; Mirabegron; Mirapex; Mirapex (pramipexole); Mirapex ER; Mirapex LA; Mirapexin; Mirapexin / Sifrol; Mirapexin extended release various strengths; Mirapexin/Sifrol; MitoQ; Moclobemide; Modafinil; Modafinil 50mg; Modal; Modiodal; Monoamine oxidase B inhibitors; Motilium; Moxifloxacin; Moxifloxacin infusion; Muscimol; Mémantine; N acetyl cysteine; N-0923; N-Acetylcysteine; N-acetylcysteine; N-acetylcysteine capsule; N.a.; N04BD02; NABILONE; NACOM 100; NACOM levodopa+cardidopa; NAL; NALOXONE HYDROCHLORIDE DIHYDRATE; NBTX-001; ND0611; ND0612; ND0612 (Levodopa/Carbidopa solution); ND1421; ND1587; ND1589; ND1590; ND1702; NERIXIA*IM EV 1F 25MG; NEUPRO; NEUPRO 2 mg/24 h parche transdérmico; NEUPRO 4 mg/24 h parche transdérmico; NEUPRO 6 mg/24 h parche transdérmico; NEUPRO 8 mg/24 h parche transdérmico; NEUPRO*28CER 2MG/24H; NEUPRO*28CER 4MG/24H; NEUPRO*28CER 6MG/24H; NEUPRO*28CER 8MG/24H; NEUPRO*7CER 4MG/24H; NEUPRO*7CER 6MG/24H; NEUPRO*7CER 8MG/24H; NEUROBLOC; NICOTINAMIDE; NICOTINE; NLY01; NMDA; NPC transplantation; NR2B NMDA Antagonist CP-101,606 (traxoprodil); NS 2330; NS2330; NT 101; NTCELL Implantation; NW-1015; NW-1015E, EMD 1195686, MSC2191632B; NYX-458; Nabilone; Nabilone 0.25 mg; Nacom; Nacom 100; Nalmefene; Naloxone; Naloxone Hydrochloride Dihydrate; Naltrexone; Nardil; Nebicapone; Nelotanserin; Neridronic Acid; Neridronic acid; Neu-120; Neupro; Neupro (Reference); Neupro 2 mg/24 h transdermal patch; Neupro 2mg/24 h transdermal patch; Neupro 2mg/24h transdermal patch; Neupro 4 mg/24 h transdermal patch; Neupro 4Mg/24Hr Transdermal Patch; Neupro 4mg/24 h transdermal patch; Neupro 4mg/24h transdermal patch; Neupro 6 mg/24 h transdermal patch; Neupro 6mg/24 h transdermal patch; Neupro 6mg/24h transdermal patch; Neupro 8 mg/24 h transdermal patch; Neupro 8mg/24h transdermal patch; Neupro®; Neuraceq; NeuroEPO; Neurobloc; Neurohormonal mechanisms; Neurpro; Niacin; Niacinamide; Nicorette 10mg/ 16 h; Nicorette 15 mg/ 16 h; Nicorette 5 mg/ 16 h; Nicotinamide; Nicotinamide Riboside; Nicotinamide riboside; Nicotine; Nicotine Nasal Spray 10 MG/ML (0.5 MG/SPRAY); Nicotine gum; Nicotine patch; Nicotine transdermal patch; Nicotinell; Nicotinell 17,5 mg/24-Stunden-Pflaster; Nicotinell 35 mg/24-Stunden-Pflaster; Nilotinib; Nilotinib 150mg oral capsule [Tasigna]; Nilotinib 300mg oral capsule [Tasigna]; Nitrogen; Normal Saline; Northera; Nortriptyline; Nortriptyline hydrochloride; Null; OC oral solution treatment A; OC oral solution treatment B; OC oral solution treatment C; OC oral solution treatment D; ODM-101; ODM-101 105mg Carbidopa; ODM-101 65mg Carbidopa; ODM-104; ONO-2160/CD; ONO-2370; ONO-2506PO; OPC; OSU 6162 similar to (-)-OSU 6162; OSU6162 similar to (-)-OSU 6162; OTHER NERVOUS SYSTEM DRUGS; OXB-102; OXN 10 mg / 5 mg PR; OXN 20 mg / 10 mg PR; OXN 5 mg/2.5 mg PR; OXYCODONE HYDROCHLORIDE; OXYTOCIN SYNTHETIC; Omeprazole; Onabotulinumtoxin A Injection; OnabotulinumtoxinA; Ondansetron; Ondansetron 8 mg film-coated tablets; Ondansetron hydrochloride dihydrate; Ongentys; Opicapone; Opicapone (OPC); Optimal drug therapy; Optimized antiparkinsonian treatment; Oral Levodopa/Carbidopa; Oral escitalopram; Oral levodopa and carbidopa; Orally disintegrating selegiline (Zelapar); Other Parkinson's Disease treatments; Other: Balance; Other: Balance Training; Other: Balance exercise; Other: Berg Balance Scale; Other: Best Medical Treatment; Other: Computer game based balance and walking rehabilitation for individuals with Parkinson's Disease; Other: Control; Other: Controlled environment tests (series of tasks of everyday life); Other: Controls Primary Cervical Dystonia (Trihexyphenidyl); Other: DYT 1 Dystonia; Other: DYT 1 Dystonia (Healthy Control); Other: Data Capture; Other: Diary completion; Other: Endurance; Other: Evaluation by Investigator; Other: Event-related evoked potential using electroencephalography (EEG).; Other: Four Square Step Test; Other: Functional Reach Test; Other: Functional mobility; Other: Gait and balance group training; Other: High intensity exercise and balance training; Other: Hoehn and Yahr Scale; Other: Imitation Surgical Procedure (ISP); Other: Lower Limb Strength; Other: MIBG label with I123 or I124; Other: MP+DDCI; Other: MP-Equivalent; Other: MP-Low; Other: MRI; Other: Mobile platform exercise; Other: Motor Assessments before taking regular PD treatment; Other: Motor Assessments on regular PD treatment; Other: Multidisciplinary intensive rehabilitation treatment; Other: Music; Other: Neupro 4 mg / 24 Hr. Transdermal Patch; Other: Non-Motor Symptoms; Other: Nordic walking (only osteoporosis group); Other: Observational cohort; Other: Optional Blood-Oxygen-level Dependent functionalMRI; Other: PD exercise intervention; Other: PD vitamin + exercise; Other: Parkinson mPower mobile application; Other: Physical Function Performance Test; Other: Physical Therapy; Other: Pittsburgh Compound B [11C]-PIB; Other: Questionnaires; Other: Recommendation with regard to nutrition; Other: Rhythmic Auditory Stimulation (RAS); Other: Rhythmic Balance-Movement Training (rBMT); Other: Rotigotine; Other: Saline; Other: Screening to prevent falls; Other: Sham Surgery; Other: Sham group; Other: Smartphone-based balance exercises; Other: Specific SL-therapy; Other: Standardized scales: MDS-UPDRS (Part II to IV) and RDRS; Other: Stool Sample; Other: Tampa Kinesiophobia Scale, Berg-Balance Test, International Physical Activity Questionnaire-Short Form, Falls Efficacy Scale; Other: Timed Up and Go Test; Other: Trunk Impairment Scale; Other: Unified Parkinson's Disease Rating Scale; Other: Usual care arm exercise; Other: Usual drug treatment of Parkinson's disease; Other: Voluntary cough test; Other: [11C]donepezil PET; Other: collection of CSF, blood, urine, saliva; Other: fog; Other: hemicellulose crystalline; Other: t-DCS group; Other: the timed 360° turn test; Other: tyramine; Over-encapsulated Entacapone Tablets; Over-encapsulated Modafinil; Oxaloacetate (OAA); Oxybate; Oxybuprocaine; Oxybutynin; Oxybutynin and darifenacin; Oxybutynin hydrochloride; Oxycodone; Oxycodone Hydrochloride; Oxycodone hydrochloride; Oxycodone/Naloxone Prolonged Release tablets; Oxycodone/naloxone prolonged release tablets 10 mg /5 mg; Oxycodone/naloxone prolonged release tablets 20 mg /10 mg; Oxycodone/naloxone prolonged release tablets 5 mg /2.5 mg; Oxygen; Oxytocin; P2B001; P2B001 once daily (pramipexole 0.3 mg / rasagiline 0.75 mg),; P2B001 once daily (pramipexole 0.6 mg / rasagiline 0.75 mg),; PARCOPA; PAT; PBF-509; PD patients H&Y=1.5-2 Medications OFF; PD patients H&Y=1.5-2 Medications ON; PD patients H&Y=3 Medications OFF; PD patients H&Y=3 Medications ON; PD vitamin supplementation; PEG; PERGOLIDE; PET; PF-06412562; PF-06649751; PF-06649751 - 15mg; PF-06649751 - 1mg; PF-06649751 - 5mg; PF-06649751 high dose (15 mg QD); PF-06649751 low dose (1 mg QD); PF-06649751 middle dose 1 (3 mg QD); PF-06649751 middle dose 2 (7 mg QD); PF-06669571; PK-Merz; PK-Merz® 200mg/500ml inj(Amantadine) , Normal saline 500ml inj; PR Oxycodone; PR001A; PRAMIPEXOLE; PRAMIPEXOLE DIHYDROCHLORIDE; PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE; PRIM-DJ2727; PROPOFOL; PROSCAR*30CPR RIV 5MG; PRX002; PRX002, ELT2, anti-alpha-synuclein monoclonal antibody; PT320 2.0 mg; PT320 2.5 mg; PXT002331; PXT002331 - 20mg; PXT002331 - dose 1; PXT002331 - dose 2; PYM50028; PYRIDOSTIGMINE BROMIDE; Paracetamol; Parapres; Parcopa; Pardaprunox; Pardoprunox; Pardoprunox hydrochloride; Paroxetine; Part 1, JM-010 component Group A; Part 1, JM-010 component Group B; Part 1, JM-010 component Group C; Part 2, JM-010 combination Group A; Part 2, JM-010 combination Group B; Part 2, JM-010 component Group C; Perampanel; Pergolide; Ph. Eur.: (2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid; Ph. Eur.: (2S)-3-(3,4-dihydroxyphenyl)-2hydrazino-2methylprop acid; PhEur.: (2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid; PhEur.: (2S)-3-(3,4-dihydroxyphenyl)-2hydrazino-2methylpropanoic acid; Phenlarmide Tablets; Phenylbutyrate; Piclozotan; Pilocarpine; Pimavanserin; Pimavanserin (ACP-103); Pimavanserin tartrate; Pimavanserin tartrate (ACP-103); Pioglitazone; Piribedil; Piribedil (Clarium); Pitolisant; Pittsburgh Compound B; Placebo; Plantago ovata husk; Posiphen; Positron Emission Tomography using [11 Carbon]-3-amino-4-(2-dimethylaminomethylphenylsulfanyl)-benzonitrile ([11C]-DASB) and [18 Fluorine]-altanserin ([18F]-altanserin); Positron Emission Tomography using [18 Fluorine]-altanserin ([18F]-altanserin); Pramipexol; Pramipexol Extended Release; Pramipexol Immediate Release; Pramipexole; Pramipexole 0.125 mg tablets; Pramipexole 0.5 mg tablets; Pramipexole ER; Pramipexole Extended Release; Pramipexole IR; Pramipexole Immediate Release; Pramipexole SR; Pramipexole dihydrochloride; Pramipexole dihydrochloride extended-release tablets; Pramipexole dihydrochloride monohydrate; Pramipexole dihydrochloride monohydrate extended release; Pramipexole extended release tablet; Pramipexole hydrochloride sustained-release tablet (Siforl®) Specification: 0.26mg/ tablet (in pramipexole); Pramipexole immediate release; Pramipexole immediate release tablet; Pramipexole or ropinirole; Praxol hydrochloride sustained release tablet Specification: 0.375mg/ tablet (in pramipexole hydrochloride); Prednisone; Preladenant; Preladenant 10 mg tablet; Preladenant 2 mg tablet; Preladenant 5 mg tablet; Premarin ®; Pridia (Donepezil Hydrochloride) 5mg; Pridia 10mg; Pridia 5mg; Pridopidine; Primary Cervical Dystonia (Trihexyphenidyl); Primavanserin tartrate; Prior Donepezil 5mg; Prior Donzepezil 10mg; ProSavin; Probiotic; Probiotic Capsule; Probiotics with prebiotic; Procedure: Biofluid samplings; Procedure: Blood analysis; Procedure: Cardiac monitoring; Procedure: DATscan and SPECT imaging; Procedure: Electroacupuncture; Procedure: Exergame; Procedure: Fluoroscopic swallow evaluation; Procedure: Home based balance training; Procedure: Lumbar Puncture; Procedure: MEG; Procedure: Motion Analysis; Procedure: PET/CT; Procedure: Percutaneous Endoscopic Gastrostomy with Jejunal Extension (PEG-J); Procedure: Sedation with IV propofol; Procedure: Sham Surgery; Procedure: Static, dynamic and functional balance exercises; Procedure: Static, dynamic and functional balance exercises with dual task; Procedure: Tissue samplings; Procedure: Umbilical cord blood therapy; Procedure: [123I]-IBZM imaging; Procedure: [123I]beta-CIT and SPECT imaging; Procedure: [123I]ß-CIT and SPECT imaging; Procedure: blood draw; Procedure: embryonic dopamine cell implant surgery; Procedure: physical exam and UPDRS part III assessment; Prolonged release tablet; Prolopa®; Propanoic acid; Propofol; Propofol-Lipuro; Propranolol; Propranolol HCl CF 40 mg tablet; Pyridostigmine; Pyridostigmine bromide; Quetiapine; R-(-)-1-(benzofuran-2-yl)-2-propylaminopentane hydrochloride; R-metHuGDNF; RAAV-GAD; RAS; RASAGILINA MESILATO; RASAGILINE; RASAGILINE MESILATE; RASAGILINE MESYLATE; REQUIP; REQUIP 21 CPR 0,25 MG; REQUIP 21 CPR 0,5 MG; REQUIP 21 CPR 1 MG; REQUIP 21 CPR 2 MG; REQUIP*21CPR 0,25MG; REQUIP*21CPR 0,5MG; REQUIP*21CPR 1MG; REQUIP*21CPR 5MG; REQUIP*28CPR 8MG R.P.; REQUIP-LP; REQUIP-MODUTAB , 2mg; REQUIP-MODUTAB , 4mg; REQUIP-MODUTAB , 8mg; REQUIP-MODUTAB, 2mg; REQUIP-MODUTAB, 4mg; REQUIP-MODUTAB, 8mg; RIV-TDS 13.3 mg/24 h; RM-131; RO; RO7046015; ROP; ROP+L-Dopa; ROPINIROLE; ROTIGOTINA; ROTIGOTINE; ROZEREM; RQ-00000010; RVG 08740; RVG 55618; RVT-101 35 mg; Raclopride; Racol; Radiation: Fluoroscopy; Radiation: H215O PET; Radiation: PET with the tracer 11C-PE2I; Radiation: PET with the tracer 18F-DPA-714; Radiation: Radiosurgical thalamotomy; Radiation: Videofluoroscopic swallow evaluation; Radiation: [18-Fluorine] Flubatine PET Scan; Ramelteon; Rasagilin; Rasagilina; Rasagilina mesilato; Rasagilina mesilato (12 weeks); Rasagiline; Rasagiline 1 mg capsule; Rasagiline 1mg tablet; Rasagiline 2 mg tablet; Rasagiline Mesylate; Rasagiline mesilate; Rasagiline mesylate; Rasagiline mesylate 1.0 mg; Rasagiline mesylate plus Mirapex; Rasagiline mesylate with Levodopa; Rasagiline mesylate with Requip; Rasagiline tablets; ReQuip CR; ReQuip PR; Recombinant human Cerebral Dopamine Neurotrophic Factor; Recombinant-methionyl human glial cell line-derived neurotrophic factor; Reduced Glutathione; Reduced Glutathione 100mg; Reduced Glutathione 200mg; Regular Novolin R; Remifentanil; Remifentanyl; Reminyl; Reminyl Retard; Repaglinide; Requip; Requip Modutab, 2mg; Requip Modutab, 4mg; Requip Modutab, 8mg; Requip PR; Requip XL prolonged-release; Requip prolonged release; Requip-Modutab; Resistant maltodextrin; Resistant starch; Restex Tabletten; Rifampicin; Rifampin; Rifampin 300mg BID + istradefylline 40mg Day 8 only; Rifaximin; Rifaximin 550 MG; Ritalin; Rivastigmin Luye Transdermal Patches - 4.6mg/24h; Rivastigmine; Rivastigmine CF; Rivastigmine Luye Transdermal Patch- 9.5mg/24h; Rivastigmine Patch 9.5 cm2; Rivastigmine Transdermal System; Rivastigmine capsule; Rivastigmine transdermal patch; Rivastigmine transdermal system 13.3 mg/24 h; Ropinirole; Ropinirole (as hydrochloride); Ropinirole CR 2mg tablet; Ropinirole CR 8mg tablet; Ropinirole Hydrochloride; Ropinirole IR; Ropinirole IR Tablets; Ropinirole Implant; Ropinirole PR; Ropinirole PR, 2mg; Ropinirole PR/XR; Ropinirole PR/XR Tablets; Ropinirole PR/XR tablets; Ropinirole Prolonged release; Ropinirole XL; Ropinirole XL (formerly CR); Ropinirole controlled-release (REQUIP CR) for RLS; Ropinirole hydrochloride; Ropinirole hydrochloride extended-release tablet; Ropinirole hydrochloride extended-release tablet placebo; Ropinirole hydrochloride prolonged release; Ropinirole immediate release; Ropinirole monotherapy; Ropinirole oral product; Ropinirole prolonged release; Ropinirole prolonged release/extended release(PR/XR); Ropinirole/L-dopa; Rosuvastatin; Rotigotin; Rotigotina; Rotigotine; Rotigotine (Reference product PR 2.1.1); Rotigotine (Test product PR 2.3.1); Rotigotine Nasal Spray; Rotigotine TTS (Test); Rotigotine hydrochloride; Rotigotine nasal spray; Rotigotine transdermal patch; Rotigotine transdermal patch 2mg/24h(10cm2); Rotigotine transdermal patch 4mg/24h (20cm2); Rotigotine transdermal patch 6mg/24h (30cm2); Rotigotine transdermal patch 8mg/24h (40cm2); Rotigotine, extended-release microspheres; Rozerem; Rytary 145 mg; Rytary 195 mg; S 90049; S 90049 - F36; S 90049 - F38; S.c. apomorphine; S90049; SA; SAFINAMIDE; SAFINAMIDE METANSOLFONATO; SAFINAMIDE METHANESULFONATE; SAGE-217; SAGE-718; SAM; SAM-e; SAR402671, GZ402671 or GZ/SAR402671; SARIZOTAN; SCH 420814; SCH 420814 10 mg; SCH 420814 100 mg; SCH 900800; SCH420814; SELEGILINE; SEP-363856; SER-214; SIFROL; SINEMET; SINEMET 10-100; SINEMET 100 mg + 25 mg compresse; SINEMET 125; SINEMET 25-100; SINEMET 25/100; SINEMET CR; SINEMET Plus; SINEMET*50CPR 100MG+25MG; SINEMET® Plus 25 mg/100 mg Tablets; SINEMET®-Plus Tablets; SIRIO*30CPR EFF 25MG+100MG; SK&F101468; SKF-101468A; SLV308; SLV308 (mono) hydro; SLV308 (mono) hydrochlo; SLV308 (mono) hydrochlori; SLV308 (mono) hydrochloride; SLV308 (mono)hydrochloride; SLV308 hydrochloride; SLV308(mono)hydrochloride; SMILAGENIN; SND 919 CL2 Y; SND 919 CL2Y; SNN0031; SOLIGEN; SPECT; SPM 926; SPM 962; SPM962; SQJZ herbal mixtures; SR57667B; STALEVO*100CPR 100/25/200MG; STALEVO*100CPR 50/12,5/200MG; SYN115; SYN115 Tablets, 60 mg; SYN120; Safety observation; Safinamida; Safinamide; Safinamide (as add-on therapy); Safinamide + Levodopa; Safinamide Methanesulfonate; Safinamide Methanesulfonate 100mg; Safinamide Methanesulfonate 150mg; Safinamide metansolfonato (12 weeks); Safinamide methansulfonate; Safinamide, MAO-B inhibitor; Safinimide 50-100 mg/day; Sage; Sage leaf; Saline; Saline Intranasal Delivery; Saracatinib; Sarcosine; Sarcosine Capsule; Sargramostim; Sarizotan; Sarizotan HC1; Sarizotan HCl; Sarizotan Hydrochloride; Sarizotan hydrochloride; Selegiline; Selegiline HCl 5 PCH; Semaglutide; Semi continuous intra-oral administration of LD/CD; Serine; Seroquel; Sertraline; Sevoflurane; Sifol; Sifrol; Sifrol 0,088; Sifrol 0,18; Sifrol 0,35; Sifrol 0,7; Sifrol, 0,35 mg Tablette; Sifrol, 0,70 mg Tablette; Sifrol, Mirapexin; Sifrol®; Sildenafil; Silicon; Silodosin; Simvastatin; Simvastatine; Sinemet; Sinemet (carbidopa/levodopa); Sinemet (comparator); Sinemet (levodopa/carbidopa); Sinemet 125 mg; Sinemet 200mg/50mg; Sinemet 25/100; Sinemet CR; Sinemet CR 25Mg-100Mg Extended-Release Tablet; Sinemet IR; Sinemet Plus; Sinemet plus; Sinemet plus (levodopa/carbidopa); Sinemet-Plus Tablets; Sinemet®; Sinemet® 100/25; Sinemet® 100/25 mg; Sinemet® CR; Sinemet® CR 100/25; Sinemet® controlled release (Carbidopa/levodopa); Sinemet®25-100; Sirolimus; Sitagliptin; Smilagenin; Sodium Oxybate; Sodium chloride; Sodium oxybate; Solifenacin; Solifenacin Succinate (VESIcare); Solifenacin succinate (VESIcare); Solu-Cortef; Solu-Cortef, powder for solution for injection, 100mg, and 'Act-O-Vial'; Solu-cortef; Sorbitol; Soy protein; Spheramine (BAY86-5280); Spiropent; Stalevo; Stalevo (levodopa/ carbidopa/ entacapone); Stalevo (levodopa/carbidopa/entacapona); Stalevo (levodopa/carbidopa/entacapone); Stalevo 100; Stalevo 100 mg/ 25 mg/ 200 mg Filmtabletten; Stalevo 100 mg/25 mg / 200 mg; Stalevo 100/25/200 mg; Stalevo 150; Stalevo 150/37.5/200 mg; Stalevo®; Standard LD/CD; Standard of Care; Stilnoct; Strattera; Study Drug; Subcutaneous apomorphine; Subcutaneous hydrocortisone 10mg; Subjects will undergo the 123-I IBVM imaging visit; Sugar Pill; Sugar pill; Sulfate; Sumanirole; Supplementation; Supressi. T-Diet plus Range; Suvorexant; Synthetic Oxytocin; Syntocinon; Syntocinon 40 IU/ml nasal spray; TACROLIMUS TABLETS; TAK-071; TAVAPADON; TCE; TCH346 (dibenz[b,f]oxepin-10-ylmethyl-prop-2-ynyl-amine, hydrogen maleate salt); TD-9855; TECHNETIUM (99MTC) EXAMETAZIME; THN02; THN102 Dosage A; THN102 Dosage B; THN102 Dosage C; TO; TOLCAPONE; TOPIRAMATE; TOZ; TOZADENANT; TRIGEL; TULOBUTEROL HYDROCHLORIDE; TVP-1012; TVP-1012 (1 mg/day) with levodopa; TVP-1012 0.5mg; TVP-1012 1mg; Tacrolimus; Tadalafil; Talampanel; Targinact 10 mg/5 mg prolonged-release tablets; Targinact 20 mg/10 mg prolonged-release tablets; Targinact 5 mg/2.5 mg prolonged-release tablets; Tasmar; Tavapadon; Tavapadon 0.25mg; Tavapadon 1mg; Tavapadon 5mg; Terazosin; Terazosin 5 MG; Tesofensine; Tigan; Tigan®; Tocovid Suprabio; Tolcapon; Tolcapone; Tolubuterol Hydrochloride; Topiramate; Topiramate (drug); Tozadenant; Tozadenant (SYN115) 120 mg BID; Tozadenant (SYN115) 180 mg BID; Tozadenant (SYN115) 240 mg BID; Tozadenant (SYN115) 60 mg BID; Traditional Chinese Medicinal Mixture (composed of Roucongrong and adjuvant); Transdermal flumazenil (Added 4/2020); Transdermal nicotine; Trihexyphenidyl; Trimethobenzamide; Trimethobenzamide Hydrochloride; Trivastal; Tropicamide; Tryptophan; Tryptophan (TRP) depletion; Tulobuterol; Tyramine; Tyrosine; UB-312; UCB0599; UCB7853; Ubiquinol; Urate; Ursodeoxycholic acid; Ursonorm; Usual dopaminergic per os treatment; V1512; V1512 and Entacapone; V81444; VARENICLINE; VARENICLINE TARTRATE; VIUSID/ALZER; VR040; VR040/Aspirair® inhaler; VY-AADC01; VY-AADC02; Valerian; Varenicline; Variation of behaviors of Parkinson's disease; Vehicle; Venglustat; Venglustat malate; Venlafaxine; ViNeuro; Vitamin B12; Vitamin B12 Supplementation; Vitamin B6; Vitamin D3; Vitamin D3 - high dose; Vitamin E; Vortioxetine; WD-1603; WD-1603 CARBIDOPA and LEVODOPA EXTENDED-RELEASE TABLETS; WD-1603 CARBIDOPA/LEVODOPA EXTENDED-RELEASE TABLETS; WIN-1001X; Warfarin; Water; Whey protein; White chocolate (0% cocoa); Wuling Powder; XADAGO (safinamide); XC130-A10H; XP21279; XP21279 and carbidopa (experimental); Xadago; Xeomin; Xiaoyao Pill; Yohimbine; Yohimbine HCl; Zelapar; Zoledronic Acid 5Mg/Bag 100Ml Inj; Zoledronic acid; Zolmitriptan; Zolpidem; Zolpidem Tartrate; Zolpidem first dose; Zolpidem second dose; Zonegran; Zonisamide; Zonisamide Capsules; Zopiclone; [11C]PBR28; [11C]PXT012253; [11C]SMW139; [123I] 5-IA; [123I] IBVM and SPECT imaging; [123I] mZINT injection and serial dynamic SPECT imaging; [123I]-IBVM; [123I]B-CIT; [123I]B-CIT SPECT imaging; [123I]CLINDE; [123I]MNI-420; [123I]beta CIT; [123I]beta CIT and SPECT imaging; [123I]beta-CIT; [123I]beta-CIT and SPECT imaging; [123I]ß CIT; [123I]ß CIT and SPECT imaging; [123I]ß-CIT; [123I]ß-CIT and SPECT imaging; [14C]-BIA 9-1067; [15O]H2O; [18F] CFPyPB; [18F] LBT-999; [18F] LBT-999 PET; [18F] PBR06; [18F]-(E)-N-(3-iodoprop-2-enyl)-2b-carbofluoroethoxy-3b-(4'-methylphenyl)nortropane; [18F]-FEPPA; [18F]DPA-714 PET scan; [18F]FDOPA; [18F]FDOPA PET/CT; [18F]FE-PE2I; [18F]FPEB; [18F]MK-9470; [18F]MNI-1126; [18F]MPPF; [18F]NOS; [18F]P17-059; [18F]PI-2620; [18F]T807 ([18F]MNI-777); [21CFR640.30] Plasma from 18 - 25 year old volunteer donors; [ABBV-951]; [F-18] Fluorodopa Positron Emission Tomography; [JNJ31-31001074]; [NA]; [na]

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04468919 (ClinicalTrials.gov)	July 1, 2021	8/7/2020	Optimizing BCI-FIT: Brain Computer Interface - Functional Implementation Toolkit	Optimizing BCI-FIT: Brain Computer Interface - Functional Implementation Toolkit	Amyotrophic Lateral Sclerosis;Brainstem Stroke;Muscular Dystrophies;Parkinson's Disease and Parkinsonism;Multiple System Atrophy;Brain Tumor Adult;Spinal Cord Injuries;Locked-in Syndrome	Behavioral: BCI-FIT multi-modal access;Behavioral: BCI-FIT adaptive signal modeling;Behavioral: BCI-FIT active querying;Behavioral: BCI-FIT language modeling	Oregon Health and Science University	NULL	Not yet recruiting	18 Years	75 Years	All	60	N/A	United States
2	NCT03309514 (ClinicalTrials.gov)	June 2021	10/10/2017	Transplantation of Neural Stem Cell-Derived Neurons for Parkinson's Disease	Clinical Investigation of Transplantation of Neural Stem Cell-derived Neurons for the Treatment of Parkinson's Disease	Parkinson's Disease	Biological: Intracerebral microinjections	NeuroGeneration	NULL	Not yet recruiting	35 Years	85 Years	All	12	Phase 1;Phase 2	NULL
3	NCT04287543 (ClinicalTrials.gov)	May 2021	21/2/2020	Melatonin on Clock Genes in Parkinson's Disease	Effect of Melatonin Administration on the PER1 and BMAL1 Clock Genes in Patients With Parkinson's Disease	Parkinson Disease	Drug: Melatonin;Drug: Placebos	Instituto Mexicano del Seguro Social	NULL	Withdrawn	20 Years	N/A	All	0	Phase 2;Phase 3	Mexico
4	NCT04322461 (ClinicalTrials.gov)	March 15, 2021	24/3/2020	Effect of Exercise, Endocannabinoids and Ketones on Cerebral Metabolism in a Cognitive Disorders Population	Effect of Exercise, Endocannabinoids and Ketones on Cerebral Metabolism in a Cognitive Disorders Population : Pilot Project PARKA	Parkinson Disease;Alzheimer Disease	Dietary Supplement: Betaquik MCT supplement	Université de Sherbrooke	Nestlé	Not yet recruiting	60 Years	N/A	All	20	N/A	NULL
5	NCT04665869 (ClinicalTrials.gov)	March 15, 2021	7/12/2020	Long-term Effects of Combined Balance and Brisk Walking in Parkinson's Disease	Long-term Effects of Combined Balance and Brisk Walking on Alleviating Motor and Non-motor Symptoms in Parkinson's Disease: a Randomized Controlled Trial	Parkinson Disease	Behavioral: Combined balance and brisk walking training;Behavioral: Flexibility and strengthening exercise	The Hong Kong Polytechnic University	NULL	Not yet recruiting	30 Years	80 Years	All	70	N/A	NULL
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
6	JPRN-jRCTs041190126	01/02/2021	10/03/2020	Study on efficacy and safety of zonisamide in at-risk subjects of Lewy body disease	Study on efficacy and safety of zonisamide in at-risk subjects of Lewy body disease - NaT-PROBEi	Lewy body disease (Parkinson's disease and dementia with Lewy bodies)	Arm zonisamide: 1.Two tablets of zonisamide 25mg after breakfast for 4 weeks 2.Four tablets of zonisamide 25mg after breakfast for 92 weeks Arm placebo: 1.Two tablets of placebo after breakfast for 4 weeks 2.Four tablets of placebo after breakfast for 92 weeks	Katsuno Masahisa	Japan Agency for Medical Research and Development	Pending	>= 50age old	< 80age old	Both	30	Phase 2	Japan
7	NCT04373317 (ClinicalTrials.gov)	January 1, 2021	29/4/2020	Pimavanserin vs. Quetiapine for the Treatment Parkinson's Psychosis	CSP #2015 - Multicenter, Randomized, Double-blind Comparator Study of Antipsychotics Pimavanserin and Quetiapine for Parkinson''s Disease Psychosis (C-SAPP)	Parkinson's Disease Psychosis	Drug: Pimavanserin;Drug: Quetiapine	VA Office of Research and Development	NULL	Not yet recruiting	40 Years	N/A	All	358	Phase 4	United States
8	NCT04625361 (ClinicalTrials.gov)	January 1, 2021	9/11/2020	Single and Multiple Dose Safety, Tolerability, PK and Food Effect Study of HEC122505MsOH Tablets in Healthy Adult Subjects	A Single Center, Randomized, Double-Blind, Placebo-Controlled Study of Single/Multiple Ascending Doses to Evaluate the Safety, Tolerability, Pharmacokinetics, and Single Center, Randomized, Double-Blind, Two Periods, Crossover, Food Effect Study of HEC122505MsOH Tablets in Healthy Chinese Subjects	Parkinson Disease	Drug: HEC122505MsOH	Sunshine Lake Pharma Co., Ltd.	NULL	Not yet recruiting	18 Years	45 Years	All	102	Phase 1	China
9	NCT04497168 (ClinicalTrials.gov)	January 2021	29/7/2020	Citalopram as a Posterior Cortical Protective Therapy in Parkinson Disease	Citalopram as a Posterior Cortical Protective Therapy in Parkinson Disease	Parkinson Disease	Drug: Citalopram 20mg;Drug: Placebo	University of Michigan	National Institute on Aging (NIA)	Not yet recruiting	65 Years	N/A	All	58	Phase 2	United States
10	NCT04590612 (ClinicalTrials.gov)	January 2021	17/9/2020	Improving Quality of Life in Early Parkinson's Disease	The Effects of Mood Symptoms Treatment on Quality of Life and Motor Function in de Novo Parkinson's Disease Patients	Parkinson Disease;Depression	Drug: Carbidopa -Levodopa 25 Mg-100 Mg Oral Tablet;Drug: Citalopram	Western University, Canada	NULL	Not yet recruiting	50 Years	80 Years	All	30	N/A	NULL
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
11	NCT04643327 (ClinicalTrials.gov)	January 2021	18/11/2020	Uncovering a Novel Therapeutic Target to Reduce Dementia Risk in Parkinson's Disease	Double-blind Randomised-controlled Within-subject Crossover Trial to Determine Levetiracetam Efficacy for Memory Impairment in Parkinson's Disease: A Proof-of-concept Study	Parkinson Disease;Mild Cognitive Impairment;Memory Impairment	Drug: Levetiracetam;Drug: Placebo	The University of Queensland	Queensland University of Technology;Johns Hopkins University;Cleveland Clinic Lou Ruvo Center for Brain Health;Royal Brisbane and Women's Hospital	Not yet recruiting	N/A	N/A	All	28	Phase 2	NULL
12	NCT04491383 (ClinicalTrials.gov)	January 2021	22/7/2020	Tocotrienols in Parkinson's Disease (PD)	Tocotrienols in Parkinson's Disease (PD): A Pilot, Randomised, Placebo-controlled Trial	Neuro-Degenerative Disease;Parkinson Disease	Drug: Tocovid Suprabio;Other: Placebo	National Neuroscience Institute	Hovid Berhad	Not yet recruiting	50 Years	90 Years	All	100	Phase 2	Singapore
13	NCT04584346 (ClinicalTrials.gov)	December 17, 2020	10/10/2020	Acute Effects of Medium Chain Triglyceride (MCT) Nutritional Ketosis on Parkinson's Disease (PD) Symptoms and Biomarkers (MCT-PD)	Acute Effects of Medium Chain Triglyceride (MCT) Nutritional Ketosis on Parkinson's Disease (PD) Symptoms and Biomarkers (MCT-PD)	Parkinson's Disease	Dietary Supplement: Liquigen MCT oil	National Institute of Neurological Disorders and Stroke (NINDS)	NULL	Recruiting	50 Years	N/A	All	32	Phase 1	United States
14	NCT04377945 (ClinicalTrials.gov)	December 1, 2020	4/5/2020	Study in Parkinson's Disease Patients With Dyskinesia With Combinations of JM-010 and Its Individual Components	A Randomized, Double-Blind, Placebo-Controlled, Two-Part Study in Parkinson's Disease Patients With Dyskinesia to Assess the Efficacy and Safety/Tolerability of Fixed Dose Combinations of JM-010 and Its Individual Components	Dyskinesia, Drug-Induced	Drug: Part 1, JM-010 component Group A;Drug: Part 1, JM-010 component Group B;Drug: Part 1, JM-010 component Group C;Drug: Part 1, Placebo Group;Drug: Part 2, JM-010 combination Group A;Drug: Part 2, JM-010 combination Group B;Drug: Part 2, Placebo Group;Drug: Part 2, JM-010 component Group C	Bukwang Pharmaceutical	NULL	Not yet recruiting	18 Years	80 Years	All	188	Phase 2	United States
15	NCT04651153 (ClinicalTrials.gov)	December 2020	25/11/2020	A Safety and Pharmacokinetics Study of UCB7853 in Healthy Study Participants and Study Participants With Parkinson's Disease (PD)	A Multicenter, Participant-Blind, Investigator-Blind, Randomized, Placebo-Controlled Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of UCB7853 in Healthy Male Study Participants and Multiple Ascending Doses in Patients With Parkinson's Disease	Parkinson's Disease	Drug: UCB7853;Other: Placebo	UCB Biopharma SRL	NULL	Not yet recruiting	18 Years	80 Years	All	64	Phase 1	NULL
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
16	NCT04147949 (ClinicalTrials.gov)	December 2020	27/10/2019	AV-101 (L-4-chlorokynurenine) in Parkinson's Disease Subjects With Levodopa-Induced Dyskinesia	Randomized, Double-Blind, Placebo-Controlled, Crossover, Proof-of-Concept Phase 2 Study to Test Efficacy and Safety of AV-101 (L-4-chlorokynurenine) in Parkinson's Disease Subjects With Levodopa-Induced Dyskinesia	Parkinson Disease;Dyskinesia, Medication-Induced;L-Dopa Causing Adverse Effects in Therapeutic Use	Drug: AV-101;Drug: Placebo	VistaGen Therapeutics, Inc.	NULL	Not yet recruiting	30 Years	80 Years	All	20	Phase 2	NULL
17	NCT04346394 (ClinicalTrials.gov)	December 2020	10/3/2020	The Role of the Noradrenergic System in the Nonmotor Symptoms of Parkinson's Disease	The Role of the Noradrenergic System in the Nonmotor Symptoms of Parkinson's Disease: Orthostatic Hypotension and Other Nonmotor Symptoms	Parkinson Disease	Drug: Yohimbine HCl	Nathaniel M. Robbins	NULL	Not yet recruiting	N/A	N/A	All	22	Early Phase 1	NULL
18	NCT04658186 (ClinicalTrials.gov)	December 2020	1/12/2020	A 18-month Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Oral UCB0599 in Study Participants With Early-stage Parkinson's Disease	A Double-Blind, Placebo-Controlled, Randomized, 18-Month Phase 2a Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Oral UCB0599 in Study Participants With Early Parkinson's Disease	Early-stage Parkinson's Disease	Drug: UCB0599;Drug: Placebo	UCB Biopharma SRL	NULL	Not yet recruiting	40 Years	70 Years	All	300	Phase 2	NULL
19	NCT04634331 (ClinicalTrials.gov)	November 15, 2020	9/11/2020	Dual-task Augmented Reality Treatment for Parkinson's Disease	Dual-task Augmented Reality Treatment for Parkinson's Disease (DART)	Parkinson Disease	Behavioral: Augmented Reality Multi-Modal Training;Behavioral: Traditional Multi-Modal Training	The Cleveland Clinic	Michael J. Fox Foundation for Parkinson's Research	Recruiting	18 Years	N/A	All	50	Phase 2	United States
20	EUCTR2019-003315-60-NL (EUCTR)	10/11/2020	08/10/2020	A study investigating the effect and safety of a new potential drug for Parkinson's disease patients.	A phase 1/2 study investigating the pharmacokinetics, safety and efficacy of a highly concentrated buccal formulation of apomorphine (APORON®) in subjects with Parkinson's Disease - Buccal apomorphine (APORON) administration	Parkinson's Disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Apo-go Product Name: APO-go ® INN or Proposed INN: Apomorphine Other descriptive name: APOMORPHINE HYDROCHLORIDE HEMIHYDRATE Product Name: APORON INN or Proposed INN: APORON Other descriptive name: APOMORPHINE HYDROCHLORIDE HEMIHYDRATE	Criceto IKM B.V.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	46	Phase 1;Phase 2	Netherlands
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
21	NCT04620382 (ClinicalTrials.gov)	November 9, 2020	27/10/2020	Effect of Midodrine vs Abdominal Compression on Cardiovascular Risk Markers in Autonomic Failure Patients	Effect of Midodrine vs Abdominal Compression on Cardiovascular Risk Markers in Autonomic Failure Patients	Neurogenic Orthostatic Hypotension;Autonomic Failure;Pure Autonomic Failure;Multiple System Atrophy;Parkinson Disease	Drug: Midodrine;Drug: Placebo pill;Device: Abdominal compression;Device: sham compression	Vanderbilt University Medical Center	NULL	Recruiting	40 Years	80 Years	All	31	Early Phase 1	United States
22	NCT04506073 (ClinicalTrials.gov)	November 9, 2020	16/7/2020	Phase IIa Randomized Placebo Controlled Trial: Mesenchymal Stem Cells as a Disease-modifying Therapy for iPD	Allogeneic Bone Marrow-derived Mesenchymal Stem Cells as a Disease-modifying Therapy for Idiopathic Parkinson's Disease: Phase IIa Double-blind Randomized Placebo Controlled Trial	Parkinson's Disease	Drug: MSC+placebo;Drug: MSC;Drug: Placebo	The University of Texas Health Science Center, Houston	Michael J. Fox Foundation for Parkinson's Research	Recruiting	50 Years	79 Years	All	45	Phase 2	United States
23	EUCTR2019-004235-23-NL (EUCTR)	09/11/2020	26/05/2020	Parkinson's Disease: An extension of Study M15-741 evaluating the safety and tolerability of ABBV-951 in subjects with Parkinson's disease.	An open-label extension of Study M15-741 to evaluate the safety and tolerability of 24-hour daily exposure of continuous subcutaneous infusion of ABBV-951 in subjects with Parkinson's disease.	Parkinson's Disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Foscarbidopa and Foslevodopa Product Code: ABBV-951 INN or Proposed INN: Foslevodopa Other descriptive name: Levodopa -4'-Monophosphate INN or Proposed INN: Foscarbidopa Other descriptive name: Carbidopa -4'-Monophosphate	Abbvie Deutschland GmbH & Co. KG	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	130	Phase 3	United States;Canada;Australia;Russian Federation;Netherlands;Italy;United Kingdom;Japan
24	EUCTR2019-002952-17-CZ (EUCTR)	04/11/2020	12/10/2020	A clinical trial which runs in multiple countries and aims to evaluate the long-term safety and tolerability of the investigational product (TAVAPADON) for patients diagnosed with Parkinson's Disease	58-Week Open-label Trial of Tavapadon in Parkinson’s Disease (TEMPO-4 Trial) - TEMPO-4	Patients (40 to 80 years age) who have diagnosis of Parkinson's Disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Tavapadon 5mg Product Code: CVL-751 INN or Proposed INN: TAVAPADON Other descriptive name: PF-06649751 Product Name: Tavapadon 1mg Product Code: CVL-751 INN or Proposed INN: TAVAPADON Other descriptive name: PF-06649751 Product Name: Tavapadon 0.25mg Product Code: CVL-751 INN or Proposed INN: TAVAPADON Other descriptive name: PF-06649751	Cerevel Therapeutics, LLC	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	854	Phase 3	United States;Serbia;Spain;Ukraine;Israel;Italy;France;Czech Republic;Hungary;Canada;Poland;Australia;Bulgaria;Germany
25	NCT04277247 (ClinicalTrials.gov)	November 2, 2020	10/2/2020	Botulinum Toxin Type A for Foot Dystonia-associated Pain in Parkinson's Disease	Botulinum Toxin A (Onabotulinumtoxin A) for Foot Dystonia-associated Pain in Parkinson's Disease: A Randomized, Double-blind Placebo Control Study	Dystonia Disorder;Parkinson Disease	Drug: Botulinum toxin type A;Drug: Placebo	University of Calgary	Allergan	Recruiting	30 Years	100 Years	All	40	Phase 2;Phase 3	Canada
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
26	ChiCTR2000038937	2020-11-01	2020-10-10	Clinical study of early diagnosis of Parkinson's disease based on substantia nigra-striatal axis multimodal imaging	Clinical study of early diagnosis of Parkinson's disease based on substantia nigra-striatal axis multimodal imaging	Parkinson's disease	Gold Standard:Clinical diagnosis by experienced movement disorder specialists after 2 years of follow-up.;Index test:Including traditional imaging feature algorithms (SUVR value, total cortical volume, bilateral cortical surface area, cortical thickness, etc.), high-dimensional imaging omics feature algorithms (energy entropy, gray-level co-occurrence matrix, and mutual information, etc.), and brain connection group Learning feature algorithm.;	Huashan Hospital, Fudan University	NULL	Recruiting	45	80	Both	Target condition:105;Difficult condition:0		China
27	NCT03903549 (ClinicalTrials.gov)	November 1, 2020	3/4/2019	Initial Investigation of [18F]P17-059 in Parkinson's Disease Patients and Healthy Volunteers	A Positron Emission Tomography (PET) Study to Investigate [18F]D6-FP-DTBZ ([18F]P17-059) for Potential Use as a Radioligand for Vesicular Monoamine Transporter (VMAT2)	Parkinson Disease	Drug: [18F]P17-059	Five Eleven Pharma, Inc.	NULL	Not yet recruiting	45 Years	90 Years	All	26	Phase 1	United States
28	NCT04386317 (ClinicalTrials.gov)	November 1, 2020	24/4/2020	Terazosin Effect on Cardiac Changes in Early Parkinson's Disease	The Effect of a1- Adrenergic Receptor Antagonist Therapy on Cardiac and Striatal Transporter Uptake in Pre-Motor and Symptomatic Parkinson's Disease	REM Sleep Behavior Disorder;Pre-motor Parkinson's Disease;Symptomatic Parkinson Disease	Drug: Terazosin	Cedars-Sinai Medical Center	NULL	Recruiting	25 Years	85 Years	All	15	Phase 2	United States
29	NCT04435431 (ClinicalTrials.gov)	October 29, 2020	15/6/2020	A Clinical Study of Mesdopetam in Patients With Parkinson's Disease Experiencing Levodopa Induced Dyskinesia	A Randomized, Double-blind, Placebo-controlled Phase IIB Study Evaluating the Efficacy of Mesdopetam on Daily ON-time Without Troublesome Dyskinesia in Patients With Parkinson's Disease	Parkinson Disease	Drug: Mesdopetam;Drug: Placebo	Integrative Research Laboratories AB	NULL	Recruiting	30 Years	79 Years	All	140	Phase 2	United States
30	NCT04542499 (ClinicalTrials.gov)	October 27, 2020	2/9/2020	Flexible-Dose, Adjunctive Therapy Trial in Adults With Parkinson's Disease With Motor Fluctuations	A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Flexible-Dose, 27-Week Trial to Evaluate the Efficacy, Safety, and Tolerability of Tavapadon as Adjunctive Therapy for Parkinson's Disease in Levodopa-Treated Adults With Motor Fluctuations (TEMPO-3 Trial)	Parkinson Disease	Drug: Tavapadon;Drug: Placebo	Cerevel Therapeutics, LLC	NULL	Recruiting	40 Years	80 Years	All	368	Phase 3	United States;Australia;Czechia;Germany;Hungary;Poland
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
31	JPRN-jRCTs031200172	26/10/2020	26/10/2020	Effects of Elobixibat administration in patients with Parkinson's syndrome complicated with chronic constipation	Multicenter, Placebo-Controlled, Randomized, Double-Blind, Parallel-Group Study Investigating the Efficacy and Safety of Elobixibat in Patients with Parkinson's Disease Complicating Chronic Constipation. - CONST-PD	Parkinson's disease, chronic constipation Parkinson's syndrome,chronic constipation,Symptomatic constipation	Take 10mg of Elobixibat or placebo once a day before meal. After the 2-week screening period, the study drug will be started on the day of enrollment.	Hatano Taku	Mochida Pharmaceutical Co., Ltd.;EA Pharma Co., Ltd.	Recruiting	>= 20age old	Not applicable	Both	100	N/A	Japan
32	NCT03947216 (ClinicalTrials.gov)	October 23, 2020	7/5/2019	Randomized Placebo Controlled Trial Evaluating the Efficacy of Pimavanserin, a Selective Serotonin 5-HydroxyTryptamine-2A (5HT2A) Inverse Agonist, to Treat Impulse Control Disorders in Parkinson's Disease.	Study of Pimavanserin Efficacy for the Treatment of Impulse Control Disorders in Parkinson's Disease	Parkinson Disease	Drug: Active drug: pimavanserin 17mg (2 strength tablets);Drug: Placebo: 2 tablets containing same excipients except active compound;Behavioral: Assessment of severity of ICD (impulse control disorders);Behavioral: Assessment of motor and non-motors symptoms of PD Evaluation of hyper- and hypodopaminergic behaviors;Behavioral: Assessment of quality of life;Behavioral: Assessment of depression;Behavioral: Assessment of cognition;Behavioral: Assessment of severity of Parkinson Disease;Procedure: Blood analysis;Procedure: Cardiac monitoring	University Hospital, Strasbourg, France	NS-PARK;EUCLID;F-CRIN	Recruiting	35 Years	75 Years	All	130	Phase 2	France
33	EUCTR2020-003796-17-GB (EUCTR)	22/10/2020	01/09/2020	A study to look at the effect of CST-103 or CST-139 on blood flow in the brain and on memory.	An Open-Label Brain Imaging and Cognition Study to Determine Changes in Cerebral Perfusion and Cognition After Oral Administration of CST-103 or CST-139	Patients with Mild Cognitive Impairment or Parkinson’s Disease MedDRA version: 21.1;Level: LLT;Classification code 10009846;Term: Cognitive impairment;System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Spiropent Product Name: Clenbuterol HCl Product Code: CST-103 INN or Proposed INN: CLENBUTEROL HYDROCHLORIDE Trade Name: Berachin Product Name: Tulobuterol Product Code: CST-139 INN or Proposed INN: Tolubuterol Hydrochloride Other descriptive name: TULOBUTEROL HYDROCHLORIDE	CuraSen Therapeutics, Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	32	Phase 2	United Kingdom
34	NCT04334317 (ClinicalTrials.gov)	October 21, 2020	30/3/2020	Effect of TAK-071 on Falls in Participants With Parkinson Disease (PD)	A Randomized, Double-blind, Placebo-Controlled, 2-Period Crossover, Phase 2 Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Oral TAK-071 in Parkinson Disease Patients With Cognitive Impairment and an Elevated Risk of Falls	Parkinson's Disease	Drug: TAK-071;Drug: Placebo	Takeda	Michael J. Fox Foundation for Parkinson's Research	Recruiting	40 Years	85 Years	All	64	Phase 2	United States
35	ChiCTR2000038852	2020-10-20	2020-10-07	Study on the effect and mechanism of cognitive-cup-tapping-balance-training on fall prevention in community Parkinson's patients: a randomized controlled trial	Study on the effect and mechanism of cognitive-cup-tapping-balance-training on fall prevention in community Parkinson's patients: a randomized controlled trial	Parkinson's disease	dual task training group :cognitive-cup-tapping balance training;single task training group:-cup-tapping balance training;control group:education;	Shanghai University of Sport	NULL	Recruiting	40	80	Both	dual task training group :29;single task training group:29;control group:29;	N/A	china
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
36	NCT04380142 (ClinicalTrials.gov)	October 19, 2020	6/5/2020	Study Comparing Continuous Subcutaneous Infusion Of ABBV-951 With Oral Carbidopa/Levodopa Tablets For Treatment Of Motor Fluctuations In Adult Participants With Advanced Parkinson's Disease	A Randomized, Double-Blind, Double-Dummy, Active-Controlled Study Comparing the Efficacy, Safety and Tolerability of ABBV-951 to Oral Carbidopa/Levodopa in Advanced Parkinson's Disease Patients	Parkinson's Disease (PD)	Drug: ABBV-951;Drug: Placebo for Levodopa /Carbidopa (LD/CD);Drug: Levodopa /Carbidopa (LD/CD);Drug: Placebo for ABBV-951	AbbVie	NULL	Recruiting	30 Years	N/A	All	130	Phase 3	United States;Australia
37	NCT04502550 (ClinicalTrials.gov)	October 15, 2020	30/7/2020	Brain Networks and Consciousness	Subcortical-cortical Network Dynamics of Anesthesia and Consciousness	Loss of Consciousness;Parkinson Disease;Essential Tremor;Anesthesia	Drug: Propofol	University of California, Los Angeles	NULL	Recruiting	18 Years	N/A	All	48		United States
38	ChiCTR2000037624	2020-10-01	2020-08-29	Clinical efficacy of dopamine agonist Pramipexol in the treatment of cognitive impairment in PATIENTS with PD-RBD and its population pharmacokinetic study	Clinical efficacy of dopamine agonist Pramipexol in the treatment of cognitive impairment in PATIENTS with PD-RBD and its population pharmacokinetic study	Parkinson's disease	experimental group:Pramipexol + dopa hydrazine combination therapy;control group: dopa hydrazine;	Shanghai General Hospital	NULL	Recruiting	18	85	Both	experimental group:50;control group:50;		China
39	ChiCTR2000036137	2020-10-01	2020-08-21	Clinical study of 18F-FDG combined with 18F-AV-133 PET/CT imaging in the diagnosis and differentiation of primary Parkinson's disease	Clinical study of 18F-FDG combined with 18F-AV-133 PET/CT imaging in the diagnosis and differentiation of primary Parkinson's disease	Parkinson’s disease	Gold Standard:UK Parkinson's disease Society Brain Bank Clinical Diagnosis Criteria;Index test:18F-FDG combined with 18F-AV-133 PET/CT imaging;	Renji Hospital (South Court), School of Medicine, Shanghai Jiao Tong University	NULL	Pending			Both	Target condition:50;Difficult condition:0		China
40	ChiCTR2000036006	2020-10-01	2020-08-21	The applications of multi- MRI in early diagnosis of Parkinson's Disease based on deep learning	The applications of multi- MRI in early diagnosis of Parkinson's Disease based on deep learning	Parkinson's disease	Gold Standard:MDS clinical diagnostic criteria for Parkinson’s disease;Index test:multimodal MRI features in locus coeruleus and substantia nigra;	Zhongshan Hospital, Fudan University	NULL	Pending	18	85	Both	Target condition:400;Difficult condition:0		China
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
41	ChiCTR2000037239	2020-10-01	2020-08-27	Construction and application of a diagnostic marker for Parkinson's disease based on gut microbiomics	Construction and application of a diagnostic marker for Parkinson's disease based on gut microbiomics	Parkinson's disease	Gold Standard:All patients satisfied the United Kingdom Parkinson's Disease Society Brain Bank criteria;Index test:Microbial gene detection chip;	Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine	NULL	Recruiting	55	80	Both	Target condition:500;Difficult condition:600		China
42	ChiCTR2000037856	2020-10-01	2020-09-02	Detection of A-synuclein Aggregate as Biomarker in Diagnosing Parkinson's Disease at Early Stage by Using Protein Misfolding Cyclic Amplification (PMCA)	Detection of A-synuclein Aggregate as Biomarker in Diagnosing Parkinson's Disease at Early Stage by Using Protein Misfolding Cyclic Amplification (PMCA)	Parkinson's Disease	Gold Standard:DAT-PET and 18F-FDG PET ;Index test:a-synuclein protein misfolding cyclic amplification;	Huashan Hospital Affiliated to Fudan University	NULL	Recruiting	50	75	Both	Target condition:150;Difficult condition:76		China
43	NCT04338997 (ClinicalTrials.gov)	October 2020	3/4/2020	PK Study in Patients With Parkinson's Disease With IZD174	An Open-label Phase 1b Study to Evaluate the Pharmacokinetics and Pharmacodynamics in Plasma and Cerebrospinal Fluid (CSF), Safety and Tolerability of Oral IZD174 in Patients With Parkinson's Disease	Parkinson Disease	Drug: IZD174	Inflazome UK Ltd	NULL	Withdrawn	45 Years	75 Years	All	0	Phase 1	NULL
44	NCT04593511 (ClinicalTrials.gov)	October 2020	21/9/2020	to Evaluate the Safety, Tolerability and Pharmacokinetics of Four Formulations of LY03009 in Healthy Volunteers	An Open-Label Study in Healthy Volunteers to Evaluate the Safety, Tolerability and Pharmacokinetics of Four Formulations of LY03009 After a Single Intramuscular Injection	Parkinson's Disease	Drug: LY03009 F1;Drug: LY03009 F2;Drug: LY03009 F3;Drug: LY03009 F4	Luye Pharma Group Ltd.	NULL	Not yet recruiting	18 Years	65 Years	All	40	Phase 1	NULL
45	NCT03665493 (ClinicalTrials.gov)	September 30, 2020	4/9/2018	Dopamine Effect on Inhibitory Control	Dopamine Effect on Inhibitory Control	Idiopathic Parkinson's Disease	Drug: PD patients H&Y=1.5-2 Medications ON;Drug: PD patients H&Y=1.5-2 Medications OFF;Behavioral: Healthy age-matched controls;Drug: PD patients H&Y=3 Medications OFF;Drug: PD patients H&Y=3 Medications ON	Giovanni Mirabella	NULL	Recruiting	40 Years	70 Years	All	102	N/A	Italy
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
46	NCT03968133 (ClinicalTrials.gov)	September 30, 2020	28/5/2019	Treating Anxiety in Parkinson's Disease With a Multi-Strain Probiotic	Treating Anxiety in Parkinson's Disease With a Multi-Strain Probiotic - a Randomized, Placebo-controlled Trial	Parkinson Disease;Anxiety	Dietary Supplement: Probiotic;Dietary Supplement: Placebo	University of British Columbia	The W. Garfield Weston Foundation	Not yet recruiting	40 Years	80 Years	All	72	Phase 2	Canada
47	EUCTR2020-001175-32-GB (EUCTR)	29/09/2020	07/08/2020	Clinical study to evaluate the effect of opicapone 50 mg in the pain associated to Parkinson’s disease.	Randomised, double-blind, placebo-controlled, clinical study to evaluate the effect of opicapone 50 mg on Parkinson’s disease patients with end-of-dose motor fluctuations and associated pain. - OpiCapone Effect on motor fluctuations and pAiN (OCEAN)	Parkinson's disease patients with wearing-off motor fluctuations andassociated pain. MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Ongentys Product Name: Ongentys INN or Proposed INN: Opicapone	Bial - Portela & Ca, S.A.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	176	Phase 4	Portugal;Spain;Germany;Italy;United Kingdom
48	NCT04591535 (ClinicalTrials.gov)	September 28, 2020	11/9/2020	PK Study of WD-1603 in Healthy Subjects	An Open Label, Balanced, Randomised, Four-treatment, Four-period, Four-sequence, Single Oral Dose, Crossover PK Study of WD-1603 in Normal, Healthy, Adult Human Subjects Under Fed Conditions	Parkinson Disease	Drug: WD-1603 CARBIDOPA/LEVODOPA EXTENDED-RELEASE TABLETS	Hong Kong WD Pharmaceutical Co., Limited	NULL	Recruiting	18 Years	45 Years	All	8	Phase 1	India
49	NCT04553978 (ClinicalTrials.gov)	September 18, 2020	13/9/2020	A Single Oral Dose, Crossover Comparative PK Study of WD-1603 in Healthy Subjects Under Fasting Conditions	An Open Label, Balanced, Randomised, 2-treatment, 2-period, 2-sequence, Single Oral Dose, Corssover Comparative PK Study of WD-1603 in Normal, Healthy, Adult Human Subjects Under Fasting Conditions	Parkinson Disease	Drug: WD-1603	Hong Kong WD Pharmaceutical Co., Limited	NULL	Not yet recruiting	18 Years	45 Years	All	8	Phase 1	NULL
50	EUCTR2019-004235-23-GB (EUCTR)	15/09/2020	28/05/2020	Parkinson's Disease: An extension of Study M15-741 evaluating the safety and tolerability of ABBV-951 in subjects with Parkinson's disease.	An open-label extension of Study M15-741 to evaluate the safety and tolerability of 24-hour daily exposure of continuous subcutaneous infusion of ABBV-951 in subjects with Parkinson's disease.	Parkinson's Disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Foscarbidopa and Foslevodopa Product Code: ABBV-951 INN or Proposed INN: Foslevodopa Other descriptive name: Levodopa -4'-Monophosphate INN or Proposed INN: Foscarbidopa Other descriptive name: Carbidopa -4'-Monophosphate	Abbvie Deutschland GmbH & Co. KG	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	130	Phase 3	United States;Canada;Australia;Russian Federation;Japan;United Kingdom
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
51	NCT04387773 (ClinicalTrials.gov)	September 15, 2020	11/5/2020	Effect of GOCOVRI on Gait in Parkinson's Disease	Effect of GOCOVRI on Quantity and Quality of Gait in Parkinson's Disease	Parkinson Disease	Drug: GOCOVRI	Oregon Health and Science University	Adamas Pharmaceuticals, Inc.	Not yet recruiting	50 Years	70 Years	All	12	Phase 4	United States
52	NCT04476017 (ClinicalTrials.gov)	September 11, 2020	15/7/2020	A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Parkinson's Disease Mild Cognitive Impairment (PD-MCI)	An Open-Label Evaluation of the Safety and Tolerability of SAGE-718 in Participants With Parkinson's Disease Mild Cognitive Impairment	Parkinson Disease;Cognitive Dysfunction	Drug: SAGE-718	Sage Therapeutics	NULL	Recruiting	50 Years	75 Years	All	22	Phase 2	United States
53	EUCTR2019-002949-38-DE (EUCTR)	07/09/2020	21/01/2020	A PHASE 3, DOUBLE-BLIND, RANDOMIZED, PLACEBO CONTROLLED, PARALLEL GROUP, 27 WEEK TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF TWO FIXED DOSES OF TAVAPADON IN EARLY PARKINSON’S DISEASE (TEMPO-1 TRIAL)	A PHASE 3, DOUBLE-BLIND, RANDOMIZED, PLACEBO CONTROLLED, PARALLEL GROUP, 27 WEEK TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF TWO FIXED DOSES OF TAVAPADON IN EARLY PARKINSON’S DISEASE (TEMPO-1 TRIAL)	Patients (18 to 60 years age) who have diagnosis of Parkinson's Disease;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Tavapadon 0.25mg Product Code: CVL-751 INN or Proposed INN: TAVAPADON Other descriptive name: PF-06649751 Product Name: Tavapadon 1mg Product Code: CVL-751 INN or Proposed INN: TAVAPADON Other descriptive name: PF-06649751 Product Name: Tavapadon 5mg Product Code: CVL-751 INN or Proposed INN: TAVAPADON Other descriptive name: PF-06649751	Cerevel Therapeutics, LLC	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	552	Phase 3	United States;Spain;Ukraine;Israel;Italy;France;Czech Republic;Hungary;Canada;Poland;Australia;Bulgaria;Germany
54	ChiCTR2000037828	2020-09-01	2020-09-02	Clinical study of Wuqinxi combined with selegilan in improving frozen gait of Parkinson's disease	Clinical study of Wuqinxi combined with selegilan in improving frozen gait of Parkinson's disease	Parkinson's disease	Group 1:Routine anti PD treatment + stretching training;Group 2:Routine anti PD treatment + stretching training + selegiline;Group 3:Routine anti PD treatment + Wuqinxi training;Group 4:Routine anti PD treatment + Wuqinxi training + selegiline;	Union Medical College Affiliated Hospital of Tongji Medical College, Huazhong University of science and technology	NULL	Recruiting	40	80	Male	Group 1:30;Group 2:30;Group 3:30;Group 4:30;		China
55	ChiCTR2000035872	2020-09-01	2020-08-19	Effect of repetitive transcranial magnetic stimulation on gait and balance function in patients with Parkinson's disease and Parkinson's syndrome	Effect of repetitive transcranial magnetic stimulation on gait and balance function in patients with Parkinson's disease and Parkinson's syndrome	Parkinson's disease and Parkinson's syndrome	Parkinson's disease observation group:Repetitive transcranial magnetic stimulation+Visual feedback balance training system+Digital treadmill ;Parkinson's disease control group:Visual feedback balance training system+Digital treadmill;Parkinson's syndrome observation group:Repetitive transcranial magnetic stimulation+Visual feedback balance training system+Digital treadmill;Parkinson's syndrome control group:Visual feedback balance training system+Digital treadmill ;	Gansu Provincial Hospital	NULL	Pending	50	85	Both	Parkinson's disease observation group:28;Parkinson's disease control group:28;Parkinson's syndrome observation group:28;Parkinson's syndrome control group:28;		China
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
56	NCT04332276 (ClinicalTrials.gov)	September 2020	25/3/2020	Dopaminergic restauratIon by intraVEntriculaire Administration	A New Concept of Continuous Dopaminergic Stimulation by Cerebroventricular Administration of A-dopamine (Dopamine Stored in Anaerobia) for Severe Motor Fluctuations in Parkinson's Disease?	Parkinson Disease	Drug: A-dopamine	University Hospital, Lille	InBrain Pharma	Not yet recruiting	45 Years	75 Years	All	20	Phase 1;Phase 2	NULL
57	EUCTR2019-004235-23-IT (EUCTR)	26/08/2020	22/10/2020	Parkinson's Disease: An extension of Study M15-741 evaluating the safety and tolerability of ABBV-951 in subjects with Parkinson's disease.	An open-label extension of Study M15-741 to evaluate the safety and tolerability of 24-hour daily exposure of continuous subcutaneous infusion of ABBV-951 in subjects with Parkinson's disease. - na	Parkinson's Disease MedDRA version: 21.1;Level: PT;Classification code 10068100;Term: Vascular parkinsonism;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Foscarbidopa and Foslevodopa Product Code: [ABBV-951] INN or Proposed INN: Foslevodopa Other descriptive name: Levodopa -4'-Monophosphate	ABBVIE DEUTSCHLAND GMBH & CO. KG	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	130	Phase 3	United States;Canada;Australia;Russian Federation;Netherlands;United Kingdom;Japan;Italy
58	ChiCTR2000035564	2020-08-17	2020-08-13	Pharmacokinetics and Bioequivalence study of Pramipexole Extended-Release Tablets in Healthy Chinese Volunteers	Pharmacokinetics and Bioequivalence study of Pramipexole Extended-Release Tablets in Healthy Chinese Volunteers	Parkinson’s disease	fasting administration group-TR:phase I: Pramipexole Extended-Release Tablets; phase II: Reference preparation;fasting administration group-RT:phase I: Reference preparation: pahse II: Test preparation;high-fat postprandial administration group-TR:phase I: Pramipexole Extended-Release Tablets; phase II: Reference preparation;high-fat postprandial administration group-RT:phase I: Pramipexole Extended-Release Tablets; phase II: Reference preparation;	West China Hospital of Sichuan University	NULL	Recruiting	18	65	Both	fasting administration group-TR:28;fasting administration group-RT:28;high-fat postprandial administration group-TR:28;high-fat postprandial administration group-RT:28;	Phase 1	China
59	NCT04524351 (ClinicalTrials.gov)	August 14, 2020	11/8/2020	Posiphen® Dose-Finding, Biomarker Study in Early Alzheimer's and Parkinson's Patients	A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Effects of Posiphen® in Subjects With Early Alzheimer's Disease (AD) or Early Parkinson's Disease (PD)	Alzheimer Disease;Parkinson Disease	Drug: Posiphen	Annovis Bio Inc.	Parexel	Recruiting	45 Years	N/A	All	68	Phase 1;Phase 2	United States
60	NCT04513340 (ClinicalTrials.gov)	August 13, 2020	12/8/2020	WD-1603 PK Study Under Fasting and Fed Conditions in Healthy Subjects	AN OPEN LABEL, BALANCED, RANDOMISED, FOUR-TREATMENT, FOUR-PERIOD, FOUR-SEQUENCE, SINGLE INTRA-ORAL AND ORAL DOSE, CROSSOVER PHARMACOKINETICS STUDY OF WD-1603 EXTENDED-RELEASE CARBIDOPA/LEVODOPA TABLETS 25/100MG IN NORMAL, HEALTHY, ADULT HUMAN SUBJECTS UNDER FASTING AND FED CONDITIONS	Parkinson Disease	Drug: WD-1603 CARBIDOPA and LEVODOPA EXTENDED-RELEASE TABLETS	Hong Kong WD Pharmaceutical Co., Limited	NULL	Recruiting	18 Years	45 Years	All	8	Phase 1	India
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
61	NCT04449484 (ClinicalTrials.gov)	August 4, 2020	23/4/2019	Multiple Ascending Dose Study of MEDI1341 in Patients With Parkinson's Disease	A Randomized, Double-blind, Placebo-controlled Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Ascending Doses of MEDI1341 in Subjects With Parkinson's Disease	Parkinson's Disease	Drug: MEDI1341;Other: Placebo	AstraZeneca	NULL	Recruiting	40 Years	85 Years	All	36	Phase 1	United States
62	ChiCTR2000034323	2020-08-01	2020-07-02	The effect and correlation of rehabilitation training mode combined with visual feedback balance system and digital treadmill on three-dimensional Gait kinematics and diffusion tensor imaging in patients with early and mid period Parkinson's disease	The effect of rehabilitation training mode combined with visual feedback balance system and digital treadmill on Gait kinematics and diffusion tensor imaging in patients with early and mid period Parkinson's disease	Parkinson's disease	experimental group:Combined Rehabilitation Training of visual feedback balance system and digital treadmill;control group:Traditional Gait Balance Rehabilitation Training;	Xianhui Feng	NULL	Pending			Both	experimental group:30;control group:30;		China
63	NCT04483479 (ClinicalTrials.gov)	July 30, 2020	20/7/2020	Orally Administered ENT-01 for Parkinson's Disease-Related Constipation Follow-on Safety Roll-over Study (Rollover)	A Multicenter, Non-Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Orally Administered ENT-01 in Improving Constipation and Neurologic Symptoms in Patients With Parkinson's Disease and Constipation Over a 14-week Period	Parkinson Disease;Constipation	Drug: Active Investigational Treatment ENT-01	Enterin Inc.	NULL	Recruiting	30 Years	90 Years	All	50	Phase 2	United States
64	EUCTR2019-002951-40-DE (EUCTR)	29/07/2020	12/02/2020	A clinical trial which runs in multiple countries and aims to analyse how efficient, safe and tolerable the investigational product (TAVAPADON) is compared with placebo treatment when given in multiple doses for patients diagnosed with Parkinson's Disease with Motor Fluctuations	A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Flexible-Dose, 27-Week Trial to Evaluate the Efficacy, Safety, and Tolerability of Tavapadon as Adjunctive Therapy for Parkinson’s Disease in Levodopa-Treated Adults With Motor Fluctuations (TEMPO-3 Trial) - TEMPO-3	Patients (40 to 80 years age) who have diagnosis of Parkinson's Disease with Motor Fluctuations MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Tavapadon 5mg Product Code: CVL-751 INN or Proposed INN: TAVAPADON Other descriptive name: PF-06649751 Product Name: Tavapadon 1mg Product Code: CVL-751 INN or Proposed INN: TAVAPADON Other descriptive name: PF-06649751 Product Name: Tavapadon 0.25mg Product Code: CVL-751 INN or Proposed INN: TAVAPADON Other descriptive name: PF-06649751	Cerevel Therapeutics, LLC	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	368	Phase 3	United States;Serbia;Spain;Ukraine;Israel;Italy;France;Czech Republic;Hungary;Canada;Poland;Australia;Bulgaria;Germany
65	NCT04275492 (ClinicalTrials.gov)	July 24, 2020	18/11/2019	Study on Bioequivalence of Pramipexole Dihydrochloride Sustained Release Tablets	Study on Bioequivalence of Pramipexole Dihydrochloride Sustained Release Tablets	Parkinson's Disease	Drug: Praxol hydrochloride sustained release tablet Specification: 0.375mg/ tablet (in pramipexole hydrochloride);Drug: Pramipexole hydrochloride sustained-release tablet (Siforl®) Specification: 0.26mg/ tablet (in pramipexole)	First Affiliated Hospital of Zhejiang University	Hongguan biological pharmaceutical co.	Recruiting	18 Years	45 Years	All	60	N/A	China
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
66	NCT04630860 (ClinicalTrials.gov)	July 7, 2020	5/11/2020	A Study to Evaluate the Pharmacokinetics and Safety of LY03003 in Patients With Advanced-stage PD	A Randomized, Open-label, Multiple Ascending Dose Study in Patients With Advanced-stage Parkinson's Disease to Evaluate the Pharmacokinetics and Safety of LY03003 Following Intramuscular Injections	Parkinson Disease	Drug: LY03003	Luye Pharma Group Ltd.	NULL	Recruiting	18 Years	80 Years	All	30	Phase 1	China
67	EUCTR2019-002951-40-HU (EUCTR)	02/07/2020	29/04/2020	A clinical trial which runs in multiple countries and aims to analyse how efficient, safe and tolerable the investigational product (TAVAPADON) is compared with placebo treatment when given in multiple doses for patients diagnosed with Parkinson's Disease with Motor Fluctuations	A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Flexible-Dose, 27-Week Trial to Evaluate the Efficacy, Safety, and Tolerability of Tavapadon as Adjunctive Therapy for Parkinson’s Disease in Levodopa-Treated Adults With Motor Fluctuations (TEMPO-3 Trial) - TEMPO-3	Patients (40 to 80 years age) who have diagnosis of Parkinson's Disease with Motor Fluctuations MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Tavapadon 5mg Product Code: CVL-751 INN or Proposed INN: TAVAPADON Other descriptive name: PF-06649751 Product Name: Tavapadon 1mg Product Code: CVL-751 INN or Proposed INN: TAVAPADON Other descriptive name: PF-06649751 Product Name: Tavapadon 0.25mg Product Code: CVL-751 INN or Proposed INN: TAVAPADON Other descriptive name: PF-06649751	Cerevel Therapeutics, LLC	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	368	Phase 3	United States;Serbia;Spain;Ukraine;Israel;Italy;France;Hungary;Czech Republic;Canada;Poland;Australia;Bulgaria;Germany;Sweden
68	NCT04193527 (ClinicalTrials.gov)	July 2020	2/12/2019	A Study to Evaluate the Diagnostic Efficacy of DaTSCAN™ Ioflupane (123I) Injection in Single Photon Emission Computed Tomography (SPECT) for the Diagnosis of Parkinsonian Syndrome (PS) in Chinese Patients	A Multicentre, Phase 3, Clinical Study to Compare the Striatal Uptake of a Dopamine Transporter Radioligand, DaTSCAN™ Ioflupane (123I) Injection, After Intravenous Administration to Chinese Patients With a Diagnosis of Parkinson's Disease, Multiple System Atrophy, Progressive Supranuclear Palsy, or Essential Tremor and to Healthy Controls	Parkinsonian Syndrome;Parkinson Disease(PD);Multiple System Atrophy (MSA);Progressive Supranuclear Palsy (PSP)	Drug: DaTSCAN ™ Ioflupane (123I) Injection	GE Healthcare	PPD	Not yet recruiting	40 Years	80 Years	All	172	Phase 3	China
69	JPRN-UMIN000040889	2020/06/24	24/06/2020	Comparison of gastrointestinal function before and after levodopa-carbidopa continuous infusion gel (LCIG) therapy for patients with Parkinson's disease	Comparison of gastrointestinal function before and after levodopa-carbidopa continuous infusion gel (LCIG) therapy for patients with Parkinson's disease - Comparison of gastrointestinal function before and after LCIG therapy for Parkinson's disease	Parkinson's disease	Levodopa-carbidopa continuous infusion gel (LCIG) therapy	Fujita Health University School of MedicineDepartment of Gastroenterology	NULL	Recruiting	20years-old	Not applicable	Male and Female	200	Phase 4	Japan
70	EUCTR2018-004156-37-PT (EUCTR)	16/06/2020	09/12/2019	A clinical study to investigate the efficacy, safety, and tolerability of continuous subcutaneous ND0612 infusion in comparison to oral treatment in subjects with Parkinson’s disease (BouNDless)	A multicenter, randomized, active-controlled, double-blind, double-dummy, parallel group clinical trial, investigating the efficacy, safety, and tolerability of continuous subcutaneous ND0612 infusion in comparison to oral IR-LD/CD in subjects with Parkinson’s disease experiencing motor fluctuations (BouNDless) - BouNDless	Parkinson's disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: levodopa /carbidopa solution Product Code: ND0612 INN or Proposed INN: Levodopa Other descriptive name: LEVODOPA INN or Proposed INN: carbidopa Other descriptive name: CARBIDOPA Trade Name: IR LD/CD Product Name: Carbidopa and Levodopa tablets, USP INN or Proposed INN: Levodopa Other descriptive name: LEVODOPA INN or Proposed INN: carbidopa Other descriptive name: CARBIDOPA	NeuroDerm Ltd.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	350	Phase 3	United States;Portugal;Serbia;Slovakia;Spain;Ukraine;Austria;Israel;Russian Federation;United Kingdom;France;Italy;Hungary;Czech Republic;Canada;Belgium;Poland;Netherlands;Sweden;Korea, Republic of
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
71	EUCTR2018-004156-37-NL (EUCTR)	14/06/2020	13/01/2020	A clinical study to investigate the efficacy, safety, and tolerability of continuous subcutaneous ND0612 infusion in comparison to oral treatment in subjects with Parkinson’s disease (BouNDless)	A multicenter, randomized, active-controlled, double-blind, double-dummy, parallel group clinical trial, investigating the efficacy, safety, and tolerability of continuous subcutaneous ND0612 infusion in comparison to oral IR-LD/CD in subjects with Parkinson’s disease experiencing motor fluctuations (BouNDless) - BouNDless	Parkinson's disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: levodopa /carbidopa solution Product Code: ND0612 INN or Proposed INN: Levodopa Other descriptive name: LEVODOPA INN or Proposed INN: carbidopa Other descriptive name: CARBIDOPA Trade Name: IR LD / CD Product Name: Carbidopa and Levodopa tablets, USP INN or Proposed INN: Levodopa Other descriptive name: LEVODOPA INN or Proposed INN: carbidopa Other descriptive name: CARBIDOPA	NeuroDerm Ltd.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	482	Phase 3	Portugal;Serbia;United States;Czechia;Slovakia;Spain;Ukraine;Austria;Israel;Russian Federation;United Kingdom;Italy;France;Czech Republic;Hungary;Poland;Belgium;Netherlands;Sweden;Korea, Republic of
72	NCT04428112 (ClinicalTrials.gov)	June 5, 2020	9/6/2020	Rural Dementia Caregiver Project	Evaluating the Effectiveness of an Online Small-Group Self-Management Workshop for Rural Caregivers of Individuals With Alzheimer's Disease and Related Dementias	Depression;Stress, Psychological;Self Efficacy;Loneliness;Social Isolation;Health Care Utilization;Dementia;Dementia Alzheimers;Dementia of Alzheimer Type;Dementia, Vascular;Dementia Frontal;Dementia, Lewy Body;Dementia, Mixed;Dementia in Parkinsons Disease;Dementia, HIV;Dementia Frontotemporal;Dementia, Multi-Infarct	Behavioral: Building Better Caregivers Workshop;Behavioral: Attention Control	University of California, San Francisco	National Institute on Aging (NIA)	Recruiting	18 Years	N/A	All	640	N/A	United States
73	EUCTR2019-002951-40-CZ (EUCTR)	03/06/2020	25/02/2020	A clinical trial which runs in multiple countries and aims to analyse how efficient, safe and tolerable the investigational product (TAVAPADON) is compared with placebo treatment when given in multiple doses for patients diagnosed with Parkinson's Disease with Motor Fluctuations	A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Flexible-Dose, 27-Week Trial to Evaluate the Efficacy, Safety, and Tolerability of Tavapadon as Adjunctive Therapy for Parkinson’s Disease in Levodopa-Treated Adults With Motor Fluctuations (TEMPO-3 Trial) - TEMPO-3	Patients (40 to 80 years age) who have diagnosis of Parkinson's Disease with Motor Fluctuations MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Tavapadon 5mg Product Code: CVL-751 INN or Proposed INN: TAVAPADON Other descriptive name: PF-06649751 Product Name: Tavapadon 1mg Product Code: CVL-751 INN or Proposed INN: TAVAPADON Other descriptive name: PF-06649751 Product Name: Tavapadon 0.25mg Product Code: CVL-751 INN or Proposed INN: TAVAPADON Other descriptive name: PF-06649751	Cerevel Therapeutics, LLC	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	368	Phase 3	Serbia;United States;Spain;Ukraine;Israel;Italy;France;Czech Republic;Hungary;Canada;Poland;Australia;Bulgaria;Germany;Sweden
74	NCT04384666 (ClinicalTrials.gov)	June 2, 2020	8/5/2020	A Randomized, Open-Label, Crossover Study to Evaluate the Pharmacokinetic Profiles of Rotigotine After a Single Dose of LY03003 (28 mg) Versus After a Week of Daily NEUPRO® Transdermal Patch (4 mg Every 24 Hours) in Healthy Volunteers	A Randomized, Open-Label, Crossover Study to Evaluate the Pharmacokinetic Profiles of Rotigotine After a Single Dose of LY03003 (28 mg) Versus After a Week of Daily NEUPRO® Transdermal Patch (4 mg Every 24 Hours) in Healthy Volunteers	Parkinson Disease	Drug: LY03003 (rotigotine extended release microspheres for intramuscular [IM] injection);Other: Neupro 4 mg / 24 Hr. Transdermal Patch	Luye Pharma Group Ltd.	NULL	Completed	18 Years	45 Years	All	56	Phase 1	United States
75	NCT04414813 (ClinicalTrials.gov)	June 2020	21/5/2019	Stereotactic Transplantation of hAESCs for Parkinson's Disease	Clinical Study of Stereotactic Transplantation of Human Amniotic Epithelial Stem Cells (hAESCs) in the Treatment of Parkinson's Disease (PD)	Parkinson's Disease	Biological: Human Amniotic Epithelial Stem Cells	Shanghai East Hospital	Shanghai iCELL Biotechnology Co., Ltd, Shanghai, China	Not yet recruiting	30 Years	70 Years	All	3	Early Phase 1	NULL
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
76	ChiCTR2000032616	2020-05-30	2020-05-04	Assistant diagnosis machinery system development based on speech and movement sensitive device for Parkinson's disease	Parkinson's disease, Assistant diagnosis machinery system, speech, movement sensitive device	Parkinson's disease	Gold Standard:clinical outcome meet 2015 MDS-probable PD criteria;Index test:Acoustic receptive and analysis device,Wearable movement sensor;	Shanghai Jiao Tong University School of Medicine affiliated Shanghai General Hospital	NULL	Pending			Both	Target condition:20;Difficult condition:80		China
77	NCT04379050 (ClinicalTrials.gov)	May 19, 2020	1/5/2020	Extension Study To Evaluate Safety And Tolerability Of 24-Hour Daily Exposure Of Continuous Subcutaneous Infusion of ABBV-951 In Adult Participants With Parkinson's Disease	An Open-label Extension of Study M15-741 to Evaluate the Safety and Tolerability of 24-hour Daily Exposure of Continuous Subcutaneous Infusion of ABBV-951 in Subjects With Parkinson's Disease	Parkinson's Disease (PD)	Drug: ABBV-951	AbbVie	NULL	Enrolling by invitation	30 Years	N/A	All	121	Phase 3	United States;Australia;Belgium;Canada;Denmark;Italy;Japan;Netherlands;Spain;United Kingdom
78	EUCTR2018-004156-37-SE (EUCTR)	18/05/2020	10/09/2019	A clinical study to investigate the efficacy, safety, and tolerability of continuous subcutaneous ND0612 infusion in comparison to oral treatment in subjects with Parkinson’s disease (BouNDless)	A multicenter, randomized, active-controlled, double-blind, double-dummy, parallel group clinical trial, investigating the efficacy, safety, and tolerability of continuous subcutaneous ND0612 infusion in comparison to oral IR-LD/CD in subjects with Parkinson’s disease experiencing motor fluctuations (BouNDless) - BouNDless	Parkinson's disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: levodopa /carbidopa solution Product Code: ND0612 INN or Proposed INN: Levodopa Other descriptive name: LEVODOPA INN or Proposed INN: carbidopa Other descriptive name: CARBIDOPA Trade Name: IR LD / CD Product Name: Carbidopa and Levodopa tablets, USP INN or Proposed INN: Levodopa Other descriptive name: LEVODOPA INN or Proposed INN: carbidopa Other descriptive name: CARBIDOPA	NeuroDerm Ltd.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	350	Phase 3	United States;Serbia;Portugal;Slovakia;Spain;Ukraine;Austria;Israel;Russian Federation;United Kingdom;Italy;France;Hungary;Czech Republic;Canada;Belgium;Poland;Netherlands;Sweden;Korea, Republic of
79	NCT03568968 (ClinicalTrials.gov)	May 15, 2020	14/6/2018	A Randomized Controlled Trial of Nicotinamide Supplementation in Early Parkinson's Disease	A Randomized Controlled Trial of Nicotinamide Supplementation in Early Parkinson's Disease: the NOPARK Study	Parkinson Disease	Dietary Supplement: Nicotinamide Riboside;Drug: Placebo	Haukeland University Hospital	NULL	Recruiting	18 Years	N/A	All	400	N/A	Norway
80	EUCTR2019-002949-38-PL (EUCTR)	13/05/2020	20/02/2020	A PHASE 3, DOUBLE-BLIND, RANDOMIZED, PLACEBO CONTROLLED, PARALLEL GROUP, 27 WEEK TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF TWO FIXED DOSES OF TAVAPADON IN EARLY PARKINSON’S DISEASE (TEMPO-1 TRIAL)	A PHASE 3, DOUBLE-BLIND, RANDOMIZED, PLACEBO CONTROLLED, PARALLEL GROUP, 27 WEEK TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF TWO FIXED DOSES OF TAVAPADON IN EARLY PARKINSON’S DISEASE (TEMPO-1 TRIAL)	Patients (40 to 80 years age) who have diagnosis of Parkinson's Disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Tavapadon 0.25mg Product Code: CVL-751 INN or Proposed INN: TAVAPADON Other descriptive name: PF-06649751 Product Name: Tavapadon 1mg Product Code: CVL-751 INN or Proposed INN: TAVAPADON Other descriptive name: PF-06649751 Product Name: Tavapadon 5mg Product Code: CVL-751 INN or Proposed INN: TAVAPADON Other descriptive name: PF-06649751	Cerevel Therapeutics, LLC	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	522	Phase 3	Serbia;United States;Spain;Ukraine;Israel;Italy;France;Czech Republic;Hungary;Canada;Poland;Australia;Bulgaria;Germany;Sweden
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
81	NCT04571164 (ClinicalTrials.gov)	May 11, 2020	21/9/2020	A Study to Evaluate the Effectiveness and Safety of LY03003 in Patients With Early Primary PD	A Multi-centre,Randomized,Double-blind,Placebo Parallel Controlled Study to Evaluate the Effectiveness and Safety of LY03003 in Patients With Early Primary PD	Parkinson Disease	Drug: LY03003(Rotigotine,extended-release microspheres);Drug: Placebo,extended-release microspheres	Luye Pharma Group Ltd.	Parexel	Recruiting	30 Years	N/A	All	294	Phase 3	China
82	EUCTR2018-002144-85-DE (EUCTR)	07/05/2020	06/06/2019	Parkinson's Disease: Safety and Tolerability of 24-Hour Daily Exposure to ABBV-951 by Continuous Subcutaneous Infusion study	A 52-Week, open-label, single-arm study to evaluate the safety and tolerability of 24-hour daily exposure of continuous subcutaneous infusion of ABBV-951 in subjects with Parkinson's disease - Galliarde	Parkinson's Disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Code: ABBV-951 INN or Proposed INN: Foslevodopa Other descriptive name: Levodopa -4'-Monophosphate INN or Proposed INN: Foscarbidopa Other descriptive name: Carbidopa -4'-Monophosphate	AbbVie Deutschland	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	130	Phase 3	United States;Canada;Spain;Denmark;Australia;Netherlands;Germany;United Kingdom;Japan
83	EUCTR2019-002950-22-HU (EUCTR)	06/05/2020	12/03/2020	A clinical trial which runs in multiple countries and aims to analyse how efficient, safe and tolerable the investigational product (TAVAPADON) is compared with placebo treatment when given in multiple doses for patients diagnosed with Parkinson's Disease	A Phase 3, Double-Blind, Randomized, Placebo Controlled, Parallel Group, Flexible-Dose, 27 Week Trial to Evaluate the Efficacy, Safety, and Tolerability of Tavapadon in Early Parkinson’s Disease (TEMPO 2 Trial)	Patients (40 to 80 years age) who have diagnosis of Parkinson's Disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Tavapadon 5mg Product Code: CVL-751 INN or Proposed INN: TAVAPADON Other descriptive name: PF-06649751 Product Name: Tavapadon 1mg Product Code: CVL-751 INN or Proposed INN: TAVAPADON Other descriptive name: PF-06649751 Product Name: Tavapadon 0.25mg Product Code: CVL-751 INN or Proposed INN: TAVAPADON Other descriptive name: PF-06649751	Cerevel Therapeutics, LLC	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	296	Phase 3	United States;Serbia;Spain;Ukraine;Israel;Italy;France;Hungary;Czech Republic;Canada;Poland;Australia;Bulgaria;Germany
84	NCT04265209 (ClinicalTrials.gov)	May 2020	6/2/2020	[18F] LBT-999 PET Compared to [123I]-FP/CIT SPECT to Distinguish Between Parkinson's Diseases and Essential Tremor	Non-inferiority Study of the Molecular Imaging of Dopamine Transporters Using [123I]-FP/CIT-SPECT and [18F] LBT-999-PET to Distinguish Between Parkinson's Disease and Essential Tremor.	Parkinson Disease;Essential Tremor	Drug: SPECT;Drug: PET	Zionexa	NULL	Not yet recruiting	35 Years	80 Years	All	112	Phase 3	NULL
85	EUCTR2018-004156-37-SK (EUCTR)	30/04/2020	13/02/2020	A clinical study to investigate the efficacy, safety, and tolerability of continuous subcutaneous ND0612 infusion in comparison to oral treatment in subjects with Parkinson’s disease (BouNDless)	A multicenter, randomized, active-controlled, double-blind, double-dummy, parallel group clinical trial, investigating the efficacy, safety, and tolerability of continuous subcutaneous ND0612 infusion in comparison to oral IR-LD/CD in subjects with Parkinson’s disease experiencing motor fluctuations (BouNDless) - BouNDless	Parkinson's disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Levodopa /Carbidopa Solution Product Code: ND0612 INN or Proposed INN: Levodopa Other descriptive name: LEVODOPA INN or Proposed INN: carbidopa Other descriptive name: CARBIDOPA Trade Name: IR LD / CD Product Name: Carbidopa and Levodopa tablets, USP INN or Proposed INN: Levodopa Other descriptive name: LEVODOPA INN or Proposed INN: carbidopa Other descriptive name: CARBIDOPA	NeuroDerm Ltd.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	482	Phase 3	United States;Serbia;Portugal;Slovakia;Spain;Ukraine;Austria;Israel;Russian Federation;United Kingdom;Italy;France;Czech Republic;Hungary;Belgium;Poland;Netherlands;Sweden;Korea, Republic of
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
86	NCT04459052 (ClinicalTrials.gov)	April 30, 2020	26/6/2020	FDOPA PET and Nutritional Support in Parkinson's Disease	Phase II: Physiological Effects of Nutritional Support in Patients With Parkinson's Disease	Parkinson Disease;Idiopathic Parkinson Disease	Dietary Supplement: N acetyl cysteine;Drug: [F-18] Fluorodopa Positron Emission Tomography	Thomas Jefferson University	NULL	Active, not recruiting	30 Years	N/A	All	50	Phase 2	United States
87	EUCTR2018-004156-37-BE (EUCTR)	27/04/2020	03/03/2020	A clinical study to investigate the efficacy, safety, and tolerability of continuous subcutaneous ND0612 infusion in comparison to oral treatment in subjects with Parkinson’s disease (BouNDless)	A multicenter, randomized, active-controlled, double-blind, double-dummy, parallel group clinical trial, investigating the efficacy, safety, and tolerability of continuous subcutaneous ND0612 infusion in comparison to oral IR-LD/CD in subjects with Parkinson’s disease experiencing motor fluctuations (BouNDless) - BouNDless	Parkinson's disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: levodopa /carbidopa solution Product Code: ND0612 INN or Proposed INN: Levodopa Other descriptive name: LEVODOPA INN or Proposed INN: carbidopa Other descriptive name: CARBIDOPA Trade Name: IR LD / CD Product Name: Carbidopa and Levodopa tablets, USP INN or Proposed INN: Levodopa Other descriptive name: LEVODOPA INN or Proposed INN: carbidopa Other descriptive name: CARBIDOPA	NeuroDerm Ltd.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	482	Phase 3	United States;Portugal;Serbia;Slovakia;Spain;Ukraine;Austria;Israel;Russian Federation;United Kingdom;Italy;France;Czech Republic;Hungary;Belgium;Poland;Netherlands;Sweden;Korea, Republic of
88	EUCTR2018-002233-37-PL (EUCTR)	23/04/2020	24/01/2020	Evaluate the safety and efficacy of IPX203 carbidopa-levodopa extended release capsules compared to carbidopa-levodopa immediate release tablets in patients with Parkinson’s with motor fluctuations.	A randomized controlled study to compare the safety and efficacy of IPX203 with immediate-release carbidopa-levodopa in Parkinson's disease patients with motor fluctuations.	Parkinson's disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0;Level: SOC;Classification code 10029205;Term: Nervous system disorders;Classification code 10028035;Term: Movement disorder;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: IPX203 Product Code: IPX203 INN or Proposed INN: Levodopa Other descriptive name: LEVODOPA INN or Proposed INN: Carbidopa Other descriptive name: ANHYDROUS CARBIDOPA Trade Name: Carbidopa and Levodopa Tablets, USP Product Name: IR CD-LD (carbidopa-levodopa) tablets Product Code: IR CD-LD INN or Proposed INN: Levodopa INN or Proposed INN: Carbidopa Other descriptive name: ANHYDROUS CARBIDOPA	Impax Laboratories, LLC	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	510	Phase 3	United States;France;Czech Republic;Canada;Spain;Poland;Germany;United Kingdom;Italy
89	EUCTR2019-002951-40-ES (EUCTR)	14/04/2020	06/03/2020	A clinical trial which runs in multiple countries and aims to analyse how efficient, safe and tolerable the investigational product (TAVAPADON) is compared with placebo treatment when given in multiple doses for patients diagnosed with Parkinson's Disease with Motor Fluctuations	A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Flexible-Dose, 27-Week Trial to Evaluate the Efficacy, Safety, and Tolerability of Tavapadon as Adjunctive Therapy for Parkinson’s Disease in Levodopa-Treated Adults With Motor Fluctuations (TEMPO-3 Trial) - TEMPO-3	Patients (40 to 80 years age) who have diagnosis of Parkinson's Disease with Motor Fluctuations MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Tavapadon 5mg Product Code: CVL-751 INN or Proposed INN: TAVAPADON Other descriptive name: PF-06649751 Product Name: Tavapadon 1mg Product Code: CVL-751 INN or Proposed INN: TAVAPADON Other descriptive name: PF-06649751 Product Name: Tavapadon 0.25mg Product Code: CVL-751 INN or Proposed INN: TAVAPADON Other descriptive name: PF-06649751	Cerevel Therapeutics, LLC	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	368	Phase 3	United States;Serbia;Spain;Ukraine;Israel;Italy;France;Czech Republic;Hungary;Canada;Poland;Australia;Bulgaria;Germany;Sweden
90	EUCTR2019-002949-38-ES (EUCTR)	07/04/2020	28/02/2020	A PHASE 3, DOUBLE-BLIND, RANDOMIZED, PLACEBO CONTROLLED, PARALLEL GROUP, 27 WEEK TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF TWO FIXED DOSES OF TAVAPADON IN EARLY PARKINSON’S DISEASE (TEMPO-1 TRIAL)	A PHASE 3, DOUBLE-BLIND, RANDOMIZED, PLACEBO CONTROLLED, PARALLEL GROUP, 27 WEEK TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF TWO FIXED DOSES OF TAVAPADON IN EARLY PARKINSON’S DISEASE (TEMPO-1 TRIAL)	Patients (18 to 60 years age) who have diagnosis of Parkinson's Disease;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Tavapadon 0.25mg Product Code: CVL-751 INN or Proposed INN: TAVAPADON Other descriptive name: PF-06649751 Product Name: Tavapadon 1mg Product Code: CVL-751 INN or Proposed INN: TAVAPADON Other descriptive name: PF-06649751 Product Name: Tavapadon 5mg Product Code: CVL-751 INN or Proposed INN: TAVAPADON Other descriptive name: PF-06649751	Cerevel Therapeutics, LLC	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	522	Phase 3	United States;Serbia;Spain;Ukraine;Israel;Italy;France;Czech Republic;Hungary;Canada;Poland;Australia;Bulgaria;Germany;Sweden
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
91	ChiCTR2000029465	2020-04-06	2020-02-02	Comparison of effects of sitagliptin and metformin on motor function and cognitive function in patients with Parkinson's disease complicated with type 2 diabetes	Comparison of effects of sitagliptin and metformin on motor function and cognitive function in patients with Parkinson's disease complicated with type 2 diabetes	Type 2 Diabetes	Sitagliptin group:Sitagliptin 100mg/d for 52 weeks;metformin group:metformin 1000-1500mg/d for 52 weeks;	Peking Union Medical College Hospital	NULL	Pending	18	75	Both	Sitagliptin group:20;metformin group:20;	Phase 4	China
92	NCT02967250 (ClinicalTrials.gov)	April 1, 2020	13/9/2016	Brain Bioenergetics in Parkinson's Disease and Response to Repeated Oral UDCA Treatment	7T Magnetic Resonance Spectroscopy Monitoring Brain Bioenergetics in Parkinson's Disease and Response to Repeated Oral UDCA Treatment	Parkinson Disease	Drug: ursodeoxycholic acid	University of Minnesota	NULL	Not yet recruiting	18 Years	N/A	All	20	Phase 1	United States
93	NCT04167540 (ClinicalTrials.gov)	April 1, 2020	7/11/2019	GDNF Gene Therapy for Parkinson's Disease	Open-Label Safety Study of Glial Cell Line-Derived Neurotrophic Factor Gene Transfer (AAV2- GDNF) in Parkinson's Disease	Parkinson's Disease	Biological: AAV2-GDNF	Brain Neurotherapy Bio, Inc.	NULL	Recruiting	35 Years	75 Years	All	12	Phase 1	United States
94	NCT04182399 (ClinicalTrials.gov)	April 1, 2020	24/11/2019	Role of Zonisamide in Advanced Parkinson's Disease (PD) in Egyptian Population: Pilot Study	Role of Zonisamide in Advanced Parkinson's Disease (PD) in Egyptian Population: Pilot Study	Parkinson Disease	Drug: Zonisamide Capsules	Ain Shams University	NULL	Recruiting	18 Years	N/A	All	90	N/A	Egypt
95	NCT04342273 (ClinicalTrials.gov)	March 31, 2020	8/4/2020	A Through QT/QTc Study of KW-6356	A Through QT/QTc Study of KW-6356 in Japanese Healthy Adults	Parkinson's Disease	Drug: KW-6356;Drug: Placebo;Drug: Moxifloxacin	Kyowa Kirin Co., Ltd.	NULL	Completed	20 Years	54 Years	All	128	Phase 1	Japan
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
96	EUCTR2020-000686-16-NL (EUCTR)	26/03/2020	09/03/2020	Validation of finger tapping in PD patients	Randomized, double-blind, placebo-controlled crossover study to validate finger tapping tasks for the quantification of levodopa/carbidopa effects in Parkinson’s Disease patients.	Parkinson's Disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: SINEMET 125 Product Name: SINEMET Product Code: RVG 08740 INN or Proposed INN: Levodopa Other descriptive name: LEVODOPA INN or Proposed INN: Carbidopamonohydraat Other descriptive name: CARBIDOPA MONOHYDRATE	Centre for Human Drug Research	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	20	Phase 2	Netherlands
97	EUCTR2019-003962-41-GB (EUCTR)	23/03/2020	06/02/2020	Trial of Ondansetron as a Parkinson's HAllucinations Treatment: TOP HAT	Trial of Ondansetron as a Parkinson’s HAllucinations Treatment - TOP HAT	Adults aged over 18 years with Parkinson's disease and visual hallucinations MedDRA version: 21.1;Level: LLT;Classification code 10047570;Term: Visual hallucinations;System Organ Class: 100000004873;Therapeutic area: Psychiatry and Psychology [F] - Mental Disorders [F03]	Trade Name: Ondansetron 8 mg film-coated tablets Product Name: Ondansetron 8 mg film-coated tablets INN or Proposed INN: Ondansetron hydrochloride dihydrate	University College London	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	216	Phase 2	United Kingdom
98	NCT04269642 (ClinicalTrials.gov)	March 19, 2020	13/1/2020	SR-Exenatide (PT320) to Eveluate Efficacy and Safety in Patients With Early Parkinson's Disease	Phase IIa Study to Evaluate the Efficacy and Safety of Subcutaneous SR-Exenatide (PT320) in Patients With Early Parkinson's Disease	Early Parkinson's Disease	Drug: PT320 2.0mg Placebo;Drug: PT320 2.0 mg;Drug: PT320 2.5 mg	Peptron, Inc.	NULL	Recruiting	40 Years	75 Years	All	99	Phase 2	Korea, Republic of
99	EUCTR2018-003941-41-AT (EUCTR)	05/03/2020	19/06/2019	This study will look at whether an investigational drug, called TD-9855, works and how safe it is when taken over a longer period of time to treat symptomatic neurogenic orthostatic hypotension (snOH) in people with Parkinson’s disease (PD), multiple system atrophy (MSA), or pure autonomic failure (PAF). It will also look at the effects of TD-9855 on general well-being and whether it can improve symptoms of neurogenic OH (nOH)	A Phase 3, 22-week, Multi-center, Randomized Withdrawal Study of TD-9855 in Treating Symptomatic NeurogenicOrthostatic Hypotension in Subjects with Primary Autonomic Failure - Redwood	Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Code: TD-9855 INN or Proposed INN: ampreloxetine hydrochloride Other descriptive name: TD-9855	Theravance Biopharma Ireland Limited	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	258	Phase 3	United States;Portugal;Estonia;Spain;Ukraine;Austria;Russian Federation;Chile;Israel;United Kingdom;Italy;France;Hungary;Mexico;Canada;Argentina;Poland;Peru;Australia;Denmark;Bulgaria;Germany;New Zealand
100	EUCTR2019-002949-38-CZ (EUCTR)	04/03/2020	19/12/2019	A PHASE 3, DOUBLE-BLIND, RANDOMIZED, PLACEBO CONTROLLED, PARALLEL GROUP, 27 WEEK TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF TWO FIXED DOSES OF TAVAPADON IN EARLY PARKINSON’S DISEASE (TEMPO-1 TRIAL)	A PHASE 3, DOUBLE-BLIND, RANDOMIZED, PLACEBO CONTROLLED, PARALLEL GROUP, 27 WEEK TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF TWO FIXED DOSES OF TAVAPADON IN EARLY PARKINSON’S DISEASE (TEMPO-1 TRIAL)	Patients (18 to 60 years age) who have diagnosis of Parkinson's Disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Tavapadon 0.25mg Product Code: CVL-751 INN or Proposed INN: TAVAPADON Other descriptive name: PF-06649751 Product Name: Tavapadon 1mg Product Code: CVL-751 INN or Proposed INN: TAVAPADON Other descriptive name: PF-06649751 Product Name: Tavapadon 5mg Product Code: CVL-751 INN or Proposed INN: TAVAPADON Other descriptive name: PF-06649751	Cerevel Therapeutics, LLC	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	522	Phase 3	Serbia;United States;Spain;Ukraine;Israel;Italy;France;Czech Republic;Hungary;Canada;Poland;Australia;Bulgaria;Germany;Sweden
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
101	NCT04127695 (ClinicalTrials.gov)	March 3, 2020	9/10/2019	A Study to Evaluate the Safety and Tolerability of ABBV-0805 in Patients With Parkinson's Disease	A Randomized, Double-Blind, Placebo Controlled Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of ABBV-0805 in Patients With Parkinson's Disease	Parkinson's Disease	Drug: ABBV-0805;Drug: Placebo ABBV-0805	AbbVie	NULL	Withdrawn	N/A	85 Years	All	0	Phase 1	United States;Puerto Rico
102	NCT04353947 (ClinicalTrials.gov)	March 2, 2020	16/4/2020	Induction and Recognition of Emotions	Induction and Recognition of Emotions in Healthy Older Adults, Alzheimer's Disease and Parkinson's Disease	Healthy Older Adults;Alzheimer's Disease;Parkinson's Disease	Diagnostic Test: Mini Cognitive Examination (MCE);Diagnostic Test: Beck Depression Inventory-II (BDI-II);Diagnostic Test: Global Deterioration Scale (GDS);Diagnostic Test: Memory alteration test (M@T);Diagnostic Test: Spanish-Complutense Verbal Learning Test (TAVEC);Diagnostic Test: Barcelona test (BT);Diagnostic Test: Rey-Osterrieth Complex Figure Test (ROCFT);Diagnostic Test: Frontal assessment battery (FAB);Diagnostic Test: Positive and Negative Affect Scale (PANAS);Diagnostic Test: Auto-Assessment Manikins (SAM)	University of Valencia	Asociación Parkinson Valencia	Recruiting	65 Years	99 Years	All	60		Spain
103	EUCTR2018-004156-37-AT (EUCTR)	02/03/2020	05/11/2019	A clinical study to investigate the efficacy, safety, and tolerability of continuous subcutaneous ND0612 infusion in comparison to oral treatment in subjects with Parkinson’s disease (BouNDless)	A multicenter, randomized, active-controlled, double-blind, double-dummy, parallel group clinical trial, investigating the efficacy, safety, and tolerability of continuous subcutaneous ND0612 infusion in comparison to oral IR-LD/CD in subjects with Parkinson’s disease experiencing motor fluctuations (BouNDless) - BouNDless	Parkinson's disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: levodopa /carbidopa solution Product Code: ND0612 INN or Proposed INN: Levodopa Other descriptive name: LEVODOPA INN or Proposed INN: carbidopa Other descriptive name: CARBIDOPA Trade Name: IR LD / CD Product Name: Carbidopa and Levodopa tablets, USP INN or Proposed INN: Levodopa Other descriptive name: LEVODOPA INN or Proposed INN: carbidopa Other descriptive name: CARBIDOPA	NeuroDerm Ltd.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	482	Phase 3	United States;Portugal;Serbia;Slovakia;Spain;Ukraine;Austria;Israel;Russian Federation;United Kingdom;Italy;France;Czech Republic;Hungary;Belgium;Poland;Netherlands;Sweden;Korea, Republic of
104	NCT04260581 (ClinicalTrials.gov)	March 1, 2020	5/2/2020	Is Long-term Use of Amantadine Effective in PD?	Is Long-term Use of Amantadine Effective in Parkinson Disease?	Parkinson Disease	Drug: Determination of drug effects through amantadine cessation	Seoul National University Hospital	NULL	Not yet recruiting	40 Years	N/A	All	32	N/A	Korea, Republic of
105	NCT04154072 (ClinicalTrials.gov)	February 27, 2020	4/11/2019	A Clinical Study of NLY01 in Patient's With Early Parkinson's Disease	Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of 36 Weeks of Treatment With NLY01 in Early-stage Parkinson's Disease	Parkinson Disease	Drug: NLY01;Drug: Vehicle	Neuraly, Inc.	NULL	Recruiting	30 Years	80 Years	All	240	Phase 2	United States;Canada
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
106	NCT04291859 (ClinicalTrials.gov)	February 26, 2020	28/2/2020	Lu AF28996 in Patients With Parkinson's Disease (PD)	Interventional, Open-label, Exploratory Study, Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Lu AF28996 in Patients With Parkinson's Disease	Parkinson Disease	Drug: Lu AF28996	H. Lundbeck A/S	NULL	Recruiting	45 Years	75 Years	All	10	Phase 1	Netherlands
107	EUCTR2019-003623-37-GB (EUCTR)	12/02/2020	02/01/2020	CANnabidiol for Parkinson’s Disease Psychosis	CANnabidiol for Parkinson’s Disease Psychosis - CAN-PDP	Parkinson's disease psychosis MedDRA version: 20.0;Level: PT;Classification code 10074835;Term: Parkinson's disease psychosis;System Organ Class: 10037175 - Psychiatric disorders;Therapeutic area: Psychiatry and Psychology [F] - Psychological processes [F02]	Product Name: Cannabidiol Product Code: Cannabidiol INN or Proposed INN: Cannabidiol (CBD)	King's College London	South London and Maudsley NHS Foundation Trust	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	144	Phase 2	United Kingdom
108	EUCTR2018-004156-37-ES (EUCTR)	11/02/2020	06/11/2019	A clinical study to investigate the efficacy, safety, and tolerability of continuous subcutaneous ND0612 infusion in comparison to oral treatment in subjects with Parkinson’s disease (BouNDless)	A multicenter, randomized, active-controlled, double-blind, double-dummy, parallel group clinical trial, investigating the efficacy, safety, and tolerability of continuous subcutaneous ND0612 infusion in comparison to oral IR-LD/CD in subjects with Parkinson’s disease experiencing motor fluctuations (BouNDless) - BouNDless	Parkinson's disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		NeuroDerm Ltd.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	350	Phase 3	Serbia;Portugal;United States;Slovakia;Spain;Ukraine;Austria;Russian Federation;Israel;United Kingdom;Italy;France;Hungary;Czech Republic;Canada;Poland;Belgium;Netherlands;Korea, Republic of;Sweden
109	NCT04292223 (ClinicalTrials.gov)	February 10, 2020	28/2/2020	Open-Label Study With Pimavanserin on Activities of Daily Living in Subjects With Parkinson's Disease Psychosis	A 16-Week Open-Label Study of the Effects of Treatment With Pimavanserin on Activities of Daily Living in Subjects With Parkinson's Disease Psychosis	Parkinson Disease Psychosis	Drug: Pimavanserin	ACADIA Pharmaceuticals Inc.	NULL	Recruiting	40 Years	N/A	All	53	Phase 4	United States
110	EUCTR2019-002949-38-HU (EUCTR)	06/02/2020	17/12/2019	A PHASE 3, DOUBLE-BLIND, RANDOMIZED, PLACEBO CONTROLLED, PARALLEL GROUP, 27 WEEK TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF TWO FIXED DOSES OF TAVAPADON IN EARLY PARKINSON’S DISEASE (TEMPO-1 TRIAL)	A PHASE 3, DOUBLE-BLIND, RANDOMIZED, PLACEBO CONTROLLED, PARALLEL GROUP, 27 WEEK TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF TWO FIXED DOSES OF TAVAPADON IN EARLY PARKINSON’S DISEASE (TEMPO-1 TRIAL)	Patients (18 to 60 years age) who have diagnosis of Parkinson's Disease	Product Name: Tavapadon 0.25mg Product Code: CVL-751 INN or Proposed INN: TAVAPADON Other descriptive name: PF-06649751 Product Name: Tavapadon 1mg Product Code: CVL-751 INN or Proposed INN: TAVAPADON Other descriptive name: PF-06649751 Product Name: Tavapadon 5mg Product Code: CVL-751 INN or Proposed INN: TAVAPADON Other descriptive name: PF-06649751	Cerevel Therapeutics, LLC	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	522	Phase 3	Serbia;United States;Spain;Ukraine;Israel;Italy;France;Hungary;Czech Republic;Canada;Poland;Australia;Bulgaria;Germany;Sweden
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
111	EUCTR2018-002234-21-GB (EUCTR)	05/02/2020	04/07/2019	An open-label extension study of the safety and clinical utility of IPX203 in Parkinson’s Disease patients with motor fluctuations	AN OPEN-LABEL EXTENSION STUDY OF THE SAFETY AND CLINICAL UTILITY OF IPX203 IN PARKINSON’S DISEASE PATIENTS WITH MOTOR FLUCTUATIONS	Parkinson's disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0;Level: SOC;Classification code 10029205;Term: Nervous system disorders;Classification code 10028035;Term: Movement disorder;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: IPX203 Product Code: IPX203 INN or Proposed INN: Levodopa Other descriptive name: LEVODOPA INN or Proposed INN: Carbidopa Other descriptive name: ANHYDROUS CARBIDOPA Product Name: IPX203 Product Code: IPX203 INN or Proposed INN: Levodopa Other descriptive name: LEVODOPA INN or Proposed INN: Carbidopa Other descriptive name: ANHYDROUS CARBIDOPA Product Name: IPX203 Product Code: IPX203 INN or Proposed INN: Levodopa Other descriptive name: LEVODOPA INN or Proposed INN: Carbidopa Other descriptive name: ANHYDROUS CARBIDOPA Product Name: IPX203 Product Code: IPX203 INN or Proposed INN: Levodopa Other descriptive name: LEVODOPA INN or Proposed INN: Carbidopa	Impax Laboratories, LLC	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	300	Phase 3	France;United States;Czech Republic;Spain;Germany;Italy;United Kingdom
112	NCT04117178 (ClinicalTrials.gov)	February 4, 2020	30/9/2019	Monitoring Anti-Dementia Drugs by Serum Levels	Monitoring Anti-Dementia Drugs by Serum Levels: Importance of Serum Levels, Drug-monitoring, Side-effects, Clinical Efficacy and Compliance (Translation of Official Danish Title)	Dementia;Dementia With Lewy Bodies;Dementia in Parkinsons Disease;Dementia Alzheimers;Alzheimer Disease	Drug: Donepezil;Drug: Memantine;Diagnostic Test: Measurement of serum level of anti-dementia drug	Zealand University Hospital	Epilepsihospitalet Filadelfia	Recruiting	18 Years	N/A	All	110	Phase 4	Denmark
113	NCT04246437 (ClinicalTrials.gov)	February 4, 2020	25/1/2020	[18F]F-DOPA Imaging in Patients With Autonomic Failure	[18F]F-DOPA Imaging in Patients With Autonomic Failure	Autonomic Failure;Pure Autonomic Failure;Parkinson Disease;Multiple System Atrophy;Dementia With Lewy Bodies	Drug: [18F]FDOPA;Drug: Carbidopa 200mg oral dose;Drug: Entacapone 400mg oral dose	Daniel Claassen	NULL	Recruiting	18 Years	N/A	All	40	Phase 1	United States
114	NCT04251585 (ClinicalTrials.gov)	February 4, 2020	28/1/2020	Intranasal Insulin in Parkinson's Disease	Single Center Safety and Tolerability Trial of Intranasal Insulin in Parkinson's Disease	Parkinson Disease	Drug: Regular Novolin R;Drug: Placebo	HealthPartners Institute	NULL	Recruiting	41 Years	89 Years	All	30	Phase 2	United States
115	EUCTR2018-003941-41-PT (EUCTR)	03/02/2020	21/08/2019	This study will look at whether an investigational drug, called TD-9855, works and how safe it is when taken over a longer period of time to treat symptomatic neurogenic orthostatic hypotension (snOH) in people with Parkinson’s disease (PD), multiple system atrophy (MSA), or pure autonomic failure (PAF). It will also look at the effects of TD-9855 on general well-being and whether it can improve symptoms of neurogenic OH (nOH)	A Phase 3, 22-week, Multi-center, Randomized Withdrawal Study of TD-9855 in Treating Symptomatic NeurogenicOrthostatic Hypotension in Subjects with Primary Autonomic Failure - Redwood	Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure MedDRA version: 20.0;Level: LLT;Classification code 10021102;Term: Hypotension orthostatic symptomatic;System Organ Class: 100000004866;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Code: TD-9855 INN or Proposed INN: ampreloxetine hydrochloride Other descriptive name: TD-9855	Theravance Biopharma Ireland Limited	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	258	Phase 3	Portugal;United States;Estonia;Spain;Ukraine;Austria;Russian Federation;Israel;Italy;United Kingdom;France;Hungary;Canada;Poland;Australia;Denmark;Bulgaria;Germany;New Zealand
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
116	NCT04428983 (ClinicalTrials.gov)	February 3, 2020	20/11/2019	The Effect of Hericium Erinaceus Mycelium in Non-motor Symptoms of Parkinson's Disease	The Effect of Hericium Erinaceus Mycelium in Non-motor Symptoms of Parkinson's Disease	Parkinson Disease	Dietary Supplement: Hericium erinaceus mycelium	National Cheng-Kung University Hospital	NULL	Recruiting	50 Years	79 Years	All	80	N/A	Taiwan
117	EUCTR2018-003289-15-DE (EUCTR)	28/01/2020	08/02/2019	This study will look at whether an investigational drug called TD-9855 works and how safe it is for treating symptomatic neurogenic orthostatic hypotension (snOH) in people with Parkinson’s disease (PD), multiple system atrophy (MSA) or pure autonomic failure (PAF)	A Phase 3, 4-week, Multicenter, Randomized, Double-blind,Placebo-controlled, Parallel-group Study of TD-9855 inTreating Symptomatic Neurogenic Orthostatic Hypotension inSubjects With Primary Autonomic Failure - Phase 3 Clinical Effect of TD-9855 for Treating snOH in Subjects With Primary Autonomic Failure	Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Code: TD-9855 INN or Proposed INN: ampreloxetine Other descriptive name: TD-9855	Theravance Biopharma Ireland Limited	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	188	Phase 3	Portugal;United States;Estonia;Spain;Ukraine;Austria;Israel;Russian Federation;United Kingdom;Italy;France;Czech Republic;Hungary;Canada;Poland;Denmark;Bulgaria;Germany
118	NCT04322227 (ClinicalTrials.gov)	January 23, 2020	29/1/2020	Study Investigating Effects of Foliglurax in Patients With Parkinson's Disease (PD) and Healthy Subjects	Interventional, Randomized, Double-blind, Placebo-controlled Three-way Crossover Study Investigating the Pharmacodynamic Effects of Two Doses of Foliglurax Using Electroencephalography in Patients With Parkinson's Disease and in Healthy Subjects	Parkinson Disease;Healthy	Drug: Foliglurax 10 mg (treatment A);Drug: Foliglurax 30 mg (treatment B);Drug: Placebo (treatment C)	H. Lundbeck A/S	NULL	Terminated	50 Years	70 Years	All	6	Phase 1	France
119	NCT04305002 (ClinicalTrials.gov)	January 21, 2020	20/2/2020	Exenatide Treatment in Parkinson's Disease	Effect of Exenatide on Disease Progression in Early Parkinson's Disease	Parkinson Disease	Drug: Exenatide;Drug: Placebo	Center for Neurology, Stockholm	Karolinska Institutet	Recruiting	25 Years	80 Years	All	60	Phase 2	Sweden
120	NCT04220762 (ClinicalTrials.gov)	January 21, 2020	17/12/2019	A Study to Determine the Dose of WIN-1001X by Evaluating Efficacy and Safety in Early Parkinson's Disease Patients	A Clinical Study to Determine the Optimal Dose of WIN-1001X by Evaluating Its Efficacy and Safety in Patients With Early Parkinson's Disease: Double-blind, Randomized, Placebo-controlled, Multicenter, Phase II Study	Parkinson Disease	Drug: WIN-1001X;Drug: Placebo	Medi Help Line	NULL	Recruiting	30 Years	N/A	All	188	Phase 2	Korea, Republic of
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
121	NCT04232969 (ClinicalTrials.gov)	January 20, 2020	10/1/2020	Exenatide Once Weekly Over 2 Years as a Potential Disease Modifying Treatment for Parkinson's Disease	A Randomised, Double Blind, Parallel Group, Placebo Controlled, Phase 3 Trial of Exenatide Once Weekly Over 2 Years as a Potential Disease Modifying Treatment for Parkinson's Disease	Parkinson's Disease	Drug: Exenatide extended release 2mg (Bydureon)	University College, London	NULL	Recruiting	25 Years	80 Years	All	200	Phase 3	United Kingdom
122	NCT04369430 (ClinicalTrials.gov)	January 16, 2020	13/4/2020	Study Assessing Efficacy and Safety of AKST4290 in Subjects With Parkinson's Disease on Stable Dopaminergic Treatment	A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of AKST4290 in Subjects With Parkinson's Disease on Stable Dopaminergic Treatment	Parkinson Disease	Drug: AKST4290;Drug: Placebo	Alkahest, Inc.	NULL	Recruiting	50 Years	80 Years	All	120	Phase 2	United States;Estonia;Germany;Poland;Slovakia;Hungary
123	EUCTR2018-004156-37-GB (EUCTR)	14/01/2020	13/09/2019	A clinical study to investigate the efficacy, safety, and tolerability of continuous subcutaneous ND0612 infusion in comparison to oral treatment in subjects with Parkinson’s disease (BouNDless)	A multicenter, randomized, active-controlled, double-blind, double-dummy, parallel group clinical trial, investigating the efficacy, safety, and tolerability of continuous subcutaneous ND0612 infusion in comparison to oral IR-LD/CD in subjects with Parkinson’s disease experiencing motor fluctuations (BouNDless) - BouNDless	Parkinson's disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: levodopa /carbidopa solution Product Code: ND0612 INN or Proposed INN: Levodopa Other descriptive name: LEVODOPA INN or Proposed INN: carbidopa Other descriptive name: CARBIDOPA Product Name: Carbidopa and Levodopa tablets, USP INN or Proposed INN: Levodopa Other descriptive name: LEVODOPA INN or Proposed INN: carbidopa Other descriptive name: CARBIDOPA	NeuroDerm Ltd.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	350	Phase 3	Serbia;Portugal;United States;Slovakia;Spain;Ukraine;Austria;Russian Federation;Israel;United Kingdom;Italy;France;Hungary;Czech Republic;Canada;Poland;Belgium;Netherlands;Korea, Republic of;Sweden
124	EUCTR2019-001657-42-SK (EUCTR)	14/01/2020	01/10/2019	A study to learn how well the drug AKST4290 works and how safeAKST4290 is in people who have Parkinson's disease that are takingdopamine based medication.	A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate theEfficacy and Safety of AKST4290 in Subjects with Parkinson's Disease onStable Dopaminergic Treatment. - N/A	Parkinson's Disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: AKST4290 Product Code: AKST4290 INN or Proposed INN: AKST4290 Other descriptive name: 2-[[[(2R)-1-[1-[(4-CHLORO-3-METHYLPHENYL)METHYL]-4- PIPERIDINYL]-5-OXO-2-PYRROLIDINYL]CARBONYL]AMINO]- N,N,6-TRIMETHYL-4-PYRIDINECARBOXAMIDE,DIHYDROCHLORIDE	Alkahest, Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	120	Phase 2	United States;Hungary;Estonia;Slovakia;Poland;Germany
125	EUCTR2018-003289-15-PT (EUCTR)	13/01/2020	21/08/2019	This study will look at whether an investigational drug called TD-9855 works and how safe it is for treating symptomatic neurogenic orthostatic hypotension (snOH) in people with Parkinson’s disease (PD), multiple system atrophy (MSA) or pure autonomic failure (PAF)	A Phase 3, 4-week, Multicenter, Randomized, Double-blind,Placebo-controlled, Parallel-group Study of TD-9855 inTreating Symptomatic Neurogenic Orthostatic Hypotension inSubjects With Primary Autonomic Failure - Sequoia study	Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Code: TD-9855 INN or Proposed INN: ampreloxetine hydrochloride	Theravance Biopharma Ireland Limited	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	188	Phase 3	Portugal;United States;Estonia;Spain;Ukraine;Austria;Russian Federation;Israel;Chile;Italy;United Kingdom;France;Hungary;Mexico;Canada;Argentina;Poland;Peru;Australia;Denmark;Bulgaria;Germany;New Zealand
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
126	NCT04295642 (ClinicalTrials.gov)	January 8, 2020	24/1/2020	A 2-Part Trial of CVL-751 in Subjects With Parkinson's Disease	A 2-Part, Open Label, Adaptive, Single and/or Multiple Oral Dose, Safety, Tolerability, and Food Effect Trial of CVL-751 in Subjects With Parkinson's Disease	Parkinson Disease	Drug: CVL-751	Cerevel Therapeutics, LLC	NULL	Recruiting	45 Years	75 Years	All	33	Phase 1	United States
127	NCT04223193 (ClinicalTrials.gov)	January 6, 2020	7/1/2020	Flexible-Dose Trial in Early Parkinson's Disease (PD)	A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Flexible-Dose, 27-Week Trial to Evaluate the Efficacy, Safety, and Tolerability of Tavapadon in Early Parkinson's Disease (TEMPO-2 Trial)	Parkinson Disease	Drug: Tavapadon;Drug: Placebo	Cerevel Therapeutics, LLC	NULL	Recruiting	40 Years	80 Years	All	296	Phase 3	United States
128	NCT04127578 (ClinicalTrials.gov)	January 3, 2020	14/10/2019	Phase 1/2a Clinical Trial of PR001A in Patients With Parkinson's Disease With at Least One GBA1 Mutation (PROPEL)	A Phase 1/2a Open-Label Ascending Dose Study to Evaluate the Safety and Effects of PR001A in Patients With Parkinson's Disease With at Least One GBA1 Mutation	Parkinson Disease	Biological: PR001A;Drug: Methylprednisolone;Drug: Sirolimus;Drug: Prednisone	Prevail Therapeutics	NULL	Recruiting	35 Years	80 Years	All	12	Phase 1;Phase 2	United States
129	NCT04226248 (ClinicalTrials.gov)	January 2, 2020	5/12/2019	CHIEF PD (CHolinesterase Inhibitor to prEvent Falls in Parkinson's Disease)	CHolinesterase Inhibitor to prEvent Falls in Parkinson's Disease: A Phase 3 Randomised, Double-blind Placebo-controlled Trial of Rivastigmine to Prevent Falls in Parkinson's Disease.	Parkinson Disease	Drug: Rivastigmine Transdermal System;Other: Placebo Transdermal System	University of Bristol	Royal United Hospitals Bath NHS Foundation Trust	Recruiting	18 Years	N/A	All	600	Phase 3	United Kingdom
130	NCT04301492 (ClinicalTrials.gov)	January 1, 2020	17/2/2020	Tolerability, Safety and Efficacy of Vortioxetine	Tolerability, Safety and Efficacy of Vortioxetine for Treatment od Depression in Parkinson's Disease: a 16 Week Open Label Study	Depression	Drug: Vortioxetine	IRCCS San Raffaele	NULL	Recruiting	30 Years	80 Years	All	20	Phase 4	Italy
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
131	NCT03808961 (ClinicalTrials.gov)	January 1, 2020	16/1/2019	Niacin for Parkinsons Disease	NAPS: Niacin for Parkinsons Disease	Parkinson's Disease	Dietary Supplement: Niacin;Dietary Supplement: Niacinamide;Other: Placebo	VA Office of Research and Development	NULL	Recruiting	35 Years	N/A	All	100	N/A	United States
132	NCT04152655 (ClinicalTrials.gov)	January 1, 2020	7/10/2019	A Study of Efficacy and Safety of Idebenone vs. Placebo in Prodromal Parkinson Disease	A Study of Efficacy and Safety of Idebenone vs. Placebo in Prodromal Parkinson Disease (SEASEiPPD)	REM Sleep Behavior Disorder;Parkinson Disease	Drug: Idebenone;Drug: Placebo oral tablet	Second Affiliated Hospital, School of Medicine, Zhejiang University	NULL	Recruiting	18 Years	N/A	All	180	Phase 2;Phase 3	China
133	NCT03446807 (ClinicalTrials.gov)	January 2020	20/2/2018	Safety and Efficacy of Droxidopa for Fatigue in Patients With Parkinsonism	Safety and Efficacy of Droxidopa for Fatigue in Patients With Parkinsonism	Parkinson Disease;Multiple System Atrophy;Progressive Supranuclear Palsy	Drug: Droxidopa;Drug: Placebo Oral Tablet	Loma Linda University	H. Lundbeck A/S	Not yet recruiting	50 Years	N/A	All	32	Phase 2	United States
134	NCT04218968 (ClinicalTrials.gov)	December 30, 2019	26/12/2019	Cardiac Changes in Early Parkinson's Disease: A Follow up Study	The Effect of Adrenergic Blocker Therapy on Cardiac and Striatal Transporter Uptake in Pre-Motor and Symptomatic Parkinson's Disease: A Follow up Study	REM Sleep Behavior Disorder;Pre-motor Parkinson Disease;Symptomatic Parkinson Disease	Drug: Carvedilol	Cedars-Sinai Medical Center	NULL	Enrolling by invitation	18 Years	85 Years	All	15	Phase 2	United States
135	EUCTR2018-004156-37-HU (EUCTR)	19/12/2019	18/10/2019	A clinical study to investigate the efficacy, safety, and tolerability of continuous subcutaneous ND0612 infusion in comparison to oral treatment in subjects with Parkinson’s disease (BouNDless)	A multicenter, randomized, active-controlled, double-blind, double-dummy, parallel group clinical trial, investigating the efficacy, safety, and tolerability of continuous subcutaneous ND0612 infusion in comparison to oral IR-LD/CD in subjects with Parkinson’s disease experiencing motor fluctuations (BouNDless) - BouNDless	Parkinson's disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		NeuroDerm Ltd.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	350	Phase 3	Serbia;Portugal;United States;Slovakia;Spain;Ukraine;Austria;Russian Federation;Israel;Italy;United Kingdom;France;Hungary;Czech Republic;Canada;Poland;Belgium;Netherlands;Korea, Republic of;Sweden
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
136	NCT03815916 (ClinicalTrials.gov)	December 19, 2019	18/1/2019	31P-MRS Imaging to Assess the Effects of CNM-Au8 on Impaired Neuronal Redox State in Parkinson's Disease	A Phase 2, Pilot Open Label, Sequential Group, Investigator Blinded Study of Magnetic Resonance Spectroscopy (31P-MRS) to Assess the Effects of CNM-Au8 for the Bioenergetic Improvement of Impaired Neuronal Redox State in Parkinson's Disease	Parkinson's Disease	Drug: Gold Nanocrystals	Clene Nanomedicine	University of Texas Southwestern Medical Center	Recruiting	30 Years	80 Years	All	30	Phase 2	United States
137	NCT04164121 (ClinicalTrials.gov)	December 17, 2019	12/11/2019	A Clinical Study Trial of Phenlarmide in China	A Randomized, Double-blind, Placebo-controlled, Single-dose, Multiple-dose, Incremental Tolerance and Pharmacokinetics Study of Phenlarmide Tablets in Chinese Healthy Adult Volunteers	Parkinson Disease	Drug: Phenlarmide Tablets;Drug: Placebos	Yiling Pharmaceutical Inc.	NULL	Recruiting	18 Years	65 Years	All	36	Phase 1	China
138	NCT04097080 (ClinicalTrials.gov)	December 15, 2019	18/9/2019	Comparative Controlled Study of Analgesic, Antiasthenic and Anti-Anxiety Effects of Xenon in Patients With Parkinson's Disease	Comparative Controlled Study of Analgesic, Antiasthenic and Anti-Anxiety Effects of Xenon in Patients With Parkinson's Disease	Parkinson Disease	Drug: NBTX-001;Drug: Standard of Care	Nobilis Therapeutics Inc.	NULL	Recruiting	18 Years	N/A	All	60	Phase 1	Russian Federation
139	NCT04201093 (ClinicalTrials.gov)	December 13, 2019	13/12/2019	Fixed-Dose Trial in Early Parkinson's Disease (PD)	A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, 27-Week Trial to Evaluate the Efficacy, Safety, and Tolerability of Two Fixed Doses of Tavapadon in Early Parkinson's Disease (TEMPO-1 TRIAL)	Parkinson Disease	Drug: Tavapadon;Drug: Placebo	Cerevel Therapeutics, LLC	NULL	Recruiting	40 Years	80 Years	All	522	Phase 3	United States;Australia
140	NCT04183634 (ClinicalTrials.gov)	December 3, 2019	28/11/2019	An Open, Randomised, Single Dose, 2-period, 2-sequence Crossover Adhesion Study of Two Different Transdermal Patches Containing Rotigotine.	An Open, Randomised, Single Dose, 2-period, 2-sequence Crossover Adhesion Study of Two Different Transdermal Patches Containing Rotigotine.	Parkinson Disease	Drug: Rotigotine TTS (Test);Drug: Neupro (Reference)	Sandoz	NULL	Terminated	18 Years	80 Years	All	31	Phase 1	Germany
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
141	NCT04249544 (ClinicalTrials.gov)	December 3, 2019	28/1/2020	Social Decision Making in Parkinson's Disease	Cognitive and Neural Mechanisms of Impaired Social Decision-Making in Parkinson's Patients Taking Dopamine Agonists	Parkinson Disease	Drug: Pramipexole;Drug: Placebo	Vanderbilt University Medical Center	United States Department of Defense	Recruiting	45 Years	80 Years	All	60	Phase 1	United States
142	EUCTR2018-003089-14-GB (EUCTR)	03/12/2019	07/10/2019	Can suppressing the immune system with azathioprine slow down the progression of Parkinson's disease?	Azathioprine Immunosuppression and Disease Modification in Parkinson’s Disease (AZA-PD): a randomised double-blind placebo-controlled phase II trial - AZA-PD	Parkinson's disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Azathioprine INN or Proposed INN: Azathioprine	Cambridge University Hospitals NHS Foundation Trust and University of Cambridge	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	60	Phase 2	United Kingdom
143	NCT04191577 (ClinicalTrials.gov)	December 2, 2019	30/10/2019	Study of CVN424 in Parkinson's Disease Patients With Motor Fluctuations	A Phase II, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of CVN424 in Parkinson's Disease Patients With Motor Fluctuations	Parkinson Disease	Drug: CVN424 Low Dose;Drug: CVN424 High Dose;Drug: Placebo	Cerevance Beta, Inc.	NULL	Recruiting	30 Years	80 Years	All	66	Phase 2	United States
144	NCT04044131 (ClinicalTrials.gov)	December 1, 2019	17/7/2019	Metabolic Cofactor Supplementation in Alzheimer's Disease (AD) and Parkinson's Disease (PD) Patients	A Phase 2, Randomized, Placebo Controlled Study to Evaluate the Efficacy, Tolerability and Safety of Metabolic Cofactor Supplementation in Alzheimer's Disease (AD) And Parkinson's Disease (PD) Patients	Alzheimer Disease;Parkinson Disease	Drug: Metabolic Cofactor Supplementation;Drug: Sorbitol	Istanbul Medipol University Hospital	ScandiBio Therapeutics AB;Alanya Alaaddin Keykubat University;Sahlgrenska University Hospital, Sweden;KTH Royal Institute of Technology	Recruiting	18 Years	N/A	All	120	Phase 2	Turkey
145	NCT03436953 (ClinicalTrials.gov)	December 2019	7/2/2018	A Phase 2 Study of CX-8998 in Adults With Tremor Associated With Parkinson's Disease	A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of CX-8998 for Tremor Associated With Parkinson's Disease	Parkinson's Disease;Tremor	Drug: CX-8998;Drug: Placebo	Jazz Pharmaceuticals	NULL	Not yet recruiting	40 Years	80 Years	All	60	Phase 2	United States
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
146	EUCTR2018-004156-37-CZ (EUCTR)	26/11/2019	26/09/2019	A clinical study to investigate the efficacy, safety, and tolerability of continuous subcutaneous ND0612 infusion in comparison to oral treatment in subjects with Parkinson’s disease (BouNDless)	A multicenter, randomized, active-controlled, double-blind, double-dummy, parallel group clinical trial, investigating the efficacy, safety, and tolerability of continuous subcutaneous ND0612 infusion in comparison to oral IR-LD/CD in subjects with Parkinson’s disease experiencing motor fluctuations (BouNDless) - BouNDless	Parkinson's disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: levodopa /carbidopa solution Product Code: ND0612 INN or Proposed INN: Levodopa Other descriptive name: LEVODOPA INN or Proposed INN: carbidopa Other descriptive name: CARBIDOPA Trade Name: IR LD / CD Product Name: Carbidopa and Levodopa tablets, USP INN or Proposed INN: Levodopa Other descriptive name: LEVODOPA INN or Proposed INN: carbidopa Other descriptive name: CARBIDOPA	NeuroDerm Ltd.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	482	Phase 3	United States;Serbia;Portugal;Czechia;Slovakia;Spain;Ukraine;Austria;Israel;Russian Federation;United Kingdom;Italy;France;Czech Republic;Hungary;Belgium;Poland;Netherlands;Sweden;Korea, Republic of
147	ChiCTR1900027306	2019-11-15	2019-11-08	Application of optical coherence tomography and detection of a-synuclein in tears in the diagnosis of Parkinson's disease	Morphological changes of retina in patients with Parkinson's disease and the role of a-synuclein in retinal damage	Parkinson's disease	Gold Standard:British brain bank Parkinson's disease diagnostic criteria;Index test:Application of optical coherence tomography to observe the retinal structure of the macular area, optic disc area and the expression level of a-synuclein in tears in the diagnosis of Parkinson's disease.;	The First Affiliated Hospital of Chengdu Medical College	NULL	Recruiting			Both	Target condition:85;Difficult condition:85		China
148	NCT03924414 (ClinicalTrials.gov)	November 15, 2019	2/4/2019	Trial of Parkinson's And Zoledronic Acid	TOPAZ: Trial of Parkinson's And Zoledronic Acid A Randomized Placebo-controlled Trial of Zoledronic Acid for the Prevention of Fractures in Patients With Parkinson's Disease	Parkinson Disease;Osteoporosis;Parkinsonism	Drug: Zoledronic Acid 5Mg/Bag 100Ml Inj;Other: Placebo	California Pacific Medical Center Research Institute	National Institute on Aging (NIA);University of California, San Francisco;Duke University;University of Pittsburgh;Parkinson's Foundation	Recruiting	60 Years	N/A	All	3500	Phase 4	United States
149	NCT04148391 (ClinicalTrials.gov)	November 14, 2019	30/10/2019	A Study to Evaluate NYX-458 in Subjects With PD-MCI	A Study to Evaluate NYX-458 in Subjects With Mild Cognitive Impairment Associated With Parkinson's Disease	Parkinson's Disease;Mild Cognitive Impairment	Drug: Placebo Oral Capsule;Drug: NYX-458	Aptinyx	CogState Ltd.;Worldwide Clinical Trials	Active, not recruiting	50 Years	80 Years	All	135	Phase 2	United States
150	NCT04175132 (ClinicalTrials.gov)	November 12, 2019	12/11/2019	Binding of Foliglurax to Regions in the Brain in Healthy Participants and in Patients With Parkinson's Disease (PD)	Interventional, Open-label, Positron Emission Tomography (PET) Study With [11C]-PXT012253 Investigating the Brain mGlu4 Receptor Occupancy, Safety, Tolerability and Pharmacokinetics of Foliglurax in Healthy Subjects and Patients With Parkinson's Disease	Healthy;Parkinson Disease	Drug: foliglurax	H. Lundbeck A/S	NULL	Terminated	50 Years	70 Years	All	6	Phase 1	Sweden
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
151	ChiCTR1900027210	2019-11-01	2019-11-05	Effects of different anesthesia methods on postoperative delirium in patients with Parkinson's disease and biological markers of postoperative delirium in patients with Parkinson's disease	Effects of different anesthesia methods on postoperative delirium in patients with Parkinson's disease and biological markers of postoperative delirium in patients with Parkinson's disease	Delirium	1:Total Intravenous Anesthesia;2:Balance Anesthesia;	Tsinghua University Yuquan Hospital	NULL	Recruiting			Female	1:60;2:60;		China
152	NCT03652870 (ClinicalTrials.gov)	November 1, 2019	8/8/2018	Antidepressants Trial in Parkinson's Disease	A Randomised Placebo-Controlled Trial of Escitalopram and Nortriptyline With Standard Psychological Care for Depression in Parkinson's Disease	Depression;Parkinson Disease	Drug: Nortriptyline;Drug: Escitalopram;Drug: Placebo	University College, London	London North West Healthcare NHS Trust;King's College London;University Hospital Plymouth NHS Trust;NHS Lothian	Not yet recruiting	18 Years	85 Years	All	408	Phase 3	NULL
153	EUCTR2018-002942-35-GB (EUCTR)	31/10/2019	05/09/2019	A Randomised Controlled Trial of Escitalopram and Nortriptyline compared with placebo, and standard psychological care, for depression in Parkinson’s disease	A Randomised Controlled Trial of Escitalopram and Nortriptyline compared with placebo and standard psychological care for depression in Parkinson’s Disease - Antidepressants Trial in Parkinson's Disease (ADepT-PD)	Depression in Parkinson's disease MedDRA version: 20.0;Level: PT;Classification code 10012378;Term: Depression;System Organ Class: 10037175 - Psychiatric disorders MedDRA version: 20.0;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Escitalopram INN or Proposed INN: Escitalopram oxalate Trade Name: Nortriptyline Product Name: Nortriptyline INN or Proposed INN: Nortriptyline hydrochloride	University College London Comprehensive Clinical Trials Unit	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	408	Phase 3	United Kingdom
154	EUCTR2018-003941-41-DK (EUCTR)	29/10/2019	24/06/2019	This study will look at whether an investigational drug, called TD-9855, works and how safe it is when taken over a longer period of time to treat symptomatic neurogenic orthostatic hypotension (snOH) in people with Parkinson’s disease (PD), multiple system atrophy (MSA), or pure autonomic failure (PAF). It will also look at the effects of TD-9855 on general well-being and whether it can improve symptoms of neurogenic OH (nOH)	A Phase 3, 22-week, Multi-center, Randomized Withdrawal Study of TD-9855 in Treating Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure - Redwood	Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Theravance Biopharma Ireland Limited	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	258	Phase 3	United States;Estonia;Spain;Ukraine;Austria;Russian Federation;Israel;Italy;United Kingdom;France;Hungary;Canada;Poland;Denmark;Australia;Bulgaria;Germany;New Zealand
155	EUCTR2019-000732-26-SE (EUCTR)	23/10/2019	07/05/2019	Exenatide Treatment in Parkinson's Disease	Effect of Exenatide on disease progression in early Parkinson's disease.	Parkinson's disease;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Bydureon 2 mg powder and solvent for prolonged-release suspension Product Name: BYDUREON INN or Proposed INN: EXENATIDE	Stockholm Health Care Services	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	60	Phase 2	Sweden
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
156	NCT04164758 (ClinicalTrials.gov)	October 23, 2019	13/11/2019	Study to Evaluate Safety and Daytime Sedation in Subjects With Parkinson's Disease With Neuropsychiatric Symptoms Treated With Pimavanserin or Low-Dose Quetiapine	A Pilot Randomized, Double-blind, Placebo-controlled Study to Evaluate Safety and Daytime Sedation in Subjects With Parkinson's Disease With Neuropsychiatric Symptoms Treated With Pimavanserin or Low-Dose Quetiapine	Parkinson's Disease	Drug: Pimavanserin;Other: Placebo;Drug: Quetiapine	ACADIA Pharmaceuticals Inc.	NULL	Terminated	50 Years	85 Years	All	11	Phase 2	United States
157	EUCTR2019-001657-42-DE (EUCTR)	22/10/2019	11/06/2019	A study to learn how well the drug AKST4290 works and how safe AKST4290 is in people who have Parkinson's disease that are taking dopamine based medication.	A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of AKST4290 in Subjects with Parkinson's Disease on Stable Dopaminergic Treatment - N/A	Parkinson's Disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: AKST4290 Product Code: AKST4290 INN or Proposed INN: AKST4290 Other descriptive name: 2-[[[(2R)-1-[1-[(4-CHLORO-3-METHYLPHENYL)METHYL]-4- PIPERIDINYL]-5-OXO-2-PYRROLIDINYL]CARBONYL]AMINO]- N,N,6-TRIMETHYL-4-PYRIDINECARBOXAMIDE,DIHYDROCHLORIDE	Alkahest, Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	120	Phase 2	United States;Estonia;Hungary;Slovakia;Poland;Germany
158	ChiCTR1900026956	2019-10-21	2019-10-27	Minimum alveolar concentration-awake of sevoflurane in patients with Parkinson's disease	Minimum alveolar concentration-awake of sevoflurane in patients with Parkinson's disease	Parkinson’s disease	Parkinson’s disease group:Sevoflurane induction;Non-Parkinson’s disease group:Sevoflurane induction;	The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China	NULL	Pending	40	64	Both	Parkinson’s disease group:30;Non-Parkinson’s disease group:30;	N/A	China
159	EUCTR2018-003337-15-ES (EUCTR)	17/10/2019	30/04/2019	A study to look at how safe, and effective the study drug K0706 is in patients with early Parkinson's Disease.	A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of K0706 in Subjects With Early Parkinson’s Disease	Early Parkinson’s Disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Sun Pharma Advanced Research Company (SPARC) Limited	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	504	Phase 2	United States;Hungary;Czech Republic;Slovakia;Poland;Spain;India
160	NCT04273932 (ClinicalTrials.gov)	October 17, 2019	31/10/2019	Effects of Lithium Therapy on Blood-based Therapeutic Targets in Parkinson's Disease.	Effects of Lithium Therapy on Blood-based Therapeutic Targets in Parkinson's Disease.	Parkinson Disease	Drug: Lithium	University at Buffalo	NULL	Recruiting	45 Years	80 Years	All	20	Phase 1	United States
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
161	NCT04157933 (ClinicalTrials.gov)	October 16, 2019	1/11/2019	Staccato Apomorphine Multi-dose PK and PD in Patients With Parkinson's Disease	A Placebo-Controlled, Double-Blind, Multiple Ascending Dose Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamic Profile of AZ-009 in Subjects With Established Parkinson's Disease	Parkinson's Disease	Drug: 009-A1;Drug: 009-A2;Drug: 009-A3;Drug: 009-A0;Drug: 009-B1 (active --> placebo) crossover;Drug: 009-B2 (placebo --> active) crossover	Alexza Pharmaceuticals, Inc.	NULL	Completed	30 Years	85 Years	All	35	Phase 1	Netherlands
162	NCT04146454 (ClinicalTrials.gov)	October 14, 2019	16/10/2019	Smartphone-based Wearable Telerehabilitation	A New Smartphone-based Wearable Telerehabilitation System for People With Parkinson's Disease	Parkinson Disease	Other: Smartphone-based balance exercises	University of Houston	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	Enrolling by invitation	50 Years	75 Years	All	44	N/A	United States
163	NCT04165837 (ClinicalTrials.gov)	October 14, 2019	13/11/2019	Safety, Tolerability, and Pharmacokinetics of Oral FB-101 in Healthy Subjects	A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending Dose and Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral FB-101 in Healthy Subjects	Parkinson's Disease	Drug: FB-101;Drug: Placebo	1ST Biotherapeutics, Inc.	NULL	Recruiting	19 Years	55 Years	All	48	Phase 1	United States
164	EUCTR2018-002233-37-GB (EUCTR)	11/10/2019	14/02/2019	Evaluate the safety and efficacy of IPX203 carbidopa-levodopa extended release capsules compared to carbidopa-levodopa immediate release tablets in patients with Parkinson’s with motor fluctuations.	A randomized controlled study to compare the safety and efficacy of IPX203 with immediate-release carbidopa-levodopa in Parkinson's disease patients with motor fluctuations.	Parkinson's disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0;Level: SOC;Classification code 10029205;Term: Nervous system disorders;Classification code 10028035;Term: Movement disorder;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: IPX203 Product Code: IPX203 INN or Proposed INN: Levodopa Other descriptive name: LEVODOPA INN or Proposed INN: Carbidopa Other descriptive name: ANHYDROUS CARBIDOPA Trade Name: Carbidopa and Levodopa Tablets, USP Product Name: IR CD-LD (carbidopa-levodopa) tablets Product Code: IR CD-LD INN or Proposed INN: Levodopa INN or Proposed INN: Carbidopa Other descriptive name: ANHYDROUS CARBIDOPA	Impax Laboratories, LLC	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	510	Phase 3	United States;France;Czech Republic;Poland;Spain;Germany;Italy;United Kingdom
165	JPRN-jRCTs031190115	11/10/2019	11/10/2019	PK & PD of coadministration of XOR inhibitor and inosine	Pharmacokinetics and pharmacodynamics study of coadministration of either allopurinol or febuxostat and inosine	Parkinson's disease neurodegenerative disease	Coadministration of allopurinol and inosine, or coadministration of febuxostat and inosine	Kamatani Naoyuki	NULL	Recruiting	>= 20age old	<= 40age old	Male	28	Phase 1	Japan
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
166	NCT04575259 (ClinicalTrials.gov)	October 10, 2019	29/9/2020	OLE Study for Patients With Parkinson's Disease With Dementia Enrolled in Study ANAVEX2-73-PDD-001	Open Label Extension Study for Patients With Parkinson's Disease With Dementia Enrolled in Study ANAVEX2-73-PDD-001	Parkinson Disease Dementia	Drug: ANAVEX2-73	Anavex Life Sciences Corp.	Anavex Australia Pty Ltd.;Anavex Germany GmbH	Recruiting	50 Years	85 Years	All	120	Phase 2	Australia;Spain
167	EUCTR2018-003289-15-BG (EUCTR)	10/10/2019	24/07/2019	This study will look at whether an investigational drug called TD-9855 works and how safe it is for treating symptomatic neurogenic orthostatic hypotension (snOH) in people with Parkinson’s disease (PD), multiple system atrophy (MSA) or pure autonomic failure (PAF)	A Phase 3, 4-week, Multicenter, Randomized, Double-blind,Placebo-controlled, Parallel-group Study of TD-9855 inTreating Symptomatic Neurogenic Orthostatic Hypotension inSubjects With Primary Autonomic Failure - Sequoia study	Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Code: TD-9855 INN or Proposed INN: ampreloxetine hydrochloride	Theravance Biopharma Ireland Limited	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	188	Phase 3	United States;Portugal;Estonia;Spain;Ukraine;Austria;Russian Federation;Chile;Israel;United Kingdom;Italy;France;Hungary;Mexico;Canada;Argentina;Poland;Peru;Australia;Denmark;Bulgaria;Germany;New Zealand
168	EUCTR2018-003941-41-BG (EUCTR)	10/10/2019	26/06/2019	This study will look at whether an investigational drug, called TD-9855, works and how safe it is when taken over a longer period of time to treat symptomatic neurogenic orthostatic hypotension (snOH) in people with Parkinson’s disease (PD), multiple system atrophy (MSA), or pure autonomic failure (PAF). It will also look at the effects of TD-9855 on general well-being and whether it can improve symptoms of neurogenic OH (nOH)	A Phase 3, 22-week, Multi-center, Randomized Withdrawal Study of TD-9855 in Treating Symptomatic NeurogenicOrthostatic Hypotension in Subjects with Primary Autonomic Failure - Redwood	Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Code: TD-9855 INN or Proposed INN: ampreloxetine hydrochloride Other descriptive name: TD-9855	Theravance Biopharma Ireland Limited	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	258	Phase 3	United States;Portugal;Estonia;Spain;Ukraine;Austria;Russian Federation;Chile;Israel;United Kingdom;Italy;France;Hungary;Mexico;Canada;Argentina;Poland;Peru;Australia;Denmark;Bulgaria;Germany;New Zealand
169	NCT03987750 (ClinicalTrials.gov)	October 2019	12/6/2019	Safinamide for Levodopa-induced Dyskinesia (PD-LID)	A Phase 3, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of 2 Doses of Safinamide Compared to Placebo in the Treatment of LID in PD Patients With Motor Fluctuations	Dyskinesia, Drug-Induced;Parkinson Disease	Drug: Safinamide Methanesulfonate 150mg;Drug: Safinamide Methanesulfonate 100mg;Drug: Safinamide Methanesulfonate matching placebo	Zambon SpA	NULL	Withdrawn	30 Years	N/A	All	0	Phase 3	NULL
170	NCT03905811 (ClinicalTrials.gov)	September 24, 2019	1/4/2019	Terazosin for Parkinson's Disease	A Pilot Study of Terazosin for Parkinson's Disease	Parkinson Disease	Drug: Terazosin 5 MG;Drug: Placebo oral capsule	Jordan Schultz	University of Iowa	Enrolling by invitation	40 Years	90 Years	All	20	Phase 1;Phase 2	United States
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
171	EUCTR2018-002234-21-DE (EUCTR)	23/09/2019	16/05/2019	An open-label extension study of the safety and clinical utility of IPX203 in Parkinson’s Disease patients with motor fluctuations	AN OPEN-LABEL EXTENSION STUDY OF THE SAFETY AND CLINICAL UTILITY OF IPX203 IN PARKINSON’S DISEASE PATIENTS WITH MOTOR FLUCTUATIONS	Parkinson's disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0;Level: SOC;Classification code 10029205;Term: Nervous system disorders;Classification code 10028035;Term: Movement disorder;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: IPX203 Product Code: IPX203 INN or Proposed INN: Levodopa Other descriptive name: LEVODOPA INN or Proposed INN: Carbidopa Other descriptive name: ANHYDROUS CARBIDOPA Product Name: IPX203 Product Code: IPX203 INN or Proposed INN: Levodopa Other descriptive name: LEVODOPA INN or Proposed INN: Carbidopa Other descriptive name: ANHYDROUS CARBIDOPA Product Name: IPX203 Product Code: IPX203 INN or Proposed INN: Levodopa Other descriptive name: LEVODOPA INN or Proposed INN: Carbidopa Other descriptive name: ANHYDROUS CARBIDOPA Product Name: IPX203 Product Code: IPX203 INN or Proposed INN: Levodopa Other descriptive name: LEVODOPA INN or Proposed INN: Carbidopa	Impax Laboratories, LLC	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	300	Phase 3	United States;Estonia;Spain;Ukraine;Lithuania;United Kingdom;Italy;France;Czech Republic;Poland;Romania;Germany;Latvia
172	EUCTR2018-002144-85-NL (EUCTR)	11/09/2019	27/03/2019	Parkinson's Disease: Safety and Tolerability of 24-Hour Daily Exposure to ABBV-951 by Continuous Subcutaneous Infusion study	A 52-Week, open-label, single-arm study to evaluate the safety and tolerability of 24-hour daily exposure of continuous subcutaneous infusion of ABBV-951 in subjects with Parkinson's disease - Galliarde	Parkinson's Disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		AbbVie Deutschland	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	130	Phase 3	United States;Canada;Spain;Denmark;Australia;Netherlands;United Kingdom;Japan
173	ChiCTR1900025894	2019-09-11	2019-09-12	Parallel randomized controlled trial for Shengyang Yiwei Granule in the treatment of early Parkinson's disease	Parallel randomized controlled trial for Shengyang Yiwei Granule in the treatment of early Parkinson's disease	parkinson disease	experimental group:Parkinson's disease routine medication, plus Shengyang Yiwei granules, water blunt, one dose, morning and evening;control group:Parkinson's disease routine medication, add Buzhong Yiqi granules, water blunt, one dose, morning and evening;	Kaida Wang	NULL	Recruiting			Both	experimental group:45;control group:23;		China
174	NCT04477161 (ClinicalTrials.gov)	September 5, 2019	22/6/2020	Effect of Ketone Esters in Parkinson's Disease	Effect of Ketone Esters on Parkinson Disease: A Pilot, Prospective Trial.	Parkinson Disease;Ketosis	Dietary Supplement: Ketone Ester Elite endurance Nutrition Drink;Other: Stool Sample	University of Florida	NULL	Recruiting	40 Years	75 Years	All	15	N/A	United States
175	EUCTR2018-003028-35-GB (EUCTR)	04/09/2019	15/11/2019	A randomised, double blind, parallel group, placebo controlled, Phase 3 trial of exenatide once weekly over 2 years as a potential disease modifying treatment for Parkinson's disease.	A randomised, double blind, parallel group, placebo controlled, Phase 3 trial of exenatide once weekly over 2 years as a potential disease modifying treatment for Parkinson's disease. - Phase 3 Trial of exenatide for Parkinson’s disease	Parkinson's disease MedDRA version: 21.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's;System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		University College London Comprehensive Clinical Trial Unit	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	200	Phase 3	United Kingdom
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
176	NCT03959540 (ClinicalTrials.gov)	September 2019	23/4/2019	Safety and Effectiveness of Opicapone Plus Standard of Care in Elderly Patients With Parkinson's Disease	A Multinational, Multicentre, Prospective Non-interventional Study to Assess Safety and Effectiveness of Opicapone Plus Standard of Care in Elderly Patients With Parkinson's Disease	Parkinson Disease	Drug: Opicapone;Drug: Levodopa (L-DOPA) + Standard care	Bial - Portela C S.A.	NULL	Not yet recruiting	75 Years	N/A	All	100		NULL
177	NCT04054960 (ClinicalTrials.gov)	September 2019	9/8/2019	A Trial of tPCS on Parkinson's Disease OFF State	A Trial of tPCS on Parkinson's Disease OFF State	Parkinson Disease	Device: Active tPCS;Device: Sham tPCS;Drug: Levodopa tablet	Western University, Canada	NULL	Not yet recruiting	40 Years	80 Years	All	15	N/A	Canada
178	NCT04075318 (ClinicalTrials.gov)	August 29, 2019	5/8/2019	Study of UB-312 in Healthy Participants and Parkinson's Disease Patients	A Phase 1 Study to Evaluate the Safety, Tolerability, and Immunogenicity of UBITh® PD Immunotherapeutic Vaccine (UB-312) in Healthy Participants and Participants With Parkinson's Disease	Parkinson Disease;Parkinsonism	Biological: UB-312;Biological: Placebo	United Neuroscience Ltd.	Centre for Human Drug Research, Netherlands;Worldwide Clinical Trials	Active, not recruiting	40 Years	85 Years	All	62	Phase 1	Netherlands
179	NCT04006210 (ClinicalTrials.gov)	August 27, 2019	30/6/2019	A Clinical Trial Investigating the Efficacy, Safety and Tolerability of Continuous Subcutaneous ND0612 Infusion in Comparison to Oral IR-LD/CD in Subjects With Parkinson's Disease Experiencing Motor Fluctuations (BouNDless).	A Multicenter, Randomized, Active-controlled, Double-blind, Double-dummy, Parallel Group Clinical Trial, Investigating the Efficacy, Safety, and Tolerability of Continuous Subcutaneous ND0612 Infusion in Comparison to Oral IR-LD/CD in Subjects With Parkinson's Disease Experiencing Motor Fluctuations (BouNDless)	Parkinson's Disease	Combination Product: ND0612 Solution for SC infusion;Combination Product: Placebo for SC infusion;Drug: Carbidopa and Levodopa 25mg/100mg;Drug: Placebo for Carbidopa and Levodopa 25mg/100mg	NeuroDerm Ltd.	NULL	Recruiting	30 Years	80 Years	All	380	Phase 3	United States;Austria;Belgium;Czechia;France;Hungary;Israel;Italy;Netherlands;Poland;Portugal;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom
180	NCT04070495 (ClinicalTrials.gov)	August 27, 2019	26/8/2019	A Drug Interaction Study of KW-6356 and Clarithromycin or Rifampicin	A Drug Interaction Study of KW-6356 and Clarithromycin or Rifampicin (A Drug Interaction Study With a CYP3A4/5 Inhibitor or Inducer)	Parkinson's Disease	Drug: KW-6356;Drug: Clarithromycin;Drug: Rifampicin	Kyowa Kirin Co., Ltd.	NULL	Completed	20 Years	44 Years	Male	20	Phase 1	Japan
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
181	EUCTR2018-003941-41-PL (EUCTR)	23/08/2019	03/06/2019	This study will look at whether an investigational drug, called TD-9855, works and how safe it is when taken over a longer period of time to treat symptomatic neurogenic orthostatic hypotension (snOH) in people with Parkinson’s disease (PD), multiple system atrophy (MSA), or pure autonomic failure (PAF). It will also look at the effects of TD-9855 on general well-being and whether it can improve symptoms of neurogenic OH (nOH)	A Phase 3, 22-week, Multi-center, Randomized Withdrawal Study of TD-9855 in Treating Symptomatic NeurogenicOrthostatic Hypotension in Subjects with Primary Autonomic Failure - Redwood	Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Code: TD-9855 INN or Proposed INN: ampreloxetine hydrochloride Other descriptive name: TD-9855	Theravance Biopharma Ireland Limited	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	258	Phase 3	Portugal;United States;Estonia;Spain;Ukraine;Austria;Israel;Russian Federation;United Kingdom;Italy;France;Hungary;Canada;Poland;Australia;Denmark;Bulgaria;Germany;New Zealand
182	EUCTR2018-002234-21-ES (EUCTR)	21/08/2019	11/06/2019	An open-label extension study of the safety and clinical utility of IPX203 in Parkinson’s Disease patients with motor fluctuations	AN OPEN-LABEL EXTENSION STUDY OF THE SAFETY AND CLINICAL UTILITY OF IPX203 IN PARKINSON’S DISEASE PATIENTS WITH MOTOR FLUCTUATIONS	Parkinson's disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0;Level: SOC;Classification code 10029205;Term: Nervous system disorders;Classification code 10028035;Term: Movement disorder;System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Impax Laboratories, LLC	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	300	Phase 3	United States;Estonia;Spain;Ukraine;Lithuania;United Kingdom;Italy;France;Czech Republic;Poland;Romania;Germany;Latvia
183	EUCTR2018-002144-85-BE (EUCTR)	20/08/2019	24/04/2019	Parkinson's Disease: Safety and Tolerability of 24-Hour Daily Exposure to ABBV-951 by Continuous Subcutaneous Infusion study	A 52-Week, open-label, single-arm study to evaluate the safety and tolerability of 24-hour daily exposure of continuous subcutaneous infusion of ABBV-951 in subjects with Parkinson's disease - Galliarde	Parkinson's Disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Code: ABBV-951 INN or Proposed INN: Foslevodopa Other descriptive name: Levodopa -4'-Monophosphate INN or Proposed INN: Foscarbidopa Other descriptive name: Carbidopa -4'-Monophosphate	AbbVie Deutschland	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	130	Phase 3	United States;Canada;Spain;Belgium;Denmark;Australia;Germany;Netherlands;United Kingdom;Japan
184	ChiCTR1900025372	2019-08-18	2019-08-25	Digital assessment of Parkinson's disease	Quantitative evaluation of drug response test in patients with Parkinson's disease and the influence of rehabilitation intervention on the evaluation of drug response and the exploration of related mechanisms	Parkinson's disease	1:rehabilitation;1:take levodopa;30:Wear wearable devices;	Tianjin Huanhu Hospital	NULL	Recruiting			Both	1:30;1:30;30:30;		China
185	NCT04062526 (ClinicalTrials.gov)	August 14, 2019	14/8/2019	Evaluation of Neuroinflammation in Parkinson's Disease Using 18F-NOS PET/CT	Evaluation of in Vivo Neuroinflammation in Parkinson's Disease Using 18F-NOS Positron Emission Tomography (PET/CT)	Parkinson Disease;Healthy Volunteer	Drug: [18F]NOS	University of Pennsylvania	NULL	Recruiting	18 Years	75 Years	All	30	Early Phase 1	United States
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
186	EUCTR2018-003941-41-ES (EUCTR)	13/08/2019	11/06/2019	This study will look at whether an investigational drug, called TD-9855, works and how safe it is when taken over a longer period of time to treat symptomatic neurogenic orthostatic hypotension (snOH) in people with Parkinson’s disease (PD), multiple system atrophy (MSA), or pure autonomic failure (PAF). It will also look at the effects of TD-9855 on general well-being and whether it can improve symptoms of neurogenic OH (nOH)	A Phase 3, 22-week, Multi-center, Randomized Withdrawal Study of TD-9855 in Treating Symptomatic NeurogenicOrthostatic Hypotension in Subjects with Primary Autonomic Failure - Redwood	Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Code: TD-9855 INN or Proposed INN: ampreloxetine hydrochloride Other descriptive name: TD-9855	Theravance Biopharma Ireland Limited	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	258	Phase 3	United States;Estonia;Spain;Ukraine;Austria;Russian Federation;Israel;Italy;United Kingdom;France;Hungary;Canada;Poland;Australia;Denmark;Bulgaria;Germany;New Zealand
187	NCT03976349 (ClinicalTrials.gov)	August 12, 2019	4/6/2019	A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BIIB094 in Adults With Parkinson's Disease	A Phase 1 Single- and Multiple-Ascending-Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB094 Administered Intrathecally to Adults With Parkinson's Disease	Parkinson's Disease	Drug: BIIB094;Drug: Placebo	Biogen	Ionis Pharmaceuticals, Inc.	Recruiting	35 Years	80 Years	All	82	Phase 1	United States;Canada;Israel;Norway;Spain;United Kingdom
188	NCT04043338 (ClinicalTrials.gov)	August 11, 2019	24/7/2019	Single Ascending Dose Study Investigating the Safety, Tolerability, and PK of XC130-A10H in Healthy Adult Subjects	A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Single Ascending Dose Study Investigating the Safety, Tolerability, and Pharmacokinetics of XC130-A10H in Healthy Adult Subjects	Parkinson's Disease	Drug: XC130-A10H;Drug: Placebo	Xoc Pharmaceuticals	Celerion	Recruiting	18 Years	75 Years	All	40	Phase 1	United States
189	EUCTR2018-003941-41-GB (EUCTR)	09/08/2019	16/05/2019	This study will look at whether an investigational drug, called TD-9855, works and how safe it is when taken over a longer period of time to treat symptomatic neurogenic orthostatic hypotension (snOH) in people with Parkinson’s disease (PD), multiple system atrophy (MSA), or pure autonomic failure (PAF). It will also look at the effects of TD-9855 on general well-being and whether it can improve symptoms of neurogenic OH (nOH)	A Phase 3, 22-week, Multi-center, Randomized Withdrawal Study of TD-9855 in Treating Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure - Redwood	Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Code: TD-9855 INN or Proposed INN: ampreloxetine hydrochloride Other descriptive name: TD-9855	Theravance Biopharma Ireland Limited	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	258	Phase 3	United States;Portugal;Estonia;Spain;Ukraine;Austria;Russian Federation;Chile;Israel;Italy;United Kingdom;France;Hungary;Mexico;Canada;Argentina;Poland;Peru;Australia;Denmark;Bulgaria;Germany;New Zealand
190	NCT03881371 (ClinicalTrials.gov)	August 1, 2019	18/3/2019	A Study to Evaluate the Efficacy and Safety of Safinamide, as add-on Therapy, in Idiopathic Chinese Parkinson's Disease (PD) Patients With Motor Fluctuations Treated With Stable Doses of Levodopa	A Randomised, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Safinamide, as add-on Therapy, in Idiopathic Chinese Parkinson's Disease (PD) Patients With Motor Fluctuations Treated With Stable Doses of Levodopa	Parkinson Disease	Drug: Safinamide;Other: Placebo	Zambon SpA	NULL	Recruiting	18 Years	N/A	All	306	Phase 3	China
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
191	JPRN-UMIN000037422	2019/08/01	01/08/2019	An open-labeled single arm study on improvement of cognitive function by istradefylline for parkinson disease	An open-labeled single arm study on improvement of cognitive function by istradefylline for parkinson disease - An open-labeled single arm study on improvement of cognitive function by istradefylline for parkinson disease	Parkinson disease	Prescription istradefylline 20 mg for 1 month, and if there are no side effects, increase to 40 mg and prescribe for 2 months.	Ichinomiya Nishi Hospital	NULL	Recruiting	40years-old	85years-old	Male and Female	25	Not selected	Japan
192	ChiCTR1900023725	2019-08-01	2019-06-09	Study for the Role of Butylphthalide in Delaying the progression of Parkinson's disease (PD), Vascular Parkinson's disease (VP) and Parkinsonism-plus syndrome (PPS)	Study for the Role of Butylphthalide in Delaying the progression of Parkinson's disease (PD), Vascular Parkinson's disease (VP) and Parkinsonism-plus syndrome (PPS)	Parkinson's disease (PD), Vascular Parkinson's disease (VP) and Parkinsonism-plus syndrome (PPS)	PD-Placebo:Placebo;PD-Butylphthalide:Butylphthalide;VP-Placebo:Placebo;VP-Butylphthalide:Butylphthalide;MSA-Placebo:Placebo;MSA-Butylphthalide :Butylphthalide ;PSP-Placebo:Placebo;PSP-Butylphthalide:Butylphthalide;	Zhujiang Hospital of Southern Medical University	NULL	Pending	18	80	Male	PD-Placebo:50;PD-Butylphthalide:50;VP-Placebo:50;VP-Butylphthalide:50;MSA-Placebo:50;MSA-Butylphthalide :50;PSP-Placebo:50;PSP-Butylphthalide:50;		China
193	JPRN-UMIN000037421	2019/08/01	01/08/2019	A study on improvement of cognitive function by istradefylline for parkinson disease	An open-labeled single arm study on improvement of cognitive function by istradefylline for parkinson disease - A study on improvement of cognitive function by istradefylline for parkinson disease	Parkinson disease	Prescription istradefylline 20 mg for 1 month. If there are no side effects, We increase to 40 mg and prescribe for 2 months. The assessments will be made in all patients participating the study, patients with MMSE scores of 26 or more, patients with MMSE score of less than 26.	Ichinomiya Nishi Hospital	NULL	Recruiting	40years-old	85years-old	Male and Female	25	Not selected	Japan
194	EUCTR2018-003941-41-HU (EUCTR)	30/07/2019	01/08/2019	This study will look at whether an investigational drug, called TD-9855, works and how safe it is when taken over a longer period of time to treat symptomatic neurogenic orthostatic hypotension (snOH) in people with Parkinson’s disease (PD), multiple system atrophy (MSA), or pure autonomic failure (PAF). It will also look at the effects of TD-9855 on general well-being and whether it can improve symptoms of neurogenic OH (nOH)	A Phase 3, 22-week, Multi-center, Randomized Withdrawal Study of TD-9855 in Treating Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure - Redwood	Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Theravance Biopharma Ireland Limited	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	258	Phase 3	United States;Estonia;Spain;Ukraine;Austria;Russian Federation;Israel;Italy;United Kingdom;France;Hungary;Canada;Poland;Australia;Denmark;Bulgaria;Germany;New Zealand
195	EUCTR2018-002144-85-GB (EUCTR)	29/07/2019	13/03/2019	Parkinson's Disease: Safety and Tolerability of 24-Hour Daily Exposure to ABBV-951 by Continuous Subcutaneous Infusion study	A 52-Week, open-label, single-arm study to evaluate the safety and tolerability of 24-hour daily exposure of continuous subcutaneous infusion of ABBV-951 in subjects with Parkinson's disease - Galliarde	Parkinson's Disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Code: ABBV-951 INN or Proposed INN: Foslevodopa Other descriptive name: Levodopa -4'-Monophosphate INN or Proposed INN: Foscarbidopa Other descriptive name: Carbidopa -4'-Monophosphate	AbbVie Deutschland	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	130	Phase 3	United States;Canada;Belgium;Spain;Denmark;Australia;Germany;Netherlands;Japan;United Kingdom
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
196	NCT04056689 (ClinicalTrials.gov)	July 23, 2019	12/8/2019	Study to Evaluate DNL151 in Subjects With Parkinson's Disease	A Phase 1b, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Determine the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL151 in Subjects With Parkinson's Disease	Parkinson's Disease	Drug: DNL151;Drug: Placebo	Denali Therapeutics Inc.	NULL	Active, not recruiting	30 Years	75 Years	All	34	Phase 1	United States;Belgium;Netherlands;United Kingdom
197	NCT03956979 (ClinicalTrials.gov)	July 22, 2019	17/5/2019	A Study in Parkinson's Disease in paTients With mOderate to seveRe dyskInesiA	A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study in Parkinson's Disease Patients With Moderate to Severe Dyskinesia to Assess the Efficacy and Safety/Tolerability of Two Dose Combinations of JM-010	Dyskinesias	Drug: JM -010 group A;Drug: JM -010 group B;Drug: Placebos	Contera Pharma	Bukwang Pharmaceutical	Recruiting	18 Years	80 Years	All	81	Phase 2	Germany
198	EUCTR2018-003289-15-PL (EUCTR)	19/07/2019	07/05/2019	This study will look at whether an investigational drug called TD-9855 works and how safe it is for treating symptomatic neurogenic orthostatic hypotension (snOH) in people with Parkinson’s disease (PD), multiple system atrophy (MSA) or pure autonomic failure (PAF)	A Phase 3, 4-week, Multicenter, Randomized, Double-blind,Placebo-controlled, Parallel-group Study of TD-9855 inTreating Symptomatic Neurogenic Orthostatic Hypotension inSubjects With Primary Autonomic Failure - Phase 3 Clinical Effect of TD-9855 for Treating snOH in Subjects With Primary Autonomic Failure	Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Code: TD-9855 INN or Proposed INN: ampreloxetine chydrochloride Other descriptive name: TD-9855	Theravance Biopharma Ireland Limited	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	188	Phase 3	United States;Portugal;Czechia;Estonia;Spain;Ukraine;Austria;Russian Federation;Chile;Israel;United Kingdom;Italy;France;Hungary;Mexico;Canada;Argentina;Poland;Peru;Australia;Denmark;Bulgaria;Germany;New Zealand
199	NCT03575195 (ClinicalTrials.gov)	July 15, 2019	21/6/2018	Microbiota Intervention to Change the Response of Parkinson's Disease	Microbiota Intervention to Change the Response of Parkinson's Disease	Parkinson Disease	Drug: Rifaximin;Other: Placebo	University of California, San Francisco	Nova Southeastern University;Gateway Institute for Brain Research	Recruiting	30 Years	N/A	All	86	Phase 1;Phase 2	United States
200	EUCTR2018-002144-85-ES (EUCTR)	11/07/2019	12/04/2019	Parkinson's Disease: Safety and Tolerability of 24-Hour Daily Exposure to ABBV-951 by Continuous Subcutaneous Infusion study	A 52-Week, open-label, single-arm study to evaluate the safety and tolerability of 24-hour daily exposure of continuous subcutaneous infusion of ABBV-951 in subjects with Parkinson's disease - Galliarde	Parkinson's Disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Code: ABBV-951 INN or Proposed INN: Foslevodopa Other descriptive name: Levodopa -4'-Monophosphate INN or Proposed INN: Foscarbidopa Other descriptive name: Carbidopa -4'-Monophosphate	AbbVie Deutschland	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	130	Phase 3	United States;Canada;Spain;Denmark;Australia;Netherlands;United Kingdom;Japan
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
201	EUCTR2018-002144-85-DK (EUCTR)	08/07/2019	14/03/2019	Parkinson's Disease: Safety and Tolerability of 24-Hour Daily Exposure to ABBV-951 by Continuous Subcutaneous Infusion study	A 52-Week, open-label, single-arm study to evaluate the safety and tolerability of 24-hour daily exposure of continuous subcutaneous infusion of ABBV-951 in subjects with Parkinson's disease - Galliarde	Parkinson's Disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Code: ABBV-951 INN or Proposed INN: Foslevodopa Other descriptive name: Levodopa -4'-Monophosphate INN or Proposed INN: Foscarbidopa Other descriptive name: Carbidopa -4'-Monophosphate	AbbVie Deutschland	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	130	Phase 3	United States;Canada;Spain;Australia;Denmark;Netherlands;United Kingdom;Japan
202	EUCTR2018-003941-41-EE (EUCTR)	04/07/2019	29/05/2019	This study will look at whether an investigational drug, called TD-9855, works and how safe it is when taken over a longer period of time to treat symptomatic neurogenic orthostatic hypotension (snOH) in people with Parkinson’s disease (PD), multiple system atrophy (MSA), or pure autonomic failure (PAF). It will also look at the effects of TD-9855 on general well-being and whether it can improve symptoms of neurogenic OH (nOH)	A Phase 3, 22-week, Multi-center, Randomized Withdrawal Study of TD-9855 in Treating Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure - Redwood	Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Theravance Biopharma Ireland Limited	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	258	Phase 3	United States;Estonia;Spain;Ukraine;Austria;Russian Federation;Israel;Italy;United Kingdom;France;Hungary;Canada;Poland;Australia;Denmark;Bulgaria;Germany;New Zealand
203	EUCTR2018-003289-15-DK (EUCTR)	02/07/2019	14/03/2019	This study will look at whether an investigational drug called TD-9855 works and how safe it is for treating symptomatic neurogenic orthostatic hypotension (snOH) in people with Parkinson’s disease (PD), multiple system atrophy (MSA) or pure autonomic failure (PAF)	A Phase 3, 4-week, Multicenter, Randomized, Double-blind,Placebo-controlled, Parallel-group Study of TD-9855 inTreating Symptomatic Neurogenic Orthostatic Hypotension inSubjects With Primary Autonomic Failure - Sequoia study	Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Code: TD-9855 INN or Proposed INN: ampreloxetine hydrochloride	Theravance Biopharma Ireland Limited	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	188	Phase 3	United States;Portugal;Estonia;Spain;Ukraine;Austria;Russian Federation;Chile;Israel;United Kingdom;Italy;France;Hungary;Mexico;Canada;Argentina;Poland;Peru;Denmark;Australia;Bulgaria;Germany;New Zealand
204	ChiCTR1900021708	2019-07-01	2019-03-05	Study for the brain network mechanism of pramipexole in the treatment of tremor-type PD patients based on DRD3 Ser9Gly polymorphi	Study for the brain network mechanism of pramipexole in the treatment of tremor-type PD patients based on DRD3 Ser9Gly polymorphism	Parkinson's Disease	Healthy control group:No;tremor-dominant phenotype PD patients group:pramipexole;	Department of Neurology, Brain Hospital Affiliated to Nanjing Medical University	NULL	Pending	50	70	Both	Healthy control group:80;tremor-dominant phenotype PD patients group:80;		China
205	NCT03977441 (ClinicalTrials.gov)	July 2019	12/5/2019	the Efficacy and Safety of Agomelatine in the Patients With Parkinson's Disease	A Multicenter, Randomized, Double-blind, Placebo-controlled Study: Evaluation of the Efficacy and Safety of Agomelatine in the Treatment of Sleep Disorders and Depression in Patients With Parkinson's Disease	Parkinson Disease;Depression;Sleep Disorders;Circadian Rhythm Disorders	Drug: Agomelatine or PIacebo	Second Affiliated Hospital of Soochow University	NULL	Not yet recruiting	30 Years	75 Years	All	240	Phase 4	NULL
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
206	EUCTR2018-003219-23-GB (EUCTR)	28/06/2019	04/06/2019	CHIEF-PD (CHolinesterase Inhibitor to prEvent Falls in Parkinson’s Disease)	CHIEF-PD (CHolinesterase Inhibitor to prEvent Falls in Parkinson’s Disease): A phase 3 randomised double-blind placebo-controlled trial of rivastigmine to prevent falls in Parkinson’s disease - CHIEF-PD	This trial will investigate the effectiveness of Rivastigmine on prevention of falls in patients with Parkinson's disease MedDRA version: 21.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's;System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Rivastigmin Luye Transdermal Patches - 4.6mg/24h Product Name: Rivastigmin Luye Transdermal Patches - 4.6mg/24h Product Code: N/A INN or Proposed INN: Rivastigmine Other descriptive name: Ethylmethylcarbamic acid 3-[(1S)-1-(dimethylamino)ethyl]phenyl ester (See other 2 names below) Trade Name: Rivastigmine Luye Transdermal Patch- 9.5mg/24h Product Name: Rivastigmine Luye Transdermal Patch- 9.5mg/24h INN or Proposed INN: Rivastigmine Other descriptive name: Ethylmethylcarbamic acid 3-[(1S)-1-(dimethylamino)ethyl]phenyl ester (See other 2 names below) Product Name: Rivastigmine transdermal system 13.3 mg/24 h Product Code: RIV-TDS 13.3 mg/24 h INN or Proposed INN: Rivastigmine Other descriptive name: Ethylmethylcarbamic acid 3-[(1S)-1-(dimethylamino)ethyl]phenyl ester (**See other 2 names below)	University of Bristol	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	600	Phase 3	United Kingdom
207	EUCTR2018-003289-15-ES (EUCTR)	26/06/2019	27/06/2019	This study will look at whether an investigational drug called TD-9855 works and how safe it is for treating symptomatic neurogenic orthostatic hypotension (snOH) in people with Parkinson’s disease (PD), multiple system atrophy (MSA) or pure autonomic failure (PAF)	A Phase 3, 4-week, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of TD-9855 in Treating Symptomatic Neurogenic Orthostatic Hypotension in Subjects With Primary Autonomic Failure - Phase 3 Clinical Effect of TD-9855 for Treating snOH in Subjects With Primary Autonomic Failure	Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Theravance Biopharma Ireland Limited	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	188	Phase 3	United States;Estonia;Spain;Ukraine;Austria;Russian Federation;Israel;Italy;United Kingdom;France;Czech Republic;Hungary;Canada;Denmark;Germany
208	EUCTR2018-003337-15-HU (EUCTR)	18/06/2019	12/04/2019	A study to look at how safe, and effective the study drug K0706 is in patients with early Parkinson's Disease.	A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of K0706 in Subjects With Early Parkinson’s Disease	Early Parkinson’s Disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Sun Pharma Advanced Research Company (SPARC) Limited	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	504	Phase 2	United States;Hungary;Slovakia;Poland;Spain;India
209	EUCTR2018-002234-21-CZ (EUCTR)	14/06/2019	30/05/2019	An open-label extension study of the safety and clinical utility of IPX203 in Parkinson’s Disease patients with motor fluctuations	AN OPEN-LABEL EXTENSION STUDY OF THE SAFETY AND CLINICAL UTILITY OF IPX203 IN PARKINSON’S DISEASE PATIENTS WITH MOTOR FLUCTUATIONS	Parkinson's disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0;Level: SOC;Classification code 10029205;Term: Nervous system disorders;Classification code 10028035;Term: Movement disorder;System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Impax Laboratories, LLC	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	300	Phase 3	United States;Estonia;Spain;Ukraine;Lithuania;United Kingdom;Italy;France;Czech Republic;Poland;Romania;Germany;Latvia
210	NCT03938922 (ClinicalTrials.gov)	June 13, 2019	18/4/2019	A Study to Evaluate ENT-01 for the Treatment of Parkinson's Disease Dementia	A Multicenter, Open Label Study to Evaluate Tolerability and Efficacy of Orally Administered ENT-01 for the Treatment of Parkinson's Disease Dementia.	Parkinson Disease;Dementia	Drug: Active Investigational Treatment ENT-01	Enterin Inc.	NULL	Active, not recruiting	30 Years	90 Years	All	40	Phase 1	United States
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
211	NCT03939559 (ClinicalTrials.gov)	June 10, 2019	3/5/2019	The Efficiency of Home Based Dual Task Training in Parkinson Disease	The Efficiency of Home Based Dual Task Training in Parkinson Disease	Parkinson Disease	Procedure: Static, dynamic and functional balance exercises;Procedure: Static, dynamic and functional balance exercises with dual task	Istanbul University-Cerrahpasa	NULL	Not yet recruiting	30 Years	80 Years	All	60	N/A	NULL
212	EUCTR2018-003337-15-SK (EUCTR)	05/06/2019	26/04/2019	A study to look at how safe, and effective the study drug K0706 is in patients with early Parkinson's Disease.	A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of K0706 in Subjects With Early Parkinson’s Disease	Early Parkinson’s Disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Code: K0706 INN or Proposed INN: K0706 Other descriptive name: K0706 Product Code: K0706 INN or Proposed INN: K0706 Other descriptive name: K0706 Product Code: K0706 INN or Proposed INN: K0706 Other descriptive name: K0706 Product Code: K0706 INN or Proposed INN: K0706 Other descriptive name: K0706	Sun Pharma Advanced Research Company (SPARC) Limited	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	504	Phase 2	United States;Hungary;Slovakia;Poland;Spain;India
213	EUCTR2018-003289-15-HU (EUCTR)	04/06/2019	05/04/2019	This study will look at whether an investigational drug called TD-9855 works and how safe it is for treating symptomatic neurogenic orthostatic hypotension (snOH) in people with Parkinson’s disease (PD), multiple system atrophy (MSA) or pure autonomic failure (PAF)	A Phase 3, 4-week, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of TD-9855 in Treating Symptomatic Neurogenic Orthostatic Hypotension in Subjects With Primary Autonomic Failure - Phase 3 Clinical Effect of TD-9855 for Treating snOH in Subjects With Primary Autonomic Failure	Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Theravance Biopharma Ireland Limited	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	188	Phase 3	United States;Estonia;Spain;Ukraine;Austria;Russian Federation;Israel;Italy;United Kingdom;France;Hungary;Czech Republic;Canada;Denmark;Germany
214	NCT04389762 (ClinicalTrials.gov)	June 4, 2019	30/4/2020	PS128 May Improve Off Duration on Parkinson's Disease	Lactobacillus Plantarum PS128 May Improve Off Duration in Parkinson's Disease: a Pilot Study	Parkinson Disease	Dietary Supplement: daily ingestion of Lactobacillus plantarum PS128	Professor Lu Neurological Clinic	NULL	Completed	40 Years	80 Years	All	60	N/A	Taiwan
215	JPRN-UMIN000036952	2019/06/04	04/06/2019	A PET study with 18F-FDOPA and 11C-Raclopride on Parkinson's disease and related disorders patients.	A PET study with 18F-FDOPA and 11C-Raclopride on Parkinson's disease and related disorders patients. - A PET study with 18F-FDOPA and 11C-Raclopride on Parkinson's disease and related disorders patients.	Patients who are suspected Parkinson's disease or related disorders, including dementia with Lewy bodies, multiple system atrophy, progressive supranuclear palsy, corticobasal degeneration, frontotemporal lobe degeneration, vascular parkinsonism, drug-induced parkinsonism, normal pressure hydrocephalus, and others.	18F-FDOPA, 11C-Raclopride PET	Nagoya City Rehabilitation Agency	NULL	Recruiting	20years-old	Not applicable	Male and Female	150	Not applicable	Japan
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
216	ChiCTR1900022534	2019-06-01	2019-04-15	Efficacy of entacapone and pramipexole for non-motor symptoms of Parkinson’s disease: a prospective randomized controlled trial	Efficacy of entacapone and pramipexole for non-motor symptoms of Parkinson’s disease: a prospective randomized controlled trial	non-motor symptoms of Parkinson’s disease	entacapone group:Patients in the entacapone group will be administered entacapone (Novartis; import drug registration certificate number: H20160680), 10 times per day, 200 mg each time, for 3 weeks. ;pramipexole group:Patients in the pramipexole group will be administered pramipexole (Boehringer-Ingelheim; import drug registration certificate number: 20140918) , 3 times per day, 1 mg each time, for 3 weeks.;	Geriatric Hospital of Hainan	NULL	Pending	40	75	Both	entacapone group:194;pramipexole group:194;	N/A	China
217	NCT04064294 (ClinicalTrials.gov)	June 1, 2019	19/8/2019	Preventing Levodopa Induced Dyskinesia in Parkinson's Disease With HMG-CoA Reductase Inhibitors	Preventing Levodopa Induced Dyskinesia in Parkinson?s Disease With Statins	Parkinson Disease;Dyskinesia, Drug-Induced	Drug: Intravenous Infusion	VA Office of Research and Development	Oregon Health and Science University	Recruiting	50 Years	N/A	All	120		United States
218	JPRN-UMIN000036908	2019/05/31	31/05/2019	A dementia study by 11C-PiB, 18F-FDG PET	A dementia study by 11C-PiB, 18F-FDG PET - A dementia study by 11C-PiB, 18F-FDG PET	mild cognitive impairment, Alzheimer's disease, dementia with Lewy bodies, cerebrovascular dementia, frontotemporal degeneration, progressive supranuclear palsy, corticobasal degeneration, Parkinson's disease with dementia, other neurodegenerative diseases, normal pressure hydrocephalus, hypoxic encephalopathy, brain tumor, brain injury etc.	11C-PiB, 18F-FDG PET	Nagoya City Rehabilitation Agency	NULL	Recruiting	20years-old	Not applicable	Male and Female	150	Not applicable	Japan
219	JPRN-jRCTs031180248	29/05/2019	12/03/2019	N/A	Intervention study for the effect of Istradefylline on adjustment of Levodopa in Parkinson's Disease - Istra adjust PD	Parkinson's disease	Arm with treatment of Istradefylline and levodopa Treatment with Istradefylline will be started at a dose of 20 mg administered once daily at Week 0. The dose of Istradefylline will be increased to 40 mg once daily if the patient has no tolerability issues and still has motor symptoms at Week 1. Dose reduction is possible if the patient has tolerability issues. Patients will visit every 4 weeks from the following day of Week0, and 50mg levodopa will be added of if CGI-S score >=4 every time. Dose reduction is possible if the patient has tolerability issues. Arm without treatment of Istradefylline 50mg levodopa will be added at Week 0. Patients will visit every 4 weeks from the following day of Week0, and 50mg levodopa will be added of if CGI-S score >=4 every time. Dose reduction is possible if the patient has tolerability issues.	Hatano Taku	Kyowa Kirin Co., Ltd	Recruiting	>= 30age old	<= 84age old	Both	111	N/A	Japan
220	NCT03971617 (ClinicalTrials.gov)	May 29, 2019	30/5/2019	Clinical Trial to Evaluate the Safety and Tolerability of Hydrogen in Patients With Parkinson's Disease	A Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Safety and Tolerability of Molecular Hydrogen in Patients With Parkinson's Disease	Parkinson Disease	Drug: Hydrogen;Drug: Placebo oral tablet	Stony Brook University	NULL	Recruiting	40 Years	80 Years	All	70	Phase 2;Phase 3	United States
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
221	NCT03970798 (ClinicalTrials.gov)	May 22, 2019	23/5/2019	A Drug Interaction Study of KW-6356 With Midazolam, Caffeine, or Rosuvastatin	A Drug Interaction Study of KW-6356 With Midazolam, Caffeine, or Rosuvastatin	Parkinson's Disease	Drug: Midazolam;Drug: Caffeine;Drug: Rosuvastatin;Drug: KW-6356	Kyowa Kirin Co., Ltd.	NULL	Completed	20 Years	44 Years	Male	50	Phase 1	Japan
222	EUCTR2018-003289-15-AT (EUCTR)	15/05/2019	22/03/2019	This study will look at whether an investigational drug called TD-9855 works and how safe it is for treating symptomatic neurogenic orthostatic hypotension (snOH) in people with Parkinson’s disease (PD), multiple system atrophy (MSA) or pure autonomic failure (PAF)	A Phase 3, 4-week, Multicenter, Randomized, Double-blind,Placebo-controlled, Parallel-group Study of TD-9855 inTreating Symptomatic Neurogenic Orthostatic Hypotension inSubjects With Primary Autonomic Failure - Sequoia study	Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Code: TD-9855 INN or Proposed INN: ampreloxetine hydrochloride Other descriptive name: TD-9855	Theravance Biopharma Ireland Limited	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	188	Phase 3	United States;Portugal;Czechia;Estonia;Spain;Ukraine;Austria;Russian Federation;Chile;Israel;United Kingdom;Italy;France;Hungary;Mexico;Canada;Argentina;Poland;Peru;Australia;Denmark;Bulgaria;Germany;New Zealand
223	NCT03552068 (ClinicalTrials.gov)	May 15, 2019	17/5/2018	Study of Clonidine Efficacy for the Treatment of Impulse Control Disorders in Parkinson's Disease:	Study of Clonidine Efficacy for the Treatment of Impulse Control Disorders in Parkinson's Disease: A Pilot Double Blind Randomized Trial	Parkinson's Disease;Mpulse Control Disorders	Drug: placebo;Drug: Clonidine	Hospices Civils de Lyon	NULL	Recruiting	30 Years	80 Years	All	38	Phase 2	France
224	NCT03671785 (ClinicalTrials.gov)	May 15, 2019	12/9/2018	Study of the Fecal Microbiome in Patients With Parkinson's Disease	A Prospective, Randomized, Placebo-Controlled Pilot Study to Characterize the Intestinal Microbiome and to Evaluate the Safety and Fecal Microbiome Changes Following Twice Weekly Administration of Lyophilized PRIM-DJ2727 or Placebo Given Orally for 12 Weeks in Subjects With Parkinson's Disease	Parkinson Disease	Drug: PRIM-DJ2727;Drug: Placebo oral capsule	The University of Texas Health Science Center, Houston	Kelsey Research Foundation	Recruiting	55 Years	75 Years	All	12	Phase 1	United States
225	NCT03693872 (ClinicalTrials.gov)	May 15, 2019	1/10/2018	Evaluation of the Nonmotor Symptomatology of Parkinsonian Patients Treated With Two Strategies Related to Apomorphine Pump Therapy in French Hospitals	Evaluation of the Nonmotor Symptomatology of Parkinsonian Patients Treated With Two Strategies Related to Apomorphine Pump Therapy in French Hospitals	Parkinson Disease	Drug: Apomorphine;Drug: Dopaminergic Agonist + Apomorphine	Rennes University Hospital	NULL	Recruiting	18 Years	N/A	All	42	N/A	France
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
226	NCT04293159 (ClinicalTrials.gov)	May 14, 2019	19/2/2020	Effect of Probiotic on Constipation in Patients With Parkinson's Disease	Effect of Probiotic on Constipation and on Neuropsychological Performance in Patients With Parkinson's Disease	Parkinson Disease;Constipation	Dietary Supplement: Lactobacillus casei DG (Enterolactis duo®)	University of Salerno	Roberto Erro;Maria Teresa Pellecchia;Antonella Santonicola;Carolina Ciacci	Recruiting	18 Years	75 Years	All	30	N/A	Italy
227	NCT03958708 (ClinicalTrials.gov)	May 13, 2019	14/5/2019	Modulation of Gut Microbiota by Rifaximin in PD Patients	Modulation of Gut Microbiota by Rifaximin in PD Patients	Parkinson Disease;Inflammation	Drug: Rifaximin 550 MG	Taipei Medical University Shuang Ho Hospital	NULL	Recruiting	45 Years	70 Years	All	20	Phase 1;Phase 2	Taiwan
228	NCT03970239 (ClinicalTrials.gov)	May 13, 2019	6/5/2019	Serotonin in Impulse Control Disorders in Parkinson's Disease	Role of the Serotoninergic System in Impulse Control Disorders in Parkinson's Disease	Parkinson Disease;Impulse Control Disorders	Drug: Positron Emission Tomography using [11 Carbon]-3-amino-4-(2-dimethylaminomethylphenylsulfanyl)-benzonitrile ([11C]-DASB) and [18 Fluorine]-altanserin ([18F]-altanserin);Drug: Positron Emission Tomography using [18 Fluorine]-altanserin ([18F]-altanserin)	Hospices Civils de Lyon	NULL	Recruiting	30 Years	80 Years	All	45	N/A	France
229	EUCTR2018-003289-15-GB (EUCTR)	08/05/2019	28/12/2018	This study will look at whether an investigational drug called TD-9855 works and how safe it is for treating symptomatic neurogenic orthostatic hypotension (snOH) in people with Parkinson’s disease (PD), multiple system atrophy (MSA) or pure autonomic failure (PAF)	A Phase 3, 4-week, Multicenter, Randomized, Double-blind,Placebo-controlled,Parallel-group Study of TD-9855 in Treating Symptomatic Neurogenic Orthostatic Hypotension in Subjects With Primary Autonomic Failure - Sequoia study	Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Code: TD-9855 INN or Proposed INN: ampreloxetine hydrochloride Other descriptive name: TD-9855	Theravance Biopharma Ireland Limited	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	188	Phase 3	United States;Portugal;Estonia;Spain;Ukraine;Austria;Russian Federation;Chile;Israel;Italy;United Kingdom;France;Hungary;Mexico;Canada;Argentina;Poland;Peru;Australia;Denmark;Bulgaria;Germany;New Zealand
230	NCT04566341 (ClinicalTrials.gov)	May 4, 2019	11/8/2020	Study of Gastrointestinal Dysfunction and Enteric Neural Pathology in Patients With Parkinson's Disease	Study of Gastrointestinal Dysfunction and Enteric Neural Pathology in Patients With Parkinson's Disease	Parkinson Disease;Parkinson	Device: OCT - TCE	Massachusetts General Hospital	NULL	Recruiting	40 Years	85 Years	All	20		United States
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
231	NCT03840837 (ClinicalTrials.gov)	May 2, 2019	11/2/2019	Cholinergic Neurotransmission in Mobility and Cognition in Parkinson Disease	Cholinergic Neurotransmission - A Common Underlying Mechanism of Cognitive and Gait Impairment in Parkinson Disease	Parkinson Disease	Drug: Rivastigmine transdermal patch	University of Maryland, Baltimore	National Institute on Aging (NIA)	Recruiting	18 Years	N/A	All	100	Phase 4	United States
232	EUCTR2019-000247-27-FR (EUCTR)	02/05/2019	05/03/2019	Study to demonstrate an at least equivalent performance of a new test in brain imaging test compared to the reference examination to establish the differential diagnosis between Parkinson's Disease and Essential Tremor.	Non-inferiority study of the molecular imaging of dopamine transporters using [123I]-FP/CIT-SPECT and [18F] LBT-999-PET to distinguish between Parkinson’s Disease and Essential Tremor. - DATTEP	Patients suffering from an essential tremor or with Parkinson's disease. MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0;Classification code 10015496;Term: Essential tremor;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Diagnosis [E01]	Trade Name: DaTSCAN 74 MBq/ml solution for injection Product Code: [18F] LBT-999	ZIONEXA	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	112	Phase 3	France
233	ChiCTR1900022715	2019-05-01	2019-04-23	Accurate treatment under the multidisciplinary cooperative diagnosis and treatment model of Parkinson's disease	Accurate treatment under the multidisciplinary cooperative diagnosis and treatment model of Parkinson's disease	Parkinson's Disease	Anteversion group:DBS;Balance dysfunction group:DBS;Gait abnormality group:DBS;	Tianjin Huanhu Hospital	NULL	Recruiting			Both	Anteversion group:40;Balance dysfunction group:40;Gait abnormality group:40;	N/A	China
234	NCT03781167 (ClinicalTrials.gov)	April 29, 2019	18/12/2018	A Study to Evaluate the Safety and Tolerability of ABBV-951 in Subjects With Parkinson's Disease (PD)	A 52-Week, Open-label, Single-arm Study to Evaluate the Safety and Tolerability of 24-hour Daily Exposure of Continuous Subcutaneous Infusion of ABBV-951 in Subjects With Parkinson's Disease	Parkinson's Disease (PD)	Drug: ABBV-951	AbbVie	NULL	Recruiting	30 Years	N/A	All	130	Phase 3	United States;Australia;Belgium;Canada;Denmark;Germany;Italy;Japan;Netherlands;Russian Federation;Spain;Sweden;United Kingdom;France
235	NCT03899324 (ClinicalTrials.gov)	April 26, 2019	29/3/2019	Evaluation of the Efficacy and Safety of Bumetanide in Parkinson's Disease	A Randomized Double-blind Placebo-controlled Multicenter Proof-of-concept Trial to Assess the Efficacy and Safety of Bumetanide in Parkinson's Disease	Parkinson Disease	Drug: Bumetanide white, oblong, scored tablet;Drug: Placebo white, oblong, scored tablet	B&A Therapeutics	NULL	Recruiting	40 Years	80 Years	All	40	Phase 2	France
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
236	JPRN-JapicCTI-194763	22/4/2019	20/05/2019	Safety and PK study of LY03003	An open-label study in Japanese patients with Parkinson's disease to evaluate the safety, pharmacokinetics and preliminary efficacy of LY03003 following intramuscular injections and its comparative bioavailability to Rotigotine transdermal patch.	Parkinson's Disease	Intervention name : Rotigotine INN of the intervention : Rotigotine Dosage And administration of the intervention : LY03003 IM injections 14, 28 and 56 mg/week. Control intervention name : Rotigotine INN of the control intervention : Rotigotine Dosage And administration of the control intervention : Rotigotine transdermal patch applications 4.5, 9 and 18 mg/day.	Shandong Luye Pharmaceutical Co., Ltd./CMIC Co., Ltd.	NULL	complete	20		BOTH	32	Phase 1	Japan
237	EUCTR2018-002233-37-DE (EUCTR)	17/04/2019	08/01/2019	Evaluate the safety and efficacy of IPX203 carbidopa-levodopa extended release capsules compared to carbidopa-levodopa immediate release tablets in patients with Parkinson’s with motor fluctuations.	A randomized controlled study to compare the safety and efficacy of IPX203 with immediate-release carbidopa-levodopa in Parkinson's disease patients with motor fluctuations.	Parkinson's disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0;Level: SOC;Classification code 10029205;Term: Nervous system disorders;Classification code 10028035;Term: Movement disorder;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: IPX203 Product Code: IPX203 INN or Proposed INN: Levodopa Other descriptive name: LEVODOPA INN or Proposed INN: Carbidopa Other descriptive name: ANHYDROUS CARBIDOPA Trade Name: Carbidopa and Levodopa Tablets, USP Product Name: IR CD-LD (carbidopa-levodopa) tablets Product Code: IR CD-LD INN or Proposed INN: Levodopa INN or Proposed INN: Carbidopa Other descriptive name: ANHYDROUS CARBIDOPA	Impax Laboratories, LLC	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	510	Phase 3	United States;France;Czechia;Poland;Spain;Germany;United Kingdom;Italy
238	NCT04420910 (ClinicalTrials.gov)	April 15, 2019	4/6/2020	Non-motor Symptoms, Balance, Muscle Strength, and Functional Mobility in Patients With Parkinson's Disease	Investigation of Non-motor Symptoms, Balance, Muscle Strength, and Functional Mobility in Patients With Parkinson's Disease	Parkinson Disease;Balance;Muscle Strength;Mobility;Non-motor Symptoms	Other: Non-Motor Symptoms;Other: Balance;Other: Lower Limb Strength;Other: Functional mobility	Ankara Yildirim Beyazit University	NULL	Completed	50 Years	65 Years	All	44		Turkey
239	EUCTR2018-003289-15-EE (EUCTR)	11/04/2019	30/01/2019	This study will look at whether an investigational drug called TD-9855 works and how safe it is for treating symptomatic neurogenic orthostatic hypotension (snOH) in people with Parkinson’s disease (PD), multiple system atrophy (MSA) or pure autonomic failure (PAF)	A Phase 3, 4-week, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of TD-9855 in Treating Symptomatic Neurogenic Orthostatic Hypotension in Subjects With Primary Autonomic Failure - Phase 3 Clinical Effect of TD-9855 for Treating snOH in Subjects With Primary Autonomic Failure	Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Theravance Biopharma Ireland Limited	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	188	Phase 3	United States;Estonia;Spain;Ukraine;Austria;Russian Federation;Israel;Italy;United Kingdom;France;Hungary;Canada;Poland;Australia;Denmark;Bulgaria;Germany;New Zealand
240	NCT03661125 (ClinicalTrials.gov)	April 11, 2019	4/9/2018	SRC Inhibition as a Potential Target for Parkinson's Disease Psychosis	A Randomised, Balanced, Double-blind Two-way Crossover Design Study to Evaluate the Effects of SRC Kinase Inhibitor, Saracatinib, on Brain Activity Associated With Visual Processing in Patients With Parkinson's Disease Psychosis.	Parkinson Disease Psychosis	Drug: Saracatinib;Drug: Placebo Oral Tablet	King's College London	AstraZeneca;King's College Hospital NHS Trust	Recruiting	40 Years	N/A	All	30	Early Phase 1	United Kingdom
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
241	NCT03841604 (ClinicalTrials.gov)	April 9, 2019	30/1/2019	Effect of Safinamide on Parkinson's Disease Related Chronic Pain	A Randomised, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Safinamide 100mg Once Daily, as add-on Therapy, in Idiopathic Parkinson's Disease (PD) Patients With Motor Fluctuations and PD Related Chronic Pain	Idiopathic Parkinson Disease	Drug: Safinamide Methanesulfonate;Drug: Safinamide methanesulfonate matching placebo	Zambon SpA	NULL	Recruiting	30 Years	N/A	All	177	Phase 4	Austria;France;Germany;Italy;Spain
242	NCT03775096 (ClinicalTrials.gov)	April 4, 2019	9/12/2018	Adrenergic Blockers for Cardiac Changes in Early Parkinson's Disease	The Effect of Adrenergic Blocker Therapy on Cardiac and Striatal Transporter Uptake in Pre-Motor and Symptomatic Parkinson's Disease	REM Sleep Behavior Disorder;Pre-motor Parkinson Disease;Symptomatic Parkinson Disease	Drug: Carvedilol	Michele Tagliati, MD	NULL	Recruiting	30 Years	75 Years	All	15	Phase 2	United States
243	EUCTR2016-000657-12-GR (EUCTR)	04/04/2019	11/01/2019	A Global Study to Assess the Drug Dynamics, Efficacy, and Safety of GZ/SAR402671 in Parkinson's Disease Patients Carrying a Glucocerebrosidase (GBA) Gene Mutation	Multicenter, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of GZ/SAR402671 in Patients with Early-stage Parkinson's Disease Carrying a GBA Mutation or Other Pre-specified Variant - MOVES-PD	Parkinson's disease (PD) carrying a GBA mutation MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Code: SAR402671, GZ402671 or GZ/SAR402671 INN or Proposed INN: - Other descriptive name: Genz-682452 -AU Product Code: SAR402671, GZ402671 or GZ/SAR402671 INN or Proposed INN: - Other descriptive name: Genz-682452 -AU	Genzyme Corporation	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	290	Phase 2	United States;Portugal;Taiwan;Greece;Spain;Austria;Israel;United Kingdom;Italy;France;Canada;Singapore;Germany;Norway;Japan;Sweden
244	NCT03877510 (ClinicalTrials.gov)	April 3, 2019	12/3/2019	Open Label Extension (OLE) Study of the Safety and Clinical Utility of IPX203 in PD Patients With Motor Fluctuations	An Open-label Extension Study of the Safety and Clinical Utility of IPX203 in Parkinson's Disease Patients With Motor Fluctuations	Parkinson Disease	Drug: IPX203 140 mg;Drug: IPX203 210 mg;Drug: IPX203 280 mg;Drug: IPX203 350 mg	Impax Laboratories, LLC	NULL	Enrolling by invitation	40 Years	N/A	All	300	Phase 3	United States;Czechia;France;Germany;Italy;Spain;United Kingdom
245	ChiCTR1800015757	2019-04-01	2018-04-18	Value of 131I-MIBG salivary gland imaging in the early diagnosis of Parkinson's disease	Value of 131I-MIBG salivary gland imaging in the early diagnosis of Parkinson's disease	Parkinson's Disease	Gold Standard:PD diagnostic criteria made by MDS in 2016;Index test:reduced uptake in salivery gland and myocardium in I-131-MIBG scintigraphic imaging;	Tongji hospital, Tongji University	NULL	Pending			Both	Target condition:30;Difficult condition:30		China
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
246	NCT03858270 (ClinicalTrials.gov)	April 1, 2019	2/10/2018	Inhibition of a-synuclein Cell-cell Transmission by NMDAR Blocker, Memantine	Inhibition of a-synuclein Cell-cell Transmission by NMDAR Blocker, Memantine	Parkinson Disease	Drug: Memantine;Other: Placebo	Wayne State University	NULL	Recruiting	45 Years	85 Years	All	50	Phase 3	United States
247	JPRN-jRCTs051180214	29/03/2019	27/03/2019	The usefulness of flutemetamol for diagnostic imaging of neurogenerative disease	The usefulness of brain amyloid image using flutemetamol and glucose metabolism for the neurogenerative disease - The usefulness of brain amyloid image using flutemetamol and glucose metabolism for the neurogenerative disease	Alzheimer's disease,Dementia with Lewy Bodies,Parkinson's syndrome,Frontotemporal lober degeneration Alzheimer's disease, Dementia with Lewy Bodies, Parkinson's syndrome, Frontotemporal lober degeneration, Parkinson's disease, Mild cognitive impairment, Non-Alzheimer's disease, Progressive aphasia, Neurodegenerative disease, Cerebral corticobasal degeneration, Progressive supranuclear palsy	Amyloid PET: Given the flutemetamol (3mL) intravenously FDG-PET:Given the FDG scanR (3mL) intravenously	Itoh Yoshiaki	NULL	Recruiting	Ages 20 and over	N/A	Both	100	N/A	Japan
248	NCT03922711 (ClinicalTrials.gov)	March 26, 2019	17/4/2019	A Study to Assess the Safety and Effectiveness of Pridopidine Compared to Placebo in the Treatment of Levodopa-Induced Dyskinesia in Patients With Parkinson's Disease	A Double-Blind, Randomized, Three-Arm, Parallel-Group Study to Assess the Efficacy and Safety of Two Doses of Pridopidine Versus Placebo for the Treatment of Levodopa-Induced Dyskinesia in Patients With Parkinson's Disease (gLIDe)	Parkinson Disease	Drug: Pridopidine;Drug: Placebo	Prilenia	NULL	Terminated	30 Years	85 Years	All	23	Phase 2	United States
249	NCT04064983 (ClinicalTrials.gov)	March 14, 2019	19/8/2019	Individual Patient Expanded Access IND of Hope Biosciences Autologous Adipose-derived Mesenchymal Stem Cells for Parkinson's Disease	Individual Patient Expanded Access IND of Hope Biosciences Autologous Adipose-derived Mesenchymal Stem Cells (HB-adMSCs) for Parkinson's Disease	Parkinson Disease	Drug: HB-adMSCs	Hope Biosciences	NULL	No longer available	18 Years	N/A	All			United States
250	NCT03716570 (ClinicalTrials.gov)	March 12, 2019	22/10/2018	A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Japanese Participants With Parkinson's Disease	A Multicenter, Blinded, Placebo-Controlled, Randomized, Single and Multiple-Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Japanese Subjects With Parkinson's Disease	Parkinson's Disease	Drug: BIIB054;Drug: Placebo	Biogen	NULL	Active, not recruiting	40 Years	80 Years	All	24	Phase 1	Japan
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
251	NCT03816020 (ClinicalTrials.gov)	March 9, 2019	7/12/2018	NAD-supplementation in Drug naïve Parkinson's Disease	NAD-PARK: A Double-blinded Randomized Pilot Trial of NAD-supplementation in Drug naïve Parkinson's Disease	Parkinson Disease;Neurodegenerative Diseases	Dietary Supplement: Nicotinamide Riboside;Other: Placebo	Haukeland University Hospital	NULL	Completed	18 Years	N/A	All	30	N/A	Norway
252	ChiCTR1900021760	2019-03-09	2019-03-08	Effect-site concentration of remifentanil for I-gel insertion in male patients with Parkinson’s disease undergoing deep brain stimulator implantation during target-controlled infusion of propofol	Effect-site concentration of remifentanil for I-gel insertion in male patients with Parkinson’s disease undergoing deep brain stimulator implantation during target-controlled infusion of propofol	Parkinson’s disease	Parkinson’s disease:propofol and remifentanil;Non-Parkinson’s disease:propofol and remifentanil;	The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China	NULL	Recruiting	40	64	Male	Parkinson’s disease:25;Non-Parkinson’s disease:25;	N/A	China
253	EUCTR2017-005170-19-FI (EUCTR)	06/03/2019	07/12/2018	A Long-Term Follow-up Safety Study for Patients with Parkinson’s Disease (PD) Implanted with the Drug Delivery System (DDS) and/or Who Received Treatment in the Main Study and/or Extension Study	A Long-Term Follow-up Safety Study for Patients with Idiopathic Parkinson’s Disease (PD) Implanted with the DDS and/or Who Received Treatment in the Main Study and/or Extension Study - Long-Term Follow-up Safety After DDS Implantation with/without CDNF Infusions	Idiopathic Parkinson's Disease MedDRA version: 21.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Cerebral Dopamine Neurotrophic Factor Product Code: CDNF INN or Proposed INN: Not Applicable Other descriptive name: recombinant human Cerebral Dopamine Neurotrophic Factor	Renishaw Neuro Solutions Ltd.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	20	Phase 1;Phase 2	Finland;Sweden
254	NCT03887884 (ClinicalTrials.gov)	March 5, 2019	1/3/2019	Pharmacokinetic Study of CVT-301 (Levodopa Inhalation Powder)	Randomized, Multi-center, Open-label, Crossover Pharmacokinetic Study of CVT-301 (Levodopa Inhalation Powder) and an Oral Dose of Carbidopa/Levodopa CD/LD Under Fed Conditions in Patients With Parkinson's Disease	Parkinson's Disease	Drug: CVT-301;Drug: Sinemet	Acorda Therapeutics	NULL	Completed	30 Years	85 Years	All	23	Phase 1	United States
255	NCT03865121 (ClinicalTrials.gov)	March 4, 2019	26/2/2019	Pilot Trial of Transnasal Nicotine in Parkinson Disease	Uncontrolled Pilot Trial of Transnasal Nicotine in Parkinson Disease	Parkinson Disease	Drug: Nicotine Nasal Spray 10 MG/ML (0.5 MG/SPRAY)	El Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez	Howard University	Completed	60 Years	N/A	All	6	Phase 2	Mexico
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
256	NCT03820037 (ClinicalTrials.gov)	March 2019	25/1/2019	Relative Bioavailability and Bioequivalence of Opicapone	A Phase I, Open-Label, Randomised, Three-Period, Three-Sequence, Partial Replicate Crossover Study to Investigate the Relative Bioavailability and Bioequivalence of Opicapone Obtained From Two Different Sources, Under Fasting Conditions After Single-dose Administration in Healthy Subjects	Parkinson Disease	Drug: Ongentys;Drug: BIA 9-1067 (test)	Bial - Portela C S.A.	NULL	Not yet recruiting	18 Years	55 Years	All	45	Phase 1	United Kingdom
257	NCT03845387 (ClinicalTrials.gov)	February 26, 2019	15/2/2019	A Clinical Study of KDT-3594 in Patients With Early Parkinson's Disease.	A Phase II Clinical Study of KDT-3594 in Patients With Early Parkinson's Disease.	Parkinson Disease	Drug: KDT-3594;Drug: Pramipexole	Kissei Pharmaceutical Co., Ltd.	NULL	Active, not recruiting	20 Years	79 Years	All	100	Phase 2	Japan
258	NCT03830528 (ClinicalTrials.gov)	February 26, 2019	3/2/2019	A Study of Single and Multiple Doses of KW-6356 in Healthy Subjects	A Phase I Study of KW-6356 in Japanese and Caucasian Healthy Adults	Parkinson's Disease	Drug: KW-6356 Low Dose;Drug: KW-6356 Middle Dose;Drug: KW-6356 High Dose;Drug: KW-6356 X Dose;Drug: KW-6356 Y Dose;Drug: Placebo	Kyowa Kirin Co., Ltd.	NULL	Completed	20 Years	44 Years	Male	48	Phase 1	Japan
259	NCT03968744 (ClinicalTrials.gov)	February 18, 2019	19/4/2019	Effect of Safinamide on Sleep Quality in Patients With Parkinson's Disease	A Prospective, Open Label, Single Arm, Clinical Study to Evaluate the Effect of Safinamide on Sleep Quality and Polysomnographic Parameters in Patients With Parkinson's Disease: the Safe Sleep Study	Idiopathic Parkinson's Disease (at Later Stage)	Drug: Safinamide	Alain Kaelin	Clinical Trial Unit Ente Ospedaliero Cantonale	Recruiting	18 Years	N/A	All	23	Phase 4	Switzerland
260	NCT03655236 (ClinicalTrials.gov)	February 18, 2019	18/8/2018	PROSEEK: A Phase 2 Study In Early Parkinson's Disease Patients Evaluating The Safety And Efficacy Of Abl Tyrosine Kinase Inhibition Using K0706	A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of K0706 in Subjects With Early Parkinson's Disease	Early Parkinson Disease	Drug: K0706;Other: placebo	Sun Pharma Advanced Research Company Limited	NULL	Recruiting	50 Years	N/A	All	504	Phase 2	United States;Hungary;Poland;Slovakia;Spain
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
261	NCT03413384 (ClinicalTrials.gov)	February 15, 2019	8/1/2018	To Assess the Efficacy and Safety of Ceftriaxone in Patients With Mild to Moderate Parkinson's Disease Dementia	A Randomized, Double Blinded, Placebo-controlled Phase II Study to Assess the Efficacy and Safety of Ceftriaxone in Patients With Mild to Moderate Parkinson's Disease Dementia	Parkinson's Disease Dementia	Drug: Ceftriaxone;Other: Placebo	BrainX Corporation	NULL	Recruiting	50 Years	80 Years	All	106	Phase 2	Taiwan
262	NCT04510922 (ClinicalTrials.gov)	February 11, 2019	9/7/2020	Lundbeck TOMs Orthostatic Hypotension	Technology-Based Objective Measures for Gait and Postural Assessment in Parkinson Disease Patients With Orthostatic Hypotension: Feasibility and Effect-Size Finding Study	Orthostatic Hypotension;Idiopathic Parkinson Disease	Drug: Droxidopa 100 MG [Northera]	Alberto Espay, MD, MSc	Lundbeck LLC	Recruiting	30 Years	80 Years	All	12	Phase 4	United States
263	NCT03815071 (ClinicalTrials.gov)	February 1, 2019	21/1/2019	A Study on the Treatment of Parkinson's Disease With Autologous Neural Stem Cells	Clinical Study of the Safety and Efficacy of Autologous Neural Stem Cells in the Treatment of Parkinson's Disease	Parkinson Disease	Drug: Ips-nsc cells	Allife Medical Science and Technology Co., Ltd.	The First People's Hospital of Yunnan Province/First People's Hospital of Yunan Provinve New Kunhua Hospital;Henan Provincial People's Hospital;Beijing Hospital	Not yet recruiting	18 Years	60 Years	All	10	Early Phase 1	NULL
264	NCT03790670 (ClinicalTrials.gov)	January 30, 2019	18/12/2018	Biomarker Assessments of Leukine During Treatment of Parkinson's Disease	Safety, Tolerability and Biomarker Assessments of Leukine (Sargramostim) During Extended Timed Treatment for Parkinson's Disease: A Phase I Pilot Study	Parkinson Disease	Drug: sargramostim	University of Nebraska	NULL	Recruiting	35 Years	85 Years	All	10	Phase 1	United States
265	EUCTR2017-003458-18-SE (EUCTR)	23/01/2019	10/12/2018	A clinical trial to study the effects of IRL790 in Parkinson's disease dyskinesia	A randomised, double-blind, placebo-controlled, phase IIA study evaluating the efficacy and tolerability of IRL790 in Parkinson's disease dyskinesia	Parkinson's disease dyskinesia MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Integrative Research Laboratories AB (IRLAB)	NULL	Not Recruiting			Female: yes Male: yes	74	Phase 2	Sweden
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
266	EUCTR2017-002426-20-AT (EUCTR)	22/01/2019	03/12/2018	Effect of Safinamide on Parkinson’s Disease Related Chronic Pain	A randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of safinamide 100 mg once daily, as add-on therapy, in idiopathic Parkinson’s Disease (IPD) patients with motor fluctuations and PD related chronic pain - Pain study	Idiopathic Parkinson's Disease, Hoehn and Yahr stage between 2-3 inclusive during the ON” phase, experiencing motor fluctuations while on stable doses of L-Dopa (with or without benserazide/carbidopa, with or without addition of a catechol O-methyltransferase (COMT) inhibitor) and may be on stable doses of other PD medications (a dopamine agonist, an anticholinergic and/or amantadine), yet are experiencing more than 2 hours of OFF time per day and chronic PD related pain. MedDRA version: 20.0;Level: LLT;Classification code 10013113;Term: Disease Parkinson's;System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Zambon SpA	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	177	Phase 4	Spain;Austria
267	EUCTR2018-002877-23-AT (EUCTR)	21/01/2019	07/12/2018	Oxytocin and social attention in healthy controls and patients with Parkinson's disease. A randomised, double-blind, placebo-controlled, crossover eye tracking study.	Oxytocin and social attention in healthy controls and patients with Parkinson's disease. A randomised, double-blind, placebo-controlled, crossover eye tracking study. - Oxytocin in healthy controls and PD	Social functioning in Parkinson's disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Syntocinon 40 IU/ml nasal spray INN or Proposed INN: Synthetic Oxytocin Other descriptive name: OXYTOCIN SYNTHETIC	Abteilung für Neurologie der Medizinischen Universität Innsbruck	NULL	Authorised-recruitment may be ongoing or finished			Female: no Male: yes	76	Phase 2	Austria
268	NCT03826134 (ClinicalTrials.gov)	January 17, 2019	30/1/2019	A Positron Emission Tomography (PET) Study to Examine the Brain Binding Properties of a Novel Radioactive Compound [11C]-PXT012253 in Healthy Subjects	Interventional, Phase I, Open-label, First in Human, Single-center Positron Emission Tomography (PET) Study Investigating Test-retest Properties of [11C]-PXT012253 as a Radiotracer in Healthy Subjects	Parkinson Disease	Drug: [11C]PXT012253	H. Lundbeck A/S	NULL	Completed	20 Years	50 Years	All	7	Early Phase 1	Sweden
269	NCT04620863 (ClinicalTrials.gov)	January 15, 2019	26/10/2020	TRANSCRANIAL DIRECT CURRENT STIMULATION (t-DCS) AS ADD-ON TO NEUROREHABILITATION OF PISA SYNDROME IN PARKINSON DISEASE	TRANSCRANIAL DIRECT CURRENT STIMULATION (t-DCS) AS ADD-ON TO NEUROREHABILITATION OF PISA SYNDROME IN PARKINSON DISEASE: A RANDOMIZED CONTROLLED TRIAL	Parkinson Disease;Pisa Syndrome	Other: t-DCS group;Other: Sham group	IRCCS National Neurological Institute C. Mondino Foundation	NULL	Completed	18 Years	80 Years	All	30	N/A	Italy
270	JPRN-UMIN000035602	2019/01/11	21/01/2019	Hydrogen gas inhalation randomized double blinded trial for Parkinson's disease	Hydrogen gas inhalation randomized double blinded trial for Parkinson's disease - Hydrogen gas inhalation randomized double blinded trial for Parkinson's disease	Parkinson's disease	hydrogen gas16 weeks inhalation two times of the inhalation for 60 minutes per day 8 weeks obsebation after the inhalation placebo gas 16 weeks inhalation two times of the inhalation for 60 minutes per day 8 weeks obsebation after the inhalation	Juntendo University Koshigaya Hospital	NULL	Complete: follow-up complete	40years-old	80years-old	Male and Female	20	Not selected	Japan
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
271	NCT03638479 (ClinicalTrials.gov)	January 8, 2019	13/8/2018	Utilizing Smart Devices to Identify New Phenotypical Characteristics in Movement Disorders	Utilizing Smart Devices to Identify New Phenotypical Characteristics in Movement Disorders	Parkinson Disease;Essential Tremor;Movement Disorders;Parkinson's Syndrome;Atypical Parkinsonism	Other: Data Capture	Westfälische Wilhelms-Universität Münster	NULL	Recruiting	18 Years	N/A	All	500		Germany
272	NCT03659682 (ClinicalTrials.gov)	January 2, 2019	3/9/2018	GLP1R in Parkinson's Disease	Effect of GLPIR Stimulation on Neuroprotection and Inflammation in Parkinson's Disease	Parkinson Disease	Drug: Semaglutide	Oslo University Hospital	NULL	Not yet recruiting	40 Years	75 Years	All	120	Phase 2	NULL
273	NCT03727295 (ClinicalTrials.gov)	January 1, 2019	30/10/2018	Idebenone Treatment of Early Parkinson's Diseasesymptoms	A Multicenter, Randomized, Double-blind, Placebo-controlled Study of Idebenone in the Treatment of Early-stage Parkinson's Disease With Motor and Non-motor Symptoms	Oxidative Stress is an Important Cause of Parkinson's Disease	Drug: Idebenone/placebo	Second Affiliated Hospital of Soochow University	Qilu Pharmaceutical Co., Ltd.	Not yet recruiting	30 Years	80 Years	All	180	Phase 4	NULL
274	ChiCTR1800019942	2018-12-31	2018-12-09	A Multicenter Randomized Controlled Trial for Effect of Zishen Pingchan Granules Combined with Pramipexole in the treatment of Depression in Parkinson’s Disease	A Multicenter Randomized Controlled Trial for Effect of Zishen Pingchan Granules Combined with Pramipexole in the treatment of Depression in Parkinson’s Disease	Parkinson’s Disease	Experimental group:Zishen Pingchan Granules combined with Pramipexole;Control group:Zishen Pingchan Granules placebo combined with Pramipexole;	The Affiliated Brain Hospital of Nanjing Medical University( Nanjing Brain Hospital)	NULL	Pending	30	85	Both	Experimental group:150;Control group:150;		China
275	NCT03391882 (ClinicalTrials.gov)	December 19, 2018	2/1/2018	A Study of an Investigational Drug to See How it Affects the People With Parkinson's Disease Complicated by Motor Fluctuations (OFF Episodes) Compared to an Approved Drug Used to Treat People With Parkinson's Disease Complicated by Motor Fluctuations (OFF Episodes)	An Open-Label, Randomized, Crossover Trial Utilizing a Single-Blinded Rater to Evaluate APL-130277 Compared to Subcutaneous Apomorphine in Levodopa Responsive Subjects With Parkinson's Disease Complicated by Motor Fluctuations	Motor OFF Episodes Associated With Parkinson's Disease	Drug: APL-130277;Drug: subcutaneous apomorphine	Sunovion	NULL	Recruiting	18 Years	N/A	All	106	Phase 3	Austria;France;Germany;Italy;Spain;United Kingdom
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
276	NCT03840005 (ClinicalTrials.gov)	December 18, 2018	11/2/2019	Trial of Ursodeoxycholic Acid (UDCA) for Parkinson's Disease: The UP Study	A Phase II, Placebo Controlled, Double Blind, Randomised Clinical Trial To Assess The Safety And Tolerability Of 30mg/kg Daily Ursodeoxycholic Acid (UDCA) In Patients With Parkinson's Disease (PD)	Parkinson's Disease	Drug: Ursonorm	Sheffield Teaching Hospitals NHS Foundation Trust	JP Moulton Charitable Foundation;PRO.MED.CS Praha a.s.;Clinical Trials Research Unit, University of Sheffield	Active, not recruiting	18 Years	75 Years	All	30	Phase 2	United Kingdom
277	NCT03781791 (ClinicalTrials.gov)	December 10, 2018	27/11/2018	Orally Administered ENT-01 for Parkinson's Disease-Related Constipation (KARMET)	A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Evaluate Safety, Tolerability and Efficacy of Orally Administered ENT-01 for the Treatment of Parkinson's Disease-Related Constipation (KARMET)	Constipation;Parkinson Disease	Drug: Active Investigational Treatment ENT-01;Drug: Placebo Treatment	Enterin Inc.	NULL	Active, not recruiting	30 Years	90 Years	All	152	Phase 2	United States
278	NCT03710707 (ClinicalTrials.gov)	December 4, 2018	15/10/2018	Study to Evaluate DNL201 in Subjects With Parkinson's Disease	A Phase 1b, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Determine the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL201 in Subjects With Parkinson's Disease	Parkinson Disease	Drug: DNL201;Drug: Placebo	Denali Therapeutics Inc.	NULL	Completed	30 Years	80 Years	All	29	Phase 1	United States
279	NCT03944447 (ClinicalTrials.gov)	December 1, 2018	3/5/2019	Outcomes Mandate National Integration With Cannabis as Medicine for Prevention and Treatment of COVID-19	Outcomes Mandate National Integration With Cannabis as Medicine for Prevention and Treatment of COVID-19	Chronic Pain;Chronic Pain Syndrome;Chronic Pain Due to Injury;Chronic Pain Due to Trauma;Fibromyalgia;Seizures;Hepatitis C;Cancer;Crohn Disease;HIV/AIDS;Multiple Sclerosis;Traumatic Brain Injury;Sickle Cell Disease;Post Traumatic Stress Disorder;Tourette Syndrome;Ulcerative Colitis;Glaucoma;Epilepsy;Inflammatory Bowel Diseases;Parkinson Disease;Amyotrophic Lateral Sclerosis;Chronic Traumatic Encephalopathy;Anxiety;Depression;Insomnia;Autism;Opioid-use Disorder;Bipolar Disorder;Covid19;SARS-CoV Infection;COVID-19;Corona Virus Infection;Coronavirus	Drug: Cannabis , Medical	OMNI Medical Services, LLC	OMNI Medical Services Inc	Recruiting	7 Years	N/A	All	200000	Phase 2	United States
280	NCT03639064 (ClinicalTrials.gov)	December 2018	4/7/2018	Cannabis Oil for Pain in Parkinson's Disease	A Phase II, Randomized, Open-label, Double-blind, Two-center Study to Evaluate the Tolerability, Safety and Dose-finding of Oil Cannabis Preparation for Pain in Parkinson's Disease	Parkinson Disease	Drug: Cannabis Oil	University Health Network, Toronto	Parkinson Society Canada	Unknown status	18 Years	N/A	All	15	Phase 2	NULL
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
281	NCT03942172 (ClinicalTrials.gov)	November 27, 2018	6/5/2019	Treatment of Balance Disorders in Parkinson's Patients Using SpotOn Balance Glasses	Treatment of Balance Disorders in Parkinson's Patients Using SpotOn Balance Glasses	Parkinson Disease	Device: SpotOn balance glasses	SpotOn Therapeutics Ltd.	NULL	Suspended	30 Years	N/A	All	50	N/A	Israel
282	NCT03822364 (ClinicalTrials.gov)	November 26, 2018	18/12/2018	Staccato Apomorphine Single and Multi Dose PK	A Randomized Study of the Safety, Tolerability, and Pharmacokinetics of AZ-009 (Staccato Apomorphine) in Healthy Volunteers and the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZ-009 in Subjects With Parkinson's Disease	Parkinson Disease	Drug: 009-1;Drug: active comparator;Drug: 009-0;Drug: 009-2;Drug: 009-3;Drug: 009-4;Drug: 009-5	Alexza Pharmaceuticals, Inc.	NULL	Completed	18 Years	60 Years	All	56	Phase 1	Netherlands
283	NCT03823638 (ClinicalTrials.gov)	November 20, 2018	20/11/2018	Safety, Tolerability and Effects of Mannitol in Parkinson's Disease	A Phase II Single Center, Randomized, Double Blind and Placebo Controlled Study Assessing the Safety, Tolerability and Effects of Progressively Increased Dose of Oral Mannitol in Parkinson's Disease	Parkinson Disease	Dietary Supplement: Oral D-Mannitol of Placebo	Hadassah Medical Organization	NULL	Recruiting	40 Years	75 Years	All	60	Phase 2	Israel
284	NCT03713957 (ClinicalTrials.gov)	November 12, 2018	18/10/2018	A Study to Assess the Safety of GRF6021 Infusions in Subjects With Parkinson's Disease and Cognitive Impairment	A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Tolerability of GRF6021 Infusions in Subjects With Parkinson's Disease and Cognitive Impairment	Parkinson Disease	Drug: GRF6021;Other: Placebo	Alkahest, Inc.	Michael J. Fox Foundation for Parkinson's Research	Completed	40 Years	85 Years	All	79	Phase 2	United States;Australia;France
285	NCT03733561 (ClinicalTrials.gov)	November 9, 2018	6/11/2018	A Study to Assess Pharmacokinetic Profiles of LY03003 and Neupro	A Randomized, Open-Label, Crossover Study to Evaluate the Pharmacokinetic Profiles of Rotigotine After a Single Dose of LY03003 (28 mg) Versus After a Week of Daily NEUPRO® Transdermal Patch (4 mg Every 24 Hours) in Healthy Volunteers	Parkinson Disease	Drug: LY03003;Drug: Neupro 4Mg/24Hr Transdermal Patch	Luye Pharma Group Ltd.	NULL	Recruiting	18 Years	45 Years	All	40	Phase 1	United States
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
286	EUCTR2018-001887-46-GB (EUCTR)	08/11/2018	19/06/2019	Trial of Ursodeoxycholic Acid (UDCA) for PD. The 'UP-study'	A Phase II, Placebo Controlled, Double Blind, Randomised Clinical Trial to assess the safety and tolerability Of 30mg/kg daily Ursodeoxycholic Acid (UDCA) in Patients with Parkinson’s Disease (PD) - Trial of Ursodeoxycholic Acid (UDCA) for PD. The 'UP-study'	Parkinson’s disease (PD) MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Sheffield Teaching Hospitals NHS Foundation Trust	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	30	Phase 2	United Kingdom
287	NCT03670953 (ClinicalTrials.gov)	November 6, 2018	12/9/2018	A Study to Evaluate the Safety and Efficacy of IPX203 in Parkinson's Disease Patients With Motor Fluctuations	A Randomized Controlled Study to Compare the Safety and Efficacy of IPX203 With Immediate-Release Carbidopa-Levodopa in Parkinson's Disease Patients With Motor Fluctuations	Parkinson's Disease (Disorder)	Drug: IR CD-LD;Drug: IPX203 ER CD-LD;Other: IPX203 placebo;Other: IR CD-LD placebo	Impax Laboratories, LLC	NULL	Recruiting	40 Years	N/A	All	510	Phase 3	United States;Czechia;France;Germany;Italy;Poland;Spain;United Kingdom
288	NCT03667404 (ClinicalTrials.gov)	November 6, 2018	10/9/2018	Resistant Maltodextrin for Gut Microbiome in Parkinson's Disease: Safety and Tolerability Study	Gut Microbial Remodeling With Resistant Maltodextrin for Motor and Non-motor Symptoms in Parkinson's Disease: Safety and Tolerability Study	Parkinson Disease;Intestinal Bacteria Flora Disturbance;Dietary Modification	Dietary Supplement: Resistant maltodextrin;Dietary Supplement: maltodextrin	Northwestern University	University of Illinois at Chicago	Recruiting	60 Years	N/A	All	30	Phase 2	United States
289	NCT04629404 (ClinicalTrials.gov)	November 5, 2018	5/11/2020	A Clinical Trial to Evaluate the Pharmacodynamics/Pharmacokinetics and Safety of LY03003 in Early PD Patients	A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Pharmacodynamics/Pharmacokinetics and Safety of Multiple Intramuscular Doses of LY03003 in Patients With Early Parkinson's Disease	Parkinson Disease	Drug: LY03003;Drug: Placebo	Luye Pharma Group Ltd.	NULL	Completed	30 Years	N/A	All	32	Phase 1	China
290	JPRN-JapicCTI-184181	01/11/2018	30/10/2018	Rasagiline Tablets Special Drug Use-Results Survey Survey on Long-term Safety	AZILECT Tablets Special Drug Use-Results Survey Survey on Long-term Safety	Parkinson's disease	Intervention name : Rasagiline INN of the intervention : rasagiline Dosage And administration of the intervention : Rasagiline 1 milligram (mg), orally, once daily for up to 24 months. Participants received interventions as part of routine medical care. Control intervention name : - INN of the control intervention : - Dosage And administration of the control intervention : -	TAKEDA PHARMACEUTICAL COMPANY LTD.	NULL	complete			BOTH	1021	NA	Japan
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
291	NCT03069911 (ClinicalTrials.gov)	November 1, 2018	28/2/2017	Trial of OnabotulinumtoxinA for Depression in Parkinson Disease	Randomized Controlled Trial of OnabotulinumtoxinA for Depression in Parkinson Disease	Parkinson Disease;Depression	Biological: OnabotulinumtoxinA;Biological: Control	Johns Hopkins University	NULL	Terminated	18 Years	95 Years	All	3	Phase 1	United States
292	NCT03727139 (ClinicalTrials.gov)	November 1, 2018	30/10/2018	Rasagiline Tablets Special Drug Use-Results Survey Survey on Long-term Safety	AZILECT Tablets Special Drug Use-Results Survey Survey on Long-term Safety	Parkinson's Disease	Drug: Rasagiline	Takeda	NULL	Active, not recruiting	N/A	N/A	All	1021		Japan
293	EUCTR2017-003415-19-ES (EUCTR)	31/10/2018	20/08/2018	A Clinical Study in Parkinson’s Disease Patients With Moderate to Severe Abnormal Movements to See If JM-010 is Effective and Safe/Tolerable.	A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study in Parkinson’s Disease Patients With Moderate to Severe Dyskinesia to Assess the Efficacy and Safety/Tolerability of Two Dose Combinations Of JM-010	Parkinson’s Disease Patients With Moderate to Severe Dyskinesia;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: JM -010 Product Code: JM -010 INN or Proposed INN: Buspirone hydrochloride INN or Proposed INN: Zolmitriptan Product Name: JM -010 Product Code: JM -010 INN or Proposed INN: Buspirone hydrochloride INN or Proposed INN: Zolmitriptan	Contera Pharma	NULL	Not Recruiting			Female: yes Male: yes	81	Phase 2	France;Spain;Germany
294	EUCTR2016-002033-30-NL (EUCTR)	31/10/2018	15/11/2017	A clinical study investigating the efficacy, tolerability, and safety of two dosing regimens of continuous subcutaneous ND0612 infusion given as adjunct treatment to oral levodopa in patients with Parkinson’s disease with motor fluctuations	A multicenter, randomized, double-blind, placebo controlled, parallel group clinical study investigating the efficacy, tolerability, and safety of two dosing regimens of continuous subcutaneous ND0612 infusion Given as adjunct treatment to oral levOdopa in patients with Parkinson’s Disease with motor fluctuations (iNDiGO) - iNDiGO	Subjects with Parkinson’s Disease with motor fluctuations MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		NeuroDerm Ltd.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	240	Phase 3	Serbia;Portugal;United States;Spain;Ukraine;Russian Federation;Chile;Israel;Italy;United Kingdom;France;Czech Republic;Hungary;Poland;Belgium;Denmark;Netherlands;Germany
295	ChiCTR1800017949	2018-10-30	2018-08-24	Clinical study for the effect of the combination of Shudipingchan prescription and Monoamine oxidase inhibitor on improving early PD symptoms and delaying the progression of the disease	Clinical study for the effect of the combination of Shudipingchan prescription and Monoamine oxidase inhibitor on improving early PD symptoms and delaying the progression of the disease	Parkinson's disease	Group 1:Selegiline and Shudipingchan granule;Group 2:Selegiline and simulant TCM granule;	Longhua Hospital Shanghai University of Traditional Chinese Medicine	NULL	Pending	30	85	Both	Group 1:72;Group 2:72;		China
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
296	ChiCTR1800018017	2018-10-30	2018-08-27	Clinical study for the effect of the combination of Shudipingchan prescription and Monoamine oxidase inhibitor on improving early Parkinson‘s Disease symptoms and delaying the progression of the disease	Clinical study for the effect of the combination of Shudipingchan prescription and Monoamine oxidase inhibitor on improving early Parkinson‘s Disease symptoms and delaying the progression of the disease	Parkinson's disease	Treatment group:Selegiline+Shudipingchan granule;Control group:Selegiline+TCM simulant;	Longhua Hospital Shanghai University of Traditional Chinese Medicine	NULL	Pending	30	85	Both	Treatment group:92;Control group:92;		China
297	EUCTR2017-002426-20-ES (EUCTR)	19/10/2018	20/08/2018	Effect of Safinamide on Parkinson’s Disease Related Chronic Pain	A randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of safinamide 100 mg once daily, as add-on therapy, in idiopathic Parkinson’s Disease (IPD) patients with motor fluctuations and PD related chronic pain - Pain study	Idiopathic Parkinson's Disease, Hoehn and Yahr stage between 2-3 inclusive during the ON” phase, experiencing motor fluctuations while on stable doses of L-Dopa (with or without benserazide/carbidopa, with or without addition of a catechol O-methyltransferase (COMT) inhibitor) and may be on stable doses of other PD medications (a dopamine agonist, an anticholinergic and/or amantadine), yet are experiencing more than 2 hours of OFF time per day and chronic PD related pain. MedDRA version: 20.0;Level: LLT;Classification code 10013113;Term: Disease Parkinson's;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Xadago Product Name: Xadago INN or Proposed INN: Safinamide methansulfonate Other descriptive name: SAFINAMIDE METHANESULFONATE Trade Name: Xadago Product Name: Xadago INN or Proposed INN: Safinamide methansulfonate Other descriptive name: SAFINAMIDE METHANESULFONATE	Zambon SpA	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	177	Phase 4	Spain
298	NCT03720418 (ClinicalTrials.gov)	October 17, 2018	16/10/2018	Study of OXB-102 (AXO-Lenti-PD) in Patients With Bilateral, Idiopathic Parkinson's Disease	A Phase I/II Safety and Dose Evaluation Study of OXB-102 in Patients With Bilateral Idiopathic Parkinson's Disease	Parkinson Disease	Drug: OXB-102;Other: Imitation Surgical Procedure (ISP)	Axovant Sciences Ltd.	Oxford BioMedica	Recruiting	30 Years	70 Years	All	30	Phase 1;Phase 2	France;United Kingdom
299	NCT04048291 (ClinicalTrials.gov)	October 15, 2018	9/10/2018	Efficacy of Brisk Walking in Parkinson's Disease	Efficacy of Brisk Walking on Improving Balance and Gait Performance, and Functional Mobility in Parkinson's Disease - a Randomized Controlled Trial	Parkinson Disease	Behavioral: Brisk walking and balance training;Behavioral: Upper limb exercise	The Hong Kong Polytechnic University	NULL	Completed	30 Years	N/A	All	80	N/A	Hong Kong
300	NCT04451096 (ClinicalTrials.gov)	October 6, 2018	19/6/2020	Probiotics-prebiotic Fiber Therapy in Parkinson's Disease Patients With Constipation	Probiotics-prebiotic Fiber Therapy Improved Bowel Opening Frequency and Whole Gut Transit Time in Parkinson's Disease Patients With Constipation: A Randomised Controlled Study	Parkinson Disease;Constipation	Dietary Supplement: Probiotics with prebiotic;Dietary Supplement: Placebo	National University of Malaysia	NULL	Completed	18 Years	N/A	All	48	Phase 3	Malaysia
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
301	EUCTR2018-000346-19-FI (EUCTR)	03/10/2018	09/07/2018	An extended clinical study to test the safety of Cerebral Dopamine Neurotrophic Factor (CDNF) by brain infusion via Drug Delivery System (DDS) in patients with Parkinson's disease.	A Randomised, Double-Blind, Multi-centre, Active Treatment, Extension and Safety Study for Patients with Idiopathic Parkinson’s Disease (PD) Who Previously Completed the CDNF/DDS Main Study HP-CD-CL-2002. - Extension Study	Idiopathic Parkinson's Disease MedDRA version: 21.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Cerebral Dopamine Neurotrophic Factor Product Code: CDNF INN or Proposed INN: Not Applicable Other descriptive name: recombinant human Cerebral Dopamine Neurotrophic Factor	Herantis Pharma Plc	NULL	Not Recruiting			Female: yes Male: yes	18	Phase 1;Phase 2	Finland;Sweden
302	EUCTR2016-004610-95-DE (EUCTR)	01/10/2018	27/02/2018	Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Participants with Parkinson’s Disease	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study, with an Active-Treatment Dose-Blinded Period, to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Subjects with Parkinson’s Disease - SPARK	Parkinson's Disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Code: BIIB054 INN or Proposed INN: n/a Other descriptive name: BIIB054	Biogen Idec Research Limited	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	357	Phase 2	United States;France;Canada;Spain;Austria;Israel;Germany;United Kingdom;Italy
303	NCT03703570 (ClinicalTrials.gov)	September 29, 2018	5/10/2018	A Study of KW-6356 in Patients With Parkinson's Disease on Treatment With Levodopa-containing Preparations	A Phase 2b Study of KW-6356 in Subjects With Parkinson's Disease on Treatment With Levodopa-containing Preparations	Parkinson's Disease	Drug: KW-6356;Drug: Placebo	Kyowa Kirin Co., Ltd.	NULL	Completed	20 Years	80 Years	All	502	Phase 2	Japan
304	NCT03665454 (ClinicalTrials.gov)	September 24, 2018	1/8/2018	PF 06412562 in Subjects With Advanced Stage Parkinson's Disease	A Phase Ib Safety, Tolerability, and Efficacy Study of Two Days of Oral Split Dose (25/20 mg) Administration of PF 06412562 in Subjects With Advanced Stage Parkinson's Disease	Parkinson Disease	Drug: PF-06412562;Drug: Standard of Care Placebo	Milton S. Hershey Medical Center	Pfizer	Completed	N/A	N/A	All	8	Phase 1	United States
305	NCT03582137 (ClinicalTrials.gov)	September 17, 2018	17/4/2018	A Study of Tolerability and Efficacy of Cannabidiol on Motor Symptoms in Parkinson's Disease	A Randomized, Double Blind, Placebo-controlled Parallel Study of Tolerability and Efficacy of Cannabidiol (CBD) on Motor Symptoms in Parkinson's Disease	Parkinson Disease	Drug: Cannabidiol;Other: Placebo	University of Colorado, Denver	Colorado Department of Public Health and Environment	Recruiting	40 Years	85 Years	All	75	Phase 2	United States
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
306	NCT04202757 (ClinicalTrials.gov)	September 14, 2018	21/9/2018	Intravenous Plasma Treatment for Parkinson's Disease	Intravenous Young Fresh Frozen Plasma (yFFP) Investigational Treatment for Parkinson's Disease - Randomized Controlled Study	Idiopathic Parkinson Disease	Biological: [21CFR640.30] Plasma from 18 - 25 year old volunteer donors;Other: Saline	The Neurology Center	Carolina Longevity Institute	Completed	45 Years	90 Years	All	18	Phase 4	United States
307	NCT03648905 (ClinicalTrials.gov)	September 6, 2018	24/8/2018	Clinical Laboratory Evaluation of Chronic Autonomic Failure	Clinical Laboratory Evaluation of Chronic Autonomic Failure	Parkinson's Disease;Multiple System Atrophy;Autonomic Failure	Drug: 18F-Dopa;Drug: 11C-methylreboxetine;Drug: 13N-Ammonia;Drug: 18F-Dopamne;Drug: Desipramine (DMI)	National Institute of Neurological Disorders and Stroke (NINDS)	NULL	Recruiting	18 Years	N/A	All	140	Phase 1	United States
308	NCT03608371 (ClinicalTrials.gov)	August 31, 2018	9/5/2018	BTRX-246040 Study in Subjects With Parkinson's Disease With Motor Fluctuations	Phase 2A, Double-blind, Placebo-controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of BTRX-246040 in Parkinson's Disease Subjects With Motor Fluctuations	Parkinson Disease;Motor Disorder	Drug: BTRX-246040;Drug: Placebo	BlackThorn Therapeutics, Inc.	NULL	Completed	30 Years	76 Years	All	24	Phase 2	United States
309	NCT03229174 (ClinicalTrials.gov)	August 23, 2018	21/4/2017	Brain Perfusion & Oxygenation in Parkinson's Disease With NOH	Evaluation of Brain Perfusion and Oxygenation in PD Patients With Neurogenic Orthostatic Hypotension: 4 Week Comparison of Droxidopa Versus Placebo	Parkinson Disease;Neurogenic Orthostatic Hypotension	Drug: Droxidopa;Drug: Placebo	William Ondo, MD	Lundbeck LLC	Recruiting	18 Years	85 Years	All	28	Phase 4	United States
310	NCT03621046 (ClinicalTrials.gov)	August 20, 2018	6/6/2018	Use of Low-dose Zolpidem in Parkinson's Disease	A Placebo Controlled Double Blind Randomised Controlled Proof of Concept Study of Zolpidem for the Treatment of Motor and Cognitive Deficits in Late-stage Parkinson's	Parkinson Disease	Drug: Zolpidem;Other: Placebo	Aston University	University Hospital Birmingham NHS Foundation Trust	Completed	40 Years	80 Years	All	28	Phase 2	United Kingdom
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
311	NCT03567447 (ClinicalTrials.gov)	August 17, 2018	21/5/2018	Effect of L-Dihydroxyphenylserine (L-DOPS) on Falls in Patients With Neurogenic Orthostatic Hypotension (NOH)	Effect of L-Dihydroxyphenylserine (L-DOPS) on Falls in Patients With Neurogenic Orthostatic Hypotension (NOH)	Parkinson Disease;Falls Patient	Drug: Droxidopa;Other: Placebo	St. Joseph's Hospital and Medical Center, Phoenix	H. Lundbeck A/S;Arizona State University	Recruiting	30 Years	83 Years	All	10	Phase 2	United States
312	NCT03675282 (ClinicalTrials.gov)	August 14, 2018	5/9/2018	Quantitative Mapping of Substantia Nigra Iron in Parkinson's Disease (Stages I-IV, REM Sleep Behavior Disorder) and Controls	Quantitative Mapping of Substantia Nigra Iron in Parkinson's Disease and Controls	Parkinson Disease;REM Sleep Behavior Disorder;Healthy	Drug: (11C)PE2I	Weill Medical College of Cornell University	National Institute of Neurological Disorders and Stroke (NINDS)	Recruiting	20 Years	100 Years	All	100	Phase 1;Phase 2	United States
313	EUCTR2016-004610-95-FR (EUCTR)	08/08/2018	01/03/2018	Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Participants with Parkinson’s Disease	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study, with an Active-Treatment Dose-Blinded Period, to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Subjects with Parkinson’s Disease - SPARK	Parkinson's Disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Biogen Idec Research Limited	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	311	Phase 2	United States;France;Canada;Spain;Austria;Israel;Germany;Italy;United Kingdom;Sweden
314	NCT03773796 (ClinicalTrials.gov)	August 6, 2018	19/7/2018	Nabilone for Non-motor Symptoms in Parkinson's Disease	Nabilone for Non-motor Symptoms in Parkinson's Disease: An Open-label Study to Evaluate Long-term Safety and Efficacy	Parkinson Disease	Drug: Nabilone 0.25 mg	Medical University Innsbruck	NULL	Recruiting	30 Years	100 Years	All	48	Phase 3	Austria
315	NCT04455555 (ClinicalTrials.gov)	August 1, 2018	28/6/2020	Efficacy and Safety of Rotigotine in the Treatment of Patients With Early Stage of Primary Parkinson's Disease	Efficacy and Safety of Rotigotine in the Treatment of Patients With Early Stage of Primary Parkinson's Disease	Parkinson's Disease	Drug: LY03003( the name of rotigotine);Other: Placebo	Peking University Third Hospital	NULL	Completed	18 Years	N/A	All	294	Phase 3	China
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
316	JPRN-UMIN000033285	2018/08/01	05/07/2018	The preventive effect of medicine for osteoporosis on osteopenia in patients with Parkinson's disease: multicenter/ non-blind/ randomised/ exploratory clinical trial	The preventive effect of medicine for osteoporosis on osteopenia in patients with Parkinson's disease: multicenter/ non-blind/ randomised/ exploratory clinical trial - The preventive effect of medicine for osteoporosis on osteopenia in patients with Parkinson's disease	Parkinson's disease	Oral bisphosphonate agent group: taking orally Minodronic Acid Hydrate (50mg) 1 tablet per 4 weeks Intravenous bisphosphonate agent group: injecting Zoledronic Acid (5mg) 1 ampule per 48 weeks	Department of Orthopaedic Surgery, Niigata University Medical and Dental Hospital	Department of Neurology, Nishi-Niigata Chuo Hospital	Pending	50years-old	Not applicable	Male and Female	100	Not selected	Japan
317	ChiCTR1800017084	2018-08-01	2018-07-11	Investigation of new approaches and technologies in the management of Parkinson's disease	The efficacy of Butylphthalide on cognitive impairment of patients with idiopathic PD and DBS patients: A Randomized, double-blind, placebo-controlled, multicenter trial	Parkinson's disease	Butylphthalide group:Butylphthalide, 2 capsules/time, 3 times/day, for 48 weeks;Control group:Placebo, 2 capsules/time, 3 times/day, for 48 weeks;	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	NULL	Recruiting	18	80	Both	Butylphthalide group:140;Control group:140;	Phase 4	China
318	JPRN-JMA-IIA00385	01/08/2018	12/09/2018	Kyoto Trial to Evaluate the Safety and Efficacy of iPSC-derived dopaminergic progenitors in the treatment of Parkinson's Disease	Kyoto Trial to Evaluate the Safety and Efficacy of iPSC-derived dopaminergic progenitors in the treatment of Parkinson's Disease	Parkinson's disease	Intervention type:DRUG. Intervention1:TACROLIMUS TABLETS, Dose form:TABLET, Route of administration:ORAL, intended dose regimen:In the early phase, the immunosuppressant is orally administered 0.03 to 0.15 mg/kg, twice a day, and the targeted blood concentration is within a range of 5-10 ng/mL as a trough value..	Kyoto University Hospital	NULL	Temporarily Closed	>=50 YEARS	<70 YEARS	BOTH	7	Phase 3	Japan
319	ChiCTR1800016949	2018-08-01	2018-07-04	Efficacy assessment and standard treatment of rasagiline in Chinese patients with early Parkinson's disease	Efficacy assessment and standard treatment of rasagiline in Chinese patients with early Parkinson's disease	Parkinson's disease	Rasagiline early start group:rasagiline-rasagiline;Rasagiline delay start group:placebo-rasagiline;	Beijing Hospital	NULL	Pending	30	80	Both	Rasagiline early start group:130;Rasagiline delay start group:130;		China
320	EUCTR2017-005170-19-SE (EUCTR)	30/07/2018	10/04/2018	A Long-Term Follow-up Safety Study for Patients with Parkinson’s Disease (PD) Implanted with the Drug Delivery System (DDS) and/or Who Received Treatment in the Main Study and/or Extension Study	A Long-Term Follow-up Safety Study for Patients with Idiopathic Parkinson’s Disease (PD) Implanted with the DDS and/or Who Received Treatment in the Main Study and/or Extension Study - Long-Term Follow-up Safety After DDS Implantation with/without CDNF Infusions	Idiopathic Parkinson's Disease MedDRA version: 21.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Cerebral Dopamine Neurotrophic Factor Product Code: CDNF INN or Proposed INN: Not Applicable Other descriptive name: recombinant human Cerebral Dopamine Neurotrophic Factor	Renishaw Neuro Solutions Ltd.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	20	Phase 1;Phase 2	Finland;Sweden
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
321	NCT03599726 (ClinicalTrials.gov)	July 30, 2018	29/6/2018	Improving Walking Automaticity in Parkinson's Disease: Levodopa or Donepezil	Improving Walking Automaticity in Parkinson's Disease: Levodopa or Donepezil	Parkinson Disease	Drug: Donepezil;Drug: Placebo	Oregon Health and Science University	Medical Research Foundation, Oregon	Completed	50 Years	90 Years	All	20	Early Phase 1	United States
322	NCT03611569 (ClinicalTrials.gov)	July 25, 2018	26/7/2018	Lu AF82422 in Healthy Non-Japanese and Japanese Subjects and in Patients With Parkinson's Disease	Interventional, Randomized, Double-blind, Sequential-group, Placebo-controlled, Single-ascending-dose Study Investigating the Safety, Tolerability and Pharmacokinetic and Pharmacodynamic Properties of Lu AF82422 in Healthy Non-Japanese and Japanese Subjects and in Patients With Parkinson's Disease	Healthy;Parkinson Disease	Drug: Lu AF82422;Drug: Placebo	H. Lundbeck A/S	NULL	Recruiting	18 Years	80 Years	All	84	Phase 1	United States
323	NCT03587168 (ClinicalTrials.gov)	July 20, 2018	3/7/2018	The Reliability, Validity, and Responsiveness of the Timed 360° Turn Test in Patients With Parkinson's Disease	The Reliability, Validity, and Responsiveness of the Timed 360° Turn Test in Patients With Parkinson's Disease	Parkinson Disease	Other: the timed 360° turn test;Other: Berg Balance Scale;Other: Four Square Step Test;Other: Functional Reach Test;Other: Trunk Impairment Scale;Other: Timed Up and Go Test;Other: Hoehn and Yahr Scale;Other: Unified Parkinson's Disease Rating Scale	Gazi University	NULL	Completed	40 Years	N/A	All	86		Turkey
324	JPRN-jRCTs052180158	19/07/2018	25/03/2019	The effect of rehabilitation robots for patients with Parkinson's disease.	A study on the effectiveness of balance rehabilitation support robot (balance exercise assist robot) for Parkinson's patient.	Parkinson's Disease;D010300	Robot group: The participants performs twelve per a session, 2sessions per a week for 8 weeks. Control group: The participants receives balance exercise by physical therapist twice a week for 8 weeks.	Domen Kazuhisa	NULL	Recruiting	>= 40age old	<= 80age old	Both	50	N/A	Japan
325	NCT03594656 (ClinicalTrials.gov)	July 15, 2018	11/7/2018	Effects of Lingzhi on Disease Progression in Patients With Untreated Early Parkinson's Disease	Effects of Lingzhi on Disease Progression in Patients With Untreated Early Parkinson's Disease: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial	Parkinson Disease	Drug: Ganoderma;Drug: Placebos	Xuanwu Hospital, Beijing	NULL	Recruiting	30 Years	80 Years	All	288	Phase 3	China
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
326	NCT03624920 (ClinicalTrials.gov)	July 12, 2018	10/7/2018	Safety and Efficacy of THN102 in Patients With Parkinson's Disease and Excessive Daytime Sleepiness	Safety and Efficacy of THN102 in Patients With Parkinson's Disease and Excessive Daytime Sleepiness	Parkinson Disease	Drug: THN102 Dosage A;Drug: THN102 Dosage B;Drug: THN102 Dosage C	Theranexus	NULL	Completed	18 Years	80 Years	All	77	Phase 2	United States;Czechia;France;Germany;Hungary
327	NCT03774459 (ClinicalTrials.gov)	July 9, 2018	8/12/2018	ANAVEX2-73 Study in Parkinson's Disease Dementia	A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of ANAVEX2-73 for Cognitive Impairment in Patients With Parkinson's Disease With Dementia	Parkinsons Disease With Dementia	Drug: High dose ANAVEX2-73;Drug: Mid dose ANAVEX2-73;Drug: Placebo oral capsule	Anavex Life Sciences Corp.	Anavex Germany GmbH	Completed	50 Years	85 Years	All	132	Phase 2	Australia;Spain
328	NCT03775538 (ClinicalTrials.gov)	July 5, 2018	11/10/2018	Safety of CDNF by Brain Infusion in Patients With Parkinson's Disease. Extension to HP-CD-CL-2002 Clinical Study	A Randomised, Double-Blind, Multi-centre, Active Treatment, Extension and Safety Study for Patients With Idiopathic Parkinson's Disease (PD) Who Previously Completed the CDNF/DDS Main Study HP-CD-CL-2002	Parkinson Disease;Movement Disorders;Neuro-Degenerative Disease;Nervous System Diseases;Brain Diseases	Drug: Cerebral Dopamine Neurotrophic Factor;Device: Renishaw Drug Delivery System	Herantis Pharma Plc.	Renishaw plc.	Completed	35 Years	75 Years	All	15	Phase 1;Phase 2	Finland;Sweden
329	NCT03146130 (ClinicalTrials.gov)	July 5, 2018	3/5/2017	Study of the Efficacy of N-acetylcysteine (NAC) on Impulse Control Disorders	Study of the Efficacy of N-acetylcysteine (NAC) on Impulse Control Disorders (TCI) Induced by Dopaminergic Treatments in Parkinson's Disease	Impulse Control Disorder;Parkinson	Biological: Variation of behaviors of Parkinson's disease	Centre Hospitalier Universitaire, Amiens	NULL	Unknown status	18 Years	N/A	All	70	Phase 3	France
330	EUCTR2017-004335-36-ES (EUCTR)	04/07/2018	11/04/2018	A Phase II, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of ANAVEX2-73 for Cognitive Impairment in Parkinson’s Disease with Dementia Patients.	A Phase II, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of ANAVEX2-73 for Cognitive Impairment in Parkinson’s Disease with Dementia Patients. - A Phase II Study to Evaluate the Safety, Tolerability, and Efficacy of ANAVEX2-73	Cognition in Parkinson’s Disease with dementia;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: ANAVEX2-73 INN or Proposed INN: ANAVEX2-73 Product Name: ANAVEX2-73 INN or Proposed INN: ANAVEX2-73	Anavex Life Sciences Corp.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	120	Phase 2	Spain
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
331	NCT03521635 (ClinicalTrials.gov)	July 3, 2018	11/4/2018	The SUSTAIN Study Compares the Effects of Sustained and Immediate-release Pramipexole on the noctUrnal Symptoms of paTients With Advanced ParkInsoN's Disease Who Also Take L-Dopa	A Two- Stage Multicenter, Open-label, Randomized, Active Controlled Parallel Group Study Comparing the Efficacy and Safety of Pramipexole SR Versus Pramipexole IR Administered Orally Over an 18-week Treatment on Nocturnal Symptoms in L-Dopa+ Treated Patients With Advanced Parkinson's Disease (PD)	Parkinson Disease	Drug: Pramipexole SR;Drug: Pramipexole IR	Boehringer Ingelheim	NULL	Completed	30 Years	N/A	All	98	Phase 4	China
332	JPRN-UMIN000033409	2018/07/02	17/07/2018	Prevention of local skin reaction by heparinoid due to rotigotine transdermal patch: a pilot randomized clinical trial.		Parkinson's disease	Pretreatment by heparinoid In the pretreatment group, heparinoid is applied daily to the sites (shoulder, upper arm, abdomen, thigh, buttocks on both sides) to be applied rotigotine transdermal patch from the beginning of 1 week before. The dose is one finger tip unit (about 0.5 g) for two palms. The period is 8 weeks. Non-pretreatment by heparinoid. The non-pretreatment group use rotigotine without using heparinoid. The period is 8 weeks.	Wakayama Medical University	NULL	Recruiting	20years-old	85years-old	Male and Female	20	Phase 1	Japan
333	NCT03566589 (ClinicalTrials.gov)	July 2, 2018	12/6/2018	Effects of PS128 on Parkinsonian Symptoms	Effects of Lactobacillus Plantarum PS128 on the Parkinsonian Symptoms in Parkinson's Disease: a Pilot Study	Parkinson Disease	Dietary Supplement: Lactobacillus plantarum PS128	Professor Lu Neurological Clinic	NULL	Completed	40 Years	80 Years	All	30	N/A	Taiwan
334	JPRN-UMIN000033454	2018/07/01	20/07/2018	A study on the effectiveness of balance rehabilitation support robot (balance exercise assist robot) for Parkinson's patient.	A study on the effectiveness of balance rehabilitation support robot (balance exercise assist robot) for Parkinson's patient. - A study on the effectiveness of balance rehabilitation support robot (balance exercise assist robot) for Parkinson's patient.	Parkinson's Disease	robot assisted balance training (RABT) The group is taken 40-minute / session, twice a week during 8-weeks. Total intervention sessions are 16. traditional balance training (TBT) The group is taken 40-minute / session, twice a week during 8-weeks. Total intervention sessions are 16.	Hyogo College of Medicine	NULL	Recruiting	40years-old	80years-old	Male and Female	50	Not selected	Japan
335	NCT03576638 (ClinicalTrials.gov)	July 2018	25/6/2018	Study to Assess Pharmacokinetics of Accordion Pill Carbidopa-Levodopa Compared to Immediate Release Carbidopa-Levodopa in Parkinson's Disease Patients	An Open Label Phase 2 Study to Assess the Pharmacokinetics of the Accordion Pill Carbidopa-Levodopa Compared to Immediate Release Carbidopa-Levodopa in Patients With Parkinson's Disease	Parkinson Disease	Drug: Accordion Pill Carbidopa/Levodopa;Drug: Sinemet CR 25Mg-100Mg Extended-Release Tablet	Intec Pharma Ltd.	NULL	Unknown status	30 Years	N/A	All	12	Phase 2	NULL
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
336	NCT03562494 (ClinicalTrials.gov)	June 28, 2018	16/5/2018	VY-AADC02 for Parkinson's Disease With Motor Fluctuations (RESTORE-1)	A Randomized, Sham Surgery Controlled, Double-blind, Multi-center, Phase 2 Clinical Trial, Evaluating the Efficacy and Safety of VY-AADC02 in Moderate to Advanced Parkinson's Disease Patients With Motor Fluctuations	Parkinson's Disease	Biological: VY-AADC02;Other: Sham (Placebo) Surgery	Neurocrine Biosciences	Voyager Therapeutics	Recruiting	40 Years	75 Years	All	85	Phase 2	United States
337	NCT03407378 (ClinicalTrials.gov)	June 26, 2018	15/1/2018	A Study to Investigate a New Treatment in Patients With Parkinson's Disease	A Proof of Concept Study to Investigate the Effect of IPT803 Adjunct Treatment in Patients With Parkinson's Disease	Parkinson Disease	Drug: IPT803;Genetic: Optional pharmacogenetic assessment;Other: Questionnaires;Other: Optional Blood-Oxygen-level Dependent functionalMRI;Other: Motor Assessments before taking regular PD treatment;Other: Motor Assessments on regular PD treatment	Tools4Patient	NULL	Completed	35 Years	N/A	All	110	Phase 1;Phase 2	United States;Belgium;France
338	EUCTR2017-001420-21-DE (EUCTR)	18/06/2018	16/02/2018	Clinical Efficacy, Safety and Tolerability of P2B001 in Early Parkinson's Disease	A Phase 3, Twelve-week, Multi-Center, Multinational, Randomized, Double-Blind, Double-Dummy, Parallel Group Study to Determine the Efficacy, Safety and Tolerability of P2B001 Once Daily Compared to its Individual Components in Subjects With Early Parkinson’s Disease and to a Calibration Arm of Pramipexole ER.	Early Parkinson's Disease MedDRA version: 20.0;Level: HLT;Classification code 10034005;Term: Parkinson's disease and parkinsonism;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Code: P2B001 INN or Proposed INN: PRAMIPEXOLE DIHYDROCHLORIDE Other descriptive name: PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE INN or Proposed INN: Rasagiline mesylate Other descriptive name: RASAGILINE MESILATE Product Name: Pramipexole dihydrochloride INN or Proposed INN: PRAMIPEXOLE DIHYDROCHLORIDE Other descriptive name: PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE Product Name: Rasagiline INN or Proposed INN: Rasagiline mesylate Other descriptive name: RASAGILINE MESILATE Trade Name: Pramipexole dihydrochloride extended-release tablets Product Name: Pramipexole dihydrochloride extended-release tablets INN or Proposed INN: PRAMIPEXOLE DIHYDROCHLORIDE Other descriptive name: PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE	Pharma Two B Ltd	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	525	Phase 3	United States;France;Canada;Spain;Germany
339	EUCTR2017-001420-21-ES (EUCTR)	13/06/2018	15/03/2018	Clinical Efficacy, Safety and Tolerability of P2B001 in Early Parkinson's Disease	A Phase 3, Twelve-week, Multi-Center, Multinational, Randomized, Double-Blind, Double-Dummy, Parallel Group Study to Determine the Efficacy, Safety and Tolerability of P2B001 Once Daily Compared to its Individual Components in Subjects With Early Parkinson’s Disease and to a Calibration Arm of Pramipexole ER.	Early Parkinson's Disease MedDRA version: 20.0;Level: HLT;Classification code 10034005;Term: Parkinson's disease and parkinsonism;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Code: P2B001 INN or Proposed INN: PRAMIPEXOLE DIHYDROCHLORIDE Other descriptive name: PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE INN or Proposed INN: Rasagiline mesylate Other descriptive name: RASAGILINE MESILATE Product Name: Pramipexole dihydrochloride INN or Proposed INN: PRAMIPEXOLE DIHYDROCHLORIDE Other descriptive name: PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE Product Name: Rasagiline INN or Proposed INN: Rasagiline mesylate Other descriptive name: RASAGILINE MESILATE Trade Name: Pramipexole dihydrochloride extended-release tablets Product Name: Pramipexole dihydrochloride extended-release tablets INN or Proposed INN: PRAMIPEXOLE DIHYDROCHLORIDE Other descriptive name: PRAMIPEXOLE DIHYDROCHLORIDE	Pharma Two B Ltd	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	525	Phase 3	United States;France;Canada;Spain;Germany
340	NCT03439943 (ClinicalTrials.gov)	June 13, 2018	13/2/2018	Study to Evaluate the Effect of Lixisenatide in Patient With Parkinson's Disease	Multicenter, Randomised, Placebo-controlled, Double Blinded, Parallel Arm Proof-of-concept Trial of Lixisenatide in Patients With Early Parkinson's Disease	Parkinson Disease	Drug: Lixisenatide;Drug: placebo	University Hospital, Toulouse	Cure Parkinson;Réseau NS-Park;EUCLID;Sanofi	Active, not recruiting	40 Years	75 Years	All	156	Phase 2	France
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
341	EUCTR2017-004006-18-NL (EUCTR)	07/06/2018	15/11/2017	The effect of inhaled levodopa on the recovery from off periods in patients with Parkinson's disease	Therapeutic effects of an inhaled levodopa dry powder formulation on the recovery from off periods in patients with Parkinson's disease - Effectiveness of inhaled levodopa in Parkinson's disease	Parkinson's disease is a progressive neurodegenerative disorder characterized by a lack of dopamine production due to the loss of dopamine producing cells in the substantia nigra. This lack of dopamine causes disruption of motor circuits in the brain resulting in motor function impairments like tremor, rigidity and bradykinesia. MedDRA version: 20.0;Level: LLT;Classification code 10013113;Term: Disease Parkinson's;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Levodopa powder for inhalation Product Code: Levodopa Cyclops INN or Proposed INN: levodopa Other descriptive name: LEVODOPA Trade Name: Madopar 125 mg, orodispersible tablet	Pharmaceutical Technology and Biopharmacy, University of Groningen	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	8	Phase 2	Netherlands
342	NCT03456687 (ClinicalTrials.gov)	June 5, 2018	1/3/2018	Effects of Exenatide on Motor Function and the Brain	Effects of Exenatide on Motor Function and the Brain	Parkinson's Disease	Drug: Exenatide	University of Florida	National Institute of Neurological Disorders and Stroke (NINDS)	Active, not recruiting	40 Years	77 Years	All	5	Phase 1	United States
343	NCT03510572 (ClinicalTrials.gov)	June 4, 2018	17/4/2018	Evaluation of [18F]PI-2620 as a Potential Positron Emission Computed Tomography Radioligand for Imaging Tau Protein in the Brain	Clinical Evaluation of [18F]PI-2620 Positron Emission Computed Tomography for Imaging Tau Protein in Patients With Tauopathies and Healthy Volunteers: Phase 0 Study	Healthy Volunteer;Alzheimer Disease;Frontotemporal Dementia;Parkinson Disease	Drug: [18F]PI-2620	Asan Medical Center	Korea Health Industry Development Institute	Completed	40 Years	80 Years	All	20	Early Phase 1	Korea, Republic of
344	EUCTR2018-000346-19-SE (EUCTR)	04/06/2018	09/04/2018	An extended clinical study to test the safety of Cerebral Dopamine Neurotrophic Factor (CDNF) by brain infusion via Drug Delivery System (DDS) in patients with Parkinson's disease.	A Randomised, Double-Blind, Multi-centre, Active Treatment, Extension and Safety Study for Patients with Idiopathic Parkinson’s Disease (PD) Who Previously Completed the CDNF/DDS Main Study HP-CD-CL-2002. - Extension Study	Idiopathic Parkinson's Disease MedDRA version: 21.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Cerebral Dopamine Neurotrophic Factor Product Code: CDNF INN or Proposed INN: Not Applicable Other descriptive name: recombinant human Cerebral Dopamine Neurotrophic Factor	Herantis Pharma Plc	NULL	Not Recruiting			Female: yes Male: yes	18	Phase 1;Phase 2	Finland;Sweden
345	NCT03532984 (ClinicalTrials.gov)	June 1, 2018	27/4/2018	Beam Walking Across the Lifespan for Falls Prediction	Beam Walking to Assess Dynamic Balance in Health and Disease: A Protocol for the 'BEAM' Multi-center Observational Study	Aging;Parkinson Disease;Stroke;Dementia;Diagnoses Disease;Cognitive Impairment;Postural; Defect	Diagnostic Test: Beam test to predict falls	University Medical Center Groningen	Dokkyo Medical University;University of Potsdam;Somogy Megyei Kaposi Mór Teaching Hospital;University of Sao Paulo	Unknown status	20 Years	80 Years	All	432		Brazil;Germany;Hungary;Japan;Netherlands
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
346	NCT03891069 (ClinicalTrials.gov)	June 1, 2018	18/3/2019	Feasibility of the AHA Exergame System in Parkinson's Disease Patients	Feasibility and Safety of the AHA Exergame System in Parkinson's Disease Patients: a Mixed Methods Study	Parkinson Disease	Device: AHA Exergame System	Campus Neurológico Sénior	University of Lisbon	Completed	40 Years	80 Years	All	10	N/A	Portugal
347	NCT03684122 (ClinicalTrials.gov)	June 1, 2018	23/9/2018	Use of Mesenchymal Stem Cells (MSCs) Differentiated Into Neural Stem Cells (NSCs) in People With Parkinson's (PD).	A Safety and Efficacy Study of the Effects of Mesenchymal Stem Cells (MSCs) Differentiated Into Neural Stem Cells (NSCs) on the Motor and Non-motor Symptoms in People With Parkinson's Disease (PD).	Parkinson Disease	Biological: Injection of Umbilical cord derived MSCs	University of Jordan	NULL	Recruiting	20 Years	75 Years	All	10	Phase 1;Phase 2	Jordan
348	EUCTR2017-002780-17-ES (EUCTR)	21/05/2018	12/02/2018	Study in Male and Female Patients with Advanced Parkinson’s Disease to Assess the blood levels of Levodopa Administered as ND0612 via a Pump System plus Additional Oral Administered Levodopa/Carbidopa versus Levodopa Administered as Duodopa.	A Pivotal, Open-Label, Randomized, Crossover, Four Sequences Study in Male and Female Patients with Advanced Parkinson’s Disease to Assess the Relative Bioavailability of Levodopa Administered as ND0612 Subcutaneous Infusion via a Pump System plus Additional Oral Administered Levodopa/Carbidopa versus Levodopa Administered as Carbidopa-Levodopa Enteral Suspension	Parkinson’s Disease MedDRA version: 20.0;Level: HLT;Classification code 10034005;Term: Parkinson's disease and parkinsonism;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: ND0612 Product Code: ND0612 INN or Proposed INN: carbidopa Other descriptive name: CARBIDOPA INN or Proposed INN: levodopa Other descriptive name: LEVODOPA Trade Name: SINEMET Plus Product Name: SINEMET INN or Proposed INN: levodopa Other descriptive name: LEVODOPA INN or Proposed INN: carbidopa Other descriptive name: CARBIDOPA Trade Name: Duodopa LD/CD 20/5 mg/mL Product Name: Duodopa LD/CD 20/5 mg/mL INN or Proposed INN: levodopa Other descriptive name: LEVODOPA INN or Proposed INN: carbidopa Other descriptive name: CARBIDOPA	NeuroDerm Ltd.	NULL	Not Recruiting			Female: yes Male: yes	50	Phase 3	France;United States;Spain;Austria;Netherlands;Italy
349	EUCTR2016-004610-95-ES (EUCTR)	18/05/2018	07/03/2018	Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Participants with Parkinson’s Disease	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study, with an Active-Treatment Dose-Blinded Period, to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Subjects with Parkinson’s Disease - SPARK	Parkinson's Disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Code: BIIB054 INN or Proposed INN: n/a Other descriptive name: BIIB054	Biogen Idec Research Limited	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	311	Phase 2	France;United States;Canada;Spain;Austria;Israel;Germany;Italy;United Kingdom;Sweden
350	NCT03589066 (ClinicalTrials.gov)	May 15, 2018	8/6/2018	Pharmacokinetic Study of LY03003 in Patients With Parkinson's Disease	An Open-label, Randomized, Parallel-group Trial to Evaluate the Pharmacokinetics of Two Formulations of LY03003 After a Single Intramuscular Injection Administered to Patients With Parkinson's Disease	Parkinson Disease	Drug: LY03003	Luye Pharma Group Ltd.	NULL	Completed	18 Years	N/A	All	24	Phase 1	United States
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
351	EUCTR2017-004475-31-CZ (EUCTR)	09/05/2018	09/05/2018	Safety and efficacy study of two THN102 doses in subjects with excessive daytime sleepiness associated with Parkinson’s disease.	Randomised, double-blind, placebo-controlled, complete 3-way cross-over phase IIa trial to investigate safety and efficacy of two THN102 doses in subjects with excessive daytime sleepiness associated with Parkinson’s disease	Excessive daytime sleepiness associated with Parkinson’s disease MedDRA version: 20.0;Level: SOC;Classification code 10029205;Term: Nervous system disorders;System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0;Level: PT;Classification code 10041349;Term: Somnolence;System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Theranexus S.A.	NULL	Not Recruiting			Female: yes Male: yes	60	Phase 2	France;United States;Hungary;Czech Republic;Germany
352	NCT03541356 (ClinicalTrials.gov)	May 8, 2018	5/4/2018	Therapeutic Potential for Intranasal Levodopa in Parkinson's Disease -Off Reversal	A Phase IIa, Randomized, Double Blind, Placebo Controlled, Single Ascending Dose, Safety and Pharmacokinetic/Pharmacodynamic Study of INP103 (POD L-dopa) Administered in the Presence of DCI to L-dopa Responsive Parkinson's Disease Patients	Parkinson's Disease	Combination Product: Placebo;Combination Product: L-dopa 35 mg;Combination Product: L-dopa 70mg;Combination Product: L-dopa 140 mg;Combination Product: L-dopa 70mg /carbidopa 7mg	Impel NeuroPharma Inc.	NULL	Completed	40 Years	80 Years	All	32	Phase 2	Australia
353	NCT03587649 (ClinicalTrials.gov)	May 7, 2018	3/7/2018	Evaluation of [18F]MNI-1126 as an Imaging Marker for Synaptic Density Loss	Evaluation of [18F]MNI-1126 as an Imaging Marker for Synaptic Density Loss in the Brain of Patients With Probable Alzheimer's Disease, Probable Parkinson's Disease (PD) Subjects as Compared to Healthy Volunteers (HV).	Alzheimer Disease;Parkinson Disease;Healthy Volunteers	Drug: [18F]MNI-1126	Invicro	NULL	Completed	18 Years	55 Years	All	12	Phase 1	United States
354	NCT04228887 (ClinicalTrials.gov)	May 4, 2018	5/8/2019	Effects of Inspiratory Muscle Training in Patients With Parkinson's Disease	Effects of Inspiratory Muscle Training on Postural Stability, Mobility, Activities of Daily Living, Quality of Life and Respiratory Function in Patients With Parkinson's Disease	Parkinson Disease	Diagnostic Test: Respiratory Muscle Strength;Device: Balance Training;Device: Inspiratory Muscle Training	Bezmialem Vakif University	NULL	Completed	60 Years	85 Years	All	30	N/A	Turkey
355	NCT03843944 (ClinicalTrials.gov)	May 1, 2018	12/2/2019	Overnight Switch From Rasagiline To Safinamide	Overnight Switch From Rasagiline To Safinamide In Fluctuating Patients With Parkinson's Disease: A Tolerability And Safety Study	Parkinson Disease	Drug: Safinamide	IRCCS San Raffaele	NULL	Completed	30 Years	80 Years	All	20	Phase 4	Italy
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
356	EUCTR2016-004610-95-GB (EUCTR)	01/05/2018	27/12/2017	Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Participants with Parkinson’s Disease	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study, with an Active-Treatment Dose-Blinded Period, to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Subjects with Parkinson’s Disease - SPARK	Parkinson's Disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Code: BIIB054 INN or Proposed INN: n/a Other descriptive name: BIIB054	Biogen Idec Research Limited	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	357	Phase 2	United States;France;Canada;Spain;Austria;Israel;Germany;Italy;United Kingdom
357	EUCTR2017-002780-17-FR (EUCTR)	26/04/2018	27/02/2018	-	A Pivotal, Open-Label, Randomized, Crossover, Four Sequences Study in Male and Female Patients with Advanced Parkinson’s Disease to Assess the Relative Bioavailability of Levodopa Administered as ND0612 Subcutaneous Infusion via a Pump System plus Additional Oral Administered Levodopa/Carbidopa versus Levodopa Administered as Carbidopa-Levodopa Enteral Suspension	Parkinson’s Disease MedDRA version: 20.0;Level: HLT;Classification code 10034005;Term: Parkinson's disease and parkinsonism;System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		NeuroDerm Ltd.	NULL	Not Recruiting			Female: yes Male: yes	50	Phase 3	United States;France;Spain;Austria;Netherlands;Italy
358	NCT03230526 (ClinicalTrials.gov)	April 20, 2018	18/7/2017	Identification of a Biomarker Predictive of Evolution of Parkinson Disease	Brain Microglial Activation in the Early Stage of the Parkinson's Disease: a Predictive Biomarker of the Evolution?	Parkinson Disease	Drug: [18F]DPA-714 PET scan	Nantes University Hospital	NULL	Recruiting	40 Years	67 Years	All	64	Phase 2	France
359	NCT03374917 (ClinicalTrials.gov)	April 18, 2018	8/12/2017	A Study in Subjects With Parkinson's Disease to Evaluate the Safety and Tolerability of Titration and Continuous Subcutaneous Infusion of ABBV-951 in an Outpatient Environment	An Open-Label Study in Subjects With Parkinson's Disease to Evaluate the Safety and Tolerability of Titration and Continuous Subcutaneous Infusion of ABBV-951 for up to 4 Weeks in an Outpatient Environment	Parkinson's Disease (PD)	Drug: ABBV-951	AbbVie	NULL	Completed	30 Years	85 Years	All	20	Phase 1	United States
360	EUCTR2017-004475-31-HU (EUCTR)	17/04/2018	09/02/2018	Safety and efficacy study of two THN102 doses in subjects with excessive daytime sleepiness associated with Parkinson’s disease.	Randomised, double-blind, placebo-controlled, complete 3-way cross-over phase IIa trial to investigate safety and efficacy of two THN102 doses in subjects with excessive daytime sleepiness associated with Parkinson’s disease	Excessive daytime sleepiness associated with Parkinson’s disease MedDRA version: 20.0;Level: SOC;Classification code 10029205;Term: Nervous system disorders;System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0;Level: PT;Classification code 10041349;Term: Somnolence;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Flecainide acetate Product Code: THN02 INN or Proposed INN: Flecainidum Other descriptive name: FLECAINIDE ACETATE Product Name: Flecainide acetate Product Code: THN02 INN or Proposed INN: Flecainidum Other descriptive name: FLECAINIDE ACETATE Trade Name: Modiodal Product Name: over-encapsulated Modafinil INN or Proposed INN: MODAFINIL	Theranexus S.A.	NULL	Not Recruiting			Female: yes Male: yes	60	Phase 2	France;United States;Czech Republic;Hungary;Germany
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
361	EUCTR2017-004253-16-AT (EUCTR)	13/04/2018	27/02/2018	Investigation of the effect of Nabilon in patients suffering from Parkinson´s Disease with non-Motor symptoms (e.g.sleeping dirsorders, cognitive dysfunction, hallucinations, autonomic dysfunction,...)	Nabilone for non-motor symptoms in Parkinson’s disease: An open-label study to evaluate long-term safety and efficacy	Subject with non-Motor symptoms of Parkinson´s disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Medizinische Universität Innsbruck, Universitätsklinik für Neurologie	NULL	Not Recruiting			Female: yes Male: yes	48	Phase 3	Austria
362	NCT03368170 (ClinicalTrials.gov)	April 12, 2018	5/12/2017	Efficacy and Tolerability of IRL790 in Parkinson's Disease Dyskinesia	A Randomized, Placebo-controlled, Phase IIa Study Evaluating the Efficacy and Tolerability of IRL790 in Parkinson's Disease Dyskinesia	Parkinson Disease	Drug: Mesdopetam (IRL790)	Integrative Research Laboratories AB	The Clinical Trial Company	Completed	18 Years	79 Years	All	75	Phase 2	Sweden;United Kingdom
363	EUCTR2017-002707-10-DK (EUCTR)	10/04/2018	03/11/2017	Measurements of drug concentration in the blood for anti-dementia drugs, in order to improve efficacy and reduce side-effects	Serum-monitoring of anti-dementia drugs, and the relevance to side-effects, clinical efficacy and compliance	Dementia in Alzheimers Disease, Parkinsons Disease and Dementia with Lewy Bodies MedDRA version: 20.0;Level: PT;Classification code 10012271;Term: Dementia Alzheimer's type;System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0;Level: LLT;Classification code 10012284;Term: Dementia due to Parkinson's disease;Classification code 10067889;Term: Dementia with Lewy bodies;Classification code 10075174;Term: Mixed dementia;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Memantin Orion INN or Proposed INN: MEMANTINE Product Name: Donepezil Sandoz Product Code: 25330 INN or Proposed INN: DONEPEZIL	Regional Dementia Research Centre, Dept of Neurology	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	110	Phase 4	Denmark
364	EUCTR2017-002780-17-IT (EUCTR)	10/04/2018	04/11/2020	study in patients with Parkinson's disease to evaluate the bioavailability of levodopa administered as subcutaneous infusion	A Pivotal, Open-Label, Randomized, Crossover, Four Sequences Study in Male and Female Patients with Advanced Parkinson¿s Disease to Assess the Relative Bioavailability of Levodopa Administered as ND0612 Subcutaneous Infusion via a Pump System plus Additional Oral Administered Levodopa/Carbidopa versus Levodopa Administered as Carbidopa-Levodopa Enteral Suspension - study in patients with Parkinson's disease to evaluate the bioavailability of levodopa administered	Parkinson¿s Disease MedDRA version: 20.0;Level: HLT;Classification code 10034005;Term: Parkinson's disease and parkinsonism;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: SINEMET Plus Product Name: SINEMET INN or Proposed INN: LEVODOPA INN or Proposed INN: CARBIDOPA Trade Name: Duodopa LD/CD 20/5 mg/mL Product Name: Duodopa LD/CD 20/5 mg/mL INN or Proposed INN: LEVODOPA Other descriptive name: levodopa INN or Proposed INN: CARBIDOPA Other descriptive name: carbidopa Product Name: ND0612 Product Code: ND0612 INN or Proposed INN: CARBIDOPA Other descriptive name: carbidopa INN or Proposed INN: LEVODOPA Other descriptive name: levodopa	NEURODERM LTD.	NULL	Not Recruiting			Female: yes Male: yes	50	Phase 3	United States;France;Spain;Austria;Netherlands;Italy
365	EUCTR2016-003456-70-DE (EUCTR)	04/04/2018	03/04/2017	A clinical trial to compare APL-130277 sublingual film to Subcutaneous Apomorphine in Parkinson’s Disease patients	An Open-Label, Randomized, Crossover Trial utilizing a Single-Blinded Rater to evaluate APL-130277 compared to s.c. Apomorphine in Levodopa Responsive Subjects with Parkinson’s Disease Complicated by Motor Fluctuations	Levodopa Responsive Patients with Parkinson’s Disease Complicated by Motor Fluctuations (OFF episodes) MedDRA version: 22.1;Level: LLT;Classification code 10034006;Term: Parkinson's disease aggravated;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Apomorphine hydrochloride Product Code: APL-130277 INN or Proposed INN: Apomorphine hydrochloride Other descriptive name: APOMORPHINE HYDROCHLORIDE Trade Name: APO-go Product Name: s.c. apomorphine INN or Proposed INN: Apomorphine hydrochloride Other descriptive name: APOMORPHINE HYDROCHLORIDE Product Name: Apomorphine hydrochloride Product Code: APL-130277 INN or Proposed INN: Apomorphine hydrochloride Other descriptive name: APOMORPHINE HYDROCHLORIDE Product Name: Apomorphine hydrochloride Product Code: APL-130277 INN or Proposed INN: Apomorphine hydrochloride Other descriptive name: APOMORPHINE HYDROCHLORIDE Product Name: Apomorphine hydrochloride Product Code: APL-130277 INN or Proposed INN: Apomor	Sunovion Pharmaceuticals Inc.	NULL	Not Recruiting			Female: yes Male: yes	106	Phase 3	France;Spain;Austria;Germany;United Kingdom;Italy
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
366	ChiCTR1800015331	2018-04-01	2018-03-23	Dopaminergic Mechanisms of Temporal Working Memory in Parkinson's Disease	Dopaminergic Mechanisms of Temporal Working Memory in Parkinson's Disease	Parkinson's disease	de novo PD patients:levodopa 4 weeks;de novo PD patients:pramipexole 4 weeks;de novo PD patients:selegiline 4 weeks;	Institute of Psychology, Chinese Academy of Sciences	NULL	Recruiting	50	80	Both	de novo PD patients:50;de novo PD patients:50;de novo PD patients:50;		China
367	NCT03827746 (ClinicalTrials.gov)	April 1, 2018	31/1/2019	The Effect of Kinesiophobia on Physical Activity, Balance and Falling in Parkinson's Disease Patients	The Effect of Kinesiophobia on Physical Activity, Balance and Falling in Parkinson's Disease Patients	Parkinson Disease;Kinesiophobia;Physical Activity;Balance;Falling	Other: Tampa Kinesiophobia Scale, Berg-Balance Test, International Physical Activity Questionnaire-Short Form, Falls Efficacy Scale	Istanbul Kültür University	Marmara University;Istanbul University-Cerrahpasa;Koç University	Completed	40 Years	85 Years	All	60		Turkey
368	EUCTR2017-004297-34-GB (EUCTR)	31/03/2018	22/06/2018	Use of low-dose zolpidem in Parkinson's.	A placebo controlled double blind randomised controlled proof of concept study of zolpidem for the treatment of motor and cognitive deficits in late-stage Parkinson’s - Zolpidem for treatment of motor and cognitive deficits in Parkinson's	Parkinson's Disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Stilnoct Product Name: Stilnoct Product Code: 207-3120 INN or Proposed INN: Zolpidem Tartrate	Aston University	NULL	Not Recruiting			Female: yes Male: yes	28	Phase 2	United Kingdom
369	NCT03648671 (ClinicalTrials.gov)	March 28, 2018	26/6/2018	Pain in Parkinson's Disease With Motor Fluctuations.	Spontaneous and Evoked Pain in Parkinson's Disease With Motor Fluctuations: an Observational, Prospective, Clinical and Neurophysiological Study in Patients Under L-dopa Add on Therapies.	Parkinson Disease	Drug: safinamide metansolfonato (12 weeks);Drug: rasagilina mesilato (12 weeks)	Universita di Verona	Azienda Ospedaliera Universitaria Integrata Verona	Unknown status	18 Years	80 Years	All	48		Italy
370	EUCTR2018-000405-23-FI (EUCTR)	27/03/2018	21/02/2018	Postitron emission tomography imaging of neuroinflammation in Parkinson´s disease	In vivo PET imaging of neuroinflammation in Parkinson’s disease using the purinergic P2X7 receptor ligand [11C]SMW139 (PRI-PD) - PRI-PD	Parkinson´s disease MedDRA version: 20.0;Level: LLT;Classification code 10034007;Term: Parkinson's disease NOS;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: (2-chloro-5-[11C]methoxy-N-(((3s,5s,7s)-3,5,7-trifluoroadamantan-1-yl)methyl) benzamide) Product Code: [11C]SMW139	Juha Rinne / PET Centre	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	14	Phase 2	Finland
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
371	EUCTR2016-004610-95-AT (EUCTR)	23/03/2018	04/01/2018	Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Participants with Parkinson’s Disease	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study, with an Active-Treatment Dose-Blinded Period, to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Subjects with Parkinson’s Disease - SPARK	Parkinson's Disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Code: BIIB054 INN or Proposed INN: n/a Other descriptive name: BIIB054	Biogen Idec Research Limited	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	357	Phase 2	United States;France;Canada;Spain;Austria;Israel;Germany;United Kingdom;Italy
372	NCT03457493 (ClinicalTrials.gov)	March 22, 2018	23/2/2018	TSPO-PET for Neuroinflammation in Parkinson's Disease	UAB Neuroinflammation in Parkinson's Disease - TSPO-PET Substudy	Parkinson Disease	Drug: DPA -714-PET/MRI	University of Alabama at Birmingham	NULL	Recruiting	30 Years	N/A	All	20	Phase 1;Phase 2	United States
373	NCT03301272 (ClinicalTrials.gov)	March 22, 2018	13/9/2017	Effectiveness of Botox on Reducing Rest Tremor in Parkinson's Disease	Effectiveness of Onabotulinumtoxin A on Reduction of Rest Tremor in Parkinson's Disease: a Pilot Study	Parkinson Disease	Drug: Onabotulinumtoxin A Injection;Other: Placebo	University of North Carolina, Chapel Hill	NULL	Completed	45 Years	80 Years	All	16	Phase 2	United States
374	NCT03482882 (ClinicalTrials.gov)	March 9, 2018	23/3/2018	Safety and Efficacy of Pimavanserin in Adults With Parkinson's Disease and Depression	An Open-label, 8-Week Study of Safety and Efficacy of Pimavanserin Treatment in Adults With Parkinson's Disease and Depression	Treatment of Depression in Adults With Parkinson's Disease (PD)	Drug: Pimavanserin	ACADIA Pharmaceuticals Inc.	NULL	Completed	50 Years	N/A	All	47	Phase 2	United States
375	NCT03462641 (ClinicalTrials.gov)	March 9, 2018	6/3/2018	Modulation of GABA-A Receptors in Parkinson Disease-Flumazenil Arm	Modulation of GABA-A Receptors and Axial Motor Impairments in Parkinson Disease-Flumazenil Arm	Parkinson Disease	Drug: Flumazenil;Drug: Placebo	University of Michigan	National Institute of Neurological Disorders and Stroke (NINDS)	Recruiting	50 Years	99 Years	All	30	Phase 1;Phase 2	United States
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
376	NCT03149809 (ClinicalTrials.gov)	March 1, 2018	9/5/2017	Behavioral or Solifenacin Therapy for Urinary Symptoms in Parkinson Disease	Behavioral or Solifenacin Therapy for Urinary Symptoms in Parkinson Disease	Overactive Bladder;Parkinson Disease	Drug: solifenacin;Behavioral: Pelvic floor muscle exercise-based behavioral therapy	VA Office of Research and Development	NULL	Recruiting	N/A	N/A	All	90	Phase 3	United States
377	NCT04265027 (ClinicalTrials.gov)	February 20, 2018	7/2/2020	Bioavailability and Bioequivalence Between Two Active Pharmaceutical Ingredient (API) Sources of Opicapone (OPC)	An Open Label, Randomised, Two Period, Crossover Study to Assess Bioavailability, Bioequivalence and S COMT Activity Between Two Active Pharmaceutical Ingredient Sources of Opicapone at Two Different Dosage Strengths (50 mg and 25 mg) After Single and Multiple Dose Administrations Under Fasting Conditions in Healthy Volunteers.	Parkinson Disease	Drug: 50 mg BIA 9 1067;Drug: 25 mg BIA9 1067;Drug: 50 mg Ongentys;Drug: 25 mg Ongentys	Bial - Portela C S.A.	NULL	Completed	18 Years	55 Years	All	72	Phase 1	United Kingdom
378	NCT03419806 (ClinicalTrials.gov)	February 16, 2018	10/1/2018	Study Comparing Intravenous and Subcutaneous Infudopa With Intestinal Duodopa in Patients With Parkinson's Disease	Levodopa Pharmacokinetics in Patients With Parkinson's Disease and Symptom Fluctuation: A Phase I, Open-label, Randomized, Multicentre, Crossover Study Comparing Intravenous and Subcutaneous Infudopa With Intestinal Duodopa	Parkinson Disease	Drug: Infudopa i.v.;Drug: Infudopa s.c.;Drug: LCIG (Duodopa)	Vastra Gotaland Region	The Swedish Research Council;Dizlin Medical Design AB;Göteborg University	Completed	30 Years	N/A	All	25	Phase 1	Sweden
379	NCT03882398 (ClinicalTrials.gov)	February 15, 2018	11/3/2019	Effects of a High-intensity Progressive-cycle Program on Quality of Life and Motor Symptomatology in Parkinson's Disease	Effects of a High-intensity Progressive-cycle Program on Quality of Life and Motor Symptomatology in Parkinson's Disease Population: a Pilot Randomized Controlled Trial	Parkinson Disease;Exercise;Physical Activity;Quality of Life	Other: Balance;Other: Endurance	University of Vigo	NULL	Completed	60 Years	80 Years	All	14	N/A	Spain
380	NCT03496870 (ClinicalTrials.gov)	February 8, 2018	1/3/2018	A Study of the Pharmacokinetics, Pharmacodynamics, and Safety of Opicapone in Subjects With Parkinson's Disease Taking Levodopa.	A Phase 1, Open-Label Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Repeated Doses of Opicapone, and Effect on Levodopa Pharmacokinetics in Subjects With Parkinson's Disease	Parkinson Disease	Drug: Opicapone;Drug: Carbidopa Levodopa	Neurocrine Biosciences	NULL	Completed	18 Years	85 Years	All	16	Phase 1	United States
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
381	EUCTR2016-003456-70-ES (EUCTR)	06/02/2018	07/12/2017	A clinical trial to compare APL-130277 sublingual film to Subcutaneous Apomorphine in Parkinson’s Disease patients	An Open-Label, Randomized, Crossover Trial utilizing a Single-Blinded Rater to evaluate APL-130277 compared to s.c. Apomorphine in Levodopa Responsive Subjects with Parkinson’s Disease Complicated by Motor Fluctuations	Levodopa Responsive Patients with Parkinson’s Disease Complicated by Motor Fluctuations (OFF episodes) MedDRA version: 20.0;Level: LLT;Classification code 10034006;Term: Parkinson's disease aggravated;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Apomorphine hydrochloride Product Code: APL-130277 INN or Proposed INN: Apomorphine hydrochloride Other descriptive name: APOMORPHINE HYDROCHLORIDE Trade Name: APO-go Product Name: s.c. apomorphine INN or Proposed INN: Apomorphine hydrochloride Other descriptive name: APOMORPHINE HYDROCHLORIDE Product Name: Apomorphine hydrochloride Product Code: APL-130277 INN or Proposed INN: Apomorphine hydrochloride Other descriptive name: APOMORPHINE HYDROCHLORIDE Product Name: Apomorphine hydrochloride Product Code: APL-130277 INN or Proposed INN: Apomorphine hydrochloride Other descriptive name: APOMORPHINE HYDROCHLORIDE Product Name: Apomorphine hydrochloride Product Code: APL-130277 INN or Proposed INN: Apomorphine hydrochloride Other descriptive name: APOMORPHINE HYDROCHLORIDE	Sunovion Pharmaceuticals Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	85	Phase 3	Spain;Austria;United Kingdom
382	NCT03189563 (ClinicalTrials.gov)	February 6, 2018	12/6/2017	Safety and Efficacy of DA-9805 for Parkinson's Disease	A Phase IIa, Randomized, Multicenter, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of DA-9805 in Subjects With Parkinson's Disease	Parkinson's Disease	Drug: DA-9805 45mg;Drug: DA-9805 90mg;Other: Placebo	Dong-A ST Co., Ltd.	NULL	Completed	30 Years	79 Years	All	60	Phase 2	United States
383	EUCTR2016-000637-43-ES (EUCTR)	06/02/2018	07/12/2017	Safety, tolerability and efficacy study to examine APL-130277 in patients with Parkinson’s Disease.	An Open-Label, Phase 3 Study Examining the Long-Term Safety, Tolerability and Efficacy of APL-130277 in Levodopa Responsive Patients with Parkinson’s Disease Complicated by Motor Fluctuations (OFF” Episodes).	Levodopa Responsive Patients with Parkinson’s Disease complicated by Motor Fluctuations (OFF” Episodes) MedDRA version: 20.0;Level: LLT;Classification code 10034006;Term: Parkinson's disease aggravated;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Apomorphine hydrochloride Product Code: APL-130277 INN or Proposed INN: Apomorphine hydrochloride Other descriptive name: APOMORPHINE HYDROCHLORIDE Product Name: Apomorphine hydrochloride Product Code: APL-130277 INN or Proposed INN: Apomorphine hydrochloride Other descriptive name: APOMORPHINE HYDROCHLORIDE Product Name: Apomorphine hydrochloride Product Code: APL-130277 INN or Proposed INN: Apomorphine hydrochloride Other descriptive name: APOMORPHINE HYDROCHLORIDE Product Name: Apomorphine hydrochloride Product Code: APL-130277 INN or Proposed INN: Apomorphine hydrochloride Other descriptive name: APOMORPHINE HYDROCHLORIDE Product Name: Apomorphine hydrochloride Product Code: APL-130277 INN or Proposed INN: Apomorphine hydrochloride	Sunovion Pharmaceuticals Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	450	Phase 3	France;United States;Canada;Spain;Austria;Germany;Italy;United Kingdom
384	EUCTR2016-000637-43-AT (EUCTR)	01/02/2018	15/12/2017	Safety, tolerability and efficacy study to examine APL-130277 in patients with Parkinson’s Disease.	An Open-Label, Phase 3 Study Examining the Long-Term Safety, Tolerability and Efficacy of APL-130277 in Levodopa Responsive Patients with Parkinson’s Disease Complicated by Motor Fluctuations (OFF” Episodes).	Levodopa Responsive Patients with Parkinson’s Disease complicated by Motor Fluctuations (OFF” Episodes) MedDRA version: 22.1;Level: LLT;Classification code 10034006;Term: Parkinson's disease aggravated;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Apomorphine hydrochloride Product Code: APL-130277 INN or Proposed INN: Apomorphine hydrochloride Other descriptive name: APOMORPHINE HYDROCHLORIDE Product Name: Apomorphine hydrochloride Product Code: APL-130277 INN or Proposed INN: Apomorphine hydrochloride Other descriptive name: APOMORPHINE HYDROCHLORIDE Product Name: Apomorphine hydrochloride Product Code: APL-130277 INN or Proposed INN: Apomorphine hydrochloride Other descriptive name: APOMORPHINE HYDROCHLORIDE Product Name: Apomorphine hydrochloride Product Code: APL-130277 INN or Proposed INN: Apomorphine hydrochloride Other descriptive name: APOMORPHINE HYDROCHLORIDE	Sunovion Pharmaceuticals Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	450	Phase 3	United States;France;Canada;Spain;Austria;Germany;United Kingdom;Italy
385	NCT03329508 (ClinicalTrials.gov)	January 29, 2018	30/10/2017	A Phase 3 Study With P2B001 in Subjects With Early Parkinson's	A Phase 3, Twelve-week Study to Determine the Efficacy, Safety and Tolerability of P2B001 Once Daily Compared to Its Individual Components in Subjects With Early Parkinson's Disease and to a Calibration Arm of Pramipexole ER.	Parkinson Disease	Drug: P2B001;Drug: Rasagiline;Drug: Pramipexole;Drug: Pramipexole ER	Pharma Two B Ltd.	NULL	Recruiting	35 Years	80 Years	All	525	Phase 3	United States;Canada;Germany;Spain
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
386	NCT03440112 (ClinicalTrials.gov)	January 29, 2018	26/1/2018	Modulation of GABA-A Receptors in Parkinson Disease-Transdermal Flumazenil Arm	Modulation of GABA-A Receptors and Axial Motor Impairments in Parkinson	Parkinson Disease	Drug: Clarithromycin (Not used as of 4/2020);Drug: Placebo (Not used as of 4/2020);Drug: Transdermal flumazenil (Added 4/2020);Drug: Placebo (Added 4/2020)	Nicolaas Bohnen, MD, PhD	National Institute of Neurological Disorders and Stroke (NINDS)	Recruiting	50 Years	N/A	All	30	Phase 1;Phase 2	United States
387	JPRN-UMIN000030930	2018/01/29	01/01/2019	Study on efficacy and safety of the simultaneous treatment with febuxostat and inosine of patients with Parkinson's disease.	Study on efficacy and safety of the simultaneous treatment with febuxostat and inosine of patients with Parkinson's disease. - Effect of febuxostat and inosine on Parkinson's disease	Parkinson's disease	Administration of febuxostat 20 mg and inosine 500 mg twice a day for 58 days	StaGen Co. Ltd.	NULL	Complete: follow-up complete	20years-old	80years-old	Male and Female	30	Not selected	Japan
388	EUCTR2016-001403-23-HU (EUCTR)	23/01/2018	22/01/2018	12-Week study comparing Levodopa-Carbidopa Intestinal Gel / Levodopa Carbidopa Enteral Suspension to Optimized Medical Treatment on dyskinesia in subjects with advanced Parkinson's disease	An Open-label, Randomized 12 Week Study Comparing Efficacy of Levodopa-Carbidopa Intestinal Gel/Carbidopa-Levodopa Enteral Suspension and Optimized Medical Treatment on Dyskinesia in Subjects with Advanced Parkinson's Disease - DYSCOVER (DYSkinesia COmparative interventional trial on Duodopa VERsus oral medication) - DYSCOVER Study	Dyskinesia in advanced Parkinson's disease MedDRA version: 20.0;Level: LLT;Classification code 10013113;Term: Disease Parkinson's;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Duodopa INN or Proposed INN: Levodopa Other descriptive name: LEVODOPA INN or Proposed INN: Carbidopa Other descriptive name: CARBIDOPA MONOHYDRATE	AbbVie Deutschland GmbH & Co. KG	NULL	Not Recruiting			Female: yes Male: yes	60	Phase 3	United States;Hungary;Slovakia;European Union;Greece;Finland;Spain
389	ChiCTR1800014542	2018-01-22	2018-01-20	Up-down sequential testing of propofol - induced half-effective dose ( ed50 ) in patients with Parkinson's disease and non - Parkinson's disease	Up-down sequential testing of propofol - induced half-effective dose ( ed50 ) in patients with Parkinson's disease and non - Parkinson's disease	Parkinson's Disease	PD group:propofol;NPD group:propofol;	Xuanwu Hospital of CCMU	NULL	Recruiting	18	65	Both	PD group:40;NPD group:40;		China
390	NCT03531086 (ClinicalTrials.gov)	January 19, 2018	8/5/2018	Idiopathic Parkinson's Progression and Dopamine Transporter SPECT	Exploring Dopamine Transporter Single-photon Emission Computer Tomography Quantification as a Measure of Disease Progression in Idiopathic Parkinson's Disease	Parkinson Disease	Drug: Ioflupane I 123	Julie Gurwell	NULL	Active, not recruiting	40 Years	75 Years	All	12		United States
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
391	NCT03331848 (ClinicalTrials.gov)	January 15, 2018	1/11/2017	Study to Evaluate the Efficacy, Safety, and Tolerability of PXT002331 (Foliglurax) in Reducing Levodopa-Induced Dyskinesia and Wearing OFF in Subjects With Parkinson's Disease Experiencing Motor Complications of Levodopa Therapy (ATTUNED)	A Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-arm Phase IIa Trial to Evaluate the Efficacy, Safety, and Tolerability of 8-week Oral Treatment With PXT002331 (Foliglurax) in Reducing Levodopa-Induced Dyskinesia and Wearing OFF in Subjects With Parkinson's Disease Experiencing Motor Complications of Levodopa Therapy (ATTUNED)	Parkinson Disease	Drug: Placebo oral capsule;Drug: PXT002331 - 20mg	Prexton Therapeutics	NULL	Withdrawn	35 Years	85 Years	All	0	Phase 2	NULL
392	NCT03318523 (ClinicalTrials.gov)	January 10, 2018	19/10/2017	Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Participants With Parkinson's Disease	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study, With an Active-Treatment Dose-Blinded Period, to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Subjects With Parkinson's Disease	Parkinson's Disease	Drug: Placebo;Drug: BIIB054	Biogen	NULL	Active, not recruiting	40 Years	80 Years	All	357	Phase 2	United States;Austria;Canada;France;Germany;Israel;Italy;Spain;United Kingdom
393	NCT03550183 (ClinicalTrials.gov)	January 10, 2018	11/5/2018	Umbilical Cord Derived Mesenchymal Stem Cells Therapy in Parkinson's Disease	Safety and Efficacy Investigation of Patients With Parkinson's Disease by Transplantation of Umbilical Cord Derived Mesenchymal Stem Cells	Parkinson's Disease	Biological: mesenchymal stem cells	Hebei Newtherapy BIo-Pharma technology Co., Ltd.	NULL	Enrolling by invitation	40 Years	80 Years	All	20	Phase 1	China
394	EUCTR2016-003456-70-AT (EUCTR)	04/01/2018	16/11/2017	A clinical trial to compare APL-130277 sublingual film to Subcutaneous Apomorphine in Parkinson’s Disease patients	An Open-Label, Randomized, Crossover Trial utilizing a Single-Blinded Rater to evaluate APL-130277 compared to s.c. Apomorphine in Levodopa Responsive Subjects with Parkinson’s Disease Complicated by Motor Fluctuations	Levodopa Responsive Patients with Parkinson’s Disease Complicated by Motor Fluctuations (OFF episodes) MedDRA version: 21.1;Level: LLT;Classification code 10034006;Term: Parkinson's disease aggravated;System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Sunovion Pharmaceuticals Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	106	Phase 3	France;Spain;Austria;Germany;Italy;United Kingdom
395	EUCTR2017-000087-15-DE (EUCTR)	21/12/2017	17/05/2017	A Study to Evaluate the Efficacy of Intravenous RO7046015/Prasinezumab (PRX002) in Participants with Early Parkinson’s Disease with a 6 -Year all-Participants-on Treatment Extension (Pasadena)	A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 52-WEEK PHASE II STUDY TO EVALUATE THE EFFICACY OF INTRAVENOUS RO7046015 (PRX002) IN PARTICIPANTS WITH EARLY PARKINSON’S DISEASE WITH A 52 WEEK BLINDED EXTENSION (PASADENA)	Parkinson’s disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: aSyn Mab Product Code: RO7046015 INN or Proposed INN: N/A Other descriptive name: PRX002, ELT2, anti-alpha-synuclein monoclonal antibody	F. Hoffmann-La Roche Ltd	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	300	Phase 2	United States;France;Spain;Austria;Germany
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
396	EUCTR2017-003458-18-GB (EUCTR)	19/12/2017	27/09/2017	A clinical trial to study the effects of IRL790 in Parkinson's disease dyskinesia	A randomised, double-blind, placebo-controlled, phase IIA study evaluating the efficacy and tolerability of IRL790 in Parkinson's disease dyskinesia	Parkinson's disease dyskinesia MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Integrative Research Laboratories AB (IRLAB)	NULL	Not Recruiting			Female: yes Male: yes	74	Phase 2	United Kingdom;Sweden
397	NCT03321019 (ClinicalTrials.gov)	December 12, 2017	20/10/2017	Airway Protective Mechanisms in PD (R01)	Mechanisms of Airway Protection Dysfunction in Parkinson's Disease	Parkinson Disease	Drug: Capsaicin;Device: Resistive respiratory loads;Other: Event-related evoked potential using electroencephalography (EEG).;Procedure: Fluoroscopic swallow evaluation	University of Florida	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	Recruiting	45 Years	85 Years	All	260		United States
398	EUCTR2017-000877-35-IT (EUCTR)	04/12/2017	10/11/2020	A phase IIb, randomized, double blind, parallel group, placebo control, multicentre, 6-week dose-finding study to assess the efficacy and safety of Bavisant for the treatment of excessive daytime sleepiness in subjects with Parkinson's disease.	Dose finding phase IIb study of Bavisant to evaluate its safety and efficacy in treatment of excessive daytime sleepiness (EDS) in parkinson's Disease (PD). - Treatment of excessive daytime sleepiness with Bavisant in Parkinson's Disease Patients (CASPAR)	Excessive daytime sleepiness with Parkinson's Disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Bavisant Product Code: JNJ31-31001074 INN or Proposed INN: Bavisant dihydrochloride monohydrate Product Name: Bavisant Product Code: [JNJ31-31001074] INN or Proposed INN: Bavisant dihydrochloride monohydrate Product Name: Bavisant Product Code: JNJ-31001074 INN or Proposed INN: Bavisant dihydrochloride monohydrate	BENEVOLENTAI BIO	NULL	Not Recruiting			Female: yes Male: yes	240	Phase 2	United States;Czechia;Czech Republic;Spain;Poland;Germany;United Kingdom;Italy
399	JPRN-UMIN000030084	2017/12/01	01/12/2017	Practical evaluation of PET studies with [18F]-GE180, [18F]-FDOPA and [18F]-FLT for a future clinical trial of iPSC-based cell therapy in Parkinson's disease		neuroinflammatory disorder, Parkinson's disease, Brain tumor	[18F]GE180 is injected intravenously as 3-4 MBq/Kg. PET is dynamically scanned for 90 minutes. Carbidopa 150mg is administrated orally 1hr before scan.[18F]FDOPA is injected intravenously as 3-4 MBq/Kg. Dynamic PET is scanned for 90 minutes. [18F]FLT is injected intravenously as 3-4 MBq/Kg. Statical PET is scanned after 60 minutes	Kyoto University	NULL	Complete: follow-up complete	50years-old	Not applicable	Male and Female	12	Phase 1;Phase 2	Japan
400	NCT03377322 (ClinicalTrials.gov)	December 1, 2017	7/12/2017	Trial of Probiotics for Constipation in Parkinson's Disease	A Randomized Double-Blinded Placebo-Controlled Trial of Probiotics for Constipation in Parkinson's Disease	Parkinson Disease	Drug: Probiotic Capsule;Drug: Placebo Capsule	University of Malaya	NULL	Completed	40 Years	85 Years	All	72	N/A	Malaysia
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
401	NCT03944785 (ClinicalTrials.gov)	November 30, 2017	1/5/2019	Clinical Outcome Assessment of Parkinson's Disease Patients Treated With XADAGO (Safinamide)	A Prospective, Observational Study to Evaluate Changes in Non-Motor Symptoms and Other Clinical Outcome Assessments of Parkinson's Disease Patients Treated With XADAGO (Safinamide)Tablets	Idiopathic Parkinson Disease	Drug: XADAGO (safinamide)	US WorldMeds LLC	NULL	Completed	30 Years	80 Years	All	209		United States
402	EUCTR2016-002033-30-GB (EUCTR)	27/11/2017	05/09/2017	A clinical study investigating the efficacy, tolerability, and safety of two dosing regimens of continuous subcutaneous ND0612 infusion given as adjunct treatment to oral levodopa in patients with Parkinson’s disease with motor fluctuations	A multicenter, randomized, double-blind, placebo controlled, parallel group clinical study investigating the efficacy, tolerability, and safety of two dosing regimens of continuous subcutaneous ND0612 infusion Given as adjunct treatment to oral levOdopa in patients with Parkinson’s Disease with motor fluctuations (iNDiGO) - iNDiGO	Subjects with Parkinson’s Disease with motor fluctuations MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		NeuroDerm Ltd.	NULL	Not Recruiting			Female: yes Male: yes	240	Phase 3	Serbia;Portugal;United States;Spain;Ukraine;Russian Federation;Chile;Israel;United Kingdom;Italy;France;Czech Republic;Hungary;Poland;Belgium;Denmark;Netherlands;Germany
403	NCT03194217 (ClinicalTrials.gov)	November 10, 2017	19/6/2017	BEN-2001 in Parkinson Disease Patients With Excessive Daytime Sleepiness	Dose Finding Phase IIb Study of Bavisant to Evaluate Its Safety and effiCacy in treAtment of exceSsive Daytime sleePiness (EDS) in PARkinson's Disease (PD).	Excessive Daytime Sleepiness;Parkinson Disease	Drug: BEN-2001;Drug: Placebo	BenevolentAI Bio	NULL	Completed	50 Years	80 Years	All	244	Phase 2	United States
404	NCT03305809 (ClinicalTrials.gov)	November 9, 2017	4/10/2017	A Study of LY3154207 in Participants With Dementia Due to Lewy Body Dementia (LBD) Associated With Idiopathic Parkinson's Disease (PD) or Dementia With Lewy Bodies (DLB)	Effect of LY3154207 on Cognition in Mild-to-Moderate Dementia Due to Lewy Body Dementia (LBD) Associated With Idiopathic Parkinson's Disease (PD) or Dementia With Lewy Bodies (DLB)	Lewy Body Dementia	Drug: LY3154207;Drug: Placebo	Eli Lilly and Company	NULL	Completed	40 Years	85 Years	All	344	Phase 2	United States;Canada;Puerto Rico;China
405	EUCTR2016-002033-30-HU (EUCTR)	08/11/2017	19/09/2017	A clinical study investigating the efficacy, tolerability, and safety of two dosing regimens of continuous subcutaneous ND0612 infusion given as adjunct treatment to oral levodopa in patients with Parkinson’s disease with motor fluctuations	A multicenter, randomized, double-blind, placebo controlled, parallel group clinical study investigating the efficacy, tolerability, and safety of two dosing regimens of continuous subcutaneous ND0612 infusion Given as adjunct treatment to oral levOdopa in patients with Parkinson’s Disease with motor fluctuations (iNDiGO) - iNDiGO	Subjects with Parkinson’s Disease with motor fluctuations MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: levodopa /carbidopa solution Product Code: ND0612 INN or Proposed INN: Levodopa Other descriptive name: Levodopa INN or Proposed INN: Carbidopa Other descriptive name: CARBIDOPA Product Name: levodopa /carbidopa solution Product Code: ND0612 INN or Proposed INN: Levodopa Other descriptive name: Levodopa INN or Proposed INN: Carbidopa Other descriptive name: CARBIDOPA	NeuroDerm Ltd.	NULL	Not Recruiting			Female: yes Male: yes	240	Phase 3	Serbia;Portugal;United States;Spain;Ukraine;Russian Federation;Chile;Israel;United Kingdom;Italy;France;Hungary;Czech Republic;Poland;Belgium;Denmark;Netherlands;Germany
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
406	NCT02611167 (ClinicalTrials.gov)	November 1, 2017	11/11/2015	Allogeneic Bone Marrow-Derived Mesenchymal Stem Cell Therapy for Idiopathic Parkinson's Disease	Pilot Phase I Study of Allogeneic Bone Marrow-Derived Mesenchymal Stem Cell Therapy for Idiopathic Parkinson's Disease	Parkinson's Disease	Biological: Allogeneic bone marrow-derived MSCs (1 x 10 6 MSC/kg);Biological: Allogeneic bone marrow-derived MSCs (3 x 10 6 MSC/kg);Biological: Allogeneic bone marrow-derived MSCs (6 x 10 6 MSC/kg);Biological: Allogeneic bone marrow-derived MSCs (10 x 10 6 MSC/kg)	The University of Texas Health Science Center, Houston	NULL	Completed	45 Years	70 Years	All	20	Phase 1	United States
407	NCT03232996 (ClinicalTrials.gov)	November 1, 2017	24/7/2017	Evaluation of a Computer Game Based Rehabilitation System for Assessment and Treatment of Balance and Gait Impairments in Individuals With Parkinson's Disease.	Evaluation of a Computer Game Based Rehabilitation System for Assessment and Treatment of Balance and Gait Impairments in Individuals With Parkinson's Disease.	Parkinson Disease;Parkinson	Other: Computer game based balance and walking rehabilitation for individuals with Parkinson's Disease	University of Manitoba	NULL	Completed	55 Years	70 Years	All	30	N/A	Canada
408	NCT03205956 (ClinicalTrials.gov)	October 19, 2017	29/6/2017	Measuring Parkinson's Disease Progression	Dopamine Buffering Capacity Measured by phMRI as a Novel Biomarker of Disease Progression in PD	Parkinson's Disease	Drug: Levodopa	Kevin J. Black, MD	The Michael J. Fox Foundation for Parkinson's Research	Completed	40 Years	79 Years	All	31	Phase 1	United States
409	EUCTR2017-000877-35-DE (EUCTR)	19/10/2017	04/09/2017	A phase IIb, randomized, double blind, parallel group, placebo control, multicentre, 6-week dose-finding study to assess the efficacy and safety of Bavisant for the treatment of excessive daytime sleepiness in subjects with Parkinson's disease.	Dose finding phase IIb study of Bavisant to evaluate its safety and effiCacy in treAtment of exceSsive daytime sleePiness (EDS) in PARkinson’s Disease (PD). CASPAR study. - Treatment of excessive daytime sleepiness with Bavisant in Parkinson’s Disease Patients (CASPAR)	Excessive daytime sleepiness with Parkinson's Disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Bavisant Product Code: JNJ-31001074 INN or Proposed INN: Bavisant dihydrochloride monohydrate Other descriptive name: BAVISANT HYDROCHLORIDE MONOHYDRATE Product Name: Bavisant Product Code: JNJ-31001074 INN or Proposed INN: Bavisant dihydrochloride monohydrate Other descriptive name: BAVISANT HYDROCHLORIDE MONOHYDRATE Product Name: Bavisant Product Code: JNJ-31001074 INN or Proposed INN: Bavisant dihydrochloride monohydrate Other descriptive name: BAVISANT HYDROCHLORIDE MONOHYDRATE	BenevolentAI Bio	NULL	Not Recruiting			Female: yes Male: yes	240	Phase 2	United States;Czech Republic;Spain;Poland;Germany;United Kingdom;Italy
410	NCT03272165 (ClinicalTrials.gov)	October 17, 2017	29/6/2017	Single Ascending Dose Study of MEDI1341 in Healthy Volunteers	A Randomized, Double-blind, Placebo-controlled Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of MEDI1341 in Healthy Male and Female Volunteers.	Parkinson's Disease	Drug: MEDI1341;Drug: Placebo	AstraZeneca	Covance;MMS Holdings, Inc;Catalent	Recruiting	18 Years	80 Years	All	48	Phase 1	United States;United Kingdom
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
411	NCT03205488 (ClinicalTrials.gov)	October 16, 2017	28/6/2017	Nilotinib in Parkinson's Disease	A Randomized, Double-Blind, Placebo-Controlled, Phase IIa, Parallel Group, Two Cohort Study to Define the Safety, Tolerability, Clinical and Exploratory Biological Activity of the Chronic Administration of Nilotinib in Participants With Parkinson's Disease	Parkinson Disease	Drug: Cohort 1:Nilotinib Oral Capsules (150mg or 300mg);Drug: Cohort 2: Nilotinib Oral Capsules (dose to be determined from Cohort 1);Drug: Placebo	Northwestern University	University of Rochester;University of Iowa;Michael J. Fox Foundation for Parkinson's Research	Completed	40 Years	79 Years	All	76	Phase 2	United States
412	NCT03250117 (ClinicalTrials.gov)	October 10, 2017	11/8/2017	Relative Bioavailability Study of Ropinirole Implants in Parkinson's Patients on L-Dopa Switched From Oral Ropinirole	An Open-Label, Relative Bioavailability Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Ropinirole Implants in Patients With Parkinson's Disease Switched From Oral Immediate-Release Ropinirole While on L-Dopa	Parkinson Disease	Drug: Ropinirole oral product;Drug: Ropinirole Implant	Titan Pharmaceuticals	NULL	Terminated	30 Years	80 Years	All	3	Phase 1;Phase 2	United States
413	NCT04045678 (ClinicalTrials.gov)	October 10, 2017	30/7/2019	A Multiple Ascending Dose Study With LY03003 in Patients With Early-stage Parkinson's Disease	A Randomized, Double-blinded, Multiple Ascending Dose Study in Patients With Early-stage Parkinson's Disease to Evaluate the Pharmacokinetics and Safety of LY03003 Following Intramuscular Injections	Parkinson Disease	Drug: LY03003 ( Rotigotine, extended-release microspheres);Drug: Placebo, extended-release microspheres	Luye Pharma Group Ltd.	Beijing Bozhiyin T&S Co., Ltd.	Completed	18 Years	75 Years	All	30	Phase 1	China
414	EUCTR2017-001673-17-FI (EUCTR)	03/10/2017	29/08/2017	A study to evaluate the safety and tolerability of IRL752 treatment inpatients with Parkinson's disease dementia.	A randomized, double-blind, placebo-controlled, multi-centre phase IIastudy evaluating the safety and tolerability of IRL752 in patients withParkinson's Disease Dementia	Dementia in Parkinson's disease MedDRA version: 20.0;Level: LLT;Classification code 10012284;Term: Dementia due to Parkinson's disease;System Organ Class: 100000014717;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: IRL752 INN or Proposed INN: IRL752	Integrative Research Laboratories AB	NULL	Not Recruiting			Female: yes Male: yes	40	Phase 2	Finland;Sweden
415	NCT03769896 (ClinicalTrials.gov)	October 3, 2017	6/12/2018	Nabilone for Non-motor Symptoms in Parkinson's Disease	Nabilone for Non-motor Symptoms in Parkinson's Disease: A Randomized Placebo-controlled, Double-blind, Parallel-group, Enriched Enrolment Randomized Withdrawal Study	Parkinson Disease	Drug: Nabilone 0.25 mg;Drug: Placebo	Medical University Innsbruck	NULL	Completed	30 Years	100 Years	All	48	Phase 2	Austria
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
416	ChiCTR1800019216	2017-09-30	2018-10-31	Study for accurate diagnosis and treatment of Parkinson's disease by using the combination of TMS-EEG	Study for accurate diagnosis and treatment of Parkinson's disease by using the combination of TMS-EEG	Parkinson's disease	Bradykinesia Group:Sick side, SAM region, 10Hz rTMS;Tremor Group:Sick side, M1 region, 1Hz rTMS;Health control:N/A;	Shenzhen People's Hospital	NULL	Recruiting	50	80	Both	Bradykinesia Group:30;Tremor Group:30;Health control:30;		China
417	NCT03257046 (ClinicalTrials.gov)	September 28, 2017	14/8/2017	Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ITI-214 in Parkinson's Disease	A Randomized, Placebo-Controlled, Double-Blind Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of ITI-214 in Patients With Idiopathic Parkinson's Disease	Parkinson Disease	Drug: ITI-214;Other: Placebo	Intra-Cellular Therapies, Inc.	NULL	Completed	50 Years	N/A	All	40	Phase 1;Phase 2	United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT04468919
(ClinicalTrials.gov)

July 1, 2021

8/7/2020

Optimizing BCI-FIT: Brain Computer Interface - Functional Implementation Toolkit

Amyotrophic Lateral Sclerosis;Brainstem Stroke;Muscular Dystrophies;Parkinson's Disease and Parkinsonism;Multiple System Atrophy;Brain Tumor Adult;Spinal Cord Injuries;Locked-in Syndrome

Behavioral: BCI-FIT multi-modal access;Behavioral: BCI-FIT adaptive signal modeling;Behavioral: BCI-FIT active querying;Behavioral: BCI-FIT language modeling

Oregon Health and Science University

NULL

Not yet recruiting

18 Years

75 Years

All

N/A

United States

NCT03309514
(ClinicalTrials.gov)

June 2021

10/10/2017

Transplantation of Neural Stem Cell-Derived Neurons for Parkinson's Disease

Clinical Investigation of Transplantation of Neural Stem Cell-derived Neurons for the Treatment of Parkinson's Disease

Parkinson's Disease

Biological: Intracerebral microinjections

NeuroGeneration

NULL

Not yet recruiting

35 Years

85 Years

All

Phase 1;Phase 2

NULL

NCT04287543
(ClinicalTrials.gov)

May 2021

21/2/2020

Melatonin on Clock Genes in Parkinson's Disease

Effect of Melatonin Administration on the PER1 and BMAL1 Clock Genes in Patients With Parkinson's Disease

Parkinson Disease

Drug: Melatonin;Drug: Placebos

Instituto Mexicano del Seguro Social

NULL

Withdrawn

20 Years

N/A

All

Phase 2;Phase 3

Mexico

NCT04322461
(ClinicalTrials.gov)

March 15, 2021

24/3/2020

Effect of Exercise, Endocannabinoids and Ketones on Cerebral Metabolism in a Cognitive Disorders Population

Effect of Exercise, Endocannabinoids and Ketones on Cerebral Metabolism in a Cognitive Disorders Population : Pilot Project PARKA

Parkinson Disease;Alzheimer Disease

Dietary Supplement: Betaquik MCT supplement

Université de Sherbrooke

Nestlé

Not yet recruiting

60 Years

N/A

All

N/A

NULL

NCT04665869
(ClinicalTrials.gov)

March 15, 2021

7/12/2020

Long-term Effects of Combined Balance and Brisk Walking in Parkinson's Disease

Long-term Effects of Combined Balance and Brisk Walking on Alleviating Motor and Non-motor Symptoms in Parkinson's Disease: a Randomized Controlled Trial

Parkinson Disease

Behavioral: Combined balance and brisk walking training;Behavioral: Flexibility and strengthening exercise

The Hong Kong Polytechnic University

NULL

Not yet recruiting

30 Years

80 Years

All

N/A

NULL

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

JPRN-jRCTs041190126

01/02/2021

10/03/2020

Study on efficacy and safety of zonisamide in at-risk subjects of Lewy body disease

Study on efficacy and safety of zonisamide in at-risk subjects of Lewy body disease - NaT-PROBEi

Lewy body disease (Parkinson's disease and dementia with Lewy bodies)

Arm zonisamide:
1.Two tablets of zonisamide 25mg after breakfast for 4 weeks
2.Four tablets of zonisamide 25mg after breakfast for 92 weeks
Arm placebo:
1.Two tablets of placebo after breakfast for 4 weeks
2.Four tablets of placebo after breakfast for 92 weeks

Katsuno Masahisa

Japan Agency for Medical Research and Development

Pending

>= 50age old

< 80age old

Both

Phase 2

Japan

NCT04373317
(ClinicalTrials.gov)

January 1, 2021

29/4/2020

Pimavanserin vs. Quetiapine for the Treatment Parkinson's Psychosis

CSP #2015 - Multicenter, Randomized, Double-blind Comparator Study of Antipsychotics Pimavanserin and Quetiapine for Parkinson''s Disease Psychosis (C-SAPP)

Parkinson's Disease Psychosis

Drug: Pimavanserin;Drug: Quetiapine

VA Office of Research and Development

NULL

Not yet recruiting

40 Years

N/A

All

358

Phase 4

United States

NCT04625361
(ClinicalTrials.gov)

January 1, 2021

9/11/2020

Single and Multiple Dose Safety, Tolerability, PK and Food Effect Study of HEC122505MsOH Tablets in Healthy Adult Subjects

A Single Center, Randomized, Double-Blind, Placebo-Controlled Study of Single/Multiple Ascending Doses to Evaluate the Safety, Tolerability, Pharmacokinetics, and Single Center, Randomized, Double-Blind, Two Periods, Crossover, Food Effect Study of HEC122505MsOH Tablets in Healthy Chinese Subjects

Parkinson Disease

Drug: HEC122505MsOH

Sunshine Lake Pharma Co., Ltd.

NULL

Not yet recruiting

18 Years

45 Years

All

102

Phase 1

China

NCT04497168
(ClinicalTrials.gov)

January 2021

29/7/2020

Citalopram as a Posterior Cortical Protective Therapy in Parkinson Disease

Parkinson Disease

Drug: Citalopram 20mg;Drug: Placebo

University of Michigan

National Institute on Aging (NIA)

Not yet recruiting

65 Years

N/A

All

Phase 2

United States

NCT04590612
(ClinicalTrials.gov)

January 2021

17/9/2020

Improving Quality of Life in Early Parkinson's Disease

The Effects of Mood Symptoms Treatment on Quality of Life and Motor Function in de Novo Parkinson's Disease Patients

Parkinson Disease;Depression

Drug: Carbidopa -Levodopa 25 Mg-100 Mg Oral Tablet;Drug: Citalopram

Western University, Canada

NULL

Not yet recruiting

50 Years

80 Years

All

N/A

NULL

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT04643327
(ClinicalTrials.gov)

January 2021

18/11/2020

Uncovering a Novel Therapeutic Target to Reduce Dementia Risk in Parkinson's Disease

Double-blind Randomised-controlled Within-subject Crossover Trial to Determine Levetiracetam Efficacy for Memory Impairment in Parkinson's Disease: A Proof-of-concept Study

Parkinson Disease;Mild Cognitive Impairment;Memory Impairment

Drug: Levetiracetam;Drug: Placebo

The University of Queensland

Queensland University of Technology;Johns Hopkins University;Cleveland Clinic Lou Ruvo Center for Brain Health;Royal Brisbane and Women's Hospital

Not yet recruiting

N/A

All

Phase 2

NULL

NCT04491383
(ClinicalTrials.gov)

January 2021

22/7/2020

Tocotrienols in Parkinson's Disease (PD)

Tocotrienols in Parkinson's Disease (PD): A Pilot, Randomised, Placebo-controlled Trial

Neuro-Degenerative Disease;Parkinson Disease

Drug: Tocovid Suprabio;Other: Placebo

National Neuroscience Institute

Hovid Berhad

Not yet recruiting

50 Years

90 Years

All

100

Phase 2

Singapore

NCT04584346
(ClinicalTrials.gov)

December 17, 2020

10/10/2020

Acute Effects of Medium Chain Triglyceride (MCT) Nutritional Ketosis on Parkinson's Disease (PD) Symptoms and Biomarkers (MCT-PD)

Parkinson's Disease

Dietary Supplement: Liquigen MCT oil

National Institute of Neurological Disorders and Stroke (NINDS)

NULL

Recruiting

50 Years

N/A

All

Phase 1

United States

NCT04377945
(ClinicalTrials.gov)

December 1, 2020

4/5/2020

Study in Parkinson's Disease Patients With Dyskinesia With Combinations of JM-010 and Its Individual Components

A Randomized, Double-Blind, Placebo-Controlled, Two-Part Study in Parkinson's Disease Patients With Dyskinesia to Assess the Efficacy and Safety/Tolerability of Fixed Dose Combinations of JM-010 and Its Individual Components

Dyskinesia, Drug-Induced

Drug: Part 1, JM-010 component Group A;Drug: Part 1, JM-010 component Group B;Drug: Part 1, JM-010 component Group C;Drug: Part 1, Placebo Group;Drug: Part 2, JM-010 combination Group A;Drug: Part 2, JM-010 combination Group B;Drug: Part 2, Placebo Group;Drug: Part 2, JM-010 component Group C

Bukwang Pharmaceutical

NULL

Not yet recruiting

18 Years

80 Years

All

188

Phase 2

United States

NCT04651153
(ClinicalTrials.gov)

December 2020

25/11/2020

A Safety and Pharmacokinetics Study of UCB7853 in Healthy Study Participants and Study Participants With Parkinson's Disease (PD)

A Multicenter, Participant-Blind, Investigator-Blind, Randomized, Placebo-Controlled Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of UCB7853 in Healthy Male Study Participants and Multiple Ascending Doses in Patients With Parkinson's Disease

Parkinson's Disease

Drug: UCB7853;Other: Placebo

UCB Biopharma SRL

NULL

Not yet recruiting

18 Years

80 Years

All

Phase 1

NULL

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT04147949
(ClinicalTrials.gov)

December 2020

27/10/2019

AV-101 (L-4-chlorokynurenine) in Parkinson's Disease Subjects With Levodopa-Induced Dyskinesia

Randomized, Double-Blind, Placebo-Controlled, Crossover, Proof-of-Concept Phase 2 Study to Test Efficacy and Safety of AV-101 (L-4-chlorokynurenine) in Parkinson's Disease Subjects With Levodopa-Induced Dyskinesia

Parkinson Disease;Dyskinesia, Medication-Induced;L-Dopa Causing Adverse Effects in Therapeutic Use

Drug: AV-101;Drug: Placebo

VistaGen Therapeutics, Inc.

NULL

Not yet recruiting

30 Years

80 Years

All

Phase 2

NULL

NCT04346394
(ClinicalTrials.gov)

December 2020

10/3/2020

The Role of the Noradrenergic System in the Nonmotor Symptoms of Parkinson's Disease

The Role of the Noradrenergic System in the Nonmotor Symptoms of Parkinson's Disease: Orthostatic Hypotension and Other Nonmotor Symptoms

Parkinson Disease

Drug: Yohimbine HCl

Nathaniel M. Robbins

NULL

Not yet recruiting

N/A

All

Early Phase 1

NULL

NCT04658186
(ClinicalTrials.gov)

December 2020

1/12/2020

A 18-month Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Oral UCB0599 in Study Participants With Early-stage Parkinson's Disease

A Double-Blind, Placebo-Controlled, Randomized, 18-Month Phase 2a Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Oral UCB0599 in Study Participants With Early Parkinson's Disease

Early-stage Parkinson's Disease

Drug: UCB0599;Drug: Placebo

UCB Biopharma SRL

NULL

Not yet recruiting

40 Years

70 Years

All

300

Phase 2

NULL

NCT04634331
(ClinicalTrials.gov)

November 15, 2020

9/11/2020

Dual-task Augmented Reality Treatment for Parkinson's Disease

Dual-task Augmented Reality Treatment for Parkinson's Disease (DART)

Parkinson Disease

Behavioral: Augmented Reality Multi-Modal Training;Behavioral: Traditional Multi-Modal Training

The Cleveland Clinic

Michael J. Fox Foundation for Parkinson's Research

Recruiting

18 Years

N/A

All

Phase 2

United States

EUCTR2019-003315-60-NL
(EUCTR)

10/11/2020

08/10/2020

A study investigating the effect and safety of a new potential drug for Parkinson's disease patients.

A phase 1/2 study investigating the pharmacokinetics, safety and efficacy of a highly concentrated buccal formulation of apomorphine (APORON®) in subjects with Parkinson's Disease - Buccal apomorphine (APORON) administration

Parkinson's Disease
MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Trade Name: Apo-go
Product Name: APO-go ®
INN or Proposed INN: Apomorphine
Other descriptive name: APOMORPHINE HYDROCHLORIDE HEMIHYDRATE
Product Name: APORON
INN or Proposed INN: APORON
Other descriptive name: APOMORPHINE HYDROCHLORIDE HEMIHYDRATE

Criceto IKM B.V.

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

Phase 1;Phase 2

Netherlands

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT04620382
(ClinicalTrials.gov)

November 9, 2020

27/10/2020

Effect of Midodrine vs Abdominal Compression on Cardiovascular Risk Markers in Autonomic Failure Patients

Neurogenic Orthostatic Hypotension;Autonomic Failure;Pure Autonomic Failure;Multiple System Atrophy;Parkinson Disease

Drug: Midodrine;Drug: Placebo pill;Device: Abdominal compression;Device: sham compression

Vanderbilt University Medical Center

NULL

Recruiting

40 Years

80 Years

All

Early Phase 1

United States

NCT04506073
(ClinicalTrials.gov)

November 9, 2020

16/7/2020

Phase IIa Randomized Placebo Controlled Trial: Mesenchymal Stem Cells as a Disease-modifying Therapy for iPD

Allogeneic Bone Marrow-derived Mesenchymal Stem Cells as a Disease-modifying Therapy for Idiopathic Parkinson's Disease: Phase IIa Double-blind Randomized Placebo Controlled Trial

Parkinson's Disease

Drug: MSC+placebo;Drug: MSC;Drug: Placebo

The University of Texas Health Science Center, Houston

Michael J. Fox Foundation for Parkinson's Research

Recruiting

50 Years

79 Years

All

Phase 2

United States

EUCTR2019-004235-23-NL
(EUCTR)

09/11/2020

26/05/2020

Parkinson's Disease: An extension of Study M15-741 evaluating the safety and tolerability of ABBV-951 in subjects with Parkinson's disease.

An open-label extension of Study M15-741 to evaluate the safety and tolerability of 24-hour daily exposure of continuous subcutaneous infusion of ABBV-951 in subjects with Parkinson's disease.

Product Name: Foscarbidopa and Foslevodopa
Product Code: ABBV-951
INN or Proposed INN: Foslevodopa
Other descriptive name: Levodopa -4'-Monophosphate
INN or Proposed INN: Foscarbidopa
Other descriptive name: Carbidopa -4'-Monophosphate

Abbvie Deutschland GmbH & Co. KG

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

130

Phase 3

United States;Canada;Australia;Russian Federation;Netherlands;Italy;United Kingdom;Japan

EUCTR2019-002952-17-CZ
(EUCTR)

04/11/2020

12/10/2020

A clinical trial which runs in multiple countries and aims to evaluate the long-term safety and tolerability of the investigational product (TAVAPADON) for patients diagnosed with Parkinson's Disease

58-Week Open-label Trial of Tavapadon in Parkinson’s Disease (TEMPO-4 Trial) - TEMPO-4

Patients (40 to 80 years age) who have diagnosis of Parkinson's Disease
MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Product Name: Tavapadon 5mg
Product Code: CVL-751
INN or Proposed INN: TAVAPADON
Other descriptive name: PF-06649751
Product Name: Tavapadon 1mg
Product Code: CVL-751
INN or Proposed INN: TAVAPADON
Other descriptive name: PF-06649751
Product Name: Tavapadon 0.25mg
Product Code: CVL-751
INN or Proposed INN: TAVAPADON
Other descriptive name: PF-06649751

Cerevel Therapeutics, LLC

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

854

Phase 3

United States;Serbia;Spain;Ukraine;Israel;Italy;France;Czech Republic;Hungary;Canada;Poland;Australia;Bulgaria;Germany

NCT04277247
(ClinicalTrials.gov)

November 2, 2020

10/2/2020

Botulinum Toxin Type A for Foot Dystonia-associated Pain in Parkinson's Disease

Botulinum Toxin A (Onabotulinumtoxin A) for Foot Dystonia-associated Pain in Parkinson's Disease: A Randomized, Double-blind Placebo Control Study

Dystonia Disorder;Parkinson Disease

Drug: Botulinum toxin type A;Drug: Placebo

University of Calgary

Allergan

Recruiting

30 Years

100 Years

All

Phase 2;Phase 3

Canada

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

ChiCTR2000038937

2020-11-01

2020-10-10

Clinical study of early diagnosis of Parkinson's disease based on substantia nigra-striatal axis multimodal imaging

Parkinson's disease

Gold Standard:Clinical diagnosis by experienced movement disorder specialists after 2 years of follow-up.;Index test:Including traditional imaging feature algorithms (SUVR value, total cortical volume, bilateral cortical surface area, cortical thickness, etc.), high-dimensional imaging omics feature algorithms (energy entropy, gray-level co-occurrence matrix, and mutual information, etc.), and brain connection group Learning feature algorithm.;

Huashan Hospital, Fudan University

NULL

Recruiting

Both

Target condition:105;Difficult condition:0

China

NCT03903549
(ClinicalTrials.gov)

November 1, 2020

3/4/2019

Initial Investigation of [18F]P17-059 in Parkinson's Disease Patients and Healthy Volunteers

A Positron Emission Tomography (PET) Study to Investigate [18F]D6-FP-DTBZ ([18F]P17-059) for Potential Use as a Radioligand for Vesicular Monoamine Transporter (VMAT2)

Parkinson Disease

Drug: [18F]P17-059

Five Eleven Pharma, Inc.

NULL

Not yet recruiting

45 Years

90 Years

All

Phase 1

United States

NCT04386317
(ClinicalTrials.gov)

November 1, 2020

24/4/2020

Terazosin Effect on Cardiac Changes in Early Parkinson's Disease

The Effect of a1- Adrenergic Receptor Antagonist Therapy on Cardiac and Striatal Transporter Uptake in Pre-Motor and Symptomatic Parkinson's Disease

REM Sleep Behavior Disorder;Pre-motor Parkinson's Disease;Symptomatic Parkinson Disease

Drug: Terazosin

Cedars-Sinai Medical Center

NULL

Recruiting

25 Years

85 Years

All

Phase 2

United States

NCT04435431
(ClinicalTrials.gov)

October 29, 2020

15/6/2020

A Clinical Study of Mesdopetam in Patients With Parkinson's Disease Experiencing Levodopa Induced Dyskinesia

A Randomized, Double-blind, Placebo-controlled Phase IIB Study Evaluating the Efficacy of Mesdopetam on Daily ON-time Without Troublesome Dyskinesia in Patients With Parkinson's Disease

Parkinson Disease

Drug: Mesdopetam;Drug: Placebo

Integrative Research Laboratories AB

NULL

Recruiting

30 Years

79 Years

All

140

Phase 2

United States

NCT04542499
(ClinicalTrials.gov)

October 27, 2020

2/9/2020

Flexible-Dose, Adjunctive Therapy Trial in Adults With Parkinson's Disease With Motor Fluctuations

A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Flexible-Dose, 27-Week Trial to Evaluate the Efficacy, Safety, and Tolerability of Tavapadon as Adjunctive Therapy for Parkinson's Disease in Levodopa-Treated Adults With Motor Fluctuations (TEMPO-3 Trial)

Parkinson Disease

Drug: Tavapadon;Drug: Placebo

Cerevel Therapeutics, LLC

NULL

Recruiting

40 Years

80 Years

All

368

Phase 3

United States;Australia;Czechia;Germany;Hungary;Poland

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

JPRN-jRCTs031200172

26/10/2020

Effects of Elobixibat administration in patients with Parkinson's syndrome complicated with chronic constipation

Multicenter, Placebo-Controlled, Randomized, Double-Blind, Parallel-Group Study Investigating the Efficacy and Safety of Elobixibat in Patients with Parkinson's Disease Complicating Chronic Constipation. - CONST-PD

Parkinson's disease, chronic constipation
Parkinson's syndrome,chronic constipation,Symptomatic constipation

Take 10mg of Elobixibat or placebo once a day before meal. After the 2-week screening period, the study drug will be started on the day of enrollment.

Hatano Taku

Mochida Pharmaceutical Co., Ltd.;EA Pharma Co., Ltd.

Recruiting

>= 20age old

Not applicable

Both

100

N/A

Japan

NCT03947216
(ClinicalTrials.gov)

October 23, 2020

7/5/2019

Randomized Placebo Controlled Trial Evaluating the Efficacy of Pimavanserin, a Selective Serotonin 5-HydroxyTryptamine-2A (5HT2A) Inverse Agonist, to Treat Impulse Control Disorders in Parkinson's Disease.

Study of Pimavanserin Efficacy for the Treatment of Impulse Control Disorders in Parkinson's Disease

Parkinson Disease

Drug: Active drug: pimavanserin 17mg (2 strength tablets);Drug: Placebo: 2 tablets containing same excipients except active compound;Behavioral: Assessment of severity of ICD (impulse control disorders);Behavioral: Assessment of motor and non-motors symptoms of PD Evaluation of hyper- and hypodopaminergic behaviors;Behavioral: Assessment of quality of life;Behavioral: Assessment of depression;Behavioral: Assessment of cognition;Behavioral: Assessment of severity of Parkinson Disease;Procedure: Blood analysis;Procedure: Cardiac monitoring

University Hospital, Strasbourg, France

NS-PARK;EUCLID;F-CRIN

Recruiting

35 Years

75 Years

All

130

Phase 2

France

EUCTR2020-003796-17-GB
(EUCTR)

22/10/2020

01/09/2020

A study to look at the effect of CST-103 or CST-139 on blood flow in the brain and on memory.

An Open-Label Brain Imaging and Cognition Study to Determine Changes in Cerebral Perfusion and Cognition After Oral Administration of CST-103 or CST-139

Patients with Mild Cognitive Impairment or Parkinson’s Disease
MedDRA version: 21.1;Level: LLT;Classification code 10009846;Term: Cognitive impairment;System Organ Class: 10029205 - Nervous system disorders
MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Trade Name: Spiropent
Product Name: Clenbuterol HCl
Product Code: CST-103
INN or Proposed INN: CLENBUTEROL HYDROCHLORIDE
Trade Name: Berachin
Product Name: Tulobuterol
Product Code: CST-139
INN or Proposed INN: Tolubuterol Hydrochloride
Other descriptive name: TULOBUTEROL HYDROCHLORIDE

CuraSen Therapeutics, Inc.

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

Phase 2

United Kingdom

NCT04334317
(ClinicalTrials.gov)

October 21, 2020

30/3/2020

Effect of TAK-071 on Falls in Participants With Parkinson Disease (PD)

A Randomized, Double-blind, Placebo-Controlled, 2-Period Crossover, Phase 2 Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Oral TAK-071 in Parkinson Disease Patients With Cognitive Impairment and an Elevated Risk of Falls

Parkinson's Disease

Drug: TAK-071;Drug: Placebo

Takeda

Michael J. Fox Foundation for Parkinson's Research

Recruiting

40 Years

85 Years

All

Phase 2

United States

ChiCTR2000038852

2020-10-20

2020-10-07

Study on the effect and mechanism of cognitive-cup-tapping-balance-training on fall prevention in community Parkinson's patients: a randomized controlled trial

Parkinson's disease

dual task training group :cognitive-cup-tapping balance training;single task training group:-cup-tapping balance training;control group:education;

Shanghai University of Sport

NULL

Recruiting

Both

dual task training group :29;single task training group:29;control group:29;

N/A

china

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT04380142
(ClinicalTrials.gov)

October 19, 2020

6/5/2020

Study Comparing Continuous Subcutaneous Infusion Of ABBV-951 With Oral Carbidopa/Levodopa Tablets For Treatment Of Motor Fluctuations In Adult Participants With Advanced Parkinson's Disease

A Randomized, Double-Blind, Double-Dummy, Active-Controlled Study Comparing the Efficacy, Safety and Tolerability of ABBV-951 to Oral Carbidopa/Levodopa in Advanced Parkinson's Disease Patients

Parkinson's Disease (PD)

Drug: ABBV-951;Drug: Placebo for Levodopa /Carbidopa (LD/CD);Drug: Levodopa /Carbidopa (LD/CD);Drug: Placebo for ABBV-951

AbbVie

NULL

Recruiting

30 Years

N/A

All

130

Phase 3

United States;Australia

NCT04502550
(ClinicalTrials.gov)

October 15, 2020

30/7/2020

Brain Networks and Consciousness

Subcortical-cortical Network Dynamics of Anesthesia and Consciousness

Loss of Consciousness;Parkinson Disease;Essential Tremor;Anesthesia

Drug: Propofol

University of California, Los Angeles

NULL

Recruiting

18 Years

N/A

All

United States

ChiCTR2000037624

2020-10-01

2020-08-29

Clinical efficacy of dopamine agonist Pramipexol in the treatment of cognitive impairment in PATIENTS with PD-RBD and its population pharmacokinetic study

Parkinson's disease

experimental group:Pramipexol + dopa hydrazine combination therapy;control group: dopa hydrazine;

Shanghai General Hospital

NULL

Recruiting

Both

experimental group:50;control group:50;

China

ChiCTR2000036137

2020-10-01

2020-08-21

Clinical study of 18F-FDG combined with 18F-AV-133 PET/CT imaging in the diagnosis and differentiation of primary Parkinson's disease

Parkinson’s disease

Gold Standard:UK Parkinson's disease Society Brain Bank Clinical Diagnosis Criteria;Index test:18F-FDG combined with 18F-AV-133 PET/CT imaging;

Renji Hospital (South Court), School of Medicine, Shanghai Jiao Tong University

NULL

Pending

Both

Target condition:50;Difficult condition:0

China

ChiCTR2000036006

2020-10-01

2020-08-21

The applications of multi- MRI in early diagnosis of Parkinson's Disease based on deep learning

Parkinson's disease

Gold Standard:MDS clinical diagnostic criteria for Parkinson’s disease;Index test:multimodal MRI features in locus coeruleus and substantia nigra;

Zhongshan Hospital, Fudan University

NULL

Pending

Both

Target condition:400;Difficult condition:0

China

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

ChiCTR2000037239

2020-10-01

2020-08-27

Construction and application of a diagnostic marker for Parkinson's disease based on gut microbiomics

Parkinson's disease

Gold Standard:All patients satisfied the United Kingdom Parkinson's Disease Society Brain Bank criteria;Index test:Microbial gene detection chip;

Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine

NULL

Recruiting

Both

Target condition:500;Difficult condition:600

China

ChiCTR2000037856

2020-10-01

2020-09-02

Detection of A-synuclein Aggregate as Biomarker in Diagnosing Parkinson's Disease at Early Stage by Using Protein Misfolding Cyclic Amplification (PMCA)

Parkinson's Disease

Gold Standard:DAT-PET and 18F-FDG PET ;Index test:a-synuclein protein misfolding cyclic amplification;

Huashan Hospital Affiliated to Fudan University

NULL

Recruiting

Both

Target condition:150;Difficult condition:76

China

NCT04338997
(ClinicalTrials.gov)

October 2020

3/4/2020

PK Study in Patients With Parkinson's Disease With IZD174

An Open-label Phase 1b Study to Evaluate the Pharmacokinetics and Pharmacodynamics in Plasma and Cerebrospinal Fluid (CSF), Safety and Tolerability of Oral IZD174 in Patients With Parkinson's Disease

Parkinson Disease

Drug: IZD174

Inflazome UK Ltd

NULL

Withdrawn

45 Years

75 Years

All

Phase 1

NULL

NCT04593511
(ClinicalTrials.gov)

October 2020

21/9/2020

to Evaluate the Safety, Tolerability and Pharmacokinetics of Four Formulations of LY03009 in Healthy Volunteers

An Open-Label Study in Healthy Volunteers to Evaluate the Safety, Tolerability and Pharmacokinetics of Four Formulations of LY03009 After a Single Intramuscular Injection

Parkinson's Disease

Drug: LY03009 F1;Drug: LY03009 F2;Drug: LY03009 F3;Drug: LY03009 F4

Luye Pharma Group Ltd.

NULL

Not yet recruiting

18 Years

65 Years

All

Phase 1

NULL

NCT03665493
(ClinicalTrials.gov)

September 30, 2020

4/9/2018

Dopamine Effect on Inhibitory Control

Idiopathic Parkinson's Disease

Drug: PD patients H&Y=1.5-2 Medications ON;Drug: PD patients H&Y=1.5-2 Medications OFF;Behavioral: Healthy age-matched controls;Drug: PD patients H&Y=3 Medications OFF;Drug: PD patients H&Y=3 Medications ON

Giovanni Mirabella

NULL

Recruiting

40 Years

70 Years

All

102

N/A

Italy

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT03968133
(ClinicalTrials.gov)

September 30, 2020

28/5/2019

Treating Anxiety in Parkinson's Disease With a Multi-Strain Probiotic

Treating Anxiety in Parkinson's Disease With a Multi-Strain Probiotic - a Randomized, Placebo-controlled Trial

Parkinson Disease;Anxiety

Dietary Supplement: Probiotic;Dietary Supplement: Placebo

University of British Columbia

The W. Garfield Weston Foundation

Not yet recruiting

40 Years

80 Years

All

Phase 2

Canada

EUCTR2020-001175-32-GB
(EUCTR)

29/09/2020

07/08/2020

Clinical study to evaluate the effect of opicapone 50 mg in the pain associated to Parkinson’s disease.

Randomised, double-blind, placebo-controlled, clinical study to evaluate the effect of opicapone 50 mg on Parkinson’s disease patients with end-of-dose motor fluctuations and associated pain. - OpiCapone Effect on motor fluctuations and pAiN (OCEAN)

Parkinson's disease patients with wearing-off motor fluctuations andassociated pain.
MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Trade Name: Ongentys
Product Name: Ongentys
INN or Proposed INN: Opicapone

Bial - Portela & Ca, S.A.

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

176

Phase 4

Portugal;Spain;Germany;Italy;United Kingdom

NCT04591535
(ClinicalTrials.gov)

September 28, 2020

11/9/2020

PK Study of WD-1603 in Healthy Subjects

An Open Label, Balanced, Randomised, Four-treatment, Four-period, Four-sequence, Single Oral Dose, Crossover PK Study of WD-1603 in Normal, Healthy, Adult Human Subjects Under Fed Conditions

Parkinson Disease

Drug: WD-1603 CARBIDOPA/LEVODOPA EXTENDED-RELEASE TABLETS

Hong Kong WD Pharmaceutical Co., Limited

NULL

Recruiting

18 Years

45 Years

All

Phase 1

India

NCT04553978
(ClinicalTrials.gov)

September 18, 2020

13/9/2020

A Single Oral Dose, Crossover Comparative PK Study of WD-1603 in Healthy Subjects Under Fasting Conditions

An Open Label, Balanced, Randomised, 2-treatment, 2-period, 2-sequence, Single Oral Dose, Corssover Comparative PK Study of WD-1603 in Normal, Healthy, Adult Human Subjects Under Fasting Conditions

Parkinson Disease

Drug: WD-1603

Hong Kong WD Pharmaceutical Co., Limited

NULL

Not yet recruiting

18 Years

45 Years

All

Phase 1

NULL

EUCTR2019-004235-23-GB
(EUCTR)

15/09/2020

28/05/2020

Parkinson's Disease: An extension of Study M15-741 evaluating the safety and tolerability of ABBV-951 in subjects with Parkinson's disease.

An open-label extension of Study M15-741 to evaluate the safety and tolerability of 24-hour daily exposure of continuous subcutaneous infusion of ABBV-951 in subjects with Parkinson's disease.

Abbvie Deutschland GmbH & Co. KG

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

130

Phase 3

United States;Canada;Australia;Russian Federation;Japan;United Kingdom

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT04387773
(ClinicalTrials.gov)

September 15, 2020

11/5/2020

Effect of GOCOVRI on Gait in Parkinson's Disease

Effect of GOCOVRI on Quantity and Quality of Gait in Parkinson's Disease

Parkinson Disease

Drug: GOCOVRI

Oregon Health and Science University

Adamas Pharmaceuticals, Inc.

Not yet recruiting

50 Years

70 Years

All

Phase 4

United States

NCT04476017
(ClinicalTrials.gov)

September 11, 2020

15/7/2020

A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Parkinson's Disease Mild Cognitive Impairment (PD-MCI)

An Open-Label Evaluation of the Safety and Tolerability of SAGE-718 in Participants With Parkinson's Disease Mild Cognitive Impairment

Parkinson Disease;Cognitive Dysfunction

Drug: SAGE-718

Sage Therapeutics

NULL

Recruiting

50 Years

75 Years

All

Phase 2

United States

EUCTR2019-002949-38-DE
(EUCTR)

07/09/2020

21/01/2020

A PHASE 3, DOUBLE-BLIND, RANDOMIZED, PLACEBO CONTROLLED, PARALLEL GROUP, 27 WEEK TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF TWO FIXED DOSES OF TAVAPADON IN EARLY PARKINSON’S DISEASE (TEMPO-1 TRIAL)

Patients (18 to 60 years age) who have diagnosis of Parkinson's Disease;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Product Name: Tavapadon 0.25mg
Product Code: CVL-751
INN or Proposed INN: TAVAPADON
Other descriptive name: PF-06649751
Product Name: Tavapadon 1mg
Product Code: CVL-751
INN or Proposed INN: TAVAPADON
Other descriptive name: PF-06649751
Product Name: Tavapadon 5mg
Product Code: CVL-751
INN or Proposed INN: TAVAPADON
Other descriptive name: PF-06649751

Cerevel Therapeutics, LLC

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

552

Phase 3

United States;Spain;Ukraine;Israel;Italy;France;Czech Republic;Hungary;Canada;Poland;Australia;Bulgaria;Germany

ChiCTR2000037828

2020-09-01

2020-09-02

Clinical study of Wuqinxi combined with selegilan in improving frozen gait of Parkinson's disease

Parkinson's disease

Group 1:Routine anti PD treatment + stretching training;Group 2:Routine anti PD treatment + stretching training + selegiline;Group 3:Routine anti PD treatment + Wuqinxi training;Group 4:Routine anti PD treatment + Wuqinxi training + selegiline;

Union Medical College Affiliated Hospital of Tongji Medical College, Huazhong University of science and technology

NULL

Recruiting

Male

Group 1:30;Group 2:30;Group 3:30;Group 4:30;

China

ChiCTR2000035872

2020-09-01

2020-08-19

Effect of repetitive transcranial magnetic stimulation on gait and balance function in patients with Parkinson's disease and Parkinson's syndrome

Parkinson's disease and Parkinson's syndrome

Parkinson's disease observation group:Repetitive transcranial magnetic stimulation+Visual feedback balance training system+Digital treadmill ;Parkinson's disease control group:Visual feedback balance training system+Digital treadmill;Parkinson's syndrome observation group:Repetitive transcranial magnetic stimulation+Visual feedback balance training system+Digital treadmill;Parkinson's syndrome control group:Visual feedback balance training system+Digital treadmill ;

Gansu Provincial Hospital

NULL

Pending

Both

Parkinson's disease observation group:28;Parkinson's disease control group:28;Parkinson's syndrome observation group:28;Parkinson's syndrome control group:28;

China

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT04332276
(ClinicalTrials.gov)

September 2020

25/3/2020

Dopaminergic restauratIon by intraVEntriculaire Administration

A New Concept of Continuous Dopaminergic Stimulation by Cerebroventricular Administration of A-dopamine (Dopamine Stored in Anaerobia) for Severe Motor Fluctuations in Parkinson's Disease?

Parkinson Disease

Drug: A-dopamine

University Hospital, Lille

InBrain Pharma

Not yet recruiting

45 Years

75 Years

All

Phase 1;Phase 2

NULL

EUCTR2019-004235-23-IT
(EUCTR)

26/08/2020

22/10/2020

Parkinson's Disease: An extension of Study M15-741 evaluating the safety and tolerability of ABBV-951 in subjects with Parkinson's disease.

An open-label extension of Study M15-741 to evaluate the safety and tolerability of 24-hour daily exposure of continuous subcutaneous infusion of ABBV-951 in subjects with Parkinson's disease. - na

Parkinson's Disease
MedDRA version: 21.1;Level: PT;Classification code 10068100;Term: Vascular parkinsonism;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Product Name: Foscarbidopa and Foslevodopa
Product Code: [ABBV-951]
INN or Proposed INN: Foslevodopa
Other descriptive name: Levodopa -4'-Monophosphate

ABBVIE DEUTSCHLAND GMBH & CO. KG

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

130

Phase 3

United States;Canada;Australia;Russian Federation;Netherlands;United Kingdom;Japan;Italy

ChiCTR2000035564

2020-08-17

2020-08-13

Pharmacokinetics and Bioequivalence study of Pramipexole Extended-Release Tablets in Healthy Chinese Volunteers

Parkinson’s disease

fasting administration group-TR:phase I: Pramipexole Extended-Release Tablets; phase II: Reference preparation;fasting administration group-RT:phase I: Reference preparation: pahse II: Test preparation;high-fat postprandial administration group-TR:phase I: Pramipexole Extended-Release Tablets; phase II: Reference preparation;high-fat postprandial administration group-RT:phase I: Pramipexole Extended-Release Tablets; phase II: Reference preparation;

West China Hospital of Sichuan University

NULL

Recruiting

Both

fasting administration group-TR:28;fasting administration group-RT:28;high-fat postprandial administration group-TR:28;high-fat postprandial administration group-RT:28;

Phase 1

China

NCT04524351
(ClinicalTrials.gov)

August 14, 2020

11/8/2020

Posiphen® Dose-Finding, Biomarker Study in Early Alzheimer's and Parkinson's Patients

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Effects of Posiphen® in Subjects With Early Alzheimer's Disease (AD) or Early Parkinson's Disease (PD)

Alzheimer Disease;Parkinson Disease

Drug: Posiphen

Annovis Bio Inc.

Parexel

Recruiting

45 Years

N/A

All

Phase 1;Phase 2

United States

NCT04513340
(ClinicalTrials.gov)

August 13, 2020

12/8/2020

WD-1603 PK Study Under Fasting and Fed Conditions in Healthy Subjects

AN OPEN LABEL, BALANCED, RANDOMISED, FOUR-TREATMENT, FOUR-PERIOD, FOUR-SEQUENCE, SINGLE INTRA-ORAL AND ORAL DOSE, CROSSOVER PHARMACOKINETICS STUDY OF WD-1603 EXTENDED-RELEASE CARBIDOPA/LEVODOPA TABLETS 25/100MG IN NORMAL, HEALTHY, ADULT HUMAN SUBJECTS UNDER FASTING AND FED CONDITIONS

Parkinson Disease

Drug: WD-1603 CARBIDOPA and LEVODOPA EXTENDED-RELEASE TABLETS

Hong Kong WD Pharmaceutical Co., Limited

NULL

Recruiting

18 Years

45 Years

All

Phase 1

India

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT04449484
(ClinicalTrials.gov)

August 4, 2020

23/4/2019

Multiple Ascending Dose Study of MEDI1341 in Patients With Parkinson's Disease

A Randomized, Double-blind, Placebo-controlled Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Ascending Doses of MEDI1341 in Subjects With Parkinson's Disease

Parkinson's Disease

Drug: MEDI1341;Other: Placebo

AstraZeneca

NULL

Recruiting

40 Years

85 Years

All

Phase 1

United States

ChiCTR2000034323

2020-08-01

2020-07-02

The effect and correlation of rehabilitation training mode combined with visual feedback balance system and digital treadmill on three-dimensional Gait kinematics and diffusion tensor imaging in patients with early and mid period Parkinson's disease

The effect of rehabilitation training mode combined with visual feedback balance system and digital treadmill on Gait kinematics and diffusion tensor imaging in patients with early and mid period Parkinson's disease

Parkinson's disease

experimental group:Combined Rehabilitation Training of visual feedback balance system and digital treadmill;control group:Traditional Gait Balance Rehabilitation Training;

Xianhui Feng

NULL

Pending

Both

experimental group:30;control group:30;

China

NCT04483479
(ClinicalTrials.gov)

July 30, 2020

20/7/2020

Orally Administered ENT-01 for Parkinson's Disease-Related Constipation Follow-on Safety Roll-over Study (Rollover)

A Multicenter, Non-Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Orally Administered ENT-01 in Improving Constipation and Neurologic Symptoms in Patients With Parkinson's Disease and Constipation Over a 14-week Period

Parkinson Disease;Constipation

Drug: Active Investigational Treatment ENT-01

Enterin Inc.

NULL

Recruiting

30 Years

90 Years

All

Phase 2

United States

EUCTR2019-002951-40-DE
(EUCTR)

29/07/2020

12/02/2020

A clinical trial which runs in multiple countries and aims to analyse how efficient, safe and tolerable the investigational product (TAVAPADON) is compared with placebo treatment when given in multiple doses for patients diagnosed with Parkinson's Disease with Motor Fluctuations

A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Flexible-Dose, 27-Week Trial to Evaluate the Efficacy, Safety, and Tolerability of Tavapadon as Adjunctive Therapy for Parkinson’s Disease in Levodopa-Treated Adults With Motor Fluctuations (TEMPO-3 Trial) - TEMPO-3

Patients (40 to 80 years age) who have diagnosis of Parkinson's Disease with Motor Fluctuations
MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Cerevel Therapeutics, LLC

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

368

Phase 3

United States;Serbia;Spain;Ukraine;Israel;Italy;France;Czech Republic;Hungary;Canada;Poland;Australia;Bulgaria;Germany

NCT04275492
(ClinicalTrials.gov)

July 24, 2020

18/11/2019

Study on Bioequivalence of Pramipexole Dihydrochloride Sustained Release Tablets

Parkinson's Disease

Drug: Praxol hydrochloride sustained release tablet Specification: 0.375mg/ tablet (in pramipexole hydrochloride);Drug: Pramipexole hydrochloride sustained-release tablet (Siforl®) Specification: 0.26mg/ tablet (in pramipexole)

First Affiliated Hospital of Zhejiang University

Hongguan biological pharmaceutical co.

Recruiting

18 Years

45 Years

All

N/A

China

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT04630860
(ClinicalTrials.gov)

July 7, 2020

5/11/2020

A Study to Evaluate the Pharmacokinetics and Safety of LY03003 in Patients With Advanced-stage PD

A Randomized, Open-label, Multiple Ascending Dose Study in Patients With Advanced-stage Parkinson's Disease to Evaluate the Pharmacokinetics and Safety of LY03003 Following Intramuscular Injections

Parkinson Disease

Drug: LY03003

Luye Pharma Group Ltd.

NULL

Recruiting

18 Years

80 Years

All

Phase 1

China

EUCTR2019-002951-40-HU
(EUCTR)

02/07/2020

29/04/2020

A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Flexible-Dose, 27-Week Trial to Evaluate the Efficacy, Safety, and Tolerability of Tavapadon as Adjunctive Therapy for Parkinson’s Disease in Levodopa-Treated Adults With Motor Fluctuations (TEMPO-3 Trial) - TEMPO-3

Cerevel Therapeutics, LLC

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

368

Phase 3

United States;Serbia;Spain;Ukraine;Israel;Italy;France;Hungary;Czech Republic;Canada;Poland;Australia;Bulgaria;Germany;Sweden

NCT04193527
(ClinicalTrials.gov)

July 2020

2/12/2019

A Study to Evaluate the Diagnostic Efficacy of DaTSCAN™ Ioflupane (123I) Injection in Single Photon Emission Computed Tomography (SPECT) for the Diagnosis of Parkinsonian Syndrome (PS) in Chinese Patients

A Multicentre, Phase 3, Clinical Study to Compare the Striatal Uptake of a Dopamine Transporter Radioligand, DaTSCAN™ Ioflupane (123I) Injection, After Intravenous Administration to Chinese Patients With a Diagnosis of Parkinson's Disease, Multiple System Atrophy, Progressive Supranuclear Palsy, or Essential Tremor and to Healthy Controls

Parkinsonian Syndrome;Parkinson Disease(PD);Multiple System Atrophy (MSA);Progressive Supranuclear Palsy (PSP)

Drug: DaTSCAN ™ Ioflupane (123I) Injection

GE Healthcare

PPD

Not yet recruiting

40 Years

80 Years

All

172

Phase 3

China

JPRN-UMIN000040889

2020/06/24

24/06/2020

Comparison of gastrointestinal function before and after levodopa-carbidopa continuous infusion gel (LCIG) therapy for patients with Parkinson's disease

Comparison of gastrointestinal function before and after levodopa-carbidopa continuous infusion gel (LCIG) therapy for patients with Parkinson's disease - Comparison of gastrointestinal function before and after LCIG therapy for Parkinson's disease

Parkinson's disease

Levodopa-carbidopa continuous infusion gel (LCIG) therapy

Fujita Health University School of MedicineDepartment of Gastroenterology

NULL

Recruiting

20years-old

Not applicable

Male and Female

200

Phase 4

Japan

EUCTR2018-004156-37-PT
(EUCTR)

16/06/2020

09/12/2019

A clinical study to investigate the efficacy, safety, and tolerability of continuous subcutaneous ND0612 infusion in comparison to oral treatment in subjects with Parkinson’s disease (BouNDless)

A multicenter, randomized, active-controlled, double-blind, double-dummy, parallel group clinical trial, investigating the efficacy, safety, and tolerability of continuous subcutaneous ND0612 infusion in comparison to oral IR-LD/CD in subjects with Parkinson’s disease experiencing motor fluctuations (BouNDless) - BouNDless

Parkinson's disease
MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Product Name: levodopa /carbidopa solution
Product Code: ND0612
INN or Proposed INN: Levodopa
Other descriptive name: LEVODOPA
INN or Proposed INN: carbidopa
Other descriptive name: CARBIDOPA
Trade Name: IR LD/CD
Product Name: Carbidopa and Levodopa tablets, USP
INN or Proposed INN: Levodopa
Other descriptive name: LEVODOPA
INN or Proposed INN: carbidopa
Other descriptive name: CARBIDOPA

NeuroDerm Ltd.

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

350

Phase 3

United States;Portugal;Serbia;Slovakia;Spain;Ukraine;Austria;Israel;Russian Federation;United Kingdom;France;Italy;Hungary;Czech Republic;Canada;Belgium;Poland;Netherlands;Sweden;Korea, Republic of

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

EUCTR2018-004156-37-NL
(EUCTR)

14/06/2020

13/01/2020

A clinical study to investigate the efficacy, safety, and tolerability of continuous subcutaneous ND0612 infusion in comparison to oral treatment in subjects with Parkinson’s disease (BouNDless)

Product Name: levodopa /carbidopa solution
Product Code: ND0612
INN or Proposed INN: Levodopa
Other descriptive name: LEVODOPA
INN or Proposed INN: carbidopa
Other descriptive name: CARBIDOPA
Trade Name: IR LD / CD
Product Name: Carbidopa and Levodopa tablets, USP
INN or Proposed INN: Levodopa
Other descriptive name: LEVODOPA
INN or Proposed INN: carbidopa
Other descriptive name: CARBIDOPA

NeuroDerm Ltd.

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

482

Phase 3

Portugal;Serbia;United States;Czechia;Slovakia;Spain;Ukraine;Austria;Israel;Russian Federation;United Kingdom;Italy;France;Czech Republic;Hungary;Poland;Belgium;Netherlands;Sweden;Korea, Republic of

NCT04428112
(ClinicalTrials.gov)

June 5, 2020

9/6/2020

Rural Dementia Caregiver Project

Evaluating the Effectiveness of an Online Small-Group Self-Management Workshop for Rural Caregivers of Individuals With Alzheimer's Disease and Related Dementias

Depression;Stress, Psychological;Self Efficacy;Loneliness;Social Isolation;Health Care Utilization;Dementia;Dementia Alzheimers;Dementia of Alzheimer Type;Dementia, Vascular;Dementia Frontal;Dementia, Lewy Body;Dementia, Mixed;Dementia in Parkinsons Disease;Dementia, HIV;Dementia Frontotemporal;Dementia, Multi-Infarct

Behavioral: Building Better Caregivers Workshop;Behavioral: Attention Control

University of California, San Francisco

National Institute on Aging (NIA)

Recruiting

18 Years

N/A

All

640

N/A

United States

EUCTR2019-002951-40-CZ
(EUCTR)

03/06/2020

25/02/2020

A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Flexible-Dose, 27-Week Trial to Evaluate the Efficacy, Safety, and Tolerability of Tavapadon as Adjunctive Therapy for Parkinson’s Disease in Levodopa-Treated Adults With Motor Fluctuations (TEMPO-3 Trial) - TEMPO-3

Cerevel Therapeutics, LLC

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

368

Phase 3

Serbia;United States;Spain;Ukraine;Israel;Italy;France;Czech Republic;Hungary;Canada;Poland;Australia;Bulgaria;Germany;Sweden

NCT04384666
(ClinicalTrials.gov)

June 2, 2020

8/5/2020

A Randomized, Open-Label, Crossover Study to Evaluate the Pharmacokinetic Profiles of Rotigotine After a Single Dose of LY03003 (28 mg) Versus After a Week of Daily NEUPRO® Transdermal Patch (4 mg Every 24 Hours) in Healthy Volunteers

Parkinson Disease

Drug: LY03003 (rotigotine extended release microspheres for intramuscular [IM] injection);Other: Neupro 4 mg / 24 Hr. Transdermal Patch

Luye Pharma Group Ltd.

NULL

Completed

18 Years

45 Years

All

Phase 1

United States

NCT04414813
(ClinicalTrials.gov)

June 2020

21/5/2019

Stereotactic Transplantation of hAESCs for Parkinson's Disease

Clinical Study of Stereotactic Transplantation of Human Amniotic Epithelial Stem Cells (hAESCs) in the Treatment of Parkinson's Disease (PD)

Parkinson's Disease

Biological: Human Amniotic Epithelial Stem Cells

Shanghai East Hospital

Shanghai iCELL Biotechnology Co., Ltd, Shanghai, China

Not yet recruiting

30 Years

70 Years

All

Early Phase 1

NULL

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

ChiCTR2000032616

2020-05-30

2020-05-04

Assistant diagnosis machinery system development based on speech and movement sensitive device for Parkinson's disease

Parkinson's disease, Assistant diagnosis machinery system, speech, movement sensitive device

Parkinson's disease

Gold Standard:clinical outcome meet 2015 MDS-probable PD criteria;Index test:Acoustic receptive and analysis device,Wearable movement sensor;

Shanghai Jiao Tong University School of Medicine affiliated Shanghai General Hospital

NULL

Pending

Both

Target condition:20;Difficult condition:80

China

NCT04379050
(ClinicalTrials.gov)

May 19, 2020

1/5/2020

Extension Study To Evaluate Safety And Tolerability Of 24-Hour Daily Exposure Of Continuous Subcutaneous Infusion of ABBV-951 In Adult Participants With Parkinson's Disease

An Open-label Extension of Study M15-741 to Evaluate the Safety and Tolerability of 24-hour Daily Exposure of Continuous Subcutaneous Infusion of ABBV-951 in Subjects With Parkinson's Disease

Parkinson's Disease (PD)

Drug: ABBV-951

AbbVie

NULL

Enrolling by invitation

30 Years

N/A

All

121

Phase 3

United States;Australia;Belgium;Canada;Denmark;Italy;Japan;Netherlands;Spain;United Kingdom

EUCTR2018-004156-37-SE
(EUCTR)

18/05/2020

10/09/2019

A clinical study to investigate the efficacy, safety, and tolerability of continuous subcutaneous ND0612 infusion in comparison to oral treatment in subjects with Parkinson’s disease (BouNDless)

Product Name: levodopa /carbidopa solution
Product Code: ND0612
INN or Proposed INN: Levodopa
Other descriptive name: LEVODOPA
INN or Proposed INN: carbidopa
Other descriptive name: CARBIDOPA
Trade Name: IR LD / CD
Product Name: Carbidopa and Levodopa tablets, USP
INN or Proposed INN: Levodopa
Other descriptive name: LEVODOPA
INN or Proposed INN: carbidopa
Other descriptive name: CARBIDOPA

NeuroDerm Ltd.

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

350

Phase 3

United States;Serbia;Portugal;Slovakia;Spain;Ukraine;Austria;Israel;Russian Federation;United Kingdom;Italy;France;Hungary;Czech Republic;Canada;Belgium;Poland;Netherlands;Sweden;Korea, Republic of

NCT03568968
(ClinicalTrials.gov)

May 15, 2020

14/6/2018

A Randomized Controlled Trial of Nicotinamide Supplementation in Early Parkinson's Disease

A Randomized Controlled Trial of Nicotinamide Supplementation in Early Parkinson's Disease: the NOPARK Study

Parkinson Disease

Dietary Supplement: Nicotinamide Riboside;Drug: Placebo

Haukeland University Hospital

NULL

Recruiting

18 Years

N/A

All

400

N/A

Norway

EUCTR2019-002949-38-PL
(EUCTR)

13/05/2020

20/02/2020

Cerevel Therapeutics, LLC

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

522

Phase 3

Serbia;United States;Spain;Ukraine;Israel;Italy;France;Czech Republic;Hungary;Canada;Poland;Australia;Bulgaria;Germany;Sweden

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT04571164
(ClinicalTrials.gov)

May 11, 2020

21/9/2020

A Study to Evaluate the Effectiveness and Safety of LY03003 in Patients With Early Primary PD

A Multi-centre,Randomized,Double-blind,Placebo Parallel Controlled Study to Evaluate the Effectiveness and Safety of LY03003 in Patients With Early Primary PD

Parkinson Disease

Drug: LY03003(Rotigotine,extended-release microspheres);Drug: Placebo,extended-release microspheres

Luye Pharma Group Ltd.

Parexel

Recruiting

30 Years

N/A

All

294

Phase 3

China

EUCTR2018-002144-85-DE
(EUCTR)

07/05/2020

06/06/2019

Parkinson's Disease: Safety and Tolerability of 24-Hour Daily Exposure to ABBV-951 by Continuous Subcutaneous Infusion study

A 52-Week, open-label, single-arm study to evaluate the safety and tolerability of 24-hour daily exposure of continuous subcutaneous infusion of ABBV-951 in subjects with Parkinson's disease - Galliarde

Product Code: ABBV-951
INN or Proposed INN: Foslevodopa
Other descriptive name: Levodopa -4'-Monophosphate
INN or Proposed INN: Foscarbidopa
Other descriptive name: Carbidopa -4'-Monophosphate

AbbVie Deutschland

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

130

Phase 3

United States;Canada;Spain;Denmark;Australia;Netherlands;Germany;United Kingdom;Japan

EUCTR2019-002950-22-HU
(EUCTR)

06/05/2020

12/03/2020

A Phase 3, Double-Blind, Randomized, Placebo Controlled, Parallel Group, Flexible-Dose, 27 Week Trial to Evaluate the Efficacy, Safety, and Tolerability of Tavapadon in Early Parkinson’s Disease (TEMPO 2 Trial)

Cerevel Therapeutics, LLC

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

296

Phase 3

United States;Serbia;Spain;Ukraine;Israel;Italy;France;Hungary;Czech Republic;Canada;Poland;Australia;Bulgaria;Germany

NCT04265209
(ClinicalTrials.gov)

May 2020

6/2/2020

[18F] LBT-999 PET Compared to [123I]-FP/CIT SPECT to Distinguish Between Parkinson's Diseases and Essential Tremor

Non-inferiority Study of the Molecular Imaging of Dopamine Transporters Using [123I]-FP/CIT-SPECT and [18F] LBT-999-PET to Distinguish Between Parkinson's Disease and Essential Tremor.

Parkinson Disease;Essential Tremor

Drug: SPECT;Drug: PET

Zionexa

NULL

Not yet recruiting

35 Years

80 Years

All

112

Phase 3

NULL

EUCTR2018-004156-37-SK
(EUCTR)

30/04/2020

13/02/2020

A clinical study to investigate the efficacy, safety, and tolerability of continuous subcutaneous ND0612 infusion in comparison to oral treatment in subjects with Parkinson’s disease (BouNDless)

Product Name: Levodopa /Carbidopa Solution
Product Code: ND0612
INN or Proposed INN: Levodopa
Other descriptive name: LEVODOPA
INN or Proposed INN: carbidopa
Other descriptive name: CARBIDOPA
Trade Name: IR LD / CD
Product Name: Carbidopa and Levodopa tablets, USP
INN or Proposed INN: Levodopa
Other descriptive name: LEVODOPA
INN or Proposed INN: carbidopa
Other descriptive name: CARBIDOPA

NeuroDerm Ltd.

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

482

Phase 3

United States;Serbia;Portugal;Slovakia;Spain;Ukraine;Austria;Israel;Russian Federation;United Kingdom;Italy;France;Czech Republic;Hungary;Belgium;Poland;Netherlands;Sweden;Korea, Republic of

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT04459052
(ClinicalTrials.gov)

April 30, 2020

26/6/2020

FDOPA PET and Nutritional Support in Parkinson's Disease

Phase II: Physiological Effects of Nutritional Support in Patients With Parkinson's Disease

Parkinson Disease;Idiopathic Parkinson Disease

Dietary Supplement: N acetyl cysteine;Drug: [F-18] Fluorodopa Positron Emission Tomography

Thomas Jefferson University

NULL

Active, not recruiting

30 Years

N/A

All

Phase 2

United States

EUCTR2018-004156-37-BE
(EUCTR)

27/04/2020

03/03/2020

A clinical study to investigate the efficacy, safety, and tolerability of continuous subcutaneous ND0612 infusion in comparison to oral treatment in subjects with Parkinson’s disease (BouNDless)

Product Name: levodopa /carbidopa solution
Product Code: ND0612
INN or Proposed INN: Levodopa
Other descriptive name: LEVODOPA
INN or Proposed INN: carbidopa
Other descriptive name: CARBIDOPA
Trade Name: IR LD / CD
Product Name: Carbidopa and Levodopa tablets, USP
INN or Proposed INN: Levodopa
Other descriptive name: LEVODOPA
INN or Proposed INN: carbidopa
Other descriptive name: CARBIDOPA

NeuroDerm Ltd.

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

482

Phase 3

United States;Portugal;Serbia;Slovakia;Spain;Ukraine;Austria;Israel;Russian Federation;United Kingdom;Italy;France;Czech Republic;Hungary;Belgium;Poland;Netherlands;Sweden;Korea, Republic of

EUCTR2018-002233-37-PL
(EUCTR)

23/04/2020

24/01/2020

Evaluate the safety and efficacy of IPX203 carbidopa-levodopa extended release capsules compared to carbidopa-levodopa immediate release tablets in patients with Parkinson’s with motor fluctuations.

A randomized controlled study to compare the safety and efficacy of IPX203 with immediate-release carbidopa-levodopa in Parkinson's disease patients with motor fluctuations.

Parkinson's disease
MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders
MedDRA version: 20.0;Level: SOC;Classification code 10029205;Term: Nervous system disorders;Classification code 10028035;Term: Movement disorder;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Product Name: IPX203
Product Code: IPX203
INN or Proposed INN: Levodopa
Other descriptive name: LEVODOPA
INN or Proposed INN: Carbidopa
Other descriptive name: ANHYDROUS CARBIDOPA
Trade Name: Carbidopa and Levodopa Tablets, USP
Product Name: IR CD-LD (carbidopa-levodopa) tablets
Product Code: IR CD-LD
INN or Proposed INN: Levodopa
INN or Proposed INN: Carbidopa
Other descriptive name: ANHYDROUS CARBIDOPA

Impax Laboratories, LLC

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

510

Phase 3

United States;France;Czech Republic;Canada;Spain;Poland;Germany;United Kingdom;Italy

EUCTR2019-002951-40-ES
(EUCTR)

14/04/2020

06/03/2020

A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Flexible-Dose, 27-Week Trial to Evaluate the Efficacy, Safety, and Tolerability of Tavapadon as Adjunctive Therapy for Parkinson’s Disease in Levodopa-Treated Adults With Motor Fluctuations (TEMPO-3 Trial) - TEMPO-3

Cerevel Therapeutics, LLC

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

368

Phase 3

United States;Serbia;Spain;Ukraine;Israel;Italy;France;Czech Republic;Hungary;Canada;Poland;Australia;Bulgaria;Germany;Sweden

EUCTR2019-002949-38-ES
(EUCTR)

07/04/2020

28/02/2020

Patients (18 to 60 years age) who have diagnosis of Parkinson's Disease;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Cerevel Therapeutics, LLC

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

522

Phase 3

United States;Serbia;Spain;Ukraine;Israel;Italy;France;Czech Republic;Hungary;Canada;Poland;Australia;Bulgaria;Germany;Sweden

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

ChiCTR2000029465

2020-04-06

2020-02-02

Comparison of effects of sitagliptin and metformin on motor function and cognitive function in patients with Parkinson's disease complicated with type 2 diabetes

Type 2 Diabetes

Sitagliptin group:Sitagliptin 100mg/d for 52 weeks;metformin group:metformin 1000-1500mg/d for 52 weeks;

Peking Union Medical College Hospital

NULL

Pending

Both

Sitagliptin group:20;metformin group:20;

Phase 4

China

NCT02967250
(ClinicalTrials.gov)

April 1, 2020

13/9/2016

Brain Bioenergetics in Parkinson's Disease and Response to Repeated Oral UDCA Treatment

7T Magnetic Resonance Spectroscopy Monitoring Brain Bioenergetics in Parkinson's Disease and Response to Repeated Oral UDCA Treatment

Parkinson Disease

Drug: ursodeoxycholic acid

University of Minnesota

NULL

Not yet recruiting

18 Years

N/A

All

Phase 1

United States

NCT04167540
(ClinicalTrials.gov)

April 1, 2020

7/11/2019

GDNF Gene Therapy for Parkinson's Disease

Open-Label Safety Study of Glial Cell Line-Derived Neurotrophic Factor Gene Transfer (AAV2- GDNF) in Parkinson's Disease

Parkinson's Disease

Biological: AAV2-GDNF

Brain Neurotherapy Bio, Inc.

NULL

Recruiting

35 Years

75 Years

All

Phase 1

United States

NCT04182399
(ClinicalTrials.gov)

April 1, 2020

24/11/2019

Role of Zonisamide in Advanced Parkinson's Disease (PD) in Egyptian Population: Pilot Study

Parkinson Disease

Drug: Zonisamide Capsules

Ain Shams University

NULL

Recruiting

18 Years

N/A

All

N/A

Egypt

NCT04342273
(ClinicalTrials.gov)

March 31, 2020

8/4/2020

A Through QT/QTc Study of KW-6356

A Through QT/QTc Study of KW-6356 in Japanese Healthy Adults

Parkinson's Disease

Drug: KW-6356;Drug: Placebo;Drug: Moxifloxacin

Kyowa Kirin Co., Ltd.

NULL

Completed

20 Years

54 Years

All

128

Phase 1

Japan

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

EUCTR2020-000686-16-NL
(EUCTR)

26/03/2020

09/03/2020

Validation of finger tapping in PD patients

Randomized, double-blind, placebo-controlled crossover study to validate finger tapping tasks for the quantification of levodopa/carbidopa effects in Parkinson’s Disease patients.

Trade Name: SINEMET 125
Product Name: SINEMET
Product Code: RVG 08740
INN or Proposed INN: Levodopa
Other descriptive name: LEVODOPA
INN or Proposed INN: Carbidopamonohydraat
Other descriptive name: CARBIDOPA MONOHYDRATE

Centre for Human Drug Research

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

Phase 2

Netherlands

EUCTR2019-003962-41-GB
(EUCTR)

23/03/2020

06/02/2020

Trial of Ondansetron as a Parkinson's HAllucinations Treatment: TOP HAT

Trial of Ondansetron as a Parkinson’s HAllucinations Treatment - TOP HAT

Adults aged over 18 years with Parkinson's disease and visual hallucinations
MedDRA version: 21.1;Level: LLT;Classification code 10047570;Term: Visual hallucinations;System Organ Class: 100000004873;Therapeutic area: Psychiatry and Psychology [F] - Mental Disorders [F03]

Trade Name: Ondansetron 8 mg film-coated tablets
Product Name: Ondansetron 8 mg film-coated tablets
INN or Proposed INN: Ondansetron hydrochloride dihydrate

University College London

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

216

Phase 2

United Kingdom

NCT04269642
(ClinicalTrials.gov)

March 19, 2020

13/1/2020

SR-Exenatide (PT320) to Eveluate Efficacy and Safety in Patients With Early Parkinson's Disease

Phase IIa Study to Evaluate the Efficacy and Safety of Subcutaneous SR-Exenatide (PT320) in Patients With Early Parkinson's Disease

Early Parkinson's Disease

Drug: PT320 2.0mg Placebo;Drug: PT320 2.0 mg;Drug: PT320 2.5 mg

Peptron, Inc.

NULL

Recruiting

40 Years

75 Years

All

Phase 2

Korea, Republic of

EUCTR2018-003941-41-AT
(EUCTR)

05/03/2020

19/06/2019

This study will look at whether an investigational drug, called TD-9855, works and how safe it is when taken over a longer period of time to treat symptomatic neurogenic orthostatic hypotension (snOH) in people with Parkinson’s disease (PD), multiple system atrophy (MSA), or pure autonomic failure (PAF). It will also look at the effects of TD-9855 on general well-being and whether it can improve symptoms of neurogenic OH (nOH)

A Phase 3, 22-week, Multi-center, Randomized Withdrawal Study of TD-9855 in Treating Symptomatic NeurogenicOrthostatic Hypotension in Subjects with Primary Autonomic Failure - Redwood

Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Product Code: TD-9855
INN or Proposed INN: ampreloxetine hydrochloride
Other descriptive name: TD-9855

Theravance Biopharma Ireland Limited

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

258

Phase 3

United States;Portugal;Estonia;Spain;Ukraine;Austria;Russian Federation;Chile;Israel;United Kingdom;Italy;France;Hungary;Mexico;Canada;Argentina;Poland;Peru;Australia;Denmark;Bulgaria;Germany;New Zealand

100

EUCTR2019-002949-38-CZ
(EUCTR)

04/03/2020

19/12/2019

Patients (18 to 60 years age) who have diagnosis of Parkinson's Disease
MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Cerevel Therapeutics, LLC

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

522

Phase 3

Serbia;United States;Spain;Ukraine;Israel;Italy;France;Czech Republic;Hungary;Canada;Poland;Australia;Bulgaria;Germany;Sweden

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

101

NCT04127695
(ClinicalTrials.gov)

March 3, 2020

9/10/2019

A Study to Evaluate the Safety and Tolerability of ABBV-0805 in Patients With Parkinson's Disease

A Randomized, Double-Blind, Placebo Controlled Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of ABBV-0805 in Patients With Parkinson's Disease

Parkinson's Disease

Drug: ABBV-0805;Drug: Placebo ABBV-0805

AbbVie

NULL

Withdrawn

N/A

85 Years

All

Phase 1

United States;Puerto Rico

102

NCT04353947
(ClinicalTrials.gov)

March 2, 2020

16/4/2020

Induction and Recognition of Emotions

Induction and Recognition of Emotions in Healthy Older Adults, Alzheimer's Disease and Parkinson's Disease

Healthy Older Adults;Alzheimer's Disease;Parkinson's Disease

Diagnostic Test: Mini Cognitive Examination (MCE);Diagnostic Test: Beck Depression Inventory-II (BDI-II);Diagnostic Test: Global Deterioration Scale (GDS);Diagnostic Test: Memory alteration test (M@T);Diagnostic Test: Spanish-Complutense Verbal Learning Test (TAVEC);Diagnostic Test: Barcelona test (BT);Diagnostic Test: Rey-Osterrieth Complex Figure Test (ROCFT);Diagnostic Test: Frontal assessment battery (FAB);Diagnostic Test: Positive and Negative Affect Scale (PANAS);Diagnostic Test: Auto-Assessment Manikins (SAM)

University of Valencia

Asociación Parkinson Valencia

Recruiting

65 Years

99 Years

All

Spain

103

EUCTR2018-004156-37-AT
(EUCTR)

02/03/2020

05/11/2019

A clinical study to investigate the efficacy, safety, and tolerability of continuous subcutaneous ND0612 infusion in comparison to oral treatment in subjects with Parkinson’s disease (BouNDless)

Product Name: levodopa /carbidopa solution
Product Code: ND0612
INN or Proposed INN: Levodopa
Other descriptive name: LEVODOPA
INN or Proposed INN: carbidopa
Other descriptive name: CARBIDOPA
Trade Name: IR LD / CD
Product Name: Carbidopa and Levodopa tablets, USP
INN or Proposed INN: Levodopa
Other descriptive name: LEVODOPA
INN or Proposed INN: carbidopa
Other descriptive name: CARBIDOPA

NeuroDerm Ltd.

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

482

Phase 3

United States;Portugal;Serbia;Slovakia;Spain;Ukraine;Austria;Israel;Russian Federation;United Kingdom;Italy;France;Czech Republic;Hungary;Belgium;Poland;Netherlands;Sweden;Korea, Republic of

104

NCT04260581
(ClinicalTrials.gov)

March 1, 2020

5/2/2020

Is Long-term Use of Amantadine Effective in PD?

Is Long-term Use of Amantadine Effective in Parkinson Disease?

Parkinson Disease

Drug: Determination of drug effects through amantadine cessation

Seoul National University Hospital

NULL

Not yet recruiting

40 Years

N/A

All

N/A

Korea, Republic of

105

NCT04154072
(ClinicalTrials.gov)

February 27, 2020

4/11/2019

A Clinical Study of NLY01 in Patient's With Early Parkinson's Disease

Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of 36 Weeks of Treatment With NLY01 in Early-stage Parkinson's Disease

Parkinson Disease

Drug: NLY01;Drug: Vehicle

Neuraly, Inc.

NULL

Recruiting

30 Years

80 Years

All

240

Phase 2

United States;Canada

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

106

NCT04291859
(ClinicalTrials.gov)

February 26, 2020

28/2/2020

Lu AF28996 in Patients With Parkinson's Disease (PD)

Interventional, Open-label, Exploratory Study, Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Lu AF28996 in Patients With Parkinson's Disease

Parkinson Disease

Drug: Lu AF28996

H. Lundbeck A/S

NULL

Recruiting

45 Years

75 Years

All

Phase 1

Netherlands

107

EUCTR2019-003623-37-GB
(EUCTR)

12/02/2020

02/01/2020

CANnabidiol for Parkinson’s Disease Psychosis

CANnabidiol for Parkinson’s Disease Psychosis - CAN-PDP

Parkinson's disease psychosis
MedDRA version: 20.0;Level: PT;Classification code 10074835;Term: Parkinson's disease psychosis;System Organ Class: 10037175 - Psychiatric disorders;Therapeutic area: Psychiatry and Psychology [F] - Psychological processes [F02]

Product Name: Cannabidiol
Product Code: Cannabidiol
INN or Proposed INN: Cannabidiol (CBD)

King's College London

South London and Maudsley NHS Foundation Trust

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

144

Phase 2

United Kingdom

108

EUCTR2018-004156-37-ES
(EUCTR)

11/02/2020

06/11/2019

A clinical study to investigate the efficacy, safety, and tolerability of continuous subcutaneous ND0612 infusion in comparison to oral treatment in subjects with Parkinson’s disease (BouNDless)

Parkinson's disease
MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

NeuroDerm Ltd.

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

350

Phase 3

Serbia;Portugal;United States;Slovakia;Spain;Ukraine;Austria;Russian Federation;Israel;United Kingdom;Italy;France;Hungary;Czech Republic;Canada;Poland;Belgium;Netherlands;Korea, Republic of;Sweden

109

NCT04292223
(ClinicalTrials.gov)

February 10, 2020

28/2/2020

Open-Label Study With Pimavanserin on Activities of Daily Living in Subjects With Parkinson's Disease Psychosis

A 16-Week Open-Label Study of the Effects of Treatment With Pimavanserin on Activities of Daily Living in Subjects With Parkinson's Disease Psychosis

Parkinson Disease Psychosis

Drug: Pimavanserin

ACADIA Pharmaceuticals Inc.

NULL

Recruiting

40 Years

N/A

All

Phase 4

United States

110

EUCTR2019-002949-38-HU
(EUCTR)

06/02/2020

17/12/2019

Patients (18 to 60 years age) who have diagnosis of Parkinson's Disease

Cerevel Therapeutics, LLC

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

522

Phase 3

Serbia;United States;Spain;Ukraine;Israel;Italy;France;Hungary;Czech Republic;Canada;Poland;Australia;Bulgaria;Germany;Sweden

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

111

EUCTR2018-002234-21-GB
(EUCTR)

05/02/2020

04/07/2019

An open-label extension study of the safety and clinical utility of IPX203 in Parkinson’s Disease patients with motor fluctuations

AN OPEN-LABEL EXTENSION STUDY OF THE SAFETY AND CLINICAL UTILITY OF IPX203 IN PARKINSON’S DISEASE PATIENTS WITH MOTOR FLUCTUATIONS

Product Name: IPX203
Product Code: IPX203
INN or Proposed INN: Levodopa
Other descriptive name: LEVODOPA
INN or Proposed INN: Carbidopa
Other descriptive name: ANHYDROUS CARBIDOPA
Product Name: IPX203
Product Code: IPX203
INN or Proposed INN: Levodopa
Other descriptive name: LEVODOPA
INN or Proposed INN: Carbidopa
Other descriptive name: ANHYDROUS CARBIDOPA
Product Name: IPX203
Product Code: IPX203
INN or Proposed INN: Levodopa
Other descriptive name: LEVODOPA
INN or Proposed INN: Carbidopa
Other descriptive name: ANHYDROUS CARBIDOPA
Product Name: IPX203
Product Code: IPX203
INN or Proposed INN: Levodopa
Other descriptive name: LEVODOPA
INN or Proposed INN: Carbidopa

Impax Laboratories, LLC

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

300

Phase 3

France;United States;Czech Republic;Spain;Germany;Italy;United Kingdom

112

NCT04117178
(ClinicalTrials.gov)

February 4, 2020

30/9/2019

Monitoring Anti-Dementia Drugs by Serum Levels

Monitoring Anti-Dementia Drugs by Serum Levels: Importance of Serum Levels, Drug-monitoring, Side-effects, Clinical Efficacy and Compliance (Translation of Official Danish Title)

Dementia;Dementia With Lewy Bodies;Dementia in Parkinsons Disease;Dementia Alzheimers;Alzheimer Disease

Drug: Donepezil;Drug: Memantine;Diagnostic Test: Measurement of serum level of anti-dementia drug

Zealand University Hospital

Epilepsihospitalet Filadelfia

Recruiting

18 Years

N/A

All

110

Phase 4

Denmark

113

NCT04246437
(ClinicalTrials.gov)

February 4, 2020

25/1/2020

[18F]F-DOPA Imaging in Patients With Autonomic Failure

Autonomic Failure;Pure Autonomic Failure;Parkinson Disease;Multiple System Atrophy;Dementia With Lewy Bodies

Drug: [18F]FDOPA;Drug: Carbidopa 200mg oral dose;Drug: Entacapone 400mg oral dose

Daniel Claassen

NULL

Recruiting

18 Years

N/A

All

Phase 1

United States

114

NCT04251585
(ClinicalTrials.gov)

February 4, 2020

28/1/2020

Intranasal Insulin in Parkinson's Disease

Single Center Safety and Tolerability Trial of Intranasal Insulin in Parkinson's Disease

Parkinson Disease

Drug: Regular Novolin R;Drug: Placebo

HealthPartners Institute

NULL

Recruiting

41 Years

89 Years

All

Phase 2

United States

115

EUCTR2018-003941-41-PT
(EUCTR)

03/02/2020

21/08/2019

A Phase 3, 22-week, Multi-center, Randomized Withdrawal Study of TD-9855 in Treating Symptomatic NeurogenicOrthostatic Hypotension in Subjects with Primary Autonomic Failure - Redwood

Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure
MedDRA version: 20.0;Level: LLT;Classification code 10021102;Term: Hypotension orthostatic symptomatic;System Organ Class: 100000004866;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Product Code: TD-9855
INN or Proposed INN: ampreloxetine hydrochloride
Other descriptive name: TD-9855

Theravance Biopharma Ireland Limited

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

258

Phase 3

Portugal;United States;Estonia;Spain;Ukraine;Austria;Russian Federation;Israel;Italy;United Kingdom;France;Hungary;Canada;Poland;Australia;Denmark;Bulgaria;Germany;New Zealand

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

116

NCT04428983
(ClinicalTrials.gov)

February 3, 2020

20/11/2019

The Effect of Hericium Erinaceus Mycelium in Non-motor Symptoms of Parkinson's Disease

Parkinson Disease

Dietary Supplement: Hericium erinaceus mycelium

National Cheng-Kung University Hospital

NULL

Recruiting

50 Years

79 Years

All

N/A

Taiwan

117

EUCTR2018-003289-15-DE
(EUCTR)

28/01/2020

08/02/2019

This study will look at whether an investigational drug called TD-9855 works and how safe it is for treating symptomatic neurogenic orthostatic hypotension (snOH) in people with Parkinson’s disease (PD), multiple system atrophy (MSA) or pure autonomic failure (PAF)

A Phase 3, 4-week, Multicenter, Randomized, Double-blind,Placebo-controlled, Parallel-group Study of TD-9855 inTreating Symptomatic Neurogenic Orthostatic Hypotension inSubjects With Primary Autonomic Failure - Phase 3 Clinical Effect of TD-9855 for Treating snOH in Subjects With Primary Autonomic Failure

Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Product Code: TD-9855
INN or Proposed INN: ampreloxetine
Other descriptive name: TD-9855

Theravance Biopharma Ireland Limited

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

188

Phase 3

Portugal;United States;Estonia;Spain;Ukraine;Austria;Israel;Russian Federation;United Kingdom;Italy;France;Czech Republic;Hungary;Canada;Poland;Denmark;Bulgaria;Germany

118

NCT04322227
(ClinicalTrials.gov)

January 23, 2020

29/1/2020

Study Investigating Effects of Foliglurax in Patients With Parkinson's Disease (PD) and Healthy Subjects

Interventional, Randomized, Double-blind, Placebo-controlled Three-way Crossover Study Investigating the Pharmacodynamic Effects of Two Doses of Foliglurax Using Electroencephalography in Patients With Parkinson's Disease and in Healthy Subjects

Parkinson Disease;Healthy

Drug: Foliglurax 10 mg (treatment A);Drug: Foliglurax 30 mg (treatment B);Drug: Placebo (treatment C)

H. Lundbeck A/S

NULL

Terminated

50 Years

70 Years

All

Phase 1

France

119

NCT04305002
(ClinicalTrials.gov)

January 21, 2020

20/2/2020

Exenatide Treatment in Parkinson's Disease

Effect of Exenatide on Disease Progression in Early Parkinson's Disease

Parkinson Disease

Drug: Exenatide;Drug: Placebo

Center for Neurology, Stockholm

Karolinska Institutet

Recruiting

25 Years

80 Years

All

Phase 2

Sweden

120

NCT04220762
(ClinicalTrials.gov)

January 21, 2020

17/12/2019

A Study to Determine the Dose of WIN-1001X by Evaluating Efficacy and Safety in Early Parkinson's Disease Patients

A Clinical Study to Determine the Optimal Dose of WIN-1001X by Evaluating Its Efficacy and Safety in Patients With Early Parkinson's Disease: Double-blind, Randomized, Placebo-controlled, Multicenter, Phase II Study

Parkinson Disease

Drug: WIN-1001X;Drug: Placebo

Medi Help Line

NULL

Recruiting

30 Years

N/A

All

188

Phase 2

Korea, Republic of

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

121

NCT04232969
(ClinicalTrials.gov)

January 20, 2020

10/1/2020

Exenatide Once Weekly Over 2 Years as a Potential Disease Modifying Treatment for Parkinson's Disease

A Randomised, Double Blind, Parallel Group, Placebo Controlled, Phase 3 Trial of Exenatide Once Weekly Over 2 Years as a Potential Disease Modifying Treatment for Parkinson's Disease

Parkinson's Disease

Drug: Exenatide extended release 2mg (Bydureon)

University College, London

NULL

Recruiting

25 Years

80 Years

All

200

Phase 3

United Kingdom

122

NCT04369430
(ClinicalTrials.gov)

January 16, 2020

13/4/2020

Study Assessing Efficacy and Safety of AKST4290 in Subjects With Parkinson's Disease on Stable Dopaminergic Treatment

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of AKST4290 in Subjects With Parkinson's Disease on Stable Dopaminergic Treatment

Parkinson Disease

Drug: AKST4290;Drug: Placebo

Alkahest, Inc.

NULL

Recruiting

50 Years

80 Years

All

120

Phase 2

United States;Estonia;Germany;Poland;Slovakia;Hungary

123

EUCTR2018-004156-37-GB
(EUCTR)

14/01/2020

13/09/2019

A clinical study to investigate the efficacy, safety, and tolerability of continuous subcutaneous ND0612 infusion in comparison to oral treatment in subjects with Parkinson’s disease (BouNDless)

Product Name: levodopa /carbidopa solution
Product Code: ND0612
INN or Proposed INN: Levodopa
Other descriptive name: LEVODOPA
INN or Proposed INN: carbidopa
Other descriptive name: CARBIDOPA
Product Name: Carbidopa and Levodopa tablets, USP
INN or Proposed INN: Levodopa
Other descriptive name: LEVODOPA
INN or Proposed INN: carbidopa
Other descriptive name: CARBIDOPA

NeuroDerm Ltd.

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

350

Phase 3

Serbia;Portugal;United States;Slovakia;Spain;Ukraine;Austria;Russian Federation;Israel;United Kingdom;Italy;France;Hungary;Czech Republic;Canada;Poland;Belgium;Netherlands;Korea, Republic of;Sweden

124

EUCTR2019-001657-42-SK
(EUCTR)

14/01/2020

01/10/2019

A study to learn how well the drug AKST4290 works and how safeAKST4290 is in people who have Parkinson's disease that are takingdopamine based medication.

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate theEfficacy and Safety of AKST4290 in Subjects with Parkinson's Disease onStable Dopaminergic Treatment. - N/A

Product Name: AKST4290
Product Code: AKST4290
INN or Proposed INN: AKST4290
Other descriptive name: 2-[[[(2R)-1-[1-[(4-CHLORO-3-METHYLPHENYL)METHYL]-4- PIPERIDINYL]-5-OXO-2-PYRROLIDINYL]CARBONYL]AMINO]- N,N,6-TRIMETHYL-4-PYRIDINECARBOXAMIDE,DIHYDROCHLORIDE

Alkahest, Inc.

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

120

Phase 2

United States;Hungary;Estonia;Slovakia;Poland;Germany

125

EUCTR2018-003289-15-PT
(EUCTR)

13/01/2020

21/08/2019

Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Product Code: TD-9855
INN or Proposed INN: ampreloxetine hydrochloride

Theravance Biopharma Ireland Limited

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

188

Phase 3

Portugal;United States;Estonia;Spain;Ukraine;Austria;Russian Federation;Israel;Chile;Italy;United Kingdom;France;Hungary;Mexico;Canada;Argentina;Poland;Peru;Australia;Denmark;Bulgaria;Germany;New Zealand

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

126

NCT04295642
(ClinicalTrials.gov)

January 8, 2020

24/1/2020

A 2-Part Trial of CVL-751 in Subjects With Parkinson's Disease

A 2-Part, Open Label, Adaptive, Single and/or Multiple Oral Dose, Safety, Tolerability, and Food Effect Trial of CVL-751 in Subjects With Parkinson's Disease

Parkinson Disease

Drug: CVL-751

Cerevel Therapeutics, LLC

NULL

Recruiting

45 Years

75 Years

All

Phase 1

United States

127

NCT04223193
(ClinicalTrials.gov)

January 6, 2020

7/1/2020

Flexible-Dose Trial in Early Parkinson's Disease (PD)

A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Flexible-Dose, 27-Week Trial to Evaluate the Efficacy, Safety, and Tolerability of Tavapadon in Early Parkinson's Disease (TEMPO-2 Trial)

Parkinson Disease

Drug: Tavapadon;Drug: Placebo

Cerevel Therapeutics, LLC

NULL

Recruiting

40 Years

80 Years

All

296

Phase 3

United States

128

NCT04127578
(ClinicalTrials.gov)

January 3, 2020

14/10/2019

Phase 1/2a Clinical Trial of PR001A in Patients With Parkinson's Disease With at Least One GBA1 Mutation (PROPEL)

A Phase 1/2a Open-Label Ascending Dose Study to Evaluate the Safety and Effects of PR001A in Patients With Parkinson's Disease With at Least One GBA1 Mutation

Parkinson Disease

Biological: PR001A;Drug: Methylprednisolone;Drug: Sirolimus;Drug: Prednisone

Prevail Therapeutics

NULL

Recruiting

35 Years

80 Years

All

Phase 1;Phase 2

United States

129

NCT04226248
(ClinicalTrials.gov)

January 2, 2020

5/12/2019

CHIEF PD (CHolinesterase Inhibitor to prEvent Falls in Parkinson's Disease)

CHolinesterase Inhibitor to prEvent Falls in Parkinson's Disease: A Phase 3 Randomised, Double-blind Placebo-controlled Trial of Rivastigmine to Prevent Falls in Parkinson's Disease.

Parkinson Disease

Drug: Rivastigmine Transdermal System;Other: Placebo Transdermal System

University of Bristol

Royal United Hospitals Bath NHS Foundation Trust

Recruiting

18 Years

N/A

All

600

Phase 3

United Kingdom

130

NCT04301492
(ClinicalTrials.gov)

January 1, 2020

17/2/2020

Tolerability, Safety and Efficacy of Vortioxetine

Tolerability, Safety and Efficacy of Vortioxetine for Treatment od Depression in Parkinson's Disease: a 16 Week Open Label Study

Depression

Drug: Vortioxetine

IRCCS San Raffaele

NULL

Recruiting

30 Years

80 Years

All

Phase 4

Italy

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

131

NCT03808961
(ClinicalTrials.gov)

January 1, 2020

16/1/2019

Niacin for Parkinsons Disease

NAPS: Niacin for Parkinsons Disease

Parkinson's Disease

Dietary Supplement: Niacin;Dietary Supplement: Niacinamide;Other: Placebo

VA Office of Research and Development

NULL

Recruiting

35 Years

N/A

All

100

N/A

United States

132

NCT04152655
(ClinicalTrials.gov)

January 1, 2020

7/10/2019

A Study of Efficacy and Safety of Idebenone vs. Placebo in Prodromal Parkinson Disease

A Study of Efficacy and Safety of Idebenone vs. Placebo in Prodromal Parkinson Disease (SEASEiPPD)

REM Sleep Behavior Disorder;Parkinson Disease

Drug: Idebenone;Drug: Placebo oral tablet

Second Affiliated Hospital, School of Medicine, Zhejiang University

NULL

Recruiting

18 Years

N/A

All

180

Phase 2;Phase 3

China

133

NCT03446807
(ClinicalTrials.gov)

January 2020

20/2/2018

Safety and Efficacy of Droxidopa for Fatigue in Patients With Parkinsonism

Parkinson Disease;Multiple System Atrophy;Progressive Supranuclear Palsy

Drug: Droxidopa;Drug: Placebo Oral Tablet

Loma Linda University

H. Lundbeck A/S

Not yet recruiting

50 Years

N/A

All

Phase 2

United States

134

NCT04218968
(ClinicalTrials.gov)

December 30, 2019

26/12/2019

Cardiac Changes in Early Parkinson's Disease: A Follow up Study

The Effect of Adrenergic Blocker Therapy on Cardiac and Striatal Transporter Uptake in Pre-Motor and Symptomatic Parkinson's Disease: A Follow up Study

REM Sleep Behavior Disorder;Pre-motor Parkinson Disease;Symptomatic Parkinson Disease

Drug: Carvedilol

Cedars-Sinai Medical Center

NULL

Enrolling by invitation

18 Years

85 Years

All

Phase 2

United States

135

EUCTR2018-004156-37-HU
(EUCTR)

19/12/2019

18/10/2019

A clinical study to investigate the efficacy, safety, and tolerability of continuous subcutaneous ND0612 infusion in comparison to oral treatment in subjects with Parkinson’s disease (BouNDless)

Parkinson's disease
MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

NeuroDerm Ltd.

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

350

Phase 3

Serbia;Portugal;United States;Slovakia;Spain;Ukraine;Austria;Russian Federation;Israel;Italy;United Kingdom;France;Hungary;Czech Republic;Canada;Poland;Belgium;Netherlands;Korea, Republic of;Sweden

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

136

NCT03815916
(ClinicalTrials.gov)

December 19, 2019

18/1/2019

31P-MRS Imaging to Assess the Effects of CNM-Au8 on Impaired Neuronal Redox State in Parkinson's Disease

A Phase 2, Pilot Open Label, Sequential Group, Investigator Blinded Study of Magnetic Resonance Spectroscopy (31P-MRS) to Assess the Effects of CNM-Au8 for the Bioenergetic Improvement of Impaired Neuronal Redox State in Parkinson's Disease

Parkinson's Disease

Drug: Gold Nanocrystals

Clene Nanomedicine

University of Texas Southwestern Medical Center

Recruiting

30 Years

80 Years

All

Phase 2

United States

137

NCT04164121
(ClinicalTrials.gov)

December 17, 2019

12/11/2019

A Clinical Study Trial of Phenlarmide in China

A Randomized, Double-blind, Placebo-controlled, Single-dose, Multiple-dose, Incremental Tolerance and Pharmacokinetics Study of Phenlarmide Tablets in Chinese Healthy Adult Volunteers

Parkinson Disease

Drug: Phenlarmide Tablets;Drug: Placebos

Yiling Pharmaceutical Inc.

NULL

Recruiting

18 Years

65 Years

All

Phase 1

China

138

NCT04097080
(ClinicalTrials.gov)

December 15, 2019

18/9/2019

Comparative Controlled Study of Analgesic, Antiasthenic and Anti-Anxiety Effects of Xenon in Patients With Parkinson's Disease

Parkinson Disease

Drug: NBTX-001;Drug: Standard of Care

Nobilis Therapeutics Inc.

NULL

Recruiting

18 Years

N/A

All

Phase 1

Russian Federation

139

NCT04201093
(ClinicalTrials.gov)

December 13, 2019

13/12/2019

Fixed-Dose Trial in Early Parkinson's Disease (PD)

A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, 27-Week Trial to Evaluate the Efficacy, Safety, and Tolerability of Two Fixed Doses of Tavapadon in Early Parkinson's Disease (TEMPO-1 TRIAL)

Parkinson Disease

Drug: Tavapadon;Drug: Placebo

Cerevel Therapeutics, LLC

NULL

Recruiting

40 Years

80 Years

All

522

Phase 3

United States;Australia

140

NCT04183634
(ClinicalTrials.gov)

December 3, 2019

28/11/2019

An Open, Randomised, Single Dose, 2-period, 2-sequence Crossover Adhesion Study of Two Different Transdermal Patches Containing Rotigotine.

Parkinson Disease

Drug: Rotigotine TTS (Test);Drug: Neupro (Reference)

Sandoz

NULL

Terminated

18 Years

80 Years

All

Phase 1

Germany

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

141

NCT04249544
(ClinicalTrials.gov)

December 3, 2019

28/1/2020

Social Decision Making in Parkinson's Disease

Cognitive and Neural Mechanisms of Impaired Social Decision-Making in Parkinson's Patients Taking Dopamine Agonists

Parkinson Disease

Drug: Pramipexole;Drug: Placebo

Vanderbilt University Medical Center

United States Department of Defense

Recruiting

45 Years

80 Years

All

Phase 1

United States

142

EUCTR2018-003089-14-GB
(EUCTR)

03/12/2019

07/10/2019

Can suppressing the immune system with azathioprine slow down the progression of Parkinson's disease?

Azathioprine Immunosuppression and Disease Modification in Parkinson’s Disease (AZA-PD): a randomised double-blind placebo-controlled phase II trial - AZA-PD

Product Name: Azathioprine
INN or Proposed INN: Azathioprine

Cambridge University Hospitals NHS Foundation Trust and University of Cambridge

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

Phase 2

United Kingdom

143

NCT04191577
(ClinicalTrials.gov)

December 2, 2019

30/10/2019

Study of CVN424 in Parkinson's Disease Patients With Motor Fluctuations

A Phase II, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of CVN424 in Parkinson's Disease Patients With Motor Fluctuations

Parkinson Disease

Drug: CVN424 Low Dose;Drug: CVN424 High Dose;Drug: Placebo

Cerevance Beta, Inc.

NULL

Recruiting

30 Years

80 Years

All

Phase 2

United States

144

NCT04044131
(ClinicalTrials.gov)

December 1, 2019

17/7/2019

Metabolic Cofactor Supplementation in Alzheimer's Disease (AD) and Parkinson's Disease (PD) Patients

A Phase 2, Randomized, Placebo Controlled Study to Evaluate the Efficacy, Tolerability and Safety of Metabolic Cofactor Supplementation in Alzheimer's Disease (AD) And Parkinson's Disease (PD) Patients

Alzheimer Disease;Parkinson Disease

Drug: Metabolic Cofactor Supplementation;Drug: Sorbitol

Istanbul Medipol University Hospital

ScandiBio Therapeutics AB;Alanya Alaaddin Keykubat University;Sahlgrenska University Hospital, Sweden;KTH Royal Institute of Technology

Recruiting

18 Years

N/A

All

120

Phase 2

Turkey

145

NCT03436953
(ClinicalTrials.gov)

December 2019

7/2/2018

A Phase 2 Study of CX-8998 in Adults With Tremor Associated With Parkinson's Disease

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of CX-8998 for Tremor Associated With Parkinson's Disease

Parkinson's Disease;Tremor

Drug: CX-8998;Drug: Placebo

Jazz Pharmaceuticals

NULL

Not yet recruiting

40 Years

80 Years

All

Phase 2

United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

146

EUCTR2018-004156-37-CZ
(EUCTR)

26/11/2019

26/09/2019

A clinical study to investigate the efficacy, safety, and tolerability of continuous subcutaneous ND0612 infusion in comparison to oral treatment in subjects with Parkinson’s disease (BouNDless)

Product Name: levodopa /carbidopa solution
Product Code: ND0612
INN or Proposed INN: Levodopa
Other descriptive name: LEVODOPA
INN or Proposed INN: carbidopa
Other descriptive name: CARBIDOPA
Trade Name: IR LD / CD
Product Name: Carbidopa and Levodopa tablets, USP
INN or Proposed INN: Levodopa
Other descriptive name: LEVODOPA
INN or Proposed INN: carbidopa
Other descriptive name: CARBIDOPA

NeuroDerm Ltd.

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

482

Phase 3

United States;Serbia;Portugal;Czechia;Slovakia;Spain;Ukraine;Austria;Israel;Russian Federation;United Kingdom;Italy;France;Czech Republic;Hungary;Belgium;Poland;Netherlands;Sweden;Korea, Republic of

147

ChiCTR1900027306

2019-11-15

2019-11-08

Application of optical coherence tomography and detection of a-synuclein in tears in the diagnosis of Parkinson's disease

Morphological changes of retina in patients with Parkinson's disease and the role of a-synuclein in retinal damage

Parkinson's disease

Gold Standard:British brain bank Parkinson's disease diagnostic criteria;Index test:Application of optical coherence tomography to observe the retinal structure of the macular area, optic disc area and the expression level of a-synuclein in tears in the diagnosis of Parkinson's disease.;

The First Affiliated Hospital of Chengdu Medical College

NULL

Recruiting

Both

Target condition:85;Difficult condition:85

China

148

NCT03924414
(ClinicalTrials.gov)

November 15, 2019

2/4/2019

Trial of Parkinson's And Zoledronic Acid

TOPAZ: Trial of Parkinson's And Zoledronic Acid A Randomized Placebo-controlled Trial of Zoledronic Acid for the Prevention of Fractures in Patients With Parkinson's Disease

Parkinson Disease;Osteoporosis;Parkinsonism

Drug: Zoledronic Acid 5Mg/Bag 100Ml Inj;Other: Placebo

California Pacific Medical Center Research Institute

National Institute on Aging (NIA);University of California, San Francisco;Duke University;University of Pittsburgh;Parkinson's Foundation

Recruiting

60 Years

N/A

All

3500

Phase 4

United States

149

NCT04148391
(ClinicalTrials.gov)

November 14, 2019

30/10/2019

A Study to Evaluate NYX-458 in Subjects With PD-MCI

A Study to Evaluate NYX-458 in Subjects With Mild Cognitive Impairment Associated With Parkinson's Disease

Parkinson's Disease;Mild Cognitive Impairment

Drug: Placebo Oral Capsule;Drug: NYX-458

Aptinyx

CogState Ltd.;Worldwide Clinical Trials

Active, not recruiting

50 Years

80 Years

All

135

Phase 2

United States

150

NCT04175132
(ClinicalTrials.gov)

November 12, 2019

12/11/2019

Binding of Foliglurax to Regions in the Brain in Healthy Participants and in Patients With Parkinson's Disease (PD)

Interventional, Open-label, Positron Emission Tomography (PET) Study With [11C]-PXT012253 Investigating the Brain mGlu4 Receptor Occupancy, Safety, Tolerability and Pharmacokinetics of Foliglurax in Healthy Subjects and Patients With Parkinson's Disease

Healthy;Parkinson Disease

Drug: foliglurax

H. Lundbeck A/S

NULL

Terminated

50 Years

70 Years

All

Phase 1

Sweden

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

151

ChiCTR1900027210

2019-11-01

2019-11-05

Effects of different anesthesia methods on postoperative delirium in patients with Parkinson's disease and biological markers of postoperative delirium in patients with Parkinson's disease

Delirium

1:Total Intravenous Anesthesia;2:Balance Anesthesia;

Tsinghua University Yuquan Hospital

NULL

Recruiting

Female

1:60;2:60;

China

152

NCT03652870
(ClinicalTrials.gov)

November 1, 2019

8/8/2018

Antidepressants Trial in Parkinson's Disease

A Randomised Placebo-Controlled Trial of Escitalopram and Nortriptyline With Standard Psychological Care for Depression in Parkinson's Disease

Depression;Parkinson Disease

Drug: Nortriptyline;Drug: Escitalopram;Drug: Placebo

University College, London

London North West Healthcare NHS Trust;King's College London;University Hospital Plymouth NHS Trust;NHS Lothian

Not yet recruiting

18 Years

85 Years

All

408

Phase 3

NULL

153

EUCTR2018-002942-35-GB
(EUCTR)

31/10/2019

05/09/2019

A Randomised Controlled Trial of Escitalopram and Nortriptyline compared with placebo, and standard psychological care, for depression in Parkinson’s disease

A Randomised Controlled Trial of Escitalopram and Nortriptyline compared with placebo and standard psychological care for depression in Parkinson’s Disease - Antidepressants Trial in Parkinson's Disease (ADepT-PD)

Depression in Parkinson's disease
MedDRA version: 20.0;Level: PT;Classification code 10012378;Term: Depression;System Organ Class: 10037175 - Psychiatric disorders
MedDRA version: 20.0;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Product Name: Escitalopram
INN or Proposed INN: Escitalopram oxalate
Trade Name: Nortriptyline
Product Name: Nortriptyline
INN or Proposed INN: Nortriptyline hydrochloride

University College London Comprehensive Clinical Trials Unit

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

408

Phase 3

United Kingdom

154

EUCTR2018-003941-41-DK
(EUCTR)

29/10/2019

24/06/2019

A Phase 3, 22-week, Multi-center, Randomized Withdrawal Study of TD-9855 in Treating Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure - Redwood

Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Theravance Biopharma Ireland Limited

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

258

Phase 3

United States;Estonia;Spain;Ukraine;Austria;Russian Federation;Israel;Italy;United Kingdom;France;Hungary;Canada;Poland;Denmark;Australia;Bulgaria;Germany;New Zealand

155

EUCTR2019-000732-26-SE
(EUCTR)

23/10/2019

07/05/2019

Exenatide Treatment in Parkinson's Disease

Effect of Exenatide on disease progression in early Parkinson's disease.

Parkinson's disease;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Trade Name: Bydureon 2 mg powder and solvent for prolonged-release suspension
Product Name: BYDUREON
INN or Proposed INN: EXENATIDE

Stockholm Health Care Services

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

Phase 2

Sweden

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

156

NCT04164758
(ClinicalTrials.gov)

October 23, 2019

13/11/2019

Study to Evaluate Safety and Daytime Sedation in Subjects With Parkinson's Disease With Neuropsychiatric Symptoms Treated With Pimavanserin or Low-Dose Quetiapine

A Pilot Randomized, Double-blind, Placebo-controlled Study to Evaluate Safety and Daytime Sedation in Subjects With Parkinson's Disease With Neuropsychiatric Symptoms Treated With Pimavanserin or Low-Dose Quetiapine

Parkinson's Disease

Drug: Pimavanserin;Other: Placebo;Drug: Quetiapine

ACADIA Pharmaceuticals Inc.

NULL

Terminated

50 Years

85 Years

All

Phase 2

United States

157

EUCTR2019-001657-42-DE
(EUCTR)

22/10/2019

11/06/2019

A study to learn how well the drug AKST4290 works and how safe AKST4290 is in people who have Parkinson's disease that are taking dopamine based medication.

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of AKST4290 in Subjects with Parkinson's Disease on Stable Dopaminergic Treatment - N/A

Alkahest, Inc.

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

120

Phase 2

United States;Estonia;Hungary;Slovakia;Poland;Germany

158

ChiCTR1900026956

2019-10-21

2019-10-27

Minimum alveolar concentration-awake of sevoflurane in patients with Parkinson's disease

Parkinson’s disease

Parkinson’s disease group:Sevoflurane induction;Non-Parkinson’s disease group:Sevoflurane induction;

The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China

NULL

Pending

Both

Parkinson’s disease group:30;Non-Parkinson’s disease group:30;

N/A

China

159

EUCTR2018-003337-15-ES
(EUCTR)

17/10/2019

30/04/2019

A study to look at how safe, and effective the study drug K0706 is in patients with early Parkinson's Disease.

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of K0706 in Subjects With Early Parkinson’s Disease

Early Parkinson’s Disease
MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Sun Pharma Advanced Research Company (SPARC) Limited

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

504

Phase 2

United States;Hungary;Czech Republic;Slovakia;Poland;Spain;India

160

NCT04273932
(ClinicalTrials.gov)

October 17, 2019

31/10/2019

Effects of Lithium Therapy on Blood-based Therapeutic Targets in Parkinson's Disease.

Parkinson Disease

Drug: Lithium

University at Buffalo

NULL

Recruiting

45 Years

80 Years

All

Phase 1

United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

161

NCT04157933
(ClinicalTrials.gov)

October 16, 2019

1/11/2019

Staccato Apomorphine Multi-dose PK and PD in Patients With Parkinson's Disease

A Placebo-Controlled, Double-Blind, Multiple Ascending Dose Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamic Profile of AZ-009 in Subjects With Established Parkinson's Disease

Parkinson's Disease

Drug: 009-A1;Drug: 009-A2;Drug: 009-A3;Drug: 009-A0;Drug: 009-B1 (active --> placebo) crossover;Drug: 009-B2 (placebo --> active) crossover

Alexza Pharmaceuticals, Inc.

NULL

Completed

30 Years

85 Years

All

Phase 1

Netherlands

162

NCT04146454
(ClinicalTrials.gov)

October 14, 2019

16/10/2019

Smartphone-based Wearable Telerehabilitation

A New Smartphone-based Wearable Telerehabilitation System for People With Parkinson's Disease

Parkinson Disease

Other: Smartphone-based balance exercises

University of Houston

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Enrolling by invitation

50 Years

75 Years

All

N/A

United States

163

NCT04165837
(ClinicalTrials.gov)

October 14, 2019

13/11/2019

Safety, Tolerability, and Pharmacokinetics of Oral FB-101 in Healthy Subjects

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending Dose and Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral FB-101 in Healthy Subjects

Parkinson's Disease

Drug: FB-101;Drug: Placebo

1ST Biotherapeutics, Inc.

NULL

Recruiting

19 Years

55 Years

All

Phase 1

United States

164

EUCTR2018-002233-37-GB
(EUCTR)

11/10/2019

14/02/2019

A randomized controlled study to compare the safety and efficacy of IPX203 with immediate-release carbidopa-levodopa in Parkinson's disease patients with motor fluctuations.

Product Name: IPX203
Product Code: IPX203
INN or Proposed INN: Levodopa
Other descriptive name: LEVODOPA
INN or Proposed INN: Carbidopa
Other descriptive name: ANHYDROUS CARBIDOPA
Trade Name: Carbidopa and Levodopa Tablets, USP
Product Name: IR CD-LD (carbidopa-levodopa) tablets
Product Code: IR CD-LD
INN or Proposed INN: Levodopa
INN or Proposed INN: Carbidopa
Other descriptive name: ANHYDROUS CARBIDOPA

Impax Laboratories, LLC

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

510

Phase 3

United States;France;Czech Republic;Poland;Spain;Germany;Italy;United Kingdom

165

JPRN-jRCTs031190115

11/10/2019

PK & PD of coadministration of XOR inhibitor and inosine

Pharmacokinetics and pharmacodynamics study of coadministration of either allopurinol or febuxostat and inosine

Parkinson's disease
neurodegenerative disease

Coadministration of allopurinol and inosine, or coadministration of febuxostat and inosine

Kamatani Naoyuki

NULL

Recruiting

>= 20age old

<= 40age old

Male

Phase 1

Japan

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

166

NCT04575259
(ClinicalTrials.gov)

October 10, 2019

29/9/2020

OLE Study for Patients With Parkinson's Disease With Dementia Enrolled in Study ANAVEX2-73-PDD-001

Open Label Extension Study for Patients With Parkinson's Disease With Dementia Enrolled in Study ANAVEX2-73-PDD-001

Parkinson Disease Dementia

Drug: ANAVEX2-73

Anavex Life Sciences Corp.

Anavex Australia Pty Ltd.;Anavex Germany GmbH

Recruiting

50 Years

85 Years

All

120

Phase 2

Australia;Spain

167

EUCTR2018-003289-15-BG
(EUCTR)

10/10/2019

24/07/2019

Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Product Code: TD-9855
INN or Proposed INN: ampreloxetine hydrochloride

Theravance Biopharma Ireland Limited

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

188

Phase 3

168

EUCTR2018-003941-41-BG
(EUCTR)

10/10/2019

26/06/2019

A Phase 3, 22-week, Multi-center, Randomized Withdrawal Study of TD-9855 in Treating Symptomatic NeurogenicOrthostatic Hypotension in Subjects with Primary Autonomic Failure - Redwood

Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Product Code: TD-9855
INN or Proposed INN: ampreloxetine hydrochloride
Other descriptive name: TD-9855

Theravance Biopharma Ireland Limited

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

258

Phase 3

169

NCT03987750
(ClinicalTrials.gov)

October 2019

12/6/2019

Safinamide for Levodopa-induced Dyskinesia (PD-LID)

A Phase 3, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of 2 Doses of Safinamide Compared to Placebo in the Treatment of LID in PD Patients With Motor Fluctuations

Dyskinesia, Drug-Induced;Parkinson Disease

Drug: Safinamide Methanesulfonate 150mg;Drug: Safinamide Methanesulfonate 100mg;Drug: Safinamide Methanesulfonate matching placebo

Zambon SpA

NULL

Withdrawn

30 Years

N/A

All

Phase 3

NULL

170

NCT03905811
(ClinicalTrials.gov)

September 24, 2019

1/4/2019

Terazosin for Parkinson's Disease

A Pilot Study of Terazosin for Parkinson's Disease

Parkinson Disease

Drug: Terazosin 5 MG;Drug: Placebo oral capsule

Jordan Schultz

University of Iowa

Enrolling by invitation

40 Years

90 Years

All

Phase 1;Phase 2

United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

171

EUCTR2018-002234-21-DE
(EUCTR)

23/09/2019

16/05/2019

An open-label extension study of the safety and clinical utility of IPX203 in Parkinson’s Disease patients with motor fluctuations

AN OPEN-LABEL EXTENSION STUDY OF THE SAFETY AND CLINICAL UTILITY OF IPX203 IN PARKINSON’S DISEASE PATIENTS WITH MOTOR FLUCTUATIONS

Product Name: IPX203
Product Code: IPX203
INN or Proposed INN: Levodopa
Other descriptive name: LEVODOPA
INN or Proposed INN: Carbidopa
Other descriptive name: ANHYDROUS CARBIDOPA
Product Name: IPX203
Product Code: IPX203
INN or Proposed INN: Levodopa
Other descriptive name: LEVODOPA
INN or Proposed INN: Carbidopa
Other descriptive name: ANHYDROUS CARBIDOPA
Product Name: IPX203
Product Code: IPX203
INN or Proposed INN: Levodopa
Other descriptive name: LEVODOPA
INN or Proposed INN: Carbidopa
Other descriptive name: ANHYDROUS CARBIDOPA
Product Name: IPX203
Product Code: IPX203
INN or Proposed INN: Levodopa
Other descriptive name: LEVODOPA
INN or Proposed INN: Carbidopa

Impax Laboratories, LLC

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

300

Phase 3

United States;Estonia;Spain;Ukraine;Lithuania;United Kingdom;Italy;France;Czech Republic;Poland;Romania;Germany;Latvia

172

EUCTR2018-002144-85-NL
(EUCTR)

11/09/2019

27/03/2019

Parkinson's Disease: Safety and Tolerability of 24-Hour Daily Exposure to ABBV-951 by Continuous Subcutaneous Infusion study

Parkinson's Disease
MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

AbbVie Deutschland

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

130

Phase 3

United States;Canada;Spain;Denmark;Australia;Netherlands;United Kingdom;Japan

173

ChiCTR1900025894

2019-09-11

2019-09-12

Parallel randomized controlled trial for Shengyang Yiwei Granule in the treatment of early Parkinson's disease

parkinson disease

experimental group:Parkinson's disease routine medication, plus Shengyang Yiwei granules, water blunt, one dose, morning and evening;control group:Parkinson's disease routine medication, add Buzhong Yiqi granules, water blunt, one dose, morning and evening;

Kaida Wang

NULL

Recruiting

Both

experimental group:45;control group:23;

China

174

NCT04477161
(ClinicalTrials.gov)

September 5, 2019

22/6/2020

Effect of Ketone Esters in Parkinson's Disease

Effect of Ketone Esters on Parkinson Disease: A Pilot, Prospective Trial.

Parkinson Disease;Ketosis

Dietary Supplement: Ketone Ester Elite endurance Nutrition Drink;Other: Stool Sample

University of Florida

NULL

Recruiting

40 Years

75 Years

All

N/A

United States

175

EUCTR2018-003028-35-GB
(EUCTR)

04/09/2019

15/11/2019

A randomised, double blind, parallel group, placebo controlled, Phase 3 trial of exenatide once weekly over 2 years as a potential disease modifying treatment for Parkinson's disease.

A randomised, double blind, parallel group, placebo controlled, Phase 3 trial of exenatide once weekly over 2 years as a potential disease modifying treatment for Parkinson's disease. - Phase 3 Trial of exenatide for Parkinson’s disease

Parkinson's disease
MedDRA version: 21.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's;System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

University College London Comprehensive Clinical Trial Unit

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

200

Phase 3

United Kingdom

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

176

NCT03959540
(ClinicalTrials.gov)

September 2019

23/4/2019

Safety and Effectiveness of Opicapone Plus Standard of Care in Elderly Patients With Parkinson's Disease

A Multinational, Multicentre, Prospective Non-interventional Study to Assess Safety and Effectiveness of Opicapone Plus Standard of Care in Elderly Patients With Parkinson's Disease

Parkinson Disease

Drug: Opicapone;Drug: Levodopa (L-DOPA) + Standard care

Bial - Portela C S.A.

NULL

Not yet recruiting

75 Years

N/A

All

100

NULL

177

NCT04054960
(ClinicalTrials.gov)

September 2019

9/8/2019

A Trial of tPCS on Parkinson's Disease OFF State

Parkinson Disease

Device: Active tPCS;Device: Sham tPCS;Drug: Levodopa tablet

Western University, Canada

NULL

Not yet recruiting

40 Years

80 Years

All

N/A

Canada

178

NCT04075318
(ClinicalTrials.gov)

August 29, 2019

5/8/2019

Study of UB-312 in Healthy Participants and Parkinson's Disease Patients

A Phase 1 Study to Evaluate the Safety, Tolerability, and Immunogenicity of UBITh® PD Immunotherapeutic Vaccine (UB-312) in Healthy Participants and Participants With Parkinson's Disease

Parkinson Disease;Parkinsonism

Biological: UB-312;Biological: Placebo

United Neuroscience Ltd.

Centre for Human Drug Research, Netherlands;Worldwide Clinical Trials

Active, not recruiting

40 Years

85 Years

All

Phase 1

Netherlands

179

NCT04006210
(ClinicalTrials.gov)

August 27, 2019

30/6/2019

A Clinical Trial Investigating the Efficacy, Safety and Tolerability of Continuous Subcutaneous ND0612 Infusion in Comparison to Oral IR-LD/CD in Subjects With Parkinson's Disease Experiencing Motor Fluctuations (BouNDless).

A Multicenter, Randomized, Active-controlled, Double-blind, Double-dummy, Parallel Group Clinical Trial, Investigating the Efficacy, Safety, and Tolerability of Continuous Subcutaneous ND0612 Infusion in Comparison to Oral IR-LD/CD in Subjects With Parkinson's Disease Experiencing Motor Fluctuations (BouNDless)

Parkinson's Disease

Combination Product: ND0612 Solution for SC infusion;Combination Product: Placebo for SC infusion;Drug: Carbidopa and Levodopa 25mg/100mg;Drug: Placebo for Carbidopa and Levodopa 25mg/100mg

NeuroDerm Ltd.

NULL

Recruiting

30 Years

80 Years

All

380

Phase 3

United States;Austria;Belgium;Czechia;France;Hungary;Israel;Italy;Netherlands;Poland;Portugal;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom

180

NCT04070495
(ClinicalTrials.gov)

August 27, 2019

26/8/2019

A Drug Interaction Study of KW-6356 and Clarithromycin or Rifampicin

A Drug Interaction Study of KW-6356 and Clarithromycin or Rifampicin (A Drug Interaction Study With a CYP3A4/5 Inhibitor or Inducer)

Parkinson's Disease

Drug: KW-6356;Drug: Clarithromycin;Drug: Rifampicin

Kyowa Kirin Co., Ltd.

NULL

Completed

20 Years

44 Years

Male

Phase 1

Japan

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

181

EUCTR2018-003941-41-PL
(EUCTR)

23/08/2019

03/06/2019

A Phase 3, 22-week, Multi-center, Randomized Withdrawal Study of TD-9855 in Treating Symptomatic NeurogenicOrthostatic Hypotension in Subjects with Primary Autonomic Failure - Redwood

Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Product Code: TD-9855
INN or Proposed INN: ampreloxetine hydrochloride
Other descriptive name: TD-9855

Theravance Biopharma Ireland Limited

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

258

Phase 3

Portugal;United States;Estonia;Spain;Ukraine;Austria;Israel;Russian Federation;United Kingdom;Italy;France;Hungary;Canada;Poland;Australia;Denmark;Bulgaria;Germany;New Zealand

182

EUCTR2018-002234-21-ES
(EUCTR)

21/08/2019

11/06/2019

An open-label extension study of the safety and clinical utility of IPX203 in Parkinson’s Disease patients with motor fluctuations

AN OPEN-LABEL EXTENSION STUDY OF THE SAFETY AND CLINICAL UTILITY OF IPX203 IN PARKINSON’S DISEASE PATIENTS WITH MOTOR FLUCTUATIONS

Parkinson's disease
MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders
MedDRA version: 20.0;Level: SOC;Classification code 10029205;Term: Nervous system disorders;Classification code 10028035;Term: Movement disorder;System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Impax Laboratories, LLC

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

300

Phase 3

United States;Estonia;Spain;Ukraine;Lithuania;United Kingdom;Italy;France;Czech Republic;Poland;Romania;Germany;Latvia

183

EUCTR2018-002144-85-BE
(EUCTR)

20/08/2019

24/04/2019

Parkinson's Disease: Safety and Tolerability of 24-Hour Daily Exposure to ABBV-951 by Continuous Subcutaneous Infusion study

Product Code: ABBV-951
INN or Proposed INN: Foslevodopa
Other descriptive name: Levodopa -4'-Monophosphate
INN or Proposed INN: Foscarbidopa
Other descriptive name: Carbidopa -4'-Monophosphate

AbbVie Deutschland

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

130

Phase 3

United States;Canada;Spain;Belgium;Denmark;Australia;Germany;Netherlands;United Kingdom;Japan

184

ChiCTR1900025372

2019-08-18

2019-08-25

Digital assessment of Parkinson's disease

Quantitative evaluation of drug response test in patients with Parkinson's disease and the influence of rehabilitation intervention on the evaluation of drug response and the exploration of related mechanisms

Parkinson's disease

1:rehabilitation;1:take levodopa;30:Wear wearable devices;

Tianjin Huanhu Hospital

NULL

Recruiting

Both

1:30;1:30;30:30;

China

185

NCT04062526
(ClinicalTrials.gov)

August 14, 2019

14/8/2019

Evaluation of Neuroinflammation in Parkinson's Disease Using 18F-NOS PET/CT

Evaluation of in Vivo Neuroinflammation in Parkinson's Disease Using 18F-NOS Positron Emission Tomography (PET/CT)

Parkinson Disease;Healthy Volunteer

Drug: [18F]NOS

University of Pennsylvania

NULL

Recruiting

18 Years

75 Years

All

Early Phase 1

United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

186

EUCTR2018-003941-41-ES
(EUCTR)

13/08/2019

11/06/2019

A Phase 3, 22-week, Multi-center, Randomized Withdrawal Study of TD-9855 in Treating Symptomatic NeurogenicOrthostatic Hypotension in Subjects with Primary Autonomic Failure - Redwood

Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Product Code: TD-9855
INN or Proposed INN: ampreloxetine hydrochloride
Other descriptive name: TD-9855

Theravance Biopharma Ireland Limited

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

258

Phase 3

United States;Estonia;Spain;Ukraine;Austria;Russian Federation;Israel;Italy;United Kingdom;France;Hungary;Canada;Poland;Australia;Denmark;Bulgaria;Germany;New Zealand

187

NCT03976349
(ClinicalTrials.gov)

August 12, 2019

4/6/2019

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BIIB094 in Adults With Parkinson's Disease

A Phase 1 Single- and Multiple-Ascending-Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB094 Administered Intrathecally to Adults With Parkinson's Disease

Parkinson's Disease

Drug: BIIB094;Drug: Placebo

Biogen

Ionis Pharmaceuticals, Inc.

Recruiting

35 Years

80 Years

All

Phase 1

United States;Canada;Israel;Norway;Spain;United Kingdom

188

NCT04043338
(ClinicalTrials.gov)

August 11, 2019

24/7/2019

Single Ascending Dose Study Investigating the Safety, Tolerability, and PK of XC130-A10H in Healthy Adult Subjects

A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Single Ascending Dose Study Investigating the Safety, Tolerability, and Pharmacokinetics of XC130-A10H in Healthy Adult Subjects

Parkinson's Disease

Drug: XC130-A10H;Drug: Placebo

Xoc Pharmaceuticals

Celerion

Recruiting

18 Years

75 Years

All

Phase 1

United States

189

EUCTR2018-003941-41-GB
(EUCTR)

09/08/2019

16/05/2019

A Phase 3, 22-week, Multi-center, Randomized Withdrawal Study of TD-9855 in Treating Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure - Redwood

Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Product Code: TD-9855
INN or Proposed INN: ampreloxetine hydrochloride
Other descriptive name: TD-9855

Theravance Biopharma Ireland Limited

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

258

Phase 3

United States;Portugal;Estonia;Spain;Ukraine;Austria;Russian Federation;Chile;Israel;Italy;United Kingdom;France;Hungary;Mexico;Canada;Argentina;Poland;Peru;Australia;Denmark;Bulgaria;Germany;New Zealand

190

NCT03881371
(ClinicalTrials.gov)

August 1, 2019

18/3/2019

A Study to Evaluate the Efficacy and Safety of Safinamide, as add-on Therapy, in Idiopathic Chinese Parkinson's Disease (PD) Patients With Motor Fluctuations Treated With Stable Doses of Levodopa

A Randomised, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Safinamide, as add-on Therapy, in Idiopathic Chinese Parkinson's Disease (PD) Patients With Motor Fluctuations Treated With Stable Doses of Levodopa

Parkinson Disease

Drug: Safinamide;Other: Placebo

Zambon SpA

NULL

Recruiting

18 Years

N/A

All

306

Phase 3

China

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

191

JPRN-UMIN000037422

2019/08/01

01/08/2019

An open-labeled single arm study on improvement of cognitive function by istradefylline for parkinson disease

An open-labeled single arm study on improvement of cognitive function by istradefylline for parkinson disease - An open-labeled single arm study on improvement of cognitive function by istradefylline for parkinson disease

Parkinson disease

Prescription istradefylline 20 mg for 1 month, and if there are no side effects, increase to 40 mg and prescribe for 2 months.

Ichinomiya Nishi Hospital

NULL

Recruiting

40years-old

85years-old

Male and Female

Not selected

Japan

192

ChiCTR1900023725

2019-08-01

2019-06-09

Study for the Role of Butylphthalide in Delaying the progression of Parkinson's disease (PD), Vascular Parkinson's disease (VP) and Parkinsonism-plus syndrome (PPS)

Parkinson's disease (PD), Vascular Parkinson's disease (VP) and Parkinsonism-plus syndrome (PPS)

PD-Placebo:Placebo;PD-Butylphthalide:Butylphthalide;VP-Placebo:Placebo;VP-Butylphthalide:Butylphthalide;MSA-Placebo:Placebo;MSA-Butylphthalide :Butylphthalide ;PSP-Placebo:Placebo;PSP-Butylphthalide:Butylphthalide;

Zhujiang Hospital of Southern Medical University

NULL

Pending

Male

PD-Placebo:50;PD-Butylphthalide:50;VP-Placebo:50;VP-Butylphthalide:50;MSA-Placebo:50;MSA-Butylphthalide :50;PSP-Placebo:50;PSP-Butylphthalide:50;

China

193

JPRN-UMIN000037421

2019/08/01

01/08/2019

A study on improvement of cognitive function by istradefylline for parkinson disease

An open-labeled single arm study on improvement of cognitive function by istradefylline for parkinson disease - A study on improvement of cognitive function by istradefylline for parkinson disease

Parkinson disease

Prescription istradefylline 20 mg for 1 month. If there are no side effects, We increase to 40 mg and prescribe for 2 months.
The assessments will be made in all patients participating the study, patients with MMSE scores of 26 or more, patients with MMSE score of less than 26.

Ichinomiya Nishi Hospital

NULL

Recruiting

40years-old

85years-old

Male and Female

Not selected

Japan

194

EUCTR2018-003941-41-HU
(EUCTR)

30/07/2019

01/08/2019

A Phase 3, 22-week, Multi-center, Randomized Withdrawal Study of TD-9855 in Treating Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure - Redwood

Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Theravance Biopharma Ireland Limited

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

258

Phase 3

United States;Estonia;Spain;Ukraine;Austria;Russian Federation;Israel;Italy;United Kingdom;France;Hungary;Canada;Poland;Australia;Denmark;Bulgaria;Germany;New Zealand

195

EUCTR2018-002144-85-GB
(EUCTR)

29/07/2019

13/03/2019

Parkinson's Disease: Safety and Tolerability of 24-Hour Daily Exposure to ABBV-951 by Continuous Subcutaneous Infusion study

Product Code: ABBV-951
INN or Proposed INN: Foslevodopa
Other descriptive name: Levodopa -4'-Monophosphate
INN or Proposed INN: Foscarbidopa
Other descriptive name: Carbidopa -4'-Monophosphate

AbbVie Deutschland

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

130

Phase 3

United States;Canada;Belgium;Spain;Denmark;Australia;Germany;Netherlands;Japan;United Kingdom

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

196

NCT04056689
(ClinicalTrials.gov)

July 23, 2019

12/8/2019

Study to Evaluate DNL151 in Subjects With Parkinson's Disease

A Phase 1b, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Determine the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL151 in Subjects With Parkinson's Disease

Parkinson's Disease

Drug: DNL151;Drug: Placebo

Denali Therapeutics Inc.

NULL

Active, not recruiting

30 Years

75 Years

All

Phase 1

United States;Belgium;Netherlands;United Kingdom

197

NCT03956979
(ClinicalTrials.gov)

July 22, 2019

17/5/2019

A Study in Parkinson's Disease in paTients With mOderate to seveRe dyskInesiA

A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study in Parkinson's Disease Patients With Moderate to Severe Dyskinesia to Assess the Efficacy and Safety/Tolerability of Two Dose Combinations of JM-010

Dyskinesias

Drug: JM -010 group A;Drug: JM -010 group B;Drug: Placebos

Contera Pharma

Bukwang Pharmaceutical

Recruiting

18 Years

80 Years

All

Phase 2

Germany

198

EUCTR2018-003289-15-PL
(EUCTR)

19/07/2019

07/05/2019

Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Product Code: TD-9855
INN or Proposed INN: ampreloxetine chydrochloride
Other descriptive name: TD-9855

Theravance Biopharma Ireland Limited

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

188

Phase 3

United States;Portugal;Czechia;Estonia;Spain;Ukraine;Austria;Russian Federation;Chile;Israel;United Kingdom;Italy;France;Hungary;Mexico;Canada;Argentina;Poland;Peru;Australia;Denmark;Bulgaria;Germany;New Zealand

199

NCT03575195
(ClinicalTrials.gov)

July 15, 2019

21/6/2018

Microbiota Intervention to Change the Response of Parkinson's Disease

Parkinson Disease

Drug: Rifaximin;Other: Placebo

University of California, San Francisco

Nova Southeastern University;Gateway Institute for Brain Research

Recruiting

30 Years

N/A

All

Phase 1;Phase 2

United States

200

EUCTR2018-002144-85-ES
(EUCTR)

11/07/2019

12/04/2019

Parkinson's Disease: Safety and Tolerability of 24-Hour Daily Exposure to ABBV-951 by Continuous Subcutaneous Infusion study

Product Code: ABBV-951
INN or Proposed INN: Foslevodopa
Other descriptive name: Levodopa -4'-Monophosphate
INN or Proposed INN: Foscarbidopa
Other descriptive name: Carbidopa -4'-Monophosphate

AbbVie Deutschland

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

130

Phase 3

United States;Canada;Spain;Denmark;Australia;Netherlands;United Kingdom;Japan

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

201

EUCTR2018-002144-85-DK
(EUCTR)

08/07/2019

14/03/2019

Parkinson's Disease: Safety and Tolerability of 24-Hour Daily Exposure to ABBV-951 by Continuous Subcutaneous Infusion study

Product Code: ABBV-951
INN or Proposed INN: Foslevodopa
Other descriptive name: Levodopa -4'-Monophosphate
INN or Proposed INN: Foscarbidopa
Other descriptive name: Carbidopa -4'-Monophosphate

AbbVie Deutschland

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

130

Phase 3

United States;Canada;Spain;Australia;Denmark;Netherlands;United Kingdom;Japan

202

EUCTR2018-003941-41-EE
(EUCTR)

04/07/2019

29/05/2019

A Phase 3, 22-week, Multi-center, Randomized Withdrawal Study of TD-9855 in Treating Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure - Redwood

Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Theravance Biopharma Ireland Limited

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

258

Phase 3

United States;Estonia;Spain;Ukraine;Austria;Russian Federation;Israel;Italy;United Kingdom;France;Hungary;Canada;Poland;Australia;Denmark;Bulgaria;Germany;New Zealand

203

EUCTR2018-003289-15-DK
(EUCTR)

02/07/2019

14/03/2019

Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Product Code: TD-9855
INN or Proposed INN: ampreloxetine hydrochloride

Theravance Biopharma Ireland Limited

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

188

Phase 3

204

ChiCTR1900021708

2019-07-01

2019-03-05

Study for the brain network mechanism of pramipexole in the treatment of tremor-type PD patients based on DRD3 Ser9Gly polymorphi

Study for the brain network mechanism of pramipexole in the treatment of tremor-type PD patients based on DRD3 Ser9Gly polymorphism

Parkinson's Disease

Healthy control group:No;tremor-dominant phenotype PD patients group:pramipexole;

Department of Neurology, Brain Hospital Affiliated to Nanjing Medical University

NULL

Pending

Both

Healthy control group:80;tremor-dominant phenotype PD patients group:80;

China

205

NCT03977441
(ClinicalTrials.gov)

July 2019

12/5/2019

the Efficacy and Safety of Agomelatine in the Patients With Parkinson's Disease

A Multicenter, Randomized, Double-blind, Placebo-controlled Study: Evaluation of the Efficacy and Safety of Agomelatine in the Treatment of Sleep Disorders and Depression in Patients With Parkinson's Disease

Parkinson Disease;Depression;Sleep Disorders;Circadian Rhythm Disorders

Drug: Agomelatine or PIacebo

Second Affiliated Hospital of Soochow University

NULL

Not yet recruiting

30 Years

75 Years

All

240

Phase 4

NULL

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

206

EUCTR2018-003219-23-GB
(EUCTR)

28/06/2019

04/06/2019

CHIEF-PD (CHolinesterase Inhibitor to prEvent Falls in Parkinson’s Disease)

CHIEF-PD (CHolinesterase Inhibitor to prEvent Falls in Parkinson’s Disease): A phase 3 randomised double-blind placebo-controlled trial of rivastigmine to prevent falls in Parkinson’s disease - CHIEF-PD

This trial will investigate the effectiveness of Rivastigmine on prevention of falls in patients with Parkinson's disease
MedDRA version: 21.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's;System Organ Class: 10029205 - Nervous system disorders
MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Trade Name: Rivastigmin Luye Transdermal Patches - 4.6mg/24h
Product Name: Rivastigmin Luye Transdermal Patches - 4.6mg/24h
Product Code: N/A
INN or Proposed INN: Rivastigmine
Other descriptive name: Ethylmethylcarbamic acid 3-[(1S)-1-(dimethylamino)ethyl]phenyl ester (**See other 2 names below)
Trade Name: Rivastigmine Luye Transdermal Patch- 9.5mg/24h
Product Name: Rivastigmine Luye Transdermal Patch- 9.5mg/24h
INN or Proposed INN: Rivastigmine
Other descriptive name: Ethylmethylcarbamic acid 3-[(1S)-1-(dimethylamino)ethyl]phenyl ester (**See other 2 names below)
Product Name: Rivastigmine transdermal system 13.3 mg/24 h
Product Code: RIV-TDS 13.3 mg/24 h
INN or Proposed INN: Rivastigmine
Other descriptive name: Ethylmethylcarbamic acid 3-[(1S)-1-(dimethylamino)ethyl]phenyl ester (**See other 2 names below)

University of Bristol

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

600

Phase 3

United Kingdom

207

EUCTR2018-003289-15-ES
(EUCTR)

26/06/2019

27/06/2019

A Phase 3, 4-week, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of TD-9855 in Treating Symptomatic Neurogenic Orthostatic Hypotension in Subjects With Primary Autonomic Failure - Phase 3 Clinical Effect of TD-9855 for Treating snOH in Subjects With Primary Autonomic Failure

Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Theravance Biopharma Ireland Limited

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

188

Phase 3

United States;Estonia;Spain;Ukraine;Austria;Russian Federation;Israel;Italy;United Kingdom;France;Czech Republic;Hungary;Canada;Denmark;Germany

208

EUCTR2018-003337-15-HU
(EUCTR)

18/06/2019

12/04/2019

A study to look at how safe, and effective the study drug K0706 is in patients with early Parkinson's Disease.

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of K0706 in Subjects With Early Parkinson’s Disease

Sun Pharma Advanced Research Company (SPARC) Limited

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

504

Phase 2

United States;Hungary;Slovakia;Poland;Spain;India

209

EUCTR2018-002234-21-CZ
(EUCTR)

14/06/2019

30/05/2019

An open-label extension study of the safety and clinical utility of IPX203 in Parkinson’s Disease patients with motor fluctuations

AN OPEN-LABEL EXTENSION STUDY OF THE SAFETY AND CLINICAL UTILITY OF IPX203 IN PARKINSON’S DISEASE PATIENTS WITH MOTOR FLUCTUATIONS

Parkinson's disease
MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders
MedDRA version: 20.0;Level: SOC;Classification code 10029205;Term: Nervous system disorders;Classification code 10028035;Term: Movement disorder;System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Impax Laboratories, LLC

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

300

Phase 3

United States;Estonia;Spain;Ukraine;Lithuania;United Kingdom;Italy;France;Czech Republic;Poland;Romania;Germany;Latvia

210

NCT03938922
(ClinicalTrials.gov)

June 13, 2019

18/4/2019

A Study to Evaluate ENT-01 for the Treatment of Parkinson's Disease Dementia

A Multicenter, Open Label Study to Evaluate Tolerability and Efficacy of Orally Administered ENT-01 for the Treatment of Parkinson's Disease Dementia.

Parkinson Disease;Dementia

Drug: Active Investigational Treatment ENT-01

Enterin Inc.

NULL

Active, not recruiting

30 Years

90 Years

All

Phase 1

United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

211

NCT03939559
(ClinicalTrials.gov)

June 10, 2019

3/5/2019

The Efficiency of Home Based Dual Task Training in Parkinson Disease

Parkinson Disease

Procedure: Static, dynamic and functional balance exercises;Procedure: Static, dynamic and functional balance exercises with dual task

Istanbul University-Cerrahpasa

NULL

Not yet recruiting

30 Years

80 Years

All

N/A

NULL

212

EUCTR2018-003337-15-SK
(EUCTR)

05/06/2019

26/04/2019

A study to look at how safe, and effective the study drug K0706 is in patients with early Parkinson's Disease.

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of K0706 in Subjects With Early Parkinson’s Disease

Early Parkinson’s Disease
MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Product Code: K0706
INN or Proposed INN: K0706
Other descriptive name: K0706
Product Code: K0706
INN or Proposed INN: K0706
Other descriptive name: K0706
Product Code: K0706
INN or Proposed INN: K0706
Other descriptive name: K0706
Product Code: K0706
INN or Proposed INN: K0706
Other descriptive name: K0706

Sun Pharma Advanced Research Company (SPARC) Limited

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

504

Phase 2

United States;Hungary;Slovakia;Poland;Spain;India

213

EUCTR2018-003289-15-HU
(EUCTR)

04/06/2019

05/04/2019

A Phase 3, 4-week, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of TD-9855 in Treating Symptomatic Neurogenic Orthostatic Hypotension in Subjects With Primary Autonomic Failure - Phase 3 Clinical Effect of TD-9855 for Treating snOH in Subjects With Primary Autonomic Failure

Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Theravance Biopharma Ireland Limited

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

188

Phase 3

United States;Estonia;Spain;Ukraine;Austria;Russian Federation;Israel;Italy;United Kingdom;France;Hungary;Czech Republic;Canada;Denmark;Germany

214

NCT04389762
(ClinicalTrials.gov)

June 4, 2019

30/4/2020

PS128 May Improve Off Duration on Parkinson's Disease

Lactobacillus Plantarum PS128 May Improve Off Duration in Parkinson's Disease: a Pilot Study

Parkinson Disease

Dietary Supplement: daily ingestion of Lactobacillus plantarum PS128

Professor Lu Neurological Clinic

NULL

Completed

40 Years

80 Years

All

N/A

Taiwan

215

JPRN-UMIN000036952

2019/06/04

04/06/2019

A PET study with 18F-FDOPA and 11C-Raclopride on Parkinson's disease and related disorders patients.

A PET study with 18F-FDOPA and 11C-Raclopride on Parkinson's disease and related disorders patients. - A PET study with 18F-FDOPA and 11C-Raclopride on Parkinson's disease and related disorders patients.

Patients who are suspected Parkinson's disease or related disorders, including dementia with Lewy bodies, multiple system atrophy, progressive supranuclear palsy, corticobasal degeneration, frontotemporal lobe degeneration, vascular parkinsonism, drug-induced parkinsonism, normal pressure hydrocephalus, and others.

18F-FDOPA, 11C-Raclopride PET

Nagoya City Rehabilitation Agency

NULL

Recruiting

20years-old

Not applicable

Male and Female

150

Not applicable

Japan

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

216

ChiCTR1900022534

2019-06-01

2019-04-15

Efficacy of entacapone and pramipexole for non-motor symptoms of Parkinson’s disease: a prospective randomized controlled trial

non-motor symptoms of Parkinson’s disease

entacapone group:Patients in the entacapone group will be administered entacapone (Novartis; import drug registration certificate number: H20160680), 10 times per day, 200 mg each time, for 3 weeks. ;pramipexole group:Patients in the pramipexole group will be administered pramipexole (Boehringer-Ingelheim; import drug registration certificate number: 20140918) , 3 times per day, 1 mg each time, for 3 weeks.;

Geriatric Hospital of Hainan

NULL

Pending

Both

entacapone group:194;pramipexole group:194;

N/A

China

217

NCT04064294
(ClinicalTrials.gov)

June 1, 2019

19/8/2019

Preventing Levodopa Induced Dyskinesia in Parkinson's Disease With HMG-CoA Reductase Inhibitors

Preventing Levodopa Induced Dyskinesia in Parkinson?s Disease With Statins

Parkinson Disease;Dyskinesia, Drug-Induced

Drug: Intravenous Infusion

VA Office of Research and Development

Oregon Health and Science University

Recruiting

50 Years

N/A

All

120

United States

218

JPRN-UMIN000036908

2019/05/31

31/05/2019

A dementia study by 11C-PiB, 18F-FDG PET

A dementia study by 11C-PiB, 18F-FDG PET - A dementia study by 11C-PiB, 18F-FDG PET

mild cognitive impairment, Alzheimer's disease, dementia with Lewy bodies, cerebrovascular dementia, frontotemporal degeneration, progressive supranuclear palsy, corticobasal degeneration, Parkinson's disease with dementia, other neurodegenerative diseases, normal pressure hydrocephalus, hypoxic encephalopathy, brain tumor, brain injury etc.

11C-PiB, 18F-FDG PET

Nagoya City Rehabilitation Agency

NULL

Recruiting

20years-old

Not applicable

Male and Female

150

Not applicable

Japan

219

JPRN-jRCTs031180248

29/05/2019

12/03/2019

N/A

Intervention study for the effect of Istradefylline on adjustment of Levodopa in Parkinson's Disease - Istra adjust PD

Parkinson's disease

Arm with treatment of Istradefylline and levodopa
Treatment with Istradefylline will be started at a dose of
20 mg administered once daily at Week 0. The dose of
Istradefylline will be increased to 40 mg once daily if
the patient has no tolerability issues and still has motor
symptoms at Week 1. Dose reduction is possible if the
patient has tolerability issues.
Patients will visit every 4 weeks from the following day
of Week0, and 50mg levodopa will be added of if CGI-S score
>=4 every time. Dose reduction is possible if the patient
has tolerability issues.
Arm without treatment of Istradefylline
50mg levodopa will be added at Week 0. Patients will visit
every 4 weeks from the following day of Week0, and 50mg
levodopa will be added of if CGI-S score >=4 every time.
Dose reduction is possible if the patient has tolerability
issues.

Hatano Taku

Kyowa Kirin Co., Ltd

Recruiting

>= 30age old

<= 84age old

Both

111

N/A

Japan

220

NCT03971617
(ClinicalTrials.gov)

May 29, 2019

30/5/2019

Clinical Trial to Evaluate the Safety and Tolerability of Hydrogen in Patients With Parkinson's Disease

A Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Safety and Tolerability of Molecular Hydrogen in Patients With Parkinson's Disease

Parkinson Disease

Drug: Hydrogen;Drug: Placebo oral tablet

Stony Brook University

NULL

Recruiting

40 Years

80 Years

All

Phase 2;Phase 3

United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

221

NCT03970798
(ClinicalTrials.gov)

May 22, 2019

23/5/2019

A Drug Interaction Study of KW-6356 With Midazolam, Caffeine, or Rosuvastatin

Parkinson's Disease

Drug: Midazolam;Drug: Caffeine;Drug: Rosuvastatin;Drug: KW-6356

Kyowa Kirin Co., Ltd.

NULL

Completed

20 Years

44 Years

Male

Phase 1

Japan

222

EUCTR2018-003289-15-AT
(EUCTR)

15/05/2019

22/03/2019

Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Product Code: TD-9855
INN or Proposed INN: ampreloxetine hydrochloride
Other descriptive name: TD-9855

Theravance Biopharma Ireland Limited

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

188

Phase 3

223

NCT03552068
(ClinicalTrials.gov)

May 15, 2019

17/5/2018

Study of Clonidine Efficacy for the Treatment of Impulse Control Disorders in Parkinson's Disease:

Study of Clonidine Efficacy for the Treatment of Impulse Control Disorders in Parkinson's Disease: A Pilot Double Blind Randomized Trial

Parkinson's Disease;Mpulse Control Disorders

Drug: placebo;Drug: Clonidine

Hospices Civils de Lyon

NULL

Recruiting

30 Years

80 Years

All

Phase 2

France

224

NCT03671785
(ClinicalTrials.gov)

May 15, 2019

12/9/2018

Study of the Fecal Microbiome in Patients With Parkinson's Disease

A Prospective, Randomized, Placebo-Controlled Pilot Study to Characterize the Intestinal Microbiome and to Evaluate the Safety and Fecal Microbiome Changes Following Twice Weekly Administration of Lyophilized PRIM-DJ2727 or Placebo Given Orally for 12 Weeks in Subjects With Parkinson's Disease

Parkinson Disease

Drug: PRIM-DJ2727;Drug: Placebo oral capsule

The University of Texas Health Science Center, Houston

Kelsey Research Foundation

Recruiting

55 Years

75 Years

All

Phase 1

United States

225

NCT03693872
(ClinicalTrials.gov)

May 15, 2019

1/10/2018

Evaluation of the Nonmotor Symptomatology of Parkinsonian Patients Treated With Two Strategies Related to Apomorphine Pump Therapy in French Hospitals

Parkinson Disease

Drug: Apomorphine;Drug: Dopaminergic Agonist + Apomorphine

Rennes University Hospital

NULL

Recruiting

18 Years

N/A

All

N/A

France

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

226

NCT04293159
(ClinicalTrials.gov)

May 14, 2019

19/2/2020

Effect of Probiotic on Constipation in Patients With Parkinson's Disease

Effect of Probiotic on Constipation and on Neuropsychological Performance in Patients With Parkinson's Disease

Parkinson Disease;Constipation

Dietary Supplement: Lactobacillus casei DG (Enterolactis duo®)

University of Salerno

Roberto Erro;Maria Teresa Pellecchia;Antonella Santonicola;Carolina Ciacci

Recruiting

18 Years

75 Years

All

N/A

Italy

227

NCT03958708
(ClinicalTrials.gov)

May 13, 2019

14/5/2019

Modulation of Gut Microbiota by Rifaximin in PD Patients

Parkinson Disease;Inflammation

Drug: Rifaximin 550 MG

Taipei Medical University Shuang Ho Hospital

NULL

Recruiting

45 Years

70 Years

All

Phase 1;Phase 2

Taiwan

228

NCT03970239
(ClinicalTrials.gov)

May 13, 2019

6/5/2019

Serotonin in Impulse Control Disorders in Parkinson's Disease

Role of the Serotoninergic System in Impulse Control Disorders in Parkinson's Disease

Parkinson Disease;Impulse Control Disorders

Drug: Positron Emission Tomography using [11 Carbon]-3-amino-4-(2-dimethylaminomethylphenylsulfanyl)-benzonitrile ([11C]-DASB) and [18 Fluorine]-altanserin ([18F]-altanserin);Drug: Positron Emission Tomography using [18 Fluorine]-altanserin ([18F]-altanserin)

Hospices Civils de Lyon

NULL

Recruiting

30 Years

80 Years

All

N/A

France

229

EUCTR2018-003289-15-GB
(EUCTR)

08/05/2019

28/12/2018

A Phase 3, 4-week, Multicenter, Randomized, Double-blind,Placebo-controlled,Parallel-group Study of TD-9855 in Treating Symptomatic Neurogenic Orthostatic Hypotension in Subjects With Primary Autonomic Failure - Sequoia study

Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Product Code: TD-9855
INN or Proposed INN: ampreloxetine hydrochloride
Other descriptive name: TD-9855

Theravance Biopharma Ireland Limited

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

188

Phase 3

230

NCT04566341
(ClinicalTrials.gov)

May 4, 2019

11/8/2020

Study of Gastrointestinal Dysfunction and Enteric Neural Pathology in Patients With Parkinson's Disease

Parkinson Disease;Parkinson

Device: OCT - TCE

Massachusetts General Hospital

NULL

Recruiting

40 Years

85 Years

All

United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

231

NCT03840837
(ClinicalTrials.gov)

May 2, 2019

11/2/2019

Cholinergic Neurotransmission in Mobility and Cognition in Parkinson Disease

Cholinergic Neurotransmission - A Common Underlying Mechanism of Cognitive and Gait Impairment in Parkinson Disease

Parkinson Disease

Drug: Rivastigmine transdermal patch

University of Maryland, Baltimore

National Institute on Aging (NIA)

Recruiting

18 Years

N/A

All

100

Phase 4

United States

232

EUCTR2019-000247-27-FR
(EUCTR)

02/05/2019

05/03/2019

Study to demonstrate an at least equivalent performance of a new test in brain imaging test compared to the reference examination to establish the differential diagnosis between Parkinson's Disease and Essential Tremor.

Non-inferiority study of the molecular imaging of dopamine transporters using [123I]-FP/CIT-SPECT and [18F] LBT-999-PET to distinguish between Parkinson’s Disease and Essential Tremor. - DATTEP

Patients suffering from an essential tremor or with Parkinson's disease.
MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders
MedDRA version: 20.0;Classification code 10015496;Term: Essential tremor;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Diagnosis [E01]

Trade Name: DaTSCAN 74 MBq/ml solution for injection
Product Code: [18F] LBT-999

ZIONEXA

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

112

Phase 3

France

233

ChiCTR1900022715

2019-05-01

2019-04-23

Accurate treatment under the multidisciplinary cooperative diagnosis and treatment model of Parkinson's disease

Parkinson's Disease

Anteversion group:DBS;Balance dysfunction group:DBS;Gait abnormality group:DBS;

Tianjin Huanhu Hospital

NULL

Recruiting

Both

Anteversion group:40;Balance dysfunction group:40;Gait abnormality group:40;

N/A

China

234

NCT03781167
(ClinicalTrials.gov)

April 29, 2019

18/12/2018

A Study to Evaluate the Safety and Tolerability of ABBV-951 in Subjects With Parkinson's Disease (PD)

A 52-Week, Open-label, Single-arm Study to Evaluate the Safety and Tolerability of 24-hour Daily Exposure of Continuous Subcutaneous Infusion of ABBV-951 in Subjects With Parkinson's Disease

Parkinson's Disease (PD)

Drug: ABBV-951

AbbVie

NULL

Recruiting

30 Years

N/A

All

130

Phase 3

United States;Australia;Belgium;Canada;Denmark;Germany;Italy;Japan;Netherlands;Russian Federation;Spain;Sweden;United Kingdom;France

235

NCT03899324
(ClinicalTrials.gov)

April 26, 2019

29/3/2019

Evaluation of the Efficacy and Safety of Bumetanide in Parkinson's Disease

A Randomized Double-blind Placebo-controlled Multicenter Proof-of-concept Trial to Assess the Efficacy and Safety of Bumetanide in Parkinson's Disease

Parkinson Disease

Drug: Bumetanide white, oblong, scored tablet;Drug: Placebo white, oblong, scored tablet

B&A Therapeutics

NULL

Recruiting

40 Years

80 Years

All

Phase 2

France

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

236

JPRN-JapicCTI-194763

22/4/2019

20/05/2019

Safety and PK study of LY03003

An open-label study in Japanese patients with Parkinson's disease to evaluate the safety, pharmacokinetics and preliminary efficacy of LY03003 following intramuscular injections and its comparative bioavailability to Rotigotine transdermal patch.

Parkinson's Disease

Intervention name : Rotigotine
INN of the intervention : Rotigotine
Dosage And administration of the intervention : LY03003 IM injections 14, 28 and 56 mg/week.
Control intervention name : Rotigotine
INN of the control intervention : Rotigotine
Dosage And administration of the control intervention : Rotigotine transdermal patch applications 4.5, 9 and 18 mg/day.

Shandong Luye Pharmaceutical Co., Ltd./CMIC Co., Ltd.

NULL

complete

BOTH

Phase 1

Japan

237

EUCTR2018-002233-37-DE
(EUCTR)

17/04/2019

08/01/2019

A randomized controlled study to compare the safety and efficacy of IPX203 with immediate-release carbidopa-levodopa in Parkinson's disease patients with motor fluctuations.

Product Name: IPX203
Product Code: IPX203
INN or Proposed INN: Levodopa
Other descriptive name: LEVODOPA
INN or Proposed INN: Carbidopa
Other descriptive name: ANHYDROUS CARBIDOPA
Trade Name: Carbidopa and Levodopa Tablets, USP
Product Name: IR CD-LD (carbidopa-levodopa) tablets
Product Code: IR CD-LD
INN or Proposed INN: Levodopa
INN or Proposed INN: Carbidopa
Other descriptive name: ANHYDROUS CARBIDOPA

Impax Laboratories, LLC

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

510

Phase 3

United States;France;Czechia;Poland;Spain;Germany;United Kingdom;Italy

238

NCT04420910
(ClinicalTrials.gov)

April 15, 2019

4/6/2020

Non-motor Symptoms, Balance, Muscle Strength, and Functional Mobility in Patients With Parkinson's Disease

Investigation of Non-motor Symptoms, Balance, Muscle Strength, and Functional Mobility in Patients With Parkinson's Disease

Parkinson Disease;Balance;Muscle Strength;Mobility;Non-motor Symptoms

Other: Non-Motor Symptoms;Other: Balance;Other: Lower Limb Strength;Other: Functional mobility

Ankara Yildirim Beyazit University

NULL

Completed

50 Years

65 Years

All

Turkey

239

EUCTR2018-003289-15-EE
(EUCTR)

11/04/2019

30/01/2019

A Phase 3, 4-week, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of TD-9855 in Treating Symptomatic Neurogenic Orthostatic Hypotension in Subjects With Primary Autonomic Failure - Phase 3 Clinical Effect of TD-9855 for Treating snOH in Subjects With Primary Autonomic Failure

Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Theravance Biopharma Ireland Limited

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

188

Phase 3

United States;Estonia;Spain;Ukraine;Austria;Russian Federation;Israel;Italy;United Kingdom;France;Hungary;Canada;Poland;Australia;Denmark;Bulgaria;Germany;New Zealand

240

NCT03661125
(ClinicalTrials.gov)

April 11, 2019

4/9/2018

SRC Inhibition as a Potential Target for Parkinson's Disease Psychosis

A Randomised, Balanced, Double-blind Two-way Crossover Design Study to Evaluate the Effects of SRC Kinase Inhibitor, Saracatinib, on Brain Activity Associated With Visual Processing in Patients With Parkinson's Disease Psychosis.

Parkinson Disease Psychosis

Drug: Saracatinib;Drug: Placebo Oral Tablet

King's College London

AstraZeneca;King's College Hospital NHS Trust

Recruiting

40 Years

N/A

All

Early Phase 1

United Kingdom

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

241

NCT03841604
(ClinicalTrials.gov)

April 9, 2019

30/1/2019

Effect of Safinamide on Parkinson's Disease Related Chronic Pain

A Randomised, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Safinamide 100mg Once Daily, as add-on Therapy, in Idiopathic Parkinson's Disease (PD) Patients With Motor Fluctuations and PD Related Chronic Pain

Idiopathic Parkinson Disease

Drug: Safinamide Methanesulfonate;Drug: Safinamide methanesulfonate matching placebo

Zambon SpA

NULL

Recruiting

30 Years

N/A

All

177

Phase 4

Austria;France;Germany;Italy;Spain

242

NCT03775096
(ClinicalTrials.gov)

April 4, 2019

9/12/2018

Adrenergic Blockers for Cardiac Changes in Early Parkinson's Disease

The Effect of Adrenergic Blocker Therapy on Cardiac and Striatal Transporter Uptake in Pre-Motor and Symptomatic Parkinson's Disease

REM Sleep Behavior Disorder;Pre-motor Parkinson Disease;Symptomatic Parkinson Disease

Drug: Carvedilol

Michele Tagliati, MD

NULL

Recruiting

30 Years

75 Years

All

Phase 2

United States

243

EUCTR2016-000657-12-GR
(EUCTR)

04/04/2019

11/01/2019

A Global Study to Assess the Drug Dynamics, Efficacy, and Safety of GZ/SAR402671 in Parkinson's Disease Patients Carrying a Glucocerebrosidase (GBA) Gene Mutation

Multicenter, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of GZ/SAR402671 in Patients with Early-stage Parkinson's Disease Carrying a GBA Mutation or Other Pre-specified Variant - MOVES-PD

Parkinson's disease (PD) carrying a GBA mutation
MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Product Code: SAR402671, GZ402671 or GZ/SAR402671
INN or Proposed INN: -
Other descriptive name: Genz-682452 -AU
Product Code: SAR402671, GZ402671 or GZ/SAR402671
INN or Proposed INN: -
Other descriptive name: Genz-682452 -AU

Genzyme Corporation

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

290

Phase 2

United States;Portugal;Taiwan;Greece;Spain;Austria;Israel;United Kingdom;Italy;France;Canada;Singapore;Germany;Norway;Japan;Sweden

244

NCT03877510
(ClinicalTrials.gov)

April 3, 2019

12/3/2019

Open Label Extension (OLE) Study of the Safety and Clinical Utility of IPX203 in PD Patients With Motor Fluctuations

An Open-label Extension Study of the Safety and Clinical Utility of IPX203 in Parkinson's Disease Patients With Motor Fluctuations

Parkinson Disease

Drug: IPX203 140 mg;Drug: IPX203 210 mg;Drug: IPX203 280 mg;Drug: IPX203 350 mg

Impax Laboratories, LLC

NULL

Enrolling by invitation

40 Years

N/A

All

300

Phase 3

United States;Czechia;France;Germany;Italy;Spain;United Kingdom

245

ChiCTR1800015757

2019-04-01

2018-04-18

Value of 131I-MIBG salivary gland imaging in the early diagnosis of Parkinson's disease

Parkinson's Disease

Gold Standard:PD diagnostic criteria made by MDS in 2016;Index test:reduced uptake in salivery gland and myocardium in I-131-MIBG scintigraphic imaging;

Tongji hospital, Tongji University

NULL

Pending

Both

Target condition:30;Difficult condition:30

China

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

246

NCT03858270
(ClinicalTrials.gov)

April 1, 2019

2/10/2018

Inhibition of a-synuclein Cell-cell Transmission by NMDAR Blocker, Memantine

Parkinson Disease

Drug: Memantine;Other: Placebo

Wayne State University

NULL

Recruiting

45 Years

85 Years

All

Phase 3

United States

247

JPRN-jRCTs051180214

29/03/2019

27/03/2019

The usefulness of flutemetamol for diagnostic imaging of neurogenerative disease

The usefulness of brain amyloid image using flutemetamol and glucose metabolism for the neurogenerative disease - The usefulness of brain amyloid image using flutemetamol and glucose metabolism for the neurogenerative disease

Alzheimer's disease,Dementia with Lewy Bodies,Parkinson's syndrome,Frontotemporal lober degeneration
Alzheimer's disease, Dementia with Lewy Bodies, Parkinson's syndrome, Frontotemporal lober degeneration, Parkinson's disease, Mild cognitive impairment, Non-Alzheimer's disease, Progressive aphasia, Neurodegenerative disease, Cerebral corticobasal degeneration, Progressive supranuclear palsy

Amyloid PET: Given the flutemetamol (3mL) intravenously
FDG-PET:Given the FDG scanR (3mL) intravenously

Itoh Yoshiaki

NULL

Recruiting

Ages 20 and over

N/A

Both

100

N/A

Japan

248

NCT03922711
(ClinicalTrials.gov)

March 26, 2019

17/4/2019

A Study to Assess the Safety and Effectiveness of Pridopidine Compared to Placebo in the Treatment of Levodopa-Induced Dyskinesia in Patients With Parkinson's Disease

A Double-Blind, Randomized, Three-Arm, Parallel-Group Study to Assess the Efficacy and Safety of Two Doses of Pridopidine Versus Placebo for the Treatment of Levodopa-Induced Dyskinesia in Patients With Parkinson's Disease (gLIDe)

Parkinson Disease

Drug: Pridopidine;Drug: Placebo

Prilenia

NULL

Terminated

30 Years

85 Years

All

Phase 2

United States

249

NCT04064983
(ClinicalTrials.gov)

March 14, 2019

19/8/2019

Individual Patient Expanded Access IND of Hope Biosciences Autologous Adipose-derived Mesenchymal Stem Cells for Parkinson's Disease

Individual Patient Expanded Access IND of Hope Biosciences Autologous Adipose-derived Mesenchymal Stem Cells (HB-adMSCs) for Parkinson's Disease

Parkinson Disease

Drug: HB-adMSCs

Hope Biosciences

NULL

No longer available

18 Years

N/A

All

United States

250

NCT03716570
(ClinicalTrials.gov)

March 12, 2019

22/10/2018

A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Japanese Participants With Parkinson's Disease

A Multicenter, Blinded, Placebo-Controlled, Randomized, Single and Multiple-Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Japanese Subjects With Parkinson's Disease

Parkinson's Disease

Drug: BIIB054;Drug: Placebo

Biogen

NULL

Active, not recruiting

40 Years

80 Years

All

Phase 1

Japan

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

251

NCT03816020
(ClinicalTrials.gov)

March 9, 2019

7/12/2018

NAD-supplementation in Drug naïve Parkinson's Disease

NAD-PARK: A Double-blinded Randomized Pilot Trial of NAD-supplementation in Drug naïve Parkinson's Disease

Parkinson Disease;Neurodegenerative Diseases

Dietary Supplement: Nicotinamide Riboside;Other: Placebo

Haukeland University Hospital

NULL

Completed

18 Years

N/A

All

N/A

Norway

252

ChiCTR1900021760

2019-03-09

2019-03-08

Effect-site concentration of remifentanil for I-gel insertion in male patients with Parkinson’s disease undergoing deep brain stimulator implantation during target-controlled infusion of propofol

Parkinson’s disease

Parkinson’s disease:propofol and remifentanil;Non-Parkinson’s disease:propofol and remifentanil;

The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China

NULL

Recruiting

Male

Parkinson’s disease:25;Non-Parkinson’s disease:25;

N/A

China

253

EUCTR2017-005170-19-FI
(EUCTR)

06/03/2019

07/12/2018

A Long-Term Follow-up Safety Study for Patients with Parkinson’s Disease (PD) Implanted with the Drug Delivery System (DDS) and/or Who Received Treatment in the Main Study and/or Extension Study

A Long-Term Follow-up Safety Study for Patients with Idiopathic Parkinson’s Disease (PD) Implanted with the DDS and/or Who Received Treatment in the Main Study and/or Extension Study - Long-Term Follow-up Safety After DDS Implantation with/without CDNF Infusions

Idiopathic Parkinson's Disease
MedDRA version: 21.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Product Name: Cerebral Dopamine Neurotrophic Factor
Product Code: CDNF
INN or Proposed INN: Not Applicable
Other descriptive name: recombinant human Cerebral Dopamine Neurotrophic Factor

Renishaw Neuro Solutions Ltd.

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

Phase 1;Phase 2

Finland;Sweden

254

NCT03887884
(ClinicalTrials.gov)

March 5, 2019

1/3/2019

Pharmacokinetic Study of CVT-301 (Levodopa Inhalation Powder)

Randomized, Multi-center, Open-label, Crossover Pharmacokinetic Study of CVT-301 (Levodopa Inhalation Powder) and an Oral Dose of Carbidopa/Levodopa CD/LD Under Fed Conditions in Patients With Parkinson's Disease

Parkinson's Disease

Drug: CVT-301;Drug: Sinemet

Acorda Therapeutics

NULL

Completed

30 Years

85 Years

All

Phase 1

United States

255

NCT03865121
(ClinicalTrials.gov)

March 4, 2019

26/2/2019

Pilot Trial of Transnasal Nicotine in Parkinson Disease

Uncontrolled Pilot Trial of Transnasal Nicotine in Parkinson Disease

Parkinson Disease

Drug: Nicotine Nasal Spray 10 MG/ML (0.5 MG/SPRAY)

El Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez

Howard University

Completed

60 Years

N/A

All

Phase 2

Mexico

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

256

NCT03820037
(ClinicalTrials.gov)

March 2019

25/1/2019

Relative Bioavailability and Bioequivalence of Opicapone

A Phase I, Open-Label, Randomised, Three-Period, Three-Sequence, Partial Replicate Crossover Study to Investigate the Relative Bioavailability and Bioequivalence of Opicapone Obtained From Two Different Sources, Under Fasting Conditions After Single-dose Administration in Healthy Subjects

Parkinson Disease

Drug: Ongentys;Drug: BIA 9-1067 (test)

Bial - Portela C S.A.

NULL

Not yet recruiting

18 Years

55 Years

All

Phase 1

United Kingdom

257

NCT03845387
(ClinicalTrials.gov)

February 26, 2019

15/2/2019

A Clinical Study of KDT-3594 in Patients With Early Parkinson's Disease.

A Phase II Clinical Study of KDT-3594 in Patients With Early Parkinson's Disease.

Parkinson Disease

Drug: KDT-3594;Drug: Pramipexole

Kissei Pharmaceutical Co., Ltd.

NULL

Active, not recruiting

20 Years

79 Years

All

100

Phase 2

Japan

258

NCT03830528
(ClinicalTrials.gov)

February 26, 2019

3/2/2019

A Study of Single and Multiple Doses of KW-6356 in Healthy Subjects

A Phase I Study of KW-6356 in Japanese and Caucasian Healthy Adults

Parkinson's Disease

Drug: KW-6356 Low Dose;Drug: KW-6356 Middle Dose;Drug: KW-6356 High Dose;Drug: KW-6356 X Dose;Drug: KW-6356 Y Dose;Drug: Placebo

Kyowa Kirin Co., Ltd.

NULL

Completed

20 Years

44 Years

Male

Phase 1

Japan

259

NCT03968744
(ClinicalTrials.gov)

February 18, 2019

19/4/2019

Effect of Safinamide on Sleep Quality in Patients With Parkinson's Disease

A Prospective, Open Label, Single Arm, Clinical Study to Evaluate the Effect of Safinamide on Sleep Quality and Polysomnographic Parameters in Patients With Parkinson's Disease: the Safe Sleep Study

Idiopathic Parkinson's Disease (at Later Stage)

Drug: Safinamide

Alain Kaelin

Clinical Trial Unit Ente Ospedaliero Cantonale

Recruiting

18 Years

N/A

All

Phase 4

Switzerland

260

NCT03655236
(ClinicalTrials.gov)

February 18, 2019

18/8/2018

PROSEEK: A Phase 2 Study In Early Parkinson's Disease Patients Evaluating The Safety And Efficacy Of Abl Tyrosine Kinase Inhibition Using K0706

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of K0706 in Subjects With Early Parkinson's Disease

Early Parkinson Disease

Drug: K0706;Other: placebo

Sun Pharma Advanced Research Company Limited

NULL

Recruiting

50 Years

N/A

All

504

Phase 2

United States;Hungary;Poland;Slovakia;Spain

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

261

NCT03413384
(ClinicalTrials.gov)

February 15, 2019

8/1/2018

To Assess the Efficacy and Safety of Ceftriaxone in Patients With Mild to Moderate Parkinson's Disease Dementia

A Randomized, Double Blinded, Placebo-controlled Phase II Study to Assess the Efficacy and Safety of Ceftriaxone in Patients With Mild to Moderate Parkinson's Disease Dementia

Parkinson's Disease Dementia

Drug: Ceftriaxone;Other: Placebo

BrainX Corporation

NULL

Recruiting

50 Years

80 Years

All

106

Phase 2

Taiwan

262

NCT04510922
(ClinicalTrials.gov)

February 11, 2019

9/7/2020

Lundbeck TOMs Orthostatic Hypotension

Technology-Based Objective Measures for Gait and Postural Assessment in Parkinson Disease Patients With Orthostatic Hypotension: Feasibility and Effect-Size Finding Study

Orthostatic Hypotension;Idiopathic Parkinson Disease

Drug: Droxidopa 100 MG [Northera]

Alberto Espay, MD, MSc

Lundbeck LLC

Recruiting

30 Years

80 Years

All

Phase 4

United States

263

NCT03815071
(ClinicalTrials.gov)

February 1, 2019

21/1/2019

A Study on the Treatment of Parkinson's Disease With Autologous Neural Stem Cells

Clinical Study of the Safety and Efficacy of Autologous Neural Stem Cells in the Treatment of Parkinson's Disease

Parkinson Disease

Drug: Ips-nsc cells

Allife Medical Science and Technology Co., Ltd.

The First People's Hospital of Yunnan Province/First People's Hospital of Yunan Provinve New Kunhua Hospital;Henan Provincial People's Hospital;Beijing Hospital

Not yet recruiting

18 Years

60 Years

All

Early Phase 1

NULL

264

NCT03790670
(ClinicalTrials.gov)

January 30, 2019

18/12/2018

Biomarker Assessments of Leukine During Treatment of Parkinson's Disease

Safety, Tolerability and Biomarker Assessments of Leukine (Sargramostim) During Extended Timed Treatment for Parkinson's Disease: A Phase I Pilot Study

Parkinson Disease

Drug: sargramostim

University of Nebraska

NULL

Recruiting

35 Years

85 Years

All

Phase 1

United States

265

EUCTR2017-003458-18-SE
(EUCTR)

23/01/2019

10/12/2018

A clinical trial to study the effects of IRL790 in Parkinson's disease dyskinesia

A randomised, double-blind, placebo-controlled, phase IIA study evaluating the efficacy and tolerability of IRL790 in Parkinson's disease dyskinesia

Parkinson's disease dyskinesia
MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Integrative Research Laboratories AB (IRLAB)

NULL

Not Recruiting

Female: yes
Male: yes

Phase 2

Sweden

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

266

EUCTR2017-002426-20-AT
(EUCTR)

22/01/2019

03/12/2018

Effect of Safinamide on Parkinson’s Disease Related Chronic Pain

A randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of safinamide 100 mg once daily, as add-on therapy, in idiopathic Parkinson’s Disease (IPD) patients with motor fluctuations and PD related chronic pain - Pain study

Idiopathic Parkinson's Disease, Hoehn and Yahr stage between 2-3 inclusive during the ON” phase, experiencing motor fluctuations while on stable doses of L-Dopa (with or without benserazide/carbidopa, with or without addition of a catechol O-methyltransferase (COMT) inhibitor) and may be on stable doses of other PD medications (a dopamine agonist, an anticholinergic and/or amantadine), yet are experiencing more than 2 hours of OFF time per day and chronic PD related pain.
MedDRA version: 20.0;Level: LLT;Classification code 10013113;Term: Disease Parkinson's;System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Zambon SpA

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

177

Phase 4

Spain;Austria

267

EUCTR2018-002877-23-AT
(EUCTR)

21/01/2019

07/12/2018

Oxytocin and social attention in healthy controls and patients with Parkinson's disease. A randomised, double-blind, placebo-controlled, crossover eye tracking study.

Oxytocin and social attention in healthy controls and patients with Parkinson's disease. A randomised, double-blind, placebo-controlled, crossover eye tracking study. - Oxytocin in healthy controls and PD

Social functioning in Parkinson's disease
MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Trade Name: Syntocinon 40 IU/ml nasal spray
INN or Proposed INN: Synthetic Oxytocin
Other descriptive name: OXYTOCIN SYNTHETIC

Abteilung für Neurologie der Medizinischen Universität Innsbruck

NULL

Authorised-recruitment may be ongoing or finished

Female: no
Male: yes

Phase 2

Austria

268

NCT03826134
(ClinicalTrials.gov)

January 17, 2019

30/1/2019

A Positron Emission Tomography (PET) Study to Examine the Brain Binding Properties of a Novel Radioactive Compound [11C]-PXT012253 in Healthy Subjects

Interventional, Phase I, Open-label, First in Human, Single-center Positron Emission Tomography (PET) Study Investigating Test-retest Properties of [11C]-PXT012253 as a Radiotracer in Healthy Subjects

Parkinson Disease

Drug: [11C]PXT012253

H. Lundbeck A/S

NULL

Completed

20 Years

50 Years

All

Early Phase 1

Sweden

269

NCT04620863
(ClinicalTrials.gov)

January 15, 2019

26/10/2020

TRANSCRANIAL DIRECT CURRENT STIMULATION (t-DCS) AS ADD-ON TO NEUROREHABILITATION OF PISA SYNDROME IN PARKINSON DISEASE

TRANSCRANIAL DIRECT CURRENT STIMULATION (t-DCS) AS ADD-ON TO NEUROREHABILITATION OF PISA SYNDROME IN PARKINSON DISEASE: A RANDOMIZED CONTROLLED TRIAL

Parkinson Disease;Pisa Syndrome

Other: t-DCS group;Other: Sham group

IRCCS National Neurological Institute C. Mondino Foundation

NULL

Completed

18 Years

80 Years

All

N/A

Italy

270

JPRN-UMIN000035602

2019/01/11

21/01/2019

Hydrogen gas inhalation randomized double blinded trial for Parkinson's disease

Hydrogen gas inhalation randomized double blinded trial for Parkinson's disease - Hydrogen gas inhalation randomized double blinded trial for Parkinson's disease

Parkinson's disease

hydrogen gas16 weeks inhalation
two times of the inhalation for 60 minutes per day
8 weeks obsebation after the inhalation
placebo gas
16 weeks inhalation
two times of the inhalation for 60 minutes per day
8 weeks obsebation after the inhalation

Juntendo University Koshigaya Hospital

NULL

Complete: follow-up complete

40years-old

80years-old

Male and Female

Not selected

Japan

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

271

NCT03638479
(ClinicalTrials.gov)

January 8, 2019

13/8/2018

Utilizing Smart Devices to Identify New Phenotypical Characteristics in Movement Disorders

Parkinson Disease;Essential Tremor;Movement Disorders;Parkinson's Syndrome;Atypical Parkinsonism

Other: Data Capture

Westfälische Wilhelms-Universität Münster

NULL

Recruiting

18 Years

N/A

All

500

Germany

272

NCT03659682
(ClinicalTrials.gov)

January 2, 2019

3/9/2018

GLP1R in Parkinson's Disease

Effect of GLPIR Stimulation on Neuroprotection and Inflammation in Parkinson's Disease

Parkinson Disease

Drug: Semaglutide

Oslo University Hospital

NULL

Not yet recruiting

40 Years

75 Years

All

120

Phase 2

NULL

273

NCT03727295
(ClinicalTrials.gov)

January 1, 2019

30/10/2018

Idebenone Treatment of Early Parkinson's Diseasesymptoms

A Multicenter, Randomized, Double-blind, Placebo-controlled Study of Idebenone in the Treatment of Early-stage Parkinson's Disease With Motor and Non-motor Symptoms

Oxidative Stress is an Important Cause of Parkinson's Disease

Drug: Idebenone/placebo

Second Affiliated Hospital of Soochow University

Qilu Pharmaceutical Co., Ltd.

Not yet recruiting

30 Years

80 Years

All

180

Phase 4

NULL

274

ChiCTR1800019942

2018-12-31

2018-12-09

A Multicenter Randomized Controlled Trial for Effect of Zishen Pingchan Granules Combined with Pramipexole in the treatment of Depression in Parkinson’s Disease

Parkinson’s Disease

Experimental group:Zishen Pingchan Granules combined with Pramipexole;Control group:Zishen Pingchan Granules placebo combined with Pramipexole;

The Affiliated Brain Hospital of Nanjing Medical University( Nanjing Brain Hospital)

NULL

Pending

Both

Experimental group:150;Control group:150;

China

275

NCT03391882
(ClinicalTrials.gov)

December 19, 2018

2/1/2018

A Study of an Investigational Drug to See How it Affects the People With Parkinson's Disease Complicated by Motor Fluctuations (OFF Episodes) Compared to an Approved Drug Used to Treat People With Parkinson's Disease Complicated by Motor Fluctuations (OFF Episodes)

An Open-Label, Randomized, Crossover Trial Utilizing a Single-Blinded Rater to Evaluate APL-130277 Compared to Subcutaneous Apomorphine in Levodopa Responsive Subjects With Parkinson's Disease Complicated by Motor Fluctuations

Motor OFF Episodes Associated With Parkinson's Disease

Drug: APL-130277;Drug: subcutaneous apomorphine

Sunovion

NULL

Recruiting

18 Years

N/A

All

106

Phase 3

Austria;France;Germany;Italy;Spain;United Kingdom

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

276

NCT03840005
(ClinicalTrials.gov)

December 18, 2018

11/2/2019

Trial of Ursodeoxycholic Acid (UDCA) for Parkinson's Disease: The UP Study

A Phase II, Placebo Controlled, Double Blind, Randomised Clinical Trial To Assess The Safety And Tolerability Of 30mg/kg Daily Ursodeoxycholic Acid (UDCA) In Patients With Parkinson's Disease (PD)

Parkinson's Disease

Drug: Ursonorm

Sheffield Teaching Hospitals NHS Foundation Trust

JP Moulton Charitable Foundation;PRO.MED.CS Praha a.s.;Clinical Trials Research Unit, University of Sheffield

Active, not recruiting

18 Years

75 Years

All

Phase 2

United Kingdom

277

NCT03781791
(ClinicalTrials.gov)

December 10, 2018

27/11/2018

Orally Administered ENT-01 for Parkinson's Disease-Related Constipation (KARMET)

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Evaluate Safety, Tolerability and Efficacy of Orally Administered ENT-01 for the Treatment of Parkinson's Disease-Related Constipation (KARMET)

Constipation;Parkinson Disease

Drug: Active Investigational Treatment ENT-01;Drug: Placebo Treatment

Enterin Inc.

NULL

Active, not recruiting

30 Years

90 Years

All

152

Phase 2

United States

278

NCT03710707
(ClinicalTrials.gov)

December 4, 2018

15/10/2018

Study to Evaluate DNL201 in Subjects With Parkinson's Disease

A Phase 1b, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Determine the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL201 in Subjects With Parkinson's Disease

Parkinson Disease

Drug: DNL201;Drug: Placebo

Denali Therapeutics Inc.

NULL

Completed

30 Years

80 Years

All

Phase 1

United States

279

NCT03944447
(ClinicalTrials.gov)

December 1, 2018

3/5/2019

Outcomes Mandate National Integration With Cannabis as Medicine for Prevention and Treatment of COVID-19

Chronic Pain;Chronic Pain Syndrome;Chronic Pain Due to Injury;Chronic Pain Due to Trauma;Fibromyalgia;Seizures;Hepatitis C;Cancer;Crohn Disease;HIV/AIDS;Multiple Sclerosis;Traumatic Brain Injury;Sickle Cell Disease;Post Traumatic Stress Disorder;Tourette Syndrome;Ulcerative Colitis;Glaucoma;Epilepsy;Inflammatory Bowel Diseases;Parkinson Disease;Amyotrophic Lateral Sclerosis;Chronic Traumatic Encephalopathy;Anxiety;Depression;Insomnia;Autism;Opioid-use Disorder;Bipolar Disorder;Covid19;SARS-CoV Infection;COVID-19;Corona Virus Infection;Coronavirus

Drug: Cannabis , Medical

OMNI Medical Services, LLC

OMNI Medical Services Inc

Recruiting

7 Years

N/A

All

200000

Phase 2

United States

280

NCT03639064
(ClinicalTrials.gov)

December 2018

4/7/2018

Cannabis Oil for Pain in Parkinson's Disease

A Phase II, Randomized, Open-label, Double-blind, Two-center Study to Evaluate the Tolerability, Safety and Dose-finding of Oil Cannabis Preparation for Pain in Parkinson's Disease

Parkinson Disease

Drug: Cannabis Oil

University Health Network, Toronto

Parkinson Society Canada

Unknown status

18 Years

N/A

All

Phase 2

NULL

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

281

NCT03942172
(ClinicalTrials.gov)

November 27, 2018

6/5/2019

Treatment of Balance Disorders in Parkinson's Patients Using SpotOn Balance Glasses

Parkinson Disease

Device: SpotOn balance glasses

SpotOn Therapeutics Ltd.

NULL

Suspended

30 Years

N/A

All

N/A

Israel

282

NCT03822364
(ClinicalTrials.gov)

November 26, 2018

18/12/2018

Staccato Apomorphine Single and Multi Dose PK

A Randomized Study of the Safety, Tolerability, and Pharmacokinetics of AZ-009 (Staccato Apomorphine) in Healthy Volunteers and the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZ-009 in Subjects With Parkinson's Disease

Parkinson Disease

Drug: 009-1;Drug: active comparator;Drug: 009-0;Drug: 009-2;Drug: 009-3;Drug: 009-4;Drug: 009-5

Alexza Pharmaceuticals, Inc.

NULL

Completed

18 Years

60 Years

All

Phase 1

Netherlands

283

NCT03823638
(ClinicalTrials.gov)

November 20, 2018

20/11/2018

Safety, Tolerability and Effects of Mannitol in Parkinson's Disease

A Phase II Single Center, Randomized, Double Blind and Placebo Controlled Study Assessing the Safety, Tolerability and Effects of Progressively Increased Dose of Oral Mannitol in Parkinson's Disease

Parkinson Disease

Dietary Supplement: Oral D-Mannitol of Placebo

Hadassah Medical Organization

NULL

Recruiting

40 Years

75 Years

All

Phase 2

Israel

284

NCT03713957
(ClinicalTrials.gov)

November 12, 2018

18/10/2018

A Study to Assess the Safety of GRF6021 Infusions in Subjects With Parkinson's Disease and Cognitive Impairment

A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Tolerability of GRF6021 Infusions in Subjects With Parkinson's Disease and Cognitive Impairment

Parkinson Disease

Drug: GRF6021;Other: Placebo

Alkahest, Inc.

Michael J. Fox Foundation for Parkinson's Research

Completed

40 Years

85 Years

All

Phase 2

United States;Australia;France

285

NCT03733561
(ClinicalTrials.gov)

November 9, 2018

6/11/2018

A Study to Assess Pharmacokinetic Profiles of LY03003 and Neupro

Parkinson Disease

Drug: LY03003;Drug: Neupro 4Mg/24Hr Transdermal Patch

Luye Pharma Group Ltd.

NULL

Recruiting

18 Years

45 Years

All

Phase 1

United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

286

EUCTR2018-001887-46-GB
(EUCTR)

08/11/2018

19/06/2019

Trial of Ursodeoxycholic Acid (UDCA) for PD. The 'UP-study'

A Phase II, Placebo Controlled, Double Blind, Randomised Clinical Trial to assess the safety and tolerability Of 30mg/kg daily Ursodeoxycholic Acid (UDCA) in Patients with Parkinson’s Disease (PD) - Trial of Ursodeoxycholic Acid (UDCA) for PD. The 'UP-study'

Parkinson’s disease (PD)
MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Sheffield Teaching Hospitals NHS Foundation Trust

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

Phase 2

United Kingdom

287

NCT03670953
(ClinicalTrials.gov)

November 6, 2018

12/9/2018

A Study to Evaluate the Safety and Efficacy of IPX203 in Parkinson's Disease Patients With Motor Fluctuations

A Randomized Controlled Study to Compare the Safety and Efficacy of IPX203 With Immediate-Release Carbidopa-Levodopa in Parkinson's Disease Patients With Motor Fluctuations

Parkinson's Disease (Disorder)

Drug: IR CD-LD;Drug: IPX203 ER CD-LD;Other: IPX203 placebo;Other: IR CD-LD placebo

Impax Laboratories, LLC

NULL

Recruiting

40 Years

N/A

All

510

Phase 3

United States;Czechia;France;Germany;Italy;Poland;Spain;United Kingdom

288

NCT03667404
(ClinicalTrials.gov)

November 6, 2018

10/9/2018

Resistant Maltodextrin for Gut Microbiome in Parkinson's Disease: Safety and Tolerability Study

Gut Microbial Remodeling With Resistant Maltodextrin for Motor and Non-motor Symptoms in Parkinson's Disease: Safety and Tolerability Study

Parkinson Disease;Intestinal Bacteria Flora Disturbance;Dietary Modification

Dietary Supplement: Resistant maltodextrin;Dietary Supplement: maltodextrin

Northwestern University

University of Illinois at Chicago

Recruiting

60 Years

N/A

All

Phase 2

United States

289

NCT04629404
(ClinicalTrials.gov)

November 5, 2018

5/11/2020

A Clinical Trial to Evaluate the Pharmacodynamics/Pharmacokinetics and Safety of LY03003 in Early PD Patients

A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Pharmacodynamics/Pharmacokinetics and Safety of Multiple Intramuscular Doses of LY03003 in Patients With Early Parkinson's Disease

Parkinson Disease

Drug: LY03003;Drug: Placebo

Luye Pharma Group Ltd.

NULL

Completed

30 Years

N/A

All

Phase 1

China

290

JPRN-JapicCTI-184181

01/11/2018

30/10/2018

Rasagiline Tablets Special Drug Use-Results Survey Survey on Long-term Safety

AZILECT Tablets Special Drug Use-Results Survey Survey on Long-term Safety

Parkinson's disease

Intervention name : Rasagiline
INN of the intervention : rasagiline
Dosage And administration of the intervention : Rasagiline 1 milligram (mg), orally, once daily for up to 24 months. Participants received interventions as part of routine medical care.
Control intervention name : -
INN of the control intervention : -
Dosage And administration of the control intervention : -

TAKEDA PHARMACEUTICAL COMPANY LTD.

NULL

complete

BOTH

1021

Japan

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

291

NCT03069911
(ClinicalTrials.gov)

November 1, 2018

28/2/2017

Trial of OnabotulinumtoxinA for Depression in Parkinson Disease

Randomized Controlled Trial of OnabotulinumtoxinA for Depression in Parkinson Disease

Parkinson Disease;Depression

Biological: OnabotulinumtoxinA;Biological: Control

Johns Hopkins University

NULL

Terminated

18 Years

95 Years

All

Phase 1

United States

292

NCT03727139
(ClinicalTrials.gov)

November 1, 2018

30/10/2018

Rasagiline Tablets Special Drug Use-Results Survey Survey on Long-term Safety

AZILECT Tablets Special Drug Use-Results Survey Survey on Long-term Safety

Parkinson's Disease

Drug: Rasagiline

Takeda

NULL

Active, not recruiting

N/A

All

1021

Japan

293

EUCTR2017-003415-19-ES
(EUCTR)

31/10/2018

20/08/2018

A Clinical Study in Parkinson’s Disease Patients With Moderate to Severe Abnormal Movements to See If JM-010 is Effective and Safe/Tolerable.

A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study in Parkinson’s Disease Patients With Moderate to Severe Dyskinesia to Assess the Efficacy and Safety/Tolerability of Two Dose Combinations Of JM-010

Parkinson’s Disease Patients With Moderate to Severe Dyskinesia;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Product Name: JM -010
Product Code: JM -010
INN or Proposed INN: Buspirone hydrochloride
INN or Proposed INN: Zolmitriptan
Product Name: JM -010
Product Code: JM -010
INN or Proposed INN: Buspirone hydrochloride
INN or Proposed INN: Zolmitriptan

Contera Pharma

NULL

Not Recruiting

Female: yes
Male: yes

Phase 2

France;Spain;Germany

294

EUCTR2016-002033-30-NL
(EUCTR)

31/10/2018

15/11/2017

A clinical study investigating the efficacy, tolerability, and safety of two dosing regimens of continuous subcutaneous ND0612 infusion given as adjunct treatment to oral levodopa in patients with Parkinson’s disease with motor fluctuations

A multicenter, randomized, double-blind, placebo controlled, parallel group clinical study investigating the efficacy, tolerability, and safety of two dosing regimens of continuous subcutaneous ND0612 infusion Given as adjunct treatment to oral levOdopa in patients with Parkinson’s Disease with motor fluctuations (iNDiGO) - iNDiGO

Subjects with Parkinson’s Disease with motor fluctuations
MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

NeuroDerm Ltd.

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

240

Phase 3

Serbia;Portugal;United States;Spain;Ukraine;Russian Federation;Chile;Israel;Italy;United Kingdom;France;Czech Republic;Hungary;Poland;Belgium;Denmark;Netherlands;Germany

295

ChiCTR1800017949

2018-10-30

2018-08-24

Clinical study for the effect of the combination of Shudipingchan prescription and Monoamine oxidase inhibitor on improving early PD symptoms and delaying the progression of the disease

Parkinson's disease

Group 1:Selegiline and Shudipingchan granule;Group 2:Selegiline and simulant TCM granule;

Longhua Hospital Shanghai University of Traditional Chinese Medicine

NULL

Pending

Both

Group 1:72;Group 2:72;

China

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

296

ChiCTR1800018017

2018-10-30

2018-08-27

Clinical study for the effect of the combination of Shudipingchan prescription and Monoamine oxidase inhibitor on improving early Parkinson‘s Disease symptoms and delaying the progression of the disease

Parkinson's disease

Treatment group:Selegiline+Shudipingchan granule;Control group:Selegiline+TCM simulant;

Longhua Hospital Shanghai University of Traditional Chinese Medicine

NULL

Pending

Both

Treatment group:92;Control group:92;

China

297

EUCTR2017-002426-20-ES
(EUCTR)

19/10/2018

20/08/2018

Effect of Safinamide on Parkinson’s Disease Related Chronic Pain

Idiopathic Parkinson's Disease, Hoehn and Yahr stage between 2-3 inclusive during the ON” phase, experiencing motor fluctuations while on stable doses of L-Dopa (with or without benserazide/carbidopa, with or without addition of a catechol O-methyltransferase (COMT) inhibitor) and may be on stable doses of other PD medications (a dopamine agonist, an anticholinergic and/or amantadine), yet are experiencing more than 2 hours of OFF time per day and chronic PD related pain.
MedDRA version: 20.0;Level: LLT;Classification code 10013113;Term: Disease Parkinson's;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Trade Name: Xadago
Product Name: Xadago
INN or Proposed INN: Safinamide methansulfonate
Other descriptive name: SAFINAMIDE METHANESULFONATE
Trade Name: Xadago
Product Name: Xadago
INN or Proposed INN: Safinamide methansulfonate
Other descriptive name: SAFINAMIDE METHANESULFONATE

Zambon SpA

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

177

Phase 4

Spain

298

NCT03720418
(ClinicalTrials.gov)

October 17, 2018

16/10/2018

Study of OXB-102 (AXO-Lenti-PD) in Patients With Bilateral, Idiopathic Parkinson's Disease

A Phase I/II Safety and Dose Evaluation Study of OXB-102 in Patients With Bilateral Idiopathic Parkinson's Disease

Parkinson Disease

Drug: OXB-102;Other: Imitation Surgical Procedure (ISP)

Axovant Sciences Ltd.

Oxford BioMedica

Recruiting

30 Years

70 Years

All

Phase 1;Phase 2

France;United Kingdom

299

NCT04048291
(ClinicalTrials.gov)

October 15, 2018

9/10/2018

Efficacy of Brisk Walking in Parkinson's Disease

Efficacy of Brisk Walking on Improving Balance and Gait Performance, and Functional Mobility in Parkinson's Disease - a Randomized Controlled Trial

Parkinson Disease

Behavioral: Brisk walking and balance training;Behavioral: Upper limb exercise

The Hong Kong Polytechnic University

NULL

Completed

30 Years

N/A

All

N/A

Hong Kong

300

NCT04451096
(ClinicalTrials.gov)

October 6, 2018

19/6/2020

Probiotics-prebiotic Fiber Therapy in Parkinson's Disease Patients With Constipation

Probiotics-prebiotic Fiber Therapy Improved Bowel Opening Frequency and Whole Gut Transit Time in Parkinson's Disease Patients With Constipation: A Randomised Controlled Study

Parkinson Disease;Constipation

Dietary Supplement: Probiotics with prebiotic;Dietary Supplement: Placebo

National University of Malaysia

NULL

Completed

18 Years

N/A

All

Phase 3

Malaysia

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

301

EUCTR2018-000346-19-FI
(EUCTR)

03/10/2018

09/07/2018

An extended clinical study to test the safety of Cerebral Dopamine Neurotrophic Factor (CDNF) by brain infusion via Drug Delivery System (DDS) in patients with Parkinson's disease.

A Randomised, Double-Blind, Multi-centre, Active Treatment, Extension and Safety Study for Patients with Idiopathic Parkinson’s Disease (PD) Who Previously Completed the CDNF/DDS Main Study HP-CD-CL-2002. - Extension Study

Product Name: Cerebral Dopamine Neurotrophic Factor
Product Code: CDNF
INN or Proposed INN: Not Applicable
Other descriptive name: recombinant human Cerebral Dopamine Neurotrophic Factor

Herantis Pharma Plc

NULL

Not Recruiting

Female: yes
Male: yes

Phase 1;Phase 2

Finland;Sweden

302

EUCTR2016-004610-95-DE
(EUCTR)

01/10/2018

27/02/2018

Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Participants with Parkinson’s Disease

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study, with an Active-Treatment Dose-Blinded Period, to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Subjects with Parkinson’s Disease - SPARK

Product Code: BIIB054
INN or Proposed INN: n/a
Other descriptive name: BIIB054

Biogen Idec Research Limited

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

357

Phase 2

United States;France;Canada;Spain;Austria;Israel;Germany;United Kingdom;Italy

303

NCT03703570
(ClinicalTrials.gov)

September 29, 2018

5/10/2018

A Study of KW-6356 in Patients With Parkinson's Disease on Treatment With Levodopa-containing Preparations

A Phase 2b Study of KW-6356 in Subjects With Parkinson's Disease on Treatment With Levodopa-containing Preparations

Parkinson's Disease

Drug: KW-6356;Drug: Placebo

Kyowa Kirin Co., Ltd.

NULL

Completed

20 Years

80 Years

All

502

Phase 2

Japan

304

NCT03665454
(ClinicalTrials.gov)

September 24, 2018

1/8/2018

PF 06412562 in Subjects With Advanced Stage Parkinson's Disease

A Phase Ib Safety, Tolerability, and Efficacy Study of Two Days of Oral Split Dose (25/20 mg) Administration of PF 06412562 in Subjects With Advanced Stage Parkinson's Disease

Parkinson Disease

Drug: PF-06412562;Drug: Standard of Care Placebo

Milton S. Hershey Medical Center

Pfizer

Completed

N/A

All

Phase 1

United States

305

NCT03582137
(ClinicalTrials.gov)

September 17, 2018

17/4/2018

A Study of Tolerability and Efficacy of Cannabidiol on Motor Symptoms in Parkinson's Disease

A Randomized, Double Blind, Placebo-controlled Parallel Study of Tolerability and Efficacy of Cannabidiol (CBD) on Motor Symptoms in Parkinson's Disease

Parkinson Disease

Drug: Cannabidiol;Other: Placebo

University of Colorado, Denver

Colorado Department of Public Health and Environment

Recruiting

40 Years

85 Years

All

Phase 2

United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

306

NCT04202757
(ClinicalTrials.gov)

September 14, 2018

21/9/2018

Intravenous Plasma Treatment for Parkinson's Disease

Intravenous Young Fresh Frozen Plasma (yFFP) Investigational Treatment for Parkinson's Disease - Randomized Controlled Study

Idiopathic Parkinson Disease

Biological: [21CFR640.30] Plasma from 18 - 25 year old volunteer donors;Other: Saline

The Neurology Center

Carolina Longevity Institute

Completed

45 Years

90 Years

All

Phase 4

United States

307

NCT03648905
(ClinicalTrials.gov)

September 6, 2018

24/8/2018

Clinical Laboratory Evaluation of Chronic Autonomic Failure

Parkinson's Disease;Multiple System Atrophy;Autonomic Failure

Drug: 18F-Dopa;Drug: 11C-methylreboxetine;Drug: 13N-Ammonia;Drug: 18F-Dopamne;Drug: Desipramine (DMI)

National Institute of Neurological Disorders and Stroke (NINDS)

NULL

Recruiting

18 Years

N/A

All

140

Phase 1

United States

308

NCT03608371
(ClinicalTrials.gov)

August 31, 2018

9/5/2018

BTRX-246040 Study in Subjects With Parkinson's Disease With Motor Fluctuations

Phase 2A, Double-blind, Placebo-controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of BTRX-246040 in Parkinson's Disease Subjects With Motor Fluctuations

Parkinson Disease;Motor Disorder

Drug: BTRX-246040;Drug: Placebo

BlackThorn Therapeutics, Inc.

NULL

Completed

30 Years

76 Years

All

Phase 2

United States

309

NCT03229174
(ClinicalTrials.gov)

August 23, 2018

21/4/2017

Brain Perfusion & Oxygenation in Parkinson's Disease With NOH

Evaluation of Brain Perfusion and Oxygenation in PD Patients With Neurogenic Orthostatic Hypotension: 4 Week Comparison of Droxidopa Versus Placebo

Parkinson Disease;Neurogenic Orthostatic Hypotension

Drug: Droxidopa;Drug: Placebo

William Ondo, MD

Lundbeck LLC

Recruiting

18 Years

85 Years

All

Phase 4

United States

310

NCT03621046
(ClinicalTrials.gov)

August 20, 2018

6/6/2018

Use of Low-dose Zolpidem in Parkinson's Disease

A Placebo Controlled Double Blind Randomised Controlled Proof of Concept Study of Zolpidem for the Treatment of Motor and Cognitive Deficits in Late-stage Parkinson's

Parkinson Disease

Drug: Zolpidem;Other: Placebo

Aston University

University Hospital Birmingham NHS Foundation Trust

Completed

40 Years

80 Years

All

Phase 2

United Kingdom

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

311

NCT03567447
(ClinicalTrials.gov)

August 17, 2018

21/5/2018

Effect of L-Dihydroxyphenylserine (L-DOPS) on Falls in Patients With Neurogenic Orthostatic Hypotension (NOH)

Parkinson Disease;Falls Patient

Drug: Droxidopa;Other: Placebo

St. Joseph's Hospital and Medical Center, Phoenix

H. Lundbeck A/S;Arizona State University

Recruiting

30 Years

83 Years

All

Phase 2

United States

312

NCT03675282
(ClinicalTrials.gov)

August 14, 2018

5/9/2018

Quantitative Mapping of Substantia Nigra Iron in Parkinson's Disease (Stages I-IV, REM Sleep Behavior Disorder) and Controls

Quantitative Mapping of Substantia Nigra Iron in Parkinson's Disease and Controls

Parkinson Disease;REM Sleep Behavior Disorder;Healthy

Drug: (11C)PE2I

Weill Medical College of Cornell University

National Institute of Neurological Disorders and Stroke (NINDS)

Recruiting

20 Years

100 Years

All

100

Phase 1;Phase 2

United States

313

EUCTR2016-004610-95-FR
(EUCTR)

08/08/2018

01/03/2018

Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Participants with Parkinson’s Disease

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study, with an Active-Treatment Dose-Blinded Period, to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Subjects with Parkinson’s Disease - SPARK

Parkinson's Disease
MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Biogen Idec Research Limited

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

311

Phase 2

United States;France;Canada;Spain;Austria;Israel;Germany;Italy;United Kingdom;Sweden

314

NCT03773796
(ClinicalTrials.gov)

August 6, 2018

19/7/2018

Nabilone for Non-motor Symptoms in Parkinson's Disease

Nabilone for Non-motor Symptoms in Parkinson's Disease: An Open-label Study to Evaluate Long-term Safety and Efficacy

Parkinson Disease

Drug: Nabilone 0.25 mg

Medical University Innsbruck

NULL

Recruiting

30 Years

100 Years

All

Phase 3

Austria

315

NCT04455555
(ClinicalTrials.gov)

August 1, 2018

28/6/2020

Efficacy and Safety of Rotigotine in the Treatment of Patients With Early Stage of Primary Parkinson's Disease

Parkinson's Disease

Drug: LY03003( the name of rotigotine);Other: Placebo

Peking University Third Hospital

NULL

Completed

18 Years

N/A

All

294

Phase 3

China

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

316

JPRN-UMIN000033285

2018/08/01

05/07/2018

The preventive effect of medicine for osteoporosis on osteopenia in patients with Parkinson's disease: multicenter/ non-blind/ randomised/ exploratory clinical trial

The preventive effect of medicine for osteoporosis on osteopenia in patients with Parkinson's disease: multicenter/ non-blind/ randomised/ exploratory clinical trial - The preventive effect of medicine for osteoporosis on osteopenia in patients with Parkinson's disease

Parkinson's disease

Oral bisphosphonate agent group: taking orally Minodronic Acid Hydrate (50mg) 1 tablet per 4 weeks
Intravenous bisphosphonate agent group: injecting Zoledronic Acid (5mg) 1 ampule per 48 weeks

Department of Orthopaedic Surgery, Niigata University Medical and Dental Hospital

Department of Neurology, Nishi-Niigata Chuo Hospital

Pending

50years-old

Not applicable

Male and Female

100

Not selected

Japan

317

ChiCTR1800017084

2018-08-01

2018-07-11

Investigation of new approaches and technologies in the management of Parkinson's disease

The efficacy of Butylphthalide on cognitive impairment of patients with idiopathic PD and DBS patients: A Randomized, double-blind, placebo-controlled, multicenter trial

Parkinson's disease

Butylphthalide group:Butylphthalide, 2 capsules/time, 3 times/day, for 48 weeks;Control group:Placebo, 2 capsules/time, 3 times/day, for 48 weeks;

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

NULL

Recruiting

Both

Butylphthalide group:140;Control group:140;

Phase 4

China

318

JPRN-JMA-IIA00385

01/08/2018

12/09/2018

Kyoto Trial to Evaluate the Safety and Efficacy of iPSC-derived dopaminergic progenitors in the treatment of Parkinson's Disease

Parkinson's disease

Intervention type:DRUG. Intervention1:TACROLIMUS TABLETS, Dose form:TABLET, Route of administration:ORAL, intended dose regimen:In the early phase, the immunosuppressant is orally administered 0.03 to 0.15 mg/kg, twice a day, and the targeted blood concentration is within a range of 5-10 ng/mL as a trough value..

Kyoto University Hospital

NULL

Temporarily Closed

>=50 YEARS

<70 YEARS

BOTH

Phase 3

Japan

319

ChiCTR1800016949

2018-08-01

2018-07-04

Efficacy assessment and standard treatment of rasagiline in Chinese patients with early Parkinson's disease

Parkinson's disease

Rasagiline early start group:rasagiline-rasagiline;Rasagiline delay start group:placebo-rasagiline;

Beijing Hospital

NULL

Pending

Both

Rasagiline early start group:130;Rasagiline delay start group:130;

China

320

EUCTR2017-005170-19-SE
(EUCTR)

30/07/2018

10/04/2018

A Long-Term Follow-up Safety Study for Patients with Parkinson’s Disease (PD) Implanted with the Drug Delivery System (DDS) and/or Who Received Treatment in the Main Study and/or Extension Study

Product Name: Cerebral Dopamine Neurotrophic Factor
Product Code: CDNF
INN or Proposed INN: Not Applicable
Other descriptive name: recombinant human Cerebral Dopamine Neurotrophic Factor

Renishaw Neuro Solutions Ltd.

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

Phase 1;Phase 2

Finland;Sweden

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

321

NCT03599726
(ClinicalTrials.gov)

July 30, 2018

29/6/2018

Improving Walking Automaticity in Parkinson's Disease: Levodopa or Donepezil

Parkinson Disease

Drug: Donepezil;Drug: Placebo

Oregon Health and Science University

Medical Research Foundation, Oregon

Completed

50 Years

90 Years

All

Early Phase 1

United States

322

NCT03611569
(ClinicalTrials.gov)

July 25, 2018

26/7/2018

Lu AF82422 in Healthy Non-Japanese and Japanese Subjects and in Patients With Parkinson's Disease

Interventional, Randomized, Double-blind, Sequential-group, Placebo-controlled, Single-ascending-dose Study Investigating the Safety, Tolerability and Pharmacokinetic and Pharmacodynamic Properties of Lu AF82422 in Healthy Non-Japanese and Japanese Subjects and in Patients With Parkinson's Disease

Healthy;Parkinson Disease

Drug: Lu AF82422;Drug: Placebo

H. Lundbeck A/S

NULL

Recruiting

18 Years

80 Years

All

Phase 1

United States

323

NCT03587168
(ClinicalTrials.gov)

July 20, 2018

3/7/2018

The Reliability, Validity, and Responsiveness of the Timed 360° Turn Test in Patients With Parkinson's Disease

Parkinson Disease

Other: the timed 360° turn test;Other: Berg Balance Scale;Other: Four Square Step Test;Other: Functional Reach Test;Other: Trunk Impairment Scale;Other: Timed Up and Go Test;Other: Hoehn and Yahr Scale;Other: Unified Parkinson's Disease Rating Scale

Gazi University

NULL

Completed

40 Years

N/A

All

Turkey

324

JPRN-jRCTs052180158

19/07/2018

25/03/2019

The effect of rehabilitation robots for patients with Parkinson's disease.

A study on the effectiveness of balance rehabilitation support robot (balance exercise assist robot) for Parkinson's patient.

Parkinson's Disease;D010300

Robot group: The participants performs twelve per a session, 2sessions per a week for 8 weeks.
Control group: The participants receives balance exercise by physical therapist twice a week for 8 weeks.

Domen Kazuhisa

NULL

Recruiting

>= 40age old

<= 80age old

Both

N/A

Japan

325

NCT03594656
(ClinicalTrials.gov)

July 15, 2018

11/7/2018

Effects of Lingzhi on Disease Progression in Patients With Untreated Early Parkinson's Disease

Effects of Lingzhi on Disease Progression in Patients With Untreated Early Parkinson's Disease: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial

Parkinson Disease

Drug: Ganoderma;Drug: Placebos

Xuanwu Hospital, Beijing

NULL

Recruiting

30 Years

80 Years

All

288

Phase 3

China

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

326

NCT03624920
(ClinicalTrials.gov)

July 12, 2018

10/7/2018

Safety and Efficacy of THN102 in Patients With Parkinson's Disease and Excessive Daytime Sleepiness

Parkinson Disease

Drug: THN102 Dosage A;Drug: THN102 Dosage B;Drug: THN102 Dosage C

Theranexus

NULL

Completed

18 Years

80 Years

All

Phase 2

United States;Czechia;France;Germany;Hungary

327

NCT03774459
(ClinicalTrials.gov)

July 9, 2018

8/12/2018

ANAVEX2-73 Study in Parkinson's Disease Dementia

A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of ANAVEX2-73 for Cognitive Impairment in Patients With Parkinson's Disease With Dementia

Parkinsons Disease With Dementia

Drug: High dose ANAVEX2-73;Drug: Mid dose ANAVEX2-73;Drug: Placebo oral capsule

Anavex Life Sciences Corp.

Anavex Germany GmbH

Completed

50 Years

85 Years

All

132

Phase 2

Australia;Spain

328

NCT03775538
(ClinicalTrials.gov)

July 5, 2018

11/10/2018

Safety of CDNF by Brain Infusion in Patients With Parkinson's Disease. Extension to HP-CD-CL-2002 Clinical Study

A Randomised, Double-Blind, Multi-centre, Active Treatment, Extension and Safety Study for Patients With Idiopathic Parkinson's Disease (PD) Who Previously Completed the CDNF/DDS Main Study HP-CD-CL-2002

Parkinson Disease;Movement Disorders;Neuro-Degenerative Disease;Nervous System Diseases;Brain Diseases

Drug: Cerebral Dopamine Neurotrophic Factor;Device: Renishaw Drug Delivery System

Herantis Pharma Plc.

Renishaw plc.

Completed

35 Years

75 Years

All

Phase 1;Phase 2

Finland;Sweden

329

NCT03146130
(ClinicalTrials.gov)

July 5, 2018

3/5/2017

Study of the Efficacy of N-acetylcysteine (NAC) on Impulse Control Disorders

Study of the Efficacy of N-acetylcysteine (NAC) on Impulse Control Disorders (TCI) Induced by Dopaminergic Treatments in Parkinson's Disease

Impulse Control Disorder;Parkinson

Biological: Variation of behaviors of Parkinson's disease

Centre Hospitalier Universitaire, Amiens

NULL

Unknown status

18 Years

N/A

All

Phase 3

France

330

EUCTR2017-004335-36-ES
(EUCTR)

04/07/2018

11/04/2018

A Phase II, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of ANAVEX2-73 for Cognitive Impairment in Parkinson’s Disease with Dementia Patients.

Cognition in Parkinson’s Disease with dementia;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Product Name: ANAVEX2-73
INN or Proposed INN: ANAVEX2-73
Product Name: ANAVEX2-73
INN or Proposed INN: ANAVEX2-73

Anavex Life Sciences Corp.

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

120

Phase 2

Spain

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

331

NCT03521635
(ClinicalTrials.gov)

July 3, 2018

11/4/2018

The SUSTAIN Study Compares the Effects of Sustained and Immediate-release Pramipexole on the noctUrnal Symptoms of paTients With Advanced ParkInsoN's Disease Who Also Take L-Dopa

A Two- Stage Multicenter, Open-label, Randomized, Active Controlled Parallel Group Study Comparing the Efficacy and Safety of Pramipexole SR Versus Pramipexole IR Administered Orally Over an 18-week Treatment on Nocturnal Symptoms in L-Dopa+ Treated Patients With Advanced Parkinson's Disease (PD)

Parkinson Disease

Drug: Pramipexole SR;Drug: Pramipexole IR

Boehringer Ingelheim

NULL

Completed

30 Years

N/A

All

Phase 4

China

332

JPRN-UMIN000033409

2018/07/02

17/07/2018

Prevention of local skin reaction by heparinoid due to rotigotine transdermal patch: a pilot randomized clinical trial.

Parkinson's disease

Pretreatment by heparinoid
In the pretreatment group, heparinoid is applied daily to the sites (shoulder, upper arm, abdomen, thigh, buttocks on both sides) to be applied rotigotine transdermal patch from the beginning of 1 week before. The dose is one finger tip unit (about 0.5 g) for two palms. The period is 8 weeks.
Non-pretreatment by heparinoid.
The non-pretreatment group use rotigotine without using heparinoid. The period is 8 weeks.

Wakayama Medical University

NULL

Recruiting

20years-old

85years-old

Male and Female

Phase 1

Japan

333

NCT03566589
(ClinicalTrials.gov)

July 2, 2018

12/6/2018

Effects of PS128 on Parkinsonian Symptoms

Effects of Lactobacillus Plantarum PS128 on the Parkinsonian Symptoms in Parkinson's Disease: a Pilot Study

Parkinson Disease

Dietary Supplement: Lactobacillus plantarum PS128

Professor Lu Neurological Clinic

NULL

Completed

40 Years

80 Years

All

N/A

Taiwan

334

JPRN-UMIN000033454

2018/07/01

20/07/2018

A study on the effectiveness of balance rehabilitation support robot (balance exercise assist robot) for Parkinson's patient.

A study on the effectiveness of balance rehabilitation support robot (balance exercise assist robot) for Parkinson's patient. - A study on the effectiveness of balance rehabilitation support robot (balance exercise assist robot) for Parkinson's patient.

Parkinson's Disease

robot assisted balance training (RABT)
The group is taken 40-minute / session, twice a week during 8-weeks. Total intervention sessions are 16.
traditional balance training (TBT)
The group is taken 40-minute / session, twice a week during 8-weeks. Total intervention sessions are 16.

Hyogo College of Medicine

NULL

Recruiting

40years-old

80years-old

Male and Female

Not selected

Japan

335

NCT03576638
(ClinicalTrials.gov)

July 2018

25/6/2018

Study to Assess Pharmacokinetics of Accordion Pill Carbidopa-Levodopa Compared to Immediate Release Carbidopa-Levodopa in Parkinson's Disease Patients

An Open Label Phase 2 Study to Assess the Pharmacokinetics of the Accordion Pill Carbidopa-Levodopa Compared to Immediate Release Carbidopa-Levodopa in Patients With Parkinson's Disease

Parkinson Disease

Drug: Accordion Pill Carbidopa/Levodopa;Drug: Sinemet CR 25Mg-100Mg Extended-Release Tablet

Intec Pharma Ltd.

NULL

Unknown status

30 Years

N/A

All

Phase 2

NULL

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

336

NCT03562494
(ClinicalTrials.gov)

June 28, 2018

16/5/2018

VY-AADC02 for Parkinson's Disease With Motor Fluctuations (RESTORE-1)

A Randomized, Sham Surgery Controlled, Double-blind, Multi-center, Phase 2 Clinical Trial, Evaluating the Efficacy and Safety of VY-AADC02 in Moderate to Advanced Parkinson's Disease Patients With Motor Fluctuations

Parkinson's Disease

Biological: VY-AADC02;Other: Sham (Placebo) Surgery

Neurocrine Biosciences

Voyager Therapeutics

Recruiting

40 Years

75 Years

All

Phase 2

United States

337

NCT03407378
(ClinicalTrials.gov)

June 26, 2018

15/1/2018

A Study to Investigate a New Treatment in Patients With Parkinson's Disease

A Proof of Concept Study to Investigate the Effect of IPT803 Adjunct Treatment in Patients With Parkinson's Disease

Parkinson Disease

Drug: IPT803;Genetic: Optional pharmacogenetic assessment;Other: Questionnaires;Other: Optional Blood-Oxygen-level Dependent functionalMRI;Other: Motor Assessments before taking regular PD treatment;Other: Motor Assessments on regular PD treatment

Tools4Patient

NULL

Completed

35 Years

N/A

All

110

Phase 1;Phase 2

United States;Belgium;France

338

EUCTR2017-001420-21-DE
(EUCTR)

18/06/2018

16/02/2018

Clinical Efficacy, Safety and Tolerability of P2B001 in Early Parkinson's Disease

A Phase 3, Twelve-week, Multi-Center, Multinational, Randomized, Double-Blind, Double-Dummy, Parallel Group Study to Determine the Efficacy, Safety and Tolerability of P2B001 Once Daily Compared to its Individual Components in Subjects With Early Parkinson’s Disease and to a Calibration Arm of Pramipexole ER.

Early Parkinson's Disease
MedDRA version: 20.0;Level: HLT;Classification code 10034005;Term: Parkinson's disease and parkinsonism;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Product Code: P2B001
INN or Proposed INN: PRAMIPEXOLE DIHYDROCHLORIDE
Other descriptive name: PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE
INN or Proposed INN: Rasagiline mesylate
Other descriptive name: RASAGILINE MESILATE
Product Name: Pramipexole dihydrochloride
INN or Proposed INN: PRAMIPEXOLE DIHYDROCHLORIDE
Other descriptive name: PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE
Product Name: Rasagiline
INN or Proposed INN: Rasagiline mesylate
Other descriptive name: RASAGILINE MESILATE
Trade Name: Pramipexole dihydrochloride extended-release tablets
Product Name: Pramipexole dihydrochloride extended-release tablets
INN or Proposed INN: PRAMIPEXOLE DIHYDROCHLORIDE
Other descriptive name: PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE

Pharma Two B Ltd

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

525

Phase 3

United States;France;Canada;Spain;Germany

339

EUCTR2017-001420-21-ES
(EUCTR)

13/06/2018

15/03/2018

Clinical Efficacy, Safety and Tolerability of P2B001 in Early Parkinson's Disease

Pharma Two B Ltd

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

525

Phase 3

United States;France;Canada;Spain;Germany

340

NCT03439943
(ClinicalTrials.gov)

June 13, 2018

13/2/2018

Study to Evaluate the Effect of Lixisenatide in Patient With Parkinson's Disease

Multicenter, Randomised, Placebo-controlled, Double Blinded, Parallel Arm Proof-of-concept Trial of Lixisenatide in Patients With Early Parkinson's Disease

Parkinson Disease

Drug: Lixisenatide;Drug: placebo

University Hospital, Toulouse

Cure Parkinson;Réseau NS-Park;EUCLID;Sanofi

Active, not recruiting

40 Years

75 Years

All

156

Phase 2

France

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

341

EUCTR2017-004006-18-NL
(EUCTR)

07/06/2018

15/11/2017

The effect of inhaled levodopa on the recovery from off periods in patients with Parkinson's disease

Therapeutic effects of an inhaled levodopa dry powder formulation on the recovery from off periods in patients with Parkinson's disease - Effectiveness of inhaled levodopa in Parkinson's disease

Parkinson's disease is a progressive neurodegenerative disorder characterized by a lack of dopamine production due to the loss of dopamine producing cells in the substantia nigra. This lack of dopamine causes disruption of motor circuits in the brain resulting in motor function impairments like tremor, rigidity and bradykinesia.
MedDRA version: 20.0;Level: LLT;Classification code 10013113;Term: Disease Parkinson's;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Product Name: Levodopa powder for inhalation
Product Code: Levodopa Cyclops
INN or Proposed INN: levodopa
Other descriptive name: LEVODOPA
Trade Name: Madopar 125 mg, orodispersible tablet

Pharmaceutical Technology and Biopharmacy, University of Groningen

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

Phase 2

Netherlands

342

NCT03456687
(ClinicalTrials.gov)

June 5, 2018

1/3/2018

Effects of Exenatide on Motor Function and the Brain

Parkinson's Disease

Drug: Exenatide

University of Florida

National Institute of Neurological Disorders and Stroke (NINDS)

Active, not recruiting

40 Years

77 Years

All

Phase 1

United States

343

NCT03510572
(ClinicalTrials.gov)

June 4, 2018

17/4/2018

Evaluation of [18F]PI-2620 as a Potential Positron Emission Computed Tomography Radioligand for Imaging Tau Protein in the Brain

Clinical Evaluation of [18F]PI-2620 Positron Emission Computed Tomography for Imaging Tau Protein in Patients With Tauopathies and Healthy Volunteers: Phase 0 Study

Healthy Volunteer;Alzheimer Disease;Frontotemporal Dementia;Parkinson Disease

Drug: [18F]PI-2620

Asan Medical Center

Korea Health Industry Development Institute

Completed

40 Years

80 Years

All

Early Phase 1

Korea, Republic of

344

EUCTR2018-000346-19-SE
(EUCTR)

04/06/2018

09/04/2018

An extended clinical study to test the safety of Cerebral Dopamine Neurotrophic Factor (CDNF) by brain infusion via Drug Delivery System (DDS) in patients with Parkinson's disease.

Product Name: Cerebral Dopamine Neurotrophic Factor
Product Code: CDNF
INN or Proposed INN: Not Applicable
Other descriptive name: recombinant human Cerebral Dopamine Neurotrophic Factor

Herantis Pharma Plc

NULL

Not Recruiting

Female: yes
Male: yes

Phase 1;Phase 2

Finland;Sweden

345

NCT03532984
(ClinicalTrials.gov)

June 1, 2018

27/4/2018

Beam Walking Across the Lifespan for Falls Prediction

Beam Walking to Assess Dynamic Balance in Health and Disease: A Protocol for the 'BEAM' Multi-center Observational Study

Aging;Parkinson Disease;Stroke;Dementia;Diagnoses Disease;Cognitive Impairment;Postural; Defect

Diagnostic Test: Beam test to predict falls

University Medical Center Groningen

Dokkyo Medical University;University of Potsdam;Somogy Megyei Kaposi Mór Teaching Hospital;University of Sao Paulo

Unknown status

20 Years

80 Years

All

432

Brazil;Germany;Hungary;Japan;Netherlands

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

346

NCT03891069
(ClinicalTrials.gov)

June 1, 2018

18/3/2019

Feasibility of the AHA Exergame System in Parkinson's Disease Patients

Feasibility and Safety of the AHA Exergame System in Parkinson's Disease Patients: a Mixed Methods Study

Parkinson Disease

Device: AHA Exergame System

Campus Neurológico Sénior

University of Lisbon

Completed

40 Years

80 Years

All

N/A

Portugal

347

NCT03684122
(ClinicalTrials.gov)

June 1, 2018

23/9/2018

Use of Mesenchymal Stem Cells (MSCs) Differentiated Into Neural Stem Cells (NSCs) in People With Parkinson's (PD).

A Safety and Efficacy Study of the Effects of Mesenchymal Stem Cells (MSCs) Differentiated Into Neural Stem Cells (NSCs) on the Motor and Non-motor Symptoms in People With Parkinson's Disease (PD).

Parkinson Disease

Biological: Injection of Umbilical cord derived MSCs

University of Jordan

NULL

Recruiting

20 Years

75 Years

All

Phase 1;Phase 2

Jordan

348

EUCTR2017-002780-17-ES
(EUCTR)

21/05/2018

12/02/2018

Study in Male and Female Patients with Advanced Parkinson’s Disease to Assess the blood levels of Levodopa Administered as ND0612 via a Pump System plus Additional Oral Administered Levodopa/Carbidopa versus Levodopa Administered as Duodopa.

A Pivotal, Open-Label, Randomized, Crossover, Four Sequences Study in Male and Female Patients with Advanced Parkinson’s Disease to Assess the Relative Bioavailability of Levodopa Administered as ND0612 Subcutaneous Infusion via a Pump System plus Additional Oral Administered Levodopa/Carbidopa versus Levodopa Administered as Carbidopa-Levodopa Enteral Suspension

Parkinson’s Disease
MedDRA version: 20.0;Level: HLT;Classification code 10034005;Term: Parkinson's disease and parkinsonism;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Product Name: ND0612
Product Code: ND0612
INN or Proposed INN: carbidopa
Other descriptive name: CARBIDOPA
INN or Proposed INN: levodopa
Other descriptive name: LEVODOPA
Trade Name: SINEMET Plus
Product Name: SINEMET
INN or Proposed INN: levodopa
Other descriptive name: LEVODOPA
INN or Proposed INN: carbidopa
Other descriptive name: CARBIDOPA
Trade Name: Duodopa LD/CD 20/5 mg/mL
Product Name: Duodopa LD/CD 20/5 mg/mL
INN or Proposed INN: levodopa
Other descriptive name: LEVODOPA
INN or Proposed INN: carbidopa
Other descriptive name: CARBIDOPA

NeuroDerm Ltd.

NULL

Not Recruiting

Female: yes
Male: yes

Phase 3

France;United States;Spain;Austria;Netherlands;Italy

349

EUCTR2016-004610-95-ES
(EUCTR)

18/05/2018

07/03/2018

Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Participants with Parkinson’s Disease

Product Code: BIIB054
INN or Proposed INN: n/a
Other descriptive name: BIIB054

Biogen Idec Research Limited

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

311

Phase 2

France;United States;Canada;Spain;Austria;Israel;Germany;Italy;United Kingdom;Sweden

350

NCT03589066
(ClinicalTrials.gov)

May 15, 2018

8/6/2018

Pharmacokinetic Study of LY03003 in Patients With Parkinson's Disease

An Open-label, Randomized, Parallel-group Trial to Evaluate the Pharmacokinetics of Two Formulations of LY03003 After a Single Intramuscular Injection Administered to Patients With Parkinson's Disease

Parkinson Disease

Drug: LY03003

Luye Pharma Group Ltd.

NULL

Completed

18 Years

N/A

All

Phase 1

United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

351

EUCTR2017-004475-31-CZ
(EUCTR)

09/05/2018

Safety and efficacy study of two THN102 doses in subjects with excessive daytime sleepiness associated with Parkinson’s disease.

Randomised, double-blind, placebo-controlled, complete 3-way cross-over phase IIa trial to investigate safety and efficacy of two THN102 doses in subjects with excessive daytime sleepiness associated with Parkinson’s disease

Excessive daytime sleepiness associated with Parkinson’s disease
MedDRA version: 20.0;Level: SOC;Classification code 10029205;Term: Nervous system disorders;System Organ Class: 10029205 - Nervous system disorders
MedDRA version: 20.0;Level: PT;Classification code 10041349;Term: Somnolence;System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Theranexus S.A.

NULL

Not Recruiting

Female: yes
Male: yes

Phase 2

France;United States;Hungary;Czech Republic;Germany

352

NCT03541356
(ClinicalTrials.gov)

May 8, 2018

5/4/2018

Therapeutic Potential for Intranasal Levodopa in Parkinson's Disease -Off Reversal

A Phase IIa, Randomized, Double Blind, Placebo Controlled, Single Ascending Dose, Safety and Pharmacokinetic/Pharmacodynamic Study of INP103 (POD L-dopa) Administered in the Presence of DCI to L-dopa Responsive Parkinson's Disease Patients

Parkinson's Disease

Combination Product: Placebo;Combination Product: L-dopa 35 mg;Combination Product: L-dopa 70mg;Combination Product: L-dopa 140 mg;Combination Product: L-dopa 70mg /carbidopa 7mg

Impel NeuroPharma Inc.

NULL

Completed

40 Years

80 Years

All

Phase 2

Australia

353

NCT03587649
(ClinicalTrials.gov)

May 7, 2018

3/7/2018

Evaluation of [18F]MNI-1126 as an Imaging Marker for Synaptic Density Loss

Evaluation of [18F]MNI-1126 as an Imaging Marker for Synaptic Density Loss in the Brain of Patients With Probable Alzheimer's Disease, Probable Parkinson's Disease (PD) Subjects as Compared to Healthy Volunteers (HV).

Alzheimer Disease;Parkinson Disease;Healthy Volunteers

Drug: [18F]MNI-1126

Invicro

NULL

Completed

18 Years

55 Years

All

Phase 1

United States

354

NCT04228887
(ClinicalTrials.gov)

May 4, 2018

5/8/2019

Effects of Inspiratory Muscle Training in Patients With Parkinson's Disease

Effects of Inspiratory Muscle Training on Postural Stability, Mobility, Activities of Daily Living, Quality of Life and Respiratory Function in Patients With Parkinson's Disease

Parkinson Disease

Diagnostic Test: Respiratory Muscle Strength;Device: Balance Training;Device: Inspiratory Muscle Training

Bezmialem Vakif University

NULL

Completed

60 Years

85 Years

All

N/A

Turkey

355

NCT03843944
(ClinicalTrials.gov)

May 1, 2018

12/2/2019

Overnight Switch From Rasagiline To Safinamide

Overnight Switch From Rasagiline To Safinamide In Fluctuating Patients With Parkinson's Disease: A Tolerability And Safety Study

Parkinson Disease

Drug: Safinamide

IRCCS San Raffaele

NULL

Completed

30 Years

80 Years

All

Phase 4

Italy

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

356

EUCTR2016-004610-95-GB
(EUCTR)

01/05/2018

27/12/2017

Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Participants with Parkinson’s Disease

Product Code: BIIB054
INN or Proposed INN: n/a
Other descriptive name: BIIB054

Biogen Idec Research Limited

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

357

Phase 2

United States;France;Canada;Spain;Austria;Israel;Germany;Italy;United Kingdom

357

EUCTR2017-002780-17-FR
(EUCTR)

26/04/2018

27/02/2018

Parkinson’s Disease
MedDRA version: 20.0;Level: HLT;Classification code 10034005;Term: Parkinson's disease and parkinsonism;System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

NeuroDerm Ltd.

NULL

Not Recruiting

Female: yes
Male: yes

Phase 3

United States;France;Spain;Austria;Netherlands;Italy

358

NCT03230526
(ClinicalTrials.gov)

April 20, 2018

18/7/2017

Identification of a Biomarker Predictive of Evolution of Parkinson Disease

Brain Microglial Activation in the Early Stage of the Parkinson's Disease: a Predictive Biomarker of the Evolution?

Parkinson Disease

Drug: [18F]DPA-714 PET scan

Nantes University Hospital

NULL

Recruiting

40 Years

67 Years

All

Phase 2

France

359

NCT03374917
(ClinicalTrials.gov)

April 18, 2018

8/12/2017

A Study in Subjects With Parkinson's Disease to Evaluate the Safety and Tolerability of Titration and Continuous Subcutaneous Infusion of ABBV-951 in an Outpatient Environment

An Open-Label Study in Subjects With Parkinson's Disease to Evaluate the Safety and Tolerability of Titration and Continuous Subcutaneous Infusion of ABBV-951 for up to 4 Weeks in an Outpatient Environment

Parkinson's Disease (PD)

Drug: ABBV-951

AbbVie

NULL

Completed

30 Years

85 Years

All

Phase 1

United States

360

EUCTR2017-004475-31-HU
(EUCTR)

17/04/2018

09/02/2018

Safety and efficacy study of two THN102 doses in subjects with excessive daytime sleepiness associated with Parkinson’s disease.

Excessive daytime sleepiness associated with Parkinson’s disease
MedDRA version: 20.0;Level: SOC;Classification code 10029205;Term: Nervous system disorders;System Organ Class: 10029205 - Nervous system disorders
MedDRA version: 20.0;Level: PT;Classification code 10041349;Term: Somnolence;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Product Name: Flecainide acetate
Product Code: THN02
INN or Proposed INN: Flecainidum
Other descriptive name: FLECAINIDE ACETATE
Product Name: Flecainide acetate
Product Code: THN02
INN or Proposed INN: Flecainidum
Other descriptive name: FLECAINIDE ACETATE
Trade Name: Modiodal
Product Name: over-encapsulated Modafinil
INN or Proposed INN: MODAFINIL

Theranexus S.A.

NULL

Not Recruiting

Female: yes
Male: yes

Phase 2

France;United States;Czech Republic;Hungary;Germany

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

361

EUCTR2017-004253-16-AT
(EUCTR)

13/04/2018

27/02/2018

Investigation of the effect of Nabilon in patients suffering from Parkinson´s Disease with non-Motor symptoms (e.g.sleeping dirsorders, cognitive dysfunction, hallucinations, autonomic dysfunction,...)

Nabilone for non-motor symptoms in Parkinson’s disease: An open-label study to evaluate long-term safety and efficacy

Subject with non-Motor symptoms of Parkinson´s disease
MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Medizinische Universität Innsbruck, Universitätsklinik für Neurologie

NULL

Not Recruiting

Female: yes
Male: yes

Phase 3

Austria

362

NCT03368170
(ClinicalTrials.gov)

April 12, 2018

5/12/2017

Efficacy and Tolerability of IRL790 in Parkinson's Disease Dyskinesia

A Randomized, Placebo-controlled, Phase IIa Study Evaluating the Efficacy and Tolerability of IRL790 in Parkinson's Disease Dyskinesia

Parkinson Disease

Drug: Mesdopetam (IRL790)

Integrative Research Laboratories AB

The Clinical Trial Company

Completed

18 Years

79 Years

All

Phase 2

Sweden;United Kingdom

363

EUCTR2017-002707-10-DK
(EUCTR)

10/04/2018

03/11/2017

Measurements of drug concentration in the blood for anti-dementia drugs, in order to improve efficacy and reduce side-effects

Serum-monitoring of anti-dementia drugs, and the relevance to side-effects, clinical efficacy and compliance

Dementia in Alzheimers Disease, Parkinsons Disease and Dementia with Lewy Bodies
MedDRA version: 20.0;Level: PT;Classification code 10012271;Term: Dementia Alzheimer's type;System Organ Class: 10029205 - Nervous system disorders
MedDRA version: 20.0;Level: LLT;Classification code 10012284;Term: Dementia due to Parkinson's disease;Classification code 10067889;Term: Dementia with Lewy bodies;Classification code 10075174;Term: Mixed dementia;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Trade Name: Memantin Orion
INN or Proposed INN: MEMANTINE
Product Name: Donepezil Sandoz
Product Code: 25330
INN or Proposed INN: DONEPEZIL

Regional Dementia Research Centre, Dept of Neurology

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

110

Phase 4

Denmark

364

EUCTR2017-002780-17-IT
(EUCTR)

10/04/2018

04/11/2020

study in patients with Parkinson's disease to evaluate the bioavailability of levodopa administered as subcutaneous infusion

A Pivotal, Open-Label, Randomized, Crossover, Four Sequences Study in Male and Female Patients with Advanced Parkinson¿s Disease to Assess the Relative Bioavailability of Levodopa Administered as ND0612 Subcutaneous Infusion via a Pump System plus Additional Oral Administered Levodopa/Carbidopa versus Levodopa Administered as Carbidopa-Levodopa Enteral Suspension - study in patients with Parkinson's disease to evaluate the bioavailability of levodopa administered

Parkinson¿s Disease
MedDRA version: 20.0;Level: HLT;Classification code 10034005;Term: Parkinson's disease and parkinsonism;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Trade Name: SINEMET Plus
Product Name: SINEMET
INN or Proposed INN: LEVODOPA
INN or Proposed INN: CARBIDOPA
Trade Name: Duodopa LD/CD 20/5 mg/mL
Product Name: Duodopa LD/CD 20/5 mg/mL
INN or Proposed INN: LEVODOPA
Other descriptive name: levodopa
INN or Proposed INN: CARBIDOPA
Other descriptive name: carbidopa
Product Name: ND0612
Product Code: ND0612
INN or Proposed INN: CARBIDOPA
Other descriptive name: carbidopa
INN or Proposed INN: LEVODOPA
Other descriptive name: levodopa

NEURODERM LTD.

NULL

Not Recruiting

Female: yes
Male: yes

Phase 3

United States;France;Spain;Austria;Netherlands;Italy

365

EUCTR2016-003456-70-DE
(EUCTR)

04/04/2018

03/04/2017

A clinical trial to compare APL-130277 sublingual film to Subcutaneous Apomorphine in Parkinson’s Disease patients

An Open-Label, Randomized, Crossover Trial utilizing a Single-Blinded Rater to evaluate APL-130277 compared to s.c. Apomorphine in Levodopa Responsive Subjects with Parkinson’s Disease Complicated by Motor Fluctuations

Levodopa Responsive Patients with Parkinson’s Disease Complicated by Motor Fluctuations (OFF episodes)
MedDRA version: 22.1;Level: LLT;Classification code 10034006;Term: Parkinson's disease aggravated;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Product Name: Apomorphine hydrochloride
Product Code: APL-130277
INN or Proposed INN: Apomorphine hydrochloride
Other descriptive name: APOMORPHINE HYDROCHLORIDE
Trade Name: APO-go
Product Name: s.c. apomorphine
INN or Proposed INN: Apomorphine hydrochloride
Other descriptive name: APOMORPHINE HYDROCHLORIDE
Product Name: Apomorphine hydrochloride
Product Code: APL-130277
INN or Proposed INN: Apomorphine hydrochloride
Other descriptive name: APOMORPHINE HYDROCHLORIDE
Product Name: Apomorphine hydrochloride
Product Code: APL-130277
INN or Proposed INN: Apomorphine hydrochloride
Other descriptive name: APOMORPHINE HYDROCHLORIDE
Product Name: Apomorphine hydrochloride
Product Code: APL-130277
INN or Proposed INN: Apomor

Sunovion Pharmaceuticals Inc.

NULL

Not Recruiting

Female: yes
Male: yes

106

Phase 3

France;Spain;Austria;Germany;United Kingdom;Italy

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

366

ChiCTR1800015331

2018-04-01

2018-03-23

Dopaminergic Mechanisms of Temporal Working Memory in Parkinson's Disease

Parkinson's disease

de novo PD patients:levodopa 4 weeks;de novo PD patients:pramipexole 4 weeks;de novo PD patients:selegiline 4 weeks;

Institute of Psychology, Chinese Academy of Sciences

NULL

Recruiting

Both

de novo PD patients:50;de novo PD patients:50;de novo PD patients:50;

China

367

NCT03827746
(ClinicalTrials.gov)

April 1, 2018

31/1/2019

The Effect of Kinesiophobia on Physical Activity, Balance and Falling in Parkinson's Disease Patients

Parkinson Disease;Kinesiophobia;Physical Activity;Balance;Falling

Other: Tampa Kinesiophobia Scale, Berg-Balance Test, International Physical Activity Questionnaire-Short Form, Falls Efficacy Scale

Istanbul Kültür University

Marmara University;Istanbul University-Cerrahpasa;Koç University

Completed

40 Years

85 Years

All

Turkey

368

EUCTR2017-004297-34-GB
(EUCTR)

31/03/2018

22/06/2018

Use of low-dose zolpidem in Parkinson's.

A placebo controlled double blind randomised controlled proof of concept study of zolpidem for the treatment of motor and cognitive deficits in late-stage Parkinson’s - Zolpidem for treatment of motor and cognitive deficits in Parkinson's

Trade Name: Stilnoct
Product Name: Stilnoct
Product Code: 207-3120
INN or Proposed INN: Zolpidem Tartrate

Aston University

NULL

Not Recruiting

Female: yes
Male: yes

Phase 2

United Kingdom

369

NCT03648671
(ClinicalTrials.gov)

March 28, 2018

26/6/2018

Pain in Parkinson's Disease With Motor Fluctuations.

Spontaneous and Evoked Pain in Parkinson's Disease With Motor Fluctuations: an Observational, Prospective, Clinical and Neurophysiological Study in Patients Under L-dopa Add on Therapies.

Parkinson Disease

Drug: safinamide metansolfonato (12 weeks);Drug: rasagilina mesilato (12 weeks)

Universita di Verona

Azienda Ospedaliera Universitaria Integrata Verona

Unknown status

18 Years

80 Years

All

Italy

370

EUCTR2018-000405-23-FI
(EUCTR)

27/03/2018

21/02/2018

Postitron emission tomography imaging of neuroinflammation in Parkinson´s disease

In vivo PET imaging of neuroinflammation in Parkinson’s disease using the purinergic P2X7 receptor ligand [11C]SMW139 (PRI-PD) - PRI-PD

Parkinson´s disease
MedDRA version: 20.0;Level: LLT;Classification code 10034007;Term: Parkinson's disease NOS;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Product Name: (2-chloro-5-[11C]methoxy-N-(((3s,5s,7s)-3,5,7-trifluoroadamantan-1-yl)methyl) benzamide)
Product Code: [11C]SMW139

Juha Rinne / PET Centre

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

Phase 2

Finland

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

371

EUCTR2016-004610-95-AT
(EUCTR)

23/03/2018

04/01/2018

Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Participants with Parkinson’s Disease

Product Code: BIIB054
INN or Proposed INN: n/a
Other descriptive name: BIIB054

Biogen Idec Research Limited

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

357

Phase 2

United States;France;Canada;Spain;Austria;Israel;Germany;United Kingdom;Italy

372

NCT03457493
(ClinicalTrials.gov)

March 22, 2018

23/2/2018

TSPO-PET for Neuroinflammation in Parkinson's Disease

UAB Neuroinflammation in Parkinson's Disease - TSPO-PET Substudy

Parkinson Disease

Drug: DPA -714-PET/MRI

University of Alabama at Birmingham

NULL

Recruiting

30 Years

N/A

All

Phase 1;Phase 2

United States

373

NCT03301272
(ClinicalTrials.gov)

March 22, 2018

13/9/2017

Effectiveness of Botox on Reducing Rest Tremor in Parkinson's Disease

Effectiveness of Onabotulinumtoxin A on Reduction of Rest Tremor in Parkinson's Disease: a Pilot Study

Parkinson Disease

Drug: Onabotulinumtoxin A Injection;Other: Placebo

University of North Carolina, Chapel Hill

NULL

Completed

45 Years

80 Years

All

Phase 2

United States

374

NCT03482882
(ClinicalTrials.gov)

March 9, 2018

23/3/2018

Safety and Efficacy of Pimavanserin in Adults With Parkinson's Disease and Depression

An Open-label, 8-Week Study of Safety and Efficacy of Pimavanserin Treatment in Adults With Parkinson's Disease and Depression

Treatment of Depression in Adults With Parkinson's Disease (PD)

Drug: Pimavanserin

ACADIA Pharmaceuticals Inc.

NULL

Completed

50 Years

N/A

All

Phase 2

United States

375

NCT03462641
(ClinicalTrials.gov)

March 9, 2018

6/3/2018

Modulation of GABA-A Receptors in Parkinson Disease-Flumazenil Arm

Modulation of GABA-A Receptors and Axial Motor Impairments in Parkinson Disease-Flumazenil Arm

Parkinson Disease

Drug: Flumazenil;Drug: Placebo

University of Michigan

National Institute of Neurological Disorders and Stroke (NINDS)

Recruiting

50 Years

99 Years

All

Phase 1;Phase 2

United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

376

NCT03149809
(ClinicalTrials.gov)

March 1, 2018

9/5/2017

Behavioral or Solifenacin Therapy for Urinary Symptoms in Parkinson Disease

Overactive Bladder;Parkinson Disease

Drug: solifenacin;Behavioral: Pelvic floor muscle exercise-based behavioral therapy

VA Office of Research and Development

NULL

Recruiting

N/A

All

Phase 3

United States

377

NCT04265027
(ClinicalTrials.gov)

February 20, 2018

7/2/2020

Bioavailability and Bioequivalence Between Two Active Pharmaceutical Ingredient (API) Sources of Opicapone (OPC)

An Open Label, Randomised, Two Period, Crossover Study to Assess Bioavailability, Bioequivalence and S COMT Activity Between Two Active Pharmaceutical Ingredient Sources of Opicapone at Two Different Dosage Strengths (50 mg and 25 mg) After Single and Multiple Dose Administrations Under Fasting Conditions in Healthy Volunteers.

Parkinson Disease

Drug: 50 mg BIA 9 1067;Drug: 25 mg BIA9 1067;Drug: 50 mg Ongentys;Drug: 25 mg Ongentys

Bial - Portela C S.A.

NULL

Completed

18 Years

55 Years

All

Phase 1

United Kingdom

378

NCT03419806
(ClinicalTrials.gov)

February 16, 2018

10/1/2018

Study Comparing Intravenous and Subcutaneous Infudopa With Intestinal Duodopa in Patients With Parkinson's Disease

Levodopa Pharmacokinetics in Patients With Parkinson's Disease and Symptom Fluctuation: A Phase I, Open-label, Randomized, Multicentre, Crossover Study Comparing Intravenous and Subcutaneous Infudopa With Intestinal Duodopa

Parkinson Disease

Drug: Infudopa i.v.;Drug: Infudopa s.c.;Drug: LCIG (Duodopa)

Vastra Gotaland Region

The Swedish Research Council;Dizlin Medical Design AB;Göteborg University

Completed

30 Years

N/A

All

Phase 1

Sweden

379

NCT03882398
(ClinicalTrials.gov)

February 15, 2018

11/3/2019

Effects of a High-intensity Progressive-cycle Program on Quality of Life and Motor Symptomatology in Parkinson's Disease

Effects of a High-intensity Progressive-cycle Program on Quality of Life and Motor Symptomatology in Parkinson's Disease Population: a Pilot Randomized Controlled Trial

Parkinson Disease;Exercise;Physical Activity;Quality of Life

Other: Balance;Other: Endurance

University of Vigo

NULL

Completed

60 Years

80 Years

All

N/A

Spain

380

NCT03496870
(ClinicalTrials.gov)

February 8, 2018

1/3/2018

A Study of the Pharmacokinetics, Pharmacodynamics, and Safety of Opicapone in Subjects With Parkinson's Disease Taking Levodopa.

A Phase 1, Open-Label Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Repeated Doses of Opicapone, and Effect on Levodopa Pharmacokinetics in Subjects With Parkinson's Disease

Parkinson Disease

Drug: Opicapone;Drug: Carbidopa Levodopa

Neurocrine Biosciences

NULL

Completed

18 Years

85 Years

All

Phase 1

United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

381

EUCTR2016-003456-70-ES
(EUCTR)

06/02/2018

07/12/2017

A clinical trial to compare APL-130277 sublingual film to Subcutaneous Apomorphine in Parkinson’s Disease patients

Levodopa Responsive Patients with Parkinson’s Disease Complicated by Motor Fluctuations (OFF episodes)
MedDRA version: 20.0;Level: LLT;Classification code 10034006;Term: Parkinson's disease aggravated;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Sunovion Pharmaceuticals Inc.

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

Phase 3

Spain;Austria;United Kingdom

382

NCT03189563
(ClinicalTrials.gov)

February 6, 2018

12/6/2017

Safety and Efficacy of DA-9805 for Parkinson's Disease

A Phase IIa, Randomized, Multicenter, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of DA-9805 in Subjects With Parkinson's Disease

Parkinson's Disease

Drug: DA-9805 45mg;Drug: DA-9805 90mg;Other: Placebo

Dong-A ST Co., Ltd.

NULL

Completed

30 Years

79 Years

All

Phase 2

United States

383

EUCTR2016-000637-43-ES
(EUCTR)

06/02/2018

07/12/2017

Safety, tolerability and efficacy study to examine APL-130277 in patients with Parkinson’s Disease.

An Open-Label, Phase 3 Study Examining the Long-Term Safety, Tolerability and Efficacy of APL-130277 in Levodopa Responsive Patients with Parkinson’s Disease Complicated by Motor Fluctuations (OFF” Episodes).

Levodopa Responsive Patients with Parkinson’s Disease complicated by Motor Fluctuations (OFF” Episodes)
MedDRA version: 20.0;Level: LLT;Classification code 10034006;Term: Parkinson's disease aggravated;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Sunovion Pharmaceuticals Inc.

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

450

Phase 3

France;United States;Canada;Spain;Austria;Germany;Italy;United Kingdom

384

EUCTR2016-000637-43-AT
(EUCTR)

01/02/2018

15/12/2017

Safety, tolerability and efficacy study to examine APL-130277 in patients with Parkinson’s Disease.

Levodopa Responsive Patients with Parkinson’s Disease complicated by Motor Fluctuations (OFF” Episodes)
MedDRA version: 22.1;Level: LLT;Classification code 10034006;Term: Parkinson's disease aggravated;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Sunovion Pharmaceuticals Inc.

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

450

Phase 3

United States;France;Canada;Spain;Austria;Germany;United Kingdom;Italy

385

NCT03329508
(ClinicalTrials.gov)

January 29, 2018

30/10/2017

A Phase 3 Study With P2B001 in Subjects With Early Parkinson's

A Phase 3, Twelve-week Study to Determine the Efficacy, Safety and Tolerability of P2B001 Once Daily Compared to Its Individual Components in Subjects With Early Parkinson's Disease and to a Calibration Arm of Pramipexole ER.

Parkinson Disease

Drug: P2B001;Drug: Rasagiline;Drug: Pramipexole;Drug: Pramipexole ER

Pharma Two B Ltd.

NULL

Recruiting

35 Years

80 Years

All

525

Phase 3

United States;Canada;Germany;Spain

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

386

NCT03440112
(ClinicalTrials.gov)

January 29, 2018

26/1/2018

Modulation of GABA-A Receptors in Parkinson Disease-Transdermal Flumazenil Arm

Modulation of GABA-A Receptors and Axial Motor Impairments in Parkinson

Parkinson Disease

Drug: Clarithromycin (Not used as of 4/2020);Drug: Placebo (Not used as of 4/2020);Drug: Transdermal flumazenil (Added 4/2020);Drug: Placebo (Added 4/2020)

Nicolaas Bohnen, MD, PhD

National Institute of Neurological Disorders and Stroke (NINDS)

Recruiting

50 Years

N/A

All

Phase 1;Phase 2

United States

387

JPRN-UMIN000030930

2018/01/29

01/01/2019

Study on efficacy and safety of the simultaneous treatment with febuxostat and inosine of patients with Parkinson's disease.

Study on efficacy and safety of the simultaneous treatment with febuxostat and inosine of patients with Parkinson's disease. - Effect of febuxostat and inosine on Parkinson's disease

Parkinson's disease

Administration of febuxostat 20 mg and inosine 500 mg twice a day for 58 days

StaGen Co. Ltd.

NULL

Complete: follow-up complete

20years-old

80years-old

Male and Female

Not selected

Japan

388

EUCTR2016-001403-23-HU
(EUCTR)

23/01/2018

22/01/2018

12-Week study comparing Levodopa-Carbidopa Intestinal Gel / Levodopa Carbidopa Enteral Suspension to Optimized Medical Treatment on dyskinesia in subjects with advanced Parkinson's disease

An Open-label, Randomized 12 Week Study Comparing Efficacy of Levodopa-Carbidopa Intestinal Gel/Carbidopa-Levodopa Enteral Suspension and Optimized Medical Treatment on Dyskinesia in Subjects with Advanced Parkinson's Disease - DYSCOVER (DYSkinesia COmparative interventional trial on Duodopa VERsus oral medication) - DYSCOVER Study

Dyskinesia in advanced Parkinson's disease
MedDRA version: 20.0;Level: LLT;Classification code 10013113;Term: Disease Parkinson's;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Trade Name: Duodopa
INN or Proposed INN: Levodopa
Other descriptive name: LEVODOPA
INN or Proposed INN: Carbidopa
Other descriptive name: CARBIDOPA MONOHYDRATE

AbbVie Deutschland GmbH & Co. KG

NULL

Not Recruiting

Female: yes
Male: yes

Phase 3

United States;Hungary;Slovakia;European Union;Greece;Finland;Spain

389

ChiCTR1800014542

2018-01-22

2018-01-20

Up-down sequential testing of propofol - induced half-effective dose ( ed50 ) in patients with Parkinson's disease and non - Parkinson's disease

Parkinson's Disease

PD group:propofol;NPD group:propofol;

Xuanwu Hospital of CCMU

NULL

Recruiting

Both

PD group:40;NPD group:40;

China

390

NCT03531086
(ClinicalTrials.gov)

January 19, 2018

8/5/2018

Idiopathic Parkinson's Progression and Dopamine Transporter SPECT

Exploring Dopamine Transporter Single-photon Emission Computer Tomography Quantification as a Measure of Disease Progression in Idiopathic Parkinson's Disease

Parkinson Disease

Drug: Ioflupane I 123

Julie Gurwell

NULL

Active, not recruiting

40 Years

75 Years

All

United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

391

NCT03331848
(ClinicalTrials.gov)

January 15, 2018

1/11/2017

Study to Evaluate the Efficacy, Safety, and Tolerability of PXT002331 (Foliglurax) in Reducing Levodopa-Induced Dyskinesia and Wearing OFF in Subjects With Parkinson's Disease Experiencing Motor Complications of Levodopa Therapy (ATTUNED)

A Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-arm Phase IIa Trial to Evaluate the Efficacy, Safety, and Tolerability of 8-week Oral Treatment With PXT002331 (Foliglurax) in Reducing Levodopa-Induced Dyskinesia and Wearing OFF in Subjects With Parkinson's Disease Experiencing Motor Complications of Levodopa Therapy (ATTUNED)

Parkinson Disease

Drug: Placebo oral capsule;Drug: PXT002331 - 20mg

Prexton Therapeutics

NULL

Withdrawn

35 Years

85 Years

All

Phase 2

NULL

392

NCT03318523
(ClinicalTrials.gov)

January 10, 2018

19/10/2017

Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Participants With Parkinson's Disease

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study, With an Active-Treatment Dose-Blinded Period, to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Subjects With Parkinson's Disease

Parkinson's Disease

Drug: Placebo;Drug: BIIB054

Biogen

NULL

Active, not recruiting

40 Years

80 Years

All

357

Phase 2

United States;Austria;Canada;France;Germany;Israel;Italy;Spain;United Kingdom

393

NCT03550183
(ClinicalTrials.gov)

January 10, 2018

11/5/2018

Umbilical Cord Derived Mesenchymal Stem Cells Therapy in Parkinson's Disease

Safety and Efficacy Investigation of Patients With Parkinson's Disease by Transplantation of Umbilical Cord Derived Mesenchymal Stem Cells

Parkinson's Disease

Biological: mesenchymal stem cells

Hebei Newtherapy BIo-Pharma technology Co., Ltd.

NULL

Enrolling by invitation

40 Years

80 Years

All

Phase 1

China

394

EUCTR2016-003456-70-AT
(EUCTR)

04/01/2018

16/11/2017

A clinical trial to compare APL-130277 sublingual film to Subcutaneous Apomorphine in Parkinson’s Disease patients

Levodopa Responsive Patients with Parkinson’s Disease Complicated by Motor Fluctuations (OFF episodes)
MedDRA version: 21.1;Level: LLT;Classification code 10034006;Term: Parkinson's disease aggravated;System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Sunovion Pharmaceuticals Inc.

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

106

Phase 3

France;Spain;Austria;Germany;Italy;United Kingdom

395

EUCTR2017-000087-15-DE
(EUCTR)

21/12/2017

17/05/2017

A Study to Evaluate the Efficacy of Intravenous RO7046015/Prasinezumab (PRX002) in Participants with Early Parkinson’s Disease with a 6 -Year all-Participants-on Treatment Extension (Pasadena)

A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 52-WEEK PHASE II STUDY TO EVALUATE THE EFFICACY OF INTRAVENOUS RO7046015 (PRX002) IN PARTICIPANTS WITH EARLY PARKINSON’S DISEASE WITH A 52 WEEK BLINDED EXTENSION (PASADENA)

Parkinson’s disease
MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Product Name: aSyn Mab
Product Code: RO7046015
INN or Proposed INN: N/A
Other descriptive name: PRX002, ELT2, anti-alpha-synuclein monoclonal antibody

F. Hoffmann-La Roche Ltd

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

300

Phase 2

United States;France;Spain;Austria;Germany

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

396

EUCTR2017-003458-18-GB
(EUCTR)

19/12/2017

27/09/2017

A clinical trial to study the effects of IRL790 in Parkinson's disease dyskinesia

A randomised, double-blind, placebo-controlled, phase IIA study evaluating the efficacy and tolerability of IRL790 in Parkinson's disease dyskinesia

Integrative Research Laboratories AB (IRLAB)

NULL

Not Recruiting

Female: yes
Male: yes

Phase 2

United Kingdom;Sweden

397

NCT03321019
(ClinicalTrials.gov)

December 12, 2017

20/10/2017

Airway Protective Mechanisms in PD (R01)

Mechanisms of Airway Protection Dysfunction in Parkinson's Disease

Parkinson Disease

Drug: Capsaicin;Device: Resistive respiratory loads;Other: Event-related evoked potential using electroencephalography (EEG).;Procedure: Fluoroscopic swallow evaluation

University of Florida

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Recruiting

45 Years

85 Years

All

260

United States

398

EUCTR2017-000877-35-IT
(EUCTR)

04/12/2017

10/11/2020

A phase IIb, randomized, double blind, parallel group, placebo control, multicentre, 6-week dose-finding study to assess the efficacy and safety of Bavisant for the treatment of excessive daytime sleepiness in subjects with Parkinson's disease.

Dose finding phase IIb study of Bavisant to evaluate its safety and efficacy in treatment of excessive daytime sleepiness (EDS) in parkinson's Disease (PD). - Treatment of excessive daytime sleepiness with Bavisant in Parkinson's Disease Patients (CASPAR)

Excessive daytime sleepiness with Parkinson's Disease
MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Product Name: Bavisant
Product Code: JNJ31-31001074
INN or Proposed INN: Bavisant dihydrochloride monohydrate
Product Name: Bavisant
Product Code: [JNJ31-31001074]
INN or Proposed INN: Bavisant dihydrochloride monohydrate
Product Name: Bavisant
Product Code: JNJ-31001074
INN or Proposed INN: Bavisant dihydrochloride monohydrate

BENEVOLENTAI BIO

NULL

Not Recruiting

Female: yes
Male: yes

240

Phase 2

United States;Czechia;Czech Republic;Spain;Poland;Germany;United Kingdom;Italy

399

JPRN-UMIN000030084

2017/12/01

01/12/2017

Practical evaluation of PET studies with [18F]-GE180, [18F]-FDOPA and [18F]-FLT for a future clinical trial of iPSC-based cell therapy in Parkinson's disease

neuroinflammatory disorder, Parkinson's disease, Brain tumor

[18F]GE180 is injected intravenously as 3-4 MBq/Kg. PET is dynamically scanned for 90 minutes.

Carbidopa 150mg is administrated orally 1hr before scan.[18F]FDOPA is injected intravenously as 3-4 MBq/Kg. Dynamic PET is scanned for 90 minutes.

[18F]FLT is injected intravenously as 3-4 MBq/Kg. Statical PET is scanned after 60 minutes

Kyoto University

NULL

Complete: follow-up complete

50years-old

Not applicable

Male and Female

Phase 1;Phase 2

Japan

400

NCT03377322
(ClinicalTrials.gov)

December 1, 2017

7/12/2017

Trial of Probiotics for Constipation in Parkinson's Disease

A Randomized Double-Blinded Placebo-Controlled Trial of Probiotics for Constipation in Parkinson's Disease

Parkinson Disease

Drug: Probiotic Capsule;Drug: Placebo Capsule

University of Malaya

NULL

Completed

40 Years

85 Years

All

N/A

Malaysia

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

401

NCT03944785
(ClinicalTrials.gov)

November 30, 2017

1/5/2019

Clinical Outcome Assessment of Parkinson's Disease Patients Treated With XADAGO (Safinamide)

A Prospective, Observational Study to Evaluate Changes in Non-Motor Symptoms and Other Clinical Outcome Assessments of Parkinson's Disease Patients Treated With XADAGO (Safinamide)Tablets

Idiopathic Parkinson Disease

Drug: XADAGO (safinamide)

US WorldMeds LLC

NULL

Completed

30 Years

80 Years

All

209

United States

402

EUCTR2016-002033-30-GB
(EUCTR)

27/11/2017

05/09/2017

NeuroDerm Ltd.

NULL

Not Recruiting

Female: yes
Male: yes

240

Phase 3

Serbia;Portugal;United States;Spain;Ukraine;Russian Federation;Chile;Israel;United Kingdom;Italy;France;Czech Republic;Hungary;Poland;Belgium;Denmark;Netherlands;Germany

403

NCT03194217
(ClinicalTrials.gov)

November 10, 2017

19/6/2017

BEN-2001 in Parkinson Disease Patients With Excessive Daytime Sleepiness

Dose Finding Phase IIb Study of Bavisant to Evaluate Its Safety and effiCacy in treAtment of exceSsive Daytime sleePiness (EDS) in PARkinson's Disease (PD).

Excessive Daytime Sleepiness;Parkinson Disease

Drug: BEN-2001;Drug: Placebo

BenevolentAI Bio

NULL

Completed

50 Years

80 Years

All

244

Phase 2

United States

404

NCT03305809
(ClinicalTrials.gov)

November 9, 2017

4/10/2017

A Study of LY3154207 in Participants With Dementia Due to Lewy Body Dementia (LBD) Associated With Idiopathic Parkinson's Disease (PD) or Dementia With Lewy Bodies (DLB)

Effect of LY3154207 on Cognition in Mild-to-Moderate Dementia Due to Lewy Body Dementia (LBD) Associated With Idiopathic Parkinson's Disease (PD) or Dementia With Lewy Bodies (DLB)

Lewy Body Dementia

Drug: LY3154207;Drug: Placebo

Eli Lilly and Company

NULL

Completed

40 Years

85 Years

All

344

Phase 2

United States;Canada;Puerto Rico;China

405

EUCTR2016-002033-30-HU
(EUCTR)

08/11/2017

19/09/2017

Subjects with Parkinson’s Disease with motor fluctuations
MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Product Name: levodopa /carbidopa solution
Product Code: ND0612
INN or Proposed INN: Levodopa
Other descriptive name: Levodopa
INN or Proposed INN: Carbidopa
Other descriptive name: CARBIDOPA
Product Name: levodopa /carbidopa solution
Product Code: ND0612
INN or Proposed INN: Levodopa
Other descriptive name: Levodopa
INN or Proposed INN: Carbidopa
Other descriptive name: CARBIDOPA

NeuroDerm Ltd.

NULL

Not Recruiting

Female: yes
Male: yes

240

Phase 3

Serbia;Portugal;United States;Spain;Ukraine;Russian Federation;Chile;Israel;United Kingdom;Italy;France;Hungary;Czech Republic;Poland;Belgium;Denmark;Netherlands;Germany

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

406

NCT02611167
(ClinicalTrials.gov)

November 1, 2017

11/11/2015

Allogeneic Bone Marrow-Derived Mesenchymal Stem Cell Therapy for Idiopathic Parkinson's Disease

Pilot Phase I Study of Allogeneic Bone Marrow-Derived Mesenchymal Stem Cell Therapy for Idiopathic Parkinson's Disease

Parkinson's Disease

Biological: Allogeneic bone marrow-derived MSCs (1 x 10 6 MSC/kg);Biological: Allogeneic bone marrow-derived MSCs (3 x 10 6 MSC/kg);Biological: Allogeneic bone marrow-derived MSCs (6 x 10 6 MSC/kg);Biological: Allogeneic bone marrow-derived MSCs (10 x 10 6 MSC/kg)

The University of Texas Health Science Center, Houston

NULL

Completed

45 Years

70 Years

All

Phase 1

United States

407

NCT03232996
(ClinicalTrials.gov)

November 1, 2017

24/7/2017

Evaluation of a Computer Game Based Rehabilitation System for Assessment and Treatment of Balance and Gait Impairments in Individuals With Parkinson's Disease.

Parkinson Disease;Parkinson

Other: Computer game based balance and walking rehabilitation for individuals with Parkinson's Disease

University of Manitoba

NULL

Completed

55 Years

70 Years

All

N/A

Canada

408

NCT03205956
(ClinicalTrials.gov)

October 19, 2017

29/6/2017

Measuring Parkinson's Disease Progression

Dopamine Buffering Capacity Measured by phMRI as a Novel Biomarker of Disease Progression in PD

Parkinson's Disease

Drug: Levodopa

Kevin J. Black, MD

The Michael J. Fox Foundation for Parkinson's Research

Completed

40 Years

79 Years

All

Phase 1

United States

409

EUCTR2017-000877-35-DE
(EUCTR)

19/10/2017

04/09/2017

Dose finding phase IIb study of Bavisant to evaluate its safety and effiCacy in treAtment of exceSsive daytime sleePiness (EDS) in PARkinson’s Disease (PD). CASPAR study. - Treatment of excessive daytime sleepiness with Bavisant in Parkinson’s Disease Patients (CASPAR)

Product Name: Bavisant
Product Code: JNJ-31001074
INN or Proposed INN: Bavisant dihydrochloride monohydrate
Other descriptive name: BAVISANT HYDROCHLORIDE MONOHYDRATE
Product Name: Bavisant
Product Code: JNJ-31001074
INN or Proposed INN: Bavisant dihydrochloride monohydrate
Other descriptive name: BAVISANT HYDROCHLORIDE MONOHYDRATE
Product Name: Bavisant
Product Code: JNJ-31001074
INN or Proposed INN: Bavisant dihydrochloride monohydrate
Other descriptive name: BAVISANT HYDROCHLORIDE MONOHYDRATE

BenevolentAI Bio

NULL

Not Recruiting

Female: yes
Male: yes

240

Phase 2

United States;Czech Republic;Spain;Poland;Germany;United Kingdom;Italy

410

NCT03272165
(ClinicalTrials.gov)

October 17, 2017

29/6/2017

Single Ascending Dose Study of MEDI1341 in Healthy Volunteers

A Randomized, Double-blind, Placebo-controlled Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of MEDI1341 in Healthy Male and Female Volunteers.

Parkinson's Disease

Drug: MEDI1341;Drug: Placebo

AstraZeneca

Covance;MMS Holdings, Inc;Catalent

Recruiting

18 Years

80 Years

All

Phase 1

United States;United Kingdom

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

411

NCT03205488
(ClinicalTrials.gov)

October 16, 2017

28/6/2017

Nilotinib in Parkinson's Disease

A Randomized, Double-Blind, Placebo-Controlled, Phase IIa, Parallel Group, Two Cohort Study to Define the Safety, Tolerability, Clinical and Exploratory Biological Activity of the Chronic Administration of Nilotinib in Participants With Parkinson's Disease

Parkinson Disease

Drug: Cohort 1:Nilotinib Oral Capsules (150mg or 300mg);Drug: Cohort 2: Nilotinib Oral Capsules (dose to be determined from Cohort 1);Drug: Placebo

Northwestern University

University of Rochester;University of Iowa;Michael J. Fox Foundation for Parkinson's Research

Completed

40 Years

79 Years

All

Phase 2

United States

412

NCT03250117
(ClinicalTrials.gov)

October 10, 2017

11/8/2017

Relative Bioavailability Study of Ropinirole Implants in Parkinson's Patients on L-Dopa Switched From Oral Ropinirole

An Open-Label, Relative Bioavailability Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Ropinirole Implants in Patients With Parkinson's Disease Switched From Oral Immediate-Release Ropinirole While on L-Dopa

Parkinson Disease

Drug: Ropinirole oral product;Drug: Ropinirole Implant

Titan Pharmaceuticals

NULL

Terminated

30 Years

80 Years

All

Phase 1;Phase 2

United States

413

NCT04045678
(ClinicalTrials.gov)

October 10, 2017

30/7/2019

A Multiple Ascending Dose Study With LY03003 in Patients With Early-stage Parkinson's Disease

A Randomized, Double-blinded, Multiple Ascending Dose Study in Patients With Early-stage Parkinson's Disease to Evaluate the Pharmacokinetics and Safety of LY03003 Following Intramuscular Injections

Parkinson Disease

Drug: LY03003 ( Rotigotine, extended-release microspheres);Drug: Placebo, extended-release microspheres

Luye Pharma Group Ltd.

Beijing Bozhiyin T&S Co., Ltd.

Completed

18 Years

75 Years

All

Phase 1

China

414

EUCTR2017-001673-17-FI
(EUCTR)

03/10/2017

29/08/2017

A study to evaluate the safety and tolerability of IRL752 treatment inpatients with Parkinson's disease dementia.

A randomized, double-blind, placebo-controlled, multi-centre phase IIastudy evaluating the safety and tolerability of IRL752 in patients withParkinson's Disease Dementia

Dementia in Parkinson's disease
MedDRA version: 20.0;Level: LLT;Classification code 10012284;Term: Dementia due to Parkinson's disease;System Organ Class: 100000014717;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Product Name: IRL752
INN or Proposed INN: IRL752

Integrative Research Laboratories AB

NULL

Not Recruiting

Female: yes
Male: yes

Phase 2

Finland;Sweden

415

NCT03769896
(ClinicalTrials.gov)

October 3, 2017

6/12/2018

Nabilone for Non-motor Symptoms in Parkinson's Disease

Nabilone for Non-motor Symptoms in Parkinson's Disease: A Randomized Placebo-controlled, Double-blind, Parallel-group, Enriched Enrolment Randomized Withdrawal Study

Parkinson Disease

Drug: Nabilone 0.25 mg;Drug: Placebo

Medical University Innsbruck

NULL

Completed

30 Years

100 Years

All

Phase 2

Austria

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

416

ChiCTR1800019216

2017-09-30

2018-10-31

Study for accurate diagnosis and treatment of Parkinson's disease by using the combination of TMS-EEG

Parkinson's disease

Bradykinesia Group:Sick side, SAM region, 10Hz rTMS;Tremor Group:Sick side, M1 region, 1Hz rTMS;Health control:N/A;

Shenzhen People's Hospital

NULL

Recruiting

Both

Bradykinesia Group:30;Tremor Group:30;Health control:30;

China

417

NCT03257046
(ClinicalTrials.gov)

September 28, 2017

14/8/2017

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ITI-214 in Parkinson's Disease

A Randomized, Placebo-Controlled, Double-Blind Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of ITI-214 in Patients With Idiopathic Parkinson's Disease

Parkinson Disease

Drug: ITI-214;Other: Placebo

Intra-Cellular Therapies, Inc.

NULL

Completed

50 Years

N/A

All

Phase 1;Phase 2

United States

418

EUCTR2015-004175-73-FI
(EUCTR)

27/09/2017

07/07/2016

A clinical study to test the safety of CDNF by brain infusion in patients with Parkinson's disease.

A Phase I-II, Randomised, Double-Blind, Placebo Controlled, Safety and Tolerability Study of Intermittent Bilateral Intraputamenal Cerebral Dopamine Neurotrophic Factor (CDNF) Infusions Administered via an Investigational Drug Delivery System to Patients with Idiopathic Parkinson’s Disease (PD) of Moderate Severity.

Product Name: CDNF
INN or Proposed INN: Not Applicable
Other descriptive name: recombinant human Cerebral Dopamine Neurotrophic Factor

Herantis Pharma Plc

NULL

Not Recruiting

Female: yes
Male: yes

Phase 1;Phase 2

Finland

419

NCT03295786
(ClinicalTrials.gov)

September 26, 2017

14/9/2017

Clinical Study to Test the Safety of CDNF by Brain Infusion in Patients With Parkinson's Disease

Phase 1-2, Randomised, Double-Blind, Placebo Controlled, Safety and Tolerability Study of Intraputamenal Cerebral Dopamine Neurotrophic Factor (CDNF) Infusions Via an Investigational Drug Delivery System to Patients With Parkinson's Disease

Parkinson Disease;Movement Disorders;Neurodegenerative Diseases;Nervous System Diseases;Brain Diseases

Drug: Cerebral Dopamine Neurotrophic Factor;Device: Renishaw Drug Delivery System

Herantis Pharma Plc.

Renishaw plc.

Completed

35 Years

75 Years

All

Phase 1;Phase 2

Finland;Sweden

420

NCT03104725
(ClinicalTrials.gov)

September 25, 2017

4/4/2017

Does N-Acetylcysteine Decrease Spontaneous Oxidation of Central Neural Dopamine in Parkinson's Disease?

Parkinson Disease;Cerebrospinal Fluid

Drug: N-Acetylcysteine;Procedure: Lumbar Puncture;Radiation: Fluoroscopy

National Institute of Neurological Disorders and Stroke (NINDS)

NULL

Completed

18 Years

N/A

All

Phase 1

United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

421

EUCTR2017-000128-81-DE
(EUCTR)

20/09/2017

06/07/2017

PHASE 2, OPEN LABEL EXTENSION STUDY TO INVESTIGATE THE LONG TERM SAFETY AND TOLERABILITY OF PF-06649751 IN SUBJECTS WITHMOTOR FLUCTUATIONS DUE TO PARKINSON’S DISEASE

Parkinson’s disease
MedDRA version: 20.0;Level: LLT;Classification code 10013113;Term: Disease Parkinson's;System Organ Class: 100000014025;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Product Code: PF-06649751 - 1mg
INN or Proposed INN: Not yet assigned
Other descriptive name: PF-06649751
Product Code: PF-06649751 - 5mg
INN or Proposed INN: Not yet assigned
Other descriptive name: PF-06649751
Product Code: PF-06649751 - 15mg
INN or Proposed INN: Not yet assigned
Other descriptive name: PF-06649751

Pfizer Inc., 235 East 42nd Street, New York, New York

NULL

Not Recruiting

Female: yes
Male: yes

198

Phase 2

France;United States;Canada;Spain;Germany

422

EUCTR2017-000192-86-AT
(EUCTR)

15/09/2017

10/08/2017

Investigation of the effect of Nabilon in patients suffering from Parkinson´s Disease with non-motor symptoms (e.g.sleeping disorders,cognitive dysfunction, hallucinations, autonomic dysfunction including urinary incontinence, constipation,...)

Nabilone for non-motor symptoms in Parkinson´s disease: A Randomized Placebo-controlled, double-blind, parallel-group, enriched enrollment randomized withdrawal Study

Subjects with non-motor symptoms of Parkinson´s disease
MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Medizinische Universität Innsbruck, Universitätsklinik für Neurologie

NULL

Not Recruiting

Female: yes
Male: yes

Phase 2

Austria

423

NCT03306329
(ClinicalTrials.gov)

September 13, 2017

25/9/2017

DNS-7801 vs. Placebo in Parkinson's Disease

A Phase 2a, Double-Blind, Placebo-Controlled Two-Part Study To Investigate the Safety and Efficacy of Increasing Doses Of DNS-7801 In Parkinson's Disease (PD) Subjects With Motor Fluctuations

Parkinson's Disease

Drug: DNS-7801 (low-dose);Drug: DNS-7801 (high dose);Drug: Placebo

Dart NeuroScience, LLC

NULL

Terminated

30 Years

N/A

All

Phase 2

United States

424

EUCTR2016-003961-25-CZ
(EUCTR)

07/09/2017

15/05/2017

A study to evaluate the safety and tolerability of tozadenant in Parkinson disease patients who are taking levodopa and experiencing wearing off

A Multicenter, Open-Label Study to Evaluate the Safety and Tolerability of Tozadenant as Adjunctive Therapy in Levodopa-Treated Patients with Parkinson’s Disease Experiencing End of Dose Wearing-Off”

Parkinson's Disease
MedDRA version: 20.0;Level: LLT;Classification code 10013113;Term: Disease Parkinson's;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Product Name: tozadenant
Product Code: TOZ
INN or Proposed INN: tozadenant
Other descriptive name: TOZADENANT

Biotie Therapies

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

450

Phase 3

United States;Hungary;Czech Republic;European Union;Canada;Spain;Australia;Germany;United Kingdom

425

NCT03272230
(ClinicalTrials.gov)

September 6, 2017

3/8/2017

Assessment of Apathy in a Real-life Situation, With a Video and Sensors-based System

Assessment of Apathy in a Real-life Situation, With a Video and Sensors-based System in Healthy Subject and Patient With Cerebral Disease

Apathy;Frontotemporal Dementia;Parkinson Disease;Depressive Symptoms

Behavioral: ECOCAPTURE;Behavioral: Cognitive and Behavioral experimental tasks;Diagnostic Test: Neuropsychological assessment;Behavioral: ICM_APATHY_TASKS;Other: MRI;Biological: Neurohormonal mechanisms;Diagnostic Test: Supplementary Neuropsychological Assessment - Parkinson's Disease

Institut National de la Santé Et de la Recherche Médicale, France

NULL

Recruiting

40 Years

85 Years

All

135

N/A

France

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

426

JPRN-jRCTs041180018

04/09/2017

20/12/2018

Pupillary autonomic dysfunction and visual hallucination in Parkinson's disease

Association between pupillary autonomic dysfunction and visual hallucination in Parkinson's disease - Pupillary autonomic dysfunction and visual hallucination in Parkinson's disease

Parkinson's disease and related diseases

Two drops of 0.05% pilocarpine hydrochloride, which is a parasympathomimetic agent, on the right eye, 2 drops of 0.04% dipivefrin hydrochloride, which is a sympathomimetic agent, to the left eye

katsuno Masahisa

NULL

Recruiting

>= 40age old

Not applicable

Both

Phase 2

Japan

427

ChiCTR-INR-17012013

2017-09-01

2017-07-17

Clinical study of botulinum toxin type A in the treatment of depressive symptoms in patients with Parkinson's disease

Parkinson‘s disease, Depression

BTX-A:BOTOX Allergan;Placebo:0.9% Sodium Chloride Injection;

Shanghai Tongji Hospital, Tongji University

NULL

Pending

Both

BTX-A:40;Placebo:40;

China

428

EUCTR2017-000128-81-ES
(EUCTR)

28/08/2017

12/07/2017

PHASE 2, OPEN LABEL EXTENSION STUDY TO INVESTIGATE THE LONG TERM SAFETY AND TOLERABILITY OF PF-06649751 IN SUBJECTS WITHMOTOR FLUCTUATIONS DUE TO PARKINSON’S DISEASE

Pfizer Inc., 235 East 42nd Street, New York, New York

NULL

Not Recruiting

Female: yes
Male: yes

198

Phase 2

France;United States;Canada;Spain;Germany

429

NCT03292016
(ClinicalTrials.gov)

August 22, 2017

11/9/2017

A Study That Compares the Extent to Which Apomorphine Becomes Available in the Body After Taking Either an Investigational Drug Containing Apomorphine or Apomorphine That is Injected Under the Skin in People With PD Complicated by OFF Episodes

A Comparative Bioavailability Study to Evaluate the Single Dose Pharmacokinetic Properties of APL-130277 With Two Different Formulations of Subcutaneous Apomorphine in a Randomized, 3-Period Crossover Design in Subjects With Parkinson's Disease Complicated by Motor Fluctuations (OFF Episodes)

Parkinson Disease

Drug: APL-130277;Drug: APO-go;Drug: Apokyn

Sunovion

NULL

Completed

18 Years

N/A

All

Phase 2

United States

430

EUCTR2017-000087-15-AT
(EUCTR)

17/08/2017

18/05/2017

A Study to Evaluate the Efficacy of Intravenous RO7046015/Prasinezumab(PRX002) in Participants with Early Parkinson's Disease with A 6-Year all-Participants-on-Treatment Extension (Pasadena)

Product Name: aSyn Mab
Product Code: RO7046015
INN or Proposed INN: N/A
Other descriptive name: PRX002, ELT2, anti-alpha-synuclein monoclonal antibody

F. Hoffmann-La Roche Ltd

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

300

Phase 2

France;United States;Spain;Austria;Germany

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

431

NCT04162275
(ClinicalTrials.gov)

August 15, 2017

22/9/2019

A Single-dose Study to Investigate the Tolerance and Pharmacokinetics of Finamine Tablets in China

A Randomized, Double-blind, Placebo-controlled, Single-dose, Dose-escalation Tolerance and Pharmacokinetics Study of Oral Taking Finamine Tablets in Chinese Healthy-adult Subjects

Parkinson Disease

Drug: Finamine tablets;Drug: Placebo tablets

Yiling Pharmaceutical Inc.

NULL

Active, not recruiting

18 Years

65 Years

All

Phase 1

China

432

NCT03204929
(ClinicalTrials.gov)

August 14, 2017

28/6/2017

Dose Escalation Study of Cu(II)ATSM in Parkinson's Disease

A Phase 1 Dose Escalation Study of Cu(II)ATSM Administered Orally to Patients With Early Idiopathic Parkinson's Disease

Parkinson Disease

Drug: Cu(II)ATSM

Collaborative Medicinal Development Pty Limited

NULL

Completed

30 Years

N/A

All

Phase 1

Australia

433

EUCTR2017-000877-35-CZ
(EUCTR)

09/08/2017

05/06/2017

Dose finding phase IIb study of Bavisant to evaluate its safety and efficacy in treatment of excessive daytime sleepiness (EDS) in parkinson’s Disease (PD). - Treatment of excessive daytime sleepiness with Bavisant in Parkinson’s Disease Patients (CASPAR)

Excessive daytime sleepiness with Parkinson's Disease
MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

BenevolentAI Bio

NULL

Not Recruiting

Female: yes
Male: yes

240

Phase 2

United States;Czech Republic;Poland;Spain;Germany;Italy;United Kingdom

434

EUCTR2017-000877-35-GB
(EUCTR)

08/08/2017

17/07/2017

BenevolentAI Bio

NULL

Not Recruiting

Female: yes
Male: yes

240

Phase 2

United States;Czech Republic;Poland;Spain;Germany;Italy;United Kingdom

435

EUCTR2017-000877-35-ES
(EUCTR)

03/08/2017

09/06/2017

BenevolentAI Bio

NULL

Not Recruiting

Female: yes
Male: yes

240

Phase 2

United Kingdom;United States;Czech Republic;Poland;Spain;Germany;Italy

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

436

NCT03187301
(ClinicalTrials.gov)

August 3, 2017

7/6/2017

A Cardiac Safety Study of an Investigational Drug to See How if Affects the Heart in People With Parkinson's Disease Complicated by Motor Fluctuations OFF Episodes

A Phase 2, Randomized, Double-Blind, Placebo Controlled, 3-Period Crossover, Positive Control, QT-Evaluation Study of APL-130277 in Subjects With Parkinson's Disease Complicated by Motor Fluctuations (OFF Episodes)

Parkinson's Disease;Off Episodes of Parkinson Disease

Drug: APL-130277;Drug: Placebo;Drug: Moxifloxacin

Sunovion

NULL

Completed

18 Years

N/A

All

Phase 2

United States;Italy

437

EUCTR2014-004865-26-GR
(EUCTR)

01/08/2017

25/04/2017

26-Week Study Comparing Levodopa-Carbidopa Intestinal Gel to Optimized Medical Treatment on Non-Motor Symptoms in Subjects with Advanced Parkinson's Disease

An Open-label, Randomized 26-Week Study Comparing Levodopa-Carbidopa INteStInal Gel (LCIG) Therapy to Optimized Medical Treatment (OMT) on Non-Motor Symptoms (NMS) in Subjects with Advanced Parkinson's Disease – INSIGHTS Study - INSIGHTS Study

Non-motor symptoms in advanced Parkinson's disease
MedDRA version: 20.0;Level: LLT;Classification code 10013113;Term: Disease Parkinson's;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Trade Name: Duodopa
INN or Proposed INN: Levodopa
Other descriptive name: LEVODOPA
INN or Proposed INN: Carbidopa
Other descriptive name: CARBIDOPA MONOHYDRATE

AbbVie Deutschland GmbH & Co. KG

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

Phase 3

United States;European Union;Canada;Greece;Spain;Australia;Germany;Italy;Sweden

438

ChiCTR-IPR-17011875

2017-08-01

2017-07-05

Effects of Baduanjin Combined Balance Training on Gait and Posture Control of Patients with Mild and Moderate Parkinson's Disease

Parkinson's Disease

Control group:Conventional drug therapy;Baduanjin group:Baduanjin aerobic exercise;Balance function training group:Balance function training group;

Affiliated Lianyungang Hospital of Xuzhou Medical University

NULL

Pending

Both

Control group:30;Baduanjin group:30;Balance function training group:30;

China

439

EUCTR2017-000087-15-FR
(EUCTR)

27/07/2017

30/10/2017

A Study to Evaluate the Efficacy of Intravenous RO7046015 (PRX002) in Participants with Early Parkinson’s Disease with A 52-Week Blinded Extension (Pasadena)

Product Name: aSyn Mab
Product Code: RO7046015
INN or Proposed INN: N/A
Other descriptive name: PRX002, ELT2, anti-alpha-synuclein monoclonal antibody

F. Hoffmann-La Roche Ltd

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

300

Phase 2

United States;France;Spain;Austria;Germany

440

EUCTR2017-000087-15-ES
(EUCTR)

26/07/2017

08/06/2017

A Study to Evaluate the Efficacy of Intravenous RO7046015 (PRX002) in Participants with Early Parkinson’s Disease with A 52-Week Blinded Extension (Pasadena)

Product Name: aSyn Mab
Product Code: RO7046015
INN or Proposed INN: N/A
Other descriptive name: PRX002, ELT2, anti-alpha-synuclein monoclonal antibody

F. Hoffmann-La Roche Ltd

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

300

Phase 2

France;United States;Spain;Austria;Germany

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

441

NCT03178786
(ClinicalTrials.gov)

July 18, 2017

5/6/2017

Visual Spatial Exploration and Art Therapy Intervention in Patients Diagnosed With Parkinson's Disease

Parkinson Disease

Behavioral: PAT sessions

NYU Langone Health

NULL

Recruiting

40 Years

75 Years

All

N/A

United States

442

NCT03412513
(ClinicalTrials.gov)

July 17, 2017

21/1/2018

Mirabegron for Treatment of Overactive Bladder Symptoms in Patients With Parkinson's Disease

Mirabegron for Treatment of Overactive Bladder Symptoms in Patients With Parkinson's Disease: a Double-blind, Randomized Placebo-controlled Trial

Overactive Bladder;Parkinson Disease

Drug: Mirabegron;Drug: Placebo

Seoul National University Hospital

NULL

Unknown status

40 Years

80 Years

All

144

Phase 4

Korea, Republic of

443

NCT03026231
(ClinicalTrials.gov)

July 15, 2017

11/1/2017

Characterization of Fecal Microbiome Changes After Administration of PRIM-DJ2727 in Parkinson's Disease Patients

A Prospective, Randomized Placebo Controlled Pilot Study to Characterize the Intestinal Microbiome and to Evaluate the Safety and Fecal Microbiome Changes Following Weekly Administration of Lyophilized PRIM-DJ2727 Given Orally in Subjects With Parkinson's Disease

Parkinson's Disease

Biological: PRIM-DJ2727;Drug: Placebo (for PRIM-DJ2727)

The University of Texas Health Science Center, Houston

Kelsey Research Foundation

Withdrawn

45 Years

70 Years

All

Phase 1;Phase 2

United States

444

NCT03555292
(ClinicalTrials.gov)

July 12, 2017

24/4/2018

11C-PIB PET/CT in Patients With Parkinson's Disease and Parkinsonian Dementia Syndromes

Safety and Diagnostic Performance of 11C-PIB PET/CT in Patients With Parkinson's Disease and Parkinsonian Dementia Syndromes

Parkinson Disease

Drug: 11C-PiB

Oriental Neurosurgery Evidence-Based-Study Team

NULL

Recruiting

18 Years

N/A

All

200

Phase 2

China

445

ChiCTR-IPR-17011987

2017-07-12

2017-07-14

The effect of conduction exercise and self-acupressure in treatment of Parkinson’s disease: a pilot study

Parkinson's Disease

Group 1:CE+ SA + routine western medications;Group 2:Routine western medications only (control);

HKBU School of Chinese Medicine

NULL

Recruiting

Both

Group 1:29;Group 2:29;

China

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

446

EUCTR2017-000135-14-ES
(EUCTR)

07/07/2017

09/06/2017

A study to look at how safe, well tolerated, and what effect on the body, study drug PXT002331 has in patients with Parkinson's Disease who are already taking the drug Levodopa

A Multi-centre, Double-blind, Randomised, Placebo-controlled, Parallel-arm Phase IIa Trial to Evaluate the Efficacy, Safety and Tolerability of 28-Day Oral Treatment with PXT002331 (foliglurax) in Reducing Motor Complications of Levodopa Therapy in Subjects with Parkinson’s Disease Experiencing End-of-dose Wearing Off and Levodopa-Induced Dyskinesia (AMBLED) - AMBLED Study

Parkinson’s Disease
MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Product Name: foliglurax
Product Code: PXT002331
INN or Proposed INN: foliglurax
Other descriptive name: CVD00118-E
Product Name: foliglurax
Product Code: PXT002331
INN or Proposed INN: foliglurax
Other descriptive name: CVD00118-E

Prexton Therapeutics B.V.

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

165

Phase 2

Spain;Austria;Germany

447

EUCTR2015-005814-31-BE
(EUCTR)

06/07/2017

05/05/2017

A multicenter, international, open-label, safety study of ND0612, a solution of levodopa/carbidopa delivered via a pump system as a continuous subcutaneous infusion in subjects with advanced Parkinson's Disease (BeyoND) - BeyoND

Subjects with advanced Parkinson's disease
MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Product Name: levodopa /carbidopa solution
Product Code: ND0612
INN or Proposed INN: Levodopa
Other descriptive name: LEVODOPA
INN or Proposed INN: carbidopa
Other descriptive name: CARBIDOPA

NeuroDerm Ltd.

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

170

Phase 2

United States;Spain;Ukraine;Austria;Israel;Russian Federation;Italy;France;Czech Republic;Hungary;Belgium;Poland;Germany

448

NCT03185481
(ClinicalTrials.gov)

July 6, 2017

9/6/2017

Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients With Motor Fluctuations

A PHASE 2, OPEN LABEL EXTENSION STUDY TO INVESTIGATE THE LONG TERM SAFETY AND TOLERABILITY OF PF-06649751 IN SUBJECTS WITH MOTOR FLUCTUATIONS DUE TO PARKINSON'S DISEASE

Parkinson's Disease With Motor Fluctuations

Drug: 1 mg QD to 15 mg QD PF-06649751;Drug: 3 mg QD to 15 mg QD PF-06649751;Drug: 7 mg QD to 15 mg QD PF-06649751;Drug: 15 mg QD PF-06649751;Drug: 1 mg QD to 7 mg QD PF-06649751 (if de-escalated in parent study);Drug: 3 mg QD to 7 mg QD PF-06649751 (de-escalated in parent study);Drug: 7 mg QD to 7 mg QD PF-06649751 (de-escalated in parent study);Drug: 15 mg QD de-escalated to 7 mg QD PF-06649751 in parent study remain at 7 mg QD

Pfizer

NULL

Terminated

40 Years

87 Years

All

Phase 2

United States

449

NCT03162874
(ClinicalTrials.gov)

July 4, 2017

19/5/2017

Study to Evaluate the Efficacy, Safety and Tolerability of PXT002331 (Foliglurax) in Reducing Motor Complications of Levodopa Therapy in Parkinson Disease's Patients

A Multi-centre, Double-blind, Randomised, Placebo-controlled, Parallel-arm Phase IIa Trial to Evaluate the Efficacy, Safety and Tolerability of 28-Day Oral Treatment With PXT002331 (Foliglurax) in Reducing Motor Complications of Levodopa Therapy in Subjects With Parkinson's Disease Experiencing End-of-dose Wearing Off and Levodopa-Induced Dyskinesia (AMBLED)

Parkinson Disease

Drug: Placebo oral capsule;Drug: PXT002331 - dose 1;Drug: PXT002331 - dose 2

Prexton Therapeutics

NULL

Completed

35 Years

85 Years

All

157

Phase 2

Austria;France;Germany;Italy;Spain;United Kingdom

450

NCT03288155
(ClinicalTrials.gov)

July 1, 2017

15/9/2017

Can a Flavonoid-rich Pure Cocoa Reduce Fatigue in People With Parkinson's (PD)

A Study to Determine Whether the Daily Consumption of Flavonoid-rich Pure Cocoa Can Reduce Fatigue in People With Parkinson's (PD)

Parkinson Disease;Fatigue

Dietary Supplement: Cocoa

Oxford Brookes University

European Parkinson Therapy Centre

Completed

18 Years

N/A

All

N/A

Italy

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

451

NCT04146519
(ClinicalTrials.gov)

July 1, 2017

18/10/2019

Parkinson's Disease Therapy Using Cell Technology

Developent and Implement a Method of Parkinson's Disease Therapy Using Cell Technology

Transplantation:Mesenchymal Stem Cell Transplantation

Biological: Autologous mesenchymal stem cells

Belarusian Medical Academy of Post-Graduate Education

NULL

Active, not recruiting

18 Years

N/A

All

Phase 2

Belarus

452

EUCTR2016-003961-25-DE
(EUCTR)

30/06/2017

01/02/2017

A study to evaluate the safety and tolerability of tozadenant in Parkinson disease patients who are taking levodopa and experiencing wearing off

Parkinson's Disease
MedDRA version: 19.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Product Name: tozadenant
Product Code: TOZ
INN or Proposed INN: tozadenant
Other descriptive name: TOZADENANT

Biotie Therapies

NULL

Not Recruiting

Female: yes
Male: yes

450

Phase 3

United States;Czech Republic;Hungary;European Union;Canada;Spain;Australia;Germany;Italy;United Kingdom

453

NCT04223245
(ClinicalTrials.gov)

June 29, 2017

2/12/2019

A Home Program Using Multimodal Sensory Feedback for People With Parkinson Disease

A Comparison Of Home Exercises With Multimodal Real-time Sensory Feedback To The Same Exercise Program With No Enhanced Feedback on Walking Automaticity in People With Parkinson Disease.

Parkinson Disease

Behavioral: exercise+multi-modal sensory feedback (MMSF);Behavioral: Exercise only

Regis University

NULL

Completed

21 Years

N/A

All

N/A

United States

454

NCT04403399
(ClinicalTrials.gov)

June 29, 2017

21/5/2020

Cholinergic Mechanisms of Gait Dysfunction in Parkinson's Disease Exp. 3 - Proj#3 (UdallP3)

Cholinergic Mechanisms of Gait Dysfunction in Parkinson's Disease Exp. 3 - Proj#3

Parkinson's Disease

Drug: Varenicline;Other: Evaluation by Investigator;Other: Placebo

University of Michigan

NULL

Completed

45 Years

N/A

All

Phase 2

United States

455

NCT03042416
(ClinicalTrials.gov)

June 29, 2017

1/2/2017

18F-DOPA PET Imaging: an Evaluation of Biodistribution and Safety

Congenital Hyperinsulinism;Neuroblastoma;Neuroendocrine Tumors;Parkinson Disease;Brain Glioma

Drug: 18F-DOPA

University of Alberta

Alberta Health Services

Active, not recruiting

N/A

All

400

Phase 3

Canada

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

456

NCT03100149
(ClinicalTrials.gov)

June 27, 2017

29/3/2017

A Study to Evaluate the Efficacy of Prasinezumab (RO7046015/PRX002) in Participants With Early Parkinson's Disease

A Randomized, Double-Blind, Placebo-Controlled, 52-Week Phase II Study to Evaluate the Efficacy of Intravenous RO7046015/Prasinezumab (PRX002) in Participants With Early Parkinson's Disease With a 6-Year All-Participants-on-Treatment Extension

Parkinson's Disease

Drug: RO7046015;Drug: Placebo

Hoffmann-La Roche

Prothena Biosciences Limited

Active, not recruiting

40 Years

80 Years

All

316

Phase 2

United States;Austria;France;Germany;Spain

457

NCT03195231
(ClinicalTrials.gov)

June 25, 2017

20/6/2017

Wuling Powder for the Treatment and Underlying Mechanism of Depressive Symptoms in Patients With Parkinson's Disease

Wuling Powder for the Treatment and Underlying Mechanism of Depressive Symptoms in Patients With Parkinson's Disease: a Randomised, Double-blind, Placebo-controlled Trial.

Antidepressive Agents

Drug: Wuling Powder;Drug: Placebo

Beijing Hospital

Tongji Hospital;Shanghai Tong Ren Hospital;The First Hospital of Hebei Medical University

Not yet recruiting

40 Years

N/A

All

120

Phase 4

NULL

458

EUCTR2015-005814-31-ES
(EUCTR)

22/06/2017

21/04/2017

Subjects with advanced Parkinson's disease
MedDRA version: 19.1;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Product Name: levodopa /carbidopa solution
Product Code: ND0612
INN or Proposed INN: Levodopa
Other descriptive name: LEVODOPA
INN or Proposed INN: carbidopa
Other descriptive name: CARBIDOPA

NeuroDerm Ltd.

NULL

Not Recruiting

Female: yes
Male: yes

170

Phase 2

United States;Spain;Ukraine;Austria;Israel;Russian Federation;Italy;France;Czech Republic;Hungary;Belgium;Poland;Germany

459

NCT03116295
(ClinicalTrials.gov)

June 20, 2017

12/4/2017

Bioavailability and Bioequivalence Study of Two Different Sources of Opicapone

A Comparative, Randomized, Open-label, Fasted, Single-dose, 2-way Crossover Bioavailability and Bioequivalence Study of Two Different Sources of Opicapone in Healthy Subjects

Parkinson Disease

Drug: Opicapone (OPC)

Bial - Portela C S.A.

NULL

Completed

18 Years

55 Years

All

Phase 1

Germany

460

EUCTR2017-000135-14-GB
(EUCTR)

15/06/2017

17/03/2017

A study to look at how safe, well tolerated, and what effect on the body, study drug PXT002331 has in patients with Parkinson's Disease who are already taking the drug Levodopa

Prexton Therapeutics B.V.

NULL

Not Recruiting

Female: yes
Male: yes

165

Phase 2

Spain;Austria;Germany;United Kingdom

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

461

EUCTR2015-005814-31-HU
(EUCTR)

14/06/2017

20/04/2017

Product Name: levodopa /carbidopa solution
Product Code: ND0612
INN or Proposed INN: Levodopa
Other descriptive name: LEVODOPA
INN or Proposed INN: carbidopa
Other descriptive name: CARBIDOPA

NeuroDerm Ltd.

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

170

Phase 2

United States;Spain;Ukraine;Austria;Israel;Russian Federation;Italy;France;Hungary;Czech Republic;Belgium;Poland;Germany

462

NCT03083132
(ClinicalTrials.gov)

June 13, 2017

7/3/2017

Modafinil for Freezing of Gait (FOG) in Parkinson's Disease (PD)

Modafinil as a Novel Therapy for the Treatment of Freezing of Gait in Parkinson's Disease

Parkinson Disease

Drug: modafinil 50mg;Drug: Placebo oral capsule

University of Arkansas

NULL

Completed

50 Years

90 Years

All

Early Phase 1

United States

463

NCT03973502
(ClinicalTrials.gov)

June 12, 2017

30/5/2019

Application of 18F-FDOPA PET and Magnetic Resonance Spectroscopy (MRS) With HCV and PD

Application of 18F-FDOPA PET and Magnetic Resonance Spectroscopy (MRS) in Research of the Association Between HCV Infection and Parkinson's Disease.

Hepatitis C;Hepatitis B;Parkinson Disease

Drug: 18F-DOPA PET

National Taiwan University Hospital

NULL

Recruiting

20 Years

N/A

All

230

N/A

Taiwan

464

EUCTR2016-003961-25-ES
(EUCTR)

08/06/2017

27/04/2017

A study to evaluate the safety and tolerability of tozadenant in Parkinson disease patients who are taking levodopa and experiencing wearing off

Product Name: tozadenant
Product Code: TOZ
INN or Proposed INN: tozadenant
Other descriptive name: TOZADENANT

Biotie Therapies

NULL

Not Recruiting

Female: yes
Male: yes

450

Phase 3

United States;Czech Republic;Hungary;European Union;Canada;Spain;Australia;Germany;United Kingdom

465

EUCTR2017-000135-14-DE
(EUCTR)

06/06/2017

10/03/2017

A study to look at how safe, well tolerated, and what effect on the body, study drug PXT002331 has in patients with Parkinson's Disease who are already taking the drug Levodopa

Prexton Therapeutics B.V.

NULL

Not Recruiting

Female: yes
Male: yes

165

Phase 2

Spain;Austria;Germany;Italy;United Kingdom

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

466

EUCTR2016-003961-25-HU
(EUCTR)

31/05/2017

03/04/2017

A study to evaluate the safety and tolerability of tozadenant in Parkinson disease patients who are taking levodopa and experiencing wearing off

Product Name: tozadenant
Product Code: TOZ
INN or Proposed INN: tozadenant
Other descriptive name: TOZADENANT

Biotie Therapies

NULL

Not Recruiting

Female: yes
Male: yes

450

Phase 3

United States;Czech Republic;Hungary;European Union;Canada;Spain;Australia;Germany;United Kingdom

467

EUCTR2017-000135-14-IT
(EUCTR)

30/05/2017

04/11/2020

A study to look at how safe, well tolerated, and what effect on the body, study drug PXT002331 has in patients with Parkinson's Disease who are already taking the drug Levodopa

Studio di fase IIa, multicentrico, in doppio cieco, randomizzato, controllato verso placebo, a gruppi paralleli per valutare l'efficacia, la sicurezza e la tollerabilit¿ del trattamento orale con PXT002331 (foliglurax) della durata di 28 giorni nella riduzione delle complicazioni motorie dovute alla terapia con levodopa nei pazienti affetti da malattia di Parkinson che manifestano deterioramento da fine dose e discinesia indotta da levodopa (AMBLED) - AMBLED Study

Product Name: foliglurax
Product Code: PXT002331
INN or Proposed INN: foliglurax
Other descriptive name: CVD00118-E
Product Name: foliglurax
Product Code: PXT002331
INN or Proposed INN: foliglurax

PREXTON THERAPEUTICS B.V.

NULL

Not Recruiting

Female: yes
Male: yes

165

Phase 2

France;Spain;Austria;Germany;United Kingdom;Italy

468

EUCTR2017-000135-14-AT
(EUCTR)

26/05/2017

08/03/2017

A study to look at how safe, well tolerated, and what effect on the body, study drug PXT002331 has in patients with Parkinson's Disease who are already taking the drug Levodopa

Prexton Therapeutics B.V.

NULL

Not Recruiting

Female: yes
Male: yes

165

Phase 2

Spain;Austria;Germany;United Kingdom

469

EUCTR2015-005814-31-PL
(EUCTR)

25/05/2017

14/02/2017

Product Name: levodopa /carbidopa solution
Product Code: ND0612
INN or Proposed INN: Levodopa
Other descriptive name: LEVODOPA
INN or Proposed INN: carbidopa
Other descriptive name: CARBIDOPA

NeuroDerm Ltd.

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

210

Phase 2

United States;France;Hungary;Czech Republic;Belgium;Spain;Poland;Austria;Israel;Germany;Italy

470

NCT03111485
(ClinicalTrials.gov)

May 24, 2017

28/3/2017

Effect of Long-acting Levodopa on Obstructive Sleep Apnea in Parkinson's Disease

Parkinson's Disease;Obstructive Sleep Apnea

Drug: Sinemet CR;Drug: Placebo oral capsule

McGill University Health Centre/Research Institute of the McGill University Health Centre

Weston Brain Institute

Recruiting

18 Years

N/A

All

Phase 4

Canada

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

471

NCT03033498
(ClinicalTrials.gov)

May 17, 2017

25/1/2017

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous Infusions of ABBV-951 in Subjects With Parkinson's Disease

A Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of 24 Hour and 72 Hour Subcutaneous Infusions of ABBV-951 in Subjects With Parkinson's Disease

Parkinson's Disease (PD)

Drug: ABBV-951

AbbVie

NULL

Completed

45 Years

85 Years

All

Phase 1

United States

472

NCT03174938
(ClinicalTrials.gov)

May 15, 2017

28/5/2017

The Swedish BioFINDER 2 Study

Dementia;Alzheimer Disease;Parkinson Disease;Lewy Body Disease;Parkinson-Dementia Syndrome;Frontotemporal Degeneration;Semantic Dementia;Progressive Nonfluent Aphasia;Progressive Supranuclear Palsy;Corticobasal Degeneration;Multiple System Atrophy;Mild Cognitive Impairment

Diagnostic Test: Flutemetamol F18 Injection;Diagnostic Test: [18F]-RO6958948;Diagnostic Test: Elecsys (Roche) Abeta42, Ttau and Ptau;Diagnostic Test: Lumipulse (Fujirebio) Abeta42, Ttau and Ptau

Skane University Hospital

Lund University

Recruiting

20 Years

100 Years

All

1505

N/A

Sweden

473

NCT03242499
(ClinicalTrials.gov)

May 15, 2017

1/8/2017

Lovastatin as a Neuroprotective Treatment for Early Stage Parkinson's Disease

Lovastatin as a Neuroprotective Treatment for Early Stage Parkinson's Disease: a Single-center, Double-blind, Placebo-controlled Randomized Trial

Parkinson Disease

Drug: Lovastatin;Drug: Placebo

National Taiwan University Hospital

NULL

Recruiting

30 Years

90 Years

All

Phase 2

Taiwan

474

NCT03047629
(ClinicalTrials.gov)

May 11, 2017

3/2/2017

Evaluation of Safety and Tolerability of ENT-01 for the Treatment of Parkinson's Disease Related Constipation

A Multi-Center, Single-Dose, Multiple-Dose, Double-Blind, Placebo-Controlled Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Orally Administered ENT-01 for the Treatment of Parkinson's Disease Related Constipation

Parkinson's Disease;Constipation

Drug: ENT-01;Other: Placebo

Enterin Inc.

NULL

Completed

30 Years

86 Years

All

Phase 1;Phase 2

United States

475

NCT03065192
(ClinicalTrials.gov)

May 11, 2017

10/2/2017

Safety and Efficacy Study of VY-AADC01 for Advanced Parkinson's Disease

An Open-label Safety and Efficacy Study of VY-AADC01 Administered by MRI-Guided Convective Infusion Using a Posterior Trajectory Into the Putamen of Participants With Parkinson's Disease With Fluctuating Responses to Levodopa

Idiopathic Parkinson's Disease;Parkinson's Disease;Basal Ganglia Disease;Brain Diseases;Central Nervous System Diseases;Movement Disorders;Nervous System Diseases;Neurodegenerative Diseases;Parkinsonian Disorders

Drug: VY-AADC01

Neurocrine Biosciences

Voyager Therapeutics

Active, not recruiting

40 Years

75 Years

All

Phase 1

United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

476

EUCTR2015-004507-23-FI
(EUCTR)

08/05/2017

30/03/2017

Comparison of two levodopa treatments, ODM-104 and Stalevo, in Parkinson's disease patients who have motor fluctuations.

Efficacy and safety of ODM-104 compared to a standard combination (Stalevo®); a randomised, double-blind, crossover proof-of-concept study in patients with Parkinson’s disease and end-of-dose wearing-off. - COMPOC

Parkinson’s disease (PD) patients with end-of-dose wearing-off (motor fluctuations);Therapeutic area: Diseases [C] - Symptoms and general pathology [C23]

Product Name: Levodopa 75 mg A CAP
INN or Proposed INN: levodopa
Other descriptive name: LEVODOPA
Product Name: Levodopa 100 mg A CAP
INN or Proposed INN: levodopa
Other descriptive name: LEVODOPA
Product Name: Levodopa 125 mg A CAP
INN or Proposed INN: levodopa
Other descriptive name: LEVODOPA
Product Name: Levodopa 150 mg A CAP
INN or Proposed INN: levodopa
Other descriptive name: LEVODOPA
Product Name: Carbidopa 65 mg capsule
INN or Proposed INN: Carbidopa
Other descriptive name: CARBIDOPA
Product Name: ODM-104
INN or Proposed INN: na
Other descriptive name: ODM-104

Orion Corporation

NULL

Not Recruiting

Female: yes
Male: yes

Phase 2

Hungary;Finland;Latvia;Germany

477

NCT02982512
(ClinicalTrials.gov)

May 1, 2017

28/11/2016

Dexmedetomidine on Basal Ganglia Neuronal Activity in Parkinson's Disease

Effects of Different Concentrations of Dexmedetomidine on Basal Ganglia Neuronal Activity (Local Field Potentials) in Parkinson's Disease

Dexmedetomidine;Deep Brain Stimulation;Parkinson Disease

Drug: Dexmedetomidine

Clinica Universidad de Navarra, Universidad de Navarra

NULL

Unknown status

18 Years

N/A

All

Phase 4

Spain

478

NCT02702076
(ClinicalTrials.gov)

May 2017

2/3/2016

Apomorphine in Parkinson's Disease Patients With Visual Hallucinations

Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy of Continuous Subcutaneous Infusion in Parkinson's Disease Patients With Refractory Visual Hallucinations

Parkinson's Disease;Hallucinations, Visual

Drug: Apomorphine;Drug: Placebo

University Medical Center Groningen

NULL

Recruiting

30 Years

N/A

All

Phase 2

Netherlands

479

NCT03119636
(ClinicalTrials.gov)

May 2017

6/4/2017

Safety and Efficacy Study of Human ESC-derived Neural Precursor Cells in the Treatment of Parkinson's Disease

A Phase I/II, Open-Label Study to Assess the Safety and Efficacy of Striatum Transplantation of Human Embryonic Stem Cells-derived Neural Precursor Cells in Patients With Parkinson's Disease

Parkinson's Disease

Biological: NPC transplantation;Drug: Levodopa

Chinese Academy of Sciences

The First Affiliated Hospital of Zhengzhou University

Recruiting

50 Years

80 Years

All

Phase 1;Phase 2

China

480

NCT03425877
(ClinicalTrials.gov)

April 22, 2017

10/1/2018

Arousal Response Tool for Neurological Disease

Parkinson Disease;Stroke;Healthy

Device: MS Band 2;Behavioral: Emotion Assessment;Behavioral: Single Task;Behavioral: Dual Task;Behavioral: Rest

IRCCS San Camillo, Venezia, Italy

Università Politecnica delle Marche;University of Padova

Unknown status

25 Years

N/A

All

N/A

Italy

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

481

ChiCTR-IPR-17011155

2017-04-20

2017-04-16

Dihydroergotoxine mesylate for the treatment of sialorrhea in Parkinson's disease

Parkinson’s disease

treatment group:dihydroergotoxine mesylate 2.5 mg, twice daily, two weeks;intervention group:identical placebo 2.5 mg, twice daily, two weeks;

Nanjing First Hospital Affiliated to Nanjing Medical University

NULL

Recruiting

Both

treatment group:10;intervention group:10;

China

482

NCT03140956
(ClinicalTrials.gov)

April 19, 2017

12/4/2017

Pharmacokinetic of Levodopa Study in Healthy Males

Pharmacokinetics of Levodopa After Repeated Doses of Different Pellet Formulations; An Open, Randomized Study With Crossover Design in Healthy Male Subjects

Parkinson Disease

Drug: Levodopa , carbidopa, ODM-104

Orion Corporation, Orion Pharma

NULL

Completed

18 Years

65 Years

Male

Phase 1

Finland

483

NCT03115827
(ClinicalTrials.gov)

April 18, 2017

9/3/2017

Norepinephrine-targeted Therapy for Action Control in Parkinson Disease

Parkinson Disease

Drug: Droxidopa;Drug: Carbidopa

Vanderbilt University Medical Center

H. Lundbeck A/S;American Academy of Neurology

Completed

18 Years

N/A

All

Phase 4

United States

484

NCT03128450
(ClinicalTrials.gov)

April 15, 2017

9/2/2017

A Study To Evaluate the Safety and Efficacy of Human Neural Stem Cells for Parkinson's Disease Patient

A Single Arm, Open-Label,Pilot Study to Evaluate the Safety and Efficacy of Human Neural Stem Cells Injection (ANGE-S003) Through Nasal Way Delivery to Patients With Parkinson's Disease

Parkinson Disease

Biological: human neural stem cell

Second Affiliated Hospital of Soochow University

NULL

Enrolling by invitation

35 Years

70 Years

All

Phase 2;Phase 3

China

485

EUCTR2016-004629-18-NL
(EUCTR)

13/04/2017

17/01/2017

The influence of stress on Parkinson's tremor

The noradrenergic basis of Parkinson’s tremor: a systems-level fMRI approach - Noradrenergic basis of Parkinson tremor

Tremor in Parkinson's disease;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Radboud University Nijmegen

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

Phase 3

Netherlands

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

486

NCT03011476
(ClinicalTrials.gov)

April 11, 2017

27/12/2016

Effect of Acetylcholinesterase Inhibitors on the Gait of the Patients With Parkinson Disease

Effect of Acetylcholinesterase Inhibitors on the Gait of the Patients With Parkinson Disease Characterized by Postural Instability and Gait Disturbance

Parkinson Disease

Drug: Donepezil;Drug: Placebos

Kyung Hee University Hospital

NULL

Unknown status

40 Years

75 Years

All

Phase 4

Korea, Republic of

487

NCT03051607
(ClinicalTrials.gov)

April 10, 2017

9/2/2017

Safety and Tolerability of Tozadenant as Adjunctive Therapy in Levodopa-Treated Patients With Parkinson's Disease.

A Multicenter, Open-Label Study to Evaluate the Safety and Tolerability of Tozadenant as Adjunctive Therapy in Levodopa-Treated Patients With Parkinson's Disease Experiencing End of Dose Wearing-Off

Idiopathic Parkinson Disease

Drug: Tozadenant

Biotie Therapies Inc.

Acorda Therapeutics

Terminated

30 Years

80 Years

All

Phase 3

United States;Canada;United Kingdom

488

JPRN-jRCTs051180185

07/04/2017

26/03/2019

APISJ Study

Intervention study of Istradefylline for the Treatment of Abnormal Posture in Patients with Parkinson's Disease - APISJ Study

Parkinson's disease
Parkinson's disease

In this research, the duration of evaluation will be 24 weeks.
Treatment with istradefylline will be started at a dose of 20 mg administered once daily. The dose of istradefylline will be increased to 40 mg once daily if the patient has no tolerability issues and still has motor symptoms at Week 4. After the Week 4, the dose will be allowed to be reduced to 20 mg once daily, if the patient exhibits any tolerability issues such as the occurrence of adverse drug reactions caused by Istradefylline.

Takahashi Makio

Kyowa Kirin Co., Ltd.

Not Recruiting

>= 30age old

Not applicable

Both

N/A

Japan

489

EUCTR2016-003961-25-GB
(EUCTR)

04/04/2017

16/02/2017

A study to evaluate the safety and tolerability of tozadenant in Parkinson disease patients who are taking levodopa and experiencing wearing off

Parkinson's Disease
MedDRA version: 20.0;Level: LLT;Classification code 10013113;Term: Disease Parkinson's;System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Biotie Therapies

NULL

Not Recruiting

Female: yes
Male: yes

450

Phase 3

United States;Czech Republic;Hungary;European Union;Canada;Spain;Australia;Germany;Italy;United Kingdom

490

NCT02953665
(ClinicalTrials.gov)

April 3, 2017

21/10/2016

Safety and Efficacy of Liraglutide in Parkinson's Disease

A Phase II, Randomized, Double-blinded, Placebo-controlled Trial of Liraglutide in Parkinson's Disease

Parkinson Disease

Drug: Liraglutide;Drug: Placebo

Cedars-Sinai Medical Center

The Cure Parkinson's Trust;Novo Nordisk A/S

Active, not recruiting

25 Years

85 Years

All

Phase 2

United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

491

JPRN-UMIN000026128

2017/04/01

01/04/2017

Association between pupillary autonomic dysfunction and visual hallucination in Parkinson's disease

Parkinson's disease

administe pilocarpine and dipivefrine
administe pilocarpine and dipivefrine

Nagoya University

NULL

Recruiting

40years-old

90years-old

Male and Female

Not selected

Japan

492

EUCTR2016-001403-23-GR
(EUCTR)

31/03/2017

14/10/2016

12-Week study comparing Levodopa-Carbidopa Intestinal Gel / Levodopa Carbidopa Enteral Suspension to Optimized Medical Treatment on dyskinesia in subjects with advanced Parkinson's disease

Dyskinesia in advanced Parkinson's disease
MedDRA version: 19.0;Level: LLT;Classification code 10013113;Term: Disease Parkinson's;System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

AbbVie Deutschland GmbH & Co. KG

NULL

Not Recruiting

Female: yes
Male: yes

Phase 3

United States;Hungary;Slovakia;European Union;Greece;Finland;Spain

493

NCT02970019
(ClinicalTrials.gov)

March 30, 2017

18/11/2016

Safety and Tolerability Study of K0706 in Subjects With Parkinson's Disease

A Double-blind, Placebo-controlled Study to Determine Safety, Tolerability, Pharmacokinetic of K0706.

Parkinson Disease

Drug: K0706;Drug: Placebo

Sun Pharma Advanced Research Company Limited

NULL

Completed

18 Years

65 Years

All

Phase 1

United States

494

EUCTR2016-003456-70-GB
(EUCTR)

22/03/2017

26/01/2017

A clinical trial to compare APL-130277 sublingual film to Subcutaneous Apomorphine in Parkinson’s Disease patients

An Open-Label, Randomized, Crossover Trial utilizing a Single-BlindedRater to evaluate APL-130277 compared to s.c. Apomorphine in LevodopaResponsive Subjects with Parkinson's Disease Complicated by MotorFluctuations

Levodopa Responsive Patients with Parkinson’s Disease Complicated by Motor Fluctuations (OFF episodes)
MedDRA version: 21.1;Level: LLT;Classification code 10034006;Term: Parkinson's disease aggravated;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Sunovion Pharmaceuticals Inc.

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

106

Phase 3

France;Spain;Austria;Germany;Italy;United Kingdom

495

EUCTR2016-001575-71-ES
(EUCTR)

16/03/2017

17/01/2017

A 15-WEEK CLINICAL STUDY TO DETERMINE THE EFFECTIVENESS, SAFETY AND TOLERABILITY OF PF-06649751 IN PATIENTS WITH EARLY PARKINSON’S DISEASE

A 15 WEEK, PHASE 2, DOUBLE BLIND, RANDOMIZED, PLACEBO CONTROLLED, FLEXIBLE DOSE STUDY TO INVESTIGATE THE EFFICACY, SAFETY AND TOLERABILITY OF PF-06649751 IN SUBJECTS WITH EARLY STAGE PARKINSON’S DISEASE

Parkinson's Disease
MedDRA version: 19.1;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Product Name: PF-06649751
Product Code: PF-06649751
INN or Proposed INN: PF-06649751
Other descriptive name: PF-06649751
Product Name: PF-06649751
Product Code: PF-06649751
INN or Proposed INN: PF-06649751
Other descriptive name: PF-06649751
Product Name: PF-06649751
Product Code: PF-06649751
INN or Proposed INN: PF-06649751
Other descriptive name: PF-06649751

Pfizer, Inc.

NULL

Not Recruiting

Female: yes
Male: yes

Phase 2

France;United States;Spain;Israel;Germany

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

496

JPRN-UMIN000026492

2017/03/15

15/03/2017

Intervention study of Istradefylline for the Treatment of Abnormal Posture in Patients with Parkinson's Disease

Intervention study of Istradefylline for the Treatment of Abnormal Posture in Patients with Parkinson's Disease - Intervention Study of Istradefylline for the Treatment of Abnormal Posture in Patients with Parkinson's Disease.

Parkinson's disease

Osaka Red Cross Hospital

Clinical Research Center, Wakayama Medical University

Complete: follow-up complete

30years-old

Not applicable

Male and Female

Not selected

Japan

497

EUCTR2015-003513-24-SK
(EUCTR)

14/03/2017

04/03/2016

OPEN-LABEL EXTENSION and FOLLOW-UP of STUDY IN 11 004

An Open-Label, Multi-Center, Follow-Up Study Designed to Evaluate the Long-Term Effects of AP-CD/LD in Fluctuating Parkinson's Disease Subjects who Completed Study IN 11 004

MedDRA version: 20.0;Level: HLT;Classification code 10034005;Term: Parkinson's disease and parkinsonism;System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Intec Pharma, Ltd.

NULL

Not Recruiting

Female: yes
Male: yes

266

Phase 3

United States;Hungary;Slovakia;Poland;Spain;Ukraine;Israel;Bulgaria;Germany;Italy;United Kingdom

498

JPRN-jRCTs071180014

08/03/2017

29/01/2019

ODYSSEI Study

Intervention Study for the effect of Istradefylline on onset of Dyskinesia in Patients with Parkinson's Disease - ODYSSEI Study

Parkinson's disease
Parkinson's disease

Arm A: Treatment with Istradefylline combined with optimal medical therapy.
Treatment with Istradefylline will be started at a dose of 20 mg administered once daily at Week 0. The dose of Istradefylline will be increased to 40 mg once daily if the patient has no tolerability issues and still has motor symptoms at Week 4.
From the following day of Week 4, Optimal medical therapy including Istradefylline will be applied to each patient.

Arm B: Optimal medical therapy without Istradefylline.
Treatment with increased dose of previously used antiparkinson drugs or addition of new antiparkinson drug other than Istradefylline will be started at Week 0.
After Week 4, Optimal medical therapy without Istradefylline will be applied to each patient.

Tsuboi Yoshio

Kyowa Kirin Co., Ltd.

Not Recruiting

>= 30age old

< 80age old

Both

280

N/A

N A;Japan

499

NCT02864004
(ClinicalTrials.gov)

March 3, 2017

15/7/2016

Apomorphine Pump in Early Stage of Parkinson's Disease (EARLY-PUMP)

Apomorphine Pump in Early Stage of Parkinson's Disease

Parkinson's Disease

Drug: Apomorphine;Other: Best Medical Treatment

Rennes University Hospital

NULL

Recruiting

18 Years

65 Years

All

192

Phase 3

France

500

EUCTR2015-005814-31-CZ
(EUCTR)

03/03/2017

01/12/2016

Subjects with advanced Parkinson's disease
MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

NeuroDerm Ltd.

NULL

Not Recruiting

Female: yes
Male: yes

210

Phase 2

France;United States;Hungary;Czech Republic;Belgium;Spain;Poland;Austria;Israel;Germany;Italy

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

501

EUCTR2015-004507-23-HU
(EUCTR)

24/02/2017

04/01/2017

Comparison of two levodopa treatments, ODM-104 and Stalevo, in Parkinson's disease patients who have motor fluctuations.

Parkinson’s disease (PD) patients with end-of-dose wearing-off (motor fluctuations);Therapeutic area: Diseases [C] - Symptoms and general pathology [C23]

Orion Corporation

NULL

Not Recruiting

Female: yes
Male: yes

Phase 2

Hungary;Finland;Latvia;Germany

502

EUCTR2016-001403-23-FI
(EUCTR)

22/02/2017

31/08/2016

12-Week study comparing Levodopa-Carbidopa Intestinal Gel / Levodopa Carbidopa Enteral Suspension to Optimized Medical Treatment on dyskinesia in subjects with advanced Parkinson's disease

AbbVie Deutschland GmbH & Co. KG

NULL

Not Recruiting

Female: yes
Male: yes

Phase 3

United States;Hungary;Slovakia;European Union;Greece;Finland;Spain

503

NCT03068481
(ClinicalTrials.gov)

February 20, 2017

26/2/2017

Clinical Study of KDT-3594 in Healthy Adult Males and Patients With Parkinson's Disease

A Phase I Clinical Study of KDT-3594 in Healthy Adult Males and Patients With Parkinson's Disease

Parkinson Disease

Drug: KDT-3594;Drug: Placebo

Kissei Pharmaceutical Co., Ltd.

NULL

Completed

20 Years

74 Years

All

Phase 1

Japan

504

EUCTR2016-000657-12-IT
(EUCTR)

16/02/2017

08/02/2017

A Global Study to Assess the Drug Dynamics, Efficacy, and Safety of GZ/SAR402671 in Parkinson's Disease Patients Carrying a Glucocerebrosidase (GBA) Gene Mutation

Parkinson's disease (PD) carrying a GBA mutation
MedDRA version: 19.1;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Product Code: SAR402671, GZ402671 or GZ/SAR402671
INN or Proposed INN: 000000
Other descriptive name: Genz-682452 -AU
Product Code: SAR402671, GZ402671 or GZ/SAR402671
INN or Proposed INN: 00000
Other descriptive name: Genz-682452 -AU

Genzyme Corporation

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

276

Phase 2

Portugal;United States;Taiwan;Spain;Austria;Israel;Italy;United Kingdom;France;Canada;Singapore;Australia;Norway;Germany;Japan;Sweden

505

NCT02799381
(ClinicalTrials.gov)

February 9, 2017

10/6/2016

A Study Comparing Efficacy of Levodopa-Carbidopa Intestinal Gel/Carbidopa-Levodopa Enteral Suspension and Optimized Medical Treatment on Dyskinesia in Subjects With Advanced Parkinson's Disease (DYSCOVER)

An Open-label, Randomized 12 Week Study Comparing Efficacy of Levodopa-Carbidopa Intestinal Gel/Carbidopa-Levodopa Enteral Suspension and Optimized Medical Treatment on Dyskinesia in Subjects With Advanced Parkinson's Disease DYSCOVER (DYSkinesia COmparative Interventional Trial on Duodopa VERsus Oral Medication)

Parkinson's Disease (PD)

Drug: Optimized antiparkinsonian treatment;Drug: Levodopa -Carbidopa Intestinal Gel (LCIG);Device: CADD-Legacy ambulatory infusion pump;Device: Percutaneous endoscopic gastrostomy tube;Device: Jejunal extension tube

AbbVie

NULL

Completed

30 Years

N/A

All

Phase 3

United States;Finland;Greece;Hungary;Italy;Slovakia;Spain

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

506

EUCTR2015-005814-31-DE
(EUCTR)

07/02/2017

24/05/2016

Subjects with advanced Parkinson's disease
MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

NeuroDerm Ltd.

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

170

Phase 2

United States;Spain;Ukraine;Austria;Russian Federation;Israel;United Kingdom;Italy;France;Czech Republic;Hungary;Canada;Poland;Belgium;Romania;Germany

507

EUCTR2015-004344-19-DE
(EUCTR)

07/02/2017

27/09/2016

An international trial of deferiprone in patients with Parkinson’s disease

A Dose-Ranging Study of the Efficacy, Safety, and Pharmacokinetics of Deferiprone Delayed Release Tablets in Patients with Parkinson’s Disease - LA48-0215

Parkinson’s disease
MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

ApoPharma

NULL

Not Recruiting

Female: yes
Male: yes

140

Phase 2

France;Canada;Germany;United Kingdom

508

JPRN-UMIN000025645

2017/02/01

17/01/2018

Cross sectional analysis of Intestinal flora of Parkinson's disease:

Parkinson's disease

Levodopa/carbidopa intestinal gel

Juntendo University School of Medicine

NULL

Pending

Not applicable

Male and Female

Not applicable

Japan

509

NCT03119194
(ClinicalTrials.gov)

January 27, 2017

13/4/2017

Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]-BIA 9-1067

An Open-Label, Single-Dose, Single-Period Study Designed to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]-BIA 9-1067 in Healthy Male Subjects

Parkinson Disease

Drug: [14C]-BIA 9-1067

Bial - Portela C S.A.

NULL

Completed

30 Years

65 Years

Male

Phase 1

United Kingdom

510

EUCTR2016-000657-12-DE
(EUCTR)

26/01/2017

17/10/2016

A Global Study to Assess the Drug Dynamics, Efficacy, and Safety of GZ/SAR402671 in Parkinson's Disease Patients Carrying a Glucocerebrosidase (GBA) Gene Mutation

Product Name: Venglustat
Product Code: SAR402671, GZ402671 or GZ/SAR402671
INN or Proposed INN: venglustat malate
Other descriptive name: Genz-682452 -AU
Product Name: Venglustat
Product Code: SAR402671, GZ402671 or GZ/SAR402671
INN or Proposed INN: venglustat malate
Other descriptive name: Genz-682452 -AU

Genzyme Corporation

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

290

Phase 2

United States;Portugal;Taiwan;Greece;Spain;Austria;Israel;United Kingdom;Italy;France;Canada;Singapore;Australia;Germany;Norway;Japan;Sweden

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

511

EUCTR2016-000657-12-PT
(EUCTR)

09/01/2017

25/10/2016

A Global Study to Assess the Drug Dynamics, Efficacy, and Safety of GZ/SAR402671 in Parkinson's Disease Patients Carrying a Glucocerebrosidase (GBA) Gene Mutation

Parkinson's disease (PD) carrying a GBA mutation
MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Genzyme Corporation

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

290

Phase 2

Portugal;United States;Taiwan;Greece;Spain;Austria;Israel;United Kingdom;Italy;France;Canada;Singapore;Norway;Germany;Japan;Sweden

512

NCT03330470
(ClinicalTrials.gov)

January 1, 2017

17/10/2017

Molecular Mediators of Physical Exercise and Carnosine Induced Effects in Patients With Preclinical and Early Stage Neurodegenerative Disease

Subjective Cognitive Impairment;Mild Cognitive Impairment;Parkinson Disease;Healthy Volunteers

Behavioral: exercise;Dietary Supplement: carnosine supplementation;Behavioral: stretching;Dietary Supplement: supplementation with placebo

Slovak Academy of Sciences

Comenius University;University Hospital Bratislava;National Cheng Kung University

Recruiting

55 Years

80 Years

All

100

N/A

Slovakia;Taiwan

513

ChiCTR-DDD-16009569

2017-01-01

2016-10-24

Differential diagnosis of primary Parkinson's disease by 18F-FDG combined with 11C-ß-CFT PET / CT imaging

Parkinson's Disease

Gold Standard:;Index test:;

Renji hospital, School of Medicine, Shanghai Jiao Tong University

NULL

Pending

Both

Target condition:0;Difficult condition:0

China

514

NCT03034564
(ClinicalTrials.gov)

January 2017

25/1/2017

A Randomized, Double-Blind, Placebo-Controlled Study of Droxidopa for Fatigue in Parkinson's Disease

Parkinson Disease;Fatigue;Parkinsonism

Drug: Northera;Drug: Placebo Oral Tablet

The Cooper Health System

NULL

Recruiting

18 Years

N/A

All

Phase 4

United States

515

NCT03037203
(ClinicalTrials.gov)

January 2017

23/1/2017

A 4-Week Study of the Safety, Efficacy, and Pharmacokinetics of JZP-110 [(R)-2-amino-3-phenylpropylcarbamate Hydrochloride] in Subjects With Parkinson's Disease and Excessive Sleepiness

A 4-Week, Double-blind, Placebo-controlled, Randomized, Multicenter, Crossover Study of the Safety, Efficacy, and Pharmacokinetics of JZP-110 [(R)-2-amino-3-phenylpropylcarbamate Hydrochloride] in Subjects With Parkinson's Disease and Excessive Sleepiness

Excessive Sleepiness;Parkinson Disease

Drug: JZP-110;Other: Placebo

Jazz Pharmaceuticals

NULL

Completed

35 Years

80 Years

All

Phase 2

United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

516

NCT02954978
(ClinicalTrials.gov)

January 2017

1/11/2016

Impact of Nilotinib on Safety, Tolerability, Pharmacokinetics and Biomarkers in Parkinson's Disease

A Randomized, Double Blind, Placebo-controlled Study to Evaluate the Impact of Low Doses of Nilotinib Treatment on Safety, Tolerability, Pharmacokinetics and Biomarkers in Parkinson's Disease

Parkinson Disease;Parkinsons Disease With Dementia

Drug: Placebo Oral Capsule;Drug: Nilotinib 150mg oral capsule [Tasigna];Drug: Nilotinib 300mg oral capsule [Tasigna]

Georgetown University

NULL

Active, not recruiting

40 Years

90 Years

All

Phase 2

United States

517

NCT02969369
(ClinicalTrials.gov)

December 31, 2016

17/11/2016

A Study to Evaluate the Efficacy, Safety and Tolerability of SEP-363856 in Subjects With Parkinson's Disease Psychosis

A Multicenter Randomized Double-blind Followed by an Open-label Extension Study to Evaluate the Efficacy, Safety, and Tolerability of SEP-363856 in Subjects With Parkinson's Disease Psychosis

Parkinson Disease Psychosis

Drug: SEP-363856;Drug: Placebo capsule

Sunovion

NULL

Completed

55 Years

105 Years

All

Phase 2

United States

518

EUCTR2016-001575-71-DE
(EUCTR)

23/12/2016

26/09/2016

A 15-WEEK CLINICAL STUDY TO DETERMINE THE EFFECTIVENESS, SAFETY AND TOLERABILITY OF PF-06649751 IN PATIENTS WITH EARLY PARKINSON’S DISEASE

Pfizer, Inc.

NULL

Not Recruiting

Female: yes
Male: yes

Phase 2

France;United States;Spain;Israel;Germany

519

ChiCTR-IOR-16010168

2016-12-20

2016-12-15

Propofol-remifetanyl vs dexmedetomidine continous infusion for deep brain stimulation implantation

Parkinson's Disease

propofol-remifentanyl group:propofol-remifentany infusion for monitored anesthesia care during awake deep brain stimulation surgery;dexmedetomidine group:dexmedetomidine infusion for monitored anesthesia care during awake deep brain stimulation surgery;

West China Hospital, Sichuan University

NULL

Recruiting

Both

propofol-remifentanyl group:25;dexmedetomidine group:25;

China

520

EUCTR2016-002033-30-BE
(EUCTR)

19/12/2016

21/11/2016

Subjects with Parkinson’s Disease with motor fluctuations
MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

NeuroDerm Ltd.

NULL

Not Recruiting

Female: yes
Male: yes

240

Phase 3

Serbia;Portugal;United States;Spain;Ukraine;Russian Federation;Chile;Israel;United Kingdom;Italy;France;Czech Republic;Hungary;Poland;Belgium;Denmark;Netherlands;Germany

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

521

NCT02906020
(ClinicalTrials.gov)

December 15, 2016

14/9/2016

A Global Study to Assess the Drug Dynamics, Efficacy, and Safety of Venglustat (GZ/SAR402671) in Parkinson's Disease Patients Carrying a Glucocerebrosidase (GBA) Gene Mutation

Multicenter, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of GZ/SAR402671 in Patients With Early-stage Parkinson's Disease Carrying a GBA Mutation or Other Pre-specified Variant.

Parkinson's Disease

Drug: GZ/SAR402671;Drug: Placebo

Genzyme, a Sanofi Company

NULL

Active, not recruiting

18 Years

80 Years

All

270

Phase 2

United States;Austria;Canada;France;Germany;Greece;Israel;Italy;Japan;Norway;Portugal;Singapore;Spain;Sweden;Taiwan;United Kingdom

522

JPRN-UMIN000024859

2016/12/14

16/11/2016

The effectiveness of motor and psychiatric symptoms for Parkinson's disease patients by switching from Dopamine agonist to Zonisamide or combining Dopamine agonist and Zonisamide.

The effectiveness of motor and psychiatric symptoms for Parkinson's disease patients by switching from Dopamine agonist to Zonisamide or combining Dopamine agonist and Zonisamide. - The effectiveness of motor and psychiatric symptoms for Parkinson's disease patients by switching from Dopamine agonist to Zonisamide or combining Dopamine agonist and Zonisamide.

Parkinson's disease

Switching from Dopamine agonist to Zonisamide.

Intervention period of 12 weeks.

Medical Corporation Abe Neurology Clinic

NULL

Complete: follow-up continuing

30years-old

Not applicable

Male and Female

Not applicable

Japan

523

ChiCTR2000037957

2016-12-01

2020-09-07

Clinical study of dexmedetomidine on deep brain stimulation in middle-aged and elderly patients with Parkinson's disease

Deep brain stimulation in patients with Parkinson's disease

Experimental group:conscious sedation with dexmedetomidine;control group:Pump in normal saline;

Shanghai Jing'an District Central Hospital

NULL

Completed

Both

Experimental group:27;control group:9;

China

524

NCT02879136
(ClinicalTrials.gov)

December 2016

23/6/2016

TAME-PD - Physical Therapy, Atomoxetine and, Methylphenidate, to Enhance Gait and Balance in Parkinson's Disease

TAME-PD - Physical Therapy, Atomoxetine and, Methylphenidate, to Enhance Gait and Balance in Parkinson's Disease: A Single Center, Randomized Pilot Study

Parkinson's Disease, Idiopathic

Drug: Methylphenidate;Other: Physical Therapy;Drug: Atomoxetine

Hubert Fernandez

NULL

Recruiting

18 Years

90 Years

All

Early Phase 1

United States

525

NCT02934919
(ClinicalTrials.gov)

December 2016

14/10/2016

Evaluation of Nalmefene in Impulse Control Disorders in Parkinson's Disease: A Prospective Open Label Study

Impulse Control Disorders;Parkinson Disease

Drug: Nalmefene

University Hospital, Clermont-Ferrand

NULL

Not yet recruiting

18 Years

80 Years

Both

Phase 2

France

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

526

NCT02789020
(ClinicalTrials.gov)

December 2016

20/5/2016

Image Parkinson's Disease Progression Study

Parkinson's Disease

Drug: Rasagiline;Other: Placebo;Device: Magnetic Resonance Imaging;Device: functional Magnetic Resonance Imaging;Other: Physical Function Performance Test

University of Florida

National Institute of Neurological Disorders and Stroke (NINDS)

Active, not recruiting

40 Years

77 Years

All

Phase 2

United States

527

NCT02941822
(ClinicalTrials.gov)

December 2016

5/9/2016

Ambroxol in Disease Modification in Parkinson Disease

A Phase IIA Prospective, Single-Centre, Open Label Clinical Trial to Evaluate the Safety, Tolerability and Pharmacodynamic Effects of Ambroxol in Patients With Parkinson Disease: Ambroxol in Disease Modification in Parkinson Disease

Parkinson Disease

Drug: Ambroxol

University College, London

The Cure Parkinson's Trust

Completed

40 Years

80 Years

All

Phase 2

United Kingdom

528

NCT03000569
(ClinicalTrials.gov)

November 30, 2016

28/11/2016

A Study to Evaluate SAGE-217 in Participants With Parkinson's Disease

A Phase 2, Two-Part Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of SAGE-217 in Subjects With Parkinson's Disease

Parkinson Disease

Drug: SAGE-217;Drug: Levodopa;Drug: Antiparkinsonian Agent(s)

Sage Therapeutics

NULL

Completed

40 Years

75 Years

All

Phase 2

United States

529

EUCTR2016-001403-23-SK
(EUCTR)

29/11/2016

07/09/2016

12-Week study comparing Levodopa-Carbidopa Intestinal Gel / Levodopa Carbidopa Enteral Suspension to Optimized Medical Treatment on dyskinesia in subjects with advanced Parkinson's disease

Dyskinesia in advanced Parkinson's disease
MedDRA version: 20.0;Level: LLT;Classification code 10013113;Term: Disease Parkinson's;System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

AbbVie Deutschland GmbH & Co. KG

NULL

Not Recruiting

Female: yes
Male: yes

Phase 3

United States;Hungary;European Union;Slovakia;Greece;Finland;Spain

530

EUCTR2016-002033-30-FR
(EUCTR)

29/11/2016

12/01/2017

A clinical study investigating the efficacy, tolerability, and safety of continuous subcutaneous ND0612 infusion given as adjunct treatment to oral levodopa in patients with Parkinson’s disease with motor fluctuations

A multicenter, randomized, double-blind, placebo controlled, parallel group clinical study investigating the efficacy, tolerability, and safety of continuous subcutaneous ND0612 infusion Given as adjunct treatment to oral levOdopa in patients with Parkinson’s Disease with motor fluctuations (iNDiGO) - iNDiGO

Subjects with Parkinson’s Disease with motor fluctuations
MedDRA version: 19.1;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

NeuroDerm Ltd.

NULL

Not Recruiting

Female: yes
Male: yes

150

Phase 3

United States;France;Hungary;Canada;Belgium;Spain;Denmark;Israel;Netherlands;United Kingdom;Sweden

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

531

JPRN-UMIN000024536

2016/11/28

25/10/2016

Intervention Study for the effect of Istradefylline on onset of Dyskinesia in Patients with Parkinson's Disease.

Intervention Study for the effect of Istradefylline on onset of Dyskinesia in Patients with Parkinson's Disease. - ODYSSEI Study(Onset of Dyskinesia and Safety/Efficacy of Istradefylline)

Parkinson's disease

Treatment with istradefylline combined with optimal medical therapy.

Treatment with istradefylline will be started at a dose of 20 mg administered once daily at Week 0. The dose of istradefylline will be increased to 40 mg once daily if the patient has no tolerability issues and still has motor symptoms at Week 4.

From the following day of Week 4, Optimal medical therapy including istradefylline will be applied to each patient.
Optimal medical therapy without istradefylline.

Treatment with increased dose of previously used antiparkinson drugs or addition of new antiparkinson drug other than istradefylline will be started at Week 0.

After Week 4, Optimal medical therapy without istradefylline will be applied to each patient.

Fukuoka University

NULL

Complete: follow-up complete

30years-old

80years-old

Male and Female

280

Not applicable

Japan

532

EUCTR2015-004912-39-ES
(EUCTR)

25/11/2016

17/05/2016

A 15-WEEK CLINICAL STUDY TO DETERMINE THEEFFECTIVENESS, SAFETY AND TOLERABILITY OF PF-06649751 IN PATIENTS WITH MOTOR FLUCTUATIONS DUE TO PARKINSON'S DISEASE

A 15-WEEK, PHASE 2, DOUBLE BLIND, RANDOMIZED, PLACEBO-CONTROLLED, DOSE RANGING STUDY TO INVESTIGATE THEEFFICACY, SAFETY AND TOLERABILITY OF PF-06649751 IN SUBJECTS WITH MOTOR FLUCTUATIONS DUE TO PARKINSON'S DISEASE

Parkinson's Disease
MedDRA version: 19.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Pfizer, Inc.

NULL

Not Recruiting

Female: yes
Male: yes

198

Phase 2

France;United States;Spain;Germany;Japan;United Kingdom

533

EUCTR2016-001690-33-FI
(EUCTR)

25/11/2016

23/11/2016

Apomorfiini-infuusiohoito edenneen Parkinsonin taudin hoidossa

Edennyt parkinsonin tauti
MedDRA version: 19.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Trade Name: Dacepton 5 mg/ml infuusioneste, liuos
Product Name: Dacepton 5 mg/ml

Eero Pekkonen

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

Phase 4

Finland

534

EUCTR2016-000102-11-NL
(EUCTR)

23/11/2016

08/11/2016

Trial to evaluate the efficacy of continuous subcutaneous apomorphine infusion in Parkinson’s disease patients with refractory visual hallucinations.

Randomized, double-blind, placebo-controlled trial to evaluate the efficacy of continuous subcutaneous apomorphine infusion in Parkinson’s disease patients with refractory visual hallucinations. - Apomorphine in PD patients with visual hallucinations: a RCT

Parkinson's disease patients with refractory visual hallucinations
MedDRA version: 19.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Trade Name: APO-go
Product Name: Apomorphine

University Medical Center Groningen

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

Phase 2;Phase 3

Netherlands

535

NCT02847442
(ClinicalTrials.gov)

November 23, 2016

21/7/2016

Efficacy and Safety of Opicapone in Clinical Practice

Efficacy and Safety of Opicapone in Clinical Practice in Parkinson's Disease Patients With Wearing-off Motor Fluctuations

Parkinson's Disease With Wearing-off Motor Fluctuations

Drug: BIA 9-1067;Drug: levodopa /dopa decarboxylase inhibitor

Bial - Portela C S.A.

NULL

Completed

30 Years

N/A

All

518

Phase 4

Germany

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

536

EUCTR2016-001403-23-ES
(EUCTR)

14/11/2016

15/11/2016

12-Week study comparing Levodopa-Carbidopa Intestinal Gel / Levodopa Carbidopa Enteral Suspension to Optimized Medical Treatment on dyskinesia in subjects with advanced Parkinson's disease

Dyskinesia in advanced Parkinson's disease
MedDRA version: 19.0;Level: LLT;Classification code 10013113;Term: Disease Parkinson's;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Trade Name: Duodopa
INN or Proposed INN: Levodopa
Other descriptive name: LEVODOPA
INN or Proposed INN: Carbidopa
Other descriptive name: CARBIDOPA MONOHYDRATE

AbbVie Deutschland GmbH & Co. KG

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

Phase 3

United States;European Union;Spain

537

NCT03007888
(ClinicalTrials.gov)

November 14, 2016

6/12/2016

A Study to Assess the PK and Pharmacodynamics of IPX203 in Subjects With Advanced Parkinson's Disease

A Randomized, Multiple Dose Study to Assess the Pharmacokinetics and Pharmacodynamics of IPX203 in Subjects With Advanced Parkinson's Disease

Advanced Parkinson's Disease

Drug: IR CD-LD;Drug: ER CD-LD

Impax Laboratories, LLC

NULL

Completed

40 Years

100 Years

All

Phase 2

United States

538

EUCTR2016-000657-12-SE
(EUCTR)

09/11/2016

12/10/2016

A Global Study to Assess the Drug Dynamics, Efficacy, and Safety of GZ/SAR402671 in Parkinson's Disease Patients Carrying a Glucocerebrosidase (GBA) Gene Mutation

Genzyme Corporation

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

290

Phase 2

United States;Portugal;Taiwan;Greece;Spain;Austria;Israel;United Kingdom;Italy;France;Canada;Singapore;Germany;Norway;Japan;Sweden

539

EUCTR2016-001762-29-IT
(EUCTR)

08/11/2016

25/05/2017

A Phase 2, Randomized, Double-Blind, Placebo Controlled, 3-Period Crossover, Positive Control, QT-Evaluation Study of APL-130277 in Subjects with Parkinson’s Disease Complicated by Motor Fluctuations (OFF” Episodes)

Parkinson's Disease (PD)
MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Product Name: APL-130277
Product Code: APL-130277
INN or Proposed INN: Apomorphine Hydrocloride Hemihydrate
Other descriptive name: Apomorphine Hydrocloride
Product Name: APL-130277
Product Code: APL-130277
INN or Proposed INN: Apomorphine Hydrocloride Hemihydrate
Other descriptive name: Apomorphine Hydrocloride
Product Name: APL-130277
Product Code: APL-130277
INN or Proposed INN: Apomorphine Hydrocloride Hemihydrate
Other descriptive name: Apomorphine Hydrocloride
Product Name: APL-130277
Product Code: APL-130277
INN or Proposed INN: Apomorphine Hydrocloride Hemihydrate
Other descriptive name: Apomorphine Hydrocloride
Product Name: APL-130277
Product Code: APL-130277
INN or Proposed INN: Apomorphine Hydrocloride Hemihydrate
Other descriptive name: Apomorphine Hydrocloride
Trade Name: AVALOX - 400 MG COMPRESSE RIVESTITE CON FILM 5 COMPRESSE IN BLISTER PP/AL
Product Name: Avalox
Product Code: n.a.
INN or Proposed INN: MOXIFLOXACINA CLORIDRATO

SUNOVION PHARMACEUTICALS

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

Phase 2

Italy

540

NCT03531060
(ClinicalTrials.gov)

November 8, 2016

10/4/2018

A Clinical Study of IRL790 in Patients With Parkinson's Disease Experiencing Levodopa Induced Dyskinesia

A Randomised, Double-blind, Placebo-controlled, Phase Ib Study Evaluating the Safety and Tolerability of IRL790 in Patients With Parkinson's Disease (PD) Experiencing Levodopa (L-Dopa) Induced Dyskinesia (LID).

Parkinson Disease

Drug: IRL790;Drug: Placebo

Integrative Research Laboratories AB

NULL

Completed

50 Years

85 Years

All

Phase 1;Phase 2

NULL

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

541

EUCTR2016-002033-30-ES
(EUCTR)

03/11/2016

25/08/2016

Subjects with Parkinson’s Disease with motor fluctuations
MedDRA version: 19.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Product Name: levodopa /carbidopa solution
Product Code: ND0612
INN or Proposed INN: Levodopa
Other descriptive name: Levodopa
INN or Proposed INN: Carbidopa
Other descriptive name: CARBIDOPA

NeuroDerm Ltd.

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

150

Phase 3

United States;France;Canada;Belgium;Spain;Denmark;Israel;Netherlands;Sweden

542

JPRN-UMIN000025638

2016/11/01

16/01/2017

Adenosine A2A receptors in Parkinson's disease

Parkinson's disease

11C-preladenant-PET scanning

Tokyo Metropolitan Institute of Gerontology

NULL

Complete: follow-up complete

40years-old

89years-old

Male and Female

Not selected

Japan

543

ChiCTR-IPR-16009395

2016-11-01

2016-10-14

Clinical trial on efficacy and safety of add-on treatment of Butylphthalide in patients with Parkinson's disease in early and moderate stage

Parkinson’s disease

Butylphthalide group and Control group:Butylphthalide 200mg/time(2 capsules) , three time/day, for 24 weeks;Control:No treatment;

The Second Affiliated Hospital of Soochow University

NULL

Pending

Both

Butylphthalide group and Control group:36;Control:36;

China

544

NCT02968433
(ClinicalTrials.gov)

November 2016

14/11/2016

The Stanford Parkinson's Disease Plasma Study

The Stanford Parkinson's Disease Plasma (SPDP) Study: Intravenously-Administered Plasma From Young Donors for Treatment of Moderate Parkinson's Disease

Parkinson Disease(PD)

Drug: Infusions of young plasma

Stanford University

NULL

Active, not recruiting

50 Years

80 Years

All

Phase 1

United States

545

NCT02857244
(ClinicalTrials.gov)

November 2016

25/7/2016

A Multidisciplinary Approach to Manage Gait Difficulty in Parkinson Patients

Parkinson's Disease

Drug: Duloxetine;Drug: Donepezil;Drug: Modafinil

University of Chicago

NULL

Withdrawn

18 Years

100 Years

All

Phase 2

United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

546

NCT03022799
(ClinicalTrials.gov)

November 2016

27/12/2016

Phase I, KM-819 in Healthy Subjects for Parkinson's Disease

A First in Human, Randomized, Double-blind, Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Following Single and Multiple Oral Doses of KM-819 in Healthy Young Adult and Elderly Subjects

Parkinson's Disease

Drug: KM-819;Drug: Placebo

Kainos Medicine Inc.

NULL

Completed

19 Years

45 Years

All

Phase 1

Korea, Republic of

547

EUCTR2015-001786-10-DE
(EUCTR)

24/10/2016

07/04/2016

A clinical study of the effects of EPI-589 on safety and indicators of oxidative stress in patients with Parkinson's disease.

A Phase 2A Safety and Biomarker Study of EPI-589 in Mitochondrial Subtype and Idiopathic Parkinson’s Disease Subjects - Safety and Biomarker Study with EPI-589 in Parkinson's Disease

Parkinson’s disease
MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

BioElectron Technology Corporation (formerly Edison Pharmaceuticals Inc.)

NULL

Not Recruiting

Female: yes
Male: yes

Phase 2

United States;Germany;United Kingdom

548

EUCTR2016-002680-34-ES
(EUCTR)

20/10/2016

05/08/2016

Effects of different concentrations of dexmedetomidine on basal ganglia neuronal activity (local field potentials) in Parkinson's disease.

Parkinson's disease
MedDRA version: 19.0;Level: LLT;Classification code 10013113;Term: Disease Parkinson's;System Organ Class: 100000004852;Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Anesthesia and Analgesia [E03]

Trade Name: Dexdor
Product Name: Dexdor
INN or Proposed INN: DEXMEDETOMIDINE
Other descriptive name: DEXMEDETOMIDINA

Clínica Universidad de Navarra/Universidad de Navarra

NULL

Not Recruiting

Female: yes
Male: yes

Phase 4

Spain

549

NCT02871427
(ClinicalTrials.gov)

October 20, 2016

15/8/2016

Open-label Study of Nelotanserin in Lewy Body Dementia With Visual Hallucinations or REM Sleep Behavior Disorder

An Open-label Study of Nelotanserin in Patients With Lewy Body Dementia Who Have Frequent Visual Hallucinations or REM Sleep Behavior Disorder

Lewy Body Dementia;Dementia With Lewy Bodies;Parkinson's Disease Dementia;Visual Hallucinations;REM Sleep Behavior Disorder

Drug: Nelotanserin

Axovant Sciences Ltd.

NULL

Terminated

50 Years

N/A

All

Phase 2

United States

550

EUCTR2016-000657-12-ES
(EUCTR)

20/10/2016

24/10/2016

A Global Study to Assess the Drug Dynamics, Efficacy, and Safety of GZ/SAR402671 in Parkinson's Disease Patients Carrying a Glucocerebrosidase (GBA) Gene Mutation

Parkinson's disease (PD) carrying a GBA mutation
MedDRA version: 19.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Product Code: SAR402671, GZ402671 or GZ/SAR402671
INN or Proposed INN: NA
Other descriptive name: Genz-682452 -AU
Product Code: SAR402671, GZ402671 or GZ/SAR402671
INN or Proposed INN: NA
Other descriptive name: Genz-682452 -AU

Genzyme Corporation

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

276

Phase 2

United States;Portugal;Taiwan;Spain;Austria;Israel;United Kingdom;Italy;France;Canada;Singapore;Australia;Germany;Norway;Japan;Sweden

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

551

NCT02847650
(ClinicalTrials.gov)

October 17, 2016

25/7/2016

Efficacy, Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients at Early Stage of the Disease

A 15-WEEK, PHASE 2, DOUBLE BLIND, RANDOMIZED, PLACEBO-CONTROLLED, FLEXIBLE DOSE STUDY TO INVESTIGATE THE EFFICACY, SAFETY AND TOLERABILITY OF PF-06649751 IN SUBJECTS WITH EARLY STAGE PARKINSON'S DISEASE

Parkinson Disease

Drug: Placebo;Drug: PF-06649751

Pfizer

NULL

Terminated

45 Years

80 Years

All

Phase 2

United States;France;Germany;Israel

552

EUCTR2016-002454-20-FR
(EUCTR)

17/10/2016

16/03/2017

Apomorphine Pump in Early Stage of Parkinson’s Disease

Apomorphine Pump in Early Stage of Parkinson’s Disease - EARLY-PUMP

Parkinson’s disease
MedDRA version: 19.1;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Trade Name: APOKINON
Product Name: APOKINON

CHU de Rennes

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

Phase 3

France

553

EUCTR2015-002571-24-GB
(EUCTR)

14/10/2016

12/02/2019

A Pilot Study to Evaluate the Safety, Tolerability (any side effects of the drug) and Pharmacodynamic (biochemical and physiological effects of drugs). The effects of Ambroxol in Patients with Parkinson Disease: Ambroxol in Disease Modification in Parkinson Disease.

A Phase IIA Prospective, Single-Centre, Open Label Clinical Trial to Evaluate the Safety, Tolerability and Pharmacodynamic Effects of Ambroxol in Patients with Parkinson Disease: Ambroxol in Disease Modification in Parkinson Disease - AiM-PD

Parkinson disease;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Joint Research Office

NULL

Not Recruiting

Female: yes
Male: yes

Phase 2

United Kingdom

554

NCT02728843
(ClinicalTrials.gov)

October 12, 2016

31/3/2016

Study of Parkinson's Early Stage With Deferiprone

A Dose-Ranging Study of the Efficacy, Safety, and Pharmacokinetics of Deferiprone Delayed Release Tablets in Patients With Parkinson's Disease

Parkinson's Disease

Drug: Deferiprone;Drug: Placebo

ApoPharma

NULL

Completed

18 Years

80 Years

All

140

Phase 2

Canada;France;Germany;United Kingdom

555

EUCTR2016-002391-27-GB
(EUCTR)

07/10/2016

04/08/2016

Opicapone in clinical practice (OPTIPARK)

This action will amend the information submitted in this data field for all relevant applications. Please refer to the guidance under the Amendment tab and consider whether further notification to review bodies is required. - Opicapone in clinical practice (OPTIPARK)_V1

Parkinson's disease (PD) patients with wearing-off motor fluctuations
MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders
MedDRA version: 20.0;System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

BIAL - Portela & Ca, S.A.

NULL

Not Recruiting

Female: yes
Male: yes

550

Phase 4

Germany;United Kingdom

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

556

EUCTR2016-002391-27-DE
(EUCTR)

05/10/2016

05/08/2016

OPTIPARK

Efficacy and safety of opicapone in clinical practice in Parkinson’s Disease patients with wearing-off motor fluctuations

Parkinson's disease (PD) patients with wearing-off motor fluctuations;Therapeutic area: Not possible to specify

BIAL - Portela & Ca, S.A.

NULL

Not Recruiting

Female: yes
Male: yes

550

Phase 4

Germany;United Kingdom

557

NCT02935842
(ClinicalTrials.gov)

October 1, 2016

18/8/2016

Evaluation of Intensive Language Therapy

Effectiveness of High-frequency Specific Speech Therapy on Verbal Fluency Decline and/ or Verbal Apraxia in Patients With Parkinson's Disease With and Without Deep Brain Stimulation (DBS) - a Randomized Controlled Single-blinded Trial

Parkinson's Disease

Other: Specific SL-therapy;Other: Rhythmic Balance-Movement Training (rBMT)

University Hospital, Basel, Switzerland

NULL

Completed

45 Years

80 Years

All

N/A

Switzerland

558

NCT02940912
(ClinicalTrials.gov)

October 2016

14/10/2016

Effect of Continuous Apomorphine During the Night on Sleep Disorders in Insomniac Patients With Parkinson's Disease

Double Bind Randomized Placebo-controlled Cross-over Study to Evaluate Effect of Continuous Apomorphine During the Night on Sleep Disorders in Insomniac Patients With Parkinson's Disease

Parkinson Disease

Drug: Apomorphine;Drug: Placebo

Clinique Beau Soleil

NULL

Recruiting

35 Years

90 Years

All

Phase 4

France

559

NCT02910102
(ClinicalTrials.gov)

October 2016

16/9/2016

Study Evaluating Intepirdine (RVT-101) on Gait and Balance in Subjects With Dementia

A Phase 2, Double-blind, Randomized, Placebo-controlled Crossover Study Evaluating the Effect of RVT-101 on Gait and Balance in Subjects With Alzheimer's Disease, Dementia With Lewy Bodies, or Parkinson's Disease Dementia

Alzheimer's Disease;Dementia With Lewy Bodies;Parkinson's Disease Dementia

Drug: RVT-101 35 mg;Drug: Placebo

Axovant Sciences Ltd.

NULL

Completed

50 Years

89 Years

All

Phase 2

United States

560

NCT02538315
(ClinicalTrials.gov)

October 2016

25/8/2015

Using [18F]FDOPA PET/CT to Monitor the Effectiveness of Fetal Dopaminergic Grafts in Parkinson Disease Patients

Using 3,4-dihydroxy-6-[18F]-Fluoro-l-phenylalanine ( [18F]FDOPA) PET/CT to Monitor the Effectiveness of Fetal Dopaminergic Grafts in Parkinson Disease Patients

Parkinson`s Disease

Drug: [18F]FDOPA PET/CT

University of Saskatchewan

University of Manitoba

Recruiting

18 Years

N/A

All

N/A

Canada

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

561

NCT02803749
(ClinicalTrials.gov)

October 2016

14/6/2016

Buspirone in Parkinson's Disease

The Tolerability of Buspirone for the Treatment of Anxiety in Parkinson's Disease

Parkinson Disease;Anxiety

Drug: Buspirone;Drug: Placebo

University of Rochester

Michael J. Fox Foundation for Parkinson's Research

Completed

18 Years

N/A

All

Phase 2

United States

562

NCT02818777
(ClinicalTrials.gov)

October 2016

6/5/2016

A Study of Tolerability and Efficacy of Cannabidiol on Tremor in Parkinson's Disease

A Randomized, Double Blind, Placebo-controlled Crossover Study of Tolerability and Efficacy of Cannabidiol (CBD) on Tremor in Parkinson's Disease

Parkinson's Disease

Drug: cannabidiol

University of Colorado, Denver

Colorado Department of Public Health and Environment;GW Research Ltd

Completed

40 Years

80 Years

All

Phase 2

United States

563

NCT03462680
(ClinicalTrials.gov)

September 28, 2016

22/2/2018

GPR109A and Parkinson's Disease: Role of Niacin in Outcome Measures

Parkinson's Disease

Dietary Supplement: niacin;Other: placebo

VA Office of Research and Development

NULL

Completed

35 Years

N/A

All

N/A

United States

564

EUCTR2015-005078-39-DE
(EUCTR)

21/09/2016

02/03/2016

A multicenter, parallel-group, rater-blinded, randomized clinical study investigating the efficacy, safety, tolerability and pharmacokinetics of 2 dosing regimens of ND0612H, a solution of levodopa/carbidopa delivered via a pump system as a continuous subcutaneous infusion in subjects with advanced Parkinson's disease

Subjects with advanced Parkinson's disease
MedDRA version: 18.1;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Product Name: levodopa /carbidopa solution
Product Code: ND0612
INN or Proposed INN: Levodopa
Other descriptive name: LEVODOPA
INN or Proposed INN: Carbidopa
Other descriptive name: CARBIDOPA

NeuroDerm Ltd.

NULL

Not Recruiting

Female: yes
Male: yes

Phase 2

United States;Austria;Israel;Germany;Italy

565

JPRN-UMIN000024312

2016/09/20

25/05/2017

Studies of efficacy and safety of the combined use of febuxostat and inosine for patients with Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis or multiple sclerosis, and changes of blood and urine purine compounds.

Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis or multiple sclerosis

Treatment with febuxostat 20 mg and inosine 0.5 g, twice a day for 2 weeks

Tsukuba International Clinical Pharmacology Clinic

NULL

Complete: follow-up complete

20years-old

80years-old

Male and Female

Not selected

Japan

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

566

EUCTR2015-003513-24-DE
(EUCTR)

08/09/2016

15/04/2016

OPEN-LABEL EXTENSION and FOLLOW-UP of STUDY IN 11 004

An Open-Label, Multi-Center, Follow-Up Study Designed to Evaluate the Long-Term Effects of AP-CD/LD in Fluctuating Parkinson's Disease Subjects who Completed Study IN 11 004

MedDRA version: 20.0;Level: HLT;Classification code 10034005;Term: Parkinson's disease and parkinsonism;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Product Name: Accordion Pill™ Carbidopa/Levodopa 50/400 mg
INN or Proposed INN: Carbidopa
Other descriptive name: CARBIDOPA
INN or Proposed INN: Levodopa
Other descriptive name: LEVODOPA
Product Name: Accordion Pill™ Carbidopa/Levodopa 50/500 mg
INN or Proposed INN: Carbidopa
Other descriptive name: CARBIDOPA
INN or Proposed INN: Levodopa
Other descriptive name: LEVODOPA

Intec Pharma, Ltd.

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

266

Phase 3

United States;Hungary;Slovakia;Poland;Spain;Ukraine;Israel;Bulgaria;Germany;Italy;United Kingdom

567

NCT02688465
(ClinicalTrials.gov)

September 5, 2016

18/2/2016

Effect of an Apomorphine Pump on the Quality of Sleep in Parkinson's Disease Patients (POMPRENELLE).

Parkinson's Disease

Drug: Apomorphine

Fondation Ophtalmologique Adolphe de Rothschild

NULL

Terminated

18 Years

N/A

All

Phase 4

France

568

NCT02815800
(ClinicalTrials.gov)

September 2, 2016

13/6/2016

Efficacy of Ethnodyne Visio in Parkinson's Disease

Parkinson's Disease

Dietary Supplement: ETHNODYNE VISIO

University Hospital, Strasbourg, France

ETHNODYNE

Completed

40 Years

75 Years

All

N/A

France

569

NCT02385500
(ClinicalTrials.gov)

September 2016

4/3/2015

Fesoterodine on Urgency Episodes in Parkinson's Disease Population

Randomized Cross-Over Study of Fesoterodine on Urgency Episodes in Parkinson's Disease Population

Urinary Bladder, Overactive;Parkinson Disease

Drug: Fesoterodine;Drug: Placebo

Sir Mortimer B. Davis - Jewish General Hospital

NULL

Terminated

50 Years

85 Years

All

Phase 4

Canada

570

NCT02939391
(ClinicalTrials.gov)

September 2016

17/10/2016

A Study of KW-6356 in Subjects With Early Parkinson's Disease

An Early Phase 2 Study of KW-6356 in Subject With Early Parkinson's Disease

Parkinson's Disease

Drug: KW-6356;Drug: Placebo

Kyowa Kirin Co., Ltd.

NULL

Completed

20 Years

80 Years

All

175

Phase 2

Japan

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

571

NCT02601586
(ClinicalTrials.gov)

September 2016

17/8/2015

Effects of PR Oxycodone and of Levodopa, vs Placebo, on Central Neuropathic Pain in Parkinson's Disease

Evaluation of the Analgesic Effects of Prolonged-release Oxycodone and of Levodopa, Versus Placebo, on Central Neuropathic Pain in Parkinson's Disease: OXYDOPA Trial

Parkinson Disease

Drug: PR Oxycodone;Drug: Levodopa;Drug: Oxycodone Placebo;Drug: Levodopa placebo

University Hospital, Toulouse

NULL

Recruiting

40 Years

75 Years

All

Phase 2;Phase 3

France

572

NCT02897063
(ClinicalTrials.gov)

September 2016

7/9/2016

Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure

The Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure Aim 2 of RDCRN (Rare Diseases Clinical Research Network) Project 2

Autonomic Failure;Pure Autonomic Failure;Multiple System Atrophy;Parkinson Disease;Orthostatic Hypotension

Drug: Droxidopa;Drug: Midodrine;Drug: Placebo

Vanderbilt University Medical Center

NULL

Recruiting

40 Years

80 Years

All

Phase 1

United States

573

NCT03192046
(ClinicalTrials.gov)

September 2016

13/6/2017

Bracing for Walking in Parkinson's Disease

Impact of Carbon Fiber AFOs on Gait and Resulting Changes in Quality of Life Across Time in Persons With PD

Gait Disorders, Neurologic;Parkinson Disease

Device: Carbon Fiber Ankle Foot Orthosis (AFO)

University of Texas Southwestern Medical Center

American Orthotic and Prosthetic Association

Recruiting

30 Years

85 Years

All

N/A

United States

574

EUCTR2015-005814-31-AT
(EUCTR)

29/08/2016

11/05/2016

Product Name: levodopa /carbidopa solution
Product Code: ND0612
INN or Proposed INN: Levodopa
Other descriptive name: LEVODOPA
INN or Proposed INN: carbidopa
Other descriptive name: CARBIDOPA

NeuroDerm Ltd.

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

210

Phase 2

United States;France;Hungary;Czech Republic;Belgium;Spain;Poland;Austria;Israel;Germany;Italy

575

EUCTR2015-003679-31-NL
(EUCTR)

09/08/2016

24/05/2016

New therapeutic strategy in Parkinson’s disease

Conservative iron chelation as a disease-modifying strategy in Parkinson’s disease - FAIRPARK II

De Novo Parkinson’s disease;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Product Name: Deferiprone DR
INN or Proposed INN: DEFERIPRONE

Centre Hospitalier Régional et Universitaire de Lille

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

Phase 2

Portugal;Spain;Austria;Netherlands

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

576

NCT02365870
(ClinicalTrials.gov)

August 2016

11/2/2015

Anxiety in Parkinson's: Use of Quantitative Methods to Guide Rational Treatment

Anxiety Disorders;Parkinson Disease

Drug: rotigotine transdermal patch;Drug: placebo

Johns Hopkins University

National Institute on Aging (NIA)

Terminated

21 Years

89 Years

All

Phase 4

United States

577

NCT02782481
(ClinicalTrials.gov)

August 2016

22/5/2016

A Clinical Study Investigating the Efficacy, Tolerability, and Safety of Continuous Subcutaneous ND0612 Infusion Given as Adjunct Treatment to Oral Levodopa in Patients With Parkinson's Disease With Motor Fluctuations

A Multicenter, Randomized, Double-blind, Placebo Controlled, Parallel Group Clinical Study Investigating the Efficacy, Tolerability, and Safety of Continuous Subcutaneous ND0612 Infusion Given as Adjunct Treatment to Oral Levodopa in Patients With Parkinson's Disease With Motor Fluctuations

Parkinson's Disease

Drug: ND0612;Drug: Placebo

NeuroDerm Ltd.

NULL

Withdrawn

30 Years

80 Years

All

Phase 3

Israel

578

EUCTR2014-001014-25-ES
(EUCTR)

20/07/2016

15/07/2016

Brain amyloid beta burden as per florbetaben PET

Brain Amyloid-Beta burden as per florbetaben (Neuraceq) pet and cognitive outcomes after deep brain stimulation in Parkinsin's disease

Trade Name: Neuraceq
Product Name: Neuraceq
INN or Proposed INN: FLORBETABEN (18F)

Fundació Clínic per la Recerca Biomèdica

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

Phase 4

Spain

579

ChiCTR-DOC-16008645

2016-07-01

2016-06-15

The study of radionuclide imaging and biomarkers in clinical diagnosis and treatment of Parkinson's disease

Parkinson Disease

Gold Standard:;Index test:;

101th Hospital of PLA

NULL

Pending

Both

Target condition:0;Difficult condition:0

NULL

580

ChiCTR-DRD-16008778

2016-07-01

2016-07-04

The study of Parkinson's disease imaging biomarkers based on MR with high resolution and multi mode

Parkinson`s Disease

Gold Standard:;Index test:;

Xiangyang Hospital, Hubei University of Medicine

NULL

Recruiting

Both

Target condition:0;Difficult condition:0

China

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

581

NCT02452723
(ClinicalTrials.gov)

July 2016

18/5/2015

A Study to Evaluate the Safety of Neural Stem Cells in Patients With Parkinson's Disease

A Single Arm, Open-Label Phase 1 Study to Evaluate the Safety and Tolerability of ISC-hpNSC Injected Into the Striatum and Substantia Nigra of Patients With Parkinson's Disease

Parkinson Disease

Biological: ISC-hpNSC

Cyto Therapeutics Pty Limited

NULL

Active, not recruiting

30 Years

70 Years

All

Phase 1

Australia

582

NCT02789592
(ClinicalTrials.gov)

July 2016

31/5/2016

Efficacy and Safety of Melatonin PR and Clonazepam in Patients With REM Sleep Behavior Disorder in Parkinson Disease

A Randomized Double-Blind, Double-Dummy, Crossover Study to Evaluate the Efficacy and Safety of Prolonged-Release Melatonin and Clonazepam in Patients With Rapid Eye Movement (REM) Sleep Behavior Disorder in Parkinson Disease

REM Sleep Behavior Disorder;Parkinson Disease

Drug: Melatonin PR;Drug: Clonazepam;Drug: Melatonin PR placebo;Drug: Clonazepam placebo

Seoul National University Hospital

Kuhnil Pharmaceutical Co., Ltd.

Not yet recruiting

30 Years

N/A

Both

Phase 2

Korea, Republic of

583

NCT02615873
(ClinicalTrials.gov)

July 2016

23/11/2015

A Study of AP-CD/LD in Fluctuating Parkinson's Disease Patients Who Completed IN 11 004

An Open-Label,Multi-Center, Follow-Up Study Designed to Evaluate the Long-Term Effects of AP-CD/LD in Fluctuating Parkinson's Disease Subjects Who Completed Study IN 11 004

Parkinson's Disease

Drug: Accordion Pill™ Carbidopa/Levodopa

Intec Pharma Ltd.

NULL

Unknown status

30 Years

100 Years

All

460

Phase 3

United States;Bulgaria;Germany;Israel;Italy;Poland;Slovakia;Spain;Ukraine;United Kingdom

584

NCT02382198
(ClinicalTrials.gov)

July 2016

21/1/2015

Study of Glycopyrrolate for Moderate-to-severe Sialorrhea in Parkinson's Disease

A Randomized, Placebo-controlled, 2-arm Parallel-group Superiority Phase II Study of GLYCOpyrrolate for Moderate-to-severe Sialorrhea in PARkinson's Disease

Sialorrhea;Parkinson's Disease

Drug: Glycopyrrolate;Drug: Placebo

Ottawa Hospital Research Institute

NULL

Unknown status

30 Years

N/A

All

Phase 2

Canada

585

EUCTR2015-004344-19-FR
(EUCTR)

29/06/2016

20/04/2016

An international trial of deferiprone in patients with parkinson’s disease

A Dose-Ranging Study of the Efficacy, Safety, and Pharmacokinetics of Deferiprone Delayed Release Tablets in Patients with Parkinson’s Disease - LA48-0215

Parkinson’s disease
MedDRA version: 19.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

ApoPharma Inc.

NULL

Not Recruiting

Female: yes
Male: yes

140

Phase 2

United States;France;Canada;Germany;Italy;United Kingdom

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

586

EUCTR2015-003513-24-BG
(EUCTR)

27/06/2016

26/04/2016

OPEN-LABEL EXTENSION and FOLLOW-UP of STUDY IN 11 004

An Open-Label, Multi-Center, Follow-Up Study Designed to Evaluate the Long-Term Effects of AP-CD/LD in Fluctuating Parkinson's Disease Subjects who Completed Study IN 11 004

Intec Pharma, Ltd.

NULL

Not Recruiting

Female: yes
Male: yes

266

Phase 3

United States;Hungary;Slovakia;Poland;Spain;Ukraine;Israel;Bulgaria;Germany;Italy;United Kingdom

587

EUCTR2015-003679-31-CZ
(EUCTR)

23/06/2016

28/01/2016

New therapeutic strategy in Parkinson’s disease

Conservative iron chelation as a disease-modifying strategy in Parkinson’s disease - FAIRPARK II

De Novo Parkinson’s disease;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Product Name: Deferiprone DR
INN or Proposed INN: DEFERIPRONE

Centre Hospitalier Régional et Universitaire de Lille

NULL

Not Recruiting

Female: yes
Male: yes

338

Phase 2

Portugal;Czech Republic;Spain;Austria;Netherlands

588

EUCTR2015-005626-19-CZ
(EUCTR)

23/06/2016

14/04/2016

A study of the safety and effectiveness of levodopa inhalation powder (CVT-301) in Parkinson's Disease Patients with OFF episodes

A 12 Month, Dose-Level Blinded Study Investigating the Safety and Efficacy of CVT-301 (Levodopa Inhalation Powder) in Parkinson's Disease Patients With Motor Response Fluctuations (OFF Phenomena)

Parkinson's Disease With Motor Response Fluctuations (OFF Phenomena)
MedDRA version: 20.0;Level: LLT;Classification code 10034007;Term: Parkinson's disease NOS;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Product Name: CVT-301
Product Code: CVT-301 35mg
INN or Proposed INN: LEVODOPA
Other descriptive name: LEVODOPA
Product Name: CVT-301
Product Code: CVT-301 50mg
INN or Proposed INN: LEVODOPA
Other descriptive name: LEVODOPA

Civitas Therapeutics, Inc.

NULL

Not Recruiting

Female: yes
Male: yes

440

Phase 3

United States;Czech Republic;Canada;Poland;Spain

589

EUCTR2015-003513-24-IT
(EUCTR)

23/06/2016

05/11/2020

OPEN-LABEL EXTENSION and FOLLOW-UP of STUDY IN 11 004

An Open-Label, Multi-Center, Follow-Up Study Designed to Evaluate the Long-Term Effects of AP-CD/LD in Fluctuating Parkinson's Disease Subjects who Completed Study IN 11 004 - OPEN-LABEL EXTENSION and FOLLOW-UP of STUDY IN 11 004

Parkinson's Disease
MedDRA version: 20.0;Level: HLT;Classification code 10034005;Term: Parkinson's disease and parkinsonism;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Product Name: Accordion Pill ¿ Carbidopa/Levodopa 50/400 mg
Product Code: [NA]
INN or Proposed INN: CARBIDOPA
INN or Proposed INN: LEVODOPA
Product Name: Accordion Pill ¿ Carbidopa/Levodopa 50/500 mg
Product Code: [NA]
INN or Proposed INN: CARBIDOPA
INN or Proposed INN: LEVODOPA

INTEC PHARMA LTD

NULL

Not Recruiting

Female: yes
Male: yes

266

Phase 3

United States;Hungary;Slovakia;Spain;Poland;Ukraine;Israel;Bulgaria;Germany;United Kingdom;Italy

590

EUCTR2015-003512-20-PL
(EUCTR)

22/06/2016

01/04/2016

Clinical Efficacy & Safety of AP CD/LD in Fluctuating Parkinson’s Disease

A Phase III, Multicenter, Randomized, Double-Blind, Double-Dummy, Active-Controlled Study Comparing the Efficacy and Safety of Gastric Retentive, Controlled Release Accordion Pill™ Carbidopa/Levodopa (AP-CD/LD) to Immediate Release CD/LD in Fluctuating Parkinson’s Disease Patients

Intec Pharma, Ltd.

NULL

Not Recruiting

Female: yes
Male: yes

420

Phase 3

United States;Hungary;Slovakia;Spain;Poland;Ukraine;Israel;Bulgaria;Germany;Italy;United Kingdom

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

591

EUCTR2015-004912-39-DE
(EUCTR)

14/06/2016

11/02/2016

A 15-WEEK CLINICAL STUDY TO DETERMINE THEEFFECTIVENESS, SAFETY AND TOLERABILITY OF PF-06649751 IN PATIENTS WITH MOTOR FLUCTUATIONS DUE TO PARKINSON’S DISEASE

Pfizer, Inc.

NULL

Not Recruiting

Female: yes
Male: yes

198

Phase 2

France;United States;Spain;Germany;Japan;United Kingdom

592

EUCTR2015-005626-19-ES
(EUCTR)

13/06/2016

20/04/2016

A study of the safety and effectiveness of levodopa inhalation powder (CVT-301) in Parkinson's Disease Patients with OFF episodes

A 12 Month, Dose-Level Blinded Study Investigating the Safety and Efficacy of CVT-301 (Levodopa Inhalation Powder) in Parkinson's Disease Patients With Motor Response Fluctuations (OFF Phenomena)

Parkinson's Disease With Motor Response Fluctuations (OFF Phenomena)
MedDRA version: 19.0;Level: LLT;Classification code 10034007;Term: Parkinson's disease NOS;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Civitas Therapeutics, a wholly owned subsidiary of Acorda

NULL

Not Recruiting

Female: yes
Male: yes

440

Phase 3

United States;Czech Republic;Canada;Poland;Spain

593

JPRN-jRCTs051180098

09/06/2016

06/03/2019

The DAT-SPECT study for the benefit of Selegilline or Zonisamide in Parkinson's Disease

A comparative randomized study for the evaluation of the overlaying effect of Selegiline or Zonisamide over Levodopa in Parkinson's disease

Parkinson's disease;034034

L-Dopa/DCI only : The drug is administered per oral at 300 mg/day. The treatment is started within 14 days after registration and continued until day 365.
L-Dopa/DCI + selegiline : L-Dopa/DCI is administered per oral at 300 mg/day and selegiline is administered at 5 mg/day. The treatment is started within 14 days after registration and continued until day 365.
L-Dopa/DCI + zonisamide : L-Dopa/DCI is administered per oral at 300 mg/day and zonisamide is administered at 25 mg/day. The treatment is started within 14 days after registration and continued until day 365.

Ito Hidefumi

NULL

Recruiting

>= 55age old

< 80age old

Both

120

Phase 2

Japan

594

EUCTR2015-003512-20-IT
(EUCTR)

08/06/2016

05/11/2020

Clinical Efficacy & Safety of AP CD/LD in Fluctuating Parkinson¿s Disease

A Phase III, Multicenter, Randomized, Double-Blind, Double-Dummy, Active-Controlled Study Comparing the Efficacy and Safety of Gastric Retentive, Controlled Release Accordion Pill¿ Carbidopa/Levodopa (AP-CD/LD) to Immediate Release CD/LD in Fluctuating Parkinson¿s Disease Patients - Clinical Efficacy & Safety of AP CD/LD in Fluctuating Parkinson¿s Disease

Parkinson's Disease
MedDRA version: 20.0;Level: HLT;Classification code 10034005;Term: Parkinson's disease and parkinsonism;System Organ Class: 100000004852
MedDRA version: 20.0;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Trade Name: SINEMET 25-100
Product Name: Immediate Release carbidopa/levodopa 25/100 mg
Product Code: [na]
INN or Proposed INN: CARBIDOPA
INN or Proposed INN: LEVODOPA
Product Name: Accordion Pill ¿ Carbidopa/Levodopa 50/400 mg
Product Code: [na]
INN or Proposed INN: CARBIDOPA
INN or Proposed INN: LEVODOPA
Product Name: Accordion Pill ¿ Carbidopa/Levodopa 50/500 mg
Product Code: [na]
INN or Proposed INN: CARBIDOPA
INN or Proposed INN: LEVODOPA

INTEC PHARMA LTD

NULL

Not Recruiting

Female: yes
Male: yes

420

Phase 3

United States;Hungary;Slovakia;Spain;Poland;Ukraine;Russian Federation;Israel;Bulgaria;Germany;United Kingdom;Italy

595

JPRN-UMIN000022529

2016/06/01

01/06/2016

Effects on the pharmacokinetics of L-DOPA formulation by Proton pump inhibitors in patients with Parkinson's disease

Parkinson's disease

8-day oral administration of L-DOPA formulation(Menesit100 Tablets or DopacolL100 Tablets,dosage in taking)and Nexium10 Capsules(once a day 2Cap,after breakfast)

Blood concentration measurement date only, oral administration of L-DOPA formulation 1tablet(100mg) and Nexium10 2Cap(20mg)
Washout 6days

8-day oral administration of L-DOPA formulation(Menesit100 Tablets or DopacolL100 Tablets,dosage in taking)and Nexium Placebo Capsules(lactose,once a day 2Cap,after breakfast)

Blood concentration measurement date only, oral administration of L-DOPA formulation 1tablet(100mg) and Nexium Placebo Capsules 2Cap
8-day oral administration of L-DOPA formulation(Menesit100 Tablets or DopacolL100 Tablets,dosage in taking)and Nexium Placebo Capsules(lactose,once a day 2Cap,after breakfast)

Blood concentration measurement date only, oral administration of L-DOPA formulation 1tablet(100mg) and Nexium Placebo Capsules 2Cap
Washout 6days

8-day oral administration of L-DOPA formulation(Menesit100 Tablets or DopacolL100 Tablets,dosage in taking)and Nexium10 Capsules(once a day 2Cap,after breakfast)

Blood concentration measurement date only, oral administration of L-DOPA formulation 1tablet(100mg) and Nexium10 2Cap(20mg)

Utano National Hospital, National Hospital Organization

NULL

Complete: follow-up complete

20years-old

85years-old

Male and Female

Phase 3

Japan

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

596

JPRN-UMIN000022533

2016/06/01

01/06/2016

A comparative randomized study for the evaluation of the overlaying effect of Selegiline or Zonisamide over Levodopa in Parkinson's disease

Parkinson's disease

L-Dopa/DCI only
The drug is administered per oral at 150 to 300 mg/day. The treatment is started within 14days after registration and continued until day 365.
L-Dopa/DCI + selegiline
L-Dopa/DCI is administered per oral at 150 to 300 mg/day and selegiline is administered at 5mg/day. The treatment is started within 14days after registration and continued until day 365.
L-Dopa/DCI + zonisamide
L-Dopa/DCI is administered per oral at 150 to 300 mg/day and zonisamide is administered at 25mg/day. The treatment is started within 14days after registration and continued until day 365.

Osaka Redcross HospitalWakayama Prefectural Medical College

NULL

Recruiting

55years-old

80years-old

Male and Female

180

Phase 2

Japan

597

NCT02785978
(ClinicalTrials.gov)

June 2016

11/5/2016

Pilot Study to Evaluate ActiMyo Measured Activity in Parkinson Disease Patients & Healthy Volunteers

Parkinson Disease;Healthy Volunteers

Drug: Levodopa acute challenge;Other: Controlled environment tests (series of tasks of everyday life);Other: Standardized scales: MDS-UPDRS (Part II to IV) and RDRS;Device: ActiMyo recording;Other: Diary completion

Institut de Myologie, France

NULL

Completed

18 Years

N/A

All

N/A

France

598

NCT02838797
(ClinicalTrials.gov)

June 2016

16/6/2016

RQ-00000010 for Gastroparesis and Constipation in Parkinson's Disease

Parkinson's Disease;Gastroparesis;Constipation

Drug: RQ-00000010;Drug: Placebo

Virginia Commonwealth University

Michael J. Fox Foundation for Parkinson's Research;RaQualia Pharma Inc.

Completed

18 Years

N/A

All

Phase 1

United States

599

NCT02807675
(ClinicalTrials.gov)

June 2016

17/6/2016

A Study of the Safety and Tolerability of a Single Dose Administration of CVT-301 (Levodopa Inhalation Powder)

A Phase 1 Study of the Safety and Tolerability of a Single Dose Administration of CVT- 301 (Levodopa Inhalation Powder) When Administered for Early Morning OFF Symptoms in Patients With Parkinson's Disease

Parkinson's Disease

Drug: CVT-301, LIP;Other: Placebo

Acorda Therapeutics

NULL

Completed

30 Years

85 Years

All

Phase 1

United States

600

NCT02642393
(ClinicalTrials.gov)

June 2016

19/12/2015

Study of Urate Elevation in Parkinson's Disease, Phase 3

A Randomized, Double-blind, Placebo-controlled Trial of Urate-elevating Inosine Treatment to Slow Clinical Decline in Early Parkinson's Disease

Parkinson's Disease

Drug: Inosine;Drug: Placebo

Michael Alan Schwarzschild

The Parkinson Study Group;Michael J. Fox Foundation for Parkinson's Research;University of Rochester;National Institute of Neurological Disorders and Stroke (NINDS)

Completed

30 Years

N/A

All

298

Phase 3

United States;Puerto Rico

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

601

NCT02812394
(ClinicalTrials.gov)

June 2016

22/6/2016

A Study to Compare Two Dose Strengths of CVT-301 (Levodopa Inhalation Powder) With an Oral Dose of Sinemet® (Carbidopa-levodopa) Tablets

A Phase 1 Single Dose Pharmacokinetic Bridging Study to Compare Two Dose Strengths of CVT-301 (Levodopa Inhalation Powder) With an Oral Dose of Sinemet® (Carbidopa-levodopa) Tablets

Parkinson Disease

Drug: CVT-301 (Dose Level 1);Drug: CVT-301 (Dose Level 2);Drug: Sinemet®

Acorda Therapeutics

NULL

Completed

25 Years

65 Years

Both

Phase 1

United States

602

EUCTR2016-000679-25-ES
(EUCTR)

31/05/2016

18/03/2016

Clinical study for the assessment of security of candesartan in Parkinson?s disease population and its potential benefit in cognitive impairment associated to Parkinson?s disease.

A prospective, randomized, double-blind and placebo-controlled, parallel group, phase II study to compare the efficacy and safety of candesartan versus placebo on cognitive impairment associated with Parkinson?s disease. Exploratory study.

Parkinson's Disease;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

INSTITUT DE RECERCA HSCSP

NULL

Not Recruiting

Female: yes
Male: yes

Phase 2

Spain

603

JPRN-UMIN000009062

2016/05/30

09/10/2012

An open-label, single-centered, non-randomized trial of inosine to assess its safety for patients with Parkinson's disease

Parkinson's disease

Take oral inosine 500-3000mg/day to achieve a serum UA level between 6.0-8.0 mg/dL

Dept. of Clinical pharmacology and Neurology

NULL

Complete: follow-up complete

20years-old

Not applicable

Male and Female

Phase 1

Japan

604

EUCTR2015-005078-39-AT
(EUCTR)

30/05/2016

09/03/2016

Subjects with advanced Parkinson's disease
MedDRA version: 19.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Product Name: levodopa /carbidopa solution
Product Code: ND0612
INN or Proposed INN: Levodopa
Other descriptive name: LEVODOPA
INN or Proposed INN: Carbidopa
Other descriptive name: CARBIDOPA

NeuroDerm Ltd.

NULL

Not Recruiting

Female: yes
Male: yes

Phase 2

United States;Austria;Israel;Germany;Italy

605

EUCTR2015-003513-24-HU
(EUCTR)

24/05/2016

02/03/2016

OPEN-LABEL EXTENSION and FOLLOW-UP of STUDY IN 11 004

An Open-Label, Multi-Center, Follow-Up Study Designed to Evaluate the Long-Term Effects of AP-CD/LD in Fluctuating Parkinson's Disease Subjects who Completed Study IN 11 004

MedDRA version: 19.0;Level: HLT;Classification code 10034005;Term: Parkinson's disease and parkinsonism;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Intec Pharma, Ltd.

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

460

Phase 3

United States;Hungary;Slovakia;Poland;Spain;Ukraine;Russian Federation;Israel;Bulgaria;Germany;Italy;United Kingdom

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

606

EUCTR2015-003512-20-ES
(EUCTR)

18/05/2016

18/03/2016

Clinical Efficacy & Safety of AP CD/LD in Fluctuating Parkinson?s Disease

A Phase III, Multicenter, Randomized, Double-Blind, Double-Dummy, Active-Controlled Study Comparing the Efficacy and Safety of Gastric Retentive, Controlled Release Accordion Pill? Carbidopa/Levodopa (AP-CD/LD) to Immediate Release CD/LD in Fluctuating Parkinson?s Disease Patients

Parkinson's Disease
MedDRA version: 18.1;Level: HLT;Classification code 10034005;Term: Parkinson's disease and parkinsonism;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Trade Name: SINEMET 25-100
Product Name: Immediate Release carbidopa/levodopa 25/100 mg
INN or Proposed INN: Carbidopa
Other descriptive name: CARBIDOPA
INN or Proposed INN: Levodopa
Other descriptive name: LEVODOPA
Trade Name: SINEMET 10-100
Product Name: Immediate Release carbidopa/levodopa 10/100 mg
INN or Proposed INN: Carbidopa
Other descriptive name: CARBIDOPA
INN or Proposed INN: Levodopa
Other descriptive name: LEVODOPA
Product Name: Accordion Pill? Carbidopa/Levodopa 50/400 mg
INN or Proposed INN: Carbidopa
Other descriptive name: CARBIDOPA
INN or Proposed INN: Levodopa
Other descriptive name: LEVODOPA
Product Name: Accordion Pill? Carbidopa/Levodopa 50/500 mg
INN or Proposed INN: Carbidopa
Other descriptive name: CARBIDOPA
INN or Proposed INN: Levodopa
Other descriptive name: LEVODOPA
Product Name: Immediate Release carbidopa/levodopa 25/100 mg
INN or Proposed INN: Carbidopa
Other descriptive name: CARBIDOPA

Intec Pharma, Ltd.

NULL

Not Recruiting

Female: yes
Male: yes

460

Phase 3

United States;Hungary;Slovakia;Poland;Spain;Ukraine;Russian Federation;Israel;Bulgaria;Germany;Italy;United Kingdom

607

EUCTR2015-003513-24-ES
(EUCTR)

18/05/2016

18/03/2016

OPEN-LABEL EXTENSION and FOLLOW-UP of STUDY IN 11 004

An Open-Label, Multi-Center, Follow-Up Study Designed to Evaluate the Long-Term Effects of AP-CD/LD in Fluctuating Parkinson's Disease Subjects who Completed Study IN 11 004

Parkinson's Disease
MedDRA version: 18.1;Level: HLT;Classification code 10034005;Term: Parkinson's disease and parkinsonism;System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Intec Pharma, Ltd.

NULL

Not Recruiting

Female: yes
Male: yes

460

Phase 3

United States;Hungary;Slovakia;Poland;Spain;Ukraine;Russian Federation;Israel;Bulgaria;Germany;Italy;United Kingdom

608

EUCTR2016-000637-43-GB
(EUCTR)

12/05/2016

04/03/2016

Safety, tolerability and efficacy study to examine APL-130277 in patients with Parkinson’s Disease.

Sunovion Pharmaceuticals Inc.

NULL

Not Recruiting

Female: yes
Male: yes

450

Phase 3

United States;France;Canada;Spain;Austria;Germany;Italy;United Kingdom

609

EUCTR2016-000636-18-GB
(EUCTR)

12/05/2016

04/03/2016

Phase 3, placebo controlled study to examine the efficacy, safety and tolerability of APL-130277 in patients with Parkinson's disease.

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Examine the Efficacy, Safety and Tolerability of APL-130277 in Levodopa Responsive Patients with Parkinson’s Disease Complicated by Motor Fluctuations (OFF” Episodes).

Levodopa Responsive Patients with Parkinson’s Disease Complicated by Motor Fluctuations (OFF” Episodes)
MedDRA version: 19.0;Level: LLT;Classification code 10034006;Term: Parkinson's disease aggravated;System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Sunuvion Pharmaceuticals Inc

NULL

Not Recruiting

Female: yes
Male: yes

126

Phase 3

United States;Canada;United Kingdom

610

JPRN-UMIN000022023

2016/05/10

10/05/2016

A randomized controlled study comparing lubiprostone and magnesium oxide for treatment of chronic constipation in patients with Parkinson disease. -to evaluation by change of intestinal bacterial flora-

Parkinson diseaseChronic constipation

Study drug group:
A 12-week administration of lubiprostone 24 microgrum (adjustable) twice daily after switching from magnesium oxide

Control group:
Continuous administration of magnesium oxide at the same dosage regimen as before the enrollmen

Dokkyo Medical University

NULL

Complete: follow-up complete

20years-old

90years-old

Male and Female

Not selected

Japan

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

611

JPRN-UMIN000022022

2016/05/10

10/05/2016

A randomized controlled study comparing lubiprostone and magnesium oxide for treatment of chronic constipation in patients with Parkinson disease

A randomized controlled study comparing lubiprostone and magnesium oxide for treatment of chronic constipation in patients with Parkinson disease - A randomized controlled study comparing lubiprostone and magnesium oxide for treatment of chronic constipation in patients with Parkinson disease

Parkinson diseaseChronic constipation

Study drug group:
A 12-week administration of lubiprostone 24 microrgrum (adjustable) twice daily after switching from magnesium oxide

Control group:
Continuous administration of magnesium oxide at the same dosage regimen as before the enrollment

Dokkyo Medical University

NULL

Complete: follow-up complete

20years-old

90years-old

Male and Female

Not selected

Japan

612

EUCTR2015-003512-20-HU
(EUCTR)

09/05/2016

02/03/2016

Clinical Efficacy & Safety of AP CD/LD in Fluctuating Parkinson’s Disease

Parkinson's Disease
MedDRA version: 19.0;Level: HLT;Classification code 10034005;Term: Parkinson's disease and parkinsonism;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Trade Name: SINEMET 25-100
Product Name: Immediate Release carbidopa/levodopa 25/100 mg
INN or Proposed INN: Carbidopa
Other descriptive name: CARBIDOPA
INN or Proposed INN: Levodopa
Other descriptive name: LEVODOPA
Trade Name: SINEMET 10-100
Product Name: Immediate Release carbidopa/levodopa 10/100 mg
INN or Proposed INN: Carbidopa
Other descriptive name: CARBIDOPA
INN or Proposed INN: Levodopa
Other descriptive name: LEVODOPA
Product Name: Accordion Pill™ Carbidopa/Levodopa 50/400 mg
INN or Proposed INN: Carbidopa
Other descriptive name: CARBIDOPA
INN or Proposed INN: Levodopa
Other descriptive name: LEVODOPA
Product Name: Accordion Pill™ Carbidopa/Levodopa 50/500 mg
INN or Proposed INN: Carbidopa
Other descriptive name: CARBIDOPA
INN or Proposed INN: Levodopa
Other descriptive name: LEVODOPA
Trade Name: SINEMET 25-100
Product Name: Immediate Release carbidopa/levodopa 25/100 mg
INN or Proposed INN: Carbidopa
Other descriptive name: CARBIDOPA

Intec Pharma, Ltd.

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

460

Phase 3

United States;Hungary;Slovakia;Poland;Spain;Ukraine;Russian Federation;Israel;Bulgaria;Germany;Italy;United Kingdom

613

EUCTR2015-003887-34-PL
(EUCTR)

06/05/2016

26/02/2016

A Phase 3, Long-term, Open-label Study of Istradefylline inSubjects with Moderate to Severe Parkinson’s Disease

Moderate to severe Parkinson's disease
MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders
MedDRA version: 20.0;Level: SOC;Classification code 10029205;Term: Nervous system disorders;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Product Name: KW-6002 (istradefylline)
Product Code: KW-6002
INN or Proposed INN: Istradefylline
Other descriptive name: ISTRADEFYLLINE
Product Name: KW-6002 (istradefylline)
Product Code: KW-6002
INN or Proposed INN: Istradefylline
Other descriptive name: ISTRADEFYLLINE

Kyowa Kirin Pharmaceutical Development, Inc.

NULL

Not Recruiting

Female: yes
Male: yes

300

Phase 3

Serbia;United States;Czech Republic;Canada;Poland;Israel;Germany

614

JPRN-UMIN000022187

2016/05/06

06/05/2016

Research on Parkinson's disease pathogenesis based on analysis of caffeine absorption in patients with Parkinson's disease

Parkinson's disease

PD group, 200 mg caffeine administration, qd, 1 day
Control group, 200 mg caffeine administration, qd, 1 day

Department of Neurology, Juntendo University

NULL

Complete: follow-up complete

40years-old

60years-old

Male and Female

Not applicable

Japan

615

NCT02762591
(ClinicalTrials.gov)

May 3, 2016

3/5/2016

Expanded Access of Pimavanserin for Patients With PD Psychosis

Expanded Access Program of Pimavanserin in Patients With Parkinson's Disease Psychosis

Parkinson's Disease Psychosis

Drug: Pimavanserin tartrate

ACADIA Pharmaceuticals Inc.

NULL

Approved for marketing

40 Years

N/A

All

N/A

NULL

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

616

NCT02812147
(ClinicalTrials.gov)

May 2016

25/5/2016

Effect of L-Dihydoxyphenylserine on Locomotion, Postural Stability, and Fall Risk Reduction in Parkinson Disease

Effect of L-Dihydoxyphenylserine (L-DOPS, Northera) a Central and Peripheral Norepinephrine Agent on Locomotion, Postural Stability (Balance), and Fall Risk Reduction in Parkinson Disease (PD)

Parkinson Disease

Drug: L-DOPS;Drug: Placebo

St. Joseph's Hospital and Medical Center, Phoenix

Arizona State University, Tempe

Active, not recruiting

30 Years

83 Years

All

Phase 2

United States

617

NCT02705755
(ClinicalTrials.gov)

May 2016

7/3/2016

TD-9855 Phase 2 in Neurogenic Orthostatic Hypotension (nOH)

A Phase 2 Study to Assess the Effect of TD-9855 in Subjects With Neurogenic Orthostatic Hypotension

Neurogenic Orthostatic Hypotension;Multiple System Atrophy (MSA) With Orthostatic Hypotension;Pure Autonomic Failure;Parkinson Disease;Hypotension, Orthostatic;Orthostatic Hypotension;Pure Autonomic Failure With Orthostatic Hypotension;Parkinson Disease With Orthostatic Hypotension

Drug: TD-9855;Drug: Placebo

Theravance Biopharma

NULL

Completed

40 Years

N/A

All

Phase 2

United States

618

NCT02784145
(ClinicalTrials.gov)

May 2016

17/5/2016

Effects of Resistant Starch on Bowel Habits, Fecal Short Chain Fatty Acids and Gut Microbiota in Parkinson Disease

Parkinson Disease

Dietary Supplement: Resistant starch;Other: Recommendation with regard to nutrition

Saarland University

NULL

Completed

18 Years

N/A

All

N/A

Germany

619

NCT02726386
(ClinicalTrials.gov)

May 2016

29/3/2016

A Clinical Study in Advanced Parkinson's Disease Investigating the Long Term Safety of ND0612 Administered as a Continuous SC Infusion

A Multicenter, International, Open-label, Safety Study of ND0612, a Solution of Levodopa/Carbidopa Delivered Via a Pump System as a Continuous Subcutaneous Infusion in Subjects With Advanced Parkinson's Disease

Parkinson's Disease

Drug: ND0612

NeuroDerm Ltd.

NULL

Active, not recruiting

30 Years

N/A

All

210

Phase 2

United States;Austria;Czechia;France;Germany;Israel;Italy;Poland;Spain

620

NCT02728947
(ClinicalTrials.gov)

May 2016

31/3/2016

Pharmacokinetic Profile of Neupro Patch Administrated at 2 mg, 4 mg, 6 mg and 8 mg/Day Weekly in Patients With Early-stage Parkinson's Disease

A Single Group and Open-label Study to Evaluate Pharmacokinetic Profile of Neupro Patch Administrated at 2 mg, 4 mg, 6 mg and 8 mg/Day Weekly in Patients With Early-stage Parkinson's Disease

Parkinson's Disease

Drug: ROTIGOTINE

Luye Pharma Group Ltd.

NULL

Completed

18 Years

99 Years

Both

Phase 1

United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

621

EUCTR2015-003513-24-GB
(EUCTR)

28/04/2016

04/03/2016

OPEN-LABEL EXTENSION and FOLLOW-UP of STUDY IN 11 004

An Open-Label, Multi-Center, Follow-Up Study Designed to Evaluate the Long-Term Effects of AP-CD/LD in Fluctuating Parkinson's Disease Subjects who Completed Study IN 11 004

Intec Pharma, Ltd.

NULL

Not Recruiting

Female: yes
Male: yes

266

Phase 3

United States;Hungary;Slovakia;Poland;Spain;Ukraine;Russian Federation;Israel;Bulgaria;Germany;Italy;United Kingdom

622

EUCTR2015-003512-20-GB
(EUCTR)

28/04/2016

03/03/2016

Clinical Efficacy & Safety of AP CD/LD in Fluctuating Parkinson’s Disease

Parkinson's Disease
MedDRA version: 20.0;Level: HLT;Classification code 10034005;Term: Parkinson's disease and parkinsonism;System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Intec Pharma, Ltd.

NULL

Not Recruiting

Female: yes
Male: yes

420

Phase 3

United States;Hungary;Slovakia;Poland;Spain;Ukraine;Russian Federation;Israel;Bulgaria;Germany;Italy;United Kingdom

623

EUCTR2015-004507-23-DE
(EUCTR)

25/04/2016

13/01/2016

Comparison of two levodopa treatments, ODM-104 and Stalevo, in Parkinson's disease patients who have motor fluctuations.

Parkinson’s disease (PD) patients with end-of-dose wearing-off (motor fluctuations);Therapeutic area: Diseases [C] - Symptoms and general pathology [C23]

Orion Corporation

NULL

Not Recruiting

Female: yes
Male: yes

Phase 2

Hungary;Finland;Latvia;Germany

624

EUCTR2015-003512-20-SK
(EUCTR)

22/04/2016

04/03/2016

Clinical Efficacy & Safety of AP CD/LD in Fluctuating Parkinson’s Disease

Parkinson's Disease
MedDRA version: 20.0;Level: HLT;Classification code 10034005;Term: Parkinson's disease and parkinsonism;System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Intec Pharma, Ltd.

NULL

Not Recruiting

Female: yes
Male: yes

420

Phase 3

United States;Hungary;Slovakia;Poland;Spain;Ukraine;Israel;Bulgaria;Germany;Italy;United Kingdom

625

EUCTR2015-003679-31-PT
(EUCTR)

18/04/2016

28/01/2016

New therapeutic strategy in Parkinson’s disease

Conservative iron chelation as a disease-modifying strategy in Parkinson’s disease - FAIRPARK II

De Novo Parkinson’s disease;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Product Name: Deferiprone DR
INN or Proposed INN: DEFERIPRONE

Centre Hospitalier Régional et Universitaire de Lille

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

338

Phase 2

Portugal;Czech Republic;Spain;Austria;Netherlands

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

626

EUCTR2015-003887-34-DE
(EUCTR)

12/04/2016

23/12/2015

A Phase 3, Long-term, Open-label Study of Istradefylline inSubjects with Moderate to Severe Parkinson’s Disease

Kyowa Kirin Pharmaceutical Development, Inc.

NULL

Not Recruiting

Female: yes
Male: yes

300

Phase 3

Serbia;United States;Czech Republic;Canada;Poland;Israel;Germany

627

EUCTR2014-005630-60-AT
(EUCTR)

12/04/2016

04/12/2015

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study with an Open-Label Phase to Determine theEfficacy and Safety of Tozadenant as Adjunctive Therapy inLevodopa-Treated Patients with Parkinson’s DiseaseExperiencing End-of-Dose Wearing-Off” (TOZ-PD)

Product Name: Tozadenant
Product Code: SYN115
INN or Proposed INN: Tozadenant
Other descriptive name: TOZADENANT

Biotie Therapies Inc.(a wholly owned subsidiary of Acorda Therapeutics Inc.)

NULL

Not Recruiting

Female: yes
Male: yes

450

Phase 3

United States;Czech Republic;European Union;Canada;Spain;Austria;Germany

628

NCT02764125
(ClinicalTrials.gov)

April 8, 2016

13/1/2016

Efficacy and Safety Proof of Concept Study in Patients With Parkinson's Disease and End-of-dose Wearing-off (COMPOC)

Efficacy and Safety of ODM-104 Compared to a Standard Combination (Stalevo®); a Randomized Double-blind, Crossover Proof-of-concept Study in Patients With Parkinson's Disease and End-of-dose Wearing-off

Parkinson's Disease

Drug: Stalevo;Drug: levodopa MR

Orion Corporation, Orion Pharma

NULL

Completed

30 Years

N/A

All

Phase 2

Finland;Germany;Hungary;Latvia

629

NCT03034538
(ClinicalTrials.gov)

April 8, 2016

25/1/2017

An Open-Label Tolerability and Exploratory Efficacy Study of Zonisamide for Dyskinesias in Parkinson's Disease

Parkinson Disease;Parkinsonism;Dyskinesias

Drug: Zonegran

The Cooper Health System

NULL

Recruiting

18 Years

N/A

All

Phase 4

United States

630

EUCTR2015-003679-31-AT
(EUCTR)

06/04/2016

11/01/2016

New therapeutic strategy in Parkinson’s disease

Conservative iron chelation as a disease-modifying strategy in Parkinson’s disease - FAIRPARK II

De Novo Parkinson’s disease;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Centre Hospitalier Régional et Universitaire de Lille

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

372

Phase 2

Portugal;France;Czech Republic;Spain;Austria;Netherlands;Germany;United Kingdom

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

631

EUCTR2015-005067-17-CZ
(EUCTR)

01/04/2016

25/01/2016

A study of the safety and effectiveness of levodopa inhalation powder (CVT-301) in Parkinson’s Disease Patients with OFF episodes

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Investigating the Efficacy and Safety of CVT-301 (Levodopa Inhalation Powder) in Parkinson’s Disease Patients With Motor Response Fluctuations (OFF Phenomena) (SPAN-PD™)

Parkinson's Disease With Motor Response Fluctuations (OFF Phenomena)
MedDRA version: 18.1;Level: LLT;Classification code 10034007;Term: Parkinson's disease NOS;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Civitas Therapeutics, Inc.

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

345

Phase 3

United States;Czech Republic;Canada;Poland;Spain

632

NCT04470037
(ClinicalTrials.gov)

April 2016

26/5/2020

Multidisciplinary Study of Novel NMDA Modulation for Neurodegenerative Disorder

Parkinson's Disease With Dementia

Drug: DAAOI-P;Drug: Placebo

China Medical University Hospital

Ministry of Science and Technology, Taiwan

Recruiting

50 Years

90 Years

All

Phase 2

Taiwan

633

NCT02775591
(ClinicalTrials.gov)

April 2016

9/5/2016

Effect of Short-term Motilitone Therapy on Health-related Quality of Life in PD Patients With Gastrointestinal Symptoms

Effect of Short-term Motilitone Therapy on Health-related Quality of Life in Parkinson's Disease Patients With Gastrointestinal Symptoms: a Multicenter, Double-blind Randomized, Placebo-controlled Trial

Parkinson Disease;Dyspepsia

Drug: DA-9701;Drug: DA-9701 placebo

Seoul National University Hospital

Samsung Medical Center;Korea University Guro Hospital;Hanyang University;Seoul Veterans Hospital;SMG-SNU Boramae Medical Center

Completed

50 Years

80 Years

All

147

Phase 4

Korea, Republic of

634

NCT02729714
(ClinicalTrials.gov)

April 2016

26/1/2016

A Pilot Study of Suvorexant for Insomnia in Parkinson Disease

A Randomized, Double-Blind, Placebo-Controlled Pilot Study of Suvorexant for Insomnia in Parkinson Disease

Insomnia

Drug: Suvorexant;Drug: Placebo

Burdick, Daniel, M.D.

Merck Sharp & Dohme Corp.

Recruiting

30 Years

80 Years

All

Phase 4

United States

635

NCT02719496
(ClinicalTrials.gov)

April 2016

15/3/2016

Prove of Concept Study, to Evaluate the Efficacy, Safety, and Tolerability of IBEROGAST in the Treatment of Bowel Troubles in Patients With Parkinson's Disease

Gastrointestinal Disorders in Parkinson's Disease

Drug: IBEROGAST

Nantes University Hospital

NULL

Completed

30 Years

80 Years

All

Phase 2

France

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

636

NCT03173781
(ClinicalTrials.gov)

April 2016

10/8/2016

Effects of Droxidopa When Measuring Gait Speed, Kyphosis, and Functional Reach in Parkinson's Disease

Parkinson's Disease

Drug: droxidopa;Drug: Placebo

Colorado Springs Neurological Associates

H. Lundbeck A/S

Completed

18 Years

N/A

All

N/A

United States

637

NCT02462603
(ClinicalTrials.gov)

March 31, 2016

20/5/2015

Safety and Biomarker Study of EPI-589 in Parkinson's Disease

A Phase 2A Safety and Biomarker Study of EPI-589 in Mitochondrial Subtype and Idiopathic Parkinson's Disease Subjects

Parkinson's Disease

Drug: EPI-589

PTC Therapeutics

NULL

Completed

21 Years

75 Years

All

Phase 2

United States;Germany;United Kingdom

638

EUCTR2015-004344-19-GB
(EUCTR)

31/03/2016

16/02/2016

An international trial of deferiprone in patients with Parkinson’s disease

A Dose-Ranging Study of the Efficacy, Safety, and Pharmacokinetics of Deferiprone Delayed Release Tablets in Patients with Parkinson’s Disease - LA48-0215

Product Name: Deferiprone 600 mg delayed release tablet
INN or Proposed INN: DEFERIPRONE

ApoPharma

NULL

Not Recruiting

Female: yes
Male: yes

140

Phase 2

France;Canada;Germany;United Kingdom

639

JPRN-jRCTs061180060

22/03/2016

18/03/2019

Randomized clinical trial to assess the disease modifying effect of oral inosine for patients with Parkinson's disease

Multi-centered, placebo-controlled, double-blind, randomized clinical trial to assess the effect of oral inosine on the onset of wearing off in patients with early stage Parkinson's disease - Multi-centered, placebo-controlled, double-blind, randomized clinical trial to assess the effect of oral inosine on the onset of wearing off in patients with early stage Parkinson's disease

Parkinson's disease;D010300

Inosine to maintain a serum urate level between 6.0-7.5 mg/dL for 2 years or placebo (500mg/CP)

Nagai Masahiro

NULL

Recruiting

>= 20age old

Not applicable

Both

100

Phase 2

Japan

640

EUCTR2015-003679-31-ES
(EUCTR)

21/03/2016

13/01/2016

New therapeutic strategy in Parkinson?s disease

Conservative iron chelation as a disease-modifying strategy in Parkinson?s disease: a multicentre, parallel-group, placebo-controlled, randomized clinical trial of deferiprone - FAIRPARK II

De Novo Parkinson?s disease
MedDRA version: 18.1;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Trade Name: Ferriprox 500 mg
Product Name: Deferiprone DR
INN or Proposed INN: DEFERIPRONE

Centre Hospitalier Régional et Universitaire de Lille

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

338

Phase 3

Spain

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

641

NCT02787590
(ClinicalTrials.gov)

March 21, 2016

26/5/2016

Simvastatin as a Neuroprotective Treatment for Moderate Parkinson's Disease

Simvastatin as a Neuroprotective Treatment for Parkinson's Disease: a Double-blind, Randomised, Placebo Controlled Futility Study in Patients of Moderate Severity.

Parkinson Disease

Drug: Simvastatin;Drug: Matched Placebo (for Simvastatin)

University Hospital Plymouth NHS Trust

University of Plymouth

Active, not recruiting

40 Years

90 Years

All

235

Phase 2

United Kingdom

642

EUCTR2015-004507-23-LV
(EUCTR)

15/03/2016

13/01/2016

Comparison of two levodopa treatments, ODM-104 and Stalevo, in Parkinson's disease patients who have motor fluctuations.

Efficacy and safety of ODM-104 compared to a standard combination (Stalevo); a randomised, double-blind, crossover proof-of-concept study in patients with Parkinson's disease and end-of-dose wearing-off. - COMPOC

Parkinson's disease (PD) patients with end-of-dose wearing-off (motor fluctuations);Therapeutic area: Diseases [C] - Symptoms and general pathology [C23]

Orion Corporation

NULL

Not Recruiting

Female: yes
Male: yes

Phase 2

Hungary;Finland;Germany;Latvia

643

EUCTR2015-005067-17-ES
(EUCTR)

14/03/2016

17/02/2016

A study of the safety and effectiveness of levodopa inhalation powder (CVT-301) in Parkinson?s Disease Patients with OFF episodes

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Investigating the Efficacy and Safety of CVT-301 (Levodopa Inhalation Powder) in Parkinson?s Disease Patients With Motor Response Fluctuations (OFF Phenomena) (SPAN-PD?)

Civitas Therapeutics, a wholly owned subsidiary of Acorda Therapeutics, Inc.

NULL

Not Recruiting

Female: yes
Male: yes

345

Phase 3

United States;Czech Republic;Canada;Poland;Spain

644

EUCTR2015-004129-15-ES
(EUCTR)

07/03/2016

24/02/2016

Subjects participating in a Parkinson Disease cohort are offered to undergo a PET imaging scan requiring an intravenous diagnostic drug (florbetaben) with the aim of identifying markers of disease progression

Evaluation of [18F] florbetaben in subjects participating in the Parkinson?s Progression Markers Initiative (PPMI) Protocol

Parkinson's Disease
MedDRA version: 18.1;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Trade Name: Neuraceq
Product Name: 18F florbetaben
INN or Proposed INN: FLORBETABEN (18F)

Institute for Neurodegenerative Disorders

NULL

Not Recruiting

Female: yes
Male: yes

Phase 2

Spain

645

NCT02687542
(ClinicalTrials.gov)

March 3, 2016

29/1/2016

Efficacy, Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients With Motor Fluctuations

A 15-WEEK, PHASE 2, DOUBLE BLIND, RANDOMIZED, PLACEBO-CONTROLLED, DOSE RANGING STUDY TO INVESTIGATE THE EFFICACY, SAFETY AND TOLERABILITY OF PF-06649751 IN SUBJECTS WITH MOTOR FLUCTUATIONS DUE TO PARKINSON'S DISEASE

Parkinson Disease

Drug: Placebo;Drug: PF-06649751 low dose (1 mg QD);Drug: PF-06649751 middle dose 1 (3 mg QD);Drug: PF-06649751 middle dose 2 (7 mg QD);Drug: PF-06649751 high dose (15 mg QD)

Pfizer

NULL

Terminated

40 Years

85 Years

All

108

Phase 2

United States;Canada;France;Germany;Japan;Spain

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

646

EUCTR2015-003887-34-CZ
(EUCTR)

02/03/2016

30/12/2015

A Phase 3, Long-term, Open-label Study of Istradefylline inSubjects with Moderate to Severe Parkinson’s Disease

Kyowa Kirin Pharmaceutical Development, Inc.

NULL

Not Recruiting

Female: yes
Male: yes

300

Phase 3

Serbia;United States;Czech Republic;Canada;Poland;Israel;Germany

647

NCT02994719
(ClinicalTrials.gov)

March 1, 2016

21/12/2015

Gait Analysis in Neurological Disease

Gait Pattern Analysis in Neurological Disease

Parkinson's Disease;Parkinsonian Disorders;Atypical Parkinson Disease;Progressive Supranuclear Palsy;Multiple System Atrophy;Corticobasal Degeneration;Gait, Frontal;Huntington Disease

Drug: Anti-Parkinson medication;Device: Deep Brain Stimulation

Beth Israel Deaconess Medical Center

NULL

Active, not recruiting

18 Years

85 Years

All

120

United States

648

JPRN-UMIN000021236

2016/03/01

01/03/2016

Investigation in effect of aroma therapy using magnetoencepharography

Normal volunteer, Epilepsy patients, Parkinson disease patients

aroma 1
Trans-nasal administration of lavender essence
Subject hold a cup with 0.05ml essence in front of the nose for 2 minutes
After the administration, MEG signals will be recorded for 4 minutes
Also, the subjects were evaluated their moods and awareness.
aroma 2
Trans-nasal administration of grapefruit essence
Subject hold a cup with 0.05ml essence in front of the nose for 2 minutes
After the administration, MEG signals will be recorded for 4 minutes
Also, the subjects were evaluated their moods and awareness.
fragrant
Trans-nasal administration of fragrant
Subject hold a cup with 0.05ml essence in front of the nose for 2 minutes
After the administration, MEG signals will be recorded for 4 minutes
Also, the subjects were evaluated their moods and awareness.

Osaka University Graduate School of Medicine Department of Neurosurgery

NULL

Complete: follow-up continuing

20years-old

80years-old

Male and Female

Phase 1

Japan

649

NCT02708186
(ClinicalTrials.gov)

March 2016

10/3/2016

Study Evaluating Nelotanserin for Treatment of REM Sleep Behavior Disorder in Subjects With Dementia (DLB or PDD)

A Phase 2, Double-blind, Randomized, Placebo-controlled Study of Nelotanserin Versus Placebo in Subjects With Dementia With Lewy Bodies (DLB) or Parkinson's Disease Dementia (PDD) Who Have REM Sleep Behavior Disorder (RBD)

Dementia With Lewy Bodies;REM Sleep Behavior Disorder;Parkinson's Disease Dementia

Drug: Nelotanserin;Drug: Placebo

Axovant Sciences Ltd.

NULL

Completed

50 Years

N/A

All

Phase 2

United States

650

NCT02605434
(ClinicalTrials.gov)

March 2016

5/11/2015

A Study to Assess the Safety and Efficacy of the of the Gastric-retentive AP-CD/LD in Advanced Parkinson's Patients

Phase 3 Multicenter Randomized Double-Blind, Double-dummy, Active-Controlled Study Comparing Efficacy/Safety of Gastric-retentive, Controlled-release Accordion Pill Carbidopa/Levodopa to Immediate Release in Fluctuating Parkinson's Patients

Parkinson's Disease

Drug: Accordion Pill™ Carbidopa/Levodopa;Drug: Sinemet®;Drug: Placebo -AP-CD/LD;Drug: Placebo- Sinemet

Intec Pharma Ltd.

NULL

Unknown status

30 Years

N/A

All

420

Phase 3

United States;Bulgaria;Germany;Israel;Italy;Poland;Slovakia;Spain;Ukraine;United Kingdom;Hungary

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

651

NCT02668497
(ClinicalTrials.gov)

March 2016

26/1/2016

Kinematic-based BoNT-A Bilateral Upper Limb PD Therapy

Kinematic Characterization of Upper Limb Parkinson's Disease Tremor for Optimized Botulinum Toxin Type A Therapy

Parkinson's Disease

Drug: Botulinum Toxin Type A

Western University, Canada

NULL

Active, not recruiting

18 Years

80 Years

All

Phase 2

Canada

652

NCT02618941
(ClinicalTrials.gov)

February 2, 2016

25/11/2015

Follow-up Study to Assess a Second Boost Immunization With AFFITOPE® PD01A With Regard to Safety and Clinical Activity (AFF008AA)

Phase IB Follow-up, Controlled, Parallel Group, Single-center Study to Assess a Second Boost Immunization With AFFITOPE® PD01A With Regard to Safety/Tolerability, Immunological and Clinical Activity in Patients Who Have Participated in the AFF008 Program

Parkinson's Disease

Biological: AFFITOPE® PD01A

Affiris AG

NULL

Completed

40 Years

68 Years

All

Phase 1

Austria

653

NCT04569656
(ClinicalTrials.gov)

February 2, 2016

24/9/2020

Treatment of Chronic Constipation in Parkinson's Disease

Pilot Study for the Evaluation of the Parameters of Activity of a Preparation of PHGG and Sodium Hyaluronate in Chronic Constipation in Patients With Parkinson's Disease

Parkinson Disease

Drug: hydrolyzed guar gum

IRCCS San Raffaele

NULL

Completed

18 Years

N/A

All

Phase 2

Italy

654

JPRN-UMIN000020288

2016/02/01

28/12/2015

Intervention Study of Istradefylline for the Treatment of Gait Disorders in Patients with Parkinson's Disease.

Parkinson's disease

In this research, the duration of evaluation will be 12 weeks.
Treatment with istradefylline will be started at a dose of 20 mg administered once daily. The dose of istradefylline will be increased to 40 mg once daily if the patient has no tolerability issues and still has motor symptoms at Week 4. After the Week 4, the dose will be allowed to be reduced to 20 mg once daily, if the patient exhibits any tolerability issues such as the occurrence of adverse drug reactions caused by istradefylline.

Juntendo University Shizuoka Hospital

NULL

Complete: follow-up complete

20years-old

Not applicable

Male and Female

Not selected

Japan

655

JPRN-UMIN000020527

2016/02/01

01/02/2016

Multi-centered, placebo-controlled, double-blind, randomized clinical trial to assess the effect of oral inosine on the onset of wearing off in patients with early stage Parkinson's disease

Parkinson's disease

Inosine to maintain a serum urate level between 6.0-7.5 mg/dL for 2 years
Lactose as a placebo for 2 years

Ehime University Graduate School of Medicine

NULL

Recruiting

20years-old

Not applicable

Male and Female

100

Phase 2

Japan

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

656

NCT02641054
(ClinicalTrials.gov)

February 2016

7/12/2015

Efficacy Phase IIa Study of CVXL-0107 in Advanced Parkinson's Disease

Double-Blind Randomized Placebo-Controlled Cross-Over Phase IIa Trial to Evaluate Efficacy of CVXL-0107 on Parkinson-Related Symptoms and Levodopa-Induced Dyskinesia in Advanced Parkinson's Disease Patients Using a Levodopa Challenge Test

Idiopathic Parkinson Disease

Drug: CVXL-0107;Drug: Placebo;Drug: Levodopa

CleveXel Pharma

NULL

Completed

40 Years

75 Years

All

Phase 2

France

657

NCT02524405
(ClinicalTrials.gov)

February 2016

13/8/2015

BEAM: Brain-Eye Amyloid Memory Study

The Brain Eye Amyloid Memory (BEAM) Study: Validation of Ocular Measures as Potential Biomarkers for Early Detection of Brain Amyloid and Neurodegeneration

Alzheimer's Disease;Mild Cognitive Impairment;Vascular Cognitive Impairment;Parkinson's Disease;Lewy Body Disease

Other: Pittsburgh Compound B [11C]-PIB

Sunnybrook Health Sciences Centre

Brain Canada;Weston Brain Institute;GE Healthcare;University Health Network, Toronto;Centre for Addiction and Mental Health;Baycrest;St. Michael's Hospital, Toronto;Kensington Eye Institute

Recruiting

50 Years

90 Years

All

345

Canada

658

NCT02655315
(ClinicalTrials.gov)

February 2016

7/1/2016

Conservative Iron Chelation as a Disease-modifying Strategy in Parkinson's Disease

Conservative Iron Chelation as a Disease-modifying Strategy in Parkinson's Disease. European Multicentre, Parallel-group, Placebo-controlled, Randomized Clinical Trial of Deferiprone

Parkinson Disease

Drug: Deferiprone;Drug: Placebo

University Hospital, Lille

European Commission;ApoPharma

Active, not recruiting

N/A

80 Years

All

372

Phase 2

Austria;Czechia;France;Germany;Netherlands;Portugal;Spain;United Kingdom;Czech Republic

659

NCT02680977
(ClinicalTrials.gov)

February 2016

9/2/2016

Mucuna Pruriens Therapy in Parkinson's Disease

Mucuna Pruriens Therapy in Parkinson's Disease: a Double-blind, Placebo-controlled, Randomized, Crossover Study.

Parkinson's Disease

Other: MP-Equivalent;Other: MP-Low;Other: MP+DDCI;Drug: LD+DDCI;Drug: LD-DDCI;Other: Placebo

ASST Gaetano Pini-CTO

Fondazione Grigioni per il Morbo di Parkinson;Fondazione Grigioni per il Morbo di Parkinson

Completed

21 Years

N/A

Both

Phase 2

Bolivia

660

NCT02683629
(ClinicalTrials.gov)

February 2016

8/2/2016

Investigation of the Safety and Efficacy of NTCELL® [Immunoprotected (Alginate-Encapsulated) Porcine Choroid Plexus Cells for Xenotransplantation] in Patients With Parkinson's Disease

A Phase IIb, Randomised, Double-blind, Placebo-controlled, Dose-range Investigation of the Safety and Efficacy of NTCELL® [Immunoprotected (Alginate-Encapsulated) Porcine Choroid Plexus Cells for Xenotransplantation] in Patients With Parkinson's Disease

Parkinson's Disease

Biological: NTCELL Implantation;Other: Sham Surgery

Living Cell Technologies

Statistecol Consultants Limited

Completed

40 Years

65 Years

All

Phase 2

New Zealand

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

661

EUCTR2015-004238-85-ES
(EUCTR)

27/01/2016

10/12/2015

Brain SPECT in premotor stage of Parkinson disease

Ictal brain SPECT in the premotor stage of Parkinson disease

Parkinson disease
MedDRA version: 18.1;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Trade Name: CERETEC (TM) Estabilizado
Product Name: Ceretec
INN or Proposed INN: Ceretec
Other descriptive name: TECHNETIUM (99MTC) EXAMETAZIME

IDIBAPS

NULL

Not Recruiting

Female: yes
Male: yes

Phase 2

Spain

662

JPRN-JapicCTI-153112

22/1/2016

25/12/2015

ONO-2370 Phase 2 study(ONO-2370-02)

ONO-2370 a Phase 2 Double-Blind, Randomised, Placebo-Controlled, Parallel-Group study, and an Open-Label, Uncontrolled, Multicenter, Long-term, Extension study(ONO-2370-02)

Parkinson's disease

Intervention name : ONO-2370
INN of the intervention : Opicapone
Dosage And administration of the intervention : ONO-2370 once-daily
Control intervention name : Placebo
INN of the control intervention : -
Dosage And administration of the control intervention : Once-daily placebo equivalent to active control

ONO PHARMACEUTICAL CO.,LTD.

NULL

complete

BOTH

399

Phase 2

Japan

663

EUCTR2015-001786-10-GB
(EUCTR)

18/01/2016

23/11/2015

A clinical study of the effects of EPI-589 on safety and indicators of oxidative stress in patients with Parkinson's disease.

A Phase 2A Safety and Biomarker Study of EPI-589 in Mitochondrial Subtype and Idiopathic Parkinson’s Disease Subjects - Safety and Biomarker Study with EPI-589 in Parkinson's Disease

Parkinson’s disease
MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders
MedDRA version: 20.0;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Product Name: EPI-589
Product Code: EPI-589
Other descriptive name: (R)-troloxamide quinone

BioElectron Technology Corporation (formerly Edison Pharmaceuticals Inc.)

NULL

Not Recruiting

Female: yes
Male: yes

Phase 2

United States;Germany;United Kingdom

664

NCT03258294
(ClinicalTrials.gov)

January 13, 2016

20/8/2017

Effect of Melatonin on Sleep Disturbances in Patients With Parkinson's Disease

Effect of Melatonin on Sleep Disturbances in Patients With Parkinson's Disease: Double Blind, Randomized, Placebo Controlled Trial

Parkinson's Disease

Drug: Melatonin (Circadin®);Drug: Placebo Oral Tablet

KIMJisun

Kuhnil Pharmaceutical Co., Ltd.

Enrolling by invitation

55 Years

N/A

All

Phase 4

NULL

665

ChiCTR-CPC-15007223

2016-01-01

2015-09-22

Characteristics andAffecting Factors Amalysis of Sleep Disorder in Parkinsons Disease

Parkinsons Disease; Sleep Disorder

The treatment group; The control group:Rotigotine patch;

Department of Neurology, Changzheng Hospital, Second Military Medical University

NULL

Pending

Both

The treatment group; The control group:100;

China

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

666

NCT02768077
(ClinicalTrials.gov)

January 2016

9/5/2016

Effect of Melatonin on Sleep Disturbances in Patients With Parkinson's Disease

Effect of Melatonin on Sleep Disturbances in Patients With Parkinson's Disease: Double Blind, Randomized, Placebo Controlled Trial

Parkinson's Disease

Drug: Melatonin (Circadin®);Drug: Placebo

Kuhnil Pharmaceutical Co., Ltd.

NULL

Enrolling by invitation

55 Years

N/A

Both

100

Phase 4

NULL

667

NCT02589340
(ClinicalTrials.gov)

January 2016

23/10/2015

Buspirone, in Combination With Amantadine, for the Treatment of Levodopa-induced Dyskinesia

Parkinson's Disease;Dyskinesias;Movement Disorders

Drug: Buspirone;Drug: Placebo

Oregon Health and Science University

Portland VA Medical Center

Active, not recruiting

18 Years

99 Years

All

Phase 1

United States

668

NCT02649608
(ClinicalTrials.gov)

January 2016

6/1/2016

An Exploratory Study Investigating Safety, Tolerability and Pharmacokinetics of Ascending Doses of Lu AE04621 in Parkinson Disease Patients

Interventional, Open-label, Exploratory Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Lu AE04621 and the Active Metabolite Lu AA40326 After Ascending Oral Doses of Lu AE04621 to Patients With Parkinson's Disease

Parkinson Disease

Drug: 0.04 mg Lu AE04621;Drug: 0.08 mg Lu AE04621;Drug: 0.2 mg Lu AE04621;Drug: 0.4 mg Lu AE04621;Drug: 0.6 mg Lu AE04621;Drug: 0.8 mg Lu AE04621;Drug: 1.0 mg Lu AE04621;Drug: 1.2 mg Lu AE04621

H. Lundbeck A/S

NULL

Completed

45 Years

75 Years

All

Phase 1

United States

669

NCT02639221
(ClinicalTrials.gov)

January 2016

17/12/2015

A Phase I, Double Blind, Placebo Controlled, First in Human, Single and Multiple Ascending Oral Dose, Safety, Tolerability and Pharmacokinetic Study in Healthy Male and Female Subjects

PXT002331 A Phase I, Double Blind, Placebo Controlled, First in Human, Single and Multiple Ascending Oral Dose, Safety, Tolerability and Pharmacokinetic Study in Healthy Male and Female Subjects

Parkinson's Disease

Drug: PXT002331

Prexton Therapeutics

NULL

Completed

18 Years

60 Years

Both

Phase 1

United Kingdom

670

NCT02579473
(ClinicalTrials.gov)

January 2016

13/10/2015

A Study of Weekly Subcutaneous Injections of SER-214 in Subjects With Parkinson's Disease (PD), to Determine the Safety, Tolerability and Pharmacokinetic (PK) Profile of SER-214

A Multi-center, Open-label, Multiple Ascending Dosage-ranging Cohort (MAD) Study in Early, Untreated or Stably Treated Subjects With Parkinson's Disease (PD), to Determine the Safety, Tolerability and Pharmacokinetics (PK) of Injections of SER-214 Administered Subcutaneously Once a Week for Two Weeks After 0-2 Weeks of Dose Titration

Parkinson's Disease

Drug: SER-214

Serina Therapeutics

NULL

Active, not recruiting

40 Years

80 Years

All

Phase 1

United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

671

NCT02549573
(ClinicalTrials.gov)

January 2016

9/9/2015

Outpatient Physical Therapy Intervention in Subjects With Parkinson's Disease Currently Using APOKYN®

Outpatient Physical Therapy Intervention in Subjects With Parkinson's DiseaseCurrently Using APOKYN®: A Phase IV Study of Outcome Assessments of Physical Therapy in Subjects in an On Versus End-of-Dose-Off Motor State

Parkinson's Disease;Motor Symptoms

Drug: APOKYN;Behavioral: Physical Therapy

US WorldMeds LLC

NULL

Terminated

18 Years

78 Years

All

Phase 4

United States

672

EUCTR2014-002600-24-AT
(EUCTR)

30/12/2015

25/09/2015

Safinamide versus placebo in patients with Parkinson’s disease for improvement of motor complications

A TWO YEAR, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY TO EVALUATE THE LONG TERM EFFICACY AND SAFETY OF SAFINAMIDE 100 MG, ONCE DAILY, AS ADD ON THERAPY, IN IDIOPATHIC PARKINSON’S DISEASE PATIENTS WITH MOTOR FLUCTUATIONS - EVEREST

Idiopathic Parkinson's Disease
MedDRA version: 18.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Trade Name: Xadago
Product Name: safinamide
Other descriptive name: SAFINAMIDE
Trade Name: Xadago
Product Name: safinamide
Other descriptive name: SAFINAMIDE

Zambon S.P.A.

NULL

Not Recruiting

Female: yes
Male: yes

556

Phase 3

France;Spain;Austria;Russian Federation;Germany;Italy;United Kingdom;Switzerland;Sweden

673

JPRN-JapicCTI-153057

14/12/2015

02/11/2015

ME2125 Phase III (ME2125-4)

A Phase III, Long-Term Treatment Study of ME2125 in Patients with Parkinson's Disease with Wearing-Off Phenomenon

Parkinson's disease

Intervention name : ME2125 (safinamide mesilate)
INN of the intervention : safinamide
Dosage And administration of the intervention : Orally administer a dose of 2 tablets once a daily in morning.
Control intervention name : Placebo
INN of the control intervention : -
Dosage And administration of the control intervention : Orally administer a dose of 2 tablets once a daily in morning.

Meiji Seika Pharma Co., Ltd.

NULL

complete

BOTH

200

Phase 3

Japan

674

EUCTR2014-005630-60-ES
(EUCTR)

11/12/2015

05/10/2015

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study with an Open-Label Phase to Determine theEfficacy and Safety of Tozadenant as Adjunctive Therapy inLevodopa-Treated Patients with Parkinson´s DiseaseExperiencing End-of-Dose Wearing-Off (TOZ-PD)

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study with an Open-Label Phase to Determine theEfficacy and Safety of Tozadenant as Adjunctive Therapy inLevodopa-Treated Patients with Parkinson´s DiseaseExperiencing End-of-Dose Wearing-Off (TOZ-PD) - TOZ-PD

Parkinson´s Disease
MedDRA version: 18.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Product Name: Tozadenant
Product Code: SYN115
INN or Proposed INN: Tozadenant
Other descriptive name: TOZADENANT

Biotie Therapies Inc.

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

450

Phase 3

United States;Czech Republic;European Union;Canada;Spain;Germany

675

EUCTR2014-002600-24-IT
(EUCTR)

11/12/2015

16/02/2018

Safinamide versus placebo in patients with Parkinson's disease for improvement of motor complications

Idiopathic Parkinson's Disease
MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Trade Name: Xadago
Product Name: Safinamide
Product Code: na
INN or Proposed INN: SAFINAMIDE METANSOLFONATO
Other descriptive name: SAFINAMIDE METANSOLFONATO
Trade Name: Xadago
INN or Proposed INN: SAFINAMIDE METANSOLFONATO
Other descriptive name: SAFINAMIDE METANSOLFONATO

ZAMBON SPA

NULL

Not Recruiting

Female: yes
Male: yes

556

Phase 3

France;Spain;Austria;Russian Federation;Germany;United Kingdom;Switzerland;Italy;Sweden

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

676

EUCTR2014-002600-24-SE
(EUCTR)

03/12/2015

30/07/2015

Safinamide versus placebo in patients with Parkinson’s disease for improvement of motor complications

Trade Name: Xadago
Product Name: safinamide
INN or Proposed INN: SAFINAMIDE
Other descriptive name: SAFINAMIDE
Trade Name: Xadago
Product Name: safinamide
INN or Proposed INN: SAFINAMIDE
Other descriptive name: SAFINAMIDE

Zambon S.P.A.

NULL

Not Recruiting

Female: yes
Male: yes

556

Phase 3

France;Spain;Austria;Russian Federation;Germany;Italy;United Kingdom;Switzerland;Sweden

677

NCT02610231
(ClinicalTrials.gov)

December 2015

13/11/2015

Long Term Study of Istradefylline in Subjects With Moderate to Severe Parkinson's Disease

A Phase 3, Long-term, Open-label Study of Istradefylline in Subjects With Moderate to Severe Parkinson's Disease

Idiopathic Parkinson's Disease

Drug: Istradefylline 20 mg or 40 mg

Kyowa Hakko Kirin Pharma, Inc.

Kyowa Kirin Co., Ltd.

Completed

30 Years

N/A

All

239

Phase 3

United States;Canada;Czechia;Germany;Israel;Italy;Poland;Serbia;Czech Republic

678

NCT02616120
(ClinicalTrials.gov)

December 2015

20/11/2015

Effect of SQJZ Herbal Mixtures on Non-motor Symptoms of Parkinson's Disease

Efficacy and Safety of SQJZ Herbal Mixtures on Non-motor Symptoms in Parkinson's Disease Patients

Parkinson's Disease

Drug: SQJZ herbal mixtures;Drug: Placebo

Dongzhimen Hospital, Beijing

NULL

Recruiting

18 Years

80 Years

All

240

Phase 2

China

679

NCT02536976
(ClinicalTrials.gov)

December 2015

28/8/2015

Mirabegron in Parkinson Disease and Impaired Cognition

A Clinical Trial of Mirabegron for Overactive Bladder Symptoms in Patients With Parkinson Disease and Impaired Cognition

Parkinson Disease;Overactive Bladder;Impaired Cognition

Drug: mirabegron;Drug: Placebo

HealthPartners Institute

NULL

Completed

25 Years

80 Years

All

Phase 4

United States

680

NCT02470780
(ClinicalTrials.gov)

December 2015

4/6/2015

Treating Bacterial Overgrowth in Parkinson's Disease

Parkinson's Disease;Small Intestinal Bacterial Overgrowth

Drug: Rifaximin;Drug: Placebo

University of Cincinnati

NULL

Completed

18 Years

N/A

All

Phase 2;Phase 3

United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

681

NCT02702102
(ClinicalTrials.gov)

December 2015

3/3/2016

Imaging Inflammation in Patients With Parkinson's Disease Dementia or Dementia With Lewy Bodies

Imaging Inflammation in Patients With Diffuse Lewy Body Disease

Diffuse Lewy Body Disease;Dementia With Lewy Bodies;Parkinson's Disease Dementia

Drug: 11C-PBR28

William Charles Kreisl

National Institute on Aging (NIA)

Completed

60 Years

N/A

All

Phase 2

United States

682

JPRN-JapicCTI-153056

24/11/2015

02/11/2015

ME2125 Phase II/III (ME2125-3)

A Phase II/III, Double-Blind, Placebo-Controlled Study of ME2125 in Patients with Parkinson's Disease with Wearing-Off Phenomenon

Parkinson's disease

Meiji Seika Pharma Co., Ltd.

NULL

complete

BOTH

410

Phase 2;Phase 3

Japan

683

EUCTR2015-002631-17-ES
(EUCTR)

19/11/2015

03/11/2015

A study comparing immediate-release oral Levodopa and L-dopa/carbidopa intestinal gel over cognition and mood in non-demented Parkinson?s disease (PD) patients

An intra-subject, randomized, double blind, crossover study comparing immediate-release oral LD (IR-LD) and L-dopa/carbidopa intestinal gel (LCIG) over cognition and mood in non-demented advanced Parkinson?s disease (PD) patients

Parkinson disease;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Institut de Recerca del Hospital de la Santa Creu i Sant Pau

NULL

Not Recruiting

Female: yes
Male: yes

Phase 4

Spain

684

EUCTR2014-002600-24-ES
(EUCTR)

19/11/2015

05/10/2015

Safinamide versus placebo in patients with Parkinson?s disease for improvement of motor complications

A TWO YEAR, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY TO EVALUATE THE LONG TERM EFFICACY AND SAFETY OF SAFINAMIDE 100 MG, ONCE DAILY, AS ADD ON THERAPY, IN IDIOPATHIC PARKINSON?S DISEASE PATIENTS WITH MOTOR FLUCTUATIONS - EVEREST

Trade Name: Xadago
Product Name: safinamide
INN or Proposed INN: safinamide
Other descriptive name: SAFINAMIDE
Trade Name: Xadago
Product Name: safinamide
INN or Proposed INN: safinamide
Other descriptive name: SAFINAMIDE

Zambon S.P.A.

NULL

Not Recruiting

Female: yes
Male: yes

556

Phase 3

France;Spain;Austria;Russian Federation;Germany;Italy;United Kingdom;Switzerland;Sweden

685

NCT02565628
(ClinicalTrials.gov)

November 16, 2015

28/9/2015

PF-06669571 In Subjects With Idiopathic Parkinson's Disease

A Phase 1b, Double Blind, Sponsor Open, Randomized, Parallel, Group Multiple Dose Study Examining The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Pf-06669571 In Subjects With Idiopathic Parkinson's Disease.

Idiopathic Parkinson's Disease

Drug: PF-06669571;Drug: Placebo

Pfizer

NULL

Completed

N/A

All

Phase 1

United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

686

JPRN-UMIN000019676

2015/11/10

10/11/2015

The double blind, placebo controlled trial of modafinil for excessive daytime sleepiness in Parkinson's disease

The double blind, placebo controlled trial of modafinil for excessive daytime sleepiness in Parkinson's disease - The double blind, placebo controlled trial of modafinil for excessive daytime sleepiness in Parkinson's disease

Parkinson's disease

taking modafinil (200 mg/day) after breakfast for 4 weeks, wash out for 2 weeks, taking matching placebo after breakfast for 4 weeks
taking matching placebo after breakfast for 4 weeks, wash out for 2 weeks, taking modafinil (200 mg/day) after breakfast for 4 weeks

Department of Neurology and Clinical Pharmacology, Ehime University Graduate School of Medicine

NULL

Complete: follow-up complete

20years-old

100years-old

Male and Female

Not selected

Japan

687

EUCTR2015-000148-40-GB
(EUCTR)

09/11/2015

16/09/2015

A trial comparing simvastatin to placebo as a neuronal protective treatment for Parkinson's disease.

Simvastatin as a neuroprotective treatment for Parkinson's disease: a double-blind, randomised, placebo controlled futility study in patients of moderate severity. - Simvastatin as a neuroprotective treatment for moderate PD (PD STAT)

Parkinson's disease
MedDRA version: 18.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders
MedDRA version: 18.0;Level: LLT;Classification code 10013113;Term: Disease Parkinson's;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Product Name: Simvastatin
INN or Proposed INN: Simvastatin

Plymouth Hospitals NHS Trust

NULL

Not Recruiting

Female: yes
Male: yes

198

Phase 3

United Kingdom

688

JPRN-UMIN000019654

2015/11/06

06/11/2015

The effect of rich-hydrogen water drinking to gut peptide

Parkinson's disease, healthy control

hydrogen water
natural water

Nagoya graduate school of medicine university

NULL

Pending

20years-old

80years-old

Male and Female

Not applicable

Japan

689

JPRN-jRCTs041180070

04/11/2015

07/03/2019

Trerief Impact in PD PET Study

Randomized, multicenter, open-label, comparative study on neuroprotective effects of zonisamide (Trerief), anti-parkinsonian drug, in patients with early Parkinson's disease: Evaluation by functional PET (positron emission tomography) images - TIPPS

Parkinson's disease
Parkinson's disease;D010300

[1] Zonisamide treatment group
Zonisamide (25 mg) once daily in addition to levodopa/DCI with fixed dosage and administration.
Note that after one-year fixed protocol period, the followings are allowed; 1) one or two tablets per day in case of developing wearing off phenomenon, 2) change of dose and/or administration of levodopa/DCI, and 3) addition of other anti-parkinsonian drugs due to exacerbation of symptoms.
[2] Zonisamide non-treatment group
Only levodopa/DCI with fixed dosage and administration.
Note that after one-year fixed protocol period, the followings are allowed; 1) change of dose and/or administration of levodopa/DCI and 2) addition of other anti-parkinsonian drugs except for zonisamide due to exacerbation of symptoms.

Ouchi Yasuomi

NULL

Not Recruiting

Not applicable

< 80age old

Both

N/A

Japan

690

JPRN-UMIN000019090

2015/11/04

01/11/2015

Reduced form of CoenzymeQ10 for Parkinson's disease - open trial of dose finding test and combination with hydrogen water

Parkinson's disease

reduced form of CoQ10 300mg 16weeks
reduced form of CoQ10 600mg 16weeks
reduced form of CoQ10 600mg 16weeks
hydrogen water 500ml(Suisosui 7.0) 16weeks

Juntendo University Koshigaya Hospital

NULL

Complete: follow-up complete

20years-old

80years-old

Male and Female

Not selected

Japan

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

691

EUCTR2014-002600-24-GB
(EUCTR)

03/11/2015

28/07/2015

Safinamide versus placebo in patients with Parkinson’s disease for improvement of motor complications

Trade Name: Xadago
Product Name: safinamide
Other descriptive name: SAFINAMIDE
Trade Name: Xadago
Product Name: safinamide
Other descriptive name: SAFINAMIDE

Zambon S.P.A.

NULL

Not Recruiting

Female: yes
Male: yes

556

Phase 3

France;Spain;Austria;Russian Federation;Germany;Switzerland;Italy;United Kingdom;Sweden

692

NCT04110678
(ClinicalTrials.gov)

November 1, 2015

18/9/2019

Tolerance to NeuroEPO in Parkinson Disease

Nasal Administration of the NeuroEPO in Parkinson Disease: Short-term Tolerance Physician Lead Trial

Parkinson Disease

Drug: NeuroEPO

International Center for Neurological Restoration, Cuba

Center of Molecular Immunology, Cuba;University of Electronic Science and Technology of China

Completed

40 Years

70 Years

All

Phase 1;Phase 2

Cuba

693

NCT02632279
(ClinicalTrials.gov)

November 2015

26/11/2015

Tryptophan Depletion in PD Patients Treated With STN DBS

Tryptophan Depletion in Parkinson's Disease Patients Treated With Deep Brain Stimulation of the Subthalamic Nucleus: Effects on Mood and Motor Functions

Parkinson's Disease

Dietary Supplement: Tryptophan (TRP) depletion;Dietary Supplement: Placebo;Device: Stimulator ON;Device: Stimulator OFF

Maastricht University Medical Center

Netherlands Brain Foundation

Terminated

N/A

All

N/A

Netherlands

694

NCT02271503
(ClinicalTrials.gov)

November 2015

13/10/2014

A Study to Assess the PK and Pharmacodynamics of IPX203 in Patients With Advanced Parkinson's Disease

A Study to Assess the Pharmacokinetics and Pharmacodynamics of a Single Dose of IPX203 in Patients With Advanced Parkinson's Disease

Parkinson's Disease

Drug: CD -LD IR;Drug: IPX203 180 mg;Drug: IPX203 270 mg;Drug: Rytary 195 mg;Drug: Rytary 145 mg

Impax Laboratories, LLC

NULL

Completed

40 Years

N/A

All

Phase 2

United States

695

NCT02577523
(ClinicalTrials.gov)

November 2015

6/10/2015

A Clinical Study Investigating the Efficacy, Safety, Tolerability and Pharmacokinetics of ND0612H, a Solution of Levodopa/Carbidopa Administered as a Continuous Subcutaneous Infusion in Subjects With Advanced Parkinson's Disease

A Multicenter, Parallel-group, Rater-blinded, Randomized Clinical Study Investigating the Efficacy, Safety, Tolerability and Pharmacokinetics of 2 Dosing Regimens of ND0612H, a Solution of Levodopa/Carbidopa Delivered Via a Pump System as a Continuous Subcutaneous Infusion in Subjects With Advanced Parkinson's Disease

Parkinson's Disease

Drug: ND0612 (Levodopa/Carbidopa solution)

NeuroDerm Ltd.

NULL

Completed

30 Years

80 Years

All

Phase 2

United States;Austria;Israel;Italy

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

696

NCT02914366
(ClinicalTrials.gov)

November 2015

8/9/2016

Ambroxol as a Treatment for Parkinson's Disease Dementia

Ambroxol as a Novel Disease Modifying Treatment for Parkinson's Disease Dementia

Parkinson's Disease Dementia

Drug: Ambroxol;Other: Placebo

Lawson Health Research Institute

Weston Brain Institute;University of Western Ontario, Canada;London Health Sciences Centre

Recruiting

50 Years

N/A

All

Phase 2

Canada

697

NCT02758730
(ClinicalTrials.gov)

November 2015

26/4/2016

Study Assessing Tolerability and Safety and Exploring the Immunogenicity and Therapeutic Activity of AFFITOPE® PD01A in PD-GBA Patients

A Randomized, Placebo-controlled, Parallel Group, Patient-blind, Single-center Phase I Pilot Study Assessing Tolerability and Safety and Exploring the Immunogenicity and Therapeutic Activity of AFFITOPE® PD01A, a New Vaccine Against Alpha-synuclein, in Patients With PD-GBA

Parkinson's Disease

Biological: AFFITOPE® PD01A + Adjuvant;Biological: Adjuvant without active component

Affiris AG

University Hospital Tuebingen

Withdrawn

40 Years

80 Years

Both

Phase 1

Germany

698

EUCTR2014-005630-60-DE
(EUCTR)

29/10/2015

07/07/2015

Product Name: Tozadenant
Product Code: SYN115
INN or Proposed INN: Tozadenant
Other descriptive name: TOZADENANT

Biotie Therapies Inc.(a wholly owned subsidiary of Acorda Therapeutics Inc.)

NULL

Not Recruiting

Female: yes
Male: yes

450

Phase 3

United States;Czech Republic;European Union;Canada;Spain;Austria;Germany

699

EUCTR2015-003045-26-SE
(EUCTR)

23/10/2015

15/09/2015

Study of Dopamine Transporters (signal substance in central nervous system)in patients with early signs of Parkinson´s disease.

[18F] FE-PE2I PET/CT study of Dopamine Transporters in Early Parkinsonian disease.

Patients with newly clinically diagnosed untreated idiopathic parkinsonism
MedDRA version: 20.0;Level: HLT;Classification code 10034005;Term: Parkinson's disease and parkinsonism;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Product Name: [18F]FE-PE2I
INN or Proposed INN: [18F]-(E)-N-(3-iodoprop-2-enyl)-2b-carbofluoroethoxy-3b-(4'-methylphenyl)nortropane
Trade Name: DaTSCAN
INN or Proposed INN: IOFLUPANE (123I)
Product Name: 15O H2O
INN or Proposed INN: [15O]H2O

Umeå University Hospital

NULL

Not Recruiting

Female: yes
Male: yes

105

Phase 2

Sweden

700

JPRN-UMIN000019082

2015/10/10

22/09/2015

the effect of smell dysfunction using hydrogen gas for parkinson disease

parkinson's disease

we measured smell test and urine 8-OHdG before and after 3.5% hydrogen gas. After two month discontinuation of administration. we measured smell test and urine 8-OHdG before and after room air.
we measured smell test and urine 8-OHdG before and after room air. After two month discontinuation of administration. we measured smell test and urine 8-OHdG before and after 3.5% hydrogen gas.

Nagoya University Graduate School of Medicine

NULL

Complete: follow-up complete

Not applicable

Male and Female

Not selected

Japan

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

701

NCT02933372
(ClinicalTrials.gov)

October 5, 2015

6/4/2016

Cholinergic Mechanisms of Gait Dysfunction in Parkinson's Disease Experiments 1 & 2 - Proj #3

Cholinergic Mechanisms of Gait Dysfunction in Parkinson's Disease Experiments 1 & 2 - Projects #3

Parkinson's Disease

Drug: Varenicline;Radiation: [18-Fluorine] Flubatine PET Scan;Other: Evaluation by Investigator

University of Michigan

NULL

Completed

45 Years

N/A

All

Phase 2

NULL

702

JPRN-UMIN000019524

2015/10/01

28/10/2015

Parkinson's Disease

Zonisamide treatment group:

Zonisamide (25 mg) once daily in addition to levodopa/DCI with fixed dosage and administration.
Note that after one-year fixed protocol period, the followings are allowed; 1) one or two tablets per day in case of developing wearing off phenomenon, 2) change of dose and/or administration of levodopa/DCI, and 3) addition of other anti-parkinsonian drugs due to exacerbation of symptoms.
Zonisamide non-treatment group:

Only Levodopa/DCI with fixed dosage and administration.
Note that after one-year fixed protocol period, the followings are allowed; 1) change of dose and/or administration of levodopa/DCI and 2) addition of other anti-parkinsonian drugs except for zonisamide due to exacerbation of symptoms.

Hamamatsu University School of Medicine

NULL

Complete: follow-up complete

Not applicable

80years-old

Male and Female

Not applicable

Japan

703

NCT02572713
(ClinicalTrials.gov)

October 2015

7/10/2015

Systemic Synuclein Sampling Study (S4)

Parkinson's Disease

Procedure: Biofluid samplings;Procedure: Tissue samplings;Drug: DaTSCAN ™

Michael J. Fox Foundation for Parkinson's Research

Indiana University;University of Iowa;Banner Health;Paracelsus Elena Klinik

Completed

40 Years

N/A

All

N/A

United States;Canada

704

NCT02562768
(ClinicalTrials.gov)

September 30, 2015

28/9/2015

A Study of LY3154207 in Healthy Participants and Participants With Parkinson's Disease

Multiple-Ascending Dose, Safety, Tolerability, and Pharmacokinetic Study of LY3154207 in Healthy Subjects and Subjects With Parkinson's Disease

Parkinson's Disease

Drug: LY3154207;Drug: Placebo

Eli Lilly and Company

NULL

Completed

20 Years

N/A

All

Phase 1

United States

705

EUCTR2014-005630-60-CZ
(EUCTR)

23/09/2015

10/07/2015

Product Name: Tozadenant
Product Code: SYN115
INN or Proposed INN: Tozadenant
Other descriptive name: TOZADENANT

Biotie Therapies Inc. (a wholly owned subsidiary of Acorda Therapeutics Inc.)

NULL

Not Recruiting

Female: yes
Male: yes

450

Phase 3

United States;Czech Republic;European Union;Canada;Spain;Austria;Germany

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

706

EUCTR2014-004865-26-IT
(EUCTR)

21/09/2015

29/05/2015

26-Week Study Comparing Levodopa-Carbidopa Intestinal Gel to Optimized Medical Treatment on Non-Motor Symptoms in Subjects with Advanced Parkinson's Disease

Non-motor symptoms in advanced Parkinson's disease
MedDRA version: 18.0;Level: LLT;Classification code 10013113;Term: Disease Parkinson's;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Trade Name: Duodopa
INN or Proposed INN: Levodopa
Other descriptive name: LEVODOPA
INN or Proposed INN: Carbidopa
Other descriptive name: CARBIDOPA MONOHYDRATE

AbbVie Deutschland GmbH & Co. KG

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

European Union;Canada;Spain;Australia;Germany;Italy;Sweden

707

NCT02549092
(ClinicalTrials.gov)

September 9, 2015

11/9/2015

A Study to Examine the Effect of Levodopa-Carbidopa Intestinal Gel (LCIG) Therapy Relative to That of Optimized Medical Treatment (OMT) on Non-motor Symptoms (NMS) Associated With Advanced Parkinson's Disease (PD)

An Open-label, Randomized 26-Week Study Comparing Levodopa-Carbidopa INteStInal Gel (LCIG) THerapy to Optimized Medical Treatment (OMT) on Non-Motor Symptoms (NMS) in Subjects With Advanced Parkinson's Disease - INSIGHTS Study

Advanced Parkinson's Disease

Drug: ABT-SLV187

AbbVie

NULL

Active, not recruiting

30 Years

99 Years

All

Phase 3

United States;Australia;Canada;Germany;Greece;Italy;Korea, Republic of;Spain;Sweden

708

NCT02542696
(ClinicalTrials.gov)

August 31, 2015

3/9/2015

Open-Label Phase 3 Study to Examine the Long-Term Safety, Tolerability and Efficacy of APL-130277 for the Acute Treatment of OFF Episodes in Patients With Parkinson's Disease

An Open-Label, Phase 3 Study Examining the Long-Term Safety, Tolerability and Efficacy of APL-130277 in Levodopa Responsive Patients With Parkinson's Disease Complicated by Motor Fluctuations (OFF Episodes)

Parkinson Disease

Drug: APL-130277

Sunovion

NULL

Recruiting

18 Years

N/A

All

226

Phase 3

United States;Austria;Canada;France;Germany;Italy;Spain;United Kingdom

709

EUCTR2014-004865-26-DE
(EUCTR)

27/08/2015

22/05/2015

26-Week Study Comparing Levodopa-Carbidopa Intestinal Gel to Optimized Medical Treatment on Non-Motor Symptoms in Subjects with Advanced Parkinson's Disease

Non-motor symptoms in advanced Parkinson's disease
MedDRA version: 19.0;Level: LLT;Classification code 10013113;Term: Disease Parkinson's;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Trade Name: Duodopa
INN or Proposed INN: Levodopa
Other descriptive name: LEVODOPA
INN or Proposed INN: Carbidopa
Other descriptive name: CARBIDOPA MONOHYDRATE

AbbVie Deutschland GmbH & Co. KG

NULL

Not Recruiting

Female: yes
Male: yes

Phase 3

European Union;Canada;Spain;Australia;Germany;Italy;Sweden

710

EUCTR2015-000373-13-DE
(EUCTR)

18/08/2015

18/05/2015

A study to examine the effectiveness and safety of a new drug for involuntary muscle movements in patients with Parkinson’s disease

Phase 2, multicenter, randomized, double-blind, placebo-controlled, four-period cross-over, dose-range finding study to evaluate the safety, tolerability and efficacy of Eltoprazine in the treatment of levodopa induced dyskinesia in patients with Parkinson's disease.

Parkinson’s disease levodopa induced dyskinesia (PD-LID)
MedDRA version: 18.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Product Name: Eltoprazine Hydrochloride
INN or Proposed INN: ELTOPRAZINE
Product Name: Eltoprazine Hydrochloride
INN or Proposed INN: ELTOPRAZINE
Product Name: Eltoprazine Hydrochloride
INN or Proposed INN: ELTOPRAZINE

Amarantus BioScience Holdings, Inc.

NULL

Not Recruiting

Female: yes
Male: yes

Phase 2

France;United States;Germany;Sweden

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

711

EUCTR2014-004865-26-SE
(EUCTR)

05/08/2015

25/05/2015

26-Week Study Comparing Levodopa-Carbidopa Intestinal Gel to Optimized Medical Treatment on Non-Motor Symptoms in Subjects with Advanced Parkinson's Disease

Non-motor symptoms in advanced Parkinson's disease
MedDRA version: 19.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Trade Name: Duodopa
INN or Proposed INN: Levodopa
Other descriptive name: LEVODOPA
INN or Proposed INN: Carbidopa
Other descriptive name: CARBIDOPA MONOHYDRATE

AbbVie Deutschland GmbH & Co. KG

NULL

Not Recruiting

Female: yes
Male: yes

Phase 3

United States;European Union;Greece;Canada;Spain;Australia;Germany;Italy;Sweden

712

NCT02554734
(ClinicalTrials.gov)

August 2015

10/6/2015

Pharmacokinetic Study in Healthy Volunteers

Pharmacokinetics of Levodopa After Repeated Doses of Carbidopa, ODM-104 and Levodopa: an Open, Randomised Study With Crossover Design in Healthy Males and Females

Parkinson's Disease

Drug: levodopa , carbidopa, ODM-104;Drug: levodopa , carbidopa, entacapone

Orion Corporation, Orion Pharma

NULL

Completed

18 Years

65 Years

Both

Phase 1

Finland

713

NCT02917122
(ClinicalTrials.gov)

August 2015

30/6/2016

The Therapeutic Effect of Transcranial Direct Current Stimulation on Depression in Parkinson's Disease

Parkinson Disease;Depression

Device: active tDCS;Drug: Sertraline;Device: sham tDCS

National Cheng-Kung University Hospital

NULL

Active, not recruiting

18 Years

75 Years

Both

Phase 1;Phase 2

NULL

714

NCT02599753
(ClinicalTrials.gov)

August 2015

1/11/2015

Investigating the Microstructural and Functional Alterations of Brain in Parkinson's Disease Patients

Investigating the Microstructural and Functional Alterations of Brain in Parkinson's Disease Patients With Neuropsychiatric Disorders by Multimodal Neuroimaging

Parkinson's Disease

Drug: 18-FDTBZ

Chang Gung Memorial Hospital

NULL

Completed

20 Years

80 Years

All

Phase 2

Taiwan

715

NCT02337751
(ClinicalTrials.gov)

July 10, 2015

9/1/2015

A Phase 3, Long-term, Extension Study of TVP-1012 (1 mg) in Early Parkinson's Disease Participants

A Multicenter, Open-label, Long-term, Extension, Phase 3 Study to Evaluate the Safety and Efficacy of TVP-1012 at 1 mg in Early Parkinson's Disease Patients Not Treated With Levodopa

Parkinson's Disease

Drug: TVP-1012 1mg

Takeda

NULL

Completed

30 Years

79 Years

All

198

Phase 3

Japan

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

716

NCT02488265
(ClinicalTrials.gov)

July 1, 2015

21/5/2015

Protocol: Balance Training in Parkinson's Disease

Randomized Controlled Trial Protocol: Balance Training With Rhythmical Cues to Improve and Maintain Balance Control in Parkinson's Disease

Parkinson Disease

Other: Balance Training;Other: Screening to prevent falls

University of Sao Paulo General Hospital

NULL

Completed

50 Years

70 Years

All

150

N/A

Brazil

717

NCT02459886
(ClinicalTrials.gov)

July 1, 2015

29/5/2015

Single-Ascending Dose Study of BIIB054 in Healthy Participants and Early Parkinson's Disease

A Phase 1 Randomized, Double-Blinded, Placebo-Controlled Single-Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of BIIB054 in Healthy Subjects and Subjects With Early Parkinson's Disease

Parkinson's Disease;Healthy

Drug: BIIB054;Drug: Placebo

Biogen

NULL

Completed

40 Years

80 Years

All

Phase 1

United States

718

NCT02453386
(ClinicalTrials.gov)

July 2015

21/5/2015

Safety and Efficacy Study of Tozadenant to Treat End of Dose Wearing Off in Parkinson's Patients

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of Tozadenant as Adjunctive Therapy in Levodopa-Treated Patients With Parkinson's Disease Experiencing End of Dose Wearing-Off (TOZ-PD)

Idiopathic Parkinson's Disease

Drug: tozadenant;Drug: placebo

Biotie Therapies Inc.

NULL

Terminated

30 Years

80 Years

All

449

Phase 3

United States;Austria;Canada;Czechia;Germany;Italy;Spain;Czech Republic

719

NCT02415062
(ClinicalTrials.gov)

July 2015

14/3/2015

The Efficacy and Safety Study of High Dose Donepezil in Parkinson's Disease With Dementia

The Efficacy of 23mg Versus 10mg of Donepezil in ParkInson's Disease With Dementia

Parkinson's Disease

Drug: Donepezil

Inje University

NULL

Recruiting

50 Years

80 Years

Both

150

Phase 2

Korea, Republic of

720

EUCTR2014-003738-24-AT
(EUCTR)

26/06/2015

01/04/2015

A clinical trial to see if ADS-5102 is safe and effective in people with drug induced abnormal movements in Parkinson's disease

ADS-5102 (Amantadine HCl) Extended Release Efficacy and Safety Study in Parkinson's Disease Patients with Levodopa-Induced Dyskinesia - EASE LID 3 STUDY

Treatment of levodopa-induced dyskinesia in subjects with Parkinson's disease
MedDRA version: 17.1;Level: PT;Classification code 10013916;Term: Dyskinesia;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Product Name: Amantadine HCl Extended Release Capsule
Product Code: ADS-5102
INN or Proposed INN: Amantadine hydrochloride (HCl)
Other descriptive name: AMANTADINE HYDROCHLORIDE

Adamas Pharmaceuticals, Inc.

NULL

Not Recruiting

Female: yes
Male: yes

Phase 3

Germany;Spain;Austria;United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

721

EUCTR2014-000657-36-NL
(EUCTR)

22/06/2015

03/06/2015

Trial to investigate the efficacy of treatments in apomorphine-induced skin reactions

Open-label crossover trial to investigate the efficacy of treatments in apomorphine-induced skin reactions - Treatment of apomorphine-induced skin reactions: a pilot study

Parkinson's disease;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

University Medical Center Groningen

NULL

Not Recruiting

Female: yes
Male: yes

Phase 2

Netherlands

722

EUCTR2014-003739-20-AT
(EUCTR)

19/06/2015

01/04/2015

A clinical trial to see if ADS-5102 is safe in people with drug induced abnormal movements in Parkinson's disease

Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa-Induced Dyskinesia

Treatment of levodopa-induced dyskinesia in subjects with Parkinson's disease
MedDRA version: 18.1;Level: PT;Classification code 10013916;Term: Dyskinesia;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Product Name: Amantadine HCl Extended Release Capsule
Product Code: ADS-5102
INN or Proposed INN: Amantadine hydrochloride (HCl)
Other descriptive name: AMANTADINE HYDROCHLORIDE

Adamas Pharmaceuticals, Inc.

NULL

Not Recruiting

Female: yes
Male: yes

250

Phase 3

United States;Spain;Austria;Germany

723

EUCTR2014-004865-26-ES
(EUCTR)

19/06/2015

15/06/2015

26-Week Study Comparing Levodopa-Carbidopa Intestinal Gel to Optimized Medical Treatment on Non-Motor Symptoms in Subjects with Advanced Parkinson's Disease

Non-motor symptoms in advanced Parkinson's disease;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

AbbVie Deutschland GmbH & Co. KG

NULL

Not Recruiting

Female: yes
Male: yes

Phase 3

European Union;Greece;Canada;Spain;Australia;Germany;Italy;Sweden

724

NCT02469090
(ClinicalTrials.gov)

June 18, 2015

9/6/2015

Efficacy, Safety and Tolerability Study of APL-130277 for the Acute Treatment of OFF Episodes in Patients With Parkinson's Disease

Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Examine the Efficacy, Safety and Tolerability of APL-130277 in Levodopa Responsive Patients With Parkinson's Disease Complicated by Motor Fluctuations (OFF Episodes)

Parkinson Disease, Off Episodes

Drug: APL-130277;Drug: Placebo

Sunovion

NULL

Completed

18 Years

N/A

All

141

Phase 3

United States;Canada;United Kingdom

725

NCT02769793
(ClinicalTrials.gov)

June 2015

9/5/2016

Efficacy of Levodopa/Benserazide Dispersible Tablet on Response Fluctuations in PD Patients With Delayed ON

Efficacy of Levodopa/Benserazide Dispersible Tablet on Response Fluctuations in Parkinson's Disease Patients With Delayed ON: a Multicenter Randomized Open-label Cross-over Trial

Parkinson Disease

Drug: Levodopa dispersible;Drug: Levodopa

Seoul National University Hospital

SMG-SNU Boramae Medical Center;Samsung Medical Center

Unknown status

31 Years

80 Years

All

Phase 4

Korea, Republic of

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

726

NCT02450786
(ClinicalTrials.gov)

June 2015

14/5/2015

Effect of Donepezil on Cognition in Parkinson's Disease With Mild Cognitive Impairment (PD-MCI)

Parkinson's Disease

Drug: Donepezil

Yonsei University

NULL

Active, not recruiting

40 Years

N/A

All

Phase 2

Korea, Republic of

727

NCT02230930
(ClinicalTrials.gov)

June 2015

29/8/2014

Treatment of Apomorphine-induced Skin Reactions: a Pilot Study

Open-label Crossover Trial to Investigate the Efficacy of Treatments in Apomorphine-induced Skin Reactions

Parkinson's Disease;Apomorphine-induced Skin Reactions

Drug: Apomorphine 0.25% (2.5mg/ml);Device: Massage with a spiky ball;Drug: Hydrocortisone cream 1%;Drug: Subcutaneous hydrocortisone 10mg

University Medical Center Groningen

NULL

Recruiting

30 Years

N/A

All

Phase 2

Netherlands

728

EUCTR2014-005422-35-GB
(EUCTR)

28/05/2015

02/04/2015

The role of Buspirone in attenuating involuntary movements (Dyskinesias) in patients with Parkinson's disease.

THE ROLE OF BUSPIRONE IN ATTENUATING LEVODOPA-INDUCED DYSKINESIAS IN PATIENTS WITH PARKINSON'S DISEASE: A CLINICAL AND POSITRON EMISSION TOMOGRAPHY STUDY WITH 11C-PHNO. - The role of buspirone in LIDs in patients with Parkinson’s disease.

Levodopa induced dyskinesias within Parkinson's disease.
MedDRA version: 17.1;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Imperial College London-Imperial College Healthcare NHS Trust

NULL

Not Recruiting

Female: yes
Male: yes

Phase 4

United Kingdom

729

JPRN-jRCTs061180028

11/05/2015

26/02/2019

Pain reduction in PD patients with depression: double blind, randomized clinical trial of duloxetine

A double-blind, randomized clinical trial to evaluate the efficacy of Duloxetine against pain associated with Parkinson's disease with depression - Pain reduction in PD patients with depression: double blind, randomized clinical trial of duloxetine

Parkinson's disease;D010300

Ando Rina

NULL

Complete

20 years old

None

Both

Phase 2

Japan

730

EUCTR2014-003799-22-AT
(EUCTR)

08/05/2015

12/01/2015

A study of the safety and drug effects of levodopa inhalation powder (CVT-301) compared to Standard of Care Observational Cohort in patients with Parkinson’s disease

A Phase 3, Randomized Study Investigating the Safety ofCVT-301 (Levodopa Inhalation Powder) in Parkinson’s DiseasePatients With Motor Response Fluctuations (OFF Phenomena)Compared to an Observational Cohort Control

Product Name: CVT-301
Product Code: CVT-301
INN or Proposed INN: LEVODOPA
Other descriptive name: LEVODOPA
Product Name: CVT-301
Product Code: CVT-301
INN or Proposed INN: LEVODOPA
Other descriptive name: LEVODOPA

Civitas Therapeutics, Inc.

NULL

Not Recruiting

Female: yes
Male: yes

408

Phase 3

Serbia;United States;Spain;Austria;Israel;United Kingdom;Italy;France;Czech Republic;Hungary;Belgium;Poland;Romania;Germany

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

731

EUCTR2010-024424-26-SK
(EUCTR)

05/05/2015

28/04/2015

Clinical study for the evaluation of the safety and efficacy of masitinib in patients suffering from parkinson's disease

A prospective, multicenter, randomised, double-blind, placebo-controlled, parallel group, phase 2 study to compare the efficacy and safety of masitinib versus placebo on cognitive impairment associated with Parkinson's disease

Parkinson's disease
MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

AB Science

NULL

Not Recruiting

Female: yes
Male: yes

Phase 2

France;United States;Hungary;Czech Republic;Slovakia;Spain;Romania;Bulgaria;South Africa;Germany

732

NCT02448914
(ClinicalTrials.gov)

May 2015

12/5/2015

A Study to Compare Plasma Levels of Levodopa, Carbidopa and Entacapone After TRIGEL or Duodopa Infusion in PD Patients

A Single Centre, Two-period, Open Label, Randomised, Cross-over Study to Assess Plasma Levodopa, Carbidopa and Entacapone Concentrations After Continuous Infusion of TRIGEL or Duodopa in Patients With Advanced Parkinson´s Disease

Parkinson's Disease

Drug: TRIGEL;Drug: Duodopa

LobSor Pharmaceuticals AB

TFS Trial Form Support

Completed

30 Years

N/A

All

Phase 1

Sweden

733

NCT02452125
(ClinicalTrials.gov)

May 2015

20/5/2015

The Effects of Nicotine Chewing Gum in Parkinson's Disease

The Effects of Nicotine Chewing Gum on Acute Low Blood Pressure in Parkinson's Disease

Low Blood Pressure;Parkinsons Disease

Dietary Supplement: Nicotine gum

New York Institute of Technology

NULL

Completed

N/A

All

N/A

United States

734

NCT02439125
(ClinicalTrials.gov)

May 2015

13/4/2015

A Study of Efficacy and Safety of Eltoprazine HCl for Treating Levodopa-induced Dyskinesia in Parkinson's Disease Patients

Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, 4-way Crossover, Dose-finding Study, of Eltoprazine Safety, Tolerability and Efficacy in the Treatment of Levodopa-induced Dyskinesia in Patients With Parkinson's Disease

Parkinson's Disease;Dyskinesia

Drug: Eltoprazine HCl;Drug: Placebo

Amarantus BioScience Holdings, Inc.

NULL

Active, not recruiting

30 Years

85 Years

Both

Phase 2

United States

735

NCT02604914
(ClinicalTrials.gov)

May 2015

3/11/2015

A Sequential Two-Part, Open-Label Study in Healthy Male and Female Subjects

1) To Identify the Concentration of CD That Provides Optimal Bioavailability of a Concomitant Fixed Concentration of LD Infused SC Continuously; 2) To Compare the Bioavailability of the Optimal LD/CD Solution to That of LD/CD Intestinal Gel

Parkinson's Disease

Drug: ND0612;Drug: LCIG

NeuroDerm Ltd.

Quotient Clinical

Completed

30 Years

65 Years

All

Phase 1

United Kingdom

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

736

NCT02439203
(ClinicalTrials.gov)

May 2015

30/4/2015

Efficacy and Safety of JM-010 in PD With Levodopa-Induced Dyskinesia

A Randomized, Double-blind, Placebo-controlled, 2-way Crossover Study in Subjects With Parkinson's Disease With Moderate to Severe Levodopa-induced Dyskinesia, to Assess the Efficacy, Safety/Tolerability and Pharmacokinetics of JM-010

Parkinson's Disease;Levodopa Induced Dyskinesia (LID)

Drug: JM -010;Drug: Placebo

Bukwang Pharmaceutical

Contera Pharma ApS

Completed

18 Years

N/A

Both

Phase 2

South Africa

737

EUCTR2014-003739-20-DE
(EUCTR)

23/04/2015

21/01/2015

A clinical trial to see if ADS-5102 is safe in people with drug induced abnormal movements in Parkinson's disease

Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa-Induced Dyskinesia

Treatment of levodopa-induced dyskinesia in subjects with Parkinson's disease
MedDRA version: 18.1;Level: PT;Classification code 10013916;Term: Dyskinesia;System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Adamas Pharmaceuticals, Inc.

NULL

Not Recruiting

Female: yes
Male: yes

250

Phase 3

France;United States;Spain;Austria;Germany

738

EUCTR2014-003738-24-DE
(EUCTR)

23/04/2015

21/01/2015

A clinical trial to see if ADS-5102 is safe and effective in people with drug induced abnormal movements in Parkinson's disease

ADS-5102 (Amantadine HCl) Extended Release Efficacy and Safety Study in Parkinson's Disease Patients with Levodopa-Induced Dyskinesia - EASE LID 3 STUDY

Treatment of levodopa-induced dyskinesia in subjects with Parkinson's disease
MedDRA version: 18.0;Level: PT;Classification code 10013916;Term: Dyskinesia;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Product Name: Amantadine HCl Extended Release Capsule
Product Code: ADS-5102
INN or Proposed INN: Amantadine hydrochloride (HCl)
Other descriptive name: AMANTADINE HYDROCHLORIDE

Adamas Pharmaceuticals, Inc.

NULL

Not Recruiting

Female: yes
Male: yes

Phase 3

United States;Spain;Austria;Germany

739

EUCTR2014-003799-22-DE
(EUCTR)

22/04/2015

04/12/2014

A study of the safety and drug effects of levodopa inhalation powder (CVT-301) compared to Standard of Care Observational Cohort in patients with Parkinson’s disease

Civitas Therapeutics, Inc.

NULL

Not Recruiting

Female: yes
Male: yes

408

Phase 3

Serbia;United States;Spain;Austria;Israel;United Kingdom;Italy;France;Czech Republic;Hungary;Belgium;Poland;Romania;Germany

740

EUCTR2014-002697-37-GB
(EUCTR)

15/04/2015

19/03/2015

Study of Melatonin for treatment of Nocturia in PD

Single-centre open label exploratory phase IIb pilot study of exogenous oral Melatonin for the treatment of Nocturia in adults with Parkinson’s disease - Study of Melatonin for treatment of Nocturia in PD

Parkinson's DiseaseNocturia
MedDRA version: 17.1;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders
MedDRA version: 17.1;Level: LLT;Classification code 10034007;Term: Parkinson's disease NOS;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Trade Name: Circadin ®
Product Name: Melatonin
Product Code: AS2
INN or Proposed INN: Melatonin

University College London

NULL

Not Recruiting

Female: yes
Male: yes

Phase 2

United Kingdom

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

741

JPRN-JapicCTI-152870

11/4/2015

14/04/2015

A parallel group comparison study of HP-3000 in patients with Parkinson's disease using L-DOPA

A phase III parallel group comparison study of HP-3000 in patients with Parkinson's disease using L-DOPA

Parkinson's disease

Intervention name : HP-3000 (ropinirole hydrochloride patch)
Dosage And administration of the intervention : Transdermal, once daily
Control intervention name : HP-3000 placebo
Dosage And administration of the control intervention : Transdermal, once daily
Control intervention name : Ropinirole hydrochloride extended-release tablet
Dosage And administration of the control intervention : Oral, once daily
Control intervention name : Ropinirole hydrochloride extended-release tablet placebo
Dosage And administration of the control intervention : Oral, once daily

Hisamitsu Pharmaceutical Co.,Inc.

NULL

BOTH

Phase 3

NULL

742

EUCTR2014-003739-20-FR
(EUCTR)

10/04/2015

19/06/2015

A clinical trial to see if ADS-5102 is safe in people with drug induced abnormal movements in Parkinson's disease

Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa-Induced Dyskinesia

Treatment of levodopa-induced dyskinesia in subjects with Parkinson's disease
MedDRA version: 18.0;Level: PT;Classification code 10013916;Term: Dyskinesia;System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Adamas Pharmaceuticals, Inc.

NULL

Not Recruiting

Female: yes
Male: yes

200

Phase 3

United States;France;Spain;Austria;Germany

743

JPRN-UMIN000017036

2015/04/03

03/04/2015

Association of ghrelin and leptin in cardiovascular autonomic dysfunction in patients with primary dysautonomia.

autonomic failure such as Parkinson's disease

blood test of Leptin and Ghrelin
blood test of Leptin and Ghrelin

Nagoya University Graduate School of Medicine

NULL

Complete: follow-up complete

40years-old

Not applicable

Male and Female

Not applicable

Japan

744

JPRN-UMIN000016734

2015/04/01

01/04/2015

The evaluation of duloxetine effect for the parkinsonism and gait freezing

Parkinson's disease

Drug ; Duloxetine
Duraion; SEP012014-AUG312016
Doseage; 20mg/day or 40mg/day
Times; one time per day P.O.

Department of Neurology, Juntendo University School of Medicine

NULL

Complete: follow-up complete

20years-old

85years-old

Male and Female

Not selected

Japan

745

JPRN-UMIN000016591

2015/04/01

20/02/2015

Clinical trial of balance exercise "Assist"

Stroke, Parkinson disease, Osteoarthrosis

use of balance exercise assist
ordinary balance exercise

Juntendo University

NULL

Complete: follow-up complete

20years-old

75years-old

Male and Female

Not applicable

Japan

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

746

NCT02390089
(ClinicalTrials.gov)

April 2015

19/2/2015

Cough According to Stimulus Type in PD

Airway Protection Deficits According to Stimulus Type in Parkinson's Disease

Parkinson's Disease

Drug: Capsaicin vapor;Other: fog;Radiation: Videofluoroscopic swallow evaluation;Device: Nebulizer

University of Florida

National Institute on Deafness and Other Communication Disorders (NIDCD)

Completed

50 Years

80 Years

All

158

Phase 1

United States

747

NCT02424708
(ClinicalTrials.gov)

April 2015

15/4/2015

Phase IIb Study of Intranasal Glutathione in Parkinson's Disease

Parkinson's Disease

Drug: Reduced Glutathione 100mg;Drug: Reduced Glutathione 200mg;Drug: Placebo

Bastyr University

Michael J. Fox Foundation for Parkinson's Research

Completed

21 Years

N/A

Both

Phase 2

United States

748

NCT02486432
(ClinicalTrials.gov)

April 2015

22/6/2015

A Single Period Investigation to Assess the Tolerability of Healthy Subjects to Oral Sinemet® (Levodopa/Carbidopa)

A Single Period Investigation to Assess the Tolerability of Healthy Subjects to Oral Sinemet® (Levodopa/Carbidopa) Doses Administered Using a Divided Dose Approach

Parkinson's Disease

Drug: Levodopa /Carbidopa (Sinemet)

NeuroDerm Ltd.

Quotient Clinical

Completed

40 Years

65 Years

Both

Phase 1

NULL

749

NCT02359448
(ClinicalTrials.gov)

April 2015

4/2/2015

Melatonin for Nocturia in Parkinson's Disease

Single-centre Open Label Exploratory Phase IIb Pilot Study of Exogenous Oral Melatonin for the Treatment of Nocturia in Adults With Parkinson's Disease

Parkinson's Disease;Nocturia

Drug: Melatonin

University College, London

NULL

Not yet recruiting

18 Years

N/A

Both

Phase 2

United Kingdom

750

EUCTR2014-003738-24-ES
(EUCTR)

24/03/2015

16/02/2015

A clinical trial to see if ADS-5102 is safe and effective in people with drug induced abnormal movements in Parkinson's disease

ADS-5102 (Amantadine HCl) Extended Release Efficacy and Safety Study in Parkinson's Disease Patients with Levodopa-Induced Dyskinesia - EASE LID 3 STUDY

Product Name: Amantadine HCl Extended Release Capsule
Product Code: ADS-5102
INN or Proposed INN: Amantadine hydrochloride (HCl)
Other descriptive name: AMANTADINE HYDROCHLORIDE

Adamas Pharmaceuticals, Inc.

NULL

Not Recruiting

Female: yes
Male: yes

Phase 3

United States;Spain;Austria;Germany

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

751

EUCTR2014-003739-20-ES
(EUCTR)

24/03/2015

16/02/2015

A clinical trial to see if ADS-5102 is safe in people with drug induced abnormal movements in Parkinson's disease

Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa-Induced Dyskinesia

Product Name: Amantadine HCl Extended Release Capsule
Product Code: ADS-5102
INN or Proposed INN: Amantadine hydrochloride (HCl)
Other descriptive name: AMANTADINE HYDROCHLORIDE

Adamas Pharmaceuticals, Inc.

NULL

Not Recruiting

Female: yes
Male: yes

200

Phase 3

United States;Spain;Austria;Germany

752

ChiCTR-DOD-15006097

2015-03-18

2015-03-16

The diagnostic value of olfactory-evoked potentials in Parkinson'sdisease

Parkinson's disease

Gold Standard:;Index test:;

Guangdong General Hospital, Guangdong Academy of Medical Sciences

NULL

Recruiting

Both

Target condition:0;Difficult condition:0

China

753

EUCTR2014-003799-22-BE
(EUCTR)

16/03/2015

16/12/2014

A study of the safety and drug effects of levodopa inhalation powder (CVT-301) compared to Standard of Care Observational Cohort in patients with Parkinson’s disease

Civitas Therapeutics, Inc.

NULL

Not Recruiting

Female: yes
Male: yes

365

Phase 3

Serbia;United States;Spain;Austria;Israel;United Kingdom;Italy;France;Czech Republic;Hungary;Belgium;Poland;Romania;Germany

754

JPRN-UMIN000016664

2015/03/01

01/03/2015

Effect of nicotine patch in Cognitive function improvement in Parkinson's disease

Parkinson's disease

nicotine patch

Department of Clinical Pharmacology and Neurology Ehime University graduated School of Medicine

NULL

Recruiting

Not applicable

Male and Female

Not selected

Japan

755

NCT02242487
(ClinicalTrials.gov)

March 2015

15/9/2014

Twelve Month Safety and Efficacy Study of CVT-301 In Parkinson's Disease Patients With OFF Episodes

A 12 Month, Dose-Level Blinded Study Investigating the Safety and Efficacy of CVT 301 (Levodopa Inhalation Powder) in Parkinson's Disease Patients With Motor Response Fluctuations (OFF Phenomena)

Idiopathic Parkinson's Disease

Drug: CVT-301

Acorda Therapeutics

NULL

Completed

30 Years

86 Years

All

325

Phase 3

United States;Canada;Czechia;Poland;Spain;Czech Republic

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

756

NCT02373072
(ClinicalTrials.gov)

March 2015

20/2/2015

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of PF-06649751 in Subjects With Idiopathic Parkinson's Disease

A Phase 1, Double Blind, Sponsor Open, Randomized, Placebo-controlled, Single Ascending Dose Study To Investigate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Pf-06649751 In Subjects With Idiopathic Parkinson's Disease

Idiopathic Parkinson Disease

Drug: PF-06649751;Drug: Trimethobenzamide Hydrochloride;Drug: Placebo

Pfizer

NULL

Completed

N/A

All

Phase 1

United States;Belgium

757

NCT02696603
(ClinicalTrials.gov)

March 2015

23/2/2016

Mobile Parkinson Observatory for Worldwide, Evidence-based Research (mPower)

Parkinson Disease;Neurodegenerative Diseases;Movement Disorders;Central Nervous System Diseases;Brain Diseases;Basal Ganglia Diseases;Parkinsonian Disorders

Behavioral: Participant self-assessment surveys;Behavioral: Phonation;Behavioral: Gait and balance;Behavioral: Memory;Behavioral: Dexterity;Behavioral: Participant open-response writing;Other: Parkinson mPower mobile application

Sage Bionetworks

Robert Wood Johnson Foundation

Recruiting

18 Years

N/A

All

20000

N/A

United States

758

NCT02352363
(ClinicalTrials.gov)

March 2015

26/1/2015

Randomized Safety Study of CVT-301 Compared to an Observational Control Group

A Phase 3, Randomized Study Investigating the Safety of CVT-301 (Levodopa Inhalation Powder) in Parkinson's Disease (PD) Patients With Motor Response Fluctuations (OFF Phenomena) Compared to an Observational Cohort Control

Idiopathic Parkinson's Disease

Drug: CVT-301;Other: Observational cohort

Acorda Therapeutics

NULL

Completed

30 Years

85 Years

All

408

Phase 3

United States;Austria;Belgium;Czechia;France;Germany;Hungary;Israel;Netherlands;Poland;Romania;Serbia;Spain;United Kingdom;Czech Republic;Italy

759

NCT02452606
(ClinicalTrials.gov)

March 2015

14/5/2015

Clock and Narcolepsy Genetic Variants and the Effects of Stalevo® (Levodopa/Carbidopa/Entacapone) on Sleep Disorders in Parkinson's Disease

Parkinson Disease;Sleep Disorders

Drug: Stalevo®

Asan Medical Center

NULL

Recruiting

20 Years

79 Years

Both

100

N/A

Korea, Republic of

760

NCT02393027
(ClinicalTrials.gov)

March 2015

6/3/2015

Quantification of Dopamine Active Transporter (DAT) in Humans: Validation of a New Radiophamaceutical, the [18F] LBT-999

Idiopathic Parkinson Disease

Drug: [18F] LBT-999 PET

University Hospital, Tours

NULL

Terminated

45 Years

75 Years

All

Early Phase 1

France

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

761

NCT02066571
(ClinicalTrials.gov)

March 2015

18/2/2014

Study to Assess the Clinical Benefit and Safety of Droxidopa in Parkinson's Disease

A Phase II, Double-Blind, Placebo-Controlled, Crossover Study to Assess Clinical Benefit and Safety of Droxidopa in the Treatment of Parkinson's Disease

Parkinson's Disease;Freezing of Gait;Cognitive Ability, General

Drug: Droxidopa;Drug: sugar pill

Henry Ford Health System

NULL

Enrolling by invitation

30 Years

N/A

Both

Phase 2

United States

762

EUCTR2014-003799-22-CZ
(EUCTR)

26/02/2015

26/11/2014

A study of the safety and drug effects of levodopa inhalation powder (CVT-301) compared to Standard of Care Observational Cohort in patients with Parkinson’s disease

Civitas Therapeutics, Inc.

NULL

Not Recruiting

Female: yes
Male: yes

408

Phase 3

Serbia;United States;Spain;Austria;Israel;United Kingdom;Italy;France;Czech Republic;Hungary;Belgium;Poland;Romania;Germany

763

JPRN-UMIN000016485

2015/02/25

09/02/2015

Pilot study about imaging method of 18F-fluoro-dopa and 11C-raclopride in Parkinson's disease and Parkinson's syndrome

Healthy subjects, Parkinson's disease patients and Parkinson's syndrome patients

Intravenous injection of 18F-fluoro-dopa and 11C-raclopride
PET imaging

Institute of Biomedical Research and Innovation

NULL

Complete: follow-up complete

35years-old

Not applicable

Male and Female

Not selected

Japan

764

EUCTR2014-003799-22-HU
(EUCTR)

11/02/2015

20/11/2014

A study of the safety and drug effects of levodopa inhalation powder (CVT-301) compared to Standard of Care Observational Cohort in patients with Parkinson’s disease

Parkinson's Disease With Motor Response Fluctuations (OFF Phenomena)
MedDRA version: 17.1;Level: LLT;Classification code 10034007;Term: Parkinson's disease NOS;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Civitas Therapeutics, Inc.

NULL

Not Recruiting

Female: yes
Male: yes

365

Phase 3

Serbia;Spain;Austria;Israel;United Kingdom;Italy;France;Hungary;Czech Republic;Belgium;Poland;Romania;Germany

765

NCT02337725
(ClinicalTrials.gov)

February 7, 2015

9/1/2015

A Phase 3 Study of TVP-1012 (1 mg) in Early Parkinson's Disease Patients

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of TVP-1012 at 1 mg in Early Parkinson's Disease Patients Not Treated With Levodopa

Parkinson's Disease

Drug: TVP-1012;Drug: Placebo

Takeda

NULL

Completed

30 Years

80 Years

All

244

Phase 3

Japan

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

766

NCT02337764
(ClinicalTrials.gov)

February 3, 2015

9/1/2015

A Long-term, Phase 3 Study of TVP-1012 (1 mg) in Levodopa Treated Parkinson's Disease Participants

A Multicenter, Open-label, Long-term, Phase 3 Study to Evaluate the Safety and Efficacy of TVP-1012 at 1 mg in Levodopa Treated Parkinson's Disease Patients

Parkinson's Disease

Drug: TVP-1012 1mg

Takeda

NULL

Completed

30 Years

79 Years

All

222

Phase 3

Japan

767

EUCTR2014-003799-22-ES
(EUCTR)

02/02/2015

16/12/2014

A study of the safety and drug effects of levodopa inhalation powder (CVT-301) compared to Standard of Care Observational Cohort in patients with Parkinson?s disease

A Phase 3, Randomized Study Investigating the Safety ofCVT-301 (Levodopa Inhalation Powder) in Parkinson?s DiseasePatients With Motor Response Fluctuations (OFF Phenomena)Compared to an Observational Cohort Control

Civitas Therapeutics, Inc.

NULL

Not Recruiting

Female: yes
Male: yes

365

Phase 3

Serbia;Spain;Austria;Israel;United Kingdom;Italy;France;Czech Republic;Hungary;Belgium;Poland;Romania;Germany

768

NCT02339064
(ClinicalTrials.gov)

February 2015

31/3/2014

Infusion of Apomorphine: Long-term Safety Study

A Phase 3, Open-Label Study of the Safety, Efficacy and Tolerability of Apomorphine Administered by Continuous Subcutaneous Infusion in Advanced Parkinson's Disease Patients With Unsatisfactory Control on Available Therapy

Idiopathic Parkinson's Disease

Drug: apomorphine infusion

US WorldMeds LLC

NULL

Active, not recruiting

30 Years

N/A

All

Phase 3

United States

769

NCT02409823
(ClinicalTrials.gov)

February 2015

1/4/2015

Clinical Registry of Patients Under Treatment With Atypical Antipsychotics

Schizophrenia;Major Depressive Disorder;Bipolar Depressive Disorder;Parkinson's Disease With Hallucinations

Drug: Atypical Antipsychotics

Pontifical Catholic University of Argentina

NULL

Completed

18 Years

N/A

Both

665

N/A

NULL

770

NCT02337738
(ClinicalTrials.gov)

January 27, 2015

9/1/2015

A Phase 2/3 Study of TVP-1012 at 0.5 mg or 1 mg in Levodopa Treated Parkinson's Disease Participants

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 2/3 Study to Evaluate the Efficacy and Safety of TVP-1012 at 0.5 mg or 1 mg in Levodopa Treated Parkinson's Disease Patients With Wearing Off

Parkinson's Disease

Drug: TVP-1012 1mg;Drug: TVP-1012 0.5mg;Drug: Placebo

Takeda

NULL

Completed

30 Years

79 Years

All

404

Phase 2;Phase 3

Japan

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

771

JPRN-JapicCTI-152762

27/1/2015

A long-term, Phase 3 Study of TVP-1012 (1 mg) in Levodopa Treated Parkinson's Disease Patients

A Multicenter, Open-label, Long-term, Phase 3 Study to Evaluate the Safety and Efficacy of TVP-1012 at 1 mg in Levodopa Treated Parkinson's Disease Patients

Parkinson's disease

Intervention name : TVP-1012 (1 mg/day) with levodopa
Dosage And administration of the intervention : TVP-1012 (1 mg/day) once daily, before or after breakfast. A levodopa combination drug will be concomitantly administered in principle without change in the dose regimen throughout the study period from the start of the screening period.
Control intervention name : null

TAKEDA PHARMACEUTICAL COMPANY LTD.

NULL

BOTH

215

Phase 3

NULL

772

EUCTR2014-003799-22-GB
(EUCTR)

15/01/2015

21/11/2014

A study of the safety and drug effects of levodopa inhalation powder (CVT-301) compared to Standard of Care Observational Cohort in patients with Parkinson’s disease

A Phase 3, Randomized Study Investigating the Safety of CVT-301 (Levodopa Inhalation Powder) in Parkinson’s Disease Patients With Motor Response Fluctuations (OFF Phenomena) Compared to an Observational Cohort Control

Parkinson's Disease With Motor Response Fluctuations (OFF Phenomena)
MedDRA version: 18.1;Level: LLT;Classification code 10034007;Term: Parkinson's disease NOS;System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Civitas Therapeutics, Inc.

NULL

Not Recruiting

Female: yes
Male: yes

365

Phase 3

Serbia;United States;Spain;Austria;Israel;United Kingdom;Italy;France;Czech Republic;Hungary;Belgium;Poland;Romania;Germany

773

NCT02406105
(ClinicalTrials.gov)

January 2015

22/2/2015

An Effectiveness and Toxicity of CyberKnife Based Radiosurgery for Parkinson Disease

An Evaluation of Effectiveness and Toxicity of CyberKnife Based Functional Radiosurgery for Parkinson Disease Patients Suffering From Tremor and Its Implementation in Poland

Parkinson Disease

Radiation: Radiosurgical thalamotomy;Drug: CyberKnife

Maria Sklodowska-Curie Memorial Cancer Center, Institute of Oncology

NULL

Recruiting

18 Years

N/A

Both

Phase 2

Poland

774

NCT02763137
(ClinicalTrials.gov)

January 2015

26/4/2016

Intermittent Oral Administration vs. Semi-continuous Intra-oral Administration of Levodopa/Carbidopa in Fluctuating Parkinsonian Patients

A Phase IIa Study to Assess the Safety, Tolerability, Plasma Pharmacokinetics and Efficacy of Intermittent Oral Administration of Standard Levodopa/Carbidopa vs. Semi-continuous Intra-oral Administration of Levodopa/Carbidopa in Patients With Advanced Parkinson's Disease Who Suffer Motor Fluctuations

Parkinson Disease

Drug: Standard LD/CD;Drug: Semi continuous intra-oral administration of LD/CD

IRCCS San Raffaele

SynAgile Corporation

Completed

35 Years

75 Years

Both

Phase 2

Italy

775

NCT02347059
(ClinicalTrials.gov)

January 2015

20/1/2015

L-dopa Versus Dopamine Agonists After Subthalamic Nucleus Deep Brain Stimulation in Parkinson's Disease

A Randomized, Single-blind Trial on the Efficacy and Safety of L-dopa Monotherapy Versus Dopamine Agonists Monotherapy After Subthalamic Nucleus Deep Brain Stimulation in Parkinson's Disease

Parkinson's Disease

Drug: L-dopa;Drug: Dopamine Agonists (pramipexole, ropirinole)

University of Toronto

Michael J. Fox Foundation for Parkinson's Research

Recruiting

N/A

Both

Phase 2

Canada

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

776

NCT02258152
(ClinicalTrials.gov)

December 22, 2014

3/10/2014

SYN120 Study to Evaluate Its Safety, Tolerability and Efficacy in Parkinson's Disease Dementia (SYNAPSE)

SYN120 a Dual 5-HT6/5-HT2A Antagonist Proof of Concept Study to Evaluate Its Safety, Tolerability and Efficacy in Parkinson's Disease Dementia (SYNAPSE)

Parkinson's Disease Dementia (PDD)

Drug: SYN120;Drug: Placebo

Biotie Therapies Inc.

Michael J. Fox Foundation for Parkinson's Research;Massachusetts General Hospital;Acorda Therapeutics

Completed

50 Years

N/A

All

Phase 2

United States

777

EUCTR2014-004501-32-NL
(EUCTR)

11/12/2014

03/12/2014

Treatment in Advanced Parkinson's disease: a cost-effectiveness analysis of two different treatments

Infusion VErsus STimulation, a cost-effectiveness analysis of the treatment in advanced Parkinson's diseasecomparing Continuous Intrajejunal Levodopa Infusion to the traditional standard treetment Deep BrainStimulation; - INVEST (INfusion VErsus STimulation)

Patients with advanced PD who's motor symptoms — severe responsefluctuations, dyskinesias, painful dystonia and / or bradykinesia —cannot be controlled despite optimal oral pharmacological therapy.;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Trade Name: Duodopa, levodopa 20 mg/ml + carbidopa 5 mg/ml, intestinal gel

Academic Medical Center

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

Netherlands

778

JPRN-JapicCTI-142748

11/12/2014

16/12/2014

Long-term study of HP-3000 in patients with Parkinson's disease

A phase III long-term study of HP-3000 in patients with Parkinson's disease

Parkinson's disease

Intervention name : HP-3000(ropinirole hydrochloride patch)
Dosage And administration of the intervention : Transdermal, once daily

Hisamitsu Pharmaceutical Co.,Inc.

NULL

BOTH

Phase 3

NULL

779

NCT02267434
(ClinicalTrials.gov)

December 2014

4/9/2014

Study Assessing Tolerability and Safety of AFFITOPE® PD03A in Patients With Early Parkinson's Disease

A Randomized, Placebo-controlled, Parallel Group, Patient-blinded, Multi-center, Phase I Pilot Study to Assess Tolerability and Safety of Two Doses of AFFITOPE® PD03A Formulated With Adjuvant to Patients With Early Parkinson's Disease

Parkinson Disease;Neurodegenerative Diseases

Biological: Low dose AFFITOPE® PD03A + Adjuvant;Biological: High dose AFFITOPE® PD03A + Adjuvant;Biological: Adjuvant without active component

Affiris AG

PROSENEX AmbulatoriumbetriebsGMBH;Medical University Innsbruck;Forschungszentrum Juelich

Completed

45 Years

70 Years

Both

Phase 1

Austria

780

NCT02480803
(ClinicalTrials.gov)

December 2014

4/5/2015

INfusion VErsus STimulation in Parkinson's Disease

Treatment in Advanced Parkinson's Disease: Continuous Intrajejunal Levodopa INfusion VErsus Deep Brain STimulation

Parkinson's Disease

Drug: Continuous intrajejunal infusion of levodopa-carbidopa;Device: deep brain stimulation

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

ZonMw: The Netherlands Organisation for Health Research and Development

Recruiting

18 Years

N/A

All

Phase 4

Netherlands

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

781

NCT02324426
(ClinicalTrials.gov)

December 2014

4/12/2014

CNS Uptake of Intranasal Glutathione

Central Nervous System Uptake of Intranasal Glutathione in Parkinson's Disease

Parkinson's Disease

Drug: Reduced Glutathione

University of Washington

Michael J. Fox Foundation for Parkinson's Research

Completed

18 Years

N/A

Both

Phase 1

United States

782

NCT03116308
(ClinicalTrials.gov)

November 21, 2014

12/4/2017

Effect of Food on Opicapone

Effect of Food on Opicapone Bioavailability and Pharmacodynamics in Healthy Subjects

Parkinson Disease

Drug: Opicapone (OPC)

Bial - Portela C S.A.

NULL

Completed

18 Years

45 Years

All

Phase 1

NULL

783

EUCTR2014-001132-10-FR
(EUCTR)

18/11/2014

18/06/2015

A 26 Week Clinical Study to Evaluate the Use of Long-Acting Amantadine to Treat Parkinson’s Disease Patients with Abnormal Involuntary Movements caused by Levodopa

A Multicenter, Randomized, Placebo-controlled, Double-blind, 26 Week Study to Evaluate the Efficacy and Safety of Amantadine HCl Extended Release Tablets in Parkinson’s Disease Subjects with Levodopa-Induced Dyskinesias

Parkinson’s Disease Subjects with Levodopa-Induced Dyskinesias
MedDRA version: 18.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Product Name: Amantadine HCl Extended Release
INN or Proposed INN: Amantadine hydrochloride
Other descriptive name: AMANTADINE HYDROCHLORIDE
Product Name: Amantadine HCl Extended Release
INN or Proposed INN: Amantadine hydrochloride
Other descriptive name: AMANTADINE HYDROCHLORIDE
Product Name: Amantadine HCl Extended Release
INN or Proposed INN: Amantadine hydrochloride
Other descriptive name: AMANTADINE HYDROCHLORIDE

Osmotica Pharmaceutical Corp.

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

162

United States;France;Canada;Spain;Germany

784

ChiCTR-DDD-17010794

2014-11-08

2017-03-05

The study on early diagnosis of Parkinson 's disease by transcranial ultrasonography

the study on early diagnosis of Parkinson 's disease by transcranial ultrasonography

Parkinson's Disease

Gold Standard:Diagnosis of Parkinson disease needs to meet 3 or more: unilateral onset;resting tremor;progressive course; long term asymmetry, the most obvious symptoms is the onset side; a good response to levodopa (70% ~ 100%); levodopa induced chorea; a reaction of levodopa lasts 5 years or more; clinical course last;Index test:Laboratory apparatus
As shown in Figure 1, The ultrasound equipment, Philips IE33-BOMJH1 color Doppler ultrasonography, Model IE-ELite, with 2-4MHz phased array probe (S5-1 probe) was used for TCS to examine SN in our study.
Transcranial ultrasound study
Ultrasonography through temporal window, alon;

Department of Neurology, Fujian Institute of Geriatrics, Fujian Medical University Union Hospital

NULL

Completed

Both

Target condition:135;Difficult condition:0

China

785

JPRN-JapicCTI-142702

01/11/2014

12/11/2014

A Phase 1 Study of ONO-2160/CD

A Phase 1 study on single and multiple oral dose administration of ONO-2160/CD in healthy adult male subjects and on multiple oral dose administration of ONO-2160/CD in Parkinson's disease patients

Parkinson's disease

Intervention name : ONO-2160/CD
Dosage And administration of the intervention : Oral administration
Control intervention name : Levodopa /carbidopa hydrate
INN of the control intervention : Levodopa /carbidopa hydrate
Dosage And administration of the control intervention : Oral administration

ONO PHARMACEUTICAL CO.,LTD.

NULL

BOTH

Phase 1

NULL

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

786

NCT02240030
(ClinicalTrials.gov)

November 2014

11/9/2014

Efficacy and Safety Study of CVT-301 In Parkinson's Disease Patients With OFF Episodes

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Investigating the Efficacy and Safety of CVT 301 (Levodopa Inhalation Powder) in Parkinson's Disease Patients With Motor Response Fluctuations (OFF Phenomena) (SPAN-PD™)

Idiopathic Parkinson's Disease

Drug: CVT-301 Low Dose;Drug: CVT-301 High Dose;Other: Placebo

Acorda Therapeutics

NULL

Completed

30 Years

85 Years

All

351

Phase 3

United States;Canada;Czechia;Poland;Spain;Czech Republic

787

NCT02168842
(ClinicalTrials.gov)

November 2014

18/6/2014

Efficacy of Isradipine in Early Parkinson Disease

Phase 3 Double-blind Placebo-controlled Parallel Group Study of Isradipine as a Disease Modifying Agent in Subjects With Early Parkinson Disease

Parkinson Disease

Drug: Isradipine;Drug: Placebo (for Isradipine)

University of Rochester

National Institute of Neurological Disorders and Stroke (NINDS);Michael J. Fox Foundation for Parkinson's Research;The Parkinson Study Group

Completed

30 Years

N/A

All

336

Phase 3

United States;Canada

788

NCT02278588
(ClinicalTrials.gov)

November 2014

28/10/2014

Effect of 2.5 Years of Rasagiline Therapy on Progression of Cognitive Biomarkers Assessed by MRI in Parkinson's Disease.

Parkinson's Disease

Drug: Rasagiline

Thomas Guttuso

NULL

Completed

N/A

All

United States

789

NCT02281474
(ClinicalTrials.gov)

November 2014

27/10/2014

Nilotinib in Cognitively Impaired Parkinson Disease Patients 001

Open Label Dose Escalation of Nilotinib in Cognitively Impaired Parkinson Disease Patients With Elevated Cerebrospinal Fluid and Blood a-Synuclein

Parkinson's Disease;Parkinson's Disease Dementia;Diffuse Lewy Body Disease

Drug: Nilotinib

Georgetown University

NULL

Completed

40 Years

90 Years

Both

Phase 1

United States

790

NCT02312232
(ClinicalTrials.gov)

November 2014

2/12/2014

Pharmacokinetic Study in Healthy Males

Pharmacokinetics of Levodopa, Carbidopa, 3-OMD and ODM-104 After Repeated Doses of Different Formulations: an Open, Randomised, Multicentre Study With Crossover Design in Healthy Males

Parkinson's Disease

Drug: levodopa , carbidopa, ODM-104

Orion Corporation, Orion Pharma

NULL

Completed

18 Years

65 Years

Male

Phase 1

Finland

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

791

EUCTR2014-000335-17-GB
(EUCTR)

28/10/2014

23/07/2014

Rotigotine and memory in Parkinson's.

The Effect of Rotigotine on Memory in Idiopathic Parkinson's Disease without Cognitive Impairment - Rotigotine and Memory in Parkinson's.

Idiopathic Parkinson's Disease;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Product Name: rotigotine
INN or Proposed INN: Rotigotine
Product Name: levodopa CR (controlled release)
INN or Proposed INN: levodopa
Product Name: Rasagiline
INN or Proposed INN: Rasagiline
Product Name: Selegiline
INN or Proposed INN: selegiline

Research and Development University Hospital of North Staffordshire

Keele University

Not Recruiting

Female: yes
Male: yes

United Kingdom

792

EUCTR2014-001132-10-ES
(EUCTR)

23/10/2014

02/09/2014

A 26 Week Clinical Study to Evaluate the Use of Long-Acting Amantadine to Treat Parkinson's Disease Patients with Abnormal Involuntary Movements caused by Levodopa

A Multicenter, Randomized, Placebo-controlled, Double-blind, 26 Week Study to Evaluate the Efficacy and Safety of Amantadine HCl Extended Release Tablets in Parkinson's Disease Subjects with Levodopa-Induced Dyskinesias

Parkinson's Disease Subjects with Levodopa-Induced Dyskinesias
MedDRA version: 17.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Osmotica Pharmaceutical Corp.

NULL

Not Recruiting

Female: yes
Male: yes

162

Phase 3

France;United States;Canada;Spain;Germany

793

EUCTR2014-001131-36-ES
(EUCTR)

23/10/2014

03/09/2014

A 16 Week Clinical Study to Evaluate the Use of Long-Acting Amantadine to Treat Parkinson's Disease Patients with Abnormal Involuntary Movements caused by Levodopa

A Multicenter, Randomized, Placebo-controlled, Double-blind, 16 Week Study to Evaluate the Efficacy and Safety of Amantadine HCl Extended Release Tablets in Parkinson's Disease Subjects with Levodopa-Induced Dyskinesias

Osmotica Pharmaceutical Corp.

NULL

Not Recruiting

Female: yes
Male: yes

162

Phase 3

France;United States;Canada;Spain;Germany

794

EUCTR2014-002295-87-IT
(EUCTR)

13/10/2014

29/09/2014

A Phase IIa study to assess the safety, tolerability, plasma pharmacokinetics and efficacy of intermittent oral administration of standard levodopa/carbidopa vs. semi-continuous intra-oral administration of levodopa/carbidopa in patients with advanced Parkinson’s disease who suffer motor fluctuations.

Parkinson's disease patients who suffer motor fluctuations willparticipate in the study
MedDRA version: 17.0;Level: SOC;Classification code 10029205;Term: Nervous system disorders;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Trade Name: SINEMET 100 mg + 25 mg compresse
Product Name: SINEMET 100 mg + 25 mg compresse
Product Code: NA

SynAgile Corporation

NULL

Not Recruiting

Female: yes
Male: yes

Phase 2

Italy

795

NCT02224664
(ClinicalTrials.gov)

October 2014

15/8/2014

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-06649751 in Parkinson`s Disease

A Phase 1b, 2-period, Open Label, Multicenter, Dose Escalation Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Pf-06649751 In Subjects With Parkinson`s Disease And Motor Fluctuations

Parkinson`s Disease

Drug: PF-06649751

Pfizer

NULL

Completed

30 Years

80 Years

All

Phase 1

United States;Belgium

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

796

NCT02274324
(ClinicalTrials.gov)

October 2014

22/10/2014

Dietary Modifications Effect on Continuous LCIG Infusion Outcomes in Patients With Advanced Parkinson&Apos;s Disease

Dietary Modifications Effect on Continuous LCIG Infusion Outcomes in Patients With Advanced Parkinson's Disease

Parkinson Disease

Dietary Supplement: different diets

Sheba Medical Center

Tel Aviv University

Not yet recruiting

40 Years

80 Years

Both

N/A

NULL

797

NCT02183519
(ClinicalTrials.gov)

October 2014

2/7/2014

Respiratory Kinematics of Cough in Healthy Older Adults and Parkinson's Disease

Respiratory Kinematics of Reflex and Voluntary Cough in Healthy Older Adults and Parkinson's Disease

Cough;Parkinson's Disease

Drug: Capsaicin;Other: Voluntary cough test

University of Florida

NULL

Completed

55 Years

85 Years

All

Phase 1;Phase 2

United States

798

NCT02259049
(ClinicalTrials.gov)

October 2014

3/10/2014

The Effects of L-Tyrosine on 24 Hour Blood Pressure and Heart Rate in Parkinson's Disease

The Effects of L-Tyrosine on Non-invasive Ambulatory Blood Pressure and Heart Rate Monitoring in Parkinson's Disease

Blood Pressure

Dietary Supplement: L-tyrosine;Dietary Supplement: Sugar Pill

New York Institute of Technology

NULL

Completed

40 Years

84 Years

Both

Phase 0

United States

799

NCT02274766
(ClinicalTrials.gov)

October 2014

22/10/2014

Efficacy and Safety Study of ADS-5102 in PD Patients With Levodopa-Induced Dyskinesia

ADS-5102 (Amantadine HCl) Extended Release Efficacy and Safety Study in Parkinson's Disease Patients With Levodopa-Induced Dyskinesia (EASE LID 3 Study)

Dyskinesia;Levodopa-Induced Dyskinesia (LID);Parkinson's Disease (PD)

Drug: ADS-5102;Other: Placebo

Adamas Pharmaceuticals, Inc.

NULL

Completed

30 Years

85 Years

All

Phase 3

United States;Austria;France;Germany;Spain

800

JPRN-UMIN000016893

2014/09/22

01/04/2015

A double-blind, randomized clinical trial to evaluate the efficacy of Duloxetine against pain associated with Parkinson's disease with depression.

A double-blind, randomized clinical trial to evaluate the efficacy of Duloxetine against pain associated with Parkinson's disease with depression. - Pain reduction in PD patients with depression: double blind, randomized clinical trial of duloxetine.

PD patients

The treatment groups consist of an active treatment arm (40mg/day Duloxetine) and a placebo arm. During the Titration Period (2 weeks), all subjects will be started on 1 capsule (10mg or placebo). During the Maintenance Period (10 weeks), subjects will take 2 capsules. Subjects who are unable to increase their dose can stay at 1 capsule.
The treatment groups consist of an active treatment arm (40mg/day Duloxetine) and a placebo arm. During the Titration Period (2 weeks), all subjects will be started on 1 capsule (10mg or placebo). During the Maintenance Period (10 weeks), subjects will take 2 capsules. Subjects who are unable to increase their dose can stay at 1 capsule.

Ehime University HospitalDept. of Clinical pharmacology and Neurology

NULL

Complete: follow-up complete

20years-old

Not applicable

Male and Female

Phase 2

Japan

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

801

NCT02236260
(ClinicalTrials.gov)

September 3, 2014

29/8/2014

Evaluation of the Benefit Provided by Acupuncture During a Surgery of Deep Brain Stimulation

Evaluation of the Benefit Provided by the Addition of Acupunctural Analgesia With Electrostimulation to Conventional Local Anesthesia Compared to Conventional Local Anesthesia Alone in Surgery of Deep Brain Stimulation for Movement Disorders.

Parkinson's Disease

Procedure: Electroacupuncture;Drug: Local Anesthesia (lidocaine hydrochloride)

Nantes University Hospital

NULL

Completed

18 Years

74 Years

All

N/A

France

802

NCT03151460
(ClinicalTrials.gov)

September 2014

9/5/2017

Dopaminergic Modulation of Declarative Memory

Parkinson's Disease

Drug: Dopamine Agent

I.R.C.C.S. Fondazione Santa Lucia

NULL

Completed

N/A

All

Phase 4

Italy

803

NCT02212678
(ClinicalTrials.gov)

September 2014

4/8/2014

Repeated-Dose Oral N-acetylcysteine for the Treatment of Parkinson's Disease

Parkinson Disease

Drug: N-acetylcysteine capsule

University of Minnesota

Parkinson's Disease Society of the United Kingdom

Completed

18 Years

N/A

All

Phase 2

United States

804

NCT02777060
(ClinicalTrials.gov)

September 2014

8/6/2015

Exploring the Effectiveness of Sensor-based Balance Training on Patient Outcome Measures

Diabetes;Cancer;Multiple Sclerosis;Arthritis;Parkinson's Disease;Cognitive Disorders;Brain Injury;Stroke

Procedure: Exergame;Procedure: Home based balance training

University of Arizona

NULL

Recruiting

18 Years

N/A

Both

200

N/A

United States

805

NCT02230904
(ClinicalTrials.gov)

September 2014

29/8/2014

A Study to Compare the Adhesiveness of 2 Different Rotigotine Patches Used for the Treatment of Parkinson's Disease

A Multicenter, Randomized, Double-blind, 2-way Cross-over Study to Compare the Adhesiveness of 2 Different Rotigotine Patch Formulations in Subjects With Parkinson's Disease

Parkinson's Disease

Drug: Rotigotine (Test product PR 2.3.1);Drug: Rotigotine (Reference product PR 2.1.1)

UCB BIOSCIENCES GmbH

Pharmaceutical Health Sciences;Bracket Global

Completed

18 Years

N/A

All

Phase 1

Germany

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

806

NCT02225548
(ClinicalTrials.gov)

September 2014

22/8/2014

Sagene 2014 - Parkinson's Disease and Erectile Dysfunction

An Open-label Trial of Oral Selegiline 5 or 10 mg and Tadalafil 2.5mg Co-administration to Male Patients With Parkinson's Disease and Moderate Erectile Dysfunction.

Parkinson's Disease;Erectile Dysfunction

Drug: Selegiline;Drug: Tadalafil

University of South Florida

NULL

Recruiting

40 Years

64 Years

Male

Phase 4

United States

807

NCT02256319
(ClinicalTrials.gov)

September 2014

30/9/2014

Dexmedetomidine vs Propofol on the Recordings of Deep Brain Activity Measured Through Implanted Stimulators

Effects of Dexmedetomidine vs Propofol on the Recordings of Deep Brain Activity (Local Field Potentials) Measured Through Implanted Stimulators

Parkinson's Disease

Drug: Dexmedetomidine;Drug: Propofol

Clinica Universidad de Navarra, Universidad de Navarra

NULL

Completed

18 Years

N/A

Both

Phase 4

Spain

808

NCT02228590
(ClinicalTrials.gov)

August 31, 2014

26/8/2014

A Study to Examine APL-130277 in Patients With Parkinson's Disease

A Phase 2 Study to Examine the Safety, Tolerability and Efficacy of APL-130277 in Patients With Parkinson's Disease

Parkinson's Disease

Drug: APL-130277

Sunovion

NULL

Completed

18 Years

80 Years

All

Phase 2

United States

809

ChiCTR-TRC-14005143

2014-08-25

2014-08-14

A traditional chinese medicine clinical intervention study of depressed Parkinson's disease - based on the Wenyang Jieyu method

A traditional chinese medicine clinical intervention study of depressed Parkinson's disease - based on the Wenyang Yieyu method

Depressed Parkinson's disease

Chinese Medicines:Formula granule;Western Medicine group:Venlafaxine hydrochloride sustained-release capsules ;

The Third Affiliated Hospital of Beijing University of Traditional Chinese Medicine

NULL

Recruiting

Both

Chinese Medicines:60;Western Medicine group:60;

2 (Phase 2 study)

China

810

NCT02153645
(ClinicalTrials.gov)

August 18, 2014

30/5/2014

Efficacy and Safety of Amantadine Hydrochloride (HCl) ER Tablets to Treat Parkinson's Disease Patients With LID.

Parkinson's Disease;Levodopa Induced Dyskinesias (LID)

Drug: 240mg Amantadine HCl ER tablets;Drug: Placebo tablets;Drug: 320mg Amantadine HCl ER tablets

Osmotica Pharmaceutical US LLC

NULL

Terminated

30 Years

85 Years

All

Phase 3

United States;Canada;France;Germany;Spain

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

811

NCT02096601
(ClinicalTrials.gov)

August 2014

18/3/2014

A Pharmacokinetic Study of ND0612 Delivered as a Continuous Subcutaneous in Parkinson's Disease Patients

A Phase I/II Pharmacokinetic (PK) Study of ND0612, a Liquid Formulation of Levodopa/Carbidopa (LD/CD), Delivered as a Continuous Subcutaneous in Parkinson's Disease (PD) Patients Treated With LD

Parkinson's Disease

Drug: Levodopa and carbidopa SC solution;Drug: Oral levodopa and carbidopa

NeuroDerm Ltd.

Michael J. Fox Foundation for Parkinson's Research

Completed

30 Years

80 Years

All

Phase 1;Phase 2

United States;Israel

812

NCT02216188
(ClinicalTrials.gov)

August 2014

12/8/2014

Follow-up Study to Assess One Boost Immunization With AFFITOPE® PD01A With Regard to Safety and Clinical Activity

Phase IB Follow-up, Randomized, Controlled, Parallel Group, Patient-blinded, Single-center Study to Assess One Boost With AFFITOPE® PD01A With Regard to Safety/Tolerability, Immunological + Clinical Activity in Patients Who Have Received the Vaccine Within the Study AFF008

Parkinson's Disease

Biological: AFFITOPE® PD01A;Other: Control

Affiris AG

NULL

Completed

40 Years

68 Years

Both

Phase 1

Austria

813

NCT02438215
(ClinicalTrials.gov)

August 2014

7/8/2014

Study of IRX4204 for Treatment of Early Parkinson's Disease

An Open-Label, Single Site Study Using [123I]ß-CIT Single Photon Emission Tomography (SPECT) to Evaluate Dopamine Transporter Binding Following Treatment With IRX4204 in Early Parkinson's Disease Subjects

Parkinson's Disease

Drug: IRX4204

Io Therapeutics

NULL

Completed

18 Years

N/A

Both

Phase 1

United States

814

NCT02236065
(ClinicalTrials.gov)

August 2014

8/9/2014

Combination Therapy of Cord Blood and G-CSF for Patients With Brain Injury or Neurodegenerative Disorders

A Pilot Study of Combination Therapy of Allogeneic Umbilical Cord Blood and Granulocyte-colony Stimulating Factor for Patients With Brain Injury or Neurodegenerative Disorders

Brain Injury;Cerebral Palsy;Amyotrophic Lateral Sclerosis;Parkinson's Disease

Procedure: Umbilical cord blood therapy;Biological: Filgrastim

MinYoung Kim, M.D.

NULL

Completed

19 Years

75 Years

All

N/A

Korea, Republic of

815

NCT02230267
(ClinicalTrials.gov)

August 2014

27/8/2014

High-intensity Exercise and Fall Prevention Boot Camp for Parkinson's Disease

Parkinson's Disease

Other: High intensity exercise and balance training;Other: Usual care arm exercise

University of Nevada, Las Vegas

NULL

Completed

45 Years

85 Years

Both

Phase 2

United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

816

NCT02153632
(ClinicalTrials.gov)

July 30, 2014

30/5/2014

Efficacy and Safety of Amantadine Hydrogen Chloride (HCl) ER Tablets in Parkinson's Disease Subjects With LID

Parkinson's Disease;Levodopa Induced Dyskinesia (LID)

Drug: amantadine HCl ER;Drug: Placebo

Osmotica Pharmaceutical US LLC

NULL

Terminated

30 Years

85 Years

All

135

Phase 3

United States;Canada;France;Germany;Spain

817

JPRN-UMIN000014709

2014/07/01

01/08/2014

Study on Parkinson's disease and related disorders with dopamine transporter ligand [C-11]PE2I

Study on Parkinson's disease and related disorders with dopamine transporter ligand [C-11]PE2I - DAT PET with [C-11]PE2I in PD and related disorders

Patients of Parkinson's disease and related disorders

The dosage in the vein of [C-11]PE2I, [C-11]raclopride, and [F-18]FDG for PET/CT imaging.

Tokyo Metropolitan Institute of Gerontology

NULL

Complete: follow-up complete

18years-old

Not applicable

Male and Female

200

Not selected

Japan

818

NCT02472210
(ClinicalTrials.gov)

July 2014

11/6/2015

The Use of Botox in Advanced Parkinson's Patients Experiencing Pain

A Study of the Utility of Botulinum Toxin Type A for Pain in Advanced Parkinson's Disease Double Blind Placebo Control Crossover Pilot Study

Parkinson's Disease

Drug: Botulinum Toxin

University Health Network, Toronto

NULL

Active, not recruiting

18 Years

N/A

Both

Phase 4

NULL

819

NCT02206620
(ClinicalTrials.gov)

July 2014

29/7/2014

Effects of Cholinergic Augmentation on Measures of Balance and Gait

Parkinson's Disease

Drug: Donepezil

Oregon Health and Science University

Michael J. Fox Foundation for Parkinson's Research

Completed

30 Years

N/A

All

Phase 2

United States

820

NCT02202551
(ClinicalTrials.gov)

July 2014

25/7/2014

Open-Label Safety Study of ADS-5102 in PD Patients With LID

Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID)

Dyskinesia;Levodopa Induced Dyskinesia (LID);Parkinson's Disease (PD)

Drug: ADS-5102

Adamas Pharmaceuticals, Inc.

NULL

Completed

30 Years

85 Years

All

223

Phase 3

United States;Austria;Canada;France;Germany;Spain

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

821

NCT02138682
(ClinicalTrials.gov)

July 2014

24/4/2014

Validation of DaTscan for Detection of Parkinson Disease Related Disorders

Validation of DaTscan for Detection of Parkinsonian Disease and Related Disorders Using Neuropathologically-confirmed Parkinson Disease From Human Brain Tissue

Parkinson Disease;Movement Disorders

Drug: l-123 Ioflupane

Wisconsin Institute for Neurologic and Sleep Disorders S.C.

Wisconsin Parkinson Association;Medical College of Wisconsin;GE Healthcare

Enrolling by invitation

75 Years

N/A

Both

United States

822

EUCTR2014-000868-17-ES
(EUCTR)

26/06/2014

17/03/2014

Effect of dexmedetomidine vs propofol on basal ganglia activity (local field potentials) recorded through implanted stimulators

Parkinson's disease
MedDRA version: 16.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's;System Organ Class: 100000004852;Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Anesthesia and Analgesia [E03]

Trade Name: Dexdor
Product Name: Dexdor
INN or Proposed INN: DEXMEDETOMIDINE
Other descriptive name: DEXMEDETOMIDINA
Trade Name: Propofol -Lipuro
Product Name: Propofol -Lipuro
INN or Proposed INN: PROPOFOL
Other descriptive name: PROPOFOL

Clínica Universidad de Navarra/Universidad de Navarra

NULL

Not Recruiting

Female: yes
Male: yes

Spain

823

ChiCTR-TRC-14004707

2014-06-09

2014-05-27

The effect of different patterns of rehabilitation training in idiopathic Parkinson's disease

Parkinson's disease

Tai Chi group:Tai Chi;Balance function training group:Balance function training;

Shanghai Tongji Hospital

NULL

Completed

Both

Tai Chi group:30;Balance function training group:30;

China

824

EUCTR2013-000980-10-DK
(EUCTR)

06/06/2014

09/01/2014

Clinical trial of apomorphine subcutaneous infusion in patients with advanced Parkinson’s disease

TOLEDO Multicenter, parallel-group, double-blind, placebo-controlled phase III study to evaluate the efficacy and safety of apomorphine subcutaneous infusion in Parkinson’s disease patients with motor complications not well controlled on medical treatment - TOLEDO

Parkinson Disease (PD) in patients with motor fluctuations not well controlled on medical treatment
MedDRA version: 18.0;Level: LLT;Classification code 10034006;Term: Parkinson's disease aggravated;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Trade Name: Apo-go®
Product Name: Apomorphine hydrochloride
Product Code: Apo-go®
INN or Proposed INN: Apomorphine hydrochloride
Other descriptive name: Apomorphine hydrochloride

Britannia Pharmaceuticals Limited

NULL

Not Recruiting

Female: yes
Male: yes

102

Phase 3

France;Spain;Austria;Denmark;Netherlands;Germany

825

NCT02157714
(ClinicalTrials.gov)

June 2014

4/6/2014

Multiple Ascending Dose Study of PRX002 in Patients With Parkinson's Disease

A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study of PRX002 Administered By Intravenous Infusion in Patients With Parkinson's Disease

Parkinson's Disease

Drug: PRX002;Other: Placebo

Prothena Biosciences Limited

Hoffmann-La Roche

Completed

40 Years

80 Years

Both

Phase 1

United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

826

NCT01971242
(ClinicalTrials.gov)

June 2014

23/10/2013

Trial of Exenatide for Parkinson's Disease

A Randomised, Double Blind, Placebo Controlled, Single Centre, 60 Week Trial of Exenatide Once Weekly for the Treatment of Moderate Severity Parkinson's Disease

Parkinson's Disease

Drug: Exenatide;Other: Placebo

University College, London

NULL

Completed

25 Years

75 Years

Both

Phase 2

United Kingdom

827

NCT02174250
(ClinicalTrials.gov)

June 2014

24/6/2014

The Effect of Rifampin on the Metabolism of Istradefylline in Healthy Volunteers.

Effect of a Strong Enzyme Inducer, Rifampin, on the Single-Dose Pharmacokinetics of Istradefylline in Healthy Subjects

Parkinson's Disease

Drug: Istradefylline 40 mg;Drug: Rifampin 300mg BID + istradefylline 40mg Day 8 only

Kyowa Hakko Kirin Pharma, Inc.

NULL

Completed

18 Years

65 Years

Both

Phase 1

United States

828

NCT02780895
(ClinicalTrials.gov)

May 2014

12/5/2016

Parkinsonian Brain Repair Using Human Stem Cells

Human OK99 Allogeneic Stem Cell Transplantation for Patients With Severe Parkinson's Disease

Idiopathic Parkinson Disease

Drug: Human Stem Cells

Celavie Bioscences, LLC

Hospital Angeles del Pedregal

Active, not recruiting

18 Years

75 Years

Both

Phase 1

Mexico

829

NCT02136914
(ClinicalTrials.gov)

May 2014

9/5/2014

ADS-5102 for the Treatment of Levodopa Induced Dyskinesia (EASE LID Study)

Efficacy and Safety of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia in Parkinson's Disease Patients (EASE LID Study)

Dyskinesia;Levodopa Induced Dyskinesia (LID);Parkinson's Disease

Drug: ADS-5102;Other: Placebo

Adamas Pharmaceuticals, Inc.

NULL

Completed

30 Years

85 Years

All

126

Phase 3

United States;Canada

830

NCT02046447
(ClinicalTrials.gov)

May 2014

23/1/2014

Neuroimaging of Dystonia

Neuroimaging of Dystonia: The Bachmann-Strauss Dystonia and Parkinson Disease Center of Excellence at the University of Florida

Primary Cervical Dystonia;DYT 1 Dystonia

Drug: Primary Cervical Dystonia (Trihexyphenidyl);Other: Controls Primary Cervical Dystonia (Trihexyphenidyl);Other: DYT 1 Dystonia (Healthy Control);Other: DYT 1 Dystonia

University of Florida

Bachmann Strauss Dystonia & Parkinson Foundation, Inc.

Completed

7 Years

70 Years

All

N/A

United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

831

EUCTR2012-005539-10-DE
(EUCTR)

29/04/2014

18/12/2013

Clinical study to investigate the efficacy and safety of two dose levels of NT 201 versus placebo in treating chronic troublesome sialorrhea in various neurological conditions.

Prospective, randomized, double-blind, placebo-controlled, parallel-group multicenter study, with an extension period of dose-blinded active treatment, to investigate the efficacy and safety of two dose levels of NT 201 in treating chronic troublesome sialorrhea in various neurological conditions - SIAXI – Sialorrhea in Adults Xeomin Investigation

Chronic troublesome sialorrhea resulting from neurological conditions in adults with Parkinson's disease or atypical parkinsonism (multiple system atrophy, corticobasal degeneration or progressive supranuclear palsy), or after stroke or traumatic brain injury.
MedDRA version: 18.1;Level: PT;Classification code 10039424;Term: Salivary hypersecretion;System Organ Class: 10017947 - Gastrointestinal disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Trade Name: Xeomin
INN or Proposed INN: NT 101
Other descriptive name: BOTULINUM TOXIN TYPE A
Trade Name: Xeomin
INN or Proposed INN: NT 101
Other descriptive name: BOTULINUM TOXIN TYPE A

Merz Pharmaceuticals GmbH

NULL

Not Recruiting

Female: yes
Male: yes

180

Phase 3

United States;Poland;Germany

832

EUCTR2013-002254-70-PL
(EUCTR)

28/04/2014

03/02/2014

Study to test the safety and effect of an investigational study drug, Istradefylline, in moderate to severe Parkinson's Disease (PD) patients who have been treated with levodopa combination therapy.

Moderate to severe Parkinson's disease
MedDRA version: 19.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders
MedDRA version: 19.0;Level: SOC;Classification code 10029205;Term: Nervous system disorders;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Kyowa Kirin Pharmaceutical Development, Inc.

NULL

Not Recruiting

Female: yes
Male: yes

609

Phase 3

Serbia;United States;Czech Republic;Canada;Poland;Israel;Germany

833

EUCTR2013-003363-64-GB
(EUCTR)

03/04/2014

11/03/2014

Trial of Exenatide for Parkinson's disease

A randomised, double blind, placebo controlled, single centre, 60 week trial of Exenatide once weekly for the treatment of moderate severity Parkinson’s disease. - Exenatide-PD

Parkinson's Disease
MedDRA version: 16.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Trade Name: Bydureon
Product Name: Exenatide
INN or Proposed INN: exenatide

University College London

NULL

Not Recruiting

Female: yes
Male: yes

Phase 2

United Kingdom

834

NCT03314597
(ClinicalTrials.gov)

April 2, 2014

15/10/2017

Instrumental or Physical-Exercise Rehabilitation of Balance in Parkinson's Disease? (IPER-PD)

Instrumental or Physical-exercise Rehabilitation of Balance Improve Both Balance and Gait in Parkinson's Disease.

Parkinson's Disease;Rehabilitation

Other: Balance exercise;Other: Mobile platform exercise

University of Pavia

Fondazione Salvatore Maugeri

Completed

50 Years

85 Years

All

N/A

NULL

835

NCT02091739
(ClinicalTrials.gov)

April 2014

18/3/2014

Clinical Study to Investigate the Efficacy and Safety of Two Dose Levels of NT 201 Versus Placebo in Treating Chronic Troublesome Sialorrhea in Various Neurological Conditions

Prospective, Randomized, Double-blind, Placebo-controlled, Parallel-group Multicenter Study, With an Extension Period of Dose-blinded Active Treatment, to Investigate the Efficacy and Safety of Two Dose Levels of NT 201 in Treating Chronic Troublesome Sialorrhea in Various Neurological Conditions

Chronic Troublesome Sialorrhea;Parkinson's Disease;Post-stroke;Traumatic Brain Injury

Drug: IncobotulinumtoxinA (100 Units);Drug: IncobotulinumtoxinA (75 Units);Drug: Placebo

Merz Pharmaceuticals GmbH

NULL

Completed

18 Years

80 Years

All

184

Phase 3

Germany;Poland;United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

836

NCT02365012
(ClinicalTrials.gov)

April 2014

10/2/2015

Treatment of Orthostatic Intolerance in Patients With Parkinson's Disease Using Midodrine

Orthostatic Intolerance;Parkinson's Disease

Drug: Midodrine

Philadelphia Veterans Affairs Medical Center

NULL

Recruiting

22 Years

89 Years

Both

N/A

United States

837

NCT01738178
(ClinicalTrials.gov)

April 2014

28/11/2012

Caffeine as a Therapy for Parkinson's Disease

Caffeine as a Therapeutic Agent in Parkinson's Disease

Parkinson's Disease

Drug: Caffeine;Drug: Placebo

McGill University Health Center

Pontifícia Universidade Católica do Paraná;University of Calgary;University of Newfoundland and Eastern Health;University Health Network, Toronto;UBC Hospital;Movement Disorder Clinic - Deer Lodge Centre;The Ottawa Hospital

Completed

45 Years

75 Years

All

119

Phase 3

Brazil;Canada

838

NCT02111122
(ClinicalTrials.gov)

April 2014

8/4/2014

Study of the Symptomatic Effects of Nocturnal Sodium Oxybate in Parkinson's Disease

A Phase II, Prospective, Randomized, Double-blind, Crossover Placebo-controlled Study of the Symptomatic Effects of Nocturnal Sodium Oxybate in Parkinson's Disease

Sleep-wake Disturbances in Motor-phase Parkinson's Disease

Drug: Sodium Oxybate;Drug: Placebo

Christian Baumann

NULL

Completed

18 Years

90 Years

All

Phase 2

Switzerland

839

NCT02741947
(ClinicalTrials.gov)

April 2014

31/3/2016

Levodopa Benserazide Generic Formulation Versus the Originator

Clinical and Pharmacokinetics Study to Evaluate the Therapeutic Equivalence and Bioequivalence of Levodopa Benserazide Generic Formulation (Teva Italia) Versus the Originator (Madopar®)

Parkinson Disease

Drug: Levodopa Benserazide Madopar;Drug: Levodopa Benserazide Teva Italia

IRCCS San Raffaele

Agenzia Italiana del Farmaco

Completed

30 Years

75 Years

Both

Phase 4

Italy

840

NCT02082249
(ClinicalTrials.gov)

March 10, 2014

14/2/2014

An Extension Study to Assess the Safety, Tolerability and Efficacy of ABT-SLV187 in Subjects With Advanced Parkinson's Disease and Persistent Motor-Complications Despite Optimized Treatment With Available Anti-Parkinsonian Medications

An Open-Label Three-Part Extension Study Assessing Safety, Tolerability and Efficacy of ABT-SLV187 in Subjects With Advanced Parkinson's Disease and Persistent Motor-Complications Despite Optimized Treatment With Available Anti-Parkinsonian Medications

Advanced Parkinson's Disease

Drug: ABT-SLV187

AbbVie

NULL

Completed

30 Years

99 Years

All

Phase 3

Japan;Korea, Republic of;Taiwan

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

841

EUCTR2013-002254-70-CZ
(EUCTR)

05/03/2014

02/12/2013

Study to test the safety and effect of an investigational study drug, Istradefylline, in moderate to severe Parkinson's Disease (PD) patients who have been treated with levodopa combination therapy.

A Phase 3, 12-week, Double-Blind, Placebo-Controlled, Randomized, Multicenter Study to Evaulate the Efficacy of Oral Istradefylline 20 and 40 mg/day as Treatment for Subjects with Moderate to Severe Parkinson's DiseaseRandomizovaná, multicentrická, dvojite zaslepená, placebem kontrolovaná, 12týdenní studie fáze 3 hodnotící úcinnost perorálního istradefylinu 20 a 40 mg/den v lécbe subjektu se stredne závažnou až závažnou Parkinsonovou nemocí

Kyowa Kirin Pharmaceutical Development, Inc.

NULL

Not Recruiting

Female: yes
Male: yes

609

Phase 3

United States;Serbia;Czech Republic;Canada;Poland;Israel;Germany

842

EUCTR2013-000980-10-FR
(EUCTR)

03/03/2014

22/11/2013

Clinical trial of apomorphine subcutaneous infusion in patients with advanced Parkinson’s disease

Parkinson Disease (PD) in patients with motor fluctuations not well controlled on medical treatment
MedDRA version: 16.1;Level: LLT;Classification code 10034006;Term: Parkinson's disease aggravated;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Trade Name: Apo-go®
Product Name: Apomorphine hydrochloride
Product Code: Apo-go®
INN or Proposed INN: Apomorphine hydrochloride
Other descriptive name: Apomorphine hydrochloride

STADA Arzneimittel AG

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

102

Phase 3

France;Spain;Denmark;Austria;Netherlands;Germany

843

NCT02006121
(ClinicalTrials.gov)

March 3, 2014

22/11/2013

Clinical Trial of Apomorphine Subcutaneous Infusion in Patients With Advanced Parkinson's Disease

Multicentre,Parallel-group,Double-blind,Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of Apomorphine sc Infusion in Parkinson's Disease Patients With Motor Complications Not Well Controlled on Medical Treatment

Parkinson's Disease

Drug: Apomorphine hydrochloride;Drug: Placebo

Britannia Pharmaceuticals Ltd.

NULL

Completed

30 Years

N/A

All

107

Phase 3

Austria;Denmark;France;Germany;Netherlands;Spain;United Kingdom

844

NCT02111330
(ClinicalTrials.gov)

March 2014

20/3/2014

Study to Assess the Safety, Tolerability and Pharmacokinetic Profile of PBF -509 (80 mg, 160 mg and 240 mg) After Multiple Oral Doses in Healthy Volunteers

Randomized, Double Blind, Placebo Controlled, Parallel Groups Study to Assess the Safety, Tolerability and Pharmacokinetic Profile of PBF -509 (80 mg, 160 mg and 240 mg) After Multiple Oral Doses in Healthy Volunteers

Parkinson Disease

Drug: PBF-509;Drug: Placebo

Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

Palo Biofarma, S.L

Completed

18 Years

45 Years

Both

Phase 1

Spain

845

NCT02095171
(ClinicalTrials.gov)

March 2014

14/3/2014

Single Ascending Dose Study of PRX002 in Healthy Subjects

A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study of PRX002 Administered by Intravenous Infusion in Healthy Subjects

Parkinson's Disease

Drug: PRX002;Other: Placebo

Prothena Biosciences Limited

Hoffmann-La Roche

Completed

21 Years

65 Years

Both

Phase 1

United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

846

NCT02305030
(ClinicalTrials.gov)

March 2014

28/11/2014

Effect of Opicapone at Steady State on Warfarin Pharmacokinetics

Effect of Opicapone at Steady State on Warfarin Pharmacokinetics in Healthy Volunteers

Parkinson's Disease

Drug: BIA 9-1067;Drug: Warfarin

Bial - Portela C S.A.

NULL

Completed

18 Years

45 Years

Both

Phase 1

NULL

847

NCT02305017
(ClinicalTrials.gov)

March 2014

28/11/2014

Effect of Paracetamol on Opicapone Pharmacokinetics in Healthy Volunteers

Parkinson's Disease

Drug: BIA 9-1067;Drug: Paracetamol

Bial - Portela C S.A.

NULL

Completed

18 Years

45 Years

All

Phase 1

NULL

848

NCT02445651
(ClinicalTrials.gov)

March 2014

23/1/2015

Physiological Effects of Nutritional Support in Patients With Parkinson's Disease

Parkinson Disease;Idiopathic Parkinson Disease

Dietary Supplement: Intravenous and Oral n-acetyl cysteine

Thomas Jefferson University

NULL

Active, not recruiting

30 Years

80 Years

All

N/A

United States

849

NCT02006290
(ClinicalTrials.gov)

March 2014

5/12/2013

Efficacy, Safety And Tolerability Study In Subjects With Parkinson's Disease

A Phase 1b, Randomized, Subject And Investigator-Blinded, Sponsor-Open, Placebo Controlled, Cross-Over Efficacy, Safety And Tolerability Study Of Single Oral Split Dose Administration Of PF-06412562 In Subjects With Parkinson's Disease

Parkinson's Disease

Drug: PF-06412562;Drug: Placebo

Pfizer

NULL

Completed

30 Years

75 Years

Both

Phase 1

United States

850

NCT02092181
(ClinicalTrials.gov)

March 2014

7/3/2014

A Pilot Study of Mirabegron and Behavioral Modification Including Pelvic Floor Exercise for Overactive Bladder in Parkinson's Disease (MAESTRO)

A Pilot Study of Mirabegron and Behavioral Modification Including Pelvic Floor Exercise for Overactive Bladder in Parkinson's Disease. (MAESTRO)

Parkinsons Disease

Drug: Mirabegron;Drug: Placebo

Daniel Burdick, MD

Astellas Pharma US, Inc.

Completed

30 Years

85 Years

All

Phase 4

United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

851

EUCTR2013-002254-70-DE
(EUCTR)

28/02/2014

19/11/2013

Study to test the safety and effect of an investigational study drug, Istradefylline, in moderate to severe Parkinson's Disease (PD) patients who have been treated with levodopa combination therapy.

Kyowa Kirin Pharmaceutical Development, Inc.

NULL

Not Recruiting

Female: yes
Male: yes

609

Phase 3

United States;Serbia;Czech Republic;Canada;Poland;Israel;Germany

852

EUCTR2013-002254-70-IT
(EUCTR)

21/02/2014

27/11/2013

Study to test the safety and effect of an investigational study drug, Istradefylline, in moderate to severe Parkinson's Disease (PD) patients who have been treated with levodopa combination therapy.

Moderate to severe Parkinson's disease
MedDRA version: 14.1;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders
MedDRA version: 14.1;Level: SOC;Classification code 10029205;Term: Nervous system disorders;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Kyowa Hakko Kirin Pharma, Inc.

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

609

Phase 3

United States;Serbia;Czech Republic;Canada;Poland;Israel;Germany;Italy

853

EUCTR2013-000980-10-ES
(EUCTR)

12/02/2014

12/11/2013

Clinical trial of apomorphine subcutaneous infusion in patients with advanced Parkinson?s disease

TOLEDO Multicenter, parallel-group, double-blind, placebo-controlled phase III study to evaluate the efficacy and safety of apomorphine subcutaneous infusion in Parkinson?s disease patients with motor complications not well controlled on medical treatment - TOLEDO

Trade Name: Apo-go®
Product Name: Apomorphine hydrochloride
Product Code: Apo-go®
INN or Proposed INN: Apomorphine hydrochloride
Other descriptive name: Apomorphine hydrochloride

STADA Arzneimittel AG

NULL

Not Recruiting

Female: yes
Male: yes

102

Phase 3

France;Spain;Denmark;Austria;Netherlands;Germany

854

EUCTR2013-000980-10-NL
(EUCTR)

06/02/2014

27/01/2014

Clinical trial of apomorphine subcutaneous infusion in patients with advanced Parkinson’s disease

Trade Name: Apo-go®
Product Name: Apomorphine hydrochloride
Product Code: Apo-go®
INN or Proposed INN: Apomorphine hydrochloride
Other descriptive name: Apomorphine hydrochloride

Britannia Pharmaceuticals Limited

NULL

Not Recruiting

Female: yes
Male: yes

102

Phase 3

France;Spain;Denmark;Austria;Germany;Netherlands

855

NCT02064166
(ClinicalTrials.gov)

February 2014

13/2/2014

Treatment of Parkinson Disease and Multiple System Atrophy Using Intranasal Insulin.

A Double-blinded Placebo-controlled Single-center Study to Evaluate the Efficacy of Intranasal Insulin 40 International Units Day as Treatment for Subjects With Parkinson Disease and Multiple System Atrophy

Parkinson Disease;Multiple System Atrophy

Drug: Intranasal Insulin

Peter Novak

NULL

Completed

18 Years

N/A

All

Phase 2

United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

856

NCT02007785
(ClinicalTrials.gov)

February 2014

14/11/2013

Study of the Effect of the Cognitive Orientation to Daily Occupational Performance (CO-OP) on Cognitive Impairment in Parkinson's Disease

Determining the Applicability of the Cognitive Orientation to Daily Occupational Performance (CO-OP) as a Meta-Cognitive Rehabilitation Strategy for Individuals With Parkinson's Disease-Related Cognitive Impairment

Parkinson's Disease;Cognitive Impairment

Behavioral: CO-OP treatment protocol

University of Manitoba

NULL

Completed

40 Years

N/A

Both

N/A

Canada

857

NCT02305316
(ClinicalTrials.gov)

February 2014

28/11/2014

Single-dose Pharmacokinetics and Relative Bioavailability of Two Different Formulations of Opicapone

Single-dose Pharmacokinetics and Relative Bioavailability of Two Different Formulations of Opicapone in Healthy Volunteers

Parkinson Disease

Drug: BIA 9-1067 non-micronized;Drug: BIA 9-1067 micronized

Bial - Portela C S.A.

NULL

Completed

18 Years

45 Years

All

Phase 1

NULL

858

NCT02103894
(ClinicalTrials.gov)

February 2014

12/2/2014

Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Tauopathies Compared to Healthy Subjects

Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Clinically Diagnosed Tauopathies in Comparison to Healthy Subjects

Alzheimer's Disease (AD);Parkinson's Disease (PD);Chronic Traumatic Encephalopathy (CTE);Progressive Supranuclear Palsy (PSP);Frontal Temporal Dementia (FTD);Pick's Disease;Tauopathies

Drug: [18F]T807 ([18F]MNI-777)

Molecular NeuroImaging

Institute for Neurodegenerative Disorders

Completed

18 Years

85 Years

Both

Phase 1

United States

859

EUCTR2013-002545-10-SE
(EUCTR)

08/01/2014

11/11/2013

An open safety study with the monoaminergic stabilizer (-)-OSU6162 in patients with mental fatigue and related vitality and wakefulness disturbances associated with neurologiacal disorders, e g Parkinson’s disease, Huntington’s disease, brain trauma, stroke, myalgic encephalomyelitis and narcolepsy.

Parkinsons diseaseHuntingtons diseaseMultiple sclerosBrain traumaStrokeMyalgic encephalomyelitisNarcolepsy;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Product Code: OSU6162 similar to (-)-OSU 6162

A. Carlsson Research AB

NULL

Not Recruiting

Female: yes
Male: yes

240

Phase 2

Sweden

860

NCT02384512
(ClinicalTrials.gov)

January 2014

4/3/2015

Azilect® In Wearing-Off (AIWO)

Azilect® In Wearing-Off (AIWO) Non-interventional Study on Efficacy and Tolerability of Rasagiline (1mg/d) add-on in Ambulatory Parkinson's Disease Patients With Wearing-off Symptoms Diagnosed by Wearing-off Questionnaire (WOQ-32)

Parkinson's Disease

Drug: Azilect ®

Teva Pharma GmbH

Anfomed GmbH

Completed

18 Years

N/A

Both

261

N/A

Germany

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

861

NCT02046434
(ClinicalTrials.gov)

January 2014

23/1/2014

Phenylbutyrate Response as a Biomarker for Alpha-synuclein Clearance From the Brain

Phenylbutyrate Response As a Biomarker for Alpha-Synuclein Clearance From Brain

Parkinson's Disease

Drug: Glycerol Phenylbutyrate

University of Colorado, Denver

NULL

Active, not recruiting

21 Years

80 Years

All

Phase 1

United States

862

NCT02103465
(ClinicalTrials.gov)

December 2013

26/3/2014

Possible Use of Rotigotine in Subjects 70 Years and Older With Late Onset of Disease

Late Onset Parkinson's Disease in Subjects 70 Years and Older: Possible Use of Rotigotine

Parkinson's Disease

Drug: Rotigotine;Drug: Placebo

Azienda Ospedaliera Cardinale G. Panico

NULL

Terminated

70 Years

N/A

Both

Phase 2

Italy

863

NCT01968460
(ClinicalTrials.gov)

December 2013

15/10/2013

Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease

A Phase 2B, Twelve-week Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study, To Determine the Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease

Parkinson's Disease

Drug: P2B001 once daily (pramipexole 0.6 mg / rasagiline 0.75 mg),;Drug: Placebo;Drug: P2B001 once daily (pramipexole 0.3 mg / rasagiline 0.75 mg),

Pharma Two B Ltd.

NULL

Completed

35 Years

75 Years

All

149

Phase 2;Phase 3

United States;Israel

864

NCT01883505
(ClinicalTrials.gov)

December 2013

9/6/2013

A Phase 2a Study Followed to Evaluate the Safety, Tolerability and Levodopa Pharmacokinetics in Levodopa-treated Parkinson's Disease Patients Receiving ND0612

A Phase 2a Multicentre Randomized Double Blind Placebo Controlled Study Followed by an Open Label Period, to Evaluate the Safety, Tolerability and Levodopa Pharmacokinetics in Levodopa-treated Parkinson's Disease Patients With Motor Fluctuations, Administered With Repeated Continuous Subcutaneous ND0612

Parkinson's Disease

Drug: Levodopa and carbidopa;Drug: Placebo

NeuroDerm Ltd.

NULL

Completed

30 Years

N/A

Both

Phase 2

Israel

865

NCT02018406
(ClinicalTrials.gov)

December 2013

30/10/2013

Establishment of Clinical Basis for Hematopoietic Growth Factors Therapy in Brain Injury

Neurological Diseases;Ischemic Stroke;Hemorrhagic Stroke;Cerebral Palsy;Atypical Parkinson Disease

Drug: Combination injection of EPO and G-CSF;Drug: Injection of normal saline

Yonsei University

NULL

Active, not recruiting

20 Years

N/A

All

Phase 1;Phase 2

Korea, Republic of

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

866

NCT02108704
(ClinicalTrials.gov)

December 2013

4/4/2014

Helicobacter Pylori Eradication Study in Parkinson's Disease

Helicobacter Pylori Eradication in Parkinson's Disease: A Double-blind Randomised Placebo Controlled Trial

Parkinson's Disease;Helicobacter Pylori Infection

Drug: Helicobacter pylori eradication therapy;Drug: Placebo

University of Malaya

NULL

Completed

18 Years

N/A

All

N/A

Malaysia

867

NCT04044547
(ClinicalTrials.gov)

November 22, 2013

30/7/2019

A Study of LY03003 in Patients With Early-stage Parkinson's Disease

A Randomized, Double-blinded, Multiple Ascending Dose Study in Patients With Early-stage Parkinson's Disease to Evaluate the Pharmacokinetics and Safety of LY03003 Following Intramuscular Injections

Parkinson Disease

Drug: Rotigotine , extended-release microspheres;Drug: Placebo, extended-release microspheres

Luye Pharma Group Ltd.

Beijing Bozhiyin T&S Co., Ltd.

Completed

18 Years

75 Years

All

Phase 1

NULL

868

EUCTR2012-002840-26-RO
(EUCTR)

12/11/2013

17/07/2014

Study to test the efficacy of two doses of Rotigotine on depressive mood (apathy) associated with Parkinson's Disease

A Multicenter, Multinational, Double-blind, Placebo-controlled, 3-arm Phase 4 Study to Evaluate the Efficacy of Rotigotine on Parkinson's Disease- Associated Apathy, Motor Symptoms, and Mood

Parkinson's disease
MedDRA version: 17.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Trade Name: Neupro
Product Name: Rotigotine
INN or Proposed INN: ROTIGOTINE
Trade Name: Neupro
Product Name: Rotigotine
INN or Proposed INN: ROTIGOTINE
Trade Name: Neupro
Product Name: Rotigotine
INN or Proposed INN: ROTIGOTINE
Trade Name: Neupro
Product Name: Rotigotine
INN or Proposed INN: ROTIGOTINE

UCB Biosciences GmbH

NULL

Not Recruiting

Female: yes
Male: yes

504

Phase 4

Serbia;United States;Slovakia;Slovenia;Spain;Ukraine;Turkey;Austria;Italy;Hungary;Poland;Romania;Croatia;Bulgaria

869

NCT01927055
(ClinicalTrials.gov)

November 2013

16/8/2013

A Clinical Study of Patients With Symptomatic NOH to Assess Sustained Effects of Droxidopa Therapy

A Clinical Study of Patients With Symptomatic Neurogenic Orthostatic Hypotension to Assess Sustained Effects of Droxidopa Therapy

Symptomatic Neurogenic Orthostatic Hypotension;Parkinson's Disease;Multiple Systems Atrophy;Pure Autonomic Failure;Dopamine Beta Hydroxylase Deficiency

Drug: Droxidopa;Drug: Placebo

Chelsea Therapeutics

NULL

Terminated

18 Years

N/A

All

Phase 3

United States

870

NCT01856738
(ClinicalTrials.gov)

November 2013

14/5/2013

Cholinesterase Inhibitors to Slow Progression of Visual Hallucinations in Parkinson&Apos;s Disease

Cholinesterase Inhibitors to Slow Progression of Visual Hallucinations in Parkinson's Disease:a Multi-center Placebo-controlled Trial.

Parkinson's Disease

Drug: Rivastigmine;Drug: Placebo (for rivastigmine)

VU University Medical Center

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA);Atrium Medical Center;University Medical Center Groningen;Leiden University Medical Center;University Medical Center Nijmegen;International Parkinson Fonds Germany GmbH;ZonMw: The Netherlands Organisation for Health Research and Development

Terminated

40 Years

N/A

All

Phase 4

Netherlands

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

871

EUCTR2011-004438-32-DE
(EUCTR)

23/10/2013

13/08/2013

The effect of repeat doses of GSK962040 on the pharmacokinetics of L-DOPA in subjects with Parkinson’s disease with slow gastric emptying

A randomized, double-blind, placebo-controlled, parallel group, dose ranging study to assess the effect of repeat doses of GSK962040 on the pharmacokinetics of levodopa in subjects with Parkinson’s disease exhibiting delayed gastric emptying - GSK962040 Parkinson's disease PoC

Investigate the ability of the motilin receptor agonist GSK962040 to improve levodopa pharmacokinetics (PK) by enhancing GE via motilin receptor agonism.
MedDRA version: 16.1;Level: PT;Classification code 10051153;Term: Diabetic gastroparesis;System Organ Class: 10017947 - Gastrointestinal disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Product Name: GSK962040
Product Code: GSK962040
INN or Proposed INN: GSK962040
Other descriptive name: GSK962040

GlaxoSmithKline Research and Development Limited

NULL

Not Recruiting

Female: yes
Male: yes

Australia;Germany;United Kingdom;Sweden

872

EUCTR2013-000980-10-AT
(EUCTR)

18/10/2013

31/07/2013

Clinical trial of apomorphine subcutaneous infusion in patients with advanced Parkinson’s disease

Trade Name: Apo-go®
Product Name: Apomorphine hydrochloride
Product Code: Apo-go®
INN or Proposed INN: Apomorphine hydrochloride
Other descriptive name: Apomorphine hydrochloride

Britannia Pharmaceuticals Limited

NULL

Not Recruiting

Female: yes
Male: yes

102

Phase 3

France;Spain;Denmark;Austria;Netherlands;Germany

873

NCT01968031
(ClinicalTrials.gov)

October 2013

18/10/2013

A 12-week Randomized Study to Evaluate Oral Istradefylline in Subjects With Moderate to Severe Parkinson's Disease

A Phase 3, 12-week, Double-Blind, Placebo-Controlled, Randomized, Multicenter Study to Evaluate the Efficacy of Oral Istradefylline 20 and 40 mg/Day as Treatment for Subjects With Moderate to Severe Parkinson's Disease

Idiopathic Parkinson's Disease

Drug: Istradefylline 40 mg;Drug: Istradefylline 20 mg;Drug: Placebo

Kyowa Hakko Kirin Pharma, Inc.

Kyowa Kirin Co., Ltd.

Completed

30 Years

N/A

All

613

Phase 3

United States;Canada;Czechia;Germany;Israel;Italy;Poland;Serbia;Czech Republic

874

NCT02207387
(ClinicalTrials.gov)

October 2013

28/7/2014

Ambulosono Rasagiline Musical Walking Study

A Sensorimotor Contingency-based Musical Walking Program for People Living With Parkinson's Disease

Parkinson's Disease

Drug: Azilect;Behavioral: Exercise;Other: Music

University of British Columbia

Teva Pharmaceutical Industries

Recruiting

19 Years

N/A

Both

N/A

Canada

875

NCT01960842
(ClinicalTrials.gov)

October 2013

9/10/2013

A Study to Assess the Efficacy, Safety and Tolerability of ABT-SLV187 Monotherapy in Subjects With Advanced Parkinson's Disease (PD) and Persistent Motor Complications, Despite Optimized Treatment With Available Anti-Parkinsonian Medications

An Open-Label, Single-Arm, Baseline-Controlled, Multicenter Study to Evaluate the Efficacy, Safety and Tolerability of ABT-SLV187 Monotherapy in Subjects With Advanced Parkinson's Disease and Persistent Motor-Complications Despite Optimized Treatment With Available Anti-Parkinsonian Medication

Advanced Parkinson's Disease

Drug: Levodopa -carbidopa intestinal gel;Device: CADD-Legacy® 1400 ambulatory infusion pump;Device: PEG tube;Device: J-tube

AbbVie

NULL

Completed

30 Years

N/A

All

Phase 3

Japan;Korea, Republic of;Taiwan

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

876

NCT01973543
(ClinicalTrials.gov)

October 2013

25/10/2013

Safety Study of AADC Gene Therapy (VY-AADC01) for Parkinson's Disease

An Open-label Safety and Efficacy Study of VY-AADC01 Administered by MRI-Guided Convective Infusion Into the Putamen of Subjects With Parkinson's Disease With Fluctuating Responses to Levodopa

Parkinson's Disease

Biological: VY-AADC01

Neurocrine Biosciences

University of California, San Francisco;Veristat, Inc.;Feinstein Institute for Medical Research;Oregon Health and Science University;Voyager Therapeutics

Completed

40 Years

70 Years

All

Phase 1

United States

877

NCT02012595
(ClinicalTrials.gov)

October 2013

26/11/2013

[11C]Donepezil PET For Imaging The Autonomous Nervous System In Parkinsons Disease

Parkinson's Disease

Other: [11C]donepezil PET

Per Borghammer

Lundbeck Foundation;Jascha Fonden;Fonden af 2. Juli 1984 til bekæmpelse af Parkinsons Sygdom

Completed

40 Years

80 Years

Both

N/A

Denmark

878

NCT02055274
(ClinicalTrials.gov)

October 2013

31/1/2014

Pharmacokinetics and Safety Study of LY03003 in Patients With Early-stage Parkinson's Disease

A Randomized, Double-blinded, Multiple Ascending Dose Study in Patients With Early-stage Parkinson's Disease to Evaluate the Pharmacokinetics and Safety of LY03003 Following Intramuscular Injections

Parkinson's Disease

Drug: LY03003;Drug: Neupro

Luye Pharma Group Ltd.

NULL

Completed

18 Years

N/A

Both

Phase 1

United States

879

EUCTR2011-002827-17-SK
(EUCTR)

17/09/2013

04/03/2013

A fixed dose, dose response study for ropinirole prolonged release (PR) in patients with early stage Parkinson’s Disease.

Early stage Parkinson's Disease.
MedDRA version: 15.1;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Trade Name: Local Trade Name, 2mg
Product Name: ropinirole PR , 2mg
Product Code: SK&F101468
INN or Proposed INN: ROPINIROLE
Trade Name: Local Trade Name, 4mg
Product Name: ropinirole PR , 2mg
Product Code: SK&F101468
INN or Proposed INN: ROPINIROLE
Trade Name: Local Trade Name, 8mg
Product Name: ropinirole PR
Product Code: SK&F101468
INN or Proposed INN: ROPINIROLE

GlaxoSmithKline Research & Development Limited

NULL

Not Recruiting

Female: yes
Male: yes

210

United States;Estonia;Slovakia;Russian Federation;Korea, Republic of

880

EUCTR2013-001881-40-GB
(EUCTR)

16/09/2013

05/08/2013

Extension study to Assess the Benefit and Safety of Administering Intermittent GDNF Infusions in Parkinson's Disease (PD)

An Extension Study to Assess the Safety and Efficacy of Intermittent Bilateral Intraputamenal Glial Cell Line-Derived Neurotrophic Factor (GDNF) Infusions Administered via onvection Enhanced Delivery (CED) in Subjects with Parkinson’s Disease - Intermittent Bilateral GDNF for Parkinson’s Disease

Parkinson's disease
MedDRA version: 18.1;Level: LLT;Classification code 10034008;Term: Parkinson's syndrome;System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

North Bristol NHS Trust (NBT)

NULL

Not Recruiting

Female: yes
Male: yes

Phase 2

United Kingdom

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

881

NCT01923584
(ClinicalTrials.gov)

September 2013

13/8/2013

A Phase 2A Trial of EPI-743 for Patients With Parkinson's Disease

Parkinson's Disease

Drug: EPI-743 400mg;Drug: EPI-743 200mg

University of South Florida

Edison Pharmaceuticals Inc

Completed

40 Years

75 Years

Both

Phase 2

United States

882

NCT01955616
(ClinicalTrials.gov)

September 2013

25/9/2013

A Phase 2 Study to Evaluate the Safety and Efficacy of RM-131 in Patients With Parkinson's Disease & Chronic Constipation

A Phase 2, Randomized, Double-blind, Placebo-controlled, Multiple Dose, Parallel Group Study to Evaluate the Pharmacodynamics, Efficacy and Safety of RM-131 Administered to Patients With Parkinson's Disease and Chronic Constipation Dissatisfied With Current Therapy

Parkinson's Disease

Drug: RM-131;Drug: Placebo

Motus Therapeutics, Inc.

Michael J. Fox Foundation for Parkinson's Research

Terminated

18 Years

80 Years

Both

Phase 2

United States

883

NCT01882010
(ClinicalTrials.gov)

September 2013

13/6/2013

Leukine (Sargramostim) for Parkinson's Disease

Parkinson's Disease

Procedure: blood draw;Procedure: physical exam and UPDRS part III assessment;Procedure: MEG;Drug: sargramostim;Drug: placebo;Behavioral: physical exam and UPDRS part III assessment;Procedure: Motion Analysis

Howard Gendelman, MD

Sanofi;National Institute of Neurological Disorders and Stroke (NINDS);UNeMed;Nebraska Neuroscience Alliance

Completed

35 Years

85 Years

Both

Phase 1

United States

884

NCT01929317
(ClinicalTrials.gov)

August 28, 2013

22/8/2013

A Study to Evaluate the Efficacy of 18 to 24mg/Day Ropinirole Controlled Release (CR) Tablets in Early and Advanced Parkinson's Disease (PD) Patients.

A Study ROP116991, Clinical Evaluation of 18 to 24mg/Day Ropinirole CR for Parkinson's Disease.

Parkinson Disease

Drug: Ropinirole CR 2mg tablet;Drug: Ropinirole CR 8mg tablet;Drug: Ropinirole CR matching Placebo tablet

GlaxoSmithKline

NULL

Terminated

20 Years

N/A

All

Phase 3

Japan

885

EUCTR2013-001722-25-NL
(EUCTR)

27/08/2013

12/08/2013

Rivastigmine as an early treatment for visual hallucinations in Parkinson’s disease (CHEVAL)

Cholinesterase inhibitors to slow progression of visual hallucinations in Parkinson’s disease: a multi-center placebo-controlled trial (CHEVAL) - CHEVAL

Parkinson's disease
MedDRA version: 18.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

VU University Medical Center

NULL

Not Recruiting

Female: yes
Male: yes

168

Phase 4

Netherlands

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

886

EUCTR2011-004438-32-SE
(EUCTR)

26/08/2013

01/07/2013

The effect of repeat doses of GSK962040 on the pharmacokinetics of L-DOPA in subjects with Parkinson’s disease with slow gastric emptying

Investigate the ability of the motilin receptor agonist GSK962040 to improve levodopa pharmacokinetics (PK) by enhancing GE via motilin receptor agonism.
MedDRA version: 16.0;Level: PT;Classification code 10051153;Term: Diabetic gastroparesis;System Organ Class: 10017947 - Gastrointestinal disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Product Name: GSK962040
Product Code: GSK962040
INN or Proposed INN: GSK962040
Other descriptive name: GSK962040

GlaxoSmithKline Research and Development Limited

NULL

Not Recruiting

Female: yes
Male: yes

Australia;Germany;United Kingdom;Sweden

887

NCT01931488
(ClinicalTrials.gov)

August 2013

14/8/2013

124I-MIBG Tracer Evaluation of Myocardial Sympathetic Denervation and Assessment of Neuroendocrine Tumors.

The Feasibility of Novel 124I-MIBG Tracer in Evaluation of Myocardial Sympathetic Denervation and Assessment of Neuroendocrine Tumors. Comparison With 123I-MIBG.

Parkinson Disease;Neuroendocrine Tumors

Other: MIBG label with I123 or I124;Device: SPECT imaging

Tel-Aviv Sourasky Medical Center

NULL

Recruiting

18 Years

N/A

Both

Phase 2

Israel

888

JPRN-UMIN000011111

2013/07/16

15/07/2013

Spinal blood flow and metabolism in neurological diseases

motor neuron disease including ALS, multiple sclerosis, stroke, Parkinson disease, spinocerebellar degeneration, multiple system atrophy

PET scan study with 11C-flumazenil
PET scan study with 18F- FDG
PET scan study with 15O-H2O

Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences

NULL

Recruiting

20years-old

Not applicable

Male and Female

Not applicable

Japan

889

NCT01767129
(ClinicalTrials.gov)

July 2013

9/1/2013

Safety and Efficacy of AVP-923 in the Treatment of Levodopa-induced Dyskinesia in Parkinson's Disease Patients

A Phase 2a, Double-blind, Randomized, Placebo-controlled, Crossover Study to Evaluate the Safety and Efficacy of AVP-923 (Dextromethorphan/Quinidine) in the Treatment of Levodopa-induced Dyskinesia in Parkinson's Disease Patients.

Dyskinesia;Parkinson's Disease

Drug: AVP-923-45;Drug: Placebo

Avanir Pharmaceuticals

Michael J. Fox Foundation for Parkinson's Research

Completed

30 Years

80 Years

All

Phase 2

United States;Canada

890

EUCTR2012-001245-40-IT
(EUCTR)

05/06/2013

17/05/2013

CLINICAL AND PHARMACOLOGICAL STUDY TO EVALUATE THE THERAPEUTIC EQUIVALENCE AND BIOEQUIVALENCE OF LEVODOPA BENSERAZIDE GENERIC FORMULATION (TEVA ITALIA) VERSUS THE ORIGINATOR (MADOPAR®)

CLINICAL AND PHARMACOKINETICS STUDY TO EVALUATE THE THERAPEUTIC EQUIVALENCE AND BIOEQUIVALENCE OF LEVODOPA BENSERAZIDE GENERIC FORMULATION (TEVA ITALIA) VERSUS THE ORIGINATOR (MADOPAR®)

PARKINSON'S DISEASE
MedDRA version: 16.0;Level: LLT;Classification code 10013113;Term: Disease Parkinson's;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Trade Name: Madopar 200+50 mg
Trade Name: LEVODOPA / BENSERAZIDE 200 + 50 MG

NULL

Not Recruiting

Female: yes
Male: yes

Italy

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

891

JPRN-JapicCTI-132189

01/6/2013

12/07/2013

A Phase 1 Study of ONO-2160/CD

A Phase 1 study on single oral dose administration of ONO-2160/CD in healthy adult male subjects and Parkinson's disease patients

Parkinson's disease

Intervention name : ONO-2160/CD
Dosage And administration of the intervention : Oral administration
Control intervention name : Levodopa /carbidopa hydrate
INN of the control intervention : Levodopa /Carbidopa Hydrate
Dosage And administration of the control intervention : Oral administration

ONO PHARMACEUTICAL CO.,LTD.

NULL

BOTH

Phase 1

NULL

892

NCT01765257
(ClinicalTrials.gov)

June 2013

8/1/2013

Evaluation of the Efficacy of Rasagiline in Apathy in Drug-naïve Patients With Parkinson's Disease by a Multi-center Study

Evaluation of the Efficacy of Rasagiline in Apathy in Drug-naïve Patients With Parkinson's Disease by a Multi-center, Randomized, Double-blind, Parallel-group, Placebo-controlled Study.

Drug-naïve Patients With Parkinson's Disease;Apathy

Drug: AZILECT ®;Drug: Placebo

University Hospital, Clermont-Ferrand

H. Lundbeck A/S, TEVA;CHU Purpan (Toulouse);Hôpital Haut-Levêque (Pessac);Centre Hospitalier de la Côte Basque;Centre Hospitalier Universitaire de Poitiers (Poitiers);CHU de Rennes (Rennes);University Hospital, Lille;CHU Dupuytren (Limoges);University Hospital, Caen;Hôpital Caremeau (NIMES);Centre Hospitalier Pays D'Aix;Hôpital de la Timone (MARSEILLE);University Hospital, Rouen;Centre Hospitalier Universitaire, Amiens;Centre Hospitalier Universitaire de Saint Etienne;Fondation Rothschild Paris

Not yet recruiting

30 Years

70 Years

Both

Phase 4

France

893

NCT02263235
(ClinicalTrials.gov)

June 2013

18/9/2014

In Vivo Alzheimer Proteomics

Use of Targeted Quantitative Proteomics and Metabolic Labelling With Stable Isotopes for the Diagnosis and the Investigation of Neurological Disorders and in Particular Alzheimer Disease

Probable Alzheimer Disease;Parkinson Disease;Neurological Disease Without Cognitive Degradation;Brain Trauma;Acute Hydrocephaly

Biological: administration of stable isotope-labelled leucine-;Other: collection of CSF, blood, urine, saliva

University Hospital, Montpellier

Assistance Publique - Hôpitaux de Paris;University Hospital, Clermont-Ferrand;International Atomic Energy Agency

Recruiting

55 Years

85 Years

Both

110

N/A

France

894

NCT01879748
(ClinicalTrials.gov)

June 2013

13/6/2013

A Study to Assess the Pharmacokinetics, Safety, and Tolerability of Single and Multiple Doses of Rasagiline

A Randomized, Double-Blind, Placebo-Controlled, Study to Assess the Pharmacokinetics, Safety, and Tolerability of Single and Multiple Doses (0.5, 1.0, and 2.0 mg) of Rasagiline Administered to Healthy Japanese and Caucasian Subjects

Parkinson's Disease

Drug: Rasagiline;Drug: Placebo

Teva Pharmaceutical Industries

NULL

Completed

20 Years

50 Years

Both

Phase 1

United States

895

NCT01850381
(ClinicalTrials.gov)

June 2013

7/5/2013

Phase 2A Study of GM 608 in Mild to Moderate Parkinson Disease

GM 608 in A Phase IIA Pilot Double-blinded, Randomized, Placebo Controlled Trial in Mild to Moderate Parkinson Disease

Parkinson's Disease

Drug: GM608;Drug: Placebo Comparator

Genervon Biopharmaceuticals, LLC

Columbia University

Completed

30 Years

N/A

All

Phase 2

United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

896

NCT02275884
(ClinicalTrials.gov)

June 2013

17/10/2014

Pharmacologically Active Constituents of Chocolate and Their Symptomatic Effects in Patients With Idiopathic Parkinson's Disease

Evaluation of Plasma Concentrations of Pharmacologically Active Constituents of Chocolate and Their Symptomatic Effects in Patients With Idiopathic Parkinson's Disease

Parkinson Disease

Dietary Supplement: Dark chocolate (85% cocoa);Dietary Supplement: White chocolate (0% cocoa)

Technische Universität Dresden

University of Wuerzburg

Recruiting

40 Years

N/A

Both

N/A

Germany

897

JPRN-UMIN000010752

2013/05/17

17/05/2013

A study on usefulness and safety of donepezil for cognitive function and phychological symptoms of patients with Parkinson's disease and Alzheimer type dementia.

Parkinson's disease

donepezil

Kansai Medical University

NULL

Complete: follow-up complete

Not applicable

Male and Female

Not selected

Japan

898

EUCTR2012-005822-31-IT
(EUCTR)

13/05/2013

20/03/2013

A study of the safety and drug effects of levodopa inhalation powder (CVT-301) in patients with Parkinson’s disease

A Phase 2b, Randomized, Double-blind, Placebo-controlled Study Investigating the Efficacy and Safety of Inhaled CVT 301 (Levodopa Inhalation Powder) in Parkinson’s Disease Patients With Motor Response Fluctuations (OFF Phenomena)

Parkinson's Disease
MedDRA version: 15.1;Level: LLT;Classification code 10034007;Term: Parkinson's disease NOS;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Product Name: CVT-301
Product Code: CVT-301
INN or Proposed INN: LEVODOPA
Other descriptive name: LEVODOPA

Civitas Therapeutics, Inc.

NULL

Not Recruiting

Female: yes
Male: yes

Phase 2b

United States;Serbia;United Kingdom;Italy

899

EUCTR2013-000827-15-IT
(EUCTR)

11/05/2013

15/03/2013

LATE ONSET PARKINSON’S DISEASE IN SUBJECTS 70 YEARS AND OLDER: POSSIBLE USE OF ROTIGOTINE

LATE ONSET PARKINSON’S DISEASE IN SUBJECTS 70 YEARS AND OLDER: POSSIBLE USE OF ROTIGOTINE - PARROT

Parkinson disease;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Trade Name: Rotigotine
Product Name: neurpro
Product Code: SPM962

Unità Malattie Neurodegenerative, Ospedale Cardinale Giovanni Panico, Tricase

NULL

Not Recruiting

Female: yes
Male: yes

Italy

900

JPRN-UMIN000010596

2013/05/01

01/05/2013

Randomized crossover trial comparing memantine or amantadine for Parkinson's disease with motor fluctuations in Juntendo

Parkinson's disease

Memantine preceding arm
Titrate the memantine, administered for 3 months. And tapering memantine and amantadine titrate the dose for 3 months.

Amantadine preceding arm
Titrate the amantadine, administered for 3 months. And tapering amantadine and memantine titrate the dose for 3 months.

Department of Neurology, Juntendo University School of Medicine

NULL

Complete: follow-up complete

20years-old

Not applicable

Male

Not selected

Japan

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

901

NCT01860794
(ClinicalTrials.gov)

May 2013

14/5/2013

Evaluation of Safety and Tolerability of Fetal Mesencephalic Dopamine Neuronal Precursor Cells for Parkinson's Disease

Investigator Clinical Trial for Evaluation of Safety and Tolerability After Transplantation of Fetal Mesencephalic Dopamine Neuronal Precursor Cells in Patients With Parkinson's Disease

Idiopathic Parkinson Disease;Primary Parkinsonism

Drug: Mesencephalic Neuronal Precursor Cells

Bundang CHA Hospital

NULL

Recruiting

18 Years

70 Years

Female

Phase 1;Phase 2

Korea, Republic of

902

NCT02473562
(ClinicalTrials.gov)

May 2013

12/6/2015

Varenicline Treatment for Excessive Daytime Sleepiness in Parkinson's Disease

Varenicline, a Partial Nicotinic Receptor Agonist for the Treatment of Excessive Daytime Sleepiness in Parkinson's Disease: a Placebo-controlled Cross-over Pilot Study

Parkinson's Disease

Drug: Varenicline;Drug: Placebo (for varenicline)

VU University Medical Center

Centre for Human Drug Research, Netherlands

Terminated

N/A

All

Phase 4

Netherlands

903

NCT02500108
(ClinicalTrials.gov)

May 2013

14/7/2015

Domperidone and Risk of Sudden Cardiac Death

Domperidone Use in Parkinson's Disease and Risk of Sudden Cardiac Death

Parkinson's Disease

Drug: Domperidone

Canadian Network for Observational Drug Effect Studies, CNODES

Drug Safety and Effectiveness Network, Canada;Canadian Institutes of Health Research (CIHR)

Completed

50 Years

N/A

Both

214962

N/A

Canada

904

NCT03022201
(ClinicalTrials.gov)

May 2013

23/11/2016

Comparing the Therapeutic Efficacy and Safety of DA-9701 With Domperidone in Patients With Parkinson's Disease

Therapeutic Efficacy of DA-9701 on Gastric Motility in Patients With Parkinson's Disease Evaluated by Magnetic Resonance Imaging: A Randomized Controlled, Double-Blind, Non-Inferiority Trial

Parkinson's Disease,Idiopathic

Drug: DA-9701;Drug: Domperidone;Drug: Placebo domperidone;Drug: Placebo DA-9701

Seoul National University Hospital

NULL

Completed

20 Years

80 Years

All

Phase 4

Korea, Republic of

905

NCT01877538
(ClinicalTrials.gov)

May 2013

11/6/2013

Study to Investigate the Ability of [11C]Donepezil PET to Image the Parasympathetic Nervous System

[11C]Donepezil PET for Imaging the Parasympathetic Nervous System in Healthy Adults

Parkinson's Disease

Other: [11C]donepezil PET

Per Borghammer

Lundbeck Foundation

Completed

45 Years

75 Years

Male

Denmark

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

906

NCT01851850
(ClinicalTrials.gov)

May 2013

1/5/2013

Continuation Treatment Protocol for Patient Who Participated in the BIA 9-1067-302 Clinical Trial

Continue Providing Care for Patient Who Participated in the BIA 9-1067-302 Clinical Trial

Parkinson Disease

Drug: Opicapone

Rabin Medical Center

NULL

Completed

30 Years

80 Years

All

Phase 3

Israel

907

EUCTR2012-002840-26-BG
(EUCTR)

26/04/2013

06/02/2013

Study to test the efficacy of two doses of Rotigotine on depressive mood (apathy) associated with Parkinson's Disease

A Multicenter, Multinational, Double-blind, Placebo-controlled, 3-arm Phase 4 Study to Evaluate the Efficacy of Rotigotine on Parkinson's Disease- Associated Apathy, Motor Symptoms, and Mood

Parkinson's disease
MedDRA version: 16.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

UCB Biosciences GmbH

NULL

Not Recruiting

Female: yes
Male: yes

504

Phase 4

Serbia;United States;Slovakia;Slovenia;Spain;Ukraine;Turkey;Austria;Italy;Hungary;Poland;Romania;Croatia;Bulgaria

908

EUCTR2011-002827-17-EE
(EUCTR)

23/04/2013

08/02/2013

A fixed dose, dose response study for ropinirole prolonged release (PR) in patients with early stage Parkinson’s Disease.

Early stage Parkinson's Disease.
MedDRA version: 14.1;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Trade Name: REQUIP-MODUTAB , 2mg
Product Name: ropinirole PR , 2mg
Product Code: SK&F101468
INN or Proposed INN: ROPINIROLE
Trade Name: REQUIP-MODUTAB , 4mg
Product Name: ropinirole PR , 2mg
Product Code: SK&F101468
INN or Proposed INN: ROPINIROLE
Trade Name: REQUIP-MODUTAB , 8mg
Product Name: ropinirole PR
Product Code: SK&F101468
INN or Proposed INN: ROPINIROLE

GlaxoSmithKline Research & Development Limited

NULL

Not Recruiting

Female: yes
Male: yes

210

United States;Estonia;Slovakia;Russian Federation;Korea, Republic of

909

EUCTR2011-002828-41-EE
(EUCTR)

23/04/2013

08/02/2013

A study to test the effectiveness of varying doses of ropinirole PR while taking L-dopa in patients with late stage Parkinson's disease.

A fixed dose, dose-response study of ropinirole prolonged release (PR) as adjunctive treatment to L-dopa in patients with advanced Parkinson's disease.

Advanced Parkinson's disease.
MedDRA version: 14.1;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Trade Name: REQUIP-MODUTAB, 2mg
Product Name: ropinirole PR , 2mg
Product Code: SK&F101468
INN or Proposed INN: ROPINIROLE
Trade Name: REQUIP-MODUTAB, 4mg
Product Name: ropinirole PR , 2mg
Product Code: SK&F101468
INN or Proposed INN: ROPINIROLE
Trade Name: REQUIP-MODUTAB, 8mg
Product Name: ropinirole PR
Product Code: SK&F101468
INN or Proposed INN: ROPINIROLE

GlaxoSmithKline Research & Development Limited

NULL

Not Recruiting

Female: yes
Male: yes

406

United States;Taiwan;Estonia;Slovakia;Argentina;Chile;Russian Federation;Korea, Republic of

910

EUCTR2012-005822-31-GB
(EUCTR)

18/04/2013

05/03/2013

A study of the safety and drug effects of levodopa inhalation powder (CVT-301) in patients with Parkinson’s disease

Parkinson's Disease
MedDRA version: 14.1;Level: LLT;Classification code 10034007;Term: Parkinson's disease NOS;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Product Name: CVT-301
Product Code: CVT-301
INN or Proposed INN: LEVODOPA
Other descriptive name: LEVODOPA

Civitas Therapeutics, Inc.

NULL

Not Recruiting

Female: yes
Male: yes

Phase 2b

United States;Serbia;Italy;United Kingdom

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

911

JPRN-UMIN000010778

2013/04/10

22/05/2013

Delayed start study of donepezil hydrocloride for cognitive decline in Parkinson disease following EDAP-1

Delayed start study of donepezil hydrocloride for cognitive decline in Parkinson disease following EDAP-1 - EDAP-2

Parkinson disease

5mg donepezil hydrocloride

National Hospital of Utano

NULL

Complete: follow-up complete

20years-old

Not applicable

Male and Female

Not selected

Japan

912

JPRN-UMIN000010371

2013/04/08

01/04/2013

Study of zonisamide ( TRERIEF® tablet 25mg ) to tremor in patients with early Parkinson's disease.

Parkinson's disease

Start 25mg of Zonisamide and carry out observation 24weeks.
Evaluate start point, after 4weeks, after 8weeks, after 16weeks, and after 24weeks.

Department of Neurology, University of Yamanashi

NULL

Pending

Not applicable

Male and Female

Not selected

Japan

913

EUCTR2012-002608-42-GB
(EUCTR)

07/04/2013

01/11/2012

A study to evaluate the efficacy of Rotigotine (the treatment) versus placebo in patients with pain associated with Parkinson's Disease

A Multicenter, Multinational, Double-blind, Placebo-controlled, 2-arm Study to Evaluate the Efficacy of Rotigotine on Parkinson's Disease-Associated Pain

Parkinson’s disease
MedDRA version: 14.1;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

UCB Biosciences GmbH

NULL

Not Recruiting

Female: yes
Male: yes

478

Phase 4

France;United States;Hungary;Mexico;Slovakia;Argentina;Poland;Ukraine;Russian Federation;Germany;United Kingdom;Korea, Republic of

914

NCT01777555
(ClinicalTrials.gov)

April 2013

23/1/2013

Efficacy and Safety Study of Inhaled CVT 301 in Parkinson's Disease Patients for Treatment of OFF Episodes

A Phase 2b, Randomized, Double-blind, Placebo-controlled Study Investigating the Efficacy and Safety of Inhaled CVT 301 (Levodopa Inhalation Powder) in Parkinson's Disease Patients With Motor Response Fluctuations (OFF Phenomena)

Idiopathic Parkinson's Disease

Drug: CVT-301;Drug: Placebo

Acorda Therapeutics

NULL

Completed

30 Years

80 Years

All

Phase 2

United States;Italy;Serbia;United Kingdom

915

NCT01829867
(ClinicalTrials.gov)

April 2013

9/4/2013

A Study With an Increased Dose Step in Patients That Have Previously Received Placebo or sNN0031.

A Phase I, Open-label Study in Patients With Parkinson's Disease to Further Assess Safety and Tolerability of sNN0031 Administered at the Total Dose of 95 µg by Intracerebroventricular Infusion

Parkinson's Disease

Drug: sNN0031

Newron Sweden AB

NULL

Terminated

55 Years

75 Years

Both

Phase 1

Sweden

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

916

NCT02005029
(ClinicalTrials.gov)

April 2013

18/9/2013

Erythromycin in Parkinson's Disease

Erythromycin in Parkinson's Disease: A Pilot Study of Its Effects on Levodopa Pharmacokinetics and Pharmacodynamics

Parkinson's Disease;Levodopa

Drug: Erythromycin;Drug: placebo

Virginia Commonwealth University

NULL

Completed

18 Years

80 Years

All

N/A

United States

917

EUCTR2011-002828-41-SK
(EUCTR)

27/03/2013

04/03/2013

A study to test the effectiveness of varying doses of ropinirole PR while taking L-dopa in patients with late stage Parkinson's disease.

A fixed dose, dose-response study of ropinirole prolonged release (PR) as adjunctive treatment to L-dopa in patients with advanced Parkinson's disease.

Advanced Parkinson's disease.
MedDRA version: 16.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Trade Name: Requip Modutab, 2mg
Product Name: ropinirole PR , 2mg
Product Code: SK&F101468
INN or Proposed INN: ROPINIROLE
Trade Name: Requip Modutab, 4mg
Product Name: ropinirole PR , 2mg
Product Code: SK&F101468
INN or Proposed INN: ROPINIROLE
Trade Name: Requip Modutab, 8mg
Product Name: ropinirole PR
Product Code: SK&F101468
INN or Proposed INN: ROPINIROLE

GlaxoSmithKline Research & Development Limited

NULL

Not Recruiting

Female: yes
Male: yes

406

United States;Estonia;Taiwan;Slovakia;Argentina;Chile;Russian Federation;Korea, Republic of

918

EUCTR2012-002840-26-SI
(EUCTR)

26/03/2013

18/03/2013

Study to test the efficacy of two doses of Rotigotine on depressive mood (apathy) associated with Parkinson's Disease

A Multicenter, Multinational, Double-blind, Placebo-controlled, 3-arm Phase 4 Study to Evaluate the Efficacy of Rotigotine on Parkinson's Disease- Associated Apathy, Motor Symptoms, and Mood

Parkinson's disease
MedDRA version: 14.1;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

UCB Biosciences GmbH

NULL

Not Recruiting

Female: yes
Male: yes

504

Phase 4

United States;Serbia;Slovenia;Slovakia;Spain;Ukraine;Turkey;Austria;Italy;Hungary;Poland;Croatia;Romania;Bulgaria

919

NCT04627155
(ClinicalTrials.gov)

March 15, 2013

5/11/2020

A Study to Evaluate the Human Tolerance and Pharmacokinetics of LY03003

A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Human Tolerance and Kinetics of LY03003 By Single Intramuscular Injection

Parkinson Disease

Drug: LY03003

Luye Pharma Group Ltd.

NULL

Completed

18 Years

45 Years

All

Phase 1

NULL

920

JPRN-UMIN000009958

2013/03/08

01/03/2013

Effects of donepezil on the prognosis of Parkinson's disease with severe olfactory dysfunction

Parkinson's disease

Donepezil hydrochloride added to standard therapy
Placebo added to standard therapy

National Hospital Organization, Sendai-Nishitaga Hospital

NULL

Complete: follow-up complete

55years-old

75years-old

Male and Female

200

Not applicable

Japan

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

921

EUCTR2012-002840-26-AT
(EUCTR)

05/03/2013

06/11/2012

Study to test the efficacy of two doses of Rotigotine on depressive mood (apathy) associated with Parkinson's Disease

A Multicenter, Multinational, Double-blind, Placebo-controlled, 3-arm Phase 4 Study to Evaluate the Efficacy of Rotigotine on Parkinson's Disease- Associated Apathy, Motor Symptoms, and Mood

UCB Biosciences GmbH

NULL

Not Recruiting

Female: yes
Male: yes

504

Phase 4

United States;Serbia;Slovakia;Slovenia;Spain;Ukraine;Turkey;Austria;Italy;Hungary;Poland;Croatia;Romania;Bulgaria

922

NCT01780467
(ClinicalTrials.gov)

March 2013

21/1/2013

Role of Dopamine on Loss Aversion Behaviour: Study on Parkinsonian Patients

Role of Dopamine on Loss Aversion Behaviour: Study on Parkinsonian Patients.

Parkinson's Disease

Behavioral: Role of dopamine

University Hospital, Clermont-Ferrand

NULL

Not yet recruiting

35 Years

75 Years

Both

Phase 4

France

923

NCT01789047
(ClinicalTrials.gov)

March 2013

7/2/2013

Topiramate as an Adjunct to Amantadine in the Treatment of Dyskinesia in Parkinson's Disease

Idiopathic Parkinson's Disease;Drug Induced Dyskinesia

Drug: Topiramate;Drug: Placebo;Drug: Amantadine

Rush University Medical Center

Michael J. Fox Foundation for Parkinson's Research

Terminated

30 Years

90 Years

All

Phase 2

United States

924

NCT01736176
(ClinicalTrials.gov)

March 2013

27/11/2012

A Study to Assess the Safety and Efficacy of Levodopa-carbidopa Intestinal Gel (LCIG) for the Treatment of Non-motor Symptoms in Patients With Advanced Parkinson's Disease

An Open-Label, Two Part, Multicenter Study to Assess the Safety and Efficacy of Levodopa-Carbidopa Intestinal Gel (LCIG) for the Treatment of Non-Motor Symptoms in Subjects With Advanced Parkinson's Disease

Advanced Parkinson's Disease

Drug: Levodopa -Carbidopa Intestinal Gel;Procedure: Percutaneous Endoscopic Gastrostomy with Jejunal Extension (PEG-J);Drug: Levodopa -carbidopa Immediate Release (LC-IR) Tablets

AbbVie (prior sponsor, Abbott)

NULL

Completed

30 Years

N/A

All

Phase 3

United States

925

JPRN-UMIN000010014

2013/02/28

13/02/2013

Randomized Double-blind, Placebo-controlled multi-center trial on molecular hydrogen water in Parkinson Disease

Parkinson's disesase

hydrogen water made by "Suisosui5.0"
placebo-water (nitrogen filling water)

Juntendo University School of Medicine, Neurology

NULL

Complete: follow-up complete

20years-old

Not applicable

Male and Female

200

Not selected

Japan

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

926

EUCTR2012-002840-26-IT
(EUCTR)

18/02/2013

11/01/2013

Study to test the efficacy of two doses of Rotigotine on depressive mood (apathy) associated with Parkinson's Disease

A MULTICENTER, MULTINATIONAL, DOUBLE-BLIND, PLACEBO-CONTROLLED, 3-ARM, PHASE 4 STUDY TO EVALUATE THE EFFICACY OF ROTIGOTINE ON PARKINSON’S DISEASE-ASSOCIATED APATHY, MOTOR SYMPTOMS, AND MOOD

Trade Name: Neupro
INN or Proposed INN: ROTIGOTINE

UCB BIOSCIENCES GMBH

NULL

Not Recruiting

Female: yes
Male: yes

600

Phase 4

United States;Hungary;Slovenia;Spain;Ukraine;Turkey;Austria;Bulgaria;Russian Federation;Italy

927

EUCTR2012-002840-26-HU
(EUCTR)

11/02/2013

13/12/2012

Study to test the efficacy of two doses of Rotigotine on depressive mood (apathy) associated with Parkinson's Disease

A Multicenter, Multinational, Double-blind, Placebo-controlled, 3-arm Phase 4 Study to Evaluate the Efficacy of Rotigotine on Parkinson's Disease- Associated Apathy, Motor Symptoms, and Mood

UCB Biosciences GmbH

NULL

Not Recruiting

Female: yes
Male: yes

504

Phase 4

Serbia;United States;Slovakia;Slovenia;Spain;Ukraine;Turkey;Austria;Italy;Hungary;Poland;Romania;Croatia;Bulgaria

928

EUCTR2012-000801-64-GB
(EUCTR)

09/02/2013

26/11/2012

A study of the effects of medication on memory in Parkinson's Disease

A Phase IV Acceptability and Feasibility Trial of the Effects of Medication on Memory in Idiopathic Nondementing Parkinson’s Disease. - Medication and Memory in Parkinson’s Disease (MeMory PaD)

Idiopathic Parkinson's Disease
MedDRA version: 17.0;Level: LLT;Classification code 10013113;Term: Disease Parkinson's;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Trade Name: Mirapexin extended release various strengths
Product Name: Pramipexole dihydrochloride monohydrate extended release
Product Code: N/A
INN or Proposed INN: pramipexole dihydrochloride monohydrate
Other descriptive name: Mirapexin
Trade Name: Requip prolonged release
Product Name: Ropinirole hydrochloride prolonged release
INN or Proposed INN: Ropinirole (as hydrochloride)
Other descriptive name: Requip XL prolonged-release

University Hospital of North Staffordshire

Keele University

Not Recruiting

Female: yes
Male: yes

Phase 4

United Kingdom

929

NCT01766128
(ClinicalTrials.gov)

February 2013

8/1/2013

Study of Zonisamide in Early Parkinson Disease

Randomized Double Blind Placebo-controlled Study of Zonisamide Effectiveness in Early Parkinson Disease

Parkinson Disease

Drug: Zonisamide

Mazandaran University of Medical Sciences

NULL

Not yet recruiting

45 Years

85 Years

Both

Phase 2;Phase 3

NULL

930

NCT02059733
(ClinicalTrials.gov)

February 2013

7/2/2014

Developing a Novel Imaging Biomarker in the Differential Diagnosis of Parkinson's Disease and Parkinsonism

Developing a Novel Imaging Biomarker in the Differential Diagnosis of Parkinson's Disease and Parkinsonism by 18F-DTBZ PET

Parkinson's Disease

Drug: 18F-DTBZ

Chang Gung Memorial Hospital

NULL

Completed

20 Years

80 Years

All

Phase 2

Taiwan

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

931

NCT01789385
(ClinicalTrials.gov)

February 2013

2/2/2013

Anesthesia for Deep Brain Stimulation

Anesthesia for Deep Brain Stimulation for the Treatment of Parkinsons Disease

Parkinsons Disease

Drug: Dexmedetomidine

Diskapi Teaching and Research Hospital

NULL

Completed

19 Years

85 Years

Both

Phase 4

Turkey

932

NCT01782222
(ClinicalTrials.gov)

February 2013

30/1/2013

Trial to Evaluate The Efficacy Of Rotigotine on Parkinson's Disease-Associated Motor Symptoms And Apathy

A Multicenter, Multinational, Double-Blind, Placebo-Controlled, 3-Arm, Phase 4 Study To Evaluate The Efficacy Of Rotigotine On Parkinson's Disease-Associated Apathy, Motor Symptoms, And Mood

Idiopathic Parkinson's Disease

Drug: Rotigotine;Other: Placebo

UCB BIOSCIENCES GmbH

NULL

Completed

18 Years

N/A

All

122

Phase 4

United States;Austria;Hungary;Poland;Slovakia;Slovenia;Spain

933

EUCTR2012-002840-26-ES
(EUCTR)

23/01/2013

29/11/2012

Study to test the efficacy of two doses of Rotigotine on depressive mood (apathy) associated with Parkinson's Disease

A Multicenter, Multinational, Double-blind, Placebo-controlled, 3-arm Phase 4 Study to Evaluate the Efficacy of Rotigotine on Parkinson's Disease- Associated Apathy, Motor Symptoms, and Mood

UCB Biosciences GmbH

NULL

Not Recruiting

Female: yes
Male: yes

504

Phase 4

Serbia;United States;Slovakia;Slovenia;Spain;Ukraine;Turkey;Austria;Italy;Hungary;Poland;Romania;Croatia;Bulgaria

934

EUCTR2012-002608-42-DE
(EUCTR)

10/01/2013

26/09/2012

A study to evaluate the efficacy of Rotigotine (the treatment) versus placebo in patients with pain associated with Parkinson's Disease

A Multicenter, Multinational, Double-blind, Placebo-controlled, 2-arm Study to Evaluate the Efficacy of Rotigotine on Parkinson's Disease-Associated Pain

Parkinson’s disease
MedDRA version: 16.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

UCB Biosciences GmbH

NULL

Not Recruiting

Female: yes
Male: yes

United States;Hungary;Slovakia;Poland;Germany;United Kingdom

935

EUCTR2012-002608-42-HU
(EUCTR)

10/01/2013

12/11/2012

A study to evaluate the efficacy of Rotigotine (the treatment) versus placebo in patients with pain associated with Parkinson's Disease

A Multicenter, Multinational, Double-blind, Placebo-controlled, 2-arm Study to Evaluate the Efficacy of Rotigotine on Parkinson's Disease-Associated Pain

Parkinson’s disease
MedDRA version: 14.1;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

UCB Biosciences GmbH

NULL

Not Recruiting

Female: yes
Male: yes

478

France;United States;Hungary;Mexico;Slovakia;Argentina;Poland;Ukraine;Russian Federation;Germany;United Kingdom;Korea, Republic of

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

936

EUCTR2012-002840-26-SK
(EUCTR)

07/01/2013

09/03/2016

Study to test the efficacy of two doses of Rotigotine on depressive mood (apathy) associated with Parkinson's Disease

A Multicenter, Multinational, Double-blind, Placebo-controlled, 3-arm Phase 4 Study to Evaluate the Efficacy of Rotigotine on Parkinson's Disease- Associated Apathy, Motor Symptoms, and Mood

Parkinson's disease
MedDRA version: 18.1;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

UCB Biosciences GmbH

NULL

Not Recruiting

Female: yes
Male: yes

504

Phase 4

Serbia;United States;Slovakia;Slovenia;Spain;Ukraine;Turkey;Austria;Italy;Hungary;Poland;Croatia;Romania;Bulgaria

937

JPRN-UMIN000017695

2013/01/01

27/05/2015

Oxybuprocaine for apraxia of lid opening in Parkinson's disease

apraxia of lid opening in Parkinson's disease

Arm 1 intervention consisted of 4%oxybuprocaine eye drop treatment, washout for 24 hours or more, and a saline eye drop treatment
Arm 2 intervention consisted of saline eye drop treatment, a washout period, and an oxybuprocaine treatment

Utano National Hospital, National Hospital Organization

NULL

Complete: follow-up complete

Not applicable

Male and Female

Not selected

Japan

938

NCT02100176
(ClinicalTrials.gov)

January 2013

24/3/2014

MIRT and Rotigotine in the Early Stage of PD

Multidisciplinary Intensive Rehabilitation Treatment and Rotigotine in the Early Stages of Parkinson's Disease: a Randomized Controlled Study.

Parkinson's Disease

Other: Multidisciplinary intensive rehabilitation treatment;Drug: Rotigotine

Ospedale Generale Di Zona Moriggia-Pelascini

NULL

Recruiting

50 Years

75 Years

Both

N/A

Italy

939

NCT01014858
(ClinicalTrials.gov)

January 2013

16/11/2009

Multi-centre UK Study of the Acetylcholinesterase Inhibitor Donepezil in Early Dementia Associated With Parkinson's Disease

Parkinson's Disease

Drug: Donepezil

Newcastle-upon-Tyne Hospitals NHS Trust

University of Newcastle Upon-Tyne;University of Cambridge;University of Manchester;University of Birmingham;Bangor University;London School of Economics and Political Science;University College, London;Lancashire Care NHS Foundation Trust;Newcastle University;King's College London

Terminated

18 Years

N/A

All

Phase 3

United Kingdom

940

NCT01803945
(ClinicalTrials.gov)

January 2013

26/2/2013

A Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AVE8112 in Patients With Parkinson's Disease

Parkinson's Disease

Drug: AVE8112;Drug: Placebo

Michael J. Fox Foundation for Parkinson's Research

Sanofi

Terminated

35 Years

70 Years

Both

Phase 1

United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

941

NCT01500707
(ClinicalTrials.gov)

January 2013

22/12/2011

Single Dose Study to Assess the Pharmacokinetics of SCH 900800 in Subjects With Parkinson's Disease Being Treated With Levodopa (L-DOPA) (P08235)

A Single Dose Study to Assess the Pharmacokinetics of SCH 900800 Administered as Oral Tablets in L-DOPA-treated Subjects With Parkinson's Disease

Parkinson's Disease

Drug: SCH 900800

Merck Sharp & Dohme Corp.

NULL

Withdrawn

30 Years

85 Years

Both

Phase 1

NULL

942

NCT03651856
(ClinicalTrials.gov)

January 2013

2/7/2018

Atomoxetine for Freezing of Gait in Parkinson's Disease

A Pilot Study of Atomoxetine for Freezing of Gait in Parkinson's Disease

Parkinson's Disease;Freezing of Gait

Drug: ATM FOG in PD

Medical University of South Carolina

NULL

Completed

18 Years

80 Years

All

Phase 3

United States

943

EUCTR2012-002608-42-SK
(EUCTR)

17/12/2012

09/03/2016

A study to evaluate the efficacy of Rotigotine (the treatment) versus placebo in patients with pain associated with Parkinson's Disease

A Multicenter, Multinational, Double-blind, Placebo-controlled, 2-arm Study to Evaluate the Efficacy of Rotigotine on Parkinson's Disease-Associated Pain

Parkinson’s disease
MedDRA version: 18.1;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

UCB Biosciences GmbH

NULL

Not Recruiting

Female: yes
Male: yes

478

France;United States;Hungary;Mexico;Slovakia;Argentina;Poland;Ukraine;Russian Federation;Germany;United Kingdom;Korea, Republic of

944

NCT01770145
(ClinicalTrials.gov)

December 2012

7/1/2013

Apokyn for Motor IMProvement of Morning AKinesia Trial (AM IMPAKT)

A Phase 4, Open-Label, Efficacy and Safety Study of Apokyn® for Rapid and Reliable Improvement of Motor Symptoms in Parkinson Disease Subjects With Delayed Onset of L-Dopa Action

Parkinson's Disease;Motor Symptoms;Akinesia;Hypomobility;Delayed Levodopa Onset

Drug: APOKYN;Drug: L-dopa;Drug: Trimethobenzamide

US WorldMeds LLC

NULL

Completed

18 Years

N/A

All

127

Phase 4

United States

945

NCT01725802
(ClinicalTrials.gov)

December 2012

4/11/2012

A Phase I/IIa Study of Safety, Tolerability and Plasma Concentration of Subcutaneous Continuously-delivered Levodopa/Carbidopa Solution (ND0612) in PD Patients

A Phase I/IIa, Single Dose, Single-centre, Randomized, Crossover, Double-blind, Placebo-controlled Study Evaluating Safety, Tolerability and Levodopa Plasma Concentration Following Administration of Subcutaneous Continuously-delivered Levodopa/Carbidopa Solution (ND0612) in PD Patients

Parkinson's Disease

Drug: levodopa and carbidopa solution for SC administration;Drug: Placebo

NeuroDerm Ltd.

NULL

Completed

30 Years

N/A

Both

Phase 1;Phase 2

Israel

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

946

NCT02112812
(ClinicalTrials.gov)

December 2012

10/4/2014

Effects of Helicobacter Pylori Infection Eradication in Patients With Parkinson's Disease

A Study on Clinical Response Following Eradication Therapy of Helicobacter Pylori Infection in Parkinson's Disease

Response to Levodopa;Motor Outcomes;Quality of Life Outcomes

Drug: Eradication therapy for H.pylori infection;Drug: Eradication of Helcobacter Pylori;Drug: Eradication therapy for Helicobacter pylori

National University of Malaysia

NULL

Completed

17 Years

N/A

Both

N/A

Malaysia

947

NCT01741701
(ClinicalTrials.gov)

December 2012

1/12/2012

A Pilot Study of Oxaloacetate in Subjects With Treated PD

A Pilot Double-Blind, Parallel Group, Placebo Controlled Study of Oxaloacetate in Subjects With Treated Parkinson's Disease (PD)

Parkinson's Disease

Drug: Oxaloacetate (OAA);Drug: Placebo

University of Kansas Medical Center

Terra Biological LLC

Completed

30 Years

N/A

All

Phase 2;Phase 3

United States

948

NCT01723228
(ClinicalTrials.gov)

November 2012

5/11/2012

Parallel-Group Study to Assess the Effect of Rasagiline on Cognition in Patients With Parkinson's Disease

A 24-Week, Multicenter, Randomized, Double-blind, Placebo-Controlled, Add-on, Parallel-Group Study to Assess the Effect of Rasagiline on Cognition in Patients With Parkinson's Disease

Parkinson's Disease

Drug: Rasagiline;Drug: Placebo

Teva Branded Pharmaceutical Products, R&D Inc.

NULL

Completed

45 Years

80 Years

All

170

Phase 4

United States

949

NCT01744496
(ClinicalTrials.gov)

November 2012

5/12/2012

Study to Evaluate the Efficacy of Rotigotine on Parkinson's Disease-Associated Pain

A Multicenter, Multinational, Double-Blind, Placebo-Controlled, 2-Arm Study to Evaluate the Efficacy of Rotigotine on Parkinson's Disease-Associated Pain

Advanced Idiopathic Parkinson's Disease

Drug: Rotigotine;Drug: Placebo

UCB BIOSCIENCES GmbH

NULL

Completed

18 Years

N/A

All

Phase 4

United States;Germany;Poland;Slovakia;Hungary;Korea, Republic of

950

NCT01738191
(ClinicalTrials.gov)

November 2012

28/11/2012

Atomoxetine Treatment for Cognitive Impairment in Parkinson's Disease (ATM-Cog)

Parkinson's Disease;Cognitive Impairment

Drug: Atomoxetine;Drug: Placebo

Medical University of South Carolina

Michael J. Fox Foundation for Parkinson's Research

Completed

35 Years

75 Years

All

Phase 2

United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

951

NCT01683253
(ClinicalTrials.gov)

November 2012

7/9/2012

Remission of ICD by Switching Dopamine Agonist to Levodopa/Carbidopa

The REmission of the Impulse Control Disorder and the Changes of the Neuropsychiatric Characteristics After Switching Into Levodopa/Carbidopa in Patients With Parkinson's Disease Who Have Developed Impulse Control Disorders Due to the Dopamine Replacement Therapy

Impulse Control Disorder

Drug: Levodopa /Carbidopa(200mg/50mg);Drug: Dopaminergic Agonists

Sandoz

NULL

Completed

30 Years

80 Years

All

150

Phase 4

NULL

952

NCT01721460
(ClinicalTrials.gov)

November 2012

30/10/2012

Effects of Dexmedetomidine on Activity in the Subthalamic Nucleus

Effects of Dexmedetomidine on Neuronal Activity in the Subthalamic Nucleus During Deep Brain Stimulation (DBS) Electrode Implantation Surgery

Parkinson's Disease;Deep Brain Stimulation Surgery

Drug: Dexmedetomidine

University of Wisconsin, Madison

NULL

Completed

18 Years

85 Years

All

Phase 4

United States

953

NCT03652363
(ClinicalTrials.gov)

October 25, 2012

21/8/2018

GDNF in ideopathicParkinsons Disease

A Placebo-Controlled, Randomised, Double-Blind Trial to Assess the Safety and Efficacy of Intermittent Bilateral Intraputamenal (GDNF) Infusions Administered Via Convection Enhanced Delivery (CED) in Subjects With Parkinson&Apos;s Disease

Idiopathic Parkinson Disease

Drug: glial cell line-derived neurotrophic factor

North Bristol NHS Trust

NULL

Completed

35 Years

75 Years

All

Phase 2

NULL

954

JPRN-UMIN000009099

2012/10/01

12/10/2012

The effect of lidocaine injection into the external oblique in Parkinson's disease patients with upper camptorcormia

Parkinson's disease

lidocaine injection into the external oblique
normal saline injection into the external oblique

Parkinson's disease and Movement Disorder Center

NULL

Recruiting

20years-old

Not applicable

Male and Female

Not applicable

Japan

955

NCT01603069
(ClinicalTrials.gov)

October 2012

14/5/2012

A Study to Assess Safety and Tolerability of Oral AZD3241 in Patients With Parkinson's Disease

A Phase IIa, 12 Week, Multicentre, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Tolerability of Oral AZD3241 in Patients With Parkinson's Disease

Parkinson's Disease

Drug: AZD3241 300 mg BID;Drug: AZD3241 600 mg BID;Drug: Placebo

AstraZeneca

NULL

Completed

30 Years

80 Years

Both

Phase 2

United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

956

NCT01560754
(ClinicalTrials.gov)

October 2012

9/3/2012

Disease-modifying Potential of Transdermal NICotine in Early Parkinson's Disease

A Randomized, Placebo-controlled, Double-blind, Multi-center Trial to Assess the Disease-modifying Potential of Transdermal Nicotine in Early Parkinson's Disease in Germany and the USA

Parkinson's Disease

Drug: nicotine transdermal patch

James BOYD MD

Michael J. Fox Foundation for Parkinson's Research;Parkinson Study Group (PSG);International Parkinson Fonds (IPF);German Parkinson Study Group (GPS);German Parkinson Society (DPG);Philipps-University Marburg, Germany

Active, not recruiting

30 Years

N/A

Both

160

Phase 2

United States;Germany

957

NCT01796483
(ClinicalTrials.gov)

October 2012

13/2/2013

EEG and Pharmacological Exploration of Executive Dysfunctions Induced by STN-DBS in PD

Exploration électroencéphalographie et Pharmacologique Des Dysfonctionnements exécutifs Induits Par la Stimulation cérébrale Profonde du Noyau Sous-thalamique Dans la Maladie de Parkinson

Parkinson Disease

Device: Clonidine (Catapressan);Device: Placebo 90 minutes before EEG

Hospices Civils de Lyon

NULL

Completed

40 Years

70 Years

All

N/A

France

958

NCT01691924
(ClinicalTrials.gov)

October 2012

13/9/2012

Study To Assess the Safety and Tolerability of PBF-509 in Male Healthy Volunteers

Randomized, Double Blind, Placebo Controlled First In-human Study To Assess the Safety and Tolerability of Single Ascending Oral Doses of PBF-509 in Male Healthy Volunteers

Parkinson Disease

Drug: PBF-509;Drug: Placebo

Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

Palo Biofarma, S.L

Completed

18 Years

45 Years

Male

Phase 1

Spain

959

NCT01723904
(ClinicalTrials.gov)

October 2012

6/11/2012

A Phase 3b, Open-Label, Safety and Efficacy Study of Rotigotine as Add-On Therapy With Low Doses of Pramipexole or Ropinirole in Patients With Advanced Parkinson's Disease

An Open-Label Study to Investigate the Safety and Efficacy of Rotigotine Add-On Therapy With Low Doses of Pramipexole or Ropinirole in Patients With Advanced Parkinson's Disease Phase 3B

Advanced Parkinson's Disease

Drug: Rotigotine

UCB BIOSCIENCES GmbH

Otsuka Pharmaceutical Co., Ltd.

Completed

30 Years

80 Years

All

Phase 3

Australia;Korea, Republic of;Malaysia;Singapore;Taiwan

960

NCT01563913
(ClinicalTrials.gov)

October 2012

16/3/2012

Reducing Dyskinesia in Parkinson's Disease With Omega-3 Fatty Acids

Reducing Dyskinesia in Parkinson Disease With Omega-3 Fatty Acids

Parkinson's Disease

Drug: Docosahexaenoic Acid (DHA);Drug: Placebo

VA Office of Research and Development

Oregon Health and Science University

Completed

21 Years

99 Years

All

Phase 1

United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

961

EUCTR2011-003866-34-GB
(EUCTR)

24/09/2012

01/05/2012

Assessing the Benefit and Safety of Administering Intermittent GDNF Infusions in Parkinson's Disease (PD)

A Placebo-Controlled, Randomised, Double-Blind Trial to Assess the Safety and Efficacy of Intermittent Bilateral Intraputamenal Glial Cell Line-Derived Neurotrophic Factor (GDNF) Infusions Administered via Convection Enhanced Delivery (CED) in Subjects with Parkinson’s Disease - Intermittent Bilateral GDNF for Parkinson’s Disease

North Bristol NHS Trust (NBT)

NULL

Not Recruiting

Female: yes
Male: yes

Phase 2

United Kingdom

962

EUCTR2011-004378-27-AT
(EUCTR)

04/09/2012

20/07/2012

Open-label, Long-term Safety Extension Study of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias

An open-label treatment study to evaluate the safety, tolerability and efficacy of AFQ056 in Parkinson’s patients with L-dopa induced dyskinesias

L-dopa induced dyskinesias in patients with Parkinson’s disease
MedDRA version: 14.1;Level: HLT;Classification code 10013929;Term: Dyskinesias and movement disorders NEC;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Product Name: AFQ056
Product Code: AFQ056
INN or Proposed INN: mavoglurant
Product Name: AFQ056
Product Code: AFQ056
INN or Proposed INN: mavoglurant
Product Name: AFQ056
Product Code: AFQ056
INN or Proposed INN: mavoglurant
Product Name: AFQ056
Product Code: AFQ056
INN or Proposed INN: mavoglurant

Novartis Pharma Services AG

NULL

Not Recruiting

Female: yes
Male: yes

United States;France;Hungary;Slovakia;Canada;Spain;Turkey;Austria;Germany;Switzerland;Italy

963

ChiCTR-OCS-12002720

2012-09-01

2012-11-26

Pharmacogenetics study of anti-parkinson's disease drug levodopa

The association between polymorphisms of DRD2, DRD2, SLC6A3 and the levodopa response

Parkinson's Disease

A:levodopa;

Institute of Clinical Pharmacology, Central South University

NULL

Completed

Both

A:200;

NULL

964

NCT01711866
(ClinicalTrials.gov)

September 2012

18/10/2012

A Phase 4, Open-label Study to Assess the Feasibility and Efficacy on Motor and Non-motor Symptoms of Switching From Pramipexole or Ropinirole to Rotigotine Transdermal Patch in Subjects With Advanced Idiopathic Parkinson's Disease

An Open-Label, Multicenter, Multinational Study to Assess the Feasibility of Switching Therapy From Pramipexole or Ropinirole to the Rotigotine Transdermal System and Its Effect on Motor and Non-Motor Symptoms in Subjects With Advanced Idiopathic Parkinson's Disease Phase 4

Advanced Idiopathic Parkinson's Disease

Drug: Rotigotine

UCB BIOSCIENCES GmbH

Otsuka Pharmaceutical Co., Ltd.

Completed

30 Years

80 Years

All

Phase 4

United States;Korea, Republic of;Malaysia;Singapore;Taiwan

965

NCT01676103
(ClinicalTrials.gov)

September 2012

28/8/2012

The Effects of Supplementing Tyrosine on Blood Pressure in Parkinson's Disease

Parkinson's Disease

Dietary Supplement: Tyrosine;Other: Placebo Comparator:Sugar Pill

New York Institute of Technology

Michael J. Fox Foundation for Parkinson's Research

Completed

50 Years

80 Years

Both

Phase 1;Phase 2

United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

966

NCT01684475
(ClinicalTrials.gov)

September 2012

11/9/2012

A STUDY TO EVALUATE THE EFFICACY OF CJH1 (CLR4001) IN PARKINSON'S DISEASE

A STUDY TO EVALUATE THE EFFICACY OF CJH1 [CLR4001] IN THE TREATMENT OF PARKINSON'S DISEASE

Parkinson's Disease

Drug: CJH1 (CLR4001)

Alexandra Marine and General Hospital

NULL

Recruiting

40 Years

85 Years

Both

Phase 1;Phase 2

Canada

967

NCT01662791
(ClinicalTrials.gov)

September 2012

7/8/2012

Weight Loss in Parkinson's Disease and Role of Small Bowel Bacterial Overgrowth

Weight Loss in Parkinson's Disease and the Potential Role of Small Bowel Bacterial Overgrowth

Parkinson's Disease

Drug: Rifaximin

Mayo Clinic

NULL

Completed

18 Years

N/A

All

Phase 3

United States

968

EUCTR2011-004803-19-FI
(EUCTR)

16/08/2012

16/05/2012

PET study in PD patients

A Phase IIA, Multi centre, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Effect of 8 Weeks Treatment with Oral AZD3241 on Microglia Activation, as Measured by Positron Emission Tomography (PET), in Patients with Parkinson’s Disease

Parkinson's Disease; Microglia activation as measured by [11C]PBR28 binding to TSPO
MedDRA version: 14.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Product Name: AZD3241 Extended release tablets 25 mg
Product Code: AZD3241
Product Name: AZD3241 Extended release tablets 100 mg
Product Code: AZD3241
Product Name: [11C]PBR28
Product Code: [11C]PBR28
Product Name: [18F]FE-PE2I
Product Code: [18F]FE-PE2I

AstraZeneca AB

NULL

Not Recruiting

Female: yes
Male: yes

Phase 2A

Finland;Sweden

969

EUCTR2012-000122-21-DK
(EUCTR)

10/08/2012

07/06/2012

Improving the blood pressure regulating system in patients with parkinsons disease

Acethylcholineesterase inhibition and orthostatic hypotension in patients with parkinsons disease

Ortostatic hypotension in patients with Parkinsons disease
MedDRA version: 14.1;Level: PT;Classification code 10031127;Term: Orthostatic hypotension;System Organ Class: 10047065 - Vascular disorders;Therapeutic area: Body processes [G] - Circulatory and Respiratory Physiological Phenomena [G09]

Trade Name: Mestinon
Product Name: Mestinon
INN or Proposed INN: PYRIDOSTIGMINE BROMIDE
Other descriptive name: Mestinon

Department of Neurology, Roskilde Hospital

NULL

Not Recruiting

Female: yes
Male: yes

Phase 2

Denmark

970

EUCTR2012-001530-34-NL
(EUCTR)

09/08/2012

Vareniciline treatment for Excessive Daytime Sleepiness in Parkinson’s Disease

Varenicline, a partial nicotinic receptor agonist for the treatment of Excessive Daytime Sleepiness in Parkinson’s Disease: a placebo-controlled cross-over study - Vareniciline for Excessive daytime Sleepiness in PArkinson’s disease (VESPA)

Idiopathic Parkinson's disease
MedDRA version: 18.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Trade Name: Champix
INN or Proposed INN: VARENICLINE
Other descriptive name: VARENICLINE TARTRATE

VU University Medical Center

Center Human Drug Research

Not Recruiting

Female: yes
Male: yes

Phase 3

Netherlands

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

971

NCT02419313
(ClinicalTrials.gov)

August 2012

27/1/2014

Investigation of the Efficacy and Safety of IncobotulinumtoxinA (Xeomin) in Parkinson's Tremor: A Customized Approach

Investigation of the Efficacy and Safety of IncobotulinumtoxinA (Xeomin) in Parkinson's Disease Tremor: A Customized Approach

Parkinson;Tremor

Drug: incobotulinumtoxinA;Drug: Saline

Yale University

NULL

Completed

18 Years

N/A

All

Phase 2

United States

972

NCT00947037
(ClinicalTrials.gov)

August 2012

24/7/2009

Gastric Retentive Carbidopa/ Levodopa in Parkinson's Patients; a One Year, Open Label, Safety Extension Study

An Open-Label, Multi-Center, Follow-Up Study Designed to Evaluate the Long-Term Effects of AP-CD/LD in Fluctuating Parkinson's Disease Subjects

Parkinson's Disease

Drug: AP -CD/LD

Intec Pharma Ltd.

NULL

Withdrawn

30 Years

95 Years

Both

Phase 2

Israel

973

NCT02764892
(ClinicalTrials.gov)

August 2012

25/9/2015

A Study in Healthy Male Volunteers to Investigate a New Drug for the Treatment of Parkinson's Disease

An Open Label Study of V81444 Using Positron Emission Tomography to Assess Occupancy of Brain Adenosine A2A Receptors & Functional & Perfusion MRI to Explore Effects on Regional Brain Activity & Perfusion in Healthy Male Volunteers

Parkinson's Disease

Drug: V81444

Vernalis (R&D) Ltd

NULL

Completed

25 Years

55 Years

Male

Phase 1

NULL

974

JPRN-UMIN000008477

2012/07/19

19/07/2012

Clinical study of selegiline hydrochloride ( FP OD tablet 2.5) to flexion of spine in Parkinson's disease.

Parkinson disease

Selegiline hydrochloride 5mg 8weeks, 7.5mg 8weeks and stop it, followed after 8weeks, and evaluate each points.

Department of Neurology, Juntendo Koshigaya Hospital

NULL

Complete: follow-up complete

20years-old

Not applicable

Male and Female

Not selected

Japan

975

JPRN-UMIN000008138

2012/07/01

01/07/2012

Efficacy and safety of silodosin on lower urinary tract symptoms (LUTS) in patients with Parkinson's disease

Parkinson's disease

Silodosin 8mg BID

Juntendo University School of Medicine

NULL

Complete: follow-up complete

Not applicable

Male

100

Not selected

Japan

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

976

NCT01646268
(ClinicalTrials.gov)

July 2012

18/7/2012

Rotigotine Versus Placebo As Double Blind Study To Evaluate The Efficacy In Early Stage Idiopathic Parkinson's Disease Patients

A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study Of The Efficacy And Safety Of The Rotigotine Transdermal Patch In Chinese Subjects With Early-stage Idiopathic Parkinson's Disease

IDIOPATHIC PARKINSON'S DISEASE

Drug: Rotigotine;Drug: Placebo Patch

UCB Pharma

NULL

Completed

30 Years

N/A

All

249

Phase 3

China

977

NCT01602549
(ClinicalTrials.gov)

July 2012

17/5/2012

A Study to Assess the Effect of Repeat Doses of GSK962040 on the Pharmacokinetics of L-DOPA in Subjects With Parkinson's Disease Exhibiting Delayed Gastric Emptying

A Randomized, Double-blind, Placebo-controlled, Parallel Group, Dose Ranging Study to Assess the Effect of Repeat Doses of GSK962040 on the Pharmacokinetics of L-DOPA in Subjects With Parkinson's Disease Exhibiting Delayed Gastric Emptying

Gastroparesis

Drug: GSK962040 (25 mg tablet);Drug: Placebo

GlaxoSmithKline

NULL

Completed

40 Years

80 Years

All

Phase 2

Australia;Germany;Sweden;United Kingdom

978

NCT01398748
(ClinicalTrials.gov)

July 2012

19/7/2011

Intranasal Glutathione in Parkinson's Disease

A Phase 1 Study of Intranasal Reduced Glutathione in Parkinson's Disease

Parkinson's Disease (PD)

Drug: Intranasal glutathione - (in)GSH;Drug: Saline Intranasal Delivery

Bastyr University

National Center for Complementary and Integrative Health (NCCIH)

Completed

21 Years

100 Years

All

Phase 1

United States

979

NCT01491022
(ClinicalTrials.gov)

July 2012

8/12/2011

A Randomized Trial to Evaluate Ampyra for Gait Impairment in Parkinson's Disease

Parkinson's Disease

Drug: Ampyra first, then Placebo;Drug: placebo first, then Ampyra

University of Miami

Acorda Therapeutics

Completed

45 Years

80 Years

All

Phase 1;Phase 2

United States

980

NCT01646255
(ClinicalTrials.gov)

July 2012

18/7/2012

Rotigotine Versus Placebo, A Study To Evaluate The Efficacy In Advanced Stage Idiopathic Parkinson's Disease Patients

A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of The Efficacy And Safety of Rotigotine Transdermal Patch In Chinese Subjects With Advanced-stage, Idiopathic Parkinson's Disease Who Are Not Well Controlled On Levodopa

Idiopathic Parkinson's Disease

Drug: Rotigotine;Drug: Placebo Patch;Drug: L-dopa

UCB Pharma

UCB Trading (Shanghai) Co. Ltd.

Completed

30 Years

N/A

All

346

Phase 3

China

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

981

EUCTR2011-003053-25-GB
(EUCTR)

18/06/2012

01/05/2012

The ReSPonD Study -Rivastigmine to Stabilise gait in Parkinson’s Disease. A study looking at whether Rivastigmine, a drug that can augment mental function, can stabilise walking in people with Parkinson's disease who have fallen.

A randomised, double blind, placebo controlled trial to evaluate the effect of Rivastigmine on gait in people with Parkinson’s disease who have fallen. - ReSPonD Study - Rivastigmine to Stabilise gait in Parkinson’s Disease

Parkinson's disease
MedDRA version: 14.1;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Research and Enterprise Department

NULL

Not Recruiting

Female: yes
Male: yes

130

Phase 2

United Kingdom

982

JPRN-JapicCTI-121880

11/6/2012

Phase II clinical study in patients with Parkinson's disease not taking L-DOPA

A randomized, double-blind, placebo-controlled, comparative study of HP-3000 in patients with Parkinson's disease not taking L-DOPA

Parkinson's disease

Hisamitsu Pharmaceutical Co.,Inc.

NULL

BOTH

Phase 2

NULL

983

JPRN-JapicCTI-121879

07/6/2012

Phase II clinical study in patients with Parkinson's disease taking L-DOPA

A randomized, double-blind, placebo-controlled, comparative study of HP-3000 in patients with Parkinson's disease taking L-DOPA

Parkinson's disease

Hisamitsu Pharmaceutical Co.,Inc.

NULL

BOTH

Phase 2

NULL

984

EUCTR2011-002074-23-AT
(EUCTR)

05/06/2012

07/05/2012

Evaluation of the Efficacy and Safety of Modified Release AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias

13-week, double-blind, placebo-controlled, fixed-dose, multicenter study to evaluate the efficacy and safety of modified release AFQ056 in reducing moderate to severe L-dopa induced dyskinesias in patients with Parkinson’s disease

L-dopa induced dyskinesias in patients with Parkinson's disease
MedDRA version: 14.1;Level: HLT;Classification code 10013929;Term: Dyskinesias and movement disorders NEC;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Product Name: AFQ056
Product Code: AFQ056
Product Name: AFQ056
Product Code: AFQ056
Product Name: AFQ056
Product Code: AFQ056
Product Name: AFQ056
Product Code: AFQ056
Product Name: AFQ056
Product Code: AFQ056
Product Name: AFQ056
Product Code: AFQ056
Product Name: AFQ056
Product Code: AFQ056
Product Name: AFQ056
Product Code: AFQ056
Product Name: AFQ056
Product Code: AFQ056
Product Name: AFQ056
Product Code: AFQ056

Novartis Pharma Services AG

NULL

Not Recruiting

Female: yes
Male: yes

140

United States;France;Hungary;Slovakia;Canada;Spain;Turkey;Austria;Germany;Switzerland;Italy

985

JPRN-UMIN000008057

2012/06/01

06/06/2012

Effect of enteral formula enriched with omega-3 fatty acid to prevention of weight reduction in patients with Parkinson's Disease

Parkinson's Disease

Daily oral administration of enteral nutrition formula (Racol NF) 400ml for 12 weeks consecutively.

St. Mariannna University School of Medicine

NULL

Complete: follow-up complete

35years-old

80years-old

Male and Female

Not applicable

Japan

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

986

NCT02786667
(ClinicalTrials.gov)

June 2012

18/5/2016

Non Motors Aspects in De Novo Parkinson's Disease

Non Motors Aspects in De Novo Parkinson's Disease: Clinical and Physiopathological Description; Dopamine Agonist Treatment Effects.

Parkinson Disease;Apathy

Drug: Rotigotine;Drug: Placebo

University Hospital, Grenoble

NULL

Active, not recruiting

30 Years

72 Years

All

199

Phase 3

France

987

NCT02319382
(ClinicalTrials.gov)

June 2012

18/11/2014

Measure of Microglial Activation in the Brain of Parkinson Disease Patients With PET

High Resolution PET Imaging of Microglial Activation in Parkinson's Disease (PD) With a New Tracer [18F]DPA-714

Parkinson's Disease With LRRK2 Mutation;Healthy Controls;Parkinson's Disease Without LRRK2 Mutation

Radiation: PET with the tracer 18F-DPA-714;Radiation: PET with the tracer 11C-PE2I;Other: MRI

Assistance Publique - Hôpitaux de Paris

France Parkinson Association

Recruiting

18 Years

N/A

Both

N/A

France

988

NCT01993680
(ClinicalTrials.gov)

June 2012

27/4/2012

Orthostatic Dysregulation and Associated Gastrointestinal Dysfunction in Parkinson's Disease -Treatment

A Monocentric Randomized, Controlled, Double Blind, Crossover Phase II Trial to Show Non-inferiority of the Effect of Pyridostigmine Bromide vs. Fludrocortisone on Symptoms of Autonomic Dysregulation in Parkinson's Disease

Autonomic Disturbances in Parkinson's Disease

Drug: Pyridostigmine bromide;Drug: fludrocortisone

Christian Baumann

NULL

Completed

50 Years

80 Years

All

Phase 2

Switzerland

989

NCT01892176
(ClinicalTrials.gov)

June 2012

30/6/2013

Effects of High-dose Coenzyme Q10 on Biomarkers of Oxidative Damage and Clinical Outcome in Parkinson Disease

Parkinson Disease

Dietary Supplement: coenzyme q10

National University Hospital, Singapore

NULL

Completed

21 Months

N/A

Both

Phase 2;Phase 3

Singapore

990

EUCTR2012-001218-40-IT
(EUCTR)

21/05/2012

23/07/2012

EFFICACY OF ROTIGOTINE ON GAIT PERFORMANCE OF PARKINSONIAN PATIENTS

Patients suffering for Idiopathic Parkinson’s Disease. H&Y stage > or = 2 with un-satisfactory control by on-going pharmacological therapy (Levodopa, COMT & MAO-inhibitors), characterised by an incomplete control of motor signs, in particular presence of early morning akinesia, as well as gait deficits in the morning.
MedDRA version: 14.1;Level: PT;Classification code 10056242;Term: Parkinsonian gait;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Trade Name: NEUPRO *7CER 4MG/24H
INN or Proposed INN: rotigotina
Trade Name: NEUPRO *7CER 6MG/24H
INN or Proposed INN: rotigotina
Trade Name: NEUPRO *7CER 8MG/24H
INN or Proposed INN: rotigotina
Trade Name: NEUPRO *28CER 2MG/24H
INN or Proposed INN: rotigotina
Trade Name: NEUPRO *28CER 4MG/24H
INN or Proposed INN: rotigotina
Trade Name: NEUPRO *28CER 6MG/24H
INN or Proposed INN: rotigotina
Trade Name: NEUPRO *28CER 8MG/24H
INN or Proposed INN: rotigotina

FONDAZIONE SANTA LUCIA

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

Italy

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

991

EUCTR2011-004378-27-DE
(EUCTR)

15/05/2012

24/02/2012

Open-label, Long-term Safety Extension Study of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias

An open-label treatment study to evaluate the safety, tolerability and efficacy of AFQ056 in Parkinson’s patients with L-dopa induced dyskinesias

Product Name: AFQ056
Product Code: AFQ056
Product Name: AFQ056
Product Code: AFQ056
Product Name: AFQ056
Product Code: AFQ056
Product Name: AFQ056
Product Code: AFQ056

Novartis Pharma Services AG

NULL

Not Recruiting

Female: yes
Male: yes

France;United States;Hungary;Slovakia;Canada;Spain;Turkey;Austria;Germany;Italy;Switzerland

992

EUCTR2011-004378-27-SK
(EUCTR)

02/05/2012

12/04/2012

Open-label, Long-term Safety Extension Study of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias

An open-label treatment study to evaluate the safety, tolerability and efficacy of AFQ056 in Parkinson’s patients with L-dopa induced dyskinesias

Novartis Pharma Services AG

NULL

Not Recruiting

Female: yes
Male: yes

France;United States;Hungary;Slovakia;Canada;Spain;Turkey;Austria;Germany;Italy;Switzerland

993

JPRN-UMIN000007896

2012/05/01

07/05/2012

Levodopa challenge test for Parkinson's disease and other parkinsonian syndromes

Parkinson's disease and other parkinsonian syndromes

The patients are given domperidone 30 mg/day for 3 days. When a patient is already on any anti-parkinson drugs, these drugs were withdrawn from the night before of the evaluation day. On the fourth day lactose powder is given to the patients and levodopa (250 mg)/carbidopa (25 mg) is given on the fifth day in a double-blind manner. On fourth and fifth day, motor symptoms of the patients are examined using the Unified Parkinson's Disease Rating Scale motor scores by a clinician who is blind to the test drug.
The patients are given domperidone 30 mg/day (standard dose in Japan) for 3 days. When a patient is already on any anti-parkinson drugs, these drugs were withdrawn from the night before of the evaluation day. On the fourth day levodopa (250 mg)/carbidopa (25 mg) is given to the patients and lactose powder is given on the fifth day in a double-blind manner. Motor symptoms of the patients are examined using the Unified Parkinson's Disease Rating Scale motor scores by a clinician who is blind to the test drug.

Kansai Medical University

NULL

Recruiting

Not applicable

Male and Female

100

Not selected

Japan

994

NCT01652313
(ClinicalTrials.gov)

May 2012

23/7/2012

Pharmacokinetic Properties of Rasagiline (Lu 00-773) in Healthy Young Chinese Men and Women

A Single Centre, Open-label, Multiple-dose Interventional Study Investigating the Pharmacokinetic Properties of Rasagiline (Lu 00-773) in Healthy Young Chinese Men and Women

Parkinson's Disease

Drug: Rasagiline

H. Lundbeck A/S

NULL

Completed

18 Years

45 Years

Both

Phase 1

China

995

NCT01617135
(ClinicalTrials.gov)

May 2012

7/5/2012

Safety, Pharmacokinetics and Efficacy Study of CVT-301 Inpatients With Parkinson's Disease and Off Episodes

A Randomized, Placebo-Controlled, Phase 2 Study of the Safety, Pharmacokinetics and Pharmacodynamics of CVT-310 (Levodopa Inhalation Powder) in Patients With Parkinson's Disease and Motor Response Fluctuations (Off Episodes)

Idiopathic Parkinson's Disease

Drug: CVT-301;Drug: Placebo;Drug: Sinemet (carbidopa/levodopa)

Acorda Therapeutics

Michael J. Fox Foundation for Parkinson's Research

Completed

30 Years

N/A

All

Phase 2

Israel;Serbia;United Kingdom

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

996

EUCTR2012-000181-37-GB
(EUCTR)

25/04/2012

27/02/2012

A study investigating the safety of CVT-301 in patients with Parkinson's Disease

A Randomized, Placebo-Controlled Phase 2 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of CVT-301 (Levodopa Inhalation Powder) in Patients with Parkinson’s Disease and Motor Response Fluctuations (Off” Episodes)

Parkinson's Disease
MedDRA version: 14.1;Level: LLT;Classification code 10034007;Term: Parkinson's disease NOS;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Product Name: CVT-301
Product Code: CVT-301
INN or Proposed INN: LEVODOPA
Trade Name: Sinemet®
Product Name: SINEMET® Plus 25 mg/100 mg Tablets
INN or Proposed INN: LEVODOPA
Other descriptive name: CARBIDOPA MONOHYDRATE

Civitas Therapeutics, Inc.

NULL

Not Recruiting

Female: yes
Male: yes

Phase 2

Serbia;Israel;United Kingdom

997

EUCTR2011-004438-32-GB
(EUCTR)

25/04/2012

18/04/2012

The effect of repeat doses of GSK962040 on the pharmacokinetics of L-DOPA in subjects with Parkinson’s disease with slow gastric emptying

Investigate the ability of the motilin receptor agonist GSK962040 to improve levodopa pharmacokinetics (PK) by enhancing GE via motilin receptor agonism.
MedDRA version: 20.1;Level: PT;Classification code 10051153;Term: Diabetic gastroparesis;System Organ Class: 10017947 - Gastrointestinal disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

GlaxoSmithKline Research and Development Limited

NULL

Not Recruiting

Female: yes
Male: yes

Phase 2

Germany;United Kingdom;Sweden

998

EUCTR2011-005839-91-ES
(EUCTR)

02/04/2012

11/01/2012

Gabapentin in the disorder of the impulse control in the Parkinson´s Disease: multicentric study, double-blind, randomized, controlled with placebo.

Gabapentin int he disorder of the impulse control in the Parkinson´s Disease: multicentric study, double-blind, randomized, controlled with placebo. - IMULPARK

PARKINSON´S DISEASE
MedDRA version: 14.1;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Trade Name: GABAPENTINA KERN PHARMA
INN or Proposed INN: GABAPENTINA
Other descriptive name: GABAPENTIN

ASOCIACIÓN INSTITUTO BIODONOSTIA

NULL

Not Recruiting

Female: yes
Male: yes

100

Phase 2

Spain

999

NCT01494532
(ClinicalTrials.gov)

April 2, 2012

1/12/2011

A Fixed Dose Study of Ropinirole Prolonged Release as Adjunctive Treatment in Patients With Advanced Parkinson's Disease

A Fixed Dose, Dose-response Study of Ropinirole Prolonged Release (PR) as Adjunctive Treatment to L-dopa in Patients With Advanced Parkinson's Disease

Parkinson Disease

Drug: ropinirole /L-dopa;Drug: placebo/L-dopa

GlaxoSmithKline

NULL

Completed

30 Years

N/A

All

352

Phase 4

United States;Argentina;Chile;Estonia;Korea, Republic of;Russian Federation;Slovakia;Poland

1000

JPRN-UMIN000007617

2012/04/01

30/03/2012

Effect of lidocaine injection for postural deformities in Parkinson's disease

Parkinson's disease

intramuscular injection of lidocaine

Dept. of Clinical pharmacology and Neurology, Ehime University

NULL

Recruiting

20years-old

80years-old

Male and Female

Not selected

Japan

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1001

ChiCTR-TTRCC-12002751

2012-04-01

2012-11-26

Clinical pharmacology study of anti-parkinson's drug pramipexole

A rondomised clinical trial of the potential drug-drug interaction between pramipexole and metformin

Parkinson's disease

A:Given pramipexole only;B:Given pramipexole and metformin simultaneously ;

Institute of Clinical Pharmacology, Central South University

NULL

Completed

Male

A:18;B:18;

I (Phase 1 study)

China

1002

JPRN-JapicCTI-122000

01/4/2012

02/11/2012

Long-term study of FPF1100NW monotherapy

Long-term study on FPF1100NW monotherapy with early Parkinson's disease patients

Early Parkinson's disease

Intervention name : FPF1100NW
INN of the intervention : Selegiline
Dosage And administration of the intervention : oral
Control intervention name : null

FP Pharmaceutical Corp.

NULL

BOTH

130

Phase 2

NULL

1003

NCT01491529
(ClinicalTrials.gov)

April 2012

12/12/2011

Evaluation of the Efficacy and Safety of Modified Release AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias

13-week, Double-blind, Placebo-controlled, Fixed-dose, Multicenter Study to Evaluate the Efficacy and Safety of Modified Release AFQ056 in Reducing Moderate to Severe L-dopa Induced Dyskinesias in Patients With Parkinson's Disease

Dyskinesias;Parkinson Disease;Movement Disorders;Parkinsonian Disorders;Anti-Dyskinesia Agents

Drug: AFQ056;Drug: Placebo

Novartis Pharmaceuticals

NULL

Completed

30 Years

80 Years

All

154

Phase 2

United States;Austria;Canada;France;Germany;Hungary;Italy;Slovakia;Spain;Switzerland;Turkey

1004

NCT01331122
(ClinicalTrials.gov)

April 2012

13/10/2010

Study to Assess Droxidopa in the Treatment of Freezing Of Gait Symptoms in Patients With Parkinson's Disease

A Phase II, Double-Blind, Placebo-Controlled Randomized Crossover Study to Assess the Clinical Benefit and Safety of Droxidopa in the Treatment of Freezing of Gait Symptoms in Patients With Parkinson's Disease

Gait Disorders, Neurologic

Drug: droxidopa

Chelsea Therapeutics

NULL

Withdrawn

30 Years

N/A

Both

Phase 1;Phase 2

United States;Canada

1005

NCT01523301
(ClinicalTrials.gov)

April 2012

27/1/2012

Rotigotine Versus Placebo to Evaluate the Efficacy on Depressive Symptoms in Idiopathic Parkinson's Disease Patients

Double Blind, Placebo-controlled, Parallel, Multicenter, Randomized Interventional Phase IV Study to Evaluate the Efficacy of Rotigotine on Depressive Symptoms in Idiopathic Parkinson's Disease Patients

Idiopathic Parkinson's Disease

Drug: Rotigotine;Drug: Placebo

UCB Korea Co., Ltd.

NULL

Completed

20 Years

N/A

All

380

Phase 4

Korea, Republic of

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1006

NCT01486628
(ClinicalTrials.gov)

April 2012

4/12/2011

Study of Subcutaneous Continuous Administration of Levodopa/Carbidopa Solution (ND0612) in Healthy Volunteers

A Phase I, Single Dose, Single-centre, Randomized, Double-blind, Placebo-controlled Dose Escalation Study Evaluating Safety, Tolerability and Levodopa Plasma Concentration Following Administration of Subcutaneous Continuously-delivered Levodopa/Carbidopa Solution (ND0612) in Healthy Volunteers

Parkinson's Disease

Drug: ND0612;Drug: Placebo

NeuroDerm Ltd.

NULL

Completed

18 Years

40 Years

Male

Phase 1

Israel

1007

NCT01556165
(ClinicalTrials.gov)

April 2012

13/3/2012

Rasagiline in Early Parkinson's Disease Patients Not Treated With Levodopa in China

Randomised, Double-blind, Parallel-group, Placebo-controlled, Fixed-dose Study of Rasagiline in Early Parkinson's Disease Patients Not Treated With Levodopa in China

Parkinson's Disease

Drug: rasagiline;Drug: placebo

H. Lundbeck A/S

NULL

Completed

35 Years

N/A

All

130

Phase 3

China

1008

NCT01550484
(ClinicalTrials.gov)

April 2012

6/3/2012

A Trial of 18F-AV-133 Positron Emission Tomography (PET) Imaging to Differentiate Subjects With Parkinson's Disease (PD) From Other Movement Disorders

An Open Label, Multicenter Study, Evaluating the Safety and Efficacy of 18F-AV-133 PET Imaging to Identify Subjects With Dopaminergic Degeneration Among Subjects Presenting to a Movement Disorders Specialty Clinic With an Uncertain Diagnosis

Parkinson's Disease;Primary Parkinsonism;Lewy Body Parkinson's Disease

Drug: 18F-AV-133

Avid Radiopharmaceuticals

NULL

Completed

40 Years

N/A

All

170

Phase 2;Phase 3

United States;Australia

1009

NCT01527695
(ClinicalTrials.gov)

April 2012

22/12/2011

PET Study in Parkinson's Disease Patients

A Phase IIA, Multi Centre, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Effect of 8 Weeks Treatment With Oral AZD3241 on Microglia Activation, as Measured by Positron Emission Tomography (PET), in Patients With Parkinson's Disease

Parkinson's Disease

Drug: ER tablet 25 mg AZD3241;Drug: ER tablet 100 mg AZD3241;Drug: Placebo for AZD3241 25 mg;Drug: Placebo for AZD3241 100 mg

AstraZeneca

NULL

Completed

45 Years

75 Years

Both

Phase 2

Sweden

1010

EUCTR2011-002074-23-ES
(EUCTR)

30/03/2012

06/02/2012

Evaluation of the Efficacy and Safety of Modified Release AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias

Novartis Farmacéutica, S.A.

NULL

Not Recruiting

Female: yes
Male: yes

France;United States;Hungary;Slovakia;Canada;Spain;Turkey;Austria;Germany;Italy;Switzerland

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1011

EUCTR2011-002074-23-SK
(EUCTR)

28/03/2012

30/03/2012

Evaluation of the Efficacy and Safety of Modified Release AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias

Novartis Pharma Services AG

NULL

Not Recruiting

Female: yes
Male: yes

United States;France;Hungary;Slovakia;Canada;Spain;Turkey;Austria;Germany;Switzerland;Italy

1012

EUCTR2011-004378-27-HU
(EUCTR)

28/03/2012

15/02/2012

Open-label, Long-term Safety Extension Study of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias

An open-label treatment study to evaluate the safety, tolerability and efficacy of AFQ056 in Parkinson’s patients with L-dopa induced dyskinesias

Novartis Pharma Services AG

NULL

Not Recruiting

Female: yes
Male: yes

United States;France;Hungary;Canada;Spain;Austria;Germany;Italy

1013

EUCTR2011-004378-27-IT
(EUCTR)

27/03/2012

02/03/2012

Open-label, Long-term Safety Extension Study of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias

An open-label treatment study to evaluate the safety, tolerability and efficacy of AFQ056 in Parkinson's patients with L-dopa induced dyskinesias

Product Name: NA
Product Code: AFQ056
INN or Proposed INN: mavoglurant
Other descriptive name: NA
Product Name: NA
Product Code: AFQ056
INN or Proposed INN: mavoglurant
Other descriptive name: NA
Product Name: NA
Product Code: AFQ056
INN or Proposed INN: mavoglurant
Other descriptive name: NA
Product Name: NA
Product Code: AFQ056
INN or Proposed INN: mavoglurant
Other descriptive name: NA

NOVARTIS FARMA

NULL

Not Recruiting

Female: yes
Male: yes

United States;Hungary;Canada;Spain;Austria;Germany;Italy

1014

EUCTR2011-002074-23-HU
(EUCTR)

21/03/2012

06/02/2012

Evaluation of the Efficacy and Safety of Modified Release AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias

Novartis Pharma Services AG

NULL

Not Recruiting

Female: yes
Male: yes

140

United States;France;Hungary;Slovakia;Canada;Spain;Turkey;Austria;Germany;Switzerland;Italy

1015

EUCTR2011-002074-23-DE
(EUCTR)

20/03/2012

06/02/2012

Evaluation of the Efficacy and Safety of Modified Release AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias

Novartis Pharma Services AG

NULL

Not Recruiting

Female: yes
Male: yes

140

France;United States;Hungary;Slovakia;Canada;Spain;Turkey;Austria;Germany;Italy;Switzerland

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1016

EUCTR2011-002074-23-IT
(EUCTR)

15/03/2012

02/03/2012

Evaluation of the Efficacy and Safety of Modified Release AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias

13-week, double-blind, placebo-controlled, fixed-dose, multicenter study to evaluate the efficacy and safety of modified release AFQ056 in reducing moderate to severe Ldopa induced dyskinesias in patients with Parkinson’s disease

Product Name: NA
Product Code: AFQ056
INN or Proposed INN: NA
Other descriptive name: NA
Product Name: NA
Product Code: AFQ056
INN or Proposed INN: NA
Other descriptive name: NA
Product Name: NA
Product Code: AFQ056
INN or Proposed INN: NA
Other descriptive name: NA
Product Name: NA
Product Code: AFQ056
INN or Proposed INN: NA
Other descriptive name: NA
Product Name: NA
Product Code: AFQ056
INN or Proposed INN: NA
Other descriptive name: NA
Product Name: NA
Product Code: AFQ056
INN or Proposed INN: NA
Other descriptive name: NA
Product Name: NA
Product Code: AFQ056
INN or Proposed INN: NA
Other descriptive name: NA
Product Name: NA
Product Code: AFQ056
INN or Proposed INN: NA
Other descriptive name: NA
Product Name: NA
Product Code: AFQ056
INN or Proposed INN: NA
Other descriptive name: NA
Product Name: NA
Product Code: AFQ056
INN or Proposed INN: NA
Other descriptive name: NA

NOVARTIS FARMA

NULL

Not Recruiting

Female: yes
Male: yes

United States;Hungary;Slovakia;Canada;Spain;Turkey;Austria;Germany;Switzerland;Italy

1017

EUCTR2011-002901-31-DE
(EUCTR)

08/03/2012

06/10/2011

not applicable

A multicentre, double-blind, randomised, placebo controlled study to determine the efficacy and tolerability of OXN PR for the treatment of severe Parkinson’s disease associated pain - A randomised placebo controlled study of OXN PR for severe Parkinson’s disease associated pain

Subjects will have idiopathic Parkinson's disease and be suffering from severe PD associated pain.
MedDRA version: 14.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Trade Name: Targinact 5 mg/2.5 mg prolonged-release tablets
Product Name: oxycodone /naloxone prolonged release tablets 5 mg /2.5 mg
Product Code: OXN 5 mg/2.5 mg PR
INN or Proposed INN: Oxycodone hydrochloride
Other descriptive name: OXYCODONE HYDROCHLORIDE
INN or Proposed INN: Naloxone Hydrochloride Dihydrate
Other descriptive name: NALOXONE HYDROCHLORIDE DIHYDRATE
Trade Name: Targinact 10 mg/5 mg prolonged-release tablets
Product Name: oxycodone /naloxone prolonged release tablets 10 mg /5 mg
Product Code: OXN 10 mg / 5 mg PR
INN or Proposed INN: Oxycodone Hydrochloride
Other descriptive name: OXYCODONE HYDROCHLORIDE
INN or Proposed INN: Naloxone Hydrochloride Dihydrate
Other descriptive name: NALOXONE HYDROCHLORIDE DIHYDRATE
Trade Name: Targinact 20 mg/10 mg prolonged-release tablets
Product Name: oxycodone /naloxone prolonged release tablets 20 mg /10 mg
Product Code: OXN 20 mg / 10 mg PR
INN or Proposed INN: OXYCODONE HYDROCHLORIDE
Other descriptive name: OXYCODONE HYDROCHLORIDE
INN or Proposed INN: NAL

Mundipharma Research GmbH & Co. KG

NULL

Not Recruiting

Female: yes
Male: yes

210

Hungary;Czech Republic;Spain;Germany;United Kingdom

1018

NCT01538329
(ClinicalTrials.gov)

March 2012

20/2/2012

Amantadine and L-DOPA-induced Dyskinesia in Early Parkinson's Disease

Impact of Amantadine on L-DOPA-induced Dyskinesia in Early Parkinson's Disease: a Placebo-controlled Randomized Study (the PREMANDYSK Study)

Parkinson Disease

Drug: placebo;Drug: Amantadine

University Hospital, Toulouse

NULL

Recruiting

35 Years

N/A

Both

202

Phase 2

France

1019

NCT01565395
(ClinicalTrials.gov)

March 2012

26/3/2012

Incobotulinum Toxin A for Sialorrhea in Parkinson's Disease (PD)/Parkinsonism and Amyotrophic Lateral Sclerosis (ALS)

Randomized Double Blind Placebo Controlled Cross-Over Study of Incobotulinum Toxin A (Xeomin®) for Troublesome Sialorrhea in Parkinson's Disease (PD)/Parkinsonism and Amyotrophic Lateral Sclerosis (ALS)

Parkinson Disease;Amyotrophic Lateral Sclerosis

Drug: Incobotulinum Toxin A;Drug: placebo

Beth Israel Deaconess Medical Center

Merz Pharmaceuticals

Withdrawn

20 Years

80 Years

All

Phase 2

United States

1020

NCT01519882
(ClinicalTrials.gov)

March 2012

24/1/2012

Sleep Efficiency Assessed by Polysomnography (PSG Sleep Lab Testing) in Advanced Parkinson's Disease

A Multi-Centre, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Effects of Rotigotine on Sleep Efficiency in Patients With Advanced Parkinson's Disease.

Advanced Idiopathic Parkinson's Disease

Other: Placebo;Other: Rotigotine

UCB Pharma SA

NULL

Terminated

18 Years

N/A

All

Phase 4

United Kingdom

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1021

NCT01653132
(ClinicalTrials.gov)

March 2012

25/7/2012

Incobotulinum Toxin A (Xeomin®) for Troublesome Sialorrhea in Parkinson's Disease (PD)/Parkinsonism

Randomized Double Blind Placebo Controlled Cross-Over Study of Incobotulinum Toxin A (Xeomin®) for Troublesome Sialorrhea in Parkinson's Disease (PD)/Parkinsonism

Sialorrhea

Drug: Incobotulinum Toxin A;Drug: Placebo

Beth Israel Deaconess Medical Center

NULL

Completed

18 Years

90 Years

All

Phase 2

United States

1022

NCT02039024
(ClinicalTrials.gov)

March 2012

15/1/2014

Imaging Non-motor Symptoms of Parkinson's Disease by Novel 18F-DTBZ and Florbetapir F-18 PET

Parkinson's Disease

Drug: 18F- DTBZ

Chang Gung Memorial Hospital

National Science Council, Taiwan

Completed

20 Years

80 Years

Both

Phase 2

Taiwan

1023

NCT01491932
(ClinicalTrials.gov)

March 2012

1/12/2011

Open-label, Long-term Safety Extension Study of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias

An Open-label Treatment Study to Evaluate the Safety, Tolerability and Efficacy of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias

Dyskinesias;Parkinson Disease;Movement Disorders;Parkinsonian Disorders;Anti-Dyskinesia Agents

Drug: AFQ056

Novartis Pharmaceuticals

NULL

Completed

N/A

All

129

Phase 2

United States;Austria;Canada;France;Germany;Hungary;Italy;Slovakia;Spain;Switzerland;Turkey

1024

NCT03061513
(ClinicalTrials.gov)

February 28, 2012

13/2/2017

Ubiquinol in Parkinson's Disease: Safety, Tolerability, and Effects Upon Oxidative Damage and Mitochondrial Biomarkers

Parkinson Disease

Drug: Ubiquinol;Dietary Supplement: Placebo

Weill Medical College of Cornell University

NULL

Completed

40 Years

75 Years

All

Phase 2

NULL

1025

EUCTR2011-004803-19-SE
(EUCTR)

22/02/2012

16/12/2011

PET study in PD patients

AstraZeneca AB

NULL

Not Recruiting

Female: yes
Male: yes

Phase 2A

Finland;Sweden

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1026

EUCTR2011-005054-59-RO
(EUCTR)

21/02/2012

13/06/2013

SYN115 in Parkinson’s disease

A double-blind, randomized, placebo-controlled study of the safety and efficacy of SYN115 as adjunctive therapy in levodopa-treated Parkinson’s subjects with end of dose wearing off - (none)

Parkinson’s disease
MedDRA version: 16.0;Level: LLT;Classification code 10013113;Term: Disease Parkinson's;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Product Name: SYN115 Tablets, 60 mg
Product Code: SYN115
INN or Proposed INN: tozadenant
Other descriptive name: tozadenant

Biotie Therapies Inc.

NULL

Not Recruiting

Female: yes
Male: yes

400

United States;Canada;Argentina;Ukraine;Romania;Chile

1027

EUCTR2010-019894-13-IT
(EUCTR)

17/02/2012

02/03/2012

The Parkinson's Progression Markers Initiative (PPMI)

The Parkinson's Progression Markers Initiative (PPMI) - PPMI

Parkinson Disease
MedDRA version: 14.1;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Diagnosis [E01]

Trade Name: DaTSCAN
INN or Proposed INN: IOFLUPANE (123I)

MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

600

Italy;United States

1028

NCT01525641
(ClinicalTrials.gov)

February 2012

1/2/2012

Safety and Efficacy of Long-term Daily Use of Mirapex®-LA Tablets in Patients With Parkinson's Disease

Special Survey on Long-term Drug Use of Mirapex®-LA Tablets in Patients With Parkinson's Disease

Parkinson Disease

Drug: Mirapex LA

Boehringer Ingelheim

NULL

Completed

N/A

All

615

N/A

Japan

1029

NCT01539837
(ClinicalTrials.gov)

February 2012

22/2/2012

A Pilot Clinical Trial With the Iron Chelator Deferiprone in Parkinson's Disease

Parkinson's Disease

Drug: Deferiprone 20mg;Drug: Placebo;Drug: Deferiprone 30mg

Imperial College London

NULL

Completed

50 Years

75 Years

All

Phase 2

United Kingdom

1030

NCT01568099
(ClinicalTrials.gov)

February 2012

16/3/2012

Tolerability and Safety of Subcutaneous Administration of Two Doses of AFFITOPE® PD01A in Early Parkinson's Disease

A Randomized, Controlled, Parallel Group, Patient-blinded, Single-center, Phase I Pilot Study to Assess Tolerability and Safety of Repeated Subcutaneous Administration of Two Doses of AFFITOPE® PD01A Formulated With Adjuvant to Patients With Parkinson's Disease

Parkinson's Disease

Biological: AFFITOPE® PD01A;Other: Control

Affiris AG

NULL

Completed

40 Years

65 Years

Both

Phase 1

Austria

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1031

NCT01673724
(ClinicalTrials.gov)

February 2012

23/8/2012

Pramipexole and Bromocriptine on Nonmotor Symptoms of Early Parkinson's Disease

Effect of Pramipexole and Bromocriptine on Nonmotor Symptoms of Early Parkinson's Disease: Multicenter, Open-label, Parallel, Randomized Study

Parkinson's Disease

Drug: pramipexole;Drug: Bromocriptine

Sandoz

NULL

Completed

30 Years

N/A

All

121

Phase 4

Korea, Republic of

1032

NCT01485172
(ClinicalTrials.gov)

January 31, 2012

1/12/2011

A Fixed Dose, Dose Response Study for Ropinirole Prolonged Release in Patients With Early Stage Parkinson's Disease

A Fixed Dose, Dose Response Study for Ropinirole Prolonged Release (PR) in Patients With Early Stage Parkinson's Disease

Parkinson Disease

Drug: ropinirole monotherapy;Drug: placebo monotherapy

GlaxoSmithKline

NULL

Completed

30 Years

N/A

All

186

Phase 4

United States;Estonia;Korea, Republic of;Russian Federation;Slovakia;Poland

1033

EUCTR2009-015170-35-GB
(EUCTR)

27/01/2012

21/12/2011

Study across 22 UK hospitals investigating if a drug called Donepezil Hydrochloride can help people with an early form of Parkinson's Disease dementia.

Multicentre UK Study of the Acetylcholinesterase Inhibitor Donepezil in Early Dementia Associated with Parkinson's Disease (MUSTARDD-PD) - Donepezil in Early Dementia Associated with Parkinson's Disease

Parkinson's disease with mild dementia (PDD);Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

The Newcastle upon Tyne Hospitals NHS Foundation Trust

NULL

Not Recruiting

Female: yes
Male: yes

500

Phase 3

United Kingdom

1034

NCT01497652
(ClinicalTrials.gov)

January 2012

20/12/2011

A Double Blind Placebo Controlled Trial Evaluating Rasagiline Effects on Cognition in Parkinson's Disease Patients With Mild Cognitive Impairment Receiving Dopaminergic Therapy

Parkinson's Disease

Drug: Rasagiline/Placebo;Drug: Rasagiline

Georgetown University

Teva Neuroscience, Inc.

Completed

40 Years

N/A

Both

Phase 4

United States

1035

NCT01515410
(ClinicalTrials.gov)

January 2012

11/1/2012

Study in Advanced Parkinson's Disease Patients With Predictable Motor Fluctuations

A Phase 2, Randomized, Open-Label, Crossover Study to Compare DM-1992, a Novel Gastric-Retentive Extended-Release Formulation of Levodopa/Carbidopa, to an Immediate-Release Carbidopa Tablet in Patients With Advanced Parkinson's Disease With Motor Fluctuations

Parkinson's Disease;Motor Fluctuations

Drug: DM -1992;Drug: Sinemet IR

Depomed

NULL

Completed

30 Years

N/A

All

Phase 2

United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1036

NCT01536015
(ClinicalTrials.gov)

January 2012

15/2/2012

Effect of Rotigotine on Motor Symptoms in Patients With Advanced Parkinson's Disease (PD) With Motor Fluctuations and Symptoms of Gastrointestinal Dysfunction

A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Assess the Effect of Rotigotine on Motor Symptoms in Patients With Advanced Parkinson's Disease With Motor Fluctuations and Symptoms of Gastrointestinal Dysfunction

Advanced Parkinson's Disease

Drug: Rotigotine;Drug: Placebo

UCB Pharma

NULL

Terminated

30 Years

N/A

All

Phase 3

United States

1037

NCT01470027
(ClinicalTrials.gov)

January 2012

4/11/2011

N-Acetylcysteine for Neuroprotection in Parkinson's Disease

Parkinson Disease

Drug: N-acetylcysteine;Drug: Placebo

Weill Medical College of Cornell University

National Institute on Aging (NIA)

Completed

50 Years

75 Years

All

Phase 1;Phase 2

United States

1038

EUCTR2011-002901-31-HU
(EUCTR)

21/12/2011

13/10/2011

not applicable

Mundipharma Research GmbH & Co. KG

NULL

Not Recruiting

Female: yes
Male: yes

210

Czech Republic;Hungary;Spain;Germany;United Kingdom

1039

EUCTR2009-017412-32-IT
(EUCTR)

13/12/2011

27/04/2010

RANDOMISED CONTROLLED TRIAL OF BOTULINUM TOXIN TYPE A AND B EFFICACY IN REDUCING DROOLING IN PARKINSON DISEASE - ND

Parkinson disease
MedDRA version: 9.1;Level: LLT;Classification code 10013363

Trade Name: BOTOX
INN or Proposed INN: Botulinum toxin
Trade Name: NEUROBLOC
INN or Proposed INN: Botulinum toxin

AZIENDA OSPEDALIERO UNIVERSITARIA OSPEDALI RIUNITI UMBERTO I - G.M.LANCISI - G.SALESI

NULL

Not Recruiting

Female: yes
Male: yes

Italy

1040

EUCTR2011-002901-31-CZ
(EUCTR)

12/12/2011

10/10/2011

not applicable

Mundipharma Research GmbH & Co. KG

NULL

Not Recruiting

Female: yes
Male: yes

210

Hungary;Czech Republic;Spain;Germany;United Kingdom

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1041

NCT02302144
(ClinicalTrials.gov)

December 2011

24/11/2014

A Multifactorial Exercise Program to Reduce Falls in People With Parkinson Disease

Parkinson Disease

Behavioral: Balance & Strengthening Exercises

Boston University Charles River Campus

NULL

Completed

18 Years

N/A

All

N/A

United States

1042

NCT01351168
(ClinicalTrials.gov)

December 2011

9/5/2011

Use of Zolpidem in Parkinson's Disease

A Randomized, Controlled, Double-Blind, Cross-over Study of Zolpidem for Patients With Parkinson's Disease

Parkinson's Disease

Drug: Levodopa;Drug: Zolpidem first dose;Drug: Zolpidem second dose;Drug: sugar pill

Rush University Medical Center

NULL

Withdrawn

30 Years

75 Years

Both

Phase 2

United States

1043

NCT01470859
(ClinicalTrials.gov)

December 2011

9/11/2011

The Effect of Pramipexole on Metabolic Network Activity Compared With Levodopa in Early Parkinson's Disease

a Pilot Follow-up Study of Investigating the Effect of Pramipexole on Metabolic Network Activity Compared With Levodopa in Chinese Patients With Early Parkinson's Disease

Idiopathic Parkinson's Disease

Drug: pramipexole;Drug: Sinemet CR

Huashan Hospital

Boehringer Ingelheim

Completed

30 Years

75 Years

All

N/A

China

1044

NCT01521117
(ClinicalTrials.gov)

December 2011

12/1/2012

The Effect of Donepezil on Gait and Balance in Parkinson's Disease

A Randomized, Double-blind, Placebo Controlled, Crossover Study to Evaluate the Effect of Donepezil on Gait and Balance in Parkinson's Disease

Parkinson's Disease

Drug: Donepezil

Oregon Health and Science University

NULL

Recruiting

N/A

Both

Phase 4

United States

1045

NCT01479530
(ClinicalTrials.gov)

December 2011

22/11/2011

Azilect® (Rasagiline) in Levodopa-treated Parkinson's Patients With Motor Fluctuations in China

Randomised, Double-blind, Parallel-group, Placebo-controlled, Fixed-dose Study of [Azilect®] Rasagiline in Levodopa-treated Parkinson's Patients With Motor Fluctuations in China

Parkinson's Disease

Drug: Placebo;Drug: Azilect ®

H. Lundbeck A/S

NULL

Completed

30 Years

N/A

All

321

Phase 3

China

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1046

NCT01519271
(ClinicalTrials.gov)

December 2011

10/1/2012

Mild Cognitive Impairment in Parkinson's Disease

A Phase IV Randomized, Double-Blind, Placebo-Controlled, Crossover Single Site Study Of Exelon® Patch (Rivastigmine Transdermal System) For Mild Cognitive Impairment In Parkinson's Disease

Parkinson's Disease;Mild Cognitive Impairment

Drug: Exelon Patch (rivastigmine transdermal system);Drug: Placebo Patches

University of Pennsylvania

NULL

Completed

40 Years

85 Years

All

Phase 4

United States

1047

EUCTR2011-002901-31-ES
(EUCTR)

30/11/2011

05/10/2011

not applicable

A multicentre, double-blind, randomised, placebo controlled study to determine the efficacy and tolerability of OXN PR for the treatment of severe Parkinson's disease associated pain - A randomised placebo controlled study of OXN PR for severe Parkinson?s disease associated pain

Subjects will have idiopathic Parkinson's disease and be suffering from severe PD associated pain.
MedDRA version: 14.0;Level: LLT;Classification code 10013113;Term: Disease Parkinson's;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Mundipharma Research GmbH & Co. KG

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

210

Hungary;Czech Republic;Germany;United Kingdom;Spain

1048

EUCTR2011-002901-31-GB
(EUCTR)

25/11/2011

21/09/2011

A multicentre, double-blind, randomised, placebo controlled study to determine the efficacy and tolerability of OXN PR for the treatment of severe Parkinson's disease associated pain

A multicentre, double-blind, randomised, placebo controlled study to determine the efficacy and tolerability of OXN PR for the treatment of severe Parkinson's disease associated pain - Efficacy of OXN PR in severe Parkinson's disease associated pain

Trade Name: Targinact 5 mg/2.5 mg prolonged-release tablets
Product Name: oxycodone /naloxone prolonged release tablets 5 mg /2.5 mg
Product Code: OXN 5 mg/2.5 mg PR
INN or Proposed INN: Oxycodone hydrochloride
Other descriptive name: Oxycodone hydrochloride
INN or Proposed INN: Naloxone Hydrochloride Dihydrate
Other descriptive name: NALOXONE HYDROCHLORIDE DIHYDRATE
Trade Name: Targinact 10 mg/5 mg prolonged-release tablets
Product Name: oxycodone /naloxone prolonged release tablets 10 mg /5 mg
Product Code: OXN 10 mg / 5 mg PR
INN or Proposed INN: Oxycodone Hydrochloride
Other descriptive name: OXYCODONE HYDROCHLORIDE
INN or Proposed INN: Naloxone Hydrochloride Dihydrate
Other descriptive name: NALOXONE HYDROCHLORIDE DIHYDRATE
Trade Name: Targinact 20 mg/10 mg prolonged-release tablets
Product Name: oxycodone /naloxone prolonged release tablets 20 mg /10 mg
Product Code: OXN 20 mg / 10 mg PR
INN or Proposed INN: OXYCODONE HYDROCHLORIDE
Other descriptive name: OXYCODONE HYDROCHLORIDE
INN or Proposed INN: NAL

Mundipharma Research GmbH & Co. KG

NULL

Not Recruiting

Female: yes
Male: yes

210

Phase 3

Hungary;Czech Republic;Spain;Germany;United Kingdom

1049

EUCTR2009-015162-57-NL
(EUCTR)

21/11/2011

11/05/2011

An Active-Controlled Extension Study to P04938 and P07037 (P06153)

A Phase 3, 40-Week, Active-Controlled, Double-Blind, Double-Dummy Extension Study of Preladenant in Subjects With Moderate to Severe Parkinson’s Disease (Phase 3, Protocol No. P06153)

Parkinson's disease
MedDRA version: 14.1;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Merck Sharp & Dohme corp.

NULL

Not Recruiting

Female: yes
Male: yes

750

Phase 3

United States;Serbia;Portugal;Spain;Ukraine;Israel;Russian Federation;Chile;Colombia;Italy;India;France;Peru;South Africa;Latvia;Netherlands;Finland;Lithuania;Turkey;Austria;United Kingdom;Czech Republic;Mexico;Canada;Argentina;Poland;Brazil;Croatia;Bulgaria;Germany;Sweden

1050

EUCTR2011-002073-30-IT
(EUCTR)

14/11/2011

06/03/2012

Evaluation of the Efficacy and Safety of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias

12-week, double-blind, placebo-controlled, fixed-dose, multicenter study to evaluate the efficacy and safety of AFQ056 in reducing moderate to severe L-dopa induced dyskinesias in patients with Parkinson's disease

L-dopa induced dyskinesias in patients with Parkinson's disease
MedDRA version: 14.1;Level: PT;Classification code 10043118;Term: Tardive dyskinesia;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Product Name: AFQ056
Product Code: AFQ056
INN or Proposed INN: NA
Other descriptive name: NA
Product Name: AFQ056
Product Code: AFQ056
INN or Proposed INN: NA
Other descriptive name: NA
Product Name: AFQ056
Product Code: AFQ056
INN or Proposed INN: NA
Other descriptive name: NA
Product Name: AFQ056
Product Code: AFQ056
INN or Proposed INN: NA
Other descriptive name: NA
Product Name: AFQ056
Product Code: AFQ056
INN or Proposed INN: NA
Other descriptive name: NA

NOVARTIS FARMA

NULL

Not Recruiting

Female: yes
Male: yes

United States;European Union;Canada;Spain;Germany;Switzerland;Italy

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1051

EUCTR2009-015162-57-PT
(EUCTR)

04/11/2011

12/08/2011

An Active-Controlled Extension Study to P04938 and P07037 (P06153)

A Phase 3, 40-Week, Active-Controlled, Double-Blind, Double-Dummy Extension Study of Preladenant in Subjects With Moderate to Severe Parkinson’s Disease (Phase 3, Protocol No. P06153)

Parkinson's disease
MedDRA version: 15.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Product Name: Preladenant
Product Code: SCH 420814
INN or Proposed INN: Preladenant
Product Name: Preladenant
Product Code: SCH 420814
INN or Proposed INN: Preladenant
Product Name: Preladenant
Product Code: SCH 420814
INN or Proposed INN: Preladenant
Trade Name: Azilect
Product Name: Azilect
INN or Proposed INN: Rasagiline mesylate
Other descriptive name: RASAGILINE MESILATE
Trade Name: Azilect
Product Name: Azilect
INN or Proposed INN: Rasagiline mesylate
Other descriptive name: RASAGILINE MESILATE

Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc

NULL

Not Recruiting

Female: yes
Male: yes

750

Phase 3

United States;Serbia;Portugal;Spain;Ukraine;Israel;Russian Federation;Chile;Colombia;Italy;India;France;Peru;South Africa;Netherlands;Latvia;Finland;Lithuania;Turkey;Austria;United Kingdom;Czech Republic;Mexico;Canada;Argentina;Poland;Brazil;Croatia;Bulgaria;Germany;Sweden

1052

NCT01385592
(ClinicalTrials.gov)

November 2011

28/6/2011

Evaluation of the Efficacy and Safety of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias

12-week, Double-blind, Placebo-controlled, Fixed-dose, Multicenter Study to Evaluate the Efficacy and Safety of AFQ056 in Reducing Moderate to Severe L-dopa Induced Dyskinesias in Patients With Parkinson's Disease

Dyskinesias;Parkinson Disease;Movement Disorders;Parkinsonian Disorders

Drug: AFQ056;Drug: Placebo

Novartis Pharmaceuticals

NULL

Completed

30 Years

80 Years

Both

Phase 2

United States;Canada;France;Germany;Hungary;Italy;Spain

1053

NCT01556100
(ClinicalTrials.gov)

November 2011

6/3/2012

Long-Term Vesicular Monoamine Transporter II Imaging and Clinical Assessment of Parkinson's Disease Progression

Parkinson Disease

Drug: 18F-DTBZ AV-133

Chang Gung Memorial Hospital

NULL

Completed

20 Years

N/A

All

Phase 2

NULL

1054

NCT01291537
(ClinicalTrials.gov)

November 2011

7/2/2011

Clinical and Economic Impact of Duodopa: Long-term Effectiveness Study in Advanced Parkinson's Disease Patients

Parkinson's Disease

Drug: Duodopa;Drug: best médical treatment

Poitiers University Hospital

NULL

Completed

18 Years

80 Years

Both

Phase 2

France

1055

NCT01457807
(ClinicalTrials.gov)

November 2011

10/10/2011

To Assess the Effect of Administration of 2 Formulation of AZD3241 on Blood Concentration in Healthy Volunteers

A Phase I, Single-centre, Double-blind, Randomised, Placebo-controlled, Parallel Group Study to Assess the Pharmacokinetics, Safety and Tolerability of Two Different Extended Release Formulations of Tablets of AZD3241 (300 mg) After Administration of Multiple Doses in Healthy Male and Female Volunteers

Parkinson's Disease

Drug: AZD3241 ER formulation 1;Drug: Placebo;Drug: AZD3241 Alternative titration scheme with formulation 1 or 2

AstraZeneca

NULL

Completed

30 Years

65 Years

Both

Phase 1

United Kingdom

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1056

NCT01736891
(ClinicalTrials.gov)

November 2011

27/11/2012

Clinical Trial of Rasagiline in Levodopa-Treated Parkinson's Disease Patients With Motor Fluctuations

Evaluation for the Efficacy,Tolerability,and Safety of Rasagiline in Levodopa-treated PD Patients With Motor Fluctuations: A Multicenter, Double Blind, Randomized, Placebo-Controlled Group Study (China)

Parkinson´s Disease

Drug: Rasagiline;Drug: Placebo

Chongqing Fortune Pharmaceutical Co., Ltd.

Beijing Bionovo Medicine Development Co., Ltd.

Completed

30 Years

75 Years

Both

268

Phase 3

China

1057

EUCTR2009-015162-57-PL
(EUCTR)

25/10/2011

30/08/2011

An Active-Controlled Extension Study to P04938 and P07037 (P06153)

A Phase 3, 40-Week, Active-Controlled, Double-Blind, Double-Dummy Extension Study of Preladenant in Subjects With Moderate to Severe Parkinson’s Disease (Phase 3, Protocol No. P06153)

Schering-Plough Research Institute, a division of Schering Corporation

NULL

Not Recruiting

Female: yes
Male: yes

750

Phase 3

1058

JPRN-JapicCTI-111673

12/10/2011

25/10/2011

Phase II clinical study in patients with Parkinson's disease.

Pharmacokinetic study of HP-3000 in patients with Parkinson's disease.

Parkinson's disease

Intervention name : HP-3000 (ropinirole hydrochloride patch)
Dosage And administration of the intervention : Transdermal, once daily

Hisamitsu Pharmaceutical Co., Inc.

NULL

BOTH

Phase 2

NULL

1059

EUCTR2011-000056-42-GB
(EUCTR)

07/10/2011

11/08/2011

Sleep efficiency assessed by Polysomnography (PSG sleep lab testing) in advanced Parkinson's disease

A MULTI-CENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFECTS OF ROTIGOTINE ON SLEEP EFFICIENCY IN PATIENTS WITH ADVANCED PARKINSON’S DISEASE - sleep efficiency assessed by polysomnography in advanced Parkinson's Disease

Advanced Parkinson's Disease
MedDRA version: 14.1;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Trade Name: Neupro 4mg/24h transdermal patch
INN or Proposed INN: ROTIGOTINE
Trade Name: Neupro 6mg/24h transdermal patch
INN or Proposed INN: ROTIGOTINE
Trade Name: Neupro 8mg/24h transdermal patch
INN or Proposed INN: ROTIGOTINE

UCB Celltech, UK - Registered Branch of UCB Pharma SA

NULL

Not Recruiting

Female: yes
Male: yes

United Kingdom

1060

JPRN-UMIN000006521

2011/10/01

11/10/2011

Switch trial from Pramipexole IR (Bi-sifrol) to Pramipexole ER (Mirapex LA) in patients with Parkinson's disease

Switch trial from Pramipexole IR (Bi-sifrol) to Pramipexole ER (Mirapex LA) in patients with Parkinson's disease - Switch trial from IR to ER of Pramipexole

Parkinson's disease

Rapid switch of Pramipexole ER (once in a day) which is same dose as IR. The period of administration is 8 weeks.

Department of Neurology, Juntendo University

NULL

Recruiting

20years-old

Not applicable

Male and Female

Not selected

Japan

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1061

NCT01385735
(ClinicalTrials.gov)

October 2011

28/6/2011

Emotion, Mood and Executive Function in Parkinson`s Disease (PD)

Effects of Azilect (Rasagiline) on Processing of Emotions, Mood and Executive Function in Parkinson`s Disease

Parkinson Disease

Drug: Rasagiline;Drug: Placebo

St. Josef Hospital Bochum

NULL

Not yet recruiting

30 Years

75 Years

Both

Phase 4

Germany

1062

NCT01439100
(ClinicalTrials.gov)

October 2011

21/9/2011

A Randomised Placebo Controlled Study of OXN PR for Severe Parkinson's Disease Associated Pain

Parkinson's Disease With Severe Pain

Drug: Oxycodone /Naloxone Prolonged Release tablets;Drug: Placebo

Mundipharma Research GmbH & Co KG

NULL

Completed

25 Years

N/A

Both

172

Phase 3

Czech Republic;Germany;Hungary;Poland;Romania;Spain;United Kingdom

1063

NCT01442610
(ClinicalTrials.gov)

October 2011

23/9/2011

Effects of Rasagiline on Sleep Disturbances in Parkinson's Disease

Effects of Rasagiline on Sleep Disturbances in PD: A Single Center, Randomized, Double-blind, Placebo run-in, Polysomnographic Clinical Phase IV Trial

Sleep Disturbances;Parkinsons's Disease

Drug: Rasagiline;Drug: Placebo

Technische Universität Dresden

Teva Pharmaceutical Industries

Completed

50 Years

85 Years

Both

Phase 4

Germany

1064

NCT01446614
(ClinicalTrials.gov)

October 2011

4/10/2011

Mesenchymal Stem Cells Transplantation to Patients With Parkinson's Disease

Phase?/?Trial of Autologous Bone Marrow Derived Mesenchymal Stem Cells to Patients With Parkinson's Disease.

Parkinson's Disease

Biological: bone marrow derived mesenchymal stem cells

Guangzhou General Hospital of Guangzhou Military Command

NULL

Recruiting

30 Years

65 Years

Both

Phase 1;Phase 2

China

1065

NCT02427646
(ClinicalTrials.gov)

October 2011

22/4/2015

Kinematic-guided BoNT-A Treatment for ET and PD Tremor

Use of Kinematic Assessment of Hand Tremor Pre- and Post- Treatment With Botulinum Toxin Type A in Essential Tremor and Parkinson Disease

Tremor

Drug: BoNT-A

Western University, Canada

NULL

Active, not recruiting

18 Years

80 Years

All

Phase 2

NULL

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1066

NCT01479127
(ClinicalTrials.gov)

October 2011

26/9/2011

Study of Safety, Tolerability, Pharmacokinetics, and Efficacy of ABT-SLV187 in Subjects With Advanced Parkinson's Disease

An Open-Label, Single-Arm, Baseline-Controlled, Multicenter Study to Explore the Safety, Tolerability, Pharmacokinetics, and Efficacy of ABT-SLV187 in Subjects With Advanced Parkinson's Disease

Advanced Parkinson's Disease

Drug: ABT-SLV187;Drug: Oral Levodopa/Carbidopa;Device: Infusion Pump: CADD-Legacy® 1400 Pump;Device: NJ-Tube: Silicon ED Tube;Device: Adaptor: Hakko Adaptor

AbbVie (prior sponsor, Abbott)

Abbott Japan Co.,Ltd

Completed

30 Years

99 Years

All

Phase 2

Japan

1067

EUCTR2010-018534-44-CZ
(EUCTR)

23/09/2011

04/07/2011

Investigation of Cogane (PYM50028) in early stage Parkinson's disease

A Phase II, multi-centre, randomised, double-blind, placebo-controlled, parallel group study to investigate the efficacy, safety and tolerability of Cogane™ (PYM50028), a novel, orally active neurotrophic factor inducer, in male and female subjects with early-stage Parkinson’s disease when administered once daily for 28 weeks - CONFIDENT-PD

Early-Stage Parkinson’s Disease
MedDRA version: 14.1;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Product Name: PYM50028
Product Code: PYM50028
INN or Proposed INN: SMILAGENIN
Other descriptive name: (3ß, 5ß, 25R)-spirostan-3-ol
Product Name: PYM50028
Product Code: PYM50028
INN or Proposed INN: SMILAGENIN
Other descriptive name: (3ß, 5ß, 25R)-spirostan-3-ol
Product Name: PYM50028
Product Code: PYM50028
INN or Proposed INN: SMILAGENIN
Other descriptive name: (3ß, 5ß, 25R)-spirostan-3-ol

Phytopharm plc

NULL

Not Recruiting

Female: yes
Male: yes

408

Phase 2

United States;Serbia;France;Hungary;Czech Republic;Canada;Poland;Romania;Germany;United Kingdom

1068

EUCTR2009-015162-57-IT
(EUCTR)

22/09/2011

27/04/2011

A Phase 3, 40-week. Active-controlled, Double-blind, Double-Dummy Extension Study of Preladenant in Subjects with moderate to severe Parkinson`s Disease. - ND

Parkinson`s disease
MedDRA version: 13.1;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders

Schering-Plough Research Institute, division of Schering Corporation

NULL

Not Recruiting

Female: yes
Male: yes

750

Phase 3

Portugal;Czech Republic;Finland;Poland;Spain;Lithuania;Bulgaria;Netherlands;Latvia;United Kingdom;Italy;Sweden

1069

EUCTR2011-000612-26-IT
(EUCTR)

19/09/2011

05/03/2012

Open-label study on the use of Finasteride in prolonged treatment (4 years) of tics in Tourette's disease and Parkinson's disease in the pounding - FINTOURPARK

Syndrome Gilles de la Tourette's disease Parkinosn Pounding
MedDRA version: 14.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Trade Name: PROSCAR*30CPR RIV 5MG
INN or Proposed INN: Finasteride

AZIENDA OSPEDALIERO UNIVERSITARIA DI CAGLIARI

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

Italy

1070

NCT01474421
(ClinicalTrials.gov)

September 15, 2011

5/10/2011

Safety and Efficacy of AQW051 in L-dopa Induced Dyskinesias in Patients With Parkinson's Disease

A Multi-centre, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multiple Oral Dose Study to Assess the Efficacy, Safety and Tolerability of AQW051 in Reducing L-dopa Induced Dyskinesias in Parkinson's Patients With Moderate to Severe L-dopa Induced Dyskinesias

Dyskinesias;Drug-induced

Drug: AQW051;Drug: Placebo

Novartis Pharmaceuticals

NULL

Completed

30 Years

85 Years

All

Phase 2

United States;France;Germany;Italy

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1071

EUCTR2011-001148-31-GB
(EUCTR)

13/09/2011

17/08/2011

A pilot clinical trial with the iron chelator Deferiprone in Parkinson's disease - Pilot clinical trial iron chelator Deferiprone in Parkinson's Vs1

Parkinson's disease

Imperial College London

NULL

Not Recruiting

Female: yes
Male: yes

Phase 2

United Kingdom

1072

NCT01178047
(ClinicalTrials.gov)

September 2011

6/8/2010

Multicenter Placebo Controlled Study to Assess the Effect of Rasagiline on Sleep-wake Disturbances in Patients With Parkinson's Disease

A Multicenter, Randomized, Double-blind Placebo Controlled Study to Assess the Effect of Rasagiline on Sleep-wake Disturbances in Patients With Parkinson's Disease (PD)

Parkinson's Disease

Drug: Rasagiline

University of Zurich

H. Lundbeck A/S

Terminated

40 Years

N/A

Both

Phase 4

Switzerland

1073

NCT01515774
(ClinicalTrials.gov)

September 2011

10/1/2012

Study to Observe the Effect of Mirapex ER® Once-daily (QD) Versus Twice-daily (BID)

An Open-label, Randomized, Multi-center, Crossover Study to Observe the Effect of Once-daily Mirapex ER® and Twice-daily Mirapex ER® in Patients With Parkinson Disease

Parkinson's Disease

Drug: Mirapex ER

Seoul National University Hospital

NULL

Recruiting

30 Years

80 Years

Both

200

Phase 4

Korea, Republic of

1074

NCT01545856
(ClinicalTrials.gov)

September 2011

2/2/2012

Cardiovascular Events in Parkinson's Disease Patients

Background Incidence of Cardiovascular Ischaemic Events in Treated Parkinson's Disease Patients in the Impact Database

Cardiovascular Event;Parkinson Disease

Drug: levodopa

GlaxoSmithKline

NULL

Completed

20 Years

N/A

All

N/A

NULL

1075

NCT02170376
(ClinicalTrials.gov)

September 2011

19/6/2014

The Effect of BIA 9-1067 at Steady-state on the Levodopa Pharmacokinetics

The Effect of BIA 9-1067 at Steady-state on the Levodopa Pharmacokinetics When Administered With Immediate-release 100/25 mg Levodopa/Carbidopa in Healthy Subjects

Parkinson's Disease (PD)

Drug: BIA 9-1067;Drug: Entacapone;Drug: Placebo;Drug: Levodopa /carbidopa

Bial - Portela C S.A.

NULL

Completed

18 Years

45 Years

All

Phase 1

France

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1076

NCT01461083
(ClinicalTrials.gov)

September 2011

27/9/2011

Evaluation of [18F]MPPF as a Brain Tracer of Serotonin Receptor 5HT1a

Phase I Evaluation of [18F]MPPF as a Brain Tracer of Serotonin Receptor 5HT1a in Subjects With Parkinson Disease and Healthy Subjects

Parkinson Disease

Drug: [18F]MPPF

Institute for Neurodegenerative Disorders

NULL

Completed

18 Years

90 Years

Both

Phase 1

United States

1077

EUCTR2010-020299-42-DE
(EUCTR)

30/08/2011

26/04/2011

A study in U.S. and Germany to show if patients with an early stage of Parkinson's disease could be treated with a nicotine patch. In this study the nicotine patch is being compared to a placebo patch. The placebo patch is identical in appearance to the nicotine patch but does not contain any active ingredients.

A randomized, placebo-controlled, double-blind, multi-center trial to assess the disease-modifying potential of transdermal nicotine in early Parkinson's disease in Germany and the USA (NIC-PD) - NIC-PD

Early PD subjects within 18 months of diagnosis and not expected to require dopamine agonist or levodopa therapy for 1 year, with Hoehn and Yahr stage <2, with stable (>2 months) MAO-B inhibitor therapy allowed
MedDRA version: 16.1;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Trade Name: Nicotinell 17,5 mg/24-Stunden-Pflaster
Product Name: Nicotinell
Other descriptive name: NICOTINE
Trade Name: Nicotinell 35 mg/24-Stunden-Pflaster
Product Name: Nicotinell
Other descriptive name: NICOTINE

Philipps-University Marburg

NULL

Not Recruiting

Female: yes
Male: yes

160

Phase 2

United States;Germany

1078

EUCTR2010-018534-44-HU
(EUCTR)

30/08/2011

08/07/2011

Investigation of Cogane (PYM50028) in early stage Parkinson's disease

Early-Stage Parkinson’s Disease
MedDRA version: 15.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Phytopharm plc

NULL

Not Recruiting

Female: yes
Male: yes

408

Phase 2

France;United States;Serbia;Czech Republic;Hungary;Canada;Poland;Romania;Germany;United Kingdom

1079

EUCTR2009-015162-57-GB
(EUCTR)

16/08/2011

26/01/2011

An Active-Controlled Extension Study to P04938 and P07037 (P06153)

A Phase 3, 40-Week, Active-Controlled, Double-Blind, Double-Dummy Extension Study of Preladenant in Subjects With Moderate to Severe Parkinson’s Disease (Phase 3, Protocol No. P06153)

Parkinson's disease
MedDRA version: 14.1;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.

NULL

Not Recruiting

Female: yes
Male: yes

750

Phase 3

1080

EUCTR2009-015162-57-BG
(EUCTR)

04/08/2011

09/06/2011

An Active-Controlled Extension Study to P04938 and P07037 (P06153)

A Phase 3, 40-Week, Active-Controlled, Double-Blind, Double-Dummy Extension Study of Preladenant in Subjects With Moderate to Severe Parkinson’s Disease (Phase 3, Protocol No. P06153)

Parkinson's disease
MedDRA version: 14.1;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.

NULL

Not Recruiting

Female: yes
Male: yes

750

Phase 3

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1081

EUCTR2010-021860-13-BG
(EUCTR)

04/08/2011

02/06/2011

EFFICACY AND SAFETY OF BIA 9-1067 IN IDIOPATHIC PARKINSON’S DISEASE PATIENTS WITH WEARING-OFF” PHENOMENON TREATED WITH LEVODOPA PLUS A DOPA DECARBOXYLASE INHIBITOR (DDCI): A DOUBLE-BLIND, RANDOMISED, PLACEBO- AND ACTIVE-CONTROLLED, PARALLEL-GROUP, MULTICENTRE CLINICAL STUDY

Adjunct to levodopa (L-DOPA)/DDCI for use in patients with Parkinson’s disease (PD) and end-of-dose motor fluctuations.
MedDRA version: 14.1;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Product Name: BIA 9-1067
Product Code: BIA 9-1067
INN or Proposed INN: BIA 9-1067
Other descriptive name: BIA 9-1067
Trade Name: Comtan®
Product Name: Over-encapsulated Entacapone Tablets
Product Code: Over-encapsulated Entacapone Tablets
INN or Proposed INN: ENTACAPONE
Product Name: BIA 9-1067
Product Code: BIA 9-1067
INN or Proposed INN: BIA 9-1067
Other descriptive name: BIA 9-1067
Product Name: BIA 9-1067
Product Code: BIA 9-1067
INN or Proposed INN: BIA 9-1067
Other descriptive name: BIA 9-1067

BIAL - Portela & Ca, S.A.

NULL

Not Recruiting

Female: yes
Male: yes

550

Portugal;Serbia;Slovakia;Spain;Ukraine;Lithuania;Austria;Russian Federation;Montenegro;Italy;France;Hungary;Czech Republic;Poland;Romania;Croatia;Bulgaria;Netherlands;Latvia;Germany;Bosnia and Herzegovina

1082

EUCTR2010-021394-37-BG
(EUCTR)

04/08/2011

02/06/2011

Placebo-controlled study in patients with Parkinson’s disease to evaluate the effect of rotigotine on nonmotor symptoms

MULTICENTER, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL-GROUP, PHASE IV STUDY TO ASSESS THE EFFECT OF ROTIGOTINE ON NON-MOTOR SYMPTOMS IN PATIENTS WITH IDIOPATHIC PARKINSON’S DISEASE - SP0976

Trade Name: Neupro 2mg/24h transdermal patch
INN or Proposed INN: ROTIGOTINE
Trade Name: Neupro 4mg/24h transdermal patch
INN or Proposed INN: ROTIGOTINE
Trade Name: Neupro 6mg/24h transdermal patch
INN or Proposed INN: ROTIGOTINE
Trade Name: Neupro 8mg/24h transdermal patch
INN or Proposed INN: ROTIGOTINE

UCB Pharma SA

NULL

Not Recruiting

Female: yes
Male: yes

345

Phase 4

Czech Republic;Hungary;Spain;Belgium;Austria;Bulgaria;Germany;Italy;Switzerland

1083

NCT01370811
(ClinicalTrials.gov)

August 2011

8/6/2011

A Relative Efficacy and Safety Study of OC Oral Solution for Sialorrhoea in Patients With Parkinson's Disease

A Phase II, Double-blind, Randomized, Placebo-controlled 4-way Crossover Study to Evaluate the Relative Efficacy and Safety of OC Oral Solution (Oxybutynin and Clonidine) for Sialorrhoea in Patients With Parkinson's Disease

Sialorrhoea

Drug: OC oral solution treatment A;Drug: OC oral solution treatment B;Drug: OC oral solution treatment C;Drug: OC oral solution treatment D

Orient Pharma Co., Ltd.

NULL

Completed

40 Years

80 Years

Both

Phase 2

United States

1084

NCT01411137
(ClinicalTrials.gov)

August 2011

4/8/2011

Carbidopa-Levodopa (CD-LD) ER Alone or in Combination With CD-LD IR to IPX066 Followed by IPX066 Extension Safety Study

An Open Label Conversion Study of Carbidopa-Levodopa (CD-LD) Extended-Release Taken Alone or in Combination With CD-LD Immediate Release to IPX066 Followed by an Open-Label Extension Safety Study of IPX066 in Advanced PD

Parkinson's Disease

Drug: IPX066

Impax Laboratories, LLC

Michael J. Fox Foundation for Parkinson's Research

Completed

30 Years

N/A

All

Phase 3

United States

1085

NCT01759888
(ClinicalTrials.gov)

August 2011

1/1/2013

Development of a Novel 18F-DTBZ PET Imaging as a Biomarker to Monitor Neurodegeneration of PARK6 and PARK8 Parkinsonism

From Mouse Models to Patients: Development of a Novel 18F-DTBZ PET Imaging as a Biomarker to Monitor Neurodegeneration of PARK6 and PARK8 Parkinsonism

Parkinson's Disease

Drug: 18F-DTBZ

Chang Gung Memorial Hospital

National Science Council, Taiwan

Completed

20 Years

80 Years

Both

Phase 2

Taiwan

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1086

NCT01634568
(ClinicalTrials.gov)

August 2011

20/6/2012

A Clinical Trial to Find Out V81444's Side Effects and Blood Levels in Healthy Men

A Double-blind, Randomised, Placebo-controlled Study of the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Oral Doses of V81444 in Healthy Male Volunteers

Parkinson's Disease

Drug: V81444

Vernalis (R&D) Ltd

NULL

Completed

18 Years

45 Years

Male

Phase 1

United Kingdom

1087

NCT01461109
(ClinicalTrials.gov)

August 2011

27/9/2011

Research Involving Subjects With Parkinson's Disease, Alzheimer Disease and Healthy Controls

Evaluation of [18F] CFPyPB PET as a Marker of Glycine Transporter-1 (GlyT1) Receptor in Subjects With Parkinson Disease, Alzheimer Disease and Healthy Subjects

Parkinson Disease;Alzheimer Disease

Drug: [18F] CFPyPB

Institute for Neurodegenerative Disorders

NULL

Completed

18 Years

90 Years

Both

Phase 1

United States

1088

NCT01437189
(ClinicalTrials.gov)

August 2011

16/9/2011

The Effects of Sertraline on Depression in Parkinson's Disease

Clinical Protocol of Self-Controlled Study on the Effects of Sertraline on Depression in Parkinson's Disease

Depression;Parkinson's Disease

Drug: Sertraline

Zhejiang University

NULL

Recruiting

35 Years

75 Years

Both

N/A

China

1089

EUCTR2009-015162-57-LT
(EUCTR)

25/07/2011

21/04/2011

An Active-Controlled Extension Study to P04938 and P07037 (P06153)

A Phase 3, 40-Week, Active-Controlled, Double-Blind, Double-Dummy Extension Study of Preladenant in Subjects With Moderate to Severe Parkinson’s Disease (Phase 3, Protocol No. P06153)

Parkinson's disease
MedDRA version: 14.1;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Schering-Plough Research Institute, a division of Schering Corporation

NULL

Not Recruiting

Female: yes
Male: yes

750

Phase 3

United States;Serbia;Portugal;Spain;Ukraine;Israel;Russian Federation;Chile;Colombia;Italy;India;France;Peru;South Africa;Netherlands;Latvia;Finland;Turkey;Lithuania;Austria;United Kingdom;Czech Republic;Mexico;Canada;Argentina;Poland;Brazil;Croatia;Bulgaria;Germany;Sweden

1090

EUCTR2010-021860-13-IT
(EUCTR)

25/07/2011

29/03/2012

EFFICACY AND SAFETY OF BIA 9-1067 IN IDIOPATHIC PARKINSON`S DISEASE PATIENTS WITH `WEARING-OFF` PHENOMENON TREATED WITH LEVODOPA PLUS A DOPA DECARBOXYLASE INHIBITOR (DDCI): A DOUBLE-BLIND, RANDOMISED, PLACEBO- AND ACTIVE-CONTROLLED, PARALLEL-GROUP, MULTICENTRE CLINICAL STUDY

EFFICACY AND SAFETY OF BIA 9-1067 IN IDIOPATHIC PARKINSON`S DISEASE PATIENTS WITH `WEARING-OFF`PHENOMENON TREATED WITH LEVODOPA PLUS A DOPA DECARBOXYLASE INHIBITOR (DDCI): A DOUBLE-BLIND, RANDOMISED, PLACEBO- AND ACTIVE-CONTROLLED, PARALLEL-GROUP, MULTICENTRE CLINICAL STUDY - BIPARK STUDY I

Adjunct to levodopa (L-DOPA)/DDCI for use in patients with Parkinson`s Disease (PD) and end-of-dose motor fluctuations
MedDRA version: 14.1;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Product Name: BIA 9-1067
Product Code: BIA 9-1067
INN or Proposed INN: NA
Other descriptive name: NA
Product Name: BIA 9-1067
Product Code: BIA 9-1067
INN or Proposed INN: NA
Other descriptive name: NA
Product Name: BIA 9-1067
Product Code: BIA 9-1067
INN or Proposed INN: NA
Other descriptive name: NA
Trade Name: ComtanÂ®
INN or Proposed INN: NA

BIAL - PORTELA & CÂª, S.A.

NULL

Not Recruiting

Female: yes
Male: yes

550

Portugal;Slovakia;Spain;Lithuania;Austria;Russian Federation;Italy;Hungary;Czech Republic;Romania;Croatia;Bulgaria;Latvia;Germany;Bosnia and Herzegovina

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1091

EUCTR2009-015162-57-LV
(EUCTR)

19/07/2011

11/05/2011

An Active-Controlled Extension Study to P04938 and P07037 (P06153 AM1)

A Phase 3, 40-Week, Active-Controlled, Double-Blind, Double-Dummy Extension Study of Preladenant in Subjects With Moderate to Severe Parkinson’s Disease (Phase 3, Protocol No. P06153)

Parkinson's disease
MedDRA version: 13.1;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Schering-Plough Research Institute, a division of Schering Corporation

NULL

Not Recruiting

Female: yes
Male: yes

750

Phase 3

Serbia;Portugal;United States;Spain;Ukraine;Israel;Russian Federation;Chile;Colombia;Italy;India;France;Peru;South Africa;Netherlands;Latvia;Finland;Lithuania;Turkey;Austria;United Kingdom;Czech Republic;Mexico;Canada;Argentina;Poland;Brazil;Croatia;Bulgaria;Germany;Sweden

1092

EUCTR2009-015162-57-SE
(EUCTR)

12/07/2011

31/05/2011

An Active-Controlled Extension Study to P04938 and P07037 (P06153)

A Phase 3, 40-Week, Active-Controlled, Double-Blind, Double-Dummy Extension Study of Preladenant in Subjects With Moderate to Severe Parkinson’s Disease (Phase 3, Protocol No. P06153)

Product Name: Preladenant
Product Code: SCH 420814
INN or Proposed INN: Preladenant
Trade Name: Azilect
Product Name: Azilect
INN or Proposed INN: Rasagiline mesylate
Other descriptive name: RASAGILINE MESILATE
Trade Name: Azilect
Product Name: Azilect
INN or Proposed INN: Rasagiline mesylate
Other descriptive name: RASAGILINE MESILATE

Schering-Plough Research Institute, a division of Schering Corporation

NULL

Not Recruiting

Female: yes
Male: yes

750

Phase 3

1093

NCT01427517
(ClinicalTrials.gov)

July 2011

30/8/2011

Intravenous N-acetylcysteine for the Treatment of Gaucher's Disease and Parkinson's Disease

Parkinson's Disease;Gaucher's Disease

Drug: N-acetylcysteine

University of Minnesota

Rare Diseases Clinical Research Network;National Center for Advancing Translational Science (NCATS);National Institute of Neurological Disorders and Stroke (NINDS);National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Completed

18 Years

N/A

All

Phase 1

United States

1094

NCT01397422
(ClinicalTrials.gov)

July 2011

18/7/2011

Extended Release Amantadine Safety and Efficacy Study in Levodopa-Induced Dyskinesia (EASED Study)

Dyskinesia;Levodopa Induced Dyskinesia;Parkinson's Disease

Drug: ADS-5102 (extended release amantadine HCl)

Adamas Pharmaceuticals, Inc.

NULL

Completed

30 Years

85 Years

All

Phase 2;Phase 3

United States

1095

EUCTR2011-001092-39-DE
(EUCTR)

29/06/2011

17/05/2011

efficacy, safety and tolerability of AQW051 in reducing L-dopa induced dyskinesias in Parkinson’s patients with moderate to severe L-dopa induced dyskinesias

A multi-centre, randomized, double-blind, placebo-controlled, parallel-group, multiple oral dose study to assess the efficacy, safety and tolerability of AQW051 in reducing L-dopa induced dyskinesiasin Parkinson’s patients with moderate to severe L-dopa induced dyskinesias

L-dopa induced dyskinesias in Parkinson’s patients with moderate to severe L-dopa induced dyskinesias
MedDRA version: 14.1;Level: HLT;Classification code 10034005;Term: Parkinson's disease and parkinsonism;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Product Name: AQW051
Product Code: AQW051
Product Name: AQW051
Product Code: AQW051

Novartis Pharma Services AG

NULL

Not Recruiting

Female: yes
Male: yes

France;United States;Germany;Italy

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1096

EUCTR2010-020112-11-LT
(EUCTR)

29/06/2011

06/04/2011

Placebo Controlled Study of Preladenant in Participants With Moderate to Severe Parkinson's Disease (P07037)

A Phase 3, 12-Week, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Preladenant in Subjects with Moderate to Severe Parkinson’s Disease. (Phase 3; Protocol No. P07037) - P07037

Product Name: Preladenant
Product Code: SCH 420814
INN or Proposed INN: Preladenant
Product Name: Preladenant
Product Code: SCH 420814
INN or Proposed INN: Preladenant

Schering-Plough Research Institute, a division of Schering Corporation

NULL

Not Recruiting

Female: yes
Male: yes

585

Phase 3

United States;Serbia;Mexico;Argentina;Ukraine;Croatia;Lithuania;Chile;South Africa;Russian Federation;Latvia;Colombia

1097

EUCTR2010-021860-13-CZ
(EUCTR)

24/06/2011

09/11/2010

Adjunct to levodopa L-DOPA/DDCI for use in patients with Parkinson’s disease (PD) and end-of-dose motor fluctuations.
MedDRA version: 17.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

BIAL - Portela & Ca, S.A.

NULL

Not Recruiting

Female: yes
Male: yes

550

Serbia;Portugal;Slovakia;Spain;Ukraine;Lithuania;Austria;Russian Federation;Montenegro;Italy;France;Czech Republic;Hungary;Poland;Romania;Croatia;Bulgaria;Netherlands;Germany;Latvia;Bosnia and Herzegovina

1098

EUCTR2010-020112-11-LV
(EUCTR)

21/06/2011

08/04/2011

Placebo Controlled Study of Preladenant in Participants With Moderate to Severe Parkinson's Disease (P07037)

A Phase 3, 12-Week, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Preladenant in Subjects with Moderate to Severe Parkinson’s Disease. (Phase 3; Protocol No. P07037) - P07037

Parkinson's disease
MedDRA version: 14.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Product Name: Preladenant
Product Code: SCH 420814
INN or Proposed INN: Preladenant

Schering-Plough Research Institute, a division of Schering Corporation

NULL

Not Recruiting

Female: yes
Male: yes

585

Phase 3

United States;Serbia;Mexico;Argentina;Ukraine;Lithuania;Croatia;South Africa;Russian Federation;Chile;Colombia;Latvia

1099

EUCTR2010-022200-46-LV
(EUCTR)

21/06/2011

01/04/2011

Efficacy and safety of ODM-101 compared to a standard combination(Stalevo®) in patients with Pakinson's disease.

Efficacy and safety of ODM-101 compared to a standard combination(Stalevo®); a randomised, double-blind, crossover, proof of conceptstudy in patients with Parkinson's disease and end-of-dose motorfluctuations. - PARPOC

Parkinson's disease
MedDRA version: 14.0;Level: LLT;Classification code 10013113;Term: Disease Parkinson's;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Product Name: ODM-101
Product Code: 75
INN or Proposed INN: LEVODOPA
Other descriptive name: na
INN or Proposed INN: CARBIDOPA
Other descriptive name: na
INN or Proposed INN: ENTACAPONE
Other descriptive name: na
Product Name: ODM-101
Product Code: 100
INN or Proposed INN: LEVODOPA
Other descriptive name: na
INN or Proposed INN: CARBIDOPA
Other descriptive name: na
INN or Proposed INN: ENTACAPONE
Other descriptive name: na
Product Name: ODM-101
Product Code: 125
INN or Proposed INN: LEVODOPA
Other descriptive name: na
INN or Proposed INN: CARBIDOPA
Other descriptive name: na

Orion Corporation

NULL

Not Recruiting

Female: yes
Male: yes

100

Finland;Lithuania;Germany;Latvia

1100

EUCTR2009-015162-57-CZ
(EUCTR)

17/06/2011

15/04/2011

An Active-Controlled Extension Study to P04938 and P07037 (P06153)

A Phase 3, 40-Week, Active-Controlled, Double-Blind, Double-Dummy Extension Study of Preladenant in Subjects With Moderate to Severe Parkinson’s Disease (Phase 3, Protocol No. P06153)

Parkinson's disease
MedDRA version: 14.1;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Schering-Plough Research Institute, a division of Schering Corporation

NULL

Not Recruiting

Female: yes
Male: yes

750

Phase 3

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1101

EUCTR2009-013552-72-PL
(EUCTR)

08/06/2011

23/02/2011

A Placebo- and Active-Controlled Study of Preladenant in Early Parkinson's Disease (Study P05664)

A Phase 3, Double-Blind, Double-Dummy, Placebo- and Active-Controlled Dose-Range-Finding Efficacy and Safety Study of Preladenant in Subjects With Early Parkinson’s Disease (Phase 3 Protocol No. P05664) - PARADYSE - Monotherapy

Product Name: Preladenant
Product Code: SCH 420814
INN or Proposed INN: Preladenant
Product Name: Preladenant
Product Code: SCH 420814
INN or Proposed INN: Preladenant
Product Name: Preladenant
Product Code: SCH 420814
INN or Proposed INN: Preladenant
Trade Name: Azilect
Product Name: Azilect
INN or Proposed INN: Rasagiline mesylate
Other descriptive name: RASAGILINE MESYLATE
Trade Name: Azilect
Product Name: Azilect
INN or Proposed INN: Rasagiline mesylate
Other descriptive name: RASAGILINE MESYLATE

Schering-Plough Research Institute, a division of Schering Corporation

NULL

Not Recruiting

Female: yes
Male: yes

1000

Phase 3

United States;Portugal;Spain;Russian Federation;Chile;Israel;Colombia;Italy;India;France;Peru;Netherlands;Finland;Turkey;Austria;United Kingdom;Czech Republic;Hungary;Mexico;Canada;Argentina;Brazil;Poland;Bulgaria;Germany;Sweden

1102

EUCTR2009-015161-31-PL
(EUCTR)

08/06/2011

23/02/2011

A Placebo- and Active Controlled Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease (Study P04938)

A Phase 3, 12-Week, Double-Blind, Double-Dummy, Placebo- and Active-Controlled Efficacy and Safety Study of Preladenant in Subjects With Moderate to Severe Parkinson’s Disease (Phase 3; Protocol No. P04938)

Product Name: Preladenant
Product Code: SCH 420814
INN or Proposed INN: Preladenant
Product Name: Preladenant
Product Code: SCH 420814
INN or Proposed INN: Preladenant
Product Name: Preladenant
Product Code: SCH 420814
INN or Proposed INN: Preladenant
Trade Name: Azilect
Product Name: Azilect
INN or Proposed INN: Rasagiline mesylate
Other descriptive name: RASAGILINE MESYLATE
Trade Name: Azilect
Product Name: Azilect
Product Code: N04BD02
INN or Proposed INN: Rasagiline mesylate
Other descriptive name: RASAGILINE MESYLATE

Schering-Plough Research Institute, a division of Schering Corporation

NULL

Not Recruiting

Female: yes
Male: yes

750

Phase 3

United States;Portugal;Finland;Spain;Turkey;Austria;Russian Federation;Israel;United Kingdom;Italy;India;France;Czech Republic;Canada;Poland;Brazil;Peru;Bulgaria;Germany;Netherlands;Sweden

1103

NCT02253563
(ClinicalTrials.gov)

June 2011

24/9/2014

Resistance Versus Balance Training in Parkinson's Disease

Resistance Training Versus Balance Training to Improve Postural Control in Patients With Parkinson's Disease - a Randomized Controlled Rater Blinded Trial

Parkinson's Disease

Behavioral: Resistance Training;Behavioral: Balance Training

University of Kiel

NULL

Completed

40 Years

100 Years

Both

N/A

NULL

1104

NCT01382342
(ClinicalTrials.gov)

June 2011

23/6/2011

The Effect of Rasagiline on Cognition in Parkinson's Disease

Parkinson's Disease

Drug: Rasagiline;Drug: Placebo

Brown University

Teva Pharmaceuticals USA

Completed

40 Years

N/A

Both

Phase 4

United States

1105

NCT01652534
(ClinicalTrials.gov)

June 2011

15/8/2011

Efficacy Study of Amantadine to Treat Gait Dysfunction and Freezing in Parkinson's Disease

Efficacy of Amantadine for Gait Dysfunction and Gait Freezing in Patients With Parkinson's Disease

Parkinson's Disease

Drug: Amantadine;Drug: Placebo

Northwestern University

NULL

Terminated

18 Years

85 Years

All

Phase 3

United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1106

NCT01528592
(ClinicalTrials.gov)

June 2011

31/1/2012

PharmacoMRI of Parkinson Disease

A Pilot Study of the Drug Effects on Brain Connectivity of Parkinson's Disease

Parkinson's Disease

Drug: Carbidopa -Levodopa

Northwestern University

NULL

Completed

30 Years

N/A

All

N/A

United States

1107

EUCTR2010-022517-25-DE
(EUCTR)

30/05/2011

14/02/2011

Safety, tolerability and efficacy of ADX48621 in patients with Parkinson's disease

Phase 2, randomized, double-blind, placebo-controlled, parallel group, multicenter study to evaluate the safety, tolerability and efficacy of ADX48621 in the treatment of levodopa induced dyskinesia in patients with Parkinson's disease

Levodopa induced dyskinesia in Parkinson's disease patients
MedDRA version: 13.1;Level: PT;Classification code 10013916;Term: Dyskinesia;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Product Name: ADX48621
Product Code: ADX48621
INN or Proposed INN: Dipraglurant

Addex Pharma SA

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

Phase 2

United States;France;Austria;Germany

1108

EUCTR2008-005492-94-BG
(EUCTR)

25/05/2011

23/03/2011

Open-Label trial to Determine the Long-term Safety of Safinamide in Parkinson's Disease Patients

Idiopathic Parkinson's Disease
MedDRA version: 14.1;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Product Name: Safinamide
Product Code: NW-1015
INN or Proposed INN: safinamide
Product Name: Safinamide
Product Code: NW-1015
INN or Proposed INN: safinamide

Newron Pharmaceuticals

NULL

Not Recruiting

Female: yes
Male: yes

1285

United States;Portugal;Taiwan;Estonia;Slovakia;Thailand;Spain;Chile;Colombia;Switzerland;Italy;India;France;Malaysia;Peru;South Africa;Netherlands;Korea, Republic of;Finland;Austria;United Kingdom;Czech Republic;Hungary;Mexico;Canada;Argentina;Brazil;Belgium;Poland;Romania;Croatia;Bulgaria;Germany;New Zealand

1109

EUCTR2009-015162-57-ES
(EUCTR)

23/05/2011

31/03/2011

Estudio de extensión de fase 3, de 40 semanas, controlado con tratamiento activo, doble ciego y doble simulación del preladenant en sujetos con enfermedad de Parkinson de moderada a grave (fase 3; n. de protocolo P06153)

Enfermedad de Parkinson
MedDRA version: 13.1;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders

Schering-Plough Research Institute, a division of Schering Corporation

NULL

Not Recruiting

Female: yes
Male: yes

750

Phase 3

Portugal;Finland;Spain;Lithuania;Austria;United Kingdom;Italy;Czech Republic;Poland;Bulgaria;Latvia;Netherlands;Sweden

1110

EUCTR2010-021394-37-AT
(EUCTR)

19/05/2011

05/01/2011

Placebo-controlled study in patients with Parkinson’s disease to evaluate the effect of rotigotine on nonmotor symptoms

MULTICENTER, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL-GROUP, PHASE IV STUDY TO ASSESS THE EFFECT OF ROTIGOTINE ON NON-MOTOR SYMPTOMS IN PATIENTS WITH IDIOPATHIC PARKINSON’S DISEASE - SP0976

UCB Pharma SA

NULL

Not Recruiting

Female: yes
Male: yes

345

Phase 4

Czech Republic;Hungary;Spain;Belgium;Austria;Germany;Italy;Switzerland

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1111

EUCTR2010-022200-46-FI
(EUCTR)

13/05/2011

23/03/2011

Efficacy and safety of ODM-101 compared to a standard combination (Stalevo®) in patients with Parkinson’s disease.

Efficacy and safety of ODM-101 compared to a standard combination (Stalevo®); a randomised, double-blind, crossover, proof of concept study in patients with Parkinson’s disease and end-of-dose motor fluctuations. - PARPOC

Parkinson's disease
MedDRA version: 14.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Orion Corporation

NULL

Not Recruiting

Female: yes
Male: yes

100

Finland;Germany;Latvia;Lithuania

1112

EUCTR2010-022200-46-LT
(EUCTR)

09/05/2011

05/04/2011

Efficacy and safety of ODM-101 compared to a standard combination (Stalevo®) in patients with Parkinson’s disease.

Orion Corporation

NULL

Not Recruiting

Female: yes
Male: yes

100

Finland;Lithuania;Germany;Latvia

1113

EUCTR2007-002964-90-BE
(EUCTR)

05/05/2011

04/09/2007

A trial to determine the efficacy and safety of a dose range of 50 to 100 mg/day of safinamide, as add-on therapy, in patients with Parkinson’s Disease with motor fluctuations, treated with levodopa and who may be receiving a dopamine agonist, an anticholinergic and/or amantadine.

Product Name: Safinamide
Product Code: NW-1015
INN or Proposed INN: Safinamide
Product Name: Safinamide
Product Code: NW-1015
INN or Proposed INN: Safinamide

Newron Pharmaceuticals SpA

NULL

Not Recruiting

Female: yes
Male: yes

605

Phase 3

United States;Estonia;Taiwan;Slovakia;Finland;Spain;Thailand;Austria;Israel;United Kingdom;Switzerland;India;France;Czech Republic;Hungary;Canada;Belgium;Malaysia;Australia;Germany;Netherlands;New Zealand;Korea, Republic of

1114

EUCTR2010-021394-37-SK
(EUCTR)

02/05/2011

16/12/2010

Placebo-controlled study in patients with Parkinson’s disease to evaluate the effect of rotigotine on nonmotor symptoms

MULTICENTER, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL-GROUP, PHASE IV STUDY TO ASSESS THE EFFECT OF ROTIGOTINE ON NON-MOTOR SYMPTOMS IN PATIENTS WITH IDIOPATHIC PARKINSON’S DISEASE - SP0976

UCB Pharma SA

NULL

Not Recruiting

Female: yes
Male: yes

345

Phase 4

Czech Republic;Hungary;Slovakia;Spain;Belgium;Austria;Bulgaria;Germany;Italy;Switzerland

1115

NCT01119131
(ClinicalTrials.gov)

May 2011

23/4/2010

Effects of Vitamin D in Parkinson's Disease (PD)

The Effects of Vitamin D on Balance in Persons With PD

Parkinson Disease;Accidental Falls

Drug: Vitamin D3;Dietary Supplement: calcium;Other: Placebo

VA Office of Research and Development

Oregon Health and Science University

Completed

50 Years

99 Years

All

101

Phase 2

United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1116

NCT01462708
(ClinicalTrials.gov)

May 2011

8/6/2011

Evaluation of [18F]MK-9470 as a Brain Tracer of Cannabinoid-1 Receptor in Parkinson's Disease and Healthy Subjects

Evaluation of [18F] MK-9470 and PET as a Marker of Cannabinoid-1 Receptor Activity in Subjects With Parkinson Disease Compared With Healthy Controls

Parkinson Disease

Drug: [18F]MK-9470

Institute for Neurodegenerative Disorders

NULL

Completed

18 Years

90 Years

Both

Phase 1

United States

1117

NCT01520987
(ClinicalTrials.gov)

May 2011

26/1/2012

Pharmacokinetics of BIA 9-1067 in Healthy Japanese and Caucasian Subjects

Randomized, Double-Blinded, Placebo-Controlled, Multiple Ascending Dose Study to Compare the Pharmacokinetics of BIA 9-1067 in Healthy Japanese and Caucasian Subjects

Parkinson Disease

Drug: BIA 9-1067;Drug: Placebo

Bial - Portela C S.A.

NULL

Completed

18 Years

65 Years

All

105

Phase 1

United States

1118

NCT01856439
(ClinicalTrials.gov)

May 2011

14/5/2013

Long Term Safety and Efficacy Study of ProSavin in Parkinson's Disease

A Multicentre, Open-label Study to Determine the Long Term Safety, Tolerability and Efficacy of ProSavin in Patients With Bilateral, Idiopathic Parkinson's Disease.

Parkinson's Disease

Drug: ProSavin

Axovant Sciences Ltd.

Oxford BioMedica

Active, not recruiting

N/A

All

Phase 1;Phase 2

France;United Kingdom

1119

NCT01504178
(ClinicalTrials.gov)

May 2011

30/12/2011

Evaluation of the Role of the Noradrenergic System in Pain Perception in Parkinson's Disease

Parkinson's Disease

Drug: duloxetine;Drug: placebo of duloxetine;Drug: injection of apomorphine;Drug: injection of placebo of apomorphine;Drug: L-Dopa;Drug: injection of placebo of L-Dopa

University Hospital, Toulouse

French Parkinson Association

Completed

30 Years

70 Years

All

Phase 3

France

1120

NCT01766258
(ClinicalTrials.gov)

May 2011

22/11/2012

Efficacy and Safety Proof of Concept Study in Patients With Parkinson's Disease and End-of-dose Motor Fluctuations

Efficacy and Safety of ODM-101 Compared to a Standard Combination (Stalevo®); a Randomised, Double-blind, Crossover, Proof of Concept Study in Patients With Parkinson's Disease and End-of-dose Motor Fluctuations

Parkinson's Disease

Drug: ODM-101 65mg Carbidopa;Drug: ODM-101 105mg Carbidopa;Drug: Stalevo

Orion Corporation, Orion Pharma

NULL

Completed

30 Years

N/A

Both

117

Phase 2

NULL

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1121

NCT01364545
(ClinicalTrials.gov)

May 2011

18/5/2011

Ketogenic Diets for Symptoms of Parkinson's Disease

Parkinson's Disease

Dietary Supplement: Ketone ester drink;Dietary Supplement: Placebo (carbohydrate containing) drink

University of Oxford

NULL

Recruiting

42 Years

N/A

Both

N/A

United Kingdom

1122

NCT01361009
(ClinicalTrials.gov)

May 2011

23/5/2011

a PMS on Safety Profile of Pramipexole in Chinese Parkinson Disease Patients

Safety of Pramipexole Monotherapy or Combination Therapy in Chinese Patients With Parkinson¿s Disease: a 12 Week Post Marketing Surveillance

Parkinson Disease

Drug: pramipexole

Boehringer Ingelheim

NULL

Completed

30 Years

75 Years

All

2017

N/A

China

1123

EUCTR2010-022366-27-CZ
(EUCTR)

21/04/2011

23/11/2010

BIPARK STUDY II

Efficacy and safety of BIA 9-1067 in idiopathic Parkinson’s disease patients with wearing-off” phenomenon treated with levodopa plus a dopa decarboxylase inhibitor (DDCI): a double-blind, randomised, placebo-controlled, parallel-group, multicentre clinical study. - BIPARK STUDY II

Idiopathic Parkinson's Disease
MedDRA version: 13.1;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Product Name: BIA 9-1067
Product Code: BIA 9-1067
INN or Proposed INN: Not yet available
Other descriptive name: 2,5-Dichloro-3-(5-(3,4-dihydroxy-5-nitrophenyl)-1,2,4-oxadiazol-3-yl)-4,6-dimethylpyridine-1-oxide
Product Name: BIA 9-1067
Product Code: BIA 9-1067
INN or Proposed INN: Not yet available
Other descriptive name: 2,5-Dichloro-3-(5-(3,4-dihydroxy-5-nitrophenyl)-1,2,4-oxadiazol-3-yl)-4,6-dimethylpyridine-1-oxide

BIAL Portela & Cª, S.A.

NULL

Not Recruiting

Female: yes
Male: yes

405

Estonia;Czech Republic;Argentina;Belgium;Australia;Israel;Chile;South Africa;Russian Federation;United Kingdom;Korea, Republic of;India

1124

EUCTR2010-022366-27-BE
(EUCTR)

18/04/2011

01/02/2011

Idiopathic Parkinson's Disease
MedDRA version: 12.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease

BIAL Portela & Cª, S.A.

NULL

Not Recruiting

Female: yes
Male: yes

405

Phase 3

Czech Republic;Estonia;Belgium;United Kingdom

1125

EUCTR2010-022517-25-AT
(EUCTR)

15/04/2011

17/02/2011

Levodopa induced dyskinesia in Parkinson's disease patients
MedDRA version: 14.0;Level: PT;Classification code 10013916;Term: Dyskinesia;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Product Name: ADX48621
Product Code: ADX48621
INN or Proposed INN: Dipraglurant

Addex Pharma SA

NULL

Not Recruiting

Female: yes
Male: yes

Phase 2

United States;France;Austria;Germany

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1126

EUCTR2008-005492-94-PT
(EUCTR)

14/04/2011

19/01/2011

Open-Label trial to Determine the Long-term Safety of Safinamide in Parkinson's Disease Patients

Idiopathic Parkinson's Disease
MedDRA version: 15.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Product Name: Safinamide
Product Code: NW-1015
INN or Proposed INN: safinamide
Product Name: Safinamide
Product Code: NW-1015
INN or Proposed INN: safinamide

Newron Pharmaceuticals

NULL

Not Recruiting

Female: yes
Male: yes

1285

1127

EUCTR2009-015161-31-DE
(EUCTR)

04/04/2011

24/08/2010

A Placebo- and Active Controlled Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease (Study P04938)

Product Name: Preladenant
Product Code: SCH 420814
INN or Proposed INN: Preladenant
Product Name: Preladenant
Product Code: SCH 420814
INN or Proposed INN: Preladenant
Product Name: Preladenant
Product Code: SCH 420814
INN or Proposed INN: Preladenant
Trade Name: Azilect
Product Name: Azilect
INN or Proposed INN: Rasagiline mesylate
Other descriptive name: RASAGILINE MESYLATE
Trade Name: Azilect
Product Name: Azilect
Product Code: N04BD02
INN or Proposed INN: Rasagiline mesylate
Other descriptive name: RASAGILINE MESYLATE

Merck Sharp & Dohme Corp., a subsidiary of Merck & Co. Inc.

NULL

Not Recruiting

Female: yes
Male: yes

750

Phase 3

Portugal;United States;Finland;Spain;Turkey;Austria;Israel;Russian Federation;Italy;United Kingdom;India;France;Czech Republic;Canada;Poland;Brazil;Peru;Bulgaria;Netherlands;Germany;Sweden

1128

JPRN-UMIN000005403

2011/04/01

08/04/2011

A Multi-center Randomized Placebo-controlled Double-blinded Study for the Efficacy of Donepezil against Psychosis in Parkinson Disease

Parkinson disease

5mg of donepezil hydrochloride
placebo

Designated Research, National Hospital Organization

NULL

Complete: follow-up complete

20years-old

80years-old

Male and Female

142

Phase 3

Japan

1129

NCT01313819
(ClinicalTrials.gov)

April 2011

10/3/2011

The Effect of IV Amantadine on Freezing of Gait (FOG) Resistant to Dopaminergic Therapy

A Double Blind, Placebo-controlled Study for the Effect of IV Amantadine on Freezing of Gait (FOG) Resistant to Dopaminergic Therapy

Parkinson`s Disease;Freezing of Gait

Drug: PK-Merz ® 200mg/500ml inj(Amantadine) , Normal saline 500ml inj

Seoul National University Hospital

NULL

Recruiting

30 Years

80 Years

Both

Phase 4

Korea, Republic of

1130

NCT01338896
(ClinicalTrials.gov)

April 2011

18/4/2011

Study to Compare Adhesiveness of Two Different Rotigotine Patch Formulations

A Multicenter, Randomized, Double-blind, Two-way Cross-over Study to Compare the Adhesiveness of Two Different Rotigotine Patch Formulations in Subjects With Parkinson's Disease

Parkinson's Disease

Drug: Rotigotine transdermal patch

UCB Pharma

NULL

Completed

18 Years

N/A

Both

Phase 1

Austria;Germany;United Kingdom

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1131

NCT01937078
(ClinicalTrials.gov)

April 2011

26/7/2012

Famotidine for Levodopa-induced Dyskinesia in PD

An 'N-of-1' Study of the Histamine H@ Antagonist, Famotidine in Levodopa-induced Dyskinesia in Parkinson's Disease

Dyskinesia

Drug: Famotidine

University Health Network, Toronto

NULL

Completed

18 Years

80 Years

Both

Phase 2

Canada

1132

NCT01662414
(ClinicalTrials.gov)

April 2011

7/8/2012

Effect of Undenatured Cysteine-Rich Whey Protein Isolate (HMS 90®) in Patients With Parkinson's Disease

Effect of Undenatured Cysteine-Rich Whey Protein Isolate (HMS 90®) in Patients With Parkinson's Disease: Changes in Biomarkers of Oxidative Stress, Profiles of Plasma Amino Acids and Their Derivatives and Brain Function

Parkinson Disease;Parkinsonian Disorders;Basal Ganglia Diseases;Brain Diseases;Central Nervous System Diseases;Nervous System Diseases;Movement Disorders;Neurodegenerative Diseases

Dietary Supplement: Whey protein;Dietary Supplement: Soy protein

Chulalongkorn University

NULL

Completed

30 Years

80 Years

Both

Phase 4

Thailand

1133

NCT01336088
(ClinicalTrials.gov)

April 2011

4/4/2011

ADX48621 for the Treatment of Levodopa Induced Dyskinesia in Patients With Parkinson's Disease

Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Group, Multicenter Study to Evaluate the Safety, Tolerability and Efficacy of ADX48621 in the Treatment of Levodopa Induced Dyskinesia in Patients With Parkinson's Disease

Parkinson's Disease

Drug: ADX48621;Drug: Placebo

Addex Pharma S.A.

NULL

Completed

30 Years

75 Years

Both

Phase 2

United States;Austria;France;Germany

1134

NCT01323855
(ClinicalTrials.gov)

March 28, 2011

24/3/2011

A Study to Assess Pharmacokinetics (PK) of Preladenant in Participants With Chronic Renal Impairment (CRI) (P06512)

A Study to Assess Pharmacokinetics of Preladenant in Subjects With Chronic Renal Impairment

Parkinson Disease

Drug: Preladenant

Merck Sharp & Dohme Corp.

NULL

Completed

18 Years

75 Years

All

Phase 1

Germany

1135

EUCTR2009-013552-72-BG
(EUCTR)

24/03/2011

26/01/2011

A Placebo- and Active-Controlled Study of Preladenant in Early Parkinson's Disease (Study P05664)

Product Name: Preladenant
Product Code: SCH 420814
INN or Proposed INN: Preladenant
Trade Name: Azilect
Product Name: Azilect
INN or Proposed INN: Rasagiline mesylate
Other descriptive name: RASAGILINE MESYLATE
Trade Name: Azilect
Product Name: Azilect
INN or Proposed INN: Rasagiline mesylate
Other descriptive name: RASAGILINE MESYLATE

Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.

NULL

Not Recruiting

Female: yes
Male: yes

1000

Phase 3

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1136

EUCTR2010-022366-27-GB
(EUCTR)

23/03/2011

30/11/2010

BIPARK STUDY II

BIAL Portela & Cª, S.A.

NULL

Not Recruiting

Female: yes
Male: yes

405

Phase 3

Estonia;Czech Republic;Argentina;Belgium;Australia;Israel;Chile;South Africa;Russian Federation;United Kingdom;Korea, Republic of;India

1137

EUCTR2009-015162-57-AT
(EUCTR)

17/03/2011

03/02/2011

An Active-Controlled Extension Study to P04938 and P07037 (P06153)

A Phase 3, 40-Week, Active-Controlled, Double-Blind, Double-Dummy Extension Study of Preladenant in Subjects With Moderate to Severe Parkinson’s Disease (Phase 3, Protocol No. P06153)

Schering-Plough Research Institute, a division of Schering Corporation

NULL

Not Recruiting

Female: yes
Male: yes

750

Phase 3

1138

EUCTR2008-005492-94-CZ
(EUCTR)

14/03/2011

03/01/2011

Open-Label trial to Determine the Long-term Safety of Safinamide in Parkinson's Disease Patients

Product Name: Safinamide
Product Code: NW-1015
INN or Proposed INN: safinamide
Product Name: Safinamide
Product Code: NW-1015
INN or Proposed INN: safinamide

Newron Pharmaceuticals

NULL

Not Recruiting

Female: yes
Male: yes

1285

Portugal;United States;Taiwan;Estonia;Slovakia;Thailand;Spain;Chile;Colombia;Italy;Switzerland;India;France;Malaysia;Peru;South Africa;Netherlands;Korea, Republic of;Finland;Austria;United Kingdom;Hungary;Czech Republic;Mexico;Canada;Argentina;Poland;Belgium;Brazil;Romania;Croatia;Bulgaria;Germany;New Zealand

1139

EUCTR2010-018534-44-DE
(EUCTR)

11/03/2011

10/08/2010

Investigation of Cogane (PYM50028) in early stage Parkinson's disease

Phytopharm plc

NULL

Not Recruiting

Female: yes
Male: yes

408

Phase 2

United States;Serbia;France;Hungary;Czech Republic;Canada;Poland;Romania;Germany;United Kingdom

1140

EUCTR2010-021394-37-CZ
(EUCTR)

09/03/2011

14/12/2010

Placebo-controlled study in patients with Parkinson’s disease to evaluate the effect of rotigotine on nonmotor symptoms

MULTICENTER, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL-GROUP, PHASE IV STUDY TO ASSESS THE EFFECT OF ROTIGOTINE ON NON-MOTOR SYMPTOMS IN PATIENTS WITH IDIOPATHIC PARKINSON’S DISEASE - SP0976

UCB Pharma SA

NULL

Not Recruiting

Female: yes
Male: yes

345

Phase 4

Hungary;Czech Republic;Spain;Belgium;Austria;Germany;Italy;Switzerland

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1141

EUCTR2010-021860-13-DE
(EUCTR)

09/03/2011

18/10/2010

Adjunct to levodopa (L-DOPA)/DDCI for use in patients with Parkinson’s disease (PD) and end-of-dose motor fluctuations.
MedDRA version: 18.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Product Name: Opicapone
Product Code: BIA 9-1067
INN or Proposed INN: BIA 9-1067
Other descriptive name: BIA 9-1067
Trade Name: Comtan®
Product Name: Over-encapsulated Entacapone Tablets
Product Code: Over-encapsulated Entacapone Tablets
INN or Proposed INN: ENTACAPONE
Product Name: Opicapone
Product Code: BIA 9-1067
INN or Proposed INN: BIA 9-1067
Other descriptive name: BIA 9-1067
Product Name: Opicapone
Product Code: BIA 9-1067
INN or Proposed INN: BIA 9-1067
Other descriptive name: BIA 9-1067

BIAL - Portela & Ca, S.A.

NULL

Not Recruiting

Female: yes
Male: yes

550

1142

EUCTR2010-021394-37-DE
(EUCTR)

08/03/2011

03/12/2010

Placebo-controlled study in patients with Parkinson's disease to evaluate the effect of rotigotine on nonmotor symptoms

MULTICENTER, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL-GROUP, PHASE IV STUDY TO ASSESS THE EFFECT OF ROTIGOTINE ON NON-MOTOR SYMPTOMS IN PATIENTS WITH IDIOPATHIC PARKINSON’S DISEASE - SP0976

UCB Pharma SA

NULL

Not Recruiting

Female: yes
Male: yes

345

Phase 4

Czech Republic;Hungary;Spain;Belgium;Austria;Bulgaria;Germany;Italy;Switzerland

1143

EUCTR2009-013552-72-GB
(EUCTR)

07/03/2011

07/07/2010

A Placebo- and Active-Controlled Study of Preladenant in Early Parkinson's Disease (Study P05664)

Parkinson's disease
MedDRA version: 14.1;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc

NULL

Not Recruiting

Female: yes
Male: yes

1000

Phase 3

1144

EUCTR2009-015161-31-GB
(EUCTR)

07/03/2011

01/07/2010

A Placebo- and Active Controlled Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease (Study P04938)

Parkinson's disease
MedDRA version: 14.1;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.

NULL

Not Recruiting

Female: yes
Male: yes

750

Phase 3

Portugal;United States;Finland;Spain;Turkey;Austria;Israel;Russian Federation;Italy;United Kingdom;India;France;Czech Republic;Canada;Poland;Brazil;Peru;Bulgaria;Netherlands;Germany;Sweden

1145

EUCTR2008-005492-94-FI
(EUCTR)

04/03/2011

13/01/2011

Open-Label trial to Determine the Long-term Safety of Safinamide in Parkinson's Disease Patients

Product Name: Safinamide
Product Code: NW-1015
INN or Proposed INN: safinamide
Product Name: Safinamide
Product Code: NW-1015
INN or Proposed INN: safinamide

Newron Pharmaceuticals

NULL

Not Recruiting

Female: yes
Male: yes

1285

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1146

EUCTR2009-015162-57-FI
(EUCTR)

02/03/2011

20/01/2011

An Active-Controlled Extension Study to P04938 and P07037 (P06153)

A Phase 3, 40-Week, Active-Controlled, Double-Blind, Double-Dummy Extension Study of Preladenant in Subjects With Moderate to Severe Parkinson’s Disease (Phase 3, Protocol No. P06153)

Parkinson's disease
MedDRA version: 14.1;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Schering-Plough Research Institute, a division of Schering Corporation

NULL

Not Recruiting

Female: yes
Male: yes

750

Phase 3

1147

EUCTR2010-021394-37-IT
(EUCTR)

01/03/2011

28/12/2011

STUDIO MULTICENTRICO, IN DOPPIO CIECO, CONTROLLATO VERSO PLACEBO, A GRUPPI PARALLELI, DI FASE IV VOLTO A VALUTARE GLI EFFETTI DELLA ROTIGOTINA NEI SINTOMI NON MOTORI IN SOGGETTI CON MALATTIA IDIOPATICA DI PARKINSON - SP0976

subjects with Parkinson’s disease.
MedDRA version: 14.1;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Trade Name: NEUPRO
INN or Proposed INN: Rotigotine
Trade Name: NEUPRO
INN or Proposed INN: Rotigotine
Trade Name: NEUPRO
INN or Proposed INN: Rotigotine
Trade Name: NEUPRO
INN or Proposed INN: Rotigotine

UCB Pharma SA

NULL

Not Recruiting

Female: yes
Male: yes

345

Czech Republic;Hungary;Spain;Belgium;Austria;Germany;Italy

1148

NCT01280123
(ClinicalTrials.gov)

March 2011

3/12/2010

Pioglitazone in Early Parkinson's Disease

A Multi-Center, Double-Blind, Placebo-Controlled Phase II Study of Pioglitazone in Early Parkinson's Disease

Parkinson's Disease

Drug: Pioglitazone;Drug: placebo

University of Rochester

National Institute of Neurological Disorders and Stroke (NINDS);Michael J. Fox Foundation for Parkinson's Research

Completed

30 Years

N/A

All

210

Phase 2

United States

1149

NCT01330290
(ClinicalTrials.gov)

March 2011

18/3/2011

Caregivers' and Physicians' Treatment Preference in Parkinson Patients Treated With Neupro® Requiring Caregiver Support

A Multi-site, Non-interventional, Cross-sectional Evaluation of the Caregivers' and the Physicians' Preferred Route of Administration and the Physicians' Rationale for the Choice of Neupro® in Patients With Parkinson Requiring Caregiver Support

Idiopathic Parkinson's Disease

Drug: Neupro ®

UCB Pharma

NULL

Completed

18 Years

N/A

All

148

N/A

Germany

1150

NCT01568073
(ClinicalTrials.gov)

March 2011

29/3/2012

Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients With Wearing-off Phenomenon

Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients With Wearing-off Phenomenon Treated With Levodopa Plus a Dopa Decarboxylase Inhibitor (DDCI): a Double-blind, Randomised, Placebo- and Active-controlled, Parallel-group, Multicentre Clinical Study

Parkinson's Disease

Drug: BIA 9-1067;Drug: Entacapone;Drug: Placebo;Drug: Levodopa;Drug: Carbidopa;Drug: Benserazide

Bial - Portela C S.A.

NULL

Completed

30 Years

83 Years

All

600

Phase 3

Portugal;Austria

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1151

NCT01264861
(ClinicalTrials.gov)

March 2011

20/12/2010

A Study to Evaluate Safinamide's Effect on Dopamine and Serotonin's Availability by Using Brain Imaging

Open-Label Escalating Dose Study Using [123|]ß-CIT SPECT Single Photon Emission Computerized Tomography (SPECT) to Evaluate Dopamine and Serotonin Transporter Occupancy by Safinamide in Parkinson Disease Patients

Parkinson Disease

Drug: Safinamide

Newron

NULL

Terminated

40 Years

80 Years

All

Phase 2

United States

1152

NCT01283594
(ClinicalTrials.gov)

March 2011

24/1/2011

Safety and Efficacy Study of SYN115 in Parkinson's Patients Using Levodopa to Treat End of Dose Wearing Off

A Double-blind, Randomized, Placebo-controlled Study of the Safety and Efficacy of SYN115 as Adjunctive Therapy in Levodopa-treated Parkinson's Subjects With End of Dose Wearing Off

Parkinson's Disease

Drug: Tozadenant (SYN115) 60 mg BID;Drug: Placebo;Drug: Levodopa (L-dopa);Drug: Tozadenant (SYN115) 120 mg BID;Drug: Tozadenant (SYN115) 180 mg BID;Drug: Tozadenant (SYN115) 240 mg BID

Biotie Therapies Inc.

NULL

Completed

30 Years

80 Years

All

420

Phase 2;Phase 3

United States;Argentina;Canada;Chile;Romania;Ukraine

1153

NCT02169427
(ClinicalTrials.gov)

March 2011

24/1/2012

An Open-label Study in Healthy Male Subjects to Assess the Absorption, Distribution, Metabolism and Excretion of [14C]-Labelled BIA 9-1067 and Metabolites

An Open-label Study in Healthy Male Subjects to Assess the Absorption, Distribution, Metabolism and Excretion of [14C]-Labelled BIA 9-1067 and Metabolites Following a Single Dose Oral Administration

Parkinson's Disease (PD)

Drug: OPC

Bial - Portela C S.A.

NULL

Completed

18 Years

55 Years

Male

Phase 1

Netherlands

1154

NCT01227655
(ClinicalTrials.gov)

March 2011

22/10/2010

Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients.

Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients With Wearing-off Phenomenon Treated With Levodopa Plus a Dopa Decarboxylase Inhibitor (DDCI): a Double-blind, Randomised, Placebo-controlled, Parallel-group, Multicentre Clinical Study.

Parkinson's Disease

Drug: BIA 9-1067;Drug: Placebo;Drug: Levodopa;Drug: Carbidopa;Drug: Benserazide

Bial - Portela C S.A.

NULL

Completed

30 Years

83 Years

All

427

Phase 3

Portugal

1155

NCT01341431
(ClinicalTrials.gov)

March 2011

30/3/2011

Bee Venom for the Treatment of Parkinson Disease

Evaluation of the Symptomatic and Neuroprotective Effects of Bee Venom for the Treatment of Parkinson Disease

Parkinson Disease

Drug: bee venom

Assistance Publique - Hôpitaux de Paris

NULL

Completed

40 Years

N/A

Both

Phase 2

France

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1156

NCT01294800
(ClinicalTrials.gov)

February 25, 2011

10/2/2011

A Dose Finding Study of Preladenant (SCH 420814) for the Treatment of Parkinson's Disease (PD) in Japanese Patients (P06402)

A Phase 2, 12-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study to Assess the Efficacy and Safety of Preladenant in Japanese Subjects With Moderate to Severe Parkinson's Disease. (Phase 2; Protocol No. P06402)

Parkinson's Disease

Drug: Preladenant;Drug: Placebo tablet to match Preladenant

Merck Sharp & Dohme Corp.

NULL

Completed

30 Years

85 Years

All

450

Phase 2

Japan

1157

EUCTR2008-001329-33-GB
(EUCTR)

24/02/2011

15/03/2010

Open Label Continuation Treatment Study With Levodopa-Carbidopa Intestinal Gel in Advanced Parkinson's Disease

Open-Label Continuation Treatment Study With Levodopa – Carbidopa Intestinal Gel In Subjects With Advanced Parkinson's Disease And Severe Motor-Fluctuations Who Have Exhibited A Persistent And Positive Effect To Treatment In Previous Studies.

Treatment with Levodopa – Carbidopa Intestinal Gel in subjects with advanced Parkinson's disease and severe motor-fluctuations who have exhibited a persistent and positive effect to treatment in previous studies
MedDRA version: 16.0;Level: LLT;Classification code 10013113;Term: Disease Parkinson's;System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

AbbVie Inc

NULL

Not Recruiting

Female: yes
Male: yes

275

Phase 3

Portugal;Czech Republic;Thailand;Poland;Australia;Israel;Russian Federation;Italy;New Zealand;United Kingdom

1158

EUCTR2010-022363-35-DE
(EUCTR)

18/02/2011

19/10/2010

Impact of Levodopa vs. Rotigotine on stress hormones and NGF in patients with Parkinson's Disease: A randomised, placebo-controlled double-blind trial.

Parkinson's disease
MedDRA version: 12.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's

Trade Name: Madopar LT
Product Name: Levodopa / Benserazid
Product Code: LD / BE
INN or Proposed INN: LEVODOPA
Other descriptive name: -
INN or Proposed INN: BENSERAZIDE HYDROCHLORIDE
Other descriptive name: -
Trade Name: Neupro
Product Name: Rotigotin
Product Code: RO
INN or Proposed INN: ROTIGOTINE
Other descriptive name: -

Clinical research lab for neurodegeneration, Dept. of Neurology, St. Josef-Hospital, Ruhr-University

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

Germany

1159

EUCTR2010-021860-13-SK
(EUCTR)

17/02/2011

09/12/2010

Adjunct to levodopa (L-DOPA)/DDCI for use in patients with Parkinson’s disease (PD) and end-of-dose motor fluctuations.
MedDRA version: 17.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

BIAL - Portela & Ca, S.A.

NULL

Not Recruiting

Female: yes
Male: yes

550

1160

EUCTR2009-015161-31-BG
(EUCTR)

17/02/2011

02/02/2011

A Placebo- and Active Controlled Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease (Study P04938)

Product Name: Preladenant
Product Code: SCH 420814
INN or Proposed INN: Preladenant
Trade Name: Azilect
Product Name: Azilect
INN or Proposed INN: Rasagiline mesylate
Other descriptive name: RASAGILINE MESYLATE
Trade Name: Azilect
Product Name: Azilect
Product Code: N04BD02
INN or Proposed INN: Rasagiline mesylate
Other descriptive name: RASAGILINE MESYLATE

Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.

NULL

Not Recruiting

Female: yes
Male: yes

750

Phase 3

Portugal;United States;Finland;Spain;Turkey;Austria;Israel;Russian Federation;Italy;United Kingdom;India;France;Czech Republic;Canada;Poland;Brazil;Peru;Bulgaria;Netherlands;Germany;Sweden

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1161

EUCTR2010-021394-37-ES
(EUCTR)

17/02/2011

22/12/2010

Estudio multicéntrico, doble ciego, controlado con placebo, de grupos paralelos, fase IV para evaluar el efecto de rotigotina sobre los síntomas no motores en pacientes con enfermedad de Parkinson idiopática(Multicenter, double-blind, placebo controlled, parallel-group, phase IV study to assess the effect of rotigotine on non-motor symptoms in patients with idiopathic parkinsons disease) - SP0976

Enfermedad de Parkinson
MedDRA version: 12.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease

Trade Name: NEUPRO 2 mg/24 h parche transdérmico
INN or Proposed INN: ROTIGOTINA
Other descriptive name: ROTIGOTINE
Trade Name: NEUPRO 4 mg/24 h parche transdérmico
INN or Proposed INN: ROTIGOTINA
Other descriptive name: ROTIGOTINE
Trade Name: NEUPRO 6 mg/24 h parche transdérmico
INN or Proposed INN: ROTIGOTINA
Other descriptive name: ROTIGOTINE
Trade Name: NEUPRO 8 mg/24 h parche transdérmico
INN or Proposed INN: ROTIGOTINA
Other descriptive name: ROTIGOTINE

UCB Pharma SA

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

345

Phase 4

Hungary;Czech Republic;Germany;Belgium;Spain;Italy;Austria

1162

EUCTR2010-021394-37-HU
(EUCTR)

14/02/2011

13/12/2010

Multicenter, double-blind, placebo controlled, parallel-group, phase IV study to assess the effect of rotigotine on non-motor symptoms in patients with idiopathic parkinson’s disease

MULTICENTER, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL-GROUP, PHASE IV STUDY TO ASSESS THE EFFECT OF ROTIGOTINE ON NON-MOTOR SYMPTOMS IN PATIENTS WITH IDIOPATHIC PARKINSON’S DISEASE - SP0976

UCB Pharma SA

NULL

Not Recruiting

Female: yes
Male: yes

345

Phase 4

Czech Republic;Hungary;Spain;Belgium;Austria;Germany;Italy;Switzerland

1163

EUCTR2009-017174-20-AT
(EUCTR)

09/02/2011

07/12/2010

A trial to determine if safinamide can attenuate levodopa induced dyskinesia in Parkinson’s disease.

A double-blind, randomized, placebo-controlled, parallel-group, dose escalation trial to explore the potential antidyskinetic properties of safinamide in patients with Parkinson's disease suffering from levodopa induced dyskinesias. - LID study

Idiopathic Parkinson's disease
MedDRA version: 14.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Product Name: Safinamide
Product Code: NW-1015E, EMD 1195686, MSC2191632B
INN or Proposed INN: safinamide
Other descriptive name: (S)-(+)-2-(4-(3-fluorobenzyl)oxybenzyl)aminopropanamide methanesulfonate

Merck Serono S.A. - Geneva

NULL

Not Recruiting

Female: yes
Male: yes

Germany;Canada;France;Austria;South Africa

1164

NCT01300819
(ClinicalTrials.gov)

February 2011

18/2/2011

Placebo-controlled Study in Patients With Parkinson's Disease to Evaluate the Effect of Rotigotine on Non-motor Symptoms

Multicenter, Double-blind, Placebo-controlled, Parallel-group, Phase IV Study to Assess the Effect of Rotigotine on Non-motor Symptoms in Patients With Idiopathic Parkinson's Disease

Idiopathic Parkinson's Disease

Other: Placebo;Drug: Rotigotine

UCB Pharma

NULL

Completed

18 Years

N/A

All

349

Phase 4

Austria;Belgium;Bulgaria;Czech Republic;France;Germany;Hungary;Italy;Romania;Slovakia;Spain;Switzerland

1165

NCT01313845
(ClinicalTrials.gov)

February 2011

10/3/2011

Effect of Intravenous Amantadine on Gait Freezing in Parkinson's Disease

Randomized Double-blind Placebo-controlled Trial of Intravenous Amantadine on Gait Freezing in Patients With Parkinson's Disease

Parkinson's Disease

Drug: amantadine sulfate;Drug: 0.9% sodium chloride

Jee-Young Lee

Seoul National University Boramae Hospital;Samsung Medical Center;Seoul National University Bundang Hospital;Hanyang University

Completed

30 Years

79 Years

Both

Phase 4

Korea, Republic of

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1166

NCT01296464
(ClinicalTrials.gov)

February 2011

14/2/2011

Comparing Different Levodopa/Carbidopa/Entacapone Treatment Regimens

Duration of Motor Response After Administration of Experimental Levodopa/Carbidopa/Entacapone Treatment Regimens Compared to Standard Treatment (Stalevo®);a Randomised,Double-blind,Crossover,Multicentre,Single Dose Study in Patients With Parkinson?s Disease and Wearing-off Symptoms

Parkinson's Disease

Drug: Carbidopa

Orion Corporation, Orion Pharma

NULL

Completed

30 Years

N/A

Both

Phase 2

Finland;Sweden

1167

NCT02880033
(ClinicalTrials.gov)

February 2011

3/8/2016

Oxidative Stress and Apoptosis of Energy Metabolism by Deferiprone From the Circulating Lymphocytes

Modulation of Oxidative Stress and Apoptosis of Energy Metabolism by Deferiprone From the Circulating Lymphocytes of Patients With Parkinson's Disease or Amyotrophic Lateral Sclerosis

Parkinson's Disease;Amyotrophic Lateral Sclerosis;Oxidative Stress;Iron Overload

Drug: deferiprone;Drug: placebo

University Hospital, Lille

NULL

Completed

18 Years

80 Years

All

N/A

France

1168

EUCTR2009-015161-31-PT
(EUCTR)

28/01/2011

29/10/2010

A Placebo- and Active Controlled Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease (Study P04938)

Product Name: Preladenant
Product Code: SCH 420814
INN or Proposed INN: Preladenant
Trade Name: Azilect
Product Name: Azilect
INN or Proposed INN: Rasagiline mesylate
Other descriptive name: RASAGILINE MESYLATE
Trade Name: Azilect
Product Name: Azilect
Product Code: N04BD02
INN or Proposed INN: Rasagiline mesylate
Other descriptive name: RASAGILINE MESYLATE

Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc

NULL

Not Recruiting

Female: yes
Male: yes

750

Phase 3

United States;Portugal;Finland;Spain;Turkey;Austria;Russian Federation;Israel;United Kingdom;Italy;India;France;Czech Republic;Canada;Poland;Brazil;Peru;Bulgaria;Germany;Netherlands;Sweden

1169

EUCTR2010-021860-13-RO
(EUCTR)

27/01/2011

25/07/2011

Adjunct to levodopa (L-DOPA)/DDCI for use in patients with Parkinson’s disease (PD) and end-of-dose motor fluctuations.
MedDRA version: 14.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

BIAL - Portela & Ca, S.A.

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

550

Portugal;Hungary;Germany;Netherlands;Bulgaria;France;Montenegro;Italy;Latvia;Austria;Lithuania;Slovakia;Russian Federation;Czech Republic;Ukraine;Serbia;Romania;Spain;Bosnia and Herzegovina;Croatia;Poland

1170

EUCTR2010-021860-13-AT
(EUCTR)

27/01/2011

11/10/2010

BIAL - Portela & Ca, S.A.

NULL

Not Recruiting

Female: yes
Male: yes

550

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1171

EUCTR2010-021394-37-BE
(EUCTR)

25/01/2011

14/12/2010

Placebo-controlled study in patients with Parkinson's disease to evaluate the effect of rotigotine on nonmotor symptoms

MULTICENTER, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL-GROUP, PHASE IV STUDY TO ASSESS THE EFFECT OF ROTIGOTINE ON NON-MOTOR SYMPTOMS IN PATIENTS WITH IDIOPATHIC PARKINSON’S DISEASE - SP0976

UCB Pharma SA

NULL

Not Recruiting

Female: yes
Male: yes

345

Phase 4

Czech Republic;Hungary;Slovakia;Spain;Belgium;Austria;Bulgaria;Germany;Italy;Switzerland

1172

EUCTR2010-021860-13-ES
(EUCTR)

24/01/2011

27/10/2010

EFFICACY AND SAFETY OF BIA 9-1067 IN IDIOPATHIC PARKINSON'S DISEASE PATIENTS WITH 'WEARING-OFF' PHENOMENON TREATED WITH LEVODOPA PLUS A DOPA DECARBOXYLASE INHIBITOR (DDCI): A DOUBLE-BLIND, RANDOMISED, PLACEBO- AND ACTIVE-CONTROLLED, PARALLEL-GROUP, MULTICENTRE CLINICAL STUDY.EFICACIA Y SEGURIDAD DE BIA 9-1067 EN PACIENTES CON ENFERMEDAD DE PARKINSON IDIOPÁTICA CON FENÓMENO DE 'WEARING OFF' TRATADOS CON LEVODOPA Y UN INHIBIDOR DE DOPA DESCAROBOXILASA (IDDC): ENSAYO CLÍNICO MULTICÉNTRICO, DOBLE CIEGO, ALEATORIZADO, CONTROLADO CON PLACEBO Y ACTIVO, DE GRUPOS PARALELOS - BIPARK STUDY I

Adjunct to levodopa (L-DOPA)/DDCI for use in patients with Parkinson's disease (PD) and end-of-dose motor fluctuations.Adjunto a levodopa/inhibidor dopa descarboxilasa para pacientes con enfermedad de Parkinson y fluctuaciones motoras de fin de dosis
MedDRA version: 12.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease

BIAL - Portela & Ca, S.A.

NULL

Not Recruiting

Female: yes
Male: yes

550

Portugal;Czech Republic;Hungary;Slovakia;Spain;Romania;Lithuania;Austria;Bulgaria;Germany;Latvia;Italy

1173

EUCTR2009-013552-72-CZ
(EUCTR)

17/01/2011

28/07/2010

A Placebo- and Active-Controlled Study of Preladenant in Early Parkinson's Disease (Study P05664)

Parkinson's disease
MedDRA version: 15.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Schering-Plough Research Institute, a division of Schering Corporation

NULL

Not Recruiting

Female: yes
Male: yes

1000

Phase 3

1174

EUCTR2009-015161-31-CZ
(EUCTR)

17/01/2011

28/07/2010

A Placebo- and Active Controlled Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease (Study P04938)

Product Name: Preladenant
Product Code: SCH 420814
INN or Proposed INN: Preladenant
Trade Name: Azilect
Product Name: Azilect
INN or Proposed INN: Rasagiline mesylate
Other descriptive name: RASAGILINE MESYLATE
Trade Name: Azilect
Product Name: Azilect
Product Code: N04BD02
INN or Proposed INN: Rasagiline mesylate
Other descriptive name: RASAGILINE MESYLATE

Schering-Plough Research Institute, a division of Schering Corporation

NULL

Not Recruiting

Female: yes
Male: yes

750

Phase 3

United States;Portugal;Finland;Spain;Turkey;Austria;Russian Federation;Israel;United Kingdom;Italy;India;France;Czech Republic;Canada;Poland;Brazil;Peru;Bulgaria;Germany;Netherlands;Sweden

1175

EUCTR2010-022915-21-SE
(EUCTR)

12/01/2011

18/11/2010

Duration of motor response after administration of experimental levodopa/carbidopa/entacapone treatment regimens compared to standard treatment (Stalevo®); a randomised, double-blind, crossover, multicentre, single dose study in patients with Parkinson’s disease and wearing-off symptoms - PARTEST

Parkinson's disease
MedDRA version: 12.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's

Product Name: carbidopa 20 mg
Product Code: NA
INN or Proposed INN: CARBIDOPA
Other descriptive name: NA
Product Name: carbidopa 27.5 mg
Product Code: NA
INN or Proposed INN: CARBIDOPA
Other descriptive name: NA
Trade Name: Stalevo 100/25/200 mg
Product Name: NA
Product Code: NA
INN or Proposed INN: LEVODOPA
Other descriptive name: NA
INN or Proposed INN: CARBIDOPA
Other descriptive name: NA
INN or Proposed INN: ENTACAPONE
Other descriptive name: NA
Trade Name: Stalevo 150/37.5/200 mg
Product Name: NA
Product Code: NA
INN or Proposed INN: LEVODOPA
Other descriptive name: NA
INN or Proposed INN: CARBIDOPA
Other descriptive name: NA
INN or Proposed INN: ENTACAPONE

Orion Corporation

NULL

Not Recruiting

Female: yes
Male: yes

Finland;Sweden

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1176

EUCTR2010-022915-21-FI
(EUCTR)

10/01/2011

11/11/2010

Parkinson's disease
MedDRA version: 12.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's

Orion Corporation

NULL

Not Recruiting

Female: yes
Male: yes

Finland;Sweden

1177

NCT01340885
(ClinicalTrials.gov)

January 2011

19/4/2011

Cognitive Decline in Non-demented PD

Cognitive Dysfunction in PD: Pathophysiology and Potential Treatments, a Pilot Study

Parkinson's Disease

Drug: Strattera;Drug: Exelon;Other: Placebo

Oregon Health and Science University

National Institute of Neurological Disorders and Stroke (NINDS)

Completed

18 Years

N/A

All

Phase 4

United States

1178

NCT01229332
(ClinicalTrials.gov)

January 2011

3/10/2010

A Safety, Tolerability and Pharmacokinetic Study of ND0611 on the Top of Different Oral Dosage Forms of Levodopa/Carbidopa in Parkinson's Disease Patients

A Phase I/II, Single-center, Randomized, Cross-over, Double-blind, Placebo-controlled Study Evaluating Safety, Tolerability and Pharmacokinetic Profile of Levodopa Following Administration of Subcutaneous Continuously-delivered Carbidopa Solution (ND0611) on the Top of Different Oral Dosage Forms of Levodopa/Carbidopa in Levodopa-treated Parkinson's Disease Patients With Motor Fluctuations

Parkinson's Disease

Drug: Saline;Drug: Carbidopa

NeuroDerm Ltd.

NULL

Completed

30 Years

N/A

Both

Phase 1;Phase 2

Israel

1179

NCT01268891
(ClinicalTrials.gov)

January 2011

30/12/2010

Study of Azilect® (Rasagiline) in Levodopa-treated Parkinson's Disease Patients With Motor Fluctuations in Korea

Randomised, Double-blind, Parallel-group, Placebo-controlled, Fixed-dose Study of [Azilect®] Rasagiline in Levodopa-treated Parkinson's Patients With Motor Fluctuations in Korea

Parkinson's Disease

Drug: Placebo;Drug: Azilect ®

H. Lundbeck A/S

NULL

Completed

30 Years

N/A

All

132

Phase 3

Korea, Republic of

1180

NCT01489982
(ClinicalTrials.gov)

January 2011

19/7/2011

Treatments for Insomnia in Patients With Parkinson's Disease

Treatments for Insomnia in Patients With Parkinson's Disease: A Pilot Study

Parkinson's Disease;Insomnia

Device: Light box (Litebook company);Behavioral: CBT and sleep hygiene;Drug: Doxepin and Zopiclone;Device: Light box ( Litebook company)

McGill University Health Center

NULL

Completed

18 Years

N/A

Both

Phase 0

Canada

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1181

NCT01301573
(ClinicalTrials.gov)

January 2011

18/2/2011

Long Term Follow-Up Study for rAAV-GAD Treated Subjects

Parkinson's Disease

Biological: rAAV-GAD

Neurologix, Inc.

NULL

Terminated

30 Years

90 Years

Both

N/A

United States

1182

NCT01341080
(ClinicalTrials.gov)

December 28, 2010

21/4/2011

Varenicline for Gait and Balance Impairment in Parkinson Disease

Varenicline for the Treatment of Postural and Gait Dysfunction in Parkinson Disease

Parkinson Disease

Drug: Varenicline;Drug: Sugar pill

Rush University Medical Center

NULL

Completed

40 Years

90 Years

All

Phase 2

United States

1183

EUCTR2010-021860-13-LV
(EUCTR)

22/12/2010

14/10/2010

Adjunct to levodopa (L-DOPA)/DDCI for use in patients with Parkinson’s disease (PD) and end-of-dose motor fluctuations.
MedDRA version: 12.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease

BIAL - Portela & Ca, S.A.

NULL

Not Recruiting

Female: yes
Male: yes

550

Portugal;Czech Republic;Hungary;Slovakia;Spain;Romania;Lithuania;Austria;Bulgaria;Germany;Latvia;Italy

1184

EUCTR2010-021860-13-PT
(EUCTR)

22/12/2010

08/11/2010

BIAL - Portela & Ca, S.A.

NULL

Not Recruiting

Female: yes
Male: yes

550

1185

EUCTR2008-004146-88-DE
(EUCTR)

20/12/2010

15/10/2010

An extension trial to investigate the long-term efficacy and safety of safinamide, as an add-on-therapy in patients with early Parkinson´s disease treated with a stable dose of a dopamine agonist

Product Name: Safinamide
Product Code: NW-1015
INN or Proposed INN: safinamide
Product Name: Safinamide
Product Code: NW-1015
INN or Proposed INN: safinamide

Newron Pharmaceuticals

NULL

Not Recruiting

Female: yes
Male: yes

498

Phase 3

Portugal;United States;Slovakia;Finland;Spain;Chile;Colombia;Italy;India;Czech Republic;Mexico;Canada;Argentina;Poland;Brazil;Croatia;Peru;South Africa;Bulgaria;Germany

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1186

EUCTR2010-022366-27-EE
(EUCTR)

10/12/2010

03/11/2010

Idiopathic Parkinson's Disease
MedDRA version: 12.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease

BIAL Portela & Cª, S.A.

NULL

Not Recruiting

Female: yes
Male: yes

405

Czech Republic;Estonia;Belgium;United Kingdom

1187

EUCTR2009-015161-31-NL
(EUCTR)

09/12/2010

09/08/2010

A Placebo- and Active Controlled Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease (Study P04938)

Product Name: Preladenant
Product Code: SCH 420814
INN or Proposed INN: Preladenant
Trade Name: Azilect
Product Name: Azilect
INN or Proposed INN: Rasagiline mesylate
Other descriptive name: RASAGILINE MESYLATE
Trade Name: Azilect
Product Name: Azilect
Product Code: N04BD02
INN or Proposed INN: Rasagiline mesylate
Other descriptive name: RASAGILINE MESYLATE

Schering-Plough Research Institute, a division of Schering Corporation

NULL

Not Recruiting

Female: yes
Male: yes

750

Phase 3

France;Czech Republic;Canada;Poland;Brazil;Peru;Bulgaria;Netherlands;Germany;Sweden;United States;Portugal;Finland;Spain;Turkey;Austria;Russian Federation;Israel;United Kingdom;Italy;India

1188

EUCTR2009-015161-31-IT
(EUCTR)

06/12/2010

28/09/2010

A Phase 3, 12-Week, Double-Blind, Placebo- and Active-Controlled Efficacy and Safety Study of Preladenant in Subjects with Moderate to Severe Parkinson’s Disease. (Phase 3; Protocol No. P04938) - ND

Parkinson`s Disease
MedDRA version: 9.1;Level: PT;Classification code 10061536

Schering-Plough Research Institute, a division of Schering Corporation

NULL

Not Recruiting

Female: yes
Male: yes

750

Phase 3

Portugal;Finland;Spain;Austria;Italy;United Kingdom;France;Czech Republic;Poland;Bulgaria;Netherlands;Germany;Sweden

1189

EUCTR2009-013552-72-IT
(EUCTR)

06/12/2010

04/11/2010

A Phase 3, Double-Blind, Placebo- and Active-Controlled Dose- Range-Finding Efficacy and Safety Study of Preladenant in Subjects With Early Parkinson’s Disease (Phase 3 Protocol No. P05664) - ND

Parkinson`s Disease
MedDRA version: 9.1;Level: PT;Classification code 10061536

Product Name: Preladenant
Product Code: SCH420814
Product Name: Preladenant
Product Code: SCH420814
Product Name: Preladenant
Product Code: SCH420814
Trade Name: Azilect
INN or Proposed INN: Rasagiline

Schering-Plough Research Institute, a division of Schering Corporation

NULL

Not Recruiting

Female: yes
Male: yes

1000

Phase 3

Hungary;Czech Republic;Finland;Poland;Spain;Bulgaria;Germany;United Kingdom;Italy;Sweden

1190

EUCTR2009-013552-72-SE
(EUCTR)

02/12/2010

06/10/2010

A Placebo- and Active-Controlled Study of Preladenant in Early Parkinson's Disease (Study P05664)

Product Name: Preladenant
Product Code: SCH 420814
INN or Proposed INN: Preladenant
Trade Name: Azilect
Product Name: Azilect
INN or Proposed INN: Rasagiline mesylate
Other descriptive name: RASAGILINE MESYLATE
Trade Name: Azilect
Product Name: Azilect
INN or Proposed INN: Rasagiline mesylate
Other descriptive name: RASAGILINE MESYLATE

Schering-Plough Research Institute, a division of Schering Corporation

NULL

Not Recruiting

Female: yes
Male: yes

1000

Phase 3

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1191

EUCTR2009-015161-31-SE
(EUCTR)

02/12/2010

06/10/2010

A Placebo- and Active Controlled Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease (Study P04938)

Product Name: Preladenant
Product Code: SCH 420814
INN or Proposed INN: Preladenant
Trade Name: Azilect
Product Name: Azilect
INN or Proposed INN: Rasagiline mesylate
Other descriptive name: RASAGILINE MESYLATE
Trade Name: Azilect
Product Name: Azilect
Product Code: N04BD02
INN or Proposed INN: Rasagiline mesylate
Other descriptive name: RASAGILINE MESYLATE

Schering-Plough Research Institute, a division of Schering Corporation

NULL

Not Recruiting

Female: yes
Male: yes

750

Phase 3

United States;Portugal;Finland;Spain;Turkey;Austria;Russian Federation;Israel;United Kingdom;Italy;India;France;Czech Republic;Canada;Poland;Brazil;Peru;Bulgaria;Germany;Netherlands;Sweden

1192

NCT01256905
(ClinicalTrials.gov)

December 2010

8/12/2010

Attention Modulation for Treatment of Parkinson's Disease and Dementia With Lewy Bodies

Parkinsons Disease;Lewy Bodies Disease

Drug: Armodafinil

New York University

Cephalon

Recruiting

50 Years

80 Years

Both

N/A

United States

1193

NCT01003002
(ClinicalTrials.gov)

December 2010

27/10/2009

Natural History of Levodopa-Induced Dyskinesia (LID)

Determining the Natural History of Levodopa-Induced Dyskinesia (LID)

Parkinson's Disease

Drug: Levodopa (delivered intravenously)

Oregon Health and Science University

Oregon Clinical and Translational Research Institute

Withdrawn

21 Years

100 Years

Both

N/A

United States

1194

NCT01244269
(ClinicalTrials.gov)

December 2010

18/11/2010

The Effect of Methylphenidate on Non-motor Symptoms and Postural Control in Parkinson's Disease.

Two-phase Randomized Controlled Trial of Low and Moderate Dose Methylphenidate for Non-motor and Postural Symptoms in Parkinson's Disease.

Parkinson's Disease

Drug: Methylphenidate;Drug: Placebo 10;Drug: Placebo 20

Laval University

Fonds de la Recherche en Santé du Québec;Quebec Memory and Motor Skills Disorders Research Center

Terminated

N/A

75 Years

Both

Phase 4

Canada

1195

EUCTR2010-021860-13-LT
(EUCTR)

30/11/2010

28/09/2010

MedDRA version: 16.1;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Product Name: BIA 9-1067
Product Code: BIA 9-1067
INN or Proposed INN: BIA 9-1067
Other descriptive name: BIA 9-1067
Trade Name: Comtan®
INN or Proposed INN: ENTACAPONE
Product Name: BIA 9-1067
Product Code: BIA 9-1067
INN or Proposed INN: BIA 9-1067
Other descriptive name: BIA 9-1067
Product Name: BIA 9-1067
Product Code: BIA 9-1067
INN or Proposed INN: BIA 9-1067
Other descriptive name: BIA 9-1067

BIAL - Portela & Ca, S.A.

NULL

Not Recruiting

Female: yes
Male: yes

550

Serbia;Portugal;Slovakia;Spain;Ukraine;Lithuania;Austria;Russian Federation;Montenegro;Italy;France;Hungary;Czech Republic;Poland;Croatia;Romania;Bulgaria;Latvia;Germany;Netherlands;Bosnia and Herzegovina

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1196

EUCTR2010-020109-34-ES
(EUCTR)

29/11/2010

23/09/2010

Estudio Fase II, doble ciego, aleatorizado, controlado con placebo, de grupos paralelos, para explorar los posibles efectos beneficiosos de safinamida en la cognición, en pacientes no dementes con enfermedad de Parkinson (EP) idiopática y deterioro cognitivo.A double-blind, randomized, placebo-controlled, parallel-group Phase II study to explore the potential beneficial effects of safinamide on cognition in non-demented patients with idiopathic Parkinson's disease (PD) and cognitive impairment.

Cognition in non-demented patients with idiopathic Parkinson's disease Cognición en sujetos no dementes con Enfermedad de Parkinson idiopática
MedDRA version: 12.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease

Product Name: Safinamida
Product Code: NW-1015
Other descriptive name: Safinamida

Merck Serono S.A. - Geneva

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

100

Phase 2

Spain;Italy

1197

EUCTR2010-020109-34-IT
(EUCTR)

24/11/2010

27/12/2010

A double-blind, randomized, placebo-controlled, parallel-group Phase II study to explore the potential beneficial effects of safinamide on cognition in non-demented patients with idiopathic Parkinson’s disease (PD) and cognitive impairment. - ND

Cognition in non-demented patients with idiopathic Parkinson’s disease
MedDRA version: 9.1;Level: PT;Classification code 10061536

Product Name: SAFINAMIDE
Product Code: NW-1015

MERCK SERONO SA

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

100

Phase 2

Spain;Italy

1198

NCT01227265
(ClinicalTrials.gov)

November 19, 2010

22/10/2010

Placebo Controlled Study of Preladenant in Participants With Moderate to Severe Parkinson's Disease (P07037)

A Phase 3, 12 Week, Double-blind, Placebo-controlled Efficacy and Safety Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease.

Parkinson Disease;Idiopathic Parkinson Disease;Idiopathic Parkinson's Disease

Drug: Preladenant;Drug: Placebo

Merck Sharp & Dohme Corp.

NULL

Completed

30 Years

85 Years

All

476

Phase 3

Argentina;Chile;Colombia;Croatia;Latvia;Lithuania;Mexico;Russian Federation;Serbia;South Africa;Ukraine;United States

1199

NCT01215227
(ClinicalTrials.gov)

November 18, 2010

4/10/2010

An Active-Controlled Extension Study to NCT01155466 [P04938] and NCT01227265 [P07037] (P06153)

A Phase 3, 40-Week, Active-Controlled, Double-Blind, Double-Dummy Extension Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease (Phase 3, Protocol No. P06153)

Parkinson Disease;Idiopathic Parkinson Disease

Drug: Preladenant;Drug: Rasagiline;Drug: Placebo to preladenant;Drug: Placebo to rasagiline

Merck Sharp & Dohme Corp.

NULL

Terminated

30 Years

85 Years

All

839

Phase 3

Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States

1200

EUCTR2010-021860-13-HU
(EUCTR)

11/11/2010

27/09/2010

BIAL - Portela & Ca, S.A.

NULL

Not Recruiting

Female: yes
Male: yes

550

Portugal;Czech Republic;Hungary;Slovakia;Spain;Romania;Lithuania;Austria;Bulgaria;Germany;Latvia;Italy

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1201

EUCTR2007-001109-26-GB
(EUCTR)

04/11/2010

05/08/2010

A phase I/II study of the safety, efficacy and dose evaluation of ProSavin®, administered using stereotactic injection to the striatum of patients with bilateral, idiopathic Parkinson’s disease

Patients with bilateral, idiopathic Parkinson's Disease

Oxford BioMedica (UK) Ltd

NULL

Not Recruiting

Female: yes
Male: yes

Phase 1;Phase 2

United Kingdom

1202

EUCTR2009-015161-31-AT
(EUCTR)

03/11/2010

17/08/2010

A Placebo- and Active Controlled Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease (Study P04938)

Product Name: Preladenant
Product Code: SCH 420814
INN or Proposed INN: Preladenant
Trade Name: Azilect
Product Name: Azilect
INN or Proposed INN: Rasagiline mesylate
Other descriptive name: RASAGILINE MESYLATE
Trade Name: Azilect
Product Name: Azilect
Product Code: N04BD02
INN or Proposed INN: Rasagiline mesylate
Other descriptive name: RASAGILINE MESYLATE

Schering-Plough Research Institute, a division of Schering Corporation

NULL

Not Recruiting

Female: yes
Male: yes

750

Phase 3

United States;Portugal;Finland;Spain;Turkey;Austria;Russian Federation;Israel;United Kingdom;Italy;India;France;Czech Republic;Canada;Poland;Brazil;Peru;Bulgaria;Germany;Netherlands;Sweden

1203

NCT01060878
(ClinicalTrials.gov)

November 2010

1/2/2010

Investigation of Cogane (PYM50028) in Early-stage Parkinson's Disease (CONFIDENT-PD)

Phase II, Randomised, Double-blind, Placebo-controlled Study to Investigate the Efficacy, Safety and Tolerability of PYM50028 in Subjects With Early-stage Parkinson's Disease Administered Once Daily for 28 Weeks

Parkinson's Disease

Drug: PYM50028;Drug: Placebo

Phytopharm

NULL

Completed

35 Years

75 Years

Both

425

Phase 2

United States;Canada;Czech Republic;France;Germany;Hungary;Poland;Romania;Serbia;United Kingdom

1204

NCT01270711
(ClinicalTrials.gov)

November 2010

9/12/2010

Study On Utilization Of Cabergoline For Compliance With Risk Minimization Activities (SUCRE)

Study on Utilization Of Cabergoline For Compliance With Risk Minimization Activities (SUCRE)

Parkinson's Disease;Hyperprolactinemia

Drug: Study Drug

Pfizer

NULL

Completed

N/A

All

22014

N/A

NULL

1205

NCT01190553
(ClinicalTrials.gov)

November 2010

26/8/2010

Pilot Study of Maintenance Therapy With Intravenous AMANTADINE

Maintenance Therapy of Intravenous Amantadine in Patients With Idiopathic Parkinson Disease Who Are Not Optimally Treated With Anti Parkinson Medications

Parkinson Disease

Drug: Amantadine

Rabin Medical Center

NULL

Not yet recruiting

30 Years

80 Years

Both

N/A

NULL

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1206

EUCTR2009-013552-72-ES
(EUCTR)

26/10/2010

27/07/2010

Estudio de eficacia y seguridad de fase 3, doble ciego, de doble simulación, controlado con placebo y tratamiento activo, de búsqueda del intervalo de dosis del preladenant en sujetos con enfermedad de Parkinson inicial (Fase 3 N.º de protocolo P05664) - PARADYSE

Enfermendad de Parkinson
MedDRA version: 13.1;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders

Schering Corporation, división Schering-Plough Research

NULL

Not Recruiting

Female: yes
Male: yes

1000

Phase 3

Hungary;Czech Republic;Finland;Poland;Spain;Bulgaria;Germany;Italy;United Kingdom;Sweden

1207

EUCTR2010-018534-44-GB
(EUCTR)

22/10/2010

09/08/2010

Investigation of Cogane (PYM50028) in early stage Parkinson's disease

Early-Stage Parkinson’s Disease
MedDRA version: 14.1;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Phytopharm plc

NULL

Not Recruiting

Female: yes
Male: yes

408

Phase 2

France;United States;Serbia;Hungary;Czech Republic;Canada;Poland;Romania;Germany;United Kingdom

1208

EUCTR2009-013552-72-HU
(EUCTR)

21/10/2010

11/08/2010

A Phase 3, Double-Blind, Placebo- and Active-Controlled Dose-Range-Finding Efficacy and Safety Study of Preladenant in Subjects With Early Parkinson's Disease - PARADYSE - Monotherapy

Parkinson's disease

Schering-Plough Research Institute, a division of Schering Corporation

NULL

Not Recruiting

Female: yes
Male: yes

1000

Phase 3

Czech Republic;Hungary;Finland;Poland;Spain;Bulgaria;Germany;Italy;United Kingdom;Sweden

1209

EUCTR2009-015161-31-FR
(EUCTR)

19/10/2010

29/07/2010

A Phase 3, 12-Week, Double-Blind, Placebo-and Active-Controlled Efficacy and Safety Study of Preladenant in Subjects with Moderate to Severe Parkinson's Disease

Parkinson's disease
MedDRA version: 12.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease

Schering-Plough Research Institute, a division of Schering Corporation

NULL

Not Recruiting

Female: yes
Male: yes

750

Phase 3

Portugal;Finland;Spain;Austria;United Kingdom;Italy;France;Czech Republic;Poland;Bulgaria;Netherlands;Germany;Sweden

1210

EUCTR2009-015928-28-SE
(EUCTR)

07/10/2010

13/08/2010

A double-blind, randomized, placebo controlled, dose finding study of oral eltoprazine for treatment of levodopa-induced dyskinesias (LID) in a levodopa challenge-dose setting in Parkinsons Disease. - ELTODYS09

Dyskinesias related to levodopa treatment in Parkinson´s disease

Product Name: Eltoprazine HCl
Product Code: Eltoprazine HCl

PsychoGenics Inc

NULL

Not Recruiting

Female: yes
Male: yes

Sweden

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1211

EUCTR2007-002964-90-CZ
(EUCTR)

06/10/2010

27/08/2010

Idiopathic Parkinson's Disease
MedDRA version: 9.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease

Product Name: Safinamide
Product Code: NW-1015
INN or Proposed INN: Safinamide
Product Name: Safinamide
Product Code: NW-1015
INN or Proposed INN: Safinamide

Merck Serono S.A. - Geneva

NULL

Not Recruiting

Female: yes
Male: yes

605

Phase 3

Hungary;Finland;United Kingdom;Germany;Czech Republic;Netherlands;Belgium;Estonia;France;Spain;Austria

1212

EUCTR2010-019418-25-DE
(EUCTR)

01/10/2010

19/07/2010

Open label, safety, tolerability and efficacy of AFQ056 in Parkinson’s patients with L-dopa induced dyskinesias

An open-label treatment study to evaluate the safety, tolerability and efficacy of AFQ056 in Parkinson’s patients with L-dopa induced dyskinesias

Moderate to severe levodopa induced dyskinesia in patients with Parkinson's disease
MedDRA version: 16.0;Level: HLT;Classification code 10013929;Term: Dyskinesias and movement disorders NEC;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Product Name: AFQ056
Product Code: AFQ065
Product Name: AFQ056
Product Code: AFQ065

Novartis Pharma Sevices AG

NULL

Not Recruiting

Female: yes
Male: yes

244

France;Canada;Finland;Australia;Germany;Italy;Japan

1213

NCT01192529
(ClinicalTrials.gov)

October 2010

30/8/2010

Evaluation of a Diet in Patients With Senile Dementia

Clinical Evaluation of an Specific Diet for People With Dementia Disease

Alzheimer's Disease;Parkinson's Disease;Senile Dementia

Dietary Supplement: Supressi. T-Diet plus Range;Dietary Supplement: High Protein. T-Diet plus Range

Vegenat, S.A.

NULL

Recruiting

70 Years

N/A

Both

184

N/A

Spain

1214

NCT01173731
(ClinicalTrials.gov)

October 2010

28/7/2010

Open Label, Safety, Tolerability and Efficacy of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias

An Open-label Treatment Study to Evaluate the Safety, Tolerability and Efficacy of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias

Parkinson Disease;Dyskinesia, Drug-Induced;Levodopa

Drug: AFQ056

Novartis Pharmaceuticals

NULL

Completed

N/A

All

Phase 2

United States;Australia;Canada;France;Germany;Italy;Finland;Spain

1215

NCT01216904
(ClinicalTrials.gov)

October 2010

6/10/2010

Nicotine Treatment of Impulsivity in Parkinson's Disease

Nicotine Treatment of Impulsivity in Parkinson's Disease: A Pilot Study

Parkinson's Disease

Drug: nicotine patch;Drug: placebo

University of Vermont

Parkinson's Disease Foundation;The Parkinson Study Group

Recruiting

18 Years

N/A

Both

Phase 4

United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1216

EUCTR2010-019418-25-FR
(EUCTR)

29/09/2010

15/07/2010

An open-label treatment study to evaluate the safety, tolerability and efficacy of AFQ056 in Parkinson’s patients with L-dopa induced dyskinesias

Moderate to severe levodopa induced dyskinesia in patients with Parkinson's disease
MedDRA version: 12.1;Level: LLT;Classification code 10013916;Term: Dyskinesia

Product Name: AFQ056
Product Code: AFQ056
Product Name: AFQ056
Product Code: AFQ056
Product Name: AFQ056
Product Code: AFQ056

Novartis Pharma AG

NULL

Not Recruiting

Female: yes
Male: yes

244

France;Finland;Germany;Italy

1217

EUCTR2009-017238-39-DE
(EUCTR)

16/09/2010

28/07/2010

A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066 in Advanced Parkinson’s Disease

Idiopathic Parkinson’s Disease (paralysis agitans)
MedDRA version: 14.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders

Product Name: IPX066
Product Code: IPX066 -95
INN or Proposed INN: CARBIDOPA
INN or Proposed INN: LEVODOPA
Product Name: IPX066
Product Code: IPX066 -145
INN or Proposed INN: CARBIDOPA
INN or Proposed INN: LEVODOPA
Product Name: IPX066
Product Code: IPX066 -195
INN or Proposed INN: CARBIDOPA
INN or Proposed INN: LEVODOPA
Product Name: IPX066
Product Code: IPX066 -245
INN or Proposed INN: CARBIDOPA
INN or Proposed INN: LEVODOPA
Trade Name: Nacom 100
INN or Proposed INN: CARBIDOPA

Impax Laboratories, Inc., acting through its Impax Pharmaceuticals Division (Impax)

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

Germany;France;Italy

1218

EUCTR2009-017238-39-FR
(EUCTR)

15/09/2010

09/07/2010

A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) in Advanced Parkinson’s Disease

Idiopathic Parkinson’s Disease (paralysis agitans)
MedDRA version: 12.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease

Impax Laboratories, Inc., acting through its Impax Pharmaceuticals Division (Impax)

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

Germany;France;Italy

1219

EUCTR2010-019418-25-FI
(EUCTR)

08/09/2010

21/07/2010

An open-label treatment study to evaluate the safety, tolerability and efficacy of AFQ056 in Parkinson’s patients with L-dopa induced dyskinesias

Moderate to severe levodopa induced dyskinesia in patients with Parkinson's disease
MedDRA version: 12.1;Level: LLT;Classification code 10013916;Term: Dyskinesia

Product Name: AFQ056
Product Code: AFQ065
Product Name: AFQ056
Product Code: AFQ065
Product Name: AFQ056
Product Code: AFQ065

Novartis Pharma AG

NULL

Not Recruiting

Female: yes
Male: yes

244

France;Finland;Germany;Italy

1220

EUCTR2009-013552-72-FI
(EUCTR)

07/09/2010

02/07/2010

A Placebo- and Active-Controlled Study of Preladenant in Early Parkinson's Disease (Study P05664)

Parkinson's disease
MedDRA version: 14.1;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Schering-Plough Research Institute, a division of Schering Corporation

NULL

Not Recruiting

Female: yes
Male: yes

1000

Phase 3

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1221

NCT01536574
(ClinicalTrials.gov)

September 2, 2010

19/1/2012

Open-Label Extension Study With REQUIP PR for Subjects From Study ROP111528

An Open Label Extension Study With REQUIP PR for Subjects From Study ROP111528

Parkinson Disease

Drug: Requip PR

GlaxoSmithKline

NULL

Completed

30 Years

N/A

All

295

Phase 3

China

1222

NCT01211587
(ClinicalTrials.gov)

September 2010

28/9/2010

A Trial to Explore the Potential Benefit of Safinamide on Cognitive Impairment Associated With Parkinson's Disease

A Double-blind, Randomized, Placebo-controlled, Parallel-group Phase II Study to Explore the Potential Beneficial Effects of Safinamide on Cognition in Non-demented Patients With Idiopathic Parkinson's Disease (PD) and Cognitive Impairment

Parkinson's Disease With Cognitive Impairments

Drug: safinamide;Drug: placebo

Newron

NULL

Completed

45 Years

80 Years

Both

103

Phase 2

United States;Spain

1223

NCT01162226
(ClinicalTrials.gov)

September 2010

24/6/2010

Computer-Based Balance Training for People With Parkinson's Disease

PD Wii: Computer-based Gait and Balance Training for Parkinson's Patients.

Parkinson's Disease

Behavioral: gait and balance training program

University of California, San Francisco

National Institute of Neurological Disorders and Stroke (NINDS)

Completed

N/A

Both

Phase 2

United States

1224

EUCTR2009-017238-39-BE
(EUCTR)

27/08/2010

14/07/2010

A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) in Advanced Parkinson’s Disease

Idiopathic Parkinson’s Disease (paralysis agitans)
MedDRA version: 12.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease

Impax Laboratories, Inc., acting through its Impax Pharmaceuticals Division (Impax)

NULL

Not Recruiting

Female: yes
Male: yes

Phase 3

France;Belgium;Germany;Italy

1225

EUCTR2009-017253-35-GB
(EUCTR)

20/08/2010

06/08/2010

Long-term study of patients who received ProSavin in the PS1/001/07 clinical trial.

A multicentre, open-label extension study to determine the long term safety, tolerability and efficacy of ProSavin® in patients with bilateral, idiopathic Parkinson’s disease

Patients with bilateral, idiopathic Parkinson's Disease;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Product Name: ProSavin
INN or Proposed INN: ProSavin

Oxford BioMedica (UK) Ltd

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

United Kingdom

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1226

EUCTR2009-015161-31-FI
(EUCTR)

17/08/2010

23/06/2010

A Placebo- and Active Controlled Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease (Study P04938)

Product Name: Preladenant
Product Code: SCH 420814
INN or Proposed INN: Preladenant
Trade Name: Azilect
Product Name: Azilect
INN or Proposed INN: Rasagiline mesylate
Other descriptive name: RASAGILINE MESYLATE
Trade Name: Azilect
Product Name: Azilect
Product Code: N04BD02
INN or Proposed INN: Rasagiline mesylate
Other descriptive name: RASAGILINE MESYLATE

Schering-Plough Research Institute, a division of Schering Corporation

NULL

Not Recruiting

Female: yes
Male: yes

750

Phase 3

United States;Portugal;Finland;Spain;Turkey;Austria;Russian Federation;Israel;United Kingdom;Italy;India;France;Czech Republic;Canada;Poland;Brazil;Peru;Bulgaria;Germany;Netherlands;Sweden

1227

EUCTR2010-020769-25-FR
(EUCTR)

10/08/2010

09/07/2010

Evaluation médico-économique de l’infusion continue intra-duodénale d’une forme gélifiée de levodopa dans le traitement des formes avancées et sévères de maladie de parkinson par l’intermédiaire d’un dispositif médical

Parkinson's disease
MedDRA version: 12.1;Level: LLT;Classification code 10034006;Term: Parkinson's disease aggravated

Trade Name: DUODOPA
INN or Proposed INN: LEVODOPA /CARBIDOPA
INN or Proposed INN: LEVODOPA /BENZERASIDE
INN or Proposed INN: PERGOLIDE
INN or Proposed INN: LISURIDE
INN or Proposed INN: BROMOCRIPTINE
INN or Proposed INN: ROPINIROLE
INN or Proposed INN: PRAMIPEXOLE
INN or Proposed INN: IPRONIAZID
Other descriptive name: MOCLOBEMIDE
INN or Proposed INN: AMANTADINE
INN or Proposed INN: CLOZAPINE
INN or Proposed INN: SELEGILINE
INN or Proposed INN: RASAGILINE
INN or Proposed INN: ENTACAPONE
INN or Proposed INN: TOLCAPONE

CHU de Poitiers

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

France

1228

NCT01824056
(ClinicalTrials.gov)

August 2010

12/3/2013

The Differential Diagnosis of Parkinson's Disease and Parkinsonism by Positron-emission Tomography

The Differential Diagnosis of Parkinson's Disease and Parkinsonism by Positron-emission Tomography With Vesicular Monoamine Transporter Ligand (18F-DTBZ)

Parkinson's Disease

Drug: 18F-FDG

Chang Gung Memorial Hospital

National Science Council, Taiwan

Completed

20 Years

80 Years

Both

120

Phase 2

Taiwan

1229

NCT01785628
(ClinicalTrials.gov)

August 2010

24/6/2011

The Impact of Pharmacological and Electric Modulation of NMDA Pathway on the Cognitive Flexibility and Volitional Movement Preparation in Patients With Parkinson's Disease

Parkinson's Disease With Dementia

Dietary Supplement: Sarcosine Capsule;Dietary Supplement: Placebo Capsule

China Medical University Hospital

National Science Council, Taiwan

Completed

N/A

All

N/A

Taiwan

1230

NCT01190735
(ClinicalTrials.gov)

August 2010

26/8/2010

Caffeine for Motor Manifestations of Parkinson's Disease

Caffeine for Motor Manifestations of Parkinson's Disease: An Open-Label Dose-Response Study.

Parkinson's Disease

Drug: Caffeine alkaloid

Ron Postuma

Canadian Institutes of Health Research (CIHR)

Completed

18 Years

N/A

Both

Phase 2

Canada

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1231

NCT01228851
(ClinicalTrials.gov)

August 2010

31/8/2010

Balance Training in Parkinson's Disease Using the Wii Balance Board

A Pilot Study of the Effects of Balance Training Using the Wii Balance Board on Balance and Ambulation in Adults With Parkinson's Disease

Parkinson's Disease

Other: Balance Training

Rehabilitation Institute of Chicago

NULL

Completed

18 Years

N/A

Both

N/A

United States

1232

NCT01191944
(ClinicalTrials.gov)

August 2010

30/8/2010

Pramipexole Extended Release Versus Pramipexole Immediate Release for 18 Weeks in Chinese Parkinson's Disease (PD) Patients

A Double-blind, Double-dummy, Randomised, Parallel-group Study Comparing the Efficacy, Safety and Tolerability of Pramipexole Extended Release Versus Pramipexole Immediate Release Administered Orally for 18 Weeks in Chinese Parkinson's Disease (PD) Patients Who Can be Concomitantly Treated With Levodopa

Parkinson Disease

Drug: pramipexole immediate release tablet;Drug: pramipexole extended release tablet

Boehringer Ingelheim

NULL

Completed

30 Years

N/A

All

475

Phase 3

China

1233

EUCTR2009-017182-38-ES
(EUCTR)

26/07/2010

25/05/2010

Estudio abierto de extensión para evaluar la seguridad y la eficacia de IPX066 en la enfermedad de Parkinson.An Open Label Extension Study of the Safety and Clinical Utility of IPX066 in Subjects with Parkinson?s Disease.

Enfermedad de Parkinson idiopática (parálisis agitante)
MedDRA version: 12.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease

Impax Laboratories, Inc. acting through its Impax Pharmaceuticals Division

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

500

Germany;Estonia;Spain;Latvia;Poland;Lithuania

1234

NCT01155466
(ClinicalTrials.gov)

July 14, 2010

30/6/2010

A Placebo- and Active Controlled Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease (P04938)

A Phase 3, 12-Week, Double-Blind, Double-Dummy, Placebo- and Active-Controlled Efficacy and Safety Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease (Phase 3;Protocol No. P04938)

Parkinson Disease

Drug: Preladenant 2 mg tablet;Drug: Preladenant 5 mg tablet;Drug: Preladenant 10 mg tablet;Drug: Placebo to Preladenant Tablet;Drug: Rasagiline 1 mg capsule;Drug: Placebo to Rasagiline capsule

Merck Sharp & Dohme Corp.

NULL

Completed

30 Years

85 Years

All

778

Phase 3

Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Japan;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States

1235

EUCTR2010-018650-12-FR
(EUCTR)

13/07/2010

06/05/2010

Evaluation du système noradrénergique dans l’altération de la perception douloureuse chez le patient Parkinsonien - DOULOX

maladie de Parkinson
MedDRA version: 12.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's

Trade Name: CYMBALTA
Product Name: duloxetine
Trade Name: APOKINON
Product Name: apomorphine
Trade Name: MODOPAR
Product Name: levodopa
Trade Name: MOTILIUM
Product Name: dompéridone

CHU de Toulouse

NULL

Not Recruiting

Female: yes
Male: yes

Phase 3

France

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1236

EUCTR2009-017182-38-LT
(EUCTR)

10/07/2010

26/04/2010

An Open-Label Extension Study of the Safety and Clinical Utility of IPX066 in Subjects with Parkinson´s Disease

Idiopathic Parkinson´s disease (paralysis agitans)
MedDRA version: 12.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease

Impax Laboratories, Inc. acting through its Impax Pharmaceutical Division (Impax)

NULL

Not Recruiting

Female: yes
Male: yes

500

Germany;Estonia;Spain;Latvia;Poland;Lithuania

1237

EUCTR2009-017182-38-DE
(EUCTR)

09/07/2010

07/05/2010

An Open Label Extension Study of the Safety and Clinical Utility of IPX066 in Subjects with Parkinson’s Disease.

Idiopathic Parkinson’s disease (paralysis agitans).
MedDRA version: 12.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease

Impax Laboratories, Inc. acting through its Impax Pharmaceuticals Division

NULL

Not Recruiting

Female: yes
Male: yes

500

Estonia;Spain;Poland;Lithuania;Latvia;Germany

1238

EUCTR2009-017182-38-PL
(EUCTR)

07/07/2010

20/05/2010

An Open Label Extension Study of the Safety and Clinical Utility of IPX066 in Subjects with Parkinson’s Disease.

Idiopathic Parkinson’s disease (paralysis agitans).
MedDRA version: 12.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease

Impax Laboratories, Inc.

NULL

Not Recruiting

Female: yes
Male: yes

500

Germany;Estonia;Spain;Latvia;Poland;Lithuania

1239

NCT01155479
(ClinicalTrials.gov)

July 6, 2010

30/6/2010

A Placebo- and Active-Controlled Study of Preladenant in Early Parkinson's Disease (PD) (P05664)

A Phase 3, Double-Blind, Double-Dummy, Placebo- and Active-Controlled Dose-Range-Finding Efficacy and Safety Study of Preladenant in Subjects With Early Parkinson's Disease

Parkinson Disease

Drug: Preladenant 2 mg tablet;Drug: Preladenant 5 mg tablet;Drug: Preladenant 10 mg tablet;Drug: Rasagiline 1 mg capsule;Drug: Placebo for Rasagiline 1 mg capsule;Drug: Placebo for Preladenant

Merck Sharp & Dohme Corp.

NULL

Terminated

30 Years

85 Years

All

1022

Phase 3

Argentina;Bulgaria;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;India;Israel;Italy;Mexico;Peru;Poland;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States

1240

NCT01174004
(ClinicalTrials.gov)

July 2010

30/7/2010

A Study of the Safety and Efficacy of Pimavanserin in Patients With Parkinson's Disease Psychosis

A Multi-Center, Placebo-Controlled, Double-Blind Trial to Examine the Safety and Efficacy of Pimavanserin in the Treatment of Psychosis in Parkinson's Disease

Parkinson's Disease Psychosis

Drug: pimavanserin tartrate;Drug: placebo

ACADIA Pharmaceuticals Inc.

NULL

Completed

40 Years

N/A

All

199

Phase 3

United States;Canada

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1241

NCT01149811
(ClinicalTrials.gov)

July 2010

10/6/2010

A Study Comparing the Safety and Tolerability of Two Doses of Fipamezole in Adult Patients With Parkinson's Disease

A Randomized, Double-Blind, Crossover Study Comparing the Safety and Tolerability of Two Dose Regimens of Oromucosal Fipamezole ODT in Adult Patients With Parkinson's Disease Who Are Receiving Levodopa

Parkinson's Disease

Drug: Fipamezole ODT;Drug: Fipamezole ODT Cohort 2

Valeant Pharmaceuticals International, Inc.

NULL

Completed

30 Years

75 Years

Both

United States

1242

NCT01174810
(ClinicalTrials.gov)

July 2010

2/8/2010

Exendin-4 as a Treatment for Parkinson's Disease - Pilot Study

An Open Label, Single Site, 12 Month, Phase II, Randomised Controlled Trial Evaluating the Safety and Efficacy of Exendin-4 (Exenatide) in the Treatment of Patients With Moderate Severity Parkinson's Disease.

Parkinson's Disease

Drug: Exenatide

University College, London

NULL

Active, not recruiting

45 Years

70 Years

Both

Phase 2

United Kingdom

1243

NCT01171313
(ClinicalTrials.gov)

July 2010

26/7/2010

A Efficacy, Safety and Pharmacokinetic Study of XP21279 and Sinemet® in Parkinson's Disease Subjects

A Phase 2 Efficacy, Safety and Pharmacokinetic Study of XP21279 BL2 and Sinemet® in Parkinson's Disease Subjects With Motor Fluctuations

Parkinson's Disease

Drug: XP21279 and carbidopa (experimental);Drug: Sinemet (comparator);Drug: Placebo for XP21279 and carbidopa;Drug: Placebo for Sinemet

XenoPort, Inc.

NULL

Completed

30 Years

80 Years

Both

Phase 2

United States

1244

NCT01435915
(ClinicalTrials.gov)

June 28, 2010

1/9/2011

Ropinirole PR Pharmacokinetics Study Among Chinese Healthy Subjects

A Single Dose and Repeat Dose Study to Investigate the Pharmacokinetics of Ropinirole After Single and Multiple Doses of a PR-formulation in Chinese Healthy Male and Female Subjects

Parkinson Disease

Drug: Ropinirole

GlaxoSmithKline

NULL

Completed

18 Years

45 Years

All

Phase 1

China

1245

EUCTR2009-017238-39-IT
(EUCTR)

21/06/2010

13/07/2010

A Study to Compare IPX066 and Carbidopa / Levodopa / Entacapone (CLE) in Advanced Parkinson’s Disease - ND

Idiopathic Parkinson’s Disease (paralysis agitans)
MedDRA version: 9.1;Level: LLT;Classification code 10061536

Product Name: IPX066
Product Code: IPX066 -95
INN or Proposed INN: CARBIDOPA LEVODOPA
Product Name: IPX066
Product Code: IPX066 -145
INN or Proposed INN: CARBIDOPA LEVODOPA
Product Name: IPX066
Product Code: IPX066 -195
INN or Proposed INN: CARBIDOPA LEVODOPA
Product Name: IPX066
Product Code: IPX066 -245
INN or Proposed INN: CARBIDOPA LEVODOPA
Trade Name: NACOM 100
INN or Proposed INN: Levodopa and decarboxylase inhibitor
Trade Name: COMTAN
INN or Proposed INN: Entacapone

IMPAX LABORATORIES, INC.

NULL

Not Recruiting

Female: yes
Male: yes

Germany;France;Italy

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1246

EUCTR2009-017182-38-LV
(EUCTR)

11/06/2010

26/04/2010

An Open-Label Extension Study of the Safety and Clinical Utility of IPX066 in Subjects with Parkinson´s Disease

Idiopathic Parkinson´s disease (paralysis agitans)
MedDRA version: 12.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease

Impax Laboratories, Inc. acting through its Impax Pharmaceutical Division (Impax)

NULL

Not Recruiting

Female: yes
Male: yes

500

Germany;Estonia;Spain;Latvia;Poland;Lithuania

1247

EUCTR2009-013886-24-SE
(EUCTR)

08/06/2010

21/12/2009

Efficacy and safety of BF2.649 in Excessive Daytime Sleepiness in Parkinson’s disease

A randomized, multicenter 12-Week double-blind placebo-controlled study to assess the efficacy and safety of BF2.649 in Excessive Daytime Sleepiness in Parkinson’s disease - HARPS-2

Excessive daytime sleepiness in Parkinson’s Disease
MedDRA version: 14.1;Level: HLT;Classification code 10034005;Term: Parkinson's disease and parkinsonism;System Organ Class: 10029205 - Nervous system disorders
MedDRA version: 14.1;Level: LLT;Classification code 10015595;Term: Excessive daytime sleepiness;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Product Name: Pitolisant
Product Code: BF2.649
INN or Proposed INN: Pitolisant
Product Name: Pitolisant
Product Code: BF2.649
INN or Proposed INN: Pitolisant
Product Name: Pitolisant
Product Code: BF2.649
INN or Proposed INN: Pitolisant

BIOPROJET

NULL

Not Recruiting

Female: yes
Male: yes

246

Czech Republic;Germany;Sweden

1248

NCT01140841
(ClinicalTrials.gov)

June 2010

8/6/2010

A Study of Safety and Tolerability of Fipamezole in Adult Subjects With Parkinson's Disease Who Are Receiving Levodopa

A Randomized, Double-Blind, Placebo-Controlled, Ascending Dose-Escalation Study of Safety and Tolerability of Oromucosal Fipamezole ODT in Adult Subjects With Parkinson's Disease Who Are Receiving Levodopa

Parkinson's Disease

Drug: Fipamezole ODT;Drug: Placebo

Valeant Pharmaceuticals International, Inc.

NULL

Completed

30 Years

75 Years

Both

United States

1249

NCT01141023
(ClinicalTrials.gov)

June 2010

8/6/2010

Study to Identify Clinical, Imaging and Biologic Markers of Parkinson Disease Progression

The Parkinson's Progression Markers Initiative (PPMI)

Parkinson Disease

Drug: DaTscan

Ken Marek, MD

Institute for Neurodegenerative Disorders

Active, not recruiting

30 Years

N/A

All

1100

Phase 2

United States;Australia;Austria;France;Germany;Greece;Israel;Italy;Norway;Spain;United Kingdom

1250

NCT01227681
(ClinicalTrials.gov)

June 2010

22/10/2010

Study of the Neuro-protective Effect of Granulocyte-colony Stimulating Factor on Early Stage Parkinson's Disease

A Double-Blind, Placebo-Control, Study of the Neuro-protective Effect of Granulocyte-colony Stimulating Factor on Early Stage Parkinson's Disease

Parkinson Disease

Drug: G-CSF;Drug: Placebo

Buddhist Tzu Chi General Hospital

NULL

Terminated

40 Years

65 Years

All

Phase 2

Taiwan

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1251

NCT01176240
(ClinicalTrials.gov)

June 2010

30/7/2010

A Two Part Study (306A/306B) to Assess Droxidopa in Treatment of NOH in Patients With Parkinson's Disease

A Multi-center, Double-blind, Randomized, Parallel-Group, Placebo-Controlled Study to Assess the Clinical Effect of Droxidopa in the Treatment of Symptomatic Neurogenic Orthostatic Hypotension in Patients With Parkinson's Disease

Orthostatic Hypotension;Parkinson's Disease

Drug: Droxidopa;Other: Placebo

Chelsea Therapeutics

NULL

Completed

18 Years

N/A

All

225

Phase 3

United States

1252

EUCTR2010-018904-94-IT
(EUCTR)

31/05/2010

14/03/2012

EFFICACY AND SAFETY OF INTRAMUSCULAR NERIDRONATE IN OSTEOPOROTIC PATIENTS AFFECTED BY PARKINSON'S DISEASE

Osteoporosis in patients affected by Parkinson's disaease at the stages 1-2-3-4 following Hoehn and Yahr criteria
MedDRA version: 14.1;Level: SOC;Classification code 10028395;Term: Musculoskeletal and connective tissue disorders;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]

Trade Name: NERIXIA*IM EV 1F 25MG
INN or Proposed INN: Bisphosphonates
Other descriptive name: Neridronic acid

FONDAZIONE SALVATORE MAUGERI - CLINICA DEL LAVORO E DELLA RIABILITAZIONE

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

Italy

1253

EUCTR2010-019354-40-AT
(EUCTR)

26/05/2010

26/04/2010

Überprüfung des Einflusses der STN-Stimulation auf die Schmerzschwelle von Patienten mit Idiopathischem Parkinsonsyndrom

Parkinson's disease
MedDRA version: 12.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's

Trade Name: Madopar
INN or Proposed INN: LEVODOPA
INN or Proposed INN: BENSERAZIDE

Universitätsklinik für Neurologie Innsbruck

NULL

Not Recruiting

Female: yes
Male: yes

Austria

1254

EUCTR2009-016143-19-AT
(EUCTR)

26/05/2010

12/05/2010

Validierung von Dyskinesie-Rating-Skalen anhand des therapeutischen Effektes von Amantadin - eine placebokontrollierte Studie

Parkinson's disease

Trade Name: Amantadin-ratiopharm 100mg
Other descriptive name: AMANTADINE HYDROCHLORIDE

CHU de Toulouse

NULL

Not Recruiting

Female: yes
Male: yes

France;Austria

1255

EUCTR2010-019396-29-IT
(EUCTR)

18/05/2010

05/03/2012

Levodopa and Pramipexole dministration modalities in patients affected by parkinson desease.

Levodopa Administration Modalities and Pramipexole in Parkinson's Disease (LAMP-PD study) A multicenter, randomized, four parallel groups, active-controlled, open-label study to evaluate the risk of dyskinesia in early PD. - LAMP-PD

Patients with idiopathic Parkinson's Disease.;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

AZIENDA OSPEDALIERO-UNIVERSITARIA POLICLINICO-VITTORIO EMANUELE

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

Italy

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1256

EUCTR2009-017182-38-EE
(EUCTR)

14/05/2010

26/04/2010

An Open-Label Extension Study of the Safety and Clinical Utility of IPX066 in Subjects with Parkinson´s Disease

Idiopathic Parkinson´s disease (paralysis agitans)
MedDRA version: 12.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease

Impax Laboratories, Inc. acting through its Impax Pharmaceutical Division (Impax)

NULL

Not Recruiting

Female: yes
Male: yes

500

Germany;Estonia;Spain;Latvia;Poland;Lithuania

1257

JPRN-UMIN000003601

2010/05/01

18/05/2010

Comparative study of ropinirole and entacapone for the treatment of wearing-off in advanced Parkinson's disease patients

Parkinson's disease

Increase dosage of ropinirole
Addition of entacapone

Kansai Medical University

NULL

Complete: follow-up complete

20years-old

75years-old

Male and Female

Not selected

Japan

1258

NCT01532115
(ClinicalTrials.gov)

May 2010

23/1/2012

Effect of BIA 9-1067 on Cardiac Repolarization in Healthy Adult Men and Women

A Randomized, Double-blind, Placebo-controlled and Open-label Active-controlled, 4-period Crossover Trial to Evaluate the Effect of BIA 9-1067 on Cardiac Repolarization in Healthy Adult Men and Women

Parkinson Disease

Drug: BIA 9-1067;Drug: Placebo;Drug: moxifloxacin

Bial - Portela C S.A.

NULL

Completed

18 Years

55 Years

Both

Phase 1

France

1259

NCT01283347
(ClinicalTrials.gov)

May 2010

11/1/2011

18F-DTBZ for l Diagnosis of Parkinson's Disease and Monitoring the Severity of Disease by VMAT2 PET Imaging

Phase II Study of 18F-DTBZ: The Differential Diagnosis of Parkinson's Disease and Monitoring the Severity of Disease by VMAT2 PET Imaging

Parkinson's Disease

Drug: 18F-DTBZ

Chang Gung Memorial Hospital

NULL

Completed

50 Years

80 Years

Both

100

Phase 2

Taiwan

1260

NCT01130493
(ClinicalTrials.gov)

May 2010

24/5/2010

A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066

A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066 in Advanced Parkinson's Disease

Parkinson's Disease

Drug: IPX066;Drug: CLE

Impax Laboratories, LLC

NULL

Completed

30 Years

N/A

All

110

Phase 3

United States;France;Germany;Italy

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1261

EUCTR2009-018137-37-GB
(EUCTR)

14/04/2010

18/03/2010

An open label, single site, 12 month, Phase II, randomised controlled trial evaluating the safety and efficacy of Exendin-4 (Exenatide) in the treatment of patients with moderate severity Parkinson's disease. - Exendin-4 as a treatment for Parkinson's disease- pilot trial

Parkinson's disease
MedDRA version: 14.1;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders

University College London

NULL

Not Recruiting

Female: yes
Male: yes

Phase 2

United Kingdom

1262

JPRN-JapicCTI-101198

01/4/2010

A double-blind confirmatory study for AD-810N (zonisamide) in patients with Parkinson's disease (Phase III)

Parkinson's disease

Intervention name : Zonisamide
Dosage And administration of the intervention : Oral
Control intervention name : null

Dainippon Sumitomo Pharma Co., Ltd.

NULL

BOTH

360

Phase 3

NULL

1263

NCT00988117
(ClinicalTrials.gov)

April 2010

29/9/2009

The Effects of the Rivastigmine Patch on Parkinson's Disease With Memory and/or Thinking Problems

The Effects of the Rivastigmine Patch on Attention and Behavior in Parkinson's Disease With Dementia (PDD)

Parkinsons Disease With Dementia;Parkinsons Disease With Mild to Moderate Memory and/or Thinking Problems

Drug: Rivastigmine Patch 9.5 cm2

University of California, San Francisco

Novartis

Completed

55 Years

N/A

All

Phase 4

United States

1264

NCT01113320
(ClinicalTrials.gov)

April 2010

8/4/2010

Safinamide in Levodopa Induced Dyskinesia in Parkinson's Disease Subjects

A Double-blind, Randomized, Placebo-controlled, Parallel-group, Dose Escalation Trial to Explore the Potential Antidyskinetic Properties of Safinamide in Patients With Parkinson's Disease Suffering From Levodopa Induced Dyskinesias

Parkinson's Disease

Drug: Placebo;Drug: Safinamide

Newron

NULL

Completed

30 Years

N/A

Both

Phase 2

Austria;Canada;France;Germany;South Africa

1265

NCT01484990
(ClinicalTrials.gov)

April 2010

28/7/2011

A Pharmacokinetic Study of Levodopa and Carbidopa Intestinal Gel in Subjects With Advanced Parkinson's Disease

Parkinson Disease

Drug: Levodopa -Carbidopa

AbbVie

Quintiles, Inc.

Completed

30 Years

99 Years

All

Phase 1

Germany;Sweden

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1266

NCT01103011
(ClinicalTrials.gov)

April 2010

12/4/2010

Safety, Tolerability and Pharmacokinetic Profile of Levodopa Administered With Continuous Administration of ND0611

A Phase I, Single Center, Blinded, Controlled Study Evaluating Safety, Tolerability and Pharmacokinetic Profile of Levodopa Following Repeated Administration of Oral Levodopa/Carbidopa and Continuously Delivered ND0611

Parkinson's Disease

Drug: ND0611

NeuroDerm Ltd.

NULL

Completed

18 Years

50 Years

Male

Phase 1

Israel

1267

EUCTR2009-017174-20-DE
(EUCTR)

15/03/2010

07/01/2010

A trial to determine if safinamide can attenuate levodopa induced dyskinesia in Parkinson’s disease.

Merck Serono S.A. - Geneva

NULL

Not Recruiting

Female: yes
Male: yes

France;Canada;Austria;South Africa;Germany

1268

EUCTR2009-013886-24-DE
(EUCTR)

03/03/2010

29/10/2009

A randomized, multicenter 12-Week double-blind placebo-controlled study to assess the efficacy and safety of BF2.649 in Excessive Daytime Sleepiness in Parkinson’s disease - HARPS-2

Excessive daytime sleepiness in Parkinson’s Disease
MedDRA version: 12.0;Level: LLT;Classification code 10015595;Term: Excessive daytime sleepiness
MedDRA version: 12.0;Level: HLT;Classification code 10034005;Term: Parkinson's disease and parkinsonism

BIOPROJET

NULL

Not Recruiting

Female: yes
Male: yes

246

Czech Republic;Germany;Sweden

1269

NCT01092065
(ClinicalTrials.gov)

March 2010

22/3/2010

Efficacy and Safety of AFQ056 When Combined With Increased Doses of L-dopa in Parkinson's Disease Patients With Moderate-severe L-dopa Induced Dyskinesia

A 6-week, Double-blind, Placebo-controlled, Randomized, Multicenter Study to Explore the Efficacy and Safety of AFQ056 When Combined With Increased Doses of L-dopa in Parkinson's Disease Patients With OFF Time and Moderate-severe L-dopa Induced Dyskinesia

Parkinson's Disease

Drug: AFQ056 with L-dopa;Drug: Placebo

Novartis

NULL

Completed

30 Years

80 Years

All

Phase 2

United States

1270

NCT01066442
(ClinicalTrials.gov)

March 2010

9/2/2010

Efficacy and Safety of BF2.649 in Excessive Daytime Sleepiness (EDS) in Parkinson's Disease

A Randomised, Multicenter 12-Week Double-blind Placebo-controlled Study to Assess the Efficacy and Safety of BF2.649 in Excessive Daytime Sleepiness in Parkinson's Disease Followed by a 38 Week Open Label Extension Phase

Parkinson's Disease

Drug: BF2.649 (Pitolisant)

Bioprojet

NULL

Completed

30 Years

80 Years

Both

273

Phase 3

Germany

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1271

NCT01097421
(ClinicalTrials.gov)

March 2010

25/3/2010

Influence of Pramipexole Extended Release on Medication Adherence in Parkinson´s Disease

Influence of Pramipexole Extended Release on Medication Adherence in Real Life Care of Parkinson's Disease

Parkinson Disease

Drug: Pramipexole Extended Release

Boehringer Ingelheim

NULL

Completed

30 Years

N/A

All

329

N/A

Sweden

1272

NCT01503944
(ClinicalTrials.gov)

March 2010

14/7/2010

A Trial of 18F-AV-133 and 18F-AV-45 Positron Emission Tomography (PET)

Detection of Striatal Dopaminergic Degeneration and Neocortical Amyloid Pathology in Patients With Dementia With Lewy Bodies, Alzheimer's Disease, Parkinson's Disease, and Healthy Elderly Volunteers

Dementia With Lewy Bodies;Alzheimer's Disease;Parkinson's Disease

Drug: 18F-AV-133;Drug: 18F-AV-45

Avid Radiopharmaceuticals

NULL

Completed

50 Years

N/A

Both

Phase 1;Phase 2

United States

1273

NCT02101190
(ClinicalTrials.gov)

March 2010

20/1/2012

Pharmacokinetics of BIA 9-1067 in Subjects With Hepatic Impairment

Open-label, Single-dose, Multi-center Study, Investigating the Pharmacokinetics of BIA 9-1067 in Subjects With Hepatic Impairment

Parkinson's Disease

Drug: BIA 9-1067

Bial - Portela C S.A.

NULL

Completed

18 Years

65 Years

All

Phase 1

France;Russian Federation

1274

NCT01096186
(ClinicalTrials.gov)

March 2010

25/3/2010

An Open Label Extension Study of the Safety and Clinical Utility of IPX066 in Subjects With Parkinson's Disease

Parkinson's Disease

Drug: IPX066 95 mg;Drug: IPX066 145 mg;Drug: IPX066 195 mg;Drug: IPX066 245 mg

Impax Laboratories, LLC

NULL

Completed

30 Years

N/A

All

617

Phase 3

United States;Canada;Estonia;Germany;Latvia;Lithuania;Poland;Romania;Spain;Ukraine

1275

NCT01055379
(ClinicalTrials.gov)

March 2010

22/1/2010

Rasagiline in Cognitive-impairment Related Depression: AzileCt in COgnitive-impairment Related DepressiOn

A Randomised, Double-blind, Placebo-controlled Study to Evaluate if Rasagiline Can Improve Depressive Symptoms and Cognitive Function in Non-demented, Idiopathic Parkinson's Disease Patients: ACCORDO Study

Depressive Symptoms;Parkinson's Disease

Drug: Rasagiline;Drug: Placebo

Lundbeck Italia S.p.A.

Teva Pharmaceutical Industries

Completed

40 Years

80 Years

All

121

Phase 4

Italy

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1276

EUCTR2009-017174-20-FR
(EUCTR)

24/02/2010

18/01/2010

Idiopathic Parkinson's disease
MedDRA version: 12.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease

Product Name: Safinamide
Product Code: NW-1015

Merck Serono S.A. - Geneva

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

Germany;France;Austria

1277

EUCTR2007-002963-28-DE
(EUCTR)

17/02/2010

22/12/2009

A trial to determine the efficacy and safety of a low (50mg/day) and high dose (100mg / day) of safinamide, as add-on therapy, in patients with early Parkinson´s Disease treated with a sigle dopamin antagonist

Idiopathic Parkinson's Disease
MedDRA version: 14.1;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders

Product Name: Safinamide
Product Code: NW-1015
INN or Proposed INN: Safinamide
Product Name: Safinamide
Product Code: NW-1015
INN or Proposed INN: Safinamide

Newron Pharmaceuticals SpA

NULL

Not Recruiting

Female: yes
Male: yes

839

Phase 3

Portugal;United States;Finland;Spain;Chile;Colombia;Italy;India;Czech Republic;Mexico;Canada;Argentina;Poland;Brazil;Croatia;Peru;Bulgaria;South Africa;Germany

1278

NCT01154166
(ClinicalTrials.gov)

February 15, 2010

29/6/2010

A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group Study of Six Months Treatment With Ropinirole PR as Adjunctive Therapy in Patients With Parkinson's Disease Who Are Not Optimally Controlled on L-Dopa

Parkinson Disease

Drug: ReQuip PR;Drug: Placebo

GlaxoSmithKline

NULL

Completed

30 Years

N/A

All

347

Phase 3

China

1279

EUCTR2009-014688-37-PL
(EUCTR)

09/02/2010

20/01/2010

A Study To Evaluate The Safety And Efficacy Of IPX066 In Advanced Parkinson’s Disease - N/A

Advanced Parkinson’s Disease subjects with motor fluctuations
MedDRA version: 13.1;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders

Product Name: IPX066
Product Code: IPX066 -95
INN or Proposed INN: CARBIDOPA
INN or Proposed INN: LEVODOPA
Trade Name: SINEMET®-Plus Tablets
Product Name: IR CD-LD
INN or Proposed INN: CARBIDOPA
INN or Proposed INN: LEVODOPA
Product Name: IPX066
Product Code: IPX066 -145
INN or Proposed INN: CARBIDOPA
INN or Proposed INN: LEVODOPA
Product Name: IPX066
Product Code: IPX066 -195
INN or Proposed INN: CARBIDOPA
INN or Proposed INN: LEVODOPA
Product Name: IPX066
Product Code: IPX066 -245
INN or Proposed INN: CARBIDOPA

Impax Laboratories, Inc.

NULL

Not Recruiting

Female: yes
Male: yes

350

Germany;France;Spain;Poland

1280

EUCTR2009-016360-37-SE
(EUCTR)

06/02/2010

04/12/2009

TREATMENT OF DYSKINESIAS IN PARKINSON’S DISEASE WITH OSU6162 – A PILOT STUDY

Parkinsons disease is complicated by dyskinesias and dystonia. Due stabilizing properties, we believe (-)-OSU6162 may alleviate dyskinesias, without causing parkinsonism. Aim: To evaluate in a double-blind cross over pilot study whether OSU6162 attenuates dyskinesias without worsening parkinsonism in PD patients with motor complications using clinical examination and patient diaries.

Björn Holmberg

NULL

Not Recruiting

Female: yes
Male: yes

Phase 1;Phase 2

Sweden

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1281

NCT01568047
(ClinicalTrials.gov)

February 2010

29/3/2012

Multicentre Study in Four Parallel Groups of Parkinson's Disease (PD) Patients

Multicentre, Double-blind, Randomised, Placebo-controlled Study in Four Parallel Groups of PD Patients Treated With Standard-release Levodopa/Carbidopa 100/25 mg (Sinemet®) or Levodopa/Benserazide 100/25 mg (Madopar®/Restex®) and With Motor Fluctuations (Wearing-off Phenomenon)

Parkinson's Disease

Drug: Placebo;Drug: BIA 9-1067;Drug: Levodopa /Carbidopa;Drug: Levodopa /Benzerazide

Bial - Portela C S.A.

NULL

Completed

30 Years

N/A

All

Phase 2

Romania;Ukraine

1282

NCT02169414
(ClinicalTrials.gov)

February 2010

24/1/2012

Effect of Three Multiple-dose Regimens of BIA 9 1067 at Steady-state on the Levodopa Pharmacokinetics

Effect of Three Multiple-dose Regimens of BIA 9 1067 at Steady-state on the Levodopa Pharmacokinetics of a Single-dose of Immediate Release 100/25 mg Levodopa/Carbidopa and 100/25 mg Levodopa/Benserazide in Healthy Subjects

Parkinson's Disease (PD)

Drug: BIA 9-1067 5 mg;Drug: BIA 9-1067 25 mg;Drug: levodopa /carbidopa 100/25;Drug: Placebo;Drug: levodopa /benserazide 100/25 mg

Bial - Portela C S.A.

NULL

Completed

18 Years

45 Years

All

Phase 1

France

1283

EUCTR2008-005492-94-BE
(EUCTR)

25/01/2010

12/08/2009

Open-Label trial to Determine the Long-term Safety of Safinamide in Parkinson's Disease Patients

Idiopathic Parkinson's Disease
MedDRA version: 9.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease

Product Name: Safinamide
Product Code: NW-1015
INN or Proposed INN: safinamide
Product Name: Safinamide
Product Code: NW-1015
INN or Proposed INN: safinamide

Merck Serono S.A. - Geneva

NULL

Not Recruiting

Female: yes
Male: yes

1285

Phase 3

Portugal;Estonia;Slovakia;Finland;Spain;Austria;Italy;United Kingdom;France;Hungary;Czech Republic;Belgium;Bulgaria;Germany;Netherlands

1284

EUCTR2009-017416-33-DE
(EUCTR)

18/01/2010

21/12/2009

Standardized clinical trial on the application of Levodopa (LD) / Carbidopa (CD) to patients with Parkinson disease vs LD / CD and Entacapon (EN) vs LD / CD and Tolcapon (TO) concerning the parameters motor function, pharmacokinetics of LD, plasma level of homocystein and serum level of cortisol.

Male and female patients with Parkinson´s disease meeting UKPDS criteria
MedDRA version: 12.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's

Trade Name: Tasmar
Product Name: Tolcapon
Product Code: TO
INN or Proposed INN: TOLCAPONE
Trade Name: Comtess
Product Name: Entacapon
Product Code: EN
INN or Proposed INN: ENTACAPONE
Trade Name: Isicom
Product Name: Levodopa /Carbidopa
Product Code: LD/CD
INN or Proposed INN: LEVODOPA
Other descriptive name: CARBIDOPA MONOHYDRATE
Trade Name: Tasmar
Product Name: Tolcapon
Product Code: TO
INN or Proposed INN: TOLCAPONE
Trade Name: Comtess
Product Name: Entacapon
Product Code: EN
INN or Proposed INN: ENTACAPONE
Trade Name: Isicom
Product Name: Levodopa /Carbidopa
Product Code: LD/CD
INN or Proposed INN: LEVODOPA
Other descriptive name: CARBIDOPA MONOHYDRATE

Clinical research lab for neurodegeneration, Dept. of Neurology, St. Josef-Hospital, Ruhr-University

NULL

Not Recruiting

Female: yes
Male: yes

Germany

1285

EUCTR2008-005492-94-NL
(EUCTR)

18/01/2010

25/09/2009

Open-Label trial to Determine the Long-term Safety of Safinamide in Parkinson's Disease Patients -

Idiopathic Parkinson's Disease
MedDRA version: 14.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders

Product Name: Safinamide
Product Code: NW-1015
INN or Proposed INN: safinamide
Product Name: Safinamide
Product Code: NW-1015
INN or Proposed INN: safinamide

Merck Serono S.A. - Geneva

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

1285

Hungary;Portugal;Germany;Netherlands;France;Bulgaria;Italy;Austria;United Kingdom;Czech Republic;Belgium;Estonia;Spain

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1286

EUCTR2008-001329-33-CZ
(EUCTR)

18/01/2010

03/12/2009

Open Label Continuation Treatment Study With Levodopa-Carbidopa Intestinal Gel in Advanced Parkinson's Disease

Treatment with Levodopa – Carbidopa Intestinal Gel in subjects with advanced Parkinson's disease and severe motor-fluctuations who have exhibited a persistent and positive effect to treatment in previous studies
MedDRA version: 16.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Trade Name: Duodopa, 20 mg/ml + 5 mg/ml, intestinal gel
INN or Proposed INN: levodopa
Other descriptive name: Ph. Eur.: (2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid
INN or Proposed INN: carbidopa monohydrate
Other descriptive name: Ph. Eur.: (2S)-3-(3,4-dihydroxyphenyl)-2hydrazino-2methylprop acid

AbbVie Inc

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

275

Portugal;Czech Republic;Thailand;Poland;Australia;Russian Federation;Israel;United Kingdom;Italy;New Zealand

1287

EUCTR2009-012643-42-NL
(EUCTR)

06/01/2010

30/11/2009

Freezing of gait in Parkinson's disease: in search of the underlying mechanism and the application of a new treatment option - Freezing of gait in Parkinson's disease

Parkinson's disease, in particular the symptom Freezing of Gait

Trade Name: Ritalin
Product Name: Not applicable
Product Code: Not applicable
INN or Proposed INN: METHYLPHENIDATE HYDROCHLORIDE
Other descriptive name: Ritalin

University Medical Center Groningen

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

Netherlands

1288

JPRN-UMIN000007497

2010/01/01

14/03/2012

Trial of molecular hydrogen water in Parkinson disease

Parkinson disease

The subjects should make 1000 ml of molecular hydrogen water which contains 1.6 ppm dissolved hydrogen by Aquerable, and consume for 48 weeks.
Placebo water which is not contained molecular hydrogen water made from pseudo-machine. The subjects consume for48 weeks.

Department of Neurology, Juntendo University School of Medicine

NULL

Complete: follow-up complete

20years-old

Not applicable

Male and Female

Not applicable

Japan

1289

JPRN-UMIN000003080

2010/01/01

30/01/2010

Double Blind Study for Effects of Donepezil Hydrochloride on Parkinson's Disease

Parkinson's disease

Donepezil hydrochloride (3mg for 2 weeks, 5mg for 2 weeks)
Placebo

Clinical Research Center, Utano National Hospital, National Hospital Organization

NULL

Complete: follow-up complete

40years-old

75years-old

Male and Female

Not applicable

Japan

1290

NCT01063621
(ClinicalTrials.gov)

January 2010

4/2/2010

Extended Long-Term Safety Study of KW-6500

Phase 3 Study of KW-6500 (Safety Study for Extended Long-Term Self-Injection at Home in Patients With Parkinson's Disease)

Parkinson's Disease

Drug: KW-6500

Kyowa Hakko Kirin Co., Ltd

NULL

Completed

20 Years

N/A

All

Phase 3

Japan

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1291

NCT01071395
(ClinicalTrials.gov)

January 2010

17/2/2010

Validation of Dyskinesia Rating Scales

Parkinson's Disease

Drug: Amantadine;Drug: Placebo

Rush University Medical Center

Michael J. Fox Foundation for Parkinson's Research

Completed

30 Years

90 Years

All

Phase 4

United States;Austria;Canada;France

1292

NCT01058291
(ClinicalTrials.gov)

January 2010

27/1/2010

Placebo-Controlled Double-Blind Crossover Comparative Study of KW-6500

Phase 3 Study of KW-6500 (Placebo-Controlled Double-Blind Crossover Comparative Study in Patients With Parkinson's Disease)

Parkinson's Disease

Drug: KW-6500;Drug: KW-6500 Placebo

Kyowa Hakko Kirin Co., Ltd

NULL

Completed

20 Years

N/A

All

Phase 3

Japan

1293

NCT01007864
(ClinicalTrials.gov)

January 2010

3/11/2009

Influence of Piribedil (Clarium®) on Vigilance and Cognitive Function in Patients With Parkinson's Disease Compared to Other Non-Ergot Dopamine Agonists

Influence of the Non-Ergot Dopamine Agonist Piribedil on Vigilance and Cognitive Function in Patients With Parkinson's Disease Compared to Other Oral Non-Ergot Dopamine Agonists

Idiopathic Parkinson's Disease

Drug: piribedil;Drug: pramipexole or ropinirole

Desitin Arzneimittel GmbH

FGK Clinical Research GmbH

Completed

35 Years

80 Years

Both

Phase 3

Germany

1294

NCT01018264
(ClinicalTrials.gov)

January 2010

19/11/2009

Solifenacin Succinate (VESIcare) for the Treatment of Overactive Bladder in Parkinson's Disease

URGE-PD: A Multi-site, Double-blind, Randomized, Placebo Controlled Trial of Solifenacin Succinate (VESIcare) for the Treatment of Overactive Bladder in Parkinson's Disease

Overactive Bladder in Parkinson's Disease

Drug: solifenacin succinate (VESIcare);Drug: placebo

University of South Florida

NULL

Completed

40 Years

80 Years

All

Phase 4

United States

1295

NCT01417598
(ClinicalTrials.gov)

January 2010

15/8/2011

BETA Study: Improving Balance Function in Elderly by Progressive and Specific Training and Physical Activity

Improving Balance Function in Elderly by Progressive and Specific Training and Physical Activity- a Randomized Controlled Study.

Elderly;Parkinsons Disease;Osteoporosis

Other: Gait and balance group training;Other: Nordic walking (only osteoporosis group)

Karolinska Institutet

The Swedish Research Council

Active, not recruiting

60 Years

N/A

All

200

N/A

Sweden

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1296

EUCTR2009-014688-37-ES
(EUCTR)

30/12/2009

21/10/2009

A Study To Evaluate The Safety And Efficacy Of IPX066 in Advanced Parkinsons DiseaseEstudio para evaluar la seguridad y eficacia de IPX066 en la enfermedad de Parkinson avanzada.

Advanced Parkinsons Disease subjects with motor fluctuationsEnfermedad de Parkinson avanzada en sujetos con fluctuaciones motoras
MedDRA version: 12.0;Level: LLT;Classification code 10061536;Term: Parkinson's disease

Product Name: IPX066
Product Code: IPX066 -95
INN or Proposed INN: CARBIDOPA
INN or Proposed INN: LEVODOPA
Trade Name: Sinemet-Plus Tablets
Product Name: IR CD-LD
INN or Proposed INN: CARBIDOPA
INN or Proposed INN: LEVODOPA
Product Name: IPX066
Product Code: IPX066 -145
INN or Proposed INN: CARBIDOPA
INN or Proposed INN: LEVODOPA
Product Name: IPX066
Product Code: IPX066 -195
INN or Proposed INN: CARBIDOPA
INN or Proposed INN: LEVODOPA
Product Name: IPX066
Product Code: IPX066 -245
INN or Proposed INN: CARBIDOPA

Impax Laboratories, Inc.

NULL

Not Recruiting

Female: yes
Male: yes

350

Germany;France;Spain;Poland

1297

EUCTR2009-011541-24-NL
(EUCTR)

30/12/2009

29/05/2009

An Open-Label, Multi-Center, Follow-Up Study Designed to Evaluate the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects who Participated in the ADAGIO Study - ADAGIO Follow-Up

Parkinson's Disease
MedDRA version: 9.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's

Trade Name: AZILECT
INN or Proposed INN: Rasagiline
Other descriptive name: Rasagiline mesylate

Teva Pharmaceutical Industries Ltd

NULL

Not Recruiting

Female: yes
Male: yes

700

Portugal;France;Hungary;Spain;Germany;Netherlands;Italy;United Kingdom

1298

EUCTR2009-014688-37-DE
(EUCTR)

15/12/2009

07/10/2009

A Study To Evaluate The Safety And Efficacy Of IPX066In Advanced Parkinson’s Disease

Advanced Parkinson’s Disease subjects with motor fluctuations
MedDRA version: 12.0;Level: LLT;Classification code 10061536;Term: Parkinson's disease

Impax Laboratories, Inc.

NULL

Not Recruiting

Female: yes
Male: yes

350

Germany;France;Spain;Poland

1299

EUCTR2008-005492-94-GB
(EUCTR)

09/12/2009

01/09/2009

Open-Label trial to Determine the Long-term Safety of Safinamide in Parkinson's Disease Patients

Idiopathic Parkinson's Disease
MedDRA version: 9.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease

Merck Serono S.A. - Geneva

NULL

Not Recruiting

Female: yes
Male: yes

1285

Phase 3

Portugal;Estonia;Slovakia;Finland;Spain;Austria;United Kingdom;Italy;France;Hungary;Czech Republic;Belgium;Bulgaria;Germany;Netherlands

1300

EUCTR2009-012897-12-RO
(EUCTR)

08/12/2009

30/03/2015

A double-blind, randomised, placebo-controlled study to investigate the tolerability and the effect of three multiple-dose regimens of BIA 9-1067 on the levodopa pharmacokinetics, catechol-0-methyltransferase activity and motor response in parkinson´s disease patients treated with levodopa/dopa-decarboxylaseinhibitor

Parkinson’s Disease
MedDRA version: 17.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's;System Organ Class: 100000004852

Product Name: BIA 9-1067
Product Code: BIA 9-1067
Product Name: BIA 9-1067
Product Code: BIA 9-1067
Trade Name: SINEMET 25/100
INN or Proposed INN: LEVODOPA
Other descriptive name: ANHYDROUS CARBIDOPA
Trade Name: Restex Tabletten
INN or Proposed INN: LEVODOPA
INN or Proposed INN: BENSERAZIDE HYDROCHLORIDE

BIAL-Portela & Ca, SA

NULL

Not Recruiting

Female: yes
Male: yes

Romania

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1301

EUCTR2009-014688-37-FR
(EUCTR)

04/12/2009

09/10/2009

A Study To Evaluate The Safety And Efficacy Of IPX066In Advanced Parkinson’s Disease

Advanced Parkinson’s Disease subjects with motor fluctuations
MedDRA version: 12.0;Level: LLT;Classification code 10061536;Term: Parkinson's disease

Impax Laboratories, Inc.

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

350

Germany;France;Spain;Poland

1302

EUCTR2009-012419-16-DE
(EUCTR)

03/12/2009

20/10/2009

Influence of the Non-Ergot Dopamine agonist Piribedil on vigilance and cognitive function in patients with Parkinson's disease compared to other oral Non-Ergot Dopamine agonists - PIVICOG-PD

idiopathic Parkinson's disease
MedDRA version: 12.0;Level: PT;Classification code 10061536;Term: Parkinson's disease

Trade Name: Clarium 50 mg Retardtabletten
INN or Proposed INN: piribedil

Desitin Arzneimittel GmbH

NULL

Not Recruiting

Female: yes
Male: yes

Germany

1303

NCT01168596
(ClinicalTrials.gov)

December 2009

19/2/2010

Rasagiline for the Symptomatic Treatment of Fatigue in Parkinson's Disease

Rasagiline for the Symptomatic Treatment of Fatigue in Parkinson's Disease: A Bi-Center, Placebo-Controlled Study (The REST Fatigue Trial)

Parkinson's Disease

Drug: Rasagiline;Drug: Placebo

University of Florida

NULL

Completed

40 Years

85 Years

All

Phase 4

United States

1304

NCT01036139
(ClinicalTrials.gov)

December 2009

11/12/2009

Efficacy and Safety of BF2.649 in Excessive Daytime Sleepiness (EDS) in Parkinson's Disease

A Randomized, Multicenter 12-Week Double-blind Placebo-controlled Study to Assess the Efficacy and Safety of BF2.649 in Excessive Daytime Sleepiness in Parkinson's Disease Followed by a 38-Week Open-label Extension Phase

Parkinson's Disease

Drug: BF2.649 (pitolisant)

Bioprojet

NULL

Completed

30 Years

80 Years

Both

268

Phase 3

France

1305

NCT01049984
(ClinicalTrials.gov)

December 2009

13/1/2010

Rasagiline as Add on to Dopamine Agonists in the Treatment of Parkinson's Disease

A Double-blind, Placebo Controlled, Randomized, Multicenter Study to Assess the Safety and Clinical Benefit of Rasagiline as an Add on Therapy to Stable Dose of Dopamine Agonists in the Treatment of Early Parkinson's Disease

Parkinson's Disease

Drug: Rasagiline;Drug: Placebo

Teva Neuroscience, Inc.

H. Lundbeck A/S

Completed

30 Years

N/A

All

328

Phase 4

United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1306

NCT01032486
(ClinicalTrials.gov)

December 2009

11/12/2009

Study for Rasagiline Effect on Sleep Trial(REST)in Parkinson's Disease

An Open-Label, Multi-Center, Single Arm Study to Evaluate the Effects of Azilect® on Sleep Disturbances in Parkinson's Disease Subjects

Parkinson's Disease

Drug: Rasagiline mesylate

Teva Pharmaceutical Industries

NULL

Completed

N/A

Both

120

Canada

1307

NCT00660387
(ClinicalTrials.gov)

December 2009

15/4/2008

Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects

A Randomized, Double-Blind, Double-Dummy, Efficacy, Safety and Tolerability Study of Levodopa - Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects Receiving Optimized Treatments With Parkinson Medicinal Products Who Continue to Experience Persistent Motor Fluctuations

Advanced Parkinson's Disease

Drug: Levodopa carbidopa intestinal gel (LCIG);Drug: Placebo Gel;Drug: Levodopa -carbidopa (LC) oral encapsulated immediate release (IR) tablets;Drug: Placebo (PBO) oral capsules;Device: CADD-Legacy® 1400 ambulatory infusion pump;Device: PEG tube;Device: J-tube

AbbVie (prior sponsor, Abbott)

Quintiles, Inc.

Completed

30 Years

N/A

All

Phase 3

United States;New Zealand

1308

NCT01070628
(ClinicalTrials.gov)

December 2009

23/11/2009

Levodopa Concentration Profile With Stalevo 75/125 mg

Levodopa Concentration Profile After Repeated Doses of Different Stalevo® Strengths With 3.5 Hours Dosing Frequency; an Open, Randomised, Crossover, Levodopa/Carbidopa Controlled Single Centre Study in Healthy Subjects, Two Parallel Groups

Parkinson's Disease

Drug: Stalevo (levodopa/ carbidopa/ entacapone);Drug: Sinemet (levodopa/carbidopa)

Orion Corporation, Orion Pharma

NULL

Completed

18 Years

70 Years

Both

Phase 1

Finland

1309

EUCTR2009-013886-24-CZ
(EUCTR)

26/11/2009

18/11/2009

A Randomized, Multicenter, 12-Week, Double-blind, Placebo-Controlled, Study to Assess the Efficacy and Safety of BF2.649 in Excessive Daytime Sleepiness (EDS) in Parkinson Disease, followed by a 9-months Open-Label Extension Phase - HARPS-2

BIOPROJET

NULL

Not Recruiting

Female: yes
Male: yes

246

Phase -

Germany;Czech Republic;Sweden

1310

EUCTR2008-005492-94-FR
(EUCTR)

25/11/2009

01/10/2009

Open-Label trial to Determine the Long-term Safety of Safinamide in Parkinson's Disease Patients -

Idiopathic Parkinson's Disease
MedDRA version: 9.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease

Product Name: Safinamide
Product Code: NW-1015
INN or Proposed INN: safinamide
Product Name: Safinamide
Product Code: NW-1015
INN or Proposed INN: safinamide

Merck Serono S.A. - Geneva

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

1285

Hungary;Portugal;Germany;Netherlands;France;Bulgaria;Italy;Austria;United Kingdom;Czech Republic;Belgium;Estonia;Spain

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1311

EUCTR2009-013885-14-FR
(EUCTR)

23/11/2009

25/09/2009

A randomized, multicenter 12-Week double-blind placebo-controlled study to assess the efficacy and safety of BF2.649 in Excessive Daytime Sleepiness in Parkinson’s disease followed by a 38-Week open-label extension phase

Product Name: Pitolisant
Product Code: BF2.649
INN or Proposed INN: Pitolisant

BIOPROJET

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

246

Phase A

France;Spain

1312

EUCTR2008-005492-94-ES
(EUCTR)

23/11/2009

18/09/2009

Open-Label trial to Determine the Long-term Safety of Safinamide in Parkinson's Disease Patients.Estudio abierto para determinar la seguridad a largo plazo de la Safinamida en pacientes con enfermedad de Parkinson -

Idiopathic Parkinson's DiseaseEnfermedad de Parkinson
MedDRA version: 9.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease

Product Name: Safinamide
Product Code: NW-1015
INN or Proposed INN: safinamide
Product Name: Safinamide
Product Code: NW-1015
INN or Proposed INN: safinamide

Merck Serono S.A. - Geneva

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

1285

Hungary;Portugal;Germany;Netherlands;France;Bulgaria;Italy;Austria;United Kingdom;Czech Republic;Belgium;Estonia;Spain

1313

NCT00660673
(ClinicalTrials.gov)

November 13, 2009

15/4/2008

Open Label Continuation Treatment Study With Levodopa-Carbidopa Intestinal Gel in Advanced PD

Open-Label Continuation Treatment Study With Levodopa - Carbidopa Intestinal Gel In Subjects With Advanced Parkinson's Disease And Severe Motor-Fluctuations Who Have Exhibited A Persistent And Positive Effect To Treatment In Previous Studies

Advanced Parkinson's Disease

Drug: Levodopa -carbidopa intestinal gel;Device: CADD-Legacy® 1400 ambulatory infusion pump

AbbVie (prior sponsor, Abbott)

Quintiles, Inc.

Active, not recruiting

30 Years

99 Years

All

262

Phase 3

United States;Australia;Canada;Czechia;Israel;New Zealand;Poland;Portugal;Russian Federation;Thailand;United Kingdom;Czech Republic

1314

EUCTR2009-013885-14-ES
(EUCTR)

12/11/2009

23/09/2009

A randomized, multicenter 12-Week double-blind placebo-controlled study to assess the efficacy and safety of BF2.649 in Excessive Daytime Sleepiness in Parkinson?s disease followed by a 38-Week open-label extension phase.Estudio multicéntrico, aleatorizado, doble ciego, controlado con placebo y de 12 semanas de duración para evaluar la eficacia y seguridad de BF2.649 en la somnolencia diurna excesiva de la enfermedad de Parkinson, seguido de una fase de extensión abierta de 38 semanas.

Excessive daytime sleepiness in Parkinson?s DiseaseSomnolencia diurna excesiva en la enfermedad de Parkinson.
MedDRA version: 12.0;Level: LLT;Classification code 10015595;Term: Excessive daytime sleepiness
MedDRA version: 12.0;Level: HLT;Classification code 10034005;Term: Parkinson's disease and parkinsonism

Product Name: Pitolisant
Product Code: BF2.649
INN or Proposed INN: Pitolisant

BIOPROJET

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

246

France;Spain

1315

EUCTR2009-013004-31-IT
(EUCTR)

02/11/2009

Early combined prolonged release ropinirole and rasagiline therapy in newly diagnosed patients with Parkinsons disease. A prospective, randomized, parallel groups, long-term follow-up study including delayed-start design of rasagiline - Early combined ropinirole and rasagiline therapy in patients with Parkinsons disease

Patients with Parkinson`s diesease
MedDRA version: 12.0;Level: LLT;Classification code 10061536;Term: Parkinson's disease

INN or Proposed INN: Rasagiline
INN or Proposed INN: Ropinirole

UNIVERSITA` DEGLI STUDI DI PARMA

NULL

Not Recruiting

Female: yes
Male: yes

Italy

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1316

NCT01532141
(ClinicalTrials.gov)

November 2009

23/1/2012

Effect of Rasagiline on BIA 9-1067 Pharmacokinetics

Effect of Rasagiline on BIA 9-1067 Pharmacokinetics in Healthy Subjects

Parkinson Disease

Drug: BIA 9-1067;Drug: Rasagiline

Bial - Portela C S.A.

NULL

Completed

18 Years

45 Years

All

Phase 1

France

1317

NCT01519284
(ClinicalTrials.gov)

November 2009

23/1/2012

Study of BIA 9-1067 to Investigate Its Effect on Levodopa Pharmacokinetic

A Double-blind, Randomised, Placebo- and Active-controlled Multiple-dose Study of BIA 9-1067 to Investigate Its Effect on Levodopa Pharmacokinetics Following a Levodopa/Carbidopa 100/25 mg Single-dose in Healthy Subjects

Parkinson Disease

Drug: BIA 9-1067 5 mg;Drug: Entacapone;Drug: Placebo;Drug: levodopa /carbidopa;Drug: BIA 9-1067 15 mg;Drug: BIA 9-1067 30 mg

Bial - Portela C S.A.

NULL

Completed

18 Years

45 Years

All

Phase 1

Portugal

1318

NCT01532128
(ClinicalTrials.gov)

November 2009

23/1/2012

Effect of BIA 9-1067 on Rasagiline Pharmacokinetics

Effect of BIA 9-1067 on Rasagiline Pharmacokinetics in Healthy Subjects

Parkinson Disease

Drug: rasagiline;Drug: BIA 9-1067

Bial - Portela C S.A.

NULL

Completed

18 Years

45 Years

All

Phase 1

France

1319

NCT01007630
(ClinicalTrials.gov)

November 2009

3/11/2009

A Study Assessing Change in Sense of Smell After Rasagiline Use in Parkinson's Patients

A Prospective Randomized Placebo-Controlled Double-Blind Study Assessing Change in Olfactory Function After Initiation of Rasagiline in Idiopathic Parkinson's Disease

Parkinson's Disease

Drug: Rasagiline;Drug: Placebo

The Parkinson's Institute

Teva Neuroscience, Inc.

Active, not recruiting

N/A

90 Years

Both

Phase 4

United States

1320

NCT01052831
(ClinicalTrials.gov)

November 2009

15/1/2010

Naltrexone for Impulse Control Disorders in Parkinson's Disease

Randomized, Double-blind, Placebo-controlled Study of Naltrexone for Impulse Control Disorders in Parkinson's Disease

Impulse Control Disorder;Parkinson Disease

Drug: Naltrexone;Drug: Placebo

University of Pennsylvania

Michael J. Fox Foundation for Parkinson's Research

Completed

18 Years

85 Years

All

Phase 4

United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1321

NCT01023282
(ClinicalTrials.gov)

November 2009

1/12/2009

Safety and Tolerability Study Evaluating ACR325 in Parkinson's Disease Patients

Randomised, Double-blind, Placebo-controlled Study Evaluating Safety and Tolerability of ACR325 in Parkinson's Disease Patients, With Evaluation of the Effect on Levodopa Induced Dyskinesias as a Secondary Measure

Parkinson's Disease;Tolerability

Drug: ACR325;Drug: Placebo

NeuroSearch A/S

NULL

Completed

30 Years

75 Years

Both

Phase 1

Germany

1322

NCT01028209
(ClinicalTrials.gov)

November 2009

8/12/2009

Evaluation of [18F] PBR06 and PET as a Marker of Inflammation in Subjects With Neurological Conditions

Alzheimer Disease;Parkinson Disease;Multiple Sclerosis

Drug: [18F] PBR06

Institute for Neurodegenerative Disorders

NULL

Terminated

18 Years

N/A

All

Phase 1

United States

1323

NCT00985517
(ClinicalTrials.gov)

October 29, 2009

25/9/2009

Safety and Efficacy of CERE-120 in Subjects With Parkinson's Disease

A Phase 1/2 Trial Assessing the Safety and Efficacy of Bilateral Intraputaminal and Intranigral Administration of CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN]) in Subjects With Idiopathic Parkinson's Disease

Idiopathic Parkinson's Disease

Biological: CERE-120: Adeno-Associated Virus Delivery of Neurturin;Procedure: Sham Surgery

Sangamo Therapeutics

NULL

Completed

35 Years

70 Years

All

Phase 1;Phase 2

United States

1324

EUCTR2008-005492-94-HU
(EUCTR)

27/10/2009

22/09/2009

Open-Label trial to Determine the Long-term Safety of Safinamide in Parkinson's Disease Patients

Idiopathic Parkinson's Disease
MedDRA version: 9.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease

Product Name: Safinamide
Product Code: NW-1015
INN or Proposed INN: safinamide
Product Name: Safinamide
Product Code: NW-1015
INN or Proposed INN: safinamide

Merck Serono S.A. - Geneva

NULL

Not Recruiting

Female: yes
Male: yes

1285

Portugal;Estonia;Spain;Austria;Italy;United Kingdom;France;Hungary;Czech Republic;Belgium;Bulgaria;Germany;Netherlands

1325

EUCTR2008-004146-88-PL
(EUCTR)

19/10/2009

31/08/2009

Idiopathic Parkinson's Disease
MedDRA version: 9.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease

Product Name: Safinamide
Product Code: NW-1015
INN or Proposed INN: Safinamide
Product Name: Safinamide
Product Code: NW-1015
INN or Proposed INN: Safinamide

Merck Serono SA - Geneva

NULL

Not Recruiting

Female: yes
Male: yes

498

Phase 3

Portugal;Czech Republic;Finland;Spain;Poland;Bulgaria;Germany;Italy

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1326

EUCTR2008-005492-94-SK
(EUCTR)

14/10/2009

22/10/2009

Open-Label trial to Determine the Long-term Safety of Safinamide in Parkinson's Disease Patients

Idiopathic Parkinson's Disease
MedDRA version: 9.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease

Product Name: Safinamide
Product Code: NW-1015
INN or Proposed INN: safinamide
Product Name: Safinamide
Product Code: NW-1015
INN or Proposed INN: safinamide

Merck Serono S.A. - Geneva

NULL

Not Recruiting

Female: yes
Male: yes

1285

Phase 3

Portugal;Estonia;Slovakia;Finland;Spain;Austria;Italy;United Kingdom;France;Hungary;Czech Republic;Belgium;Bulgaria;Germany;Netherlands

1327

EUCTR2009-011541-24-GB
(EUCTR)

09/10/2009

29/05/2009

A trial to follow-up subjects with Parkinson's disease who participated to the ADAGIO study in order to study the long-term effects of the drug rasagiline

An Open-Label, Multi-Center, Follow-Up Study Designed to Evaluate the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects who Participated in the ADAGIO Study - ADAGIO Follow-Up

Parkinson's Disease
MedDRA version: 13.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's;System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Teva Pharmaceutical Industries Ltd

NULL

Not Recruiting

Female: yes
Male: yes

700

Phase 4

Portugal;United States;Spain;Israel;United Kingdom;Italy;France;Hungary;Canada;Argentina;Romania;Germany;Netherlands

1328

EUCTR2008-005492-94-AT
(EUCTR)

02/10/2009

03/09/2009

Open-Label trial to Determine the Long-term Safety of Safinamide in Parkinson's Disease Patients

Product Name: Safinamide
Product Code: NW-1015
INN or Proposed INN: safinamide
Product Name: Safinamide
Product Code: NW-1015
INN or Proposed INN: safinamide

Newron Pharmaceuticals

NULL

Not Recruiting

Female: yes
Male: yes

1285

1329

EUCTR2008-001329-33-PT
(EUCTR)

02/10/2009

19/08/2009

Open Label Continuation Treatment Study With Levodopa-Carbidopa Intestinal Gel in Advanced Parkinson's Disease

Treatment with Levodopa – Carbidopa Intestinal Gel in subjects with advanced Parkinson's disease and severe motor-fluctuations who have exhibited a persistent and positive effect to treatment in previous studies
MedDRA version: 16.0;Level: LLT;Classification code 10013113;Term: Disease Parkinson's;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

AbbVie Inc

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

275

Portugal;Czech Republic;Thailand;Poland;Australia;Israel;Russian Federation;Italy;United Kingdom;New Zealand

1330

EUCTR2008-005492-94-EE
(EUCTR)

01/10/2009

15/09/2009

Open-Label trial to Determine the Long-term Safety of Safinamide in Parkinson's Disease Patients

Product Name: Safinamide
Product Code: NW-1015
INN or Proposed INN: safinamide
Product Name: Safinamide
Product Code: NW-1015
INN or Proposed INN: safinamide

Newron Pharmaceuticals

NULL

Not Recruiting

Female: yes
Male: yes

1285

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1331

NCT01016470
(ClinicalTrials.gov)

October 2009

28/9/2009

Efficacy of Nutritional Supplement VIUSID/ALZER in Patients With Parkinson`s Disease

Parkinson`s Disease

Dietary Supplement: VIUSID/ALZER;Dietary Supplement: Placebo

Catalysis SL

NULL

Completed

20 Years

90 Years

Both

100

Phase 3

Cuba

1332

NCT01108029
(ClinicalTrials.gov)

October 2009

20/7/2009

Study of Memantine for Gait Disorders And Attention Deficit In Parkinson's Disease

Study of Memantine to Treat Gait Disorders And Attention Deficit In Parkinson's Disease: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Monocentric Trial

Parkinson's Disease;Gait Disorders, Neurologic

Drug: memantine;Drug: placebo

University Hospital, Lille

NULL

Completed

30 Years

80 Years

Both

Phase 4

France

1333

NCT00943748
(ClinicalTrials.gov)

October 2009

20/7/2009

Efficacy and Safety of the Iron Chelator Deferiprone in Parkinson's Disease

Efficacy and Safety of the Iron Chelator Deferiprone on Iron Overload in the Brain in Parkinson's Disease

Parkinson's Disease

Drug: deferiprone;Drug: placebo

University Hospital, Lille

NULL

Completed

30 Years

80 Years

Both

Phase 2;Phase 3

France

1334

NCT01631825
(ClinicalTrials.gov)

October 2009

25/6/2012

A Long-Term Extension Trial From of SPM 962 in Advanced Parkinson's Disease Patients

An Open-label Long-term Extension Trial From Phase III of SPM962 (243-08-002) in Advanced Parkinson's Disease Patients With Concomitant Treatment of L-dopa

Parkinson's Disease

Drug: SPM 962

Otsuka Pharmaceutical Co., Ltd.

NULL

Completed

N/A

All

321

Phase 3

Japan

1335

NCT00914095
(ClinicalTrials.gov)

October 2009

2/6/2009

Study of Methylphenidate to Treat Gait Disorders And Attention Deficit In Parkinson's Disease (PARKGAIT-II)

Study of Methylphenidate to Treat Gait Disorders And Attention Deficit In Parkinson's Disease: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicentric Trial

Parkinson's Disease;Gait Disorders, Neurologic;Dementia

Drug: methylphenidate;Drug: placebo

University Hospital, Lille

NULL

Completed

30 Years

80 Years

Both

Phase 4

France

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1336

NCT00957203
(ClinicalTrials.gov)

October 2009

7/8/2009

Long-Term Safety Study of KW-6002 (Istradefylline) in Parkinson's Disease Patients

Long-Term Safety Study of KW-6002 (Istradefylline) in the Treatment of Parkinson's Disease (Phase 3)

Parkinson's Disease

Drug: Istradefylline

Kyowa Hakko Kirin Company, Limited

NULL

Completed

20 Years

N/A

Both

308

Phase 3

Japan

1337

NCT00957918
(ClinicalTrials.gov)

October 2009

11/8/2009

Study of NP002 in Subjects With Idiopathic Parkinson's Disease to Treat Dyskinesias Due to Levodopa Therapy

Randomized, Double-Blind, Parallel Group, Placebo Controlled Safety, Tolerability and Efficacy Study of NP002 in Subjects With Idiopathic Parkinson's Disease With Dyskinesias Due to Levodopa Therapy

Parkinson's Disease

Drug: nicotine;Other: placebo comparator

Neuraltus Pharmaceuticals, Inc.

NULL

Completed

30 Years

83 Years

Both

Phase 1;Phase 2

United States

1338

NCT01028586
(ClinicalTrials.gov)

October 2009

7/12/2009

MOTION, Safinamide in Early Idiopathic Parkinson's Disease (IPD), as add-on to Dopamine Agonist (Extension of Trial 27918)

A Phase III, Double-blind, Placebo-controlled Extension Trial to Investigate the Long-term Efficacy and Safety of Low (50 mg/Day) and High (100 mg/Day) Dose Safinamide, as add-on Therapy in Subjects With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist

Idiopathic Parkinson's Disease

Drug: Safinamide , MAO-B inhibitor;Drug: Placebo

Newron

NULL

Terminated

30 Years

80 Years

Both

507

Phase 3

Switzerland

1339

ChiCTR-TRC-12002150

2009-09-29

2012-05-06

Study on Optimization of The Comprehensive Therapeutic Plan for Parkinson's Disease in Different Stages

Study on Optimization of The Comprehensive Therapeutic Plan by Stages for Parkinson's Disease

Parkinson's Disease

The early treatment group:Xifeng Dingchan Pill;The early control group:Madopar tablets;Interim treatment group:Xifeng Dingchan Pill, Madopar tablets and Piribedil tablets;

Henan University of Traditional Chinese Medicine

NULL

Recruiting

Both

The early treatment group:80;The early control group:80;Interim treatment group:160;

China

1340

EUCTR2006-005186-18-NL
(EUCTR)

25/09/2009

29/05/2008

Open-Label, 6-12 Months Safety and Efficacy Study of Levodopa – Carbidopa Intestinal Gel in Levodopa-Responsive Subjects with Advanced Parkinson's Disease and Severe Motor-Fluctuations

Treatment of levodopa-responsive Parkinson's subjects with severe motor fluctuations.
MedDRA version: 9.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's

Trade Name: DUODOPA®Intestinal Gel
INN or Proposed INN: Levodopa
Other descriptive name: PhEur.: (2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid
INN or Proposed INN: Carbidopa Monohydrate
Other descriptive name: PhEur.: (2S)-3-(3,4-dihydroxyphenyl)-2hydrazino-2methylpropanoic acid

Solvay Pharmaceuticals B.V.

NULL

Not Recruiting

Female: yes
Male: yes

250

Portugal;Czech Republic;Finland;Spain;Germany;Netherlands;United Kingdom;Italy

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1341

EUCTR2009-011541-24-DE
(EUCTR)

22/09/2009

27/07/2009

An Open-Label, Multi-Center, Follow-Up Study Designed to Evaluate the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects who Participated in the ADAGIO Study - ADAGIO Follow-Up

Parkinson's Disease
MedDRA version: 9.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's

Trade Name: AZILECT
INN or Proposed INN: Rasagiline
Other descriptive name: Rasagiline mesylate

Teva Pharmaceutical Industries Ltd

NULL

Not Recruiting

Female: yes
Male: yes

700

Portugal;France;Hungary;Spain;Netherlands;Germany;Italy;United Kingdom

1342

NCT01371682
(ClinicalTrials.gov)

September 18, 2009

10/6/2010

A Study Conducted in Healthy Subjects to Demonstrate Bioequivalence Between Ropinirole Prolonged Release Tablets Manufactured at Crawley and Aranda

An Open Label Study Conducted in Healthy Subjects to Demonstrate Bioequivalence Between Ropinirole Prolonged Release Tablets (Ropinirole XL, Marketed as REQUIP-MODUTAB™, REQUIP XL™ at 2 mg) Manufactured at Crawley and Aranda

Parkinson Disease

Drug: Ropinirole XL

GlaxoSmithKline

NULL

Completed

18 Years

50 Years

All

Phase 1

Belgium

1343

EUCTR2009-011541-24-PT
(EUCTR)

09/09/2009

29/07/2009

An Open-Label, Multi-Center, Follow-Up Study Designed to Evaluate the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects who Participated in the ADAGIO Study - ADAGIO Follow-Up

Parkinson's Disease
MedDRA version: 9.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's

Trade Name: AZILECT
INN or Proposed INN: Rasagiline
Other descriptive name: Rasagiline mesylate

Teva Pharmaceutical Industries Ltd

NULL

Not Recruiting

Female: yes
Male: yes

700

France;Portugal;Hungary;Spain;Germany;Netherlands;Italy;United Kingdom

1344

NCT00909883
(ClinicalTrials.gov)

September 2009

19/5/2009

Foot Dystonia Treatment by Botulinum Toxin Injections in Parkinson Disease : Efficiency of Injections Made in Extrinsic Muscle (Flexor Digitorum Longus Muscle) Compared to Intrinsic Muscle (Flexor Digitorum Brevis or Quadratus Plantae Muscles)

Parkinson's Disease;Foot Dystonia

Drug: Botulinum Toxin: Xeomin;Drug: Placebo

University Hospital, Clermont-Ferrand

Merz Pharma France

Recruiting

30 Years

75 Years

Both

Phase 3

France

1345

NCT00794313
(ClinicalTrials.gov)

September 2009

19/11/2008

Quantification of the Antidyskinetic Effect of Amantadine and Topiramate in Parkinson's Disease

Parkinson's Disease

Drug: Amantadine 300 mg;Drug: Topiramate;Drug: Sugar Pill

Oregon Health and Science University

NULL

Terminated

21 Years

N/A

All

N/A

United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1346

NCT00903838
(ClinicalTrials.gov)

September 2009

14/5/2009

A Pilot Study to Assess Efficacy and Safety of Pardoprunox as Adjunct Therapy to L-dopa in the Treatment of Patients With Parkinson's Disease Experiencing Motor Fluctuations and Dyskinesia.

A Multicenter, Randomized, Double Blind, Pramipexole Controlled Pilot Study to Assess Efficacy and Safety of Pardoprunox as Adjunct Therapy to L-dopa in the Treatment of Patients With Parkinson's Disease Experiencing Motor Fluctuations and Dyskinesia.

Advanced Stage Parkinson's Disease

Drug: pardoprunox;Drug: pramipexole

Abbott Products

NULL

Terminated

30 Years

N/A

Both

Phase 2

Germany;Italy;Portugal

1347

NCT00974974
(ClinicalTrials.gov)

September 2009

10/9/2009

A Study To Evaluate The Safety And Efficacy Of IPX066 In Advanced Parkinson's Disease (ADVANCE-PD).

A Study To Evaluate The Safety And Efficacy Of IPX066 In Advanced Parkinson's Disease

Parkinson's Disease

Drug: IPX066;Drug: IR CD-LD

Impax Laboratories, LLC

NULL

Completed

30 Years

N/A

All

471

Phase 3

United States;Canada;France;Germany;Poland;Romania;Spain;Ukraine

1348

NCT01026428
(ClinicalTrials.gov)

September 2009

1/12/2009

A Study to Assess the Effect of Safinamide on Levodopa Pharmacokinetics

A Randomised, Double-blind, Placebo-controlled, Two-period, Two-sequence-crossover Interaction Study to Assess the Effect of Safinamide on Levodopa Pharmacokinetics in Subjects With Parkinson's Disease

Idiopathic Parkinson's Disease

Drug: Safinamide + Levodopa;Other: Placebo + Levodopa

Newron

NULL

Completed

30 Years

N/A

Both

Phase 1;Phase 2

Italy

1349

NCT00907972
(ClinicalTrials.gov)

September 2009

22/5/2009

The Effects of Vitamin D and Bone Loss in Parkinson's Disease

Effect of Vitamin D3 Supplementation in Parkinson's Disease Patients - A Pilot Study

Parkinson Disease

Dietary Supplement: Vitamin D3;Other: Placebo

Memorial Medical Center

Department of Defense

Completed

18 Years

N/A

Both

Phase 2

United States

1350

NCT00986245
(ClinicalTrials.gov)

September 2009

24/9/2009

Study to Compare the Effect of Ropinirole Prolonged Release Once-daily Versus Twice-daily

An Open-label, Multi-center, Crossover Study to Compare the Effect of Once-daily Ropinirole PR and Twice-daily Ropinirole PR in Patients With Parkinson Disease

Parkinson Disease

Drug: Ropinirole Prolonged release

Seoul National University Hospital

NULL

Completed

30 Years

80 Years

All

Phase 4

Korea, Republic of

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1351

NCT00986414
(ClinicalTrials.gov)

September 2009

29/9/2009

Evaluation of the Efficacy and Safety of AFQ056 in Reducing Moderate to Severe L-dopa Induced Dyskinesias in Patients With Parkinson's Disease

13-week, Double-blind, Placebo-controlled, Fixed-dose, Multicenter Study to Evaluate the Efficacy and Safety of AFQ056 in Reducing Moderate to Severe L-dopa Induced Dyskinesias in Patients With Parkinson's Disease

Parkinson Disease;Dyskinesias

Drug: AFQ056;Drug: Placebo

Novartis

NULL

Completed

30 Years

80 Years

All

260

Phase 2

Australia;Canada;Finland;France;Germany;Italy;Japan;Spain

1352

EUCTR2009-011541-24-ES
(EUCTR)

27/08/2009

26/06/2009

An Open-Label, Multi-Center, Follow-Up Study Designed to Evaluate the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects who Participated in the ADAGIO Study. Estudio de seguimiento, multicéntrico, abierto diseñado para evaluar los efectos a largo plazo de Rasagilina en pacientes con enfermedad de Parkinson que participaron en el estudio ADAGIO - ADAGIO Follow-Up

Parkinson's Disease Enfermedad de Parkinson
MedDRA version: 9.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's

Teva Pharmaceutical Industries Ltd

NULL

Not Recruiting

Female: yes
Male: yes

700

Phase 4

Portugal;France;Hungary;Spain;Germany;Netherlands;Italy;United Kingdom

1353

EUCTR2008-004146-88-BG
(EUCTR)

13/08/2009

13/07/2009

An extension trial to investigate the long-term efficacy and safety of safinamide, as add-on therapy in patients with early Parkinson’s disease treated with a stable dose of a dopamine agonist

Idiopathic Parkinson's Disease
MedDRA version: 15.1;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Product Name: Safinamide
Product Code: NW-1015
Product Name: Safinamide
Product Code: NW-1015

Newron Pharmaceuticals

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

498

Phase 3

United States;Portugal;Slovakia;Finland;Spain;Chile;Colombia;Italy;India;Czech Republic;Mexico;Canada;Argentina;Poland;Brazil;Croatia;Peru;South Africa;Bulgaria;Germany

1354

EUCTR2008-008712-98-DE
(EUCTR)

07/08/2009

13/07/2009

13-week, double-blind, placebo-controlled, fixed-dose, multicenter study to evaluate the efficacy and safety of AFQ056 in reducing moderate to severe L-dopa induced dyskinesias in patients with Parkinson’s disease

moderate to severe levodopa induced dyskinesia in patients with Parkinson's disease
MedDRA version: 9.1;Level: LLT;Classification code 10013916;Term: Dyskinesia

Product Name: AFQ056
Product Code: AFQ056
Other descriptive name: AFQ056
Product Name: AFQ056
Product Code: AFQ056
Other descriptive name: AFQ056
Product Name: AFQ056
Product Code: AFQ056
Other descriptive name: AFQ056

Novartis Pharma AG

NULL

Not Recruiting

Female: yes
Male: yes

198

France;Finland;Spain;Germany;Italy

1355

NCT00970333
(ClinicalTrials.gov)

August 2009

31/8/2009

Evaluation of [18F] FEPPA and PET Imaging as a Marker of Inflammation in Subjects With Neurological Conditions

Evaluation of [18F] FEPPA and PET as a Marker of Inflammation in Subjects With Neurological Conditions

Alzheimer Disease;Parkinson Disease;Multiple Sclerosis

Drug: [18F]-FEPPA

Institute for Neurodegenerative Disorders

NULL

Completed

18 Years

N/A

Both

Phase 1

United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1356

NCT01580787
(ClinicalTrials.gov)

August 2009

16/4/2012

Functional Improvement in Patients With Parkinson's Disease After Training in Real or Virtual Environment

Parkinson´s Disease

Device: Balance Training with Nintendo Wii Fit;Other: Physical Therapy

Sao Camilo University Center

NULL

Completed

65 Years

85 Years

Both

N/A

NULL

1357

NCT03316365
(ClinicalTrials.gov)

August 2009

16/10/2017

Long-term Training Effects of Rhythmic Auditory Stimulation on Gait in Patients With Parkinson's Disease

Continuous Rhythmic Auditory Stimulation;Intermittent Rhythmic Auditory Stimulation

Other: Rhythmic Auditory Stimulation (RAS)

University of Toronto

Poudre Valley Health System Fort Collins CO;Colorado State University

Completed

18 Years

N/A

All

N/A

NULL

1358

EUCTR2008-004146-88-PT
(EUCTR)

31/07/2009

14/04/2009

Idiopathic Parkinson's Disease
MedDRA version: 9.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease

Product Name: Safinamide
Product Code: NW-1015
INN or Proposed INN: Safinamide
Product Name: Safinamide
Product Code: NW-1015
INN or Proposed INN: Safinamide

Merck Serono SA - Geneva

NULL

Not Recruiting

Female: yes
Male: yes

498

Phase 3

Portugal;Czech Republic;Finland;Poland;Spain;Bulgaria;Germany;Italy

1359

EUCTR2009-011736-35-FR
(EUCTR)

27/07/2009

06/08/2009

Etude pilote de phase II, N=1 en crossover répétés, en double aveugle, randomiséeversus placebo, multicentrique, évaluant l’efficacité de la SIMVAstatine sur lesDYSkinésies induites par la L-Dopa chez des patients atteints de maladie de Parkinson - SIMVADYS

Maladie de Parkinson
MedDRA version: 9.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's

Trade Name: LODALÈS®
Product Code: simvastatine

CHU de Bordeaux

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

Phase 2

France

1360

EUCTR2009-011541-24-FR
(EUCTR)

17/07/2009

19/06/2009

An Open-Label, Multi-Center, Follow-Up Study Designed to Evaluate the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects who Participated in the ADAGIO Study - ADAGIO Follow-Up

Parkinson's Disease
MedDRA version: 9.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's

Teva Pharmaceutical Industries Ltd

NULL

Not Recruiting

Female: yes
Male: yes

700

Phase 4

Portugal;France;Hungary;Spain;Germany;Netherlands;Italy;United Kingdom

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1361

EUCTR2009-011541-24-HU
(EUCTR)

10/07/2009

05/06/2009

An Open-Label, Multi-Center, Follow-Up Study Designed to Evaluate the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects who Participated in the ADAGIO Study - ADAGIO Follow-Up

Parkinson's Disease
MedDRA version: 9.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's

Teva Pharmaceutical Industries Ltd

NULL

Not Recruiting

Female: yes
Male: yes

700

Phase 4

Portugal;France;Hungary;Spain;Germany;Netherlands;Italy;United Kingdom

1362

NCT00955318
(ClinicalTrials.gov)

July 2009

7/8/2009

Long-Term Safety Study of KW-6500 in Patients With Parkinson's Disease

Phase 3 Study of KW-6500 (Safety Study for Long-Term Self-Administration at Home in Patients With Parkinson's Disease

Parkinson's Disease

Drug: KW-6500

Kyowa Hakko Kirin Co., Ltd

NULL

Completed

20 Years

N/A

All

Phase 3

Japan

1363

NCT00955604
(ClinicalTrials.gov)

July 2009

6/8/2009

Azilect + Antidepressant Chart Review

Investigation of the Occurrence of Serotonin Toxicity in Parkinson's Disease (PD) Patients Treated Concomitantly With Rasagiline and Antidepressants, Using Retrospective Chart Review

Serotonin Syndrome

Drug: Group R+AD Rasagiline + Antidepressant;Drug: Group R Rasagiline;Drug: Group AD Anti-PD + Antidepressant

Teva Pharmaceutical Industries

NULL

Completed

N/A

All

1500

N/A

United States

1364

NCT00909545
(ClinicalTrials.gov)

July 2009

26/5/2009

Safety, Tolerability and Efficacy Assessment of Dynacirc CR in Parkinson Disease

A Pilot Phase II Double-Blind, Placebo-Controlled, Tolerability and Dosage Finding Study of Isradipine CR as a Disease Modifying Agent in Patients With Early Parkinson Disease

Parkinson Disease

Drug: Isradipine CR 5mg;Drug: Isradipine CR 10mg;Drug: Isradipine CR 20mg;Drug: Placebo

Northwestern University

Michael J. Fox Foundation for Parkinson's Research;Northwestern University Dixon Fund;The Parkinson Study Group

Completed

30 Years

N/A

All

Phase 2

United States;Canada

1365

NCT00936676
(ClinicalTrials.gov)

July 2009

8/7/2009

ADAGIO Follow Up Study: Evaluation of the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects

An Open-Label, Multi-Center, Follow-Up Study Designed to Evaluate the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects Who Participated in the ADAGIO Study

Parkinson's Disease

Drug: rasagiline mesylate

Teva Pharmaceutical Industries

Teva Neuroscience, Inc.;H. Lundbeck A/S

Completed

N/A

Both

684

N/A

United States;Argentina;Canada;France;Germany;Hungary;Israel;Italy;Netherlands;Portugal;Romania;Spain;United Kingdom

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1366

NCT00918177
(ClinicalTrials.gov)

July 2009

1/6/2009

An Evaluation of the Pharmacokinetics and Pharmacodynamics of AP09004 in Patients With Parkinson's Disease

Dual Release Gastric Retentive AP09004, Vs. Active Control; a Pharmacokinetic/Pharmacodynamic, Comparative, Safety Evaluation in Parkinson's Patients

Parkinson's Disease

Drug: AP09004;Drug: Carbidopa /Levodopa, immediate release

Intec Pharma Ltd.

NULL

Completed

18 Years

N/A

Both

Phase 2

Israel

1367

NCT00955526
(ClinicalTrials.gov)

July 2009

7/8/2009

Study of KW-6002 (Istradefylline) for the Treatment of Parkinson's Disease in Patients Taking Levodopa

Placebo-Controlled, Double-Blind, Parallel Group, Fixed Dose Study of KW-6002 (Istradefylline) in the Treatment of Parkinson's Disease (Phase 3)

Parkinson's Disease

Drug: Istradefylline;Drug: Placebo

Kyowa Hakko Kirin Company, Limited

NULL

Completed

20 Years

N/A

Both

373

Phase 3

Japan

1368

NCT00970229
(ClinicalTrials.gov)

July 2009

31/8/2009

Evaluation of [123I]MNI-420 and SPECT as a Marker of the Adenosine A2a Receptor in PD, HD and Healthy Subjects.

Evaluation of [123I]MNI-420 and SPECT as a Marker of the Adenosine A2a Receptor in Subjects With Parkinson Disease, Huntington Disease, and Healthy Controls

Parkinson Disease;Huntington Disease

Drug: [123I]MNI-420

Institute for Neurodegenerative Disorders

NULL

Completed

18 Years

N/A

All

Phase 1

United States

1369

EUCTR2008-004146-88-ES
(EUCTR)

16/06/2009

16/04/2009

A phase III, double-blind, placebo-controlled extension trial to investigate the long-term efficacy and safety of low (50 mg/day) and high (100 mg/day) dose safinamide, as add-on therapy in subjects with early idiopathic Parkinson?s disease treated with a stable dose of a single dopamine agonist.Ensayo de extensión de fase III, doble ciego y controlado con placebo para investigar la eficacia y la seguridad a largo plazo de la safinamida en dosis bajas (50 mg/día) y altas (100 mg/días), como tratamiento añadido en sujetos con enfermedad de Parkinson idiopática temprana que reciben una dosis estable de un único agonista dopaminérgico - Safinamide in early PD patients treated with a single dopamine agonist. Extension Trial to 27918

Idiopathic Parkinson's DiseaseEnfermedad de Parkinson Idiopática
MedDRA version: 9.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease

Product Name: Safinamide
Product Code: NW-1015
INN or Proposed INN: Safinamide
Product Name: Safinamide
Product Code: NW-1015
INN or Proposed INN: Safinamide

Merck Serono SA - Geneva

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

498

Phase 3

Portugal;Finland;Germany;Czech Republic;Bulgaria;Spain;Italy;Poland

1370

EUCTR2008-001966-10-EE
(EUCTR)

16/06/2009

13/05/2009

A phase III, double blind, placebo-controlled extension trial to investigate the long-term efficacy and safety of safinamide (50 to 100 mg/day), as add on therapy, in subjects with idiopathic Parkinson’s disease with motor fluctuations, treated with a stable dose of levodopa and who may be receiving concomitant treatment with stable doses of a dopamine agonist, an anticholinergic and/or amantadine - Safinamide in PD with motor fluctuations, as add-on to levodopa. Extension to trial 27919

Idiopathic Parkinson's Disease
MedDRA version: 9.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease

Product Name: Safinamide
Product Code: NW-1015
Product Name: Safinamide
Product Code: NW-1015

Merck Serono SA - Geneva

NULL

Not Recruiting

Female: yes
Male: yes

416

Phase 3

Hungary;United Kingdom;Estonia;Austria

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1371

EUCTR2008-008712-98-FR
(EUCTR)

10/06/2009

28/04/2009

moderate to severe levodopa induced dyskinesia in patients with Parkinson's disease
MedDRA version: 9.1;Level: LLT;Classification code 10013916;Term: Dyskinesia

Novartis Pharma AG

NULL

Not Recruiting

Female: yes
Male: yes

234

France;Finland;Spain;Germany;Italy

1372

EUCTR2009-012529-12-FR
(EUCTR)

10/06/2009

18/05/2009

A randomised, REQUIP® IR-controlled, n-of-1, multiple crossover, pilot trial of the effect of REQUIP®CR on abnormal daytime somnolence in patients with Parkinson’s Disease - REQUIP

parkinson's disease
MedDRA version: 9.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's

Trade Name: REQUIP -LP
Product Name: ropinirole
Trade Name: REQUIP
Product Name: ropinirole

CHU de Toulouse

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

France

1373

EUCTR2008-004146-88-CZ
(EUCTR)

08/06/2009

07/04/2009

An extension trial to investigate the long-term efficacy and safety of safinamide, as add-on therapy in patients with early Parkinson’s disease treated with a stable dose of a dopamine agonist

Product Name: Safinamide
Product Code: NW-1015
Product Name: Safinamide
Product Code: NW-1015

Newron Pharmaceuticals

NULL

Not Recruiting

Female: yes
Male: yes

498

Phase 3

United States;Portugal;Slovakia;Finland;Spain;Chile;Colombia;Italy;India;Czech Republic;Mexico;Canada;Argentina;Poland;Brazil;Croatia;Peru;South Africa;Bulgaria;Germany

1374

EUCTR2009-010193-38-LV
(EUCTR)

04/06/2009

24/08/2009

A Placebo-Controlled Study to Evaluate the Safety and Efficacy of IPX066 in Subjects with Parkinson's Disease

Idiopathic Parkinson's disease (paralysis agitans)
MedDRA version: 9.1;Level: LLT;Classification code 10034010;Term: Parkinsonism

Product Name: IPX066
Product Code: IPX066 -95
INN or Proposed INN: LEVODOPA
INN or Proposed INN: CARBIDOPA
Product Name: IPX066
Product Code: IPX066 -145
INN or Proposed INN: LEVODOPA
INN or Proposed INN: CARBIDOPA
Product Name: IPX066
Product Code: IPX066 -195
INN or Proposed INN: LEVODOPA
INN or Proposed INN: CARBIDOPA
Product Name: IPX066
Product Code: IPX066 -245
INN or Proposed INN: LEVODOPA
INN or Proposed INN: CARBIDOPA

IMPAX Laboratories, Inc.

NULL

Not Recruiting

Female: yes
Male: yes

350

Estonia;Latvia;Lithuania

1375

NCT00921128
(ClinicalTrials.gov)

June 2, 2009

13/6/2009

Convection-Enhanced Delivery to Study the Pathophysiology Underlying the Clinical Features of Parkinson s Disease

Convection Enhanced Delivery of Muscimol to Study the Pathophysiology Underlying the Clinical Features of Parkinson's Disease

Parkinson's Disease

Drug: Muscimol

National Institute of Neurological Disorders and Stroke (NINDS)

NULL

Withdrawn

18 Years

N/A

All

Phase 1

United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1376

EUCTR2009-010193-38-LT
(EUCTR)

02/06/2009

26/03/2009

A Placebo-Controlled Study to Evaluate the Safety and Efficacy of IPX066 in Subjects with Parkinson's Disease

Idiopathic Parkinson's disease (paralysis agitans)
MedDRA version: 9.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease

IMPAX Pharmaceuticals a Division of IMPAX Laboratories, Inc.

NULL

Not Recruiting

Female: yes
Male: yes

350

Estonia;Latvia;Lithuania

1377

NCT01519856
(ClinicalTrials.gov)

June 2009

12/3/2010

PIRLONG-PD Safety and Efficacy of Piribedil in Parkinson's Disease During Long Term Therapy

Efficacy and Safety of Long-term Therapy With Piribedil (CLARIUM) in Patients With M. Parkinson Under Consideration of Quality of Life Parameters and Cognitive Function

Parkinson's Disease

Drug: piribedil (Clarium)

Desitin Arzneimittel GmbH

NULL

Completed

18 Years

N/A

Both

908

N/A

Germany

1378

NCT00360568
(ClinicalTrials.gov)

June 2009

3/8/2006

Safety/Efficacy Study of Levodopa-Carbidopa Intestinal Gel in Parkinson's Subjects

Open-Label, 12-Month Safety and Efficacy Study of Levodopa - Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Disease Subjects

Dyskinesias;Parkinson's Disease;Severe Motor Fluctuations

Drug: Levodopa -carbidopa intestinal gel;Device: CADD-Legacy® 1400 ambulatory infusion pump;Device: PEG tube;Device: J-tube

AbbVie (prior sponsor, Abbott)

Quintiles, Inc.

Completed

30 Years

N/A

All

Phase 3

United States;Germany;New Zealand

1379

NCT02169440
(ClinicalTrials.gov)

June 2009

24/1/2012

Effect of BIA 9-1067 on the Pharmacokinetics and Pharmacodynamics of Warfarin

Effect of BIA 9-1067 on the Pharmacokinetics and Pharmacodynamics of Warfarin in Healthy Volunteers

Parkinson's Disease (PD)

Drug: BIA 9-1067;Drug: Warfarin

Bial - Portela C S.A.

NULL

Completed

18 Years

45 Years

All

Phase 1

Portugal

1380

NCT01536366
(ClinicalTrials.gov)

June 2009

23/1/2012

Effect of BIA 9-1067 on the Pharmacokinetics of Repaglinide

Effect of BIA 9-1067 on the Pharmacokinetics of Repaglinide in Healthy Volunteers

Parkinson Disease

Drug: BIA 9-1067;Drug: Repaglinide

Bial - Portela C S.A.

NULL

Completed

18 Years

45 Years

All

Phase 1

Portugal

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1381

NCT00669461
(ClinicalTrials.gov)

June 2009

28/4/2008

Lubiprostone as a Treatment for Constipation in Parkinson's Disease

Constipation;Parkinson's Disease

Drug: Lubiprostone

University of Arkansas

Takeda

Terminated

50 Years

85 Years

All

N/A

United States

1382

NCT01628926
(ClinicalTrials.gov)

June 2009

24/6/2012

A Placebo- and Ropinirole-Controlled Study for SPM 962 in Advanced Parkinson's Disease Patients

A Double-Blind, 3-Arm, Parallel Group, Placebo- and Ropinirole-Controlled Study for SPM 962 in Advanced Parkinson's Disease Patients With Concomitant Treatment of L-dopa

Parkinson's Disease

Drug: SPM 962;Drug: Ropinirole;Drug: Placebo

Otsuka Pharmaceutical Co., Ltd.

NULL

Completed

30 Years

79 Years

All

420

Phase 3

Japan

1383

NCT00833690
(ClinicalTrials.gov)

June 2009

27/1/2009

Safety of Urate Elevation in Parkinson's Disease

A Randomized, Double-blind, Placebo-controlled, Dose-ranging Trial of Oral Inosine to Assess Safety and Ability to Elevate Urate in Early Parkinson's Disease

Parkinson Disease

Drug: Placebo;Drug: inosine

The Parkinson Study Group

Massachusetts General Hospital;Harvard School of Public Health;University of Rochester;Michael J. Fox Foundation for Parkinson's Research

Completed

30 Years

N/A

All

Phase 2

United States

1384

EUCTR2008-001966-10-AT
(EUCTR)

27/05/2009

08/04/2009

Idiopathic Parkinson's Disease
MedDRA version: 9.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease

Product Name: Safinamide
Product Code: NW-1015
INN or Proposed INN: Safinamide
Product Name: Safinamide
Product Code: NW-1015
INN or Proposed INN: Safinamide

Merck Serono SA - Geneva

NULL

Not Recruiting

Female: yes
Male: yes

416

Phase 3

Hungary;United Kingdom;Estonia;Austria

1385

EUCTR2008-004146-88-IT
(EUCTR)

26/05/2009

27/04/2009

Idiopatic Parkinson Disease
MedDRA version: 9.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's

Product Name: Safinamide
INN or Proposed INN: Safinamide
Product Name: Safinamide
INN or Proposed INN: Safinamide

MERCK SERONO SA

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

498

Phase 3

Portugal;Finland;Germany;Czech Republic;Bulgaria;Spain;Italy;Poland

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1386

EUCTR2008-001966-10-SK
(EUCTR)

25/05/2009

28/05/2009

Idiopathic Parkinson's Disease
MedDRA version: 9.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease

Product Name: Safinamide
Product Code: NW-1015
INN or Proposed INN: Safinamide
Other descriptive name: NW-1015
Product Name: Safinamide
Product Code: NW-1015
INN or Proposed INN: Safinamide

Merck Serono SA - Geneva

NULL

Not Recruiting

Female: yes
Male: yes

416

Phase 3

Estonia;Hungary;Slovakia;Austria;United Kingdom

1387

EUCTR2008-004146-88-SK
(EUCTR)

25/05/2009

28/05/2009

Idiopathic Parkinson's Disease
MedDRA version: 9.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease

Product Name: Safinamide
Product Code: NW-1015
INN or Proposed INN: Safinamide
Product Name: Safinamide
Product Code: NW-1015
INN or Proposed INN: Safinamide

Merck Serono SA - Geneva

NULL

Not Recruiting

Female: yes
Male: yes

498

Phase 3

Portugal;Czech Republic;Slovakia;Finland;Poland;Spain;Bulgaria;Germany;Italy

1388

EUCTR2008-004146-88-FI
(EUCTR)

19/05/2009

06/04/2009

An extension trial to investigate the long-term efficacy and safety of safinamide, as add-on therapy in patients with early Parkinson’s disease treated with a stable dose of a dopamine agonist

Product Name: Safinamide
Product Code: NW-1015
Product Name: Safinamide
Product Code: NW-1015

Newron Pharmaceuticals

NULL

Not Recruiting

Female: yes
Male: yes

498

Phase 3

United States;Portugal;Slovakia;Finland;Spain;Chile;Colombia;Italy;India;Czech Republic;Mexico;Canada;Argentina;Poland;Brazil;Croatia;Peru;South Africa;Bulgaria;Germany

1389

EUCTR2008-008712-98-FI
(EUCTR)

18/05/2009

08/04/2009

moderate to severe levodopa induced dyskinesias in patients with Parkinson's disease
MedDRA version: 9.1;Level: LLT;Classification code 10013916;Term: Dyskinesia

Product Name: AFQ056
Product Code: AFQ056
Product Name: AFQ056
Product Code: AFQ056
Product Name: AFQ056
Product Code: AFQ056

Novartis Pharma AG

NULL

Not Recruiting

Female: yes
Male: yes

198

Finland;Germany;France;Spain;Italy

1390

EUCTR2008-008712-98-IT
(EUCTR)

14/05/2009

05/05/2009

moderate to severe levodopa induced dyskinesia with Parkinson`s disease
MedDRA version: 9.1;Level: LLT;Classification code 10013916;Term: Dyskinesia

Product Code: AFQ056
Product Code: AFQ056
Product Code: AFQ056

NOVARTIS FARMA

NULL

Not Recruiting

Female: yes
Male: yes

234

Finland;Germany;France;Spain;Italy

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1391

EUCTR2008-001966-10-GB
(EUCTR)

12/05/2009

27/04/2009

Idiopathic Parkinson's Disease
MedDRA version: 9.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease

Product Name: Safinamide
Product Code: NW-1015
INN or Proposed INN: Safinamide
Product Name: Safinamide
Product Code: NW-1015
INN or Proposed INN: Safinamide

Merck Serono SA - Geneva

NULL

Not Recruiting

Female: yes
Male: yes

416

Phase 3

Hungary;United Kingdom;Estonia;Austria

1392

EUCTR2008-000400-81-DE
(EUCTR)

11/05/2009

29/01/2009

A Multicenter, Randomized, Double Blind, Pramipexole Controlled Pilot Study to Assess Efficacy and Safety of Pardoprunox as Adjunct Therapy to L-dopa in the Treatment of Patients with Parkinson’s Disease Experiencing Motor Fluctuations and Dyskinesia

Advanced Parkinson's Disease
MedDRA version: 9.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's

Product Name: Pardoprunox
Product Code: SLV308
INN or Proposed INN: Pardoprunox hydrochloride
Other descriptive name: SLV308 hydrochloride
Product Name: Pardoprunox
Product Code: SLV308
INN or Proposed INN: Pardoprunox hydrochloride
Other descriptive name: SLV308 hydrochloride
Product Name: Pardoprunox
Product Code: SLV308
INN or Proposed INN: Pardoprunox hydrochloride
Other descriptive name: SLV308 hydrochloride
Trade Name: Mirapex
Product Name: pramipexole
INN or Proposed INN: pramipexole
Other descriptive name: pramipexole dihydrochloride monohydrate
Trade Name: Mirapex
Product Name: Pramipexole
INN or Proposed INN: Pramipexole
Other descriptive name: pramipexole dihydrochloride monohydrate

Abbott Healthcare Products B.V.

NULL

Not Recruiting

Female: yes
Male: yes

Portugal;Germany;Italy

1393

EUCTR2006-000578-53-DE
(EUCTR)

08/05/2009

30/10/2008

Open-Label, 12-Month Safety and Efficacy Study of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Disease Subjects

Open-Label, 12-Month Safety and Efficacy Study of Levodopa – Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Disease Subjects

Treatment of levodopa-responsive Parkinson's subjects with severe motor fluctuations.
MedDRA version: 14.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Trade Name: Duodopa , 20 mg/ml + 5 mg/ml, intestinal gel
Product Name: Duodopa
INN or Proposed INN: Levodopa
Other descriptive name: PhEur.: (2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid
INN or Proposed INN: Carbidopa Monohydrate
Other descriptive name: PhEur.: (2S)-3-(3,4-dihydroxyphenyl)-2hydrazino-2methylpropanoic acid

Abbott Laboratories

NULL

Not Recruiting

Female: yes
Male: yes

United States;Germany;New Zealand

1394

EUCTR2009-010193-38-EE
(EUCTR)

07/05/2009

15/04/2009

A Placebo-Controlled Study to Evaluate the Safety and Efficacy of IPX066 in Subjects with Parkinson's Disease

Idiopathic Parkinson's disease (paralysis agitans)
MedDRA version: 9.1;Level: LLT;Classification code 10034010;Term: Parkinsonism

IMPAX Laboratories, Inc.

NULL

Not Recruiting

Female: yes
Male: yes

350

Estonia;Latvia;Lithuania

1395

EUCTR2008-001966-10-HU
(EUCTR)

04/05/2009

06/04/2009

Idiopathic Parkinson's Disease
MedDRA version: 9.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease

Product Name: Safinamide
Product Code: NW-1015
INN or Proposed INN: Safinamide
Product Name: Safinamide
Product Code: NW-1015
INN or Proposed INN: Safinamide

Merck Serono SA - Geneva

NULL

Not Recruiting

Female: yes
Male: yes

416

Phase 3

Hungary;United Kingdom;Estonia;Austria

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1396

EUCTR2007-002963-28-BG
(EUCTR)

03/05/2009

21/05/2009

A trial to determine the efficacy and safety of a low (50 mg/day) and high (100 mg/day) dose of safinamide, as add-on therapy, in patients with early Parkinson’s Disease treated with a single dopamine agonist.

Product Name: Safinamide
Product Code: NW-1015
INN or Proposed INN: Safinamide
Product Name: Safinamide
Product Code: NW-1015
INN or Proposed INN: Safinamide

Newron Pharmaceuticals SpA

NULL

Not Recruiting

Female: yes
Male: yes

839

Phase 3

Portugal;United States;Finland;Spain;Chile;Colombia;Italy;India;Czech Republic;Mexico;Canada;Argentina;Poland;Brazil;Croatia;Peru;Bulgaria;South Africa;Germany

1397

NCT00902941
(ClinicalTrials.gov)

May 2009

13/5/2009

Olfaction in Patients With Parkinson's Disease Following Treatment With Rasagiline

Reversibility of Olfactory Loss in Patients With Idiopathic Parkinson's Disease Following Treatment With Rasagiline

Parkinson´s Disease

Drug: Azilect 1mg;Drug: Placebo

Technische Universität Dresden

NULL

Completed

18 Years

64 Years

Both

Phase 4

Germany

1398

NCT00907595
(ClinicalTrials.gov)

May 2009

20/5/2009

Treating Sleep/Wake Cycle Disturbances in Basal Ganglia Disorders With Ramelteon

Treating Sleep Wake Cycle Disturbances in Basal Ganglia Neurodegenerative Disorder Subjects With Ramelteon- A Double Blind, Placebo Controlled Trial

Huntington's Disease;Parkinson's Disease;Dementia With Lewy Bodies;Sleep Disorders;Circadian Dysregulation

Drug: Ramelteon;Drug: Placebo

Massachusetts General Hospital

NULL

Withdrawn

20 Years

90 Years

Both

N/A

United States

1399

NCT00892450
(ClinicalTrials.gov)

May 2009

28/4/2009

Anticholinergic Therapy for Overactive Bladder in Parkinson's Disease

Anticholinergic Therapy for Overactive Bladder in Parkinson's Disease: A Randomized, Double-blind, Crossover Pilot Study

Parkinson's Disease;Overactive Bladder

Drug: Oxybutynin and darifenacin

Department of Veterans Affairs

NULL

Completed

N/A

Both

N/A

United States

1400

NCT00906763
(ClinicalTrials.gov)

May 2009

20/5/2009

Effects of Chocolate on Motor Symptoms of Parkinson's Disease

Effects of Chocolate on Motor Symptoms of Parkinson's Disease - A Monocenter, Prospective, Observer-blinded Interventional Trial

Parkinson's Disease

Dietary Supplement: Chocolate

Technische Universität Dresden

NULL

Recruiting

18 Years

N/A

Both

N/A

Germany

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1401

NCT01515891
(ClinicalTrials.gov)

May 2009

19/1/2012

Absorption, Distribution, Metabolism and Excretion of [14C]-Labeled BIA 9-1067 and Metabolites

An Open-label Study in Healthy Male Subjects to Assess the Absorption, Distribution, Metabolism and Excretion of [14C]-Labeled BIA 9-1067 and Metabolites Following a Single-dose Oral Administration

Parkinson Disease

Drug: BIA 9-1067

Bial - Portela C S.A.

NULL

Completed

40 Years

55 Years

Male

Phase 1

Switzerland

1402

NCT00767546
(ClinicalTrials.gov)

May 2009

5/10/2008

Botulinum Toxin for Treatment of Seborrhic Dermatitis in Parkinsonian Patients

Parkinson Disease;Parkinsonism;Seborrheic Dermatitis

Drug: Botulinum toxin

Rabin Medical Center

NULL

Not yet recruiting

18 Years

N/A

Both

Phase 1

NULL

1403

NCT00914602
(ClinicalTrials.gov)

May 2009

3/6/2009

An Exploratory Study of XP21279 (With Lodosyn®) and Sinemet® in Parkinson's Disease Subjects

An Exploratory Pharmacokinetic, Pharmacodynamic and Safety Study of XP21279 (With Lodosyn®) and Sinemet® in Parkinson's Disease Subjects With Motor Fluctuations

Parkinson's Disease

Drug: XP21279;Drug: Sinemet®;Drug: Lodosyn®

XenoPort, Inc.

NULL

Completed

30 Years

75 Years

Both

Phase 1;Phase 2

United States

1404

EUCTR2008-002769-30-IT
(EUCTR)

30/04/2009

22/04/2009

A randomised, double-blind, placebo-controlled, two-period, two-sequence-crossover interaction study to assess the effect of safinamide on levodopa pharmacokinetics in subjects with Parkinson?s disease - A study to assess the effect of safinamide on levodopa pharmacokinetics

Parkinson Disease
MedDRA version: 9.1;Level: LLT;Classification code 10013113

Product Name: Safinamide
INN or Proposed INN: Safinamide
INN or Proposed INN: NACOM levodopa+cardidopa

MERCK SERONO SA

NULL

Not Recruiting

Female: yes
Male: yes

Italy

1405

EUCTR2008-005492-94-IT
(EUCTR)

30/04/2009

15/04/2009

OPEN LABEL TRIAL TO DETERMINE THE LONG TERM SAFETY OF SAFINAMIDE IN PARKINSON`S DISEASE PATIENTS - ND

IDIOPATHIC PARKINSON`S DISEASE
MedDRA version: 9.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease

Product Name: SAFINAMIDE
Product Code: NW-1015
Product Name: SAFINAMIDE
Product Code: NW-1015

MERCK SERONO SA

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

700

Hungary;Portugal;Germany;Netherlands;France;Bulgaria;Italy;Austria;United Kingdom;Czech Republic;Belgium;Estonia;Spain

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1406

NCT00845000
(ClinicalTrials.gov)

April 21, 2009

13/2/2009

Acute Effects of Preladenant (SCH 420814) on Dyskinesia and Parkinsonism in Levodopa Treated Participants (P05550)

Acute Effects of SCH 420814 on Dyskinesia and Parkinsonism in Levodopa Treated Patients

Parkinson Disease

Drug: SCH 420814 10 mg;Drug: SCH 420814 100 mg;Drug: Placebo;Drug: Levodopa;Drug: Carbidopa

Merck Sharp & Dohme Corp.

Oregon Health and Science University

Completed

18 Years

N/A

All

Phase 1

United States

1407

EUCTR2008-008210-38-FR
(EUCTR)

16/04/2009

19/03/2009

Effet d’un traitement anti-glutamatergique sur les troubles de la marche avec freezing et sur l’attention dans la maladie de Parkinson: freezing of gait and glutamate: FOGG-I” - FOGG-I

Patients ayant une maladie de Parkinson Patients à un stade évolué de la maladie avec des troubles de la marche sévères
MedDRA version: 9.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease
MedDRA version: 9.1;Level: PT;Term: Parkinson's disease

Trade Name: EBIXA®
Product Name: mémantine
Trade Name: L-Dopa / MODOPAR
Product Name: L-Dopa

Chru de Lille

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

France

1408

EUCTR2007-004234-16-AT
(EUCTR)

14/04/2009

10/03/2008

Long-term safety study of open-label pramipexole extended release(ER) in patients with early Parkinson’s disease (PD).

Male or female patients with early idiopathic Parkinson´s disease (PD) with Modified Hoehn and Yahr stage I-III.
MedDRA version: 9.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease

Product Name: Pramipexole ER
Product Code: SND 919 CL2 Y
INN or Proposed INN: Pramipexole
Product Name: Pramipexole ER
Product Code: SND 919 CL2 Y
INN or Proposed INN: Pramipexole
Product Name: Pramipexole ER
Product Code: SND 919 CL2 Y
INN or Proposed INN: Pramipexole
Product Name: Pramipexole ER
Product Code: SND 919 CL2 Y
INN or Proposed INN: Pramipexole
Product Name: Pramipexole ER
Product Code: SND 919 CL2 Y
INN or Proposed INN: Pramipexole

Boehringer Ingelheim RCV GmbH & Co KG

NULL

Not Recruiting

Female: yes
Male: yes

520

Finland;Hungary;Czech Republic;Netherlands;France;Austria

1409

EUCTR2007-001095-36-SK
(EUCTR)

09/04/2009

09/04/2008

The Van Gogh Study: A Multicenter, Randomized, Double-blind, Parallel-group, Placebo and Pramipexole Controlled Study to Assess Efficacy and Safety of SLV308 as Adjunct Therapy to L-dopa in Patients with Parkinson’s Disease Experiencing Motor Fluctuations - The Van Gogh Study

advanced stage of idiopathic PD with dose-dependent motor fluctuations.
MedDRA version: 8.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's

Product Name: Pardoprunox
Product Code: SLV308
INN or Proposed INN: Pardoprunox hydrochloride
Product Name: Pardoprunox
Product Code: SLV308
INN or Proposed INN: Pardoprunox hydrochloride
Product Name: Pardoprunox
Product Code: SLV308
INN or Proposed INN: Pardoprunox hydrochloride
Product Name: Pardoprunox
Product Code: SLV308
INN or Proposed INN: Pardoprunox hydrochloride
Product Name: Pardoprunox
Product Code: SLV308
INN or Proposed INN: Pardoprunox hydrochloride
Product Name: Pardoprunox
Product Code: SLV308

Solvay Pharmaceuticals

NULL

Not Recruiting

Female: yes
Male: yes

625

Phase 3

Hungary;Slovakia

1410

EUCTR2008-005085-30-DE
(EUCTR)

06/04/2009

04/03/2009

Reversibility of olfactory loss in patients with Idiopathic Parkinson’s disease following treatment with Rasagiline

Einfluss von Rasagilin auf das Riechvermögen von Patienten mit idiopathischem Parkinson-Syndrom(Reversibility of olfactory loss in patients with Idiopathic Parkinson’s disease following treatment with Rasagiline) - Olfaction

Idiopathic Parkinson syndrome (IPS), State according to Hoehn & Yahr: maximum III
MedDRA version: 13.1;Level: LLT;Classification code 10034008;Term: Parkinson's syndrome;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Trade Name: Azilect
INN or Proposed INN: Rasagilin

Technische Universität Dresden

NULL

Not Recruiting

Female: yes
Male: yes

Germany

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1411

EUCTR2008-000400-81-PT
(EUCTR)

03/04/2009

27/01/2009

A Multicenter, Randomized, Double Blind, Pramipexole Controlled Pilot Study to Assess Efficacy and Safety of Pardoprunox as Adjunct Therapy to L-dopa in the Treatment of Patients with Parkinson’s Disease Experiencing Motor Fluctuations and Dyskinesia

Advanced Parkinson's Disease
MedDRA version: 9.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's

Solvay Pharmaceuticals BV

NULL

Not Recruiting

Female: yes
Male: yes

Portugal;Germany;Italy

1412

EUCTR2007-002963-28-PL
(EUCTR)

02/04/2009

27/02/2009

A trial to determine the efficacy and safety of a low (50mg/day) and high (100mg/day) dose of safinamide, as an add-on therapy, in patients with early Parkinson's Disease treated with a single dopamine agonist.

Idiopathic Parkinson's Disease
MedDRA version: 14.1;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders

Product Name: Safinamide
Product Code: NW-1015
INN or Proposed INN: Safinamide
Product Name: Safinamide
Product Code: NW-1015
INN or Proposed INN: Safinamide

Newron Pharmaceuticals SpA

NULL

Not Recruiting

Female: yes
Male: yes

839

Phase 3

Portugal;Czech Republic;Finland;Spain;Poland;Bulgaria;Germany;Italy

1413

EUCTR2007-004235-37-AT
(EUCTR)

02/04/2009

10/03/2008

Long-term safety study of open-label pramipexole extended release(ER) in patients with advanced Parkinson’s disease (PD). - Open label extension in advanced PD

Male or female patients, with idiopathic PD diagnosed for at least 2 years, 30 years of age or older at time of diagnosis, with a modified Hoehn and Yahr scale of 2 to 4 at on-time.
MedDRA version: 9.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease

Boehringer Ingelheim RCV GmbH & Co KG

NULL

Not Recruiting

Female: yes
Male: yes

390

Hungary;Czech Republic;United Kingdom;Spain;Italy;Poland;Austria;Sweden

1414

EUCTR2007-002964-90-AT
(EUCTR)

02/04/2009

13/02/2008

Product Name: Safinamide
Product Code: NW-1015
INN or Proposed INN: Safinamide
Product Name: Safinamide
Product Code: NW-1015
INN or Proposed INN: Safinamide

Newron Pharmaceuticals SpA

NULL

Not Recruiting

Female: yes
Male: yes

605

Phase 3

United States;Estonia;Taiwan;Finland;Spain;Thailand;Austria;Israel;United Kingdom;Switzerland;India;France;Czech Republic;Hungary;Canada;Malaysia;Belgium;Australia;Germany;Netherlands;New Zealand;Korea, Republic of

1415

JPRN-UMIN000001841

2009/04/01

02/04/2009

A randomized, double blind, comparative study of vitamin D3 versus placebo in patients with Parkinson disease aged between 45 and 85 years old to improve neurological signs and quality of life

Parkinson disease

Vitamin D3
placebo

Jikei University School of Medicine

NULL

Complete: follow-up complete

45years-old

85years-old

Male and Female

120

Not selected

Japan

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1416

JPRN-JapicCTI-090888

01/4/2009

A Double-Blind, 3-Arm, Parallel Group, Placebo-and Ropinirole-Controlled Study of SPM 962 in Subjects with Parkinson's Disease Treated Concomitantly with L-dopa

Parkinson's Disease Treated Concomitantly with L-dopa

Intervention name : SPM 962
Dosage And administration of the intervention : SPM 962: transdermal application, 1 time per day. Initial dose:4.5mg/day, weekly increment of 4.5mg/day, maximal maintenance dose : 36.0mg/day. Placebo of ropinirole: oral application 3 times per day. Initial dose:0.75mg placebo/day, weekly increment of 0.75mg placebo/day (up to 3.0mg placebo/day), then 1.5mg placebo/day (up to 15.0mg placebo/day), maximal maintenance dose 15.0 mg placebo/day
Control intervention name : Ropinirole
Dosage And administration of the control intervention : placebo SPM 962: transdermal application, 1 time per day. Initial dose: 4.5mg placebo/day, weekly increment of 4.5mg placebo/day, maximal maintenance dose : 36.0mg placebo/day. Ropinirole: oral application 3 times per day. Initial dose:0.75mg/day, weekly increment of 0.75mg/day (up to 3.0mg/day), then 1.5mg/day (up to 15.0mg/day), maximal maintenance dose 15.0 mg/day.
Control intervention name : Placebo
Dosage And administration of the control intervention : placebo SPM 962: transermal application, 1 time per day. Initial dose: 4.5mg placebo/day, weekly increment of 4.5mg placebo/day, maximal maintenance dose : 36.0mg placebo/day. Placebo ropinirole: oral application 3 times per day. Initial dose:0.75mg placebo/day, weekly increment of 0.75mg placebo/day (up to 3.0mg placebo/day), then 1.5mg placebo/day (up to 15.0mg placebo/day), maximal maintenance dose 15.0 mg placebo/day.

Otsuka Pharmaceutical Co., Ltd.

NULL

BOTH

400

Phase 3

NULL

1417

NCT00875316
(ClinicalTrials.gov)

April 2009

2/4/2009

Safety and Tolerability Study of Cogane™ in Healthy Volunteers and Parkinson's Disease Patients

A Randomised, Double-blind, Multiple Dose-ascending, Placebo-controlled Study in Healthy Volunteers and Parkinson's Disease Patients to Assess the Safety, Tolerability and PK of Daily Oral Administration of Cogane™ Over One Month

Parkinson's Disease

Drug: Cogane ™ (PYM50028)

Phytopharm

NULL

Completed

40 Years

80 Years

Both

Phase 1

United Kingdom

1418

NCT00914134
(ClinicalTrials.gov)

April 2009

1/6/2009

Duodenal Levodopa Infusion, Quality of Life and Autonomic Nervous System in Parkinson's Disease

Effect of Duodenal Levodopa Infusion on Quality of Life and Autonomic Dysfunction in Patients With Parkinson's Disease

Parkinson's Disease

Drug: Levodopa infusion

Helsinki University

Solvay Pharmaceuticals

Completed

40 Years

80 Years

Both

Phase 4

Finland

1419

NCT00865579
(ClinicalTrials.gov)

April 2009

10/3/2009

Open-Label Trial to Determine the Long-Term Safety of Safinamide in Parkinson's Disease Patients

Parkinson's Disease

Drug: Safinamide

Newron

NULL

Terminated

30 Years

N/A

All

964

Phase 3

Romania

1420

NCT01568034
(ClinicalTrials.gov)

April 2009

29/3/2012

A Study to Investigate the Tolerability and Effect of Three Single-dose Regimens of BIA 9-1067

A Double-blind, Randomised, Placebo-controlled, Cross-over Study to Investigate the Tolerability and Effect of Three Single-dose Regimens of BIA 9-1067 on the Levodopa Pharmacokinetics, Motor Response, and Erythrocyte Soluble Catechol-O-methyltransferase Activity in Parkinson's Disease Patients Concomitantly Treated With Levodopa/Dopa-decarboxylase Inhibitor

Parkinson's Disease

Drug: BIA 9-1067;Drug: Placebo;Drug: Levodopa /Carbidopa;Drug: Levodopa /Benzerazide

Bial - Portela C S.A.

NULL

Completed

30 Years

75 Years

All

Phase 2

Portugal;Romania;Ukraine

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1421

NCT00880620
(ClinicalTrials.gov)

April 2009

3/4/2009

A Study To Evaluate The Safety And Efficacy Of IPX066 In Subjects With Parkinson's Disease

A Placebo-Controlled Study To Evaluate The Safety And Efficacy Of IPX066 In Subjects With Parkinson's Disease

Parkinson's Disease

Drug: Placebo;Drug: IPX066 95 mg LD;Drug: IPX066 145 mg LD;Drug: IPX066 195 mg LD;Drug: IPX066 245 mg LD

Impax Laboratories, LLC

NULL

Completed

30 Years

N/A

All

381

Phase 3

United States;Canada;Estonia;Latvia;Lithuania;Romania;Ukraine

1422

EUCTR2008-000400-81-IT
(EUCTR)

31/03/2009

17/04/2009

A Multicenter, Randomized, Double Blind, Pramipexole Controlled Pilot Study to Assess Efficacy and Safety of Pardoprunox as Adjunct Therapy to L-dopa in the Treatment of Patients with Parkinson?s Disease Experiencing Motor Fluctuations and Dyskinesia - ND

Advanced Parkinson`s Disease
MedDRA version: 9.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's

Product Name: Pardoprunox
Product Code: SLV308
INN or Proposed INN: Pardoprunox hydrochloride
Product Name: Pardoprunox
Product Code: SLV308
INN or Proposed INN: Pardoprunox hydrochloride
Product Name: Pardoprunox
Product Code: SLV308
INN or Proposed INN: Pardoprunox hydrochloride
Trade Name: Mirapex
INN or Proposed INN: Pramipexole
Trade Name: Mirapex
INN or Proposed INN: Pramipexole
Trade Name: Mirapex
INN or Proposed INN: Pramipexole

SOLVAY PHARMACEUTICALS B.V.

NULL

Not Recruiting

Female: yes
Male: yes

Portugal;Germany;Italy

1423

EUCTR2007-003035-22-AT
(EUCTR)

30/03/2009

26/05/2008

A Multi-Center, Open-Label Extension Study to Examine the Safety and Tolerability of ACP-103 in the Treatment of Psychosis in Parkinson’s Disease

Psychosis in Parkinson's Disease
MedDRA version: 9.1;Level: LLT;Classification code 10037241;Term: Psychosis NOS

Product Name: Pimavanserin tartrate
Product Code: ACP-103
INN or Proposed INN: Pimavanserin tartrate

Acadia Pharmaceuticals Inc

NULL

Not Recruiting

Female: yes
Male: yes

560

Phase 2;Phase 3

Portugal;France;Belgium;Austria;Italy;United Kingdom;Sweden

1424

EUCTR2008-004447-11-GB
(EUCTR)

27/03/2009

07/01/2009

A Phase IIb Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study Investigating the Efficacy and Safety of Apomorphine Inhalation Powder in Patients With On-Off” or Wearing-Off” Effects Associated With Parkinson’s Disease

Unpredictable motor fluctuation or On-Off” or Wearing-Off” Effects Fluctuating associated with Idiopathic Parkinson’s Disease
MedDRA version: 11;Level: LLT;Classification code 10067209;Term:

Vectura Limited

NULL

Not Recruiting

Female: yes
Male: yes

Phase 2b

Germany;United Kingdom;Italy

1425

EUCTR2007-002963-28-PT
(EUCTR)

26/03/2009

07/01/2009

Idiopathic Parkinson's Disease
MedDRA version: 9.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease

Product Name: Safinamide
Product Code: NW-1015
INN or Proposed INN: Safinamide
Product Name: Safinamide
Product Code: NW-1015
INN or Proposed INN: Safinamide

Merck Serono S.A-Geneva

NULL

Not Recruiting

Female: yes
Male: yes

1036

Phase 3

Portugal;Czech Republic;Finland;Poland;Spain;Bulgaria;Germany;Italy

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1426

EUCTR2007-002964-90-FR
(EUCTR)

09/03/2009

12/11/2007

Ideopathic Parkinson's Disease
MedDRA version: 9.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease

Product Name: Safinamide
Product Code: NW-1015
INN or Proposed INN: Safinamide
Product Name: Safinamide
Product Code: NW-1015
INN or Proposed INN: Safinamide

Merck Serono S.A. - Geneva

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

1121

Phase 3

Hungary;Finland;Czech Republic;United Kingdom;Germany;Netherlands;Belgium;Estonia;France;Spain;Austria

1427

NCT00758368
(ClinicalTrials.gov)

March 2009

23/9/2008

Comparison of Continuous and Pulsatile Apomorphine in Parkinson's Disease

Comparison of Continuous and Pulsatile Apomorphine Administration in Parkinson's Disease Complicated by Levodopa-induced Dyskinesia

Parkinson's Disease

Drug: Apomorphine

Oregon Health and Science University

National Institute of Neurological Disorders and Stroke (NINDS)

Withdrawn

21 Years

N/A

All

Phase 2

United States

1428

NCT00940914
(ClinicalTrials.gov)

March 2009

16/7/2009

Dopaminergic Loss and Pain in Parkinson's Disease

Evaluation of Radioligand Uptake (FP-CIT) of Dopamine Transporters in Patients Suffering From Parkinson's Disease With or Without Pain

Parkinson's Disease;Pain

Drug: ioflupane 123I (DATSCAN®)

University Hospital, Toulouse

NULL

Completed

30 Years

70 Years

All

Phase 2

France

1429

NCT01533116
(ClinicalTrials.gov)

March 2009

24/1/2012

Effect of BIA 9-1067 at Steady-state on the Pharmacokinetics of Levodopa/Carbidopa and Levodopa/Benserazide

Effect of BIA 9-1067 at Steady-state on the Pharmacokinetics of a Single-dose of Immediate-release 100/25 mg Levodopa/Carbidopa and 100/25 mg Levodopa/Benserazide in Healthy Subjects

Parkinson Disease

Drug: BIA 9-1067;Drug: Placebo;Drug: levodopa /carbidopa;Drug: levodopa /benserazide

Bial - Portela C S.A.

NULL

Completed

25 Years

45 Years

All

Phase 1

Canada

1430

NCT00823836
(ClinicalTrials.gov)

March 2009

15/1/2009

Clinical Evaluation of Ropinirole Prolonged Release/Extended Release (PR/XR) Tablet for Adjunctive Therapy to L-dopa in Subjects With Advanced Parkinson's Disease

Clinical Evaluation of Ropinirole PR/XR Tablet for Adjunctive Therapy to L-dopa in Subjects With Advanced Parkinson's Disease

Parkinson Disease

Drug: ropinirole PR/XR;Drug: ropinirole IR

GlaxoSmithKline

NULL

Completed

20 Years

N/A

All

302

Phase 3

Japan

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1431

NCT00888004
(ClinicalTrials.gov)

March 2009

23/4/2009

Efficacy and Safety of AFQ056 in Reducing L-dopa Induced Dyskinesias in Parkinson's Disease Patients

A Multi-centre, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multiple Oral Dose Study to Assess the Efficacy and Tolerability of AFQ056 in Reducing L-dopa Induced Dyskinesias in Parkinson's Patients With Severe L-dopa Induced Dyskinesias

Parkinson's Disease;L-dopa Induced Dyskinesia

Drug: AFQ056;Drug: Placebo

Novartis

NULL

Completed

30 Years

85 Years

Both

Phase 2

Germany

1432

NCT00767091
(ClinicalTrials.gov)

March 2009

1/9/2008

Study of Rivastigmine to Treat Parkinsonian Apathy Without Dementia

A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicentric Trial

Parkinson's Disease;Apathy;no Dementia

Drug: rivastigmine;Drug: placebo

University Hospital, Lille

NULL

Completed

15 Years

80 Years

Both

Phase 3

France

1433

NCT01533077
(ClinicalTrials.gov)

March 2009

24/1/2012

Pharmacokinetic Interaction Between BIA 9-1067 and Standard-release Levodopa/Carbidopa

Pharmacokinetic Interaction Between BIA 9-1067 and Standard-release Levodopa/Carbidopa in Healthy Subjects

Parkinson Disease

Drug: BIA 9-1067;Drug: Sinemet® 100/25 mg

Bial - Portela C S.A.

NULL

Completed

18 Years

45 Years

All

Phase 1

Canada

1434

NCT00870974
(ClinicalTrials.gov)

March 2009

26/3/2009

A PET Brain Imaging Study of mGluR5 in Subjects With Neuropsychiatric Conditions

Evaluation of [18F]PEB and Positron Emission Tomography (PET) as a Marker of mGluR5 in Subjects w/ Neuropsychiatric Conditions

Parkinson Disease;Huntington Disease;Autistic Spectrum Disorders;Fragile X Syndrome;Alzheimer Disease;Mild Cognitive Impairment

Drug: [18F]FPEB

Institute for Neurodegenerative Disorders

NULL

Completed

18 Years

85 Years

All

Phase 1

United States

1435

NCT00866502
(ClinicalTrials.gov)

March 2009

18/3/2009

A Safety and Tolerability Study of Intracerebroventricular Administration of sNN0031 to Patients With Parkinson's Disease

A Randomized, Double-blind, Placebo Controlled, Safety and Tolerability Study of Intracerebroventricular Administration of sNN0031 to Patients With Idiopathic Parkinson's Disease (PD) of Moderate Severity, Using an Implanted Catheter and a SynchroMed® II Pump.

Parkinson's Disease

Drug: sNN0031;Drug: Placebo

Newron Sweden AB

Medtronic;Quintiles

Completed

30 Years

75 Years

Both

Phase 1;Phase 2

Sweden

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1436

NCT01399905
(ClinicalTrials.gov)

March 2009

21/7/2011

High and Low Dose Carbidopa Treatment of Parkinson's Disease

A Randomized Controlled Trial of Four Week Outpatient Treatment of Parkinson's Disease Comparing High and Low Dose Carbidopa.

Parkinson's Disease

Drug: carbidopa

Oregon Health and Science University

NULL

Completed

35 Years

85 Years

All

Phase 2

United States

1437

EUCTR2006-005186-18-CZ
(EUCTR)

09/02/2009

21/11/2007

Levodopa-Carbidopa Intestinal Gel Open-Label Study in Advanced Parkinson’s Disease

An Open-Label, 12-Month Safety and Efficacy Study of Levodopa – Carbidopa Intestinal Gel in Levodopa-Responsive Subjects with Advanced Parkinson's Disease and Severe Motor- Fluctuations Despite Optimized Treatment with Available Parkinson’s Disease Medications”

Trade Name: DUODOPA ®Intestinal Gel
Product Name: Duodopa
INN or Proposed INN: Levodopa
Other descriptive name: PhEur.: (2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid
INN or Proposed INN: Carbidopa Monohydrate
Other descriptive name: PhEur.: (2S)-3-(3,4-dihydroxyphenyl)-2hydrazino-2methylpropanoic acid

Abbott Healthcare Products B.V.

NULL

Not Recruiting

Female: yes
Male: yes

320

United States;Portugal;Finland;Thailand;Spain;Israel;Russian Federation;United Kingdom;Italy;Czech Republic;Canada;Poland;Australia;Germany;Netherlands;New Zealand

1438

EUCTR2008-006278-13-NL
(EUCTR)

04/02/2009

15/10/2008

Motor function optimization in advanced Parkinson’s disease patients, combined with galantamine to prevent visual hallucinations.

patients with advanced (>5 years) Parkinson's disease and visual hallucinations.
MedDRA version: 9.1;Level: LLT;Classification code 10047570;Term: Visual hallucinations
MedDRA version: 9.1;Classification code 10013113;Term: Disease Parkinson's

Trade Name: Reminyl Retard
Trade Name: Sinemet 125 mg

UMCG

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

Netherlands

1439

NCT01421719
(ClinicalTrials.gov)

February 2009

19/8/2011

Safety and Efficacy of botulinumA Toxin (BotoxA) for Treatment of Neurogenic Bladder of Parkinson's Disease

Onabotulinum Toxin Type A (BTX-A) For Treatment of Neurogenic Overactive Bladder Due to Parkinson's Disease: Safety and Efficacy

Parkinson's Disease;Neurogenic Bladder;Urinary Incontinence;Clostridium Botulinum Toxin Adverse Reaction

Drug: Cystoscopic injection of Botox into the urinary bladder

Stanford University

Allergan

Completed

50 Years

85 Years

All

Phase 4

United States

1440

NCT00627640
(ClinicalTrials.gov)

February 2009

13/2/2008

Safinamide in Idiopathic Parkinson's Disease (IPD) With Motor Fluctuations, as add-on to Levodopa

A Phase III, Double-blind, Placebo-controlled, Randomised Trial to Determine the Efficacy and Safety of a Dose Range of 50 to 100 mg/Day of Safinamide, as add-on Therapy, in Subjects With Idiopathic Parkinson's Disease With Motor Fluctuations, Treated With a Stable Dose of Levodopa and Who May be Receiving Concomitant Treatment With Stable Doses of a Dopamine Agonist, an Anticholinergic and/or Amantadine

Idiopathic Parkinson's Disease

Drug: Safinimide 50-100 mg/day;Drug: Matching Placebo

Newron

NULL

Completed

30 Years

80 Years

Both

549

Phase 3

United States;Australia;Austria;Belgium;Canada;Estonia;France;Germany;Hungary;India;Israel;Korea, Republic of;Malaysia;Netherlands;New Zealand;Slovakia;Spain;Switzerland;Taiwan;Thailand;United Kingdom

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1441

NCT01039090
(ClinicalTrials.gov)

February 2009

22/12/2009

Efficacy of Continuous Apomorphine Infusion on Cognitive and Neuropsychological Functions in Parkinson's Disease

Prospective, Randomised, Comparative Study Comparing Efficacy of Continuous Apomorphine Infusion Versus Usual Dopaminergic Per os Treatment on Cognitive and Neuropsychological Functions in Parkinson's Disease: a Clinical and PET-scan Study

Parkinsons's Disease

Drug: Continuous Apomorphine infusion;Drug: Usual dopaminergic per os treatment

Rennes University Hospital

NULL

Completed

18 Years

N/A

All

Phase 3

France

1442

NCT00806468
(ClinicalTrials.gov)

February 2009

9/12/2008

Effect of Desmopressin on the Nocturnal Micturition Frequency in Patients With Parkinson Disease

A Double Blind, Placebo Controlled, Randomized, Monocentre Cross-over Study to Investigate the Effect of Desmopressin on the Nocturnal Micturition Frequency in Patients With Parkinson Disease

Parkinson Disease

Drug: Desmotabs

Johannes Gutenberg University Mainz

NULL

Terminated

18 Years

85 Years

Male

Phase 4

Germany

1443

NCT00873392
(ClinicalTrials.gov)

February 2009

31/3/2009

Efficacy of Transdermal Nicotine, on Motor Symptoms in Advanced Parkinson's Disease

Efficacy of Transdermal Nicotine, on Motor Symptoms in Advanced Parkinson's Disease(One Daily Administration).A Controlled Randomised Study, in Two Parallel Groups and Single Blind in 40 Patients.

Idiopathic Parkinson's Disease

Drug: Transdermal nicotine;Other: Usual drug treatment of Parkinson's disease

Assistance Publique - Hôpitaux de Paris

NULL

Completed

35 Years

70 Years

Both

Phase 2

France

1444

NCT00908076
(ClinicalTrials.gov)

February 2009

21/5/2009

Amitiza in Constipation Associated With PD (Parkinson's Disease)

Randomized Double-Blind Placebo-Controlled Trial of Lubiprostone in the Treatment of Constipation Associated With Parkinson's Disease

Parkinson's Disease

Drug: LUBIPROSTONE

Baylor College of Medicine

University of South Florida

Completed

18 Years

85 Years

All

Phase 4

United States

1445

EUCTR2007-007853-30-SE
(EUCTR)

28/01/2009

21/12/2007

A randomized, double-blind, placebo controlled, safety and tolerability study of intracerebroventricular administration of sNN0031 to patients with idiopathic Parkinson's disease (PD) of moderate severity, using an implanted catheter and a SynchroMed® II pump.

Idiopathic Parkinson's disease (PD) of moderate severity (modified Hoehn & Yahr Stage IIb - III)

Product Name: sNN0031
Product Code: sNN0031

NeuroNova AB

NULL

Not Recruiting

Female: yes
Male: yes

Sweden

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1446

EUCTR2009-015833-66-IT
(EUCTR)

20/01/2009

18/04/2012

Ropinirole 24h prolonged release and motor fluctuations: a study to control the wearing-off induced by dopamine agonists immediate release

Parkinson's Disease
MedDRA version: 14.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Trade Name: REQUIP*28CPR 8MG R.P.
INN or Proposed INN: ROPINIROLE
Other descriptive name: NA
Trade Name: REQUIP*21CPR 5MG
INN or Proposed INN: ROPINIROLE
Other descriptive name: NA
Trade Name: MIRAPEXIN*30CPR 0,7MG
INN or Proposed INN: PRAMIPEXOLE
Other descriptive name: NA

CASA DI CURA PRIVATA S.RAFFAELE - PISANA

NULL

Not Recruiting

Female: yes
Male: yes

Italy

1447

EUCTR2007-002963-28-CZ
(EUCTR)

19/01/2009

30/10/2007

A trial to determine the efficacy and safety of a low (50 mg/day) and high (100 mg/day) dose of safinamide, as add-on therapy, in patients with early Parkinson's Disease treated with a single dopamine agonist.

Idiopathic Parkinson's Disease
MedDRA version: 14.1;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders

Product Name: Safinamide
Product Code: NW-1015
INN or Proposed INN: Safinamide
Product Name: Safinamide
Product Code: NW-1015
INN or Proposed INN: Safinamide

Newron Pharmaceuticals SpA

NULL

Not Recruiting

Female: yes
Male: yes

839

Phase 3

Portugal;United States;Finland;Spain;Chile;Colombia;Italy;India;Czech Republic;Mexico;Canada;Argentina;Poland;Brazil;Croatia;Peru;Bulgaria;South Africa;Germany

1448

EUCTR2007-003035-22-PT
(EUCTR)

09/01/2009

01/07/2008

A safety and tolerability study of ACP-103 in patients with Parkinson's Disease Psychosis

A Multi-Center, Open-Label Extension Study to Examine the Safety and Tolerability of ACP-103 in the Treatment of Psychosis in Parkinson’s Disease

MedDRA version: 18.0;Level: LLT;Classification code 10037241;Term: Psychosis NOS;System Organ Class: 100000004873 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

ACADIA Pharmaceuticals Inc

NULL

Not Recruiting

Female: yes
Male: yes

400

Phase 3

Portugal;United States;Ukraine;Austria;Russian Federation;United Kingdom;Italy;India;France;European Union;Canada;Belgium;Sweden

1449

EUCTR2007-003035-22-IT
(EUCTR)

07/01/2009

23/07/2008

A Multi-Center, Open-Label Extension Study to Examine the Safety and Tolerability of ACP-103 in the Treatment of Psychosis in Parkinson's Disease - ACP-103-015

Psychosis in Parkinson?s Disease
MedDRA version: 9.1;Level: LLT;Classification code 10037241;Term: Psychosis NOS

Product Name: primavanserin tartrate
Product Code: ACP-103
INN or Proposed INN: primavanserin tartrate

ACADIA PHARMACEUTICALS INC.

NULL

Not Recruiting

Female: yes
Male: yes

486

Portugal;United Kingdom;Belgium;France;Italy;Austria;Sweden

1450

EUCTR2008-004906-15-FR
(EUCTR)

05/01/2009

16/03/2009

EVALUATION DE LA CAPTATION D’UN RADIOLIGAND DES TRANSPORTEURS DE LA DOPAMINE CHEZ DES SUJETS ATTEINTS DE LA MALADIE DE PARKINSON ET PRESENTANT OU NON DES DOULEURS EN RAPPORT AVEC CETTE PATHOLOGIE - dénervation dopaminergique et douleur dans la maladie de Parkinson

Maladie de Parkinson
MedDRA version: 9.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's

Trade Name: DATSCAN

CHU Toulouse

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

France

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1451

NCT02169466
(ClinicalTrials.gov)

January 2009

20/1/2012

Pharmacokinetic-pharmacodynamic Interaction Between Three Different Single Doses of BIA 9-1067 and a Single-dose of Controlled-release 100/25 mg Levodopa/Benserazide

Pharmacokinetic-pharmacodynamic Interaction Between Three Different Single Doses of BIA 9-1067 and a Single-dose of Controlled-release 100/25 mg Levodopa/Benserazide: a Double-blind, Randomized, Four-way Crossover, Placebo-controlled Study in Healthy Male Subjects

Parkinson's Disease (PD)

Drug: BIA 9-1067;Drug: Placebo;Drug: Madopar® HBS

Bial - Portela C S.A.

NULL

Completed

18 Years

45 Years

Male

Phase 1

Portugal

1452

NCT00357994
(ClinicalTrials.gov)

January 2009

27/7/2006

Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects

Advanced Parkinson's Disease

Drug: Levodopa carbidopa intestinal gel (LCIG);Drug: Placebo gel;Drug: Levodopa carbidopa (LC) oral encapsulated immediate release (IR) tablets;Drug: Placebo (PBO) oral capsules;Device: CADD-Legacy® 1400 ambulatory infusion pump;Device: PEG tube;Device: J-tube

AbbVie (prior sponsor, Abbott)

Quintiles, Inc.

Completed

30 Years

N/A

All

Phase 3

United States;Germany

1453

NCT00857532
(ClinicalTrials.gov)

January 2009

5/3/2009

Florbetapir F 18 PET Imaging of Beta-amyloid in Parkinson's Disease Patients

A Phase 2 Trial of Florbetapir F18 PET Imaging of ß-amyloid in Parkinson's Disease Patients With Cognitive Impairment

Parkinson's Disease

Drug: florbetapir F 18

Avid Radiopharmaceuticals

National Institutes of Health (NIH);National Institute of Neurological Disorders and Stroke (NINDS)

Completed

60 Years

N/A

All

Phase 2

United States

1454

EUCTR2004-000148-26-AT
(EUCTR)

31/12/2008

26/11/2008

A multi-centre, multinational, phase 3, open-label extension trial to assess the safety of long-term treatment of rotigotine patch in subjects with advanced stage, idiopathic Parkinson's disease who are not well controlled on levodopa - N/A

Parkinson's Disease

Product Name: Rotigotine
Product Code: SPM 962
INN or Proposed INN: Rotigotine
Other descriptive name: (6S)-6-{propyl-[2-[2-thienyl]ethyl]amino}-5,6,7,8-tetrahydro-1-naphtalenol

Schwarz BioSciences Inc.

NULL

Not Recruiting

Female: yes
Male: yes

360

Phase 3

Czech Republic;Hungary;Finland;Spain;Austria;Italy;Sweden

1455

EUCTR2008-003966-25-DE
(EUCTR)

23/12/2008

04/11/2008

Double-blind, placebo controlled, randomised, monocenter cross-over studie to evaluate the effect of Desmopressin on the nocturnal polyuria in patients with idiopathic Parkinson Syndrome compared to placebo. - DEPOPA

Effect of Desmopressin on the nocturnal polyuria in patients with idiopathic Parkinson Syndrome
MedDRA version: 9.1;Level: LLT;Classification code 10064016;Term: Nocturnal polyuria
MedDRA version: 9.1;Classification code 10061536;Term: Parkinson's disease

Trade Name: Desmotabs® 0,2 mg Tabletten
Product Name: Desmotabs® 0,2mg Tabletten
INN or Proposed INN: Desmopressin Acetat

Universität Mainz, Klinik und Poliklinik für Neurologie

NULL

Not Recruiting

Female: no
Male: yes

Germany

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1456

NCT00740714
(ClinicalTrials.gov)

December 2008

22/8/2008

Effects of Coenzyme Q10 (CoQ) in Parkinson Disease

Effects of Coenzyme Q10 in Parkinson Disease - Phase III

Parkinson Disease

Drug: Coenzyme Q10 with vitamin E;Drug: placebo with vitamin E

Weill Medical College of Cornell University

National Institute of Neurological Disorders and Stroke (NINDS);University of Rochester

Terminated

30 Years

N/A

All

600

Phase 3

United States;Canada

1457

NCT00809302
(ClinicalTrials.gov)

December 2008

15/12/2008

Efficacy and Safety Study of Aplindore in Patients With Early Parkinson Disease

A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Three Doses of Aplindore MR (1, 3, and 6 mg Twice Daily) in Patients With Early Parkinson Disease (APLIED)

Early Parkinson Disease

Drug: aplindore MR tablets or Placebo

Neurogen Corporation

NULL

Terminated

30 Years

N/A

Both

Phase 2

United States

1458

EUCTR2008-004943-12-SK
(EUCTR)

24/11/2008

10/10/2008

The Rubens Study:A Multicenter, Randomized, Double-blind, Parallel Group, Placebo and Pramipexole Controlled Study to Explore the Efficacy, Tolerability and Safety of Different Doses and Titration Schedules of Pardoprunox Monotherapy in the Treatment of Patients with Early Stage Parkinson’s Disease - The Rubens Study

Early Stage Parkinson’s Disease
MedDRA version: 9.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's

Product Name: Pardoprunox
Product Code: SLV308
INN or Proposed INN: Pardoprunox hydrochloride
Other descriptive name: SLV308 hydrochloride
Product Name: Pardoprunox
Product Code: SLV308
INN or Proposed INN: Pardoprunox hydrochloride
Other descriptive name: SLV308 hydrochloride
Product Name: Pardoprunox
Product Code: SLV308
INN or Proposed INN: Pardoprunox hydrochloride
Other descriptive name: SLV308 hydrochloride
Product Name: Pardoprunox
Product Code: SLV308
INN or Proposed INN: Pardoprunox hydrochloride
Other descriptive name: SLV308 hydrochloride
Trade Name: Mirapex
INN or Proposed INN: Pramipexole
Other descriptive name: pramipexole dihydrochloride monohydrate

Solvay Pharmaceuticals B.V.

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

320

Phase 2

Slovakia

1459

EUCTR2006-005186-18-GB
(EUCTR)

19/11/2008

27/06/2008

Levodopa-Carbidopa Intestinal Gel Open-Label Study in Advanced Parkinson’s Disease

Treatment of levodopa-responsive Parkinson's subjects with severe motor fluctuations.
MedDRA version: 14.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's;System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Abbott Healthcare Products B.V.

NULL

Not Recruiting

Female: yes
Male: yes

320

Phase 3

Portugal;United States;Finland;Spain;Thailand;Israel;Russian Federation;Italy;United Kingdom;Czech Republic;Canada;Poland;Australia;Netherlands;Germany;New Zealand

1460

EUCTR2007-006721-27-GB
(EUCTR)

11/11/2008

25/02/2009

A Phase II, Multicenter, Randomized and Controlled Open-Label Trial Comparing the Safety and Efficacy of Bilateral Intraputaminal (IPu) Administration of CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN]) Combined with Best Medical Therapy (BMT) versus BMT-alone in Subjects With Idiopathic Parkinson’s Disease.

idiopathic Parkinson's Disease
MedDRA version: 9.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease

Product Name: CERE-120
Product Code: CERE-120

Ceregene Inc.

NULL

Not Recruiting

Female: yes
Male: yes

Phase 2

United Kingdom

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1461

EUCTR2007-003051-36-BE
(EUCTR)

06/11/2008

21/05/2008

A Multi-Center, Placebo-Controlled, Double-Blind Trial to Examine the Safety and Efficacy of ACP-103 in the Treatment of Psychosis in Parkinson’s Disease

Psychosis in Parkinson's Disease
MedDRA version: 9.1;Level: LLT;Classification code 10037241;Term: Psychosis NOS

Acadia Pharmaceuticals Inc

NULL

Not Recruiting

Female: yes
Male: yes

280

Austria;Sweden;Portugal;Spain;Belgium

1462

EUCTR2007-003035-22-GB
(EUCTR)

05/11/2008

20/12/2007

A safety and tolerability study of ACP-103 in patients with Parkinson's Disease Psychosis

A Multi-Center, Open-Label Extension Study to Examine the Safety and Tolerability of ACP-103 in the Treatment of Psychosis in Parkinson’s Disease - ACP-103-015

Psychosis in Parkinson's Disease
MedDRA version: 20.0;Level: LLT;Classification code 10037241;Term: Psychosis NOS;System Organ Class: 100000004873 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

ACADIA Pharmaceuticals Inc.

NULL

Not Recruiting

Female: yes
Male: yes

400

Phase 3

United States;Portugal;Ukraine;Austria;Russian Federation;United Kingdom;Italy;India;France;European Union;Canada;Belgium;Sweden

1463

NCT00869791
(ClinicalTrials.gov)

November 2008

24/3/2009

A Study to Compare Pharmacokinetics and Pharmacodynamics of IPX066 to Standard Carbidopa-Levodopa

Parkinson's Disease

Drug: IPX066;Drug: IR CD-LD

Impax Laboratories, LLC

NULL

Completed

30 Years

N/A

All

Phase 2

United States

1464

NCT00629161
(ClinicalTrials.gov)

November 2008

25/2/2008

Clinical Trial on the Effectiveness of Traditional Chinese Medicinal Mixture in Parkinson Disease

Parkinson Disease

Drug: Traditional Chinese Medicinal Mixture (composed of Roucongrong and adjuvant);Drug: placebo

Fudan University

NULL

Recruiting

50 Years

N/A

Both

144

Phase 2;Phase 3

China

1465

EUCTR2007-006721-27-AT
(EUCTR)

20/10/2008

15/09/2008

idiopathic Parkinson's Disease
MedDRA version: 9.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease

Product Name: CERE-120
Product Code: CERE-120

Ceregene Inc.

NULL

Not Recruiting

Female: yes
Male: yes

Phase 2

Austria;United Kingdom

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1466

EUCTR2007-004890-24-PT
(EUCTR)

07/10/2008

25/06/2008

A Phase II, Randomised, Placebo-Controlled, Double-Blind, Replicated Crossover, Pilot Study on the Effect of Fipamezole on Neurogenic Orthostatic Hypotension in Patients with Multiple System Atrophy or Parkinson’s Disease - FOEHN

Neurogenic orthostatic hypotension in patients with multiple system atrophy or Parkinson's disease
MedDRA version: 9.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's
MedDRA version: 9.1;Classification code 10064060;Term: Multiple system atrophy

Product Name: Fipamezole hydrochloride 90 mg oral disintegrating tablets
Product Code: JP-1730/F01
INN or Proposed INN: Fipamezole hydrochloride
Product Name: Fipamezole hydrochloride 60 mg oral disintegrating tablets
Product Code: JP-1730/F02
INN or Proposed INN: Fipamezole hydrochloride
Product Name: Fipamezole hydrochloride 30 mg oral disintegrating tablets
Product Code: JP-1730/F03
INN or Proposed INN: Fipamezole hydrochloride

Juvantia Pharma Ltd

NULL

Not Recruiting

Female: yes
Male: yes

Phase 2

Portugal;France

1467

EUCTR2008-003869-72-PT
(EUCTR)

03/10/2008

25/06/2008

A DOUBLE-BLIND, RANDOMISED, PLACEBO-CONTROLLED, CROSS-OVER STUDY TO INVESTIGATE THE TOLERABILITY AND EFFECT OF THREE SINGLE-DOSE REGIMENS OF BIA 9-1067 ON THE LEVODOPA PHARMACOKINETICS, MOTOR RESPONSE, AND ERYTHROCYTE SOLUBLE CATECHOL-O-METHYLTRANSFERASE ACTIVITY IN PARKINSON'S DISEASE PATIENTS CONCOMITANTLY TREATED WITH LEVODOPA/DOPA-DECARBOXYLASE INHIBITOR

Parkinson
MedDRA version: 9.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's

Product Code: BIA 9-1067
Trade Name: SINEMET 25/100
INN or Proposed INN: LEVODOPA
INN or Proposed INN: CARBIDOPA
Product Code: BIA 9-1067

Bial - Portela & Cª, S.A.

NULL

Not Recruiting

Female: yes
Male: yes

Portugal

1468

EUCTR2007-004235-37-IT
(EUCTR)

02/10/2008

28/11/2007

Long-term safety study of open-label pramipexole extended release (ER) in patients with advanced Parkinson?s disease (PD). - ND

Patients with advanced idiopathic PD
MedDRA version: 9.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease

Product Name: Pramipexole ER
Product Code: SND 919 CL2Y
INN or Proposed INN: Pramipexole
Product Name: Pramipexole ER
Product Code: SND 919 CL2Y
INN or Proposed INN: Pramipexole
Product Name: Pramipexole ER
Product Code: SND 919 CL2Y
INN or Proposed INN: Pramipexole
Product Name: Pramipexole ER
Product Code: SND 919 CL2Y
INN or Proposed INN: Pramipexole
Product Name: Pramipexole ER
Product Code: SND 919 CL2Y
INN or Proposed INN: Pramipexole

BOEHRINGER ING.

NULL

Not Recruiting

Female: yes
Male: yes

390

Hungary;Czech Republic;United Kingdom;Spain;Italy;Poland;Austria;Sweden

1469

EUCTR2007-000350-31-IT
(EUCTR)

02/10/2008

11/02/2008

A 76-week prospective, open-label, multicenter study to evaluate the long-term effect of Exelon capsule and transdermal patch on worsening of the underlying motor symptoms of PD in patients with mild to moderately severe dementia associated with Parkinson?s disease (PDD) - ND

mild to moderately severe dementia associated with Parkinson?s disease (PDD)
MedDRA version: 9.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease

Product Name: Exelon path transdermal
Product Code: ENA713B
INN or Proposed INN: Rivastigmine
Trade Name: EXELON
INN or Proposed INN: Rivastigmine
Trade Name: EXELON
INN or Proposed INN: Rivastigmine
Trade Name: EXELON
INN or Proposed INN: Rivastigmine
Trade Name: EXELON
INN or Proposed INN: Rivastigmine
Product Name: Exelon path transdermal
Product Code: ENA713B
INN or Proposed INN: Rivastigmine

NOVARTIS FARMA

NULL

Not Recruiting

Female: yes
Male: yes

550

France;Spain;Italy

1470

NCT01048229
(ClinicalTrials.gov)

October 2008

12/1/2010

Evaluation of the Tolerance and Acceptability of Rasagiline in the Treatment of Early-stage Parkinson's Disease

Early-stage Parkinson's Disease

Drug: Rasagiline;Drug: Pramipexole

Qualissima

H. Lundbeck A/S

Terminated

18 Years

70 Years

Both

112

Phase 4

NULL

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1471

NCT02092168
(ClinicalTrials.gov)

October 2008

20/1/2012

Pharmacokinetics of BIA 9-1067 and Its Metabolites in Healthy Male Elderly Subjects and in Healthy Male Young Subjects

Single-dose and Steady-state Pharmacokinetics of BIA 9-1067 and Its Metabolites in Healthy Male Elderly Subjects Compared With Those in Healthy Male Young Subjects

Parkinson Disease

Drug: BIA 9-1067

Bial - Portela C S.A.

NULL

Completed

18 Years

N/A

Male

Phase 1

France

1472

NCT00611481
(ClinicalTrials.gov)

October 2008

6/2/2008

Study of Tai Chi Exercise and Balance in Persons With Parkinson's Disease

Phase II Study of Tai Chi Exercise in Relation to Balance in Persons With Parkinson's Disease

Parkinson's Disease

Behavioral: Tai Chi;Behavioral: Strength training;Behavioral: Low-Impact Exercise Control

Oregon Research Institute

National Institute of Neurological Disorders and Stroke (NINDS)

Completed

40 Years

85 Years

Both

195

Phase 2

United States

1473

NCT02169453
(ClinicalTrials.gov)

October 2008

20/1/2012

Pharmacokinetic-pharmacodynamic Interaction Between Each of Three Different Single Doses of BIA 9-1067 and a Single-dose of Controlled-release 100/25 mg Levodopa/Carbidopa

Pharmacokinetic-pharmacodynamic Interaction Between Each of Three Different Single Doses of BIA 9-1067 and a Single-dose of Controlled-release 100/25 mg Levodopa/Carbidopa: a Double-blind, Randomized, Four-way Crossover, Placebo-controlled Study in Healthy Male Subjects

Parkinson's Disease (PD)

Drug: BIA 9-1067;Drug: Placebo;Drug: Sinemet® CR 100/25

Bial - Portela C S.A.

NULL

Completed

18 Years

45 Years

Male

Phase 1

Canada

1474

NCT00906828
(ClinicalTrials.gov)

October 2008

19/5/2009

Pharmacokinetics of Levodopa/Carbidopa Infusion With and Without Oral Catechol-O-methyl Transferase (COMT) Inhibitors

Pharmacokinetics of Levodopa in Patients With Parkinson's Disease Treated With Levodopa/Carbidopa Infusion With and Without Oral COMT Inhibitors

Parkinson Disease

Drug: levodopa /carbidopa;Drug: entacapone;Drug: tolcapone

Uppsala University

Swedish Parkinson's Disease Foundation;Swedish Society for Medical Research

Completed

30 Years

90 Years

Both

Phase 4

Sweden

1475

EUCTR2006-005186-18-DE
(EUCTR)

30/09/2008

13/11/2008

Levodopa-Carbidopa Intestinal Gel Open-Label Study in Advanced Parkinson’s Disease

Abbott Healthcare Products B.V.

NULL

Not Recruiting

Female: yes
Male: yes

320

Portugal;United States;Finland;Spain;Thailand;Israel;Russian Federation;Italy;United Kingdom;Czech Republic;Canada;Poland;Australia;Netherlands;Germany;New Zealand

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1476

EUCTR2008-003225-16-FI
(EUCTR)

10/09/2008

30/05/2008

Aivostimulaattorin ja levodopainfuusion vaikutus elämänlaatuun ja autonomisen hermoston toimintaan Parkinsonin tautia sairastavilla potilailla

Vaikeahoitoinen Parkinsonin tauti potilailla, joille on aiemmin asetettu aivostimulaattori, tai on päädytty päivittäisten oireiden vuoksi aloittamaan Duodopa-infuusio.
MedDRA version: 9.1;Level: LLT;Classification code 10034007;Term: Parkinson's disease NOS

Trade Name: Duodopa

Organisation name was not entered

NULL

Not Recruiting

Female: yes
Male: yes

Finland

1477

EUCTR2007-003051-36-AT
(EUCTR)

10/09/2008

29/04/2008

A Multi-Center, Placebo-Controlled, Double-Blind Trial to Examine the Safety and Efficacy of ACP-103 in the Treatment of Psychosis in Parkinson’s Disease

Psychosis in Parkinson's Disease
MedDRA version: 9.1;Level: LLT;Classification code 10037241;Term: Psychosis NOS

Acadia Pharmaceuticals Inc

NULL

Not Recruiting

Female: yes
Male: yes

280

Portugal;Spain;Austria;Sweden

1478

EUCTR2007-003051-36-PT
(EUCTR)

05/09/2008

27/05/2008

A Multi-Center, Placebo-Controlled, Double-Blind Trial to Examine the Safety and Efficacy of ACP-103 in the Treatment of Psychosis in Parkinson’s Disease

Psychosis in Parkinson's Disease
MedDRA version: 9.1;Level: LLT;Classification code 10037241;Term: Psychosis NOS

Acadia Pharmaceuticals Inc

NULL

Not Recruiting

Female: yes
Male: yes

280

Portugal;Spain;Austria;Sweden

1479

EUCTR2007-003035-22-BE
(EUCTR)

02/09/2008

21/05/2008

A Multi-Center, Open-Label Extension Study to Examine the Safety and Tolerability of ACP-103 in the Treatment of Psychosis in Parkinson’s Disease

Psychosis in Parkinson's Disease
MedDRA version: 9.1;Level: LLT;Classification code 10037241;Term: Psychosis NOS

Product Name: Pimavanserin tartrate
Product Code: pimavanserin (ACP-103)
INN or Proposed INN: Pimavanserin tartrate

Acadia Pharmaceuticals Inc

NULL

Not Recruiting

Female: yes
Male: yes

400

Phase 2;Phase 3

Portugal;France;Belgium;Austria;Italy;United Kingdom;Sweden

1480

NCT00758849
(ClinicalTrials.gov)

September 2008

24/9/2008

Fipamezole in Neurogenic Orthostatic Hypotension

A Phase II, Randomised, Placebo-Controlled, Double-Blind, Replicated Crossover, Pilot Study on the Effect of Fipamezole on Neurogenic Orthostatic Hypotension in Patients With Multiple System Atrophy or Parkinson's Disease

Symptomatic Neurogenic Orthostatic Hypotension (NOH);Parkinson's Disease;Multiple System Atrophy

Drug: Placebo;Drug: Fipamezole

Juvantia Pharma Ltd

Santhera Pharmaceuticals

Not yet recruiting

30 Years

80 Years

Both

Phase 2

France;Portugal

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1481

NCT02169895
(ClinicalTrials.gov)

September 2008

20/1/2012

Pharmacokinetic-pharmacodynamic Interaction Between Three Different Single Doses of BIA 9-1067 and a Single-dose of Immediate-release Levodopa/Benserazide

Pharmacokinetic-pharmacodynamic Interaction Between Each of Three Different Single Doses of BIA 9-1067 and a Single-dose of Immediate-release 100/25 mg Levodopa/Benserazide: a Doubleblind, Randomized, Four-way Crossover, Placebo-controlled Study in Healthy Male Subjects

Parkinson's Disease (PD)

Drug: BIA 9-1067;Drug: Placebo;Drug: Prolopa®

Bial - Portela C S.A.

NULL

Completed

25 Years

45 Years

Male

Phase 1

Canada

1482

NCT02169479
(ClinicalTrials.gov)

September 2008

20/1/2012

Pharmacokinetic-pharmacodynamic Interaction Between Each of Three Diferente Single Doses of BIA 9-1067 and a Single-dose of Immediate-release 100/25 mg Levodopa/Carbidopa

Pharmacokinetic-pharmacodynamic Interaction Between Each of Three Diferente Single Doses of BIA 9-1067 and a Single-dose of Immediate-release 100/25 mg Levodopa/Carbidopa: a Doubleblind, Randomized, Four-way Crossover, Placebo-controlled Study in Healthy Male Subjects

Parkinson's Disease (PD)

Drug: BIA 9-1067;Drug: Placebo;Drug: Sinemet® 100/25

Bial - Portela C S.A.

NULL

Completed

18 Years

45 Years

Male

Phase 1

Canada

1483

NCT00755027
(ClinicalTrials.gov)

September 2008

17/9/2008

Rasagiline and Apathy in Parkinson's Disease

A Randomised Placebo-controlled Trial of Rasagiline in Parkinson Disease Patients With Symptoms of Apathy

Parkinson's Disease

Drug: Rasagiline

Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

NULL

Completed

18 Years

80 Years

Both

Phase 4

Spain

1484

EUCTR2007-004235-37-GB
(EUCTR)

19/08/2008

26/11/2007

Long-term safety study of open-label pramipexole extended release(ER) in patients with advanced Parkinson’s disease (PD). - Open label extension in advanced PD

Boehringer Ingelheim

NULL

Not Recruiting

Female: yes
Male: yes

390

Hungary;Czech Republic;United Kingdom;Spain;Italy;Poland;Austria;Sweden

1485

EUCTR2004-005234-39-DE
(EUCTR)

11/08/2008

02/12/2005

Multicentre, randomised, double-blind study to compare Stalevo® to levodopa/carbidopa in patients with Parkinson's disease experiencing symptoms of early wearing-off - SEWOP

Parkinson's disease
MedDRA version: 7.0;Level: LLT;Classification code 10061536

Trade Name: Stalevo
Product Name: Stalevo
INN or Proposed INN: Levodopa
INN or Proposed INN: Carbidopa
INN or Proposed INN: Entacapone
Trade Name: Stalevo
Product Name: Stalevo
INN or Proposed INN: Levodopa
INN or Proposed INN: Carbidopa
INN or Proposed INN: Entacapone
Trade Name: Sinemet
Product Name: Sinemet
INN or Proposed INN: Levodopa
INN or Proposed INN: Carbidopa
Trade Name: Sinemet
Product Name: Sinemet
INN or Proposed INN: Levodopa
INN or Proposed INN: Carbidopa

Orion Corporation, ORION PHARMA, 02200 Espoo, Finland

NULL

Not Recruiting

Female: yes
Male: yes

244

Finland;United Kingdom;Germany;Denmark;Ireland;Latvia;Lithuania;Sweden

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1486

NCT00656253
(ClinicalTrials.gov)

August 2008

7/4/2008

Clinical Trial on the Effectiveness of Herbal Medicinal Mixture in Parkinson Disease

Parkinson's Disease

Drug: Herbal Medicinal Mixture (Roucongrong, Heshouwu etc.);Drug: Placebo

Fudan University

China's Ministry of Health; Administration of Traditional Chinese Medicine (SATCM)

Completed

50 Years

N/A

Both

158

Phase 2;Phase 3

China

1487

NCT00745277
(ClinicalTrials.gov)

August 2008

2/9/2008

High and Low Dose Treatment of Carbidopa in Parkinson's Disease

A Randomized Controlled Trial of Four Week Outpatient Treatment of Parkinson's Disease Comparing High and Low Dose Carbidopa.

Parkinson's Disease

Drug: Carbidopa -Levodopa;Drug: Carbidopa - Levodopa

Oregon Health and Science University

Parkinson Disease Research, Education and Clinical Center at Portland VA Hospital;RJG Foundation;Oregon Clinical and Translational Research Institute

Completed

35 Years

85 Years

Both

Phase 2

United States

1488

NCT01010802
(ClinicalTrials.gov)

August 2008

8/11/2009

Safety Study of Erythropoietin (EPO) in Parkinson's Disease

Phase 1 Study of Recombinant Human Erythropoietin (rhEPO) in Parkinson's Disease (PD)

Parkinson Disease

Drug: Erythropoietin human recombinant (EPOrh)

International Center for Neurological Restoration, Cuba

Centro de Immunologia Molecular, Cuba

Completed

45 Years

75 Years

All

Phase 1

Cuba

1489

NCT00601978
(ClinicalTrials.gov)

August 2008

11/1/2008

Carbidopa/Levodopa Versus Carbidopa/Levodopa/Entacapone on Markers of Event Related Potentials (ERPs) in Patients With Idiopathic Parkinson's Disease (PD) and End-of-dose Wearing Off

A 12-Week, Multi-center, Randomized, Prospective, Open-Label, Blinded Rater, Crossover Study of the Effects of Immediate-Release Carbidopa/Levodopa Versus Carbidopa/Levodopa/Entacapone on Markers of Event-Related Potentials (ERPs) in Patients With Idiopathic Parkinson's Disease and End-of-Dose Wearing Off

Parkinson's Disease

Drug: carbidopa /levodopa;Drug: Carbidopa /Levodopa /Entacapone

Novartis Pharmaceuticals

NULL

Withdrawn

45 Years

75 Years

Both

Phase 4

United States

1490

EUCTR2004-000148-26-HU
(EUCTR)

26/07/2008

19/07/2004

Parkinson's Disease

Product Name: Rotigotine
Product Code: SPM 962
INN or Proposed INN: Rotigotine
Other descriptive name: (6S)-6-{propyl-[2-[2-thienyl]ethyl]amino}-5,6,7,8-tetrahydro-1-naphtalenol

Schwarz BioSciences Inc.

NULL

Not Recruiting

Female: yes
Male: yes

360

Phase 3

Finland;Hungary;Czech Republic;Spain;Italy;Sweden

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1491

EUCTR2008-003581-26-SE
(EUCTR)

18/07/2008

30/05/2008

Pharmacokinetics of levodopa using duodenal levodopa/carbidopa infusion with and without oral COMT inhibitors - DuoCOMT

Parkinson's disease (G20.9), advanced, patients presently on Duodopa treatment.
MedDRA version: 9.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's

Trade Name: Duodopa
INN or Proposed INN: levodopa
INN or Proposed INN: carbidopa
Trade Name: Comtess
INN or Proposed INN: entacapone
Trade Name: Tasmar
INN or Proposed INN: tolcapone

Dept of Neuroscience, Uppsala University

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

Sweden

1492

EUCTR2008-001336-13-FR
(EUCTR)

16/07/2008

09/06/2008

Effet de la Nicotine transdermique sur les symptomes moteurs de la maladie de Parkinson avancée (une administration quotidienne) .Etude contrôlée, randomisée, en deux groupes parallèles et en simple insu sur 40 patients. - NICOPARK2

Maladie Parkinson
MedDRA version: 8.1;Level: PT;Classification code 10061536;Term: Parkinson's disease

Trade Name: Nicorette 5 mg/ 16 h
Product Name: Nicorette 5 mg/ 16 h
INN or Proposed INN: Nicotine
Product Name: Nicorette 10mg/ 16 h
INN or Proposed INN: Nicotine
Product Name: Nicorette 15 mg/ 16 h
INN or Proposed INN: Nicotine

ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

France

1493

EUCTR2007-003051-36-ES
(EUCTR)

01/07/2008

05/05/2008

Ensayo multicéntrico, doble ciego y controlado con placebo para evaluar la seguridad y la eficacia de ACP-103 en el tratamiento de la psicosis en la enfermedad de Parkinson.A Multi-Center, Placebo-Controlled, Double-Blind Trial to Examine the Safety and Efficacy of ACP-103 in the Treatment of Psychosis in Parkinson’s Disease

Psicosis en la enfermedad de Parkinson.Psychosis in Parkinson's Disease
MedDRA version: 9.1;Level: LLT;Classification code 10037241;Term: Psychosis NOS

Acadia Pharmaceuticals Inc

NULL

Not Recruiting

Female: yes
Male: yes

280

Portugal;Spain;Austria;Sweden

1494

EUCTR2007-002963-28-IT
(EUCTR)

30/06/2008

04/01/2008

Idiopathic Parkinson's Disease
MedDRA version: 6.1;Level: PT;Classification code 10061536

Product Name: safinamide
Product Name: safinamide

MERCK SERONO INTERNATIONAL SA

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

666

Phase 3

Portugal;Finland;Germany;Czech Republic;Bulgaria;Spain;Italy;Poland

1495

EUCTR2007-003051-36-SE
(EUCTR)

30/06/2008

16/05/2008

A Multi-Center, Placebo-Controlled, Double-Blind Trial to Examine the Safety and Efficacy of ACP-103 in the Treatment of Psychosis in Parkinson’s Disease

Psychosis in Parkinson's Disease
MedDRA version: 9.1;Level: LLT;Classification code 10037241;Term: Psychosis NOS

Product Name: Pimavanserin tartrate
Product Code: ACP-103
INN or Proposed INN: Pimavanserin tartrate
Product Name: Pimavanserin tartrate
Product Code: ACP-103
INN or Proposed INN: Pimavanserin tartrate
Product Name: Pimavanserin tartrate
Product Code: ACP-103
INN or Proposed INN: Pimavanserin tartrate
Product Name: Pimavanserin tartrate
Product Code: ACP-103
INN or Proposed INN: Pimavanserin tartrate

Acadia Pharmaceuticals Inc

NULL

Not Recruiting

Female: yes
Male: yes

280

Portugal;Spain;Austria;Sweden

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1496

EUCTR2007-003134-42-DE
(EUCTR)

19/06/2008

20/02/2008

A 12-Week, Multi-center, Randomized, Prospective, Open-Label, Blinded Rater, Crossover Study of the Effects of Immediate-Release Carbidopa/Levodopa Versus Stalevo® on Markers of Event-Related Potentials (ERPs) in Patients with Idiopathic Parkinson’s Disease and End-of-Dose Wearing Off.

Idiopathic Parkinson’s disease and end-of-dose wearing off.
MedDRA version: 9.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease

Trade Name: Stalevo 100 mg/ 25 mg/ 200 mg Filmtabletten
Product Name: Stalevo
INN or Proposed INN: LEVODOPA
INN or Proposed INN: CARBIDOPA
INN or Proposed INN: ENTACAPONE
Trade Name: Nacom 100
Product Name: Nacom
INN or Proposed INN: LEVODOPA
INN or Proposed INN: CARBIDOPA
Other descriptive name: CARBIDOPA MONOHYDRATE

Novartis Pharma Services AG

NULL

Not Recruiting

Female: yes
Male: yes

Germany

1497

EUCTR2007-003035-22-SE
(EUCTR)

11/06/2008

16/05/2008

A Multi-Center, Open-Label Extension Study to Examine the Safety and Tolerability of ACP-103 in the Treatment of Psychosis in Parkinson’s Disease

Psychosis in Parkinson's Disease
MedDRA version: 9.1;Level: LLT;Classification code 10037241;Term: Psychosis NOS

Product Name: Pimavanserin tartrate
Product Code: pimavanserin (ACP-103)
INN or Proposed INN: Pimavanserin tartrate

Acadia Pharmaceuticals Inc

NULL

Not Recruiting

Female: yes
Male: yes

400

Phase 2;Phase 3

Portugal;France;Belgium;Austria;Italy;United Kingdom;Sweden

1498

EUCTR2007-002964-90-HU
(EUCTR)

03/06/2008

15/11/2007

Idiopathic Parkinson's Disease
MedDRA version: 9.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease

Product Name: Safinamide
Product Code: NW-1015
INN or Proposed INN: Safinamide
Product Name: Safinamide
Product Code: NW-1015
INN or Proposed INN: Safinamide

Merck Serono S.A.-Geneva

NULL

Not Recruiting

Female: yes
Male: yes

1121

Phase 3

France;Czech Republic;Estonia;Hungary;Finland;Spain;Belgium;Austria;Germany;Netherlands;United Kingdom

1499

NCT00822913
(ClinicalTrials.gov)

June 2008

14/1/2009

Botulinum A Toxin in Patients With Parkinson's Disease

The Use of Toxin Botulinum A Toxin in Patients With Parkinson's Disease and Multiple System Disease, Affected by Refractory Detrusor Overactivity.

Parkinson's Disease;Multiple System Atrophy;Detrusor Overactivity

Drug: Intravesical injection of Botulinum A toxin

University Of Perugia

University of Roma La Sapienza

Enrolling by invitation

18 Years

80 Years

Both

Phase 4

NULL

1500

EUCTR2007-004235-37-PL
(EUCTR)

29/05/2008

16/04/2008

Long-term safety study of open-label pramipexole extended release(ER) in patients with advanced Parkinson’s disease (PD). - Open label extension in advanced PD

Boehringer Ingelheim Pharma Ges mbH

NULL

Not Recruiting

Female: yes
Male: yes

390

Hungary;Czech Republic;United Kingdom;Spain;Italy;Austria;Poland;Sweden

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1501

EUCTR2007-004009-93-IT
(EUCTR)

20/05/2008

14/07/2008

Prevalence of depression,anxiety and impulse control disorder (ICD) in patients with Parkinson's disease and effectiveness of escitalopram

Depression, anxiety and ICD
MedDRA version: 14.1;Level: SOC;Classification code 10037175;Term: Psychiatric disorders;System Organ Class: 10037175 - Psychiatric disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Trade Name: CIPRALEX
INN or Proposed INN: Escitalopram
Trade Name: CIPRALEX
INN or Proposed INN: Escitalopram

LUNDBECK ITALIA

NULL

Not Recruiting

Female: yes
Male: yes

Italy

1502

EUCTR2007-004890-24-FR
(EUCTR)

07/05/2008

09/05/2008

Juvantia Pharma Ltd

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

Phase 2

Portugal;France

1503

EUCTR2006-006752-35-DE
(EUCTR)

06/05/2008

23/03/2007

RECOVER: RANDOMIZED EVALUATION OF THE 24-HOUR COVERAGE: EFFICACY OF ROTIGOTINEPHASE 3B, MULTICENTER, MULTINATIONAL, DOUBLE-BLIND, PLACEBO CONTROLLED, 2-ARM TRIAL TO EVALUATE THE EFFECT OF THE 24-HOUR TRANSDERMAL DELIVERY OF ROTIGOTINE ON THE CONTROL OF EARLY MORNING MOTOR FUNCTION, SLEEP QUALITY, NOCTURNAL SYMPTOMS, AND NON-MOTOR SYMPTOMS IN SUBJECTS WITH IDIOPATHIC PARKINSON’S DISEASE - RECOVER

Parkinson's disease
MedDRA version: 9.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease

Trade Name: Neupro 2mg/24 h transdermal patch
Product Code: ND1587
INN or Proposed INN: Rotigotine
Trade Name: Neupro 4mg/24 h transdermal patch
Product Code: ND1589
INN or Proposed INN: Rotigotine
Trade Name: Neupro 6mg/24 h transdermal patch
Product Code: ND1590
INN or Proposed INN: Rotigotine
Trade Name: Neupro 8 mg/24 h transdermal patch
Product Code: ND1702
INN or Proposed INN: Rotigotine

Schwarz Biosciences GmbH

NULL

Not Recruiting

Female: yes
Male: yes

400

Phase 3B

Hungary;Finland;Spain;Austria;Germany;United Kingdom;Italy

1504

NCT01416818
(ClinicalTrials.gov)

May 2008

11/8/2011

Treatment of Depression in Parkinson's Disease

A Randomized, Double-Blind, Placebo-Controlled Study of Xiaoyao Pill Treatment of Depression in Patients With Parkinson's Disease

Depression in Parkinson's Disease

Drug: Xiaoyao Pill;Drug: Bupleurum+Ginkgo;Drug: placebo

Xuanwu Hospital, Beijing

NULL

Recruiting

30 Years

80 Years

Both

Phase 2

China

1505

NCT01238926
(ClinicalTrials.gov)

May 2008

9/11/2010

Vitamin B6, B12, Folic Acid and Exercise in Parkinson's Disease

Effects of Vitamin Supplementation and Strength Training in Parkinson's Disease

Parkinson's Disease

Dietary Supplement: PD vitamin supplementation;Other: PD exercise intervention;Other: PD vitamin + exercise

New York Institute of Technology

Stony Brook University

Active, not recruiting

50 Years

80 Years

Both

N/A

United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1506

EUCTR2007-004235-37-SE
(EUCTR)

23/04/2008

25/03/2008

Long-term safety study of open-label pramipexole extended release(ER) in patients with advanced Parkinson’s disease (PD). - Open label extension in advanced PD

Boehringer Ingelheim AB

NULL

Not Recruiting

Female: yes
Male: yes

390

Hungary;Czech Republic;United Kingdom;Spain;Italy;Poland;Austria;Sweden

1507

EUCTR2007-004234-16-FI
(EUCTR)

16/04/2008

12/02/2008

Long-term safety study of open-label pramipexole extended release(ER) in patients with early Parkinson’s disease (PD).

Male or female patients with early idiopathic Parkinson´s disease (PD) with Modified Hoehn and Yahr stage I-III.
MedDRA version: 9.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease

Boehringer Ingelheim Finland Ky

NULL

Not Recruiting

Female: yes
Male: yes

520

Hungary;Finland;Czech Republic;Netherlands;France;Austria

1508

EUCTR2007-002906-23-BG
(EUCTR)

16/04/2008

07/07/2008

A Multi-Center, Placebo-Controlled, Double-Blind Trial To Examine the Safety and Efficacy of ACP-103 in the Treatment of Psychosis in Parkinson's Disease

Psychosis in Parkinson's Disease
MedDRA version: 9.1;Level: LLT;Classification code 10037241;Term: Psychosis NOS

Product Name: Pimavanserin tartrate
Product Code: ACP-103
INN or Proposed INN: Pimavanserin tartrate

Acadia Pharmaceuticals Inc

NULL

Not Recruiting

Female: yes
Male: yes

280

United Kingdom;France;Bulgaria

1509

EUCTR2007-001096-10-SK
(EUCTR)

11/04/2008

09/04/2008

An Extension of the Van Gogh Study: An Open Label SLV308 Safety Extension to Study S308.3.004 in Patients with Parkinson’s Disease Experiencing Motor Fluctuations - An Extension of the Van Gogh Study

advanced stage of idiopathic PD with dose-dependent motor fluctuations.
MedDRA version: 8.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's

Solvay Pharmaceuticals

NULL

Not Recruiting

Female: yes
Male: yes

500

Phase 3

Hungary;Slovakia

1510

NCT02071810
(ClinicalTrials.gov)

April 2008

19/1/2012

Tolerability, Pharmacokinetics and Pharmacodynamics of BIA 9-1067

A Double-blind, Randomised, Placebo-controlled Study to Evaluate the Tolerability, Pharmacokinetics and Pharmacodynamics of Four Multiple Rising Dose Regimens of BIA 9-1067 in Healthy Male Volunteers

Parkinson's Disease (PD)

Drug: BIA 9-1067;Drug: Placebo

Bial - Portela C S.A.

NULL

Completed

18 Years

45 Years

Male

Phase 1

France

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1511

NCT00651183
(ClinicalTrials.gov)

April 2008

31/3/2008

Non-motor Symptoms (Depressive Symptoms) of Parkinson's Disease and Their Course Under Pramipexole Treatment

Parkinson Disease

Drug: Pramipexole immediate release

Boehringer Ingelheim

NULL

Completed

18 Years

N/A

All

286

Austria

1512

NCT00605553
(ClinicalTrials.gov)

April 2008

15/1/2008

Study to Evaluate SYN115 in Parkinson's Disease

A Randomized, Double-blind, Placebo Controlled, Two-way Cross-over Study to Explore the Effects of 7 Days of Dosing With SYN115 20 mg p.o. BID or 60 mg p.o. BID on Clinical and fMRI Response to Intravenous Levodopa in Patients With Mild to Moderate Parkinson's Disease

Parkinson's Disease

Drug: Placebo;Drug: Tozadenant

Biotie Therapies Inc.

NULL

Completed

40 Years

75 Years

All

Phase 2

United States

1513

NCT00753636
(ClinicalTrials.gov)

April 2008

13/9/2008

Parkinson's Disease Isradipine Safety Study

Phase II Safety and Tolerability of Isradipine (A Potential Neuroprotective Agent) in Patients With Parkinson's Disease- Stage II

Parkinson's Disease

Drug: Dynacirc CR (Isradipine)

Northwestern University

Northwestern Memorial Hospital

Completed

30 Years

75 Years

All

Phase 2

United States

1514

EUCTR2007-001095-36-HU
(EUCTR)

27/03/2008

06/02/2008

advanced stage of idiopathic PD with dose-dependent motor fluctuations.
MedDRA version: 8.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's

Solvay Pharmaceuticals

NULL

Not Recruiting

Female: yes
Male: yes

625

Hungary

1515

EUCTR2007-001096-10-HU
(EUCTR)

27/03/2008

15/02/2008

advanced stage of idiopathic PD with dose-dependent motor fluctuations.
MedDRA version: 8.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's

Solvay Pharmaceuticals

NULL

Not Recruiting

Female: yes
Male: yes

500

Hungary

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1516

EUCTR2006-003732-30-PL
(EUCTR)

27/03/2008

08/01/2008

Transdermal Use of Lisuride in Early Parkinson´s Disease: A double blind, randomized, Placebo and Pramipexole controlled study to evaluate the efficacy and safety of Lisuride TTS - TULEP 1

Early Parkinson's Disease
MedDRA version: 8.1;Level: PT;Classification code 10061536;Term: Parkinson's disease

Product Name: Lisuride TTS 10cm²
INN or Proposed INN: LISURIDE
Trade Name: Sifrol 0,088
INN or Proposed INN: PRAMIPEXOLE
Product Name: Lisuride TTS 20cm²
INN or Proposed INN: LISURIDE
Trade Name: Sifrol 0,18
INN or Proposed INN: PRAMIPEXOLE
Trade Name: Sifrol 0,35
INN or Proposed INN: PRAMIPEXOLE
Trade Name: Sifrol 0,7
INN or Proposed INN: PRAMIPEXOLE

NeuroBiotec Pharma AG

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

350

Germany;Italy;Poland

1517

EUCTR2007-005033-11-DE
(EUCTR)

27/03/2008

04/01/2008

A Comparison Of The Safety And Bioavailability Of Modified-Release Formulations Of Levodopa-Carbidopa In Subjects With Parkinson’s Disease

Patients with Parkinson's Disease

Product Name: Levodopa -Carbidopa Multilayer Extended Release Tablet
Product Code: Levodopa -Carbidopa XL tablet (M)
INN or Proposed INN: Levodopa
INN or Proposed INN: Carbidopa
Trade Name: Sinemet® CR
Product Name: Sinemet CR
INN or Proposed INN: Levodopa
INN or Proposed INN: Carbidopa

CombinatoRx, Inc

NULL

Not Recruiting

Female: yes
Male: yes

Germany

1518

EUCTR2007-002964-90-GB
(EUCTR)

20/03/2008

14/01/2009

Ideopathic Parkinson's Disease
MedDRA version: 9.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease

Merck Serono S.A - Geneva

NULL

Not Recruiting

Female: yes
Male: yes

605

Phase 3

France;Czech Republic;Estonia;Hungary;Slovakia;Finland;Spain;Belgium;Austria;Germany;Netherlands;United Kingdom

1519

EUCTR2007-004234-16-HU
(EUCTR)

17/03/2008

17/01/2008

Long-term safety study of open-label pramipexole extended release(ER) in patients with early Parkinson’s disease (PD).

Male or female patients with early idiopathic Parkinson´s disease (PD) with Modified Hoehn and Yahr stage I-III.
MedDRA version: 9.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease

Boehringer Ingelheim Pharma Ges mbH

NULL

Not Recruiting

Female: yes
Male: yes

520

Finland;Hungary;Czech Republic;Netherlands;France;Austria

1520

EUCTR2007-004235-37-HU
(EUCTR)

17/03/2008

17/01/2008

Long-term safety study of open-label pramipexole extended release(ER) in patients with advanced Parkinson’s disease (PD). - Open label extension in advanced PD

Boehringer Ingelheim Pharma Ges mbH

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

390

Hungary;Czech Republic;United Kingdom;Spain;Italy;Poland;Austria;Sweden

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1521

EUCTR2006-005186-18-PT
(EUCTR)

07/03/2008

14/11/2007

Treatment of levodopa-responsive Parkinson's subjects with severe motor fluctuations.
MedDRA version: 9.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's

Abbott Healthcare Products B.V.

NULL

Not Recruiting

Female: yes
Male: yes

320

Portugal;Czech Republic;Finland;Spain;Germany;Netherlands;United Kingdom;Italy

1522

NCT00658567
(ClinicalTrials.gov)

March 2008

10/4/2008

A Study of Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis

Parkinson's Disease Psychosis

Drug: Pimavanserin tartrate (ACP-103)

ACADIA Pharmaceuticals Inc.

NULL

Completed

40 Years

N/A

All

123

Phase 3

United States;Austria;Belgium;Italy;Poland;Portugal;Serbia;Spain;Sweden

1523

NCT00607451
(ClinicalTrials.gov)

March 2008

22/1/2008

Safety, Tolerability, PK and PD Study of Neu-120 in the Treatment of Levodopa-induced Dyskinesia

A Double-blind, Placebo Controlled, Crossover, Ascending Single Dose Safety Tolerability, Pharmacokinetic and Pharmacodynamic Study of Neu-120 in Patients With Advanced Phase Idiopathic Parkinson's Disease With Levodopa Induced Dyskinesia

Levodopa-induced Dyskinesia

Drug: Neu-120

Neurim Pharmaceuticals Ltd.

NULL

Terminated

30 Years

80 Years

All

Phase 1;Phase 2

Israel

1524

NCT00642356
(ClinicalTrials.gov)

March 2008

19/3/2008

Carbidopa/Levodopa/Entacapone Versus Immediate Release (IR) Carbidopa/Levodopa on Non-motor Symptoms in Patients With Idiopathic Parkinson's Disease and Demonstrating Non-motor Symptoms of Wearing Off

An 8-week, Prospective, Randomized, Double-blind, Double-dummy, Active-controlled, Multi-center Comparison Study of the Effects of Carbidopa/Levodopa/Entacapone Versus Immediate Release Carbidopa/Levodopa on Non-motor Symptoms in Patients With Idiopathic Parkinson's Disease and Demonstrating Non-motor Symptoms of Wearing Off

Parkinson's Disease

Drug: Carbidopa /levodopa/entacapone;Drug: Immediate release carbidopa/levodopa

Novartis

NULL

Terminated

30 Years

85 Years

All

Phase 4

United States

1525

NCT00761137
(ClinicalTrials.gov)

March 2008

25/9/2008

Safety and Efficacy Study of NH004 Films for Relief of Sialorrhea Symptoms in Parkinson's Disease Patients

A Two-Phase, Double Blind, Placebo-Controlled, Randomized, Crossover Study of the Safety and Efficacy of Intra-Oral NH004 Films for the Short-Term Relief of Sialorrhea Symptoms in Parkinson's Disease Patients

Sialorrhea Secondary to Parkinson's Disease

Drug: 0.3 mg tropicamide;Drug: 1 mg tropicamide;Drug: 3 mg tropicamide;Drug: 0 mg tropicamide

NeuroHealing Pharmaceuticals Inc.

Michael J. Fox Foundation for Parkinson's Research

Completed

50 Years

80 Years

All

Phase 2

Argentina

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1526

NCT00727727
(ClinicalTrials.gov)

March 2008

31/7/2008

SEDPARK2: Post Marketing Surveillance to Observe Safety and Efficacy of Piribedil in Parkinson's Disease (PIR-002/K)

Stabilization on, or Change-Over to the Non-Ergot Dopamine Agonist Piribedil in Patients With Morbus Parkinson - a Post Marketing Surveillance Study in Private Practices.

Parkinson's Disease

Drug: Piribedil

Desitin Arzneimittel GmbH

NULL

Completed

18 Years

N/A

Both

750

N/A

Germany

1527

EUCTR2007-003035-22-FR
(EUCTR)

29/02/2008

15/02/2008

A Multi-Center, Open-Label Extension Study to Examine the Safety and Tolerability of ACP-103 in the Treatment of Psychosis in Parkinson’s Disease

Psychosis in Parkinson's Disease
MedDRA version: 9.1;Level: LLT;Classification code 10037241;Term: Psychosis NOS

Acadia Pharmaceuticals Inc

NULL

Not Recruiting

Female: yes
Male: yes

486

Phase 2;Phase 3

Portugal;France;Belgium;Austria;Italy;United Kingdom;Sweden

1528

EUCTR2007-002964-90-DE
(EUCTR)

28/02/2008

17/12/2008

Idiopathic Parkinson's Disease
MedDRA version: 14.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders

Product Name: Safinamide
Product Code: NW-1015
INN or Proposed INN: Safinamide
Product Name: Safinamide
Product Code: NW-1015
INN or Proposed INN: Safinamide

Merck Serono S.A. - Geneva

NULL

Not Recruiting

Female: yes
Male: yes

484

Phase 3

France;Czech Republic;Estonia;Hungary;Finland;Spain;Belgium;Austria;Netherlands;Germany;United Kingdom

1529

EUCTR2007-002964-90-EE
(EUCTR)

13/02/2008

02/01/2008

Product Name: Safinamide
Product Code: NW-1015
INN or Proposed INN: Safinamide
Product Name: Safinamide
Product Code: NW-1015
INN or Proposed INN: Safinamide

Newron Pharmaceuticals SpA

NULL

Not Recruiting

Female: yes
Male: yes

605

Phase 3

1530

EUCTR2007-000350-31-ES
(EUCTR)

13/02/2008

21/12/2007

Estudio prospectivo, multicéntrico y en condiciones abiertas de 76 semanas de duración para evaluar el efecto a largo plazo de Exelon® cápsula y parche transdérmico en el empeoramiento de los síntomas motores subyacentes de la EP en pacientes con demencia leve a moderadamente grave asociada a enfermedad de Parkinson (DEP)

Demencia leve a moderadamente grave asociada a enfermedad de Parkinson (DEP).
MedDRA version: 9.1;Level: LLT;Classification code 10012284;Term: Dementia due to Parkinson's disease

Trade Name: Exelon
INN or Proposed INN: rivastigmine
Trade Name: Exelon
INN or Proposed INN: rivastigmine
Trade Name: Exelon
INN or Proposed INN: rivastigmine
Trade Name: Exelon
INN or Proposed INN: rivastigmine
Trade Name: Exelon 4.6 mg/24 h transdermal patch
INN or Proposed INN: rivastigmine
Trade Name: Exelon 9.5 mg/24 h transdermal patch
INN or Proposed INN: rivastigmine

Novartis Farmacéutica S.A

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

550

France;Spain;Italy

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1531

EUCTR2006-005186-18-IT
(EUCTR)

08/02/2008

14/11/2007

Open-Label, 6-12 Months Safety and Efficacy Study of Levodopa ? Carbidopa Intestinal Gel in Levodopa-Responsive Subjects with Advanced Parkinson's Disease and Severe Motor-Fluctuations - ND

Parkinson Disease
MedDRA version: 9.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease

Trade Name: Duodopa gel intestinale
INN or Proposed INN: Levodopa
INN or Proposed INN: Carbidopa

Solvay Pharmaceuticals BV.

NULL

Not Recruiting

Female: yes
Male: yes

250

Portugal;Finland;Germany;United Kingdom;Czech Republic;Netherlands;Spain;Italy

1532

EUCTR2007-002195-34-FR
(EUCTR)

04/02/2008

07/12/2007

Evaluation of the effect of 6 months treatment with DC158AM on fatigue in patients with Parkinson’s disease. Multicentre, randomised, double-blind, placebo-controlled study in parallel groups.

Fatigue symptoms in Parkinson's disease.
MedDRA version: 9.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's

PIERRE FABRE MEDICAMENT

NULL

Not Recruiting

Female: yes
Male: yes

120

Phase 3

France

1533

NCT02236728
(ClinicalTrials.gov)

February 2008

10/9/2014

Observational Study in Parkinson's Disease of the Primary Care Population of Patients Treated With Pramipexole

Observational Study in Parkinson's Disease of the Primary Care Population of Patients Treated With Pramipexole by Neurologists in France (ETAP)

Parkinson Disease

Drug: Pramipexole

Boehringer Ingelheim

NULL

Completed

N/A

Both

497

N/A

NULL

1534

NCT00624741
(ClinicalTrials.gov)

February 2008

15/2/2008

Compassionate Use Study of Pergolide in Patients With Parkinson's Disease

Compassionate Use of Pergolide as Adjunctive Therapy to Levodopa/Carbidopa for Treating Parkinson's Disease

Parkinson Disease

Drug: Pergolide

Valeant Pharmaceuticals International, Inc.

NULL

No longer available

N/A

Both

N/A

NULL

1535

NCT00888186
(ClinicalTrials.gov)

February 2008

24/4/2009

Different Dyskinesias in Parkinson's Disease and Their Relation to Levodopa Pharmacokinetics

Parkinson Disease;Dyskinesias

Drug: levodopa /carbidopa

Uppsala University

Swedish Parkinson's Disease Foundation;Swedish Society for Medical Research

Completed

30 Years

90 Years

Both

Phase 4

Sweden

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1536

EUCTR2007-004235-37-ES
(EUCTR)

24/01/2008

08/03/2010

Long-term safety study of open-label pramipexole extended release(ER) in patients with advanced Parkinson’s disease (PD).Estudio abierto de seguridad a largo plazo de pramipexol de liberación prolongada (ER) en pacientes con enfermedad de Parkinson avanzada - Open label extension in advanced PD

Boehringer Ingelheim España, S.A.

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

390

Hungary;Czech Republic;United Kingdom;Spain;Italy;Poland;Austria;Sweden

1537

EUCTR2007-002467-27-GB
(EUCTR)

24/01/2008

26/11/2007

Antidyskinetic Properties of Topiramate: A Double-Blind, Placebo-Controlled Trial in Patients with Parkinson's Disease and Levodopa-Induced Dyskinesias - Antidyskinetic properties of topiramate

Patients with idiopathic Parkinson's disease and levodopa-induced dyskinesias
MedDRA version: 13.1;Level: PT;Classification code 10013916;Term: Dyskinesia;System Organ Class: 10029205 - Nervous system disorders
MedDRA version: 13.1;Classification code 10061536;Term: Parkinson's disease;Level: HLT;Classification code 10034005;Term: Parkinson's disease and parkinsonism;System Organ Class: 10029205 - Nervous system disorders

Product Name: Topiramate
INN or Proposed INN: TOPIRAMATE

Salford Royal NHS Foundation Trust

NULL

Not Recruiting

Female: yes
Male: yes

United Kingdom

1538

EUCTR2006-005186-18-ES
(EUCTR)

23/01/2008

29/11/2007

Open-Label, 6-12 Months Safety and Efficacy Study of Levodopa – Carbidopa Intestinal Gel in Levodopa-Responsive Subjects with Advanced Parkinson's Disease and Severe Motor-FluctuationsEstudio abierto de 6-12 meses de duración que evaluará la seguridad y eficacia de un gel intestinal de Levodopa-Carbidopa en pacientes con enfermedad de Parkinson avanzada que responde a Levodopa y fluctuaciones motoras severas -

Treatment of levodopa-responsive Parkinson's subjects with severe motor fluctuations.Tratamiento de la enfermedad de Parkinson avanzada que responde a Levidopa con fluctuaciones motoras severas
MedDRA version: 9.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's

Solvay Pharmaceuticals B.V.

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

250

Portugal;Finland;Germany;United Kingdom;Czech Republic;Netherlands;Spain;Italy

1539

EUCTR2007-000350-31-FR
(EUCTR)

22/01/2008

25/10/2007

A 76-week prospective, open-label, multicenter study to evaluate the long-term effect of Exelon® capsule and transdermal patch on worsening of the underlying motor symptoms of PD in patients with mild to moderately severe dementia associated with Parkinson’s disease (PDD).

Mild to moderately severe dementia associated with Parkinson’s disease (PDD).
MedDRA version: 9.1;Level: LLT;Classification code 10012284;Term: Dementia due to Parkinson's disease

Novartis Pharma AG

NULL

Not Recruiting

Female: yes
Male: yes

550

France;Spain;Italy

1540

EUCTR2007-004235-37-CZ
(EUCTR)

21/01/2008

18/12/2007

Long-term safety study of open-label pramipexole extended release(ER) in patients with advanced Parkinson’s disease (PD). - Open label extension in advanced PD

Boehringer Ingelheim Pharma Ges mbH

NULL

Not Recruiting

Female: yes
Male: yes

390

Hungary;United Kingdom;Czech Republic;Spain;Italy;Poland;Austria;Sweden

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1541

EUCTR2007-004234-16-CZ
(EUCTR)

21/01/2008

18/12/2007

Long-term safety study of open-label pramipexole extended release(ER) in patients with early Parkinson’s disease (PD).

Male or female patients with early idiopathic Parkinson´s disease (PD) with Modified Hoehn and Yahr stage I-III.
MedDRA version: 9.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease

Boehringer Ingelheim RCV GmbH & Co KG

NULL

Not Recruiting

Female: yes
Male: yes

520

Finland;Hungary;Czech Republic;Netherlands;France;Austria

1542

EUCTR2006-006752-35-IT
(EUCTR)

21/01/2008

24/04/2007

PHASE 3B, MULTICENTER, MULTINATIONAL, DOUBLE-BLIND, PLACEBO-CONTROLLED, 2-ARM TRIAL TO EVALUATE THE EFFECT OF THE 24-HOUR TRANSDERMAL DELIVERY OF ROTIGOTINE ON THE CONTROL OF EARLY MORNING MOTOR FUNCTION, SLEEP QUALITY, NOCTURNAL SYMPTOMS, AND NON-MOTOR SYMPTOMS IN SUBJECTS WITH IDIOPATHIC PARKINSON S DISEASE - RECOVER

Idiopathic Parkinson Disease
MedDRA version: 9.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease

Trade Name: Neupro
Trade Name: Neupro
Trade Name: Neupro
Trade Name: Neupro

SCHWARZ PHARMA

NULL

Not Recruiting

Female: yes
Male: yes

336

Phase 3B

Hungary;Finland;Spain;Austria;Germany;United Kingdom;Italy

1543

EUCTR2007-002964-90-ES
(EUCTR)

18/01/2008

30/11/2007

A phase III, double-blind, placebo-controlled, randomised trial to determine the efficacy and safety of a dose range of 50 to 100 mg/day of safinamide, as add-on therapy, in subjects with idiopathic Parkinson’s Disease with motor fluctuations, treated with a stable dose of levodopa and who may be receivingconcomitant treatment with stable doses of a dopamine agonist, an anticholinergic and/or amantadine.Ensayo fase III aleatorizado, doble ciego y controlado con placebo, para determinar la eficacia y la seguridad de un rango de dosis de 50 - 100 mg/día de safinamida, como terapia añadida, en pacientes con enfermedad de Parkinson idiopática con fluctuaciones motoras tratados con una dosis estable de levodopa y que podrían estar recibiendo tratamiento concomitante con dosis estables de un agonista de la dopamina, un anticolinérgico y/o amantadina. - Safinamide in IPD with motor fluctuations, as add-on to levodopa

Ideopathic Parkinson's Disease Enfermedad de Parkinson Idiopática
MedDRA version: 9.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease

Product Name: Safinamide
Product Code: NW-1015
INN or Proposed INN: Safinamide
Product Name: Safinamide
Product Code: NW-1015
INN or Proposed INN: Safinamide

Merck Serono International S.A.

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

1121

Phase 3

Hungary;Finland;Czech Republic;United Kingdom;Germany;Netherlands;Belgium;Estonia;France;Spain;Austria

1544

EUCTR2007-002963-28-ES
(EUCTR)

17/01/2008

16/11/2007

A phase III, double-blind, placebo-controlled randomised trial to determine the efficacy and safety of a low (50 mg/day) and high (100 mg/day) dose of safinamide, as add-on therapy, in subjects with early idiopathic Parkinson’s Disease treated with a stable dose of a single dopamine agonist.Ensayo en fase III aleatorizado, doble ciego y controlado con placebo, para determinar la eficacia y la seguridad de una dosis baja (50 mg/día) y una alta (100 mg/día) de safinamida, como terapia añadida en pacientes con enfermedad de Parkinson idiopática precoz tratados con una dosis estable de un único agonista de la dopamina. - Safinamide in early IPD, as add-on to dopamine agonist

Idiopathic Parkinson's DiseaseEnfermedad de Parkinson Idiopática
MedDRA version: 9.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease

Product Name: Safinamide
Product Code: NW-1015
INN or Proposed INN: Safinamide
Product Name: Safinamide
Product Code: NW-1015
INN or Proposed INN: Safinamide

Merck Serono International S.A.

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

1036

Phase 3

Portugal;Finland;Germany;Czech Republic;Bulgaria;Spain;Italy;Poland

1545

EUCTR2007-004234-16-SK
(EUCTR)

14/01/2008

18/04/2008

Long-term safety study of open-label pramipexole extended release(ER) in patients with early Parkinson’s disease (PD).

Male or female patients with early idiopathic Parkinson´s disease (PD) with Modified Hoehn and Yahr stage I-III.
MedDRA version: 9.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease

Boehringer Ingelheim RCV GmbH & Co KG

NULL

Not Recruiting

Female: yes
Male: yes

520

Phase 3

France;Hungary;Czech Republic;Slovakia;Finland;Austria;Netherlands

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1546

EUCTR2007-004235-37-SK
(EUCTR)

14/01/2008

16/04/2008

Long-term safety study of open-label pramipexole extended release(ER) in patients with advanced Parkinson’s disease (PD). - Open label extension in advanced PD

Boehringer Ingelheim RCV GmbH & Co KG

NULL

Not Recruiting

Female: yes
Male: yes

390

Phase 3

Hungary;Czech Republic;Slovakia;Spain;Poland;Austria;Italy;United Kingdom;Sweden

1547

EUCTR2007-004234-16-FR
(EUCTR)

11/01/2008

19/11/2007

Long-term safety study of open-label pramipexole extended release(ER) in patients with early Parkinson’s disease (PD).

Male or female patients with early idiopathic Parkinson´s disease (PD) with Modified Hoehn and Yahr stage I-III.
MedDRA version: 9.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease

BOEHRINGER INGELHEIM

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

520

Finland;Hungary;Czech Republic;Netherlands;France;Austria

1548

NCT00623324
(ClinicalTrials.gov)

January 2008

14/2/2008

The Effects of Aplindore on the Treatment of Signs and Symptoms of Parkinson's Disease

A Phase II, Dose Ranging, Randomized, Double Blind, Placebo-controlled, Multi-center, Pilot Study to Assess the Safety, Tolerability, Efficacy and Pharmacokinetics of Aplindore in Patients With Early Stage Parkinson's Disease

Early Stage Parkinson's Disease

Drug: Aplindore;Drug: Placebo

Ligand Pharmaceuticals

NULL

Completed

30 Years

N/A

Both

Phase 2

United States

1549

NCT00335153
(ClinicalTrials.gov)

January 2008

8/6/2006

Levodopa-Carbidopa Intestinal Gel Open-Label Study in Advanced Parkinson's Disease

An Open-Label, 12-Month Safety and Efficacy Study of Levodopa - Carbidopa Intestinal Gel in Levodopa-Responsive Subjects With Advanced Parkinson's Disease and Severe Motor Fluctuations Despite Optimized Treatment With Available Parkinson's Disease Medications

Advanced Parkinson's Disease

Drug: Levodopa -carbidopa intestinal gel;Device: CADD-Legacy® 1400 ambulatory infusion pump;Device: PEG tube;Device: J-tube

AbbVie (prior sponsor, Abbott)

Quintiles, Inc.

Completed

30 Years

N/A

All

354

Phase 3

United States;Australia;Canada;Czech Republic;Finland;Germany;Israel;Italy;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Spain;Thailand;United Kingdom;Greece

1550

NCT00627588
(ClinicalTrials.gov)

January 2008

31/1/2008

Phase I/II Study of the Safety, Efficacy and Dose Evaluation of ProSavin for the Treatment of Bilateral Idiopathic Parkinson's Disease

A Phase I/II Study of the Safety, Efficacy and Dose Evaluation of ProSavin®, Administered Using Stereotactic Injection to the Striatum of Patients With Bilateral, Idiopathic Parkinson's Disease.

Parkinson's Disease

Biological: ProSavin

Oxford BioMedica

NULL

Completed

48 Years

65 Years

Both

Phase 1;Phase 2

France;United Kingdom

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1551

NCT00608231
(ClinicalTrials.gov)

January 2008

7/1/2008

Dexmedetomidine Effects on Microelectrode Recording in Deep Brain Stimulation

Parkinson's Disease;Essential Tremor;Dystonia

Drug: Dexmedetomidine Hydrochloride Infusion;Drug: Normal Saline

Vanderbilt University

NULL

Withdrawn

18 Years

N/A

Both

Phase 2;Phase 3

United States

1552

NCT00664209
(ClinicalTrials.gov)

January 2008

21/4/2008

Treating H. Pylori in Parkinson's Patients With Motor Fluctuations

Helicobacter Pylori Eradication and Motor Fluctuations in Parkinson's Disease

Parkinson's Disease;Helicobacter Infections;Motor Fluctuations

Drug: clartihromycin, amoxicillin, and omeprazole;Drug: placebo

University of California, Los Angeles

Michael J. Fox Foundation for Parkinson's Research

Terminated

N/A

Male

Phase 3

United States

1553

NCT00562198
(ClinicalTrials.gov)

January 2008

19/11/2007

PET-Study: Effects of Single Doses of Stalevo and Levodopa/Carbidopa on Striatal 11C-Raclopride Binding

Effects of Single Doses of Stalevo 200 and Levodopa/Carbidopa 200/50mg on Striatal 11C-Raclopride Binding Potential in Parkinson's Disease Patients With Wearing-Off Symptoms;an Open, Randomised, Active-Controlled,Two-Period Crossover Study.

Parkinson´s Disease

Drug: entacapone and carbidopa;Drug: Sinemet 200mg/50mg

Orion Corporation, Orion Pharma

NULL

Terminated

45 Years

80 Years

Both

Phase 2

Finland

1554

NCT00725478
(ClinicalTrials.gov)

January 2008

28/7/2008

SEDPARK1: Safety and Efficacy Study With the Non-ergot Dopamine-agonist Piribedil in Parkinson's Disease

Stabilization on, or Change-over to the Non-ergot Dopamine Agonist Piribedil in Patients With Morbus Parkinson - a Post Marketing Surveillance Study in Parkinson Clinic Ambulances and Larger Private Practices.

Parkinson's Disease

Drug: Piribedil

Desitin Arzneimittel GmbH

NULL

Completed

18 Years

N/A

Both

250

N/A

NULL

1555

NCT00601523
(ClinicalTrials.gov)

January 2008

15/1/2008

Long-term Safety Study of Open-label Pramipexole Extended Release (ER) in Patients With Early Parkinson´s Disease (PD).

Parkinson Disease

Drug: Placebo;Drug: Pramipexole

Boehringer Ingelheim

NULL

Completed

30 Years

N/A

All

511

Phase 3

United States;Austria;Czech Republic;Finland;France;Germany;Hungary;India;Japan;Malaysia;Netherlands;Russian Federation;Slovakia;Taiwan;Ukraine;Argentina

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1556

NCT01628965
(ClinicalTrials.gov)

January 2008

25/6/2012

A Long-Term Extension Trial From Phase II/III of SPM 962 in Early Parkinson's Disease Patients

An Open-label Long-term Extension Trial From Phase II/III of SPM962 (243-07-001) in Early Parkinson's Disease Patients With Non-concomitant Treatment of L-dopa

Parkinson's Disease

Drug: SPM 962

Otsuka Pharmaceutical Co., Ltd.

NULL

Completed

N/A

All

143

Phase 2;Phase 3

Japan

1557

NCT00612872
(ClinicalTrials.gov)

January 2008

16/1/2008

Evaluation of [123I]CLINDE and SPECT as a Marker of Inflammation in Subjects With PD or AD and in Healthy Subjects

Evaluation of [123I]CLINDE and SPECT as a Marker of Inflammation in Subjects With Parkinson Disease or Alzheimer Disease and in Healthy Subjects

Parkinson Disease;Alzheimer Disease;Healthy Controls;Multiple Sclerosis

Drug: [123I]CLINDE

Institute for Neurodegenerative Disorders

NULL

Terminated

30 Years

50 Years

All

Phase 1

United States

1558

NCT00600093
(ClinicalTrials.gov)

January 2008

13/1/2008

Perioperative Treatment of Parkinsonian Patients With Parenteral Amantadine

Parkinson Disease;Perioperative Care

Drug: Amantadine

Rabin Medical Center

NULL

Terminated

N/A

Both

Phase 2

Israel

1559

NCT00623103
(ClinicalTrials.gov)

January 2008

14/2/2008

Long-term Safety of Rivastigmine Capsule and Patch in Patients With Mild to Moderately-severe Dementia Associated With Parkinson's Disease (PDD)

A 76-week Prospective, Open-label, Multicenter Study to Evaluate the Long-term Effect of Rivastigmine Capsule and Transdermal Patch on Worsening of the Underlying Motor Symptoms of PD in Patients With Mild to Moderately Severe Dementia Associated With Parkinson's Disease (PDD)

Parkinson's Disease Dementia

Drug: Rivastigmine capsule;Drug: Rivastigmine transdermal patch

Novartis

NULL

Completed

50 Years

85 Years

All

583

Phase 3

United States;Argentina;Australia;Austria;Belgium;Canada;France;Germany;Italy;Netherlands;Spain;Turkey;United Kingdom

1560

EUCTR2006-003732-30-IT
(EUCTR)

31/12/2007

13/02/2008

Transdermal Use of Lisuride in Early ParkinsonŽs Disease: A double blind, randomized, Placebo and Pramipexole controlled study to evaluate the efficacy and safety of Lisuride TTS - Tulep I

Diagnosys of Early-stage idiopathic Parkinson's Disease for longest 1 year
MedDRA version: 9.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease

Product Name: lisuride TTS
INN or Proposed INN: Lisuride
Trade Name: mirapexin
INN or Proposed INN: Pramipexole

NEUROBIOTEC GMBH

NULL

Not Recruiting

Female: yes
Male: yes

350

Germany;Italy;Poland

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1561

EUCTR2007-004400-12-ES
(EUCTR)

27/12/2007

03/01/2008

ENSAYO RANDOMIZADO A DOBLE CIEGO Y CONTROLADO CON PLACEBO DE RASAGILINA EN PACIENTES CON ENFERMEDAD DE PARKINSON Y SINTOMAS DE APATIA - Rasagiline and Apathy

Apatía en la Enfermedad de Parkinson
MedDRA version: 9.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease

Trade Name: Azilect
INN or Proposed INN: RASAGILINE

Institut de Recerca de l'Hospital de la santa Creu i Sant Pau

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

Spain

1562

EUCTR2007-004654-81-GB
(EUCTR)

20/12/2007

16/10/2007

A phase IIa study to evaluate the relative efficacy and safety/tolerability of a single agent vs. a combination treatment for reducing saliva secretion in Parkinson’s disease patients

Sialorrhoea associated with Parkinson's Disease
MedDRA version: 9.1;Level: LLT;Classification code 10059812;Term: Sialorrhoea

Trade Name: Catapres ampoules
INN or Proposed INN: Clonidine hydrochloride
Trade Name: Ditropan elixir
INN or Proposed INN: Oxybutynin hydrochloride

Summit (Cambridge) Ltd.

NULL

Not Recruiting

Female: yes
Male: yes

Phase 2a

United Kingdom

1563

EUCTR2007-000801-30-HU
(EUCTR)

20/12/2007

15/11/2007

Parkinson's Disease
MedDRA version: 9.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's

Product Name: E2007
Product Code: MARS

Eisai Limited

NULL

Not Recruiting

Female: yes
Male: yes

726

Hungary;Czech Republic;France;Estonia;Spain;Italy;Latvia;Poland;Lithuania

1564

EUCTR2006-006907-35-IT
(EUCTR)

19/12/2007

20/04/2007

A multicenter, multinational, phase 3b, open label extension trial, to evaluate the long term effect of the 24 hour transdermal delivery of rotigotine on motor function, sleep quality, and nocturnal and non motor symptoms in subjects with idiopathic Parkinson disease. - SP915, Long term extension of RECOVER

Patient with Idiopathic Parkinson Diesease
MedDRA version: 9.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease

Product Name: rotigotine
INN or Proposed INN: rotigotine

SCHWARZ PHARMA

NULL

Not Recruiting

Female: yes
Male: yes

270

Phase 3b

Hungary;Finland;United Kingdom;Germany;Spain;Italy;Austria

1565

EUCTR2004-000185-12-GB
(EUCTR)

13/12/2007

11/02/2005

A long term, double-blind, randomized, parallel-group, carbidopa/levodopa controlled, multi-center study to evaluate the effect of Stalevo® in patients with Parkinson’s disease requiring initiation of levodopa therapy. - STRIDE-PD

Parkinson's disease
MedDRA version: 7.0;Level: LLT;Classification code 10061536

Orion Corporation, ORION PHARMA, 02200 Espoo, Finland

NULL

Not Recruiting

Female: yes
Male: yes

740

Phase 3

Finland;Austria;Italy;United Kingdom;Sweden

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1566

EUCTR2007-002963-28-FI
(EUCTR)

12/12/2007

18/10/2007

A trial to determine the efficacy and safety of a low (50mg/day) and high (100mg/day) dose of safinamide, as add-on therapy, in patients with early Parkinson's Disease treated with a single dopamine agonist.

Idiopathic Parkinson's Disease
MedDRA version: 14.1;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders

Product Name: Safinamide
Product Code: NW-1015
INN or Proposed INN: Safinamide
Product Name: Safinamide
Product Code: NW-1015
INN or Proposed INN: Safinamide

Newron Pharmaceuticals SpA

NULL

Not Recruiting

Female: yes
Male: yes

839

Phase 3

Portugal;United States;Finland;Spain;Chile;Colombia;Italy;India;Czech Republic;Mexico;Canada;Argentina;Poland;Brazil;Croatia;Bulgaria;South Africa;Germany

1567

EUCTR2007-002964-90-NL
(EUCTR)

11/12/2007

Ideopathic Parkinson's Disease
MedDRA version: 9.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease

Product Name: Safinamide
Product Code: NW-1015
INN or Proposed INN: Safinamide
Product Name: Safinamide
Product Code: NW-1015
INN or Proposed INN: Safinamide

Merck Serono International S.A.

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

1121

Phase 3

Hungary;Finland;Czech Republic;United Kingdom;Germany;Netherlands;Belgium;Estonia;France;Spain;Austria

1568

EUCTR2007-002964-90-SK
(EUCTR)

06/12/2007

16/04/2008

Idiopathic Parkinson's Disease
MedDRA version: 9.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease

Product Name: Safinamide
Product Code: NW-1015
INN or Proposed INN: Safinamide
Product Name: Safinamide
Product Code: NW-1015
INN or Proposed INN: Safinamide

Merck Serono S.A. - Geneva

NULL

Not Recruiting

Female: yes
Male: yes

540

Phase 3

France;Czech Republic;Estonia;Hungary;Slovakia;Finland;Spain;Belgium;Austria;Germany;Netherlands;United Kingdom

1569

EUCTR2007-002963-28-SK
(EUCTR)

06/12/2007

16/04/2008

Idiopathic Parkinson's Disease
MedDRA version: 9.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease

Product Name: Safinamide
Product Code: NW-1015
INN or Proposed INN: Safinamide
Product Name: Safinamide
Product Code: NW-1015
INN or Proposed INN: Safinamide

Merck Serono S.A. - Geneva

NULL

Not Recruiting

Female: yes
Male: yes

839

Phase 3

Portugal;Czech Republic;Slovakia;Finland;Poland;Spain;Bulgaria;Germany;Italy

1570

EUCTR2007-002964-90-FI
(EUCTR)

04/12/2007

18/10/2007

Ideopathic Parkinson's Disease
MedDRA version: 9.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease

Product Name: Safinamide
Product Code: NW-1015
INN or Proposed INN: Safinamide
Product Name: Safinamide
Product Code: NW-1015
INN or Proposed INN: Safinamide

Merck Serono International S.A.

NULL

Not Recruiting

Female: yes
Male: yes

1121

Phase 3

Hungary;Finland;Czech Republic;United Kingdom;Germany;Netherlands;Belgium;Estonia;France;Spain;Austria

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1571

NCT00526630
(ClinicalTrials.gov)

December 2007

5/9/2007

Methylphenidate for the Treatment of Gait Impairment in Parkinson's Disease

Methylphenidate for the Treatment of Gain Impairment in Parkinson's Disease: a Randomized Double-Blind, Placebo-Controlled, Cross-over Study

Parkinson's Disease;Gait Impairment

Drug: Methylphenidate (MPD);Drug: Placebo

University of Cincinnati

Michael J. Fox Foundation for Parkinson's Research

Completed

35 Years

85 Years

All

Phase 4

United States

1572

NCT00577460
(ClinicalTrials.gov)

December 2007

19/12/2007

Long-term Safety Study of Open-label Pramipexole ER in Patients With Advanced PD

Long-term Safety Study of Open-label Pramipexole Extended Release (ER) in Patients With Advanced Parkinson's Disease (PD)

Parkinson Disease

Drug: Pramipexole;Drug: Placebo

Boehringer Ingelheim

NULL

Completed

32 Years

N/A

All

391

Phase 3

Austria;Czech Republic;Hungary;India;Italy;Korea, Republic of;Philippines;Poland;Russian Federation;Slovakia;Spain;Sweden;Ukraine;United Kingdom

1573

NCT00584025
(ClinicalTrials.gov)

December 2007

21/12/2007

Keppra IV for the Treatment of Motor Fluctuations in Parkinson's Disease

Parkinson's Disease

Drug: levetiracetam;Drug: Placebo

University of South Florida

NULL

Withdrawn

30 Years

80 Years

All

Phase 4

United States

1574

EUCTR2007-000801-30-ES
(EUCTR)

29/11/2007

12/09/2007

A Multi-centre, Open Label Extension Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of E2007 as an Adjunctive Therapy in Levodopa Treated Parkinson's Disease Subjects with Motor FluctuationsEstudio de extensión abierto y multicéntrico para la evaluación a largo plazo de la seguridad, la tolerabilidad y la eficacia de E2007 como tratamiento complementario en pacientes con enfermedad de Parkinson tratados con levodopa que padecen fluctuaciones motoras

Parkinson's DiseaseEnfermedad de Parkinson
MedDRA version: 9.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's

Product Name: E2007
Product Code: MARS

Eisai Limited

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

726

Hungary;Czech Republic;France;Estonia;Spain;Italy;Latvia;Poland;Lithuania

1575

EUCTR2007-004985-41-SE
(EUCTR)

29/11/2007

10/10/2007

Different dyskinesias in Parkinson's disease and their relation to levodopa pharmacokinetics - The dyskinesia study

Parkinson's disease, G20.9. Different dyskinesias related to advanced Parkinson's disease will be investigated.

Trade Name: Duodopa
INN or Proposed INN: levodopa
INN or Proposed INN: carbidopa

Department of Neuroscience, neurology

NULL

Not Recruiting

Female: yes
Male: yes

Sweden

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1576

NCT00537017
(ClinicalTrials.gov)

November 23, 2007

27/9/2007

Follow Up Safety Study of SCH 420814 in Subjects With Parkinson's Disease (P05175)

A Phase 2, 36-Week, Open-Label, Uncontrolled Safety Follow-up Study Assessing SCH 420814 (Preladenant) 5 mg BID (P05175)

Parkinson Disease;Neurodegenerative Diseases;Central Nervous System Diseases;Movement Disorders;Brain Diseases

Drug: Preladenant;Drug: L-dopa;Drug: Other Parkinson's Disease treatments

Merck Sharp & Dohme Corp.

NULL

Completed

30 Years

N/A

All

140

Phase 2

Argentina;Australia;Canada;Chile;Colombia;France;Guatemala;Hong Kong;Singapore;Spain;United States

1577

EUCTR2006-005186-18-FI
(EUCTR)

16/11/2007

04/10/2007

Open-Label, 6-12 Months Safety and Efficacy Study of Levodopa – Carbidopa Intestinal Gel in Levodopa-Responsive Subjects with Advanced Parkinson's Disease and Severe Motor-Fluctuations

Treatment of levodopa-responsive Parkinson's subjects with severe motor fluctuations.
MedDRA version: 9.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's

Solvay Pharmaceuticals B.V.

NULL

Not Recruiting

Female: yes
Male: yes

250

Portugal;Czech Republic;Finland;Spain;Germany;Netherlands;United Kingdom;Italy

1578

EUCTR2007-002906-23-GB
(EUCTR)

14/11/2007

15/08/2007

A Multi-Center, Placebo-Controlled, Double-Blind Trial To Examine the Safety and Efficacy of ACP-103 in the Treatment of Psychosis in Parkinson's Disease

Psychosis in Parkinson's Disease
MedDRA version: 9.1;Level: LLT;Classification code 10037241;Term: Psychosis NOS

Product Name: Pimavanserin tartrate
Product Code: ACP-103
INN or Proposed INN: Pimavanserin tartrate

Acadia Pharmaceuticals Inc

NULL

Not Recruiting

Female: yes
Male: yes

280

United Kingdom;Bulgaria;France

1579

EUCTR2007-002496-14-FI
(EUCTR)

05/11/2007

14/09/2007

Effects of single doses of Stalevo 200 and levodopa/carbidopa 200/50 mg on striatal 11C-raclopride binding potential in Parkinson’s disease patients with wearing-off symptoms. An open, randomised, active-controlled, two-period crossover study.

Parkinson’s disease
MedDRA version: 9.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease

Product Name: Stalevo®
INN or Proposed INN: Levodopa
INN or Proposed INN: Carbidopa
INN or Proposed INN: Entacapone
Trade Name: Sinemet®
INN or Proposed INN: Levodopa
INN or Proposed INN: Carbidopa
Product Name: 11C-Raclopride
Other descriptive name: 11C-Raclopride

Orion Corporation Orion Pharma

NULL

Not Recruiting

Female: yes
Male: yes

Finland

1580

ChiCTR-TRC-07000027

2007-11-01

2007-11-09

A randomized controlled clinical study of Pramipexole for Parkinson's disease

Primary Parkinson's disease

Group 1:Artane oral 1-2mg, tid,+ Mirapexin, 0.25 mg/d at beginning, and add to 1.0 mg/d at the end of the second week; the dose will be added from the second weekend to the eighth week to 4. 5 mg/d(1.5 mg, tid); maintain the dose during 12 weeks and reduce the dose during 1-4weeks;Group 3:Artane oral 1-2mg, tid + Madopar, 62.5~500 mg, 2~4 times a day depends on the serious of disease + Mirapexin, the dose is same as group 1;Group 2:Artane oral 1-2mg, tid+ Benserazide-Levodopa (Madopar), oral 62.5~500 mg, 2~4 times a day depends on the serious of the disease;

First Affiliated Hospital of Xinjiang Medical University

NULL

Completed

Both

Group 1:45;Group 3:45;Group 2:45;

China

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1581

NCT00584090
(ClinicalTrials.gov)

November 2007

21/12/2007

Solifenacin Succinate (VESIcare) for the Treatment of Urinary Incontinence in Parkinson's Disease

Urinary Incontinence;Parkinson's Disease

Drug: Solifenacin Succinate (VESIcare);Drug: Placebo

University of South Florida

NULL

Withdrawn

30 Years

80 Years

Both

Phase 4

United States

1582

NCT00605683
(ClinicalTrials.gov)

November 2007

19/12/2007

MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist

A Phase III, Double-blind, Placebo-controlled Randomised Trial to Determine the Efficacy and Safety of a Low (50 mg/Day) and High (100 mg/Day) Dose of Safinamide, as add-on Therapy, in Subjects With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist

Idiopathic Parkinson's Disease

Drug: Safinamide (as add-on therapy)

Newron

NULL

Completed

30 Years

80 Years

Both

679

Phase 3

United States;Argentina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;Germany;India;Italy;Mexico;Peru;Poland;Portugal;Slovakia;South Africa;Spain;Israel

1583

NCT00632762
(ClinicalTrials.gov)

November 2007

20/2/2008

Long-Term Effects of Amantadine in Parkinsonian (AMANDYSK)

Evaluation of the Long-term Effects of Amantadine in Parkinsonian's Suffering From Dyskinesia Induced by Levodopa: Study Randomised Double-blind, Placebo - Cessation of a Chronic Prescription. STUDY AMANDYSK.

Parkinson's Disease

Drug: mantadix

University Hospital, Toulouse

NULL

Completed

30 Years

80 Years

Both

Phase 4

France

1584

NCT00560508
(ClinicalTrials.gov)

November 2007

16/11/2007

A 12-week Study of Pramipexole Extended Release (ER) in Patients With Parkinson's Disease (PD), Followed by a 52-week Long-term Treatment Period

A Double-blind, Double-dummy, Randomised, Parallel-group Study to Investigate the Safety, Tolerability, Trough Plasma Concentration, and Efficacy of Pramipexole ER Versus Pramipexole Immediate Release (IR) Administered Orally for 12 Weeks in Patients With Parkinson's Disease (PD) on L-dopa Therapy, Followed by a 52-week Open-label Long-term Treatment Period to Evaluate the Long-term Safety and Efficacy of Pramipexole ER

Parkinson Disease

Drug: Pramipexole Immediate Release;Drug: Pramipexole Extended Release

Boehringer Ingelheim

NULL

Completed

1 Year

N/A

All

112

Phase 2;Phase 3

Japan

1585

NCT01301651
(ClinicalTrials.gov)

November 2007

18/2/2011

Effects of Virtual Reality Training in Patients With Parkinson's Disease

Effects of Virtual Reality Augmented Balance Training for Postural Control in Patients With Parkinson's Disease

Parkinson's Disease

Behavioral: balance training

National Taiwan University Hospital

National Science Council, Taiwan

Completed

50 Years

80 Years

Both

Phase 1

Taiwan

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1586

NCT00558337
(ClinicalTrials.gov)

November 2007

12/11/2007

Efficacy, Safety, and Pharmacokinetics/Pharmacodynamic Study of L-Dopa/Carbidopa To Treat Parkinson's Disease

An Efficacy, Safety, and Pharmacokinetics/Pharmacodynamic Relationship Study of L-Dopa/Carbidopa in a Novel Release Formulation in Parkinson's Disease Patients

Parkinson's Disease

Drug: levodopa -carbidopa

Osmotica Pharmaceutical Corp.

NULL

Completed

30 Years

80 Years

Both

Phase 2

Argentina

1587

NCT00610103
(ClinicalTrials.gov)

November 2007

22/1/2008

Phase 2 Clinical Study of KW-6500 in Parkinson's Disease Patients With Motor Response Complication on Levodopa Therapy

A Phase 2 Clinical Study of KW-6500 (Apomorphine Hydrochloride) in Patients With Parkinson's Disease

Parkinson's Disease

Drug: apomorphine hydrochloride

Kyowa Kirin Co., Ltd.

NULL

Completed

20 Years

N/A

All

Phase 2

Japan

1588

EUCTR2007-004234-16-NL
(EUCTR)

29/10/2007

17/10/2007

Long-term safety study of open-label pramipexole extended release(ER) in patients with early Parkinson’s disease (PD).

Male or female patients with early idiopathic Parkinson´s disease (PD) with Modified Hoehn and Yahr stage I-III.
MedDRA version: 9.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease

Boehringer Ingelheim bv

NULL

Not Recruiting

Female: yes
Male: yes

520

Finland;Hungary;Czech Republic;Netherlands;France;Austria

1589

EUCTR2007-001717-42-FR
(EUCTR)

25/10/2007

11/09/2007

A Phase 2, 36 Week, Open-Label, Uncontrolled Safety Follow-Up Study Assessing SCH 420814 5 mg BID - N/A

Patients with Moderate to Severe Parkinson's Disease Experiencing Motor Fluctuations and Dyskinesias

Product Name: SCH 420814
Product Code: N/A

Schering Plough Research Institute

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

200

Phase 2

France;Spain

1590

EUCTR2007-002906-23-FR
(EUCTR)

25/10/2007

21/08/2007

A Multi-Center, Placebo-Controlled, Double-Blind Trial To Examine the Safety and Efficacy of ACP-103 in the Treatment of Psychosis in Parkinson's Disease

Psychosis in Parkinson's Disease
MedDRA version: 9.1;Level: LLT;Classification code 10037241;Term: Psychosis NOS

Product Name: Pimavanserin tartrate
Product Code: ACP-103
INN or Proposed INN: Pimavanserin tartrate

Acadia Pharmaceuticals Inc

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

280

United Kingdom;Bulgaria;France

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1591

EUCTR2007-003353-90-NL
(EUCTR)

23/10/2007

07/08/2007

A double-blind, double-dummy, randomized, parallel groups study toassess the Efficacy, Safety and Tolerability of switching patients withearly Parkinson’s disease (PD) from Pramipexole IR to Pramipexole ERor Pramipexole IR.

Male or female patients with idiopathic Parkinson's disease diagnosed within 5 years, with a modified Hoehn and Yahr scale of 1 to 3.
MedDRA version: 9.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease

Boehringer Ingelheim

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

145

Germany;Netherlands;France

1592

EUCTR2007-000801-30-FR
(EUCTR)

22/10/2007

23/07/2007

Parkinson's Disease
MedDRA version: 9.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's

Product Name: E2007
Product Code: MARS

Eisai Limited

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

726

Hungary;Czech Republic;Estonia;France;Spain;Italy;Latvia;Poland;Lithuania

1593

EUCTR2007-003353-90-FR
(EUCTR)

17/10/2007

27/08/2007

BOEHRINGER INGELHEIM

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

145

Germany;Netherlands;France

1594

EUCTR2006-006907-35-GB
(EUCTR)

09/10/2007

26/04/2007

Long-term extension of RECOVER A MULTICENTER, MULTINATIONAL, PHASE 3B, OPEN-LABEL EXTENSION TRIAL TO EVALUATE THE LONG-TERM EFFECT OF THE 24-HOUR TRANSDERMAL DELIVERY OF ROTIGOTINE ON MOTOR FUNCTION, SLEEP QUALITY, AND NOCTURNAL AND NON-MOTOR SYMPTOMS IN SUBJECTS WITH IDIOPATHIC PARKINSON’S DISEASE - Long-term extension of RECOVER

Parkinson's disease
MedDRA version: 9.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease

Trade Name: Neupro 2mg/24h transdermal patch
Product Code: ND1587
INN or Proposed INN: Rotigotine
Trade Name: Neupro 4mg/24h transdermal patch
Product Code: ND1589
INN or Proposed INN: Rotigotine
Trade Name: Neupro 6mg/24h transdermal patch
Product Code: ND1590
INN or Proposed INN: Rotigotine
Trade Name: Neupro 8mg/24h transdermal patch
Product Code: ND1702
INN or Proposed INN: Rotigotine

Schwarz Biosciences GmbH, UCB Group

NULL

Not Recruiting

Female: yes
Male: yes

270

Phase 3

Hungary;Finland;Spain;Austria;Germany;Italy;United Kingdom

1595

EUCTR2005-005791-32-SE
(EUCTR)

04/10/2007

30/07/2007

Chemical Safety/Tolerability of HF0220 and its Effect on Biochemical Markers Relevant to Patients with a Diagnosis of Mild to Moderate Alzheimer's Disease.

HF0220 experimentally appears to exert its potential beneficial effects within the CNS and possibly other tissues by attenuating the adverse effects of oxidative stress. It is believed that this mechanism has the potential to reduce disease progression in a wide range of disorders of the nervous system, e.g. Alzheimer's and Parkinson's disease, and brain damage due to acute stroke and head injury. It may also apply to the protection of peripheral tissues, such as the heart and/or kidney.
MedDRA version: 9.1;Level: HLT;Classification code 10001897;Term: Alzheimer's disease (incl subtypes)

Product Name: HF0220
Product Code: HF0220
Other descriptive name: 7-beta-hydroxyepiandrosterone

Hunter-Fleming Ltd

NULL

Not Recruiting

Female: yes
Male: yes

United Kingdom;Sweden

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1596

EUCTR2007-002900-16-DE
(EUCTR)

01/10/2007

21/08/2007

A multi-centre, randomized, double-blind, placebo-controlled, parallel-group, multiple oral dose titration study in patients with Parkinson’s disease to assess the efficacy of AFQ056 in reducing L-dopa induced dyskinesias, and the safety and tolerability of AFQ056 in combination with L-dopa

The main objective of this study is to assess the efficacy of AFQ056 in reducing L-dopa induced dyskinesias.

Product Code: AFQ056
Product Code: AFQ056

Novartis Pharma Services AG

NULL

Not Recruiting

Female: yes
Male: yes

Germany

1597

NCT00558025
(ClinicalTrials.gov)

October 2007

12/11/2007

Overnight Switch Trial From Pramipexole IR to Pramipexole ER in Patients With Early Parkinson Disease

A Double-blind, Double-dummy, Randomized, Parallel Groups Study to Assess the Efficacy, Safety and Tolerability of Switching Patients With Early Parkinson's Disease (PD) From Pramipexole IR to Pramipexole ER or Pramipexole IR

Parkinson Disease

Drug: Pramipexole Extended Release;Drug: Pramipexole Immediate Release

Boehringer Ingelheim

NULL

Completed

30 Years

N/A

All

156

Phase 3

France;Germany;Netherlands

1598

NCT00559871
(ClinicalTrials.gov)

October 2007

15/11/2007

Safety and Efficacy Study of Fipamezole in Treatment of Motor Dysfunctions in Parkinson's Disease

A Phase II, Randomized, Double-Blind, Placebo-Controlled, Dose Response Study of the Efficacy, Safety and Tolerability of Fipamezole as an Oromucosal Fast Dissolving Tablet in the Treatment of Parkinson's Disease Patients.

Parkinson's Disease

Drug: fipamezole

Juvantia Pharma Ltd

Santhera Pharmaceuticals

Completed

30 Years

N/A

Both

180

Phase 2

United States;India

1599

NCT00642928
(ClinicalTrials.gov)

October 2007

21/3/2008

Dose Range Finding Study of BF2.649 Versus Placebo to Treat Excessive Daytime Sleepiness in Parkinson's Disease Patients

Randomized, Dose-finding Study of BF 2.649 5, 10 20 and 40 mg/d in Comparison to Placebo in Excessive Daytime Sleepiness in Parkinson's Disease Patients (PD)

Excessive Daytime Sleepiness;Parkinson's Disease

Drug: Placebo;Drug: BF 2.649 5 mg;Drug: BF 2.649 10 mg;Drug: BF 2.649 20 mg;Drug: BF 2.649 40 mg

Bioprojet

NULL

Completed

18 Years

N/A

Both

108

Phase 2

France

1600

NCT00582673
(ClinicalTrials.gov)

October 2007

21/12/2007

Efficacy and Safety of AFQ056 in Reducing L-dopa Induced Dyskinesias in Parkinson's Disease Patients, and Safety in Combination With L-dopa

A Multi-centre, Randomized, Double-blind, Placebo Controlled, Parallel-group, Multiple Oral Dose Titration Study in Patients With Parkinson's Disease to Assess the Efficacy of AFQ056 in Reducing L-dopa Induced Dyskinesias, and the Safety and Tolerability of AFQ056 in Combination With L-dopa

Parkinson's Disease

Drug: AFQ056;Drug: Placebo

Novartis

NULL

Completed

30 Years

85 Years

Both

Phase 2

Germany

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1601

NCT00547911
(ClinicalTrials.gov)

October 2007

19/10/2007

Augmenting Effects of L-DOPS With Carbidopa and Entacapone

L-Dihydroxyphenylserine (L-DOPS) for Norepinephrine Deficiency: Interactions With Carbidopa and Entacapone

Parkinson Disease;Multiple System Atrophy;Autonomic Nervous System Diseases

Drug: Droxidopa;Drug: Carbidopa;Drug: Entacapone

National Institute of Neurological Disorders and Stroke (NINDS)

NULL

Terminated

18 Years

N/A

All

Phase 1;Phase 2

United States

1602

NCT00566462
(ClinicalTrials.gov)

October 2007

29/11/2007

Assessment of Perampanel (E2007) on Synaptic Dopamine in Mild-moderate PD Patients: A Pilot Study With [^123I]-IBZM SPECT

Parkinson's Disease

Drug: perampanel;Drug: placebo

Eisai Inc.

NULL

Terminated

30 Years

N/A

All

Phase 2

United States

1603

NCT01520727
(ClinicalTrials.gov)

October 2007

18/1/2012

A Single Oral Ascending Dose Study of BIA 9-1067 in Healthy Male Subjects

A Single Oral Ascending Dose Study to Investigate the Safety, Pharmacokinetics and Catechol-O-methyltransferase (COMT) Inhibition Profiles of BIA 9-1067 in Healthy Male Subjects

Parkinson Disease

Drug: BIA 9-1067;Drug: Placebo

Bial - Portela C S.A.

NULL

Completed

18 Years

45 Years

Male

Phase 1

France

1604

EUCTR2006-002937-20-HU
(EUCTR)

20/09/2007

17/05/2007

A Multi-centre, Randomised, Double-blind, Placebo- and Entacapone-controlled, Parallel Group Study of the Efficacy, Safety and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients with Motor Fluctuations

Parkinson's Disease
MedDRA version: 8.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's

Product Name: E2007
Product Code: MARS
Trade Name: Comtess
Product Name: Entacapone

Eisai Limited

NULL

Not Recruiting

Female: yes
Male: yes

702

Hungary;Czech Republic;France;Estonia;Spain;Italy;Latvia;Lithuania

1605

EUCTR2007-002899-34-GB
(EUCTR)

18/09/2007

26/06/2007

Pilot Controlled Clinical Trial of Salvia Officinalis (Sage) for cognitive impairments in Parkinson's Disease

Cognitive impairment in Parkinson's Disease

Product Name: Sage leaf

Newcastle Upon tyne Hospitals NHS Foundation Trust

NULL

Not Recruiting

Female: yes
Male: yes

United Kingdom

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1606

EUCTR2007-002874-75-IT
(EUCTR)

10/09/2007

14/01/2008

Safety and effectivness of Open- Label Melperone in the treatment of Patients with Psycosis Associated with Parkinson's Disease'' - OV-1005

Psycosis associated to Parkinson's Disease
MedDRA version: 9.1;Level: HLT;Classification code 10027361;Term: Mental disorders due to a general medical condition NEC

Product Name: Melperon

OVATION PHARMACEUTICALS INC

NULL

Not Recruiting

Female: yes
Male: yes

Italy

1607

EUCTR2007-000801-30-LT
(EUCTR)

07/09/2007

05/07/2007

Parkinson's Disease
MedDRA version: 9.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's

Product Name: E2007
Product Code: MARS

Eisai Limited

NULL

Not Recruiting

Female: yes
Male: yes

726

Hungary;Czech Republic;France;Estonia;Spain;Italy;Latvia;Poland;Lithuania

1608

EUCTR2007-003353-90-DE
(EUCTR)

05/09/2007

08/08/2007

Boehringer Ingelheim Pharma GmbH & Co. KG

NULL

Not Recruiting

Female: yes
Male: yes

132

Germany;Netherlands;France

1609

NCT00537485
(ClinicalTrials.gov)

September 2007

27/9/2007

A Placebo-controlled Study for SPM 962 in Early Parkinson's Disease Patients

A Placebo-controlled Study for SPM 962 in Early Parkinson's Disease Patients With Non-concomitant Treatment of L-dopa

Early Parkinson's Disease

Drug: SPM 962;Drug: placebo

Otsuka Pharmaceutical Co., Ltd.

NULL

Completed

30 Years

79 Years

All

180

Phase 2;Phase 3

Japan

1610

NCT00524914
(ClinicalTrials.gov)

September 2007

4/9/2007

Apomorphine Effect on Nociceptive Perception in Parkinson's: a Clinical and Imaging Study

Apomorphine Effect on Nociceptive Perception in Parkinson's: a Clinical and Imaging Study.

Parkinson's Disease

Drug: apomorphine;Drug: placebo

University Hospital, Toulouse

NULL

Completed

30 Years

70 Years

Both

N/A

France

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1611

NCT00594464
(ClinicalTrials.gov)

September 2007

21/12/2007

A Trial of Neupro® (Rotigotine Transdermal Patch) in Patients With Parkinson's Disease Undergoing Surgery

An Explorative, Multicenter, Open-label Pilot Trial With Neupro® (Rotigotine Transdermal Patch) Once Daily Treatment Administered Perioperatively in Patients With Idiopathic Parkinson's Disease

Parkinson's Disease

Drug: Rotigotine

UCB Pharma

NULL

Completed

18 Years

80 Years

All

Phase 4

Germany

1612

EUCTR2007-000801-30-PL
(EUCTR)

29/08/2007

17/07/2007

Parkinson's Disease
MedDRA version: 9.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's

Product Name: E2007
Product Code: MARS

Eisai Limited

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

726

Hungary;Czech Republic;France;Estonia;Spain;Italy;Latvia;Poland;Lithuania

1613

EUCTR2007-003512-57-FR
(EUCTR)

24/08/2007

23/07/2007

Randomized, dose-finding study of BF 2.649 5, 10, 20 and 40 mg/d in comparison to placebo in Excessive Daytime Sleepiness in Parkinson’s Disease patients (PD)

Excessive daytime sleepiness associated to Parkinson disease
MedDRA version: 9.1;Level: LLT;Classification code 10041014;Term: Sleepiness
MedDRA version: 9.1;Classification code 10061536;Term: Parkinson's disease

Product Name: BF 2.649
Product Code: BF 2.649
Product Name: BF 2.649
Product Code: BF 2.649
Product Name: BF 2.649
Product Code: BF 2.649
Product Name: BF 2.649
Product Code: BF 2.649

Bioprojet

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

130

France

1614

EUCTR2007-000801-30-EE
(EUCTR)

22/08/2007

17/07/2007

Parkinson's Disease
MedDRA version: 9.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's

Product Name: E2007
Product Code: MARS

Eisai Limited

NULL

Not Recruiting

Female: yes
Male: yes

726

Hungary;Czech Republic;France;Estonia;Spain;Italy;Latvia;Poland;Lithuania

1615

EUCTR2006-000859-18-DE
(EUCTR)

13/08/2007

05/04/2007

An open label SLV308 safety extension to study S308.3.003 in early PD patients - An extension to the Vermeer study

Parkinson's Disease Early stage

Solvay pharmaceuticals

NULL

Not Recruiting

Female: yes
Male: yes

225

Portugal;Czech Republic;Germany;Netherlands;Estonia;Italy;Lithuania

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1616

EUCTR2007-000074-23-HU
(EUCTR)

10/08/2007

01/06/2007

Product Name: Pramipexole ER
Product Code: SND 919 CL2Y
INN or Proposed INN: Pramipexole
Product Name: Pramipexole ER
Product Code: SND 919 CL2Y
INN or Proposed INN: Pramipexole
Product Name: Pramipexole ER
Product Code: SND 919 CL2Y
INN or Proposed INN: Pramipexole
Product Name: Pramipexole ER
Product Code: SND 919 CL2Y
INN or Proposed INN: Pramipexole
Product Name: Pramipexole ER
Product Code: SND 919 CL2Y
INN or Proposed INN: Pramipexole
Trade Name: SIFROL
INN or Proposed INN: Pramipexole

Boehringer Ingelheim Pharma Ges mbH

NULL

Not Recruiting

Female: yes
Male: yes

516

Phase 1

Hungary;United Kingdom;Spain;Italy;Austria;Sweden

1617

EUCTR2007-000801-30-CZ
(EUCTR)

01/08/2007

15/06/2007

Parkinson's Disease
MedDRA version: 9.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's

Product Name: E2007
Product Code: MARS

Eisai Limited

NULL

Not Recruiting

Female: yes
Male: yes

726

Hungary;Czech Republic;France;Estonia;Spain;Italy;Latvia;Poland;Lithuania

1618

NCT01286935
(ClinicalTrials.gov)

August 2007

23/8/2010

18-month Study of Long-term Efficacy & Safety of Safinamide as add-on Therapy in Patients With Mid-late Stage PD

A Phase III, Double-blind, Placebo-controlled, 18-mon Ext Study Long-term Efficacy & Safety of 50 & 100mg/Day Doses of Safinamide, as add-on Therapy, in Idiopathic PD Pts With Motor Fluctuations, Treated With Levodopa, Who May be Receiving DA, and/or Anticholinergic

Parkinson's Disease

Drug: Safinamide;Drug: Placebo

Newron

NULL

Completed

30 Years

80 Years

Both

544

Phase 3

NULL

1619

NCT00442780
(ClinicalTrials.gov)

August 2007

1/3/2007

Dose-Finding Safety Study of BIIB014 in Early-Stage Parkinson's Disease

A Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study of Multiple Doses of BIIB014 Administered Orally in Subjects With Early Parkinson's Disease

Parkinson's Disease

Drug: BIIB014;Drug: Placebo

Biogen Idec

NULL

Completed

30 Years

N/A

Both

Phase 2

Israel;Poland;Serbia;Former Serbia and Montenegro

1620

NCT00335374
(ClinicalTrials.gov)

August 2007

8/6/2006

An Open Label SLV308 Safety Extension to Study S308.3.003 in Early PD Patients

Early Stage Parkinson's Disease

Drug: Pardoprunox

Solvay Pharmaceuticals

NULL

Completed

30 Years

N/A

Both

202

Phase 3

United States;Australia;Czech Republic;Estonia;Germany;India;Italy;Lithuania;Malaysia;Netherlands;Poland;Portugal;South Africa;Taiwan;Thailand;France;Spain;United Kingdom

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1621

NCT00407095
(ClinicalTrials.gov)

August 2007

30/11/2006

An Open Label SLV308 Safety Extension to Study S308.3.002 in Patients With Parkinson's Disease Experiencing Motor Fluctuations.

Advanced Stage Parkinson's Disease

Drug: Pardoprunox

Solvay Pharmaceuticals

NULL

Completed

30 Years

N/A

Both

140

Phase 3

United States;Albania;Argentina;Brazil;Bulgaria;Canada;Chile;Colombia;Latvia;Lithuania;Peru;Russian Federation;Ukraine

1622

EUCTR2007-000801-30-LV
(EUCTR)

27/07/2007

05/07/2007

Parkinson's Disease
MedDRA version: 9.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's

Product Name: E2007
Product Code: MARS

Eisai Limited

NULL

Not Recruiting

Female: yes
Male: yes

726

Hungary;Czech Republic;France;Estonia;Spain;Italy;Latvia;Poland;Lithuania

1623

EUCTR2006-006752-35-GB
(EUCTR)

23/07/2007

13/01/2009

RECOVER: RANDOMIZED EVALUATION OF THE 24-HOUR COVERAGE: EFFICACY OF ROTIGOTINE PHASE 3B, MULTICENTER, MULTINATIONAL, DOUBLE-BLIND, PLACEBO CONTROLLED, 2-ARM TRIAL TO EVALUATE THE EFFECT OF THE 24-HOUR TRANSDERMAL DELIVERY OF ROTIGOTINE ON THE CONTROL OF EARLY MORNING MOTOR FUNCTION, SLEEP QUALITY, NOCTURNAL SYMPTOMS, AND NON-MOTOR SYMPTOMS IN SUBJECTS WITH IDIOPATHIC PARKINSON’S DISEASE - Recover

Parkinson's disease
MedDRA version: 9.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease

Schwarz Biosciences GmbH, UCB Group

NULL

Not Recruiting

Female: yes
Male: yes

400

Phase 3

Hungary;Finland;Spain;Austria;Germany;Italy;United Kingdom

1624

EUCTR2007-000801-30-IT
(EUCTR)

17/07/2007

13/11/2007

Parkinson's Disease Subjects with Motor Fluctuations
MedDRA version: 6.1;Level: PT;Classification code 10061536

Product Name: E2007

EISAI LTD UK

NULL

Not Recruiting

Female: yes
Male: yes

726

Phase 3

France;Hungary;Estonia;Czech Republic;Spain;Poland;Lithuania;Latvia;Italy

1625

EUCTR2006-005318-11-FR
(EUCTR)

06/07/2007

10/05/2007

Effet de l'apomorphine sur la perception douloureuse chez le patient parkinsonien : étude clinique et en tomographie par émission de positons.

maladie de Parkinson
MedDRA version: 8.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's

Trade Name: APOKINON

CHU Toulouse

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

France

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1626

NCT00515437
(ClinicalTrials.gov)

July 2007

10/8/2007

A Multi-Center Study of MYOBLOC for the Treatment of Sialorrhea in Parkinson's Disease Patients

A Multi-Center, Randomized, Double-blind, Placebo-Controlled,Sequential Dose Escalation, Safety, Tolerability, and Preliminary Efficacy Study of MYOBLOC for the Treatment of Sialorrhea in Parkinson's Disease Patients

Drooling

Biological: Botulinum Toxin Type B (Myobloc);Biological: Matched placebo to Myobloc

Solstice Neurosciences

NULL

Completed

18 Years

85 Years

All

Phase 2

United States

1627

NCT00522379
(ClinicalTrials.gov)

July 2007

28/8/2007

Trial to Assess Parkinson's Disease (PD) Symptom Control to Four Doses of Rotigotine in a Transdermal Patch

A Multicenter, Randomized, Double-blind, Placebo-controlled, 5-arm, Parallel-group Trial to Assess Rotigotine Transdermal System Dose Response in Subjects With Advanced-stage Parkinson's Disease

Parkinson's Disease

Drug: Rotigotine;Other: Placebo

UCB Pharma

NULL

Completed

30 Years

N/A

All

514

Phase 3

United States;Chile;India;Mexico;Peru

1628

NCT00519532
(ClinicalTrials.gov)

July 2007

21/8/2007

Long-term Extension of RECOVER- Long-term Effect of the 24h Transdermal Delivery of Rotigotine in Subjects With Idiopathic Parkinson's Disease

A Multicenter, Multinational, Phase 3b, Open-label Extension Trial to Evaluate the Long-term Effect of the 24-hour Transdermal Delivery of Rotigotine on Motor Function, Sleep Quality, and Nocturnal and Non-motor Symptoms in Subjects With Idiopathic Parkinson's Disease

Parkinson's Disease

Drug: Rotigotine

UCB Pharma

NULL

Terminated

18 Years

N/A

All

Phase 3

United States;Australia;Finland;Germany;Hungary;Italy;New Zealand;Poland;South Africa;Spain;United Kingdom;Austria

1629

NCT00593606
(ClinicalTrials.gov)

July 2007

21/12/2007

Safety and Tolerability Trial of Switching From Ropinirole to Rotigotine

A Phase 3b, Open-Label, Multicenter Trial to Assess the Safety and Tolerability of Switching Korean Subjects From Ropinirole to the Rotigotine Transdermal System and Its Effect on Symptoms in Idiopathic Parkinson's Disease

Parkinson's Disease

Drug: Rotigotine

UCB Pharma

NULL

Completed

18 Years

N/A

All

124

Phase 3

NULL

1630

NCT00550238
(ClinicalTrials.gov)

July 2007

26/10/2007

A Study of the Safety and Tolerability of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis

A Multi-Center, Open-Label Extension Study to Examine the Safety and Tolerability of ACP-103 in the Treatment of Psychosis in Parkinson's Disease

Parkinson's Disease Psychosis

Drug: Pimavanserin tartrate (ACP-103)

ACADIA Pharmaceuticals Inc.

NULL

Completed

40 Years

N/A

All

459

Phase 3

United States;Austria;Belgium;Canada;France;India;Italy;Poland;Portugal;Russian Federation;Serbia;Sweden;Ukraine;United Kingdom

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1631

NCT00505622
(ClinicalTrials.gov)

July 2007

9/7/2007

Evaluation of the Long-term Safety, Tolerability, and Efficacy of Perampanel (E2007) as an Adjunctive Therapy in Levodopa Treated Parkinson's Disease Subjects With Motor Fluctuations

A Multi-centre, Open Label Extension Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Perampanel (E2007) as an Adjunctive Therapy in Levodopa Treated Parkinson's Disease Subjects With Motor Fluctuations

Parkinson's Disease

Drug: Perampanel

Eisai Limited

NULL

Terminated

30 Years

N/A

All

328

Phase 3

France

1632

NCT00556764
(ClinicalTrials.gov)

July 2007

8/11/2007

Development of Cognitive Assessment Tools in Parkinson Disease

Parkinson Disease

Drug: [123I] IBVM and SPECT imaging;Drug: Subjects will undergo the 123-I IBVM imaging visit

Institute for Neurodegenerative Disorders

Department of Defense;University of Oklahoma

Completed

30 Years

N/A

Both

Phase 0

United States

1633

EUCTR2006-006752-35-HU
(EUCTR)

22/06/2007

12/04/2007

Parkinson's disease
MedDRA version: 9.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease

Schwarz Biosciences GmbH

NULL

Not Recruiting

Female: yes
Male: yes

400

Phase 3B

Hungary;Finland;Spain;Austria;Germany;United Kingdom;Italy

1634

EUCTR2007-000074-23-CZ
(EUCTR)

18/06/2007

31/05/2007

Product Name: Pramipexole ER
Product Code: SND 919 CL2Y
INN or Proposed INN: Pramipexole
Product Name: Pramipexole ER
Product Code: SND 919 CL2Y
INN or Proposed INN: Pramipexole
Product Name: Pramipexole ER
Product Code: SND 919 CL2Y
INN or Proposed INN: Pramipexole
Product Name: Pramipexole ER
Product Code: SND 919 CL2Y
INN or Proposed INN: Pramipexole
Product Name: Pramipexole ER
Product Code: SND 919 CL2Y
INN or Proposed INN: Pramipexole
Trade Name: SIFROL
INN or Proposed INN: Pramipexole

Boehringer Ingelheim RCV GmbH & Co KG

NULL

Not Recruiting

Female: yes
Male: yes

516

Phase 3

Hungary;Czech Republic;Spain;Austria;Italy;United Kingdom;Sweden

1635

EUCTR2007-000073-39-CZ
(EUCTR)

18/06/2007

18/04/2007

Male or female patients with idiopathic Parkinson’s disease (PD), diagnosed within 5 years, having Modified Hoehn and Yahr stage of 1 to 3.
MedDRA version: 9.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease

Product Name: Pramipexole ER
Product Code: SND 919 CL2 Y
INN or Proposed INN: Pramipexole
Other descriptive name: Prolonged release tablet
Product Name: Pramipexole ER
Product Code: SND 919 CL2 Y
INN or Proposed INN: Pramipexole
Other descriptive name: Prolonged release tablet
Product Name: Pramipexole ER
Product Code: SND 919 CL2 Y
INN or Proposed INN: Pramipexole
Other descriptive name: Prolonged release tablet
Product Name: Pramipexole ER
Product Code: SND 919 CL2 Y
INN or Proposed INN: Pramipexole
Other descriptive name: Prolonged release tablet
Product Name: Pramipexole ER
Product Code: SND 919 CL2 Y
INN or Proposed INN: Pramipexole
Other descriptive name: Prolonged release tablet

Boehringer Ingelheim RCV GmbH & Co KG

NULL

Not Recruiting

Female: yes
Male: yes

500

Phase 1

Hungary;Finland;Czech Republic;Austria

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1636

EUCTR2006-000678-57-CZ
(EUCTR)

18/06/2007

02/08/2006

A multicenter, randomized, double blind, parallel-group placebo and pramipexole controlled study to assess efficacy and safety of SLV308 monotherapy in the treatment of patients with early stage Parkinson’s disease. - The Vermeer study

Parkinson 's Disease early stage
MedDRA version: 8.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's

Solvay pharmaceuticals

NULL

Not Recruiting

Female: yes
Male: yes

330

Portugal;United Kingdom;Germany;Czech Republic;Netherlands;France;Estonia;Italy;Lithuania

1637

EUCTR2007-000073-39-SK
(EUCTR)

14/06/2007

09/04/2008

Boehringer Ingelheim Pharma Ges mbH

NULL

Not Recruiting

Female: yes
Male: yes

500

Phase 3

Hungary;Czech Republic;Slovakia;Finland;Austria;Germany

1638

EUCTR2007-000073-39-HU
(EUCTR)

14/06/2007

31/05/2007

Boehringer Ingelheim Pharma Ges mbH

NULL

Not Recruiting

Female: yes
Male: yes

500

Phase 1

Finland;Hungary;Czech Republic;Austria

1639

EUCTR2007-000074-23-SK
(EUCTR)

14/06/2007

09/04/2008

Product Name: Pramipexole ER
Product Code: SND 919 CL2Y
INN or Proposed INN: Pramipexole
Product Name: Pramipexole ER
Product Code: SND 919 CL2Y
INN or Proposed INN: Pramipexole
Product Name: Pramipexole ER
Product Code: SND 919 CL2Y
INN or Proposed INN: Pramipexole
Product Name: Pramipexole ER
Product Code: SND 919 CL2Y
INN or Proposed INN: Pramipexole
Product Name: Pramipexole ER
Product Code: SND 919 CL2Y
INN or Proposed INN: Pramipexole
Trade Name: SIFROL
INN or Proposed INN: Pramipexole

Boehringer Ingelheim Pharma Ges mbH

NULL

Not Recruiting

Female: yes
Male: yes

516

Phase 3

Hungary;Czech Republic;Slovakia;Spain;Austria;Italy;United Kingdom;Sweden

1640

EUCTR2006-005438-19-DE
(EUCTR)

12/06/2007

28/03/2007

An explorative, multicenter, open-label pilot trial with Neupro® (Rotigotine transdermal patch) once daily treatment administered perioperatively in Patients with idiopathic Parkinson´s disease. - NEUPOS

idiopathic Parkinson´s disease
MedDRA version: 9.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease

Trade Name: Neupro 2 mg/24 h transdermal patch
INN or Proposed INN: Rotigotine
Trade Name: Neupro 4 mg/24 h transdermal patch
INN or Proposed INN: Rotigotine
Trade Name: Neupro 6 mg/24 h transdermal patch
INN or Proposed INN: Rotigotine
Trade Name: Neupro 8 mg/24 h transdermal patch
INN or Proposed INN: Rotigotine

SCHWARZ PHARMA Deutschland GmbH

NULL

Not Recruiting

Female: yes
Male: yes

Germany

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1641

EUCTR2006-005861-21-IT
(EUCTR)

11/06/2007

05/01/2007

A PHASE III, DOUBLE-BLIND, PLACEBO-CONTROLLED, 12-MONTH EXTENSION STUDY TO INVESTIGATE THE LONG-TERM EFFICACY AND SAFETY OF A LOW (50 MG/DAY) AND HIGH (100 MG/DAY) DOSE OF SAFINAMIDE, AS ADD-ON THERAPY, IN PATIENTS WITH IDIOPATHIC PARKINSON`S DISEASE WITH MOTOR FLUCTUATIONS, TREATED WITH A STABLE DOSE OF LEVODOPA AND WHO MAY BE RECEIVING CONCOMITANT TREATMENT WITH STABLE DOSES OF A DOPAMINE AGONIST, AND/OR AN ANTICHOLINERGIC.

Patients with idiopathic Parkinson's disease with motor fluctuations
MedDRA version: 14.1;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Product Name: Safinamide
Product Code: NW-1015
INN or Proposed INN: Monoamine oxidase B inhibitors
Product Name: Safinamide
Product Code: NW-1015
INN or Proposed INN: Monoamine oxidase B inhibitors

NEWRON PHARMACEUTICALS

NULL

Not Recruiting

Female: yes
Male: yes

500

Phase 3

Italy

1642

EUCTR2006-006684-22-FR
(EUCTR)

08/06/2007

27/03/2007

Evaluation des effets à long terme de l’amantadine chez le parkinsonien souffrant de dyskinésies induites par la lévodopa : Etude randomisée en double-insu versus placebo de l’arrêt d’une prescription chronique. - AMANDYSK

maladie de parkinson
MedDRA version: 9.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's
MedDRA version: 9.1;Classification code 10013916;Term: Dyskinesia

Trade Name: MANTADIX

CHU Toulouse

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

France

1643

EUCTR2006-000858-45-SE
(EUCTR)

05/06/2007

04/04/2007

An open label SLV308 safety extension to study S308.3.001 in early PD patients. - An extension of the Rembrandt study

Parkinson's Disease Early Stage

Solvay Pharmaceuticals

NULL

Not Recruiting

Female: yes
Male: yes

300

Finland;Sweden

1644

JPRN-UMIN000000780

2007/06/01

01/08/2007

A randomized, double-blind, placebo-controlled, cross-over, multi-center study concerning the efficacy and safety of amantadine hydrochloride in treatment of dyskinesias in Parkinson's disease

Parkinson's disease

An observation period (2 to 3 weeks)

An administration of amantadine hydrochloride (27 days)

A wash out period (15 days)

An administration of placebo (27 days)
An observation period (2 to 3 weeks)

An administration of placebo (27 days)

A wash out period (15 days)

An administration of amantadine hydrochloride (27 days)

Comprehensive clinical study group concerning diagnosis, treatment, and prevention of the neurological disorders

Musashi Hospital, National Center of Neurology and Psychiatry, JapanEhime University Hospital

Complete: follow-up complete

20years-old

75years-old

Male and Female

Not applicable

Japan

1645

NCT00460954
(ClinicalTrials.gov)

June 2007

16/4/2007

A Multiple-Dose Study of Sinemet® CR (Carbidopa/Levodopa) in Healthy Subjects

An Open Label, Multiple-Dose Study ot Determine the Plasma Levodopa Profiles of Sinemet® CR (Carbidopa/Levodopa) at 4 Daily Dose Levels in Healthy Subjects

Parkinson's Disease

Drug: Sinemet® controlled release (Carbidopa/levodopa)

Bristol-Myers Squibb

NULL

Completed

50 Years

75 Years

Both

N/A

Canada

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1646

NCT00485069
(ClinicalTrials.gov)

June 2007

11/6/2007

REQUIP (Ropinirole Hydrochloride) IR Long-Term Phase 4 Study

Post-Marketing Clinical Study of REQUIP (Ropinirole Hydrochloride) Tablets in Patients With Parkinson's Disease- Evaluation of Long-Term Efficacy and Safety -

Parkinson Disease;Parkinson's Disease

Drug: ROP;Drug: ROP +L-Dopa

GlaxoSmithKline

NULL

Completed

20 Years

N/A

All

123

Phase 4

Japan

1647

NCT00477672
(ClinicalTrials.gov)

June 2007

22/5/2007

A Study of the Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis

A Multi-Center, Placebo-Controlled, Double-Blind Trial to Examine the Safety and Efficacy of ACP-103 in the Treatment of Psychosis in Parkinson's Disease

Parkinson's Disease Psychosis

Drug: Pimavanserin tartrate (ACP-103);Drug: Placebo

ACADIA Pharmaceuticals Inc.

NULL

Completed

40 Years

N/A

All

298

Phase 3

United States;Bulgaria;France;India;Russian Federation;Ukraine;United Kingdom

1648

NCT00571285
(ClinicalTrials.gov)

June 2007

7/12/2007

Clinical Effects of Vitamin D Repletion in Patients With Parkinson's Disease

Parkinson's Disease

Dietary Supplement: Vitamin D3;Dietary Supplement: Vitamin D3 - high dose;Dietary Supplement: Placebo

Emory University

NULL

Terminated

18 Years

89 Years

All

Phase 4

United States

1649

NCT00696215
(ClinicalTrials.gov)

June 2007

10/6/2008

The Effects of Rasagiline on Cognitive Deficits Associated With Parkinson's Disease

The Effects of Rasagiline on Cognitive Deficits Associated With Parkinson's Disease: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study Over 3 Months

Parkinson's Disease

Drug: placebo;Drug: rasagiline

Istanbul University

NULL

Recruiting

N/A

Both

Phase 4

Turkey

1650

NCT00462254
(ClinicalTrials.gov)

June 2007

16/4/2007

Ramelteon (ROZEREM) in the Treatment of Sleep Disturbances Associated With Parkinson's Disease

Parkinson's Disease

Drug: ROZEREM;Drug: Ramelteon

Southern California Institute for Research and Education

NULL

Terminated

45 Years

85 Years

Both

Phase 4

United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1651

EUCTR2007-000074-23-AT
(EUCTR)

30/05/2007

05/06/2007

Product Name: Pramipexole ER
Product Code: SND 919 CL2Y
INN or Proposed INN: Pramipexole
Product Name: Pramipexole ER
Product Code: SND 919 CL2Y
INN or Proposed INN: Pramipexole
Product Name: Pramipexole ER
Product Code: SND 919 CL2Y
INN or Proposed INN: Pramipexole
Product Name: Pramipexole ER
Product Code: SND 919 CL2Y
INN or Proposed INN: Pramipexole
Product Name: Pramipexole ER
Product Code: SND 919 CL2Y
INN or Proposed INN: Pramipexole
Trade Name: SIFROL
INN or Proposed INN: Pramipexole

Boehringer Ingelheim Pharma GmbH & Co. KG

NULL

Not Recruiting

Female: yes
Male: yes

516

Phase 1

Hungary;United Kingdom;Spain;Italy;Austria;Sweden

1652

EUCTR2007-000073-39-AT
(EUCTR)

30/05/2007

05/06/2007

Boehringer Ingelheim Pharma Ges mbH

NULL

Not Recruiting

Female: yes
Male: yes

500

Phase 1

Hungary;Finland;Czech Republic;Austria

1653

EUCTR2007-000073-39-DE
(EUCTR)

29/05/2007

26/02/2007

Boehringer Ingelheim Pharma GmbH & Co. KG

NULL

Not Recruiting

Female: yes
Male: yes

500

Phase 1

Hungary;Czech Republic;Finland;Austria;Germany

1654

EUCTR2007-000074-23-ES
(EUCTR)

29/05/2007

02/03/2010

A double-blind, double-dummy, placebo-controlled, randomized, three parallel groups study comparing the Efficacy, Safety and Tolerability of Pramipexole ER versus placebo and versus Pramipexole IR administered orally over a 26-week maintenance phase in L-Dopa+ treated patients with advanced Parkinson’s disease (PD).Estudio aleatorizado, doble ciego, doble simulación, controlado con placebo de tres grupos paralelos que compara la eficacia, la seguridad y la tolerabilidad de pramipexol ER frente a placebo y frente a pramipexol IR administrados por vía oral durante una fase de mantenimiento de 26 semanas de duración en pacientes con enfermedad de Parkinson (EP) avanzada tratados con L-Dopa+.

Pacientes varones o mujeres, diagnosticados de enfermedad de Parkinson idiopática, al menos dos años antes, con 30 años o más de edad en el momento del diagnóstico, con un estadío entre 2 y 4 en la escala modificada de Hoehn y Yahr en el periodo on.Male or female patients, with idiopathic PD diagnosed for at least 2 years, 30 years of age or older at time of diagnosis, with a modified Hoehn and Yahr scale of 2 to 4 at on-time.
MedDRA version: 9.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease

Product Name: Pramipexole ER
Product Code: SND 919 CL2Y
INN or Proposed INN: Pramipexole
Product Name: Pramipexole ER
Product Code: SND 919 CL2Y
INN or Proposed INN: Pramipexole
Product Name: Pramipexole ER
Product Code: SND 919 CL2Y
INN or Proposed INN: Pramipexole
Product Name: Pramipexole ER
Product Code: SND 919 CL2Y
INN or Proposed INN: Pramipexole
Product Name: Pramipexole ER
Product Code: SND 919 CL2Y
INN or Proposed INN: Pramipexole
Trade Name: SIFROL
INN or Proposed INN: Pramipexole

Boehringer Ingelheim España, S.A.

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

516

Phase 1

Hungary;United Kingdom;Spain;Italy;Austria;Sweden

1655

EUCTR2006-006752-35-ES
(EUCTR)

27/05/2007

27/03/2007

RECOVER: EVALUACIÓN ALEATORIZADA DE LA COBERTURA 24 HORAS: EFICACIA DE ROTIGOTINA. ESTUDIO DE FASE 3B, MULTICÉNTRICO, MULTINACIONAL, DOBLE CIEGO, CONTROLADO CON PLACEBO, DE 2 BRAZOS PARA EVALUAR EL EFECTO DE LA ADMINISTRACIÓN TRANSDÉRMICA 24 HORAS DE ROTIGOTINA SOBRE EL CONTROL DE LA FUNCIÓN MOTORA A PRIMERA HORA DE LA MAÑANA, LA CALIDAD DEL SUEÑO, LOS SÍNTOMAS NOCTURNOS Y LOS SÍNTOMAS NO MOTORES EN SUJETOS CON ENFERMEDAD DE PARKINSON IDIOPÁTICA.(RECOVER: RANDOMIZED EVALUATION OF THE 24-HOUR COVERAGE: EFFICACY OF ROTIGOTINEPHASE 3B, MULTICENTER, MULTINATIONAL, DOUBLE-BLIND, PLACEBO CONTROLLED, 2-ARM TRIAL TO EVALUATE THE EFFECT OF THE 24-HOUR TRANSDERMAL DELIVERY OF ROTIGOTINE ON THE CONTROL OF EARLY MORNING MOTOR FUNCTION, SLEEP QUALITY, NOCTURNAL SYMPTOMS, AND NON-MOTOR SYMPTOMS IN SUBJECTS WITH IDIOPATHIC PARKINSON’S DISEASE) - Recover

Enfermedad de Parkinson(Parkinson's disease)
MedDRA version: 9.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease

Schwarz Biosciences GmbH

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

400

Phase 3B

Hungary;Finland;Spain;Austria;Germany;United Kingdom;Italy

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1656

EUCTR2006-006907-35-ES
(EUCTR)

27/05/2007

27/03/2007

EXTENSIÓN A LARGO PLAZO DE RECOVER. ESTUDIO DE EXTENSIÓN MULTICÉNTRICO, MULTINACIONAL, DE FASE 3B, ABIERTO, PARA EVALUAR EL EFECTO A LARGO PLAZO DE LA ADMINISTRACIÓN TRANSDÉRMICA DURANTE 24 HORAS DE ROTIGOTINA SOBRE LA FUNCIÓN MOTORA, LA CALIDAD DEL SUEÑO Y LOS SÍNTOMAS NOCTURNOS Y SÍNTOMAS NO MOTORES EN SUJETOS CON ENFERMEDAD DE PARKINSON IDIOPÁTICA.(Long-term extension of RECOVER A MULTICENTER, MULTINATIONAL, PHASE 3B, OPEN-LABEL EXTENSION TRIAL TO EVALUATE THE LONG-TERM EFFECT OF THE 24-HOUR TRANSDERMAL DELIVERY OF ROTIGOTINE ON MOTOR FUNCTION, SLEEP QUALITY, AND NOCTURNAL AND NON-MOTOR SYMPTOMS IN SUBJECTS WITH IDIOPATHIC PARKINSON’S DISEASE) - Long-term extension of RECOVER

Enfermedad de Parkinson(Parkinson's disease)
MedDRA version: 9.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease

Trade Name: Neupro 2mg/24h transdermal patch
Product Code: ND1587
INN or Proposed INN: Rotigotine
Trade Name: Neupro 4mg/24h transdermal patch
Product Code: ND1589
INN or Proposed INN: Rotigotine
Trade Name: Neupro 6mg/24h transdermal patch
Product Code: ND1590
INN or Proposed INN: Rotigotine
Trade Name: Neupro 8mg/24h transdermal patch
Product Code: ND1702
INN or Proposed INN: Rotigotine

Schwarz Biosciences GmbH

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

270

Phase 3B

Hungary;Finland;United Kingdom;Germany;Spain;Italy;Austria

1657

EUCTR2007-000074-23-IT
(EUCTR)

17/05/2007

06/04/2007

Patients with advanced idiopathic Parkinson s disease
MedDRA version: 9.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease

Product Name: pramipexole ER
Product Code: SND 919 CL2Y
Product Name: Pramipexole ER
Product Code: SND 919 CL2Y
Product Name: Pramipexole ER
Product Code: SND 919 CL2Y
Product Name: Pramipexole ER
Product Code: SND 919 CL2Y
Product Name: Pramipexole ER
Product Code: SND 919 CL2Y
Trade Name: Sifrol
Trade Name: Sifrol

BOEHRINGER ING.

NULL

Not Recruiting

Female: yes
Male: yes

645

Phase 1

Hungary;United Kingdom;Spain;Italy;Austria;Sweden

1658

EUCTR2006-006907-35-HU
(EUCTR)

17/05/2007

12/04/2007

Parkinson's disease
MedDRA version: 9.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease

Trade Name: Neupro 2mg/24h transdermal patch
Product Code: ND1587
INN or Proposed INN: Rotigotine
Trade Name: Neupro 4mg/24h transdermal patch
Product Code: ND1589
INN or Proposed INN: Rotigotine
Trade Name: Neupro 6mg/24h transdermal patch
Product Code: ND1590
INN or Proposed INN: Rotigotine
Trade Name: Neupro 8mg/24h transdermal patch
Product Code: ND1702
INN or Proposed INN: Rotigotine

Schwarz Biosciences GmbH

NULL

Not Recruiting

Female: yes
Male: yes

270

Phase 3B

Finland;Hungary;United Kingdom;Germany;Spain;Italy;Austria

1659

EUCTR2007-000074-23-GB
(EUCTR)

11/05/2007

29/03/2007

Product Name: Pramipexole ER
Product Code: SND 919 CL2Y
INN or Proposed INN: Pramipexole
Product Name: Pramipexole ER
Product Code: SND 919 CL2Y
INN or Proposed INN: Pramipexole
Product Name: Pramipexole ER
Product Code: SND 919 CL2Y
INN or Proposed INN: Pramipexole
Product Name: Pramipexole ER
Product Code: SND 919 CL2Y
INN or Proposed INN: Pramipexole
Product Name: Pramipexole ER
Product Code: SND 919 CL2Y
INN or Proposed INN: Pramipexole
Trade Name: SIFROL
INN or Proposed INN: Pramipexole

Boehringer Ingelheim Limited

NULL

Not Recruiting

Female: yes
Male: yes

516

Phase 1

Hungary;United Kingdom;Spain;Italy;Austria;Sweden

1660

EUCTR2006-006752-35-FI
(EUCTR)

09/05/2007

21/03/2007

Parkinson's disease
MedDRA version: 9.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease

Schwarz Biosciences GmbH

NULL

Not Recruiting

Female: yes
Male: yes

400

Phase 3B

Hungary;Finland;Spain;Austria;Germany;United Kingdom;Italy

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1661

EUCTR2006-006907-35-FI
(EUCTR)

09/05/2007

21/03/2007

Parkinson's disease
MedDRA version: 9.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease

Trade Name: Neupro 2mg/24h transdermal patch
Product Code: ND1587
INN or Proposed INN: Rotigotine
Trade Name: Neupro 4mg/24h transdermal patch
Product Code: ND1589
INN or Proposed INN: Rotigotine
Trade Name: Neupro 6mg/24h transdermal patch
Product Code: ND1590
INN or Proposed INN: Rotigotine
Trade Name: Neupro 8mg/24h transdermal patch
Product Code: ND1702
INN or Proposed INN: Rotigotine

Schwarz Biosciences GmbH

NULL

Not Recruiting

Female: yes
Male: yes

270

Phase 3B

Hungary;Finland;United Kingdom;Germany;Spain;Italy;Austria

1662

EUCTR2007-000074-23-SE
(EUCTR)

02/05/2007

02/04/2007

Product Name: Pramipexole ER
Product Code: SND 919 CL2Y
INN or Proposed INN: Pramipexole
Product Name: Pramipexole ER
Product Code: SND 919 CL2Y
INN or Proposed INN: Pramipexole
Product Name: Pramipexole ER
Product Code: SND 919 CL2Y
INN or Proposed INN: Pramipexole
Product Name: Pramipexole ER
Product Code: SND 919 CL2Y
INN or Proposed INN: Pramipexole
Product Name: Pramipexole ER
Product Code: SND 919 CL2Y
INN or Proposed INN: Pramipexole
Trade Name: SIFROL
INN or Proposed INN: Pramipexole

Boehringer Ingelheim AB

NULL

Not Recruiting

Female: yes
Male: yes

516

Phase 1

Hungary;United Kingdom;Spain;Italy;Austria;Sweden

1663

NCT00505843
(ClinicalTrials.gov)

May 2007

24/7/2007

A Study of MK0657 in Parkinson's Disease Patients (0657-006)

A Randomized, Double-Blind, Placebo-Controlled, 2-Period Crossover Study to Evaluate Effectiveness of Single-Dose MK0657 in Combination With Levodopa on Motor Symptoms and Dyskinesias in Patients With Parkinson's Disease

Parkinson's Disease

Drug: MK0657;Drug: Comparator: Placebo (unspecified);Drug: Comparator: levodopa;Drug: Comparator: carbidopa

Merck Sharp & Dohme Corp.

NULL

Completed

40 Years

80 Years

Both

Phase 1

United States

1664

NCT00477802
(ClinicalTrials.gov)

May 2007

22/5/2007

Botulinum Toxin Type A (Botox) in the Management of Levodopa-Induced Peak-Dose Dyskinesias in Parkinson's Disease

Botulinum Toxin Type A (Botox) in the Management of Levodopa-Induced Peak-Dose Dyskinesias in Parkinson's Disease: A Double-Blind, Randomized, Placebo Controlled, Cross-Over Design Study

Parkinson Disease

Biological: Botulinum Toxin Type A;Biological: Placebo

University of Cincinnati

Allergan

Terminated

35 Years

75 Years

Both

Phase 4

United States

1665

NCT00489255
(ClinicalTrials.gov)

May 2007

20/6/2007

Safety/Efficacy of Tigan® to Control Nausea/Vomiting Experienced During Apokyn® Initiation and Treatment

A Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Trimethobenzamide (Tigan®) in the Control of Nausea and Vomiting During Initiation and Continued Treatment With Subcutaneous Apomorphine (Apokyn®) in Apomorphine-naïve Subjects With Parkinson's Disease Suffering From Acute Intermittent Off Episodes, With Phased Withdrawal of Subjects From Tigan® to Placebo

Parkinson's Disease

Drug: Tigan ®;Drug: Placebo

Ipsen

INC Research Limited

Completed

18 Years

N/A

All

117

Phase 4

United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1666

NCT00474058
(ClinicalTrials.gov)

May 2007

14/5/2007

Randomized Evaluation of the 24-Hour Coverage: Efficacy of Rotigotine

Phase 3B, Multicenter, Multinational, Double-Blind, Placebo Controlled, 2-Arm Trial to Evaluate the Effect of the 24-Hour Transdermal Delivery of Rotigotine on the Control of Early Morning Motor Function, Sleep Quality, Nocturnal Symptoms, and Non-Motor Symptoms in Subjects With Idiopathic Parkinson's Disease

Parkinson's Disease

Drug: Rotigotine;Other: Placebo

UCB Pharma

NULL

Completed

18 Years

N/A

All

287

Phase 3

United States;Australia;Austria;Finland;Germany;Hungary;Italy;New Zealand;Poland;South Africa;Spain;United Kingdom

1667

NCT00479401
(ClinicalTrials.gov)

May 2007

25/5/2007

Efficacy, Safety, Tolerability of Pramipexol ER Versus Pramipexol IR Versus Placebo in Early PD Patients

A Double-blind, Double-dummy, Placebo-controlled, Randomized, Three Parallel Groups Study Comparing the Efficacy, Safety and Tolerability of Pramipexole ER Versus Placebo and Versus Pramipexole IR Administered Orally Over a 26-week Maintenance Phase in Patients With Early Parkinsons Disease (PD).

Early Parkinson Disease (Early PD)

Drug: Pramipexol Extended Release;Drug: Pramipexol Immediate Release;Drug: Placebo

Boehringer Ingelheim

NULL

Completed

30 Years

N/A

All

539

Phase 3

United States;Argentina;Austria;Czech Republic;Finland;Germany;Hungary;India;Japan;Malaysia;Russian Federation;Slovakia;Taiwan;Ukraine;Brazil

1668

EUCTR2006-002937-20-ES
(EUCTR)

27/04/2007

26/04/2007

Estudio Multicéntrico, Randomizado, Doble ciego, Controlado con Placebo y Entacapona, de Grupos Paralelos, para evaluar la eficacia, Seguridad y Tolerabilidad de E2007 en Pacientes con Enfermedad de Parkinson Tratados con Levodopa, y Fluctuaciones Motoras

Enfermedad de Parkinson
MedDRA version: 8.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's

Product Name: E2007
Product Code: MARS
Trade Name: Comtess
Product Name: Entacapone

Eisai Limited

NULL

Not Recruiting

Female: yes
Male: yes

702

Hungary;Czech Republic;France;Estonia;Spain;Italy;Latvia;Lithuania

1669

EUCTR2006-002339-26-PT
(EUCTR)

27/04/2007

07/03/2007

Levodopa treated Parkinson's disease patients with motor fluctuations.
MedDRA version: 8.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease

Product Name: MARS
Product Code: E2007

Eisai Limited

NULL

Not Recruiting

Female: yes
Male: yes

1400

Hungary;Portugal;Germany;United Kingdom;Czech Republic;Estonia;Spain;Italy;Austria;Sweden;Lithuania

1670

EUCTR2006-000577-29-DE
(EUCTR)

27/04/2007

12/10/2006

Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson’s Subjects

A Randomized, Double-Blind, Double-Dummy, Efficacy, Safety and Tolerability Study Levodopa - Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson’s Subjects Receiving Optimized Treatments with Parkinson Medicinal Products who Continue toExperience Persistent Motor Fluctuations

Treatment of levodopa-responsive Parkinson's subjects with severe motor fluctuations.
MedDRA version: 14.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Trade Name: DUODOPA®Intestinal Gel
INN or Proposed INN: Levodopa
Other descriptive name: 3-(3,4-Dihydroxyphenyl)-L-alanine; L-3-(3,4-Dihydroxyphenyl)alanine; L-DOPA
INN or Proposed INN: Carbidopa Monohydrate
Other descriptive name: (minus)-L-alpha-hydrazino-3,4-dihydroxy-alpha-methylbenzenepropanoic acid monohydrate
Trade Name: Sinemet®25-100
INN or Proposed INN: Levodopa
Other descriptive name: 3-(3,4-Dihydroxyphenyl)-L-alanine; L-3-(3,4-Dihydroxyphenyl)alanine; L-DOPA
INN or Proposed INN: Carbidopa Monohydrate
Other descriptive name: (minus)-L-alpha-hydrazino-3,4-dihydroxy-alpha-methylbenzenepropanoic acid monohydrate

Abbott Products, Inc (Abbott Products Inc. is part of the parent company, Abbott Laboratories)

NULL

Not Recruiting

Female: yes
Male: yes

United States;Germany

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1671

EUCTR2007-000073-39-FI
(EUCTR)

25/04/2007

06/03/2007

Boehringer Ingelheim Finland Ky

NULL

Not Recruiting

Female: yes
Male: yes

500

Phase 1

Hungary;Finland;Czech Republic;Austria

1672

EUCTR2007-000307-15-IT
(EUCTR)

24/04/2007

23/08/2007

Safety and Efficacy of Melperone in the Treatment of Patients with Psychosis Associated with Parkinson's Disease.

Psicosi associata al morbo di Parkinson
MedDRA version: 9.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's

Product Name: Melperon
INN or Proposed INN: melperon

OVATION PHARMACEUTICALS INC

NULL

Not Recruiting

Female: yes
Male: yes

Italy

1673

EUCTR2006-002339-26-ES
(EUCTR)

19/04/2007

30/01/2007

A Multi-centre, Open Label Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of E2007 as an Adjunctive Therapy in Levodopa Treated Parkinson's Disease Patients with Motor Fluctuations.Estudio de extensión abierto, multicéntrico para evaluar la seguridad, tolerabilidad y eficacia a largo plazo de E2007 como terapia complementaria en pacientes con enfermedad de Parkinson tratados con Levodopa y fluctuaciones motoras.

Levodopa treated Parkinson's disease patients with motor fluctuations.Pacientes con enfermedad de Parkinson tratados con Levodopa y fluctuaciones motoras
MedDRA version: 8.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease

Product Name: MARS
Product Code: E2007

Eisai Limited

NULL

Not Recruiting

Female: yes
Male: yes

1400

Portugal;Hungary;Germany;United Kingdom;Czech Republic;Estonia;Spain;Italy;Austria;Sweden;Lithuania

1674

EUCTR2006-006907-35-AT
(EUCTR)

17/04/2007

21/05/2007

Parkinson's disease
MedDRA version: 9.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease

Trade Name: Neupro 2mg/24h transdermal patch
Product Code: ND1587
INN or Proposed INN: Rotigotine
Trade Name: Neupro 4mg/24h transdermal patch
Product Code: ND1589
INN or Proposed INN: Rotigotine
Trade Name: Neupro 6mg/24h transdermal patch
Product Code: ND1590
INN or Proposed INN: Rotigotine
Trade Name: Neupro 8mg/24h transdermal patch
Product Code: ND1702
INN or Proposed INN: Rotigotine

Schwarz Biosciences GmbH

NULL

Not Recruiting

Female: yes
Male: yes

270

Phase 3B

Hungary;Finland;United Kingdom;Germany;Spain;Italy;Austria

1675

EUCTR2006-006752-35-AT
(EUCTR)

17/04/2007

21/05/2007

Parkinson's disease
MedDRA version: 9.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease

Schwarz Biosciences GmbH

NULL

Not Recruiting

Female: yes
Male: yes

400

Phase 3B

Hungary;Finland;Spain;Austria;Germany;United Kingdom;Italy

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1676

EUCTR2006-002339-26-DE
(EUCTR)

10/04/2007

22/12/2006

Levodopa treated Parkinson's disease patients with motor fluctuations.
MedDRA version: 8.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease

Product Name: MARS
Product Code: E2007

Eisai Limited

NULL

Not Recruiting

Female: yes
Male: yes

1400

Portugal;Hungary;United Kingdom;Czech Republic;Germany;Estonia;Spain;Italy;Austria;Sweden;Lithuania

1677

NCT00434304
(ClinicalTrials.gov)

April 9, 2007

9/2/2007

Clinical Evaluation of Ropinirole PR/XR Tablets in Monotherapy for Parkinson's Disease (PD)

Clinical Evaluation of Ropinirole PR/XR Tablets in Monotherapy for Parkinson's Disease - an Open-Label, Uncontrolled Study -

Parkinson Disease

Drug: Ropinirole prolonged release/extended release(PR/XR)

GlaxoSmithKline

NULL

Completed

20 Years

N/A

All

Phase 2

Japan

1678

NCT00466167
(ClinicalTrials.gov)

April 2007

25/4/2007

Pivotal Study in Advanced Parkinsons Disease Patients

A Double-blind, Double-dummy, Placebo-controlled, Randomized, Three Parallel Groups Study Comparing the Efficacy, Safety and Tolerability of Pramipexole Extended Release (ER) Versus Placebo and Versus Pramipexole Immediate Release (IR) Administered Orally Over a 26-week Maintenance Phase in L-Dopa+ Treated Patients With Advanced Parkinsons Disease (PD).

Parkinson Disease

Drug: Pramipexol Extended Release;Drug: Pramipexol Immediate Release;Drug: Placebo

Boehringer Ingelheim

NULL

Completed

32 Years

N/A

All

517

Phase 3

Austria;Czech Republic;Hungary;India;Italy;Korea, Republic of;Philippines;Poland;Russian Federation;Slovakia;Spain;Sweden;Ukraine;United Kingdom

1679

NCT00623363
(ClinicalTrials.gov)

April 2007

2/1/2008

Preliminary Study of Piclozotan in Patients With Motor Complications Associated With Parkinson's Disease

Parkinson's Disease

Drug: piclozotan;Drug: 0.9% sodium chloride (normal saline)

Asubio Pharmaceuticals, Inc.

NULL

Completed

40 Years

85 Years

Both

Phase 2

United States;Guatemala;Romania

1680

NCT00459420
(ClinicalTrials.gov)

April 2007

11/4/2007

Caffeine for Excessive Daytime Somnolence in Parkinson's Disease

Parkinson's Disease;Excessive Daytime Somnolence

Drug: Caffeine 100-200 mg BID;Drug: placebo

Ron Postuma

Canadian Institutes of Health Research (CIHR);University of Toronto

Completed

18 Years

N/A

Both

Phase 2;Phase 3

Canada

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1681

NCT00438607
(ClinicalTrials.gov)

April 2007

20/2/2007

Dose-Finding Safety Study of BIIB014 in Combination With Levodopa in Moderate to Late Stage Parkinson's Disease

A Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study of Single and Multiple Oral Dose Administration of BIIB014 in Subjects With Moderate to Late Stage Parkinson's Disease Who Are Also Receiving Treatment With Levodopa

Parkinson's Disease

Drug: BIIB014;Drug: Placebo

Biogen Idec

NULL

Completed

30 Years

N/A

Both

Phase 2

India;Israel;United Kingdom

1682

NCT00460148
(ClinicalTrials.gov)

April 2007

11/4/2007

Parkinson's Disease Patient Study On Absorption, Distribution, Metabolism And Excretion Of Ropinirole

An Open Label, Repeat Dose, Dose Escalation Study Conducted in Parkinson's Disease Patients to Characterize the Pharmacokinetics and Effect of Food on Ropinirole Prolonged Release (PR/CR) 12mg Tablets.

Parkinson Disease

Drug: Ropinirole

GlaxoSmithKline

NULL

Completed

30 Years

85 Years

Both

Phase 2

Germany;South Africa

1683

EUCTR2006-006209-94-DE
(EUCTR)

15/03/2007

26/01/2007

An open label, repeat dose, dose escalation study conducted in Parkinson’s Disease patients to characterize the pharmacokinetics and effect of food on ropinirole prolonged release (PR/CR) 12mg tablets.

Parkinson's disease
MedDRA version: 9.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease

Trade Name: Requip-Modutab
Product Name: Requip-Modutab
Product Code: SK&F101468
INN or Proposed INN: Ropinirole
Trade Name: Requip-Modutab
Product Name: Requip-Modutab
Product Code: SK&F101468
INN or Proposed INN: Ropinirole
Trade Name: Requip-Modutab
Product Name: Requip-Modutab
Product Code: SK&F101468
INN or Proposed INN: Ropinirole
Product Name: Ropinirole
Product Code: SK&F101468
INN or Proposed INN: Ropinirole

GlaxoSmithKline Research & Development Limited

NULL

Not Recruiting

Female: yes
Male: yes

Germany

1684

EUCTR2006-002937-20-FR
(EUCTR)

12/03/2007

12/02/2007

Parkinson's Disease
MedDRA version: 8.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's

Product Name: E2007
Product Code: MARS
Trade Name: Comtess
Product Name: Entacapone
INN or Proposed INN: entacapone

Eisai Limited

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

702

Hungary;Czech Republic;Estonia;France;Spain;Italy;Latvia;Lithuania

1685

NCT00443872
(ClinicalTrials.gov)

March 2007

3/3/2007

Efficacy of Orally Disintegrating Selegiline in Parkinson's Patients Experiencing Adverse Effects With Dopamine Agonists

Adding Orally Disintegrating Selegiline (Zelapar) to Patients Taking Dopamine Agonists and Experiencing Complications

Parkinson's Disease

Drug: orally disintegrating selegiline (Zelapar)

Parkinson's Disease and Movement Disorder Center of Boca Raton

Valeant Pharmaceuticals International, Inc.

Completed

30 Years

90 Years

All

Phase 4

United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1686

NCT00437125
(ClinicalTrials.gov)

March 2007

16/2/2007

Study on the Tolerability of Duloxetine in Depressed Patients With Parkinson's Disease

An Open Label Pilot Study on the Tolerability of Duloxetine in the Treatment of Depressed Patients With Parkinson's Disease

Major Depressive Disorder;Idiopathic Parkinson Disease

Drug: Duloxetine hydrochloride

Eli Lilly and Company

NULL

Completed

30 Years

75 Years

All

151

Phase 4

Italy

1687

NCT00449865
(ClinicalTrials.gov)

March 2007

20/3/2007

NET-PD LS-1 Creatine in Parkinson's Disease

A Multicenter, Double-Blind, Parallel Group, Placebo Controlled Study of Creatine in Subjects With Treated Parkinson's Disease (PD) Long Term Study (LS-1)

Parkinson's Disease

Drug: creatine;Other: placebo

University of Rochester

National Institute of Neurological Disorders and Stroke (NINDS)

Terminated

N/A

All

1741

Phase 3

United States;Canada

1688

NCT00451633
(ClinicalTrials.gov)

March 2007

21/3/2007

The Effect Of E2007 On Pharmacodynamic Responses To Levodopa Among Patients With Parkinson's Disease Who Experience Dyskinesia And Motor Fluctuations

A Randomized, Double Blind, Placebo-Controlled Study To Investigate The Effect Of E2007 On Pharmacodynamic Responses To Levodopa Among Patients With Parkinson's Disease Who Experience Dyskinesia And Motor Fluctuations

Parkinson's Disease

Drug: E2007

Eisai Inc.

NULL

Withdrawn

30 Years

80 Years

Both

Phase 2

Germany;Italy

1689

NCT00406588
(ClinicalTrials.gov)

March 2007

30/11/2006

SLV308 for Treatment of Patients With Parkinson's Disease Experiencing Motor Fluctuations

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of SLV308 as Adjunct Therapy to Levodopa in Patients With Parkinson's Disease Experiencing Motor Fluctuations.

Advanced Stage Parkinson's Disease

Drug: Pardoprunox;Drug: Placebo Comparator

Solvay Pharmaceuticals

NULL

Completed

30 Years

N/A

Both

295

Phase 3

United States;Argentina;Brazil;Bulgaria;Canada;Chile;Colombia;Latvia;Lithuania;Peru;Russian Federation;Ukraine

1690

NCT01693081
(ClinicalTrials.gov)

March 2007

21/9/2012

Phase IIa Multicentre Study Investigating of VR040 in Parkinson's Disease

A Clinic-Based, Phase IIa, Double-Blind, Placebo- Controlled, Ascending-Dose, Multicentre Study of Safety, Tolerability, Efficacy and Pharmacokinetics of VR040 in Parkinson's Disease

Parkinson's Disease

Drug: VR040/Aspirair® inhaler;Drug: placebo

South Glasgow University Hospitals NHS Trust

Vectura Limited

Completed

30 Years

90 Years

Both

Phase 2

Serbia;United Kingdom

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1691

NCT00455507
(ClinicalTrials.gov)

March 2007

2/4/2007

A Phase 2b Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease in Patients Taking Levodopa

Placebo-controlled, Double-blind, Parallel Group, Fixed Dose Study of KW-6002 (Istradefylline) in the Treatment of Parkinson's Disease (Phase 2 Study)

Parkinson's Disease

Drug: Istradefylline;Drug: Placebo

Kyowa Hakko Kirin Company, Limited

NULL

Completed

20 Years

N/A

Both

363

Phase 2

Japan

1692

EUCTR2006-005714-12-IT
(EUCTR)

27/02/2007

03/08/2007

A randomized, double blind, placebo-controlled study to investigate the effect of E2007 on pharmacodynamic responses to levodopa among patients with Parkinson's disease who experience dyskinesia and motor fluctuations. - E2007-E044-213

Patients with idiopathic Parkinson's disease who respond to levodopa treatment but who experience peak-effect levodopa-induced dyskinesia and end-of-dose 'wearing-off' motor fluctuations
MedDRA version: 6.1;Level: HLT;Classification code 10034005

Product Name: E2007
Product Code: E2007
INN or Proposed INN: OTHER NERVOUS SYSTEM DRUGS
Trade Name: SINEMET
INN or Proposed INN: levodopa -carbidopa

EISAI LTD UK

NULL

Not Recruiting

Female: yes
Male: yes

Italy

1693

EUCTR2005-002038-36-GR
(EUCTR)

27/02/2007

09/10/2006

A randomised, double-blind, placebo-controlled, 6-month study of the efficacy and safety of memantine in patients with Parkinson’s disease dementia or dementia with Lewy Bodies

Patients with Parkinson’s disease dementia or dementia with Lewy Bodies
MedDRA version: 8.1;Level: LLT;Classification code 10012284;Term: Dementia due to Parkinson's disease

H. Lundbeck A/S

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

200

Germany;United Kingdom;France;Spain;Italy;Greece;Austria

1694

EUCTR2006-002408-32-ES
(EUCTR)

27/02/2007

07/02/2007

Modulación dopaminérgica de las funciones cognitivas y afectivas por el tratamiento con diferentes métodos de estimulación dopaminérgica en la enfermedad de Parkinson . Implicaciones para el tratamiento con levodopa.

Fluctuaciones motoras, cognitivas y del humor en la enfermedad de Parkinson.
MedDRA version: 8.1;Level: PT;Classification code 10061536;Term: Parkinson's disease

Trade Name: Stalevo 150
Product Name: Levodopa -carbidopa-entacapone
Trade Name: Sinemet
Product Name: Levodopa /Carbidopa

Institut de Recerca del Hospital de la Santa Creu i Sant Pau

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

Spain

1695

EUCTR2006-005183-91-LT
(EUCTR)

14/02/2007

20/12/2006

An open label SLV308 safety extension to study S308.3.002 in patients with Parkinson’s disease experiencing motor fluctuations. - An extension of the Mondrian study

Advanced stage Parkinson's disease with motor fluctuations.
MedDRA version: 9.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's

Product Name: SLV308(mono)hydrochloride
Product Code: SLV308(mono)hydrochloride
Product Name: SLV308(mono)hydrochloride
Product Code: SLV308(mono)hydrochloride
Product Name: SLV308(mono)hydrochloride
Product Code: SLV308(mono)hydrochloride
Product Name: SLV308(mono)hydrochloride
Product Code: SLV308(mono)hydrochloride
Product Name: SLV308(mono)hydrochloride
Product Code: SLV308(mono)hydrochloride
Product Name: SLV308(mono)hydrochloride
Product Code: SLV308(mono)hydrochloride

Solvay Pharmaceuticals

NULL

Not Recruiting

Female: yes
Male: yes

220

Latvia;Lithuania

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1696

EUCTR2006-005182-20-LT
(EUCTR)

13/02/2007

20/12/2006

A multicenter, randomized, double-blind, placebo-controlled, parallel group study of SLV308 as adjunct therapy to levodopa in patients with Parkinson’s disease experiencing motor fluctuations. - The Mondriaan study

Advanced stage Parkinson's disease with motor fluctuations.
MedDRA version: 9.1;Level: LLT;Classification code 10034007;Term: Parkinson's disease NOS

Solvay Pharmaceuticals

NULL

Not Recruiting

Female: yes
Male: yes

280

Latvia;Lithuania

1697

EUCTR2006-005182-20-LV
(EUCTR)

02/02/2007

28/12/2006

Advanced stage Parkinson's disease with motor fluctuations.

Solvay Pharmaceuticals

NULL

Not Recruiting

Female: yes
Male: yes

280

Latvia;Lithuania

1698

EUCTR2006-005183-91-LV
(EUCTR)

02/02/2007

11/01/2007

An open label SLV308 safety extension to study S308.3.002 in patients with Parkinson’s disease experiencing motor fluctuations. - An extension of the Mondriaan study

Advanced stage Parkinson's disease with motor fluctuations.

Solvay Pharmaceuticals

NULL

Not Recruiting

Female: yes
Male: yes

140

Latvia;Lithuania

1699

NCT00480701
(ClinicalTrials.gov)

February 2007

30/5/2007

Evaluation of 123-I Iodobenzovesamicol (IBVM) and SPECT Imaging of Healthy Subjects and Patients With Alzheimer Disease

Evaluation of 123-I Iodobenzovesamicol (IBVM) and SPECT as a Marker of Acetylcholine Transporter Density in the Brain of Healthy Subjects and Patients With Alzheimer Disease

Alzheimer Disease;Parkinson Disease

Drug: [123I]-IBVM

Institute for Neurodegenerative Disorders

NULL

Completed

50 Years

N/A

Both

Phase 2

United States

1700

NCT00427011
(ClinicalTrials.gov)

February 2007

24/1/2007

A Study of E2007 In Patients With Parkinson's Disease

A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of E2007 In Patients With Parkinson's Disease Who Experience End-of-Dose Wearing-Off Motor Fluctuations

Parkinson's Disease

Drug: E2007

Eisai Inc.

NULL

Terminated

18 Years

N/A

All

Phase 2

United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1701

NCT00332917
(ClinicalTrials.gov)

February 2007

1/6/2006

An Open Label SLV308 Safety Extension to Study S308.3.001 in Early PD Patients

Early Stage Parkinson's Disease

Drug: Pardoprunox

Solvay Pharmaceuticals

NULL

Completed

30 Years

N/A

Both

224

Phase 3

United States;Argentina;Belgium;Bulgaria;Canada;Chile;Colombia;Croatia;Finland;India;Israel;Mexico;New Zealand;Peru;Romania;Russian Federation;Serbia;Slovakia;South Africa;Sweden;Ukraine;Former Serbia and Montenegro

1702

EUCTR2006-003732-30-DE
(EUCTR)

31/01/2007

29/11/2006

Transdermal Use of Lisuride in Early Parkinson´s Disease: A double blind, randomized, Placebo and Pramipexole controlled study to evaluate the efficacy and safety of Lisuride TTS - TULEP 1

Early Parkinson's Disease
MedDRA version: 8.1;Level: PT;Classification code 10061536;Term: Parkinson's disease

Axxonis Pharma AG

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

350

Germany;Italy;Poland

1703

EUCTR2006-000859-18-NL
(EUCTR)

25/01/2007

05/04/2007

An open label SLV308 safety extension to study S308.3.003 in early PD patients - An extension to the Vermeer study

Parkinson's Disease Early stage

Solvay pharmaceuticals

NULL

Not Recruiting

Female: yes
Male: yes

247

Portugal;Germany;Czech Republic;Netherlands;Estonia;Italy;Lithuania

1704

EUCTR2006-002339-26-HU
(EUCTR)

24/01/2007

24/08/2006

Levodopa treated Parkinson's disease patients with motor fluctuations.
MedDRA version: 8.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease

Product Name: MARS
Product Code: E2007

Eisai Limited

NULL

Not Recruiting

Female: yes
Male: yes

1400

Portugal;Hungary;Germany;United Kingdom;Czech Republic;Estonia;Spain;Italy;Austria;Sweden;Lithuania

1705

EUCTR2006-000678-57-FR
(EUCTR)

09/01/2007

10/10/2006

Parkinson 's Disease early stage
MedDRA version: 8.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's

Solvay pharmaceuticals

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

330

Portugal;United Kingdom;Germany;Czech Republic;Netherlands;Estonia;France;Italy;Lithuania

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1706

EUCTR2006-000859-18-PT
(EUCTR)

04/01/2007

18/09/2006

An open label SLV308 safety extension to study S308.3.003 in early PD patients - An extension to the Vermeer study

Parkinson's Disease Early stage

Solvay pharmaceuticals

NULL

Not Recruiting

Female: yes
Male: yes

225

Portugal;Germany;Czech Republic;Netherlands;Estonia;Italy;Lithuania

1707

NCT00640159
(ClinicalTrials.gov)

January 2007

18/3/2008

Tolerability and Efficacy of Switch From Oral Selegiline to Orally Disintegrating Selegiline (Zelapar) in Patients With Parkinson's Disease

Tolerability and Efficacy of Switch From Oral Selegiline to Orally Disintegrating Selegiline (Zelapar) in Patients With Parkinson's Disease.

Parkinson's Disease

Drug: Zelapar

Baylor College of Medicine

NULL

Completed

30 Years

90 Years

Both

Phase 4

United States

1708

NCT00855686
(ClinicalTrials.gov)

January 2007

3/3/2009

Memantine Versus Placebo in Parkinson's Disease Dementia or Dementia With Lewy Bodies

A Randomised, Double-blind, Placebo-controlled, 6-month Study of the Efficacy and Safety of Memantine in Patients With Parkinson's Disease Dementia or Dementia With Lewy Bodies

Parkinson's Disease Dementia;Dementia With Lewy Bodies

Drug: Memantine;Drug: Placebo

H. Lundbeck A/S

NULL

Completed

50 Years

N/A

Both

199

Phase 4

Germany

1709

NCT00465452
(ClinicalTrials.gov)

January 2007

24/4/2007

Impact of Switching to Continuous Release Dopamine Agonists

The Impact of Switching to Continuous Release Dopamine Agonists on Non-Motor Side Effects

Parkinson Disease

Drug: Continuous Release Dopamine Agonists

University of Toledo Health Science Campus

NULL

Completed

55 Years

N/A

Both

Phase 3

United States

1710

NCT01187966
(ClinicalTrials.gov)

January 2007

31/5/2010

Efficacy and Safety of Safinamide (50 and 100mg/Day) Versus Placebo, in Patients With Mid-late Stage Parkinson's Disease

A Phase III, Double-blind, Placebo-controlled Study to Determine the Efficacy and Safety of a Low (50 mg/Day) and High (100 mg/Day) Dose of Safinamide, as add-on Therapy, in Patients With Idiopathic Parkinson's Disease With Motor Fluctuations, Treated With a Stable Dose of Levodopa and Who May be Receiving Concomitant Treatment With Stable Doses of a Dopamine Agonist, and/or an Anticholinergic

Parkinson's Disease

Drug: Safinamide;Drug: Placebo

Newron

NULL

Completed

30 Years

80 Years

Both

669

Phase 3

NULL

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1711

NCT00427674
(ClinicalTrials.gov)

January 2007

25/1/2007

Assessment of the Biodistribution and Safety of 123-I MZINT in Healthy Subjects and Parkinson Disease Patients

Phase I Evaluation of (123-I)MZINT as a Brain SPECT Tracer of Serotonin Transporters in Healthy Human Subjects

Parkinson Disease

Drug: [123I] mZINT injection and serial dynamic SPECT imaging

Institute for Neurodegenerative Disorders

Molecular NeuroImaging

Terminated

18 Years

70 Years

Both

Phase 1

United States

1712

EUCTR2006-000678-57-PT
(EUCTR)

29/12/2006

10/08/2006

Parkinson 's Disease early stage
MedDRA version: 8.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's

Solvay pharmaceuticals B.V.

NULL

Not Recruiting

Female: yes
Male: yes

330

Portugal;United Kingdom;Germany;Czech Republic;Netherlands;France;Estonia;Italy;Lithuania

1713

EUCTR2006-002339-26-GB
(EUCTR)

28/12/2006

16/10/2006

Levodopa treated Parkinson's disease patients with motor fluctuations.
MedDRA version: 8.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease

Product Name: MARS
Product Code: E2007

Eisai Limited

NULL

Not Recruiting

Female: yes
Male: yes

1400

Portugal;Hungary;Germany;Czech Republic;United Kingdom;Estonia;Spain;Italy;Austria;Sweden;Lithuania

1714

EUCTR2005-002654-21-NO
(EUCTR)

28/12/2006

06/11/2006

A long-term health economics study of intraduodenal levodopa (Duodopa®) in routine care for patients with advanced idiopathic Parkinson’s disease with severe motor fluctuations and hyper-/dyskinesia. - DAPHNE

Treatment of advanced levodopa-responsive Parkinson’s disease with severe motor fluctuations and hyper-/dyskinesia when available combinations of Parkinson medicinal products have not given satisfactory results.

Trade Name: Duodopa intestinalgel
INN or Proposed INN: Levodopa
INN or Proposed INN: Carbidopa

Solvay Pharmaceuticals GmbH

NULL

Not Recruiting

Female: yes
Male: yes

Norway;Sweden

1715

EUCTR2006-000678-57-DE
(EUCTR)

22/12/2006

06/10/2006

Parkinson 's Disease early stage
MedDRA version: 8.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's

Solvay pharmaceuticals

NULL

Not Recruiting

Female: yes
Male: yes

376

Portugal;United Kingdom;Czech Republic;Germany;Netherlands;France;Estonia;Italy;Lithuania

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1716

EUCTR2006-005509-79-GB
(EUCTR)

21/12/2006

07/12/2006

A Clinic-Based, Phase IIa, Randomised, Double-Blind, Placebo-Controlled, Ascending-Dose, Multicentre Study Investigating the Safety, Tolerability, Efficacy, and Pharmacokinetics of VR040 in Patients with Established Idiopathic Parkinson’s Disease

Idiopathic Parkinson's Disease patients who have motor fluctuations with recognisable motor off” periods

Product Name: apomorphine hydrochloride
Product Code: VR040
INN or Proposed INN: apomorphine hydrochloride

Vectura Group plc

NULL

Not Recruiting

Female: yes
Male: yes

Phase 2

United Kingdom

1717

EUCTR2006-003490-27-GB
(EUCTR)

19/12/2006

29/09/2006

A Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study of Single and Multiple Oral Dose Administration of BIIB014 in Subjects with Moderate to Late Stage Parkinson’s Disease Who Are Also Receiving Treatment with Levodopa

Parkinson's disease
MedDRA version: 8.1;Level: PT;Classification code 10061536;Term: Parkinson's disease

BIOGEN IDEC LTD

NULL

Not Recruiting

Female: yes
Male: yes

137

Phase 2

United Kingdom

1718

EUCTR2006-005860-14-IT
(EUCTR)

19/12/2006

17/03/2009

A phase III, double-blind, placebo-controlled study to determine the efficacy and safety of a low (50 mg/day) and high (100 mg/day) dose of safinamide, as add-on therapy, in patients with idiopathic parkinson?s disease with motor fluctuations, treated with a stable dose of levodopa and who may be receiving concomitant treatment with stable doses of a dopamine agonist and/or an anticholinergic - ND

PATIENTS WITH IDIOPATHIC PARKINSON?S DISEASE WITH MOTOR FLUCTUATIONS
MedDRA version: 9.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease

Product Name: Safinamide
Product Code: NW-1015
Product Name: Safinamide
Product Code: NW-1015

NEWRON PHARMACEUTICALS

NULL

Not Recruiting

Female: yes
Male: yes

600

Phase 3

Italy

1719

EUCTR2005-000314-12-DE
(EUCTR)

19/12/2006

25/01/2007

Effect of 3 doses ( 20, 40 and 60 mg) of a sublingual formulation of piribedil ( S 90049) in combination with levodopa on end-of-dose fluctuations in advanced Parkinson's disease patients after a 14 day treatment-period ( one administration t.i.d). A randomized, double-blind study consisting of 3 cross-over: 40 mg versus placebo, 20 mg versus 60 mg and 40 mg versus 20 mg. - PARKOPI

Parkinson's Disease aggravated
MedDRA version: 7.0;Level: LLT;Classification code 10034006

Product Name: S90049
Product Code: S90049
INN or Proposed INN: piribedil
Product Name: S90049
Product Code: S90049
INN or Proposed INN: piribedil

Institut de Recherches Internationales Servier

NULL

Not Recruiting

Female: yes
Male: yes

Phase 2

Spain;Germany

1720

EUCTR2006-000858-45-FI
(EUCTR)

18/12/2006

26/06/2006

An open label SLV308 safety extension to study S308.3.001 in early PD patients. - An extension of the Rembrandt study

Parkinson's Disease Early Stage

Solvay Pharmaceuticals

NULL

Not Recruiting

Female: yes
Male: yes

300

Finland;Sweden

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1721

EUCTR2006-002339-26-IT
(EUCTR)

16/12/2006

05/06/2007

Studio di Estensione Multi-centrico, in Aperto per Valutare Sicurezza, Tollerabilita' ed Efficacia a Lungo Termine di E2007 come Terapia Aggiuntiva in Pazienti affetti da Morbo di Parkinson con Fluttuazioni Motorie Trattati con Levodopa. - E2007-G000-303

Levodopa treated Parkinson's Disease Patients with Motor Fluctuations
MedDRA version: 6.1;Level: PT;Classification code 10061536

Product Name: E2007

EISAI LTD UK

NULL

Not Recruiting

Female: yes
Male: yes

1400

Phase 3

Portugal;Hungary;Czech Republic;Estonia;Spain;Belgium;Lithuania;Austria;Germany;United Kingdom;Italy;Sweden

1722

EUCTR2006-002937-20-CZ
(EUCTR)

14/12/2006

24/10/2006

Parkinson's Disease
MedDRA version: 8.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's

Product Name: E2007
Product Code: MARS
Trade Name: Comtess
Product Name: Entacapone

Eisai Limited

NULL

Not Recruiting

Female: yes
Male: yes

702

Hungary;Czech Republic;France;Estonia;Spain;Italy;Latvia;Lithuania

1723

EUCTR2006-005140-89-NL
(EUCTR)

11/12/2006

01/12/2006

A PHASE I, DOUBLE BLIND, PLACEBO CONTROLLED, RANDOMIZED (WITHIN EACH GROUP) STUDY TO EVALUATE THE INTERACTION BETWEEN ORALLY ADMINISTERED TYRAMINE HYDROCHLORIDE AND RASAGILINE MESILATE IN HEALTHY SUBJECTS - Tyramine challenge study

This postmarketing Phase I study is performed in healthy volunteers. The IMP rasagiline 1mg is indicated for the treatment of Parkinson's Disease (PD).
MedDRA version: 9.1;Level: PT;Classification code 10061536

Trade Name: Selegiline HCl 5 PCH
Trade Name: Nardil
Product Name: Rasagiline 1mg tablet
Product Code: TVP-1012
INN or Proposed INN: Rasagiline
Other descriptive name: Rasagiline mesilate
Product Name: Rasagiline 2 mg tablet
Product Code: TVP-1012
INN or Proposed INN: Rasagiline
Other descriptive name: Rasagiline mesilate

TEVA Pharmaceuticals Industries Ltd

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

160

Phase 1

Netherlands

1724

EUCTR2006-002937-20-EE
(EUCTR)

11/12/2006

19/10/2006

Parkinson's Disease
MedDRA version: 8.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's

Product Name: E2007
Product Code: MARS
Trade Name: Comtess
Product Name: Entacapone

Eisai Limited

NULL

Not Recruiting

Female: yes
Male: yes

702

Hungary;Czech Republic;France;Estonia;Spain;Italy;Latvia;Lithuania

1725

EUCTR2006-002937-20-LT
(EUCTR)

04/12/2006

02/11/2006

Parkinson's Disease
MedDRA version: 8.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's

Product Name: E2007
Product Code: MARS
Trade Name: Comtess
Product Name: Entacapone
INN or Proposed INN: entacapone

Eisai Limited

NULL

Not Recruiting

Female: yes
Male: yes

702

Hungary;Czech Republic;France;Estonia;Spain;Italy;Latvia;Lithuania

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1726

EUCTR2005-002038-36-FR
(EUCTR)

01/12/2006

24/08/2010

A randomised, double-blind, placebo-controlled, 6-month study of the efficacy and safety of memantine in patients with Parkinson’s disease dementia or dementia with Lewy Bodies

Patients with Parkinson’s disease dementia or dementia with Lewy Bodies

Trade Name: Ebixa
Product Name: Ebixa
INN or Proposed INN: MEMANTINE HYDROCHLORIDE
Trade Name: Ebixa
Product Name: Ebixa
INN or Proposed INN: MEMANTINE HYDROCHLORIDE
Trade Name: Ebixa
Product Name: Ebixa
INN or Proposed INN: MEMANTINE HYDROCHLORIDE
Trade Name: Ebixa
Product Name: Ebixa
INN or Proposed INN: MEMANTINE HYDROCHLORIDE
Trade Name: Ebixa
Product Name: Ebixa
INN or Proposed INN: MEMANTINE HYDROCHLORIDE
Trade Name: Ebixa
Product Name: Ebixa
INN or Proposed INN: MEMANTINE HYDROCHLORIDE

H. Lundbeck A/S

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

200

Germany;United Kingdom;France;Spain;Italy;Greece;Austria

1727

NCT00853879
(ClinicalTrials.gov)

December 2006

26/2/2009

An Exploratory, Randomized, Blinded, Placebo-Controlled Trial of Folic Acid and L-methylfolate in Parkinson's Disease

Parkinson's Disease

Dietary Supplement: Folic Acid , Vitamin B6, Vitamin B12;Dietary Supplement: B6, B12, L-methylfolate;Dietary Supplement: B6, B12, Placebo

North Shore Long Island Jewish Health System

NULL

Terminated

30 Years

N/A

Both

150

N/A

United States

1728

NCT01964573
(ClinicalTrials.gov)

December 2006

14/10/2013

Trial to Evaluate the Pharmacokinetics, Safety, and Tolerability of Rotigotine in Healthy Korean Subjects

A Single-site, Randomized, Double-blind, Placebo-controlled, Repeated-dose Trial to Evaluate the Pharmacokinetics, Safety, and Tolerability of Rotigotine in 2 Different Dosages (2 mg / 24 Hours [10 cm2], 4 mg / 24 Hours [20 cm2]) in Healthy Korean Subjects

Parkinson's Disease

Drug: Rotigotine;Other: Placebo

UCB Pharma

NULL

Completed

19 Years

45 Years

Both

Phase 1

Korea, Republic of

1729

NCT01631812
(ClinicalTrials.gov)

December 2006

25/6/2012

A Long-Term Extension Trial From Late Phase II of SPM 962 in Advanced Parkinson's Disease Patients

An Open-label Long-term Extension Trial From Late Phase II of SPM962 (243-05-001) in Advanced Parkinson's Disease Patients With Concomitant Treatment of L-dopa

Parkinson's Disease

Drug: SPM 962

Otsuka Pharmaceutical Co., Ltd.

NULL

Completed

N/A

All

130

Phase 2

Japan

1730

NCT00036296
(ClinicalTrials.gov)

December 2006

8/5/2002

Effects of Talampanel on Patients With Advanced Parkinson's Disease

Effects of Talampanel on Patients With Advanced Parkinson's Disease Who Have Been on Sinemet for More Than 5 Years and Have Dyskinesia (Abnormal Involuntary Movements)

Dyskinesias;Parkinson Disease;Movement Disorders

Drug: talampanel

Teva Pharmaceutical Industries

NULL

Completed

40 Years

85 Years

Both

Phase 1;Phase 2

United States;Canada

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1731

EUCTR2005-002038-36-DE
(EUCTR)

29/11/2006

19/01/2007

A randomised, double-blind, placebo-controlled, 6-month study of the efficacy and safety of memantine in patients with Parkinson’s disease dementia or dementia with Lewy Bodies

Patients with Parkinson’s disease dementia or dementia with Lewy Bodies

Trade Name: Ebixa
Product Name: Memantine
INN or Proposed INN: MEMANTINE HYDROCHLORIDE
Product Name: Memantine
INN or Proposed INN: MEMANTINE HYDROCHLORIDE
Trade Name: Ebixa
Product Name: Memantine
INN or Proposed INN: MEMANTINE HYDROCHLORIDE
Product Name: Memantine
INN or Proposed INN: MEMANTINE HYDROCHLORIDE

H. Lundbeck A/S

NULL

Not Recruiting

Female: yes
Male: yes

200

United Kingdom;Germany;France;Spain;Italy;Greece;Austria

1732

EUCTR2006-001755-36-GB
(EUCTR)

20/11/2006

29/09/2006

Efficacy and safety of Stalevo in subjects with early wearing-off identified using a screening tool WOQ-9; An open, non-randomised, multinational, multi-centre 6-week direct switch study in levodopa-treated Parkinson's disease patients - SENSE

Parkinson’s disease
MedDRA version: 8.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease

Orion Corporation Orion Pharma

NULL

Not Recruiting

Female: yes
Male: yes

100

Phase 4

Germany;United Kingdom;Sweden

1733

NCT00406029
(ClinicalTrials.gov)

November 20, 2006

30/11/2006

Dyskinesia in Parkinson's Disease (Study P04501)

A Phase 2, 12-Week, Double-Blind, Dose-Finding, Placebo-Controlled Study to Assess the Efficacy and Safety of a Range of SCH 420814 Doses in Subjects With Moderate to Severe Parkinson's Disease Experiencing Motor Fluctuations and Dyskinesias

Parkinson Disease;Movement Disorders;Central Nervous System Diseases;Neurodegenerative Diseases;Brain Diseases

Drug: Preladenant;Drug: Placebo;Drug: L-dopa;Drug: Other Parkinson's Disease treatments

Merck Sharp & Dohme Corp.

NULL

Completed

30 Years

N/A

All

253

Phase 2

Argentina;Australia;Canada;Chile;Colombia;France;Guatemala;Hong Kong;Italy;New Zealand;Peru;Singapore;South Africa;Spain;United States

1734

EUCTR2006-004112-51-IT
(EUCTR)

14/11/2006

04/12/2006

A randomised, double-blind, double-dummy, two-period, cross-over study to determine the pharmacokinetics, pharmacodynamics and safety of multiple doses of V1512 effervescent tablets in Parkinson s Disease PD patients compared to standard levodopa/carbidopa Sinemet oral tablets - ND

Parkinson s disease
MedDRA version: 8.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease

Trade Name: SIRIO*30CPR EFF 25MG+100MG
INN or Proposed INN: Melevodopa and decarboxylase inhibitor
Trade Name: SINEMET*50CPR 100MG+25MG
INN or Proposed INN: LEVODOPA DC.IT FU
INN or Proposed INN: CARBIDOPA FU

VERNALIS DEVELOPMENT LIMITED

NULL

Not Recruiting

Female: yes
Male: yes

Italy

1735

EUCTR2006-000678-57-GB
(EUCTR)

14/11/2006

30/05/2007

Parkinson 's Disease early stage
MedDRA version: 8.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's

Solvay pharmaceuticals

NULL

Not Recruiting

Female: yes
Male: yes

330

Phase 3

France;Portugal;Estonia;Czech Republic;Lithuania;Netherlands;Germany;Italy;United Kingdom

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1736

EUCTR2006-000859-18-LT
(EUCTR)

07/11/2006

07/09/2006

An open label SLV308 safety extension to study S308.3.003 in early PD patients - An extension to the Vermeer study

Parkinson's Disease Early stage

Solvay pharmaceuticals

NULL

Not Recruiting

Female: yes
Male: yes

225

Portugal;Germany;Czech Republic;Netherlands;Estonia;Italy;Lithuania

1737

EUCTR2006-000678-57-LT
(EUCTR)

07/11/2006

07/09/2006

Parkinson 's Disease early stage
MedDRA version: 8.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's

Solvay pharmaceuticals

NULL

Not Recruiting

Female: yes
Male: yes

330

Portugal;United Kingdom;Germany;Czech Republic;Netherlands;France;Estonia;Italy;Lithuania

1738

EUCTR2006-001793-24-PT
(EUCTR)

07/11/2006

31/07/2006

A MULTICENTRE, DOUBLE-BLIND, RANDOMIZED, ACTIVE- AND PLACEBO-CONTROLLED TRIAL TO INVESTIGATE THE EFFICACY AND TOLERABILITY OF NEBICAPONE IN PARKINSON’S DISEASE PATIENTS WITH WEARING-OFF” PHENOMENON TREATED WITH LEVODOPA/CARBIDOPA OR LEVODOPA/BENSERAZIDE - not available

Patients with idiopathic Parkinson’s disease (PD) and with end-of-dose deterioration (wearing-off) phenomenon although currently treated with levodopa/DDCI.
MedDRA version: 7;Level: LLT;Classification code 10061536

Product Name: Nebicapone
Product Code: BIA 3-202
Trade Name: COMTAN®
Product Name: Entacapone
INN or Proposed INN: Entacapone
Product Name: Nebicapone
Product Code: BIA 3-202
Product Name: Nebicapone
Product Code: BIA 3-202

BIAL - Portela & Cª, SA

NULL

Not Recruiting

Female: yes
Male: yes

250

Portugal;Austria

1739

EUCTR2006-000678-57-EE
(EUCTR)

03/11/2006

01/09/2006

Parkinson 's Disease early stage
MedDRA version: 8.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's

Solvay pharmaceuticals

NULL

Not Recruiting

Female: yes
Male: yes

330

Portugal;United Kingdom;Germany;Czech Republic;Netherlands;France;Estonia;Italy;Lithuania

1740

EUCTR2006-000859-18-EE
(EUCTR)

03/11/2006

01/09/2006

An open label SLV308 safety extension to study S308.3.003 in early PD patients - An extension to the Vermeer study

Parkinson's Disease Early stage

Solvay pharmaceuticals

NULL

Not Recruiting

Female: yes
Male: yes

225

Portugal;Germany;Czech Republic;Netherlands;Estonia;Italy;Lithuania

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1741

EUCTR2006-004582-33-GB
(EUCTR)

03/11/2006

23/01/2012

A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Escalating Study Investigating the Efficacy and Safety of VR040 in the Treatment of Unpredictable Off” or End-of-Dose Wearing Off” Episodes in Patients With Advanced Idiopathic Parkinson’s Disease

Hypomobility (off or freezing) episodes associated with advanced Parkinson's disease

Product Name: Apomorphine hydrochloride
Product Code: VR040

Vectura Group plc

NULL

Not Recruiting

Female: yes
Male: yes

Phase 2

United Kingdom

1742

EUCTR2006-002937-20-LV
(EUCTR)

01/11/2006

02/11/2006

Parkinson's Disease
MedDRA version: 8.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's

Product Name: E2007
Product Code: MARS
Trade Name: Comtess
Product Name: Entacapone

Eisai Limited

NULL

Not Recruiting

Female: yes
Male: yes

702

Hungary;Czech Republic;France;Estonia;Spain;Italy;Latvia;Lithuania

1743

EUCTR2006-002339-26-CZ
(EUCTR)

01/11/2006

21/08/2006

Levodopa treated Parkinson's disease patients with motor fluctuations.
MedDRA version: 8.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease

Product Name: MARS
Product Code: E2007

Eisai Limited

NULL

Not Recruiting

Female: yes
Male: yes

1400

Portugal;Hungary;Germany;United Kingdom;Czech Republic;Estonia;Spain;Italy;Austria;Sweden;Lithuania

1744

NCT00402233
(ClinicalTrials.gov)

November 2006

19/11/2006

A Randomized, Double-blind, Active (Pramipexole 0.5 mg Tid) and Placebo Controlled, Study of Pramipexole Given 0.5 mg and 0.75 mg Bid Over 12-week Treatment in Early Parkinson's Disease (PD) Patients

A Randomized, Double-blind, Active (Pramipexole 0.5 mg Tid) and Placebo Controlled, Efficacy Study of Pramipexole Given 0.5 mg and 0.75 mg Bid Over a 12-week Treatment Phase in Early Parkinson's Disease Patients (PramiBID)

Parkinson Disease

Drug: Pramipexole;Drug: Placebo

Boehringer Ingelheim

NULL

Completed

31 Years

N/A

All

312

Phase 4

United States

1745

NCT00335166
(ClinicalTrials.gov)

November 2006

8/6/2006

SLV 308 and Pramipexole for Treatment of Patients With Early Parkinson Disease

A Multicenter, Randomized, Double Blind, Parallel-Group Placebo and Pramipexole Controlled Study to Assess Efficacy and Safety of SLV308 Monotherapy in the Treatment of Patients With Early Stage Parkinson's Disease.

Early Stage Parkinson Disease

Drug: Pardaprunox;Drug: pramipexole;Drug: Placebo Comparator

Solvay Pharmaceuticals

NULL

Completed

30 Years

N/A

Both

330

Phase 3

United States;Australia;Czech Republic;Estonia;France;Germany;India;Italy;Lithuania;Malaysia;Netherlands;Poland;Portugal;South Africa;Spain;Taiwan;Thailand;United Kingdom

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1746

NCT00360308
(ClinicalTrials.gov)

November 2006

2/8/2006

Efficacy, Safety and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients With Motor Fluctuations

A Multi-centre, Randomised, Double-blind, Placebo and Entacapone Controlled, Parallel Group Study of the Efficacy, Safety and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients With Motor Fluctuations

Parkinson's Disease

Drug: Placebo;Drug: E2007

Eisai Limited

NULL

Terminated

30 Years

N/A

All

723

Phase 3

France

1747

NCT00387075
(ClinicalTrials.gov)

November 2006

10/10/2006

A Study Evaluating Potential Screening Tools for Detecting Parkinson Disease

Parkinson Associated Risk Factor Study (PARS): Evaluating Potential Screening Tools for Parkinson Disease

Parkinson Disease

Procedure: [123I]ß-CIT and SPECT imaging;Drug: [123I]ß-CIT

Institute for Neurodegenerative Disorders

United States Department of Defense;Molecular NeuroImaging

Active, not recruiting

50 Years

N/A

All

3000

Phase 2

United States

1748

NCT00397696
(ClinicalTrials.gov)

November 2006

7/11/2006

Evaluation of 5-[123I]-A-85380 and SPECT Imaging in Individuals With Parkinsons Disease

Evaluation of 5-[123I]-A-85380 and SPECT Imaging as a Marker of Nicotinic Receptor Density in the Brain of Parkinson Disease Subjects

Parkinson Disease

Drug: [123I] 5-IA

Institute for Neurodegenerative Disorders

Department of Defense

Completed

21 Years

N/A

Both

Phase 2

United States

1749

NCT00404170
(ClinicalTrials.gov)

November 2006

22/11/2006

Assessing Imaging as a Tool in Monitoring and Predicting the Progression of Parkinson Disease

Assessing the Determinants of PD Progression - Long-term Dopamine Transporter Imaging in the PRECEPT Cohort

Parkinson Disease

Drug: B-CIT and SPECT imaging

Institute for Neurodegenerative Disorders

United States Department of Defense

Completed

30 Years

N/A

All

396

Phase 2

United States

1750

NCT00491998
(ClinicalTrials.gov)

November 2006

26/6/2007

PK, PD and Safety of Multiple Doses of V1512 Tablets in PD Patients Compared to Standard Levodopa/Carbidopa Oral Tablets

Randomised, Double-blind, Double-dummy, Two-period, Cross-over Study to Determine the PK, PD and Safety of Multiple Doses of V1512 Effervescent Tablets in Parkinson's Disease Patients Compared to Sinemet® Oral Tablets

Parkinson's Disease

Drug: V1512;Drug: V1512 and Entacapone

Vernalis (R&D) Ltd

Cita NeuroPharmaceuticals;INC Research

Completed

30 Years

N/A

Both

Phase 1;Phase 2

Italy

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1751

NCT00400634
(ClinicalTrials.gov)

November 2006

15/11/2006

Double-Blind, Multicenter, Sham Surgery Controlled Study of CERE-120 in Subjects With Idiopathic Parkinson's Disease

Multicenter, Randomized, Double-Blind, Sham Surgery-Controlled Study of CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN]) to Assess the Efficacy and Safety of Bilateral Intraputaminal (IPu) Delivery in Subjects With Idiopathic Parkinson's Disease

Idiopathic Parkinson's Disease

Drug: CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN]);Procedure: Sham Surgery

Ceregene

NULL

Completed

35 Years

75 Years

All

Phase 2

United States

1752

NCT00468078
(ClinicalTrials.gov)

November 2006

30/4/2007

Efficacy and Safety of F-18 FPCIT PET in Parkinson's Disease and Essential Tremor Patients

The Single Center, Phase III Clinical Trial to Evaluate the Efficacy and the Safety of [18F]FPCIT Positron Emission Tomography in Parkinson's Disease and Essential Tremor Patients

Parkinson's Disease

Procedure: PET/CT;Drug: F-18 FPCIT

Asan Medical Center

NULL

Completed

40 Years

N/A

Both

Phase 3

Korea, Republic of

1753

NCT00397228
(ClinicalTrials.gov)

November 2006

6/11/2006

ALTROPANE® SPECT Imaging in Patients With Parkinson Disease

Optimizing the Performance of ALTROPANE® SPECT Imaging in Patients With Parkinson Disease

Parkinson Disease

Drug: ALTROPANE ®

Molecular NeuroImaging

Institute for Neurodegenerative Disorders

Completed

30 Years

N/A

Both

Phase 2

United States

1754

EUCTR2005-002038-36-GB
(EUCTR)

31/10/2006

09/10/2006

A randomised, double-blind, placebo-controlled, 6-month study of the efficacy and safety of memantine in patients with Parkinson’s disease dementia or dementia with Lewy Bodies

Patients with Parkinson’s disease dementia or dementia with Lewy Bodies
MedDRA version: 8.1;Level: LLT;Classification code 10012284;Term: Dementia due to Parkinson's disease

H. Lundbeck A/S

NULL

Not Recruiting

Female: yes
Male: yes

200

Phase 4

France;Greece;Spain;Austria;Germany;Italy;United Kingdom

1755

EUCTR2006-002339-26-EE
(EUCTR)

20/10/2006

15/08/2006

Levodopa treated Parkinson's disease patients with motor fluctuations.
MedDRA version: 8.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease

Product Name: MARS
Product Code: E2007

Eisai Limited

NULL

Not Recruiting

Female: yes
Male: yes

1400

Portugal;Hungary;Germany;United Kingdom;Czech Republic;Estonia;Spain;Italy;Austria;Sweden;Lithuania

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1756

EUCTR2006-002339-26-SE
(EUCTR)

19/10/2006

22/09/2006

Levodopa treated Parkinson's disease patients with motor fluctuations.
MedDRA version: 8.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease

Product Name: MARS
Product Code: E2007

Eisai Limited

NULL

Not Recruiting

Female: yes
Male: yes

1400

Portugal;Hungary;Germany;United Kingdom;Czech Republic;Estonia;Spain;Italy;Austria;Lithuania;Sweden

1757

EUCTR2006-002339-26-BE
(EUCTR)

16/10/2006

24/08/2006

Levodopa treated Parkinson's disease patients with motor fluctuations.
MedDRA version: 8.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease

Product Name: MARS
Product Code: E2007

Eisai Limited

NULL

Not Recruiting

Female: yes
Male: yes

1400

Portugal;Hungary;Czech Republic;Estonia;Spain;Belgium;Lithuania;Austria;Germany;Italy;United Kingdom;Sweden

1758

EUCTR2006-000858-45-SK
(EUCTR)

11/10/2006

28/09/2006

An open label SLV308 safety extension to study S308.3.001 in early PD patients. - An extension of the Rembrandt study

Parkinson's Disease Early Stage

Solvay Pharmaceuticals

NULL

Not Recruiting

Female: yes
Male: yes

300

Phase 3

Slovakia;Finland;Sweden

1759

EUCTR2006-002339-26-LT
(EUCTR)

05/10/2006

07/08/2006

Levodopa treated Parkinson's disease patients with motor fluctuations.
MedDRA version: 8.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease

Product Name: MARS
Product Code: E2007

Eisai Limited

NULL

Not Recruiting

Female: yes
Male: yes

1400

Portugal;Hungary;Germany;United Kingdom;Czech Republic;Estonia;Spain;Italy;Austria;Sweden;Lithuania

1760

NCT00590122
(ClinicalTrials.gov)

October 2006

28/12/2007

Parcopa Versus Carbidopa-Levodopa in a Single Dose Cross-Over Comparison Study

COMPARISON OF ORALLY DISSOLVING LEVODOPA (PARCOPA®) TO CONVENTIONAL ORAL LEVODOPA: A SINGLE DOSE, DOUBLE-BLIND, PLACEBO CONTROLLED, CROSS-OVER TRIAL

Parkinson's Disease

Drug: Parcopa;Drug: carbidopa -levodopa

Baylor College of Medicine

UCB Pharma

Completed

31 Years

80 Years

Both

Phase 4

United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1761

NCT00360412
(ClinicalTrials.gov)

October 2006

2/8/2006

A Study of E2007 as an Adjunctive Therapy in Levodopa Treated Parkinson's Disease Patients With Motor Fluctuations

Parkinson's Disease

Drug: E2007

Eisai Inc.

NULL

Terminated

30 Years

N/A

Male

997

Phase 3

Germany

1762

NCT00373087
(ClinicalTrials.gov)

October 2006

6/9/2006

COMT Polymorphism and Entacapone Efficacy

Influence of Catechol-O-methyltransferase Polymorphism on Entacapone Efficacy in Parkinson's Disease

Parkinson's Disease

Drug: entacapone;Drug: l dopa versus placebo

Assistance Publique - Hôpitaux de Paris

NULL

Completed

30 Years

N/A

Both

Phase 4

France

1763

NCT00399477
(ClinicalTrials.gov)

October 2006

10/11/2006

A Non-Blinded Study Demonstrating the Effectiveness and Safety of Azilect Alone or in Combination Therapy in Parkinson's Disease

Open-label, Multicenter, Effectiveness and Safety Study of Once Daily AZILECT® as Mono- or Adjunct Therapy in Patients With Idiopathic Parkinson's Disease (PD)

Parkinson's Disease

Drug: rasagiline mesylate;Drug: Rasagiline mesylate plus Mirapex;Drug: Rasagiline mesylate with Levodopa;Drug: Rasagiline mesylate with Requip

Teva Neuroscience, Inc.

NULL

Completed

30 Years

N/A

Both

200

Phase 4

United States

1764

NCT00391898
(ClinicalTrials.gov)

October 2006

24/10/2006

Efficacy of Levodopa/Carbidopa/Entacapone vs Levodopa/Carbidopa in Parkinson's Disease Patients With Early Wearing-off

A 3-month, Multi-center, Double-blind, Randomized Study to Evaluate the Efficacy of Levodopa/Carbidopa/Entacapone vs Levodopa/Carbidopa in Parkinson's Disease Patients With Impairment of Activities of Daily Living and Early Wearing-off With Levodopa

Parkinson's Disease

Drug: Levodopa /carbidopa /entacapone;Drug: Levodopa /carbidopa

Novartis

NULL

Completed

30 Years

80 Years

All

Phase 4

Spain

1765

NCT03103399
(ClinicalTrials.gov)

September 26, 2006

28/3/2017

Efficacy and Tolerability of Nebicapone in Parkinson's Disease Patients With Wearingoff Phenomenon

A Multicentre, Double-blind, Randomised, Active- and Placebo-controlled Trial to Investigate the Efficacy and Tolerability of Nebicapone in Parkinson's Disease Patients With Wearingoff Phenomenon Treated With Levodopa/Carbidopa or Levodopa/Benserazide

Parkinson Disease

Drug: Comtan®;Drug: Nebicapone;Drug: Levodopa /DDCI;Drug: Placebo

Bial - Portela C S.A.

NULL

Completed

30 Years

80 Years

All

254

Phase 2

NULL

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1766

EUCTR2006-002339-26-AT
(EUCTR)

25/09/2006

18/10/2006

Levodopa treated Parkinson's disease patients with motor fluctuations.
MedDRA version: 8.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease

Product Name: MARS
Product Code: E2007

Eisai Limited

NULL

Not Recruiting

Female: yes
Male: yes

1400

Portugal;Hungary;Germany;United Kingdom;Czech Republic;Estonia;Spain;Italy;Austria;Sweden;Lithuania

1767

EUCTR2005-002038-36-AT
(EUCTR)

22/09/2006

09/10/2006

A randomised, double-blind, placebo-controlled, 6-month study of the efficacy and safety of memantine in patients with Parkinson’s disease dementia or dementia with Lewy Bodies

Patients with Parkinson’s disease dementia or dementia with Lewy Bodies

H. Lundbeck A/S

NULL

Not Recruiting

Female: yes
Male: yes

200

Germany;United Kingdom;France;Spain;Italy;Greece;Austria

1768

EUCTR2006-000678-57-IT
(EUCTR)

14/09/2006

26/06/2007

A multicenter, randomized, double-blind, parallel-group placebo and pramipexole controlled study to assess efficacy and safety of SLV308 monotherapy in the treatment of patients with early stage Parkinson's Disease. - ND

Parkinson's Disease
MedDRA version: 9.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease

Product Name: SLV308 (mono)hydrochloride
Product Code: SLV308
Product Name: Pramipexole
INN or Proposed INN: Pramipexole
Product Name: SLV308 (mono)hydrochloride
Product Code: SLV308
Product Name: SLV308 (mono)hydrochloride
Product Code: SLV308
Product Name: SLV308 (mono)hydrochloride
Product Code: SLV308
Product Name: SLV308 (mono)hydrochloride
Product Code: SLV308
Product Name: SLV308 (mono)hydrochloride
Product Code: SLV308

SOLVAY PHARMACEUTICALS B.V.

NULL

Not Recruiting

Female: yes
Male: yes

390

Portugal;United Kingdom;Germany;Czech Republic;Netherlands;France;Estonia;Italy;Lithuania

1769

EUCTR2005-005146-39-IT
(EUCTR)

14/09/2006

06/12/2006

A Phase-2, 12-week, Double-Blind, Dose-Finding, Placebo-Controlled Study to Assess the Efficacy and Safety of a range of SCH 420814 Doses 1 mg BID, 2 mg BID, 5 mg BID and Possibly 10 mg BID in Subjects With Moderate to Severe Parkinson s Disease Experiencing Motor Fluctuations and Dyskinesias. - ND

Moderate to severe Parkinson s disease with motor fluctuation and dyskinesias.
MedDRA version: 8.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease

Product Code: SCH 420814
Product Code: SCH 420814

Schering Plough Research Institute

NULL

Not Recruiting

Female: yes
Male: yes

160

Phase -2

Italy

1770

EUCTR2006-000859-18-CZ
(EUCTR)

11/09/2006

02/08/2006

An open label SLV308 safety extension to study S308.3.003 in early PD patients - An extension to the Vermeer study

Parkinson's Disease Early stage

Solvay Pharmaceuticals

NULL

Not Recruiting

Female: yes
Male: yes

225

Portugal;Germany;Czech Republic;Netherlands;Estonia;Italy;Lithuania

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1771

EUCTR2005-004949-34-SE
(EUCTR)

06/09/2006

27/03/2006

Parkinson's disease
MedDRA version: 6.1;Level: pref;Classification code 10061536

Product Name: Sifrol
Product Code: SND 919 CL2 Y
INN or Proposed INN: Pramipexole
Product Name: Sifrol
Product Code: SND 919 CL2 Y
INN or Proposed INN: Pramipexole
Product Name: Sifrol
Product Code: SND 919 CL2 Y
INN or Proposed INN: Pramipexole

Boehringer Ingelheim AB

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

500

Finland;Germany;United Kingdom;Spain;Italy;Austria;Sweden

1772

EUCTR2004-005234-39-LV
(EUCTR)

06/09/2006

29/09/2006

Multicentre, randomised, double-blind study to compare Stalevo® to levodopa/carbidopa in patients with Parkinson's disease experiencing symptoms of early wearing-off - SEWOP

Parkinson's disease
MedDRA version: 8.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease

Trade Name: Stalevo
INN or Proposed INN: Levodopa
INN or Proposed INN: Carbidopa
INN or Proposed INN: Entacapone
Trade Name: Stalevo
INN or Proposed INN: Levodopa
INN or Proposed INN: Carbidopa
INN or Proposed INN: Entacapone
Trade Name: Sinemet
INN or Proposed INN: Levodopa
INN or Proposed INN: Carbidopa
Trade Name: Sinemet
INN or Proposed INN: Levodopa
INN or Proposed INN: Carbidopa

Orion Corporation, ORION PHARMA, 02200 Espoo, Finland

NULL

Not Recruiting

Female: yes
Male: yes

244

Finland;Germany;United Kingdom;Denmark;Ireland;Latvia;Lithuania;Sweden

1773

EUCTR2005-001006-12-CZ
(EUCTR)

06/09/2006

24/08/2006

Double-blind, placebo-controlled, randomized, multicentre Phase II / III study to evaluate the efficacy and safety of Lisparin®, applied subcutaneously by means of a minipump in patients with advanced Parkinson’s Disease refractory to conventional oral therapy. - CALIPSO

Patients with advanced Parkinson’s disease with motor fluctuations and OFF” periods refractory to conventional treatment.
MedDRA version: 9.1;Level: LLT;Classification code 10034006;Term: Parkinson's disease aggravated

Product Name: Lisparin
INN or Proposed INN: Lisuride Hydrogenmaleate
Other descriptive name: 3- (9,10- Didehydro- 6- methyl- 8?- ergolinyl)-1,1- diethylurea hydrogenmaleate
Product Name: Pramipexol
INN or Proposed INN: Pramipexol
Other descriptive name: (S)- 2- Amino- 4,5,6,7- tetrahydro- 6- (propylamino)benzothiazol
Product Name: Pramipexol
INN or Proposed INN: Pramipexol
Other descriptive name: (S)- 2- Amino- 4,5,6,7- tetrahydro- 6- (propylamino)benzothiazol
Product Name: Cabergoline
INN or Proposed INN: Cabergoline
Other descriptive name: 1[(6- Allyl- 8ß- ergolinyl)carbonyl]- 1- [3- (dimethylamino)propyl]- 3- ethylurea
Product Name: Cabergoline
INN or Proposed INN: Cabergoline
Other descriptive name: 1[(6- Allyl- 8ß- ergolinyl)carbonyl]- 1- [3- (dimethylamino)propyl]- 3- ethylurea

Axxonis Pharma GmbH

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

Phase 2

Germany;Czech Republic;Italy;Austria

1774

EUCTR2005-005423-34-HU
(EUCTR)

04/09/2006

05/07/2006

A Randomised, Double-Blind, Double-Dummy, Parallel Group Comparison of 24 Weeks of Treatment with Ropinirole Immediate Release (IR) Tablets or Ropinirole Prolonged Release / Extended Release (PR/XR) Tablets in Advanced Stage Parkinson’s Disease Subjects who are not Adequately Controlled on L-dopa.

Parkinson's disease
MedDRA version: 8.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease

Product Name: Ropinirole PR/XR Tablets
INN or Proposed INN: Ropinirole
Other descriptive name: Ropinirole hydrochloride
Product Name: Ropinirole PR/XR Tablets
INN or Proposed INN: Ropinirole
Other descriptive name: Ropinirole hydrochloride
Product Name: Ropinirole PR/XR Tablets
INN or Proposed INN: Ropinirole
Other descriptive name: Ropinirole hydrochloride
Product Name: Ropinirole IR Tablets
INN or Proposed INN: Ropinirole
Other descriptive name: Ropinirole hydrochloride
Product Name: Ropinirole IR Tablets
INN or Proposed INN: Ropinirole
Other descriptive name: Ropinirole hydrochloride
Product Name: Ropinirole IR Tablets

GlaxoSmithKline Research & Development Ltd

NULL

Not Recruiting

Female: yes
Male: yes

516

Hungary;United Kingdom;Czech Republic;Germany;Spain;Italy

1775

NCT00208611
(ClinicalTrials.gov)

September 2006

13/9/2005

Vitamin B12 Status and Response to Vitamin B12 Supplementation in Patients With Parkinson's Disease

Assessment of Cobalamin Status and Responses to Supplementation in Patients With Parkinson's Disease : a Pilot Study

Parkinson's Disease

Dietary Supplement: Vitamin B12 Supplementation

Emory University

National Institutes of Health (NIH)

Terminated

21 Years

N/A

Both

Phase 2;Phase 3

United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1776

NCT00355927
(ClinicalTrials.gov)

September 2006

23/7/2006

Sedation During Microelectrode Recordings Before Deep Brain Stimulation for Movement Disorders.

Changes of the Neuronal Activity in the Subthalamic Nucleus Under Propofol Sedation During Stereotactic Electrode Implantation.

Movement Disorders;Parkinson Disease;Parkinsonian Disorders;Dystonia;Tourette Syndrome

Procedure: Sedation with IV propofol

Hadassah Medical Organization

NULL

Enrolling by invitation

N/A

Both

N/A

Israel

1777

NCT00462007
(ClinicalTrials.gov)

September 2006

17/4/2007

Study to Evaluate Initiation of Stalevo in Early Wearing-off

Efficacy and Safety of Stalevo® in Subjects With Early Wearing-off Identified Using a Screening Tool WOQ-9; an Open, Non-randomised, Multinational, Multicentre 6-week Direct Switch Study in Levodopa-treated Parkinson's Disease Patients

Parkinson's Disease

Drug: Stalevo

Orion Corporation, Orion Pharma

NULL

Completed

35 Years

N/A

Both

115

Phase 4

Germany;Sweden;United Kingdom

1778

NCT00507715
(ClinicalTrials.gov)

September 2006

25/7/2007

Study of the Modification of the Pharmacokinetic Profile of Levodopa by the Fiber Plantago Ovata Husk

Clinical Trial to Study the Modification of the Pharmacokinetic Profile of Levodopa by the Fiber Plantago Ovata Husk

Parkinson's Disease, Idiopathic

Drug: Plantago ovata husk;Other: hemicellulose crystalline

Rottapharm Spain

NULL

Completed

60 Years

80 Years

Both

Phase 1

Spain

1779

EUCTR2005-006033-32-SE
(EUCTR)

15/08/2006

22/06/2006

A Randomized, Double-blind, Placebo Controlled Parallel-group Fixed and Flexible SLV308 Dose Arm Study to Assess Efficacy and Safety of SLV308 Monotherapy in the Treatment of Patients with Early Stage Parkinson’s Disease - The Rembrandt study

Parkinson's Disease Early Stage

Solvay Pharmaceuticals

NULL

Not Recruiting

Female: yes
Male: yes

440

Finland;Slovakia;Sweden

1780

EUCTR2006-001755-36-SE
(EUCTR)

09/08/2006

30/06/2006

Parkinson’s disease
MedDRA version: 8.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease

Orion Corporation Orion Pharma, FI-02200 Espoo, Finland

NULL

Not Recruiting

Female: yes
Male: yes

100

United Kingdom;Germany;Sweden

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1781

EUCTR2005-004314-33-PT
(EUCTR)

09/08/2006

10/05/2006

A Multi-centre, Randomised, Double-blind, Placebo-controlled, Parallel Group Study of the Efficacy, Safety and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients with Motor Fluctuations

Levodopa treated Parkinson's disease patients with motor fluctuations
MedDRA version: 8.1;Classification code 10061536

Product Name: MARS
Product Code: E2007
Product Name: MARS
Product Code: E2007

Eisai Limited

NULL

Not Recruiting

Female: yes
Male: yes

1260

Hungary;Portugal;Germany;United Kingdom;Estonia;Spain;Italy;Lithuania;Sweden

1782

EUCTR2005-004949-34-DE
(EUCTR)

04/08/2006

30/03/2006

Parkinson's disease
MedDRA version: 6.1;Level: pref;Classification code 10061536

Trade Name: Sifrol
Product Name: Sifrol
Product Code: SND 919 CL2 Y
INN or Proposed INN: Pramipexole
Trade Name: Sifrol
Product Name: Sifrol
Product Code: SND 919 CL2 Y
INN or Proposed INN: Pramipexole
Trade Name: SIFROL
Product Name: Sifrol
Product Code: SND 919 CL2 Y
INN or Proposed INN: Pramipexole

Boehringer Ingelheim Pharma GmbH & Co. KG

NULL

Not Recruiting

Female: yes
Male: yes

500

Finland;Spain;Austria;Germany;Italy;United Kingdom;Sweden

1783

EUCTR2006-000678-57-NL
(EUCTR)

03/08/2006

04/04/2007

Parkinson 's Disease early stage
MedDRA version: 8.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's

Solvay pharmaceuticals

NULL

Not Recruiting

Female: yes
Male: yes

330

Portugal;United Kingdom;Germany;Czech Republic;Netherlands;France;Estonia;Italy;Lithuania

1784

NCT00640952
(ClinicalTrials.gov)

August 2006

28/12/2007

Acamprosate for Treatment of Compulsive Behaviors and Craving in Parkinson's Disease

Parkinson's Disease

Drug: acamprosate

Baylor College of Medicine

National Parkinson Foundation

Withdrawn

18 Years

N/A

Both

N/A

United States

1785

NCT01628848
(ClinicalTrials.gov)

August 2006

24/6/2012

A Dose-finding Study for SPM 962 in Advanced Parkinson's Disease Patients

A Placebo-controlled Dose-finding Study for SPM 962 in Advanced Parkinson's Disease Patients With Concomitant Treatment of L-dopa

Parkinson's Disease

Drug: SPM 962;Drug: Placebo

Otsuka Pharmaceutical Co., Ltd.

NULL

Completed

30 Years

79 Years

All

174

Phase 2

Japan

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1786

NCT00368108
(ClinicalTrials.gov)

August 2006

22/8/2006

Efficacy, Safety, and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients With Motor Fluctuations

A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy, Safety, and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients With Motor Fluctuations

Parkinson's Disease

Drug: 2 mg perampanel;Drug: 4 mg perampanel;Drug: placebo comparator

Eisai Inc.

NULL

Completed

30 Years

N/A

All

752

Phase 3

United States;Canada

1787

EUCTR2006-001793-24-AT
(EUCTR)

31/07/2006

24/07/2006

Product Name: Nebicapone
Product Code: BIA 3-202
Product Name: Entacapone
INN or Proposed INN: Entacapone
Product Name: Nebicapone
Product Code: BIA 3-202
Product Name: Nebicapone
Product Code: BIA 3-202

BIAL - Portela & Cª, SA

NULL

Not Recruiting

Female: yes
Male: yes

250

Portugal;Austria

1788

EUCTR2006-000391-32-NL
(EUCTR)

18/07/2006

10/05/2006

A 2 Treatment Period Study with Period 1 Comprising a 3-Week Randomised, Double-Blind, Crossover Comparison of Apomorphine Nasal Powder (2 and 4 mg) and Placebo in Combination with a 12-Week Open, Active, Efficacy, safety and Tolerability Assessment of APO Nasal Powder (2 and 4 mg) in the Alleviation of Acute Episodes of Motor Symptoms Associated with PD, Followed by Period 2 Comprising a 36-Week Open, Active Treatment, Safety Assessment of APO Nasal Powder (2 and 4 mg), in Subjects with PD. - Apomorphine Nasal Powder (2 and 4 mg) and Placebo in Subjects with Parkinson's Disease

Alleviation of acute episodes of motor symptoms associated with Parkinson's Disease
MedDRA version: 8.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease

Product Name: Apomorphine Nasal Powder
Other descriptive name: 6aß - apomorphine-10,11-diol hydrochloride hemihydrate

Britannia Pharmaceuticals Limited

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

130

Germany;United Kingdom;Netherlands

1789

NCT03097211
(ClinicalTrials.gov)

July 17, 2006

27/3/2017

Effect of BIA 6-512 at Steady-state on the Levodopa Pharmacokinetics With a Single-dose of Levodopa/Benserazide 200/50 mg or With a Single-dose of Levodopa/Benserazide 200/50 mg Plus a Single-dose of Nebicapone 150 mg

A Double-blind, Randomised, Placebo-controlled, Rising Multiple Dose Study in Healthy Volunteers to Investigate the Effect of BIA 6-512 at Steady-state on the Levodopa Pharmacokinetics When Administered in Combination With a Single-dose of Levodopa/Benserazide 200/50 mg or With a Single-dose of Levodopa/Benserazide 200/50 mg Plus a Single-dose of Nebicapone 150 mg

Parkinson Disease

Drug: Placebo;Drug: BIA 6-512;Drug: Madopar® 250;Drug: Nebicapone

Bial - Portela C S.A.

NULL

Completed

18 Years

45 Years

All

Phase 1

Portugal

1790

EUCTR2006-003717-41-IT
(EUCTR)

13/07/2006

12/07/2007

EVALUATE THE TOLERABILITY AND EFFICACY OF OMEGA 3 ON MOOD ANDMOTOR SYMPTOMS OF PATIENTS SUFFERING FROM PARKINSON DISEASE - ND

MOOD DEPRESSION
MedDRA version: 6.1;Level: PT;Classification code 10012374

POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI

NULL

Not Recruiting

Female: yes
Male: yes

Italy

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1791

EUCTR2006-000680-28-ES
(EUCTR)

07/07/2006

22/05/2006

Estudio multicéntrico, doble ciego, aleatorizado y de tres meses de seguimiento para evaluar la eficacia de levodopa/carbidopa/entacapona frente a levodopa/carbidopa en pacientes con enfermedad de Parkinson y wearing-off”A 3-months, multicenter, double-blind, randomized study to evaluate the efficacy of levodopa/carbidopa/entacapone vs. levodopa/carbidopa in Parkinson's disease patients with 'wearing-off' - DERBI

Enfermedad de Parkinson (Parkinson Disease)

Trade Name: Stalevo 100
Product Name: Stalevo (levodopa/carbidopa/entacapona)
INN or Proposed INN: LEVODOPA
INN or Proposed INN: CARBIDOPA
INN or Proposed INN: ENTACAPONA
Trade Name: Sinemet plus
Product Name: Sinemet plus (levodopa/carbidopa)
INN or Proposed INN: LEVODOPA
INN or Proposed INN: CARBIDOPA
Trade Name: Stalevo 150
Product Name: Stalevo (levodopa/carbidopa/entacapona)
INN or Proposed INN: LEVODOPA
INN or Proposed INN: CARBIDOPA
INN or Proposed INN: ENTACAPONA

NOVARTIS FARMACEUTICA, S.A

NULL

Not Recruiting

Female: yes
Male: yes

200

Spain

1792

EUCTR2006-000391-32-DE
(EUCTR)

04/07/2006

27/04/2006

Alleviation of acute episodes of motor symptoms associated with Parkinson's Disease

Product Name: Apomorphine Nasal Powder
Other descriptive name: 6aß - apomorphine-10,11-diol hydrochloride hemihydrate

Britannia Pharmaceuticals Limited

NULL

Not Recruiting

Female: yes
Male: yes

130

United Kingdom;Germany;Netherlands

1793

NCT00408915
(ClinicalTrials.gov)

July 2006

5/12/2006

Continuous Application of Lisuride in Parkinson's Disease by Subcutaneous Infusion

Double-blind, Placebo-controlled, Randomized, Multicentre Phase II/III Study to Evaluate the Efficacy and Safety of Lisuride, Applied Subcutaneously by Means of a Minipump in Patients With Advanced Parkinson's Disease Refractory to Conventional Oral Therapy

Parkinson's Disease

Drug: Continuous Subcutaneous Lisuride Infusion

Axxonis Pharma AG

NULL

Completed

18 Years

75 Years

Both

Phase 3

Germany

1794

NCT00354133
(ClinicalTrials.gov)

July 2006

19/7/2006

Controlled Trial With Deep Brain Stimulation in Patients With Early Parkinson's Disease

The Effect of Deep Brain Stimulation of the Subthalamic Nucleus (STN-DBS) on Quality of Life in Comparison to Best Medical Treatment in Patients With Complicated Parkinson's Disease and Preserved Psychosocial Competence (EARLYSTIM-study)

Parkinson Disease

Device: Kinetra and Soletra (neurostimulator, Medtronic);Drug: Best Medical Treatment

German Parkinson Study Group (GPS)

University Hospital Schleswig-Holstein;Assistance Publique - Hôpitaux de Paris;KKS Netzwerk

Active, not recruiting

18 Years

60 Years

All

251

Phase 4

France;Germany

1795

NCT00346827
(ClinicalTrials.gov)

July 2006

29/6/2006

Apomorphine Nasal Powder in the Treatment of Parkinson's Disease Off Periods.

Parkinson's Disease

Drug: Apomorphine Nasal Powder

Britannia Pharmaceuticals Ltd.

NULL

Completed

18 Years

85 Years

All

Phase 2;Phase 3

NULL

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1796

EUCTR2006-000361-11-GB
(EUCTR)

23/06/2006

01/02/2006

A Proof of Concept Study to Determine the Minimum Effective Dose and to Assess the Efficacy and Safety of Subcutaneous Injections of FPFS-1169 in Parkinson's Disease Patients - Parkinson's Disease FPFS-1169 Proof of Concept Study (RD639/24201)

Treatment of Parkinson's Disease
MedDRA version: 8.0;Classification code 10029205

Fujimoto Pharmaceutical Corporation

NULL

Not Recruiting

Female: yes
Male: yes

Phase 2

United Kingdom

1797

EUCTR2005-004314-33-DE
(EUCTR)

21/06/2006

01/12/2005

Levodopa treated Parkinson's disease patients with motor fluctuations
MedDRA version: 8.1;Classification code 10061536

Product Name: MARS
Product Code: E2007
Product Name: MARS
Product Code: E2007

Eisai Limited

NULL

Not Recruiting

Female: yes
Male: yes

1260

Portugal;Hungary;United Kingdom;Germany;Estonia;Spain;Italy;Lithuania;Sweden

1798

NCT00331149
(ClinicalTrials.gov)

June 20, 2006

26/5/2006

A Comparison of Ropinirole Immediate Release With Ropinirole Prolonged Release in Patients With Advanced Parkinson's

A Randomised, Double-Blind, Double-Dummy, Parallel Group Comparison of 24 Weeks of Treatment With Ropinirole Immediate Release Tablets (REQUIP IR) or Ropinirole Prolonged Release Tablets (SK&F-101468) in Advanced Stage Parkinson's Disease Subjects Who Are Not Adequately Controlled on L-dopa.

Parkinson Disease

Drug: Ropinirole prolonged release;Drug: ropinirole immediate release

GlaxoSmithKline

NULL

Completed

30 Years

N/A

All

343

Phase 3

Bulgaria;Canada;Czechia;France;Germany;Hungary;Italy;Poland;Romania;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;Czech Republic

1799

EUCTR2005-005423-34-DE
(EUCTR)

19/06/2006

02/03/2006

Parkinson's disease

GlaxoSmithKline Research & Development Ltd

NULL

Not Recruiting

Female: yes
Male: yes

516

Hungary;United Kingdom;Czech Republic;Germany;Spain;Italy

1800

EUCTR2005-004949-34-GB
(EUCTR)

19/06/2006

24/03/2006

Parkinson's disease
MedDRA version: 6.1;Level: pref;Classification code 10061536

Boehringer Ingelheim Ltd

NULL

Not Recruiting

Female: yes
Male: yes

500

Phase 4

Finland;Spain;Austria;Germany;Italy;United Kingdom;Sweden

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1801

EUCTR2005-006033-32-SK
(EUCTR)

13/06/2006

02/05/2006

Parkinson's Disease Early Stage

Solvay Pharmaceuticals

NULL

Not Recruiting

Female: yes
Male: yes

440

Finland;Slovakia;Sweden

1802

EUCTR2006-000391-32-GB
(EUCTR)

06/06/2006

21/04/2006

Alleviation of acute episodes of motor symptoms associated with Parkinson's Disease
MedDRA version: 8.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease

Product Name: Apomorphine Nasal Powder
Other descriptive name: 6aß - apomorphine-10,11-diol hydrochloride hemihydrate

Britannia Pharmaceuticals Limited

NULL

Not Recruiting

Female: yes
Male: yes

130

Phase 3

Netherlands;Germany;United Kingdom

1803

NCT00269516
(ClinicalTrials.gov)

June 2006

22/12/2005

SLV308 for Treatment of Patients With Early Parkinson's Disease

A Randomized, Double Blind, Placebo Controlled Parallel-Group Fixed and Flexible SLV308 Dose Arm Study to Assess Efficacy and Safety of SLV308 Monotherapy in the Treatment of Patients With Early Stage Parkinson's Disease

Early Stage Parkinson's Disease

Drug: pardoprunox;Drug: Pardoprunox;Drug: Placebo

Solvay Pharmaceuticals

NULL

Completed

30 Years

N/A

Both

468

Phase 3

1804

EUCTR2005-004949-34-ES
(EUCTR)

29/05/2006

21/04/2006

A randomized, double-blind, placebo-controlled, parallel-group clinical trial to examine the efficacy and safety of early pramipexole treatment versus delayed pramipexole treatment in patients with new onset Parkinson’s disease. Protocol includes DAT SPECT of a sub-set of patients Estudio aleatorizado, doble ciego, controlado con placebo, para examinar la eficacia y seguridad del tratamiento temprano frente al tratamiento retrasado con pramipexol en pacientes con inicio de Parkinson - Pramipexole Early Start Study

Parkinson's disease
MedDRA version: 6.1;Level: pref;Classification code 10061536

Trade Name: Sifrol, Mirapexin
Product Name: Sifrol, Mirapexin
Product Code: SND 919 CL2 Y
INN or Proposed INN: Pramipexole
Trade Name: Sifrol, Mirapexin
Product Name: Sifrol, Mirapexin
Product Code: SND 919 CL2 Y
INN or Proposed INN: Pramipexole
Trade Name: Sifrol, Mirapexin
Product Name: Sifrol, Mirapexin
Product Code: SND 919 CL2 Y
INN or Proposed INN: Pramipexole

Boehringer Ingelheim España, S.A.

NULL

Not Recruiting

Female: yes
Male: yes

500

Finland;Spain;Austria;Germany;Italy;United Kingdom;Sweden

1805

EUCTR2005-005423-34-ES
(EUCTR)

19/05/2006

29/03/2006

Parkinson's disease

GlaxoSmithKline

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

516

Hungary;United Kingdom;Czech Republic;Germany;Spain;Italy

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1806

EUCTR2005-004314-33-ES
(EUCTR)

19/05/2006

15/03/2006

Levodopa treated Parkinson's disease patients with motor fluctuations
MedDRA version: 8.1;Classification code 10061536

Eisai Limited

NULL

Not Recruiting

Female: yes
Male: yes

1260

Phase 3

Portugal;Czech Republic;Hungary;Estonia;Belgium;Spain;Lithuania;Austria;Germany;Italy;United Kingdom;Sweden

1807

EUCTR2005-004949-34-FI
(EUCTR)

17/05/2006

21/04/2006

Parkinson's disease
MedDRA version: 6.1;Level: pref;Classification code 10061536

Trade Name: Sifrol
Product Name: Sifrol
Product Code: SND 919 CL2 Y
INN or Proposed INN: Pramipexole
Trade Name: Sifrol
Product Name: Sifrol
Product Code: SND 919 CL2 Y
INN or Proposed INN: Pramipexole
Trade Name: Sifrol
Product Name: Sifrol
Product Code: SND 919 CL2 Y
INN or Proposed INN: Pramipexole

Boehringer Ingelheim

Boehringer Ingelheim Finland Ky

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

500

Finland;Germany;United Kingdom;Spain;Italy;Austria;Sweden

1808

EUCTR2005-005423-34-GB
(EUCTR)

11/05/2006

17/03/2006

Parkinson's disease

GlaxoSmithKline Research & Development Ltd

NULL

Not Recruiting

Female: yes
Male: yes

516

Phase 3

Hungary;Czech Republic;Spain;Germany;Italy;United Kingdom

1809

EUCTR2004-005234-39-LT
(EUCTR)

09/05/2006

24/03/2006

Multicentre, randomised, double-blind study to compare Stalevo® to levodopa/carbidopa in patients with Parkinson's disease experiencing symptoms of early wearing-off - SEWOP

Parkinson's disease
MedDRA version: 8.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease

Orion Corporation, ORION PHARMA, 02200 Espoo, Finland

NULL

Not Recruiting

Female: yes
Male: yes

244

Finland;Germany;United Kingdom;Denmark;Ireland;Latvia;Sweden;Lithuania

1810

EUCTR2005-005423-34-IT
(EUCTR)

08/05/2006

03/10/2006

A Randomised, Double-Blind, Double-Dummy, Parallel Group Comparison of 24 Weeks of Treatment with Ropinirole Immediate Release IR Tablets or Ropinirole Prolonged Release / Extended Release PR/XR Tablets in Advanced Stage Parkinson s Disease Subjects who are not Adequately Controlled on L-dopa. - ND

Parkinson disease
MedDRA version: 6.1;Level: PT;Classification code 10061536

Product Name: ropinirole PR/XR tablets
Product Code: SKF-101468A
INN or Proposed INN: Ropinirole
Trade Name: REQUIP*21CPR 0,25MG
INN or Proposed INN: Ropinirole
Product Name: ropinirole PR/XR tablets
Product Code: SKF-101468A
INN or Proposed INN: Ropinirole
Product Name: ropinirole PR/XR tablets
Product Code: SKF-101468A
INN or Proposed INN: Ropinirole
Trade Name: REQUIP*21CPR 0,5MG
INN or Proposed INN: Ropinirole
Trade Name: REQUIP*21CPR 1MG
INN or Proposed INN: Ropinirole

GlaxoSmithKline R D

NULL

Not Recruiting

Female: yes
Male: yes

516

Hungary;United Kingdom;Czech Republic;Germany;Spain;Italy

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1811

NCT00291733
(ClinicalTrials.gov)

May 2006

14/2/2006

Levetiracetam Administration for the Management of Levodopa-Induced Dyskinesias in Parkinson's Disease

Levetiracetam Administration for the Management of Levodopa-Induced Dyskinesias in Parkinson's Disease: A Double-Blind,Placebo-Controlled, Crossover Trial

Levodopa Induced Dyskinesia

Drug: Levetiracetam;Drug: Placebo

1st Hospital of Social Security Services

UCB Pharma

Active, not recruiting

30 Years

80 Years

Both

Phase 2

Greece

1812

NCT00321854
(ClinicalTrials.gov)

May 2006

3/5/2006

Study of (Mirapex) Pramipexole for the Early Treatment of Parkinsons Disease (PD)

A Randomized, Double-blind, Placebo-controlled, Parallel-group Clinical Trial to Examine the Efficacy and Safety of Early Pramipexole (PPX) Treatment Versus Delayed Pramipexole Treatment in Patients With New Onset Parkinson's Disease.

Parkinson Disease

Drug: pramipexole

Boehringer Ingelheim

NULL

Completed

30 Years

79 Years

All

535

Phase 4

United States;Austria;Finland;France;Germany;Italy;Japan;Spain;Sweden;United Kingdom

1813

NCT00329056
(ClinicalTrials.gov)

May 2006

22/5/2006

A Trial of MitoQ for the Treatment of People With Parkinson's Disease

A Double-Blind, Prospective, Randomized Comparison of 2 Doses of MitoQ and Placebo for the Treatment of Patients With Parkinson's Disease

Parkinson's Disease

Drug: MitoQ

Antipodean Pharmaceuticals, Inc.

NULL

Completed

30 Years

N/A

Both

128

Phase 2

Australia;New Zealand

1814

NCT00324896
(ClinicalTrials.gov)

May 2006

9/5/2006

Treatment of Insomnia in Patients With Parkinson's Disease: A Multi-site, Placebo-controlled Study of Eszopiclone

Parkinson's Disease;Insomnia

Drug: eszopiclone;Other: placebo

University of Medicine and Dentistry of New Jersey

Sunovion

Completed

35 Years

85 Years

All

Phase 3

United States

1815

NCT03094156
(ClinicalTrials.gov)

April 26, 2006

23/3/2017

Effect of BIA 6-512 at Steady-state on the Levodopa Pharmacokinetics

Parkinson Disease

Drug: Placebo;Drug: BIA 6-512;Drug: Madopar® 250;Drug: Comtan®

Bial - Portela C S.A.

NULL

Completed

18 Years

45 Years

All

Phase 1

Portugal

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1816

EUCTR2005-005791-32-GB
(EUCTR)

24/04/2006

17/02/2006

Chemical Safety/Tolerability of HF0220 and its Effect on Biochemical Markers Relevant to Patients with a Diagnosis of Mild to Moderate Alzheimer's Disease.

Hunter-Fleming Ltd

NULL

Not Recruiting

Female: yes
Male: yes

Phase 2

United Kingdom;Sweden

1817

EUCTR2005-006033-32-FI
(EUCTR)

20/04/2006

06/03/2006

Parkinson's Disease Early Stage

Solvay Pharmaceuticals

NULL

Not Recruiting

Female: yes
Male: yes

440

Finland;Slovakia;Sweden

1818

EUCTR2005-005423-34-CZ
(EUCTR)

20/04/2006

03/03/2006

Parkinson's disease

GlaxoSmithKline Research & Development Ltd

NULL

Not Recruiting

Female: yes
Male: yes

516

Hungary;United Kingdom;Germany;Czech Republic;Spain;Italy

1819

EUCTR2005-004949-34-AT
(EUCTR)

18/04/2006

21/03/2006

Parkinson's disease
MedDRA version: 6.1;Level: pref;Classification code 10061536

Boehringer Ingelheim Austria GmbH

NULL

Not Recruiting

Female: yes
Male: yes

500

Finland;Germany;United Kingdom;Spain;Italy;Austria;Sweden

1820

EUCTR2005-001006-12-AT
(EUCTR)

02/04/2006

28/02/2006

Patients with advanced Parkinson’s disease with motor fluctuations and OFF” periods refractory to conventional treatment.

Product Name: Lisparin
INN or Proposed INN: Lisuride Hydrogenmaleate
Other descriptive name: 3- (9,10- Didehydro- 6- methyl- 8?- ergolinyl)-1,1- diethylurea hydrogenmaleate
Trade Name: Sifrol, 0,35 mg Tablette
Product Name: Pramipexol
INN or Proposed INN: Pramipexol
Other descriptive name: (S)- 2- Amino- 4,5,6,7- tetrahydro- 6- (propylamino)benzothiazol
Trade Name: Sifrol, 0,70 mg Tablette
Product Name: Pramipexol
INN or Proposed INN: Pramipexol
Other descriptive name: (S)- 2- Amino- 4,5,6,7- tetrahydro- 6- (propylamino)benzothiazol
Trade Name: Cabaseril, 1,0 mg Tablette
Product Name: Cabergoline
INN or Proposed INN: Cabergoline
Other descriptive name: 1[(6- Allyl- 8ß- ergolinyl)carbonyl]- 1- [3- (dimethylamino)propyl]- 3- ethylurea
Trade Name: Cabaseril, 2,0 mg Tablette
Product Name: Cabergoline
INN or Proposed INN: Cabergoline
Other descriptive name: 1[(6- Allyl- 8ß- ergolinyl)carbonyl]- 1- [3- (dimethylamino)propyl]-

Axxonis Pharma GmbH

NULL

Not Recruiting

Female: yes
Male: yes

Phase 2

Germany;Czech Republic;Italy;Austria

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1821

NCT00461942
(ClinicalTrials.gov)

April 2006

17/4/2007

Efficacy and Safety of Green Tea Polyphenol in De Novo Parkinson's Disease Patients

A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study to Assess the Neuroprotection Effect of Green Tea Polyphenol in De Novo Parkinson's Disease Patients

Parkinson's Disease

Drug: Green Tea Polyphenols (EGCG/ECG)

Xuanwu Hospital, Beijing

Ministry of Health, China;Michael J. Fox Foundation for Parkinson's Research

Completed

30 Years

N/A

Both

480

Phase 2

China

1822

NCT00349310
(ClinicalTrials.gov)

April 2006

5/7/2006

Profile of Depressive Symptoms in Parkinsons Disease

Profile of Depressive Symptoms in Parkinson's Disease (PRODEST-PD)

Parkinson Disease;Depression

Drug: Pramipexole

Boehringer Ingelheim

NULL

Completed

18 Years

N/A

Both

1018

Austria;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom

1823

NCT00467597
(ClinicalTrials.gov)

April 2006

27/4/2007

Developing Objective Measures of Levodopa Induced Dyskinesia: (Study 1)

Quantification of Levodopa Induced Dyskinesia in Parkinson Disease: Developing Objective Measures of Levodopa Induced Dyskinesia (Study One)

Dyskinesias;Movement Disorders;Parkinson Disease

Drug: Levodopa (delivered intravenously)

VA Office of Research and Development

Oregon Health and Science University

Completed

21 Years

N/A

All

N/A

United States

1824

NCT00294554
(ClinicalTrials.gov)

April 2006

21/2/2006

Memantine for Treatment of Cognitive Impairment in Patients With Parkinson's Disease and Dementia

Double-Blind Placebo-Controlled Trial of Memantine for Treatment of Cognitive Impairment in Patients With Parkinson's Disease and Dementia

Parkinson's Disease;Cognitive Impairment;Dementia

Drug: Memantine;Drug: Placebo Oral Tablet

Johns Hopkins University

Forest Laboratories

Completed

50 Years

N/A

All

N/A

United States

1825

NCT00646204
(ClinicalTrials.gov)

April 2006

28/12/2007

Namenda (Memantine) for Non-Motor Symptoms in Parkinson's Disease

A 16 WEEK, INVESTIGATOR-INITIATED, SINGLE-CENTER, DOUBLE BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL OF NAMENDA® (MEMANTINE HCL) FOR NON-MOTOR SYMPTOMS IN PARKINSON'S DISEASE

Parkinson's Disease

Drug: Memantine;Drug: placebo

Baylor College of Medicine

Forest Laboratories

Completed

18 Years

80 Years

Both

Phase 4

United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1826

EUCTR2005-004109-27-SE
(EUCTR)

24/03/2006

24/01/2006

A double-blind, placebo-controlled multi-centre trial of memantine in patients with Parkinsons’ disease dementia or dementia with Lewy bodies - MEMDLBPDD

Parkinsons disease (PD)and dementia with Lewy bodies (DLB) are both common disease of the elderly. The majority of patients who survive for more than 10 years with PD eventually develope dementia (PDD). The brain changes and clinical presentations of PDD and DLB are similar. The clinical characteristics are cognitive impairment with pronounced visuospatial and executive impairment, visual hallucinations, parkinsonism, fluctuations in cognition and REM sleep disorder.

Trade Name: Ebixa
Product Name: Ebixa

Neuropsychiatric clinic

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

Sweden

1827

EUCTR2005-001032-72-PT
(EUCTR)

23/03/2006

11/11/2005

A 39-week randomized, double-blind, parallel group, multicenter study to evaluate the effect of fixed dose Stalevo 100 (t.i.d.) vs. immediate release carbidopa/levodopa (t.i.d.) in Parkinson's disease patients requiring levodopa. - First Step

Parkinson disease

Trade Name: Stalevo
Product Code: ELC200
INN or Proposed INN: levodopa /carbidopa /entacapone
Trade Name: SINEMET
Product Name: sinemet
INN or Proposed INN: levodopa /carbidopa

Novartis Pharma AG

NULL

Not Recruiting

Female: yes
Male: yes

424

Portugal;Czech Republic;Italy

1828

EUCTR2005-001006-12-DE
(EUCTR)

09/03/2006

05/09/2006

Axxonis Pharma GmbH

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

Phase 2

Czech Republic;Germany;Italy;Austria

1829

EUCTR2005-003788-22-SE
(EUCTR)

03/03/2006

19/12/2005

Trade Name: Sifrol
Product Name: Sifrol
Product Code: SND 919 CL2 Y
INN or Proposed INN: Pramipexole
Trade Name: Sifrol
Product Name: Sifol
Product Code: SND 919 CL2 Y
INN or Proposed INN: Pramipexole
Trade Name: Sifrol
Product Name: Sifol
Product Code: SND 919 CL2 Y
INN or Proposed INN: Pramipexole
Trade Name: Sifrol
Product Name: Sifol
Product Code: SND 919 CL2 Y
INN or Proposed INN: Pramipexole

Boehringer Ingelheim AB

NULL

Not Recruiting

Female: yes
Male: yes

354

Phase 1

Finland;Germany;United Kingdom;Spain;Italy;Sweden

1830

EUCTR2005-004314-33-HU
(EUCTR)

01/03/2006

20/12/2005

Levodopa treated Parkinson's disease patients with motor fluctuations
MedDRA version: 8.1;Classification code 10061536

Product Name: MARS
Product Code: E2007
Product Name: MARS
Product Code: E2007

Eisai Limited

NULL

Not Recruiting

Female: yes
Male: yes

1260

Portugal;Hungary;Germany;United Kingdom;Estonia;Spain;Italy;Lithuania;Sweden

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1831

EUCTR2005-004314-33-GB
(EUCTR)

01/03/2006

29/11/2005

Levodopa treated Parkinson's disease patients with motor fluctuations
MedDRA version: 8.1;Classification code 10061536

Eisai Limited

NULL

Not Recruiting

Female: yes
Male: yes

1260

Phase 3

Portugal;Czech Republic;Hungary;Estonia;Spain;Belgium;Lithuania;Austria;Germany;Italy;United Kingdom;Sweden

1832

NCT00307450
(ClinicalTrials.gov)

March 2006

27/3/2006

Efficacy and Safety of Levetiracetam Versus Placebo on Levodopa-induced Dyskinesias in Advanced Parkinson's Disease

Efficacy and Safety of Levetiracetam Versus Placebo on Levodopa-induced Dyskinesias in Advanced Parkinson's Disease (LeLeDys Study) - A Multicenter, Randomized, Stratified, Double-blinded, Placebo-controlled Phase IV Study

Parkinson's Disease

Drug: Levetiracetam

Technische Universität Dresden

UCB GmbH, Huettenstrasse 205, 50170 Kerpen, Germany

Completed

30 Years

80 Years

Both

Phase 4

Germany

1833

NCT00282152
(ClinicalTrials.gov)

March 2006

23/1/2006

Deep Brain Stimulation (DBS) for Early Stage Parkinson's Disease (PD)

Safety and Tolerability of Neurostimulation in Early Stage Parkinson's Disease

Parkinson's Disease

Device: B-STN DBS;Drug: Optimal drug therapy

Vanderbilt University Medical Center

NULL

Completed

50 Years

75 Years

All

N/A

United States

1834

NCT00141518
(ClinicalTrials.gov)

March 2006

30/8/2005

Long-term Study of Duodopa (Levodopa/Carbidopa) in Advanced Parkinson's: Health Outcomes & Net Economic Impact

A Long-term Health Economics Study of Intraduodenal Levodopa (Duodopa®) in Routine Care for Patients With Advanced Idiopathic Parkinson's Disease With Severe Motor Fluctuations and Hyper-/Dyskinesia

Advanced Idiopathic Parkinson's Disease

Drug: Levodopa -carbidopa intestinal gel (LCIG);Device: CADD-Legacy® 1400 ambulatory infusion pump;Device: percutaneous endoscopic gastrostomy tube (PEG tube);Device: jejunal extension tube (J-tube)

AbbVie (prior sponsor, Abbott)

NULL

Completed

18 Years

99 Years

All

Phase 4

Norway;Sweden

1835

NCT00305331
(ClinicalTrials.gov)

March 2006

20/3/2006

Domperidone as a Treatment for Dopamine Agonist-induced Peripheral Edema in Patients With Parkinson's Disease

Phase II Clinical Trial of Domperidone as a Treatment for Dopamine Agonist-induced Peripheral Edema in Patients With Parkinson's Disease

Parkinson's Disease;Peripheral Edema

Drug: Domperidone (drug)

University Health Network, Toronto

NULL

Terminated

30 Years

90 Years

Both

Phase 2

Canada

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1836

NCT00393562
(ClinicalTrials.gov)

March 2006

26/10/2006

Comparison of Modafinil and Methylphenidate in Treatment of Excessive Daytime Sleepiness in Patients With Parkinson's Disease

Parkinson's Disease

Drug: modafinil;Drug: methylphenidate

Department of Veterans Affairs

NULL

Withdrawn

50 Years

80 Years

Both

N/A

United States

1837

NCT00297778
(ClinicalTrials.gov)

March 2006

28/2/2006

Pramipexole Versus Placebo in Parkinson's Disease (PD) Patients With Depressive Symptoms

A Randomized, Double-blind, Placebo-controlled, Parallel Group Efficacy Study of Pramipexole and Placebo Administered Orally Over a 12 Week Treatment Phase in Parkinson's Disease Patients With Stable Motor Function and Depressive Symptoms

Parkinson Disease;Depression

Drug: Pramipexole;Other: Placebo

Boehringer Ingelheim

NULL

Completed

30 Years

80 Years

All

296

Phase 4

Austria;Finland;France;Germany;Italy;Netherlands;Norway;Romania;Russian Federation;South Africa;Spain;Sweden;Ukraine;United Kingdom

1838

EUCTR2005-003788-22-AT
(EUCTR)

22/02/2006

18/01/2006

Boehringer Ingelheim Austria GmbH

NULL

Not Recruiting

Female: yes
Male: yes

318

Phase 1

Finland;Spain;Austria;Germany;Italy;United Kingdom;Sweden

1839

EUCTR2005-001032-72-CZ
(EUCTR)

16/02/2006

12/01/2006

Trade Name: Stalevo 100 mg/25 mg / 200 mg
Product Code: ELC200
Trade Name: SINEMET CR
Product Name: SINEMET CR

Novartis Pharma AG

NULL

Not Recruiting

Female: yes
Male: yes

424

Portugal;Czech Republic;Italy

1840

EUCTR2005-003788-22-ES
(EUCTR)

09/02/2006

28/12/2005

A randomized, double-blind, placebo-controlled, parallel group, efficacy study of pramipexole and placebo administered orally over a 12-week treatment phase in Parkinson’s disease patients with stable motor function and depressive symptoms.Estudio aleatorizado, doble ciego, controlado con placebo sobre la eficacia de pramipexol y placebo administrados por vía oral durante una fase de tratamiento de 12 semanas en pacientes con Parkinson con función motora estable y síntomas depresivos

Trade Name: Mirapexin / Sifrol
Product Name: Sifol
Product Code: SND 919 CL2 Y
INN or Proposed INN: Pramipexole
Trade Name: Mirapexin/Sifrol
Product Name: Sifol
Product Code: SND 919 CL2 Y
INN or Proposed INN: Pramipexole
Trade Name: Mirapexin/Sifrol
Product Name: Sifol
Product Code: SND 919 CL2 Y
INN or Proposed INN: Pramipexole
Trade Name: Mirapexin/Sifrol
Product Name: Sifol
Product Code: SND 919 CL2 Y
INN or Proposed INN: Pramipexole

Boehringer Ingelheim España S.A.

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

318

Phase 1

Finland;Germany;United Kingdom;Spain;Italy;Sweden

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1841

EUCTR2005-004290-19-GB
(EUCTR)

03/02/2006

09/01/2006

A double-blind, placebo-controlled, parallel group, proof of concept trial to assess the tolerabiltiy, safety and efficacy of rotigotine nasal spray for the acute treatment of 'off' symptoms in subjects with advanced-stage, idiopathic Parkinson's disease

advanced-stage, idiopathic Parkinson's disease
MedDRA version: 8.1;Level: LLT;Classification code 10061536

Schwarz Biosciences GmbH

NULL

Not Recruiting

Female: yes
Male: yes

100

Phase 2

Spain;Austria;Germany;United Kingdom

1842

EUCTR2005-004314-33-SE
(EUCTR)

03/02/2006

13/12/2005

Levodopa treated Parkinson's disease patients with motor fluctuations
MedDRA version: 8.1;Classification code 10061536

Product Name: MARS
Product Code: E2007
Product Name: MARS
Product Code: E2007

Eisai Limited

NULL

Not Recruiting

Female: yes
Male: yes

1260

Portugal;Hungary;Germany;United Kingdom;Estonia;Spain;Italy;Lithuania;Sweden

1843

EUCTR2005-004314-33-BE
(EUCTR)

02/02/2006

24/11/2005

Levodopa treated Parkinson's disease patients with motor fluctuations
MedDRA version: 8.1;Classification code 10061536

Product Name: MARS
Product Code: E2007
Product Name: MARS
Product Code: E2007

Eisai Limited

NULL

Not Recruiting

Female: yes
Male: yes

1260

Portugal;Hungary;Estonia;Spain;Belgium;Lithuania;Austria;Germany;Italy;United Kingdom;Sweden

1844

EUCTR2005-004314-33-LT
(EUCTR)

01/02/2006

03/01/2006

Levodopa treated Parkinson's disease patients with motor fluctuations
MedDRA version: 8.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease

Product Name: MARS
Product Code: E2007
Product Name: MARS
Product Code: E2007

Eisai Limited

NULL

Not Recruiting

Female: yes
Male: yes

1260

Portugal;Hungary;Germany;United Kingdom;Estonia;Spain;Italy;Sweden;Lithuania

1845

EUCTR2005-003788-22-DE
(EUCTR)

01/02/2006

07/12/2005

Trade Name: Sifrol
Product Name: Sifrol
Product Code: SND 919 CL2 Y
INN or Proposed INN: Pramipexole
Trade Name: Sifrol
Product Name: Sifrol
Product Code: SND 919 CL2 Y
INN or Proposed INN: Pramipexole
Trade Name: Sifrol
Product Name: Sifrol
Product Code: SND 919 CL2 Y
INN or Proposed INN: Pramipexole
Trade Name: Sifrol
Product Name: Sifrol
Product Code: SND 919 CL2 Y
INN or Proposed INN: Pramipexole

Boehringer Ingelheim Pharma GmbH & Co. KG

NULL

Not Recruiting

Female: yes
Male: yes

354

Phase 1

Finland;Spain;Austria;Germany;Italy;United Kingdom;Sweden

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1846

EUCTR2005-004314-33-CZ
(EUCTR)

01/02/2006

11/01/2006

Levodopa treated Parkinson's disease patients with motor fluctuations
MedDRA version: 8.1;Classification code 10061536

Product Name: MARS
Product Code: E2007
Product Name: MARS
Product Code: E2007

Eisai Limited

NULL

Not Recruiting

Female: yes
Male: yes

1260

Portugal;Hungary;Estonia;Czech Republic;Spain;Belgium;Lithuania;Austria;Germany;Italy;United Kingdom;Sweden

1847

NCT00286897
(ClinicalTrials.gov)

February 2006

3/2/2006

The Efficacy, Safety and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients With Motor Fluctuations

Parkinson's Disease

Drug: E2007

Eisai Limited

NULL

Completed

30 Years

N/A

Both

702

Phase 3

Austria;Belgium;Czech Republic;Estonia;France;Germany;Hungary;Israel;Italy;Lithuania;Poland;Portugal;Serbia;South Africa;Spain;Sweden;United Kingdom;Former Serbia and Montenegro

1848

NCT00296192
(ClinicalTrials.gov)

February 2006

22/2/2006

Efficacy, Safety and Tolerability of Rotigotine Nasal Spray for the Acute Treatment of Parkinson Symptoms

A Double-Blind, Placebo-Controlled, Parallel-Group, Proof of Concept Trial to Assess the Tolerability, Safety, and Efficacy of Rotigotine Nasal Spray for the Acute Treatment of OFF Symptoms in Subjects With Advanced-Stage, Idiopathic Parkinson Disease

Parkinson's Disease

Drug: Rotigotine nasal spray;Other: Placebo

UCB Pharma

NULL

Completed

30 Years

N/A

All

Phase 2

Germany

1849

NCT00630500
(ClinicalTrials.gov)

February 2006

27/2/2008

Efficacy and Safety of Memantine for Parkinson's Disease Dementia (PDD) and Dementia With Lewy Bodies (DLB)

A Double-blind, Placebo-controlled Multicentre Trial of Memantine in Patients With Parkinson's Disease Dementia or Dementia With Lewy Bodies

Dementia Associated With Parkinson's Disease;Dementia With Lewy Bodies

Drug: Memantine;Drug: Placebo

Helse Stavanger HF

King's College London;Lund University

Completed

N/A

Both

Phase 2

Norway;Sweden;United Kingdom

1850

EUCTR2005-004314-33-IT
(EUCTR)

31/01/2006

07/09/2007

Parkinson's Desease patients with Motor Fluctuations who are on optimised and stabilised therapy with Levodopa.
MedDRA version: 6.1;Level: PT;Classification code 10061536

Product Name: E2007
Product Name: E2007

EISAI LTD UK

NULL

Not Recruiting

Female: yes
Male: yes

900

Portugal;Hungary;Germany;United Kingdom;Estonia;Spain;Italy;Lithuania;Sweden

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1851

EUCTR2005-004290-19-DE
(EUCTR)

25/01/2006

05/12/2005

advanced-stage, idiopathic Parkinson's disease
MedDRA version: 8.1;Level: LLT;Classification code 10061536

Product Name: Rotigotine Nasal Spray
Product Code: ND1421
INN or Proposed INN: Rotigotine hydrochloride

Schwarz Biosciences GmbH

NULL

Not Recruiting

Female: yes
Male: yes

100

United Kingdom;Germany;Spain

1852

NCT03095105
(ClinicalTrials.gov)

January 24, 2006

23/3/2017

Pharmacokinetic Profile of BIA 6-512 in Healthy Elderly Subjects Versus Healthy Young Subjects

An Open-label, Parallel-group Study to Compare the Pharmacokinetic Profile in Healthy Elderly Subjects Versus Healthy Young Subjects After Single and Repeated Oral Administration of BIA 6-512 (Trans-resveratrol)

Parkinson Disease

Drug: 200 mg BIA 6-512

Bial - Portela C S.A.

NULL

Completed

18 Years

N/A

All

Phase 1

Germany

1853

EUCTR2005-004314-33-EE
(EUCTR)

17/01/2006

24/11/2005

Levodopa treated Parkinson's disease patients with motor fluctuations
MedDRA version: 8.1;Classification code 10061536

Product Name: MARS
Product Code: E2007
Product Name: MARS
Product Code: E2007

Eisai Limited

NULL

Not Recruiting

Female: yes
Male: yes

1260

Portugal;Hungary;Germany;United Kingdom;Estonia;Spain;Italy;Lithuania;Sweden

1854

EUCTR2005-003788-22-FI
(EUCTR)

17/01/2006

07/12/2005

Boehringer Ingelheim Finland Ky

Not Recruiting

Female: yes
Male: yes

318

Phase 1

Finland;Germany;United Kingdom;Spain;Italy;Sweden

1855

EUCTR2005-003788-22-GB
(EUCTR)

06/01/2006

11/11/2005

Boehringer Ingelheim Limited

NULL

Not Recruiting

Female: yes
Male: yes

318

Phase 4

Finland;Spain;Austria;Germany;Italy;United Kingdom;Sweden

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1856

NCT00273351
(ClinicalTrials.gov)

January 2006

4/1/2006

Imaging and Genetic Biomarkers of Parkinson Disease (PD) Onset and Progression in High-risk Families

Assessment of Pre-symptomatic and Symptomatic Patients With Parkinson Disease to Identify and Characterize Genetic and Phenotypic Biomarkers for Disease Onset and Progression.

Parkinson Disease;Parkinsonian Syndrome

Drug: [123I]B-CIT

Institute for Neurodegenerative Disorders

Department of Defense;Molecular NeuroImaging

Completed

21 Years

N/A

Both

Phase 2

United States

1857

NCT01683292
(ClinicalTrials.gov)

January 2006

7/9/2012

Single-Centre Study of VR040(Inhaled Apomorphine) in Idiopathic Parkinson's Disease

An Ascending-Dose, Single-Centre Study Investigating the Safety, Tolerability, Efficacy, and Pharmacokinetics of VR040(Inhaled Apomorphine)in Parkinson's Disease

Parkinson's Disease

Drug: Inhaled VR040;Drug: Placebo for VR040

South Glasgow University Hospitals NHS Trust

Vectura Limited

Completed

30 Years

N/A

Both

Phase 2

United Kingdom

1858

NCT00315250
(ClinicalTrials.gov)

January 2006

14/4/2006

Development of Imaging, Clinical and Biochemical Bio-Markers for Parkinson's Disease

Parkinson's Disease;Parkinsonian Syndrome

Drug: [123I]ß-CIT

Institute for Neurodegenerative Disorders

Department of Defense;Molecular NeuroImaging

Completed

22 Years

N/A

Both

225

Phase 2

United States

1859

NCT00292227
(ClinicalTrials.gov)

January 2006

14/2/2006

Cardiac Effects of Rotigotine Transdermal System in Subjects With Advanced-stage Idiopathic Parkinson's Disease

Double-blind, Randomized, Placebo- and Positive-controlled, Parallel-group Trial to Assess the Potential Electrocardiographic Effects of Rotigotine Transdermal System up to 120 cm2/54.0 mg/Day in Subjects With Advanced-stage Idiopathic Parkinson's Disease: A Thorough QT/QTc Trial.

Parkinson's Disease

Drug: Rotigotine;Other: Placebo;Drug: Moxifloxacin infusion;Other: Placebo infusion

UCB Pharma

NULL

Completed

18 Years

N/A

All

130

Phase 1

South Africa

1860

NCT02772614
(ClinicalTrials.gov)

January 2006

12/5/2016

Absorption, Distribution, Metabolism and Excretion of [14C]-Labelled BIA 3-202 and Metabolites

An Open-label Study in Healthy Male Subjects to Assess the Absorption, Distribution, Metabolism and Excretion of [14C]-Labelled BIA 3-202 and Metabolites Following a Single-dose Oral Administration

Parkinson's Disease

Drug: BIA 3-202 (200 mg)

Bial - Portela C S.A.

NULL

Completed

40 Years

55 Years

Male

Phase 1

Switzerland

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1861

NCT00275275
(ClinicalTrials.gov)

January 2006

9/1/2006

Pramipexole Conversion to Ropinirole Controlled Release (CR)

An Open Label Conversion Study of Pramipexole to Ropinirole Controlled Release (CR) in Patients With Parkinson's Disease.

Parkinson Disease

Drug: Requip PR;Drug: Mirapex

Rajesh Pahwa, MD

GlaxoSmithKline

Completed

18 Years

N/A

All

Phase 3

United States

1862

NCT00272688
(ClinicalTrials.gov)

January 2006

6/1/2006

Continuous Delivery of Levodopa in Patients With Advanced Idiopathic Parkinsons Disease - Cost-benefit

Continuous Delivery of Levodopa/Carbidopa (Duodopa) in Patients With Advanced Idiopathic Parkinsons Disease - a Health Economic Evaluation

Parkinson Disease

Drug: Levodopa (drug), intraduodenal administration

University Hospital, Akershus

Solvay Pharmaceuticals

Completed

N/A

Both

Phase 4

Norway

1863

NCT00279825
(ClinicalTrials.gov)

January 2006

18/1/2006

Comparison of IPX054, IR Carbidopa-Levodopa, and CR Carbidopa-Levodopa in Subjects With Parkinson's Disease

A Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Compare IPX054 200 mg and 250 mg to CD-LD IR 200 (2x100) mg Tablets and CD-LD CR 200 mg Tablet in Subjects With Parkinson's Disease

Idiopathic Parkinson's Disease

Drug: IPX054 200 mg;Drug: IPX054 250 mg;Drug: CD -LD IR;Drug: CD -LD CR;Drug: IPX054 200 mg Placebo;Drug: IPX054 250 mg Placebo;Drug: CD -LD IR Placebo;Drug: CD -LD CR Placebo

Impax Laboratories, LLC

NULL

Completed

30 Years

N/A

All

Phase 2

United States

1864

EUCTR2005-005120-13-GB
(EUCTR)

21/12/2005

02/11/2005

A clinic based, Phase IIa, randomised, double-blind, placebo-controlled, ascending dose, single centre study investigating the safety, tolerability, efficacy, and pharmacokinetics of VR040 in patients with established idiopathic Parkinson’s Disease

Hypomobility (off” or freezing”) episodes associated with advanced Parkinson’s disease

Product Name: Apomorphine hydrochloride
Product Code: VR040
INN or Proposed INN: apomorphine hydrochloride

Vectura Group plc

NULL

Not Recruiting

Female: yes
Male: yes

Phase 2

United Kingdom

1865

EUCTR2005-001032-72-IT
(EUCTR)

25/11/2005

26/03/2007

A 39-week randomized, double-blind, parallel group, multicenter study to evaluate the effect of fixed dose Stalevo 100 t.i.d. vs. immediate release carbidopa/levodopa t.i.d. in Parkinsons disease patients requiring levodopa.

Parkinson s Disease
MedDRA version: 6.1;Level: PT;Classification code 10061536

Trade Name: Stalevo
INN or Proposed INN: ENTACAPONE INN
INN or Proposed INN: LEVODOPA INN
INN or Proposed INN: CARBIDOPA INN
Trade Name: Sinemet
INN or Proposed INN: LEVODOPA
INN or Proposed INN: CARBIDOPA ANIDRA

NOVARTIS FARMA

NULL

Not Recruiting

Female: yes
Male: yes

424

Portugal;Czech Republic;Italy

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1866

EUCTR2005-002432-10-MT
(EUCTR)

25/11/2005

10/10/2005

A multicenter, randomized, double-blind, placebo-controlled, ascending dose, parallel group study exploring effects of SLV308 up to 42 mg/day administered as an adjunctive therapy to l-dopa in patients with advanced stage Parkinson’s disease

Parkinson Disease late stage

Solvay Pharmaceuticals

NULL

Not Recruiting

Female: yes
Male: yes

Malta

1867

EUCTR2005-000444-84-GB
(EUCTR)

23/11/2005

13/09/2005

An open-label, multicenter, multinational Phase III follow-up study to investigate the long-term safety and efficacy of Sarizotan HCl 1 mg b.i.d. in patients with Parkinson's disease suffering from treatment-associated dyskinesia - PADDY-O

Treatment-Associated Dyskinesia in Parkinson's Disease

Product Code: EMD128130
INN or Proposed INN: Sarizotan hydrochloride

Merck KGaA

NULL

Not Recruiting

Female: yes
Male: yes

800

Phase 3

Finland;Spain;Austria;Italy;United Kingdom

1868

EUCTR2005-002010-38-DE
(EUCTR)

21/11/2005

10/02/2006

Assessment of the acceptability of a sublingual formulation of piribedil (S90049), 10 to 30 mg on request (maximum 5 times a day) on the top of L-dopa and a dopamine agonist in advanced Parkinson Disease patients with motor fluctuations: a 4-week open label pilot study

Advanced Parkinson´s Disease

Product Name: Trivastal
Product Code: S 90049
INN or Proposed INN: Piribedil

Institut de Recherches Internationales Servier (I.R.I.S.)

NULL

Not Recruiting

Female: yes
Male: yes

Germany

1869

EUCTR2005-001416-42-PT
(EUCTR)

07/11/2005

25/08/2005

A Multicenter, Double-Blind, Randomized Start, Placebo-Controlled, Parallel-Group Study to Assess Rasagiline as a Disease Modifying Therapy in Early Parkinson’s Disease Subjects - ADAGIO

Parkinson's Disease
MedDRA version: 7.1;Level: PT;Classification code 10061536

Trade Name: AZILECT
Product Name: rasagiline tablets
Product Code: TVP-1012
INN or Proposed INN: rasagiline
Other descriptive name: rasagiline mesilate

Teva Pharmaceuticals Industries LtD

NULL

Not Recruiting

Female: yes
Male: yes

1100

Hungary;Portugal;Germany;United Kingdom;Spain;Italy

1870

NCT00253084
(ClinicalTrials.gov)

November 2005

11/11/2005

Comparison of IPX054 and Immediate-Release Carbidopa-Levodopa in Patients With Parkinson's Disease

A Randomized, Double-Blind, Cross-Over Study to Compare IPX054 to Carbidopa-Levodopa Immediate-Release Tablets in Subjects With Parkinson's Disease

Parkinson's Disease

Drug: IPX054 200 mg;Drug: CD -LD IR;Drug: IPX054 Placebo;Drug: CD -LD IR Placebo

Impax Laboratories, LLC

NULL

Completed

30 Years

N/A

All

Phase 2

United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1871

NCT00256204
(ClinicalTrials.gov)

November 2005

16/11/2005

A Randomized Placebo Controlled Study to Show That Rasagiline May Slow Disease Progression for Parkinson's Disease

A Multi Center, Double Blind, Randomized Start, Placebo-Controlled, Parallel-Group Study to Assess Rasagiline as a Disease Modifying Therapy in Early Parkinson's Disease Subjects

Parkinson's Disease

Drug: Rasagiline Mesylate;Other: Placebo

Teva Pharmaceutical Industries

NULL

Completed

30 Years

80 Years

All

1174

Phase 3

Argentina;Austria;Canada;France;Germany;Hungary;Israel;Italy;Netherlands;Portugal;Romania;Spain;United Kingdom;United States

1872

NCT00260793
(ClinicalTrials.gov)

November 2005

1/12/2005

Open Label High Dose Ropinirole (Requip) Study for Patients With Parkinson's Disease

Open Label Prospective Study of High Dose Ropinirole for Motor Fluctuations and Dyskinesias in Advanced Parkinson's Disease

Parkinson's Disease

Drug: Ropinirole Hydrochloride

Agarwal, Pinky, M.D.

Colorado Neurology;GlaxoSmithKline

Recruiting

25 Years

N/A

Both

Phase 3

United States

1873

NCT00250393
(ClinicalTrials.gov)

November 2005

4/11/2005

A Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease

Placebo-Controlled , Crossover , Double-Blind Study of KW-6002(Istradefylline) in the Treatment of Parkinson's Disease. [Monotherapy]

Parkinson's Disease

Drug: Istradefylline (KW-6002)

Kyowa Hakko Kirin Company, Limited

NULL

Completed

30 Years

N/A

Both

Phase 2

Japan

1874

EUCTR2004-005234-39-IE
(EUCTR)

20/10/2005

16/08/2005

Multicentre, randomised, double-blind study to compare Stalevo® to levodopa/carbidopa in patients with Parkinson's disease experiencing symptoms of early wearing-off - SEWOP

Parkinson's disease
MedDRA version: 7.0;Level: LLT;Classification code 10061536

Orion Corporation, ORION PHARMA, 02200 Espoo, Finland

NULL

Not Recruiting

Female: yes
Male: yes

240

Phase 4

Finland;Ireland;Lithuania;Denmark;Latvia;Germany;United Kingdom;Sweden

1875

EUCTR2005-000314-12-ES
(EUCTR)

14/10/2005

08/09/2005

Effect of 3 doses (20, 40 and 60 mg) of a sublingual formulation of piribedil (S 90049) in combination with levodopa on end-of-dose fluctuations in advanced Parkinson’s disease patients after a 14-day treatment-period (one administration t.i.d.). A randomised, double-blind study consisting of 3 cross-over: 40 mg versus placebo, 20 mg versus 60 mg and 40 mg versus 20 mg. - PARKOPI

Parkinson's Disease aggravated
MedDRA version: 7.0;Level: LLT;Classification code 10034006

Product Name: piribedil
Product Code: S 90049 - F36
INN or Proposed INN: piribedil
Product Name: piribedil
Product Code: S 90049 - F38
INN or Proposed INN: piribedil

Institut de Recherches Internationales Servier

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

Germany;Spain

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1876

NCT00199381
(ClinicalTrials.gov)

October 2005

12/9/2005

An Extension of Istradefylline in North American Parkinson's Disease Patients Who Have Completed Study 6002-INT-001

An Open-Label Multicenter Study of the Continued Safety of Istradefylline (KW-6002) In Subjects With Parkinson's Disease Who Have Recently Completed One Year of Treatment With Istradefylline.

Parkinson's Disease

Drug: Istradefylline

Kyowa Kirin Pharmaceutical Development, Inc.

NULL

Terminated

30 Years

N/A

All

504

Phase 3

United States

1877

NCT00239564
(ClinicalTrials.gov)

October 2005

13/10/2005

Pharmacokinetics and Pharmacodynamics of IPX054 in Subjects With Parkinson's Disease

An Open-Label Study to Assess the Pharmacokinetics and Pharmacodynamics of IPX054 in Subjects With Parkinson's Disease

Idiopathic Parkinson's Disease

Drug: IPX054 100 mg;Drug: IPX054 150 mg;Drug: IPX054 200 mg;Drug: IPX054 250 mg;Drug: IPX054 300 mg

Impax Laboratories, LLC

NULL

Completed

30 Years

N/A

All

Phase 1;Phase 2

United States

1878

NCT00472355
(ClinicalTrials.gov)

October 2005

10/5/2007

Low Dose Apomorphine and Parkinsonism

Does Presynaptic Dopamine Receptor Stimulation Transiently Worsen Parkinsonism?

Parkinson's Disease

Drug: apomorphine

Oregon Health and Science University

National Institute of Neurological Disorders and Stroke (NINDS)

Withdrawn

35 Years

85 Years

All

Phase 2

United States

1879

NCT00134251
(ClinicalTrials.gov)

October 2005

22/8/2005

Ascending Dose Tolerability/Safety of SLV308 for the Treatment of Parkinson's Disease

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Ascending Dose, Parallel Group Study Exploring Effects of SLV308 up to 42 mg/Day Administered as an Adjunctive Therapy to L-Dopa in Patients With Advanced Stage Parkinson's Disease

Parkinson's Disease

Drug: SLV308

Solvay Pharmaceuticals

NULL

Completed

30 Years

N/A

Both

Phase 3

Bulgaria;Malta;Serbia;Former Serbia and Montenegro

1880

NCT00517842
(ClinicalTrials.gov)

October 2005

15/8/2007

A Triple-blinded, Randomised, Placebo-controlled Trial to Examine the Efficacy and Safety of ViNeuro in Patients With Parkinson's Disease

Parkinson Disease

Drug: ViNeuro

Hospital Authority, Hong Kong

Vigconic (International) Ltd.

Completed

30 Years

N/A

Both

160

N/A

China

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1881

NCT00912808
(ClinicalTrials.gov)

October 2005

2/6/2009

Cholinergic Augmentation in Frequently Falling Subjects With Parkinson's Disease

A Study of Cholinergic Augmentation in Frequently Falling Subjects With Parkinson's

Parkinson's Disease

Drug: Donepezil;Drug: Sugar Pill (placebo)

Oregon Health and Science University

NULL

Completed

21 Years

N/A

All

N/A

NULL

1882

EUCTR2005-001416-42-HU
(EUCTR)

27/09/2005

20/06/2005

A Multicenter, Double-Blind, Randomized Start, Placebo-Controlled, Parallel-Group Study to Assess Rasagiline as a Disease Modifying Therapy in Early Parkinson’s Disease Subjects - ADAGIO

Parkinson's Disease
MedDRA version: 7.1;Level: PT;Classification code 10061536

Trade Name: AZILECT
Product Name: rasagiline tablets
Product Code: TVP-1012
INN or Proposed INN: rasagiline
Other descriptive name: rasagiline mesilate

Teva Pharmaceuticals Industries LtD

NULL

Not Recruiting

Female: yes
Male: yes

1100

Portugal;Hungary;Germany;United Kingdom;Spain;Italy

1883

EUCTR2004-005234-39-FI
(EUCTR)

22/09/2005

03/06/2005

Multicentre, randomised, double-blind study to compare Stalevo® to levodopa/carbidopa in patients with Parkinson's disease experiencing symptoms of early wearing-off - SEWOP

Parkinson's disease
MedDRA version: 7.0;Level: LLT;Classification code 10061536

Orion Corporation, ORION PHARMA

NULL

Not Recruiting

Female: yes
Male: yes

240

Finland;Germany;United Kingdom;Denmark;Ireland;Latvia;Lithuania;Sweden

1884

EUCTR2005-001416-42-GB
(EUCTR)

15/09/2005

13/06/2005

A Multicenter, Double-Blind, Randomized Start, Placebo-Controlled, Parallel-Group Study to Assess Rasagiline as a Disease Modifying Therapy in Early Parkinson’s Disease Subjects - ADAGIO

Parkinson's Disease
MedDRA version: 7.1;Level: PT;Classification code 10061536

Teva Pharmaceuticals Industries LtD

NULL

Not Recruiting

Female: yes
Male: yes

1100

Phase 3

Portugal;Hungary;Spain;Austria;Germany;Italy;United Kingdom

1885

EUCTR2005-000444-84-FI
(EUCTR)

08/09/2005

26/07/2005

Treatment-Associated Dyskinesia in Parkinson's Disease

Product Code: EMD128130
INN or Proposed INN: Sarizotan hydrochloride

Merck KGaA

NULL

Not Recruiting

Female: yes
Male: yes

800

Phase 3

Finland;United Kingdom;Spain;Italy

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1886

EUCTR2005-001416-42-DE
(EUCTR)

01/09/2005

17/10/2005

A Multicenter, Double-Blind, Randomized Start, Placebo-Controlled, Parallel-Group Study to Assess Rasagiline as a Disease Modifying Therapy in Early Parkinson’s Disease Subjects - ADAGIO

Parkinson's Disease
MedDRA version: 7.1;Level: PT;Classification code 10061536

Product Name: rasagiline tablets
Product Code: TVP-1012
INN or Proposed INN: rasagiline
Other descriptive name: rasagiline mesilate
Product Name: rasagiline tablets
Product Code: TVP-1012
INN or Proposed INN: rasagiline
Other descriptive name: rasagiline mesilate
Product Name: rasagiline tablets
Product Code: TVP-1012
INN or Proposed INN: rasagiline
Other descriptive name: rasagiline mesilate

Teva Pharmaceuticals Industries LtD

NULL

Not Recruiting

Female: yes
Male: yes

1100

Portugal;Hungary;United Kingdom;Germany;Spain;Italy

1887

NCT00165789
(ClinicalTrials.gov)

September 2005

12/9/2005

A Study to Explore the Safety And Tolerability of Doses of E2007 Up to a Maximum of 8 mg In Patients With Parkinson's Disease Who Experience End-of-Dose Wearing Off Motor Fluctuations

A Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Explore the Safety And Tolerability of Doses of E2007 Up to a Maximum of 8 mg In Patients With Parkinson's Disease Who Experience End-of-Dose Wearing Off Motor Fluctuations

Parkinson's Disease

Drug: E2007

Eisai Inc.

NULL

Completed

18 Years

N/A

All

Phase 2

United States

1888

NCT02774564
(ClinicalTrials.gov)

September 2005

13/5/2016

Pharmacokinetic-pharmacodynamic Interaction Between BIA 3-202 and Levodopa/Carbidopa

Pharmacokinetic-pharmacodynamic Interaction Between Three Different Single Doses of BIA 3-202 and a Single Dose of Controlled-release 200/50 mg Levodopa/Carbidopa (Sinemet® cr 200/50): a Double-blind, Randomised, Four-way Crossover, Placebo-controlled Study in Healthy Volunteers

Parkinson's Disease

Drug: BIA 3-202;Drug: Placebo;Drug: Sinemet®

Bial - Portela C S.A.

NULL

Completed

18 Years

45 Years

Both

Phase 1

Portugal

1889

NCT02778594
(ClinicalTrials.gov)

September 2005

18/5/2016

Pharmacokinetic-pharmacodynamic Interaction Between BIA 3-202 and Levodopa/Benserazide

Pharmacokinetic-pharmacodynamic Interaction Between Three Different Single Doses of BIA 3-202 and a Single-dose of Controlled-release 100/25 mg Levodopa/Benserazide (Madopar® HBS 125): a Double-blind, Randomised, Four-way Crossover, Placebo-controlled Study in Healthy Volunteers

Parkinson's Disease (PD)

Drug: BIA 3-202;Drug: Placebo;Drug: levodopa 100 mg / benserazide 25 mg

Bial - Portela C S.A.

NULL

Completed

18 Years

45 Years

Both

Phase 1

Portugal

1890

NCT00224263
(ClinicalTrials.gov)

September 2005

20/9/2005

Efficacy and Safety of Lingzhi in Patients With Early Parkinson's Disease

A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study to Assess the Efficacy and Safety of Lingzhi in Patients With Early Parkinson's Disease Receiving Stable L-dopa/DCI

Parkinson's Disease

Drug: Lingzhi (Ganoderma)

Xuanwu Hospital, Beijing

NULL

Completed

30 Years

80 Years

Both

360

Phase 2

China

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1891

EUCTR2005-001416-42-AT
(EUCTR)

24/08/2005

20/07/2005

A Multicenter, Double-Blind, Randomized Start, Placebo-Controlled, Parallel-Group Study to Assess Rasagiline as a Disease Modifying Therapy in Early Parkinson’s Disease Subjects - ADAGIO

Parkinson's Disease
MedDRA version: 7.1;Level: PT;Classification code 10061536

Trade Name: AZILECT
Product Name: rasagiline tablets
Product Code: TVP-1012
INN or Proposed INN: rasagiline
Other descriptive name: rasagiline mesilate

Teva Pharmaceuticals Industries LtD

NULL

Not Recruiting

Female: yes
Male: yes

1100

Portugal;Hungary;Spain;Austria;Germany;Italy;United Kingdom

1892

EUCTR2005-002654-21-SE
(EUCTR)

08/08/2005

14/06/2005

Trade Name: Duodopa intestinal gel
INN or Proposed INN: Levodopa
INN or Proposed INN: Carbidopa

Solvay Pharmaceuticals GmbH

NULL

Not Recruiting

Female: yes
Male: yes

Sweden

1893

EUCTR2004-005234-39-DK
(EUCTR)

04/08/2005

31/05/2005

Multicentre, randomised, double-blind study to compare Stalevo® to levodopa/carbidopa in patients with Parkinson's disease experiencing symptoms of early wearing-off - SEWOP

Parkinson's disease
MedDRA version: 7.0;Level: LLT;Classification code 10061536

Orion Corporation, ORION PHARMA, 02200 Espoo, Finland

NULL

Not Recruiting

Female: yes
Male: yes

240

Finland;Germany;United Kingdom;Denmark;Ireland;Latvia;Lithuania;Sweden

1894

NCT00134966
(ClinicalTrials.gov)

August 2005

23/8/2005

A Study to Evaluate Fixed Dose Carbidopa/Levodopa/Entacapone Versus Immediate Release Carbidopa/Levodopa

A 39 Week Randomized, Double-Blind, Parallel Group, Multicenter Study to Evaluate the Effect of Fixed Dose Carbidopa/Levodopa/Entacapone 100 mg t.i.d. vs. Immediate Release Carbidopa/Levodopa 25/100 mg (t.i.d.) in Parkinson's Disease Patients Requiring Levodopa

Parkinson's Disease

Drug: capsules containing: carbidopa (25 mg), levodopa (100 mg), entacapone (200 mg)

Novartis

NULL

Completed

30 Years

80 Years

All

493

Phase 3

United States;Canada;Czechia;Israel;Italy;Poland;Portugal;Turkey;Czech Republic

1895

NCT00692328
(ClinicalTrials.gov)

August 2005

4/6/2008

Expectation and Response to Levodopa and Acupuncture in Parkinson's Disease

Expectation and Response to Levodopa & Acupuncture in Parkinson's Disease

Parkinson's Disease

Behavioral: Levodopa or acupuncture

Oregon Health and Science University

National Center for Complementary and Integrative Health (NCCIH)

Completed

18 Years

80 Years

Both

N/A

United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1896

NCT00125567
(ClinicalTrials.gov)

August 2005

29/7/2005

Stalevo in Early Wearing-Off Patients

Multicentre, Randomised, Double-Blind Study to Compare Stalevo to Levodopa/Carbidopa in Patients With Parkinson's Disease Experiencing Symptoms of Early Wearing-Off

Idiopathic Parkinson's Disease

Drug: Stalevo (levodopa/carbidopa/entacapone);Drug: Levodopa /carbidopa

Orion Corporation, Orion Pharma

NULL

Completed

30 Years

N/A

Both

223

Phase 4

Denmark;Finland;Germany;Ireland;Sweden;United Kingdom

1897

EUCTR2005-001416-42-ES
(EUCTR)

28/07/2005

28/06/2005

A Multicenter, Double-Blind, Randomized Start, Placebo-Controlled, Parallel-Group Study to Assess Rasagiline as a Disease Modifying Therapy in Early Parkinson’s Disease Subjects. Estudio multicéntrico, doble ciego, de inicio randomizado, controlado con placebo, de grupos paralelos, para valorar Rasagilina como una terapia que modifica la enfermedad de Parkinson en pacientes con enfermedad de Parkinson en fase temprana - ADAGIO

Parkinson's Disease
MedDRA version: 7.1;Level: PT;Classification code 10061536

Teva Pharmaceuticals Industries LtD

NULL

Not Recruiting

Female: yes
Male: yes

1100

Phase 3

Portugal;Hungary;Spain;Austria;Germany;Italy;United Kingdom

1898

EUCTR2004-001485-41-GB
(EUCTR)

26/07/2005

21/06/2005

A single-blinded assessment of the short-term effects of cabergoline vs. carbidopa/levodopa on SPECT dopamine transporter density in out-patient subjects with Parkinson’s Disease - N/A

Approximately 120 recently diagnosed/early Parkinson’s disease subjects, who are untreated (see exclusionary criteria).

Trade Name: Sinemet
Product Name: Sinemet
INN or Proposed INN: carbidopa /levodopa
Trade Name: Cabaser
Product Name: Cabaseril
INN or Proposed INN: Cabergoline
Trade Name: DaTSCAN
Product Name: DatSCAN
INN or Proposed INN: Ioflupane [123 I]

Institute for Neurodegenerative Disorders

NULL

Not Recruiting

Female: yes
Male: yes

120

United Kingdom;Spain

1899

EUCTR2004-002844-93-AT
(EUCTR)

20/07/2005

15/06/2005

A Long-Term, Multicenter, Open-Label Safety Study with Oral 20 or 40 mg/d Doses of KW-6002 (Istradefylline) as Treatment for Parkinson’s Disease in Patients with Motor Response Complications on Levodopa Therapy

Parkinson's Disease

Product Name: Istradefylline
Product Code: KW-6002
INN or Proposed INN: Istradefylline

Kyowa Hakko U.K. Limited

NULL

Not Recruiting

Female: yes
Male: yes

1175

Estonia;Spain;Lithuania;Austria;Latvia;Italy;United Kingdom

1900

EUCTR2004-000835-27-ES
(EUCTR)

18/07/2005

23/05/2006

A PHASE III, DOUBLE-BLIND, PLACEBO-CONTROLLED, 12-MONTH EXTENSION STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF A DOSE RANGE OF SAFINAMIDE OF 50-200 MG/DAY, AS ADD-ON THERAPY IN PATIENTS WITH EARLY IDIOPATHIC PARKINSON’S DISEASE TREATED WITH A STABLE DOSE OF A SINGLE DOPAMINE AGONIST.

Early idiopathic Parkinson's disease
MedDRA version: 7.0;Level: LLT;Classification code 10013113

Product Name: Safinamide
Product Code: NW-1015
INN or Proposed INN: Safinamide
Product Name: Safinamide
Product Code: NW-1015
INN or Proposed INN: Safinamide
Product Name: Safinamide
Product Code: NW-1015
INN or Proposed INN: Safinamide
Product Name: Safinamide
Product Code: NW-1015
INN or Proposed INN: Safinamide

Newron Pharmaceuticals S.P.A

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

212

Phase 3

Spain;Italy

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1901

EUCTR2005-004290-19-AT
(EUCTR)

17/07/2005

06/12/2005

advanced-stage, idiopathic Parkinson's disease
MedDRA version: 8.1;Level: LLT;Classification code 10061536

Product Name: Rotigotine Nasal Spray
Product Code: ND1421
INN or Proposed INN: Rotigotine hydrochloride

Schwarz Biosciences GmbH

NULL

Not Recruiting

Female: yes
Male: yes

100

Spain;Austria;Germany;United Kingdom

1902

EUCTR2005-001416-42-IT
(EUCTR)

14/07/2005

21/06/2005

A Multicenter, Double-Blind, Randomized Start, Placebo-Controlled, Parallel-Group Study to Assess Rasagiline as a Disease Modifying Therapy in Early Parkinson's Disease Subjects

Neuroprotective early treatment of Parkinson's disease subjects
MedDRA version: 6.1;Level: PT;Classification code 10061536

Product Name: NA
Product Code: NA
Other descriptive name: NA
Product Name: rasagiline
Product Code: TVP-1012

TEVA

NULL

Not Recruiting

Female: yes
Male: yes

Portugal;Hungary;Germany;United Kingdom;Spain;Italy

1903

EUCTR2005-000444-84-ES
(EUCTR)

12/07/2005

22/05/2006

An open-label, multicenter, multinational Phase IIIfollow-up study to investigate the long-term safetyand efficacy of Sarizotan HCl 1 mg b.i.d. inpatients with Parkinson's disease suffering fromtreatment-associated dyskinesia (PADDY-O) - PADDY-O

Treatment- Associated Dyskinesia in Parkinson´s Disease

Product Code: EMD128130
INN or Proposed INN: Sarizotan hydrochloride

Merck KGaA

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

800

Phase 3

Finland;United Kingdom;Spain;Italy

1904

EUCTR2004-002844-93-IT
(EUCTR)

06/07/2005

21/09/2005

A Long-Term, Multicenter, Open-Label Safety Study with Oral 20 or 40 mg/d Doses of KW-6002 (Istradefylline) as Treatment for Parkinson's Disease in Patients with Motor Response Complications on Levodopa Therapy. -

Parkinson's Disease.
MedDRA version: 6.1;Level: PT;Classification code 10061536

Product Name: Istradefylline
Product Code: KW-6002
Other descriptive name: NA

KYOWA HAKKO UK LTD

NULL

Not Recruiting

Female: yes
Male: yes

United Kingdom;Estonia;Spain;Italy;Latvia;Lithuania

1905

NCT00143026
(ClinicalTrials.gov)

July 2005

31/8/2005

Study to Compare the Effect of Treatment With Carbidopa/Levodopa/Entacapone on the Quality of Life of Patients With Parkinson's Disease. This Study is Not Recruiting in the United States

Study to Compare the Effect of Treatment With Carbidopa/Levodopa/Entacapone on the Quality of Life of Patients With Parkinson's Disease.

Parkinson's Disease

Drug: carbidopa , levodopa, entacapone

Novartis

NULL

Completed

30 Years

N/A

All

184

Phase 4

Australia;Philippines;Taiwan;Thailand

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1906

NCT00125138
(ClinicalTrials.gov)

July 2005

27/7/2005

Melperone (an Anti-Psychotic) in Patients With Psychosis Associated With Parkinson's Disease

Safety and Efficacy of Melperone in the Treatment of Patients With Psychosis Associated With Parkinson's Disease

Parkinson's Disease;Psychotic Disorders

Drug: Melperone HCl;Drug: Placebo

Lundbeck LLC

NULL

Completed

N/A

All

Phase 2

United States;India;Italy

1907

EUCTR2005-000444-84-AT
(EUCTR)

22/06/2005

18/05/2005

Treatment-Associated Dyskinesia in Parkinson's Disease

Product Code: EMD128130
INN or Proposed INN: Sarizotan hydrochloride

Merck KGaA

NULL

Not Recruiting

Female: yes
Male: yes

800

Phase 3

Finland;Spain;Austria;Italy;United Kingdom

1908

EUCTR2005-004314-33-AT
(EUCTR)

16/06/2005

05/12/2005

Levodopa treated Parkinson's disease patients with motor fluctuations
MedDRA version: 8.1;Classification code 10061536

Product Name: MARS
Product Code: E2007
Product Name: MARS
Product Code: E2007

Eisai Limited

NULL

Not Recruiting

Female: yes
Male: yes

1260

Portugal;Hungary;Estonia;Spain;Lithuania;Austria;Germany;Italy;United Kingdom;Sweden

1909

EUCTR2004-005234-39-SE
(EUCTR)

08/06/2005

02/05/2005

Multicentre, randomised, double-blind study to compare Stalevo® to levodopa/carbidopa in patients with Parkinson's disease experiencing symptoms of early wearing-off - SEWOP

Parkinson's disease
MedDRA version: 7.0;Level: LLT;Classification code 10061536

Orion Corporation, ORION PHARMA, 02200 Espoo, Finland

NULL

Not Recruiting

Female: yes
Male: yes

240

Finland;Germany;United Kingdom;Denmark;Ireland;Latvia;Lithuania;Sweden

1910

NCT00086190
(ClinicalTrials.gov)

June 2005

28/6/2004

Study of Antidepressants in Parkinson's Disease

Parkinson Disease;Depression

Drug: paroxetine;Drug: venlafaxine;Other: placebo

University of Rochester

National Institute of Neurological Disorders and Stroke (NINDS)

Completed

30 Years

N/A

All

115

Phase 3

United States;Canada;Puerto Rico

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1911

NCT00139880
(ClinicalTrials.gov)

June 2005

29/8/2005

A Single Center, Randomized, Double-blind, Crossover Pilot Trial Comparing the Onset of Action of Parcopa™ With Sinemet® in Subjects With Stable Parkinson's Disease

Parkinson's Disease

Drug: Parcopa

UCB Pharma

NULL

Completed

40 Years

N/A

Both

Phase 3

United States

1912

NCT00642889
(ClinicalTrials.gov)

June 2005

21/3/2008

Safinamide as Add-On Therapy in Patients With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist (12 Month Extension)

A PHASE III, DOUBLE-BLIND, PLACEBO-CONTROLLED, 12-MONTH EXTENSION STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF A DOSE RANGE OF SAFINAMIDE OF 50-200 MG/DAY, AS ADD-ON THERAPY IN PATIENTS WITH EARLY IDIOPATHIC PARKINSON'S DISEASE TREATED WITH A STABLE DOSE OF A SINGLE DOPAMINE AGONIST.

Parkinson's Disease

Drug: Safinamide;Drug: Placebo

Newron

NULL

Completed

30 Years

80 Years

Both

227

Phase 3

NULL

1913

NCT00148369
(ClinicalTrials.gov)

June 2005

6/9/2005

A Multi-Center, Observational Safety Registry of Subjects With Idiopathic Parkinson's Disease Previously Treated With Intraputaminal Infusion of Liatermin

Idiopathic Parkinson's Disease

Drug: Safety observation

Amgen

Medtronic

Completed

35 Years

70 Years

Both

N/A

Canada;United Kingdom;United States

1914

EUCTR2004-005234-39-GB
(EUCTR)

27/05/2005

22/03/2005

Multicentre, randomised, double-blind study to compare Stalevo® to levodopa/carbidopa in patients with Parkinson's disease experiencing symptoms of early wearing-off - SEWOP

Parkinson's disease
MedDRA version: 7.0;Level: LLT;Classification code 10061536

Orion Corporation, ORION PHARMA, Finland

NULL

Not Recruiting

Female: yes
Male: yes

240

Phase 4

Finland;Ireland;Lithuania;Denmark;Latvia;Germany;United Kingdom;Sweden

1915

NCT03095092
(ClinicalTrials.gov)

May 23, 2005

23/3/2017

Effect of Food on BIA 6-512 (Trans-resveratrol)

The Effect of Food on the Pharmacokinetics of a Single 400 mg Oral Dose of BIA 6-512 (Trans-resveratrol) in Healthy Subjects

Parkinson Disease

Drug: BIA 6-512 400 mg

Bial - Portela C S.A.

NULL

Completed

18 Years

45 Years

All

Phase 1

Portugal

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1916

EUCTR2004-005034-39-GB
(EUCTR)

17/05/2005

20/04/2005

Nicotinamide,vitamin B3, metabolic pathways in patients with early idiopathic parkinson's disease

Idiopathic Parkinson's disease

Trade Name: Nicotinamide
Product Name: NICOTINAMIDE
INN or Proposed INN: Nicotinamide

Queen Elizabeth Hospital

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

United Kingdom

1917

EUCTR2004-002608-13-GB
(EUCTR)

16/05/2005

19/04/2005

Pragmatic Randomised Control Trial of Quetiapine for psychosis in Parkinson’s Disease - Quetiapine for psychosis in Parkinson’s disease

Parkinson's Disease with psychosis

King’s College London & King’s College Hospital

NULL

Not Recruiting

Female: yes
Male: yes

Phase 4

United Kingdom

1918

EUCTR2004-002641-12-GB
(EUCTR)

16/05/2005

30/06/2005

A multicenter, multinational, phase 3b, open-label extension trial to assess the safety and tolerability of long-term treatment of rotigotine patch in subjects with idiopathic Parkinson's disease

Parkinson's disease

Schwarz Biosciences GmbH

NULL

Not Recruiting

Female: yes
Male: yes

220

Phase 3

Spain;Austria;Italy;United Kingdom

1919

NCT03093389
(ClinicalTrials.gov)

May 11, 2005

22/3/2017

Tolerability and Steady-state Pharmacokinetics of BIA 6-512

A Double-blind, Randomised, Placebo-controlled, Rising Multiple-dose Study to Investigate the Tolerability and Steady-state Pharmacokinetics of BIA 6-512 (Trans-resveratrol) in Healthy Volunteers

Parkinson Disease

Drug: BIA 6-512;Drug: Placebo

Bial - Portela C S.A.

NULL

Completed

18 Years

45 Years

All

Phase 1

Portugal

1920

NCT00199433
(ClinicalTrials.gov)

May 2005

12/9/2005

A Study of Istradefylline (KW-6002) as Monotherapy in Parkinson's Disease (PD) Patients

A Phase 2, Double-blind, Placebo-controlled, Randomized, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of 40mg/Day KW-6002 (Istradefylline) as Monotherapy in Subjects With Parkinson's Disease

Parkinson's Disease;Movement Disorder Syndrome

Drug: Istradefylline (KW-6002)

Kyowa Kirin Pharmaceutical Development, Inc.

NULL

Completed

30 Years

N/A

Both

160

Phase 2

United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1921

NCT00163085
(ClinicalTrials.gov)

May 2005

9/9/2005

The Effects of an NR2B NMDA Antagonist, CP-101,606, in Patients With Parkinson's Disease

A Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Explore The Efficacy And Safety Of The NR2B NMDA Antagonist CP-101,606 In Patients With Idiopathic Parkinson's Disease

Parkinson's Disease

Drug: NR2B NMDA Antagonist CP-101,606 (traxoprodil)

Pfizer

NULL

Completed

30 Years

80 Years

Both

Phase 2

United States

1922

EUCTR2004-001485-41-ES
(EUCTR)

28/04/2005

30/01/2006

A single-blinded assessment of the short-term effects of cabergoline vs. carbidopa/levodopa on SPECT dopamine transporter density in out-patient subjects with Parkinson’s Disease

Approximately 120 recently diagnosed/early Parkinson’s disease subjects, who are untreated (see exclusionary criteria).

Trade Name: SINEMET
Product Name: carbodopa/levadopa
INN or Proposed INN: CARBODOPA LEVADOPA
Trade Name: SOLIGEN
Product Name: Cabergoline
INN or Proposed INN: CABERGOLINA
Trade Name: DaTSCAN
INN or Proposed INN: Ioflupane [123I]

Institute for Neurodegenerative Disorders

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

120

United Kingdom;Spain

1923

EUCTR2004-002641-12-ES
(EUCTR)

25/04/2005

10/07/2006

A multicenter, multinational, phase 3b, open-label extension trial to assess the safety and tolerability of long-term treatment of rotigotine patch in subjects with idiopathic Parkinson's disease

Parkinson's disease

Schwarz Biosciences GmbH

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

220

Phase 3b

United Kingdom;Spain;Italy

1924

EUCTR2004-004139-74-DK
(EUCTR)

20/04/2005

22/03/2005

Parkinson’s Disease: PET scan and evaluation of memantines pharmacological effect.(Parkinsons sygdom bedømt med PET skanning, herunder memantins farmakologiske effekt.) - N/A

Parkinson's Disease

Trade Name: Ebixa
Product Name: Ebixa
INN or Proposed INN: memantine

Neurologisk afdeling F

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

Phase 2

Denmark

1925

EUCTR2004-001485-41-AT
(EUCTR)

20/04/2005

16/03/2005

A single-blinded assessment of the short-term effects of cabergoline vs. carbidopa/levodopa on SPECT dopamine transporter density in out-patient subjects with Parkinson’s Disease - N/A

Approximately 120 recently diagnosed/early Parkinson’s disease subjects, who are untreated (see exclusionary criteria).

Trade Name: Sinemet
Product Name: Sinemet
INN or Proposed INN: carbidopa /levodopa
Trade Name: Cabaseril
Product Name: Cabaseril
INN or Proposed INN: Cabergoline
Trade Name: DaTSCAN
Product Name: DatSCAN
INN or Proposed INN: Ioflupane [123 I]

Institute for Neurodegenerative Disorders

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

120

Spain;Austria;United Kingdom

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1926

EUCTR2004-000817-20-IT
(EUCTR)

06/04/2005

13/04/2005

A 16-week, Double-Blind, Placebo-Controlled, Randomised, Parallel-Group, Multicentre, International Study to Evaluate the Efficacy and Safety of 40 mg/day KW-6002 (Istradefylline) and that of Entacapone versus Placebo as Treatment for Parkinson's Disease in Patients with Motor Response Complications on Levodopa Therapy

Parkinson's Disease
MedDRA version: 6.1;Level: PT;Classification code 10061536

Product Name: istradefylline
Product Code: KW-6002
Other descriptive name: NA
Trade Name: COMTAN 200* 60 CPR 200 MG
Product Name: NA
Product Code: NA
INN or Proposed INN: Entacapone

KYOWA HAKKO UK LTD

NULL

Not Recruiting

Female: yes
Male: yes

405

Spain;Italy;Latvia;Lithuania

1927

EUCTR2004-002844-93-ES
(EUCTR)

01/04/2005

04/11/2005

Parkinson's Disease

Product Name: Istradefylline
Product Code: KW-6002
INN or Proposed INN: Istradefylline

Kyowa Hakko U.K. Limited

NULL

Not Recruiting

Female: yes
Male: yes

1175

United Kingdom;Estonia;Spain;Italy;Latvia;Lithuania

1928

NCT00199355
(ClinicalTrials.gov)

April 2005

12/9/2005

A Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease in Patients Taking Levodopa

Placebo-Controlled , Double-Blind , Exploratory Study of KW-6002(Istradefylline) in the Treatment of Parkinson's Disease. [Adjunctive Therapy to Levodopa]

Parkinson's Disease

Drug: Istradefylline (KW-6002)

Kyowa Hakko Kirin Company, Limited

NULL

Completed

30 Years

N/A

Both

Phase 2

Japan

1929

NCT00375778
(ClinicalTrials.gov)

April 2005

12/9/2006

Parkinson's Disease Evaluated by PET and the Effect of Memantine

Parkinson's Disease Evaluated by Positron Emission Tomography and the Effect of the NMDA Receptor Antagonist Memantine

Parkinson's Disease

Drug: memantine (drug)

University of Aarhus

Lundbeck Foundation

Completed

50 Years

70 Years

Both

N/A

Denmark

1930

NCT00108667
(ClinicalTrials.gov)

April 2005

15/4/2005

Talampanel to Treat Parkinson's Disease

AMPA Receptor Antagonist Treatment of Parkinson's Disease

Parkinson Disease

Drug: IV Levodopa;Drug: Talampanel

National Institute of Neurological Disorders and Stroke (NINDS)

NULL

Completed

N/A

Both

Phase 2

United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1931

EUCTR2004-001593-10-GB
(EUCTR)

21/03/2005

25/08/2005

A double-blind, placebo-controlled, multicenter, multinational Phase III study to evaluate the safety and efficacy of Sarizotan HCl 1 mg b.i.d. in patients with Parkinson's disease suffering from treatment-associated dyskinesia (PADDY 1) - PADDY 1

Treatment-Associated Dyskinesia in Parkinson's Disease

Merck KGaA

NULL

Not Recruiting

Female: yes
Male: yes

600

Phase 3

Italy;United Kingdom

1932

EUCTR2004-002844-93-EE
(EUCTR)

08/03/2005

07/03/2005

Parkinson's Disease

Product Name: Istradefylline
Product Code: KW-6002
INN or Proposed INN: Istradefylline

Kyowa Hakko U.K. Limited

NULL

Not Recruiting

Female: yes
Male: yes

1175

United Kingdom;Estonia;Spain;Italy;Latvia;Lithuania

1933

EUCTR2004-002598-21-GB
(EUCTR)

02/03/2005

07/07/2005

A phase 3b, open-label. multicenter, multinational trial to evaluate the effects of rotigotine transdermal patch on early morning motor impairment and sleep disorders in patients with idiopathic Parkinson's disease

Idiopathic Parkinson's disease

Schwarz Biosciences GmbH

NULL

Not Recruiting

Female: yes
Male: yes

Phase 3

Austria;United Kingdom

1934

NCT00203957
(ClinicalTrials.gov)

March 2005

13/9/2005

Study of KW-6002 (Istradefylline) in Parkinson's Disease in Patients With Motor Response Complications on Levodopa

A Long-Term, Multicenter, Open-Label Safety Study With Oral 20 or 40 mg/d Doses of KW-6002 (Istradefylline) as Treatment for Parkinson's Disease in Patients With Motor Response Complications on Levodopa Therapy

Parkinson's Disease

Drug: Istradefylline

University of Chicago

NULL

Completed

18 Years

N/A

Both

Phase 3

United States

1935

NCT02834507
(ClinicalTrials.gov)

March 2005

13/7/2016

Effect of Two Multiple-dose Regimens of BIA 3-202 on the Pharmacokinetics and Motor Response of Levodopa, and on the Erythrocyte Comt Activity in Parkinson's Disease Patients

A Double-blind, Randomised, Placebo- and Active-controlled, Cross-over Study to Investigate the Effect of Two Multiple-dose Regimens of BIA 3-202 on the Pharmacokinetics and Motor Response of Levodopa, and on the Erythrocyte Comt Activity in Parkinson's Disease Patients

Parkinson's Disease (PD)

Drug: Placebo;Drug: BIA 3-202;Drug: Comtan®;Drug: Sinemet®

Bial - Portela C S.A.

NULL

Completed

30 Years

75 Years

Both

Phase 2

NULL

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1936

EUCTR2004-002844-93-LT
(EUCTR)

08/02/2005

03/01/2005

Parkinson's Disease

Product Name: Istradefylline
Product Code: KW-6002
INN or Proposed INN: Istradefylline

Kyowa Hakko U.K. Limited

NULL

Not Recruiting

Female: yes
Male: yes

1175

United Kingdom;Estonia;Spain;Italy;Latvia;Lithuania

1937

EUCTR2004-002650-59-GB
(EUCTR)

03/02/2005

30/06/2005

A phase 3b, open-label, multicentre, multinational trial to assess the tolerability of switching subjects from ropinerole, pramipexole or cabergoline to the rotigotine transdermal system and its effect on symptoms with idiopathic Parkinson's disease - n/a

Idiopathic Parkinson's disease

Product Name: rotigotine
Product Code: SPM 962
INN or Proposed INN: rotigotine

SCHWARZ BIOSCIENCES

NULL

Not Recruiting

Female: yes
Male: yes

130

Phase 3

United Kingdom

1938

EUCTR2004-000817-20-AT
(EUCTR)

02/02/2005

29/12/2004

A 16-week, Double-Blind, Placebo-Controlled, Randomised, Parallel-Group, Multicentre, International Study to Evaluate the Efficacy and Safety of 40 mg/day KW-6002 (istradefylline) and that of Entacapone versus Placebo as Treatment for Parkinson's Disease in Patients with Motor Response Complications on Levodopa Therapy.

Parkinson's Disease

Product Name: Istradefylline
Product Code: KW-6002
INN or Proposed INN: Istradefylline
Trade Name: Comtess
Product Name: Comtess
INN or Proposed INN: Entacapone

Kyowa Hakko U.K. Limited

NULL

Not Recruiting

Female: yes
Male: yes

405

Spain;Lithuania;Austria;Latvia;Italy

1939

EUCTR2004-001594-25-AT
(EUCTR)

02/02/2005

29/12/2004

Treatment-Associated Dyskinesia in Parkinson's Disease

Product Code: EMD128130
INN or Proposed INN: Sarizotan hydrochloride

Merck KGaA

NULL

Not Recruiting

Female: yes
Male: yes

600

Phase 3

Finland;Spain;Austria

1940

EUCTR2004-002844-93-GB
(EUCTR)

01/02/2005

23/02/2005

Parkinson's Disease

Product Name: Istradefylline
Product Code: KW-6002
INN or Proposed INN: Istradefylline

Kyowa Hakko U.K. Limited

NULL

Not Recruiting

Female: yes
Male: yes

1175

Italy;Latvia;Lithuania;United Kingdom;Estonia;Spain

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1941

NCT00505687
(ClinicalTrials.gov)

February 2005

20/7/2007

An Open-Label Extension Trial to Assess the Safety and Tolerability of Long Term Treatment of Rotigotine in Subjects With Idiopathic Parkinson's Disease

A Multicenter, Multinational, Phase 3b, Open-Label Extension Trial to Assess the Safety and Tolerability of Long-Term Treatment of Rotigotine Patch in Subjects With Idiopathic Parkinson's Disease

Idiopathic Parkinson's Disease

Drug: Rotigotine

UCB Pharma

NULL

Completed

31 Years

N/A

All

186

Phase 3

United States;Austria;Germany;Israel;Italy;South Africa;Spain;United Kingdom

1942

NCT00153972
(ClinicalTrials.gov)

February 2005

7/9/2005

Dopamine Turnover Rate as Surrogate Parameter for Diagnosis of Early Parkinson's Disease

Dopamine Turnover Rate Measured With F-Dopa-PET as Surrogate Parameter for Diagnosis and Progression Analysis of Early Parkinson's Disease

Parkinson's Disease

Drug: Cabergoline;Drug: Levodopa

Technische Universität Dresden

Pfizer

Completed

40 Years

85 Years

Both

Phase 4

Germany

1943

EUCTR2004-002844-93-LV
(EUCTR)

28/01/2005

31/01/2005

Parkinson's Disease

Product Name: Istradefylline
Product Code: KW-6002
INN or Proposed INN: Istradefylline

Kyowa Hakko U.K. Limited

NULL

Not Recruiting

Female: yes
Male: yes

1175

United Kingdom;Estonia;Spain;Italy;Latvia;Lithuania

1944

EUCTR2004-002641-12-AT
(EUCTR)

21/01/2005

17/12/2004

A multicenter, multinational, phase 3b, open-label extension trial to assess the safety and tolerability of long-term treatment of rotigotine patch in subjects with idiopathic Parkinson's disease

Parkinson's disease

Schwarz Biosciences GmbH

NULL

Not Recruiting

Female: yes
Male: yes

220

Phase 3b

Spain;Austria;Italy;United Kingdom

1945

NCT00286949
(ClinicalTrials.gov)

January 6, 2005

3/2/2006

Treatment of Executive Dysfunction in Parkinson's Disease

Atomoxetine for the Treatment of Executive Dysfunction in Patients With Parkinson's Disease: A Pilot Open-label Study

Parkinson's Disease

Drug: Atomoxetine

Johns Hopkins University

Eli Lilly and Company

Completed

21 Years

65 Years

All

N/A

United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1946

NCT00144300
(ClinicalTrials.gov)

January 2005

2/9/2005

Ophthalmologic Safety Study of Pramipexole Immediate Release (IR) Versus Ropinirole in Early Parkinson's Disease (PD) Patients

A Two Year Open Label, Randomized, Parallel Group, Blinded Assessment Ophthalmologic Safety Study of Pramipexole IR Versus Ropinirole in Early Parkinson's Disease Patients

Parkinson Disease

Drug: Mirapex;Drug: Requip

Boehringer Ingelheim

NULL

Completed

30 Years

N/A

All

246

Phase 4

United States

1947

NCT00219284
(ClinicalTrials.gov)

January 2005

30/6/2005

Effects of Carbidopa/Levodopa/Entacapone on Motor Function and Quality of Life in Patients With Parkinson's Disease

A Prospective, Multi-center, Randomized, Open-label Study With Blinded Raters to Evaluate the Effects of Immediate Versus Delayed Switch to Carbidopa/Levodopa/Entacapone on Motor Function and Quality of Life in Patients With Parkinson's Disease With End-of-dose Wearing Off

Parkinson's Disease With End of Dose Wearing Off

Drug: Carbidopa /levodopa/entacapone

Novartis Pharmaceuticals

NULL

Completed

30 Years

85 Years

All

359

Phase 4

United States;Puerto Rico

1948

NCT00129181
(ClinicalTrials.gov)

January 2005

9/8/2005

Study of the Effects of Dopaminergic Medications on Dopamine Transporter Density in Subjects With Parkinson's Disease

A Single-blinded Assessment of the Short-term Effects of Cabergoline vs. Carbidopa/Levodopa on SPECT Dopamine Transporter Density in Out-patient Subjects With Parkinson's Disease

Parkinson Disease;Parkinsonian Syndrome

Drug: cabergoline;Drug: carbidopa /levodopa;Procedure: DATscan and SPECT imaging

Institute for Neurodegenerative Disorders

Pfizer;GE Healthcare

Completed

40 Years

N/A

Both

N/A

Austria;Germany;Italy;Spain;United Kingdom

1949

NCT01634243
(ClinicalTrials.gov)

January 2005

27/6/2012

A Dose-ranging Study for SPM 962 in Parkinson's Disease Patients

A Open-label Dose-ranging Study for SPM 962 in Parkinson's Disease Patients

Parkinson's Disease

Drug: SPM 962

Otsuka Pharmaceutical Co., Ltd.

NULL

Completed

30 Years

79 Years

All

Phase 2

Japan

1950

NCT00103597
(ClinicalTrials.gov)

January 2005

11/2/2005

Efficacy of Therapeutic Interventions for Orthostatic Hypotension in Parkinson's Disease and Multiple System Atrophy

Parkinson's Disease;Multiple System Atrophy;Orthostatic Hypotension

Drug: Fludrocortisone;Drug: Domperidone;Behavioral: Conservative Measures for Orthostatic Hypotension

Royal Brisbane and Women's Hospital

NULL

Completed

40 Years

95 Years

Both

Phase 1

Australia

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1951

EUCTR2004-001594-25-FI
(EUCTR)

30/12/2004

26/10/2004

Treatment-Associated Dyskinesia in Parkinson's Disease

Product Code: EMD128130
INN or Proposed INN: Sarizotan hydrochloride

Merck KGaA

NULL

Not Recruiting

Female: yes
Male: yes

600

Phase 3

Finland;Spain

1952

EUCTR2004-002598-21-AT
(EUCTR)

22/12/2004

17/11/2004

A phase 3b, open-label, multicenter, multinational trial to evaluate the effects of rotigotine transdermal patch on early morning motor impairment and sleep disorders in patients with idiopathic Parkinson's disease

Parkinson's Disease

Schwarz Biosciences GmbH

NULL

Not Recruiting

Female: yes
Male: yes

Phase 3b

Austria;United Kingdom

1953

EUCTR2004-002609-66-IT
(EUCTR)

21/12/2004

03/03/2006

A phase 3, randomized, open-label, two-arm, parallel-group, multicenter, multinational trial to compare the efficacy of rotigotine transdermal patch to that of ropinirole on early morning motor impairment and sleep disorders in subjects with early-stage, idiopathic Parkinson s disease

Idiopathic Parkinson Disease in early stage
MedDRA version: 6.1;Level: PT;Classification code 10061536

Product Name: rotigotine
Product Code: SPM 926
Trade Name: REQUIP 21 CPR 0,25 MG
INN or Proposed INN: Ropinirole
Product Name: rotigotine
Product Code: SPM 962
Trade Name: REQUIP 21 CPR 0,5 MG
INN or Proposed INN: Ropinirole
Product Name: rotigotine
Product Code: SPM 962
Product Name: rotigotine
Product Code: SPM 962
Trade Name: REQUIP 21 CPR 1 MG
INN or Proposed INN: Ropinirole
Trade Name: REQUIP 21 CPR 2 MG
INN or Proposed INN: Ropinirole

SCHWARZ PHARMA

NULL

Not Recruiting

Female: yes
Male: yes

Phase 3

Germany;Italy

1954

EUCTR2004-000817-20-ES
(EUCTR)

10/12/2004

04/05/2005

Parkinson's Disease

Product Name: Istradefylline
Product Code: KW-6002
INN or Proposed INN: Istradefylline
Trade Name: Comtan
Product Name: Comtess
INN or Proposed INN: Entacapone

Kyowa Hakko U.K. Limited

NULL

Not Recruiting

Female: yes
Male: yes

405

Spain;Italy;Latvia;Lithuania

1955

EUCTR2004-002609-66-DE
(EUCTR)

06/12/2004

22/04/2005

Parkinson's Disease

Product Name: Rotigotine
Product Code: SPM962
INN or Proposed INN: Rotigotine
Product Name: Rotigotine
Product Code: SPM962
INN or Proposed INN: Rotigotine
Product Name: Rotigotine
Product Code: SPM962
INN or Proposed INN: Rotigotine
Product Name: Rotigotine
Product Code: SPM962
INN or Proposed INN: Rotigotine
Trade Name: Requip
Product Name: Requip
INN or Proposed INN: Ropinirole
Trade Name: Requip
Product Name: Requip
INN or Proposed INN: Ropinirole
Trade Name: Requip
Product Name: Requip
INN or Proposed INN: Ropinirole
Trade Name: Requip
Product Name: Requip
INN or Proposed INN: Ropinirole

Schwarz Biosciences GmbH

NULL

Not Recruiting

Female: yes
Male: yes

Phase 3

Germany;Italy

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1956

EUCTR2004-000835-27-IT
(EUCTR)

03/12/2004

21/07/2005

A phase III, double-blind, placebo-controlled, 12-month extension study to investigate the efficacy and safety of a dose range of safinamide of 50-200 mg/day, as add-on therapy in patients with early idiopathic Parkinson's Disease treated with a stable dose of a single dopamine agonist

Parkinson's Disease
MedDRA version: 6.1;Level: PT;Classification code 10061536

Product Name: Safinamide
Product Code: NW-1015

NEWRON PHARMACEUTICALS

NULL

Not Recruiting

Female: yes
Male: yes

Phase 3

Spain;Italy

1957

EUCTR2004-000833-12-IT
(EUCTR)

02/12/2004

15/03/2005

A Phase III, double-blind, placebo-controlled study to determine the efficacy and safety of a low (50-100 mg/day) and high (150-200 mg/day) dose range of safinamide, as add-on therapy, in patients with early idiopathic Parkinson's Disease treated with a stable dose of a single dopamine agonist

Parkinson's Disease
MedDRA version: 6.1;Level: PT;Classification code 10061536

Product Name: Safinamide
Product Code: NW-1015
INN or Proposed INN: Monoamine oxidase B inhibitors

NEWRON PHARMACEUTICALS

NULL

Not Recruiting

Female: yes
Male: yes

Phase 3

Spain;Italy

1958

EUCTR2004-001593-10-IT
(EUCTR)

02/12/2004

03/01/2005

Treatment-Associated Dyskinesia in Parkinson's Disease

Product Name: Sarizotan hydrochloride
Product Code: EMD 128130
INN or Proposed INN: Sarizotan hydrochloride

MERCK S.P.A.

NULL

Not Recruiting

Female: yes
Male: yes

Phase 3

United Kingdom;Italy

1959

EUCTR2004-000833-12-ES
(EUCTR)

02/12/2004

23/11/2004

A phase III, double-blind, placebo-controlled study to determine the efficacy and safety of a low (50-100 mg/day) and high (150-200 mg/day) dose range of safinamide, as add-on therapy, in patients with early idiopathic parkinson’s disease treated with a stable dose of a single dopamine agonist.

Early idiopathic Parkinson’s disease
MedDRA version: 7.0;Level: LLT;Classification code 10013113

Newron Pharmaceuticals S.p.A.

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

250

Phase 3

Spain;Italy

1960

EUCTR2004-000185-12-IT
(EUCTR)

02/12/2004

27/06/2005

A long term, double-blind, randomized, parallel-group, carbidopa/levodopa controlled, multi-center study to evaluate the effect of Stalevo in patients with Parkinson's disease

Parkinson's Disease
MedDRA version: 6.1;Level: PT;Classification code 10061536

Trade Name: Stalevo
Product Name: NA
Product Code: NA
INN or Proposed INN: carbidopa
INN or Proposed INN: levodopa
INN or Proposed INN: entecapone
Trade Name: Sinemet
Product Name: NA
Product Code: NA
INN or Proposed INN: LEVODOPA (DC.IT) (FU)
INN or Proposed INN: CARBIDOPA (FU)
Trade Name: Stalevo
Product Name: NA
Product Code: NA
INN or Proposed INN: carbidopa
INN or Proposed INN: levodopa
INN or Proposed INN: entecapone
Trade Name: Sinemet
Product Name: NA
Product Code: NA
INN or Proposed INN: LEVODOPA (DC.IT) (FU)
INN or Proposed INN: CARBIDOPA (FU)
Trade Name: Sinemet
Product Name: NA
Product Code: NA
INN or Proposed INN: LEVODOPA (DC.IT) (FU)
INN or Proposed INN: CARBIDOPA (FU)

NOVARTIS FARMA

NULL

Not Recruiting

Female: yes
Male: yes

740

Finland;United Kingdom;Italy;Sweden

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1961

NCT00243945
(ClinicalTrials.gov)

December 2004

24/10/2005

A Trial to Evaluate the Effects of Rotigotine Transdermal Patch on Early Morning Motor Impairment and Sleep Disorders Idiopathic Parkinson's Disease

A Phase 3b, Open-Label, Multicenter, Multinational Trial to Evaluate the Effects of Rotigotine Transdermal Patch on Early Morning Motor Impairment and Sleep Disorders in Patients With Idiopathic Parkinson's Disease

IDIOPATHIC PARKINSON'S DISEASE

Drug: Rotigotine

UCB Pharma

NULL

Completed

18 Years

N/A

Both

Phase 3

Germany

1962

NCT00643045
(ClinicalTrials.gov)

December 2004

21/3/2008

Safinamide as Add-On Therapy in Patients With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist

A Phase III, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of a Low (50 100 mg/Day) and High (150 200 mg/Day) Dose Range of Safinamide as Add-On Therapy in Patients With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist

Idiopathic Parkinson's Disease

Drug: Safinamide;Drug: Placebo

Newron

NULL

Completed

30 Years

80 Years

Both

269

Phase 3

NULL

1963

NCT00242008
(ClinicalTrials.gov)

December 2004

18/10/2005

A Trial To Assess Switching From Ropinirole, Pramipexole Or Cabergoline To The Rotigotine Transdermal System In Idiopathic Parkinson's Disease

A Phase 3b, Open-Label, Multicenter, Multinational Trial To Assess The Tolerability Of Switching Subjects From Ropinirole, Pramipexole Or Cabergoline To The Rotigotine Transdermal System And Its Effect On Symptoms In Subjects With Idiopathic Parkinson's Disease

Parkinson's Disease

Drug: Rotigotine

UCB Pharma

NULL

Completed

18 Years

N/A

Both

Phase 3

United States

1964

EUCTR2004-000185-12-AT
(EUCTR)

25/11/2004

21/10/2004

Parkinson's disease
MedDRA version: 7.0;Level: LLT;Classification code 10061536

Orion Corporation, ORION PHARMA, 02200 Espoo, Finland

NULL

Not Recruiting

Female: yes
Male: yes

740

Finland;Austria;Italy;United Kingdom;Sweden

1965

EUCTR2004-001594-25-ES
(EUCTR)

24/11/2004

02/11/2004

A double-blind, placebo controlled, multicenter, multinational, phase III study to evaluate the safety and efficacy of Sarizotan HCl 1 mg b.i.d in patients with Parkinson' s disease suffering from treatment-associated dyskinesia. - PADDY-2

Treatment-Associated Dyskinesia in Parkinson's Disease

Product Name: Sarizotan
Product Code: EMD 128130
INN or Proposed INN: Sarizotan Hydrochloride

MERCK KGaA

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

600

Phase 3

Finland;Spain

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1966

NCT01518309
(ClinicalTrials.gov)

November 17, 2004

16/12/2008

An Open-label Safety Study of Pimavanserin in Parkinson's Disease Patients

An Open-Label Safety Study of Pimavanserin in Parkinson's Disease Patients

Parkinson's Disease Psychosis

Drug: pimavanserin tartrate (ACP-103)

ACADIA Pharmaceuticals Inc.

NULL

Completed

N/A

All

Phase 2

United States

1967

EUCTR2004-000185-12-SE
(EUCTR)

11/11/2004

03/09/2004

Parkinson's disease
MedDRA version: 7.0;Level: LLT;Classification code 10061536

Orion Corporation, ORION PHARMA, 02200 Espoo, Finland

NULL

Not Recruiting

Female: yes
Male: yes

740

Finland;United Kingdom;Italy;Sweden

1968

EUCTR2004-000817-20-GB
(EUCTR)

08/11/2004

11/02/2005

Parkinson's Disease

Product Name: Istradefylline
Product Code: KW-6002
INN or Proposed INN: Istradefylline
Trade Name: Comtess
Product Name: Comtess
INN or Proposed INN: Entacapone

Kyowa Hakko U.K. Limited

NULL

Not Recruiting

Female: yes
Male: yes

405

Phase 3

Spain;Lithuania;Austria;Latvia;Italy;United Kingdom

1969

NCT03091868
(ClinicalTrials.gov)

November 3, 2004

21/3/2017

Pharmacokinetics of Rising Single-doses of BIA 6-512 and Their Effect on the Levodopa Pharmacokinetics

A Double-blind, Randomised, Placebo-controlled Study in Healthy Volunteers to Investigate the Tolerability and Pharmacokinetics of Rising Single-doses of BIA 6-512 and Their Effect on the Levodopa Pharmacokinetics When Administered in Combination With a Single-dose of Levodopa/Carbidopa 100/25 mg or With a Single-dose of Levodopa/Carbidopa 100/25 mg Plus a Single-dose of Entacapone 200 mg

Parkinson Disease

Drug: Placebo oral capsule;Drug: Sinemet® 100/25;Drug: Comtan®;Drug: BIA 6-512 25 mg;Drug: BIA 6-512 100 mg

Bial - Portela C S.A.

NULL

Completed

18 Years

45 Years

All

Phase 1

Portugal

1970

NCT00296946
(ClinicalTrials.gov)

November 2004

23/2/2006

Ipratropium Spray for Drooling Saliva in Parkinson's Disease

Phase II Clinical Trial of Ipratropium Bromide Spray as a Treatment for Sialorrhea in Patients With Parkinson's Disease

Parkinson's Disease

Drug: ipratropium bromide (drug)

University Health Network, Toronto

Parkinson's Disease Foundation

Completed

30 Years

N/A

All

Phase 2

Canada

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1971

NCT00199394
(ClinicalTrials.gov)

November 2004

12/9/2005

A Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease

A 16-week, Double-Blind, Placebo-Controlled, Randomised, Parallel-Group, Multicentre, International Study to Evaluate the Efficacy and Safety of 40 mg/Day KW-6002 (Istradefylline) and That of Entacapone Versus Placebo as Treatment for Parkinson's Disease in Patients With Motor Response Complications on Levodopa Therapy.

Parkinson's Disease

Drug: Istradefylline (KW-6002)

Kyowa Hakko Kirin UK, Ltd.

NULL

Completed

30 Years

N/A

Both

405

Phase 3

United Kingdom

1972

NCT01634360
(ClinicalTrials.gov)

November 2004

3/7/2012

Long-Term Safety, Tolerability and Efficacy in Perampanel Treated Parkinson's Disease Patients With Motor Fluctuations

A 48-month Open Label Multi-centered Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of E2007 in Patients With Parkinson's Disease With Wearing Off Motor Fluctuations and on Period Dyskinesias

Parkinson's Disease

Drug: Perampanel

Eisai Inc.

NULL

Terminated

N/A

All

185

Phase 2

NULL

1973

NCT00243971
(ClinicalTrials.gov)

November 2004

24/10/2005

A Trial to Compare the Efficacy of Rotigotine Transdermal Patch to That of Ropinirole on Early Morning Motor Impairment and Sleep Disorders in Subjects With Early-Stage, Idiopathic Parkinson's Disease

A Phase 3, Randomized, Open-Label, Two-Arm, Parallel-Group, Multicenter, Multinational Trial to Compare the Efficacy of Rotigotine Transdermal Patch to That of Ropinirole on Early Morning Motor Impairment and Sleep Disorders in Subjects With Early-Stage, Idiopathic Parkinson's Disease

Parkinson's Disease

Drug: SPM 962

UCB Pharma

NULL

Completed

18 Years

N/A

Both

Phase 3

Germany

1974

EUCTR2004-000817-20-LV
(EUCTR)

22/10/2004

27/10/2004

Parkinson's Disease

Product Name: Istradefylline
Product Code: KW-6002
INN or Proposed INN: Istradefylline
Trade Name: Comtess
Product Name: Comtess
INN or Proposed INN: Entacapone

Kyowa Hakko U.K. Limited

NULL

Not Recruiting

Female: yes
Male: yes

405

Spain;Italy;Latvia;Lithuania

1975

EUCTR2004-000361-35-IT
(EUCTR)

22/10/2004

23/05/2005

A 12-MONTH OPEN LABEL MULTI-CENTERED EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY, TOLERABILITY AND EFFICACY OF E2007 IN PATIENTS WITH PARKINSON'S DISEASE WITH WEARING OFF MOTOR FLUCTUATIONS AND ON PERIOD DYSKINESIAS.

Parkinson's disease.
MedDRA version: 6.1;Level: PT;Classification code 10061536

Product Name: NA
Product Code: E2007
Other descriptive name: NA

EISAI LTD UK

NULL

Not Recruiting

Female: yes
Male: yes

Czech Republic;Italy

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1976

EUCTR2004-000361-35-CZ
(EUCTR)

18/10/2004

22/10/2004

A 48-MONTH OPEN LABEL MULTI-CENTERED EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY, TOLERABILITY AND EFFICACY OF E2007 IN PATIENTS WITH PARKINSON’S DISEASE WITH WEARING OFF” MOTOR FLUCTUATIONS AND ON” PERIOD DYSKINESIAS.

Parkinson's Disease

Product Name: MARS
Product Code: E2007
Other descriptive name: MARS
Other descriptive name: MARS
Other descriptive name: MARS

Eisai Limited

NULL

Not Recruiting

Female: yes
Male: yes

225

Czech Republic;Italy

1977

EUCTR2004-000148-26-ES
(EUCTR)

13/10/2004

16/09/2004

Parkinson's Disease

Product Name: Rotigotine
Product Code: SPM 962
INN or Proposed INN: Rotigotine
Other descriptive name: (6S)-6-{propyl-[2-[2-thienyl]ethyl]amino}-5,6,7,8-tetrahydro-1-naphtalenol
Product Name: Rotigotine
Product Code: SPM 962
INN or Proposed INN: Rotigotine
Other descriptive name: (6S)-6-{propyl-[2-[2-thienyl]ethyl]amino}-5,6,7,8-tetrahydro-1-naphtalenol
Product Name: Rotigotine
Product Code: SPM 962
INN or Proposed INN: Rotigotine
Other descriptive name: (6S)-6-{propyl-[2-[2-thienyl]ethyl]amino}-5,6,7,8-tetrahydro-1-naphtalenol

Schwarz BioSciences Inc.

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

360

Phase 3

Hungary;Finland;Czech Republic;Spain;Italy;Sweden

1978

EUCTR2004-000148-26-CZ
(EUCTR)

12/10/2004

11/10/2004

Parkinson's Disease

Schwarz BioSciences Inc.

NULL

Not Recruiting

Female: yes
Male: yes

360

Phase 3

Hungary;Finland;Czech Republic;Spain;Italy;Sweden

1979

NCT00199368
(ClinicalTrials.gov)

October 2004

12/9/2005

An Extension of Istradefylline in Parkinson's Disease Patients Who Have Completed Studies 6002-EU-007, 6002-US-013 or 6002-US-018

Parkinson's Disease

Drug: Istradefylline ( KW-6002)

Kyowa Kirin Pharmaceutical Development, Inc.

Kyowa Hakko Kirin UK, Ltd.

Completed

30 Years

N/A

Both

1100

Phase 3

United States

1980

NCT00105508
(ClinicalTrials.gov)

September 30, 2004

15/3/2005

Sarizotan HC1 in Patients With Parkinson's Disease Suffering From Treatment-associated Dyskinesia

A Double-blind, Placebo-controlled, Multicenter, Multinational Phase III Study to Evaluate the Safety and Efficacy of Sarizotan HCl 1 mg b.i.d. in Patients With Parkinson's Disease Suffering From Treatment-associated Dyskinesia

Parkinson's Disease;Dyskinesia

Drug: Sarizotan;Drug: Placebo

EMD Serono

NULL

Completed

30 Years

N/A

All

506

Phase 3

United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1981

EUCTR2004-000148-26-SE
(EUCTR)

29/09/2004

05/07/2004

Parkinson's Disease

Schwarz BioSciences Inc.

NULL

Not Recruiting

Female: yes
Male: yes

360

Phase 3

Hungary;Finland;Czech Republic;Spain;Italy;Sweden

1982

EUCTR2004-000185-12-FI
(EUCTR)

21/09/2004

23/07/2004

Parkinson's disease
MedDRA version: 7.0;Level: LLT;Classification code 10061536

Orion Corporation, ORION PHARMA

NULL

Not Recruiting

Female: yes
Male: yes

740

Finland;United Kingdom;Italy;Sweden

1983

EUCTR2004-000817-20-LT
(EUCTR)

16/09/2004

07/01/2005

Parkinson's Disease

Product Name: Istradefylline
Product Code: KW-6002
INN or Proposed INN: Istradefylline
Trade Name: Comtess
Product Name: Comtess
INN or Proposed INN: Entacapone

Kyowa Hakko U.K. Limited

NULL

Not Recruiting

Female: yes
Male: yes

405

Spain;Italy;Latvia;Lithuania

1984

EUCTR2004-003355-39-AT
(EUCTR)

14/09/2004

08/10/2004

A 52-week, multicentre, open label extension study of the safety, tolerability and efficacy of donepezil (Aricept) in Parkinson's disease patients with dementia.

Dementia associated with Parkinson's disease

Trade Name: Aricept 5 mg-Filmtabletten
Product Name: Aricept 5mg-Filmtabletten

Eisai Limited

NULL

Not Recruiting

Female: yes
Male: yes

468

Austria

1985

NCT00641186
(ClinicalTrials.gov)

September 2004

18/3/2008

Trial of Xyrem for Excessive Daytime Sleepiness and Sleep Disturbance in Parkinson's Disease (PD)

A Phase II, Eight Week, Multi-Center, Open Label Trial of Xyrem(R) (Sodium Oxybate) for Excessive Daytime Sleepiness and Nocturnal Sleep Disturbance in Patients With Mild to Moderate Parkinson's Disease

Parkinson Disease

Drug: sodium oxybate

Baylor College of Medicine

Jazz Pharmaceuticals

Completed

30 Years

75 Years

Both

Phase 2

NULL

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1986

NCT00105521
(ClinicalTrials.gov)

September 2004

15/3/2005

Sarizotan HCl in Patients With Parkinson's Disease Suffering From Treatment-Associated Dyskinesia

Parkinson's Disease;Dyskinesia

Drug: Sarizotan HC1

EMD Serono

NULL

Completed

30 Years

N/A

All

594

Phase 3

United States

1987

NCT00296959
(ClinicalTrials.gov)

September 2004

23/2/2006

Topiramate as a Treatment for Levodopa-Induced Dyskinesia in Parkinson's Disease

Anti-Dyskinetic Properties of Topiramate: A Double-Blind, Placebo-Controlled Trial in Patients With Parkinson's Disease and Levodopa-Induced Dyskinesias

Parkinson's Disease

Drug: topiramate (drug)

University Health Network, Toronto

NULL

Terminated

30 Years

75 Years

Both

Phase 2

Canada

1988

NCT00099268
(ClinicalTrials.gov)

September 2004

10/12/2004

Efficacy and Safety of Carbidopa/Levodopa/Entacapone in Patients With Parkinson's Disease Requiring Initiation of Levodopa Therapy

A Long Term, Double-blind, Randomized, Parallel-group, Carbidopa/Levodopa Controlled, Multi-center Study to Evaluate the Effect of Carbidopa/Levodopa/Entacapone in Patients With Parkinson's Disease Requiring Initiation of Levodopa Therapy

Parkinson's Disease

Drug: Carbidopa /levodopa/entacapone;Drug: Immediate release carbidopa/levodopa

Novartis Pharmaceuticals

Orion Corporation, Orion Pharma

Completed

30 Years

70 Years

All

747

Phase 3

United States;Austria;Belgium;Canada;Finland;France;Germany;Greece;Italy;Spain;Sweden;Switzerland;Turkey;United Kingdom

1989

NCT00089622
(ClinicalTrials.gov)

August 4, 2004

6/8/2004

Lisuride Patch to Treat Parkinson's Disease

Transcutaneous Lisuride Therapy of Parkinson's Disease

Parkinson Disease

Drug: Intravenous Levodopa;Drug: Lisuride Transdermal System

National Institute of Neurological Disorders and Stroke (NINDS)

NULL

Completed

40 Years

80 Years

All

Phase 2

United States

1990

NCT00501969
(ClinicalTrials.gov)

August 2004

16/7/2007

An Open-Label Extension Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Advanced-Stage Parkinson's Disease

An Open-Label Extension to the Double-Blind SP515 (NCT00244387) Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Subjects With Advanced-Stage Idiopathic Parkinson's Disease Who Are Not Well Controlled on L-Dopa

Advanced Stage Parkinson's Disease

Drug: Rotigotine

UCB Pharma

NULL

Completed

31 Years

N/A

All

395

Phase 3

Australia;Austria;Croatia;Czech Republic;Finland;France;Germany;Hungary;Israel;Italy;New Zealand;Norway;Poland;South Africa;Spain;Sweden;United Kingdom

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1991

EUCTR2004-000148-26-FI
(EUCTR)

30/07/2004

28/06/2004

Parkinson's Disease

Product Name: Rotigotine
Product Code: SPM 962
INN or Proposed INN: Rotigotine
Other descriptive name: (6S)-6-{propyl-[2-[2-thienyl]ethyl]amino}-5,6,7,8-tetrahydro-1-naphtalenol

Schwarz BioSciences Inc.

NULL

Not Recruiting

Female: yes
Male: yes

360

Phase 3

Czech Republic;Hungary;Finland;Spain;Italy;Sweden

1992

NCT00359723
(ClinicalTrials.gov)

July 2004

31/7/2006

Methylphenidate and Parkinson's Disease

Subacute Trial of Methylphenidate in Parkinson's Disease

Parkinson's Disease

Drug: methylphenidate

Oregon Health and Science University

National Institute of Neurological Disorders and Stroke (NINDS)

Completed

21 Years

N/A

All

Phase 2

United States

1993

NCT00199420
(ClinicalTrials.gov)

July 2004

12/9/2005

A Study of Istradefylline (KW-6002) in Treating Patients With Parkinson's Disease on Levodopa

A 12-week, Double Blind, Placebo-controlled, Randomized, Parallel Group, Multicenter, Fixed Dose Study to Evaluate the Efficacy and Safety of 10, 20 and 40 mg/d Oral Dose of KW-6002 (Istradefylline) as Treatment for Parkinson's Disease in Patients With Motor Response Complications on Levodopa/Carbidopa Therapy.

Parkinson's Disease

Drug: Istradefylline (KW-6002)

Kyowa Kirin Pharmaceutical Development, Inc.

NULL

Completed

30 Years

N/A

Both

580

Phase 3

United States

1994

NCT00174239
(ClinicalTrials.gov)

July 2004

9/9/2005

Study Of Cabaser and Sinemet CR For The Treatment Of Nighttime Symptoms Associated With Parkinson's Disease.

A Double-Blind, Randomized, Comparative Study of Cabaser and Sinemet CR For The Treatment Of Nocturnal Disability In Levodopa -Treated Parkinson's Disease Patients.

Parkinson Disease

Drug: cabergoline;Drug: controlled-release levodopa / carbidopa

Pfizer

NULL

Terminated

18 Years

80 Years

Both

220

Phase 4

Australia;Italy;Spain;United Kingdom

1995

NCT00304161
(ClinicalTrials.gov)

July 2004

15/3/2006

Effectiveness of Antidepressant Treatment for Depression in People With Parkinson's Disease

Depression Diagnosis and Treatment in Parkinson Disease

Depressive Disorder;Parkinson Disease

Drug: Atomoxetine;Drug: Placebo

University of Pennsylvania

National Institute of Mental Health (NIMH)

Completed

30 Years

79 Years

All

Phase 4

United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

1996

NCT00086294
(ClinicalTrials.gov)

June 25, 2004

29/6/2004

ACP-103 to Treat Parkinson's Disease

5HT2A/C Serotonin Blockade in Parkinson's Disease

Parkinson's Disease;Dyskinesias

Drug: Intravenous Levodopa;Drug: ACP-103

National Institute of Neurological Disorders and Stroke (NINDS)

NULL

Completed

30 Years

80 Years

All

Phase 2

United States

1997

EUCTR2004-000148-26-IT
(EUCTR)

14/06/2004

26/07/2007

A multi-center, multinational, phase 3, open-label extension trial to assess the safety of long term treatment of rotigotine patch in subjects with advanced stage, idiopathic Parkinsons disease who are not well controlled on levodopa

Advanced stage Parkinson's Disease

INN or Proposed INN: rotigotine

SCHWARZ PHARMA

NULL

Not Recruiting

Female: yes
Male: yes

360

Phase 3

Hungary;Finland;Czech Republic;Spain;Italy;Sweden

1998

NCT00211588
(ClinicalTrials.gov)

June 2004

13/9/2005

Galantamine Executive Function in Parkinson's Disease

Investigator Initiated Study: Galantamine CR Potential Enhancement of Attentional and Executive Function in Non-Demented Patients With Parkinson's Disease

Parkinson's Disease

Drug: galantamine

Memorial Hospital of Rhode Island

Ortho-McNeil Neurologics, Inc.

Active, not recruiting

60 Years

85 Years

Both

N/A

United States

1999

NCT00203138
(ClinicalTrials.gov)

June 2004

13/9/2005

Safety, Tolerability, and Effectiveness of Rasagiline Mesylate in Patients With Parkinson's Disease

A Multicenter, Open-Label, Phase III Study for the Safety, Tolerability and Clinical Effect of Rasagiline Mesylate in Patients With Parkinson's Disease

Parkinson's Disease

Drug: rasagiline mesylate

Teva Pharmaceutical Industries

NULL

Completed

35 Years

N/A

Both

306

Phase 3

United States

2000

NCT00199407
(ClinicalTrials.gov)

June 2004

12/9/2005

A Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease in Patients Taking Levodopa

A 12-week, Double Blind, Placebo-controlled, Randomized, Parallel Group, Multicenter, Fixed Dose Study to Evaluate the Efficacy and Safety of a 20 mg/d Oral Dose of KW-6002 (Istradefylline) as Treatment for Parkinson's Disease in Patients With Motor Response Complications on Levodopa/Carbidopa Therapy.

Parkinson's Disease

Drug: Istradefylline (KW-6002)

Kyowa Kirin Pharmaceutical Development, Inc.

NULL

Completed

30 Years

N/A

Both

230

Phase 3

United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

2001

NCT03091543
(ClinicalTrials.gov)

May 4, 2004

21/3/2017

Tolerability, Safety and Pharmacokinetics of Four Single-doses of BIA 6-512 (Trans-resveratrol) and Their Effect on the Levodopa Pharmacokinetics

A Double-blind, Randomised, Crossover, Placebo-controlled Study in Healthy Volunteers to Investigate the Tolerability, Safety and Pharmacokinetics of Four Single-doses of BIA 6-512 (Trans-resveratrol) and Their Effect on the Levodopa Pharmacokinetics When Administered in Combination With a Single-dose of Levodopa/Benserazide 100/25 mg

Parkinson Disease

Drug: Madopar® HBS 125;Drug: Placebo;Drug: BIA 6-512 25 mg dose;Drug: BIA 6-512 50 mg dose;Drug: BIA 6-512 100 mg dose;Drug: BIA 6-512 200 mg dose

Bial - Portela C S.A.

NULL

Completed

18 Years

45 Years

All

Phase 1

Portugal

2002

NCT01172379
(ClinicalTrials.gov)

May 2004

26/7/2010

A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Safety, Tolerability and Efficacy of E2007 in Parkinson's Disease Patients With Wearing Off Motor Fluctuations and On Period Dyskinesias

Parkinson's Disease

Drug: E2007;Other: Placebo Comparator

Eisai Limited

NULL

Completed

30 Years

75 Years

Both

Phase 2

Czech Republic;France;Germany;Italy;Serbia;Spain

2003

NCT00087542
(ClinicalTrials.gov)

March 2004

9/7/2004

Treatment of Hallucinosis/Psychosis in Parkinson's Disease by an Investigational Drug

Hallucinations;Psychoses;Parkinson's Disease

Drug: ACP-103

ACADIA Pharmaceuticals Inc.

NULL

Completed

N/A

Both

Phase 2

United States

2004

NCT00200447
(ClinicalTrials.gov)

March 2004

12/9/2005

An Open-Label Feasibility/Pilot Study With [123I]-IBZM SPECT (DOPA-SYN)

Assessment of Carbidopa/l-Dopa and Carbidopa/l Dopa/Entacapone on Synaptic Dopamine in Parkinson's Patients: An Open-Label Feasibility/Pilot Study With [123I]-IBZM SPECT (DOPA-SYN)

Parkinson's Disease

Drug: carbidopa /l-dopa;Drug: carbidopa /l-dopa /entacapone;Drug: Stalevo;Procedure: [123I]-IBZM imaging

Molecular NeuroImaging

NULL

Completed

30 Years

N/A

Both

Phase 2

NULL

2005

NCT00244387
(ClinicalTrials.gov)

March 2004

24/10/2005

Rotigotine Patch in Subjects With Advanced Stage, Idiopathic Parkinson's Disease Who Are Not Well Controlled on Levodopa

A Multi-centre, Multi-national, Phase 3, Randomized, Double-blind, Double-dummy, 3- Arm Parallel Group, Placebo- and Pramipexole- Controlled Trial of the Efficacy and Safety of Rotigotine Patch in Subjects With Advanced Stage, Idiopathic Parkinson's Disease Who Are Not Well Controlled on Levodopa

Parkinson Disease, Idiopathic

Drug: SPM 962

UCB Pharma

NULL

Completed

30 Years

N/A

Both

506

Phase 3

Germany

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

2006

NCT02248181
(ClinicalTrials.gov)

February 2004

22/9/2014

Post Marketing Surveillance Study of Sifrol® in Patients With Idiopathic Parkinson's Disease

Post Marketing Surveillance Study of Sifrol® - Monotherapy in Patients With Idiopathic Parkinson's Disease

Parkinson Disease

Drug: Pramipexole

Boehringer Ingelheim

NULL

Completed

N/A

Both

442

N/A

NULL

2007

NCT00632736
(ClinicalTrials.gov)

February 2004

4/3/2008

An Open-label Continuation Study Evaluating the Long-term Safety of Extended Release Ropinirole XL (Formerly CR) in Parkinson''s Disease

An Open-Label Extension Study With REQUIP (Ropinirole) CR for Subjects From Studies 101468/165, 101468/168 and 101468/169

Parkinson Disease;Parkinson's Disease

Drug: Ropinirole XL (formerly CR)

GlaxoSmithKline

NULL

Completed

30 Years

N/A

All

419

Phase 3

United States;Belgium;Czech Republic;France;Hungary;Italy;Poland;Spain;United Kingdom;Germany;Philippines

2008

NCT00096720
(ClinicalTrials.gov)

February 2004

12/11/2004

Study of the Effects of Dopaminergic Medications on Dopamine Transporter Imaging in Parkinson's Disease

Investigating Effects of Short-term Treatment With Pramipexole or Levodopa on [123I]B-CIT and SPECT Imaging in Early Parkinson's

Parkinson Disease;Parkinsonian Syndrome

Drug: levodopa;Drug: Mirapex (pramipexole);Procedure: [123I]ß-CIT and SPECT imaging

Institute for Neurodegenerative Disorders

Boehringer Ingelheim;Department of Defense

Completed

30 Years

N/A

Both

112

Phase 2

United States

2009

NCT00674310
(ClinicalTrials.gov)

February 2004

5/5/2008

A Single-Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalency Study of Ropinirole 0.25 mg Tablets Under Fed Conditions

Parkinson's Disease;Restless Leg Syndrome

Drug: Ropinirole Hydrochloride

Roxane Laboratories

NULL

Completed

18 Years

45 Years

All

N/A

NULL

2010

NCT00673088
(ClinicalTrials.gov)

February 2004

5/5/2008

A Single Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalency Study of Ropinirole 0.25 mg Tablets Und Fasted Conditions

Parkinson's Disease;Restless Leg Syndrome

Drug: Ropinirole Hydrochloride

Roxane Laboratories

NULL

Completed

18 Years

45 Years

All

N/A

NULL

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

2011

NCT00220272
(ClinicalTrials.gov)

January 2004

16/9/2005

Study of the Effect of SR57667B on 18F-Dopa PET Imaging in Patients With Parkinson's Disease

A Phase II, Randomized, Multicenter, Multinational, Double-Blind, Placebo-Controlled, Study of the Effect of SR57667B on Dopaminergic Nigro-Striatal Function Assessed by 18F-Dopa PET Imaging in Outpatients With Early Parkinson's Disease

Parkinson Disease

Drug: SR57667B

Sanofi

NULL

Completed

35 Years

N/A

Both

183

Phase 2

Canada;Finland;France;Netherlands;Spain;Switzerland;United Kingdom

2012

NCT02231905
(ClinicalTrials.gov)

January 2004

3/9/2014

Safety, Tolerability and Efficacy of Switching From Talipexole to Pramipexole in Patients With Parkinson's Disease

Open Label, Exploratory Clinical Trial to Assess the Safety, Tolerability and Effectiveness of a Switching From Talipexole to Pramipexole

Parkinson Disease

Drug: BI-Sifrol®

Boehringer Ingelheim

NULL

Completed

20 Years

N/A

Both

Phase 4

NULL

2013

NCT00076674
(ClinicalTrials.gov)

January 2004

28/1/2004

Levetiracetam Treatment of L-dopa Induced Dyskinesias

Dyskinesias;Parkinson Disease

Drug: Intravenous Levodopa

National Institute of Neurological Disorders and Stroke (NINDS)

NULL

Completed

N/A

Both

Phase 2

United States

2014

NCT00076492
(ClinicalTrials.gov)

January 2004

23/1/2004

NINDS Parkinson's Disease Neuroprotection Trial of CoQ10 and GPI 1485

A Multi-center, Double-blind, Pilot Study of CoQ10 and GPI 1485 in Subjects With Early Untreated Parkinson's Disease

Parkinson Disease

Drug: CoQ10;Drug: GPI 1485

University of Rochester

National Institute of Neurological Disorders and Stroke (NINDS)

Completed

30 Years

N/A

Both

195

Phase 2

United States

2015

NCT00139867
(ClinicalTrials.gov)

January 2004

29/8/2005

A Multicenter, Open-label Trial to Assess Subject Preference of PARCOPA, Carbidopa/Levodopa Orally Disintegrating Tablets, Compared to Conventional Carbidopa/Levodopa Tablets in Subjects With Stable Parkinson's Disease

Parkinson's Disease

Drug: PARCOPA

UCB Pharma

NULL

Completed

18 Years

N/A

Both

Phase 3

United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

2016

NCT00212693
(ClinicalTrials.gov)

January 2004

13/9/2005

Controlled Study of ONO-2506PO in Patients With Parkinson's Disease in Japan

Parkinson's Disease

Drug: ONO-2506PO

Ono Pharmaceutical Co. Ltd

NULL

Completed

20 Years

79 Years

Both

165

Phase 2

NULL

2017

NCT00111982
(ClinicalTrials.gov)

December 2003

27/5/2005

Trial of Extended Treatment With Liatermin (r-metHuGDNF) Administered by Continuous Intraputaminal (IPu)Infusion to Subjects With Idiopathic Parkinson's Disease Who Have Completed a Previous Trial of Liatermin

Multi-Center, Open-Label Trial of Extended Treatment With Liatermin (r-metHuGDNF) Administered by Continuous Intraputaminal (IPu) Infusion to Subjects With Idiopathic Parkinson's Disease Who Have Completed a Previous Trial of Liatermin (Protocol 20020168)

Parkinson's Disease

Biological: Liatermin

Amgen

Medtronic

Completed

35 Years

70 Years

Both

Phase 1;Phase 2

United States

2018

NCT00363727
(ClinicalTrials.gov)

December 2003

7/8/2006

Onset Motor Complications Using REQUIP CR (Ropinirole Controlled-release) As Add-on Therapy To L-dopa In Parkinson's

A Two Year Phase IIIb Randomised, Multicenter, Double-blind, SINEMET Controlled, Parallel Group, Flexible Dose Study, to Assess the Effectiveness of Controlled Release Ropinirole add-on Therapy to L-dopa at Increasing the Time to Onset of Dyskinesia in Parkinson's Disease Subjects.

Parkinson's Disease;Parkinson Disease;Dyskinesias

Drug: ropinirole controlled-release (REQUIP CR) for RLS

GlaxoSmithKline

NULL

Completed

30 Years

70 Years

All

209

Phase 3

United States

2019

NCT01941732
(ClinicalTrials.gov)

November 2003

10/9/2013

Motor Response to Sildenafil in PD

Motor Response to Acute Challenge to Sildenafil in Parkinsons Disease

Parkinsons Disease;Erectile Dysfunction

Drug: Sildenafil

Bispebjerg Hospital

NULL

Completed

18 Years

80 Years

Male

Phase 4

Denmark

2020

NCT00234676
(ClinicalTrials.gov)

October 2003

5/10/2005

POETRY: Study of Estrogen Replacement Therapy in Postmenopausal Women With Parkinson's Disease

A Multi-Center, Double Blind, Randomized, Placebo-Controlled, Parallel Group Study for the Safety, Tolerability and Efficacy of Estrogen Replacement Therapy (Conjugated Equine Estrogens 0.625 mg Daily) in Post Menopausal Women With Parkinson's Disease

Parkinson's Disease

Drug: Premarin ®

The Parkinson Study Group

Wyeth is now a wholly owned subsidiary of Pfizer;Joseph and Rosalyn Newman Foundation

Completed

N/A

75 Years

Female

Phase 2

United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

2021

NCT00615472
(ClinicalTrials.gov)

October 2003

9/1/2008

Intravenous Versus Inhalational Anesthesia in Parkinson's Disease

Intravenous General Anesthesia Versus Inhalational General Anesthesia in Parkinson's Disease

Parkinson's Disease

Drug: Isoflurane;Drug: Remifentanil;Drug: Propofol

Columbia University

NULL

Terminated

18 Years

N/A

All

N/A

United States

2022

NCT01177319
(ClinicalTrials.gov)

September 2003

5/8/2010

Glutathione (GSH) In The Treatment of Parkinson's Disease

Parkinson's Disease

Drug: Glutathione

University of South Florida

Wellness Health & Pharmaceuticals, Inc.

Completed

18 Years

N/A

Both

Phase 2

United States

2023

NCT00180037
(ClinicalTrials.gov)

September 2003

9/9/2005

Coenzyme Q10 as a Symptomatic Treatment in Parkinson's Disease

Multicenter, Placebo Controlled, Randomized, Double-Blinded Study: Coenzyme Q10 Nanodispersion Versus Placebo as Symptomatic Treatment in Parkinson's Disease

Parkinson's Disease

Drug: Coenzyme Q10 Nanodispersion (Nanoquinone);Drug: Placebo

Technische Universität Dresden

Deutsche Parkinson-Vereinigung e.V.;MSE Pharmazeutika GmbH, Bad Homburg

Completed

40 Years

75 Years

Both

132

Phase 3

Germany

2024

NCT00215904
(ClinicalTrials.gov)

August 2003

18/9/2005

D-serine Adjuvant Treatment for Parkinson's Disease

Parkinson's Disease

Drug: D-serine (~2g/day)

Herzog Hospital

NULL

Completed

30 Years

75 Years

Both

Phase 4

Israel

2025

NCT00095810
(ClinicalTrials.gov)

July 2003

9/11/2004

Aripiprazole in Patients With Psychosis Associated With Parkinson's Disease

An Open-Label Study of Aripiprazole to Evaluate the Safety and Tolerability in Patients With Psychosis Associated With Parkinson's Disease

Parkinson's Disease;Psychoses

Drug: aripiprazole

Otsuka Pharmaceutical Development & Commercialization, Inc.

Otsuka America Pharmaceutical

Completed

50 Years

N/A

Both

Phase 4

United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

2026

NCT00160576
(ClinicalTrials.gov)

July 2003

8/9/2005

Levetiracetam Treatment in Adult Subjects With Parkinson's Disease Experiencing Troublesome Dyskinesias

A Therapeutic Exploratory, Single Arm, Multicenter Trial to Evaluate the Efficacy and Safety of Levetiracetam up to 4000 mg/Day (500mg Oral Tablets) on Levodopa Induced Dyskinesias in Adults With Idiopathic Parkinson's Disease

Idiopathic Parkinson Disease

Drug: Levetiracetam

UCB Pharma

NULL

Completed

30 Years

N/A

Both

Phase 2

NULL

2027

NCT00228150
(ClinicalTrials.gov)

July 2003

26/9/2005

Study of the Effect of SR57667B on the Progression of Symptoms in Patients With Parkinson's Disease

A Phase II, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy, Safety and Tolerability Study of SR57667B in Outpatients With Early Parkinson's Disease

Parkinson Disease

Drug: SR57667B

Sanofi

NULL

Completed

35 Years

N/A

Both

564

Phase 2

Austria;Canada;Denmark;France;Germany;Morocco;Netherlands;Portugal;South Africa;Spain;Sweden;Tunisia;United Kingdom

2028

NCT00070941
(ClinicalTrials.gov)

July 2003

9/10/2003

SAM-e for the Treatment of Depression in Patients With Parkinson's Disease

SAM-e Treatment of Depression in Parkinson's Disease.

Parkinson's Disease;Depression

Drug: SAM -e;Drug: oral escitalopram;Drug: placebo

New York University School of Medicine

National Center for Complementary and Integrative Health (NCCIH);Office of Dietary Supplements (ODS)

Completed

30 Years

80 Years

All

Phase 2;Phase 3

United States

2029

NCT00240409
(ClinicalTrials.gov)

July 2003

14/10/2005

Randomized Single-blind Placebo Controlled Comparative Trial of Pramipexole and Bromocriptine in Parkinson's Disease

A Randomized Single-blind Placebo Controlled Comparative Trial of Pramipexole Tablets and Bromocriptine Tablets in Patients With Parkinson's Disease.

Parkinson Disease

Drug: Pramipexole;Drug: Bromocriptine

Boehringer Ingelheim

NULL

Completed

30 Years

80 Years

Both

208

Phase 3

China

2030

NCT00666653
(ClinicalTrials.gov)

July 2003

23/4/2008

Effects of a Dopamine Agonist on Pharmacodynamics of Levodopa in Parkinson's Disease

Effects of a Dopamine Agonist on Pharmacodynamics of Levodopa in Parkinson's Disease: a Double-Blind Placebo Controlled Crossover Study

Parkinson's Disease

Drug: pramipexole

Oregon Health and Science University

Boehringer Ingelheim

Completed

30 Years

80 Years

Both

Phase 1

United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

2031

NCT00148486
(ClinicalTrials.gov)

June 2003

7/9/2005

A Fourteen-Week Placebo-Controlled Dose-Response Efficacy and Safety Study of NS 2330 in Early Parkinson's Disease Patients (Study for Proof of Concept in Early Parkinson's Disease of a Triple Reuptake Inhibitor, NS 2330 / SCEPTRE)

A Fourteen-week Placebo-controlled Dose-response Efficacy and Safety Study of NS 2330 in Early Parkinson's Disease Patients (Study for Proof of Concept in Early Parkinson's Disease of a Triple Reuptake Inhibitor, NS 2330 / SCEPTRE)

Parkinson Disease

Drug: NS 2330

Boehringer Ingelheim

NULL

Completed

40 Years

80 Years

Both

261

Phase 2

United States;Canada

2032

NCT00062738
(ClinicalTrials.gov)

June 2003

12/6/2003

Treatment of Depression in Parkinson's Disease Trial

Treatment of Depression in Patients With Parkinson's Disease

Parkinson Disease;Depression

Drug: paroxetine;Drug: Nortriptyline;Other: placebo

Rutgers, The State University of New Jersey

GlaxoSmithKline

Completed

35 Years

80 Years

All

Phase 2

United States

2033

NCT00381472
(ClinicalTrials.gov)

June 2003

26/9/2006

Investigational Parkinson's Disease In Patients Not Well Controlled On L-dopa

A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group Study of Six Months Treatment With Ropinirole CR as Adjunctive Therapy in Patients With Parkinson's Disease Who Are Not Optimally Controlled on L-dopa

Parkinson Disease

Drug: Ropinirole

GlaxoSmithKline

NULL

Completed

30 Years

N/A

All

393

Phase 3

United States;Belgium;Czech Republic;France;Germany;Hungary;Italy;Poland;Spain

2034

NCT00063193
(ClinicalTrials.gov)

May 2003

23/6/2003

National Institute of Neurological Disorders and Stroke (NINDS) Parkinson's Disease Neuroprotection Trial

A Multi-center, Double-blind, Pilot Study of Minocycline and Creatine in Subjects With Early Untreated Parkinson's Disease

Parkinson's Disease

Drug: minocycline;Drug: creatine

University of Rochester

National Institute of Neurological Disorders and Stroke (NINDS)

Completed

30 Years

N/A

Both

195

Phase 2

United States

2035

NCT00058838
(ClinicalTrials.gov)

April 2003

14/4/2003

Study Evaluating Sumanirole for the Treatment of the Signs and Symptoms of Early Parkinson's Disease

A Phase III, Double-Blind, Placebo-Controlled, Fixed-Dose Response Study Comparing the Efficacy and Safety of Sumanirole Versus Placebo in Patients With Early Parkinson's Disease.

Parkinson Disease

Drug: sumanirole

Pfizer

NULL

Completed

30 Years

N/A

Both

854

Phase 3

United States;Argentina;Australia;Austria;Belgium;Colombia;France;Germany;Greece;Italy;Mexico;Peru;Puerto Rico;Spain

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

2036

NCT00058721
(ClinicalTrials.gov)

April 2003

11/4/2003

Single Photon Emission Computed Tomography to Study Receptors in Parkinson's Disease

SPECT Evaluation of Nicotinic Cholinergic Receptors in Parkinson's Disease

Parkinson Disease

Drug: I-123 -5-IA85380

National Institute of Neurological Disorders and Stroke (NINDS)

NULL

Completed

N/A

Both

N/A

United States

2037

NCT00148512
(ClinicalTrials.gov)

March 2003

7/9/2005

A Randomized, Double-blind, Placebo-controlled, Five Parallel Groups Efficacy and Safety Study of NS 2330 (Tesofensine) (0.125 mg, 0.25 mg, 0.5 mg and 1.0 mg) Administered Orally Once Daily Over 14 Weeks in Levodopa Treated Parkinson Patients With Motor Fluctuations

A Randomized, Double-blind, Placebo-controlled, Five Parallel Groups Efficacy and Safety Exploratory Study of NS 2330 (0.125 mg, 0.25 mg, 0.5 mg and 1.0 mg) Administered Orally Once Daily Over 14 Weeks in Levodopa Treated Parkinson Patients With Motor Fluctuations (Study for Proof of Concept in ADVAnced Parkinson Disease of NS 2330 / ADVANS)

Parkinson Disease

Drug: 1. Tesofensine (NS 2330)

Boehringer Ingelheim

NULL

Completed

42 Years

80 Years

Both

254

Phase 2

Austria;France;Germany;Netherlands;Spain;United Kingdom;El Salvador

2038

NCT01327859
(ClinicalTrials.gov)

March 2003

30/3/2011

Safety, Tolerability, and Efficacy of Donepezil (Aricept) in Parkinson' s Disease (PD) Patients With Dementia

A 52-week, Multicentre Open Label Extension Study of the Safety Tolerability and Efficacy of Donepezil (Aricept) in Parkinson's Disease (PD) Patients With Dementia

Parkinson's Disease;Dementia

Drug: Prior Donepezil 5mg;Drug: Prior Donzepezil 10mg;Drug: Prior Placebo

Eisai Inc.

NULL

Completed

40 Years

N/A

Both

357

Phase 3

United Kingdom

2039

NCT00115427
(ClinicalTrials.gov)

March 2003

22/6/2005

Study of Liatermin (r-metHuGDNF) Administered by Bilateral Intraputaminal (IPu) Infusion to Subjects With Idiopathic Parkinson's Disease

Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial of Liatermin (r-metHuGDNF) Administered by Bilateral Intraputaminal (IPu) Infusion to Subjects With Idiopathic Parkinson's Disease

Idiopathic Parkinson's Disease

Drug: Liatermin (r-metHuGDNF)

Amgen

NULL

Completed

35 Years

70 Years

Both

Phase 1

United States

2040

NCT00129675
(ClinicalTrials.gov)

February 2003

11/8/2005

Study of Individuals With Parkinson's Symptoms But in Whom There is Diagnostic Uncertainty

Development of a Imaging Marker for Parkinson's Disease Through Use of Dynamic SPECT Imaging With [123I] Beta-CIT in Individuals With Parkinson's Symptoms

Parkinsonian Syndrome

Drug: [123I]ß CIT

Institute for Neurodegenerative Disorders

Molecular NeuroImaging

Completed

21 Years

N/A

Both

169

Phase 2

United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

2041

NCT00237263
(ClinicalTrials.gov)

February 2003

7/10/2005

An Extension Study of Entacapone in Patients With Parkinson's Disease With End-of-dose Wearing-off. This Study is Not Recruiting in the United States

An Extension Study to Phase IIb Dose-finding Study of Entacapone in Patients With Parkinson's Disease With End-of-dose Wearing-off

Parkinson's Disease

Drug: Entacapone

Novartis

NULL

Completed

20 Years

N/A

All

285

Phase 2

United States

2042

NCT00056524
(ClinicalTrials.gov)

February 2003

15/3/2003

Safety Study of AVP-923 in the Treatment of IEED (Involuntary Emotional Expression Disorder) Also Known as Pseudobulbar Affect (Episodes of Uncontrolled Crying and/or Laughter)

An Open-Label Multicenter Study to Assess the Safety of AVP-923 in the Treatment of Patients With Pseudobulbar Affect.

Alzheimer's Disease;Stroke;Parkinson's Disease;Traumatic Brain Injury

Drug: AVP-923

Avanir Pharmaceuticals

NULL

Completed

18 Years

80 Years

Both

600

Phase 3

United States

2043

NCT00206687
(ClinicalTrials.gov)

January 2003

13/9/2005

STEPS Trial - Spheramine Safety and Efficacy Study

Study of the Safety, Tolerability and Efficacy of Spheramine Implanted Bilaterally Into the Postcommissural Putamen of Patients With Advanced Parkinson's Disease

Parkinson Disease

Biological: Spheramine (BAY86-5280);Procedure: Placebo

Bayer

Titan Pharmaceuticals

Terminated

30 Years

70 Years

Both

Phase 2

United States;Germany;Spain;Austria;France

2044

NCT00451815
(ClinicalTrials.gov)

January 2003

31/1/2006

BIIB014 Phase 2a Monotherapy

A Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study of Multiple Oral Dose Administration of BIIB014 in Subjects With Early Parkinson’s Disease

Parkinson's Disease

Drug: active drug (BIIB014) at 10, 30, 100, or 300 mg once daily.;Drug: placebo

Biogen Idec

NULL

Withdrawn

30 Years

78 Years

Both

Phase 2

NULL

2045

NCT02248207
(ClinicalTrials.gov)

January 2003

22/9/2014

Tolerability of Sifrol® in Ambulatory Patients Suffering From Parkinson's Disease

Management of Parkinson's Disease Patients at Their First Visits in a Neurological Practice

Parkinson Disease

Drug: Pramipexole

Boehringer Ingelheim

NULL

Completed

N/A

Both

1293

N/A

NULL

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

2046

NCT00247247
(ClinicalTrials.gov)

December 2002

31/10/2005

Comtess® Versus Cabaseril® as Add-on to Levodopa in the Treatment of Parkinsonian Patients Suffering From Wearing- Off.

Efficacy and Tolerability of Comtess® Versus Cabaseril® as Add-on to Levodopa in the Treatment of Parkinsonian Patients Suffering From Wearing-Off Phenomenon

Parkinson's Disease

Drug: Comtess®

Orion Corporation, Orion Pharma

NULL

Completed

60 Years

N/A

Both

300

Phase 4

Germany

2047

NCT00209508
(ClinicalTrials.gov)

November 2002

13/9/2005

2 Year Study to Evaluate the Effects of GPI 1485 on [123I]b-CIT/SPECTScanning and Clinical Efficacy in Patients With PD

Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 2-Year Study To Evaluate The Effects Of GPI 1485 On [123I]b-CIT/SPECT Scanning And Clinical Efficacy In Symptomatic PD Patients Receiving Dopamine Agonist Therapy.

Parkinson's Disease

Drug: GPI 1485

Eisai Inc.

Symphony Neuro Development Company

Completed

40 Years

80 Years

Both

200

Phase 2

NULL

2048

NCT00955045
(ClinicalTrials.gov)

August 2002

4/8/2009

A Long-Term, Safety Study With a Flexible Dose Range of KW-6002 in Patients With Motor Response Complications on Levodopa/Carbidopa Therapy

A Long-Term, Multicenter, Open-Label, Safety Study With a Flexible Dose Range of KW-6002 as Treatment for Parkinson's Disease in Patients With Motor Response Complications on Levodopa/Carbidopa Therapy

Parkinson's Disease

Drug: istradefylline

Kyowa Kirin Pharmaceutical Development, Inc.

NULL

Completed

30 Years

N/A

Both

Phase 2;Phase 3

United States

2049

NCT00165815
(ClinicalTrials.gov)

August 2002

13/9/2005

The Efficacy, Tolerability and Safety of Donepezil (Aricept) in Parkinson's Disease Patients With Dementia

Dementia With Parkinson's Disease

Drug: ARICEPT

Eisai Limited

NULL

Completed

40 Years

N/A

Both

Phase 3

Germany;Ireland

2050

NCT00599196
(ClinicalTrials.gov)

August 2002

24/12/2007

An Open-Label Extension Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Early-Stage Parkinson's Disease

An Open-Label Extension to the Double-Blind SP513 Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Subjects With Early-Stage Idiopathic Parkinson's Disease

Early Stage Parkinson's Disease

Drug: Rotigotine

UCB Pharma

NULL

Completed

30 Years

N/A

All

381

Phase 3

Australia;Austria;Belgium;Croatia;Czech Republic;Finland;France;Germany;Hungary;Israel;Italy;Netherlands;New Zealand;Norway;Poland;South Africa;Spain;Sweden;Switzerland;United Kingdom

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

2051

NCT00594386
(ClinicalTrials.gov)

August 2002

24/12/2007

An Open-Label Extension Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Advance-Stage Parkinson's Disease

An Open-Label Extension to the Double-Blind SP650 Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Subjects With Advanced-Stage Idiopathic Parkinson's Disease.

Parkinson's Disease

Drug: Rotigotine

UCB Pharma

NULL

Completed

31 Years

N/A

All

258

Phase 3

United States;Canada

2052

NCT00043849
(ClinicalTrials.gov)

July 2002

14/8/2002

Treatment of Agitation/Psychosis in Dementia/Parkinsonism (TAP/DAP)

Dementia;Parkinson Disease

Drug: Quetiapine

National Institute on Aging (NIA)

NULL

Completed

50 Years

N/A

Both

Phase 4

United States

2053

NCT00314288
(ClinicalTrials.gov)

July 2002

12/4/2006

Sarizotan in Parkinson Patients With L-dopa-induced Dyskinesia

A Multicenter, Multinational, Randomised, Double-blind, Placebo-controlled, Parallel-group, Dose-finding Study to Investigate the Anti-dyskinetic Efficacy and Safety of Sarizotan in Parkinson Patients With L-dopa-induced Dyskinesia

Parkinson's Disease;Dyskinesia

Drug: Sarizotan HCl

EMD Serono

NULL

Completed

30 Years

N/A

All

360

Phase 2

United States;Belgium;Bulgaria;Canada;France;Germany;Hungary;Portugal;Romania;South Africa;United Kingdom

2054

NCT00040209
(ClinicalTrials.gov)

June 2002

21/6/2002

JP-1730 to Treat Parkinson's Disease

Alpha-2 Adrenergic Antagonist Treatment of Parkinson's Disease

Parkinson Disease

Drug: JP 1730;Drug: IV Levodopa;Drug: IV Apomorphine

National Institute of Neurological Disorders and Stroke (NINDS)

NULL

Completed

N/A

Both

Phase 2

United States

2055

NCT00594165
(ClinicalTrials.gov)

June 2002

24/12/2007

An Open-Label Extension Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Early-Stage Parkinson's Disease.

An Open-Label Extension to the Double-Blind SP512 Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Subjects With Early-Stage Idiopathic Parkinson's Disease.

Early-Stage Parkinson's Disease

Drug: Rotigotine

UCB Pharma

NULL

Completed

31 Years

N/A

All

217

Phase 3

United States;Canada

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

2056

NCT00203164
(ClinicalTrials.gov)

May 2002

13/9/2005

Study to Evaluate the Safety and Tolerability of Rasagiline in Advanced Parkinson's Disease Patients

A Bi-national, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Tolerability of Rasagiline Mesylate in Advanced Parkinson's Disease (PD) Patients With Motor Fluctuations Treated With Chronic Levodopa/Carbidopa Therapy

Parkinson's Disease

Drug: rasagiline mesylate

Teva Pharmaceutical Industries

NULL

Completed

30 Years

N/A

Both

254

Phase 3

United States

2057

NCT01044992
(ClinicalTrials.gov)

May 2002

6/1/2010

Motor Activation in Multiple System Atrophy and Parkinson Disease: a Positron Emission Tomography (PET) Study

Motor Activation in Patients With Multi Systemic Atrophy and Comparison With Parkinson Disease and Dopaminergic Challenge

Multisystemic Atrophy

Radiation: H215O PET;Drug: Levodopa

University Hospital, Toulouse

NULL

Completed

40 Years

75 Years

Both

N/A

France

2058

NCT00650104
(ClinicalTrials.gov)

May 2002

27/3/2008

Long-term Extension Study Evaluating Extended Release Ropinirole XL (Formerly Referred to as Ropinirole CR) in Patients Who Already Completed Either Study 167 or 164

101648/196: A Long-Term, Open-Label Continuation Study of Once Daily Administration of Ropinirole CR Tablets to Patients With Parkinson's Disease Who Completed the Previous Ropinirole CR Studies 167 or 164

Parkinson Disease

Drug: Ropinirole XL (formerly CR)

GlaxoSmithKline

NULL

Completed

30 Years

N/A

All

Phase 3

United States;Belgium;France;Netherlands;Norway

2059

NCT00456586
(ClinicalTrials.gov)

April 2002

3/4/2007

12-Week, Double-Blind, Placebo-Controlled, Randomized Study of the Efficacy of 40 mg/Day KW-6002 in Parkinson's Disease Patients on Levodopa/Carbidopa

A 12-Week, Double-Blind, Placebo-Controlled, Randomized, Multicenter Study of the Efficacy of 40 mg/Day KW-6002 as Treatment for Parkinson's Disease in Patients With Motor Response Complications on Levodopa/Carbidopa Therapy

Parkinson's Disease

Drug: KW-6002 (istradefylline)

Kyowa Kirin Pharmaceutical Development, Inc.

NULL

Completed

30 Years

N/A

Both

180

Phase 2

United States

2060

NCT00040404
(ClinicalTrials.gov)

March 2002

26/6/2002

Safety and Efficacy Study of CEP-1347 in the Treatment of Parkinson's Disease

A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study to Assess the Efficacy and Safety of CEP-1347 in Patients With Parkinson's Disease

Parkinson Disease

Drug: CEP-1347 10mg;Drug: CEP1347 25mg;Drug: CEP-1347 50mg;Other: Placebo Comparator

Cephalon

H. Lundbeck A/S;The Parkinson Study Group

Terminated

30 Years

N/A

Both

806

Phase 2;Phase 3

United States;Canada;Puerto Rico

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

2061

NCT00032812
(ClinicalTrials.gov)

March 2002

3/4/2002

The Role of Dopamine in Motor Learning in Healthy Subjects and Patients With Parkinson's Disease

Motor Memory: Study of the Role of Dopamine in Healthy Subjects and Patients With Parkinson's Disease Using PET and EEG

Parkinson Disease;Healthy

Drug: Raclopride

National Institute of Neurological Disorders and Stroke (NINDS)

NULL

Completed

N/A

Both

N/A

United States

2062

NCT00456794
(ClinicalTrials.gov)

March 2002

3/4/2007

12-Week, Double-Blind, Placebo-Controlled Study of 20 and 60 mg/Day Istradefylline in Parkinson's Disease Patients on Levodopa/Carbodopa

A 12-Week, Double-Blind, Placebo-Controlled, Randomized, Multicenter Study of the Efficacy of Doses of 20 and 60 mg/Day Istradefylline as Treatment for Parkinson's Disease in Patients With Motor Response Complications on Levodopa/Carbidopa

Parkinson's Disease

Drug: Istradefylline (KW-6002)

Kyowa Kirin Pharmaceutical Development, Inc.

NULL

Completed

30 Years

N/A

Both

325

Phase 2

United States

2063

NCT02248168
(ClinicalTrials.gov)

March 2002

22/9/2014

Post Marketing Surveillance And Special Surveillance for Mirapex® Tablet in Patients With Idiopathic Parkinson's Disease

Mirapex PMS Study Final Report

Parkinson Disease

Drug: Pramipexole

Boehringer Ingelheim

NULL

Completed

N/A

Both

1449

N/A

NULL

2064

NCT02162979
(ClinicalTrials.gov)

February 2002

26/12/2007

Sildenafil (Viagra) for the Treatment of Dyskinesias in Parkinson's Disease

A Double-Blind, Placebo-Controlled, Cross-Over Study of Sildenafil (Viagra) for the Treatment of Dyskinesias in Parkinson's Disease

Parkinson's Disease

Drug: sildenafil;Drug: Placebo

Loma Linda University

NULL

Terminated

18 Years

80 Years

All

Phase 2

United States

2065

NCT02231255
(ClinicalTrials.gov)

February 2002

2/9/2014

Post Marketing Surveillance Study in Patients With Idiopathic Parkinson's Disease

Switch Post Marketing Surveillance Study in Patients With Idiopathic Parkinson's Disease

Parkinson Disease

Drug: Sifrol®

Boehringer Ingelheim

NULL

Completed

N/A

Both

1216

N/A

NULL

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

2066

NCT00030979
(ClinicalTrials.gov)

February 2002

15/2/2002

Donepezil to Treat Dementia in Parkinson's Disease

Donepezil for Dementia in Parkinson's Disease: A Randomized, Double Blinded Placebo Controlled Crossover Trial

Parkinson Disease

Drug: Donepezil

National Institute of Neurological Disorders and Stroke (NINDS)

NULL

Completed

N/A

Both

Phase 4

United States

2067

NCT00407212
(ClinicalTrials.gov)

January 2002

30/11/2006

A Study of Three Doses of TCH346 in Patients With Early Parkinson's Disease to Evaluate Safety and Efficacy

A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Dose-ranging, Efficacy and Safety Study of Three Doses of TCH346 (1mg, 5mg and 20mg Daily) in Patients With Early Parkinson's Disease

Parkinson's Disease

Drug: TCH346 (dibenz[b,f]oxepin-10-ylmethyl-prop-2-ynyl-amine, hydrogen maleate salt)

Novartis

NULL

Completed

30 Years

80 Years

Both

301

Phase 1;Phase 2

United States;Brazil;Canada;France;Germany;Italy;Netherlands;Portugal;United Kingdom

2068

NCT00036218
(ClinicalTrials.gov)

December 2001

8/5/2002

Study Evaluating Sumanirole for the Treatment of the Signs and Symptoms of Early Parkinson's Disease.

A Phase III, Double-Blind, Placebo-Controlled, Randomized Study Comparing the Efficacy, Safety, and Tolerability of Sumanirole Versus Placebo or Ropinirole in Patients With Early Parkinson's Disease.

Parkinson Disease

Drug: sumanirole;Drug: ropinirole

Pfizer

NULL

Completed

30 Years

N/A

Both

600

Phase 3

United States;Argentina;Mexico;Puerto Rico

2069

NCT00203177
(ClinicalTrials.gov)

October 2001

13/9/2005

Rasagiline in Advanced Parkinson's Disease Patients With Motor Fluctuations Treated With Levodopa/Carbidopa Therapy.

Parkinson's Disease

Drug: rasagiline mesylate;Drug: rasagiline mesylate 1.0 mg

Teva Pharmaceutical Industries

NULL

Completed

30 Years

N/A

Both

254

Phase 3

United States;Canada

2070

NCT02772627
(ClinicalTrials.gov)

September 2001

12/5/2016

Study to Investigate the Tolerability, Steady-state Pharmacokinetics and Erythrocyte COMT Inhibition of BIA 3-202

A Double-blind, Randomised, Placebo-controlled, Rising Multiple Dose Study to Investigate the Tolerability, Steady-state Pharmacokinetics and Erythrocyte COMT Inhibition of BIA 3-202 in Healthy Volunteers.

Parkinson's Disease

Drug: Nebicapone;Drug: Placebo

Bial - Portela C S.A.

NULL

Completed

18 Years

45 Years

Both

Phase 1

Portugal

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

2071

NCT00200525
(ClinicalTrials.gov)

July 2001

13/9/2005

Continued Efficacy and Safety of Apomorphine in Patients With Late-Stage Parkinsons Disease

A Randomized, Placebo-Controlled Study of the Continued Efficacy and Safety of SC Apomorphine in the Treatment of Off Episodes in Patients With On/Off or Wearing-Off Effects Associated With Late-Stage PD After Apomorphine Use

Parkinson Disease

Drug: apomorphine HCl injection

Mylan Bertek Pharmaceuticals

NULL

Completed

18 Years

N/A

Both

Phase 3

NULL

2072

NCT02763852
(ClinicalTrials.gov)

April 2001

4/5/2016

Pharmacokinetic-Pharmacodynamic Interaction Between Four Different Single Doses of BIA 3-202 and a Single Dose of Levodopa/Benserazide (100/25 mg)

Pharmacokinetic-Pharmacodynamic Interaction Between Four Different Single Doses of BIA 3-202 and a Single Dose of Levodopa/Benserazide (100/25 mg): a Double-blind, Randomised, Crossover, Placebo Controlled Study in Healthy Volunteers

Parkinson's Disease

Drug: BIA 3-202;Drug: Placebo;Drug: Madopar® 125

Bial - Portela C S.A.

NULL

Completed

18 Years

45 Years

Both

Phase 1

Portugal

2073

NCT02763839
(ClinicalTrials.gov)

April 2001

4/5/2016

Pharmacokinetic-Pharmacodynamic Interaction Between Four Different Single Doses of BIA 3-202 and a Single Dose of Levodopa/Carbidopa (100/25 mg)

Pharmacokinetic-Pharmacodynamic Interaction Between Four Different Single Doses of BIA 3-202 and a Single Dose of Levodopa/Carbidopa (100/25 mg): a Double-blind, Randomised, Crossover, Placebo Controlled Study in Healthy Volunteers

Parkinson's Disease

Drug: BIA 3-202;Drug: Placebo;Drug: Sinemet 25/100

Bial - Portela C S.A.

NULL

Completed

18 Years

45 Years

Both

Phase 1

Portugal

2074

NCT00117819
(ClinicalTrials.gov)

March 2001

30/6/2005

A Study of Brain Imaging With Nuclear Medicine Technology in Individuals With and at Risk for Parkinson's Disease

Dynamic SPECT Imaging With [123I] B-CIT in Individuals With Parkinsonian Syndrome (PS) and in Individuals at Risk for Parkinsonian Syndrome

Parkinsonian Syndrome

Drug: [123I]ß CIT and SPECT imaging

Institute for Neurodegenerative Disorders

Indiana University;Albany Medical College

Completed

22 Years

N/A

Both

232

Phase 2

United States

2075

NCT00013624
(ClinicalTrials.gov)

March 2001

24/3/2001

Riluzole to Treat Parkinson's Disease

Effect of Antiglutamatergic Treatment in Parkinson's Disease

Parkinson's Disease

Drug: IV Levodopa

National Institute of Neurological Disorders and Stroke (NINDS)

NULL

Completed

N/A

Both

Phase 2

United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

2076

NCT00145171
(ClinicalTrials.gov)

February 2001

2/9/2005

A Sub-Study With Patients in APO401 to Evaluate Adverse Events During Dose Introduction in Apomorphine-naïve Patients.

Study of Orthostatic Changes Upon Apomorphine Dose Initiation in Late Stage Parkinson’s Disease Patients. A Dose Escalation Study With a Double-Blind Placebo-Controlled Efficacy Determination at 4 Mg.

Parkinson Disease

Drug: apomorphine HCl injection

Mylan Bertek Pharmaceuticals

NULL

Completed

18 Years

N/A

Both

Phase 3

NULL

2077

NCT00009048
(ClinicalTrials.gov)

January 2001

23/1/2001

EMD 128130 for the Treatment of Parkinson's Disease

Effect of Serotoninergic Treatment in Parkinson's Disease

Parkinson's Disease

Drug: EMD 128130;Drug: IV Levodopa

National Institute of Neurological Disorders and Stroke (NINDS)

NULL

Completed

N/A

Both

Phase 2

United States

2078

NCT00006488
(ClinicalTrials.gov)

October 2000

8/11/2000

Continuously Infused Intracerebral (IC) Recombinant-Methionyl Human Glial Cell Line-Derived Neurotrophic Factor (r-metHuGDNF) for the Treatment of Idiopathic Parkinson's Disease

Parkinson Disease

Drug: recombinant-methionyl human glial cell line-derived neurotrophic factor

National Center for Research Resources (NCRR)

NULL

Completed

18 Years

75 Years

Both

Phase 1

United States

2079

NCT00006337
(ClinicalTrials.gov)

October 2000

4/10/2000

KW-6002 to Treat Parkinson's Disease

Adenosine A2A Blockade With KW-6002 in Parkinson's Disease

Parkinson's Disease

Drug: KW-6002;Drug: IV Levodopa

National Institute of Neurological Disorders and Stroke (NINDS)

NULL

Completed

N/A

Both

Phase 2

United States

2080

NCT00203125
(ClinicalTrials.gov)

October 2000

13/9/2005

A Study to Evaluate the Effects of Tyramine in Patients Who Completed the PRESTO Study.

Sub-study to Evaluate the Effect of An Oral Dose of Tyramine in Subjects Completing 26 Weeks of Participation in PRESTO (TVP-1012/133)

Parkinson's Disease

Drug: rasagiline mesylate;Other: tyramine

Teva Pharmaceutical Industries

NULL

Completed

N/A

Both

Phase 3

United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

2081

NCT00070928
(ClinicalTrials.gov)

September 2000

9/10/2003

Valerian to Improve Sleep in Patients With Parkinson's Disease

Polysomnographic Assessment of Alternative Treatments for Sleep Disturbance in Parkinson's Disease

Insomnia;Parkinson's Disease

Drug: valerian

National Center for Complementary and Integrative Health (NCCIH)

NULL

Completed

30 Years

80 Years

Both

Phase 2

United States

2082

NCT02763800
(ClinicalTrials.gov)

September 2000

4/5/2016

Study to Investigate the Safety, Tolerability, Steady State Pharmacokinetic and Pharmacodynamic Profile of BIA 3-202

Double-Blind, Randomised, Placebo-Controlled, Rising Multiple Dose Study to Investigate the Safety, Tolerability, Steady State Pharmacokinetic and Pharmacodynamic Profile of BIA 3-202, in Young Healthy Volunteers

Parkinson's Disease

Drug: BIA 3-202;Drug: Placebo

Bial - Portela C S.A.

NULL

Completed

18 Years

35 Years

Male

Phase 1

United Kingdom

2083

NCT00036205
(ClinicalTrials.gov)

August 2000

8/5/2002

Open Label Sumanirole Study of Safety, Tolerability, and Therapeutic Response In Patients With Parkinson's Disease

Open-Label, Long Term, Flexible Dose Study Of Safety, Tolerability, And Therapeutic Response In Patients With Parkinson's Disease.

Parkinson Disease

Drug: sumanirole

Pfizer

NULL

Terminated

30 Years

N/A

Both

984

Phase 3

United States;Argentina;Colombia;Puerto Rico

2084

NCT00006077
(ClinicalTrials.gov)

August 2000

4/8/2000

Effects of Monoamine Reuptake Inhibitor NS2330 in Parkinson's Disease

Parkinson's Disease

Drug: NS2330;Drug: Levodopa and Domperidone

National Institute of Neurological Disorders and Stroke (NINDS)

NULL

Completed

N/A

Both

Phase 2

United States

2085

NCT02231294
(ClinicalTrials.gov)

July 2000

2/9/2014

The Effect of Sifrol® on Tremor and Depression in Patients With Idiopathic Parkinson's Disease

The Effect of SIFROL® on Tremor and Depression in Patients With Idiopathic Parkinson's Disease Patients.

Parkinson Disease

Drug: Sifrol®

Boehringer Ingelheim

NULL

Completed

N/A

Both

1464

N/A

NULL

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

2086

NCT00203034
(ClinicalTrials.gov)

May 2000

13/9/2005

Multicenter Study of Rasagiline in Parkinson's Disease Patients Using Levodopa and Experiencing Motor Fluctuations

A Multicenter, US and Canada, Double Blind, Randomized, Placebo-Controlled, Parallel Group Study, for the Efficacy, Tolerability and Safety of Rasagiline Mesylate in Levodopa Treated Parkinson's Disease Patients With Motor Fluctuations

Parkinson's Disease

Drug: rasagiline mesylate;Drug: 1.0 mg rasagiline mesylate;Other: Placebo

Teva Pharmaceutical Industries

NULL

Completed

30 Years

N/A

Both

472

Phase 3

United States

2087

NCT00134784
(ClinicalTrials.gov)

April 2000

23/8/2005

Long-Term Dopamine Transporter Imaging and Clinical Assessment of Parkinson's Disease Progression

[123I]ß-CIT and SPECT in Vivo Three Year Imaging Assessment of Dopamine Transporter Density in Subjects With Early Parkinson's Disease Participating in Earlier vs. Later Levodopa in Parkinson's Disease

Parkinson Disease

Drug: [123I]B-CIT SPECT imaging

Institute for Neurodegenerative Disorders

United States Department of Defense

Completed

22 Years

N/A

All

142

Phase 2

NULL

2088

NCT02763787
(ClinicalTrials.gov)

April 2000

4/5/2016

Safety, Tolerability, Pharmacokinetics (Including Food Interaction), and Pharmacodynamics of BIA 3-202

A Phase I Study to Investigate the Safety, Tolerability, Pharmacokinetics (Including Food Interaction), and Pharmacodynamics of Single Doses of BIA 3-202 in Healthy Volunteers.

Parkinson's Disease

Drug: BIA 3-202;Drug: Placebo

Bial - Portela C S.A.

NULL

Completed

18 Years

35 Years

Male

Phase 1

United Kingdom

2089

NCT00761436
(ClinicalTrials.gov)

February 2000

26/9/2008

Pilot Study of Safety and Efficacy of Spheramine

Stereotactic Intrastriatal Implantation of Spheramine in Advanced Parkinson's Disease Patients: A Pilot Study of Tolerability and Efficacy.

Parkinson's Disease

Biological: Spheramine (BAY86-5280)

Bayer

Titan Pharmaceuticals

Terminated

40 Years

70 Years

Both

Phase 2

United States

2090

NCT00004576
(ClinicalTrials.gov)

February 2000

17/2/2000

Study of LY300164 for the Treatment of Parkinson's Disease

AMPA Receptor Blockade With LY300164 in the Treatment of Parkinson's Disease

Dyskinesias;Parkinson Disease

Drug: LY300164

National Institute of Neurological Disorders and Stroke (NINDS)

NULL

Completed

N/A

Both

Phase 2

United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

2091

NCT00037830
(ClinicalTrials.gov)

November 1999

22/5/2002

GM1 Ganglioside Effects on Parkinson's Disease

The Study of GM1 Ganglioside, A Potential New Parkinson's Disease Medication

Parkinson Disease

Drug: GM1 ganglioside;Drug: Placebo

Thomas Jefferson University

National Institute of Neurological Disorders and Stroke (NINDS)

Completed

39 Years

85 Years

All

Phase 2

United States

2092

NCT00200512
(ClinicalTrials.gov)

September 1999

13/9/2005

Continued Efficacy of Apomorphine After Previous Exposure of at Least Three Months

A Prospective, Randomized, Placebo-Controlled, Crossover Study of the Safety and Effectiveness of Subcutaneous Injections of Apomorphine in the Treatment of Off Episodes in Patients With On/Off or Wearing Off Effects Associated With Late Stage Parkinson's Disease

Parkinson Disease

Drug: apomorphine HCl injection

Mylan Bertek Pharmaceuticals

NULL

Completed

18 Years

N/A

Both

Phase 2;Phase 3

United Kingdom

2093

NCT00142545
(ClinicalTrials.gov)

July 1999

31/8/2005

Long Term Safety and Efficacy of SC Apomorphine in Treatment of Off Episodes in Late-Stage Parkinson's Disease

Long-Term Safety and Effectiveness of Subcutaneous Injections of Apomorphine in the Treatment of Off” Episodes in Patients With On-Off” or Wearing-Off” Effects Associated With Late-Stage Parkinson’s Disease

Parkinson Disease

Drug: apomorphine HCl injection

Mylan Bertek Pharmaceuticals

NULL

Completed

18 Years

N/A

Both

800

Phase 3

United States

2094

NCT00001931
(ClinicalTrials.gov)

May 1999

31/7/2007

Treatment of Parkinson's Disease With a Transdermal Skin Patch

Transdermal Application of Dopamine Agonist N-0923 in Parkinson's Disease

Parkinson Disease

Drug: N-0923

National Institute of Neurological Disorders and Stroke (NINDS)

NULL

Completed

N/A

Both

Phase 2

United States

2095

NCT02172573
(ClinicalTrials.gov)

April 1999

20/6/2014

Safety and Efficacy of Pramipexole and Bromocriptine Combined With L-dopa in Parkinson's Disease

A Double-blind, Placebo-controlled, Randomised, Multicenter Trial to Compare the Safety and Efficacy of Oral Administration of Pramipexole up to 4.5mg and Bromocriptine up to 22.5mg Combined With L-dopa in Advanced Parkinson's Disease

Parkinson Disease

Drug: Pramipexole;Drug: Bromocriptine;Drug: Placebo pramipexole;Drug: Placebo bromocriptine

Boehringer Ingelheim

NULL

Completed

20 Years

N/A

Both

315

Phase 3

NULL

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

2096

NCT00001929
(ClinicalTrials.gov)

March 1999

3/11/1999

Treatment of Parkinson's Disease With Eliprodil

NMDA-Receptor Blockade With Eliprodil in Parkinson's Disease

Movement Disorders;Parkinson Disease

Drug: Eliprodil

National Institute of Neurological Disorders and Stroke (NINDS)

NULL

Completed

N/A

Both

Phase 2

United States

2097

NCT00274131
(ClinicalTrials.gov)

December 1998

9/1/2006

Long-term Administration Study of SND 919 Tablets in Parkinson's Disease

Parkinson Disease

Drug: Pramipexole 0.125 mg tablets;Drug: Pramipexole 0.5 mg tablets

Boehringer Ingelheim

NULL

Completed

20 Years

N/A

Both

170

Phase 3

NULL

2098

NCT02177357
(ClinicalTrials.gov)

November 1998

24/6/2014

Pramipexole in Untreated and Levodopa-treated Parkinson's Disease Patients

Pramipexole: Efficacy, Safety and Tolerability Study in Untreated and Levodopa-Treated Parkinson's Disease Patients, a Multinational Study

Parkinson Disease

Drug: Pramipexole;Drug: Placebo

Boehringer Ingelheim

NULL

Completed

30 Years

N/A

Both

150

Phase 3

NULL

2099

NCT02248220
(ClinicalTrials.gov)

October 1998

22/9/2014

Efficacy and Tolerability of Sifrol® (Pramipexole) in Patients With Advanced Idiopathic Parkinson's Disease

Observation of the Efficacy and Tolerability of Sifrol® (Pramipexole) in Patients With Advanced Idiopathic Parkinson's Disease

Parkinson Disease

Drug: Pramipexole

Boehringer Ingelheim

NULL

Completed

N/A

Both

657

N/A

NULL

2100

NCT00004731
(ClinicalTrials.gov)

September 1998

25/2/2000

Parkinson's Disease Treatment With Coenzyme Q10

Effects of Coenzyme Q10 in Early Parkinson's Disease

Parkinson's Disease

Drug: Coenzyme Q10

National Institute of Neurological Disorders and Stroke (NINDS)

NULL

Completed

30 Years

N/A

Both

Phase 2

United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

2101

NCT02233023
(ClinicalTrials.gov)

June 1998

4/9/2014

Ophthalmologic Safety of Long Term Treatment With Pramipexole Compared to Bromocriptine or Other Dopamine Agonists in Patients With Parkinson's Disease

Matched Pair, Assessor Blinded, Open Label Clinical Trial to Assess the Ophthalmologic Safety of Long Term Oral Treatment With Pramipexole Compared to Bromocriptine or Other Dopamine Agonists in Patients With Parkinson's Disease

Parkinson Disease

Drug: Pramipexole;Drug: Bromocriptine and other dopamine agonists

Boehringer Ingelheim

NULL

Completed

N/A

Both

705

Phase 4

NULL

2102

NCT00004451
(ClinicalTrials.gov)

March 1998

18/10/1999

Randomized Study of the Effects of Glucose on Cognition in Healthy Young and Elderly People and Parkinson's Disease Patients

Parkinson Disease

Drug: Glucose

National Institute of Mental Health (NIMH)

University of Virginia

Completed

18 Years

N/A

Both

120

N/A

United States

2103

NCT00004733
(ClinicalTrials.gov)

January 1998

25/2/2000

Timing of Levodopa Treatment in Parkinson's Disease

Earlier Versus Later L-Dopa in Parkinson's Disease

Parkinson's Disease

Drug: levodopa

National Institute of Neurological Disorders and Stroke (NINDS)

NULL

Completed

30 Years

N/A

Both

Phase 3

United States

2104

NCT00226460
(ClinicalTrials.gov)

August 1997

23/9/2005

Phase 2, Double-blind, Randomized, Controlled Multi-center Clinical Trial of the Safety and Efficacy of Transplanted Fetal Porcine Cells in Patients With Parkinson's Disease.

Parkinson's Disease

Drug: Fetal porcine cells, Neurocell-PD

Genzyme, a Sanofi Company

Diacrin/Genzyme Corporation LLC

Completed

40 Years

70 Years

Both

Phase 2

United States

2105

NCT00203060
(ClinicalTrials.gov)

July 1997

13/9/2005

Effectiveness, Tolerability and Safety of Rasagiline in Early Parkinson's Disease Patients Not Treated With Levodopa

A Multicenter, Double-Blind, Placebo-Controlled, Parallel Group, Phase III Clinical Trial For The Efficacy, Tolerability And Safety Of Two Doses Of Rasagiline Mesylate In Early Parkinson's Disease (PD) Patients Not Treated With Levodopa

Parkinson's Disease

Drug: Rasagiline Mesylate;Drug: placebo

Teva Neuroscience, Inc.

NULL

Completed

35 Years

N/A

Both

404

Phase 3

United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

2106

NCT00038116
(ClinicalTrials.gov)

May 1995

29/5/2002

Embryonic Dopamine Cell Implants for Parkinson's Disease

Embryonic Dopamine Cell Implants for Parkinson's Disease: A Double-Blind Study

Parkinson Disease

Procedure: embryonic dopamine cell implant surgery;Procedure: placebo

University of Colorado, Denver

NULL

Completed

20 Years

75 Years

Both

Phase 3

United States

2107

NCT00004826
(ClinicalTrials.gov)

October 1993

24/2/2000

Study of Clozapine for the Treatment of Psychosis in Patients With Idiopathic Parkinson's Disease

Parkinson Disease

Drug: clozapine

Memorial Hospital of Rhode Island

NULL

Completed

N/A

Both

N/A

NULL

2108

NCT00001365
(ClinicalTrials.gov)

July 1993

3/11/1999

Dextromethorphan for the Treatment of Parkinson's Disease and Similar Conditions of the Nervous System

NMDA Receptor Antagonist Treatment of Neurodegenerative Disease

Neurodegenerative Disease;Parkinson's Disease

Drug: dextromethorphan

National Institute of Neurological Disorders and Stroke (NINDS)

NULL

Completed

N/A

Both

Phase 2

United States

2109

NCT00132626
(ClinicalTrials.gov)

September 1992

18/8/2005

Study of Brain Imaging With Nuclear Technology in Individuals With Parkinsonian Syndrome

Dynamic SPECT Imaging With [123I]ß-CIT in Patients With Parkinsonism

Parkinson's Disease;Parkinsonian Syndrome

Drug: [123I]ß-CIT and SPECT imaging

Institute for Neurodegenerative Disorders

Molecular NeuroImaging;National Institutes of Health (NIH)

Completed

35 Years

N/A

All

500

Phase 2

NULL

2110

EUCTR2008-005492-94-DE
(EUCTR)

11/08/2009

Open-Label trial to Determine the Long-term Safety of Safinamide in Parkinson's Disease Patients

Product Name: Safinamide
Product Code: NW-1015
INN or Proposed INN: safinamide
Product Name: Safinamide
Product Code: NW-1015
INN or Proposed INN: safinamide

Newron Pharmaceuticals

NULL

Not Recruiting

Female: yes
Male: yes

1285

United States;Portugal;Taiwan;Estonia;Slovakia;Spain;Thailand;Chile;Colombia;Italy;India;France;Malaysia;Peru;South Africa;Netherlands;Korea, Republic of;Finland;Austria;United Kingdom;Hungary;Czech Republic;Mexico;Canada;Argentina;Poland;Belgium;Brazil;Romania;Croatia;Bulgaria;Germany;New Zealand

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

2111

EUCTR2009-013552-72-DE
(EUCTR)

23/08/2010

A Placebo- and Active-Controlled Study of Preladenant in Early Parkinson's Disease (Study P05664)

Product Name: Preladenant
Product Code: SCH 420814
INN or Proposed INN: Preladenant
Product Name: Preladenant
Product Code: SCH 420814
INN or Proposed INN: Preladenant
Product Name: Preladenant
Product Code: SCH 420814
INN or Proposed INN: Preladenant
Trade Name: Azilect
Product Name: Azilect
INN or Proposed INN: Rasagiline mesylate
Other descriptive name: RASAGILINE MESYLATE
Trade Name: Azilect
Product Name: Azilect
INN or Proposed INN: Rasagiline mesylate
Other descriptive name: RASAGILINE MESYLATE

Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.

NULL

Not Recruiting

Female: yes
Male: yes

1000

Phase 3

2112

EUCTR2006-001755-36-DE
(EUCTR)

15/08/2006

Parkinson’s disease
MedDRA version: 8.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease

Orion Corporation Orion Pharma

NULL

Not Recruiting

Female: yes
Male: yes

100

United Kingdom;Germany;Sweden

2113

JPRN-JapicCTI-050099

12/09/2005

Double blind, parallel-group clinical study of AD-810N (zonisamide) for Parkinson's disease

Parkinson's disease

Intervention name : AD-810N (zonisamide)
Dosage And administration of the intervention : oral

Dainippon Sumitomo Pharma Co., Ltd.

NULL

BOTH

NULL

2114

JPRN-JapicCTI-121954

Phase III study on FPF1100NW monotherapy

Randomized, double-blind, placebo-controlled study on FPF1100NW monotherapy with early Parkinson's disease patients (Phase III study)

Early Parkinson's disease

Intervention name : FPF1100NW
INN of the intervention : Selegiline
Dosage And administration of the intervention : oral
Control intervention name : null

FP Pharmaceutical Corp.

NULL

BOTH

280

Phase 3

NULL

2115

JPRN-JapicCTI-111699

22/11/2011

Study of Safety, Tolerability, Pharmacokinetics, and Efficacy of ABT-SLV187 in Subjects With Advanced Parkinson's Disease

An Open-Label, Single-Arm, Baseline-Controlled, Multicenter Study to Explore the Safety, Tolerability, Pharmacokinetics, and Efficacy of ABT-SLV187 in Subjects with Advanced Parkinson's Disease

Advanced Parkinson's disease

Intervention name : ABT-SLV187
Dosage And administration of the intervention : Usually 2-6 ml/hour (40-120 mg levodopa/hour), dose will be individually optimized for each subject based on the subject's symptoms
Control intervention name : null

Abbott Japan Co., Ltd.

NULL

BOTH

Phase 2

NULL

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

2116

JPRN-JapicCTI-101020

Phase II study on FPF1100NW monotherapy

Study on FPF1100NW monotherapy with early Parkinson's disease patients (Phase II study)

Parkinson's disease

Intervention name : FPF1100NW
INN of the intervention : Selegiline
Dosage And administration of the intervention : oral
Control intervention name : null

FP Pharmaceutical Corp.

NULL

BOTH

Phase 2

NULL

2117

EUCTR2010-022200-46-DE
(EUCTR)

13/04/2011

Efficacy and safety of ODM-101 compared to a standard combination (Stalevo®) in patients with Pakinson’s disease.

Orion Corporation

NULL

Not Recruiting

Female: yes
Male: yes

100

Finland;Lithuania;Latvia;Germany

2118

JPRN-JapicCTI-070377

28/03/2007

Double-blind, parallel-group confirmatory study of AD-810N (zonisamide) in patients with Parkinson's disease

Parkinson's disease

Intervention name : AD-810N (zonisamide)
Dosage And administration of the intervention : oral

Dainippon Sumitomo Pharma Co., Ltd.

NULL

BOTH

Phase 3

NULL

2119

EUCTR2011-002073-30-DE
(EUCTR)

20/09/2011

Evaluation of the Efficacy and Safety of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias

Novartis Pharma Services AG

NULL

Not Recruiting

Female: yes
Male: yes

France;United States;Hungary;Canada;Spain;Germany;Italy

2120

EUCTR2009-014341-84-DE
(EUCTR)

07/10/2009

Non-GI: A multi site, open-label, interventional Pilot study assessing the switch from oral treatment to rotigotine transdermal patch (Neupro) in Parkinson's disease patients with identified gastrointestinal symptoms.

idiopathic Parkinson's disease
MedDRA version: 12.0;Level: LLT;Classification code 10061536;Term: Parkinson's disease

Trade Name: Neupro 2 mg/24 h transdermal patch
Product Name: Rotigotine transdermal patch 2mg/24h(10cm2)
INN or Proposed INN: Rotigotine
Trade Name: Neupro 4 mg/24 h transdermal patch
Product Name: Rotigotine transdermal patch 4mg/24h (20cm2)
INN or Proposed INN: Rotigotine
Trade Name: Neupro 6 mg/24 h transdermal patch
Product Name: Rotigotine transdermal patch 6mg/24h (30cm2)
INN or Proposed INN: Rotigotine
Trade Name: Neupro 8 mg/24 h transdermal patch
Product Name: Rotigotine transdermal patch 8mg/24h (40cm2)
INN or Proposed INN: rotigotine

Schwarz Pharma Deutschland GmbH, UCB Group

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

Germany

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

2121

EUCTR2006-006907-35-DE
(EUCTR)

30/01/2007

Parkinson's disease
MedDRA version: 9.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease

Trade Name: Neupro 2mg/24h transdermal patch
Product Code: ND1587
INN or Proposed INN: Rotigotine
Trade Name: Neupro 4mg/24h transdermal patch
Product Code: ND1589
INN or Proposed INN: Rotigotine
Trade Name: Neupro 6mg/24h transdermal patch
Product Code: ND1590
INN or Proposed INN: Rotigotine
Trade Name: Neupro 8mg/24h transdermal patch
Product Code: ND1702
INN or Proposed INN: Rotigotine

Schwarz Biosciences GmbH

NULL

Not Recruiting

Female: yes
Male: yes

270

Phase 3B

Hungary;Finland;United Kingdom;Germany;Spain;Italy;Austria

2122

EUCTR2016-000657-12-AT
(EUCTR)

17/10/2016

A Global Study to Assess the Drug Dynamics, Efficacy, and Safety of GZ/SAR402671 in Parkinson's Disease Patients Carrying a Glucocerebrosidase (GBA) Gene Mutation

Genzyme Corporation

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

290

Phase 2

United States;Portugal;Taiwan;Greece;Spain;Austria;Israel;United Kingdom;Italy;France;Canada;Singapore;Australia;Germany;Norway;Japan;Sweden

2123

EUCTR2008-004447-11-DE
(EUCTR)

17/10/2008

Unpredictable motor fluctuation or On-Off” or Wearing-Off” Effects Fluctuating associated with Idiopathic Parkinson’s Disease
MedDRA version: 11;Level: LLT;Classification code 10067209;Term:

Vectura Limited

NULL

Not Recruiting

Female: yes
Male: yes

Phase 2b

Germany;Italy;United Kingdom